CLINICAL STUDY REPORT

EFFICACY AND SAFETY STUDY OF F373280 FOR MAINTENANCE OF SINUS RHYTHM AFTER ELECTRICAL CARDIOVERSION IN PATIENTS WITH PERSISTENT ATRIAL FIBRILLATION AND CHRONIC HEART FAILURE

16. APPENDICES

16.1. STUDY INFORMATION

16.1.1. Protocol and protocol amendments
Study F323280 CA 2 01

16.1. STUDY INFORMATION

16.1.1. Protocol and protocol amendments


16.1.1.3. Protocol amendment n° PA01 - local (Italy) and substantial - dated on 01 March 2013 linked to Protocol and appendices (version 3: 01 March 2013)


16.1.1.5. Protocol amendment n° PA03 - General and substantial - dated on 23 October 2013 linked to Protocol and appendices (version 5: 23 October 2013)

16.1.1.6. Protocol and appendices (version 6: 02 December 2013)

16.1.1.7. Protocol amendment n° PA04 - General and non-substantial - dated on 03 June 2014 linked to Protocol and appendices (version 7: 03 June 2014)

16.1.1.8. Protocol amendment n° PA05 - General and substantial - dated on 22 October 2014 linked to Protocol and appendices (version 8: 22 October 2014)

16.1.1.9. Protocol amendment n° PA06 - General and non-substantial - dated on 06 June 2016


16.1.1.11. Protocol amendment n° PA07 - Local (Italy) and non-substantial - dated on 06 December 2016 linked to Protocol and appendices (version 9: 06 December 2016)
16.1.1.1. Protocol and appendices
(version 1: 09 November 2012)
CLINICAL STUDY PROTOCOL

Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

F373280 / Soft Capsules / 1g

Pierre Fabre Study Code: F 373280 CA 2 01
EudraCT Number: 2012 – 003487 - 48

Sponsor's Representative: Marlène GUIRAUD, Pharm D
INSTITUT DE RECHERCHE PIERRE FABRE - Centre de R&D Pierre Fabre - BP 13562
3 avenue Hubert Curien
31035 TOULOUSE Cédex 1
Phone: +33 5 34 50 63 48
Fax:+33 5 34 50 65 92
E-mail:marlene.guiraud@pierre-fabre.com

Study Coordinating Investigator

Pr Savina NODARI
Section of Cardiology
Department of Experimental and Applied Sciences
University of Brescia
BRESCIA, ITALY
Phone: +39 030 3996 587 - Fax: +39 030 3700 359
E-mail: savinanodari@gmail.com

Version 1– 09 NOV 2012

The information contained in this document is confidential and is the property of the Sponsor, Pierre Fabre Medicament. This information is given for the needs of the study and must not be disclosed without prior written consent of the Sponsor Pierre Fabre Medicament. Persons to whom this information is given for the needs of the study must be informed that it is confidential and must not be disclosed.
SPONSOR PERSONNEL

PIERRE FABRE MEDICAMENT
represented by
Institut de Recherche Pierre Fabre

Clinical Study Manager (Monitor)
Marlène GUIRAUD, Pharm D
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1
Phone: +33 5 34 50 63 48
Fax: + 33 5 34 50 65 92
E-mail: marlene.guiraud@pierre-fabre.com

Head of Therapeutic Area
Alain DELARUE, MD
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1
Phone: + 33 5 34 50 61 88
Fax: +33 5 34 50 65 92
E-mail: alain.delarue@pierre-fabre.com

Clinical Development Physician
Richard ROCHÉ, MD
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1
Phone: +33 5 34 50 61 94
Fax: +33 5 34 50 65 92
E-mail: richard.roche@pierre-fabre.com
CONTRACT RESEARCH ORGANISATIONS

For Feasibility, Monitoring and Regulatory issues:
Pharmaceutical Service Network (PSN)
Rufino Gonzalez
28 037 Madrid - SPAIN
Phone: +34 91 375 6930 - Fax: +34 91 375 6931
E-mail: www.psnglobal.org

For Centralised Randomisation and Electronic Case Report Form
S-Clinica
6, Chaussée de Boondael
B-1050 Brussels - BELGIUM
Phone: +32 2 645 0567 - Fax: +32 2 645 0569
E-mail: irena.seredina@s-clinica.com

For Centralised Reading of Holder ECG and TTEM and equipment supply:
Biomedical System
1945 Chaussée de Wavre
B-1160 Brussels - BELGIUM
Phone: +32 2 661 20 70 - Fax: +32 2 661 20 71
E-mail: sjacobs@biomedsys.com

For intra erythrocyte DHA dosage
Agrocampus Ouest
Laboratoire de Biochimie
65 rue de Saint Brieuc – CS 84215
35042 RENNES Cedex - FRANCE
Phone: +33 2 23 48 55 49 - Fax: +33 2 23 48 55 50
E-mail: daniel.catheline@agrocampus-ouest.fr
Protocol F 373280 CA 2 01

APPROVAL FORM

Protocol Version 1 – 09 NOV 2012

Sponsor's Representative: 

Head of Therapeutic Area: 
Alain DELARUE, MD

Date: 12 November 2012

Signature:

Date: 16 November 2012

Signature:

F373280 Clinical Study Protocol – Version 1 – 09NOV2012
By my signature below, I, Dr / Pr " 

, hereby confirm that I agree:

- to conduct the trial described in the protocol F 373280 CA 2 01, dated 09 November 2012 in compliance with GCP, with applicable regulatory requirements and with the protocol agreed upon by the Sponsor Pierre Fabre Médicament and given approval / favourable* opinion by the Ethics Committee;
- to document the delegation of significant study-related tasks and to notify the Sponsor of changes in site personnel involved in the study;
- to comply with the procedure for data recording and reporting;
- to allow monitoring, auditing and inspection;
- to retain the trial-related essential documents until the Sponsor informs that these documents are no longer needed.

Furthermore, I hereby confirm that I will have and will use the available adequate resources, personnel and facilities for conduct this trial.

I have been informed that certain regulatory authorities require the Sponsor Pierre Fabre Médicament to obtain and supply details about the investigator’s ownership interest in the Sponsor or the study drug, and more generally about his/her financial relationships with the Sponsor. The Sponsor will use and disclose the information solely for the purpose of complying with regulatory requirements.

Hence I agree:

- to supply the Sponsor with any information regarding ownership interest and financial relationships with the Sponsor (including those of my spouse and dependent children);
- to promptly update this information if any relevant changes occur during the course of the study and for 1 year following completion of the study;
- that the Sponsor may disclose this information about such ownership interests and financial relationships to regulatory authorities.

* To be adapted

Date: 

Signature:
# TABLE OF CONTENTS OF CLINICAL STUDY PROTOCOL

1. **INTRODUCTION AND STUDY RATIONALE**.......................... 21
   
   1.1. TARGET PATHOLOGY AND THERAPY .................................................. 21
   
   1.2. INFORMATION ON THE TEST PRODUCT ........................................... 23
   
   1.2.1. Chemical and pharmaceutical characteristics.............................. 24
   
   1.2.1.1. Nomenclature and structure....................................................... 24
   
   1.2.1.2. Physical and chemical general properties................................. 24
   
   1.2.2. Non-clinical Data ........................................................................... 25
   
   1.2.2.1. Pharmacological profile............................................................ 25
   
   1.2.2.2. Safety pharmacology ................................................................. 26
   
   1.2.2.3. Toxicology profile ..................................................................... 26
   
   1.2.2.4. Pharmacokinetic data ................................................................. 26
   
   1.2.3. Clinical data .................................................................................. 26
   
   1.3. STUDY RATIONALE .......................................................................... 29
   
   1.4. OVERALL RISK AND BENEFIT ASSESSMENT ...................................... 29

2. **STUDY OBJECTIVES** ................................................................. 32

   2.1. PRIMARY OBJECTIVE ......................................................................... 32
   
   2.2. SECONDARY OBJECTIVES .................................................................. 32

3. **ETHICAL CONSIDERATIONS RELATING TO THE STUDY** ............... 32

4. **STUDY DESIGN** ............................................................................ 34

   4.1. OVERALL DESCRIPTION ..................................................................... 34
   
   4.2. DISCUSSION OF THE STUDY DESIGN .............................................. 35
   
   4.2.1. Choice of the Study Population ....................................................... 35
   
   4.2.2. Choice of the Study Design ............................................................ 36
   
   4.2.3. Choice of the Dose ......................................................................... 37
   
   4.2.4. Choice of the Sample Size .............................................................. 38

5. **STUDY POPULATION** .................................................................... 38

   5.1. INCLUSION CRITERIA ......................................................................... 38
   
   5.2. NON INCLUSION CRITERIA ................................................................. 38
   
   5.3. NUMBER OF PATIENTS ....................................................................... 39
   
   5.4. RECRUITMENT MODALITIES .............................................................. 40
   
   5.5. PATIENTS IDENTIFICATION ............................................................... 40
   
   5.6. WITHDRAWAL CRITERIA ..................................................................... 40
   
   5.7. REPLACEMENT OF PATIENTS ............................................................ 41
   
   5.8. POST-STUDY EXCLUSION PERIOD .................................................... 41
   
   5.9. STUDY CARD ...................................................................................... 41
6. STUDY TREATMENT........................................................................................................42

6.1. SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT .................................................................42

6.2. PACKAGING AND LABELLING ........................................................................................................42

6.2.1. Packaging ..........................................................................................................................42

6.2.2. Labelling ............................................................................................................................43

6.3. DISTRIBUTION TO CENTRE AND STORAGE........................................................................44

6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT ....................44

6.5. DRUG ADMINISTRATION ...............................................................................................46

6.5.1. Duration of Treatment .......................................................................................................46

6.5.2. Dose Schedule ...................................................................................................................46

6.5.3. Route and Conditions of Administration ...........................................................................46

6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT ..............................................................46

6.7. RECALL OF INVESTIGATIONAL PRODUCTS ........................................................................47

7. CONCOMITANT TREATMENTS .....................................................................................47

7.1. ANTI-VITAMIN K TREATMENT .....................................................................................48

7.2. PROHIBITED TREATMENTS ............................................................................................48

7.3. AUTHORISED TREATMENTS .........................................................................................48

8. EVALUATION CRITERIA .................................................................................................49

8.1. PRIMARY EFFICACY CRITERION: ................................................................................ 49

8.1.1. Time to the first Atrial Fibrillation Recurrence .................................................................49

8.1.1.1. Definition ........................................................................................................................ 49

8.1.1.2. Schedule .........................................................................................................................49

8.1.1.3. Evaluation Methods ........................................................................................................ 49

8.1.2. Secondary Efficacy Criteria ..............................................................................................50

8.1.2.1. Numbers of Atrial Fibrillation episodes in the first week following visit 3 (ECV visit) ........................................................................................................................................50

8.1.2.2. Duration of Atrial Fibrillation episodes in the first week following visit 3 (ECV visit) ........................................................................................................................................51

8.1.2.3. Clinical parameters evaluation ....................................................................................... 51

8.1.2.4. Cardioversion assessment ............................................................................................... 52

8.1.2.5. Evolution of echocardiographic parameters ...................................................................53

8.2. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA ........................................................................................................................................53

8.2.1. Definition ...........................................................................................................................53

8.2.2. Blood samples ...................................................................................................................54

8.2.2.1. Collection schedule ........................................................................................................ 54

8.2.2.2. Technical handling .......................................................................................................... 54

8.2.3. DHA concentration measurement .....................................................................................54

8.3. SAFETY ASSESSMENT ....................................................................................................55
8.3.1. Adverse Events .................................................................................................................. 55
8.3.2. Laboratory Investigations ................................................................................................. 55
8.3.2.1. Schedule ......................................................................................................................... 55
8.3.2.2. Technical Procedures and Parameters ............................................................................ 55
8.3.3. Global Physical Examination ............................................................................................ 56
8.3.4. Vital Signs ......................................................................................................................... 56
8.3.4.1. Schedule ......................................................................................................................... 56
8.3.4.2. Technical Procedure and Parameters .............................................................................. 57
8.3.5. Electrocardiogram (ECG) .................................................................................................. 57
8.3.5.1. Schedule ......................................................................................................................... 57
8.3.5.2. Technical Procedure and Parameters .............................................................................. 57
8.3.6. Coagulation parameters ..................................................................................................... 57
8.3.7. Concomitant Treatments ................................................................................................... 58
8.4. COMPLIANCE .................................................................................................................... 58

9. STUDY PROCEDURES ....................................................................................................... 59

10. ADVERSE EVENTS: DEFINITION AND REPORTING ................................................. 65
10.1. ADVERSE EVENTS ........................................................................................................... 65
10.1.1. Definition of Adverse Events ............................................................................................ 65
10.1.2. Grading of Adverse Events ............................................................................................... 65
10.1.3. Reporting of Adverse Events ............................................................................................ 66
10.2. SERIOUS ADVERSE EVENTS (SAE) .............................................................................. 66
10.2.1. Definition ........................................................................................................................... 66
10.2.2. Reporting of SAE .............................................................................................................. 67
10.2.3. Follow-up of SAE ............................................................................................................. 67
10.2.4. SAE Occurring After the Study ......................................................................................... 67
10.3. REPORTING OF OVERDOSAGE TO THE SPONSOR ................................................... 68
10.4. REPORTING OF PREGNANCY TO THE SPONSOR ...................................................... 68
10.5. SPONSOR'S RESPONSIBILITIES FOR SAFETY REPORTING PURPOSES ............... 69

11. DATA COLLECTION AND STUDY MONITORING ..................................................... 69
11.1. DATA COLLECTION ......................................................................................................... 69
11.1.1. Case Report Form .............................................................................................................. 69
11.1.2. Source Documents ............................................................................................................. 70
11.2. STUDY MONITORING ...................................................................................................... 70
11.2.1. Monitoring visits ............................................................................................................... 70
11.2.1.1. Site Preselection Visit .................................................................................................... 70
11.2.1.2. Initiation Visit ................................................................................................................. 71
11.2.1.3. Follow-up Visits ............................................................................................................. 71
11.2.1.4. Closing Visit ................................................................................................................... 71
11.2.2. Direct Access to Source Documents ................................................................................. 72
11.3. INDEPENDENT DATA MONITORING COMMITTEE ................................................... 72

12. DATA MANAGEMENT ...................................................................................................... 72
13. STATISTICAL ANALYSIS

13.1. GENERAL CONSIDERATIONS

13.2. SAMPLE SIZE

13.3. PROTOCOL DEVIATIONS

13.4. DATA SETS ANALYSED

13.5. HANDLING OF DROPOUTS AND MISSING DATA

13.5.1. Dropouts

13.5.2. Repositioning of Visits

13.5.3. Missing Data

13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS

13.7. EFFICACY ANALYSIS

13.7.1. Primary Criterion

13.7.1.1. Primary Analysis

13.7.1.2. Supportive Analysis

13.7.2. Secondary Criteria

13.7.2.1. Numbers of Atrial Fibrillation Episodes

13.7.2.2. Duration of Atrial Fibrillation Episodes

13.7.2.3. Time to first AF recurrence less than 10 minutes or symptomatic

13.7.2.4. Clinical parameters evaluation

13.7.2.5. Biomarker analysis: red blood cell concentrations of DHA

13.8. SAFETY ANALYSIS

13.8.1. Adverse Events

13.8.2. Clinical Laboratory Evaluation

13.8.3. Global Physical Examination

13.8.4. Vital Signs, Physical Findings and Other Observations Related to Safety

13.8.4.1. Vital Sign Measurements Over Time

13.8.4.2. Body weight

13.8.4.3. Individual Patient Changes

13.8.5. ECG

13.8.6. Coagulation parameters

13.9. CONCOMITANT TREATMENTS

13.10. COMPLIANCE

13.11. INTERIM ANALYSIS AND DATA MONITORING

14. GENERAL ETHICAL CONSIDERATIONS
**SYNOPSIS**

<table>
<thead>
<tr>
<th>Name of Sponsor:</th>
<th>Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Finished Product:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Name of Active Substance:</td>
<td>F373280 (Panthenyl-Ester of DHA)</td>
</tr>
<tr>
<td>Title of the Study:</td>
<td>Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.</td>
</tr>
<tr>
<td>Abbreviated Title:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Study Coordinating Investigator:</td>
<td>Pr Savina NODARI</td>
</tr>
<tr>
<td>Study Centres:</td>
<td>International, multicentric</td>
</tr>
</tbody>
</table>
| Publication / Rationale: | F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation (AF) patients with chronic heart failure. The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of Atrial Fibrillation (AF) induced by burst pacing. Moreover, the effectiveness of PUFA (Poly Unsaturated Fatty Acid) has been proven in the following conditions:  
- Prevention of Atrial Fibrillation recurrence in patients with persistent Atrial Fibrillation, in co-administration with amiodarone (add on therapy)  
- Improvement of ventricular functional parameters, morbi -mortality and duration of hospitalisation in patients with heart failure |
| Planned Study Period: | January 2013 – April 2014 |
| Clinical Phase: | IIA |
| Objectives: | Primary:  
- Efficacy of F373280 on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure  
Secondary:  
- Efficacy of F373280 on the efficiency of direct electrical cardioversion  
- Effect of F373280 on echocardiographic parameters  
- Safety and tolerability of F373280 |
| Methodology: | - International, multicentre, randomised, double-blind, placebo-controlled  
- Selection period  
- Start of treatment 4 weeks before ECV  
  - Condition to ECV:  
    - INR 2-3 (anti-vitamin K should be given at least 3 weeks before ECV)  
    - No spontaneous cardioversion before ECV  
- Follow-up 20 weeks after visit 3 (ECV visit)  
  - Condition: successful ECV or spontaneous CV  
- Cardiac monitoring:  
  - 7-days continuous ECG ambulatory recording (Holter ECG) between visit 3 (ECV visit) and visit 4 (week 5) in patients with sinusal rhythm  
  - TTEM: daily transmission from week 6 to week 8; then every two days from week 9 to week 24, and in case of AF symptoms  
- Treatment duration: 24 weeks |
| Study Schedule | 9 visits will be scheduled:  
- V1/ W-4 to W-1: selection visit (7 to 28 days before the inclusion visit)  
- V2/ D1: Inclusion visit (start of treatment)  
- V3/ W4 (D28 -2/+7 days): cardioversion visit (Outpatient or hospitalization according to
Number of Patients: 76 x 2 patients

Diagnosis and Criteria for Inclusion:

Inclusion Criteria:

Demographic Characteristics and Other Baseline Characteristics:

1. Men or women aged more than 18 years (inclusive),
2. Patients with persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted.
3. History of first documented persistent AF less than 1 year
4. History of ischemic or non ischemic heart failure
5. NYHA class I or II chronic heart failure at selection and at inclusion
6. Reduced left ventricular ejection fraction between 30% and 45% inclusive (using the two-dimensional echocardiography biplane Simpson’s rule) at selection and at inclusion
7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or beta blockers
8. Left atrial area ≤ 40 cm² at selection and at inclusion
9. Patients treated or having to be treated by anti-vitamin K
10. For female patient of child-bearing potential:
   - use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator, for at least 2 months before the selection in the study, and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment
   - documented as surgically sterilized
11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion

Ethical/legal considerations:

12. Having signed his/her written informed consent,
13. Affiliated to a social security system, or is beneficiary (if applicable in the national regulation)

Non-Inclusion Criteria:

Criteria related to pathologies:

1. History of first documented episode of persistent AF more than 1 year
2. More than two successful cardioversions (electrical or pharmacological) in the last 6 months
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV)
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be checked in case of treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic coronaropathy assessed by coronaryography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
7. Severe chronic kidney disease (creatinine 25 mg/L or estimated glomerular filtration rate < 30 mL/min) at selection
8. Bradycardia (HR ≤ 50 bpm)
9. Hyperkalemia or hypokalemia (K>5.5 mEq/L or K < 3.5 mEq/L) at selection
10. Cardiac surgery within 3 months before selection or planned during the study duration
### Criteria related to treatments:

11. Previously ineffective pharmacological or electrical cardioversion  
12. Concomitant treatment with any anti-arhythmic drug (within 7 days prior to selection),  
    except stable dose of digoxin, beta-blockers, calcium-blockers  
13. Previous treatment with oral amiodarone within 12 months prior to inclusion  
14. Previous treatment with intravenous amiodarone within 6 months prior to inclusion  
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT  
    implantation within the last 6 months  
16. Treatment with any Polysaturated Fatty Acid (PUFA) within the last 3 months  
17. Dietary supplement with ω3 or ω6 according to investigator’s judgement  
18. Having undergone any form of ablation therapy for AF  
19. Patient treated with other anticoagulant treatment than antivitamin K: thrombin inhibitor  
    such as Dabigatran or treated with antiaggregant P2Y12 inhibitors such as Clopidogrel  
    or Prasugrel  

### Other criteria:

20. Patient liable not to comply with protocol instructions and/or with treatment, in the  
    investigator’s opinion  
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a  
    trial at the time of selection  
22. Patient linguistically or mentally unable to understand the nature, objectives and  
    possible consequences of the trial, or refusing to patient himself/herself to its constraints  
23. Patient family member or work associate (secretary, nurse, technician,..) of the  
    Investigator  
24. Patient having forfeited his / her freedom by administrative or legal award or being  
    under guardianship  

### Exclusion criteria before V3:

Patients not stabilized for INR (i.e. values between 2 and 3) on at least 3 consecutive weekly  
tests performed before ECV will be excluded from the study, unless the presence of atrial  
thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed  
in the same day (before ECV)  
ECV will be performed in patients without dyskalemia  
If necessary for obtaining stabilized INR between 2 and 3, the ECV (and following visits)  
could be postponed by 7 days.

### Test Product:

<table>
<thead>
<tr>
<th>Dose:</th>
<th>1g of F373280 Soft Capsules</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mode of Administration:</td>
<td>Oral, one capsule each evening with dinner.</td>
</tr>
</tbody>
</table>

### Duration of Treatment:

24 weeks of treatment exposure with F373280 (25 weeks if ECV postponed by 1 week)

### Reference Therapy:

Placebo soft capsules  
Placebo will be administered in the same conditions as the tested product.

### Evaluation Criteria:

<table>
<thead>
<tr>
<th>Efficacy evaluation variables:</th>
</tr>
</thead>
</table>
| **Primary evaluation variable:**  
- Time to first Atrial Fibrillation recurrence defined by the first episode of Atrial Fibrillation lasting for at least 10 minutes (Follow up of 20 weeks after visit 3 (ECV visit)  
Handling of AF recurrences: 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) between visit 3 (ECV visit) and visit 4 (week 5). Then, the follow up will be documented using the TTEM; daily transmission from week 6 to week 8. Then, every two days from week 9 to week 24.  
For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF will be assessed after visit 3 (week 5).  
Moreover, during this TTEM period, if patient experiences any AF symptoms, it should be recorded and documented using the TTEM.  
All ECG traces will be evaluated by a Central Reading Laboratory. |
| **Secondary evaluation variables:**  
During the 7-day continuous ECG monitoring,  
- Numbers of AF episodes |
Duration of AF episodes

Clinical parameters:
During the whole study:
- Number of recurrence of symptomatic AF episodes
- EHRA score
- Hospitalization for cardiovascular events
- Hospitalization for thromboembolic stroke
- All cause of hospitalization

Cardioversion:
- Assessment of spontaneous cardioversion
- Assessment of successful cardioversion
- Number of patients needing an other cardioversion after the initial ECV

Other:
- Evolution of echocardiographic parameters (from V4 to V6 and V9) (Left atrial diameter (mm), Left atrial area (cm²), Left atrial volume (mL), Left atrial volume/BSA (mL/m²), Left ventricular ejection fraction (%), Left ventricular volume (mL), Left ventricular volume/BSA (mL/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL) Left ventricular end systolic diameter (mm), Left ventricular end systolic volume (mL))
- Evolution of omega 3 index and intra erythrocyte DHA (For this assessment samples will be centralized).

Safety criteria:
- Adverse events (observed and / or spontaneously reported)
- Vital signs (Blood pressure (supine and standing), heart rate
- Physical examination (body weight),
- Standard 12-lead ECG: heart rate (bpm), PR (ms), QRS (ms), QT (ms), repolarisation patterns (ECG not centralized).
- Haematology: haematocrit, haemoglobin, RBC, WBC, differential count, platelets
- Biochemistry: sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatin phosphokinase (CPK) fibrinogen (local laboratory)
- Coagulation parameters: Activated partial thromboplastin time (aPTT), thrombin clotting time (TCT), INR (local laboratory), Prothrombine Time (PT)

Statistical Methods:
Sample Size:
Assuming an AF recurrence rate under placebo of 85%, a power of 80%, an alpha risk of 5% and a rate of not assessable patients of 15%, 76 randomised patients per group will be necessary to achieve, using a log-rank test of survival curves, a difference between groups of 20%.

Primary Efficacy Analysis
The primary analysis, performed on the Full Analysis Set (FAS: all randomised patients with at least one dose of treatment and with a successful cardioversion observed at visit 3), will be a survival analysis using the Kaplan Meier method and Cox regression model.

Secondary Analyses
All secondary efficacy criteria will be described and compared using appropriate tests on the FAS.

Safety Analyses
Descriptive statistics will be performed on the Safety Set (all randomised patients with at least one dose of treatment)
STUDY FLOW-CHART
<table>
<thead>
<tr>
<th>Weeks</th>
<th>V1</th>
<th>V2</th>
<th>V3</th>
<th>V4</th>
<th>V5</th>
<th>V6</th>
<th>V7</th>
<th>V8</th>
<th>V9</th>
</tr>
</thead>
<tbody>
<tr>
<td>W-4 to W-1</td>
<td>D1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W4</td>
<td>(28 -2D/+7 D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W5</td>
<td>(35 +/-2 D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W8</td>
<td>(56 +/-17 D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W12</td>
<td>(84 +/-17 D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W16</td>
<td>(116 +/-17 D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W20</td>
<td>(140 +/-17 D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W24</td>
<td>(168 +/-17 D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Outpatient or Hospitalization (1)**
  - X
- **Informed consent**
  - X
- **Demographic characteristics**
  - X
- **Medico-surgical history**
  - X
- **Concomitant disease**
  - X
- **Concomitant treatment**
  - X
- **Habits**
  - X
- **Global physical examination (body weight)**
  - X
- **Echocardiography**
  - X
- **Eligibility criteria check**
  - X
- **Blood pressure, heart rate**
  - X
- **12-Lead ECG Recording**
  - X
- **INR**
  - X
- **aPTT, TCT**
  - X
- **Biochemistry**
  - X
- **Hematology**
  - X
- **Urinary pregnancy test**
  - X
- **Red Blood Cell concentrations of DHA**
  - X
- **Treatment allocation**
  - X
- **IVRS**
  - X
- **ECV (3)**
  - X
- **Drug administration**
  - X
- **Adverse events recording**
  - X
- **Holter ECG**
  - X
- **TTEM (6)**
  - X

(1) Outpatient or hospitalization according to clinical practice of the centre (less or more than 24 hours)
(2) In case of AVK introduction: INR 2 to 3 times a week, then weekly until the ECV, then every 4 weeks after ECV.
(3) In patients with AF
(4) 24-hour Holter ECG
(5) 7-day Holter ECG
(6) TTEM everyday from week 6 to week 8. Then every 2 days from week 9 to week 24. In case of AF symptoms, in case of AF recurrence for at least 10 minutes and the patient does not stop the study treatment then TTEM every 4 weeks
**LIST OF ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>aPTT</td>
<td>Activated partial thromboplastin time</td>
</tr>
<tr>
<td>AE</td>
<td>Adverse event</td>
</tr>
<tr>
<td>AERP</td>
<td>Atrial effective refractory period</td>
</tr>
<tr>
<td>AF</td>
<td>Atrial fibrillation</td>
</tr>
<tr>
<td>ALA</td>
<td>Alpha-linoleic acid</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine aminotransferase</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate aminotransferase</td>
</tr>
<tr>
<td>AUC</td>
<td>Area under the plasma concentration versus time curve</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;inf&lt;/sub&gt;</td>
<td>Total area under the curve extrapolated to infinity</td>
</tr>
<tr>
<td>AVK</td>
<td>Anti vitamin K</td>
</tr>
<tr>
<td>βHCG</td>
<td>beta human chorionic gonadotrophin</td>
</tr>
<tr>
<td>BLQ</td>
<td>Below the limit of quantification</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>BP</td>
<td>Blood pressure</td>
</tr>
<tr>
<td>BSA</td>
<td>Body Surface Area</td>
</tr>
<tr>
<td>CEP</td>
<td>Protocol evaluation committee</td>
</tr>
<tr>
<td>CHF</td>
<td>Congestive heart failure</td>
</tr>
<tr>
<td>CHMP</td>
<td>Committee for medicinal products for human use</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td>Maximum concentration</td>
</tr>
<tr>
<td>C&lt;sub&gt;min&lt;/sub&gt;</td>
<td>Minimum concentration</td>
</tr>
<tr>
<td>CNALV</td>
<td>Clinically noteworthy abnormal laboratory value</td>
</tr>
<tr>
<td>CPK</td>
<td>Creatin phosphokinase</td>
</tr>
<tr>
<td>CPP</td>
<td>Comité de protection des personnes</td>
</tr>
<tr>
<td>CRA</td>
<td>Clinical research associate</td>
</tr>
<tr>
<td>CRT</td>
<td>Cardiac resynchronization therapy</td>
</tr>
<tr>
<td>CSC</td>
<td>“Clinically Significant Change”, i.e., Predefined potentially clinically significant change leading to a potentially clinically significant value (vital signs)</td>
</tr>
<tr>
<td>CV</td>
<td>Coefficient of variation</td>
</tr>
<tr>
<td>DBP</td>
<td>Diastolic blood pressure</td>
</tr>
<tr>
<td>DHA</td>
<td>Docosahexaenoic acid</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics committee</td>
</tr>
<tr>
<td>ECG</td>
<td>Electrocardiogram</td>
</tr>
<tr>
<td>ECHO–TE</td>
<td>Trans-esophageal echocardiograph</td>
</tr>
<tr>
<td>ECV</td>
<td>Electrical cardioversion</td>
</tr>
<tr>
<td>EHRA</td>
<td>European heart rhythm association</td>
</tr>
<tr>
<td>EPA</td>
<td>Eicosapentaenoic acid</td>
</tr>
<tr>
<td>eCRF</td>
<td>Electronic case report form</td>
</tr>
<tr>
<td>FAS</td>
<td>Full analysis set</td>
</tr>
<tr>
<td>Fe</td>
<td>Fraction of the administered drug excreted in urine</td>
</tr>
</tbody>
</table>
GCP : Good clinical practice
GFR : Glomerular Filtration Rate
HBs : Hepatitis B antigen
HCV : Hepatitis C virus
HDL : High density lipoprotein
HF : Heart failure
HIV : Human immunodeficiency virus
HR : Heart rate
ICH : International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use
IDMC : Independent data monitoring committee
INR : International normalized ratio
IRPF : Institut de Recherche Pierre Fabre
IVRS : Interactive voice response system
LAA : Left atrial area
LC/MS-MS : Liquid chromatography with tandem mass spectrometry
LDL : Low density lipoprotein
LOQ : Limit of quantification
LVEF : Left ventricular ejection fraction
MedDRA : Medical dictionary for regulatory activities
MR : Mineralocorticoid receptor
MR perfusion : Magnetic Resonance perfusion
MTD : Maximum tolerated dose
N : Number of determinations or replicates
NOAEL : No observed adverse effect level
NYHA : New York heart association
od : Once a day
PC : “Predefined Change”, i.e., Predefined potentially clinically significant change
   (lab or vital signs)
PCA : PC leading to an out-of-range value (lab values)
PFB : *Pierre Fabre Biométrie*
POC : Proof of concept
PUFA : PolyUnsaturated fatty acid
PK : Pharmacokinetics
p.o. : Per os
PP : Per protocol data set
RBC : Red blood cells
SAE : Serious adverse event
SBP : Systolic blood pressure
SD : Standard deviation
T1/2 : Terminal half-life
T0 : Time of drug administration
Tmax : Time to reach the maximal concentration
TCT : Thrombin clotting time
TEAEs : Treatment emergent adverse events
TTEM : TransTelephonic ECG monitoring
VTP : Ventricular tachypacing
1. INTRODUCTION AND STUDY RATIONALE

1.1. TARGET PATHOLOGY AND THERAPY

Atrial Fibrillation (AF) is a supraventricular arrhythmia characterized by uncoordinated atrial electric activity with consequent deterioration of atrial mechanical function. It is the most common sustained cardiac rhythm disorder, increasing in prevalence with age. Haemodynamic impairment and thromboembolic events related to AF result in significant morbidity and mortality [7].

In 2009, Decision Resources estimated that there were 7.8 million diagnosed prevalent cases of atrial fibrillation (AF) in US, Europe and Japan. This age-related pathology should increase to 9.4 million cases in 2019.

Except for the conventional class I and class III anti-arrhythmic agents, the PUFAs (Polyunsaturated Fatty Acids) constitute one emerging antiarrhythmic therapy. These compounds potently address the AF substrate by directly targeting both the electrical and the structural remodelling of the deficient atria. The n-3 PUFAs, essential for human, are ALA, EPA and DHA. First, PUFAs specifically modulate ionic channels by fastening their inactivating mode which renders these compounds selective for pathological situations (such as AF) without any major effect in normal conditions. PUFAs are “open Kv1.5 channel blockers” leading to a lengthening of atrial action potential duration and are “persistent Na\textsubscript{v}1.5 channel blockers” leading to hyperpolarization of diastolic resting potential. Second, PUFAs influence structural remodelling through their anti-inflammatory effects as they directly compete with arachidonic acid in the production of inflammatory eicosanoids. In summary, PUFAs share unique, well-tolerated antiarrhythmic potential by interacting with the electrical and structural remodelling during sustained AF. In animal studies, it was recently demonstrated that DHA is particularly effective in pathologic conditions such as ischemia and/or atrial fibrillation.
The potential anti-arrythmic effects of a PUFA was previously developed in atrial fibrillation: nicotinyl ester of DHA (pro-drug based on DHA delivery) were assessed in a two-week ventricular tachypaced canine model. Dogs were subjected to 4 weeks of medication prior to undergoing an electrophysiology study, and received either placebo or nicotinyl ester of DHA. Dogs were tachypaced at 240 beats per min for the final two weeks of the treatment plan. The results showed that the tested PUFA reduced the duration of atrial fibrillation (AF) induced by burst pacing, and the incidence of sustained AF, compared to dogs treated with the placebo [1].

In clinical practice, Nodari and coll assessed n-3 Polyunsaturated Fatty Acids in the prevention of atrial fibrillation recurrences after electrical cardioversion. All included patients were treated with amiodarone and a renin-angiotensin-aldosterone system inhibitor. The 199 patients were assigned either to placebo or n-3 PUFAs 2 g/d and then underwent direct electrical cardioversion (ECV) 4 weeks later. The primary end point was the maintenance of sinus rhythm at 1 year after cardioversion. At the 1-year follow up, the maintenance of sinus rhythm was significantly higher in the n-3 PUFAs treated patients compared with the placebo group (hazard ratio, 0.62 [95% confidence interval, 0.52 to 0.72] and 0.36 [95% confidence interval, 0.26 to 0.46], respectively; p = 0.0001). The study concludes that in patients with persistent atrial fibrillation on amiodarone and a renin-angiotensin-aldosterone system inhibitor, the addition of n-3 PUFAs 2 g/d improves the probability of the maintenance of sinus rhythm after direct current cardioversion [2].

Previously, during the World Congress of Cardiology in 2006, an abstract reported the effectiveness of PUFA on top of traditional treatment (amiodarone, beta blockers, renin-angiotensin-aldosterone system inhibitor) in the prevention of AF relapses in patients having undergone ECV. In the PUFA group, AF relapses were significantly lower than placebo group at one month (3.3% vs 10%; p=0.043), at 3 months (10% vs 25%; p=0.004) and at 6 months (13.3% vs 40%; p<0.0001) [19].

In contrast, in the general AF population (paroxystic atrial fibrillation and persistent atrial fibrillation), PUFAs failed to prove their efficacy [7] because of the absence of cardiac remodelling or because of a short pre-treatment duration before ECV (1 week) [8]. The effect of PUFAs were only observed in patients with persistent AF on add on therapy and after a sufficient pre-treatment before ECV. Persistent AF is commonly associated to heart failure. Previous studies performed in heart failure population demonstrated the benefit of PUFAs on the improvement of
functional ventricular parameters and morbi-mortality, and on the reduction of hospitalisation [3, 4, 5].

Nodari and coll [3] performed a trial in patients with a chronic heart failure (NYHA I to III and LVEF< 45%). After a treatment of 133 patients with PUFAs (n=67) or placebo (n=66) at a dosage of 5 g/day for 1 month, then 2 g/day for 11 months, the n-3 PUFAs group and the placebo group differed significantly (p <0.001) in regard to:

- LVEF (increased by 10.4% and decreased by 5.0%, respectively)
- peak VO2 (increased by 6.2% and decreased by 4.5%, respectively)
- exercise duration (increased by 7.5% and decreased by 4.8%, respectively)
- mean New York Heart Association functional class (decreased from 1.88+/ - 0.33 to 1.61 +/- 0.49 and increased from 1.83+/ - 0.38 to 2.14 +/- 0.65, respectively).

The hospitalization rates for HF were 6% in the n-3 PUFAs and 30% in the placebo group (p <0.0002).

Moertl and coll [4] performed a dose-ranging study in patients with a more severe chronic heart failure (NYHA III and IV and LVEF < 35%). It was a double-blind, randomised, controlled pilot trial in 43 patients treated with PUFAs or placebo for 3 months (1 g/d n3-PUFA (n = 14), 4 g/d n3-PUFA (n = 13), or placebo (n = 16)). After treatment, left ventricular ejection fraction increased in a dose-dependent manner (P = 0.01 for linear trend) in the 4 g/d (baseline vs 3 months [mean ± SD]: 24% ± 7% vs 29% ± 8%, p = 0.005) and 1 g/d treatment groups (24% ± 8% vs 27% ± 8%, P = 0.02).

No changes in any investigated parameters were noted with placebo.

Taking into account these studies performed with PUFAs, it seems that the best target for DHA is persistent AF in patients with heart failure. The aim of this proof of concept study is to assess in stand alone therapy (without association of other anti-arrhythmic treatments), the effect of F373280 in patients with persistent atrial fibrillation and heart failure in the maintenance of sinus rhythm after electrical cardioversion.

1.2. INFORMATION ON THE TEST PRODUCT

F373280 or panthenyl ester of DHA (docosahexaenoic acid) is the mono-ester of panthotenic alcohol and DHA, selected to be developed for the management of atrial fibrillation.

F373280 is a prodrug of DHA.
A brief summary of F373280 known characteristics is presented in this section. For further details, please refer to the F373280 Investigator’s Brochure. [1]

1.2.1. Chemical and pharmaceutical characteristics

1.2.1.1. Nomenclature and structure

Chemical name (IUPAC):

(4Z,7Z,10Z,13Z,16Z,19Z)-3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido) propyl docos-4,7,10,13,16,19-hexaenoate

Structural formula:

![Structural formula image]

Laboratory code: F373280

Molecular formula: C₃₁H₄₉NO₅

Molecular mass: 515.7

1.2.1.2. Physical and chemical general properties

Appearance: Clear oily viscous liquid

Solubilities:
- Water: Practically insoluble
- Alcohol: Very soluble
- Trimethylpentane: Slightly soluble
1.2.2. Non-clinical Data

Non-clinical data are exhaustively detailed in the Investigator’s brochure [1]. A brief summary is provided below.

1.2.2.1. Pharmacological profile

F373280 (mono-ester of panthotenic alcohol and DHA) is a novel pro-drug of DHA which exerts antiarrhythmic properties by interacting with the electrical and structural remodelling of the atria.

Experimental investigations were conducted in HEK293 cell line transfected with human Kv1.5 channel using the whole cell patch clamp technique to evaluate whether F373280 could block the sustained component of I<sub>Kv1.5</sub>. F373280 concentration-dependently reduced Kv1.5 channel activity with an IC<sub>50</sub> value of 13.7 µM.

The effects of F373280 on atrial effective refractory period (AERP) were investigated in anesthetized pig using a conventional pacing protocol through epicardial electrodes placed on the left atrium. F373280 administered as a bolus and an infusion (10 mg/kg) significantly increased AERP (23.8 ± 2.2 ms versus -7.3 ± 11.5 ms in the presence of vehicle, P<0.05). In addition, F373280 was devoid of significant effect on the hemodynamic and the ECG intervals.

Proof of the pharmacological concept was performed with a different DHA derivative named: Nicotinyl ester of DHA (pro-drug based on DHA delivery). Ventricular tachypacing (VTP)-induced congestive heart failure (CHF) provides a clinically-relevant animal model of AF associated with structural remodelling, as is often seen clinically. It has been shown that sustained oral PUFA administration suppresses CHF-induced AF-promotion and fibrosis in the VTP canine model. Nicotinyl ester of DHA was tested in this model, at 1g/day and 5g/day, during 4 weeks, to prevent CHF-related atrial structural remodelling and AF promotion in dogs. Nicotinyl ester of DHA dose dependently reduced heart failure-induced increases in atrial fibrillation duration (989 ± 111 sec, n=5 in the presence of placebo versus 637 ± 196 sec, n=5 in the presence of 1g/kg/d Nicotinyl ester of DHA and 79 ± 51 sec, n=5, in the presence of 5g/kg/d Nicotinyl ester of DHA. The protective effect of Nicotinyl ester of DHA was associated with a marked increase of plasma level of DHA and important incorporation of DHA in the left atrial tissue. Because F373280
similarly to Nicotinyl ester of DHA increases plasma level of DHA, it could be estimated that the compound may exert a similar protective effect [1].

1.2.2.2. Safety pharmacology

A battery of safety pharmacology studies was performed to evaluate the effects of F373280 on the central nervous, cardiovascular and respiratory systems. Data of these studies are exhaustively detailed in the Investigator’s brochure [1].

No particular alerts were evidenced with F373280.

1.2.2.3. Toxicology profile

Concerning the toxicological data, 4-week and 26-week repeat-dose studies in rat and dog were performed. Compared to the high administered doses of F373280 (500 to 2000 gm/kg/day), low circulating concentrations of F373280 were measured.

During these toxicity studies, no toxicity was observed in rat after 4 and 26 weeks of dosing and in dog after 4 weeks of dosing. A NOAEL of 2000 mg/kg/day was established in these repeat toxicity studies.

During the 26-week toxicity study in dogs, the NOAEL was set at 1000 mg/kg/day based on changes observed on red blood cell parameters.

Based on toxicological profiles, F373280 is considered to support the proposed clinical trial.

1.2.2.4. Pharmacokinetic data

According to animal studies described in the Investigator’s brochure [1], the non-clinical pharmacokinetic profile of F373280 is not associated with particular alerts concerning the proposed clinical phase IIa study.

1.2.3. Clinical data

Part A: single dose
6 consecutive single ascending doses were tested (0.5g, 1g, 2g, 4g, 8g and 16g) on 6 independent cohorts of 8 subjects (6 verum + 2 placebo). 49 subjects were treated and 48 completed the study.

No Serious Adverse Events occurred in the course of the study.

Regarding the reported Treatment Emergent Adverse Events (TEAEs) that were judged by the Investigator as having a causal relationship with the study drug administration in the absence of an alternative explanation, 4 were observed in the placebo group (palpitation, dizziness in standing position, 2 symptomatic orthostatic hypotensions without loss of consciousness) and 4 in the group of F373280 at the dosage of 16g (meteorism, liquid stool, symptomatic orthostatic hypotension and dizziness in standing position). None of these adverse events were reported in the groups of F373280 at the dosages of 0.5g, 1g, 2g, 4g and 8g.

After a single administration of the different tested doses no difference between the tested product and placebo has been reported, regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters (related to coagulation: platelets and fibrinogen) and coagulation parameters (bleeding time, prothrombin time/INR, activated partial thromboplastin time, thrombin clotting time). Variations of these parameters were within the physiological ranges.

After single oral administration of F373280 from 0.5g to 16 g in 36 young male healthy subjects (6 per dose level), the following was observed:

- **F373280**: Whatever the tested dose there is no circulating F373280 in plasma: only few, sparse and non consecutive samples with quantifiable level of F373280 close to LOQ were observed. This confirm that F373280 is a prodrug.

- **Panthenol**: Cmax and AUC increased with the administered dose between 0.5 and 16g. Panthenol concentrations were rapidly cleared from plasma with a mean terminal half-life around 2 hours.

- **DHA**: after 0.5 and 1g, low increased in DHA plasma concentrations compared to the baseline levels led to a high inter-individual variability of the corresponding PK parameters. Plasma exposure in DHA increased with the administered dose between 2 and 16g with no departure from proportionality (baseline corrected parameters).
**Part B: Multiple dose**

Three consecutive repeated ascending doses (1, 2 and 4g) were tested on 3 independent cohorts of 12 subjects (9 verum + 3 placebo, double blind). 36 subjects completed the study. Each treatment was administered over a period of 28 days. Pharmacokinetic parameters were assessed over a period of 14 days.

Among the TEAE judged by the investigator as suspected to F373280 5/9 TEAE were classified according the SOC in vascular system disorder with orthostatic hypotension (2 in the 1 g group, 1 in the 2 g group and 2 in the 4 g group) and 4/9 were classified in nervous system disorder with 3 dizziness (2 in the 2 g group and 1 in the 4 g group) and 1 migraine (in the 1 g group). These TEAE have already been reported with Poly Unsaturated Fatty Acids and are commonly observed in phase I studies.

After a repeated administration of the different tested doses, no difference between the tested products and placebo was reported regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters. The assessment of coagulation parameters and platelet function after administration of repeated dose of F373280 did not report any bleeding issue. The reported changes in coagulation parameters and platelet function were within physiological ranges.

After a 14-day repeated oral administration of F373280 from 1 g to 4 g, the following was observed:

- **Panthenol**: Cmax and AUC increased with the administered dose between 1 and 4 g. No accumulation of panthenol in plasma was observed.

- **DHA**: Plasma exposure increased with dose. A 2-fold accumulation in total plasma exposure of DHA was observed after 14 days of administration, whatever the administered dose.
1.3. STUDY RATIONALE

F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation (AF) patients with chronic heart failure.

The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of atrial fibrillation (AF) induced by burst pacing [1].

Moreover, the effectiveness of PUFA has been proven in the following conditions:

- Prevention of atrial fibrillation recurrence in patients with persistent atrial fibrillation in co-administration with amiodarone (add on therapy) [2],

- Improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]

Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent atrial fibrillation and chronic heart failure.

This phase IIa study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure.

1.4. OVERALL RISK AND BENEFIT ASSESSMENT

F373280 is a new pro-drug of DHA.

DHA is a well-known long chain PUFAs with a long-term clinical experience in cardiovascular diseases. DHA is contained in several medicinal products such as Omacor®, (1g of Omacor contains about 320 mg of DHA acid) marketed by Laboratoires Pierre Fabre for hypertriglyceridemia and as an adjuvant treatment for secondary prevention after myocardial infarction. According to the summary product characteristics of Omacor®, [9]:

Final version 33/1185
- The frequencies of adverse reactions are ranked according to the following: common (> 1/100, < 1/10); uncommon (>1/1000 < 1/100); rare (>1/10000, < 1/1000); very rare ( < 1/10000), not known (cannot be estimated from the available data).

- The reported adverse events are:

  - Infection and infestations
    Uncommon: gastroenteritis
  - Immune system disorders:
    Uncommon: hypersensitivity
  - Metabolism and nutrition disorders:
    Rare: hyperglycaemia
  - Nervous system disorders:
    Uncommon: dizziness, dysgeusia
    Rare: headache
  - Vascular disorders:
    Very rare: hypotension
  - Respiratory thoracic and mediastinal disorders:
    Very rare: nasal dryness
  - Gastrointestinal disorders:
    Common: dyspepsia, nausea
    Uncommon: abdominal pain, gastrointestinal disorders, gastritis, abdominal pain upper
    Rare: gastrointestinal pain
    Very rare: lower gastrointestinal haemorrhage
  - Hepatobiliary disorders:
    Rare: hepatic disorders
  - Skin and subcutaneous tissue disorders:
    Rare: acne, rash pruritic
    Very rare: urticaria
  - General disorders and administration site conditions:
    Rare: malaise sensation
• Investigations:
  Very rare: white blood count increased, blood lactate dehydrogenase increased

Moderate elevation of transaminases has been reported in patients with hypertriglyceridaemia.

Panthenol is a well-known substance with a long-term experience in medical, nutraceutical and cosmetic uses. According to the summary product characteristics of a product such as Bépanthene® (tablet indicated in alopecia) which contains panthenol (100 mg), adverse event observed are rare cases of urticaria and erythema [10]. Panthenol is metabolised in panthotenic acid, i.e. B5 vitamin.

Concerning toxicological studies performed results can support the administration of F373280 in the proposed clinical phase II study without particular alert [1].

Any safety warning was reported during a phase I study performed with F373280 administered to 84 healthy volunteers in single dose in a range between 500 mg and 16 g or in repeated dose during 28 days in a range between 1g and 4g. Adverse events reported and related to study treatment were minor to moderate. The adverse events were palpitations, orthostatic hypotension, dizziness, meteorism and liquid stool. Most were reported in both groups (placebo and F373280) without a dose relationship. The assessment of coagulation parameters and platelet function after administration of repeated dose of F373280 did not report any bleeding concern: the reported changes in coagulation parameters and platelet function were within physiological ranges.

Moreover, DHA has been associated with anticoagulant products in Atrial Fibrillation studies [2, 8]. The range of PUFAs doses tested was between 2g to 3g (640 mg to 960 mg of DHA) and the range of study durations between 6 to 12 months. This association did not report a significant side effect of bleeding.

DHA has already been used in heart failure patients in several studies without safety concern [3, 4, 5]. The range of PUFAs doses tested was between 1g to 5g (1g of the tested PUFAs contains about 320 mg of DHA acid) and the range of study durations was between 3 months to 3.9 years.
Thus, inclusion of patients with no specific antiarrhythmic treatment is acceptable. They will receive an anticoagulant treatment to prevent the thrombo-embolic complications of AF (particularly stroke) and the adequate treatments to control the heart rate and heart failure.

In conclusion, the overall available data allow in safe conditions the treatment of patients with persistent AF and chronic heart failure with F373280 in safe conditions.

2. STUDY OBJECTIVES

2.1. PRIMARY OBJECTIVE

The primary objective of the study is to assess the efficacy of F373280 on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure.

2.2. SECONDARY OBJECTIVES

The secondary objectives of the study are to assess:

- the efficacy of F373280 on the efficiency of direct electrical cardioversion
- the effect of F373280 on echocardiographic parameters
- the safety and tolerability of F373280

3. ETHICAL CONSIDERATIONS RELATING TO THE STUDY

The trial is conducted according to Good Clinical Practices (CPMP/ICH/135/95), the National regulations and the Declaration of Helsinki and its subsequent amendments (see Appendix 17.1). This protocol and the informed consent form will be submitted for approval to independent local or national Institutional Review Boards/Ethics Committees before the study set up, according to national regulation.

All the protocol amendments or critical events liable to increase the risks incurred by the patients or to compromise the validity of the study or patients' rights will be submitted to the coordinator and to the Ethics Committees.
After being informed orally and in writing of all potential risks and constraints of the trial, as well as their freedom to withdraw their participation at any time, patients will then sign a consent.

A time of reflection will be given to the patients, before giving a written consent and starting the study procedures.

The use of a placebo is in accordance with EMA Addendum to the guideline on antiarrhythmics on atrial fibrillation and atrial flutter (EMA/CHMP/EWP/213056/2010) [21] and is acceptable because the included patients will remain under the standard treatment of atrial fibrillation and chronic heart failure. Except antiarrhythmics, they will receive anticoagulant (AVK), rate control treatment, chronic heart failure treatment. During the study, in case of AF recurrence that would require a cardioversion or an introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms, patients will be withdrawn and the tested product stopped. These patients will be considered as treatment failure.

In this study, patients will be carefully screened, particularly for their cardiac condition, with ECG, 24-hour holter monitor and echocardiographic data, and their biologic and coagulation condition.

The study will be addressed only to patients requiring an ECV due to their persistent AF, in the following conditions:

- ECV in patients not presenting a contra-indication,
- Anticoagulation with anti-vitamin K for at least 3 weeks before ECV,
- ECV in patients with stabilized INR (i.e. values between 2 and 3) on at least 3 consecutive weekly tests performed. Patients not stabilized for INR (i.e. values between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO-TE (trans-esophageal echocardiograph) performed in the same day (before ECV)
Patients who do not revert to sinus rhythm or present an early relapse within the observation period after ECV will be withdrawn and the tested product stopped.

During the whole study, patients will remain under medical control: visits in cardiology units will be scheduled at least every month. This follow up will include clinical signs, ECG, biological and coagulation parameters. Moreover, patient’s cardiac rhythm will be monitored between visits using daily, then every 2 days Trans Telephonic ECG Monitoring (TTEM) reviewed by a Central Reading Laboratory.

Patients may withdraw from the study at any time without having to give a reason and can expect to receive regular conventional therapy.

4. STUDY DESIGN

4.1. OVERALL DESCRIPTION

This phase IIa trial will be conducted as an international, multicentric, 24 weeks, double-blind, placebo-controlled, randomised, parallel group design, trial in 152 patients suffering from persistent atrial fibrillation and chronic heart failure.

After a 1 to 4-week of run-in period without treatment, patients will be randomised into one of the following treatment groups: F373280 1g or placebo for 24 weeks.

Nine visits are planned for the study:

- Visit 1 (V1): W-4 to W-1: Selection visit (7 to 28 days before the Inclusion Visit)
- Visit 2 (V2): D1: Inclusion visit (start of treatment)
- Visit 3 (V3): W4 (D28 -2/+7D): cardioversion visit (outpatient or hospitalization according to clinical practice of the centre) (installation of the Holter ECG device)
- Visit 4 (V4): W5 (D35 ± 2D): follow-up visit (removing of Holter ECG device and installation of the TTEM)
- Visit 5 (V5): W8 (D56 ± 7D): follow-up visit
- Visit 6 (V6): W12 (D84 ± 7D): follow-up visit
- Visit 7 (V7): W16 (D112 ± 7D): follow-up visit
- Visit 8 (V8): W20 (D140 ± 7D): follow-up visit
4.2. DISCUSSION OF THE STUDY DESIGN

4.2.1. Choice of the Study Population

The target indication of F373280 will be the maintenance of sinus rhythm after cardioversion of patients with persistent atrial fibrillation and chronic heart failure. In the present proof of concept study, the evaluation will focus on patients within this indication. This target population is justified by:

- The proved efficacy of PUFAs in patients with persistent atrial fibrillation with or without heart failure in co-administration with amiodarone (add on therapy) [2]
- The proved efficacy of PUFAs on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]

The study aim is to investigate the product effect in patients with:

- early persistent atrial fibrillation history (less than one year) with a duration of a the current episode between 7 days to 6 months
- a moderately abnormal moderately systolic heart failure (Left Ventricular Ejection Fraction (LVEF) between 30 to 45% as defined in the report from the American Society of Echocardiography’s Guideline). According to a sub-group analysis performed in patients with persistent atrial fibrillation associated to heart failure (Nodari S. personal data), PUFAs would be effective to prevent recurrence of AF after cardioversion in patients with moderately abnormal LVEF.

- A Left Atrial Area (LAA) not severely abnormal (less than 40 cm² as defined in the report from the American Society of Echocardiography’s Guideline). According to a sub-group analysis performed in patients with persistent atrial fibrillation associated to heart failure (Nodari S. personal data), PUFAs would not be effective to prevent recurrence of AF after cardioversion of patients with severely abnormal LAA.

For the successful rate of electrical cardioversion, patients should have a stable medical treatment of heart failure and should not have myocardial infarction or unstable angina or
unstable ischemic coronaryopathy (assessed by coronaryography or cardiac stress test or effort test within 6 months before selection).

### 4.2.2. Choice of the Study Design

As the target indication would be the prevention of AF recurrence after ECV, the study design meets the requirements of EMA guideline on anti-arrhythmics on atrial fibrillation (EMA/CHMP/EWP/213056/2010) [21].

As F373280 aims to be developed as a safe treatment for the prevention of AF recurrence, it will not be tested as an add-on therapy during the study. To avoid any interaction with the tested product, anti-arhythmics class I and III will be forbidden during the study.

The study design is defined in order to avoid methodological bias. A double blind study is appropriate to assess the efficacy and safety of the use of F373280 to prevent recurrence of AF episodes. Moreover, this study design is similar to the design of almost all trials that have assessed intervention for rhythm control [2, 8, 11, 12].

According to the target indication, only patients with persistent atrial fibrillation and requiring an electrical cardioversion will be included in order to assess the time to first documented recurrence of atrial fibrillation since cardioversion.

To confirm the persistent nature of atrial fibrillation, a 24-hour holter monitoring will be performed during the selection visit.

Eligible participants will enter a selection phase in which anticoagulant treatment (anti-vitamin K) will be adjusted to achieve an International Normalized Ratio (INR) of 2.0 to 3.0 before electrical cardioversion. According to guidelines for the management of atrial fibrillation [6], anti-vitamin K should be given at least 3 weeks before cardioversion because of risk of thrombo-embolism due to post-cardioversion.

Experimental data suggest that the maximal incorporation, of n-3 PUFAs in the myocardial cell membrane takes up to 28 days to occur [22]. In addition, as shown in Nodary study [2], the duration of pre-treatment with PUFA before cardioversion appears to be a contributing factor in
success. Therefore, before starting follow up for the assessment of AF recurrence, treatment with F373280 should be started 28 days before ECV.

Detection of atrial fibrillation recurrence will be performed using systematic (scheduled) ECG recording, thus allowing detection of asymptomatic (about 50% of episodes) as well as symptomatic AF episodes. According to previous studies, most of atrial fibrillation recurrence occurred during the first days after cardioversion [11, 15]. So that, the heart rhythm will be closely monitored during the first week after successful cardioversion using an ambulatory continuous 7-day holter ECG recording in order to increase sensibility to detect asymptomatic AF episodes. Thereafter, to improve patient compliance, this follow up will be continued using a more easy to carry and easy to use device, a TTEM.

Finally, during the study, patients will be scheduled for a clinical visit every month (with an additional visit 7 days after visit 3 (ECV visit)) in order to ensure a close medical monitoring and to assess efficacy and safety parameters.

4.2.3. Choice of the Dose

According to a previous study in patients with atrial fibrillation [2], the tested PUFA product (Omacor®) at the dose of 2 g (i.e. 640 mg of DHA acid) was effective in the prevention of atrial fibrillation after cardioversion. Moreover, PUFAs at dosage of 1g and 2g were also effective on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5].

From the F373280 phase I study, after a 14-day repeated administration of F373280 (1g/day), observed plasma concentrations of DHA measured before treatment (Cmin) were similar to that of an effective dose of Omacor® at 2 g/day (60 to 95mg/mL and 60 to 90mg/mL, respectively) (phase I study of F373280 and Salm and coll study) [16]. With regard to the rhythm of administration, mean peak/trough fluctuation (baseline corrected) was around 0.3. This value supports a once-daily administration allowing a 24-hour plasma exposure in DHA. Therefore, a dose of 1 g daily of F373280 is considered to be appropriate to be tested in this POC study.
4.2.4. Choice of the Sample Size

See chapter 13.

5. STUDY POPULATION

Each patient fulfilling all the inclusion criteria and none of the non inclusion criteria will be eligible.

5.1. INCLUSION CRITERIA

Demographic Characteristics and Other Baseline Characteristics:

1. Men or women aged more than 18 years (inclusive),
2. Patient with persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted.
3. History of first documented persistent AF less than 1 year
4. History of ischemic or non ischemic heart failure
5. NYHA class I or II chronic heart failure at selection and at inclusion
6. Reduced left ventricular ejection fraction between 30% and 45% inclusive (using the two-dimensional echocardiography biplane Simpson’s rule) at selection and at inclusion
7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers
8. Left atrial area $\leq 40$ cm² at selection and at inclusion
9. Patient treated or having to be treated by anti-vitamin K
10. For female patient of child-bearing potential:
    - use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator, for at least 2 months before the selection in the study and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment or
    - documented as surgically sterilized
11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion

Ethical/legal considerations:
12. Having signed his/her written informed consent,
13. Affiliated to a social security system, or is a beneficiary (if applicable in the national regulation),

5.2. NON INCLUSION CRITERIA

Criteria related to pathologies:

1. History of first documented episode of persistent AF more than 1 year,
2. More than two successful cardioversions (electrical or pharmacological) in the last 6 months,
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV),
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be check in case of treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic coronaryopathy assessed by coronaryography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
7. Severe chronic kidney disease (creatinine 25 mg/L or estimated glomerular filtration rate < 30 mL/min) at selection
8. Bradycardia (HR \( \leq \) 50 bpm)
9. Hyperkalemia or hypokalemia (K > 5.5 mEq/L or K < 3.5 mEq/L) at selection
10. Cardiac surgery within 3 months before selection or planned during the study duration

**Criteria related to treatments:**

11. Previously ineffective pharmacological or electrical cardioversion
12. Concomitant treatment with any anti-arrhythmic drug (within 7 days prior to selection), except stable dose of digoxin, beta-blockers, calcium-blockers.
13. Previous treatment with oral amiodarone within 12 months prior to inclusion
14. Previous treatment with intravenous amiodarone within 6 months prior to inclusion
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT implantation within the last 6 months
16. Treatment with any Polyunsaturated Fatted Acid within the last 3 months
    Dietary supplement with \( \omega_3 \) or \( \omega_6 \) according to investigator’s judgment
18. Having undergone any form of ablation therapy for AF
19. Patient treated with other anticoagulant treatment than antivitamin K: thrombin inhibitor such as Dabigatran or treated with antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel

**Others criteria:**

20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion,
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection,
22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself / herself to its constraints,
23. Patient family member or work associate (secretary, nurse, technician…) of the Investigator,
24. Patient having forfeited his / her freedom by administrative or legal award or being under guardianship.

**5.3. NUMBER OF PATIENTS**

76 x 2 patients (taking into account 15 % of non evaluable patients).
5.4. RECRUITMENT MODALITIES

Patients will be recruited within the medical consultation of each centre involved in the study. If necessary and when authorized by local and national regulation, some specific supports or tools will be used to improve the recruitment (announcement, mailing to general practitioners, leaflet, website including ClinicalTrials.gov, CRO,…).

Before implementation, the documents will be submitted to and approved by the Ethics Committee.

5.5. PATIENTS IDENTIFICATION

The patient's code will contain 7 digits: the 2 first digits corresponding to the country number, the following 2 digits corresponding to the centre number and the last 3 digits corresponding to the patient's chronological order once having signed the written informed consent.

5.6. WITHDRAWAL CRITERIA

The reasons for a patient's premature withdrawal from the study may be the following:

- The patient's decision. A patient who wishes to withdraw from the study for any reason may do so at any time but must inform the investigator. In all cases, the Investigator should attempt to contact the patient as soon as possible for a final assessment in order to:
  - have the patient's decision written on the consent form
  - obtain the reason(s) for withdrawal and report it/them in the case report form
  - evaluate the patient's clinical condition
  - if necessary, take appropriate therapeutic measures: management of an adverse effect or concomitant disease, prescription of another treatment.

- The Investigator's decision in the patient's interest. Particularly, if a serious adverse event occurs and is considered by the Investigator liable to threaten the health of the patient. The monitor will be informed by phone or fax and a letter or report explaining the withdrawal will be forwarded to the monitor as soon as possible.
• An erroneous inclusion according to the study protocol. Any inclusion not respecting inclusion / non inclusion criteria will immediately be withdrawn and an appropriate treatment will be instored by the investigator under his/her responsibility. Erroneous inclusions will not be paid to the investigator.

• Patients who could not be treated with anti-vitamin K for at least 3 weeks before ECV,

• Patients who will not stabilize INR between 2 and 3 on at least 3 consecutive weekly tests

• Patients with only 2 consecutives INR tests between 2 and 3 in the last 3 week for whom a trans-oesophagoal echocardiography can not be performed before ECV or for whom a trans-oesophagoal echocardiography shows a thrombus in the atria.

• Patients who will not revert to sinus rhythm or with early relapse within the observation period after ECV (i.e. unsuccessful ECV) will be considered to have finished follow-up.

• An occurrence of AF recurrence that would require, at the investigator’s judgement, a cardioversion or an introduction of an anti-arrhythmic because of intolerable and uncomfortable clinical symptoms.

5.7. REPLACEMENT OF PATIENTS

Withdrawn patients will not be replaced.

5.8. POST-STUDY EXCLUSION PERIOD

Patients will not be allowed to participate to another clinical trial during 3 months following the study termination.

5.9. STUDY CARD

The patient will receive from the Investigating Centre at Visit 1 - Selection Visit, a personal card to be kept all along the study duration and providing the following information: patient's name, sponsor's name, study code, EUDRACT number, start date and expected end date of the study, complete address of the Investigating Centre with the name and phone number of the Investigator.
and a sponsor 24H/24 phone contact number in case of emergency (French and English languages): 33 (0)5 63 35 25 83.

6. STUDY TREATMENT

The Clinical Pharmacy Department of the Institut de Recherche Pierre Fabre (IRPF) will supply the investigational centres with the treatment necessary for the conduct of the trial.

6.1. SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT

F373280 and placebo will be prepared in Soft Capsules similar presentation.

- **F373280**

  Formulation of F373280, 1g, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: Panthenyl ester of DHA, gelatine, glycerol, titanium, dioxide, purified water.

- **Placebo**

  Formulation of placebo matching tested product, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: paraffin liquid, fish flavour, gelatine, glycerol, titanium, dioxide, purified water.

Placebo and F373280 capsules will be packaged in opaque blisters.

6.2. PACKAGING AND LABELLING

The treatment units will be packed and labelled by the Clinical Pharmacy Department of the IRPF according to European Directive and local requirements.

6.2.1. Packaging

Each treatment unit will be composed of 3 cases for a 12-week treatment period.

The Investigator will provide the patient with the treatment according to the following schedule:

At Inclusion Visit (V2): a 12-week treatment unit will contain 3 cases, each case containing:
10 blister packs of four 1g F373280 soft capsules or placebo soft capsules each.

At Visit 6 (V6): a 12-week treatment unit will contain 3 cases, each case containing:
   • 10 blister packs of four 1g F373280 soft capsules or placebo soft capsules each.

6.2.2. **Labelling**

Investigational Products will be labelled according to the following rules:

- Labelling should comply with the local requirements for Investigational Medicinal Products.

On the treatment units and cases, the labels will bear the following indications:

   a) name and address of the sponsor
   b) protocol number,
   c) packaging batch number,
   d) the treatment number
   e) storage conditions
   f) expiry date
   g) pharmaceutical dose form
   h) route of administration
   i) quantity of dosage units
   j) direction for use
   k) legal statements:
      - “for clinical trial only”, “keep out of the reach and the sight of children”, “please return to your doctor any unused product”, respect the prescribed dose”.

On the treatment unit, another label will be affixed with the mention of the investigator name and patient number (completed by the investigator).

In addition, on each case, will be mentioned the case number and a detachable label will bear the following indications:

   - Protocol number
   - Packaging batch number
   - Expiry date
   - Case number
   - Treatment number

On the blister pack, the label will mention the protocol number, the packaging batch number, the case number and the treatment number.
6.3. DISTRIBUTION TO CENTRE AND STORAGE

The Clinical Pharmacy Department of the IRPF will supply the Investigational Centre with the treatment units along the study according to the need, upon request triggered by the patient’s selection.

As soon as the Pharmacist or the Investigator receives the trial medication, he/she will check the contents and immediately acknowledges the receipt in the IVRS/IWRS. The copy of the acknowledgement will be kept in the Investigator's file. The same procedure will be applied to all further supplies during the course of the trial.

At the time of the delivery to the Centre, the following information will be provided:

- Details of storage conditions that should be respected
- And, upon request and for the 1st delivery only, a letter of release for the Investigational Medicinal Product from the Sponsor's Qualified Person.

The CRA will ensure during the monitoring visits that trial medications have been received in good conditions and the acknowledgment of receipt has been performed adequately.

Treatment units should remain intact until dispensation to the patients. They should be kept at temperature below 30°C in an appropriate lockable room only accessible to the person authorised to dispense them, under the responsibility of the Pharmacist or the Investigator.

In the case of undue delay in study execution, the Pharmacist or the Investigator should ensure that the expiry date has not been exceeded.

6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT

A randomisation list will be established by the Clinical Pharmacy Department of the IRPF. This list will be computer-generated with internal software. The randomisation methodology is validated by the Biometry Department before generation.

Treatments F373280 or placebo will be balanced in a 1:1 ratio.
As the treatment units are prepared for 12-week treatment periods, the Investigator will have to allocate a treatment number at inclusion Visit and another one at Visit 6.

For each patient, the treatment number given at Visit 6 will not be the same that the one given at inclusion visit (V2).

The treatment numbers will be given through the IVRS/IWRS.

Practically, once the patient’s eligibility is confirmed, at selection visit:

- **The Investigator:**
  - Calls the vocal server
  - Answers the questions relating to the patient
  - In return, the treatment number to be allocated for the first 12-week period to the patient is given by the vocal server.

- **The IVRS/IWRS company:**
  - Confirms this information by fax/email to the Investigator
  - Fills the “Request for Delivery of Investigational Product” form and sends it by email and/or fax to the Clinical Pharmacy Department of the IRPF.

- **The Clinical Pharmacy Department of the IRPF** sends the corresponding treatment unit to the Investigator within 5 days from reception of the email request form.

The Investigator will dispense to the patient the case which label indicates the treatment number and the administration period.

At visit 5, the Investigator will contact again the IVRS/IWRS to obtain for visit 6 the treatment number for the last 12-week period of treatment according to the same process as described above.
6.5. DRUG ADMINISTRATION

6.5.1. Duration of Treatment

For a patient completing the study, the theoretical study treatment exposure will be 24 weeks, with F373280 or placebo.

If the ECV is postponed by 1 week to allow INR stabilization, the treatment duration will be 25 weeks.

6.5.2. Dose Schedule

One soft capsule of 1g of F373280 or placebo to be taken each day during 24 weeks.

6.5.3. Route and Conditions of Administration

The soft capsules are to be taken orally. One soft capsule is to be taken each evening with the dinner during 24 weeks.

6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT

The Investigator should maintain accurate written records of drug received, dispensed, returned and any remaining treatment units, on the drug accountability form. These records should be made available for Clinical Research Associate (CRA) monitoring. The packaging of the medication should remain intact until just before the dispensation.

At each visit, the Investigator will record the number of soft capsules returned by each patient using the appropriate page of the e-CRF.

At the end of the study, all used and unused treatments including packaging should be noted, and return is organised by the CRA to the Clinical Pharmacy Department of the IRPF for destruction. A copy of the drug accountability form should be provided by the Investigator to the CRA.
6.7. RECALL OF INVESTIGATIONAL PRODUCTS

In case of recall of investigational products (decided by the Competent Authorities or the Sponsor), the Investigator will immediately be informed by the Sponsor.

The Investigator, in collaboration with the Sponsor representatives (Study Manager, CRA) must urgently:

- Stop the delivery of the concerned investigational products to the patients.
- Inform the concerned patients that they must immediately stop taking these investigational products and bring them back.

The Study Manager/CRA organises the return of the recalled products to the Clinical Pharmacy Department of the IRPF, according to the Sponsor’s procedures.

7. CONCOMITANT TREATMENTS

Any existing concomitant treatment (Selection Visit), any new concomitant treatment or change in the dosage of an existing concomitant treatment during the course of the study must be noted on e-CRF. All treatments should be evaluated by the investigator at selection and their prolongation during the study or their stop should be considered.

For all concomitant treatments taken during the study, the following information must be noted in the relevant section(s) of the e-CRF:

- The name of the treatment and its form
- The reason for prescription
- The route of administration
- The daily dose
- The duration of treatment.
7.1. **ANTI-VITAMIN K TREATMENT**

Anti-vitamin K should be given for at least 3 weeks before ECV and continued for the whole study duration. The anti-vitamin K used will be left to the decision of the each investigator according to his/her local practice.

7.2. **PROHIBITED TREATMENTS**

- Class I and class III antiarrhythmic treatments:
  - Class I
    - Class IA: Disopyramide, Procainamide, Quinidine
    - Class IB: Lidocaine, Mexiletine
    - Class IC: Flecainide, Propafenone
  - Class III: Dofetilide, Ibutilide, Sotalol, Amiodarone, Dronedarone.
- Any Polyunsaturated Fatty Acid (PUFA)
- Any anticoagulant treatment other than antivitamin K: thrombin inhibitor such as Dabigatran or antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel
- Dietary supplement with Omega 3 or Omega 6

Prohibited treatments at selection must not be prescribed for the duration of the study except in case of occurrence of an adverse event or AF episode that requires a corrective treatment in the interest of the patient’s health.

7.3. **AUTHORISED TREATMENTS**

Other treatments will be authorised during the study duration.

However, if medication other than study drugs is administered at any time from the start of the study, details must be recorded in the case report form. During the study, patients must be asked whether they have been on a course of prescribed drug treatment or have taken any OTC or herbal drugs since the visit.
8. EVALUATION CRITERIA

8.1. PRIMARY EFFICACY CRITERION:

8.1.1. Time to the first Atrial Fibrillation Recurrence

8.1.1.1. Definition
Time to first Atrial Fibrillation recurrence is defined by the first episode of Atrial Fibrillation (symptomatic or not) lasting for at least 10 minutes.

8.1.1.2. Schedule
The heart rhythm follow up will be performed from the end of electrical cardioversion visit (visit 3) to the final study visit (visit 9).

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF will be assessed after visit 3 (week 5).

8.1.1.3. Evaluation Methods
- 7-day holter monitor:

The heart rhythm monitoring will be carried out from visit 3 to visit 4 using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) fixed after ECV visit.

Following holter monitoring the heart rhythm will be documented using Trans Telephonic ECG Monitoring (TTEM)

- Trans Telephonic ECG Monitoring (TTEM):

Thus, the follow up will be documented using the TTEM: daily transmission from visit 4 to visit 6. Then, every two days from visit 6 to visit 9.

Moreover, during this TTEM period, if patient experiences AF symptoms, it should be documented using the TTEM.
In case of AF recurrence, and provided that the patient does not required a cardioversion or an introduction of an anti-arrhythmic at the investigator’s judgement, he/she could be maintained in the study with the treatment, in order to assess a spontaneous cardioversion. For that purpose the patient will continue to transmit a TTEM once a week.

The TTEM will be centralized by the Central Reading Laboratory. The patient will be requested to contact the Central Reading Laboratory for transmission of each stored TTEM. The TTEM will be validated by a trained technician, then analysed by a cardiologist. The cardiologist interpretation will be faxed to the site. The investigator will be asked to review and sign this document.

The TTEM process will be fully described in a separate document.

8.1.2. Secondary Efficacy Criteria

8.1.2.1. Numbers of Atrial Fibrillation episodes in the first week following visit 3 (ECV visit)

8.1.2.1.1. Definition
Number of Atrial Fibrillation episodes will consist in the assessment of episodes of AF with duration at least 10 minutes (N\text{Sup10}) and of less than 10 minutes (N\text{Inf10}), respectively.

8.1.2.1.2. Schedule
The heart rhythm follow up will be performed from the end of successful electrical cardioversion visit (visit 3) to the study visit 4.

8.1.2.1.3. Evaluation Methods
• 7-day holter monitor:

The heart rhythm monitoring will start using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) after ECV visit from visit 3 to visit 4.
8.1.2.2. Duration of Atrial Fibrillation episodes in the first week following visit 3 (ECV visit)

8.1.2.2.1. Definition
Duration of AF episodes will consist in the sum of duration of each AF episodes.

8.1.2.2.2. Schedule
The heart rhythm follow up will be performed from the end of successful electrical cardioversion visit (visit 3) to the follow up study visit (visit 4).

8.1.2.2.3. Evaluation Methods
Duration of AF episodes will be assessed using the 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording.

8.1.2.3. Clinical parameters evaluation

8.1.2.3.1. EHRA score assessment

8.1.2.3.1.1. Definition:
AF related symptoms will be evaluated by the EHRA (European Heart Rhythm Association) score [20]. The following items “during presumed arrhythmia episodes” are checked to determine the score: palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety.

Classification of AF-related symptoms (EHRA score) are as follows:

- **EHRA I** - ‘No symptoms’
- **EHRA II** - ‘Mild symptoms’; normal daily activity not affected
- **EHRA III** - ‘Severe symptoms’; normal daily activity affected
- **EHRA IV** - ‘Disabling symptoms’; normal daily activity discontinued

This classification relates exclusively to the patient-reported symptoms.
In addition to this score, the frequency will be classified in three groups, namely occasionally (less than once per month); intermediate (1/month to almost daily); and frequent at least daily.

8.1.2.3.1.2. Schedule

This evaluation will be performed in case of symptoms evocative of arrhythmia.

8.1.2.3.1.3. Evaluation Methods

This evaluation will be collected by Central Reading Laboratory during all the study period.

8.1.2.3.2. Number of recurrence of symptomatic AF

It consists of number of AF recurrence associated with a symptom (Palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety) and confirmed by an ECG in atrial fibrillation.

8.1.2.3.3. Number and duration of hospitalization

- Number and duration of hospitalization for cardiovascular events
  - Hospitalization for AF treatment
  - Hospitalization for worsening of heart failure
  - Hospitalization for myocardial infarction
  - All cause of hospitalization
- Number and duration of hospitalization for thromboembolic stroke

8.1.2.4. Cardioversion assessment

- Assessment of spontaneous cardioversion before visit 3
- Assessment of successful cardioversion at visit 3 (i.e. return to sinus rhythm)
- Shock distribution (1, 2 or 3 shocks)
- Number of patients needing another cardioversion after initial ECV
8.1.2.5. Evolution of echocardiographic parameters

8.1.2.5.1. Definition

The following echocardiographic parameters will be assessed: Left atrial diameter (mm), Left atrial area (cm²), Left atrial volume (mL), Left atrial volume/BSA (mL/m²), Left ventricular ejection fraction (%), Left ventricular volume (mL), Left ventricular volume/BSA (mL/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL), Left ventricular end systolic diameter (mm), and Left ventricular end systolic volume (mL).

8.1.2.5.2. Schedule

The measurements will be performed at visit 1 and visit 2 to check the eligibility of the patient. The measurements performed at visit 4, visit 6, and visit 9 are done to follow the echocardiographic evolution of the patients in sinus rhythm.

8.1.2.5.3. Evaluation method

The echography evaluations will be carried out according to the recommendations for chamber quantification drawn up by the American Society of Echocardiography and the European Association of Echocardiography [23]. So, for volume measurements, the recommended method is to use the biplane method of discs (modified Simpson’s rule) from 2-D measurement.

8.2. Biomarker Assessment: Red Blood Cell Concentrations of DHA

8.2.1. Definition

Because of the limited accessibility of human tissues for biopsy, red blood cell DHA contents is a marker for tissue DHA concentration [13], [14].
8.2.2. Blood samples

8.2.2.1. Collection schedule

Blood samples will be collected for determination of red blood cells (RBC) concentrations of DHA.

Blood samples will be performed as follows:

- Visit 2 before treatment, visit 3, visit 6 and visit 9.

Actual sampling times will be individually reported in the electronic Case Report Forms (e-CRFs).

8.2.2.2. Technical handling

Two blood samples will be collected containing EDTA. They will be gently shaken and centrifuged at 3000g for 15 min at room temperature, within 30 minutes after collection. Plasma and white blood cells will be discarded. Red blood cells will be stored at +4°C (no freezing will be allowed) and sent to Analytical Centre in refrigerated conditions (between +2°C and +8°C) within 3 weeks following collection. Analysis will be performed within 2 weeks following reception at the Analytical centre.

8.2.3. DHA concentration measurement

Analytical determination of RBC concentrations of DHA will be carried out by the Analytical Centre.

Lipids will be extracted from red blood cells samples with a mixture of hexane/isopropanol, after acidification [17]. Total lipid extracts will be saponified and methylated. The fatty acid methyl esters (FAME) will be extracted and analyzed by Gas Chromatography.

Identification of FAME will be based on retention times obtained for FAME prepared from fatty acid standards. The area under peaks will be determined using ChemStation Software (Agilent) and results will be expressed as % of total fatty acids. DHA concentration will be calculated using the internal standard and expressed as µg/g for red blood cells samples. Thus, omega-3 index will
be assessed. The omega-3 index represents the content of EPA plus DHA in red blood cells (expressed as a percent of total fatty acids). It is a biomarker considered as a new marker of risk for death from coronary disease [18].

Results of this analytical determination will be kept confidential by the dosing centre until the end of the study, and will be provided only at the end of the study (after database lock), in a separate file.

8.3. SAFETY ASSESSMENT

8.3.1. Adverse Events
At selection, any concomitant disease will be reported on the e-CRF. At each further visit, the occurrence of adverse events (AEs) since the last visit will be based on the patient's spontaneous reporting, the investigator's non-leading questioning and his/her clinical evaluation. All AEs will be reported on the e-CRF (see section 10).

8.3.2. Laboratory Investigations

8.3.2.1. Schedule
Laboratory investigations will be performed at visit 1 (before treatment) and visit 9 (end of treatment) or End of Treatment visit.

Furthermore the kaliemia will be checked before electrical cardioversion at visit 3.

The volume of blood samples complete haematology, biochemistry should not exceed 30 mL.

8.3.2.2. Technical Procedures and Parameters
The following tests will be performed:

**Haematology:** Hematocrit, haemoglobin, Red blood cells (RBC) count, white blood cells (WBC) count, WBC differential counts (% and absolute), platelets.

**Chemistry:** sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinin, aspartate
aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatine phosphokinase (CPK), fibrinogen.

Blood samples will be taken in the morning, in fasting conditions.

The estimation of GFR at selection relies on the measurement of serum creatinine and the Cockcroft-Gault formula

- with serum creatinine expressed as mg/L:
  
  in men:
  \[
  \text{GFR (mL/min)} = \frac{(140-\text{age}) \times \text{weight}}{7.2 \times \text{serum creatinine in mg/L}},
  \]

  in women:
  \[
  \text{GFR (mL/min)} = \frac{(140-\text{age}) \times \text{weight}}{7.2 \times \text{serum creatinine in mg/L}} \times 0.85
  \]

- with serum creatinine expressed as μmol/l:
  
  GFR (mL/min) = \frac{(140-\text{age}) \times \text{weight}}{\text{serum creatinine in μmol/l}} \times k, \text{where } k = 1.23 \text{ for men, 1.04 for women.}

(weight in kg, age in years)

Additional tests may be done at the Investigator’s discretion, in the patients’ interest. In case of any abnormal or clinically significant results, the Investigator will order laboratory control tests.

8.3.3. Global Physical Examination

A global physical examination including the measurement of body weight will be carried out on each body system at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.

The physical examination will be globally evaluated as “normal/abnormal”. Further target inspection will be undertaken for any abnormal finding.

8.3.4. Vital Signs

Vital signs will consist in blood pressure and heart rate at rest.

8.3.4.1. Schedule

Vital signs will be measured at each visit.
8.3.4.2. *Technical Procedure and Parameters*

Systolic (SBP) and diastolic (DBP), expressed in mmHg, will be measured after at least 5 minutes in supine position and after 2 minutes in standing position.

The heart rate (HR), expressed in beats per minute (bpm), will be measured by auscultation, after at least 5 minutes in supine position and after 2 minutes in standing position by counting the beats for at least 30 seconds.

Bodyweight will be measured in patient in underwear and with the same balance at each visit.

8.3.5. **Electrocardiogram (ECG)**

8.3.5.1. *Schedule*

An electrocardiogram will be recorded at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9 using an usual standardised 12-lead cardiograph.

8.3.5.2. *Technical Procedure and Parameters*

- Electrocardiogram (ECG):

  The global interpretation from manual reading (normality, clinical relevance) and heart rate (bpm), PR (ms), QRS (ms), QT (ms), repolarisation patterns will be reported in the e-CRF. Each print-out will include the patient’s code, date, time, technician's initials and investigator's signature.

  In case of thermic paper ECG print out, a photocopy will be made by the centre to ensure safe filing.

- 24 hour-Holter - ECG

  An ambulatory continuous 24-hour ECG (5-leads/2 or 3 channels) will be recorded at selection visit using a holter ECG, in order to confirm persistent atrial fibrillation.

8.3.6. **Coagulation parameters**

The assessment of coagulation will be evaluated by the following parameters:
– Prothrombin Time/INR (PT/INR)
– Activated Partial Thromboplastin Time (aPTT)
– Thrombin Clotting Time (TCT)

During the pre-cardioversion period, if the anticoagulation by AVK should be initiated, then the INR monitoring will be as follow:
– INR 2-3 times a week for the first week of treatment
– INR weekly up to ECV,
– INR every 4 weeks after ECV

For patients already treated with AVK, INR monitoring will be as follow:
– INR weekly up to ECV,
– INR every 4 weeks after ECV

aPTT and TCT will be performed at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.

Anti-coagulation by anti-vitamin K should be given at least 3 weeks before ECV and continued for the whole study duration.
The quantity of blood samples collected at each time for coagulation parameters will be 2 mL.

8.3.7. Concomitant Treatments
Concomitant treatments will be evaluated at each study visit.

Requirements relating to patient's concomitant treatments started before screening visit and continued throughout the trial, or started during the trial can be found in section 7.

8.4. COMPLIANCE
The patient will be reminded at each visit to bring back any remaining soft capsules, blister, case (used or unused) at the following visit.

At each visit, the Investigator will record the number of supplied and remaining Soft Capsules in the e-CRF.
9. **STUDY PROCEDURES**

**Visit 1 - Selection Visit (Week -4 to Week -1)**

The patient considered eligible for selection by the Investigator will be informed of the characteristics and the consequences of the trial both verbally and by reviewing the patient’s information sheet and consent form (see section 14.3). If he/she accepts to participate in the study, he/she will sign the informed consent and will keep a copy.

The patient will be assessed for the following:

- Demographic characteristics (gender, age, height, body surface area)
- Personal and medico-surgical history
- Habits (Tobacco, alcohol consumption, dietary habits including fish consumption…)
- Cardiovascular diseases, mainly detailed history of Heart Failure and Atrial Fibrillation characteristics
- Echocardiography using a two-dimensional echocardiography.
- 12-lead ECG
- Concomitant diseases, adverse signs or symptoms (able to be used for treatment emergent AE determination)
- Concomitant treatments (authorised, disallowed)
- Global physical examination/bodyweight
- Vital signs
- Biology: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Biology assessment of renal function: creatinine or estimated glomerular filtration rate

If the results of the above assessments are compatible with the selection criteria
• A 24-hour continuous ECG ambulatory recording (Holter ECG) device will be installed on the patient to monitor the patient heart rhythm. The patient will be requested to bring back the device after the termination of 24 hours recording. The recording will be transmitted from the Investigational site to the Central Reading Laboratory (CRL). The CRL will send his/her assessment regarding the confirmation of persistent atrial fibrillation within 2 working days to the Investigator.

• The patient will enter the selection period in which anticoagulant (anti-vitamin K) will be adjusted to achieve an International Normalized Ratio (INR) of 2 to 3 before electrical cardioversion.

At the end of the visit, the Investigator will contact the IVRS/IWRS system to confirm the patient selection and order the treatment delivery and organise the appointment for the next visit.

The patient will receive from the investigational centre the study card to be kept for the duration of the study.
Visit 2 - Inclusion Visit (Day 1)

If the patient's behaviour during the selection period and/or the result of complementary examinations particularly the confirmation of the presence of persistent atrial fibrillation by the CRL during this period, the INR and laboratory tests, are compatible with the inclusion criteria, the patient will be assessed for the following:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: red blood cell concentrations of DHA and coagulation parameters Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Global Physical examination/bodyweight
- Vital signs
- Echocardiography using a two-dimensional echocardiography.
- 12-lead ECG
- Urine pregnancy test for women of child bearing potential.

If the results of the above assessments are compatible with the inclusion criteria, the patient will be included and allocated a treatment number using the IVRS/IWRS system.

Between this Inclusion visit and the next visit (V3), the INR will be closely monitored (refer to paragraph 8.3.6), in order to ensure that the INR is stable, between 2 to 3 before electrical cardioversion.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week period.

Visit 3 (Week 4: D28 -2/+7 days) cardioversion

Patient will be assessed for the following criteria:
• Adverse events

• Concomitant treatments (authorised, disallowed)

• Laboratory examination: Red Blood Cell concentrations of DHA, Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)

• Global Physical examination /bodyweight

• Vital signs

• 12-lead ECG

• Electrocardioversion (ECV): ECV has to be scheduled 4 weeks after randomization and after target international normalized ratio levels will be stabilized (between 2 and 3) on at least 3 consecutive weekly tests in patients with AF. Patients not stabilized for INR (i.e. values between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed in the same day (before ECV). ECV will be performed in the morning, with the patient in the fasting state and without dyskalemia. Anesthesia will be induced and patients will be cardioverted with administration of a synchronized, biphasic current. The initial shock will be set at 100 J if the body weight is less than 70 kg and at 150 J for higher body weights. Successful cardioversion will be defined as recovery of sinus rhythm lasting at least 1 minute after the shock. If unsuccessful, a second 200-J shock, and eventually a third 200-J shock, will be administered. Failure of ECV is defined as the persistence of AF after the third attempt at cardioversion. After the procedure, patients will be monitored on telemetry for at least 6 hours before discharge. Patients who will not revert to sinus rhythm or with early relapse within the observation period after ECV will be withdrawn from the study and will be considered to have finished their follow-up.

At the end of the visit, a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) will be installed on the patient in order to monitor the patient heart rhythm after ECV.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week period.
Visit 4 (Week 5: D35 ± 2 days)

After removal of the continuous ECG ambulatory device, the patient will be assessed for the following criteria:

- Assessment of Adverse Events
- Concomitant treatments (authorised, disallowed)
- Vitals Signs
- Echocardiography using a two-dimensional echocardiography

At the end of the visit, the patient will be given the TTEM device (Trans Telephonic ECG Monitoring) for cardiac monitoring. The patient will be clearly instructed on the frequency and modalities of transmission. The patient will be requested to perform daily transmission from week 6 to week 8, then every 2 days from week 9 to week 24. Moreover, in case of AF symptoms additional transmission may be performed.

Visit 5 (Week 8: D56 ± 7 days) – Visit 6 (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days) - Visit 8 (Week 20: D140 ± 7 days)

Patient will be assessed for the following criteria:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT). However, in case of discontinuation of anticoagulation after ECV, the monitoring of INR, aPTT and TCT should be stopped.
- Global Physical examination/bodyweight
- Vital signs
- 12-lead ECG
The cardiac monitoring will be continued using a TTEM device (Trans Telephonic ECG Monitoring). The device will be given to the patient who will be requested to perform daily transmission from week 6 to week 8, then every 2 days from week 9 to week 24. Moreover, in case of AF symptoms additional transmission may be performed.

The Investigator will collect all the cases, blisters and any unused soft capsules and count the unused capsules for each 4-week treatment period.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week treatment period.

In addition:

- at visit 5, the investigator will contact the IVRS/IWRS to obtain another treatment unit to be dispensed at visit 6 for the last 12-week period.

- at visit 6, an echocardiography will be performed and, the red blood cell concentration of DHA will be measured.

**End-of-Study Visit - Visit 9 (Week 24: D168 ± 7 days)**

Patient will be assessed for the following:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Global Physical examination/bodyweight
- Vital signs
- 12-lead ECG
- Laboratory examination: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT). Red blood cell concentration of DHA.
- Urine pregnancy test for women of childbearing potential
• Echocardiography using a two-dimensional echocardiography

The Investigator will collect all the cases, blisters and any unused soft capsules and count the unused soft capsules.

10. ADVERSE EVENTS: DEFINITION AND REPORTING

10.1. ADVERSE EVENTS

10.1.1. Definition of Adverse Events

An adverse event is any adverse change from the patient's baseline condition, i.e. any subjective signs and symptoms or change in a concomitant disease present at the Selection Visit considered or not related to the treatment.

This includes intercurrent signs, symptoms, illnesses and significant deviations from baseline for vital signs and laboratory values, which may occur during the course of the clinical study.

All laboratory tests for which abnormal results are collected after study treatment initiation should be repeated until the values return to normal or to a stable status. Abnormal results are defined as those falling out of the laboratory normal ranges and that are clinically significant. The frequency of such checks should be defined by the Investigator according to the degree of abnormality.

In all cases, the aetiology should, as much as possible, be identified and Pierre Fabre Médicament notified.

10.1.2. Grading of Adverse Events

Adverse or intercurrent events are graded as follows:

• Mild: awareness of signs or symptoms, but easily tolerated
• Moderate: uncomfortable enough to cause interference with usual activity
• Severe: incapacity with inability to work or do usual activity.
10.1.3. Reporting of Adverse Events

The records of adverse events in the electronic Case Report Form (e-CRF) describe the nature (diagnosis, signs and symptoms), severity, onset date, stop date, outcome and actions taken, and relationship to study treatment (in the Investigator's opinion). It must be specified whether the event is serious or not.

10.2. SERIOUS ADVERSE EVENTS (SAE)

10.2.1. Definition

A serious adverse event (SAE) includes, but is not necessarily restricted to any event which:

- Results in death (whatever may be the cause)
- Is life-threatening
- Results in persistent or significant disability/incapacity
- Requires the patient's hospitalisation or prolongation of current hospitalisation *
- Is a congenital anomaly or birth defect.

Other events such as cancer, and any additional adverse experience or abnormal laboratory values occurring during the study period, defined by the protocol as serious or which the Investigator considers significant enough, or that suggest a significant hazard, contra-indications, side effect or precaution, must be handled as serious adverse events.

Any overdosage meeting a seriousness criteria should be reported as a SAE (see section 10.3).

Any pregnancy occurring during/after exposure to the study drug(s) should be reported on the SAE notification form (see section 10.4).

* any hospitalisation, or prolongation of hospitalisation due to the circumstances listed below:
  - planned (as per protocol) medical/surgical procedure,
  - preparation for routine health assessment/procedure (e.g. routine colonoscopy),
  - planned medical/surgical admission (planned prior to entry into study trial, appropriate documentation required),
  - administrative or social reasons (e.g. lack of housing, economic inadequacy, care-giver respite, family circumstances)
10.2.2. Reporting of SAE

All serious adverse events, according to the above-mentioned definitions and regardless of treatment or relationship to study drug, must be recorded by the Investigator as soon as he/she is informed of the event.

The Investigator must notify the Sponsor of this event by sending, within 24 hours, the "Notification of serious adverse event" form ("first notification") (see appendix 17.2) with all the available information about the event, to the Sponsor's representative:

Marlène GUIRAUD, Pharm D
INSTITUT DE RECHERCHE PIERRE FABRE,
Centre de R&D Pierre Fabre – BP 13562
3 Avenue Hubert Curien
31035 TOULOUSE Cedex 1
Phone: +33 5 35 50 63 48
Fax: + 33 5 34 50 65 92
Email: marlene.guiraud@pierre-fabre.com

In case of non-inclusion the reporting period ends when the non-inclusion is documented.

10.2.3. Follow-up of SAE

The Investigator must draw-up a specific clinical report and use the "Notification of serious adverse event" form ("follow-up") (see appendix 17.2) and collect the results of the carried out examinations and the reports of hospitalisation.

The serious adverse events must be followed up until resolution or stabilisation.

10.2.4. SAE Occurring After the Study

Any SAE occurring during 30 days following the end of the study for the patient should be notified to the Sponsor.

Must also be notified to the Sponsor any event occurring at any time after the end of the study for the patient which may be related to the study treatment in the Investigator's opinion.
10.3. REPORTING OF OVERDOSAGE TO THE SPONSOR

For the purpose of this trial an overdosage will be defined as any dose exceeding the planned prescribed dose of the study drug or the administration of any dose of an associated product that is considered both excessive and medically important.

In the absence of seriousness criteria, the overdosage, and associated adverse event if any, are reported only on the Adverse Event page of the CRF. **If the definition of seriousness criteria is met**, the SAE notification form must be also transmitted to the sponsor.

10.4. REPORTING OF PREGNANCY TO THE SPONSOR

Pregnancies discovered in the period in between the informed consent form signed but before any study drug exposure are not to be reported to the sponsor unless associated to a seriousness criteria (e.g. serious adverse event study-protocol related procedure). If pregnancy is confirmed, the women must not be administered the study drug and be withdrawn immediately from the study.

If pregnancy is suspected while the patient is receiving study treatment, the study drug(s) should be discontinued immediately until the result of the pregnancy testing is known. If pregnancy is confirmed, then the study treatment is permanently discontinued in an appropriate manner and the patient is discontinued from the study.

The investigators must report to the sponsor any pregnancy which occurs during or after the patient has been exposed to the study drug and until 30 days after the last study drug administration. The investigator must immediately notify the sponsor using the SAE notification form and also report the pregnancy on the AE page of the e-CRF.

Women who become pregnant after exposure to the study drug must be followed by the investigator until the completion/termination of the pregnancy. If the pregnancy goes to term, the outcome will have to be reported to the sponsor (baby's healthy status).
10.5. SPONSOR'S RESPONSIBILITIES FOR SAFETY REPORTING PURPOSES

Sponsor will submit expedited and periodic reports to both Competent Authorities and Ethics Committees per corporate standard operating procedures as regards to the EU directive 2001/20/EC taking into account local specific requirements.

11. DATA COLLECTION AND STUDY MONITORING

11.1. DATA COLLECTION

11.1.1. Case Report Form

An electronic Case Report Forms (e-CRF) will be used to record all patient data required by the protocol except the central ECG (Holter ECG, TTEM) and DHA data which will be transferred from vendors to the subcontractor as electronic data files and which will be loaded into the study database.

The e-CRF should be fully validated, compliant with ICH-GCP requirements and European regulations and include a traceability system for data corrections and deletions (audit trail).

Prior to the start of the study, the Investigator will complete a "Delegation of significant study-related duties" form. The signature and initials of all personal in charge of e-CRF completion should be recorded on this form. Each person involved in e-CRF completion, review, correction and / or validation will be trained and will have an individual login and access code to the e-CRF.

Training sessions will be held by the subcontractor for all participants who will use this tool. An e-CRF user manual will be available for investigators and CRAs.

All the information included into the e-CRF will be recorded from source documents onto the e-CRF by an authorised person.

The Investigator is responsible for the management and accuracy of the information on the e-CRF. At each monitoring visit, the e-CRF(s) should be at the CRA's disposition for review and validation.
At the end of the study, a CD-ROM containing the pdf version of all e-CRF (including audit-trail) will be sent by the subcontractor to the Sponsor and to the investigational sites for archiving. The subcontractor must store all study data for at least 15 years after the end of the study and ensure their legibility and accessibility during all the storage period.

11.1.2. Source Documents

A source document is an original record or certified copy of an original record of clinical findings, observations or any other medical or paramedical activities performed during the clinical trial, necessary for the transcription and the verification of the collected data.

Source documents along with all other trial-related documents (copies of all "informed consent" forms, e-CRFs CD-ROM, drug inventories and any correspondence related to the study) must be kept in the investigator's file throughout the study, and then, must be stored in the study centre's archives for a period of at least 15 years or as per local legal requirements, whatever is the longest.

For further details see section 15.2.

11.2. STUDY MONITORING

11.2.1. Monitoring visits

On-site visits will be carried out by a representative of the Sponsor's staff (Study Manager or CRA) prior to study initiation and at regular intervals (every 4 to 6 weeks) throughout the study. Additional visits and communication by telephone fax or meeting may be performed if necessary. Any site visit performed by the Sponsor's representatives will be recorded in the Investigator's study file.

11.2.1.1. Site Preselection Visit

Before selecting a centre for the study, a visit will be carried out by the CRA and/or the Study Manager to ensure that the Investigator has the necessary capacities (availability, patient's recruitment, environment), technical means and staff to carry out the study.
11.2.1.2. **Initiation Visit**

Before the start of the study at all investigation sites, an initiation visit will be carried out by the CRA to check at the latest that:

- The Investigator:
  - has received the technical protocol, administrative and financial agreement signed by all parties
  - has received the written statement of the Ethics Committee approval and the list of its members and their functions
- The original dated and signed *curriculum vitae* of the investigator(s) has been collected
- Laboratory normal ranges have been collected
- All study materials are available on the study site
- All participants agree with the monitoring procedures and know the study procedures
- All participants are aware of a possible audit or inspection

The CRA has also to provide training on the study protocol requirements and study specific procedures.

11.2.1.3. **Follow-up Visits**

Throughout the study, regular follow-up visits will be carried out by the CRA to check compliance with GCP, patient’s informed consents, strict application of the protocol, conformity of the data entered on the e-CRF with the source documents and ensure its correct completion, adverse events reporting, proper retention, storage and management of the study medication, as well as the source and other trial-related documents.

11.2.1.4. **Closing Visit**

At the end of the study, a final visit will be carried out by the CRA to:

- Verify that the e-CRFs CD-ROM with pdf files are correctly stored
• Control the accountability of intact and used treatment units and return them to the Clinical Pharmacy Department of the IRPF for destruction

• Obtain the last data clarifications and/or solutions if any

• Collect the patient's consent forms in sealed envelopes,

• Make an on-site review of all study documentation and complete it if necessary

• And finally, remind the Investigator of his regulatory obligations, study document archiving process and duration.

11.2.2. Direct Access to Source Documents

In accordance to the requirements of the GCP, all Sponsor representatives (Study Manager, CRA and Auditors) have to be given a direct access to all source and study data to perform quality monitoring/audit, thus ensuring accuracy and completeness of data).

Investigators are reminded that all Sponsor representatives keep professional confidentiality with regards to the patient data.

11.3. INDEPENDENT DATA MONITORING COMMITTEE

An Independent Data Monitoring Committee (IDMC) will be established to assess at intervals the progress of the clinical trial, the compliance with the inclusion criteria, the quality of follow up, the quality of measures of primary end point, the safety data and to recommend to the Sponsor whether to continue, modify, or to stop the study.

The IDMC operating procedures will be described in an independent document.

12. DATA MANAGEMENT

All clinical data related to the study will be collected and saved in a computerised database by the Data Management Department of the subcontractor and under the supervision of the Data Manager of Pierre Fabre Biometry (PFB) according to the following procedures.
12.1. **DATA ENTRY**

All required data will be collected by the Investigator or authorised designee (duly identified into the delegation task list) on a e-CRF.

The e-CRF used for this study will be developed and maintained by the Data Management Department of the subcontractor and approved by the Sponsor.

Electronic data (Holter ECG, TTEM and DHA) will be transferred by the 3rd party vendor according to the specifications given by the Data Manager of the subcontractor. These data will be captured and handled in accordance with the European GCP ICH E6 guideline.

12.2. **DATA CLEANING**

The subcontractor will define in the Data Validation Plan for reviewing and querying data, descriptions of both manual and electronic edit checks. Upon Sponsor approval, the subcontractor will program the checks.

The subcontractor will review the data over the course of the study, working with the Sponsor to identify data inconsistencies. The Investigator will be asked to resolve queries by making changes directly into the e-CRF.

12.3. **DATA CODING**

Adverse events, concomitant diseases, medical/surgical histories will be coded by the subcontractor using the MedDRA dictionary (latest version in use).

Concomitant medication will be coded by the subcontractor using the WHO-DRUG dictionary (latest version in use).

The Sponsor Clinical Development Physician will validate coding.

12.4. **DATA STORAGE**

The computer data files, as well as their modifications, will be archived by the subcontractor and kept available upon request of the Sponsor.
12.5. DATABASE LOCK

The validated database will be locked by the subcontractor upon request of the Data Manager of PFB following the completion of all steps required, i.e.: data entry and check of all data, resolution of all queries, validation of the coding, Clinical and Products Safety databases reconciliation and validation committee.

Then, the subcontractor will transfer the locked database in SAS format to the Data Manager of PFB who assume storage on the PFB secured server.

13. STATISTICAL ANALYSIS

After the database lock and the randomisation code release, the statistical analysis will be performed by Pierre Fabre Biométrie (PFB) or under the supervision of the statistician of PFB using SAS® software, according to the Statistical Analysis Plan (SAP) approved by the Validation Committee.

13.1. GENERAL CONSIDERATIONS

The main objective of the study is to assess the efficacy of F373280 versus placebo on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure.

Only the primary analysis of the primary efficacy criterion, on which is based the sample size justification, may lead to a causal interpretation. All other statistical results are to be regarded within a descriptive perspective.

The statistical significance level of the various two sided tests of all analyses will be 5 %.

13.2. SAMPLE SIZE

Assuming an AF recurrence rate of 85% under placebo and 65% under active group, i.e. a clinically relevant difference $\Delta$ of 20%, a sample size of 64 evaluable patients per group is required to achieve, using a log-rang test of survival curves with a 80 % power and a 5 % two-sided significance level.
According to the previous assumptions and assuming a rate of not assessable patients of 15%, a minimum of 76 patients will have to be randomised per group.

13.3. PROTOCOL DEVIATIONS

Prior to the database lock and the randomisation code release, the Validation Committee members will review the protocol deviations and will classify them as either minor or major. A protocol deviation will be considered major when it is likely to bias significantly the treatment effect estimate based on the primary efficacy criterion.

Patients with major deviation(s) will be excluded from the Per Protocol data set (see section 13.4).

A listing of all protocol deviations will be provided for all randomised patients, including the type (major/minor) of protocol deviations according to the decisions made by the members of the Validation Committee.

The number and percentage of patients with major protocol deviations will be tabulated by treatment group and type of major protocol deviations on the Full Analysis Set defined in section 13.4.

13.4. DATA SETS ANALYSED

The following 2 data sets will be analysed (as defined by the Validation Committee):

- The Safety Set composed of all randomised patients having received at least one dose of the study treatment. This data set will be used to perform analyses of Safety.
- The Full Analysis Set (FAS) composed of all randomised patients having received at least one dose of the study treatment and with a successful cardioversion observed at visit 3. This data set will be used to perform analyses of Efficacy.
- The Per Protocol Set (PP) which is the subset of the Full Analysis Set composed of all patients with a primary efficacy criteria available and without any major protocol deviation or other source of bias for primary criteria analyses.
13.5. HANDLING OF DROPOUTS AND MISSING DATA

13.5.1. Dropouts

The number of patients who withdraw from the study after their randomisation will be provided by treatment group for all treated patients (Safety Set). All withdrawn patients will be further described regarding their time to dropout and reasons for withdrawal.

13.5.2. Repositioning of Visits

No repositioning of visits will be done.

13.5.3. Missing Data

Missing values will not be substituted by estimated values, but considered as missing in statistical analysis.

13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS

Before the first trial drug intake, patient's background, medical and surgical history, demographic data and disease characteristics will be described by treatment group on the Safety Set.

- **Quantitative parameters** will be described by treatment group and overall using the following: number of patients, number of missing data, mean, standard deviation, minimum, median and maximum values.

- **Qualitative parameters** will be described by treatment group and overall using frequencies.

Concomitant diseases, as well as medical and surgical histories will be tabulated descriptively by treatment group and overall using the MedDRA codes of System Organ Classes and preferred terms.

If more than 10% of patients are excluded from the FAS and PP set, the description of patients by treatment group at selection and inclusion will be repeated on the FAS and PP set for all parameters.

No statistical test of comparability of treatment groups at baseline will be performed.
13.7. **Efficacy Analysis**

13.7.1. **Primary Criterion**

13.7.1.1. **Primary Analysis**

The primary criteria, time to first recurrence, will be analysed using the Kaplan Meier method and compared with the Log rank test. Hazard ratios and 95% confidence intervals will be estimated with the Cox regression model.

The primary analysis will be performed on the FAS.

13.7.1.2. **Supportive Analysis**

The primary analysis will be repeated on the PP set.

13.7.2. **Secondary Criteria**

All secondary analyses will be performed on the FAS. If more than 10% of patients are excluded from the PP set, the secondary analyses will be repeated on the PP set.

13.7.2.1. **Numbers of Atrial Fibrillation Episodes**

Both the numbers of AF episodes (symptomatic or not) lasting for at least 10 minutes and with duration less than 10 minutes ($N_{\text{Sup10}}$ and $N_{\text{Inf10}}$) will be described by treatment group and compared by the chi-square test (or CMH test adjusted for centre) or Fisher’s exact Test.

13.7.2.2. **Duration of Atrial Fibrillation Episodes**

The duration of all AF Episodes will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centres effects) or Wilcoxon test.

13.7.2.3. **Time to first AF recurrence less than 10 minutes or symptomatic**

The time to the first AF recurrence less than 10 minutes and the time to the first symptomatic AF recurrence will be analysed as the primary analysis.
13.7.2.4. **Clinical parameters evaluation**

The EHRA score will be described by treatment group and analysed using a chi-squared test (or CMH test adjusted for centre) or Fisher’s exact Test.

The frequency of presumed arrhythmia will be described by treatment group.

The number of recurrence of symptomatic AF, of hospitalizations (for cardiovascular events, for thromboembolic stroke and for all causes), of spontaneous cardioversion, of successful cardioversion (including number of shocks distribution) and the number of patients needing cardioversion after initial ECV will be described by treatment group and compared using a chi-square test or a Fisher Test (if the numbers are relevant).

The duration of hospitalizations for cardiovascular events, for thromboembolic stroke and for any cause will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centre effects) or Wilcoxon test.

The echocardiographic parameters values will be described at each time (V1, V2, V4, V6 and V9) and changes described from V4 to V9 and from V2 to V9.

13.7.2.5. **Biomarker analysis: red blood cell concentrations of DHA**

Values and changes from baseline for red blood cell concentration of DHA will be performed by treatment group and assessment time.

13.8. **SAFETY ANALYSIS**

The Safety Set will be used to perform all analyses of the safety criteria.

13.8.1. **Adverse Events**

Any adverse event having been reported during the study for a given patients will be classified by preferred term and corresponding system organ class using the MedDRA terminology.

Adverse events will be classified as:
• Treatment emergent adverse events, *i.e.*, any adverse event which occurs or worsens on study treatment during the randomised period.

• Or non treatment emergent adverse events, *i.e.*, any adverse event which occurs during the run-in period (before V2) or is reported as concomitant disease with the same intensity.

For each study period, any patient with at least one reported adverse event will be classified as a patient:

• With at least one adverse event
• With at least one treatment emergent adverse event
• With one TEAE
• With two TEAE
• With at least three TEAE
• With at least one related TEAE
• With an adverse event leading to the study treatment discontinuation (definitive or temporary)
• With an adverse event leading to withdrawal
• With at least one serious adverse event.

• Numbers and percentages of patient with at least one reported treatment emergent adverse event will be tabulated by treatment group:
  • By system organ class
  • By system organ class and preferred term
  • By system organ class and preferred term, taking into consideration its most severe intensity
  • And by system organ class and preferred term, taking into consideration the most severe relationship to the study treatment.
Recurring adverse events (i.e., adverse events classified with the same preferred term) for a given patient will only be counted once and only their most severe intensity or most severe relationship to the study treatment will be tabulated.

"The number and percentage of patient with at least one most common (reported in 1% patients in any group) drug related TE AE ("not excluded or unassessable") will be tabulated by Preferred Term and Treatment group in decreasing order for the treatment group (for all patient).

The number and percentage of patients with at least one reported most common treatment emergent adverse event will also be plotted by treatment group. This graphical representation will highlight the frequencies of the most severe intensities reported by system organ class and preferred term.

Serious adverse events will also be described on an individual basis: treatment group, patient's code, sex and age, Investigator's reported term, preferred term, time of onset according to the time of the first study treatment administration, duration, action taken regarding the study treatment administration, use of a corrective treatment, outcome and relationship to the study treatment in the Investigator's opinion.

13.8.2. Clinical Laboratory Evaluation

For each laboratory parameter, data will be tabulated by treatment group and assessment time. The absolute changes post-trial drug administration - baseline (the baseline value being the value measured on the last blood sample collected before the first trial drug administration) will be calculated and tabulated by parameter, treatment group and post-trial drug administration assessment time. Results of retests performed post-trial drug administration will not be analysed and tabulated. They will only be displayed in individual data listings.

For all blood laboratory parameters, scatter plots highlighting individual results will display the baseline and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 24 value in the ordinate. Each treatment group will be identified differently. The first bisecting line (45° line), the lines of lower
and upper normal range, the lines of PSC range and CNALV range added on the plots (see Appendix 17.3).

For all blood laboratory parameters, shift tables will be provided to depict the numbers of patients with post-trial drug administration variations at each assessment time as compared to the baseline values (measured on the last blood sample collected before the first trial drug administration) by treatment group. A 3-point scale (low, normal, high) will be used as defined by the normal ranges in use in the laboratory in charge of the assays.

Clinically noteworthy abnormal laboratory values (CNALV) (see in Appendix 17.3) will be identified and described on an individual basis. If relevant, five separate individual data listings by treatment group will be provided:

- CNALV for haemoglobin (including corresponding individual results of erythrocytes and haematocrit)
- CNALV for neutrophils or leucocytes (including corresponding individual results of basophils, eosinophils, lymphocytes and monocytes)
- CNALV for platelets (including corresponding individual results of erythrocytes and leucocytes)
- CNALV for liver function parameters (including corresponding individual results of gamma-GT)
- CNALV for serum creatinine

13.8.3. Global Physical Examination

Recorded data of the global physical examination performed will not be tabulated as any abnormal findings post-randomisation should be reported as AEs (if clinically significant).

Physical examination assessments will be provided in the listings of individual data.
13.8.4. Vital Signs, Physical Findings and Other Observations Related to Safety

13.8.4.1. Vital Sign Measurements Over Time

For each parameter (systolic blood pressure, diastolic blood pressure and heart rate in supine and standing positions), descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.

13.8.4.2. Body weight

Descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.

13.8.4.3. Individual Patient Changes

The number and percentage of patient with at least one Predefined Potentially Clinically Significant Change (PSC) and with at least one PSC Leading to Clinically Significant Value (PSCV) will be tabulated by treatment group (see Table 1 in Appendix 17.3).

According to the pharmacological drug profile mentioned previously in this Protocol, the changes from baseline to the maximum and/or minimum post-baseline value could be categorized and tabulated by treatment group with frequencies and decreasing cumulative percentages.

If there is a signal of a drug effect toward one direction rather than the other, additionally shift tables of variations from baseline to the maximum or minimum post-baseline value could be also provided (see Table 2 to 4 in Appendix 17.3).

An individual data listing of patients with symptomatic or asymptomatic orthostatic hypotension will be provided by treatment group (see Table 5 in Appendix 17.3).

13.8.5. ECG

Frequencies on the clinical interpretation (normal, abnormal CS or NCS) will be presented by treatment group and assessment time. Individual tabulated data for ECG abnormalities will be also displayed.
13.8.6. **Coagulation parameters**

Scatter plots highlighting individual results for coagulation parameters (prothrombin time/INR, activated partial thromboplastin time and thrombin clotting time) before and after study treatment administration will be produced.

13.9. **CONCOMITANT TREATMENTS**

Concomitant treatments will be tabulated by treatment group within a descriptive perspective. They will be classified by therapeutic area according to the WHO-DRUG dictionary using the "anatomical therapeutic chemical" (ATC) classification on the safety set.

13.10. **COMPLIANCE**

The percentage of compliance will be described by treatment group using the quantity

\[
Compliance(%) = \frac{Estimated\ actual\ consumption}{Theoretical\ consumption} \times 100
\]

with: \( Estimated\ actual\ consumption = number\ of\ tablets\ provided\ at\ the\ start\ of\ study\ (Visit 2) - number\ of\ tablets\ returned\ at\ the\ end\ of\ study\ (Visit 9) \)

\( Theoretical\ consumption = number\ of\ days\ of\ treatment\ intake\ planned\ between\ the\ start\ and\ the\ end\ of\ study\ (168\ days\ ±\ 7\ days). \)

13.11. **INTERIM ANALYSIS AND DATA MONITORING**

No interim analysis is planned.
14. GENERAL ETHICAL CONSIDERATIONS

14.1. ETHICAL CONDITIONS

This study is performed in accordance with the principles stated in the Declaration of Helsinki (1964) and subsequent amendments and in accordance with the Good Clinical Practice Guideline (CPMP/ICH/135/95).

14.2. ETHICS COMMITTEE AND LEGAL REQUIREMENTS

All the documents required by National Regulations and any other informative documents that may be requested are submitted for review to an Ethics Committee whose procedures and operations meet the GCP and National Legal Requirements.

Depending on National Regulations, the application is submitted to the Ethics Committee by the Sponsor (or representative) or by the Investigator.

A copy of the formal written approval from the Ethics Committee is provided to the Sponsor (directly by the Ethics Committee or via the Investigator) with a list of names and qualifications of its members.

The request for authorisation by the Competent Authority or its notification if required (depending on National Regulations) is carried out by the Sponsor.

The screening of patients does not start before the approval of the Ethics Committee has been obtained and the study authorised by the Competent Authority or notified to the Competent Authority (depending on National Regulations).

14.3. PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM

An information must be given to the patients before their decision to participate or abstain from participation.
This information is based on the elements set out in the Declaration of Helsinki and the ICH GCP Guidelines. It must also describe the measures taken to safeguard patient’s privacy and protection of personal data, according to European Directive 95/46 EC or other local regulation.

Restraints and risks must be explained, as well as the right to discontinue participation in the study at any stage, without affecting their further relationship with the Investigator and/or their future care.

The written information and consent form must be submitted to the patient with an oral explanation. It must be agreed and signed by the patient before any study-related procedure starts.

This information and consent procedure is under the Investigator’s responsibility.

The information and consent document are made in triplicate: the original copy is kept by the Investigator, one copy is given to the patient and the last copy is kept by the Clinical Quality Assurance Unit of the Sponsor in a sealed envelope at the end of study.

Specific areas of the Sponsor’s copy are not triplicated to avoid the reading of the patient’s surname (except the first 3 letters), first name, address and signature.

If any information becomes available during the trial that may be relevant to the patient’s willingness to keep on participating in the trial, an updated written informed consent must be submitted to the patient to confirm agreement to continue participating.

14.4. **PERSONAL DATA PROTECTION**

All information from this study (excluding data from the informed consent) is entered into a computer under the Sponsor’s responsibility in accordance with the French law, "Loi Informatique et Libertés" (January 6, 1978, and subsequent amendments) and with the European Directive 95/46/CE.

14.5. **INSURANCE POLICY**

In accordance with the provisions of the law and the GCP, the Sponsor Pierre Fabre Médicament, has an insurance policy intended to guarantee against possible damage resulting from the research.
The studies and/or experiments performed on behalf of the Sponsor Pierre Fabre Médicament, are specifically and expressly guaranteed.

It is advisable to underline that non compliance with the Research Legal Conditions is a cause for guarantee exclusion.

15. ADMINISTRATIVE PROCEDURES

15.1. PROTOCOL AMENDMENT

Neither the Investigator nor the Sponsor may alter the protocol without the authorisation of the other party.

All changes to the protocol are subject to an amendment which must be dated and signed by both parties and must appear as an amendment to the protocol.

Substantial amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities

Urgent amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities, but could be implemented immediately under specific conditions defined with the Sponsor.

15.2. SOURCE DOCUMENTS, INVESTIGATOR'S FILE STORAGE

The Investigator:

- Keeps all trial-related documents in appropriate file folders. Records of patient, original informed consent forms, source documents, a CD Rom containing a pdf copy of e-CRF, drug inventory, Ethics Committees and Sponsor correspondence pertaining to the study must be kept on file.

- Retains all documents relating to the screening (consent and investigation results) of all patients included in the trial or not
• Retains a list of the patient’s names, addresses (and/or number of medical file), code numbers to allow checking of data reported on e-CRFs with those from source documents

• Authorises direct access to source documents for monitoring, audits and inspections

• The trial-related documents must be retained as strictly confidential at the Investigator’s site for at least 15 years or according to local requirements, whatever is the longest after the completion or discontinuation of the trial (European Directive 2003/63/EC).

15.3. END OF THE STUDY

15.3.1. Definition of the End of Study

The end of study is the last visit of the last patient undergoing the trial.

Any change to this definition during the study, for whatever reason, must be notified as a substantial amendment.

15.3.2. Early Study Termination

15.3.2.1. Early Study Termination Decided by the Sponsor

The Sponsor may discontinue the study at any time for any of the following reasons:

• Lack of recruitment

• Deviations from good clinical practice and/or regulations

• Poor product safety

• New information that could jeopardise the patient’s safety

• Stopping of the development …

15.3.2.2. Early Study Termination Decided by the Competent Authorities

The Competent Authorities may suspend or prohibit a study if it considers that the conditions of authorisation are not being met or has doubt about the safety or scientific validity of the study.
15.4. AUDIT

The Sponsor is responsible for making sure that both his representatives (Study Manager, CRA, ...) and the Investigator fulfil the requirements as specified by the GCP Guideline.

An audit can be organised internally at Pierre Fabre Médicament and at the investigational site where the e-CRFs are matched against source documents.

All study documentation must be directly accessible to auditors.

The practical conditions for the audit are discussed between the Investigator and the Clinical Quality Assurance Department.

Oral information about the audit results are given to the Investigator.

15.5. INSPECTION

The Health Authorities may inspect any investigation site or the Sponsor in the course of the study or after its completion, to verify the conduct of the study and quality of the data. The Investigator must provide to the inspectors direct access to study documents.

15.6. CONFIDENTIALITY

The present materials (protocol and related documentation, e-CRF, Investigator's Brochure) contain confidential information.

Except if agreed to in writing with the Study Manager, the investigators must hold such information confidential, and must not disclose it to others (except where required by Applicable Law).

15.7. CLINICAL STUDY REPORT

Data analysis, and clinical study report writing are under the Sponsor’s responsibility.

Upon completion of the data analysis, a final report, including a review of the objectives and methods, a presentation and discussion of the results are drawn up according to ICH Guidelines (Structure and Content of Clinical Study Reports, ICH-E3, CPMP/ICH/137/95).
The report is a clinical and statistical integrated report. It must be signed by the Sponsor's representative(s) and the Coordinating Investigator.

15.8. STUDY RESULTS COMMUNICATION

Upon completion of the study, the global results of the Research are communicated to the investigator. According to the Local Regulation, the patient can ask the Investigator for the results.

15.9. STUDY RESULTS PUBLICATION

The information and data collected during the conduct of this clinical study are considered confidential and are used by the Sponsor in connection with the development of the study drug. This information may be disclosed if deemed necessary by the Sponsor.

To allow use of the information derived from this clinical study and to insure compliance with Current Regulations, the Investigator must provide the Sponsor with complete test results and all data collected during the study.

Only the Sponsor may make study information available to physicians and to Regulatory Agencies, except as required by Current Regulations.

All the results of this study including data, reports, discoveries and inventions resulting from the study, are the property of the Sponsor.

In the event the Sponsor chooses to publish study data, the manuscript must be provided to the author(s) at least 30 days prior to the expected date of submission to the intended publisher.

The investigator(s) can reserve the right to publish or present study data; if so, the manuscript or abstract must be provided to the Sponsor for review at least 30 days prior to the expected date of submission to the intended publisher or of planned presentation.

In addition, if necessary, (the) investigator(s) shall withhold publication for an additional 60 days, to allow the filing of a patent application, or to allow the Sponsor to take any measures he deems appropriate to establish and preserve his proprietary rights.
It is agreed that publication of study results by each site shall be made only as part of a publication of the study results obtained by all sites performing the protocol, once the study is completed and finalised.

The authors list is agreed by all investigators prior to publication. The names of the authors are provided according to their participation in the design of the protocol as well as their recruitment of eligible and analysable patients.
16. REFERENCES

[1] F373280 INVESTIGATOR'S BROCHURE, version October 2012

n-3 Polyunsaturated Fatty Acids in the prevention of atrial Fibrillation Recurrences after electrical cardioversion. A prospective, Randomised study
_Circulation, 2011; 124:1100-1106_

Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy
_J. Am. Coll. Cardiol. 2011;57;870-879_

Dose-dependant effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of non ischemic origin: A double-blind, placebo-controlled, 3-arm study
_American Heart Journal 2011; 161:915.e1-915.e9 - volume 161, number 5_

[5] GISSI-HF INVESTIGATORS
Effects of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GSSI-HF Trial): a randomised, double-blind, placebo-controlled trial
_The lancet on line - August 2008_

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
_European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Eur Heart J. 2010 Oct;31(19):2369-429_

[7] KOWEY PR, REIFFEL JA, ELLENBOGEN KA, NACCARELLI GV, PRATT CM.
Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomised controlled trial.
_JAMA. 2010;304:2363–2372._
N-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomised, double-blind, multicentre study
_Europace (2011) 13, 174-181_

[9] **OMACOR**® SUMMARY PRODUCT CHARACTERISTICS (SPC) dated 17/02/2012

[10] **BEPANTHENE**® SUMMARY PRODUCT CHARACTERISTICS (SPC)

Dronedarone for prevention of atrial fibrillation: a dose-ranging study.

[12] LE HEUZEY JY AND ALL.
A Short-Term, Randomised, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study.
_J Cardiovasc Electrophysiol._

Effects of fish-oil supplementation on myocardial fatty acids in humans.
_Am J Clin Nutr_ (2007); 85 : 1225.

Distribution, interconversion and dose response of n-3 fatty acids in humans.
_Am J Clin Nutr_ (2006);83 : 1469-1473S.

Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodelling of the atria?
_J. Am. Coll. Cardiol._ 1998;31;167-173

[16] SALM P, TAYLOR PJ, KOSTNER K
Simultaneous quantification of total eicosapentaenoic acid, docosahexaenoic acid and arachidonic acid in plasma by high-performance liquid chromatography-tandem mass spectrometry.
The consumption of food products from linseed-fed animals maintains erythrocyte omega-3 fatty acids in obese human

[18] HARRIS WS, VON SCHACKY C.
The Omega-3 Index: a new risk factor for death from coronary heart disease?

Effects of Polyunsaturated Fatty Acids n-3 (PUFA n-3) in the prophylaxis of atrial fibrillation relapses after external electric cardioversion
World Congress of Cardiology 2006, 2-6 September, Barcelona – Spain

Outcome parameters from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association.
Europace 2007, 9, 1006-1023

[21] EUROPEAN MEDICINES AGENCY
Addendum to the guideline on antiarrhythmics on atrial fibrillation and atrial flutter.
EMACHM/CHMA/EWP/213056/2010

Dietary fish oil dose- and time-response effects on cardiac phospholipid fatty acid composition.
Lipids. 2004;39:955–961

[23] ROBERTO M. LANG, MICHELLE BIERIG, RICHARD B. DEVEREUX, FRANK A. FLACHSKAMPF*, ELYSE FOSTER, PATRICIA A. PELLIKKA, MICHAEL H. PICARD, MARY J. ROMAN, JAMES SEWARD, JACK SHANEWISE, SCOTT SOLOMON, KIRK T. SPENCER, MARTIN ST. JOHN SUTTON, WILLIAM STEWART.
Recommendations for chamber quantification
17. APPENDICES
17.1. DECLARATION OF HELSINKI

WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI
ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING
HUMAN SUBJECTS


A. INTRODUCTION

1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of ethical principles for medical research involving human subjects, including research on identifiable human material and data. The Declaration is intended to be read as a whole and each of its constituent paragraphs should not be applied without consideration of all other relevant paragraphs.

2. Although the Declaration is addressed primarily to physicians, the WMA encourages other participants in medical research involving human subjects to adopt these principles.

3. It is the duty of the physician to promote and safeguard the health of patients, including those who are involved in medical research. The physician's knowledge and conscience are dedicated to the fulfilment of this duty.

4. The Declaration of Geneva of the WMA binds the physician with the words, “The health of my patient will be my first consideration,” and the International Code of Medical Ethics declares that, “A physician shall act in the patient's best interest when providing medical care.”

5. Medical progress is based on research that ultimately must include studies involving human subjects. Populations that are underrepresented in medical research should be provided appropriate access to participation in research.

6. In medical research involving human subjects, the well-being of the individual research subject must take precedence over all other interests.

7. The primary purpose of medical research involving human subjects is to understand the causes, development and effects of diseases and improve preventive, diagnostic and therapeutic interventions (methods, procedures and treatments). Even the best current interventions must be evaluated continually through research for their safety, effectiveness, efficiency, accessibility and quality.

8. In medical practice and in medical research, most interventions involve risks and burdens.

9. Medical research is subject to ethical standards that promote respect for all human subjects and protect their health and rights. Some research populations are particularly vulnerable and need special protection. These include those who cannot give or refuse consent for themselves and those who may be vulnerable to coercion or undue influence.

10. Physicians should consider the ethical, legal and regulatory norms and standards for research involving human subjects in their own countries as well as applicable international norms and standards. No national or international ethical, legal or regulatory requirement should reduce or eliminate any of the protections for research subjects set forth in this Declaration.
B. PRINCIPLES FOR ALL MEDICAL RESEARCH

11. It is the duty of physicians who participate in medical research to protect the life, health, dignity, integrity, right to self-determination, privacy, and confidentiality of personal information of research subjects.

12. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and adequate laboratory and, as appropriate, animal experimentation. The welfare of animals used for research must be respected.

13. Appropriate caution must be exercised in the conduct of medical research that may harm the environment.

14. The design and performance of each research study involving human subjects must be clearly described in a research protocol. The protocol should contain a statement of the ethical considerations involved and should indicate how the principles in this Declaration have been addressed. The protocol should include information regarding funding, sponsors, institutional affiliations, other potential conflicts of interest, incentives for subjects and provisions for treating and/or compensating subjects who are harmed as a consequence of participation in the research study. The protocol should describe arrangements for post-study access by study subjects to interventions identified as beneficial in the study or access to other appropriate care or benefits.

15. The research protocol must be submitted for consideration, comment, guidance and approval to a research ethics committee before the study begins. This committee must be independent of the researcher, the sponsor and any other undue influence. It must take into consideration the laws and regulations of the country or countries in which the research is to be performed as well as applicable international norms and standards but these must not be allowed to reduce or eliminate any of the protections for research subjects set forth in this Declaration. The committee must have the right to monitor ongoing studies. The researcher must provide monitoring information to the committee, especially information about any serious adverse events. No change to the protocol may be made without consideration and approval by the committee.

16. Medical research involving human subjects must be conducted only by individuals with the appropriate scientific training and qualifications. Research on patients or healthy volunteers requires the supervision of a competent and appropriately qualified physician or other health care professional. The responsibility for the protection of research subjects must always rest with the physician or other health care professional and never the research subjects, even though they have given consent.

17. Medical research involving a disadvantaged or vulnerable population or community is only justified if the research is responsive to the health needs and priorities of this population or community and if there is a reasonable likelihood that this population or community stands to benefit from the results of the research.

18. Every medical research study involving human subjects must be preceded by careful assessment of predictable risks and burdens to the individuals and communities involved in the research in comparison with foreseeable benefits to them and to other individuals or communities affected by the condition under investigation.

19. Every clinical trial must be registered in a publicly accessible database before recruitment of the first subject.
20. Physicians may not participate in a research study involving human subjects unless they are confident that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians must immediately stop a study when the risks are found to outweigh the potential benefits or when there is conclusive proof of positive and beneficial results.

21. Medical research involving human subjects may only be conducted if the importance of the objective outweighs the inherent risks and burdens to the research subjects.

22. Participation by competent individuals as subjects in medical research must be voluntary. Although it may be appropriate to consult family members or community leaders, no competent individual may be enrolled in a research study unless he or she freely agrees.

23. Every precaution must be taken to protect the privacy of research subjects and the confidentiality of their personal information and to minimize the impact of the study on their physical, mental and social integrity.

24. In medical research involving competent human subjects, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail, and any other relevant aspects of the study. The potential subject must be informed of the right to refuse to participate in the study or to withdraw consent to participate at any time without reprisal. Special attention should be given to the specific information needs of individual potential subjects as well as to the methods used to deliver the information. After ensuring that the potential subject has understood the information, the physician or another appropriately qualified individual must then seek the potential subject’s freely-given informed consent, preferably in writing. If the consent cannot be expressed in writing, the non-written consent must be formally documented and witnessed.

25. For medical research using identifiable human material or data, physicians must normally seek consent for the collection, analysis, storage and/or reuse. There may be situations where consent would be impossible or impractical to obtain for such research or would pose a threat to the validity of the research. In such situations the research may be done only after consideration and approval of a research ethics committee.

26. When seeking informed consent for participation in a research study the physician should be particularly cautious if the potential subject is in a dependent relationship with the physician or may consent under duress. In such situations the informed consent should be sought by an appropriately qualified individual who is completely independent of this relationship.

27. For a potential research subject who is incompetent, the physician must seek informed consent from the legally authorized representative. These individuals must not be included in a research study that has no likelihood of benefit for them unless it is intended to promote the health of the population represented by the potential subject, the research cannot instead be performed with competent persons, and the research entails only minimal risk and minimal burden.

28. When a potential research subject who is deemed incompetent is able to give assent to decisions about participation in research, the physician must seek that assent in addition to the consent of the legally authorized representative. The potential subject’s dissent should be respected.
29. Research involving subjects who are physically or mentally incapable of giving consent, for example, unconscious patients, may be done only if the physical or mental condition that prevents giving informed consent is a necessary characteristic of the research population. In such circumstances the physician should seek informed consent from the legally authorized representative. If no such representative is available and if the research cannot be delayed, the study may proceed without informed consent provided that the specific reasons for involving subjects with a condition that renders them unable to give informed consent have been stated in the research protocol and the study has been approved by a research ethics committee. Consent to remain in the research should be obtained as soon as possible from the subject or a legally authorized representative.

30. Authors, editors and publishers all have ethical obligations with regard to the publication of the results of research. Authors have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports. They should adhere to accepted guidelines for ethical reporting. Negative and inconclusive as well as positive results should be published or otherwise made publicly available. Sources of funding, institutional affiliations and conflicts of interest should be declared in the publication. Reports of research not in accordance with the principles of this Declaration should not be accepted for publication.

C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH MEDICAL CARE

31. The physician may combine medical research with medical care only to the extent that the research is justified by its potential preventive, diagnostic or therapeutic value and if the physician has good reason to believe that participation in the research study will not adversely affect the health of the patients who serve as research subjects.

32. The benefits, risks, burdens and effectiveness of a new intervention must be tested against those of the best current proven intervention, except in the following circumstances:
   - The use of placebo, or no treatment, is acceptable in studies where no current proven intervention exists; or
   - Where for compelling and scientifically sound methodological reasons the use of placebo is necessary to determine the efficacy or safety of an intervention and the patients who receive placebo or no treatment will not be subject to any risk of serious or irreversible harm. Extreme care must be taken to avoid abuse of this option.

33. At the conclusion of the study, patients entered into the study are entitled to be informed about the outcome of the study and to share any benefits that result from it, for example, access to interventions identified as beneficial in the study or to other appropriate care or benefits.

34. The physician must fully inform the patient which aspects of the care are related to the research. The refusal of a patient to participate in a study or the patient’s decision to withdraw from the study must never interfere with the patient-physician relationship.

35. In the treatment of a patient, where proven interventions do not exist or have been ineffective, the physician, after seeking expert advice, with informed consent from the patient or a legally authorized representative, may use an unproven intervention if in the physician's judgement it offers hope of saving life, re-establishing health or alleviating suffering. Where possible, this intervention should be made the object of research, designed to evaluate its safety and efficacy. In all cases, new information should be recorded and, where appropriate, made publicly available.
17.2. SAE REPORT FORM
NOTIFICATION OF SERIOUS ADVERSE EVENT (SAE) OR PREGNANCY TO PIERRE FABRE PRODUCT SAFETY DEPARTMENT

TO BE TRANSMITTED TO THE MONITOR BY FAX WITHIN 24H: M. GUIRAUD ............... Fax n° +33 5 34 50 65 92

Transmission date ___________ ___________ ___________ ___________ (dd/mm/yyyy) Country: ........................................

SAE N° _______ FIRST NOTIFICATION ☐ FOLLOW-UP ☐

▸ SUBJECT CHARACTERISTICS

<table>
<thead>
<tr>
<th>Surname</th>
<th>First name</th>
<th>Birth date</th>
<th>Gender 1=M, 2=F</th>
<th>Height cm</th>
<th>Weight kg</th>
</tr>
</thead>
</table>

▸ DESCRIPTION OF THE EVENT

The serious adverse event resulted in:
- ☐ Death (whatever may be the cause)
- ☐ Hospitalisation (*) or extension thereof
- ☐ Life threatening
- ☐ Invalidity or disability
- ☐ Congenital abnormality or abnormal pregnancy outcome
- ☐ Cancer
- ☐ Other (any other serious clinical or laboratory event according to the investigator or the protocol, overdosage meeting seriousness criteria, suicide attempts)
- ☐ Other fact to be notified:
  - ☐ Pregnancy exposure

Nature of the event (if clinical nature, indicate the diagnosis or the major symptom):

AE onset date | __ | __ | __ | __ | __ | __ | (dd/mm/yyyy)

Seriousness onset date | __ | __ | __ | __ | __ | __ | __ | __ | __ | __ | __ | __ | (dd/mm/yyyy)

Summary description (if clinical cause, significant history, progression of event, available laboratory results, etc...):

(*) Except hospitalisations with durations and goals planned in the protocol

▸ THE SAE IN RELATION TO THE TRIAL

| TREATMENT NUMBER | _______ _______ _______ _______ | _______ _______ _______ _______ _______ | _______ _______ _______ _______ _______ | _______ _______ _______ _______ _______ | _______ _______ _______ _______ _______ | _______ _______ _______ _______ _______ | _______ _______ _______ _______ _______ |

- ☐ Time of occurrence of SAE
  - ☐ During the selection or run-in period
  - ☐ During the administration phase of the study treatment
  - ☐ After the administration phase of the study treatment

- ☐ Date of first study treatment administration | _______ _______ _______ _______ _______ _______ | (dd/mm/yyyy)
- ☐ Date of last study treatment administration before the occurrence of SAE | _______ _______ _______ _______ _______ _______ _______ _______ | (dd/mm/yyyy)

- ☐ Was the blind broken? ☐ Yes ☐ No ☐ Not applicable
  - If yes, or if this is an open study, drug(s) administered:

  Conditions of administration (cycles(s), daily dose(s), route(s) of administration, etc..):

Final version 104/1185
SAE N° \[ \text{FIRST NOTIFICATION} \quad \text{FOLLOW-UP} \]

**CONCOMITANT MEDICATION SINCE TRIAL INITIATION and UP UNTIL THE OCCURRENCE OF THE SAE**
*(EXCEPT THE TREATMENTS GIVEN FOR THE SAE)*

<table>
<thead>
<tr>
<th>INN or trade name</th>
<th>Daily dose</th>
<th>Start date (ddmmyy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (ddmmyy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>□</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**MEASURES TAKEN FOLLOWING THE SAE**

- **Study treatment**
  - □ No change
  - □ Dosage modification, specify : ........................................... Modification Date : ___/___/____
  - □ Temporarily discontinued Readministration date : ___/___/____
  - □ Withdrawn End date : ___/___/____
  - □ Not applicable

- **The event led to :**
  - □ Prescription of corrective or symptomatic treatments (specify names and dosages) :
  - □ Discontinuation of concomitant treatments (specify names) :
  - □ Others, specify :

**OUTCOME**

- □ Not recovered/Not resolved
- □ Recovering/Resolving
- □ Recovered/Resolved
- □ Recovered/Resolved with sequelaes
- □ Fatal
- □ Unknown

In case of death, has an autopsy been conducted ? □ Yes □ No

**INVESTIGATOR CAUSALITY ASSESSMENT** *(investigator’s assessment to be done as soon as possible)*

- □ Not Suspected
- □ Suspected
- □ Insufficient data

comments : .............................................................................................................................................................

Enclose in the notification the results of carried out examinations, reports of hospitalisation, etc...
17.3. **PREDEFINED LIMITS OF LABORATORY AND VITAL SIGN POTENTIALLY CLINICALLY SIGNIFICANT CHANGES AND VALUES**

List of Predefined Potentially Clinically Significant Change For Laboratory Values

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>UNIT</th>
<th>Decrease</th>
<th>PSC</th>
<th>Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MUSCLE</strong></td>
<td>Creatine Phosphokinase</td>
<td>U / l</td>
<td>-</td>
<td>236</td>
</tr>
<tr>
<td><strong>KIDNEY</strong></td>
<td>Creatinine</td>
<td>µmol/l</td>
<td>-</td>
<td>35</td>
</tr>
<tr>
<td>Urea</td>
<td>mmol/l</td>
<td>-</td>
<td>3.2</td>
<td></td>
</tr>
<tr>
<td>Uric acid</td>
<td>µmol/l</td>
<td>-</td>
<td>119</td>
<td></td>
</tr>
<tr>
<td>Phosphate</td>
<td>mmol/l</td>
<td>0.39</td>
<td>0.39</td>
<td></td>
</tr>
<tr>
<td>Calcium</td>
<td>mmol/l</td>
<td>0.30</td>
<td>0.30</td>
<td></td>
</tr>
<tr>
<td><strong>ELECTROLYTES</strong></td>
<td>Sodium</td>
<td>mmol/l</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Potassium</td>
<td>mmol/l</td>
<td>1.1</td>
<td>1.1</td>
<td></td>
</tr>
<tr>
<td>Chloride</td>
<td>mmol/l</td>
<td>8</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>mmol/l</td>
<td>7</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td><strong>METABOLISM/NUTRITIONAL</strong></td>
<td>Glucose (random)</td>
<td>mmol/l</td>
<td>3</td>
<td>3.7</td>
</tr>
<tr>
<td>Albumin</td>
<td>g/l</td>
<td>6</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Protein</td>
<td>g/l</td>
<td>11</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Cholesterol</td>
<td>mmol/l</td>
<td>-</td>
<td>1.97</td>
<td></td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>mmol/l</td>
<td>0.91</td>
<td>0.85</td>
<td></td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>mmol/l</td>
<td>2.17</td>
<td>2.04</td>
<td></td>
</tr>
<tr>
<td>Triglycerides</td>
<td>mmol/l</td>
<td>-</td>
<td>2.91</td>
<td></td>
</tr>
<tr>
<td><strong>ERYTHROCYTES</strong></td>
<td>Erythrocyte count</td>
<td>T/l</td>
<td>0.7</td>
<td>0.7</td>
</tr>
<tr>
<td>Haemoglobin</td>
<td>g/l</td>
<td>20</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Haematocrit</td>
<td>l</td>
<td>0.06</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>MCV</td>
<td>fl</td>
<td>7</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>MCH (Fe)</td>
<td>fmol</td>
<td>0.19</td>
<td>0.19</td>
<td></td>
</tr>
<tr>
<td>MCHC (Fe)</td>
<td>mmol/l</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>LEUKOCYTES</strong></td>
<td>Leukocyte count</td>
<td>G/l</td>
<td>4.2</td>
<td>3.8</td>
</tr>
<tr>
<td><strong>DIFFERENTIAL COUNT</strong></td>
<td>Neutrophils</td>
<td>G/l</td>
<td>3.47</td>
<td>3.19</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>G/l</td>
<td>1.76</td>
<td>1.63</td>
<td></td>
</tr>
<tr>
<td>Monocytes</td>
<td>G/l</td>
<td>-</td>
<td>0.49</td>
<td></td>
</tr>
<tr>
<td>Eosinophils</td>
<td>G/l</td>
<td>-</td>
<td>0.41</td>
<td></td>
</tr>
<tr>
<td>Basophils</td>
<td>G/l</td>
<td>-</td>
<td>0.14</td>
<td></td>
</tr>
<tr>
<td><strong>URINE</strong></td>
<td>Specific gravity</td>
<td>-</td>
<td>0.017</td>
<td>0.015</td>
</tr>
<tr>
<td>pH</td>
<td>-</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>LIVER</strong></td>
<td>Total bilirubin</td>
<td>µmol/l</td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td>ASAT (SGOT)</td>
<td>U/l</td>
<td>-</td>
<td>N x (23/36)</td>
<td></td>
</tr>
<tr>
<td>ALAT (SGPT)</td>
<td>U/l</td>
<td>-</td>
<td>N x (28/45)</td>
<td></td>
</tr>
<tr>
<td>Gamma GT</td>
<td>U/l</td>
<td>-</td>
<td>N x (25/38)</td>
<td></td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>U/l</td>
<td>--</td>
<td>N x (30/95)</td>
<td></td>
</tr>
</tbody>
</table>

N = upper limit of normal range

Definition of Clinically Noteworthy Abnormal Laboratory Values (CNALV)

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>CNALV</th>
</tr>
</thead>
</table>
| HAEMOGLOBIN | • Decrease of at least 2g/dl and value < 10 g/dl whatever the baseline value  
• If missing baseline : value < 10g/dl |
| NEUTROPHILS | • < 1 500/mm³ whatever the baseline value |
| WBC (if missing value for neutrophils) | • < 3 000/mm³ whatever the baseline value |
| PLATELETS | • < 100 000/mm³ whatever the baseline value |
| SERUM CREATININE | • Increase of at least 30 % as compared to baseline value and value > 150 µmol/l whatever the baseline value  
• If missing baseline : value > 150 µmol/l |
| LIVER FUNCTION TESTS | |
| ALAT | • If normal baseline :  
• ALAT > 2 N  
• If abnormal baseline :  
→ if baseline value ≤ 2.5 N :  
• increase of at least 100 % as compared to baseline value  
→ if baseline value > 2.5 N :  
• value > 5 N |
| and/or ASAT | • If normal baseline :  
• ASAT > 2 N  
• If abnormal baseline :  
→ if baseline value ≤ 2.5 N :  
• increase of at least 100 % as compared to baseline value  
→ if baseline value > 2.5 N :  
• value > 5 N |
| and/or Alkaline phosphatase (AP) | • If normal baseline :  
• AP > 1.25 N  
• If abnormal baseline :  
• AP > 2 N |
| and/or Total bilirubin (TB) | • If normal baseline :  
• TB > 1.5 N  
• If abnormal baseline :  
• TB > 2 N |

N=upper limit of normal range

Cardiovascular Safety

Table 1: Predefined Limits for Potentially Clinically Significant Changes (PSC) and PSC Leading to Clinically Significant Values (PSCV)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>PSC</th>
<th>PSCV</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP</td>
<td>Increase ≥ 20 mmHg</td>
<td>SBP ≥ 160 mmHg and increase ≥ 20 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 20 mmHg</td>
<td>SBP ≤ 90 mmHg and decrease ≥ 20 mmHg</td>
</tr>
<tr>
<td></td>
<td>Increase ≥ 10 mmHg</td>
<td>DBP ≥ 100 mmHg and increase ≥ 10 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 mmHg</td>
<td>DBP ≤ 50 mmHg and decrease ≥ 10 mmHg</td>
</tr>
<tr>
<td>HR</td>
<td>Increase ≥ 10 bpm</td>
<td>HR ≥ 110 bpm and increase ≥ 10 bpm</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 bpm</td>
<td>HR ≤ 50 bpm and decrease ≥ 10 bpm</td>
</tr>
</tbody>
</table>

Table 2: Predefined Classes for changes from Baseline to the Maximum (and/ or Minimum) Post-baseline Value

<table>
<thead>
<tr>
<th>Classes of Change from Baseline to the Maximum Post-baseline Value</th>
<th>Classes of Change from Baseline to the Minimum Post-baseline Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>----------</td>
<td>----------</td>
</tr>
<tr>
<td>All</td>
<td>All</td>
</tr>
<tr>
<td>≥ 0</td>
<td>≥ 0</td>
</tr>
<tr>
<td>&gt; 0</td>
<td>&gt; 0</td>
</tr>
<tr>
<td>≥ 10</td>
<td>≥ 5</td>
</tr>
<tr>
<td>≥ 20</td>
<td>≥ 10</td>
</tr>
<tr>
<td>≥ 30</td>
<td>≥ 15</td>
</tr>
<tr>
<td>≥ 40</td>
<td>≥ 20</td>
</tr>
<tr>
<td></td>
<td>≥ 25</td>
</tr>
<tr>
<td></td>
<td>≥ 30</td>
</tr>
</tbody>
</table>

Table 3: Classes for Vital Signs Maximum or Minimum Values

<table>
<thead>
<tr>
<th>Classes for the Maximum Post-baseline Value for each parameter</th>
<th>Classes for the Minimum Post-baseline Value for each parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>&lt; 120</td>
<td>[80;90]</td>
</tr>
<tr>
<td>[120;140]</td>
<td>[90;100]</td>
</tr>
<tr>
<td>≥ 160</td>
<td>≥ 100</td>
</tr>
</tbody>
</table>

Table 4: Classes for Maximum or Minimum of BP in its entirety

<table>
<thead>
<tr>
<th>Classification of Maximum Values for Blood Pressure (mmHg)</th>
<th>Classification of Minimum Values Blood Pressure (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP &lt; 140 and DBP &lt; 90</td>
<td>SBP &gt; 90 and DBP &gt; 50</td>
</tr>
<tr>
<td>SBP [140;160] and DBP &lt; 100 or DBP [90;100] and SBP &lt; 160</td>
<td>SBP ≤ 90 or DBP ≤ 50</td>
</tr>
<tr>
<td>SBP ≥ 160 or DBP ≥ 100</td>
<td>SBP &gt; 90 and DBP &gt; 50</td>
</tr>
</tbody>
</table>

Table 5: Definition of orthostatic hypotension

Orthostatic Hypotension *

SBP Decrease ≥ 20 mmHg or DBP Decrease ≥ 10 mmHg between supine and standing positions

16.1.1.2. Protocol and appendices
(version 2: 15 January 2013)
CLINICAL STUDY PROTOCOL

Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

F373280 / Soft Capsules / 1g

Pierre Fabre Study Code: F 373280 CA 2 01
EudraCT Number: 2012 – 003487 - 48

Sponsor's Representative:
Marlène GUIRAUD, Pharm D
INSTITUT DE RECHERCHE PIERRE FABRE - Centre de R&D Pierre Fabre - BP 13562
3 avenue Hubert Curien
31035 TOULOUSE Cédex 1
Phone: +33 5 34 50 63 48
Fax:+33 5 34 50 65 92
E-mail:marlene.guiraud@pierre-fabre.com

Pr Savina NODARI
Section of Cardiology
Department of Experimental and Applied Sciences
University of Brescia
BRESCIA, ITALY
Phone: +39 030 3996 587 - Fax: +39 030 3700 359
E-mail: savinanodari@gmail.com

Version 2– 15 JAN 2013

The information contained in this document is confidential and is the property of the Sponsor, Pierre Fabre Medicament. This information is given for the needs of the study and must not be disclosed without prior written consent of the Sponsor Pierre Fabre Medicament. Persons to whom this information is given for the needs of the study must be informed that it is confidential and must not be disclosed.
SPONSOR PERSONNEL

PIERRE FABRE MEDICAMENT
represented by
Institut de Recherche Pierre Fabre

Clinical Study Manager (Monitor)
Marlène GUIRAUD, Pharm D
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1
Phone: +33 5 34 50 63 48
Fax: + 33 5 34 50 65 92
E-mail: marlene.guiraud@pierre-fabre.com

Head of Therapeutic Area
Alain DELARUE, MD
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1
Phone: +33 5 34 50 61 88
Fax: +33 5 34 50 65 92
E-mail: alain.delarue@pierre-fabre.com

Clinical Development Physician
Richard ROCHE, MD
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1
Phone: +33 5 34 50 61 94
Fax: +33 5 34 50 65 92
E-mail: richard.roche@pierre-fabre.com
CONTRACT RESEARCH ORGANISATIONS

For Feasibility, Monitoring and Regulatory issues:
Pharmaceutical Service Network (PSN)
Rufino Gonzalez
28 037 Madrid - SPAIN
Phone: +34 91 375 6930 - Fax: +34 91 375 6931
E-mail: www.psnglobal.org

For Centralised Randomisation and Electronic Case Report Form
S-Clinica
6, Chaussée de Boondael
B-1050 Brussels - BELGIUM
Phone: +32 2 645 0567 - Fax: +32 2 645 0569
E-mail: irena.seredina@s-clinica.com

For Centralised Reading of Holder ECG and TTEM and equipment supply:
Biomedical System
1945 Chaussée de Wavre
B-1160 Brussels - BELGIUM
Phone: +32 2 661 20 70 - Fax: +32 2 661 20 71
E-mail: sjacobs@biomedsys.com

For intra erythrocyte DHA dosage
Agrocampus Ouest
Laboratoire de Biochimie
65 rue de Saint Brieuc – CS 84215
35042 RENNES Cedex - FRANCE
Phone: +33 2 23 48 55 49 - Fax: +33 2 23 48 55 50
E-mail: daniel.catheline@agrocampus-ouest.fr
Protocol F 373280 CA 2 01

APPROVAL FORM

Sponsor’s Representative:

Head of Therapeutic Area:
Alain DELARUE, MD

Date: 18 January 2013
Signature: [Signature]

I confirm that my original signature was dated on 18 January 2013.

Date: 08 October 2013
Signature: [Signature]

Study Coordinating Investigator:
Savina NODARI, MD

Date: 29/01/2013
Signature: [Signature]
Country: ........................

Country Coordinating Investigator:

"Name"                  Date:              Signature:


Protocol F 373280 CA 2 01

INVESTIGATOR SIGNATURE FORM


By my signature below, I, Dr / Pr " " , hereby confirm that I agree:

- to conduct the trial described in the protocol F 373280 CA 2 01, dated 15 January 2013 in compliance with GCP, with applicable regulatory requirements and with the protocol agreed upon by the Sponsor Pierre Fabre Médicament and given approval / favourable* opinion by the Ethics Committee;
- to document the delegation of significant study-related tasks and to notify the Sponsor of changes in site personnel involved in the study;
- to comply with the procedure for data recording and reporting;
- to allow monitoring, auditing and inspection;
- to retain the trial-related essential documents until the Sponsor informs that these documents are no longer needed.

Furthermore, I hereby confirm that I will have and will use the available adequate resources, personnel and facilities for conduct this trial.

I have been informed that certain regulatory authorities require the Sponsor Pierre Fabre Médicament to obtain and supply details about the investigator’s ownership interest in the Sponsor or the study drug, and more generally about his/her financial relationships with the Sponsor. The Sponsor will use and disclose the information solely for the purpose of complying with regulatory requirements.

Hence I agree:

- to supply the Sponsor with any information regarding ownership interest and financial relationships with the Sponsor (including those of my spouse and dependent children);
- to promptly update this information if any relevant changes occur during the course of the study and for 1 year following completion of the study;
- that the Sponsor may disclose this information about such ownership interests and financial relationships to regulatory authorities.

* To be adapted

Date: 
Signature:
# TABLE OF CONTENTS OF CLINICAL STUDY PROTOCOL

1. **INTRODUCTION AND STUDY RATIONALE** ............................................................... 21

1.1. TARGET PATHOLOGY AND THERAPY ................................................................. 21

1.2. INFORMATION ON THE TEST PRODUCT ............................................................. 23

1.2.1. Chemical and pharmaceutical characteristics ............................................... 24

1.2.1.1. Nomenclature and structure ................................................................. 24

1.2.1.2. Physical and chemical general properties .............................................. 24

1.2.2. Non-clinical Data ............................................................................................ 25

1.2.2.1. Pharmacological profile ......................................................................... 25

1.2.2.2. Safety pharmacology .............................................................................. 25

1.2.2.3. Toxicology profile .................................................................................. 26

1.2.2.4. Pharmacokinetic data .............................................................................. 26

1.2.3. Clinical data .................................................................................................. 26

1.3. STUDY RATIONALE .......................................................................................... 29

1.4. OVERALL RISK AND BENEFIT ASSESSMENT .................................................... 29

2. **STUDY OBJECTIVES** ......................................................................................... 32

2.1. PRIMARY OBJECTIVE ...................................................................................... 32

2.2. SECONDARY OBJECTIVES ............................................................................... 32

3. **ETHICAL CONSIDERATIONS RELATING TO THE STUDY** ............................ 32

4. **STUDY DESIGN** .................................................................................................. 34

4.1. OVERALL DESCRIPTION ................................................................................. 34

4.2. DISCUSSION OF THE STUDY DESIGN .............................................................. 35

4.2.1. Choice of the Study Population .................................................................. 35

4.2.2. Choice of the Study Design ........................................................................ 36

4.2.3. Choice of the Dose ...................................................................................... 37

4.2.4. Choice of the Sample Size ......................................................................... 38

5. **STUDY POPULATION** ......................................................................................... 38

5.1. INCLUSION CRITERIA ....................................................................................... 38

5.2. NON INCLUSION CRITERIA ............................................................................ 38

5.3. NUMBER OF PATIENTS .................................................................................... 39

5.4. RECRUITMENT MODALITIES .......................................................................... 40

5.5. PATIENTS IDENTIFICATION ........................................................................... 40

5.6. WITHDRAWAL CRITERIA .................................................................................. 40

5.7. REPLACEMENT OF PATIENTS ........................................................................ 41

5.8. POST-STUDY EXCLUSION PERIOD ................................................................. 41

5.9. STUDY CARD ................................................................................................... 41
6. STUDY TREATMENT ......................................................................................................... 42
   6.1. SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT ........................................................................................................................... 42
   6.2. PACKAGING AND LABELLING ..................................................................................... 42
      6.2.1. Packaging .......................................................................................................................... 42
      6.2.2. Labelling ............................................................................................................................ 43
   6.3. DISTRIBUTION TO CENTRE AND STORAGE .............................................................. 44
   6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT ................... 44
   6.5. DRUG ADMINISTRATION ............................................................................................... 46
      6.5.1. Duration of Treatment ....................................................................................................... 46
      6.5.2. Dose Schedule ................................................................................................................... 46
      6.5.3. Route and Conditions of Administration ........................................................................... 46
   6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT ...................................................................................... 46
   6.7. RECALL OF INVESTIGATIONAL PRODUCTS ............................................................. 47
7. CONCOMITANT TREATMENTS ..................................................................................... 47
   7.1. ANTI-VITAMIN K TREATMENT ..................................................................................... 48
   7.2. PROHIBITED TREATMENTS ........................................................................................... 48
   7.3. AUTHORISED TREATMENTS ......................................................................................... 48
8. EVALUATION CRITERIA ................................................................................................. 49
   8.1. PRIMARY EFFICACY CRITERION: ................................................................................ 49
      8.1.1. Time to the first Atrial Fibrillation Recurrence ................................................................. 49
         8.1.1.1. Definition ........................................................................................................................ 49
         8.1.1.2. Schedule ......................................................................................................................... 49
         8.1.1.3. Evaluation Methods ........................................................................................................ 49
      8.1.2. Secondary Efficacy Criteria .............................................................................................. 50
         8.1.2.1. Numbers of Atrial Fibrillation episodes in the first week following visit 3 (ECV visit) ................................................................................................................................ 50
      8.1.2.2. Duration of Atrial Fibrillation episodes in the first week following visit 3 (ECV visit) ................................................................................................................................ 50
      8.1.2.3. Clinical parameters evaluation ....................................................................................... 51
      8.1.2.4. Cardioversion assessment ............................................................................................... 52
      8.1.2.5. Evolution of echocardiographic parameters ................................................................... 53
   8.2. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA ..................................................................................................................................... 53
      8.2.1. Definition ........................................................................................................................... 53
      8.2.2. Blood samples ................................................................................................................... 54
         8.2.2.1. Collection schedule ........................................................................................................ 54
         8.2.2.2. Technical handling ......................................................................................................... 54
      8.2.3. DHA concentration measurement ..................................................................................... 54
   8.3. SAFETY ASSESSMENT .................................................................................................... 55
8.3.1. Adverse Events ................................................................. 55
8.3.2. Laboratory Investigations ............................................... 55
8.3.2.1. Schedule .................................................................. 55
8.3.2.2. Technical Procedures and Parameters ........................ 55
8.3.3. Global Physical Examination ........................................... 56
8.3.4. Vital Signs ...................................................................... 56
8.3.4.1. Schedule .................................................................. 57
8.3.4.2. Technical Procedure and Parameters ........................ 57
8.3.5. Electrocardiogram (ECG) ................................................ 57
8.3.5.1. Schedule .................................................................. 57
8.3.5.2. Technical Procedure and Parameters ........................ 57
8.3.6. Coagulation parameters .................................................. 58
8.3.7. Concomitant Treatments .................................................. 58
8.4. COMPLIANCE .................................................................... 58
9. STUDY PROCEDURES ............................................................... 59
10. ADVERSE EVENTS: DEFINITION AND REPORTING .................. 64
10.1. ADVERSE EVENTS ............................................................ 64
10.1.1. Definition of Adverse Events ......................................... 64
10.1.2. Grading of Adverse Events ........................................... 65
10.1.3. Reporting of Adverse Events ......................................... 65
10.2. SERIOUS ADVERSE EVENTS (SAE) ............................ 65
10.2.1. Definition .................................................................... 65
10.2.2. Reporting of SAE ........................................................ 66
10.2.3. Follow-up of SAE ........................................................ 67
10.2.4. SAE Occurring After the Study ...................................... 67
10.3. REPORTING OF OVERDOSAGE TO THE SPONSOR .......... 67
10.4. REPORTING OF PREGNANCY TO THE SPONSOR ............ 67
10.5. SPONSOR'S RESPONSIBILITIES FOR SAFETY REPORTING PURPOSES ... 68
11. DATA COLLECTION AND STUDY MONITORING ............... 68
11.1. DATA COLLECTION .......................................................... 68
11.1.1. Case Report Form ......................................................... 68
11.1.2. Source Documents ....................................................... 69
11.2. STUDY MONITORING ....................................................... 70
11.2.1. Monitoring visits .......................................................... 70
11.2.1.1. Site Preselection Visit .............................................. 70
11.2.1.2. Initiation Visit ........................................................ 70
11.2.1.3. Follow-up Visits ...................................................... 71
11.2.1.4. Closing Visit .......................................................... 71
11.2.2. Direct Access to Source Documents .............................. 71
11.3. INDEPENDENT DATA MONITORING COMMITTEE ............. 72
12. DATA MANAGEMENT ............................................................. 72
12.1. DATA ENTRY ..................................................................................................................... 72
12.2. DATA CLEANING ............................................................................................................. 72
12.3. DATA CODING .................................................................................................................. 73
12.4. DATA STORAGE ............................................................................................................... 73
12.5. DATABASE LOCK ............................................................................................................. 73

13. STATISTICAL ANALYSIS ................................................................................................. 73

13.1. GENERAL CONSIDERATIONS ........................................................................................ 74
13.2. SAMPLE SIZE ..................................................................................................................... 74
13.3. PROTOCOL DEVIATIONS ................................................................................................ 74
13.4. DATA SETS ANALYSED .................................................................................................. 75
13.5. HANDLING OF DROPOUTS AND MISSING DATA ..................................................... 75
13.5.1. Dropouts ............................................................................................................................ 75
13.5.2. Repositioning of Visits ...................................................................................................... 75
13.5.3. Missing Data ...................................................................................................................... 75
13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS ............................... 76
13.7. EFFICACY ANALYSIS ...................................................................................................... 76
13.7.1. Primary Criterion ............................................................................................................... 76
13.7.1.1. Primary Analysis ............................................................................................................ 76
13.7.1.2. Supportive Analysis ....................................................................................................... 76
13.7.2. Secondary Criteria ............................................................................................................. 77
13.7.2.1. Numbers of Atrial Fibrillation Episodes ........................................................................ 77
13.7.2.2. Duration of Atrial Fibrillation Episodes ......................................................................... 77
13.7.2.3. Time to first AF recurrence less than 10 minutes or symptomatic .............................. 77
13.7.2.4. Clinical parameters evaluation ....................................................................................... 77
13.7.2.5. Biomarker analysis: red blood cell concentrations of DHA ........................................... 78
13.8. SAFETY ANALYSIS .......................................................................................................... 78
13.8.1. Adverse Events .................................................................................................................. 78
13.8.2. Clinical Laboratory Evaluation ......................................................................................... 80
13.8.3. Global Physical Examination .......................................................................................... 81
13.8.4. Vital Signs, Physical Findings and Other Observations Related to Safety .................... 81
13.8.4.1. Vital Sign Measurements Over Time ............................................................................. 81
13.8.4.2. Body weight ................................................................................................................... 81
13.8.4.3. Individual Patient Changes ............................................................................................. 82
13.8.5. ECG ................................................................................................................................... 82
13.8.6. Coagulation parameters ..................................................................................................... 82
13.9. CONCOMITANT TREATMENTS ..................................................................................... 82
13.10. COMPLIANCE .................................................................................................................. 83
13.11. INTERIM ANALYSIS AND DATA MONITORING ........................................................ 83

14. GENERAL ETHICAL CONSIDERATIONS .................................................................... 83

14.1. ETHICAL CONDITIONS ................................................................................................... 83
14.2. ETHICS COMMITTEE AND LEGAL REQUIREMENTS .................................................. 83
14.3. PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM........84
14.4. PERSONAL DATA PROTECTION ........................................................................85
14.5. INSURANCE POLICY ..........................................................................................85

15. ADMINISTRATIVE PROCEDURES ........................................................................85
15.1. PROTOCOL AMENDMENT ...............................................................................85
15.2. SOURCE DOCUMENTS, INVESTIGATOR'S FILE STORAGE ..................................86
15.3. END OF THE STUDY .......................................................................................86
15.3.1. Definition of the End of Study .................................................................86
15.3.2. Early Study Termination ...........................................................................87
15.3.2.1. Early Study Termination Decided by the Sponsor ................................87
15.3.2.2. Early Study Termination Decided by the Competent Authorities........87
15.4. AUDIT .............................................................................................................87
15.5. INSPECTION ..................................................................................................88
15.6. CONFIDENTIALITY .......................................................................................88
15.7. CLINICAL STUDY REPORT .........................................................................88
15.8. STUDY RESULTS COMMUNICATION ..........................................................88
15.9. STUDY RESULTS PUBLICATION .................................................................88

16. REFERENCES .....................................................................................................90

17. APPENDICES .....................................................................................................93
17.1. DECLARATION OF HELSINKI ....................................................................94
17.2. SAE REPORT FORM ....................................................................................98
17.3. PREDEFINED LIMITS OF LABORATORY AND VITAL SIGN POTENTIALLY
     CLINICALLY SIGNIFICANT CHANGES AND VALUES.................................101
## SYNOPSIS

<table>
<thead>
<tr>
<th>Name of Sponsor:</th>
<th>Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Finished Product:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Name of Active Substance:</td>
<td>F373280 (Panthenyl-Ester of DHA)</td>
</tr>
<tr>
<td>Title of the Study:</td>
<td>Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.</td>
</tr>
<tr>
<td>Abbreviated Title:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Study Coordinating Investigator:</td>
<td>Pr Savina NODARI</td>
</tr>
<tr>
<td>Study Centres:</td>
<td>International, multicentric</td>
</tr>
<tr>
<td>Publication / Rationale:</td>
<td>F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation (AF) patients with chronic heart failure. The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of Atrial Fibrillation (AF) induced by burst pacing.[1] Moreover, the effectiveness of PUFA (PolyUnsaturated Fatty Acid) has been proven in the following conditions: - prevention of Atrial Fibrillation recurrence in patients with persistent Atrial Fibrillation, in co-administration with amiodarone (add on therapy) [2] - Improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5] Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent atrial fibrillation and chronic heart failure. This phase Ila study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after electrical cardioversion (ECV) in patients with persistent atrial fibrillation and chronic heart failure.</td>
</tr>
<tr>
<td>Planned Study Period:</td>
<td>January 2013 – April 2014</td>
</tr>
</tbody>
</table>
| Objectives:                       | **Primary:** Efficacy of F373280 on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure  
  **Secondary:** Efficacy of F373280 on the efficiency of direct electrical cardioversion  
  - Effect of F373280 on echocardiographic parameters  
  - Safety and tolerability of F373280 |
| Methodology:                      | - International, multicentre, randomised, double-blind, placebo-controlled  
  - Selection period  
  - Start of treatment 4 weeks before ECV  
    - Condition to ECV:  
      - INR 2-3 (anti-vitamin K should be given at least 3 weeks before ECV)  
      - No spontaneous cardioversion before ECV  
  - Follow-up 20 weeks after visit 3 (ECV visit)  
    - Condition: successful ECV or spontaneous CV  
  - Cardiac monitoring:  
    - 7-days continuous ECG ambulatory recording (Holter ECG) between visit 3 (ECV visit) and visit 4 (week 5) in patients with sinus rhythm  
    - TTEM: daily transmission from week 6 to week 8; then every two days from week 9 to week 24, and in case of AF symptoms  
  - Treatment duration: 24 weeks |
| Study Schedule                    | 9 visits will be scheduled:  
  - V1/ W-4 to W-1: selection visit (7 to 28 days before the inclusion visit)  
  - V2/ D1: Inclusion visit (start of treatment)  
  - V3/ W4 (D28 -2/+7 days): cardioversion visit (Outpatient or hospitalization according to... |
clinical practice of the centre) (installation of the Holter device)
- V4/ W5 (D35± 2 days): follow-up visit (removing of the Holter device and installation of the TTEM)
- V5/ W8 (D56± 7 days): follow-up visit
- V6/ W12 (D84 ± 7 days): follow-up visit
- V7/ W16 (D112 ± 7 days): follow-up visit
- V8/ W20 (D140 ± 7 days): follow-up visit
- V9/ W24 (D168 ± 7 days): final study visit

Number of Patients: 76 x 2 patients

Diagnosis and Criteria for Inclusion:

Inclusion Criteria:

Demographic Characteristics and Other Baseline Characteristics:
1. Men or women aged more than 18 years (inclusive),
2. Patients with persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted.
3. History of first documented persistent AF less than 1 year
4. History of ischemic or non ischemic heart failure
5. NYHA class I or II chronic heart failure at selection and at inclusion
6. Reduced left ventricular ejection fraction between 30% and 45% inclusive (using the two-dimensional echocardiography biplane Simpson’s rule) at selection and at inclusion
7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers
8. Left atrial area ≤ 40 cm² at selection and at inclusion
9. Patients treated or having to be treated by anti-vitamin K
10. For female patient of child-bearing potential:
   - use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator, for at least 2 months before the selection in the study, and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment
   - documented as surgically sterilized
11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion

Ethical/legal considerations:
12. Having signed his/her written informed consent,
13. Affiliated to a social security system, or is beneficiary (if applicable in the national regulation)

Non-Inclusion Criteria:
Criteria related to pathologies:
1. History of first documented episode of persistent AF more than 1 year
2. More than two successful cardioversions (electrical or pharmacological) in the last 6 months
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV)
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be checked in case of treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic coronaropathy assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
7. Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration rate < 30 mL/min) at selection
8. Bradycardia (HR ≤ 50 bpm)
9. Hyperkalemia or hypokalemia (K>5.5 mEq/L or K < 3.5 mEq/L) at selection
10. Cardiac surgery within 3 months before selection or planned during the study duration
<table>
<thead>
<tr>
<th>Criteria related to treatments:</th>
</tr>
</thead>
<tbody>
<tr>
<td>11. Previously ineffective pharmacological or electrical cardioversion</td>
</tr>
<tr>
<td>12. Concomitant treatment with any anti-arrhythmic drug (within 7 days prior to selection), except stable dose of digoxin, betablockers, calcium-blockers</td>
</tr>
<tr>
<td>13. Previous treatment with oral amiodarone within 12 months prior to inclusion</td>
</tr>
<tr>
<td>14. Previous treatment with intravenous amiodarone within 6 months prior to inclusion</td>
</tr>
<tr>
<td>15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT implantation within the last 6 months</td>
</tr>
<tr>
<td>16. Treatment with any Polysaturated Fatty Acid (PUFA) within the last 3 months</td>
</tr>
<tr>
<td>17. Dietary supplement with ω3 or ω6 according to investigator’s judgement</td>
</tr>
<tr>
<td>18. Having undergone any form of ablation therapy for AF</td>
</tr>
<tr>
<td>19. Patient treated with other anticoagulant treatment than antivitamin K: thrombin inhibitor such as Dabigatran or treated with antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion</td>
</tr>
<tr>
<td>21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection</td>
</tr>
<tr>
<td>22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself/herself to its constraints</td>
</tr>
<tr>
<td>23. Patient family member or work associate (secretary, nurse, technician,..) of the Investigator</td>
</tr>
<tr>
<td>24. Patient having forfeited his / her freedom by administrative or legal award or being under guardianship</td>
</tr>
<tr>
<td>25. Breastfeeding female patient</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Exclusion criteria before V3:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients not stabilized for INR (i.e. values between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO–TE (trans-esophageal echocardiograph) performed in the same day (before ECV)</td>
</tr>
<tr>
<td>ECV will be performed in patients without dyskalemia</td>
</tr>
<tr>
<td>If necessary for obtaining stabilized INR between 2 and 3, the ECV (and following visits) could be postponed by 7 days.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Product:</th>
</tr>
</thead>
<tbody>
<tr>
<td>F373280 Soft Capsules</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dose:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arm with 1g of F373280</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mode of Administration:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral, one capsule each evening with dinner</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Duration of Treatment:</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 weeks of treatment exposure with F373280 (25 weeks if ECV postponed by 1 week)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reference Therapy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Placebo soft capsules</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mode of Administration:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral, one capsule each evening with dinner</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Evaluation Criteria:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy evaluation variables:</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Primary evaluation variable:</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Time to first Atrial Fibrillation recurrence defined by the first episode of Atrial Fibrillation lasting for at least 10 minutes (Follow up of 20 weeks after visit 3 (ECV visit))</td>
</tr>
<tr>
<td>Handling of AF recurrences: 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) between visit 3 (ECV visit) and visit 4 (week 5). Then, the follow up will be documented using the TTEM: daily transmission from week 6 to week 8. Then, every two days from week 9 to week 24.</td>
</tr>
<tr>
<td>For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF will be assessed after visit 3 (week 5).</td>
</tr>
<tr>
<td>Moreover, during this TTEM period, if patient experiences any AF symptoms, it should be recorded and documented using the TTEM.</td>
</tr>
<tr>
<td>All ECG traces will be evaluated by a Central Reading Laboratory.</td>
</tr>
</tbody>
</table>

| Secondary evaluation variables: |
During the 7-day continuous ECG monitoring,
- Numbers of AF episodes
- Duration of AF episodes

Clinical parameters:
During the whole study:
- Number of recurrence of symptomatic AF episodes
- EHRA score
- Hospitalization for cardiovascular events
- Hospitalization for thromboembolic stroke
- All cause of hospitalization

Cardioversion:
- Assessment of spontaneous cardioversion
- Assessment of successful cardioversion
- Number of patients needing an other cardioversion after the initial ECV

Other:
- Evolution of echocardiographic parameters (from V4 to V6 and V9) (Left atrial diameter (mm), Left atrial area (cm²), Left atrial volume (mL), Left atrial volume/BSA (mL/m²), Left ventricular ejection fraction (%), Left ventricular volume (mL), Left ventricular volume/BSA (mL/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL) Left ventricular end systolic diameter (mm), Left ventricular end systolic volume (mL))
- Evolution of omega 3 index and intra erythrocyte DHA (For this assessment samples will be centralized).

Safety criteria:
- Adverse events (observed and / or spontaneously reported)
- Vital signs (Blood pressure (supine and standing), heart rate
- Physical examination (body weight),
- Standard 12-lead ECG: heart rate (bpm), PR (ms), QRS (ms), QT (ms), repolarisation patterns (ECG not centralized).
- Haematology: haematocrit, haemoglobin, RBC, WBC, differential count, platelets
- Biochemistry: sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatin phosphokinase (CPK) fibrinogen (local laboratory)
- Coagulation parameters: Activated partial thromboplastin time (aPTT), thrombin clotting time (TCT), INR (local laboratory), Prothrombine Time (PT)

Statistical Methods:

Sample Size:
Assuming an AF recurrence rate under placebo of 85%, a power of 80%, an alpha risk of 5% and a rate of not assessable patients of 15%, 76 randomised patients per group will be necessary, using a log-rank test of survival curves, a difference between groups of 20%.

Primary Efficacy Analysis
The primary analysis, performed on the Full Analysis Set (FAS: all randomised patients with at least one dose of treatment and with a successful cardioversion observed at visit 3), will be a survival analysis using the Kaplan Meier method and Cox regression model.

Secondary Analyses
All secondary efficacy criteria will be described and compared using appropriate tests on the FAS.

Safety Analyses
Descriptive statistics will be performed on the Safety Set (all randomised patients with at least one dose of treatment)
<table>
<thead>
<tr>
<th>F373280 CA 201</th>
<th>V1</th>
<th>V2</th>
<th>V3</th>
<th>V4</th>
<th>V5</th>
<th>V6</th>
<th>V7</th>
<th>V8</th>
<th>V9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Weeks</td>
<td>W-4 to W-1</td>
<td>D1</td>
<td>W4 (28-20+7 D)</td>
<td>W5 (25+/-2 D)</td>
<td>W8 (56+/-7D)</td>
<td>W12 (84+/-7D)</td>
<td>W16 (112+/-7D)</td>
<td>W20 (140+/-7D)</td>
<td>W24 (168+/-7D)</td>
</tr>
<tr>
<td>Outpatient or Hospitalization (1)</td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographic characteristics</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medico-surgical history</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant disease</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Concomitant treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Habits</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global physical examination (body weight)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Echocardiography</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Eligibility criteria check</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood pressure, heart rate</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>12-Lead ECG Recording</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>INR (2)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>aPTT, TCT</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood biochemistry</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematology</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary pregnancy test</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Red Blood Cell concentrations of DHA</td>
<td>x</td>
<td>x</td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment allocation</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IVRS</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EGV (3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug administration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events recording</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Holter ECG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TTEM (6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Outpatient or hospitalization according to clinical practice of the centre (less or more than 24 hours)
2. In case of AVK introduction: INR 2 to 3 times a week, then weekly until the ECV, then every 4 weeks after ECV.
3. In patients with AF
4. 24-hour Holter ECG
5. 7-day Holter ECG
6. TTEM everyday from week 6 to week 8. Then every 2 days from week 9 to week 24. In case of AF symptoms. In case of AF recurrence for at least 10 minutes and the patient does not stop the study treatment than TTEM every 4 weeks.

Final version 127/1185
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>aPTT</td>
<td>Activated partial thromboplastin time</td>
</tr>
<tr>
<td>AE</td>
<td>Adverse event</td>
</tr>
<tr>
<td>AERP</td>
<td>Atrial effective refractory period</td>
</tr>
<tr>
<td>AF</td>
<td>Atrial fibrillation</td>
</tr>
<tr>
<td>ALA</td>
<td>Alpha-linoleic acid</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine aminotransferase</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate aminotransferase</td>
</tr>
<tr>
<td>AUC</td>
<td>Area under the plasma concentration versus time curve</td>
</tr>
<tr>
<td>AUC_{inf}</td>
<td>Total area under the curve extrapolated to infinity</td>
</tr>
<tr>
<td>AVK</td>
<td>Anti vitamin K</td>
</tr>
<tr>
<td>βHCG</td>
<td>beta human chorionic gonadotrophin</td>
</tr>
<tr>
<td>BLQ</td>
<td>Below the limit of quantification</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>BP</td>
<td>Blood pressure</td>
</tr>
<tr>
<td>BSA</td>
<td>Body Surface Area</td>
</tr>
<tr>
<td>CEP</td>
<td>Protocol evaluation committee</td>
</tr>
<tr>
<td>CHF</td>
<td>Congestive heart failure</td>
</tr>
<tr>
<td>CHMP</td>
<td>Committee for medicinal products for human use</td>
</tr>
<tr>
<td>C_{max}</td>
<td>Maximum concentration</td>
</tr>
<tr>
<td>C_{min}</td>
<td>Minimum concentration</td>
</tr>
<tr>
<td>CNALV</td>
<td>Clinically noteworthy abnormal laboratory value</td>
</tr>
<tr>
<td>CPK</td>
<td>Creatin phosphokinase</td>
</tr>
<tr>
<td>CPP</td>
<td>Comité de protection des personnes</td>
</tr>
<tr>
<td>CRA</td>
<td>Clinical research associate</td>
</tr>
<tr>
<td>CRT</td>
<td>Cardiac resynchronization therapy</td>
</tr>
<tr>
<td>CSC</td>
<td>“Clinically Significant Change”, i.e., Predefined potentially clinically significant change leading to a potentially clinically significant value (vital signs)</td>
</tr>
<tr>
<td>CV</td>
<td>Coefficient of variation</td>
</tr>
<tr>
<td>DBP</td>
<td>Diastolic blood pressure</td>
</tr>
<tr>
<td>DHA</td>
<td>Docosahexaenoic acid</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics committee</td>
</tr>
<tr>
<td>ECG</td>
<td>Electrocardiogram</td>
</tr>
<tr>
<td>ECHO–TE</td>
<td>Trans-esophageal echocardiograph</td>
</tr>
<tr>
<td>ECV</td>
<td>Electrical cardioversion</td>
</tr>
<tr>
<td>EHRA</td>
<td>European heart rhythm association</td>
</tr>
<tr>
<td>EPA</td>
<td>Eicosapentaenoic acid</td>
</tr>
<tr>
<td>eCRF</td>
<td>Electronic case report form</td>
</tr>
<tr>
<td>FAS</td>
<td>Full analysis set</td>
</tr>
<tr>
<td>Fe</td>
<td>Fraction of the administered drug excreted in urine</td>
</tr>
<tr>
<td>GCP</td>
<td>Good clinical practice</td>
</tr>
<tr>
<td>GFR</td>
<td>Glomerular Filtration Rate</td>
</tr>
<tr>
<td>ABBREVIATION</td>
<td>DEFINITION</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>HBs</td>
<td>Hepatitis B antigen</td>
</tr>
<tr>
<td>HCV</td>
<td>Hepatitis C virus</td>
</tr>
<tr>
<td>HDL</td>
<td>High density lipoprotein</td>
</tr>
<tr>
<td>HF</td>
<td>Heart failure</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>HR</td>
<td>Heart rate</td>
</tr>
<tr>
<td>ICH</td>
<td>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use</td>
</tr>
<tr>
<td>IDMC</td>
<td>Independent data monitoring committee</td>
</tr>
<tr>
<td>INR</td>
<td>International normalized ratio</td>
</tr>
<tr>
<td>IRPF</td>
<td>Institut de Recherche Pierre Fabre</td>
</tr>
<tr>
<td>IVRS</td>
<td>Interactive voice response system</td>
</tr>
<tr>
<td>LAA</td>
<td>Left atrial area</td>
</tr>
<tr>
<td>LC/MS-MS</td>
<td>Liquid chromatography with tandem mass spectrometry</td>
</tr>
<tr>
<td>LDL</td>
<td>Low density lipoprotein</td>
</tr>
<tr>
<td>LOQ</td>
<td>Limit of quantification</td>
</tr>
<tr>
<td>LVEF</td>
<td>Left ventricular ejection fraction</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical dictionary for regulatory activities</td>
</tr>
<tr>
<td>MR</td>
<td>Mineralocorticoid receptor</td>
</tr>
<tr>
<td>MR perfusion</td>
<td>Magnetic Resonance perfusion</td>
</tr>
<tr>
<td>MTD</td>
<td>Maximum tolerated dose</td>
</tr>
<tr>
<td>N</td>
<td>Number of determinations or replicates</td>
</tr>
<tr>
<td>NOAEL</td>
<td>No observed adverse effect level</td>
</tr>
<tr>
<td>NYHA</td>
<td>New York heart association</td>
</tr>
<tr>
<td>od</td>
<td>Once a day</td>
</tr>
<tr>
<td>“Predefined Change”, i.e., Predefined potentially clinically significant change (lab or vital signs)</td>
<td></td>
</tr>
<tr>
<td>PC</td>
<td>PC leading to an out-of-range value (lab values)</td>
</tr>
<tr>
<td>PCA</td>
<td>PC leading to an out-of-range value (lab values)</td>
</tr>
<tr>
<td>PFB</td>
<td>Pierre Fabre Biométrie</td>
</tr>
<tr>
<td>POC</td>
<td>Proof of concept</td>
</tr>
<tr>
<td>PUFA</td>
<td>PolyUnsaturated fatty acid</td>
</tr>
<tr>
<td>PK</td>
<td>Pharmacokinetics</td>
</tr>
<tr>
<td>p.o.</td>
<td>Per os</td>
</tr>
<tr>
<td>PP</td>
<td>Per protocol data set</td>
</tr>
<tr>
<td>RBC</td>
<td>Red blood cells</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious adverse event</td>
</tr>
<tr>
<td>SBP</td>
<td>Systolic blood pressure</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>T1/2</td>
<td>Terminal half-life</td>
</tr>
<tr>
<td>T0</td>
<td>Time of drug administration</td>
</tr>
<tr>
<td>T\text{max}</td>
<td>Time to reach the maximal concentration</td>
</tr>
<tr>
<td>TCT</td>
<td>Thrombin clotting time</td>
</tr>
<tr>
<td>TEAEs</td>
<td>Treatment emergent adverse events</td>
</tr>
<tr>
<td>TTEM</td>
<td>TransTelephonic ECG monitoring</td>
</tr>
<tr>
<td>VTP</td>
<td>Ventricular tachypacing</td>
</tr>
<tr>
<td>WBC</td>
<td>White blood cells</td>
</tr>
<tr>
<td>WHO-DRUG</td>
<td>World health organization drug reference list</td>
</tr>
</tbody>
</table>
1. INTRODUCTION AND STUDY RATIONALE

1.1. TARGET PATHOLOGY AND THERAPY

Atrial Fibrillation (AF) is a supraventricular arrhythmia characterized by uncoordinated atrial electric activity with consequent deterioration of atrial mechanical function. It is the most common sustained cardiac rhythm disorder, increasing in prevalence with age. Haemodynamic impairment and thromboembolic events related to AF result in significant morbidity and mortality [7].

In 2009, Decision Resources estimated that there were 7.8 million diagnosed prevalent cases of atrial fibrillation (AF) in US, Europe and Japan. This age-related pathology should increase to 9.4 million cases in 2019.

Except for the conventional class I and class III anti-arrhythmic agents, the PUFAs (Polyunsaturated Fatty Acids) constitute one emerging antiarrhythmic therapy. These compounds potently address the AF substrate by directly targeting both the electrical and the structural remodelling of the deficient atria. The n-3 PUFAs, essential for human, are ALA, EPA and DHA. First, PUFAs specifically modulate ionic channels by fastening their inactivating mode which renders these compounds selective for pathological situations (such as AF) without any major effect in normal conditions. PUFAs are “open Kv1.5 channel blockers” leading to a lengthening of atrial action potential duration and are “persistent Na\textsubscript{v}1.5 channel blockers” leading to hyperpolarization of diastolic resting potential. Second, PUFAs influence structural remodelling through their anti-inflammatory effects as they directly compete with arachidonic acid in the production of inflammatory eicosanoids. In summary, PUFAs share unique, well-tolerated antiarrhythmic potential by interacting with the electrical and structural remodelling during sustained AF. In animal studies, it was recently demonstrated that DHA is particularly effective in pathologic conditions such as ischemia and/or atrial fibrillation.

The potential anti-arrhythmic effects of a PUFA was previously developed in atrial fibrillation: nicotinyl ester of DHA (pro-drug based on DHA delivery) were assessed in a two-week
ventricular tachypaced canine model. Dogs were subjected to 4 weeks of medication prior to undergoing an electrophysiology study, and received either placebo or nicotinyl ester of DHA. Dogs were tachypaced at 240 beats per min for the final two weeks of the treatment plan. The results showed that the tested PUFA reduced the duration of atrial fibrillation (AF) induced by burst pacing, and the incidence of sustained AF, compared to dogs treated with the placebo [1].

In clinical practice, Nodari and coll assessed n-3 Polyunsaturated Fatty Acids in the prevention of atrial fibrillation recurrences after electrical cardioversion. All included patients were treated with amiodarone and a renin-angiotensin-aldosterone system inhibitor. The 199 patients were assigned either to placebo or n-3 PUFAs 2 g/d and then underwent direct electrical cardioversion (ECV) 4 weeks later. The primary end point was the maintenance of sinus rhythm at 1 year after cardioversion. At the 1-year follow up, the maintenance of sinus rhythm was significantly higher in the n-3 PUFAs treated patients compared with the placebo group (hazard ratio, 0.62 [95% confidence interval, 0.52 to 0.72] and 0.36 [95% confidence interval, 0.26 to 0.46], respectively; p = 0.0001). The study concludes that in patients with persistent atrial fibrillation on amiodarone and a renin-angiotensin-aldosterone system inhibitor, the addition of n-3 PUFAs 2 g/d improves the probability of the maintenance of sinus rhythm after direct current cardioversion [2].

Previously, during the World Congress of Cardiology in 2006, an abstract reported the effectiveness of PUFA on top of traditional treatment (amiodarone, beta blockers, renin-angiotensin-aldosterone system inhibitor) in the prevention of AF relapses in patients having undergone ECV. In the PUFA group, AF relapses were significantly lower than placebo group at one month (3.3% vs 10%; p=0.043), at 3 months (10% vs 25%; p=0.004) and at 6 months (13.3% vs 40%; p<0.0001) [19].

In contrast, in the general AF population (paroxystic atrial fibrillation and persistent atrial fibrillation), PUFAs failed to prove their efficacy [7] because of the absence of cardiac remodelling or because of a short pre-treatment duration before ECV (1 week) [8]. The effect of PUFAs were only observed in patients with persistent AF on add on therapy and after a sufficient pre-treatment before ECV. Persistent AF is commonly associated to heart failure. Previous studies performed in heart failure population demonstrated the benefit of PUFAs on the improvement of functional ventricular parameters and morbi-mortality, and on the reduction of hospitalisation [3, 4, 5].
Nodari and coll [3] performed a trial in patients with a chronic heart failure (NYHA I to III and LVEF< 45%). After a treatment of 133 patients with PUFAs (n=67) or placebo (n=66) at a dosage of 5 g/day for 1 month, then 2 g/day for 11 months, the n-3 PUFAs group and the placebo group differed significantly (p <0.001) in regard to:

- LVEF (increased by 10.4% and decreased by 5.0%, respectively)
- peak VO₂ (increased by 6.2% and decreased by 4.5%, respectively)
- exercise duration (increased by 7.5% and decreased by 4.8%, respectively)
- mean New York Heart Association functional class (decreased from 1.88 +/- 0.33 to 1.61 +/- 0.49 and increased from 1.83 +/- 0.38 to 2.14 +/- 0.65, respectively).

The hospitalization rates for HF were 6% in the n-3 PUFAs and 30% in the placebo group (p <0.0002).

Moertl and coll [4] performed a dose-ranging study in patients with a more severe chronic heart failure (NYHA III and IV and LVEF < 35%). It was a double-blind, randomised, controlled pilot trial in 43 patients treated with PUFAs or placebo for 3 months (1 g/d n3-PUFA (n = 14), 4 g/d n3-PUFA (n = 13), or placebo (n = 16)). After treatment, left ventricular ejection fraction increased in a dose-dependent manner (P = 0.01 for linear trend) in the 4 g/d (baseline vs 3 months [mean ± SD]: 24% ± 7% vs 29% ± 8%, p = 0.005) and 1 g/d treatment groups (24% ± 8% vs 27% ± 8%, P = 0.02).

No changes in any investigated parameters were noted with placebo.

Taking into account these studies performed with PUFAs, it seems that the best target for DHA is persistent AF in patients with heart failure. The aim of this proof of concept study is to assess in stand alone therapy (without association of other anti-arrhythmic treatments), the effect of F373280 in patients with persistent atrial fibrillation and heart failure in the maintenance of sinus rhythm after electrical cardioversion.

1.2. INFORMATION ON THE TEST PRODUCT

F373280 or panthenyl ester of DHA (docosahexaenoic acid) is the mono-ester of panthotenic alcohol and DHA, selected to be developed for the management of atrial fibrillation.

F373280 is a prodrug of DHA.
A brief summary of F373280 known characteristics is presented in this section. For further details, please refer to the F373280 Investigator’s Brochure. [1]

1.2.1. Chemical and pharmaceutical characteristics

1.2.1.1. Nomenclature and structure

Chemical name (IUPAC):

(4Z,7Z,10Z,13Z,16Z,19Z)-3-((R)-2,4-dihydroxy-3,3-diméthylbutanamido) propyl docosa-4,7,10,13,16,19-hexaenoate

Structural formula:

![Structural formula]

Laboratory code: F373280

Molecular formula: C₃₁H₄₉NO₅

Molecular mass: 515.7

1.2.1.2. Physical and chemical general properties

Appearance: Clear oily viscous liquid

Solubilities:

− Water: Practically insoluble
− Alcohol: Very soluble
− Trimethylpentane: Slightly soluble
1.2.2. Non-clinical Data

Non-clinical data are exhaustively detailed in the Investigator’s brochure [1]. A brief summary is provided below.

1.2.2.1. Pharmacological profile

F373280 (mono-ester of panthotenic alcohol and DHA) is a novel pro-drug of DHA which exerts antiarrhythmic properties by interacting with the electrical and structural remodelling of the atria.

Experimental investigations were conducted in HEK293 cell line transfected with human Kv1.5 channel using the whole cell patch clamp technique to evaluate whether F373280 could block the sustained component of I_{Kv1.5}. F373280 concentration-dependently reduced Kv1.5 channel activity with an IC_{50} value of 13.7 µM.

The effects of F373280 on atrial effective refractory period (AERP) were investigated in anesthetized pig using a conventional pacing protocol through epicardial electrodes placed on the left atrium. F373280 administered as a bolus and an infusion (10 mg/kg) significantly increased AERP (23.8 ± 2.2 ms versus -7.3 ± 11.5 ms in the presence of vehicle, P<0.05). In addition, F373280 was devoid of significant effect on the hemodynamic and the ECG intervals.

Proof of the pharmacological concept was performed with a different DHA derivative named: Nicotinyl ester of DHA (pro-drug based on DHA delivery). Ventricular tachypacing (VTP)-induced congestive heart failure (CHF) provides a clinically-relevant animal model of AF associated with structural remodelling, as is often seen clinically. It has been shown that sustained oral PUFA administration suppresses CHF-induced AF-promotion and fibrosis in the VTP canine model. Nicotinyl ester of DHA was tested in this model, at 1g/day and 5g/day, during 4 weeks, to prevent CHF-related atrial structural remodelling and AF promotion in dogs. Nicotinyl ester of DHA dose dependently reduced heart failure-induced increases in atrial fibrillation duration (989 ± 111 sec, n=5 in the presence of placebo versus 637 ± 196 sec, n=5 in the presence of 1g/kg/d Nicotinyl ester of DHA and 79 ± 51 sec, n=5, in the presence of 5g/kg/d Nicotinyl ester of DHA.

The protective effect of Nicotinyl ester of DHA was associated with a marked increase of plasma level of DHA and important incorporation of DHA in the left atrial tissue. Because F373280
similarly to Nicotinyl ester of DHA increases plasma level of DHA, it could be estimated that the compound may exert a similar protective effect [1].

1.2.2.2. Safety pharmacology

A battery of safety pharmacology studies was performed to evaluate the effects of F373280 on the central nervous, cardiovascular and respiratory systems. Data of these studies are exhaustively detailed in the Investigator’s brochure [1]. No particular alerts were evidenced with F373280.

1.2.2.3. Toxicology profile

Concerning the toxicological data, 4-week and 26-week repeat-dose studies in rat and dog were performed. Compared to the high administered doses of F373280 (500 to 2000 gm/kg/day), low circulating concentrations of F373280 were measured.

During these toxicity studies, no toxicity was observed in rat after 4 and 26 weeks of dosing and in dog after 4 weeks of dosing. A NOAEL of 2000 mg/kg/day was established in these repeat toxicity studies.

During the 26-week toxicity study in dogs, the NOAEL was set at 1000 mg/kg/day based on changes observed on red blood cell parameters.

Based on toxicological profiles, F373280 is considered to support the proposed clinical trial.

1.2.2.4. Pharmacokinetic data

According to animal studies described in the Investigator’s brochure [1], the non-clinical pharmacokinetic profile of F373280 is not associated with particular alerts concerning the proposed clinical phase IIa study.

1.2.3. Clinical data

Part A: single dose
6 consecutive single ascending doses were tested (0.5g, 1g, 2g, 4g, 8g and 16g) on 6 independent cohorts of 8 subjects (6 verum + 2 placebo). 49 subjects were treated and 48 completed the study.

No Serious Adverse Events occurred in the course of the study.

Regarding the reported Treatment Emergent Adverse Events (TEAEs) that were judged by the Investigator as having a causal relationship with the study drug administration in the absence of an alternative explanation, 4 were observed in the placebo group (palpitation, dizziness in standing position, 2 symptomatic orthostatic hypotensions without loss of consciousness) and 4 in the group of F373280 at the dosage of 16g (meteorism, liquid stool, symptomatic orthostatic hypotension and dizziness in standing position). None of these adverse events were reported in the groups of F373280 at the dosages of 0.5g, 1g, 2g, 4g and 8g.

After a single administration of the different tested doses no difference between the tested product and placebo has been reported, regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters (related to coagulation: platelets and fibrinogen) and coagulation parameters (bleeding time, prothrombin time/INR, activated partial thromboplastin time, thrombin clotting time). Variations of these parameters were within the physiological ranges.

After single oral administration of F373280 from 0.5g to 16g in 36 young male healthy subjects (6 per dose level), the following was observed:

- **F373280**: Whatever the tested dose there is no circulating F373280 in plasma: only few, sparse and non consecutive samples with quantifiable level of F373280 close to LOQ were observed. This confirm that F373280 is a prodrug.
- **Panthenol**: Cmax and AUC increased with the administered dose between 0.5 and 16g. Panthenol concentrations were rapidly cleared from plasma with a mean terminal half-life around 2 hours.
- **DHA**: after 0.5 and 1g, low increased in DHA plasma concentrations compared to the baseline levels led to a high inter-individual variability of the corresponding PK parameters. Plasma exposure in DHA increased with the administered dose between 2 and 16g with no departure from proportionality (baseline corrected parameters).
Part B: Multiple dose

Three consecutive repeated ascending doses (1, 2 and 4g) were tested on 3 independent cohorts of 12 subjects (9 verum + 3 placebo, double blind). 36 subjects completed the study. Each treatment was administered over a period of 28 days. Pharmacokinetic parameters were assessed over a period of 14 days.

Among the TEAE judged by the investigator as suspected to F373280 5/9 TEAE were classified according the SOC in vascular system disorder with orthostatic hypotension (2 in the 1 g group, 1 in the 2 g group and 2 in the 4 g group) and 4/9 were classified in nervous system disorder with 3 dizziness (2 in the 2 g group and 1 in the 4 g group) and 1 migraine (in the 1 g group). These TEAE have already been reported with Poly Unsaturated Fatty Acids and are commonly observed in phase I studies.

After a repeated administration of the different tested doses, no difference between the tested products and placebo was reported regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters. The assessment of coagulation parameters and platelet function after administration of repeated dose of F373280 did not report any bleeding issue. The reported changes in coagulation parameters and platelet function were within physiological ranges.

After a 14-day repeated oral administration of F373280 from 1 g to 4 g, the following was observed:

- **Panthenol**: Cmax and AUC increased with the administered dose between 1 and 4 g. No accumulation of panthenol in plasma was observed.
- **DHA**: Plasma exposure increased with dose. A 2-fold accumulation in total plasma exposure of DHA was observed after 14 days of administration, whatever the administered dose.
1.3. STUDY RATIONALE

F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation (AF) patients with chronic heart failure.

The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of atrial fibrillation (AF) induced by burst pacing [1].

Moreover, the effectiveness of PUFA has been proven in the following conditions:

- Prevention of atrial fibrillation recurrence in patients with persistent atrial fibrillation in co-administration with amiodarone (add on therapy) [2],
- Improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]

Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent atrial fibrillation and chronic heart failure.

This phase IIa study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure.

1.4. OVERALL RISK AND BENEFIT ASSESSMENT

F373280 is a new pro-drug of DHA.

DHA is a well-known long chain PUFAs with a long-term clinical experience in cardiovascular diseases. DHA is contained in several medicinal products such as Omacor®, (1g of Omacor contains about 320 mg of DHA acid) marketed by Laboratoires Pierre Fabre for hypertriglyceridemia and as an adjuvant treatment for secondary prevention after myocardial infarction. According to the summary product characteristics of Omacor®, [9]:

...
- The frequencies of adverse reactions are ranked according to the following: common (>1/100, < 1/10); uncommon (>1/1000 < 1/100); rare (>1/10000, < 1/1000); very rare ( < 1/10000), not known (cannot be estimated from the available data).

- The reported adverse events are:

  • Infection and infestations
    Uncommon: gastroenteritis
  • Immune system disorders:
    Uncommon: hypersensitivity
  • Metabolism and nutrition disorders:
    Rare: hyperglycaemia
  • Nervous system disorders:
    Uncommon: dizziness, dysgeusia
    Rare: headache
  • Vascular disorders:
    Very rare: hypotension
  • Respiratory thoracic and mediastinal disorders:
    Very rare: nasal dryness
  • Gastrointestinal disorders:
    Common: dyspepsia, nausea
    Uncommon: abdominal pain, gastrointestinal disorders, gastritis, abdominal pain upper
    Rare: gastrointestinal pain
    Very rare: lower gastrointestinal haemorrhage
  • Hepatobiliary disorders:
    Rare: hepatic disorders
  • Skin and subcutaneous tissue disorders:
    Rare: acne, rash pruritic
    Very rare: urticaria
  • General disorders and administration site conditions:
    Rare: malaise sensation
• Investigations:

  Very rare: white blood count increased, blood lactate dehydrogenase increased

Moderate elevation of transaminases has been reported in patients with hypertriglyceridaemia.

Panthenol is a well-known substance with a long-term experience in medical, nutraceutic and cosmetic uses. According to the summary product characteristics of a product such as Bépanthene® (tablet indicated in alopecia) which contains panthenol (100 mg), adverse event observed are rare cases of urticaria and erythema [10]. Panthenol is metabolised in panthotenic acid, i.e. B5 vitamin.

Concerning toxicological studies performed results can support the administration of F373280 in the proposed clinical phase II study without particular alert [1].

Any safety warning was reported during a phase I study performed with F373280 administered to 84 healthy volunteers in single dose in a range between 500 mg and 16 g or in repeated dose during 28 days in a range between 1g and 4g. Adverse events reported and related to study treatment were minor to moderate. The adverse events were palpitations, orthostatic hypotension, dizziness, meteorism and liquid stool. Most were reported in both groups (placebo and F373280) without a dose relationship. The assessment of coagulation parameters and platelet function after administration of repeated dose of F373280 did not report any bleeding concern: the reported changes in coagulation parameters and platelet function were within physiological ranges.

Moreover, DHA has been associated with anticoagulant products in Atrial Fibrillation studies [2, 8]. The range of PUFAs doses tested was between 2g to 3g (640 mg to 960 mg of DHA) and the range of study durations between 6 to 12 months. This association did not report a significant side effect of bleeding.

DHA has already been used in heart failure patients in several studies without safety concern [3, 4, 5]. The range of PUFAs doses tested was between 1g to 5g (1g of the tested PUFAs contains about 320 mg of DHA acid) and the range of study durations was between 3 months to 3.9 years.
Thus, inclusion of patients with no specific antiarrhythmic treatment is acceptable. They will receive an anticoagulant treatment to prevent the thrombo-embolic complications of AF (particularly stroke) and the adequate treatments to control the heart rate and heart failure.

In conclusion, the overall available data allow in safe conditions the treatment of patients with persistent AF and chronic heart failure with F373280 in safe conditions.

2. STUDY OBJECTIVES

2.1. PRIMARY OBJECTIVE

The primary objective of the study is to assess the efficacy of F373280 on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure.

2.2. SECONDARY OBJECTIVES

The secondary objectives of the study are to assess:

- the efficacy of F373280 on the efficiency of direct electrical cardioversion
- the effect of F373280 on echocardiographic parameters
- the safety and tolerability of F373280

3. ETHICAL CONSIDERATIONS RELATING TO THE STUDY

The trial is conducted according to Good Clinical Practices (CPMP/ICH/135/95), the National regulations and the Declaration of Helsinki and its subsequent amendments (see Appendix 17.1). This protocol and the informed consent form will be submitted for approval to independent local or national Institutional Review Boards/Ethics Committees before the study set up, according to national regulation.

All the protocol amendments or critical events liable to increase the risks incurred by the patients or to compromise the validity of the study or patients’ rights will be submitted to the coordinator and to the Ethics Committees.
After being informed orally and in writing of all potential risks and constraints of the trial, as well as their freedom to withdraw their participation at any time, patients will then sign a consent.

A time of reflection will be given to the patients, before giving a written consent and starting the study procedures.

The use of a placebo is in accordance with EMA Addendum to the guideline on antiarrhythmics on atrial fibrillation and atrial flutter (EMA/CHMP/EWP/213056/2010) [21] and is acceptable because the included patients will remain under the standard treatment of atrial fibrillation and chronic heart failure. Except antiarrythmics, they will receive anticoagulant (AVK), rate control treatment, chronic heart failure treatment. During the study, in case of AF recurrence that would require a cardioversion or an introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms, patients will be withdrawn and the tested product stopped. These patients will be considered as treatment failure.

In this study, patients will be carefully screened, particularly for their cardiac condition, with ECG, 24-hour holter monitor and echocardiographic data, and their biologic and coagulation condition.

The study will be addressed only to patients requiring an ECV due to their persistent AF, in the following conditions:

- ECV in patients not presenting a contra-indication,
- Anticoagulation with anti-vitamin K for at least 3 weeks before ECV,
- ECV in patients with stabilized INR (i.e. values between 2 and 3) on at least 3 consecutive weekly tests performed. Patients not stabilized for INR (i.e. values between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed in the same day (before ECV)
Patients who do not revert to sinus rhythm or present an early relapse within the observation period after ECV will be withdrawn and the tested product stopped.

During the whole study, patients will remain under medical control: visits in cardiology units will be scheduled at least every month. This follow up will include clinical signs, ECG, biological and coagulation parameters. Moreover, patient’s cardiac rhythm will be monitored between visits using daily, then every 2 days Trans Telephonic ECG Monitoring (TTEM) reviewed by a Central Reading Laboratory.

Patients may withdraw from the study at any time without having to give a reason and can expect to receive regular conventional therapy.

4. STUDY DESIGN

4.1. OVERALL DESCRIPTION

This phase IIa trial will be conducted as an international, multicentric, 24 weeks, double-blind, placebo-controlled, randomised, parallel group design, trial in 152 patients suffering from persistent atrial fibrillation and chronic heart failure.

After a 1 to 4-week of run-in period without treatment, patients will be randomised into one of the following treatment groups: F373280 1g or placebo for 24 weeks.

Nine visits are planned for the study:

- Visit 1 (V1): W-4 to W-1: Selection visit (7 to 28 days before the Inclusion Visit)
- Visit 2 (V2): D1: Inclusion visit (start of treatment)
- Visit 3 (V3): W4 (D28 -2/+7D): cardioversion visit (outpatient or hospitalization according to clinical practice of the centre) (installation of the Holter ECG device)
- Visit 4 (V4): W5 (D35 ± 2D): follow-up visit (removing of Holter ECG device and installation of the TTEM)
- Visit 5 (V5): W8 (D56 ± 7D): follow-up visit
- Visit 6 (V6): W12 (D84 ± 7D): follow-up visit
- Visit 7 (V7): W16 (D112 ± 7D): follow-up visit
- Visit 8 (V8): W20 (D140 ± 7D): follow-up visit
4.2. DISCUSSION OF THE STUDY DESIGN

4.2.1. Choice of the Study Population

The target indication of F373280 will be the maintenance of sinus rhythm after cardioversion of patients with persistent atrial fibrillation and chronic heart failure. In the present proof of concept study, the evaluation will focus on patients within this indication. This target population is justified by:

– The proved efficacy of PUFAs in patients with persistent atrial fibrillation with or without heart failure in co-administration with amiodarone (add on therapy) [2]
– The proved efficacy of PUFAs on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]

The study aim is to investigate the product effect in patients with:

– early persistent atrial fibrillation history (less than one year) with a duration of a the current episode between 7 days to 6 months
– a moderately abnormal moderately systolic heart failure (Left Ventricular Ejection Fraction (LVEF) between 30 to 45% as defined in the report from the American Society of Echocardiography’s Guideline). According to a sub-group analysis performed in patients with persistent atrial fibrillation associated to heart failure (Nodari S. personnel data), PUFAs would be effective to prevent recurrence of AF after cardioversion in patients with moderately abnormal LVEF.

– A Left Atrial Area (LAA) not severely abnormal (less than 40 cm² as defined in the report from the American Society of Echocardiography’s Guideline). According to a sub-group analysis performed in patients with persistent atrial fibrillation associated to heart failure (Nodari S. personnel data), PUFAs would not be effective to prevent recurrence of AF after cardioversion of patients with severely abnormal LAA.

For the successful rate of electrical cardioversion, patients should have a stable medical treatment of heart failure and should not have myocardial infarction or unstable angina or
unstable ischemic coronaryopathy (assessed by coronarography or cardiac stress test or effort test within 6 months before selection).

4.2.2. Choice of the Study Design

As the target indication would be the prevention of AF recurrence after ECV, the study design meets the requirements of EMA guideline on anti-arrhythmics on atrial fibrillation (EMA/CHMP/EWP/213056/2010) [21].

As F373280 aims to be developed as a safe treatment for the prevention of AF recurrence, it will not be tested as an add-on therapy during the study. To avoid any interaction with the tested product, anti-arhythmics class I and III will be forbidden during the study.

The study design is defined in order to avoid methodological bias. A double blind study is appropriate to assess the efficacy and safety of the use of F373280 to prevent recurrence of AF episodes. Moreover, this study design is similar to the design of almost all trials that have assessed intervention for rhythm control [2, 8, 11, 12].

According to the target indication, only patients with persistent atrial fibrillation and requiring an electrical cardioversion will be included in order to assess the time to first documented recurrence of atrial fibrillation since cardioversion.

To confirm the persistent nature of atrial fibrillation, a 24-hour holter monitoring will be performed during the selection visit.

Eligible participants will enter a selection phase in which anticoagulant treatment (anti-vitamin K) will be adjusted to achieve an International Normalized Ratio (INR) of 2.0 to 3.0 before electrical cardioversion. According to guidelines for the management of atrial fibrillation [6], anti-vitamin K should be given at least 3 weeks before cardioversion because of risk of thrombo-embolism due to post-cardioversion.

Experimental data suggest that the maximal incorporation, of n-3 PUFAs in the myocardial cell membrane takes up to 28 days to occur [22]. In addition, as shown in Nodary study [2], the duration of pre-treatment with PUFA before cardioversion appears to be a contributing factor in
success. Therefore, before starting follow up for the assessment of AF recurrence, treatment with F373280 should be started 28 days before ECV.

Detection of atrial fibrillation recurrence will be performed using systematic (scheduled) ECG recording, thus allowing detection of asymptomatic (about 50% of episodes) as well as symptomatic AF episodes. According to previous studies, most of atrial fibrillation recurrence occurred during the first days after cardioversion \[11, 15\]. So that, the heart rhythm will be closely monitored during the first week after successful cardioversion using an ambulatory continuous 7-day holter ECG recording in order to increase sensibility to detect asymptomatic AF episodes. Thereafter, to improve patient compliance, this follow up will be continued using a more easy to carry and easy to use device, a TTEM.

Finally, during the study, patients will be scheduled for a clinical visit every month (with an additional visit 7 days after visit 3 (ECV visit)) in order to ensure a close medical monitoring and to assess efficacy and safety parameters.

### 4.2.3. Choice of the Dose

According to a previous study in patients with atrial fibrillation [2], the tested PUFA product (Omacor®) at the dose of 2 g (i.e. 640 mg of DHA acid) was effective in the prevention of atrial fibrillation after cardioversion. Moreover, PUFAs at dosage of 1g and 2g were also effective on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5].

From the F373280 phase I study, after a 14-day repeated administration of F373280 (1g/day), observed plasma concentrations of DHA measured before treatment (Cmin) were similar to that of an effective dose of Omacor® at 2 g/day (60 to 95mg/mL and 60 to 90mg/mL, respectively) (phase I study of F373280 and Salm and coll study) [16]. With regard to the rhythm of administration, mean peak/trough fluctuation (baseline corrected) was around 0.3. This value supports a once-daily administration allowing a 24-hour plasma exposure in DHA. Therefore, a dose of 1 g daily of F373280 is considered to be appropriate to be tested in this POC study.
4.2.4. Choice of the Sample Size

See chapter 13.

5. STUDY POPULATION

Each patient fulfilling all the inclusion criteria and none of the non inclusion criteria will be eligible.

5.1. INCLUSION CRITERIA

**Demographic Characteristics and Other Baseline Characteristics:**

1. Men or women aged more than 18 years (inclusive),
2. Patient with persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted.
3. History of first documented persistent AF less than 1 year
4. History of ischemic or non ischemic heart failure
5. NYHA class I or II chronic heart failure at selection and at inclusion
6. Reduced left ventricular ejection fraction between 30% and 45% inclusive (using the two-dimensional echocardiography biplane Simpson’s rule) at selection and at inclusion
7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers
8. Left atrial area ≤ 40 cm² at selection and at inclusion
9. Patient treated or having to be treated by anti-vitamin K
10. For female patient of child-bearing potential:
    - use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator, for at least 2 months before the selection in the study and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment or
    - documented as surgically sterilized
11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion

**Ethical/legal considerations:**

12. Having signed his/her written informed consent,
13. Affiliated to a social security system, or is a beneficiary (if applicable in the national regulation),

5.2. NON INCLUSION CRITERIA

**Criteria related to pathologies:**

1. History of first documented episode of persistent AF more than 1 year,
2. More than two successful cardioversions (electrical or pharmacological) in the last 6 months,
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV),
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be check in case of treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic coronaryopathy assessed by coronaryography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
7. Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration rate < 30 mL/min) at selection
8. Bradycardia (HR ≤ 50 bpm)
9. Hyperkalemia or hypokalemia (K > 5.5 mEq/L or K < 3.5 mEq/L) at selection
10. Cardiac surgery within 3 months before selection or planned during the study duration

**Criteria related to treatments:**

11. Previously ineffective pharmacological or electrical cardioversion
12. Concomitant treatment with any anti-arrhythmic drug (within 7 days prior to selection), except stable dose of digoxin, beta-blockers, calcium-blockers.
13. Previous treatment with oral amiodarone within 12 months prior to inclusion
14. Previous treatment with intravenous amiodarone within 6 months prior to inclusion
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT implantation within the last 6 months
16. Treatment with any Polyunsaturated Fatted Acid within the last 3 months
   Dietary supplement with ω3 or ω6 according to investigator’s judgment
18. Having undergone any form of ablation therapy for AF
19. Patient treated with other anticoagulant treatment than antivitamin K: thrombin inhibitor such as Dabigatran or treated with antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel

**Others criteria:**

20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion,
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection,
22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself / herself to its constraints,
23. Patient family member or work associate (secretary, nurse, technician…) of the Investigator,
24. Patient having forfeited his / her freedom by administrative or legal award or being under guardianship,

**5.3. NUMBER OF PATIENTS**

76 x 2 patients (taking into account 15 % of non evaluable patients).
5.4. RECRUITMENT MODALITIES

Patients will be recruited within the medical consultation of each centre involved in the study. If necessary and when authorized by local and national regulation, some specific supports or tools will be used to improve the recruitment (announcement, mailing to general practitioners, leaflet, website including ClinicalTrials.gov, CRO,…).

Before implementation, the documents will be submitted to and approved by the Ethics Committee.

5.5. PATIENTS IDENTIFICATION

The patient's code will contain 7 digits: the 2 first digits corresponding to the country number, the following 2 digits corresponding to the centre number and the last 3 digits corresponding to the patient's chronological order once having signed the written informed consent.

5.6. WITHDRAWAL CRITERIA

The reasons for a patient's premature withdrawal from the study may be the following:

- The patient's decision. A patient who wishes to withdraw from the study for any reason may do so at any time but must inform the investigator. In all cases, the Investigator should attempt to contact the patient as soon as possible for a final assessment in order to:
  - have the patient's decision written on the consent form
  - obtain the reason(s) for withdrawal and report it/them in the case report form
  - evaluate the patient's clinical condition
  - if necessary, take appropriate therapeutic measures: management of an adverse effect or concomitant disease, prescription of another treatment.

- The Investigator's decision in the patient's interest. Particularly, if a serious adverse event occurs and is considered by the Investigator liable to threaten the health of the patient. The monitor will be informed by phone or fax and a letter or report explaining the withdrawal will be forwarded to the monitor as soon as possible.
• An erroneous inclusion according to the study protocol. Any inclusion not respecting inclusion / non inclusion criteria will immediately be withdrawn and an appropriate treatment will be instored by the investigator under his/her responsibility. Erroneous inclusions will not be paid to the investigator.

• Patients who could not be treated with anti-vitamin K for at least 3 weeks before ECV,

• Patients who will not stabilize INR between 2 and 3 on at least 3 consecutive weekly tests

• Patients with only 2 consecutives INR tests between 2 and 3 in the last 3 week for whom a trans-oesophageal echocardiography can not be performed before ECV or for whom a trans-oesophageal echocardiography shows a thrombus in the atria.

• Patients who will not revert to sinus rhythm or with early relapse within the observation period after ECV (i.e. unsuccessful ECV) will be considered to have finished follow-up.

• An occurrence of AF recurrence that would require, at the investigator’s judgement, a cardioversion or an introduction of an anti-arrhythmic because of intolerable and uncomfortable clinical symptoms.

5.7. REPLACEMENT OF PATIENTS
Withdrawn patients will not be replaced.

5.8. POST-STUDY EXCLUSION PERIOD
Patients will not be allowed to participate to another clinical trial during 3 months following the study termination.

5.9. STUDY CARD
The patient will receive from the Investigating Centre at Visit 1 - Selection Visits, a personal card to be kept all along the study duration and providing the following information: patient's name, sponsor's name, study code, EUDRACT number, start date and expected end date of the study, complete address of the Investigating Centre with the name and phone number of the Investigator.
and a sponsor 24H/24 phone contact number in case of emergency (French and English languages): 33 (0)5 63 35 25 83.

6.  STUDY TREATMENT

The Clinical Pharmacy Department of the *Institut de Recherche Pierre Fabre (IRPF)* will supply the investigational centres with the treatment necessary for the conduct of the trial.

6.1.  SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT

F373280 and placebo will be prepared in Soft Capsules similar presentation.

- **F373280**

Formulation of F373280, 1g, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: Panthenyl ester of DHA, gelatine, glycerol, titanium, dioxide, purified water.

- **Placebo**

Formulation of placebo matching tested product, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: paraffin liquid, fish flavour, gelatine, glycerol, titanium, dioxide, purified water.

Placebo and F373280 capsules will be packaged in opaque blisters.

6.2.  PACKAGING AND LABELLING

The treatment units will be packed and labelled by the Clinical Pharmacy Department of the *IRPF* according to European Directive and local requirements.

6.2.1.  Packaging

Each treatment unit will be composed of 3 cases for a 12-week treatment period.

The Investigator will provide the patient with the treatment according to the following schedule:

At Inclusion Visit (V2): a 12-week treatment unit will contain 3 cases, each case containing:
– 10 blister packs of four 1g F373280 soft capsules or placebo soft capsules each.

At Visit 6 (V6): a 12-week treatment unit will contain 3 cases, each case containing:
– 10 blister packs of four 1g F373280 soft capsules or placebo soft capsules each.

6.2.2. Labelling

Investigational Products will be labelled according to the following rules:

Labelling should comply with the local requirements for Investigational Medicinal Products.

On the treatment units and cases, the labels will bear the following indications:

   a) name and address of the sponsor
   b) protocol number,
   c) packaging batch number,
   d) the treatment number
   e) storage conditions
   f) expiry date
   g) pharmaceutical dose form
   h) route of administration
   i) quantity of dosage units
   j) direction for use
   k) legal statements:
      – “for clinical trial only”, “keep out of the reach and the sight of children”, “please return to your doctor any unused product”, respect the prescribed dose”.

On the treatment unit, another label will be affixed with the mention of the investigator name and patient number (completed by the investigator).

In addition, on each case, will be mentioned the case number and a detachable label will bear the following indications:

– Protocol number
– Packaging batch number
– Expiry date
– Case number
– Treatment number

On the blister pack, the label will mention the protocol number, the packaging batch number, the case number and the treatment number.
6.3. DISTRIBUTION TO CENTRE AND STORAGE

The Clinical Pharmacy Department of the IRPF will supply the Investigational Centre with the treatment units along the study according to the need, upon request triggered by the patient’s selection.

As soon as the Pharmacist or the Investigator receives the trial medication, he/she will check the contents and immediately acknowledges the receipt in the IVRS/IWRS. The copy of the acknowledgement will be kept in the Investigator’s file. The same procedure will be applied to all further supplies during the course of the trial.

At the time of the delivery to the Centre, the following information will be provided:

- Details of storage conditions that should be respected
- And, upon request and for the 1st delivery only, a letter of release for the Investigational Medicinal Product from the Sponsor's Qualified Person.

The CRA will ensure during the monitoring visits that trial medications have been received in good conditions and the acknowledgment of receipt has been performed adequately.

Treatment units should remain intact until dispensation to the patients. They should be kept at temperature below 30°C in an appropriate lockable room only accessible to the person authorised to dispense them, under the responsibility of the Pharmacist or the Investigator.

In the case of undue delay in study execution, the Pharmacist or the Investigator should ensure that the expiry date has not been exceeded.

6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT

A randomisation list will be established by the Clinical Pharmacy Department of the IRPF. This list will be computer-generated with internal software. The randomisation methodology is validated by the Biometry Department before generation.

Treatments F373280 or placebo will be balanced in a 1:1 ratio.
As the treatment units are prepared for 12-week treatment periods, the Investigator will have to allocate a treatment number at inclusion Visit and another one at Visit 6.

For each patient, the treatment number given at Visit 6 will not be the same that the one given at inclusion visit (V2).

The treatment numbers will be given through the IVRS/IWRS.

Practically, once the patient’s eligibility is confirmed, at selection visit:

- The Investigator:
  - Calls the vocal server
  - Answers the questions relating to the patient
  - In return, the treatment number to be allocated for the first 12-week period to the patient is given by the vocal server.

- The IVRS/IWRS company:
  - Confirms this information by fax/email to the Investigator
  - Fills the “Request for Delivery of Investigational Product” form and sends it by email and/or fax to the Clinical Pharmacy Department of the IRPF.

- The Clinical Pharmacy Department of the IRPF sends the corresponding treatment unit to the Investigator within 5 days from reception of the email request form.

The Investigator will dispense to the patient the case which label indicates the treatment number and the administration period.

At visit 5, the Investigator will contact again the IVRS/IWRS to obtain for visit 6 the treatment number for the last 12-week period of treatment according to the same process as described above.
6.5. **DRUG ADMINISTRATION**

6.5.1. **Duration of Treatment**

For a patient completing the study, the theoretical study treatment exposure will be 24 weeks, with F373280 or placebo.

If the ECV is postponed by 1 week to allow INR stabilization, the treatment duration will be 25 weeks.

6.5.2. **Dose Schedule**

One soft capsule of 1g of F373280 or placebo to be taken each day during 24 weeks.

6.5.3. **Route and Conditions of Administration**

The soft capsules are to be taken orally. One soft capsule is to be taken each evening with the dinner during 24 weeks.

6.6. **ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT**

The Investigator should maintain accurate written records of drug received, dispensed, returned and any remaining treatment units, on the drug accountability form. These records should be made available for Clinical Research Associate (CRA) monitoring. The packaging of the medication should remain intact until just before the dispensation.

At each visit, the Investigator will record the number of soft capsules returned by each patient using the appropriate page of the e-CRF.

At the end of the study, all used and unused treatments including packaging should be noted, and return is organised by the CRA to the Clinical Pharmacy Department of the IRPF for destruction. A copy of the drug accountability form should be provided by the Investigator to the CRA.
6.7. RECALL OF INVESTIGATIONAL PRODUCTS

In case of recall of investigational products (decided by the Competent Authorities or the Sponsor), the Investigator will immediately be informed by the Sponsor.

The Investigator, in collaboration with the Sponsor representatives (Study Manager, CRA) must urgently:

- Stop the delivery of the concerned investigational products to the patients.
- Inform the concerned patients that they must immediately stop taking these investigational products and bring them back.

The Study Manager/CRA organises the return of the recalled products to the Clinical Pharmacy Department of the IRPF, according to the Sponsor’s procedures.

7. CONCOMITANT TREATMENTS

Any existing concomitant treatment (Selection Visit), any new concomitant treatment or change in the dosage of an existing concomitant treatment during the course of the study must be noted on e-CRF. All treatments should be evaluated by the investigator at selection and their prolongation during the study or their stop should be considered.

For all concomitant treatments taken during the study, the following information must be noted in the relevant section(s) of the e-CRF:

- The name of the treatment and its form
- The reason for prescription
- The route of administration
- The daily dose
- The duration of treatment.
7.1. ANTI-VITAMIN K TREATMENT

Anti-vitamin K should be given for at least 3 weeks before ECV and continued for the whole study duration. The anti-vitamin K used will be left to the decision of the each investigator according to his/her local practice.

7.2. PROHIBITED TREATMENTS

- Class I and class III antiarrhythmic treatments:
  - Class I
    - Class IA: Disopyramide, Procainamide, Quinidine
    - Class IB: Lidocaine, Mexiletine
    - Class IC: Flecainide, Propafenone
  - Class III: Dofetilide, Ibutilide, Sotalol, Amiodarone, Dronedarone.
- Any Polyunsaturated Fatty Acid (PUFA)
- Any anticoagulant treatment other than antivitamin K: thrombin inhibitor such as Dabigatran or antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel
- Dietary supplement with Omega 3 or Omega 6

Prohibited treatments at selection must not be prescribed for the duration of the study except in case of occurrence of an adverse event or AF episode that requires a corrective treatment in the interest of the patient’s health.

7.3. AUTHORISED TREATMENTS

Other treatments will be authorised during the study duration.

However, if medication other than study drugs is administered at any time from the start of the study, details must be recorded in the case report form. During the study, patients must be asked whether they have been on a course of prescribed drug treatment or have taken any OTC or herbal drugs since the visit.
8. EVALUATION CRITERIA

8.1. PRIMARY EFFICACY CRITERION:

8.1.1. Time to the first Atrial Fibrillation Recurrence

8.1.1.1. Definition

Time to first Atrial Fibrillation recurrence is defined by the first episode of Atrial Fibrillation (symptomatic or not) lasting for at least 10 minutes.

8.1.1.2. Schedule

The heart rhythm follow up will be performed from the end of electrical cardioversion visit (visit 3) to the final study visit (visit 9).

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF will be assessed after visit 3 (week 5).

8.1.1.3. Evaluation Methods

- 7-day holter monitor:

  The heart rhythm monitoring will be carried out from visit 3 to visit 4 using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) fixed after ECV visit.

  Following holter monitoring the heart rhythm will be documented using Trans Telephonic ECG Monitoring (TTEM)

- Trans Telephonic ECG Monitoring (TTEM):

  Thus, the follow up will be documented using the TTEM: daily transmission from visit 4 to visit 6. Then, every two days from visit 6 to visit 9.

  Moreover, during this TTEM period, if patient experiences AF symptoms, it should be documented using the TTEM.
In case of AF recurrence, and provided that the patient does not required a cardioversion or an introduction of an anti-arrhythmic at the investigator’s judgement, he/she could be maintained in the study with the treatment, in order to assess a spontaneous cardioversion. For that purpose the patient will continue to transmit a TTEM once a week.

The TTEM will be centralized by the Central Reading Laboratory. The patient will be requested to contact the Central Reading Laboratory for transmission of each stored TTEM. The TTEM will be validated by a trained technician, then analysed by a cardiologist. The cardiologist interpretation will be faxed to the site. The investigator will be asked to review and sign this document.

The TTEM process will be fully described in a separate document.

8.1.2. **Secondary Efficacy Criteria**

8.1.2.1. **Numbers of Atrial Fibrillation episodes in the first week following visit 3 (ECV visit)**

8.1.2.1.1. **Definition**

Number of Atrial Fibrillation episodes will consist in the assessment of episodes of AF with duration at least 10 minutes ($N_{\text{Sup10}}$) and of less than 10 minutes ($N_{\text{Inf10}}$), respectively.

8.1.2.1.2. **Schedule**

The heart rhythm follow up will be performed from the end of successful electrical cardioversion visit (visit 3) to the study visit 4.

8.1.2.1.3. **Evaluation Methods**

- 7-day holter monitor:

The heart rhythm monitoring will start using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) after ECV visit from visit 3 to visit 4.
8.1.2.2.  

**Duration of Atrial Fibrillation episodes in the first week following visit 3 (ECV visit)**

8.1.2.2.1. **Definition**

Duration of AF episodes will consist in the sum of duration of each AF episodes.

8.1.2.2.2. **Schedule**

The heart rhythm follow up will be performed from the end of successful electrical cardioversion visit (visit 3) to the follow up study visit (visit 4).

8.1.2.2.3. **Evaluation Methods**

Duration of AF episodes will be assessed using the 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording.

8.1.2.3. **Clinical parameters evaluation**

8.1.2.3.1. **EHRA score assessment**

8.1.2.3.1.1. **Definition:**

AF related symptoms will be evaluated by the EHRA (European Heart Rhythm Association) score [20]. The following items “during presumed arrhythmia episodes” are checked to determine the score: palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety.

Classification of AF-related symptoms (EHRA score) are as follows:

- **EHRA I** - ‘No symptoms’
- **EHRA II** - ‘Mild symptoms’; normal daily activity not affected
- **EHRA III** - ‘Severe symptoms’; normal daily activity affected
- **EHRA IV** - ‘Disabling symptoms’; normal daily activity discontinued

This classification relates exclusively to the patient-reported symptoms.
In addition to this score, the frequency will be classified in three groups, namely occasionally (less than once per month); intermediate (1/month to almost daily); and frequent at least daily.

8.1.2.3.1.2. Schedule
This evaluation will be performed in case of symptoms evocative of arrhythmia.

8.1.2.3.1.3. Evaluation Methods
This evaluation will be collected by Central Reading Laboratory during all the study period.

8.1.2.3.2. Number of recurrence of symptomatic AF
It consists of number of AF recurrence associated with a symptom (Palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety) and confirmed by an ECG in atrial fibrillation.

8.1.2.3.3. Number and duration of hospitalization
- Number and duration of hospitalization for cardiovascular events
  - Hospitalization for AF treatment
  - Hospitalization for worsening of heart failure
  - Hospitalization for myocardial infarction
  - All cause of hospitalization
- Number and duration of hospitalization for thromboembolic stroke

8.1.2.4. Cardioversion assessment
- Assessment of spontaneous cardioversion before visit 3
- Assessment of successful cardioversion at visit 3 (i.e. return to sinus rhythm)
- Shock distribution (1, 2 or 3 shocks)
- Number of patients needing another cardioversion after initial ECV
8.1.2.5.  **Evolution of echocardiographic parameters**

8.1.2.5.1.  **Definition**

The following echocardiographic parameters will be assessed: Left atrial diameter (mm), Left atrial area (cm$^2$), Left atrial volume (mL), Left atrial volume/BSA (mL/m$^2$), Left ventricular ejection fraction (%), Left ventricular volume (mL), Left ventricular volume/BSA (mL/m$^2$), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL), Left ventricular end systolic diameter (mm) and Left ventricular end systolic volume (mL).

8.1.2.5.2.  **Schedule**

The measurements will be performed at visit 1 and visit 2 to check the eligibility of the patient.

The measurements performed at visit 4, visit 6 and visit 9 are done to follow the echocardiographic evolution of the patients in sinus rhythm.

8.1.2.5.3.  **Evaluation method**

The echography evaluations will be carried out according to the recommendations for chamber quantification drawn up by the American Society of Echocardiography and the European Association of Echocardiography [23]. So, for volume measurements, the recommended method is to use the biplane method of discs (modified Simpson’s rule) from 2-D measurement.

8.2.  **BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA**

8.2.1.  **Definition**

Because of the limited accessibility of human tissues for biopsy, red blood cell DHA contents is a marker for tissue DHA concentration [13], [14].
8.2.2. Blood samples

8.2.2.1. Collection schedule

Blood samples will be collected for determination of red blood cells (RBC) concentrations of DHA.

Blood samples will be performed as follows:

- Visit 2 before treatment, visit 3, visit 6 and visit 9.

Actual sampling times will be individually reported in the electronic Case Report Forms (e-CRFs).

8.2.2.2. Technical handling

Two blood samples will be collected containing EDTA. They will be gently shaken and centrifuged at 3000g for 15 min at room temperature, within 30 minutes after collection. Plasma and white blood cells will be discarded. Red blood cells will be stored at +4°C (no freezing will be allowed) and sent to Analytical Centre in refrigerated conditions (between +2°C and +8°C) within 3 weeks following collection. Analysis will be performed within 2 weeks following reception at the Analytical centre.

8.2.3. DHA concentration measurement

Analytical determination of RBC concentrations of DHA will be carried out by the Analytical Centre.

Lipids will be extracted from red blood cells samples with a mixture of hexane/isopropanol, after acidification [17]. Total lipid extracts will be saponified and methylated. The fatty acid methyl esters (FAME) will be extracted and analyzed by Gas Chromatography.

Identification of FAME will be based on retention times obtained for FAME prepared from fatty acid standards. The area under peaks will be determined using ChemStation Software (Agilent) and results will be expressed as % of total fatty acids. DHA concentration will be calculated using the internal standard and expressed as µg/g for red blood cells samples. Thus, omega-3 index will
be assessed. The omega-3 index represents the content of EPA plus DHA in red blood cells (expressed as a percent of total fatty acids). It is a biomarker considered as a new marker of risk for death from coronary disease [18].

Results of this analytical determination will be kept confidential by the dosing centre until the end of the study, and will be provided only at the end of the study (after database lock), in a separate file.

8.3. SAFETY ASSESSMENT

8.3.1. Adverse Events

At selection, any concomitant disease will be reported on the e-CRF. At each further visit, the occurrence of adverse events (AEs) since the last visit will be based on the patient's spontaneous reporting, the investigator's non-leading questioning and his/her clinical evaluation. All AEs will be reported on the e-CRF (see section 10).

8.3.2. Laboratory Investigations

8.3.2.1. Schedule

Laboratory investigations will be performed at visit 1 (before treatment) and visit 9 (end of treatment) or End of Treatment visit.

At visit 3 and 6, only an haematology examination will be performed.

Furthermore the kaliemia will be checked before electrical cardioversion at visit 3.

The volume of blood samples complete haematology, biochemistry should not exceed 30 mL.

8.3.2.2. Technical Procedures and Parameters

The following tests will be performed:

**Haematology:** Hematocrit, haemoglobin, Red blood cells (RBC) count, white blood cells (WBC) count, WBC differential counts (% and absolute), reticulocytes, platelets.
Chemistry: sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatine phosphokinase (CPK), fibrinogen.

Blood samples will be taken in the morning, in fasting conditions.

The estimation of GFR at selection relies on the measurement of serum creatinine and the Cockcroft-Gault formula

- with serum creatinine expressed as mg/L:

\[
GFR \text{ (mL/min)} = \frac{[(140 - \text{age}) \times \text{weight}]}{7.2 \times \text{serum creatinine in mg/L}},
\]

- with serum creatinine expressed as μmol/l:

\[
GFR \text{ (mL/min)} = \frac{[(140 - \text{age}) \times \text{weight}]}{\text{serum creatinine in μmol/l}} \times k, \text{where } k = 1.23 \text{ for men, 1.04 for women.}
\]

(weight in kg, age in years)

Additional tests may be done at the Investigator’s discretion, in the patients’ interest. In case of any abnormal or clinically significant results, the Investigator will order laboratory control tests.

8.3.3. Global Physical Examination

A global physical examination including the measurement of body weight will be carried out on each body system at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.

The physical examination will be globally evaluated as “normal/abnormal”. Further target inspection will be undertaken for any abnormal finding.

8.3.4. Vital Signs

Vital signs will consist in blood pressure and heart rate at rest.
8.3.4.1. Schedule
Vital signs will be measured at each visit.

8.3.4.2. Technical Procedure and Parameters
Systolic (SBP) and diastolic (DBP), expressed in mmHg, will be measured after at least 5 minutes in supine position and after 2 minutes in standing position.

The heart rate (HR), expressed in beats per minute (bpm), will be measured by auscultation, after at least 5 minutes in supine position and after 2 minutes in standing position by counting the beats for at least 30 seconds.

Bodyweight will be measured in patient in underwear and with the same balance at each visit.

8.3.5. Electrocardiogram (ECG)

8.3.5.1. Schedule
An electrocardiogram will be recorded at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9 using an usual standardised 12-lead cardiograph.

8.3.5.2. Technical Procedure and Parameters
- Electrocardiogram (ECG):

  The global interpretation from manual reading (normality, clinical relevance) and heart rate (bpm), PR (ms), QRS (ms), QT (ms), repolarisation patterns will be reported in the e-CRF. Each print-out will include the patient’s code, date, time, technician's initials and investigator's signature.

  In case of thermic paper ECG print out, a photocopy will be made by the centre to ensure safe filing.

- 24 hour-Holter - ECG

  An ambulatory continuous 24-hour ECG (5-leads/2 or 3 channels) will be recorded at selection visit using a holter ECG, in order to confirm persistent atrial fibrillation.
8.3.6. Coagulation parameters

The assessment of coagulation will be evaluated by the following parameters:
- Prothrombin Time/INR (PT/INR)
- Activated Partial Thromboplastin Time (aPTT)
- Thrombin Clotting Time (TCT)

During the pre-cardioversion period, if the anticoagulation by AVK should be initiated, then the INR monitoring will be as follow:
- INR 2-3 times a week for the first week of treatment
- INR weekly up to ECV,
- INR every 4 weeks after ECV

For patients already treated with AVK, INR monitoring will be as follow:
- INR weekly up to ECV,
- INR every 4 weeks after ECV

aPTT and TCT will be performed at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.

Anti-coagulation by anti-vitamin K should be given at least 3 weeks before ECV and continued for the whole study duration.

The quantity of blood samples collected at each time for coagulation parameters will be 2 mL.

8.3.7. Concomitant Treatments

Concomitant treatments will be evaluated at each study visit.

Requirements relating to patient's concomitant treatments started before screening visit and continued throughout the trial, or started during the trial can be found in section 7.

8.4. COMPLIANCE

The patient will be reminded at each visit to bring back any remaining soft capsules, blister, case (used or unused) at the following visit.

At each visit, the Investigator will record the number of supplied and remaining Soft Capsules in the e-CRF.
9. STUDY PROCEDURES

Visit 1 - Selection Visit (Week -4 to Week -1)

The patient considered eligible for selection by the Investigator will be informed of the characteristics and the consequences of the trial both verbally and by reviewing the patient's information sheet and consent form (see section 14.3). If he/she accepts to participate in the study, he/she will sign the informed consent and will keep a copy.

The patient will be assessed for the following:

- Demographic characteristics (gender, age, height, body surface area)
- Personal and medico-surgical history
- Habits (Tobacco, alcohol consumption, dietary habits including fish consumption…)
- Cardiovascular diseases, mainly detailed history of Heart Failure and Atrial Fibrillation characteristics
- Echocardiography using a two-dimensional echocardiography.
- 12-lead ECG
- Concomitant diseases, adverse signs or symptoms (able to be used for treatment emergent AE determination)
- Concomitant treatments (authorised, disallowed)
- Global physical examination/bodyweight
- Vital signs
- Biology: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Biology assessment of renal function: creatinine or estimated glomerular filtration rate

If the results of the above assessments are compatible with the selection criteria
- A 24-hour continuous ECG ambulatory recording (Holter ECG) device will be installed on the patient to monitor the patient heart rhythm. The patient will be requested to bring back the device after the termination of 24 hours recording. The recording will be transmitted from the Investigational site to the Central Reading Laboratory (CRL). The CRL will send his/her assessment regarding the confirmation of persistent atrial fibrillation within 2 working days to the Investigator.

- The patient will enter the selection period in which anticoagulant (anti-vitamin K) will be adjusted to achieve an International Normalized Ratio (INR) of 2 to 3 before electrical cardioversion.

At the end of the visit, the Investigator will contact the IVRS/IWRS system to confirm the patient selection and order the treatment delivery and organise the appointment for the next visit.

The patient will receive from the investigational centre the study card to be kept for the duration of the study.

**Visit 2 - Inclusion Visit (Day 1)**

If the patient's behaviour during the selection period and/or the result of complementary examinations particularly the confirmation of the presence of persistent atrial fibrillation by the CRL during this period, the INR and laboratory tests, are compatible with the inclusion criteria, the patient will be assessed for the following:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: red blood cell concentrations of DHA and coagulation parameters Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Global Physical examination/bodyweight
- Vital signs
- Echocardiography using a two-dimensional echocardiography.
- 12-lead ECG
- Urine pregnancy test for women of child bearing potential.

If the results of the above assessments are compatible with the inclusion criteria, the patient will be included and allocated a treatment number using the IVRS/IWRS system.

Between this Inclusion visit and the next visit (V3), the INR will be closely monitored (refer to paragraph 8.3.6), in order to ensure that the INR is stable, between 2 to 3 before electrical cardioversion.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week period.

**Visit 3 (Week 4: D28 -2/+7 days) cardioversion**

Patient will be assessed for the following criteria:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: Haematology, Red Blood Cell concentrations of DHA, Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Global Physical examination /bodyweight
- Vital signs
- 12-lead ECG

- Electrocardioversion (ECV): ECV has to be scheduled 4 weeks after randomization and after target international normalized ratio levels will be stabilized (between 2 and 3) on at least 3 consecutive weekly tests in patients with AF. Patients not stabilized for INR (i.e. values between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed in the same day (before ECV). ECV will be performed in the morning, with the patient in the fasting state and without dyskalemia. Anesthesia will be
induced and patients will be cardioverted with administration of a synchronized, biphasic current. The initial shock will be set at 100 J if the body weight is less than 70 kg and at 150 J for higher body weights. Successful cardioversion will be defined as recovery of sinus rhythm lasting at least 1 minute after the shock. If unsuccessful, a second 200-J shock, and eventually a third 200-J shock, will be administered. Failure of ECV is defined as the persistence of AF after the third attempt at cardioversion. After the procedure, patients will be monitored on telemetry for at least 6 hours before discharge. Patients who will not revert to sinus rhythm or with early relapse within the observation period after ECV will be withdrawn from the study and will be considered to have finished their follow-up.

At the end of the visit, a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) will be installed on the patient in order to monitor the patient heart rhythm after ECV.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week period.

**Visit 4 (Week 5: D35 ± 2 days)**

After removal of the continuous ECG ambulatory device, the patient will be assessed for the following criteria:

- Assessment of Adverse Events
- Concomitant treatments (authorised, disallowed)
- Vitals Signs
- Echocardiography using a two-dimensional echocardiography

At the end of the visit, the patient will be given the TTEM device (Trans Telephonic ECG Monitoring) for cardiac monitoring. The patient will be clearly instructed on the frequency and modalities of transmission. The patient will be requested to performed daily transmission from week 6 to week 8, then every 2 days from week 9 to week 24. Moreover, in case of AF symptoms additional transmission may be performed.
Visit 5 (Week 8: D56 ± 7 days) – Visit 6 (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days) - Visit 8 (Week 20: D140 ± 7 days)

Patient will be assessed for the following criteria:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT). However, in case of discontinuation of anticoagulation after ECV, the monitoring of INR, aPTT and TCT should be stopped.
- Global Physical examination/bodyweight
- Vital signs
- 12-lead ECG
- The cardiac monitoring will be continued using a TTEM device (Trans Telephonic ECG Monitoring). The device will be given to the patient who will be requested to performed daily transmission from week 6 to week 8, then every 2 days from week 9 to week 24. Moreover, in case of AF symptoms additional transmission may be performed.

The Investigator will collect all the cases, blisters and any unused soft capsules and count the unused capsules for each 4-week treatment period.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week treatment period.

In addition:

- at visit 5, the investigator will contact the IVRS/IWRS to obtain another treatment unit to be dispensed at visit 6 for the last 12-week period.

- at visit 6, an echocardiography will be performed, an haematology examination will be done and the red blood cell concentration of DHA will be measured.

**End-of-Study Visit - Visit 9 (Week 24: D168 ± 7 days)**
Patient will be assessed for the following:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Global Physical examination/bodyweight
- Vital signs
- 12-lead ECG
- Laboratory examination: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT). Red blood cell concentration of DHA.
- Urine pregnancy test for women of childbearing potential
- Echocardiography using a two-dimensional echocardiography

The Investigator will collect all the cases, blisters and any unused soft capsules and count the unused soft capsules.

10. ADVERSE EVENTS: DEFINITION AND REPORTING

10.1. ADVERSE EVENTS

10.1.1. Definition of Adverse Events

An adverse event is any adverse change from the patient's baseline condition, *i.e.* any subjective signs and symptoms or change in a concomitant disease present at the Selection Visit considered or not related to the treatment.

This includes intercurrent signs, symptoms, illnesses and significant deviations from baseline for vital signs and laboratory values, which may occur during the course of the clinical study.

All laboratory tests for which abnormal results are collected after study treatment initiation should be repeated until the values return to normal or to a stable status. Abnormal results are defined as
those falling out of the laboratory normal ranges and that are clinically significant. The frequency of such checks should be defined by the Investigator according to the degree of abnormality.

In all cases, the aetiology should, as much as possible, be identified and Pierre Fabre Médicament notified.

10.1.2. Grading of Adverse Events

Adverse or intercurrent events are graded as follows:

- **Mild**: awareness of signs or symptoms, but easily tolerated
- **Moderate**: uncomfortable enough to cause interference with usual activity
- **Severe**: incapacity with inability to work or do usual activity.

10.1.3. Reporting of Adverse Events

The records of adverse events in the electronic Case Report Form (e-CRF) describe the nature (diagnosis, signs and symptoms), severity, onset date, stop date, outcome and actions taken, and relationship to study treatment (in the Investigator's opinion). It must be specified whether the event is serious or not.

10.2. SERIOUS ADVERSE EVENTS (SAE)

10.2.1. Definition

A serious adverse event (SAE) includes, but is not necessarily restricted to any event which:

- Results in death (whatever may be the cause)
- Is life-threatening
- Results in persistent or significant disability/incapacity
- Requires the patient's hospitalisation or prolongation of current hospitalisation *
- Is a congenital anomaly or birth defect.
Other events such as cancer, and any additional adverse experience or abnormal laboratory values occurring during the study period, defined by the protocol as serious or which the Investigator considers significant enough, or that suggest a significant hazard, contra-indications, side effect or precaution, must be handled as serious adverse events.

Any overdosage meeting a seriousness criteria should be reported as a SAE (see section 10.3).

Any pregnancy occurring during/after exposure to the study drug(s) should be reported on the SAE notification form (see section 10.4).

* any hospitalisation, or prolongation of hospitalisation due to the circumstances listed below:
  - planned (as per protocol) medical/surgical procedure,
  - preparation for routine health assessment/procedure (e.g. routine colonoscopy),
  - planned medical/surgical admission (planned prior to entry into study trial, appropriate documentation required),
  - administrative or social reasons (e.g. lack of housing, economic inadequacy, care-giver respite, family circumstances)

will not be reported as a SAE.

10.2.2. Reporting of SAE

All serious adverse events, according to the above-mentioned definitions and regardless of treatment or relationship to study drug, must be recorded by the Investigator as soon as he/she is informed of the event.

The Investigator must notify the Sponsor of this event by sending, within 24 hours, the "Notification of serious adverse event" form ("first notification") (see appendix 17.2) with all the available information about the event, to the Sponsor's representative:

Marlène GUIRAUD, Pharm D
INSTITUT DE RECHERCHE PIERRE FABRE,
Centre de R&D Pierre Fabre – BP 13562
3 Avenue Hubert Curien
31035 TOULOUSE Cedex 1
Phone: +33 5 35 50 63 48
Fax: +33 5 34 50 65 92
Email: marlene.guiraud@pierre-fabre.com
In case of non-inclusion the reporting period ends when the non-inclusion is documented.

10.2.3. Follow-up of SAE

The Investigator must draw-up a specific clinical report and use the "Notification of serious adverse event" form ("follow-up") (see appendix 17.2) and collect the results of the carried out examinations and the reports of hospitalisation.

The serious adverse events must be followed up until resolution or stabilisation.

10.2.4. SAE Occurring After the Study

Any SAE occurring during 30 days following the end of the study for the patient should be notified to the Sponsor.

Must also be notified to the Sponsor any event occurring at any time after the end of the study for the patient which may be related to the study treatment in the Investigator's opinion.

10.3. REPORTING OF OVERDOSAGE TO THE SPONSOR

For the purpose of this trial an overdosage will be defined as any dose exceeding the planned prescribed dose of the study drug or the administration of any dose of an associated product that is considered both excessive and medically important.

In the absence of seriousness criteria, the overdosage, and associated adverse event if any, are reported only on the Adverse Event page of the CRF. If the definition of seriousness criteria is met, the SAE notification form must be also transmitted to the sponsor.

10.4. REPORTING OF PREGNANCY TO THE SPONSOR

Pregnancies discovered in the period in between the informed consent form signed but before any study drug exposure are not to be reported to the sponsor unless associated to a seriousness criteria (e.g. serious adverse event study-protocol related procedure). If pregnancy is confirmed, the women must not be administered the study drug and be withdrawn immediately from the study.
If pregnancy is suspected while the patient is receiving study treatment, the study drug(s) should be discontinued immediately until the result of the pregnancy testing is known. If pregnancy is confirmed, then the study treatment is permanently discontinued in an appropriate manner and the patient is discontinued from the study.

The investigators must report to the sponsor any pregnancy which occurs during or after the patient has been exposed to the study drug and until 30 days after the last study drug administration. The investigator must immediately notify the sponsor using the SAE notification form and also report the pregnancy on the AE page of the e-CRF.

Women who become pregnant after exposure to the study drug must be followed by the investigator until the completion/termination of the pregnancy. If the pregnancy goes to term, the outcome will have to be reported to the sponsor (baby's healthy status).

10.5. SPONSOR'S RESPONSIBILITIES FOR SAFETY REPORTING PURPOSES

Sponsor will submit expedited and periodic reports to both Competent Authorities and Ethics Committees per corporate standard operating procedures as regards to the EU directive 2001/20/EC taking into account local specific requirements.

11. DATA COLLECTION AND STUDY MONITORING

11.1. DATA COLLECTION

11.1.1. Case Report Form

An electronic Case Report Forms (e-CRF) will be used to record all patient data required by the protocol except the central ECG (Holter ECG, TTEM) and DHA data which will be transferred from vendors to the subcontractor as electronic data files and which will be loaded into the study database.

The e-CRF should be fully validated, compliant with ICH-GCP requirements and European regulations and include a traceability system for data corrections and deletions (audit trail).
Prior to the start of the study, the Investigator will complete a "Delegation of significant study-related duties" form. The signature and initials of all personal in charge of e-CRF completion should be recorded on this form. Each person involved in e-CRF completion, review, correction and/or validation will be trained and will have an individual login and access code to the e-CRF.

Training sessions will be held by the subcontractor for all participants who will use this tool. An e-CRF user manual will be available for investigators and CRAs.

All the information included into the e-CRF will be recorded from source documents onto the e-CRF by an authorised person.

The Investigator is responsible for the management and accuracy of the information on the e-CRF. At each monitoring visit, the e-CRF(s) should be at the CRA's disposition for review and validation.

At the end of the study, a CD-ROM containing the pdf version of all e-CRF (including audit-trail) will be sent by the subcontractor to the Sponsor and to the investigational sites for archiving. The subcontractor must store all study data for at least 15 years after the end of the study and ensure their legibility and accessibility during all the storage period.

11.1.2. Source Documents

A source document is an original record or certified copy of an original record of clinical findings, observations or any other medical or paramedical activities performed during the clinical trial, necessary for the transcription and the verification of the collected data.

Source documents along with all other trial-related documents (copies of all "informed consent" forms, e-CRFs CD-ROM, drug inventories and any correspondence related to the study) must be kept in the investigator's file throughout the study, and then, must be stored in the study centre's archives for a period of at least 15 years or as per local legal requirements, whatever is the longest.

For further details see section 15.2.
11.2. STUDY MONITORING

11.2.1. Monitoring visits

On-site visits will be carried out by a representative of the Sponsor's staff (Study Manager or CRA) prior to study initiation and at regular intervals (every 4 to 6 weeks) throughout the study. Additional visits and communication by telephone, fax or meeting may be performed if necessary. Any site visit performed by the Sponsor's representatives will be recorded in the Investigator's study file.

11.2.1.1. Site Preselection Visit

Before selecting a centre for the study, a visit will be carried out by the CRA and/or the Study Manager to ensure that the Investigator has the necessary capacities (availability, patient's recruitment, environment), technical means and staff to carry out the study.

11.2.1.2. Initiation Visit

Before the start of the study at all investigation sites, an initiation visit will be carried out by the CRA to check at the latest that:

- The Investigator:
  - has received the technical protocol, administrative and financial agreement signed by all parties
  - has received the written statement of the Ethics Committee approval and the list of its members and their functions

- The original dated and signed *curriculum vitae* of the investigator(s) has been collected

- Laboratory normal ranges have been collected

- All study materials are available on the study site

- All participants agree with the monitoring procedures and know the study procedures

- All participants are aware of a possible audit or inspection
The CRA has also to provide training on the study protocol requirements and study specific procedures.

11.2.1.3. **Follow-up Visits**

Throughout the study, regular follow-up visits will be carried out by the CRA to check compliance with GCP, patient’s informed consents, strict application of the protocol, conformity of the data entered on the e-CRF with the source documents and ensure its correct completion, adverse events reporting, proper retention, storage and management of the study medication, as well as the source and other trial-related documents.

11.2.1.4. **Closing Visit**

At the end of the study, a final visit will be carried out by the CRA to:

- Verify that the e-CRFs CD-ROM with pdf files are correctly stored
- Control the accountability of intact and used treatment units and return them to the Clinical Pharmacy Department of the **IRPF** for destruction
- Obtain the last data clarifications and/or solutions if any
- Collect the patient's consent forms in sealed envelopes,
- Make an on-site review of all study documentation and complete it if necessary
- And finally, remind the Investigator of his regulatory obligations, study document archiving process and duration.

11.2.2. **Direct Access to Source Documents**

In accordance to the requirements of the GCP, all Sponsor representatives (Study Manager, CRA and Auditors) have to be given a direct access to all source and study data to perform quality monitoring/audit, thus ensuring accuracy and completeness of data).

Investigators are reminded that all Sponsor representatives keep professional confidentiality with regards to the patient data.
11.3. INDEPENDENT DATA MONITORING COMMITTEE

An Independent Data Monitoring Committee (IDMC) will be established to assess at intervals the progress of the clinical trial, the compliance with the inclusion criteria, the quality of follow up, the quality of measures of primary end point, the safety data and to recommend to the Sponsor whether to continue, modify, or to stop the study.

The IDMC operating procedures will be described in an independent document.

12. DATA MANAGEMENT

All clinical data related to the study will be collected and saved in a computerised database by the Data Management Department of the subcontractor and under the supervision of the Data Manager of Pierre Fabre Biometry (PFB) according to the following procedures.

12.1. DATA ENTRY

All required data will be collected by the Investigator or authorised designee (duly identified into the delegation task list) on a e-CRF.

The e-CRF used for this study will be developed and maintained by the Data Management Department of the subcontractor and approved by the Sponsor.

Electronic data (Holter ECG, TTEM and DHA) will be transferred by the 3rd party vendor according to the specifications given by the Data Manager of the subcontractor. These data will be captured and handled in accordance with the European GCP ICH E6 guideline.

12.2. DATA CLEANING

The subcontractor will define in the Data Validation Plan for reviewing and querying data, descriptions of both manual and electronic edit checks. Upon Sponsor approval, the subcontractor will program the checks.
The subcontractor will review the data over the course of the study, working with the Sponsor to identify data inconsistencies. The Investigator will be asked to resolve queries by making changes directly into the e-CRF.

12.3. DATA CODING

Adverse events, concomitant diseases, medical/surgical histories will be coded by the subcontractor using the MedDRA dictionary (latest version in use).

Concomitant medication will be coded by the subcontractor using the WHO-DRUG dictionary (latest version in use).

The Sponsor Clinical Development Physician will validate coding.

12.4. DATA STORAGE

The computer data files, as well as their modifications, will be archived by the subcontractor and kept available upon request of the Sponsor.

12.5. DATABASE LOCK

The validated database will be locked by the subcontractor upon request of the Data Manager of PFB following the completion of all steps required, i.e.: data entry and check of all data, resolution of all queries, validation of the coding, Clinical and Products Safety databases reconciliation and validation committee.

Then, the subcontractor will transfer the locked database in SAS format to the Data Manager of PFB who assume storage on the PFB secured server.

13. STATISTICAL ANALYSIS

After the database lock and the randomisation code release, the statistical analysis will be performed by Pierre Fabre Biométrie (PFB) or under the supervision of the statistician of PFB using SAS® software, according to the Statistical Analysis Plan (SAP) approved by the Validation Committee.
13.1. GENERAL CONSIDERATIONS

The main objective of the study is to assess the efficacy of F373280 versus placebo on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure.

Only the primary analysis of the primary efficacy criterion, on which is based the sample size justification, may lead to a causal interpretation. All other statistical results are to be regarded within a descriptive perspective.

The statistical significance level of the various two sided tests of all analyses will be 5 %.

13.2. SAMPLE SIZE

Assuming an AF recurrence rate of 85% under placebo and 65% under active group, i.e. a clinically relevant difference $\Delta$ of 20%, a sample size of 64 evaluable patients per group is required, using a log-rang test of survival curves with a 80 % power and a 5 % two-sided significance level.

According to the previous assumptions and assuming a rate of not assessable patients of 15%, a minimum of 76 patients will have to be randomised per group.

13.3. PROTOCOL DEVIATIONS

Prior to the database lock and the randomisation code release, the Validation Committee members will review the protocol deviations and will classify them as either minor or major. A protocol deviation will be considered major when it is likely to bias significantly the treatment effect estimate based on the primary efficacy criterion.

Patients with major deviation(s) will be excluded from the Per Protocol data set (see section 13.4).

A listing of all protocol deviations will be provided for all randomised patients, including the type (major/minor) of protocol deviations according to the decisions made by the members of the Validation Committee.
The number and percentage of patients with major protocol deviations will be tabulated by treatment group and type of major protocol deviations on the Full Analysis Set defined in section 13.4.

13.4. DATA SETS ANALYSED

The following 2 data sets will be analysed (as defined by the Validation Committee):

- The Safety Set composed of all randomised patients having received at least one dose of the study treatment. This data set will be used to perform analyses of Safety.

- The Full Analysis Set (FAS) composed of all randomised patients having received at least one dose of the study treatment and with a successful cardioversion observed at visit 3. This data set will be used to perform analyses of Efficacy.

- The Per Protocol Set (PP) which is the subset of the Full Analysis Set composed of all patients with a primary efficacy criteria available and without any major protocol deviation or other source of bias for primary criteria analyses.

13.5. HANDLING OF DROPOUTS AND MISSING DATA

13.5.1. Dropouts

The number of patients who withdraw from the study after their randomisation will be provided by treatment group for all treated patients (Safety Set). All withdrawn patients will be further described regarding their time to dropout and reasons for withdrawal.

13.5.2. Repositioning of Visits

No repositioning of visits will be done.

13.5.3. Missing Data

Missing values will not be substituted by estimated values, but considered as missing in statistical analysis.
13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS

Before the first trial drug intake, patient’s background, medical and surgical history, demographic data and disease characteristics will be described by treatment group on the Safety Set.

- **Quantitative parameters** will be described by treatment group and overall using the following: number of patients, number of missing data, mean, standard deviation, minimum, median and maximum values.

- **Qualitative parameters** will be described by treatment group and overall using frequencies.

Concomitant diseases, as well as medical and surgical histories will be tabulated descriptively by treatment group and overall using the MedDRA codes of System Organ Classes and preferred terms.

If more than 10% of patients are excluded from the FAS and PP set, the description of patients by treatment group at selection and inclusion will be repeated on the FAS and PP set for all parameters.

No statistical test of comparability of treatment groups at baseline will be performed.

13.7. EFFICACY ANALYSIS

13.7.1. Primary Criterion

13.7.1.1. Primary Analysis

The primary criteria, time to first recurrence, will be analysed using the Kaplan Meier method and compared with the Log rank test. Hazard ratios and 95% confidence intervals will be estimated with the Cox regression model.

The primary analysis will be performed on the FAS.

13.7.1.2. Supportive Analysis

The primary analysis will be repeated on the PP set.
13.7.2. Secondary Criteria

All secondary analyses will be performed on the FAS. If more than 10% of patients are excluded from the PP set, the secondary analyses will be repeated on the PP set.

13.7.2.1. Numbers of Atrial Fibrillation Episodes

Both the numbers of AF episodes (symptomatic or not) lasting for at least 10 minutes and with duration less than 10 minutes ($N_{\text{Sup10}}$ and $N_{\text{Inf10}}$) will be described by treatment group and compared by the chi-square test (or CMH test adjusted for centre) or Fisher’s exact Test.

13.7.2.2. Duration of Atrial Fibrillation Episodes

The duration of all AF Episodes will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centres effects) or Wilcoxon test.

13.7.2.3. Time to first AF recurrence less than 10 minutes or symptomatic

The time to the first AF recurrence less than 10 minutes and the time to the first symptomatic AF recurrence will be analysed as the primary analysis.

13.7.2.4. Clinical parameters evaluation

The EHRA score will be described by treatment group and analysed using a chi-squared test (or CMH test adjusted for centre) or Fisher’s exact Test.

The frequency of presumed arrhythmia will be described by treatment group.

The number of recurrence of symptomatic AF, of hospitalizations (for cardiovascular events, for thromboembolic stroke and for all causes), of spontaneous cardioversion, of successful cardioversion (including number of shocks distribution) and the number of patients needing cardioversion after initial ECV will be described by treatment group and compared using a chi-square test or a Fisher Test (if the numbers are relevant).
The duration of hospitalizations for cardiovascular events, for thromboembolic stroke and for any cause will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centre effects) or Wilcoxon test.

The echocardiographic parameters values will be described at each time (V1, V2, V4, V6 and V9) and changes described from V4 to V9 and from V2 to V9.

13.7.2.5. **Biomarker analysis: red blood cell concentrations of DHA**

Values and changes from baseline for red blood cell concentration of DHA will be performed by treatment group and assessment time.

13.8. **SAFETY ANALYSIS**

The Safety Set will be used to perform all analyses of the safety criteria.

13.8.1. **Adverse Events**

Any adverse event having been reported during the study for a given patients will be classified by preferred term and corresponding system organ class using the MedDRA terminology.

Adverse events will be classified as:

- Treatment emergent adverse events, *i.e.*, any adverse event which occurs or worsens on study treatment during the randomised period.
- Or non treatment emergent adverse events, *i.e.*, any adverse event which occurs during the run-in period (before V2) or is reported as concomitant disease with the same intensity.

For each study period, any patient with at least one reported adverse event will be classified as a patient:

- With at least one adverse event
- With at least one treatment emergent adverse event
- With one TEAE
- With two TEAE
• With at least three TEAE
• With at least one related TEAE
• With an adverse event leading to the study treatment discontinuation (definitive or temporary)
• With an adverse event leading to withdrawal
• With at least one serious adverse event.
• Numbers and percentages of patient with at least one reported treatment emergent adverse event will be tabulated by treatment group:
  • By system organ class
  • By system organ class and preferred term
  • By system organ class and preferred term, taking into consideration its most severe intensity
  • And by system organ class and preferred term, taking into consideration the most severe relationship to the study treatment.

Recurring adverse events (i.e., adverse events classified with the same preferred term) for a given patient will only be counted once and only their most severe intensity or most severe relationship to the study treatment will be tabulated.

"The number and percentage of patient with at least one most common (reported in 1% patients in any group) drug related TE AE ("not excluded or unassessable") will be tabulated by Preferred Term and Treatment group in decreasing order for the treatment group (for all patient).

The number and percentage of patients with at least one reported most common treatment emergent adverse event will also be plotted by treatment group. This graphical representation will highlight the frequencies of the most severe intensities reported by system organ class and preferred term.

Serious adverse events will also be described on an individual basis: treatment group, patient's code, sex and age, Investigator's reported term, preferred term, time of onset according to the time
of the first study treatment administration, duration, action taken regarding the study treatment administration, use of a corrective treatment, outcome and relationship to the study treatment in the Investigator's opinion.

13.8.2. Clinical Laboratory Evaluation

For each laboratory parameter, data will be tabulated by treatment group and assessment time.

The absolute changes post-trial drug administration - baseline (the baseline value being the value measured on the last blood sample collected before the first trial drug administration) will be calculated and tabulated by parameter, treatment group and post-trial drug administration assessment time. Results of retests performed post-trial drug administration will not be analysed and tabulated. They will only be displayed in individual data listings.

For all biochemistry parameters, scatter plots highlighting individual results will display the baseline and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 24 value in the ordinate.

For all haematology parameters, scatter plots highlighting individual results will display the baseline and week 4, week 12 and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 4, week 12 and week 24 value in the ordinate.

Each treatment group will be identified differently. The first bisecting line (45° line), the lines of lower and upper normal range, the lines of PSC range and CNALV range added on the plots (see Appendix 17.3).

For all blood laboratory parameters, shift tables will be provided to depict the numbers of patients with post-trial drug administration variations at each assessment time as compared to the baseline values (measured on the last blood sample collected before the first trial drug administration) by treatment group. A 3-point scale (low, normal, high) will be used as defined by the normal ranges in use in the laboratory in charge of the assays.
Clinically noteworthy abnormal laboratory values (CNALV) (see in Appendix 17.3) will be identified and described on an individual basis. If relevant, five separate individual data listings by treatment group will be provided:

- CNALV for haemoglobin (including corresponding individual results of erythrocytes and haematocrit)
- CNALV for neutrophils or leucocytes (including corresponding individual results of basophils, eosinophils, lymphocytes and monocytes)
- CNALV for platelets (including corresponding individual results of erythrocytes and leucocytes)
- CNALV for liver function parameters (including corresponding individual results of gamma-GT)
- CNALV for serum creatinine

13.8.3. Global Physical Examination

Recorded data of the global physical examination performed will not be tabulated as any abnormal findings post-randomisation should be reported as AEs (if clinically significant).

Physical examination assessments will be provided in the listings of individual data.

13.8.4. Vital Signs, Physical Findings and Other Observations Related to Safety

13.8.4.1. Vital Sign Measurements Over Time

For each parameter (systolic blood pressure, diastolic blood pressure and heart rate in supine and standing positions), descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.

13.8.4.2. Body weight

Descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.
13.8.4.3. **Individual Patient Changes**

The number and percentage of patients with at least one Predefined Potentially Clinically Significant Change (PSC) and with at least one PSC Leading to Clinically Significant Value (PSCV) will be tabulated by treatment group (see Table 1 in Appendix 17.3).

According to the pharmacological drug profile mentioned previously in this Protocol, the changes from baseline to the maximum and/or minimum post-baseline value could be categorized and tabulated by treatment group with frequencies and decreasing cumulative percentages.

If there is a signal of a drug effect toward one direction rather than the other, additionally shift tables of variations from baseline to the maximum or minimum post-baseline value could be also provided (see Table 2 to 4 in Appendix 17.3).

An individual data listing of patients with symptomatic or asymptomatic orthostatic hypotension will be provided by treatment group (see Table 5 in Appendix 17.3).

13.8.5. **ECG**

Frequencies on the clinical interpretation (normal, abnormal CS or NCS) will be presented by treatment group and assessment time. Individual tabulated data for ECG abnormalities will be also displayed.

13.8.6. **Coagulation parameters**

Scatter plots highlighting individual results for coagulation parameters (prothrombin time/INR, activated partial thromboplastin time and thrombin clotting time) before and after study treatment administration will be produced.

13.9. **CONCOMITANT TREATMENTS**

Concomitant treatments will be tabulated by treatment group within a descriptive perspective. They will be classified by therapeutic area according to the WHO-DRUG dictionary using the "anatomical therapeutic chemical" (ATC) classification on the safety set.
13.10. **COMPLIANCE**

The percentage of compliance will be described by treatment group using the quantity

\[ \text{Compliance}(\%) = \frac{\text{Estimated actual consumption}}{\text{Theoretical consumption}} \times 100 \]

with: *Estimated actual consumption* = number of tablets provided at the start of study (Visit 2) – number of tablets returned at the end of study (Visit 9).

*Theoretical consumption* = number of days of treatment intake planned between the start and the end of study (168 days ± 7 days).

13.11. **INTERIM ANALYSIS AND DATA MONITORING**

No interim analysis is planned.

14. **GENERAL ETHICAL CONSIDERATIONS**

14.1. **ETHICAL CONDITIONS**

This study is performed in accordance with the principles stated in the Declaration of Helsinki (1964) and subsequent amendments and in accordance with the Good Clinical Practice Guideline (CPMP/ICH/135/95).

14.2. **ETHICS COMMITTEE AND LEGAL REQUIREMENTS**

All the documents required by National Regulations and any other informative documents that may be requested are submitted for review to an Ethics Committee whose procedures and operations meet the GCP and National Legal Requirements.

Depending on National Regulations, the application is submitted to the Ethics Committee by the Sponsor (or representative) or by the Investigator.
A copy of the formal written approval from the Ethics Committee is provided to the Sponsor (directly by the Ethics Committee or via the Investigator) with a list of names and qualifications of its members.

The request for authorisation by the Competent Authority or its notification if required (depending on National Regulations) is carried out by the Sponsor.

The screening of patients does not start before the approval of the Ethics Committee has been obtained and the study authorised by the Competent Authority or notified to the Competent Authority (depending on National Regulations).

14.3. PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM

An information must be given to the patients before their decision to participate or abstain from participation.

This information is based on the elements set out in the Declaration of Helsinki and the ICH GCP Guidelines. It must also describe the measures taken to safeguard patient’s privacy and protection of personal data, according to European Directive 95/46 EC or other local regulation.

Restraints and risks must be explained, as well as the right to discontinue participation in the study at any stage, without affecting their further relationship with the Investigator and/or their future care.

The written information and consent form must be submitted to the patient with an oral explanation. It must be agreed and signed by the patient before any study-related procedure starts.

This information and consent procedure is under the Investigator’s responsibility.

The information and consent document are made in triplicate: the original copy is kept by the Investigator, one copy is given to the patient and the last copy is kept by the Clinical Quality Assurance Unit of the Sponsor in a sealed envelope at the end of study.
Specific areas of the Sponsor’s copy are not triplicated to avoid the reading of the patient’s surname (except the first 3 letters), first name, address and signature.

If any information becomes available during the trial that may be relevant to the patient’s willingness to keep on participating in the trial, an updated written informed consent must be submitted to the patient to confirm agreement to continue participating.

14.4. PERSONAL DATA PROTECTION

All information from this study (excluding data from the informed consent) is entered into a computer under the Sponsor’s responsibility in accordance with the French law, "Loi Informatique et Libertés" (January 6, 1978, and subsequent amendments) and with the European Directive 95/46/CE.

14.5. INSURANCE POLICY

In accordance with the provisions of the law and the GCP, the Sponsor Pierre Fabre Médicament, has an insurance policy intended to guarantee against possible damage resulting from the research.

The studies and/or experiments performed on behalf of the Sponsor Pierre Fabre Médicament, are specifically and expressly guaranteed.

It is advisable to underline that non compliance with the Research Legal Conditions is a cause for guarantee exclusion.

15. ADMINISTRATIVE PROCEDURES

15.1. PROTOCOL AMENDMENT

Neither the Investigator nor the Sponsor may alter the protocol without the authorisation of the other party.

All changes to the protocol are subject to an amendment which must be dated and signed by both parties and must appear as an amendment to the protocol.
Substantial amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities

Urgent amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities, but could be implemented immediately under specific conditions defined with the Sponsor.

15.2. SOURCE DOCUMENTS, INVESTIGATOR'S FILE STORAGE

The Investigator:

- Keeps all trial-related documents in appropriate file folders. Records of patient, original informed consent forms, source documents, a CD Rom containing a pdf copy of e-CRF, drug inventory, Ethics Committees and Sponsor correspondence pertaining to the study must be kept on file.
- Retains all documents relating to the screening (consent and investigation results) of all patients included in the trial or not
- Retains a list of the patient’s names, addresses (and/or number of medical file), code numbers to allow checking of data reported on e-CRFs with those from source documents
- Authorises direct access to source documents for monitoring, audits and inspections
- The trial-related documents must be retained as strictly confidential at the Investigator’s site for at least 15 years or according to local requirements, whatever is the longest after the completion or discontinuation of the trial (European Directive 2003/63/EC).

15.3. END OF THE STUDY

15.3.1. Definition of the End of Study

The end of study is the last visit of the last patient undergoing the trial.

Any change to this definition during the study, for whatever reason, must be notified as a substantial amendment.
15.3.2. Early Study Termination

15.3.2.1. Early Study Termination Decided by the Sponsor

The Sponsor may discontinue the study at any time for any of the following reasons:

- Lack of recruitment
- Deviations from good clinical practice and/or regulations
- Poor product safety
- New information that could jeopardise the patient’s safety
- Stopping of the development …

15.3.2.2. Early Study Termination Decided by the Competent Authorities

The Competent Authorities may suspend or prohibit a study if it considers that the conditions of authorisation are not being met or has doubt about the safety or scientific validity of the study.

15.4. AUDIT

The Sponsor is responsible for making sure that both his representatives (Study Manager, CRA, ...) and the Investigator fulfil the requirements as specified by the GCP Guideline.

An audit can be organised internally at Pierre Fabre Médicament and at the investigational site where the e-CRFs are matched against source documents.

All study documentation must be directly accessible to auditors.

The practical conditions for the audit are discussed between the Investigator and the Clinical Quality Assurance Department.

Oral information about the audit results are given to the Investigator.
15.5. INSPECTION

The Health Authorities may inspect any investigation site or the Sponsor in the course of the study or after its completion, to verify the conduct of the study and quality of the data. The Investigator must provide to the inspectors direct access to study documents.

15.6. CONFIDENTIALITY

The present materials (protocol and related documentation, e-CRF, Investigator's Brochure) contain confidential information.

Except if agreed to in writing with the Study Manager, the investigators must hold such information confidential, and must not disclose it to others (except where required by Applicable Law).

15.7. CLINICAL STUDY REPORT

Data analysis, and clinical study report writing are under the Sponsor’s responsibility.

Upon completion of the data analysis, a final report, including a review of the objectives and methods, a presentation and discussion of the results are drawn up according to ICH Guidelines (Structure and Content of Clinical Study Reports, ICH-E3, CPMP/ICH/137/95).

The report is a clinical and statistical integrated report. It must be signed by the Sponsor's representative(s) and the Coordinating Investigator.

15.8. STUDY RESULTS COMMUNICATION

Upon completion of the study, the global results of the Research are communicated to the investigator. According to the Local Regulation, the patient can ask the Investigator for the results.

15.9. STUDY RESULTS PUBLICATION

The information and data collected during the conduct of this clinical study are considered confidential and are used by the Sponsor in connection with the development of the study drug. This information may be disclosed if deemed necessary by the Sponsor.
To allow use of the information derived from this clinical study and to insure compliance with Current Regulations, the Investigator must provide the Sponsor with complete test results and all data collected during the study.

Only the Sponsor may make study information available to physicians and to Regulatory Agencies, except as required by Current Regulations.

All the results of this study including data, reports, discoveries and inventions resulting from the study, are the property of the Sponsor.

In the event the Sponsor chooses to publish study data, the manuscript must be provided to the author(s) at least 30 days prior to the expected date of submission to the intended publisher.

The investigator(s) can reserve the right to publish or present study data; if so, the manuscript or abstract must be provided to the Sponsor for review at least 30 days prior to the expected date of submission to the intended publisher or of planned presentation.

In addition, if necessary, (the) investigator(s) shall withhold publication for an additional 60 days, to allow the filing of a patent application, or to allow the Sponsor to take any measures he deems appropriate to establish and preserve his proprietary rights.

It is agreed that publication of study results by each site shall be made only as part of a publication of the study results obtained by all sites performing the protocol, once the study is completed and finalised.

The authors list is agreed by all investigators prior to publication. The names of the authors are provided according to their participation in the design of the protocol as well as their recruitment of eligible and analysable patients.
REFERENCES


n-3 Polyunsaturated Fatty Acids in the prevention of atrial Fibrillation Recurrences after electrical cardioversion. A prospective, Randomised study
Circulation, 2011; 124:1100-1106


Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy
J. Am. Coll. Cardiol. 2011;57;870-879


Dose-dependant effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of non ischemic origin: A double-blind, placebo-controlled, 3-arm study
American Heart Journal 2011; 161:915.e1-915.e9 - volume 161, number 5

[5] GISSI-HF INVESTIGATORS

Effects of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GSSI-HF Trial): a randomised, double-blind, placebo-controlled trial
The lancet on line - August 2008


Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Eur Heart J. 2010 Oct;31(19):2369-429

[7] KOWEY PR, REIFFEL JA, ELLENBOGEN KA, NACCARELLI GV, PRATT CM.

Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomised controlled trial.
*Europace (2011)* 13, 174-181

[9] **OMACOR®** SUMMARY PRODUCT CHARACTERISTICS (SPC) dated 17/02/2012

[10] **BEPANTHENE®** SUMMARY PRODUCT CHARACTERISTICS (SPC)


The consumption of food products from linseed-fed animals maintains erythrocyte omega-3 fatty acids in obese human

[18] HARRIS WS, VON SCHACKY C.
The Omega-3 Index: a new risk factor for death from coronary heart disease?

Effects of Polyunsaturated Fatty Acids n-3 (PUFA n-3) in the prophylaxis of atrial fibrillation relapses after external electric cardioversion
World Congress of Cardiology 2006, 2-6 September, Barcelona – Spain

Outcome parameters from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association.
Europace 2007, 9, 1006-1023

[21] EUROPEAN MEDICINES AGENCY
Addendum to the guideline on antiarrhythmics on atrial fibrillation and atrial flutter.
EMA/CHMA/EWP/213056/2010

Dietary fish oil dose- and time-response effects on cardiac phospholipid fatty acid composition.
Lipids. 2004;39:955–961

[23] ROBERTO M. LANG, MICHELLE BIERIG, RICHARD B. DEVEREUX, FRANK A. FLACHSKAMPF*, ELYSE FOSTER, PATRICIA A. PELLIKKA, MICHAEL H. PICARD, MARY J. ROMAN, JAMES SEWARD, JACK SHANEWISE, SCOTT SOLOMON, KIRK T. SPENCER, MARTIN ST. JOHN SUTTON, WILLIAM STEWART.
Recommendations for chamber quantification
17. APPENDICES
A. INTRODUCTION

1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of ethical principles for medical research involving human subjects, including research on identifiable human material and data. The Declaration is intended to be read as a whole and each of its constituent paragraphs should not be applied without consideration of all other relevant paragraphs.

2. Although the Declaration is addressed primarily to physicians, the WMA encourages other participants in medical research involving human subjects to adopt these principles.

3. It is the duty of the physician to promote and safeguard the health of patients, including those who are involved in medical research. The physician's knowledge and conscience are dedicated to the fulfilment of this duty.

4. The Declaration of Geneva of the WMA binds the physician with the words, “The health of my patient will be my first consideration,” and the International Code of Medical Ethics declares that, “A physician shall act in the patient's best interest when providing medical care.”

5. Medical progress is based on research that ultimately must include studies involving human subjects. Populations that are underrepresented in medical research should be provided appropriate access to participation in research.

6. In medical research involving human subjects, the well-being of the individual research subject must take precedence over all other interests.

7. The primary purpose of medical research involving human subjects is to understand the causes, development and effects of diseases and improve preventive, diagnostic and therapeutic interventions (methods, procedures and treatments). Even the best current interventions must be evaluated continually through research for their safety, effectiveness, efficiency, accessibility and quality.

8. In medical practice and in medical research, most interventions involve risks and burdens.

9. Medical research is subject to ethical standards that promote respect for all human subjects and protect their health and rights. Some research populations are particularly vulnerable and need special protection. These include those who cannot give or refuse consent for themselves and those who may be vulnerable to coercion or undue influence.

10. Physicians should consider the ethical, legal and regulatory norms and standards for research involving human subjects in their own countries as well as applicable international norms and standards. No national or international ethical, legal or regulatory requirement should reduce or eliminate any of the protections for research subjects set forth in this Declaration.
B. PRINCIPLES FOR ALL MEDICAL RESEARCH

11. It is the duty of physicians who participate in medical research to protect the life, health, dignity, integrity, right to self-determination, privacy, and confidentiality of personal information of research subjects.

12. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and adequate laboratory and, as appropriate, animal experimentation. The welfare of animals used for research must be respected.

13. Appropriate caution must be exercised in the conduct of medical research that may harm the environment.

14. The design and performance of each research study involving human subjects must be clearly described in a research protocol. The protocol should contain a statement of the ethical considerations involved and should indicate how the principles in this Declaration have been addressed. The protocol should include information regarding funding, sponsors, institutional affiliations, other potential conflicts of interest, incentives for subjects and provisions for treating and/or compensating subjects who are harmed as a consequence of participation in the research study. The protocol should describe arrangements for post-study access by study subjects to interventions identified as beneficial in the study or access to other appropriate care or benefits.

15. The research protocol must be submitted for consideration, comment, guidance and approval to a research ethics committee before the study begins. This committee must be independent of the researcher, the sponsor and any other undue influence. It must take into consideration the laws and regulations of the country or countries in which the research is to be performed as well as applicable international norms and standards but these must not be allowed to reduce or eliminate any of the protections for research subjects set forth in this Declaration. The committee must have the right to monitor ongoing studies. The researcher must provide monitoring information to the committee, especially information about any serious adverse events. No change to the protocol may be made without consideration and approval by the committee.

16. Medical research involving human subjects must be conducted only by individuals with the appropriate scientific training and qualifications. Research on patients or healthy volunteers requires the supervision of a competent and appropriately qualified physician or other health care professional. The responsibility for the protection of research subjects must always rest with the physician or other health care professional and never the research subjects, even though they have given consent.

17. Medical research involving a disadvantaged or vulnerable population or community is only justified if the research is responsive to the health needs and priorities of this population or community and if there is a reasonable likelihood that this population or community stands to benefit from the results of the research.

18. Every medical research study involving human subjects must be preceded by careful assessment of predictable risks and burdens to the individuals and communities involved in the research in comparison with foreseeable benefits to them and to other individuals or communities affected by the condition under investigation.

19. Every clinical trial must be registered in a publicly accessible database before recruitment of the first subject.
20. Physicians may not participate in a research study involving human subjects unless they are confident that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians must immediately stop a study when the risks are found to outweigh the potential benefits or when there is conclusive proof of positive and beneficial results.

21. Medical research involving human subjects may only be conducted if the importance of the objective outweighs the inherent risks and burdens to the research subjects.

22. Participation by competent individuals as subjects in medical research must be voluntary. Although it may be appropriate to consult family members or community leaders, no competent individual may be enrolled in a research study unless he or she freely agrees.

23. Every precaution must be taken to protect the privacy of research subjects and the confidentiality of their personal information and to minimize the impact of the study on their physical, mental and social integrity.

24. In medical research involving competent human subjects, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail, and any other relevant aspects of the study. The potential subject must be informed of the right to refuse to participate in the study or to withdraw consent to participate at any time without reprisal. Special attention should be given to the specific information needs of individual potential subjects as well as to the methods used to deliver the information. After ensuring that the potential subject has understood the information, the physician or another appropriately qualified individual must then seek the potential subject’s freely-given informed consent, preferably in writing. If the consent cannot be expressed in writing, the non-written consent must be formally documented and witnessed.

25. For medical research using identifiable human material or data, physicians must normally seek consent for the collection, analysis, storage and/or reuse. There may be situations where consent would be impossible or impractical to obtain for such research or would pose a threat to the validity of the research. In such situations the research may be done only after consideration and approval of a research ethics committee.

26. When seeking informed consent for participation in a research study the physician should be particularly cautious if the potential subject is in a dependent relationship with the physician or may consent under duress. In such situations the informed consent should be sought by an appropriately qualified individual who is completely independent of this relationship.

27. For a potential research subject who is incompetent, the physician must seek informed consent from the legally authorized representative. These individuals must not be included in a research study that has no likelihood of benefit for them unless it is intended to promote the health of the population represented by the potential subject, the research cannot instead be performed with competent persons, and the research entails only minimal risk and minimal burden.

28. When a potential research subject who is deemed incompetent is able to give assent to decisions about participation in research, the physician must seek that assent in addition to the consent of the legally authorized representative. The potential subject’s dissent should be respected.
29. Research involving subjects who are physically or mentally incapable of giving consent, for example, unconscious patients, may be done only if the physical or mental condition that prevents giving informed consent is a necessary characteristic of the research population. In such circumstances the physician should seek informed consent from the legally authorized representative. If no such representative is available and if the research cannot be delayed, the study may proceed without informed consent provided that the specific reasons for involving subjects with a condition that renders them unable to give informed consent have been stated in the research protocol and the study has been approved by a research ethics committee. Consent to remain in the research should be obtained as soon as possible from the subject or a legally authorized representative.

30. Authors, editors and publishers all have ethical obligations with regard to the publication of the results of research. Authors have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports. They should adhere to accepted guidelines for ethical reporting. Negative and inconclusive as well as positive results should be published or otherwise made publicly available. Sources of funding, institutional affiliations and conflicts of interest should be declared in the publication. Reports of research not in accordance with the principles of this Declaration should not be accepted for publication.

C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH MEDICAL CARE

31. The physician may combine medical research with medical care only to the extent that the research is justified by its potential preventive, diagnostic or therapeutic value and if the physician has good reason to believe that participation in the research study will not adversely affect the health of the patients who serve as research subjects.

32. The benefits, risks, burdens and effectiveness of a new intervention must be tested against those of the best current proven intervention, except in the following circumstances:
   • The use of placebo, or no treatment, is acceptable in studies where no current proven intervention exists; or
   • Where for compelling and scientifically sound methodological reasons the use of placebo is necessary to determine the efficacy or safety of an intervention and the patients who receive placebo or no treatment will not be subject to any risk of serious or irreversible harm. Extreme care must be taken to avoid abuse of this option.

33. At the conclusion of the study, patients entered into the study are entitled to be informed about the outcome of the study and to share any benefits that result from it, for example, access to interventions identified as beneficial in the study or to other appropriate care or benefits.

34. The physician must fully inform the patient which aspects of the care are related to the research. The refusal of a patient to participate in a study or the patient’s decision to withdraw from the study must never interfere with the patient-physician relationship.

35. In the treatment of a patient, where proven interventions do not exist or have been ineffective, the physician, after seeking expert advice, with informed consent from the patient or a legally authorized representative, may use an unproven intervention if in the physician's judgement it offers hope of saving life, re-establishing health or alleviating suffering. Where possible, this intervention should be made the object of research, designed to evaluate its safety and efficacy. In all cases, new information should be recorded and, where appropriate, made publicly available.
17.2. **SAE REPORT FORM**
NOTIFICATION OF SERIOUS ADVERSE EVENT (SAE) OR PREGNANCY TO PIERRE FABRE PRODUCT SAFETY DEPARTMENT

TO BE TRANSMITTED TO THE MONITOR BY FAX WITHIN 24H: M. GUIRAUD .......... Fax n° +33 5 34 50 65 92

Transmission date __________ (ddmmyyyy)  Country: ........................................

SAE N° __________ FIRST NOTIFICATION □ FOLLOW-UP □

SUBJECT CHARACTERISTICS

<table>
<thead>
<tr>
<th>Surname</th>
<th>First name</th>
<th>Birth date</th>
<th>Height (cm)</th>
<th>Weight (kg)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

GENDER 1=M, 2=F

DESCRIPTION OF THE EVENT

The serious adverse event resulted in:

- Death (whatever may be the cause)
- Hospitalisation (*) or extension thereof
- Life threatening
- Invalidity or disability
- Congenital abnormality or abnormal pregnancy outcome
- Cancer
- Other (any other serious clinical or laboratory event according to the investigator or the protocol, overdosage meeting seriousness criteria, suicide attempts)
- Other fact to be notified:
  - Pregnancy exposure

Nature of the event (if clinical nature, indicate the diagnosis or the major symptom):

-...........................................................................................................................................................................................................
-...........................................................................................................................................................................................................
-...........................................................................................................................................................................................................

AE onset date __________ (ddmmyyyy)

Seriousness onset date __________(ddmmyyyy)

Summary description (if clinical cause, significant history, progression of event, available laboratory results, etc...):

(*) Except hospitalisations with durations and goals planned in the protocol

THE SAE IN RELATION TO THE TRIAL

- Time of occurrence of SAE
  - During the selection or run-in period
  - During the administration phase of the study treatment
  - After the administration phase of the study treatment

- Date of first study treatment administration __________ (ddmmyyyy)

- Date of last study treatment administration before the occurrence of SAE __________ (ddmmyyyy)

- Was the blind broken?
  - Yes
  - No
  - Not applicable

If yes, or if this is an open study, drug(s) administered:

Conditions of administration (cycles(s), daily dose(s), route(s) of administration, etc..):

Final version 208/1185
**CONCOMITANT MEDICATION SINCE TRIAL INITIATION and UP UNTIL THE OCCURRENCE OF THE SAE (EXCEPT THE TREATMENTS GIVEN FOR THE SAE)**

<table>
<thead>
<tr>
<th>INN or trade name</th>
<th>Daily dose</th>
<th>Start date (ddmmyy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (ddmmyy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>□</td>
<td>□</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□</td>
<td>□</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□</td>
<td>□</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□</td>
<td>□</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>□</td>
<td>□</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**MEASURES TAKEN FOLLOWING THE SAE**

- **Study treatment**
  - No change
  - Dosage modification, specify: ........................................ Modification Date: ___/___/____
  - Temporarily discontinued Readministration date: ___/___/____
  - Withdrawn End date: ___/___/____
  - Not applicable

- **The event led to:**
  - Prescription of corrective or symptomatic treatments (specify names and dosages): 
  - Discontinuation of concomitant treatments (specify names): 
  - Others, specify: 

**OUTCOME**

- Not recovered/Not resolved
- Recovering/Resolving
- Recovered/Resolved
- Recovered/Resolved with sequelae
- Fatal
- Unknown

In case of death, has an autopsy been conducted? Yes No

**INVESTIGATOR CAUSALITY ASSESSMENT (investigator’s assessment to be done as soon as possible)**

- Not Suspected
- Suspected
- Insufficient data

Comments: ..........................................................................................................................................................
17.3. PREDEFINED LIMITS OF LABORATORY AND VITAL SIGN POTENTIALLY CLINICALLY SIGNIFICANT CHANGES AND VALUES

List of Predefined Potentially Clinically Significant Change For Laboratory Values

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>UNIT</th>
<th>PSC</th>
</tr>
</thead>
<tbody>
<tr>
<td>MUSCLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatine Phosphokinase</td>
<td>U / l</td>
<td>-</td>
</tr>
<tr>
<td>KIDNEY</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine</td>
<td>µmol/l</td>
<td>-</td>
</tr>
<tr>
<td>Urea</td>
<td>mmol/l</td>
<td>-</td>
</tr>
<tr>
<td>Uric acid</td>
<td>µmol/l</td>
<td>-</td>
</tr>
<tr>
<td>Phosphate</td>
<td>mmol/l</td>
<td>0.39</td>
</tr>
<tr>
<td>Calcium</td>
<td>mmol/l</td>
<td>0.30</td>
</tr>
<tr>
<td>ELECTROLYTES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium</td>
<td>mmol/l</td>
<td>8</td>
</tr>
<tr>
<td>Potassium</td>
<td>mmol/l</td>
<td>1.1</td>
</tr>
<tr>
<td>Chloride</td>
<td>mmol/l</td>
<td>8</td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>mmol/l</td>
<td>7</td>
</tr>
<tr>
<td>METABOLISM/NUTRITIONAL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose (random)</td>
<td>mmol/l</td>
<td>3</td>
</tr>
<tr>
<td>Albumin</td>
<td>g/l</td>
<td>6</td>
</tr>
<tr>
<td>Protein</td>
<td>g/l</td>
<td>11</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>mmol/l</td>
<td>-</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>mmol/l</td>
<td>0.91</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>mmol/l</td>
<td>2.17</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>mmol/l</td>
<td>-</td>
</tr>
<tr>
<td>ERYTHROCYTES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythrocyte count</td>
<td>T/l</td>
<td>0.7</td>
</tr>
<tr>
<td>Haemoglobin</td>
<td>g/l</td>
<td>20</td>
</tr>
<tr>
<td>Haematocrit</td>
<td>l</td>
<td>0.06</td>
</tr>
<tr>
<td>MCV</td>
<td>fl</td>
<td>7</td>
</tr>
<tr>
<td>MCH (Fe)</td>
<td>fmol</td>
<td>0.19</td>
</tr>
<tr>
<td>MCHC (Fe)</td>
<td>mmol/l</td>
<td>2</td>
</tr>
<tr>
<td>LEUKOCYTES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukocyte count</td>
<td>G/l</td>
<td>4.2</td>
</tr>
<tr>
<td>DIFFERENTIAL COUNT</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophils</td>
<td>G/l</td>
<td>3.47</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>G/l</td>
<td>1.76</td>
</tr>
<tr>
<td>Monocytes</td>
<td>G/l</td>
<td>-</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>G/l</td>
<td>-</td>
</tr>
<tr>
<td>Basophils</td>
<td>G/l</td>
<td>-</td>
</tr>
<tr>
<td>URINE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specific gravity</td>
<td>-</td>
<td>0.017</td>
</tr>
<tr>
<td>pH</td>
<td>-</td>
<td>2</td>
</tr>
<tr>
<td>LIVER</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>µmol/l</td>
<td>-</td>
</tr>
<tr>
<td>ASAT (SGOT)</td>
<td>U/l</td>
<td>-</td>
</tr>
<tr>
<td>ALAT (SGPT)</td>
<td>U/l</td>
<td>-</td>
</tr>
<tr>
<td>Gamma GT</td>
<td>U/l</td>
<td>-</td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>U/l</td>
<td>--</td>
</tr>
</tbody>
</table>

N = upper limit of normal range

### Definition of Clinically Noteworthy Abnormal Laboratory Values (CNALV)

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>CNALV</th>
</tr>
</thead>
</table>
| **HAEMOGLOBIN**          | • Decrease of at least 2g/dl and value < 10 g/dl whatever the baseline value  
                          • If missing baseline : value <10g/dl                                                                                                                     |
| **NEUTROPHILS**         | • < 1 500/mm³ whatever the baseline value                                                                                                                     |
| **WBC** (if missing value for neutrophils) | • < 3 000/mm³ whatever the baseline value                                                                                                                     |
| **PLATELETS**           | • < 100 000/mm³ whatever the baseline value                                                                                                                    |
| **SERUM CREATININE**    | • Increase of at least 30 % as compared to baseline value and value > 150 µmol/l whatever the baseline value  
                          • If missing baseline : value > 150 µmol/l                                                                                                                   |
| **LIVER FUNCTION TESTS**|                                                                                                                                                              |
| **ALAT**                | • If normal baseline :  
                          • ALAT > 2 N  
                          • If abnormal baseline :  
                          → if baseline value ≤ 2.5 N :  
                          • increase of at least 100 % as compared to baseline value  
                          → if baseline value > 2.5 N :  
                          • value > 5 N  
| and/or **ASAT**         | • If normal baseline :  
                          • ASAT > 2 N  
                          • If abnormal baseline :  
                          → if baseline value ≤ 2.5 N :  
                          • increase of at least 100 % as compared to baseline value  
                          → if baseline value > 2.5 N :  
                          • value > 5 N  
| and/or **Alkaline phosphatase (AP)** | • If normal baseline :  
                          • AP > 1.25 N  
                          • If abnormal baseline :  
                          • AP > 2 N  
| and/or **Total bilirubin (TB)** | • If normal baseline :  
                          • TB > 1.5 N  
                          • If abnormal baseline :  
                          • TB > 2 N  

\(N=\text{upper limit of normal range}\)


Cardiovascular Safety

**Table 1: Predefined Limits for Potentially Clinically Significant Changes (PSC) and PSC Leading to Clinically Significant Values (PSCV)**

<table>
<thead>
<tr>
<th>Parameter</th>
<th>PSC</th>
<th>PSCV</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP</td>
<td>Increase ≥ 20 mmHg</td>
<td>SBP ≥ 160 mmHg and increase ≥ 20 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 20 mmHg</td>
<td>SBP ≤ 90 mmHg and decrease ≥ 20 mmHg</td>
</tr>
<tr>
<td>DBP</td>
<td>Increase ≥ 10 mmHg</td>
<td>DBP ≥ 100 mmHg and increase ≥ 10 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 mmHg</td>
<td>DBP ≤ 50 mmHg and decrease ≥ 10 mmHg</td>
</tr>
<tr>
<td>HR</td>
<td>Increase ≥ 10 bpm</td>
<td>HR ≥ 110 bpm and increase ≥ 10 bpm</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 bpm</td>
<td>HR ≤ 50 bpm and decrease ≥ 10 bpm</td>
</tr>
</tbody>
</table>

**Table 2: Predefined Classes for changes from Baseline to the Maximum (and/ or Minimum) Post-baseline Value**

<table>
<thead>
<tr>
<th>Classes of Change from Baseline to the Maximum Post-baseline Value</th>
<th>Classes of Change from Baseline to the Minimum Post-baseline Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>≥ 120</td>
<td>[120; 140]</td>
</tr>
<tr>
<td>[140; 160]</td>
<td>≥ 100</td>
</tr>
<tr>
<td>≥ 160</td>
<td>≥ 100</td>
</tr>
<tr>
<td>&lt; 80</td>
<td>≤ 50</td>
</tr>
<tr>
<td>[80; 90]</td>
<td>≤ 50</td>
</tr>
<tr>
<td>[90; 100]</td>
<td>[75; 100]</td>
</tr>
<tr>
<td>[75; 100]</td>
<td>[75; 100]</td>
</tr>
</tbody>
</table>

**Table 3: Classes for Vital Signs Maximum or Minimum Values**

<table>
<thead>
<tr>
<th>Classes for the Maximum Post-baseline Value for each parameter</th>
<th>Classes for the Minimum Post-baseline Value for each parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>&lt; 120</td>
<td>≤ 90</td>
</tr>
<tr>
<td>[120; 140]</td>
<td>≤ 50</td>
</tr>
<tr>
<td>[140; 160]</td>
<td>≤ 50</td>
</tr>
<tr>
<td>≥ 160</td>
<td>≤ 50</td>
</tr>
<tr>
<td>&lt; 80</td>
<td>≤ 90</td>
</tr>
<tr>
<td>[80; 90]</td>
<td>≤ 50</td>
</tr>
<tr>
<td>[90; 100]</td>
<td>[75; 100]</td>
</tr>
<tr>
<td>[75; 100]</td>
<td>[75; 100]</td>
</tr>
</tbody>
</table>

**Table 4: Classes for Maximum or Minimum of BP in its entirety**

<table>
<thead>
<tr>
<th>Classification of Maximum Values for Blood Pressure (mmHg)</th>
<th>Classification of Minimum Values Blood Pressure (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP &lt; 140 and DBP &lt; 90</td>
<td>SBP &gt; 90 and DBP &gt; 50</td>
</tr>
<tr>
<td>SBP [140; 160] and DBP &lt; 100 or DBP [90; 100] and SBP &lt; 160</td>
<td>SBP ≤ 90 or DBP ≤ 50</td>
</tr>
<tr>
<td>SBP ≥ 160 or DBP ≥ 100</td>
<td>SBP &gt; 90 and DBP &gt; 50</td>
</tr>
</tbody>
</table>

**Table 5: Definition of orthostatic hypotension**

<table>
<thead>
<tr>
<th>Orthostatic Hypotension *</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP Decrease ≥ 20 mmHg or DBP Decrease ≥ 10 mmHg between supine and standing positions</td>
</tr>
</tbody>
</table>

16.1.1.3. Protocol amendment n° PA01
Local (Italy) and substantial dated on 01 March 2013 linked to Protocol and appendices (version3: 01 March 2013)
Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Pierre Fabre Study Code: F373280 CA 2 01
EudraCT Number: 2012-003487-48
Sponsor’s Representative: Marlène GUIRAUD
Coordinating Investigator: Pr Savina NODARI
Date of amendment PA01: 1st March 2013
Clinical Study Protocol Amendment n° PA01 – Version 1

Local (Italy) - Substantial
SIGNATURE FORM

Sponsor's representative:

- Head of Therapeutic Area

  Alain DELARUE, MD

  Date: 05-03-2013

Study Coordinating Investigator:

Pr Savina NODARI

Date: 
Signature:
Clinical Study Protocol Amendment n° PA 01 – Version 1
Local (Italy) - Substantial

COUNTRY COORDINATING INVESTIGATOR SIGNATURE FORM

Country Coordinating Investigator: Date: Signature:

Pr Savina NODARI
By my signature below, I, Dr __________, hereby confirm that I have read, taken note of (and will apply) the modifications brought by the protocol amendment n° PA 01, dated __/__/ and I will conduct the trial according to these new modalities.

Date: __________

Signature: __________
## HISTORY OF PROTOCOL VERSIONS

<table>
<thead>
<tr>
<th>PROTOCOL VERSIONS</th>
<th>MODIFICATIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version 1</td>
<td>Initial version</td>
<td>Version 1 submitted in Italy (to Central Ethics Committee)</td>
</tr>
<tr>
<td>09/11/2012</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Version 2</td>
<td>Following French CA request (ANSM) : - Add of a non inclusion criteria : “Breast-feeding female patient” - Add of haematology examination at visit 3 and 6</td>
<td>Version 2 not submitted to CEC in Italy – The version 3 will be directly submitted</td>
</tr>
<tr>
<td>15/01/2013</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
1. AMENDMENT RATIONALE

This substantial local amendment follows the submission of the study protocol and Informed Consent Form (ICF) to the Central Ethics Committee (CEC) and Competent Authority (CA) in Italy. According to the CEC and CA requirements and, in order to harmonise the protocol and the ICF, the following changes have been done to the study protocol:
- adjustment of the selection criteria n°10 related to the contraception method
- addition of a letter that is given by the patient to his/her general practitioner (GP)
- precision that the sponsor can not collect a copy of the Informed Consent Form
- precision that the patient card is in Italian language only (without any English mention)

In addition, the modification performed in the protocol version 2, on French Medicinal Agency have been included:
- Addition of a non-inclusion criteria related to breast-feeding female patient
- Addition of haematology dosage at visit 3 and 6
2. CHANGES DESCRIPTION

<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
</table>

### STUDY SYNOPSIS AND 5.1 INCLUSION CRITERIA

#### Demographic Characteristics and Other Baseline Characteristics:

10. For female patient of child-bearing potential:
   - absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
   - use of double barrier contraception method (use of effective medical contraception method) from at least 2 months before the start of the study to the entire duration of the study and for a month after the end of the study or
   - documented as surgically sterilized

11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion

12. For male with a childbearing potential partner:
   - absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
   - use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to a month after the end of the study.
surgical
ly
sterilize
d

11. For female patient of childbearing potential: negative urine pregnancy test at inclusion
<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
</table>
| **STUDY SYNOPSIS AND 5.2 NON INCLUSION CRITERIA**  

*Others criteria:*  
20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion,  
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection,  
22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself / herself to its constraints,  
23. Patient family member or work associate (secretary, nurse, technician…) of the Investigator,  
24. Patient having forfeited his / her freedom by administrative or legal award or being under guardianship,  
25. Breastfeeding female patient. | **STUDY SYNOPSIS AND 5.2 NON INCLUSION CRITERIA**  

*Others criteria:*  
20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion,  
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection,  
22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself / herself to its constraints,  
23. Patient family member or work associate (secretary, nurse, technician…) of the Investigator,  
24. Patient having forfeited his / her freedom by administrative or legal award or being under guardianship,  
### 5.9 STUDY CARD

The patient will receive from the Investigating Centre at Visit 1 - Selection Visit, a personal card to be kept all along the study duration and providing the following information: patient's name, sponsor's name, study code, EUDRACT number, start date and expected end date of the study, complete address of the Investigating Centre with the name and phone number of the Investigator and a sponsor 24H/24 phone contact number in case of emergency (French and English languages): 33 (0)5 63 35 25 83.

### 5.9 STUDY CARD AND LETTER FOR GENERAL PRACTITIONERS (GP)

The patient will receive from the Investigating Centre at Visit 1 - Selection Visit:

- a personal card to be kept all along the study duration and providing the following information: patient's name, sponsor's name, study code, EUDRACT number, start date and expected end date of the study, complete address of the Investigating Centre with the name and phone number of the Investigator and a sponsor 24H/24 phone contact number in case of emergency (French and English languages): 33 (0)5 63 35 25 83. This card will be in Italian without any English mention.

- a letter to be given to his/her general practitioner. This letter intends to inform the GP (and any other doctors who take care of the patient) that the patient participate to this clinical study. It describes the study treatment and includes some information on the forbidden treatment during the study.
<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>8.3 SAFETY ASSESSMENT</strong></td>
<td><strong>8.3 SAFETY ASSESSMENT</strong></td>
</tr>
<tr>
<td><strong>8.3.2 Laboratory Investigations</strong></td>
<td><strong>8.3.2 Laboratory Investigations</strong></td>
</tr>
<tr>
<td><strong>8.3.2.1 Schedule</strong></td>
<td><strong>8.3.2.1 Schedule</strong></td>
</tr>
<tr>
<td>Laboratory investigations will be performed at visit 1 (before treatment) and visit 9 (end of treatment) or End of Treatment visit. Furthermore the kaliemia will be checked before electrical cardioversion at visit 3.</td>
<td>Laboratory investigations will be performed at visit 1 (before treatment) and visit 9 (end of treatment) or End of Treatment visit. Furthermore the kaliemia will be checked before electrical cardioversion at visit 3.</td>
</tr>
<tr>
<td><strong>8.3.2.2 Technical Procedures and Parameters</strong></td>
<td><strong>8.3.2.2 Technical Procedures and Parameters</strong></td>
</tr>
<tr>
<td>The following tests will be performed: <strong>Haematology:</strong> Hematocrit, haemoglobin, Red blood cells (RBC) count, white blood cells (WBC) count, WBC differential counts (% and absolute), platelets.</td>
<td>The following tests will be performed: <strong>Haematology:</strong> Hematocrit, haemoglobin, Red blood cells (RBC) count, white blood cells (WBC) count, WBC differential counts (% and absolute), reticulocytes, platelets.</td>
</tr>
</tbody>
</table>
### 9. STUDY PROCEDURES

**Visit 3 (Week 4: D28 -2/+7 days) cardioversion**

Patient will be assessed for the following criteria:

- …

- Laboratory examination: Red Blood Cell concentrations of DHA, Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)

**Visit 5 (Week 8: D56 ± 7 days) – Visit 6 (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days) - Visit 8 (Week 20: D140 ± 7 days)**

Patient will be assessed for the following criteria:

- …

- at visit 6, an echocardiography will be performed and the red blood cell concentration of DHA will be measured.

**Visit 5 (Week 8: D56 ± 7 days) – Visit 6 (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days) - Visit 8 (Week 20: D140 ± 7 days)**

Patient will be assessed for the following criteria:

- …

- at visit 6, an echocardiography will be performed, an **haematology examination will be done** and the red blood cell concentration of DHA will be measured.

---

<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>9. STUDY PROCEDURES</td>
<td>9. STUDY PROCEDURES</td>
</tr>
<tr>
<td>Visit 3 (Week 4: D28 -2/+7 days) cardioversion</td>
<td>Visit 3 (Week 4: D28 -2/+7 days) cardioversion</td>
</tr>
<tr>
<td>Patient will be assessed for the following criteria:</td>
<td>Patient will be assessed for the following criteria:</td>
</tr>
<tr>
<td>…</td>
<td>…</td>
</tr>
<tr>
<td>- Laboratory examination: Red Blood Cell concentrations of DHA, Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)</td>
<td>- Laboratory examination: <strong>Haematology</strong>, Red Blood Cell concentrations of DHA, Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)</td>
</tr>
<tr>
<td>Visit 5 (Week 8: D56 ± 7 days) – Visit 6 (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days) - Visit 8 (Week 20: D140 ± 7 days)</td>
<td>Visit 5 (Week 8: D56 ± 7 days) – Visit 6 (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days) - Visit 8 (Week 20: D140 ± 7 days)</td>
</tr>
<tr>
<td>Patient will be assessed for the following criteria:</td>
<td>Patient will be assessed for the following criteria:</td>
</tr>
<tr>
<td>…</td>
<td>…</td>
</tr>
<tr>
<td>- at visit 6, an echocardiography will be performed and the red blood cell concentration of DHA will be measured.</td>
<td>- at visit 6, an echocardiography will be performed, an <strong>haematology examination will be done</strong> and the red blood cell concentration of DHA will be measured.</td>
</tr>
<tr>
<td>…</td>
<td>…</td>
</tr>
</tbody>
</table>
### 11.2. STUDY MONITORING

#### 11.2.1.4. Closing Visit

At the end of the study, a final visit will be carried out by the CRA to:

- Verify that the e-CRFs CD-ROM with pdf files are correctly stored
- Control the accountability of intact and used treatment units and return them to the Clinical Pharmacy Department of the IRPF for destruction
- Obtain the last data clarifications and/or solutions if any
- Collect the patient's consent forms in sealed envelopes,
- Make an on-site review of all study documentation and complete it if necessary
- And finally, remind the Investigator of his regulatory obligations, study document archiving process and duration.

### 11.2. STUDY MONITORING

#### 11.2.1.4. Closing Visit

At the end of the study, a final visit will be carried out by the CRA to:

- Verify that the e-CRFs CD-ROM with pdf files are correctly stored
- Control the accountability of intact and used treatment units and return them to the Clinical Pharmacy Department of the IRPF for destruction
- Obtain the last data clarifications and/or solutions if any
- Collect the patient's consent forms in sealed envelopes (except in case of specific country requirement),
- Make an on-site review of all study documentation and complete it if necessary
- And finally, remind the Investigator of his regulatory obligations, study document archiving process and duration.
<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>13.8 SAFETY ANALYSIS</strong></td>
<td><strong>13.8 SAFETY ANALYSIS</strong></td>
</tr>
<tr>
<td>13.8.2 Clinical Laboratory Evaluation</td>
<td>13.8.2 Clinical Laboratory Evaluation</td>
</tr>
<tr>
<td>For all blood laboratory parameters, scatter plots highlighting individual</td>
<td>For all <strong>biochemistry</strong> parameters, scatter plots highlighting individual</td>
</tr>
<tr>
<td>results will display the baseline and week 24 of the laboratory measurements</td>
<td>results will display the baseline and week 24 of the laboratory</td>
</tr>
<tr>
<td>for each patient by locating the point defined by the baseline value on the</td>
<td>measurements for each patient by locating the point defined by the baseline</td>
</tr>
<tr>
<td>abscissa and respectively week 24 value in the ordinate.</td>
<td>value on the abscissa and respectively week 24 value in the ordinate.</td>
</tr>
<tr>
<td>Each treatment group will be identified differently. The first bisecting</td>
<td>For all <strong>haematology</strong> parameters, scatter plots highlighting individual</td>
</tr>
<tr>
<td>line (45° line), the lines of lower and upper normal range, the lines of</td>
<td>results will display the baseline and week 4, week 12 and week 24 of the</td>
</tr>
<tr>
<td>PSC range and CNALV range added on the plots (see Appendix 17.3).</td>
<td>laboratory measurements for each patient by locating the point defined by the</td>
</tr>
<tr>
<td></td>
<td>baseline value on the abscissa and respectively week 4, week 12 and week 24</td>
</tr>
<tr>
<td></td>
<td>value in the ordinate.</td>
</tr>
<tr>
<td></td>
<td>Each treatment group will be identified</td>
</tr>
<tr>
<td></td>
<td>differently. The first bisecting line (45° line), the lines of lower and upper</td>
</tr>
<tr>
<td></td>
<td>normal range, the lines of PSC range and CNALV range added on the plots (see</td>
</tr>
<tr>
<td></td>
<td>Appendix 17.3).</td>
</tr>
</tbody>
</table>

Final version 229/1185
<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>14.3 PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM</strong></td>
<td></td>
</tr>
<tr>
<td>The information and consent document are made in triplicate: the original copy is kept by the Investigator, one copy is given to the patient and the last copy is kept by the Clinical Quality Assurance Unit of the Sponsor in a sealed envelope at the end of study.</td>
<td><strong>14.3 PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM</strong></td>
</tr>
<tr>
<td></td>
<td>The information and consent document are made in triplicate: the original copy is kept by the Investigator, one copy is given to the patient and the last copy is kept by the Clinical Quality Assurance Unit of the Sponsor in a sealed envelope at the end of study (except in case of specific country requirement).</td>
</tr>
</tbody>
</table>
CLINICAL STUDY PROTOCOL

Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

F373280 / Soft Capsules / 1g

Pierre Fabre Study Code: F 373280 CA 2 01
EudraCT Number: 2012 – 003487 - 48

Sponsor's Representative:
Marlène GUIRAUD, Pharm D
INSTITUT DE RECHERCHE PIERRE FABRE - Centre de R&D Pierre Fabre - BP 13562
3 avenue Hubert Curien
31035 TOULOUSE Cédex 1
Phone: +33 5 34 50 63 48
Fax: +33 5 34 50 65 92
E-mail: marlene.guiraud@pierre-fabre.com

Study Coordinating Investigator
Pr Savina NODARI
Section of Cardiology
Department of Experimental and Applied Sciences
University of Brescia
BRESCIA, ITALY
Phone: +39 030 3996 587 - Fax: +39 030 3700 359
E-mail: savinanodari@gmail.com

Version 3– 01 MAR 2013

The information contained in this document is confidential and is the property of the Sponsor, Pierre Fabre Medicament. This information is given for the needs of the study and must not be disclosed without prior written consent of the Sponsor Pierre Fabre Medicament. Persons to whom this information is given for the needs of the study must be informed that it is confidential and must not be disclosed.
SPONSOR PERSONNEL

PIERRE FABRE MEDICAMENT
represented by
Institut de Recherche Pierre Fabre

Clinical Study Manager (Monitor)
Marlène GUIRAUD, Pharm D
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1

Phone: +33 5 34 50 63 48
Fax: + 33 5 34 50 65 92
E-mail: marlene.guiraud@pierre-fabre.com

Head of Therapeutic Area
Alain DELARUE, MD
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1

Phone: + 33 5 34 50 61 88
Fax: +33 5 34 50 65 92
E-mail: alain.delarue@pierre-fabre.com

Clinical Development Physician
Richard ROCHE, MD
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1

Phone: +33 5 34 50 61 94
Fax: +33 5 34 50 65 92
E-mail: richard.roche@pierre-fabre.com
CONTRACT RESEARCH ORGANISATIONS

For Feasibility, Monitoring and Regulatory issues:
Pharmaceutical Service Network (PSN)
Rufino Gonzalez
28 037 Madrid - SPAIN
Phone: +34 91 375 6930 - Fax: +34 91 375 6931
E-mail: www.psnglobal.org

For Centralised Randomisation and Electronic Case Report Form
S-Clinica
6, Chaussée de Boondael
B-1050 Brussels - BELGIUM
Phone: +32 2 645 0567 - Fax: +32 2 645 0569
E-mail: irena.seredina@s-clinica.com

For Centralised Reading of Holder ECG and TTEM and equipment supply:
Biomedical System
1945 Chaussée de Wavre
B-1160 Brussels - BELGIUM
Phone: +32 2 661 20 70 - Fax: +32 2 661 20 71
E-mail: sjacobs@biomedsys.com

For intra erythrocyte DHA dosage
Agrocampus Ouest
Laboratoire de Biochimie
65 rue de Saint Brieuc – CS 84215
35042 RENNES Cedex - FRANCE
Phone: +33 2 23 48 55 49 - Fax: +33 2 23 48 55 50
E-mail: daniel.catheline@agrocampus-ouest.fr
Protocol F 373280 CA 2 01

APPROVAL FORM
Protocol Version 3 – 01 MAR 2013

Sponsor's Representative:

Head of Therapeutic Area:  
Alain DELARUE, MD

Date:                      
Signature:                 
05.03.2013

Study Coordinating Investigator:

Savina NODARI, MD         
Date:                      
Signature:                 

F373280 Clinical Study Protocol – Version 3 – 01MAR2013

5/104
Country: ………………………

Country Coordinating Investigator:

"Name"  Date:  Signature:

________________________
By my signature below, I, Dr / Pr "

" hereby confirm that I agree:

- to conduct the trial described in the protocol F 373280 CA 2 01, dated 1st March 2013 in compliance with GCP, with applicable regulatory requirements and with the protocol agreed upon by the Sponsor Pierre Fabre Médicament and given approval / favourable* opinion by the Ethics Committee;
- to document the delegation of significant study-related tasks and to notify the Sponsor of changes in site personnel involved in the study;
- to comply with the procedure for data recording and reporting;
- to allow monitoring, auditing and inspection;
- to retain the trial-related essential documents until the Sponsor informs that these documents are no longer needed.

Furthermore, I hereby confirm that I will have and will use the available adequate resources, personnel and facilities for conduct this trial.

I have been informed that certain regulatory authorities require the Sponsor Pierre Fabre Médicament to obtain and supply details about the investigator’s ownership interest in the Sponsor or the study drug, and more generally about his/her financial relationships with the Sponsor. The Sponsor will use and disclose the information solely for the purpose of complying with regulatory requirements.

Hence I agree:

- to supply the Sponsor with any information regarding ownership interest and financial relationships with the Sponsor (including those of my spouse and dependent children);
- to promptly update this information if any relevant changes occur during the course of the study and for 1 year following completion of the study;
- that the Sponsor may disclose this information about such ownership interests and financial relationships to regulatory authorities.

* To be adapted

Date: Signature:
# TABLE OF CONTENTS OF CLINICAL STUDY PROTOCOL

1. INTRODUCTION AND STUDY RATIONALE ........................................................................ 22
   1.1. TARGET PATHOLOGY AND THERAPY ................................................................. 22
   1.2. INFORMATION ON THE TEST PRODUCT ........................................................ 24
      1.2.1. Chemical and pharmaceutical characteristics ........................................... 25
         1.2.1.1. Nomenclature and structure ................................................................. 25
         1.2.1.2. Physical and chemical general properties ........................................... 25
      1.2.2. Non-clinical Data .......................................................................................... 26
         1.2.2.1. Pharmacological profile ...................................................................... 26
         1.2.2.2. Safety pharmacology ........................................................................... 27
         1.2.2.3. Toxicology profile ................................................................................ 27
         1.2.2.4. Pharmacokinetic data .......................................................................... 27
      1.2.3. Clinical data .................................................................................................. 27
   1.3. STUDY RATIONALE .............................................................................................. 30
   1.4. OVERALL RISK AND BENEFIT ASSESSMENT ................................................ 30

2. STUDY OBJECTIVES .................................................................................................. 33
   2.1. PRIMARY OBJECTIVE ....................................................................................... 33
   2.2. SECONDARY OBJECTIVES ................................................................................ 33

3. ETHICAL CONSIDERATIONS RELATING TO THE STUDY .................................... 33

4. STUDY DESIGN ......................................................................................................... 35
   4.1. OVERALL DESCRIPTION .................................................................................. 35
   4.2. DISCUSSION OF THE STUDY DESIGN .......................................................... 36
      4.2.1. Choice of the Study Population ................................................................. 36
      4.2.2. Choice of the Study Design ...................................................................... 37
      4.2.3. Choice of the Dose ................................................................................... 38
      4.2.4. Choice of the Sample Size ...................................................................... 39

5. STUDY POPULATION ................................................................................................. 39
   5.1. INCLUSION CRITERIA ........................................................................................ 39
   5.2. NON INCLUSION CRITERIA ............................................................................. 40
   5.3. NUMBER OF PATIENTS .................................................................................... 41
   5.4. RECRUITMENT MODALITIES .......................................................................... 41
   5.5. PATIENTS IDENTIFICATION .......................................................................... 41
   5.6. WITHDRAWAL CRITERIA ................................................................................ 41
   5.7. REPLACEMENT OF PATIENTS ...................................................................... 42
   5.8. POST-STUDY EXCLUSION PERIOD ............................................................... 43
   5.9. STUDY CARD .................................................................................................... 43
6. STUDY TREATMENT

6.1. SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT

6.2. PACKAGING AND LABELLING

6.2.1. Packaging

6.2.2. Labelling

6.3. DISTRIBUTION TO CENTRE AND STORAGE

6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT

6.5. DRUG ADMINISTRATION

6.5.1. Duration of Treatment

6.5.2. Dose Schedule

6.5.3. Route and Conditions of Administration

6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT

6.7. RECALL OF INVESTIGATIONAL PRODUCTS

7. CONCOMITANT TREATMENTS

7.1. ANTI-VITAMIN K TREATMENT

7.2. PROHIBITED TREATMENTS

7.3. AUTHORISED TREATMENTS

8. EVALUATION CRITERIA

8.1. PRIMARY EFFICACY CRITERION:

8.1.1. Time to the first Atrial Fibrillation Recurrence

8.1.1.1. Definition

8.1.1.2. Schedule

8.1.1.3. Evaluation Methods

8.1.2. Secondary Efficacy Criteria

8.1.2.1. Numbers of Atrial Fibrillation episodes in the first week following visit 3 (ECV visit)

8.1.2.2. Duration of Atrial Fibrillation episodes in the first week following visit 3 (ECV visit)

8.1.2.3. Clinical parameters evaluation

8.1.2.4. Cardioversion assessment

8.1.2.5. Evolution of echocardiographic parameters

8.2. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA

8.2.1. Definition

8.2.2. Blood samples

8.2.2.1. Collection schedule

8.2.2.2. Technical handling

8.2.3. DHA concentration measurement

8.3. SAFETY ASSESSMENT
8.3.1. Adverse Events .......................................................... 56
8.3.2. Laboratory Investigations ............................................. 56
8.3.2.1. Schedule ................................................................ 56
8.3.2.2. Technical Procedures and Parameters ......................... 56
8.3.3. Global Physical Examination ......................................... 57
8.3.4. Vital Signs ............................................................... 57
8.3.4.1. Schedule ................................................................ 58
8.3.4.2. Technical Procedure and Parameters ......................... 58
8.3.5. Electrocardiogram (ECG) ............................................... 58
8.3.5.1. Schedule ................................................................ 58
8.3.5.2. Technical Procedure and Parameters ......................... 58
8.3.6. Coagulation parameters ............................................... 59
8.3.7. Concomitant Treatments .............................................. 59
8.4. COMPLIANCE .............................................................. 59

9. STUDY PROCEDURES ...................................................... 60

10. ADVERSE EVENTS: DEFINITION AND REPORTING .......... 65
10.1. ADVERSE EVENTS ....................................................... 65
10.1.1. Definition of Adverse Events ....................................... 65
10.1.2. Grading of Adverse Events ......................................... 66
10.1.3. Reporting of Adverse Events ....................................... 66
10.2. SERIOUS ADVERSE EVENTS (SAE) .............................. 66
10.2.1. Definition ............................................................... 66
10.2.2. Reporting of SAE ...................................................... 67
10.2.3. Follow-up of SAE ....................................................... 68
10.2.4. SAE Occurring After the Study .................................... 68
10.3. REPORTING OF OVERDOSAGE TO THE SPONSOR ............ 68
10.4. REPORTING OF PREGNANCY TO THE SPONSOR ............. 68
10.5. SPONSOR'S RESPONSIBILITIES FOR SAFETY REPORTING PURPOSES ....... 69

11. DATA COLLECTION AND STUDY MONITORING .............. 69
11.1. DATA COLLECTION ...................................................... 69
11.1.1. Case Report Form ..................................................... 69
11.1.2. Source Documents .................................................... 70
11.2. STUDY MONITORING .................................................. 71
11.2.1. Monitoring visits ....................................................... 71
11.2.1.1. Site Preselection Visit .............................................. 71
11.2.1.2. Initiation Visit ....................................................... 71
11.2.1.3. Follow-up Visits .................................................... 72
11.2.1.4. Closing Visit ....................................................... 72
11.2.2. Direct Access to Source Documents ............................. 72
11.3. INDEPENDENT DATA MONITORING COMMITTEE .......... 73

12. DATA MANAGEMENT .................................................. 73
12.1. DATA ENTRY ..................................................................................................................... 73
12.2. DATA CLEANING ............................................................................................................. 73
12.3. DATA CODING .................................................................................................................. 74
12.4. DATA STORAGE ............................................................................................................... 74
12.5. DATABASE LOCK............................................................................................................. 74

13. STATISTICAL ANALYSIS .................................................................................................................. 74

13.1. GENERAL CONSIDERATIONS ........................................................................................ 75
13.2. SAMPLE SIZE ..................................................................................................................... 75
13.3. PROTOCOL DEVIATIONS ................................................................................................ 75
13.4. DATA SETS ANALYSED .................................................................................................. 76
13.5. HANDLING OF DROPOUTS AND MISSING DATA ..................................................... 76
13.5.1. Dropouts ............................................................................................................................ 76
13.5.2. Repositioning of Visits ...................................................................................................... 76
13.5.3. Missing Data ...................................................................................................................... 76
13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS ............................... 77
13.7. EFFICACY ANALYSIS ...................................................................................................... 77
13.7.1. Primary Criterion ............................................................................................................... 77
13.7.1.1. Primary Analysis ............................................................................................................ 77
13.7.1.2. Supportive Analysis ....................................................................................................... 77
13.7.2. Secondary Criteria ............................................................................................................. 78
13.7.2.1. Numbers of Atrial Fibrillation Episodes ........................................................................ 78
13.7.2.2. Duration of Atrial Fibrillation Episodes ......................................................................... 78
13.7.2.3. Time to first AF recurrence less than 10 minutes or symptomatic .............................. 78
13.7.2.4. Clinical parameters evaluation ....................................................................................... 78
13.7.2.5. Biomarker analysis: red blood cell concentrations of DHA ........................................... 79
13.8. SAFETY ANALYSIS .......................................................................................................... 79
13.8.1. Adverse Events .................................................................................................................. 79
13.8.2. Clinical Laboratory Evaluation ......................................................................................... 81
13.8.3. Global Physical Examination ............................................................................................ 82
13.8.4. Vital Signs, Physical Findings and Other Observations Related to Safety ................. 82
13.8.4.1. Vital Sign Measurements Over Time ............................................................................. 82
13.8.4.2. Body weight ................................................................................................................... 82
13.8.4.3. Individual Patient Changes ............................................................................................. 83
13.8.5. ECG ................................................................................................................................... 83
13.8.6. Coagulation parameters ..................................................................................................... 83
13.9. CONCOMITANT TREATMENTS ..................................................................................... 83
13.10. COMPLIANCE .................................................................................................................... 84
13.11. INTERIM ANALYSIS AND DATA MONITORING ........................................................ 84

14. GENERAL ETHICAL CONSIDERATIONS ............................................................................... 84

14.1. ETHICAL CONDITIONS ................................................................................................... 84
14.2. ETHICS COMMITTEE AND LEGAL REQUIREMENTS .................................................. 84
SYNOPSIS

<table>
<thead>
<tr>
<th>Name of Sponsor:</th>
<th>Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Finished Product:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Name of Active Substance:</td>
<td>F373280 (Panthenyl-Ester of DHA)</td>
</tr>
<tr>
<td>Title of the Study:</td>
<td>Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.</td>
</tr>
<tr>
<td>Abbreviated Title:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Study Coordinating Investigator:</td>
<td>Pr Savina NODARI</td>
</tr>
<tr>
<td>Study Centres:</td>
<td>International, multicentric</td>
</tr>
<tr>
<td>Publication / Rationale:</td>
<td>F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation (AF) patients with chronic heart failure. The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of Atrial Fibrillation (AF) induced by burst pacing.[1] Moreover, the effectiveness of PUFA (PolyUnsaturated Fatty Acid) has been proven in the following conditions: - prevention of Atrial Fibrillation recurrence in patients with persistent Atrial Fibrillation, in co-administration with amiodarone (add on therapy) [2] - Improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5] Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent atrial fibrillation and chronic heart failure. This phase Ila study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after electrical cardioversion (ECV) in patients with persistent atrial fibrillation and chronic heart failure.</td>
</tr>
<tr>
<td>Planned Study Period:</td>
<td>January 2013 – April 2014</td>
</tr>
<tr>
<td>Clinical Phase:</td>
<td>Ila</td>
</tr>
<tr>
<td>Objectives:</td>
<td>Primary: - Efficacy of F373280 on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure Secondary: - Efficacy of F373280 on the efficiency of direct electrical cardioversion - Effect of F373280 on echocardiographic parameters - Safety and tolerability of F373280</td>
</tr>
<tr>
<td>Methodology:</td>
<td>- International, multicentre, randomised, double-blind, placebo-controlled - Selection period - Start of treatment 4 weeks before ECV • Condition to ECV: - INR 2-3 (anti-vitamin K should be given at least 3 weeks before ECV) - No spontaneous cardioversion before ECV - Follow-up 20 weeks after visit 3 (ECV visit) • Condition: successful ECV or spontaneous CV - Cardiac monitoring: • 7-days continuous ECG ambulatory recording (Holter ECG) between visit 3 (ECV visit) and visit 4 (week 5) in patients with sinusal rhythm • TTEM: daily transmission from week 6 to week 8; then every two days from week 9 to week 24, and in case of AF symptoms - Treatment duration: 24 weeks</td>
</tr>
<tr>
<td>Study Schedule</td>
<td>9 visits will be scheduled: - V1/W-4 to W-1: selection visit (7 to 28 days before the inclusion visit) - V2/D1: Inclusion visit (start of treatment) - V3/W4 (D28 -2/+7 days): cardioversion visit (Outpatient or hospitalization according to...</td>
</tr>
</tbody>
</table>
Number of Patients: 76 x 2 patients

Diagnosis and Criteria for Inclusion:

Inclusion Criteria:

Demographic Characteristics and Other Baseline Characteristics:

1. Men or women aged more than 18 years (inclusive).
2. Patients with persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted.
3. History of first documented persistent AF less than 1 year.
4. History of ischemic or non ischemic heart failure.
5. NYHA class I or II chronic heart failure at selection and at inclusion.
6. Reduced left ventricular ejection fraction between 30% and 45% inclusive (using the two-dimensional echocardiography biplane Simpson’s rule) at selection and at inclusion.
7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or beta-blockers.
8. Left atrial area ≤ 40 cm² at selection and at inclusion.
9. Patients treated or having to be treated by anti-vitamin K.
10. For female patient of child-bearing potential:
   • in all the countries except Italy:
     - use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator, for at least 2 months before the selection in the study, and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment.
     - documented as surgically sterilized.
   • in Italy only:
     - absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
     - use of double barrier contraception method (use of effective medical contraception method) from at least 2 months before the start of the study to the entire duration of the study and for a month after the end of the study or
     - documented as surgically sterilized.
11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion.
12. For male with a child-bearing potential partner (in Italy only):
   - Absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
   - use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to a month after the end of the study.

Ethical/legal considerations:

13. Having signed his/her written informed consent.
14. Affiliated to a social security system, or is beneficiary (if applicable in the national regulation).

Non-Inclusion Criteria:

Criteria related to pathologies:

1. History of first documented episode of persistent AF more than 1 year.
2. More than two successful cardioversions (electrical or pharmacological) in the last 6 months
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV)
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be checked in case of treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic coronaropathy assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
7. Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration rate < 30 mL/min) at selection
8. Bradycardia (HR ≤ 50 bpm)
9. Hyperkalemia or hypokalemia (K>5.5 mEq/L or K < 3.5 mEq/L) at selection
10. Cardiac surgery within 3 months before selection or planned during the study duration

Criteria related to treatments:
11. Previously ineffective pharmacological or electrical cardioversion
12. Concomitant treatment with any anti-arrhythmic drug (within 7 days prior to selection), except stable dose of digoxin, betablockers, calcium-blockers
13. Previous treatment with oral amiodarone within 12 months prior to inclusion
14. Previous treatment with intravenous amiodarone within 6 months prior to inclusion
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT implantation within the last 6 months
16. Treatment with any Polynsaturated Fatty Acid (PUFA) within the last 3 months
17. Dietary supplement with ω3 or ω6 according to investigator’s judgement
18. Having undergone any form of ablation therapy for AF
19. Patient treated with other anticoagulant treatment than antivitamin K: thrombin inhibitor such as Dabigatran or treated with antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel

Other criteria:
20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection
22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself/herself to its constraints
23. Patient family member or work associate (secretary, nurse, technician,..) of the Investigator
24. Patient having forfeited his / her freedom by administrative or legal award or being under guardianship
25. Breastfeeding female patient

Exclusion criteria before V3:
Patients not stabilized for INR (i.e. values between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed in the same day (before ECV). ECV will be performed in patients without dyskalemia. If necessary for obtaining stabilized INR between 2 and 3, the ECV (and following visits) could be postponed by 7 days.

Test Product: F373280
Dose: Soft Capsules
Mode of Administration: Arm with 1g of F373280
Oral, one capsule each evening with dinner.
Duration of Treatment: 24 weeks of treatment exposure with F373280 (25 weeks if ECV postponed by 1 week)
Reference Therapy Placebo soft capsules
Placebo will be administered in the same conditions as the tested product.
### Mode of Administration:
Oral, one capsule each evening with dinner

### Evaluation Criteria:

#### Efficacy evaluation variables:

**Primary evaluation variable:**
- Time to first Atrial Fibrillation recurrence defined by the first episode of Atrial Fibrillation lasting for at least 10 minutes (Follow up of 20 weeks after visit 3 (ECV visit))

Handling of AF recurrences: 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) between visit 3 (ECV visit) and visit 4 (week 5). Then, the follow up will be documented using the TTEM: daily transmission from week 6 to week 8. Then, every two days from week 9 to week 24.

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF will be assessed after visit 3 (week 5).

Moreover, during this TTEM period, if patient experiences any AF symptoms, it should be recorded and documented using the TTEM.

All ECG traces will be evaluated by a Central Reading Laboratory.

**Secondary evaluation variables:**
- Numbers of AF episodes
- Duration of AF episodes

#### Clinical parameters:
During the whole study:
- Number of recurrence of symptomatic AF episodes
- EHRA score
- Hospitalization for cardiovascular events
- Hospitalization for thromboembolic stroke
- All cause of hospitalization

#### Cardioversion:
- Assessment of spontaneous cardioversion
- Assessment of successful cardioversion
- Number of patients needing an other cardioversion after the initial ECV

**Other:**
- Evolution of echocardiographic parameters (from V4 to V6 and V9) (Left atrial diameter (mm), Left atrial area (cm²), Left atrial volume (mL), Left atrial volume/BSA (mL/m²), Left ventricular ejection fraction (%), Left ventricular volume (mL), Left ventricular volume/BSA (mL/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL) Left ventricular end systolic diameter (mm), Left ventricular end systolic volume (mL))
- Evolution of omega 3 index and intra erythrocyte DHA *(For this assessment samples will be centralized).*

### Safety criteria:
- **Adverse events** (observed and / or spontaneously reported)
- **Vital signs** (Blood pressure (supine and standing), heart rate)
- **Physical examination** (body weight),
- **Standard 12-lead ECG:** heart rate (bpm), PR (ms), QRS (ms), QT (ms), repolarisation patterns (ECG not centralized).
- **Haematology:** haematocrit, haemoglobin, RBC, WBC, differential count, platelets
- **Biochemistry:** sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatin phosphokinase (CPK) fibrinogen *(local laboratory)*
- **Coagulation parameters:** Activated partial thromboplastin time (aPTT), thrombin clotting time (TCT), INR *(local laboratory)*, Prothrombine Time (PT)

### Statistical Methods:
**Sample Size:**
Assuming an AF recurrence rate under placebo of 85%, a power of 80%, an alpha risk of 5% and a rate of not assessable patients of 15%, 76 randomised patients per group will be necessary, using a log-rank test of survival curves, a difference between groups of 20%.
| **Primary Efficacy Analysis**<br>The primary analysis, performed on the Full Analysis Set (FAS: all randomised patients with at least one dose of treatment and with a successful cardioversion observed at visit 3), will be a survival analysis using the Kaplan Meier method and Cox regression model. | **Secondary Analyses**<br>All secondary efficacy criteria will be described and compared using appropriate tests on the FAS. | **Safety Analyses**<br>Descriptive statistics will be performed on the Safety Set (all randomised patients with at least one dose of treatment) |
STUDY FLOW-CHART
<table>
<thead>
<tr>
<th>Weeks</th>
<th>V1</th>
<th>V2</th>
<th>V3</th>
<th>V4</th>
<th>V5</th>
<th>V6</th>
<th>V7</th>
<th>V8</th>
<th>V9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outpatient or Hospitalization (1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographic characteristics</td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medico-surgical history</td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant disease</td>
<td></td>
<td></td>
<td></td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant treatment</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Habits</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>Global physical examination (body weight)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>Echocardiography</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility criteria check</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood pressure, heart rate</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>12-Lead ECG Recording</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>INR</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>aPTT, TCT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>Eligibility criteria check</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood pressure, heart rate</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>12-Lead ECG Recording</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>INR</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>aPTT, TCT</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>Biochemistry</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>Hematology</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary pregnancy test</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Red Blood Cell concentrations of DHA</td>
<td></td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td>x</td>
</tr>
<tr>
<td>Treatment allocation</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IVRS</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECV (3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>x</td>
</tr>
</tbody>
</table>

**Drug administration**

**Adverse events recording**

**Holter ECG**

**TTEM (6)**

---

(1) Outpatient or hospitalization according to clinical practice of the centre (less or more than 24 hours)

(2) In case of AVK introduction: INR 2 to 3 times a week, then weekly until the ECV, then every 4 weeks after ECV.

(3) In patients with AF

(4) 24-hour Holter ECG

(5) 7-day Holter ECG

(6) TTEM everyday from week 6 to week 8. Then every 2 days from week 9 to week 24. In case of AF symptoms. In case of AF recurrence for at least 10 minutes and the patient does not stop the study treatment than TTEM every 4 weeks.
### LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>aPTT</td>
<td>Activated partial thromboplastin time</td>
</tr>
<tr>
<td>AE</td>
<td>Adverse event</td>
</tr>
<tr>
<td>AERP</td>
<td>Atrial effective refractory period</td>
</tr>
<tr>
<td>AF</td>
<td>Atrial fibrillation</td>
</tr>
<tr>
<td>ALA</td>
<td>Alpha-linoleic acid</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine aminotransferase</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate aminotransferase</td>
</tr>
<tr>
<td>AUC</td>
<td>Area under the plasma concentration versus time curve</td>
</tr>
<tr>
<td>AUC&lt;sub&gt;inf&lt;/sub&gt;</td>
<td>Total area under the curve extrapolated to infinity</td>
</tr>
<tr>
<td>AVK</td>
<td>Anti vitamin K</td>
</tr>
<tr>
<td>βHCG</td>
<td>beta human chorionic gonadotrophin</td>
</tr>
<tr>
<td>BLQ</td>
<td>Below the limit of quantification</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>BP</td>
<td>Blood pressure</td>
</tr>
<tr>
<td>BSA</td>
<td>Body Surface Area</td>
</tr>
<tr>
<td>CEP</td>
<td>Protocol evaluation committee</td>
</tr>
<tr>
<td>CHF</td>
<td>Congestive heart failure</td>
</tr>
<tr>
<td>CHMP</td>
<td>Committee for medicinal products for human use</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td>Maximum concentration</td>
</tr>
<tr>
<td>C&lt;sub&gt;min&lt;/sub&gt;</td>
<td>Minimum concentration</td>
</tr>
<tr>
<td>CNALV</td>
<td>Clinically noteworthy abnormal laboratory value</td>
</tr>
<tr>
<td>CPK</td>
<td>Creatin phosphokinase</td>
</tr>
<tr>
<td>CPP</td>
<td>Comité de protection des personnes</td>
</tr>
<tr>
<td>CRA</td>
<td>Clinical research associate</td>
</tr>
<tr>
<td>CRT</td>
<td>Cardiac resynchronization therapy</td>
</tr>
<tr>
<td>CSC</td>
<td>“Clinically Significant Change”, i.e., Predefined potentially clinically significant change leading to a potentially clinically significant value (vital signs)</td>
</tr>
<tr>
<td>CV</td>
<td>Coefficient of variation</td>
</tr>
<tr>
<td>DBP</td>
<td>Diastolic blood pressure</td>
</tr>
<tr>
<td>DHA</td>
<td>Docosahexaenoic acid</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics committee</td>
</tr>
<tr>
<td>ECG</td>
<td>Electrocardiogram</td>
</tr>
<tr>
<td>ECHO –TE</td>
<td>Trans-esophageal echocardiograph</td>
</tr>
<tr>
<td>ECV</td>
<td>Electrical cardioversion</td>
</tr>
<tr>
<td>EHRA</td>
<td>European heart rhythm association</td>
</tr>
<tr>
<td>EPA</td>
<td>Eicosapentaenoic acid</td>
</tr>
<tr>
<td>eCRF</td>
<td>Electronic case report form</td>
</tr>
<tr>
<td>FAS</td>
<td>Full analysis set</td>
</tr>
<tr>
<td>Fe</td>
<td>Fraction of the administered drug excreted in urine</td>
</tr>
<tr>
<td>GCP</td>
<td>Good clinical practice</td>
</tr>
<tr>
<td>GFR</td>
<td>Glomerular Filtration Rate</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>HBs</td>
<td>Hepatitis B antigen</td>
</tr>
<tr>
<td>HCV</td>
<td>Hepatitis C virus</td>
</tr>
<tr>
<td>HDL</td>
<td>High density lipoprotein</td>
</tr>
<tr>
<td>HF</td>
<td>Heart failure</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>HR</td>
<td>Heart rate</td>
</tr>
<tr>
<td>ICH</td>
<td>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use</td>
</tr>
<tr>
<td>IDMC</td>
<td>Independent data monitoring committee</td>
</tr>
<tr>
<td>INR</td>
<td>International normalized ratio</td>
</tr>
<tr>
<td>IRPF</td>
<td>Institut de Recherche Pierre Fabre</td>
</tr>
<tr>
<td>IVRS</td>
<td>Interactive voice response system</td>
</tr>
<tr>
<td>LAA</td>
<td>Left atrial area</td>
</tr>
<tr>
<td>LC/MS-MS</td>
<td>Liquid chromatography with tandem mass spectrometry</td>
</tr>
<tr>
<td>LDL</td>
<td>Low density lipoprotein</td>
</tr>
<tr>
<td>LOQ</td>
<td>Limit of quantification</td>
</tr>
<tr>
<td>LVEF</td>
<td>Left ventricular ejection fraction</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical dictionary for regulatory activities</td>
</tr>
<tr>
<td>MR</td>
<td>Mineralocorticoid receptor</td>
</tr>
<tr>
<td>MR perfusion</td>
<td>Magnetic Resonance perfusion</td>
</tr>
<tr>
<td>MTD</td>
<td>Maximum tolerated dose</td>
</tr>
<tr>
<td>N</td>
<td>Number of determinations or replicates</td>
</tr>
<tr>
<td>NOAEL</td>
<td>No observed adverse effect level</td>
</tr>
<tr>
<td>NYHA</td>
<td>New York heart association</td>
</tr>
<tr>
<td>od</td>
<td>Once a day</td>
</tr>
<tr>
<td>“Predefined Change”, i.e., Predefined potentially clinically significant change (lab or vital signs)</td>
<td></td>
</tr>
<tr>
<td>PC</td>
<td>PC leading to an out-of-range value (lab values)</td>
</tr>
<tr>
<td>PCA</td>
<td>PC leading to an out-of-range value (lab values)</td>
</tr>
<tr>
<td>PFB</td>
<td>Pierre Fabre Biométrie</td>
</tr>
<tr>
<td>POC</td>
<td>Proof of concept</td>
</tr>
<tr>
<td>PUFA</td>
<td>PolyUnsaturated fatty acid</td>
</tr>
<tr>
<td>PK</td>
<td>Pharmacokinetics</td>
</tr>
<tr>
<td>p.o.</td>
<td>Per os</td>
</tr>
<tr>
<td>PP</td>
<td>Per protocol data set</td>
</tr>
<tr>
<td>RBC</td>
<td>Red blood cells</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious adverse event</td>
</tr>
<tr>
<td>SBP</td>
<td>Systolic blood pressure</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>T1/2</td>
<td>Terminal half-life</td>
</tr>
<tr>
<td>T0</td>
<td>Time of drug administration</td>
</tr>
<tr>
<td>Tmax</td>
<td>Time to reach the maximal concentration</td>
</tr>
<tr>
<td>TCT</td>
<td>Thrombin clotting time</td>
</tr>
<tr>
<td>TEAEs</td>
<td>Treatment emergent adverse events</td>
</tr>
<tr>
<td>TTEEM</td>
<td>TransTelephonic ECG monitoring</td>
</tr>
<tr>
<td>VTP</td>
<td>Ventricular tachypacing</td>
</tr>
<tr>
<td>WBC</td>
<td>White blood cells</td>
</tr>
<tr>
<td>WHO-DRUG</td>
<td>World health organization drug reference list</td>
</tr>
</tbody>
</table>
1. INTRODUCTION AND STUDY RATIONALE

1.1. TARGET PATHOLOGY AND THERAPY

Atrial Fibrillation (AF) is a supraventricular arrhythmia characterized by uncoordinated atrial electric activity with consequent deterioration of atrial mechanical function. It is the most common sustained cardiac rhythm disorder, increasing in prevalence with age. Haemodynamic impairment and thromboembolic events related to AF result in significant morbidity and mortality [7].

In 2009, Decision Resources estimated that there were 7.8 million diagnosed prevalent cases of atrial fibrillation (AF) in US, Europe and Japan. This age-related pathology should increase to 9.4 million cases in 2019.

Except for the conventional class I and class III anti-arrhythmic agents, the PUFAs (Polyunsaturated Fatty Acids) constitute one emerging antiarrhythmic therapy. These compounds potently address the AF substrate by directly targeting both the electrical and the structural remodelling of the deficient atria. The n-3 PUFAs, essential for human, are ALA, EPA and DHA. First, PUFAs specifically modulate ionic channels by fastening their inactivating mode which renders these compounds selective for pathological situations (such as AF) without any major effect in normal conditions. PUFAs are “open K_v1.5 channel blockers” leading to a lengthening of atrial action potential duration and are “persistent Na_v1.5 channel blockers” leading to hyperpolarization of diastolic resting potential. Second, PUFAs influence structural remodelling through their anti-inflammatory effects as they directly compete with arachidonic acid in the production of inflammatory eicosanoids. In summary, PUFAs share unique, well-tolerated antiarrhythmic potential by interacting with the electrical and structural remodelling during sustained AF. In animal studies, it was recently demonstrated that DHA is particularly effective in pathologic conditions such as ischemia and/or atrial fibrillation.

The potential anti-arrhythmic effects of a PUFA was previously developed in atrial fibrillation: nicotinyl ester of DHA (pro-drug based on DHA delivery) were assessed in a two-week
ventricular tachypaced canine model. Dogs were subjected to 4 weeks of medication prior to undergoing an electrophysiology study, and received either placebo or nicotinyl ester of DHA. Dogs were tachypaced at 240 beats per min for the final two weeks of the treatment plan. The results showed that the tested PUFA reduced the duration of atrial fibrillation (AF) induced by burst pacing, and the incidence of sustained AF, compared to dogs treated with the placebo [1].

In clinical practice, Nodari and coll assessed n-3 Polyunsaturated Fatty Acids in the prevention of atrial fibrillation recurrences after electrical cardioversion. All included patients were treated with amiodarone and a renin-angiotensin-aldosterone system inhibitor. The 199 patients were assigned either to placebo or n-3 PUFAs 2 g/d and then underwent direct electrical cardioversion (ECV) 4 weeks later. The primary end point was the maintenance of sinus rhythm at 1 year after cardioversion. At the 1-year follow up, the maintenance of sinus rhythm was significantly higher in the n-3 PUFAs treated patients compared with the placebo group (hazard ratio, 0.62 [95% confidence interval, 0.52 to 0.72] and 0.36 [95% confidence interval, 0.26 to 0.46], respectively; p = 0.0001). The study concludes that in patients with persistent atrial fibrillation on amiodarone and a renin-angiotensin-aldosterone system inhibitor, the addition of n-3 PUFAs 2 g/d improves the probability of the maintenance of sinus rhythm after direct current cardioversion [2].

Previously, during the World Congress of Cardiology in 2006, an abstract reported the effectiveness of PUFA on top of traditional treatment (amiodarone, beta blockers, renin-angiotensin-aldosterone system inhibitor) in the prevention of AF relapses in patients having undergone ECV. In the PUFA group, AF relapses were significantly lower than placebo group at one month (3.3% vs 10%; p=0.043), at 3 months (10% vs 25%; p=0.004) and at 6 months (13.3% vs 40%; p<0.0001) [19].

In contrast, in the general AF population (paroxystic atrial fibrillation and persistent atrial fibrillation), PUFAs failed to prove their efficacy [7] because of the absence of cardiac remodelling or because of a short pre-treatment duration before ECV (1 week) [8]. The effect of PUFAs were only observed in patients with persistent AF on add on therapy and after a sufficient pre-treatment before ECV. Persistent AF is commonly associated to heart failure. Previous studies performed in heart failure population demonstrated the benefit of PUFAs on the improvement of functional ventricular parameters and morbi-mortality, and on the reduction of hospitalisation [3, 4, 5].
Nodari and coll [3] performed a trial in patients with a chronic heart failure (NYHA I to III and LVEF< 45%). After a treatment of 133 patients with PUFAs (n=67) or placebo (n=66) at a dosage of 5 g/day for 1 month, then 2 g/day for 11 months, the n-3 PUFAs group and the placebo group differed significantly (p <0.001) in regard to:

- LVEF (increased by 10.4% and decreased by 5.0%, respectively)
- peak VO2 (increased by 6.2% and decreased by 4.5%, respectively)
- exercise duration (increased by 7.5% and decreased by 4.8%, respectively)
- mean New York Heart Association functional class (decreased from 1.88 +/- 0.33 to 1.61 +/- 0.49 and increased from 1.83 +/- 0.38 to 2.14 +/- 0.65, respectively).

The hospitalization rates for HF were 6% in the n-3 PUFAs and 30% in the placebo group (p <0.0002).

Moertl and coll [4] performed a dose-ranging study in patients with a more severe chronic heart failure (NYHA III and IV and LVEF < 35%). It was a double-blind, randomised, controlled pilot trial in 43 patients treated with PUFAs or placebo for 3 months (1 g/d n3-PUFA (n = 14), 4 g/d n3-PUFA (n = 13), or placebo (n = 16)). After treatment, left ventricular ejection fraction increased in a dose-dependent manner (P = 0.01 for linear trend) in the 4 g/d (baseline vs 3 months [mean ± SD]: 24% ± 7% vs 29% ± 8%, p = 0.005) and 1 g/d treatment groups (24% ± 8% vs 27% ± 8%, P = 0.02).

No changes in any investigated parameters were noted with placebo.

Taking into account these studies performed with PUFAs, it seems that the best target for DHA is persistent AF in patients with heart failure. The aim of this proof of concept study is to assess in stand alone therapy (without association of other anti-arrhythmic treatments), the effect of F373280 in patients with persistent atrial fibrillation and heart failure in the maintenance of sinus rhythm after electrical cardioversion.

1.2. INFORMATION ON THE TEST PRODUCT

F373280 or panthenyl ester of DHA (docosahexaenoic acid) is the mono-ester of panthotenic alcohol and DHA, selected to be developed for the management of atrial fibrillation.

F373280 is a prodrug of DHA.
A brief summary of F373280 known characteristics is presented in this section. For further details, please refer to the F373280 Investigator’s Brochure. [1]

1.2.1. Chemical and pharmaceutical characteristics

1.2.1.1. Nomenclature and structure

Chemical name (IUPAC):

\((4Z,7Z,10Z,13Z,16Z,19Z)-3-((R)-2,4\text{-dihydroxy-3,3\text{-dimethylbutanamido})\text{ propyl docosa-}4,7,10,13,16,19\text{-hexaenoate}}\)

Structural formula:

\[
\begin{align*}
\text{O} & \quad \text{O} \\
\text{N} & \quad \text{H} \\
\text{O} & \quad \text{O} \\
\text{O} & \quad \text{H} \\
\text{H} & \\
\end{align*}
\]

Laboratory code: F373280

Molecular formula: C\(_{31}\)H\(_{49}\)NO\(_5\)

Molecular mass: 515.7

1.2.1.2. Physical and chemical general properties

Appearance: Clear oily viscous liquid

Solubilities:

- Water: Practically insoluble
- Alcohol: Very soluble
- Trimethylpentane: Slightly soluble
1.2.2. Non-clinical Data

Non-clinical data are exhaustively detailed in the Investigator’s brochure [1]. A brief summary is provided below.

1.2.2.1. Pharmacological profile

F373280 (mono-ester of panthotenic alcohol and DHA) is a novel pro-drug of DHA which exerts antiarrhythmic properties by interacting with the electrical and structural remodelling of the atria.

Experimental investigations were conducted in HEK293 cell line transfected with human Kv1.5 channel using the whole cell patch clamp technique to evaluate whether F373280 could block the sustained component of I_{Kv1.5}. F373280 concentration-dependently reduced Kv1.5 channel activity with an IC_{50} value of 13.7 µM.

The effects of F373280 on atrial effective refractory period (AERP) were investigated in anesthetized pig using a conventional pacing protocol through epicardial electrodes placed on the left atrium. F373280 administered as a bolus and an infusion (10 mg/kg) significantly increased AERP (23.8 ± 2.2 ms versus -7.3 ± 11.5 ms in the presence of vehicle, P<0.05). In addition, F373280 was devoid of significant effect on the hemodynamic and the ECG intervals.

Proof of the pharmacological concept was performed with a different DHA derivative named: Nicotinyl ester of DHA (pro-drug based on DHA delivery). Ventricular tachypacing (VTP)-induced congestive heart failure (CHF) provides a clinically-relevant animal model of AF associated with structural remodelling, as is often seen clinically. It has been shown that sustained oral PUFA administration suppresses CHF-induced AF-promotion and fibrosis in the VTP canine model. Nicotinyl ester of DHA was tested in this model, at 1g/day and 5g/day, during 4 weeks, to prevent CHF-related atrial structural remodelling and AF promotion in dogs. Nicotinyl ester of DHA dose dependently reduced heart failure-induced increases in atrial fibrillation duration (989 ± 111 sec, n=5 in the presence of placebo versus 637 ± 196 sec, n=5 in the presence of 1g/kg/d Nicotinyl ester of DHA and 79 ± 51 sec, n=5, in the presence of 5g/kg/d Nicotinyl ester of DHA. The protective effect of Nicotinyl ester of DHA was associated with a marked increase of plasma level of DHA and important incorporation of DHA in the left atrial tissue. Because F373280
similarly to Nicotinyl ester of DHA increases plasma level of DHA, it could be estimated that the compound may exert a similar protective effect [1].

1.2.2.2. **Safety pharmacology**

A battery of safety pharmacology studies was performed to evaluate the effects of F373280 on the central nervous, cardiovascular and respiratory systems. Data of these studies are exhaustively detailed in the Investigator’s brochure [1]. No particular alerts were evidenced with F373280.

1.2.2.3. **Toxicology profile**

Concerning the toxicological data, 4-week and 26-week repeat-dose studies in rat and dog were performed. Compared to the high administered doses of F373280 (500 to 2000 gm/kg/day), low circulating concentrations of F373280 were measured.

During these toxicity studies, no toxicity was observed in rat after 4 and 26 weeks of dosing and in dog after 4 weeks of dosing. A NOAEL of 2000 mg/kg/day was established in these repeat toxicity studies.

During the 26-week toxicity study in dogs, the NOAEL was set at 1000 mg/kg/day based on changes observed on red blood cell parameters.

Based on toxicological profiles, F373280 is considered to support the proposed clinical trial.

1.2.2.4. **Pharmacokinetic data**

According to animal studies described in the Investigator’s brochure [1], the non-clinical pharmacokinetic profile of F373280 is not associated with particular alerts concerning the proposed clinical phase IIa study.

1.2.3. **Clinical data**

*Part A: single dose*
6 consecutive single ascending doses were tested (0.5g, 1g, 2g, 4g, 8g and 16g) on 6 independent cohorts of 8 subjects (6 verum + 2 placebo). 49 subjects were treated and 48 completed the study.

No Serious Adverse Events occurred in the course of the study.

Regarding the reported Treatment Emergent Adverse Events (TEAEs) that were judged by the Investigator as having a causal relationship with the study drug administration in the absence of an alternative explanation, 4 were observed in the placebo group (palpitation, dizziness in standing position, 2 symptomatic orthostatic hypotensions without loss of consciousness) and 4 in the group of F373280 at the dosage of 16g (meteorism, liquid stool, symptomatic orthostatic hypotension and dizziness in standing position). None of these adverse events were reported in the groups of F373280 at the dosages of 0.5g, 1g, 2g, 4g and 8g.

After a single administration of the different tested doses no difference between the tested product and placebo has been reported, regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters (related to coagulation: platelets and fibrinogen) and coagulation parameters (bleeding time, prothrombin time/INR, activated partial thromboplastin time, thrombin clotting time). Variations of these parameters were within the physiological ranges.

After single oral administration of F373280 from 0.5g to 16g in 36 young male healthy subjects (6 per dose level), the following was observed:

- **F373280**: Whatever the tested dose there is no circulating F373280 in plasma: only few, sparse and non consecutive samples with quantifiable level of F373280 close to LOQ were observed. This confirm that F373280 is a prodrug.

- **Panthenol**: Cmax and AUC increased with the administered dose between 0.5 and 16g. Panthenol concentrations were rapidly cleared from plasma with a mean terminal half-life around 2 hours.

- **DHA**: after 0.5 and 1g, low increased in DHA plasma concentrations compared to the baseline levels led to a high inter-individual variability of the corresponding PK parameters. Plasma exposure in DHA increased with the administered dose between 2 and 16g with no departure from proportionality (baseline corrected parameters).
**Part B: Multiple dose**

Three consecutive repeated ascending doses (1, 2 and 4g) were tested on 3 independent cohorts of 12 subjects (9 verum + 3 placebo, double blind). 36 subjects completed the study. Each treatment was administered over a period of 28 days. Pharmacokinetic parameters were assessed over a period of 14 days.

Among the TEAE judged by the investigator as suspected to F373280 5/9 TEAE were classified according the SOC in vascular system disorder with orthostatic hypotension (2 in the 1 g group, 1 in the 2 g group and 2 in the 4 g group) and 4/9 were classified in nervous system disorder with 3 dizziness (2 in the 2 g group and 1 in the 4 g group) and 1 migraine (in the 1 g group). These TEAE have already been reported with Poly Unsaturated Fatty Acids and are commonly observed in phase I studies.

After a repeated administration of the different tested doses, no difference between the tested products and placebo was reported regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters. The assessment of coagulation parameters and platelet function after administration of repeated dose of F373280 did not report any bleeding issue. The reported changes in coagulation parameters and platelet function were within physiological ranges.

After a 14-day repeated oral administration of F373280 from 1 g to 4 g, the following was observed:

- **Panthenol**: Cmax and AUC increased with the administered dose between 1 and 4 g. No accumulation of panthenol in plasma was observed.

- **DHA**: Plasma exposure increased with dose. A 2-fold accumulation in total plasma exposure of DHA was observed after 14 days of administration, whatever the administered dose.
1.3. STUDY RATIONALE

F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation (AF) patients with chronic heart failure.

The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of atrial fibrillation (AF) induced by burst pacing [1].

Moreover, the effectiveness of PUFA has been proven in the following conditions:

- Prevention of atrial fibrillation recurrence in patients with persistent atrial fibrillation in co-administration with amiodarone (add on therapy) [2],

- Improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]

Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent atrial fibrillation and chronic heart failure.

This phase IIa study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure.

1.4. OVERALL RISK AND BENEFIT ASSESSMENT

F373280 is a new pro-drug of DHA.

DHA is a well-known long chain PUFAs with a long-term clinical experience in cardiovascular diseases. DHA is contained in several medicinal products such as Omacor®, (1g of Omacor contains about 320 mg of DHA acid) marketed by Laboratoires Pierre Fabre for hypertriglyceridermia and as an adjuvant treatment for secondary prevention after myocardial infarction. According to the summary product characteristics of Omacor®, [9]:

Final version
- The frequencies of adverse reactions are ranked according to the following: common (> 1/100, < 1/10); uncommon (>1/1000 < 1/100); rare (>1/10000, < 1/1000); very rare (< 1/10000), not known (cannot be estimated from the available data).

- The reported adverse events are:

  - Infection and infestations
    Uncommon: gastroenteritis
  - Immune system disorders:
    Uncommon: hypersensitivity
  - Metabolism and nutrition disorders:
    Rare: hyperglycaemia
  - Nervous system disorders:
    Uncommon: dizziness, dysgeusia
    Rare: headache
  - Vascular disorders:
    Very rare: hypotension
  - Respiratory thoracic and mediastinal disorders:
    Very rare: nasal dryness
  - Gastrointestinal disorders:
    Common: dyspepsia, nausea
    Uncommon: abdominal pain, gastrointestinal disorders, gastritis, abdominal pain upper
    Rare: gastrointestinal pain
    Very rare: lower gastrointestinal haemorrhage
  - Hepatobiliary disorders:
    Rare: hepatic disorders
  - Skin and subcutaneous tissue disorders:
    Rare: acne, rash pruritic
    Very rare: urticaria
  - General disorders and administration site conditions:
    Rare: malaise sensation
• Investigations:

Very rare: white blood count increased, blood lactate dehydrogenase increased

Moderate elevation of transaminases has been reported in patients with hypertriglyceridaemia.

Panthenol is a well-known substance with a long-term experience in medical, nutraceutic and cosmetic uses. According to the summary product characteristics of a product such as Bépanthene® (tablet indicated in alopecia) which contains panthenol (100 mg), adverse event observed are rare cases of urticaria and erythema [10]. Panthenol is metabolised in panthotenic acid, i.e. B5 vitamin.

Concerning toxicological studies performed results can support the administration of F373280 in the proposed clinical phase II study without particular alert [1].

Any safety warning was reported during a phase I study performed with F373280 administered to 84 healthy volunteers in single dose in a range between 500 mg and 16 g or in repeated dose during 28 days in a range between 1g and 4g. Adverse events reported and related to study treatment were minor to moderate. The adverse events were palpitations, orthostatic hypotension, dizziness, meteorism and liquid stool. Most were reported in both groups (placebo and F373280) without a dose relationship. The assessment of coagulation parameters and platelet function after administration of repeated dose of F373280 did not report any bleeding concern: the reported changes in coagulation parameters and platelet function were within physiological ranges.

Moreover, DHA has been associated with anticoagulant products in Atrial Fibrillation studies [2, 8]. The range of PUFAs doses tested was between 2g to 3g (640 mg to 960 mg of DHA) and the range of study durations between 6 to 12 months. This association did not report a significant side effect of bleeding.

DHA has already been used in heart failure patients in several studies without safety concern [3, 4, 5]. The range of PUFAs doses tested was between 1g to 5g (1g of the tested PUFAs contains about 320 mg of DHA acid) and the range of study durations was between 3 months to 3.9 years.
Thus, inclusion of patients with no specific antiarrhythmic treatment is acceptable. They will receive an anticoagulant treatment to prevent the thrombo-embolic complications of AF (particularly stroke) and the adequate treatments to control the heart rate and heart failure.

In conclusion, the overall available data allow in safe conditions the treatment of patients with persistent AF and chronic heart failure with F373280 in safe conditions.

2. **STUDY OBJECTIVES**

2.1. **PRIMARY OBJECTIVE**

The primary objective of the study is to assess the efficacy of F373280 on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure.

2.2. **SECONDARY OBJECTIVES**

The secondary objectives of the study are to assess:

- the efficacy of F373280 on the efficiency of direct electrical cardioversion
- the effect of F373280 on echocardiographic parameters
- the safety and tolerability of F373280

3. **ETHICAL CONSIDERATIONS RELATING TO THE STUDY**

The trial is conducted according to Good Clinical Practices (CPMP/ICH/135/95), the National regulations and the Declaration of Helsinki and its subsequent amendments (see Appendix 17.1). This protocol and the informed consent form will be submitted for approval to independent local or national Institutional Review Boards/Ethics Committees before the study set up, according to national regulation.

All the protocol amendments or critical events liable to increase the risks incurred by the patients or to compromise the validity of the study or patients' rights will be submitted to the coordinator and to the Ethics Committees.
After being informed orally and in writing of all potential risks and constraints of the trial, as well as their freedom to withdraw their participation at any time, patients will then sign a consent.

A time of reflection will be given to the patients, before giving a written consent and starting the study procedures.

The use of a placebo is in accordance with EMA Addendum to the guideline on antiarrhythmics on atrial fibrillation and atrial flutter (EMA/CHMP/EWP/213056/2010) [21] and is acceptable because the included patients will remain under the standard treatment of atrial fibrillation and chronic heart failure. Except antiarrhythmics, they will receive anticoagulant (AVK), rate control treatment, chronic heart failure treatment. During the study, in case of AF recurrence that would require a cardioversion or an introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms, patients will be withdrawn and the tested product stopped. These patients will be considered as treatment failure.

In this study, patients will be carefully screened, particularly for their cardiac condition, with ECG, 24-hour holter monitor and echocardiographic data, and their biologic and coagulation condition.

The study will be addressed only to patients requiring an ECV due to their persistent AF, in the following conditions:

- ECV in patients not presenting a contra-indication,

- Anticoagulation with anti-vitamin K for at least 3 weeks before ECV,

- ECV in patients with stabilized INR (i.e. values between 2 and 3) on at least 3 consecutive weekly tests performed. Patients not stabilized for INR (i.e. values between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed in the same day (before ECV)
- Patients who do not revert to sinus rhythm or present an early relapse within the observation period after ECV will be withdrawn and the tested product stopped.

During the whole study, patients will remain under medical control: visits in cardiology units will be scheduled at least every month. This follow up will include clinical signs, ECG, biological and coagulation parameters. Moreover, patient’s cardiac rhythm will be monitored between visits using daily, then every 2 days Trans Telephonic ECG Monitoring (TTEM) reviewed by a Central Reading Laboratory.

Patients may withdraw from the study at any time without having to give a reason and can expect to receive regular conventional therapy.

4. STUDY DESIGN

4.1. OVERALL DESCRIPTION

This phase IIa trial will be conducted as an international, multicentric, 24 weeks, double-blind, placebo-controlled, randomised, parallel group design, trial in 152 patients suffering from persistent atrial fibrillation and chronic heart failure.

After a 1 to 4-week of run-in period without treatment, patients will be randomised into one of the following treatment groups: F373280 1g or placebo for 24 weeks.

Nine visits are planned for the study:

- Visit 1 (V1): W-4 to W-1: Selection visit (7 to 28 days before the Inclusion Visit)
- Visit 2 (V2): D1: Inclusion visit (start of treatment)
- Visit 3 (V3): W4 (D28 -2/+7D): cardioversion visit (outpatient or hospitalization according to clinical practice of the centre) (installation of the Holter ECG device)
- Visit 4 (V4): W5 (D35 ± 2D): follow-up visit (removing of Holter ECG device and installation of the TTEM)
- Visit 5 (V5): W8 (D56 ± 7D): follow-up visit
- Visit 6 (V6): W12 (D84 ± 7D): follow-up visit
- Visit 7 (V7): W16 (D112 ± 7D): follow-up visit
- Visit 8 (V8): W20 (D140 ± 7D): follow-up visit
4.2. DISCUSSION OF THE STUDY DESIGN

4.2.1. Choice of the Study Population

The target indication of F373280 will be the maintenance of sinus rhythm after cardioversion of patients with persistent atrial fibrillation and chronic heart failure. In the present proof of concept study, the evaluation will focus on patients within this indication. This target population is justified by:

- The proved efficacy of PUFAs in patients with persistent atrial fibrillation with or without heart failure in co-administration with amiodarone (add on therapy) [2]
- The proved efficacy of PUFAs on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]

The study aim is to investigate the product effect in patients with:

- early persistent atrial fibrillation history (less than one year) with a duration of a the current episode between 7 days to 6 months
- a moderately abnormal moderately systolic heart failure (Left Ventricular Ejection Fraction (LVEF) between 30 to 45% as defined in the report from the American Society of Echocardiography’s Guideline). According to a sub-group analysis performed in patients with persistent atrial fibrillation associated to heart failure (Nodari S. personal data), PUFAs would be effective to prevent recurrence of AF after cardioversion in patients with moderately abnormal LVEF.

- A Left Atrial Area (LAA) not severely abnormal (less than 40 cm² as defined in the report from the American Society of Echocardiography’s Guideline). According to a sub-group analysis performed in patients with persistent atrial fibrillation associated to heart failure (Nodari S. personal data), PUFAs would not be effective to prevent recurrence of AF after cardioversion of patients with severely abnormal LAA.

For the successful rate of electrical cardioversion, patients should have a stable medical treatment of heart failure and should not have myocardial infarction or unstable angina or
unstable ischemic coronaryopathy (assessed by coronarography or cardiac stress test or effort test within 6 months before selection).

4.2.2. Choice of the Study Design

As the target indication would be the prevention of AF recurrence after ECV, the study design meets the requirements of EMA guideline on anti-arrhythmics on atrial fibrillation (EMA/CHMP/EWP/213056/2010) [21].

As F373280 aims to be developed as a safe treatment for the prevention of AF recurrence, it will not be tested as an add-on therapy during the study. To avoid any interaction with the tested product, anti-arhythmics class I and III will be forbidden during the study.

The study design is defined in order to avoid methodological bias. A double blind study is appropriate to assess the efficacy and safety of the use of F373280 to prevent recurrence of AF episodes. Moreover, this study design is similar to the design of almost all trials that have assessed intervention for rhythm control [2, 8, 11, 12].

According to the target indication, only patients with persistent atrial fibrillation and requiring an electrical cardioversion will be included in order to assess the time to first documented recurrence of atrial fibrillation since cardioversion.

To confirm the persistent nature of atrial fibrillation, a 24-hour holter monitoring will be performed during the selection visit.

Eligible participants will enter a selection phase in which anticoagulant treatment (anti-vitamin K) will be adjusted to achieve an International Normalized Ratio (INR) of 2.0 to 3.0 before electrical cardioversion. According to guidelines for the management of atrial fibrillation [6], anti-vitamin K should be given at least 3 weeks before cardioversion because of risk of thrombo-embolism due to post-cardioversion.

Experimental data suggest that the maximal incorporation, of n-3 PUFAs in the myocardial cell membrane takes up to 28 days to occur [22]. In addition, as shown in Nodary study [2], the duration of pre-treatment with PUFA before cardioversion appears to be a contributing factor in
success. Therefore, before starting follow up for the assessment of AF recurrence, treatment with F373280 should be started 28 days before ECV.

Detection of atrial fibrillation recurrence will be performed using systematic (scheduled) ECG recording, thus allowing detection of asymptomatic (about 50% of episodes) as well as symptomatic AF episodes. According to previous studies, most of atrial fibrillation recurrence occurred during the first days after cardioversion [11, 15]. So that, the heart rhythm will be closely monitored during the first week after successful cardioversion using an ambulatory continuous 7-day holter ECG recording in order to increase sensibility to detect asymptomatic AF episodes. Thereafter, to improve patient compliance, this follow up will be continued using a more easy to carry and easy to use device, a TTEM.

Finally, during the study, patients will be scheduled for a clinical visit every month (with an additional visit 7 days after visit 3 (ECV visit)) in order to ensure a close medical monitoring and to assess efficacy and safety parameters.

4.2.3. Choice of the Dose

According to a previous study in patients with atrial fibrillation [2], the tested PUFA product (Omacor®) at the dose of 2 g (i.e. 640 mg of DHA acid) was effective in the prevention of atrial fibrillation after cardioversion. Moreover, PUFAs at dosage of 1g and 2g were also effective on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5].

From the F373280 phase I study, after a 14-day repeated administration of F373280 (1g/day), observed plasma concentrations of DHA measured before treatment (Cmin) were similar to that of an effective dose of Omacor® at 2 g/day (60 to 95mg/mL and 60 to 90mg/mL, respectively) (phase I study of F373280 and Salm and coll study) [16]. With regard to the rhythm of administration, mean peak/trough fluctuation (baseline corrected) was around 0.3. This value supports a once-daily administration allowing a 24-hour plasma exposure in DHA. Therefore, a dose of 1 g daily of F373280 is considered to be appropriate to be tested in this POC study.
4.2.4. Choice of the Sample Size

See chapter 13.

5. STUDY POPULATION

Each patient fulfilling all the inclusion criteria and none of the non inclusion criteria will be eligible.

5.1. INCLUSION CRITERIA

**Demographic Characteristics and Other Baseline Characteristics:**

1. Men or women aged more than 18 years (inclusive),
2. Patient with persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted.
3. History of first documented persistent AF less than 1 year
4. History of ischemic or non ischemic heart failure
5. NYHA class I or II chronic heart failure at selection and at inclusion
6. Reduced left ventricular ejection fraction between 30% and 45% inclusive (using the two-dimensional echocardiography biplane Simpson’s rule) at selection and at inclusion
7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers
8. Left atrial area \( \leq 40 \text{ cm}^2 \) at selection and at inclusion
9. Patient treated or having to be treated by anti-vitamin K
10. For female patient of child-bearing potential:
    - in all the countries except Italy:
      - use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator, for at least 2 months before the selection in the study and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment or
      - documented as surgically sterilized
    - in Italy only:
      - absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
      - use of double barrier contraception method (use of effective medical contraception method) from at least 2 months before the start of the study to the entire duration of the study and for a month after the end of the study or
      - documented as surgically sterilized
11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion
12. For male with a child-bearing potential partner (in Italy only):
    - absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to a month after the end of the study.

**Ethical/legal considerations:**
13. Having signed his/her written informed consent,
14. Affiliated to a social security system, or is a beneficiary (if applicable in the national regulation),

### 5.2. NON INCLUSION CRITERIA

#### Criteria related to pathologies:
1. History of first documented episode of persistent AF more than 1 year,
2. More than two successful cardioversions (electrical or pharmacological) in the last 6 months,
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV),
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be check in case of treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic coronaryopathy assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
7. Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration rate < 30 mL/min) at selection
8. Bradycardia (HR ≤ 50 bpm)
9. Hyperkalemia or hypokalemia (K > 5.5 mEq/L or K < 3.5 mEq/L) at selection
10. Cardiac surgery within 3 months before selection or planned during the study duration

#### Criteria related to treatments:
11. Previously ineffective pharmacological or electrical cardioversion
12. Concomitant treatment with any anti-arrhythmic drug (within 7 days prior to selection), except stable dose of digoxin, beta-blockers, calcium-blockers.
13. Previous treatment with oral amiodarone within 12 months prior to inclusion
14. Previous treatment with intravenous amiodarone within 6 months prior to inclusion
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT implantation within the last 6 months
16. Treatment with any Polyunsaturated Fatted Acid within the last 3 months
   Dietary supplement with ω3 or ω6 according to investigator’s judgment
18. Having undergone any form of ablation therapy for AF
19. Patient treated with other anticoagulant treatment than antivitamin K: thrombin inhibitor such as Dabigatran or treated with antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel

#### Others criteria:
20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion,
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection,
22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself / herself to its constraints,
23. Patient family member or work associate (secretary, nurse, technician…) of the Investigator,
24. Patient having forfeited his / her freedom by administrative or legal award or being under guardianship,

5.3. NUMBER OF PATIENTS

76 x 2 patients (taking into account 15 % of non evaluable patients).

5.4. RECRUITMENT MODALITIES

Patients will be recruited within the medical consultation of each centre involved in the study. If necessary and when authorized by local and national regulation, some specific supports or tools will be used to improve the recruitment (announcement, mailing to general practitioners, leaflet, website including ClinicalTrials.gov, CRO,…).

Before implementation, the documents will be submitted to and approved by the Ethics Committee.

5.5. PATIENTS IDENTIFICATION

The patient's code will contain 7 digits: the 2 first digits corresponding to the country number, the following 2 digits corresponding to the centre number and the last 3 digits corresponding to the patient's chronological order once having signed the written informed consent.

5.6. WITHDRAWAL CRITERIA

The reasons for a patient's premature withdrawal from the study may be the following:

- The patient's decision. A patient who wishes to withdraw from the study for any reason may do so at any time but must inform the investigator. In all cases, the Investigator should attempt to contact the patient as soon as possible for a final assessment in order to:
  - have the patient's decision written on the consent form
- obtain the reason(s) for withdrawal and report it/them in the case report form
- evaluate the patient's clinical condition
- if necessary, take appropriate therapeutic measures: management of an adverse effect or concomitant disease, prescription of another treatment.

- The Investigator's decision in the patient's interest. Particularly, if a serious adverse event occurs and is considered by the Investigator liable to threaten the health of the patient. The monitor will be informed by phone or fax and a letter or report explaining the withdrawal will be forwarded to the monitor as soon as possible.

- An erroneous inclusion according to the study protocol. Any inclusion not respecting inclusion / non inclusion criteria will immediately be withdrawn and an appropriate treatment will be instored by the investigator under his/her responsibility. Erroneous inclusions will not be paid to the investigator.

- Patients who could not be treated with anti-vitamin K for at least 3 weeks before ECV,
- Patients who will not stabilize INR between 2 and 3 on at least 3 consecutive weekly tests
- Patients with only 2 consecutives INR tests between 2 and 3 in the last 3 week for whom a trans-oesphagoal echocardiography can not be performed before ECV or for whom a trans-oesphagoal echocardiography shows a thrombus in the atria.
- Patients who will not revert to sinus rhythm or with early relapse within the observation period after ECV (i.e. unsuccessful ECV) will be considered to have finished follow-up.
- An occurrence of AF recurrence that would require, at the investigator’s judgement, a cardioversion or an introduction of an anti-arrhythmic because of intolerable and uncomfortable clinical symptoms.

5.7. REPLACEMENT OF PATIENTS

Withdrawn patients will not be replaced.
5.8. **POST-STUDY EXCLUSION PERIOD**

Patients will not be allowed to participate to another clinical trial during 3 months following the study termination.

5.9. **STUDY CARD AND LETTER FOR GENERAL PRACTITIONER(S)**

The patient will receive from the Investigating Centre at Visit 1 - Selection Visit :

- a personal card to be kept all along the study duration and providing the following information: patient's name, sponsor's name, study code, EUDRACT number, start date and expected end date of the study, complete address of the Investigating Centre with the name and phone number of the Investigator and a sponsor 24H/24 phone contact number in case of emergency (French and English languages): 33 (0)5 63 35 25 83. For Italy, this card will be in Italian only, without any English mention.

- in Italy, a letter to be given to his/her general practitioner. This letter intends to inform the general practitioner(s) (and any other doctors who take care of the patient) that the patient participates to the clinical study. It describes the study treatment and includes some information on the forbidden treatment during the study.

6. **STUDY TREATMENT**

The Clinical Pharmacy Department of the Institut de Recherche Pierre Fabre (IRPF) will supply the investigational centres with the treatment necessary for the conduct of the trial.

6.1. **SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT**

F373280 and placebo will be prepared in Soft Capsules similar presentation.

- **F373280**

Formulation of F373280, 1g, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: Panthenyl ester of DHA, gelatine, glycerol, titanium, dioxide, purified water.
• Placebo

Formulation of placebo matching tested product, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: paraffin liquid, fish flavour, gelatine, glycerol, titanium, dioxide, purified water.

Placebo and F373280 capsules will be packaged in opaque blisters.

6.2. PACKAGING AND LABELLING

The treatment units will be packed and labelled by the Clinical Pharmacy Department of the IRPF according to European Directive and local requirements.

6.2.1. Packaging

Each treatment unit will be composed of 3 cases for a 12-week treatment period.

The Investigator will provide the patient with the treatment according to the following schedule:

At Inclusion Visit (V2): a 12-week treatment unit will contain 3 cases, each case containing:
- 10 blister packs of four 1g F373280 soft capsules or placebo soft capsules each.

At Visit 6 (V6): a 12-week treatment unit will contain 3 cases, each case containing:
- 10 blister packs of four 1g F373280 soft capsules or placebo soft capsules each.

6.2.2. Labelling

Investigational Products will be labelled according to the following rules:

Labelling should comply with the local requirements for Investigational Medicinal Products.

On the treatment units and cases, the labels will bear the following indications:

a) name and address of the sponsor
b) protocol number,
c) packaging batch number,
d) the treatment number
e) storage conditions
f) expiry date
g) pharmaceutical dose form
h) route of administration
i) quantity of dosage units
j) direction for use
k) legal statements:
   – “for clinical trial only”, “keep out of the reach and the sight of children”, “please return to your doctor any unused product”, respect the prescribed dose”.

On the treatment unit, another label will be affixed with the mention of the investigator name and patient number (completed by the investigator).

In addition, on each case, will be mentioned the case number and a detachable label will bear the following indications:
   – Protocol number
   – Packaging batch number
   – Expiry date
   – Case number
   – Treatment number

On the blister pack, the label will mention the protocol number, the packaging batch number, the case number and the treatment number.

6.3. DISTRIBUTION TO CENTRE AND STORAGE

The Clinical Pharmacy Department of the IRPF will supply the Investigational Centre with the treatment units along the study according to the need, upon request triggered by the patient’s selection.

As soon as the Pharmacist or the Investigator receives the trial medication, he/she will check the contents and immediately acknowledges the receipt in the IVRS/IWRS. The copy of the acknowledgement will be kept in the Investigator’s file. The same procedure will be applied to all further supplies during the course of the trial.

At the time of the delivery to the Centre, the following information will be provided:

• Details of storage conditions that should be respected

• And, upon request and for the 1st delivery only, a letter of release for the Investigational Medicinal Product from the Sponsor’s Qualified Person.
The CRA will ensure during the monitoring visits that trial medications have been received in good conditions and the acknowledgment of receipt has been performed adequately.

Treatment units should remain intact until dispensation to the patients. They should be kept at temperature below 30°C in an appropriate lockable room only accessible to the person authorised to dispense them, under the responsibility of the Pharmacist or the Investigator.

In the case of undue delay in study execution, the Pharmacist or the Investigator should ensure that the expiry date has not been exceeded.

6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT

A randomisation list will be established by the Clinical Pharmacy Department of the IRPF. This list will be computer-generated with internal software. The randomisation methodology is validated by the Biometry Department before generation.

Treatments F373280 or placebo will be balanced in a 1:1 ratio.

As the treatment units are prepared for 12-week treatment periods, the Investigator will have to allocate a treatment number at inclusion Visit and another one at Visit 6.

For each patient, the treatment number given at Visit 6 will not be the same that the one given at inclusion visit (V2).

The treatment numbers will be given through the IVRS/IWRS.

Practically, once the patient’s eligibility is confirmed, at selection visit:

- The Investigator:
  - Calls the vocal server
  - Answers the questions relating to the patient
  - In return, the treatment number to be allocated for the first 12-week period to the patient is given by the vocal server.

- The IVRS/IWRS company:
  - Confirms this information by fax/email to the Investigator
– Fills the “Request for Delivery of Investigational Product” form and sends it by email and/or fax to the Clinical Pharmacy Department of the IRPF.

• The Clinical Pharmacy Department of the IRPF sends the corresponding treatment unit to the Investigator within 5 days from reception of the email request form.

The Investigator will dispense to the patient the case which label indicates the treatment number and the administration period.

At visit 5, the Investigator will contact again the IVRS/IWRS to obtain for visit 6 the treatment number for the last 12-week period of treatment according to the same process as described above.

6.5. DRUG ADMINISTRATION

6.5.1. Duration of Treatment

For a patient completing the study, the theoretical study treatment exposure will be 24 weeks, with F373280 or placebo.

If the ECV is postponed by 1 week to allow INR stabilization, the treatment duration will be 25 weeks.

6.5.2. Dose Schedule

One soft capsule of 1g of F373280 or placebo to be taken each day during 24 weeks.

6.5.3. Route and Conditions of Administration

The soft capsules are to be taken orally. One soft capsule is to be taken each evening with the dinner during 24 weeks.

6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT

The Investigator should maintain accurate written records of drug received, dispensed, returned and any remaining treatment units, on the drug accountability form. These records should be made
available for Clinical Research Associate (CRA) monitoring. The packaging of the medication should remain intact until just before the dispensation.

At each visit, the Investigator will record the number of soft capsules returned by each patient using the appropriate page of the e-CRF.

At the end of the study, all used and unused treatments including packaging should be noted, and return is organised by the CRA to the Clinical Pharmacy Department of the IRPF for destruction. A copy of the drug accountability form should be provided by the Investigator to the CRA.

6.7. RECALL OF INVESTIGATIONAL PRODUCTS

In case of recall of investigational products (decided by the Competent Authorities or the Sponsor), the Investigator will immediately be informed by the Sponsor.

The Investigator, in collaboration with the Sponsor representatives (Study Manager, CRA) must urgently:

- Stop the delivery of the concerned investigational products to the patients.
- Inform the concerned patients that they must immediately stop taking these investigational products and bring them back.

The Study Manager/CRA organises the return of the recalled products to the Clinical Pharmacy Department of the IRPF, according to the Sponsor’s procedures.

7. CONCOMITANT TREATMENTS

Any existing concomitant treatment (Selection Visit), any new concomitant treatment or change in the dosage of an existing concomitant treatment during the course of the study must be noted on e-CRF. All treatments should be evaluated by the investigator at selection and their prolongation during the study or their stop should be considered.

For all concomitant treatments taken during the study, the following information must be noted in the relevant section(s) of the e-CRF:
• The name of the treatment and its form
• The reason for prescription
• The route of administration
• The daily dose
• The duration of treatment.

7.1. ANTI-VITAMIN K TREATMENT

Anti-vitamin K should be given for at least 3 weeks before ECV and continued for the whole study duration. The anti-vitamin K used will be left to the decision of the each investigator according to his/her local practice.

7.2. PROHIBITED TREATMENTS

- Class I and class III antiarrhythmic treatments:
  - Class I
    - Class IA: Disopyramide, Procainamide, Quinidine
    - Class IB: Lidocaine, Mexiletine
    - Class IC: Flecaïnide, Propafenone
  - Class III: Dofetilide, Ibutilide, Sotalol, Amiodarone, Dronedarone.
- Any Polyunsaturated Fatty Acid (PUFA)
- Any anticoagulant treatment other than antivitamin K: thrombin inhibitor such as Dabigatran or antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel
- Dietary supplement with Omega 3 or Omega 6

Prohibited treatments at selection must not be prescribed for the duration of the study except in case of occurrence of an adverse event or AF episode that requires a corrective treatment in the interest of the patient’s health.

7.3. AUTHORISED TREATMENTS

Other treatments will be authorised during the study duration.
However, if medication other than study drugs is administered at any time from the start of the study, details must be recorded in the case report form. During the study, patients must be asked whether they have been on a course of prescribed drug treatment or have taken any OTC or herbal drugs since the visit.

8. EVALUATION CRITERIA

8.1. PRIMARY EFFICACY CRITERION:

8.1.1. Time to the first Atrial Fibrillation Recurrence

8.1.1.1. Definition
Time to first Atrial Fibrillation recurrence is defined by the first episode of Atrial Fibrillation (symptomatic or not) lasting for at least 10 minutes.

8.1.1.2. Schedule
The heart rhythm follow up will be performed from the end of electrical cardioversion visit (visit 3) to the final study visit (visit 9).

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF will be assessed after visit 3 (week 5).

8.1.1.3. Evaluation Methods
- 7-day holter monitor:

The heart rhythm monitoring will be carried out from visit 3 to visit 4 using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) fixed after ECV visit.

Following holter monitoring the heart rhythm will be documented using Trans Telephonic ECG Monitoring (TTEM)

- Trans Telephonic ECG Monitoring (TTEM):
Thus, the follow up will be documented using the TTEM: daily transmission from visit 4 to visit 6. Then, every two days from visit 6 to visit 9.

Moreover, during this TTEM period, if patient experiences AF symptoms, it should be documented using the TTEM.

In case of AF recurrence, and provided that the patient does not required a cardioversion or an introduction of an anti-arrhythmic at the investigator’s judgement, he/she could be maintained in the study with the treatment, in order to assess a spontaneous cardioversion. For that purpose the patient will continue to transmit a TTEM once a week.

The TTEM will be centralized by the Central Reading Laboratory. The patient will be requested to contact the Central Reading Laboratory for transmission of each stored TTEM. The TTEM will be validated by a trained technician, then analysed by a cardiologist. The cardiologist interpretation will be faxed to the site. The investigator will be asked to review and sign this document.

The TTEM process will be fully described in a separate document.

8.1.2. Secondary Efficacy Criteria

8.1.2.1. Numbers of Atrial Fibrillation episodes in the first week following visit 3 (ECV visit)

8.1.2.1.1. Definition

Number of Atrial Fibrillation episodes will consist in the assessment of episodes of AF with duration at least 10 minutes (\(N_{\text{Sup10}}\)) and of less than 10 minutes (\(N_{\text{Inf10}}\)), respectively.

8.1.2.1.2. Schedule

The heart rhythm follow up will be performed from the end of successful electrical cardioversion visit (visit 3) to the study visit 4.

8.1.2.1.3. Evaluation Methods

- 7-day holter monitor:
The heart rhythm monitoring will start using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) after ECV visit from visit 3 to visit 4.

8.1.2.2. **Duration of Atrial Fibrillation episodes in the first week following visit 3 (ECV visit)**

8.1.2.2.1. **Definition**

Duration of AF episodes will consist in the sum of duration of each AF episodes.

8.1.2.2.2. **Schedule**

The heart rhythm follow up will be performed from the end of successful electrical cardioversion visit (visit 3) to the follow up study visit (visit 4).

8.1.2.2.3. **Evaluation Methods**

Duration of AF episodes will be assessed using the 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording.

8.1.2.3. **Clinical parameters evaluation**

8.1.2.3.1. **EHRA score assessment**

8.1.2.3.1.1. **Definition:**

AF related symptoms will be evaluated by the EHRA (European Heart Rhythm Association) score [20]. The following items “during presumed arrhythmia episodes" are checked to determine the score: palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety.

Classification of AF-related symptoms (EHRA score) are as follows:

- **EHRA I** - ‘No symptoms’
- **EHRA II** - ‘Mild symptoms’; normal daily activity not affected
- **EHRA III** - ‘Severe symptoms’; normal daily activity affected
- **EHRA IV** - ‘Disabling symptoms’; normal daily activity discontinued
This classification relates exclusively to the patient-reported symptoms.

In addition to this score, the frequency will be classified in three groups, namely occasionally (less than once per month); intermediate (1/month to almost daily); and frequent at least daily.

8.1.2.3.1.2. Schedule

This evaluation will be performed in case of symptoms evocative of arrhythmia.

8.1.2.3.1.3. Evaluation Methods

This evaluation will be collected by Central Reading Laboratory during all the study period.

8.1.2.3.2. Number of recurrence of symptomatic AF

It consists of number of AF recurrence associated with a symptom (Palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety) and confirmed by an ECG in atrial fibrillation.

8.1.2.3.3. Number and duration of hospitalization

- Number and duration of hospitalization for cardiovascular events
  - Hospitalization for AF treatment
  - Hospitalization for worsening of heart failure
  - Hospitalization for myocardial infarction
  - All cause of hospitalization

- Number and duration of hospitalization for thromboembolic stroke

8.1.2.4. Cardioversion assessment

- Assessment of spontaneous cardioversion before visit 3
- Assessment of successful cardioversion at visit 3 (i.e. return to sinus rhythm)
- Shock distribution (1, 2 or 3 shocks)
- Number of patients needing another cardioversion after initial ECV
8.1.2.5.  **Evolution of echocardiographic parameters**

8.1.2.5.1.  **Definition**

The following echocardiographic parameters will be assessed: Left atrial diameter (mm), Left atrial area (cm²), Left atrial volume (mL), Left atrial volume/BSA (mL/m²), Left ventricular ejection fraction (%), Left ventricular volume (mL), Left ventricular volume/BSA (mL/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL), Left ventricular end systolic diameter (mm), and Left ventricular end systolic volume (mL).

8.1.2.5.2.  **Schedule**

The measurements will be performed at visit 1 and visit 2 to check the eligibility of the patient.

The measurements performed at visit 4, visit 6 and visit 9 are done to follow the echocardiographic evolution of the patients in sinus rhythm.

8.1.2.5.3.  **Evaluation method**

The echography evaluations will be carried out according to the recommendations for chamber quantification drawn up by the American Society of Echocardiography and the European Association of Echocardiography [23]. So, for volume measurements, the recommended method is to use the biplane method of discs (modified Simpson’s rule) from 2-D measurement.

8.2.  **BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA**

8.2.1.  **Definition**

Because of the limited accessibility of human tissues for biopsy, red blood cell DHA contents is a marker for tissue DHA concentration [13], [14].
8.2.2. Blood samples

8.2.2.1. Collection schedule

Blood samples will be collected for determination of red blood cells (RBC) concentrations of DHA.

Blood samples will be performed as follows:

- Visit 2 before treatment, visit 3, visit 6 and visit 9.

Actual sampling times will be individually reported in the electronic Case Report Forms (e-CRFs).

8.2.2.2. Technical handling

Two blood samples will be collected containing EDTA. They will be gently shaken and centrifuged at 3000g for 15 min at room temperature, within 30 minutes after collection. Plasma and white blood cells will be discarded. Red blood cells will be stored at +4°C (no freezing will be allowed) and sent to Analytical Centre in refrigerated conditions (between +2°C and +8°C) within 3 weeks following collection. Analysis will be performed within 2 weeks following reception at the Analytical centre.

8.2.3. DHA concentration measurement

Analytical determination of RBC concentrations of DHA will be carried out by the Analytical Centre.

Lipids will be extracted from red blood cells samples with a mixture of hexane/isopropanol, after acidification [17]. Total lipid extracts will be saponified and methylated. The fatty acid methyl esters (FAME) will be extracted and analyzed by Gas Chromatography.

Identification of FAME will be based on retention times obtained for FAME prepared from fatty acid standards. The area under peaks will be determined using ChemStation Software (Agilent) and results will be expressed as % of total fatty acids. DHA concentration will be calculated using the internal standard and expressed as µg/g for red blood cells samples. Thus, omega-3 index will
be assessed. The omega-3 index represents the content of EPA plus DHA in red blood cells (expressed as a percent of total fatty acids). It is a biomarker considered as a new marker of risk for death from coronary disease [18].

Results of this analytical determination will be kept confidential by the dosing centre until the end of the study, and will be provided only at the end of the study (after database lock), in a separate file.

8.3. SAFETY ASSESSMENT

8.3.1. Adverse Events

At selection, any concomitant disease will be reported on the e-CRF. At each further visit, the occurrence of adverse events (AEs) since the last visit will be based on the patient's spontaneous reporting, the investigator's non-leading questioning and his/her clinical evaluation. All AEs will be reported on the e-CRF (see section 10).

8.3.2. Laboratory Investigations

8.3.2.1. Schedule

Laboratory investigations will be performed at visit 1 (before treatment) and visit 9 (end of treatment) or End of Treatment visit.

At visit 3 and 6, only an haematology examination will be performed.

Furthermore the kaliemia will be checked before electrical cardioversion at visit 3.

The volume of blood samples complete haematology, biochemistry should not exceed 30 mL.

8.3.2.2. Technical Procedures and Parameters

The following tests will be performed:

Haematology: Hematocrit, haemoglobin, Red blood cells (RBC) count, white blood cells (WBC) count, WBC differential counts (% and absolute), reticulocytes, platelets.
Chemistry: sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatine phosphokinase (CPK), fibrinogen.

Blood samples will be taken in the morning, in fasting conditions.

The estimation of GFR at selection relies on the measurement of serum creatinine and the Cockcroft-Gault formula

Cockcroft-Gault formula

- with serum creatinine expressed as mg/L:

GFR (mL/min) = \[\frac{[(140-\text{age}) \times \text{weight}}{7.2 \times \text{serum creatinine in mg/L}}\],

- with serum creatinine expressed as μmol/l:

GFR (mL/min) = \[\frac{[(140-\text{age}) \times \text{weight}}{\text{serum creatinine in μmol/l}}\] x \text{k}, where \text{k} = 1.23 for men, 1.04 for women.

(weight in kg, age in years)

Additional tests may be done at the Investigator’s discretion, in the patients’ interest. In case of any abnormal or clinically significant results, the Investigator will order laboratory control tests.

8.3.3. Global Physical Examination

A global physical examination including the measurement of body weight will be carried out on each body system at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.

The physical examination will be globally evaluated as “normal/abnormal”. Further target inspection will be undertaken for any abnormal finding.

8.3.4. Vital Signs

Vital signs will consist in blood pressure and heart rate at rest.
8.3.4.1.  **Schedule**

Vital signs will be measured at each visit.

8.3.4.2.  **Technical Procedure and Parameters**

Systolic (SBP) and diastolic (DBP), expressed in mmHg, will be measured after at least 5 minutes in supine position and after 2 minutes in standing position.

The heart rate (HR), expressed in beats per minute (bpm), will be measured by auscultation, after at least 5 minutes in supine position and after 2 minutes in standing position by counting the beats for at least 30 seconds.

Bodyweight will be measured in patient in underwear and with the same balance at each visit.

8.3.5.  **Electrocardiogram (ECG)**

8.3.5.1.  **Schedule**

An electrocardiogram will be recorded at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9 using an usual standardised 12-lead cardiograph.

8.3.5.2.  **Technical Procedure and Parameters**

- Electrocardiogram (ECG):

  The global interpretation from manual reading (normality, clinical relevance) and heart rate (bpm), PR (ms), QRS (ms), QT (ms), repolarisation patterns will be reported in the e-CRF. Each print-out will include the patient’s code, date, time, technician's initials and investigator's signature.

  In case of thermic paper ECG print out, a photocopy will be made by the centre to ensure safe filing.

- 24 hour-Holter - ECG

  An ambulatory continuous 24-hour ECG (5-leads/2 or 3 channels) will be recorded at selection visit using a holter ECG, in order to confirm persistent atrial fibrillation.
8.3.6. Coagulation parameters

The assessment of coagulation will be evaluated by the following parameters:

- Prothrombin Time/INR (PT/INR)
- Activated Partial Thromboplastin Time (aPTT)
- Thrombin Clotting Time (TCT)

During the pre-cardioversion period, if the anticoagulation by AVK should be initiated, then the INR monitoring will be as follow:

- INR 2-3 times a week for the first week of treatment
- INR weekly up to ECV,
- INR every 4 weeks after ECV

For patients already treated with AVK, INR monitoring will be as follow:

- INR weekly up to ECV,
- INR every 4 weeks after ECV

aPTT and TCT will be performed at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.

Anti-coagulation by anti-vitamin K should be given at least 3 weeks before ECV and continued for the whole study duration.

The quantity of blood samples collected at each time for coagulation parameters will be 2 mL.

8.3.7. Concomitant Treatments

Concomitant treatments will be evaluated at each study visit.

Requirements relating to patient's concomitant treatments started before screening visit and continued throughout the trial, or started during the trial can be found in section 7.

8.4. COMPLIANCE

The patient will be reminded at each visit to bring back any remaining soft capsules, blister, case (used or unused) at the following visit.

At each visit, the Investigator will record the number of supplied and remaining Soft Capsules in the e-CRF.
9. STUDY PROCEDURES

Visit 1 - Selection Visit (Week -4 to Week -1)

The patient considered eligible for selection by the Investigator will be informed of the characteristics and the consequences of the trial both verbally and by reviewing the patient's information sheet and consent form (see section 14.3). If he/she accepts to participate in the study, he/she will sign the informed consent and will keep a copy.

The patient will be assessed for the following:

- Demographic characteristics (gender, age, height, body surface area)
- Personal and medico-surgical history
- Habits (Tobacco, alcohol consumption, dietary habits including fish consumption…)
- Cardiovascular diseases, mainly detailed history of Heart Failure and Atrial Fibrillation characteristics
- Echocardiography using a two-dimensional echocardiography.
- 12-lead ECG
- Concomitant diseases, adverse signs or symptoms (able to be used for treatment emergent AE determination)
- Concomitant treatments (authorised, disallowed)
- Global physical examination/bodyweight
- Vital signs
- Biology: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Biology assessment of renal function: creatinine or estimated glomerular filtration rate

If the results of the above assessments are compatible with the selection criteria
• A 24-hour continuous ECG ambulatory recording (Holter ECG) device will be installed on the patient to monitor the patient heart rhythm. The patient will be requested to bring back the device after the termination of 24 hours recording. The recording will be transmitted from the Investigational site to the Central Reading Laboratory (CRL). The CRL will send his/her assessment regarding the confirmation of persistent atrial fibrillation within 2 working days to the Investigator.

• The patient will enter the selection period in which anticoagulant (anti-vitamin K) will be adjusted to achieve an International Normalized Ratio (INR) of 2 to 3 before electrical cardioversion.

At the end of the visit, the Investigator will contact the IVRS/IWRS system to confirm the patient selection and order the treatment delivery and organise the appointment for the next visit.

The patient will receive from the investigational centre the study card to be kept for the duration of the study.

Visit 2 - Inclusion Visit (Day 1)

If the patient's behaviour during the selection period and/or the result of complementary examinations particularly the confirmation of the presence of persistent atrial fibrillation by the CRL during this period, the INR and laboratory tests, are compatible with the inclusion criteria, the patient will be assessed for the following:

• Adverse events

• Concomitant treatments (authorised, disallowed)

• Laboratory examination: red blood cell concentrations of DHA and coagulation parameters Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)

• Global Physical examination/bodyweight

• Vital signs

• Echocardiography using a two-dimensional echocardiography.
• 12-lead ECG
• Urine pregnancy test for women of child bearing potential.

If the results of the above assessments are compatible with the inclusion criteria, the patient will be included and allocated a treatment number using the IVRS/IWRS system.

Between this Inclusion visit and the next visit (V3), the INR will be closely monitored (refer to paragraph 8.3.6), in order to ensure that the INR is stable, between 2 to 3 before electrical cardioversion.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week period.

**Visit 3 (Week 4: D28 -2/+7 days) cardioversion**

Patient will be assessed for the following criteria:

• Adverse events
• Concomitant treatments (authorised, disallowed)
• Laboratory examination: Haematology, Red Blood Cell concentrations of DHA, Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
• Global Physical examination /bodyweight
• Vital signs
• 12-lead ECG
• Electrocardioversion (ECV): ECV has to be scheduled 4 weeks after randomization and after target international normalized ratio levels will be stabilized (between 2 and 3) on at least 3 consecutive weekly tests in patients with AF. Patients not stabilized for INR (i.e. values between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed in the same day (before ECV). ECV will be performed in the morning, with the patient in the fasting state and without dyskalemia. Anesthesia will be...
induced and patients will be cardioverted with administration of a synchronized, biphasic current. The initial shock will be set at 100 J if the body weight is less than 70 kg and at 150 J for higher body weights. Successful cardioversion will be defined as recovery of sinus rhythm lasting at least 1 minute after the shock. If unsuccessful, a second 200-J shock, and eventually a third 200-J shock, will be administered. Failure of ECV is defined as the persistence of AF after the third attempt at cardioversion. After the procedure, patients will be monitored on telemetry for at least 6 hours before discharge. Patients who will not revert to sinus rhythm or with early relapse within the observation period after ECV will be withdrawn from the study and will be considered to have finished their follow-up.

At the end of the visit, a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) will be installed on the patient in order to monitor the patient heart rhythm after ECV.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week period.

**Visit 4 (Week 5: D35 ± 2 days)**

After removal of the continuous ECG ambulatory device, the patient will be assessed for the following criteria:

- Assessment of Adverse Events
- Concomitant treatments (authorised, disallowed)
- Vitals Signs
- Echocardiography using a two-dimensional echocardiography

At the end of the visit, the patient will be given the TTEM device (Trans Telephonic ECG Monitoring) for cardiac monitoring. The patient will be clearly instructed on the frequency and modalities of transmission. The patient will be requested to performed daily transmission from week 6 to week 8, then every 2 days from week 9 to week 24. Moreover, in case of AF symptoms additional transmission may be performed.
Visit 5 (Week 8: D56 ± 7 days) – Visit 6 (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days) - Visit 8 (Week 20: D140 ± 7 days)

Patient will be assessed for the following criteria:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT). However, in case of discontinuation of anticoagulation after ECV, the monitoring of INR, aPTT and TCT should be stopped.
- Global Physical examination/bodyweight
- Vital signs
- 12-lead ECG
- The cardiac monitoring will be continued using a TTEM device (Trans Telephonic ECG Monitoring). The device will be given to the patient who will be requested to performed daily transmission from week 6 to week 8, then every 2 days from week 9 to week 24. Moreover, in case of AF symptoms additional transmission may be performed.

The Investigator will collect all the cases, blisters and any unused soft capsules and count the unused capsules for each 4-week treatment period.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week treatment period.

In addition:

- at visit 5, the investigator will contact the IVRS/IWRS to obtain another treatment unit to be dispensed at visit 6 for the last 12-week period.

- at visit 6, an echocardiography will be performed, an haematology examination will be done and the red blood cell concentration of DHA will be measured.

**End-of-Study Visit - Visit 9 (Week 24: D168 ± 7 days)**
Patient will be assessed for the following:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Global Physical examination/bodyweight
- Vital signs
- 12-lead ECG
- Laboratory examination: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT). Red blood cell concentration of DHA.
- Urine pregnancy test for women of childbearing potential
- Echocardiography using a two-dimensional echocardiography

The Investigator will collect all the cases, blisters and any unused soft capsules and count the unused soft capsules.

10. ADVERSE EVENTS: DEFINITION AND REPORTING

10.1. ADVERSE EVENTS

10.1.1. Definition of Adverse Events

An adverse event is any adverse change from the patient's baseline condition, i.e. any subjective signs and symptoms or change in a concomitant disease present at the Selection Visit considered or not related to the treatment.

This includes intercurrent signs, symptoms, illnesses and significant deviations from baseline for vital signs and laboratory values, which may occur during the course of the clinical study.

All laboratory tests for which abnormal results are collected after study treatment initiation should be repeated until the values return to normal or to a stable status. Abnormal results are defined as
those falling out of the laboratory normal ranges and that are clinically significant. The frequency of such checks should be defined by the Investigator according to the degree of abnormality.

In all cases, the aetiology should, as much as possible, be identified and Pierre Fabre Médicament notified.

10.1.2. Grading of Adverse Events

Adverse or intercurrent events are graded as follows:

- Mild: awareness of signs or symptoms, but easily tolerated
- Moderate: uncomfortable enough to cause interference with usual activity
- Severe: incapacity with inability to work or do usual activity.

10.1.3. Reporting of Adverse Events

The records of adverse events in the electronic Case Report Form (e-CRF) describe the nature (diagnosis, signs and symptoms), severity, onset date, stop date, outcome and actions taken, and relationship to study treatment (in the Investigator's opinion). It must be specified whether the event is serious or not.

10.2. SERIOUS ADVERSE EVENTS (SAE)

10.2.1. Definition

A serious adverse event (SAE) includes, but is not necessarily restricted to any event which:

- Results in death (whatever may be the cause)
- Is life-threatening
- Results in persistent or significant disability/incapacity
- Requires the patient's hospitalisation or prolongation of current hospitalisation *
- Is a congenital anomaly or birth defect.
Other events such as cancer, and any additional adverse experience or abnormal laboratory values occurring during the study period, defined by the protocol as serious or which the Investigator considers significant enough, or that suggest a significant hazard, contra-indications, side effect or precaution, must be handled as serious adverse events.

Any overdosage meeting a seriousness criteria should be reported as a SAE (see section 10.3).

Any pregnancy occurring during/after exposure to the study drug(s) should be reported on the SAE notification form (see section 10.4).

* any hospitalisation, or prolongation of hospitalisation due to the circumstances listed below:
  - planned (as per protocol) medical/surgical procedure,
  - preparation for routine health assessment/procedure (e.g. routine colonoscopy),
  - planned medical/surgical admission (planned prior to entry into study trial, appropriate documentation required),
  - administrative or social reasons (e.g. lack of housing, economic inadequacy, care-giver respite, family circumstances)

will not be reported as a SAE.

10.2.2. Reporting of SAE

All serious adverse events, according to the above-mentioned definitions and regardless of treatment or relationship to study drug, must be recorded by the Investigator as soon as he/she is informed of the event.

The Investigator must notify the Sponsor of this event by sending, within 24 hours, the "Notification of serious adverse event" form ("first notification") (see appendix 17.2) with all the available information about the event, to the Sponsor's representative:

Marlène GUIRAUD, Pharm D
INSTITUT DE RECHERCHE PIERRE FABRE,
Centre de R&D Pierre Fabre – BP 13562
3 Avenue Hubert Curien
31035 TOULOUSE Cedex 1
Phone: +33 5 35 50 63 48
Fax: + 33 5 34 50 65 92
Email: marlene.guiraud@pierre-fabre.com
In case of non-inclusion the reporting period ends when the non-inclusion is documented.

10.2.3. Follow-up of SAE

The Investigator must draw-up a specific clinical report and use the "Notification of serious adverse event" form ("follow-up") (see appendix 17.2) and collect the results of the carried out examinations and the reports of hospitalisation.

The serious adverse events must be followed up until resolution or stabilisation.

10.2.4. SAE Occurring After the Study

Any SAE occurring during 30 days following the end of the study for the patient should be notified to the Sponsor.

Must also be notified to the Sponsor any event occurring at any time after the end of the study for the patient which may be related to the study treatment in the Investigator's opinion.

10.3. REPORTING OF OVERDOSAGE TO THE SPONSOR

For the purpose of this trial an overdosage will be defined as any dose exceeding the planned prescribed dose of the study drug or the administration of any dose of an associated product that is considered both excessive and medically important.

In the absence of seriousness criteria, the overdosage, and associated adverse event if any, are reported only on the Adverse Event page of the CRF. If the definition of seriousness criteria is met, the SAE notification form must be also transmitted to the sponsor.

10.4. REPORTING OF PREGNANCY TO THE SPONSOR

Pregnancies discovered in the period in between the informed consent form signed but before any study drug exposure are not to be reported to the sponsor unless associated to a seriousness criteria (e.g. serious adverse event study-protocol related procedure). If pregnancy is confirmed, the women must not be administered the study drug and be withdrawn immediately from the study.
If pregnancy is suspected while the patient is receiving study treatment, the study drug(s) should be discontinued immediately until the result of the pregnancy testing is known. If pregnancy is confirmed, then the study treatment is permanently discontinued in an appropriate manner and the patient is discontinued from the study.

The investigators must report to the sponsor any pregnancy which occurs during or after the patient has been exposed to the study drug and until 30 days after the last study drug administration. The investigator must immediately notify the sponsor using the SAE notification form and also report the pregnancy on the AE page of the e-CRF.

Women who become pregnant after exposure to the study drug must be followed by the investigator until the completion/termination of the pregnancy. If the pregnancy goes to term, the outcome will have to be reported to the sponsor (baby's healthy status).

10.5. SPONSOR'S RESPONSIBILITIES FOR SAFETY REPORTING PURPOSES

Sponsor will submit expedited and periodic reports to both Competent Authorities and Ethics Committees per corporate standard operating procedures as regards to the EU directive 2001/20/EC taking into account local specific requirements.

11. DATA COLLECTION AND STUDY MONITORING

11.1. DATA COLLECTION

11.1.1. Case Report Form

An electronic Case Report Forms (e-CRF) will be used to record all patient data required by the protocol except the central ECG (Holter ECG, TTEM) and DHA data which will be transferred from vendors to the subcontractor as electronic data files and which will be loaded into the study database.

The e-CRF should be fully validated, compliant with ICH-GCP requirements and European regulations and include a traceability system for data corrections and deletions (audit trail).
Prior to the start of the study, the Investigator will complete a "Delegation of significant study-related duties" form. The signature and initials of all personal in charge of e-CRF completion should be recorded on this form. Each person involved in e-CRF completion, review, correction and/or validation will be trained and will have an individual login and access code to the e-CRF.

Training sessions will be held by the subcontractor for all participants who will use this tool. An e-CRF user manual will be available for investigators and CRAs.

All the information included into the e-CRF will be recorded from source documents onto the e-CRF by an authorised person.

The Investigator is responsible for the management and accuracy of the information on the e-CRF. At each monitoring visit, the e-CRF(s) should be at the CRA's disposition for review and validation.

At the end of the study, a CD-ROM containing the pdf version of all e-CRF (including audit-trail) will be sent by the subcontractor to the Sponsor and to the investigational sites for archiving. The subcontractor must store all study data for at least 15 years after the end of the study and ensure their legibility and accessibility during all the storage period.

11.1.2. Source Documents

A source document is an original record or certified copy of an original record of clinical findings, observations or any other medical or paramedical activities performed during the clinical trial, necessary for the transcription and the verification of the collected data.

Source documents along with all other trial-related documents (copies of all "informed consent" forms, e-CRFs CD-ROM, drug inventories and any correspondence related to the study) must be kept in the investigator's file throughout the study, and then, must be stored in the study centre's archives for a period of at least 15 years or as per local legal requirements, whatever is the longest.

For further details see section 15.2.
11.2. STUDY MONITORING

11.2.1. Monitoring visits

On-site visits will be carried out by a representative of the Sponsor's staff (Study Manager or CRA) prior to study initiation and at regular intervals (every 4 to 6 weeks) throughout the study. Additional visits and communication by telephone, fax, or meeting may be performed if necessary. Any site visit performed by the Sponsor's representatives will be recorded in the Investigator's study file.

11.2.1.1. Site Preselection Visit

Before selecting a centre for the study, a visit will be carried out by the CRA and/or the Study Manager to ensure that the Investigator has the necessary capacities (availability, patient's recruitment, environment), technical means and staff to carry out the study.

11.2.1.2. Initiation Visit

Before the start of the study at all investigation sites, an initiation visit will be carried out by the CRA to check at the latest that:

- The Investigator:
  - has received the technical protocol, administrative and financial agreement signed by all parties
  - has received the written statement of the Ethics Committee approval and the list of its members and their functions
- The original dated and signed curriculum vitae of the investigator(s) has been collected
- Laboratory normal ranges have been collected
- All study materials are available on the study site
- All participants agree with the monitoring procedures and know the study procedures
- All participants are aware of a possible audit or inspection
The CRA has also to provide training on the study protocol requirements and study specific procedures.

11.2.1.3. **Follow-up Visits**

Throughout the study, regular follow-up visits will be carried out by the CRA to check compliance with GCP, patient’s informed consents, strict application of the protocol, conformity of the data entered on the e-CRF with the source documents and ensure its correct completion, adverse events reporting, proper retention, storage and management of the study medication, as well as the source and other trial-related documents.

11.2.1.4. **Closing Visit**

At the end of the study, a final visit will be carried out by the CRA to:

- Verify that the e-CRFs CD-ROM with pdf files are correctly stored
- Control the accountability of intact and used treatment units and return them to the Clinical Pharmacy Department of the IRPF for destruction
- Obtain the last data clarifications and/or solutions if any
- Collect the patient's consent forms in sealed envelopes (except in case of specific country requirements),
- Make an on-site review of all study documentation and complete it if necessary
- And finally, remind the Investigator of his regulatory obligations, study document archiving process and duration.

11.2.2. **Direct Access to Source Documents**

In accordance to the requirements of the GCP, all Sponsor representatives (Study Manager, CRA and Auditors) have to be given a direct access to all source and study data to perform quality monitoring/audit, thus ensuring accuracy and completeness of data).

Investigators are reminded that all Sponsor representatives keep professional confidentiality with regards to the patient data.
11.3. INDEPENDENT DATA MONITORING COMMITTEE

An Independent Data Monitoring Committee (IDMC) will be established to assess at intervals the progress of the clinical trial, the compliance with the inclusion criteria, the quality of follow up, the quality of measures of primary end point, the safety data and to recommend to the Sponsor whether to continue, modify, or to stop the study.

The IDMC operating procedures will be described in an independent document.

12. DATA MANAGEMENT

All clinical data related to the study will be collected and saved in a computerised database by the Data Management Department of the subcontractor and under the supervision of the Data Manager of Pierre Fabre Biometry (PFB) according to the following procedures.

12.1. DATA ENTRY

All required data will be collected by the Investigator or authorised designee (duly identified into the delegation task list) on a e-CRF.

The e-CRF used for this study will be developed and maintained by the Data Management Department of the subcontractor and approved by the Sponsor.

Electronic data (Holter ECG, TTEM and DHA) will be transferred by the 3rd party vendor according to the specifications given by the Data Manager of the subcontractor. These data will be captured and handled in accordance with the European GCP ICH E6 guideline.

12.2. DATA CLEANING

The subcontractor will define in the Data Validation Plan for reviewing and querying data, descriptions of both manual and electronic edit checks. Upon Sponsor approval, the subcontractor will program the checks.
The subcontractor will review the data over the course of the study, working with the Sponsor to identify data inconsistencies. The Investigator will be asked to resolve queries by making changes directly into the e-CRF.

12.3. DATA CODING

Adverse events, concomitant diseases, medical/surgical histories will be coded by the subcontractor using the MedDRA dictionary (latest version in use).

Concomitant medication will be coded by the subcontractor using the WHO-DRUG dictionary (latest version in use).

The Sponsor Clinical Development Physician will validate coding.

12.4. DATA STORAGE

The computer data files, as well as their modifications, will be archived by the subcontractor and kept available upon request of the Sponsor.

12.5. DATABASE LOCK

The validated database will be locked by the subcontractor upon request of the Data Manager of PFB following the completion of all steps required, i.e.: data entry and check of all data, resolution of all queries, validation of the coding, Clinical and Products Safety databases reconciliation and validation committee.

Then, the subcontractor will transfer the locked database in SAS format to the Data Manager of PFB who assume storage on the PFB secured server.

13. STATISTICAL ANALYSIS

After the database lock and the randomisation code release, the statistical analysis will be performed by Pierre Fabre Biométrie (PFB) or under the supervision of the statistician of PFB using SAS® software, according to the Statistical Analysis Plan (SAP) approved by the Validation Committee.
13.1.  GENERAL CONSIDERATIONS

The main objective of the study is to assess the efficacy of F373280 versus placebo on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure.

Only the primary analysis of the primary efficacy criterion, on which is based the sample size justification, may lead to a causal interpretation. All other statistical results are to be regarded within a descriptive perspective.

The statistical significance level of the various two sided tests of all analyses will be 5 %.

13.2.  SAMPLE SIZE

Assuming an AF recurrence rate of 85% under placebo and 65% under active group, i.e. a clinically relevant difference $\Delta$ of 20%, a sample size of 64 evaluable patients per group is required, using a log-rang test of survival curves with a 80 % power and a 5 % two-sided significance level.

According to the previous assumptions and assuming a rate of not assessable patients of 15%, a minimum of 76 patients will have to be randomised per group.

13.3.  PROTOCOL DEVIATIONS

Prior to the database lock and the randomisation code release, the Validation Committee members will review the protocol deviations and will classify them as either minor or major. A protocol deviation will be considered major when it is likely to bias significantly the treatment effect estimate based on the primary efficacy criterion.

Patients with major deviation(s) will be excluded from the Per Protocol data set (see section 13.4).

A listing of all protocol deviations will be provided for all randomised patients, including the type (major/minor) of protocol deviations according to the decisions made by the members of the Validation Committee.
The number and percentage of patients with major protocol deviations will be tabulated by treatment group and type of major protocol deviations on the Full Analysis Set defined in section 13.4.

13.4. DATA SETS ANALYSED

The following 2 data sets will be analysed (as defined by the Validation Committee):

- The Safety Set composed of all randomised patients having received at least one dose of the study treatment. This data set will be used to perform analyses of Safety.
- The Full Analysis Set (FAS) composed of all randomised patients having received at least one dose of the study treatment and with a successful cardioversion observed at visit 3. This data set will be used to perform analyses of Efficacy.
- The Per Protocol Set (PP) which is the subset of the Full Analysis Set composed of all patients with a primary efficacy criteria available and without any major protocol deviation or other source of bias for primary criteria analyses.

13.5. HANDLING OF DROPOUTS AND MISSING DATA

13.5.1. Dropouts

The number of patients who withdraw from the study after their randomisation will be provided by treatment group for all treated patients (Safety Set). All withdrawn patients will be further described regarding their time to dropout and reasons for withdrawal.

13.5.2. Repositioning of Visits

No repositioning of visits will be done.

13.5.3. Missing Data

Missing values will not be substituted by estimated values, but considered as missing in statistical analysis.
13.6. **DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS**

Before the first trial drug intake, patient’s background, medical and surgical history, demographic data and disease characteristics will be described by treatment group on the Safety Set.

- **Quantitative parameters** will be described by treatment group and overall using the following: number of patients, number of missing data, mean, standard deviation, minimum, median and maximum values.

- **Qualitative parameters** will be described by treatment group and overall using frequencies.

Concomitant diseases, as well as medical and surgical histories will be tabulated descriptively by treatment group and overall using the MedDRA codes of System Organ Classes and preferred terms.

If more than 10% of patients are excluded from the FAS and PP set, the description of patients by treatment group at selection and inclusion will be repeated on the FAS and PP set for all parameters.

No statistical test of comparability of treatment groups at baseline will be performed.

13.7. **EFFICACY ANALYSIS**

13.7.1. **Primary Criterion**

13.7.1.1. **Primary Analysis**

The primary criteria, time to first recurrence, will be analysed using the Kaplan Meier method and compared with the Log rank test. Hazard ratios and 95% confidence intervals will be estimated with the Cox regression model.

The primary analysis will be performed on the FAS.

13.7.1.2. **Supportive Analysis**

The primary analysis will be repeated on the PP set.
13.7.2. **Secondary Criteria**

All secondary analyses will be performed on the FAS. If more than 10% of patients are excluded from the PP set, the secondary analyses will be repeated on the PP set.

13.7.2.1. **Numbers of Atrial Fibrillation Episodes**

Both the numbers of AF episodes (symptomatic or not) lasting for at least 10 minutes and with duration less than 10 minutes (N<sub>Sup10</sub> and N<sub>Inf10</sub>) will be described by treatment group and compared by the chi-square test (or CMH test adjusted for centre) or Fisher's exact Test.

13.7.2.2. **Duration of Atrial Fibrillation Episodes**

The duration of all AF Episodes will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centres effects) or Wilcoxon test.

13.7.2.3. **Time to first AF recurrence less than 10 minutes or symptomatic**

The time to the first AF recurrence less than 10 minutes and the time to the first symptomatic AF recurrence will be analysed as the primary analysis.

13.7.2.4. **Clinical parameters evaluation**

The EHRA score will be described by treatment group and analysed using a chi-squared test (or CMH test adjusted for centre) or Fisher’s exact Test.

The frequency of presumed arrhythmia will be described by treatment group.

The number of recurrence of symptomatic AF, of hospitalizations (for cardiovascular events, for thromboembolic stroke and for all causes), of spontaneous cardioversion, of successful cardioversion (including number of shocks distribution) and the number of patients needing cardioversion after initial ECV will be described by treatment group and compared using a chi-square test or a Fisher Test (if the numbers are relevant).
The duration of hospitalizations for cardiovascular events, for thromboembolic stroke and for any cause will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centre effects) or Wilcoxon test.

The echocardiographic parameters values will be described at each time (V1, V2, V4, V6 and V9) and changes described from V4 to V9 and from V2 to V9.

13.7.2.5. Biomarker analysis: red blood cell concentrations of DHA

Values and changes from baseline for red blood cell concentration of DHA will be performed by treatment group and assessment time.

13.8. SAFETY ANALYSIS

The Safety Set will be used to perform all analyses of the safety criteria.

13.8.1. Adverse Events

Any adverse event having been reported during the study for a given patients will be classified by preferred term and corresponding system organ class using the MedDRA terminology.

Adverse events will be classified as:

- Treatment emergent adverse events, *i.e.*, any adverse event which occurs or worsens on study treatment during the randomised period.
- Or non treatment emergent adverse events, *i.e.*, any adverse event which occurs during the run-in period (before V2) or is reported as concomitant disease with the same intensity.

For each study period, any patient with at least one reported adverse event will be classified as a patient:

- With at least one adverse event
- With at least one treatment emergent adverse event
- With one TEAE
- With two TEAE
• With at least three TEAE
• With at least one related TEAE
• With an adverse event leading to the study treatment discontinuation (definitive or temporary)
• With an adverse event leading to withdrawal
• With at least one serious adverse event.
• Numbers and percentages of patient with at least one reported treatment emergent adverse event will be tabulated by treatment group:
  • By system organ class
  • By system organ class and preferred term
  • By system organ class and preferred term, taking into consideration its most severe intensity
  • And by system organ class and preferred term, taking into consideration the most severe relationship to the study treatment.

Recurring adverse events (i.e., adverse events classified with the same preferred term) for a given patient will only be counted once and only their most severe intensity or most severe relationship to the study treatment will be tabulated.

"The number and percentage of patient with at least one most common (reported in 1% patients in any group) drug related TE AE ("not excluded or unassessable") will be tabulated by Preferred Term and Treatment group in decreasing order for the treatment group (for all patient).

The number and percentage of patients with at least one reported most common treatment emergent adverse event will also be plotted by treatment group. This graphical representation will highlight the frequencies of the most severe intensities reported by system organ class and preferred term.

Serious adverse events will also be described on an individual basis: treatment group, patient's code, sex and age, Investigator's reported term, preferred term, time of onset according to the time
of the first study treatment administration, duration, action taken regarding the study treatment administration, use of a corrective treatment, outcome and relationship to the study treatment in the Investigator's opinion.

13.8.2. Clinical Laboratory Evaluation

For each laboratory parameter, data will be tabulated by treatment group and assessment time.

The absolute changes post-trial drug administration - baseline (the baseline value being the value measured on the last blood sample collected before the first trial drug administration) will be calculated and tabulated by parameter, treatment group and post-trial drug administration assessment time. Results of retests performed post-trial drug administration will not be analysed and tabulated. They will only be displayed in individual data listings.

For all biochemistry parameters, scatter plots highlighting individual results will display the baseline and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 24 value in the ordinate.

For all haematology parameters, scatter plots highlighting individual results will display the baseline and week 4, week 12 and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 4, week 12 and week 24 value in the ordinate.

Each treatment group will be identified differently. The first bisecting line (45° line), the lines of lower and upper normal range, the lines of PSC range and CNALV range added on the plots (see Appendix 17.3).

For all blood laboratory parameters, shift tables will be provided to depict the numbers of patients with post-trial drug administration variations at each assessment time as compared to the baseline values (measured on the last blood sample collected before the first trial drug administration) by treatment group. A 3-point scale (low, normal, high) will be used as defined by the normal ranges in use in the laboratory in charge of the assays.
Clinically noteworthy abnormal laboratory values (CNALV) (see in Appendix 17.3) will be identified and described on an individual basis. If relevant, five separate individual data listings by treatment group will be provided:

- CNALV for haemoglobin (including corresponding individual results of erythrocytes and haematocrit)
- CNALV for neutrophils or leucocytes (including corresponding individual results of basophils, eosinophils, lymphocytes and monocytes)
- CNALV for platelets (including corresponding individual results of erythrocytes and leucocytes)
- CNALV for liver function parameters (including corresponding individual results of gamma-GT)
- CNALV for serum creatinine

13.8.3. **Global Physical Examination**

Recorded data of the global physical examination performed will not be tabulated as any abnormal findings post-randomisation should be reported as AEs (if clinically significant).

Physical examination assessments will be provided in the listings of individual data.

13.8.4. **Vital Signs, Physical Findings and Other Observations Related to Safety**

13.8.4.1. **Vital Sign Measurements Over Time**

For each parameter (systolic blood pressure, diastolic blood pressure and heart rate in supine and standing positions), descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.

13.8.4.2. **Body weight**

Descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.
13.8.4.3. **Individual Patient Changes**

The number and percentage of patient with at least one Predefined Potentially Clinically Significant Change (PSC) and with at least one PSC Leading to Clinically Significant Value (PSCV) will be tabulated by treatment group (see Table 1 in Appendix 17.3).

According to the pharmacological drug profile mentioned previously in this Protocol, the changes from baseline to the maximum and/or minimum post-baseline value could be categorized and tabulated by treatment group with frequencies and decreasing cumulative percentages.

If there is a signal of a drug effect toward one direction rather than the other, additionally shift tables of variations from baseline to the maximum or minimum post-baseline value could be also provided (see Table 2 to 4 in Appendix 17.3).

An individual data listing of patients with symptomatic or asymptomatic orthostatic hypotension will be provided by treatment group (see Table 5 in Appendix 17.3).

13.8.5. **ECG**

Frequencies on the clinical interpretation (normal, abnormal CS or NCS) will be presented by treatment group and assessment time. Individual tabulated data for ECG abnormalities will be also displayed.

13.8.6. **Coagulation parameters**

Scatter plots highlighting individual results for coagulation parameters (prothrombin time/INR, activated partial thromboplastin time and thrombin clotting time) before and after study treatment administration will be produced.

13.9. **CONCOMITANT TREATMENTS**

Concomitant treatments will be tabulated by treatment group within a descriptive perspective. They will be classified by therapeutic area according to the WHO-DRUG dictionary using the "anatomical therapeutic chemical" (ATC) classification on the safety set.
13.10. **COMPLIANCE**

The percentage of compliance will be described by treatment group using the quantity

\[
\text{Compliance(\%)} = \frac{\text{Estimated actual consumption}}{\text{Theoretical consumption}} \times 100
\]

with: \text{Estimated actual consumption} = \text{number of tablets provided at the start of study (Visit 2) – number of tablets returned at the end of study (Visit 9)}

\text{Theoretical consumption} = \text{number of days of treatment intake planned between the start and the end of study (168 days ± 7 days)}.

13.11. **INTERIM ANALYSIS AND DATA MONITORING**

No interim analysis is planned.

14. **GENERAL ETHICAL CONSIDERATIONS**

14.1. **ETHICAL CONDITIONS**

This study is performed in accordance with the principles stated in the Declaration of Helsinki (1964) and subsequent amendments and in accordance with the Good Clinical Practice Guideline (CPMP/ICH/135/95).

14.2. **ETHICS COMMITTEE AND LEGAL REQUIREMENTS**

All the documents required by National Regulations and any other informative documents that may be requested are submitted for review to an Ethics Committee whose procedures and operations meet the GCP and National Legal Requirements.

Depending on National Regulations, the application is submitted to the Ethics Committee by the Sponsor (or representative) or by the Investigator.
A copy of the formal written approval from the Ethics Committee is provided to the Sponsor (directly by the Ethics Committee or via the Investigator) with a list of names and qualifications of its members.

The request for authorisation by the Competent Authority or its notification if required (depending on National Regulations) is carried out by the Sponsor.

The screening of patients does not start before the approval of the Ethics Committee has been obtained and the study authorised by the Competent Authority or notified to the Competent Authority (depending on National Regulations).

14.3. PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM

An information must be given to the patients before their decision to participate or abstain from participation.

This information is based on the elements set out in the Declaration of Helsinki and the ICH GCP Guidelines. It must also describe the measures taken to safeguard patient’s privacy and protection of personal data, according to European Directive 95/46 EC or other local regulation.

Restraints and risks must be explained, as well as the right to discontinue participation in the study at any stage, without affecting their further relationship with the Investigator and/or their future care.

The written information and consent form must be submitted to the patient with an oral explanation. It must be agreed and signed by the patient before any study-related procedure starts.

This information and consent procedure is under the Investigator’s responsibility.

The information and consent document are made in triplicate: the original copy is kept by the Investigator, one copy is given to the patient and the last copy is kept by the Clinical Quality Assurance Unit of the Sponsor in a sealed envelope at the end of study (except in case of specific country requirement).
Specific areas of the Sponsor’s copy are not triplicated to avoid the reading of the patient’s surname (except the first 3 letters), first name, address and signature.

If any information becomes available during the trial that may be relevant to the patient’s willingness to keep on participating in the trial, an updated written informed consent must be submitted to the patient to confirm agreement to continue participating.

14.4. PERSONAL DATA PROTECTION

All information from this study (excluding data from the informed consent) is entered into a computer under the Sponsor’s responsibility in accordance with the French law, "Loi Informatique et Libertés" (January 6, 1978, and subsequent amendments) and with the European Directive 95/46/CE.

14.5. INSURANCE POLICY

In accordance with the provisions of the law and the GCP, the Sponsor Pierre Fabre Médicament, has an insurance policy intended to guarantee against possible damage resulting from the research.

The studies and/or experiments performed on behalf of the Sponsor Pierre Fabre Médicament, are specifically and expressly guaranteed.

It is advisable to underline that non compliance with the Research Legal Conditions is a cause for guarantee exclusion.

15. ADMINISTRATIVE PROCEDURES

15.1. PROTOCOL AMENDMENT

Neither the Investigator nor the Sponsor may alter the protocol without the authorisation of the other party.

All changes to the protocol are subject to an amendment which must be dated and signed by both parties and must appear as an amendment to the protocol.
Substantial amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities

Urgent amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities, but could be implemented immediately under specific conditions defined with the Sponsor.

15.2. SOURCE DOCUMENTS, INVESTIGATOR'S FILE STORAGE

The Investigator:

- Keeps all trial-related documents in appropriate file folders. Records of patient, original informed consent forms, source documents, a CD Rom containing a pdf copy of e-CRF, drug inventory, Ethics Committees and Sponsor correspondence pertaining to the study must be kept on file.

- Retains all documents relating to the screening (consent and investigation results) of all patients included in the trial or not

- Retains a list of the patient’s names, addresses (and/or number of medical file), code numbers to allow checking of data reported on e-CRFs with those from source documents

- Authorises direct access to source documents for monitoring, audits and inspections

- The trial-related documents must be retained as strictly confidential at the Investigator’s site for at least 15 years or according to local requirements, whatever is the longest after the completion or discontinuation of the trial (European Directive 2003/63/EC).

15.3. END OF THE STUDY

15.3.1. Definition of the End of Study

The end of study is the last visit of the last patient undergoing the trial.

Any change to this definition during the study, for whatever reason, must be notified as a substantial amendment.
15.3.2. Early Study Termination

15.3.2.1. Early Study Termination Decided by the Sponsor

The Sponsor may discontinue the study at any time for any of the following reasons:

- Lack of recruitment
- Deviations from good clinical practice and/or regulations
- Poor product safety
- New information that could jeopardise the patient’s safety
- Stopping of the development …

15.3.2.2. Early Study Termination Decided by the Competent Authorities

The Competent Authorities may suspend or prohibit a study if it considers that the conditions of authorisation are not being met or has doubt about the safety or scientific validity of the study.

15.4. AUDIT

The Sponsor is responsible for making sure that both his representatives (Study Manager, CRA, ...) and the Investigator fulfil the requirements as specified by the GCP Guideline.

An audit can be organised internally at Pierre Fabre Médicament and at the investigational site where the e-CRFs are matched against source documents.

All study documentation must be directly accessible to auditors.

The practical conditions for the audit are discussed between the Investigator and the Clinical Quality Assurance Department.

Oral information about the audit results are given to the Investigator.
15.5. **INSPECTION**

The Health Authorities may inspect any investigation site or the Sponsor in the course of the study or after its completion, to verify the conduct of the study and quality of the data. The Investigator must provide to the inspectors direct access to study documents.

15.6. **CONFIDENTIALITY**

The present materials (protocol and related documentation, e-CRF, Investigator's Brochure) contain confidential information.

Except if agreed to in writing with the Study Manager, the investigators must hold such information confidential, and must not disclose it to others (except where required by Applicable Law).

15.7. **CLINICAL STUDY REPORT**

Data analysis, and clinical study report writing are under the Sponsor’s responsibility.

Upon completion of the data analysis, a final report, including a review of the objectives and methods, a presentation and discussion of the results are drawn up according to ICH Guidelines (Structure and Content of Clinical Study Reports, ICH-E3, CPMP/ICH/137/95).

The report is a clinical and statistical integrated report. It must be signed by the Sponsor's representative(s) and the Coordinating Investigator.

15.8. **STUDY RESULTS COMMUNICATION**

Upon completion of the study, the global results of the Research are communicated to the investigator. According to the Local Regulation, the patient can ask the Investigator for the results.

15.9. **STUDY RESULTS PUBLICATION**

The information and data collected during the conduct of this clinical study are considered confidential and are used by the Sponsor in connection with the development of the study drug. This information may be disclosed if deemed necessary by the Sponsor.
To allow use of the information derived from this clinical study and to insure compliance with Current Regulations, the Investigator must provide the Sponsor with complete test results and all data collected during the study.

Only the Sponsor may make study information available to physicians and to Regulatory Agencies, except as required by Current Regulations.

All the results of this study including data, reports, discoveries and inventions resulting from the study, are the property of the Sponsor.

In the event the Sponsor chooses to publish study data, the manuscript must be provided to the author(s) at least 30 days prior to the expected date of submission to the intended publisher.

The investigator(s) can reserve the right to publish or present study data; if so, the manuscript or abstract must be provided to the Sponsor for review at least 30 days prior to the expected date of submission to the intended publisher or of planned presentation.

In addition, if necessary, (the) investigator(s) shall withhold publication for an additional 60 days, to allow the filing of a patent application, or to allow the Sponsor to take any measures he deems appropriate to establish and preserve his proprietary rights.

It is agreed that publication of study results by each site shall be made only as part of a publication of the study results obtained by all sites performing the protocol, once the study is completed and finalised.

The authors list is agreed by all investigators prior to publication. The names of the authors are provided according to their participation in the design of the protocol as well as their recruitment of eligible and analysable patients.
16. REFERENCES


   n-3 Polyunsaturated Fatty Acids in the prevention of atrial Fibrillation Recurrences after
electrical cardioversion. A prospective, Randomised study
   Circulation, 2011; 124:1100-1106

   Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional
capacity in patients with dilated cardiomypathy
   J. Am. Coll. Cardiol. 2011;57:870-879

   Dose-dependant effects of omega-3-polyunsaturated fatty acids on systolic left ventricular
   function, endothelial function, and markers of inflammation in chronic heart failure of non
   ischemic origin: A double-blind, placebo-controlled, 3-arm study
   American Heart Journal 2011; 161:915.e1-915.e9 - volume 161, number 5

[5] GISSI-HF INVESTIGATORS
   Effects of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GSSI-
   HF Trial): a randomised, double-blind, placebo-controlled trial
   The lancet on line - August 2008

   VAN GELDER I.C., AL-ATTAR N., HINDRICKS G., PRENDERGAST B.,
   HEIDBUCHEL H., ALFIERI O., ANGELINI A., ATAR D., COLONNA P., DE
   CATERINA R., DE SUTTER J., GOETTE A., GORENEK B., HELDAL M.,
   HOHLOSER S.H., KOLH P., LE HEUZYE J.Y., PONIKOWSKI P., RUTTEN F.H.
   Guidelines for the management of atrial fibrillation: the Task Force for the Management of
   Atrial Fibrillation of the European Society of Cardiology (ESC).
   European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery,

[7] KOWEY PR, REIFFEL JA, ELENBOGEN KA, NACCARELLI GV, PRATT CM.
   Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent
   symptomatic atrial fibrillation: a randomised controlled trial.

[9] OMACOR® SUMMARY PRODUCT CHARACTERISTICS (SPC) dated 17/02/2012

[10] BEPANTHENE® SUMMARY PRODUCT CHARACTERISTICS (SPC)


The consumption of food products from linseed-fed animals maintains erythrocyte omega-3 fatty acids in obese human 

[18] HARRIS WS, VON SCHACKY C. 
The Omega-3 Index: a new risk factor for death from coronary heart disease? 

Effects of Polynunsaturated Fatty Acids n-3 (PUFA n-3) in the prophylaxis of atrial fibrillation relapses after external electric cardioversion 
World Congress of Cardiology 2006, 2-6 September, Barcelona – Spain

Outcome parameters from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. 
Europace 2007, 9, 1006-1023

[21] EUROPEAN MEDICINES AGENCY 
Addendum to the guideline on antiarrhythmics on atrial fibrillation and atrial flutter. 
EMA/CHMA/EWP/213056/2010

Dietary fish oil dose- and time-response effects on cardiac phospholipid fatty acid composition. 
Lipids. 2004;39:955–961

[23] ROBERTO M. LANG, MICHELLE BIERIG, RICHARD B. DEVEREUX, FRANK A. FLACHSKAMPF*, ELYSE FOSTER, PATRICIA A. PELLIKKA, MICHAEL H. PICARD, MARY J. ROMAN, JAMES SEWARD, JACK SHANEWISE, SCOTT SOLOMON, KIRK T. SPENCER, MARTIN ST. JOHN SUTTON, WILLIAM STEWART. 
Recommendations for chamber quantification 
17. APPENDICES
A. INTRODUCTION

1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of ethical principles for medical research involving human subjects, including research on identifiable human material and data. The Declaration is intended to be read as a whole and each of its constituent paragraphs should not be applied without consideration of all other relevant paragraphs.

2. Although the Declaration is addressed primarily to physicians, the WMA encourages other participants in medical research involving human subjects to adopt these principles.

3. It is the duty of the physician to promote and safeguard the health of patients, including those who are involved in medical research. The physician's knowledge and conscience are dedicated to the fulfilment of this duty.

4. The Declaration of Geneva of the WMA binds the physician with the words, “The health of my patient will be my first consideration,” and the International Code of Medical Ethics declares that, “A physician shall act in the patient's best interest when providing medical care.”

5. Medical progress is based on research that ultimately must include studies involving human subjects. Populations that are underrepresented in medical research should be provided appropriate access to participation in research.

6. In medical research involving human subjects, the well-being of the individual research subject must take precedence over all other interests.

7. The primary purpose of medical research involving human subjects is to understand the causes, development and effects of diseases and improve preventive, diagnostic and therapeutic interventions (methods, procedures and treatments). Even the best current interventions must be evaluated continually through research for their safety, effectiveness, efficiency, accessibility and quality.

8. In medical practice and in medical research, most interventions involve risks and burdens.

9. Medical research is subject to ethical standards that promote respect for all human subjects and protect their health and rights. Some research populations are particularly vulnerable and need special protection. These include those who cannot give or refuse consent for themselves and those who may be vulnerable to coercion or undue influence.

10. Physicians should consider the ethical, legal and regulatory norms and standards for research involving human subjects in their own countries as well as applicable international norms and standards. No national or international ethical, legal or regulatory requirement should reduce or eliminate any of the protections for research subjects set forth in this Declaration.
B. PRINCIPLES FOR ALL MEDICAL RESEARCH

11. It is the duty of physicians who participate in medical research to protect the life, health, dignity, integrity, right to self-determination, privacy, and confidentiality of personal information of research subjects.

12. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and adequate laboratory and, as appropriate, animal experimentation. The welfare of animals used for research must be respected.

13. Appropriate caution must be exercised in the conduct of medical research that may harm the environment.

14. The design and performance of each research study involving human subjects must be clearly described in a research protocol. The protocol should contain a statement of the ethical considerations involved and should indicate how the principles in this Declaration have been addressed. The protocol should include information regarding funding, sponsors, institutional affiliations, other potential conflicts of interest, incentives for subjects and provisions for treating and/or compensating subjects who are harmed as a consequence of participation in the research study. The protocol should describe arrangements for post-study access by study subjects to interventions identified as beneficial in the study or access to other appropriate care or benefits.

15. The research protocol must be submitted for consideration, comment, guidance and approval to a research ethics committee before the study begins. This committee must be independent of the researcher, the sponsor and any other undue influence. It must take into consideration the laws and regulations of the country or countries in which the research is to be performed as well as applicable international norms and standards but these must not be allowed to reduce or eliminate any of the protections for research subjects set forth in this Declaration. The committee must have the right to monitor ongoing studies. The researcher must provide monitoring information to the committee, especially information about any serious adverse events. No change to the protocol may be made without consideration and approval by the committee.

16. Medical research involving human subjects must be conducted only by individuals with the appropriate scientific training and qualifications. Research on patients or healthy volunteers requires the supervision of a competent and appropriately qualified physician or other health care professional. The responsibility for the protection of research subjects must always rest with the physician or other health care professional and never the research subjects, even though they have given consent.

17. Medical research involving a disadvantaged or vulnerable population or community is only justified if the research is responsive to the health needs and priorities of this population or community and if there is a reasonable likelihood that this population or community stands to benefit from the results of the research.

18. Every medical research study involving human subjects must be preceded by careful assessment of predictable risks and burdens to the individuals and communities involved in the research in comparison with foreseeable benefits to them and to other individuals or communities affected by the condition under investigation.

19. Every clinical trial must be registered in a publicly accessible database before recruitment of the first subject.
20. Physicians may not participate in a research study involving human subjects unless they are confident that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians must immediately stop a study when the risks are found to outweigh the potential benefits or when there is conclusive proof of positive and beneficial results.

21. Medical research involving human subjects may only be conducted if the importance of the objective outweighs the inherent risks and burdens to the research subjects.

22. Participation by competent individuals as subjects in medical research must be voluntary. Although it may be appropriate to consult family members or community leaders, no competent individual may be enrolled in a research study unless he or she freely agrees.

23. Every precaution must be taken to protect the privacy of research subjects and the confidentiality of their personal information and to minimize the impact of the study on their physical, mental and social integrity.

24. In medical research involving competent human subjects, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail, and any other relevant aspects of the study. The potential subject must be informed of the right to refuse to participate in the study or to withdraw consent to participate at any time without reprisal. Special attention should be given to the specific information needs of individual potential subjects as well as to the methods used to deliver the information. After ensuring that the potential subject has understood the information, the physician or another appropriately qualified individual must then seek the potential subject’s freely-given informed consent, preferably in writing. If the consent cannot be expressed in writing, the non-written consent must be formally documented and witnessed.

25. For medical research using identifiable human material or data, physicians must normally seek consent for the collection, analysis, storage and/or reuse. There may be situations where consent would be impossible or impractical to obtain for such research or would pose a threat to the validity of the research. In such situations the research may be done only after consideration and approval of a research ethics committee.

26. When seeking informed consent for participation in a research study the physician should be particularly cautious if the potential subject is in a dependent relationship with the physician or may consent under duress. In such situations the informed consent should be sought by an appropriately qualified individual who is completely independent of this relationship.

27. For a potential research subject who is incompetent, the physician must seek informed consent from the legally authorized representative. These individuals must not be included in a research study that has no likelihood of benefit for them unless it is intended to promote the health of the population represented by the potential subject, the research cannot instead be performed with competent persons, and the research entails only minimal risk and minimal burden.

28. When a potential research subject who is deemed incompetent is able to give assent to decisions about participation in research, the physician must seek that assent in addition to the consent of the legally authorized representative. The potential subject’s dissent should be respected.
29. Research involving subjects who are physically or mentally incapable of giving consent, for example, unconscious patients, may be done only if the physical or mental condition that prevents giving informed consent is a necessary characteristic of the research population. In such circumstances the physician should seek informed consent from the legally authorized representative. If no such representative is available and if the research cannot be delayed, the study may proceed without informed consent provided that the specific reasons for involving subjects with a condition that renders them unable to give informed consent have been stated in the research protocol and the study has been approved by a research ethics committee. Consent to remain in the research should be obtained as soon as possible from the subject or a legally authorized representative.

30. Authors, editors and publishers all have ethical obligations with regard to the publication of the results of research. Authors have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports. They should adhere to accepted guidelines for ethical reporting. Negative and inconclusive as well as positive results should be published or otherwise made publicly available. Sources of funding, institutional affiliations and conflicts of interest should be declared in the publication. Reports of research not in accordance with the principles of this Declaration should not be accepted for publication.

C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH MEDICAL CARE

31. The physician may combine medical research with medical care only to the extent that the research is justified by its potential preventive, diagnostic or therapeutic value and if the physician has good reason to believe that participation in the research study will not adversely affect the health of the patients who serve as research subjects.

32. The benefits, risks, burdens and effectiveness of a new intervention must be tested against those of the best current proven intervention, except in the following circumstances:
   - The use of placebo, or no treatment, is acceptable in studies where no current proven intervention exists; or
   - Where for compelling and scientifically sound methodological reasons the use of placebo is necessary to determine the efficacy or safety of an intervention and the patients who receive placebo or no treatment will not be subject to any risk of serious or irreversible harm. Extreme care must be taken to avoid abuse of this option.

33. At the conclusion of the study, patients entered into the study are entitled to be informed about the outcome of the study and to share any benefits that result from it, for example, access to interventions identified as beneficial in the study or to other appropriate care or benefits.

34. The physician must fully inform the patient which aspects of the care are related to the research. The refusal of a patient to participate in a study or the patient’s decision to withdraw from the study must never interfere with the patient-physician relationship.

35. In the treatment of a patient, where proven interventions do not exist or have been ineffective, the physician, after seeking expert advice, with informed consent from the patient or a legally authorized representative, may use an unproven intervention if in the physician's judgement it offers hope of saving life, re-establishing health or alleviating suffering. Where possible, this intervention should be made the object of research, designed to evaluate its safety and efficacy. In all cases, new information should be recorded and, where appropriate, made publicly available.
17.2. SAE REPORT FORM
NOTIFICATION OF SERIOUS ADVERSE EVENT (SAE) OR PREGNANCY
TO PIERRE FABRE PRODUCT SAFETY DEPARTMENT

TO BE TRANSMITTED TO THE MONITOR BY FAX WITHIN 24H:

M. GUIRAUD  ..............
Fax n° +33 5 34 50 65 92

Transmission date  (ddmmyyyy)  Country :

SAE N°  FIRST NOTIFICATION  FOLLOW-UP  

SUBJECT CHARACTERISTICS

Surname First name Birth date Gender 1=M, 2=F Height cm Weight  

DESCRIPTION OF THE EVENT

The serious adverse event resulted in :

- Death (whatever may be the cause)
- Hospitalisation (*) or extension thereof
- Life threatening
- Invalidity or disability
- Congenital abnormality or abnormal pregnancy outcome
- Cancer
- Other (any other serious clinical or laboratory event according to the investigator or the protocol, overdosage meeting seriousness criteria, suicide attempts)
- Other fact to be notified :
- Pregnancy exposure

Nature of the event (if clinical nature, indicate the diagnosis or the major symptom) :

AE onset date  (ddmmyyyy)

Seriousness onset date  (ddmmyyyy)

Summary description (if clinical cause, significant history, progression of event, available laboratory results, etc...) :

(*) Except hospitalisations with durations and goals planned in the protocol

THE SAE IN RELATION TO THE TRIAL

TREATMENT NUMBER  

- Time of occurrence of SAE
  - During the selection or run-in period
  - During the administration phase of the study treatment
  - After the administration phase of the study treatment

- Date of first study treatment administration  (ddmmyyyy)

- Date of last study treatment administration before the occurrence of SAE  (ddmmyyyy)

- Was the blind broken ?  Yes  No  Not applicable
  If yes, or if this is an open study, drug(s) administered :

Conditions of administration (cycles(s), daily dose(s), route(s) of administration, etc..) :
Transmission date: [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)  Country: ............................................

SAE N°: [ ] [ ]  FIRST NOTIFICATION  [ ]  FOLLOW-UP  [ ]

> CONCOMITANT MEDICATION SINCE TRIAL INITIATION and UP UNTIL THE OCCURRENCE OF THE SAE (EXCEPT THE TREATMENTS GIVEN FOR THE SAE)

<table>
<thead>
<tr>
<th>INN or trade name</th>
<th>Daily dose</th>
<th>Start date (ddmmyy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (ddmmyy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>[ ] [ ]</td>
<td>[ ] [ ]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>[ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>[ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>[ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ]</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>[ ] [ ]</td>
<td>[ ] [ ]</td>
<td>[ ]</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

> MEASURES TAKEN FOLLOWING THE SAE

• **Study treatment**
  - [ ] No change
  - [ ] Dosage modification, specify: .......................................................... Modification Date: [ ] [ ] [ ]
  - [ ] Temporarily discontinued Readministration date: [ ] [ ] [ ]
  - [ ] Withdrawn End date: [ ] [ ] [ ]
  - [ ] Not applicable

• **The event led to:**
  - [ ] Prescription of corrective or symptomatic treatments (specify names and dosages):
  - [ ] Discontinuation of concomitant treatments (specify names):
  - [ ] Others, specify:

> OUTCOME

- [ ] Not recovered/Not resolved  - [ ] Recovering/Resolving  - [ ] Recovered/Resolved
- [ ] Recovered/Resolved with sequelae  - [ ] Fatal  - [ ] Unknown

In case of death, has an autopsy been conducted?  [ ] Yes  [ ] No

> INVESTIGATOR CAUSALITY ASSESSMENT (investigator’s assessment to be done as soon as possible)

- [ ] Not Suspected  - [ ] Suspected  - [ ] Insufficient data

Comments: .................................................................................................................................

Enclose in the notification the results of carried out examinations, reports of hospitalisation, etc...
## 17.3. PREDEFINED LIMITS OF LABORATORY AND VITAL SIGN POTENTIALLY CLINICALLY SIGNIFICANT CHANGES AND VALUES

### List of Predefined Potentially Clinically Significant Change For Laboratory Values

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>UNIT</th>
<th>PSC</th>
<th>Decrease</th>
<th>Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MUSCLE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatine Phosphokinase</td>
<td>U / l</td>
<td>-</td>
<td>236</td>
<td>236</td>
</tr>
<tr>
<td><strong>KIDNEY</strong></td>
<td>µmol/l</td>
<td>-</td>
<td>35</td>
<td>35</td>
</tr>
<tr>
<td>Creatinine</td>
<td>µmol/l</td>
<td>-</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Urea</td>
<td>mmol/l</td>
<td>-</td>
<td>3.2</td>
<td>3.2</td>
</tr>
<tr>
<td>Uric acid</td>
<td>µmol/l</td>
<td>-</td>
<td>119</td>
<td>119</td>
</tr>
<tr>
<td>Phosphate</td>
<td>mmol/l</td>
<td>0.39</td>
<td>0.39</td>
<td>0.39</td>
</tr>
<tr>
<td>Calcium</td>
<td>mmol/l</td>
<td>0.30</td>
<td>0.30</td>
<td>0.30</td>
</tr>
<tr>
<td><strong>ELECTROLYTES</strong></td>
<td>mmol/l</td>
<td>8</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Sodium</td>
<td>mmol/l</td>
<td>1.1</td>
<td>1.1</td>
<td>1.1</td>
</tr>
<tr>
<td>Potassium</td>
<td>mmol/l</td>
<td>8</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>Chloride</td>
<td>mmol/l</td>
<td>7</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>mmol/l</td>
<td>-</td>
<td>2.71</td>
<td>2.71</td>
</tr>
<tr>
<td><strong>METABOLISM/NUTRITIONAL</strong></td>
<td>mmol/l</td>
<td>3</td>
<td>3.7</td>
<td>3.7</td>
</tr>
<tr>
<td>Glucose (random)</td>
<td>g/l</td>
<td>6</td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Albumin</td>
<td>g/l</td>
<td>11</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Protein</td>
<td>g/l</td>
<td>-</td>
<td>1.97</td>
<td>1.97</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>mmol/l</td>
<td>0.91</td>
<td>0.85</td>
<td>0.85</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>mmol/l</td>
<td>2.17</td>
<td>2.04</td>
<td>2.04</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>mmol/l</td>
<td>-</td>
<td>2.91</td>
<td>2.91</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>mmol/l</td>
<td>-</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td><strong>ERYTHROCYTES</strong></td>
<td>T/l</td>
<td>0.7</td>
<td>0.7</td>
<td>0.7</td>
</tr>
<tr>
<td>Erythrocyte count</td>
<td>g/l</td>
<td>20</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Haemoglobin</td>
<td>g/l</td>
<td>0.06</td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td>Haematocrit</td>
<td>l</td>
<td>7</td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>MCV</td>
<td>fl</td>
<td>0.19</td>
<td>0.19</td>
<td>0.19</td>
</tr>
<tr>
<td>MCH (Fe)</td>
<td>fmol</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>MCHC (Fe)</td>
<td>mmol/l</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td><strong>LEUKOCYTES</strong></td>
<td>G/l</td>
<td>6.2</td>
<td>6.2</td>
<td>6.2</td>
</tr>
<tr>
<td>Leukocyte count</td>
<td>G/l</td>
<td>3.8</td>
<td>3.8</td>
<td>3.8</td>
</tr>
<tr>
<td><strong>DIFFERENTIAL COUNT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophils</td>
<td>G/l</td>
<td>3.47</td>
<td>3.19</td>
<td>3.19</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>G/l</td>
<td>1.76</td>
<td>1.63</td>
<td>1.63</td>
</tr>
<tr>
<td>Monocytes</td>
<td>G/l</td>
<td>-</td>
<td>0.49</td>
<td>0.49</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>G/l</td>
<td>-</td>
<td>0.41</td>
<td>0.41</td>
</tr>
<tr>
<td>Basophils</td>
<td>G/l</td>
<td>-</td>
<td>0.14</td>
<td>0.14</td>
</tr>
<tr>
<td><strong>URINE</strong></td>
<td>Specific gravity</td>
<td>-</td>
<td>0.017</td>
<td>0.015</td>
</tr>
<tr>
<td>pH</td>
<td>-</td>
<td>2</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td><strong>LIVER</strong></td>
<td>µmol/l</td>
<td>-</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>µmol/l</td>
<td>-</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ASAT (SGOT)</td>
<td>U/l</td>
<td>N x (23/36)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>ALAT (SGPT)</td>
<td>U/l</td>
<td>N x (28/45)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Gamma GT</td>
<td>U/l</td>
<td>N x (25/38)</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>U/l</td>
<td>N x (30/95)</td>
<td>-</td>
<td>-</td>
</tr>
</tbody>
</table>

N = upper limit of normal range

### Definition of Clinically Noteworthy Abnormal Laboratory Values (CNALV)

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>CNALV</th>
</tr>
</thead>
</table>
| **HAEMOGLOBIN**       | • Decrease of at least 2g/dl and value < 10 g/dl whatever the baseline value  
                        | • If missing baseline : value <10g/dl                                   |
| **NEUTROPHILS**       | • < 1 500/mm³ whatever the baseline value                              |
| **WBC** (if missing value for neutrophils) | • < 3 000/mm³ whatever the baseline value                              |
| **PLATELETS**         | • < 100 000/mm³ whatever the baseline value                            |
| **SERUM CREATININE**  | • Increase of at least 30 % as compared to baseline value and value > 150 µmol/l whatever the baseline value  
                        | • If missing baseline : value > 150 µmol/l                             |

**LIVER FUNCTION TESTS**

| ALAT                  | • If normal baseline :  
                        | • ALAT > 2 N  
                        | • If abnormal baseline :  
                        | → if baseline value ≤ 2.5 N :  
                        | • increase of at least 100 % as compared to baseline value  
                        | → if baseline value > 2.5 N :  
                        | • value > 5 N  
                        | and/or ASAT          | • If normal baseline :  
                        | • ASAT > 2 N  
                        | • If abnormal baseline :  
                        | → if baseline value ≤ 2.5 N :  
                        | • increase of at least 100 % as compared to baseline value  
                        | → if baseline value > 2.5 N :  
                        | • value > 5 N  
                        | and/or Alkaline phosphatase (AP) | • If normal baseline :  
                        | • AP > 1.25 N  
                        | • If abnormal baseline :  
                        | • AP > 2 N  
                        | and/or Total bilirubin (TB) | • If normal baseline :  
                        | • TB > 1.5 N  
                        | • If abnormal baseline :  
                        | • TB > 2 N  

N=upper limit of normal range


Cardiovascular Safety

Table 1: Predefined Limits for Potentially Clinically Significant Changes (PSC) and PSC Leading to Clinically Significant Values (PSCV)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>PSC</th>
<th>PSCV</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP</td>
<td>Increase ≥ 20 mmHg</td>
<td>SBP ≥ 160 mmHg and increase ≥ 20 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 20 mmHg</td>
<td>SBP ≤ 90 mmHg and decrease ≥ 20 mmHg</td>
</tr>
<tr>
<td>DBP</td>
<td>Increase ≥ 10 mmHg</td>
<td>DBP ≥ 100 mmHg and increase ≥ 10 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 mmHg</td>
<td>DBP ≤ 50 mmHg and decrease ≥ 10 mmHg</td>
</tr>
<tr>
<td>HR</td>
<td>Increase ≥ 10 bpm</td>
<td>HR ≥ 110 bpm and increase ≥ 10 bpm</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 bpm</td>
<td>HR ≤ 50 bpm and decrease ≥ 10 bpm</td>
</tr>
</tbody>
</table>

Table 2: Predefined Classes for changes from Baseline to the Maximum (and/ or Minimum) Post-baseline Value

<table>
<thead>
<tr>
<th>Classes of Change from Baseline to the Maximum Post-baseline Value</th>
<th>Classes of Change from Baseline to the Minimum Post-baseline Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>All</td>
<td>All</td>
</tr>
<tr>
<td>≥ 0</td>
<td>≥ 0</td>
</tr>
<tr>
<td>&gt; 0</td>
<td>&gt; 0</td>
</tr>
<tr>
<td>≥ 10</td>
<td>≥ 5</td>
</tr>
<tr>
<td>≥ 20</td>
<td>≥ 10</td>
</tr>
<tr>
<td>≥ 30</td>
<td>≥ 15</td>
</tr>
<tr>
<td>≥ 40</td>
<td>≥ 20</td>
</tr>
<tr>
<td></td>
<td>≥ 25</td>
</tr>
<tr>
<td></td>
<td>≥ 30</td>
</tr>
</tbody>
</table>

Table 3: Classes for Vital Signs Maximum or Minimum Values

<table>
<thead>
<tr>
<th>Classes for the Maximum Post-baseline Value for each parameter</th>
<th>Classes for the Minimum Post-baseline Value for each parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>&lt; 120</td>
<td>&lt; 80</td>
</tr>
<tr>
<td>[120 ;140]</td>
<td>[80;90]</td>
</tr>
<tr>
<td>[140;160]</td>
<td>[90;100]</td>
</tr>
<tr>
<td>≥ 160</td>
<td>≥ 100</td>
</tr>
</tbody>
</table>

Table 4: Classes for Maximum or Minimum of BP in its entirety

<table>
<thead>
<tr>
<th>Classification of Maximum Values for Blood Pressure (mmHg)</th>
<th>Classification of Minimum Values Blood Pressure (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP &lt; 140 and DBP &lt; 90</td>
<td>SBP &gt; 90 and DBP &gt; 50</td>
</tr>
<tr>
<td>SBP [140;160] and DBP &lt; 100 or DBP [90;100] and SBP &lt; 160</td>
<td>SBP ≤ 90 or DBP ≤ 50</td>
</tr>
<tr>
<td>SBP ≥ 160 or DBP ≥ 100</td>
<td></td>
</tr>
</tbody>
</table>

Table 5: Definition of orthostatic hypotension

<table>
<thead>
<tr>
<th>Orthostatic Hypotension *</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP Decrease ≥ 20 mmHg or DBP Decrease ≥ 10 mmHg between supine and standing positions</td>
</tr>
</tbody>
</table>

16.1.1.4. Protocol amendment n° PA02
General and non-substantial dated on 28 March 2013 linked to Protocol and appendices (version 4: 28 March 2013)
CLINICAL STUDY PROTOCOL AMENDMENT n° PA02 – Version 1

General – Non Substantial

Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Pierre Fabre Study Code: F373280 CA 2 01
EudraCT Number: 2012-003487-48
Sponsor’s Representative: Gaëlle ALCARAZ
Coordinating Investigator: Pr Savina NODARI
Date of amendment PA02: 28 March 2013
Clinical Study Protocol Amendment n° PA02 – Version 1
General – Non Substantial
SIGNATURE FORM

Sponsor’s representative:
- Medical Director
  Richard ROCHE, MD
  Date: 14/05/13 Signature:

Study Coordinating Investigator:
Pr Savina NODARI
  Date: 28/05/13 Signature:

Clinical study protocol amendment n° PA 02 – Version 1 (General) Non substantial Date: 28MAR13

Page 3 on 16
| Country Coordinating Investigator: | Date: | Signature: |
Clinical Study Protocol Amendment n° PA 02 – Version 1

General – Non Substantial

INVESTIGATOR SIGNATURE FORM

By my signature below, I, Dr ____________________________, hereby confirm that I have read, taken note of (and will apply) the modifications brought by the protocol amendment n° PA 02, dated 28 MAR 2013 and I will conduct the trial according to these new modalities.

Date: ____________________________ Signature: ____________________________
<table>
<thead>
<tr>
<th>PROTOCOL VERSIONS</th>
<th>DATE</th>
<th>MODIFICATIONS</th>
<th>COMMENTS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Version 1</td>
<td>09/11/2012</td>
<td>Initial version</td>
<td>General</td>
</tr>
</tbody>
</table>
| Version 2 (General) | 15/01/2013 | Following French CA request (ANSM):  
- Add of a non inclusion criteria: “Breast-feeding female patient”  
- Add of haematology examination at visit 3 and 6                                                                                                                                                                                                 | General     |
| Version 3 (Local Italy) | 01/03/2013 | Following to the Italian Central Ethics Committee and Competent Authority requirements and, in order to harmonise the protocol and the Informed Consent Form, the following changes have been done to the study protocol:  
- adjustment of the selection criteria n°10 related to the contraception method  
- addition of a letter that is given by the patient to his/her general practitioner (GP)  
- precision that the sponsor can not collect a copy of the Informed Consent Form  
- precision that the patient card is in Italian language only (without any English mention)                                                                                                                                                                                                 | Local Italy |
<table>
<thead>
<tr>
<th>N°</th>
<th>DATES</th>
<th>TYPE</th>
<th>APPLICATION AREA</th>
<th>MODIFICATIONS</th>
<th>PROTOCOL VERSIONS</th>
</tr>
</thead>
</table>
| NA  | _____  | NA       | General          | Following French CA request (ANSM) :
- Add of a non inclusion criteria : “Breast-feeding female patient”
- Add of haematology examination at visit 3 and 6                                                                                           | Version 1 09/11/2012 |
| NA  | _____  | NA       | General          | Following to the Italian Central Ethics Committee and Competent Authority requirements and, in order to harmonise the protocol and the Informed Consent Form, the following changes have been done to the study protocol :
- Integration of the modification included in the protocol version 2
- Harmonisation of the protocol and the Informed Consent Form :
  * adjustment of the selection criteria n°10 related to the contraception method
  * addition of a letter that is given by the patient to his/her general practitioner (GP)
  * precision that the sponsor can not collect a copy of the Informed Consent Form
  * precision that the patient card is in Italian language only (without any English mention) | Version 2 15/01/2013 |
| PA01| 01.03.2013 | Substantial | Local (Italy)   |                                                                                                                                                      | Version 3 01/03/2013 |
1. AMENDMENT RATIONALE

The clinical study protocol is updated with the following changes:

- change of Sponsor’s Representative (Clinical Study Manager),

- modification of the technical handling of the blood samples for determination of red blood cells concentration of DHA: the centrifugation is no more needed,

- precision on the function and address of the International Study Coordinator Pr Nodari,

- add of address and contacts details of two CRO newly involved in the study: Theradis (in charge of transportation of blood samples to the Analytical centre and material supply) and “Clinact” (in charge of refund of patients expenses linked to the study),

- adjustment of the wording, in agreement with the commitment to the French Ethics Committee. In the paragraph 8.3.2.1, the wording "hematology examination" is replaced by "standard hematologic dosage",

- precision of the full title in the study synopsis (in agreement with the commitment to the Spanish Ethics Committee),

- correction of a mistake in section 8.1.1.3 (related to TTEM transmission) and sections 3, 9 and study synopsis (related to the definition of INR not stabilized).

- addition of the changes included in the local italian substantial protocol amendment (i.e.: contraception method, letter to General Practitioner, patient card in Italian and no collection of the consent form by the sponsor in Italy).
2. CHANGES DESCRIPTION

<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
</table>
| **Sponsor's Representative:** Marlène GUIRAUD, Pharm D  
INSTITUT DE RECHERCHE PIERRE FABRE - Centre de R&D Pierre Fabre - BP 13562  
3 avenue Hubert Curien  
31035 TOULOUSE Cédex 1  
Phone: +33 5 34 50 63 48  
Fax:+33 5 34 50 65 92  
E-mail:marlene.guiraud@pierre-fabre.com | **Sponsor's Representative:** Gaëlle ALCARAZ  
INSTITUT DE RECHERCHE PIERRE FABRE - Centre de R&D Pierre Fabre - BP 13562  
3 avenue Hubert Curien  
31035 TOULOUSE Cédex 1  
Phone: +33 5 34 50 62 16  
Fax:+33 5 34 50 XX XX (TBC)  
E-mail:gaelle.alcaraz@pierre-fabre.com |
| **Study Coordinating Investigator:**  
Pr Savina NODARI  
Section of Cardiology  
Department of Experimental and Applied Sciences  
University of Brescia  
BRESCIA, ITALY  
Phone: +39 030 3996 587 - Fax: +39 030 3700 359  
E-mail: savinanodari@gmail.com | **Study Coordinating Investigator:**  
Pr Savina NODARI –  
Associate Professor of Cardiology  
Department of Clinical and Surgical Specialities, Radiological Science and Public Health  
Section of Cardiovascular Diseases  
University Medical School and Spedali Civili Hospital of Brescia  
c/o Spedali Civili di Brescia  
Piazzale Spedali Civili, 1  
25123 - BRESCIA, ITALY  
Phone: +39 030 3996 587 – +39 030 393849  
Fax:+39 030 3700359  
E-mail: savinanodari@gmail.com ; nodari@med.unibs.it |
<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CONTRACT RESEARCH ORGANISATIONS</strong></td>
<td><strong>CONTRACT RESEARCH ORGANISATIONS</strong></td>
</tr>
<tr>
<td>...</td>
<td>...</td>
</tr>
<tr>
<td>For intra erythrocyte DHA dosage:</td>
<td>For intra erythrocyte DHA dosage:</td>
</tr>
<tr>
<td>Agrocampus Ouest</td>
<td>Agrocampus Ouest</td>
</tr>
<tr>
<td>Laboratoire de Biochimie</td>
<td>Laboratoire de Biochimie</td>
</tr>
<tr>
<td>65 rue de Saint Brieuc – CS 84215</td>
<td>65 rue de Saint Brieuc – CS 84215</td>
</tr>
<tr>
<td>35042 RENNES Cedex - FRANCE</td>
<td>35042 RENNES Cedex - FRANCE</td>
</tr>
<tr>
<td>Phone: +33 2 23 48 55 49 - Fax: +33 2 23 48 55 50</td>
<td>Phone: +33 2 23 48 55 49 - Fax: +33 2 23 48 55 50</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:daniel.catheline@agrocampus-ouest.fr">daniel.catheline@agrocampus-ouest.fr</a></td>
<td>E-mail: <a href="mailto:daniel.catheline@agrocampus-ouest.fr">daniel.catheline@agrocampus-ouest.fr</a></td>
</tr>
<tr>
<td><strong>For transportation of blood sample to the Analytical centre (Agrocampus) and</strong></td>
<td><strong>For transportation of blood sample to the Analytical centre (Agrocampus) and</strong></td>
</tr>
<tr>
<td>material supply:**</td>
<td>material supply:**</td>
</tr>
<tr>
<td>Theradis Pharma</td>
<td>Theradis Pharma</td>
</tr>
<tr>
<td>41, chemin des Presses</td>
<td>41, chemin des Presses</td>
</tr>
<tr>
<td>06800 CAGNES-SUR-MER – France</td>
<td>06800 CAGNES-SUR-MER – France</td>
</tr>
<tr>
<td>Phone : +33 (0)4 97 02 07 07</td>
<td>Phone : +33 (0)4 97 02 07 07</td>
</tr>
<tr>
<td>Fax : +33 (0)4 97 10 08 78</td>
<td>Fax : +33 (0)4 97 10 08 78</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:chantal.raffy@theradis.pharma.com">chantal.raffy@theradis.pharma.com</a></td>
<td>E-mail: <a href="mailto:chantal.raffy@theradis.pharma.com">chantal.raffy@theradis.pharma.com</a></td>
</tr>
<tr>
<td>For refund of patients expenses linked to the patients expenses linked to the study:</td>
<td>For refund of patients expenses linked to the patients expenses linked to the study:</td>
</tr>
<tr>
<td>CLINACT</td>
<td>CLINACT</td>
</tr>
<tr>
<td>6-10 rue TROYON</td>
<td>6-10 rue TROYON</td>
</tr>
<tr>
<td>92310 SEVRES – FRANCE</td>
<td>92310 SEVRES – FRANCE</td>
</tr>
<tr>
<td>Phone : +33 1 46 90 27 27</td>
<td>Phone : +33 1 46 90 27 27</td>
</tr>
<tr>
<td>Fax : +33 1 46 23 01 56</td>
<td>Fax : +33 1 46 23 01 56</td>
</tr>
<tr>
<td>Email : <a href="mailto:sebastien.beaumont@clinact.com">sebastien.beaumont@clinact.com</a></td>
<td>Email : <a href="mailto:sebastien.beaumont@clinact.com">sebastien.beaumont@clinact.com</a></td>
</tr>
</tbody>
</table>
**STUDY SYNOPSIS AND 5.1 INCLUSION CRITERIA**

**Demographic Characteristics and Other Baseline Characteristics:**

10. For female patient of child-bearing potential:

- **in all the countries except Italy:**
  - use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator, for at least 2 months before the selection in the study and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment or
  - documented as surgically sterilized

- **in Italy only:**
  - absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
  - use of double barrier contraception method (use of effective medical contraception method) from at least 2 months before the start of the study to the entire duration of the study and for a month after the end of the study or
  - documented as surgically sterilized

11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion

12. For male with a childbearing potential partner (In Italy only):

- absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
- use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to a month after the end of the study.
11. For female patient of childbearing potential: negative urine pregnancy test at inclusion.
PREVIOUS VERSION

STUDY SYNOPSIS, SECTION 3. Ethical CONSIDERATIONS RELATING TO THE STUDY and section 9. Study procedures:

Patients not stabilized for INR (i.e. values between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed in the same day (before ECV)

5.9 Study CARD

The patient will receive from the Investigating Centre at Visit 1 - Selection Visit, a personal card to be kept all along the study duration and providing the following information: patient's name, sponsor's name, study code, EUDRACT number, start date and expected end date of the study, complete address of the Investigating Centre with the name and phone number of the Investigator and a sponsor 24H/24 phone contact number in case of emergency (French and English languages): 33 (0)5 63 35 25 83.

MODIFIED VERSION

STUDY SYNOPSIS, SECTION 3. Ethical CONSIDERATIONS RELATING TO THE STUDY and section 9. Study procedures:

Patients not stabilized for INR (i.e. values not between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed in the same day (before ECV)

5.9 Study CARD and LETTER FOR GENERAL PRACTITIONERS (GP)

The patient will receive from the Investigating Centre at Visit 1 - Selection Visit:

- a personal card to be kept all along the study duration and providing the following information: patient's name, sponsor's name, study code, EUDRACT number, start date and expected end date of the study, complete address of the Investigating Centre with the name and phone number of the Investigator and a sponsor 24H/24 phone contact number in case of emergency (French and English languages): 33 (0)5 63 35 25 83. For Italy, this card will be in Italian without any English mention.

- a letter to be given to his/her general practitioner. This letter intends to inform the GP (and any other doctors who take care of the patient) that the patient participates to this clinical study. It describes the study treatment and includes some information on the forbidden treatment during the study.
### 8.1. PRIMARY EFFICACY CRITERION:

**8.1.1.3. Evaluation Methods**

- **Trans Telephonic ECG Monitoring (TTEM):**
  
  Thus, the follow up will be documented using the TTEM: daily transmission from visit 4 to visit 6. Then, every two days from visit 6 to visit 9.

### 8.2 BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA

**8.2.2.2 Technical handling**

Two blood samples will be collected containing EDTA. They will be gently shaken and centrifuged at 3000g for 15 min at room temperature, within 30 minutes after collection. Plasma and white blood cells will be discarded. Red blood cells will be stored at +4°C (no freezing will be allowed) and sent to Analytical Centre in refrigerated conditions (between +2°C and +8°C) within 3 weeks following collection. Analysis will be performed within 2 weeks following reception at the Analytical centre.
<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>8.3 SAFETY ASSESSMENT</strong></td>
<td><strong>8.3 SAFETY ASSESSMENT</strong></td>
</tr>
<tr>
<td><strong>8.3.2 Laboratory Investigations</strong></td>
<td><strong>8.3.2 Laboratory Investigations</strong></td>
</tr>
<tr>
<td>Laboratory investigations will be performed at visit 1 (before treatment) and visit 9 (end of treatment) or End of Treatment visit.</td>
<td>Laboratory investigations will be performed at visit 1 (before treatment) and visit 9 (end of treatment) or End of Treatment visit.</td>
</tr>
<tr>
<td>At visit 3 and 6, only an haematology examination will be performed.</td>
<td>At visit 3 and 6, only a standard haematologic dosage will be performed.</td>
</tr>
</tbody>
</table>

**10.2 Reporting of SAE**

Marlène GUIRAUD, Pharm D

INSTITUT DE RECHERCHE PIERRE FABRE, Centre de R&D Pierre Fabre – BP 13562 3 Avenue Hubert Curien 31035 TOULOUSE Cedex 1

Phone: +33 5 35 50 63 48
Fax: + 33 5 34 50 65 92
Email: marlene.guiraud@pierre-fabre.com

Gaëlle ALCARAZ

INSTITUT DE RECHERCHE PIERRE FABRE, Centre de R&D Pierre Fabre – BP 13562 3 Avenue Hubert Curien 31035 TOULOUSE Cedex 1

Phone: +33 5 35 50 62 16
Fax: + 33 5 34 50 65 92
Email: gaelle.alcaraz@pierre-fabre.com
11.2. STUDY MONITORING

11.2.1.4. Closing Visit

At the end of the study, a final visit will be carried out by the CRA to:

- Verify that the e-CRFs CD-ROM with pdf files are correctly stored
- Control the accountability of intact and used treatment units and return them to the Clinical Pharmacy Department of the IRPF for destruction
- Obtain the last data clarifications and/or solutions if any
- Collect the patient's consent forms in sealed envelopes,

- Make an on-site review of all study documentation and complete it if necessary
- And finally, remind the Investigator of his regulatory obligations, study document archiving process and duration.
<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>14.3 PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM</strong></td>
<td><strong>14.3 PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM</strong></td>
</tr>
<tr>
<td>The information and consent document are made in triplicate: the original copy is kept by the Investigator, one copy is given to the patient and the last copy is kept by the Clinical Quality Assurance Unit of the Sponsor in a sealed envelope at the end of study.</td>
<td>The information and consent document are made in triplicate: the original copy is kept by the Investigator, one copy is given to the patient and the last copy is kept by the Clinical Quality Assurance Unit of the Sponsor in a sealed envelope at the end of study (except in case of specific country requirement).</td>
</tr>
</tbody>
</table>
CLINICAL STUDY PROTOCOL

Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study
F373280 / Soft Capsules / 1g

Pierre Fabre Study Code: F 373280 CA 2 01
EudraCT Number: 2012 – 003487 - 48

Sponsor's Representative:
Gaëlle ALCARAZ
INSTITUT DE RECHERCHE PIERRE FABRE - Centre de R&D Pierre Fabre - BP 13562
3 avenue Hubert Curien
31035 TOULOUSE Cèdex 1
Phone: +33 5 34 50 62 16
Fax:+33 5 34 50 65 92
E-mail: gaelle.alcaraz@pierre-fabre.com

Study Coordinating Investigator
Pr Savina NODARI –
Associate Professor of Cardiology
Department of Clinical and Surgical Specialities,
Radiological Science and Public Health
Section of Cardiovascular Diseases
University Medical School and Spedali Civili Hospital of Brescia
c/o Spedali Civili di Brescia
Piazzale Spedali Civili, 1
25123 - BRESCIA, ITALY
Phone: +39 030 3996 587 – +39 030 393849
Fax: +39 030 3700 359
E-mail: savinanodari@gmail.com; nodari@med.unibs.it

Version 4– 28 MAR 2013

The information contained in this document is confidential and is the property of the Sponsor, Pierre Fabre Medicament. This information is given for the needs of the study and must not be disclosed without prior written consent of the Sponsor Pierre Fabre Medicament. Persons to whom this information is given for the needs of the study must be informed that it is confidential and must not be disclosed.
SPONSOR PERSONNEL

PIERRE FABRE MEDICAMENT
represented by
Institut de Recherche Pierre Fabre

Clinical Study Manager (Monitor)
Gaëlle ALCARAZ
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1

Phone: +33 5 34 50 62 16
Fax: +33 5 34 50 65 92
E-mail: gaelle.alcaraz@pierre-fabre.com

Medical Director
Richard ROCHE, MD
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1

Phone: +33 5 34 50 61 94
Fax: +33 5 34 50 65 92
E-mail: richard.roche@pierre-fabre.com
CONTRACT RESEARCH ORGANISATIONS

For Feasibility, Monitoring and Regulatory issues:
Pharmaceutical Service Network (PSN)
Rufino Gonzalez
28 037 Madrid - SPAIN
Phone: +34 91 375 6930 - Fax: +34 91 375 6931
E-mail: www.psnglobal.org

For Centralised Randomisation and Electronic Case Report Form
S-Clinica
6, Chaussée de Boondael
B-1050 Brussels - BELGIUM
Phone: +32 2 645 0567 - Fax: +32 2 645 0569
E-mail: irena.seredina@s-clinica.com

For Centralised Reading of Holder ECG and TTEM and equipment supply:
Biomedical System
1945 Chaussée de Wavre
B-1160 Brussels - BELGIUM
Phone: +32 2 661 20 70 - Fax: +32 2 661 20 71
E-mail: sjacobs@biomedsys.com

For intra erythrocyte DHA dosage:
Agrocampus Ouest
Laboratoire de Biochimie
65 rue de Saint Brieuc – CS 84215
35042 RENNES Cedex - FRANCE
Phone: +33 2 23 48 55 49 - Fax: +33 2 23 48 55 50
E-mail: daniel.catheline@agrocampus-ouest.fr

For transportation of blood sample to the Analytical centre (Agrocampus) and material supply:
Theradis Pharma
41, chemin des Presses
06800 CAGNES-SUR-MER – France
Phone : +33 (0)4 97 02 07 07
Fax : +33 (0)4 97 10 08 78
E-mail: chantal.raffy@theradis.pharma.com
CONTRACT RESEARCH ORGANISATIONS

For refund of patients expenses linked to the study (in France):
CLINACT
6-10 rue TROYON
92310 SEVRES – FRANCE
Phone : +33 1 46 90 27 27
Fax : +33 1 46 23 01 56
Email : sebastien.beaumont@clinact.com
Protocol F 373280 CA 2 01

APPROVAL FORM


Sponsor's Representative:

Medical Director:
Richard ROCHE, MD

Date: 4/05/13
Signature:

Study Coordinating Investigator:

Savina NODARI, MD

Date: 5/13
Signature:

Country: ……………………..

Country Coordinating Investigator:

"Name"                     Date:                        Signature:

_____________________________
Protocol F 373280 CA 2 01

INVESTIGATOR SIGNATURE FORM


By my signature below, I, Dr / Pr "

", hereby confirm that I agree:

- to conduct the trial described in the protocol F 373280 CA 2 01, dated 28 March 2013 in
compliance with GCP, with applicable regulatory requirements and with the protocol
agreed upon by the Sponsor Pierre Fabre Médicament and given approval / favourable* opinion by the Ethics Committee;
- to document the delegation of significant study-related tasks and to notify the Sponsor of
changes in site personnel involved in the study;
- to comply with the procedure for data recording and reporting;
- to allow monitoring, auditing and inspection;
- to retain the trial-related essential documents until the Sponsor informs that these documents
are no longer needed.

Furthermore, I hereby confirm that I will have and will use the available adequate resources,
personnel and facilities for conduct this trial.

I have been informed that certain regulatory authorities require the Sponsor Pierre Fabre
Médicament to obtain and supply details about the investigator’s ownership interest in the
Sponsor or the study drug, and more generally about his/her financial relationships with the
Sponsor. The Sponsor will use and disclose the information solely for the purpose of complying
with regulatory requirements.

Hence I agree:

- to supply the Sponsor with any information regarding ownership interest and financial
relationships with the Sponsor (including those of my spouse and dependent children);
- to promptly update this information if any relevant changes occur during the course of the
study and for 1 year following completion of the study;
- that the Sponsor may disclose this information about such ownership interests and financial
relationships to regulatory authorities.

* To be adapted

Date: 

Signature:
6. STUDY TREATMENT

6.1. SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT

6.2. PACKAGING AND LABELLING

6.2.1. Packaging

6.2.2. Labelling

6.3. DISTRIBUTION TO CENTRE AND STORAGE

6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT

6.5. DRUG ADMINISTRATION

6.5.1. Duration of Treatment

6.5.2. Dose Schedule

6.5.3. Route and Conditions of Administration

6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT

6.7. RECALL OF INVESTIGATIONAL PRODUCTS

7. CONCOMITANT TREATMENTS

7.1. ANTI-VITAMIN K TREATMENT

7.2. PROHIBITED TREATMENTS

7.3. AUTHORISED TREATMENTS

8. EVALUATION CRITERIA

8.1. PRIMARY EFFICACY CRITERION:

8.1.1. Time to the first Atrial Fibrillation Recurrence

8.1.1.1. Definition

8.1.1.2. Schedule

8.1.1.3. Evaluation Methods

8.1.2. Secondary Efficacy Criteria

8.1.2.1. Numbers of Atrial Fibrillation episodes in the first week following visit 3 (ECV visit)

8.1.2.2. Duration of Atrial Fibrillation episodes in the first week following visit 3 (ECV visit)

8.1.2.3. Clinical parameters evaluation

8.1.2.4. Cardioversion assessment

8.1.2.5. Evolution of echocardiographic parameters

8.2. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA

8.2.1. Definition

8.2.2. Blood samples

8.2.2.1. Collection schedule

8.2.2.2. Technical handling

8.2.3. DHA concentration measurement

8.3. SAFETY ASSESSMENT
12.1. DATA ENTRY ..................................................................................................................... 74
12.2. DATA CLEANING ............................................................................................................. 74
12.3. DATA CODING .................................................................................................................. 75
12.4. DATA STORAGE ............................................................................................................... 75
12.5. DATABASE LOCK ............................................................................................................. 75

13. STATISTICAL ANALYSIS ..................................................................................................... 75

13.1. GENERAL CONSIDERATIONS ........................................................................................ 76
13.2. SAMPLE SIZE ..................................................................................................................... 76
13.3. PROTOCOL DEVIATIONS ................................................................................................ 76
13.4. DATA SETS ANALYSED .................................................................................................. 77
13.5. HANDLING OF DROPOUTS AND MISSING DATA ..................................................... 77
  13.5.1. Dropouts ............................................................................................................................ 77
  13.5.2. Repositioning of Visits ...................................................................................................... 77
  13.5.3. Missing Data ...................................................................................................................... 77
13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS ............................... 78
13.7. EFFICACY ANALYSIS ...................................................................................................... 78
  13.7.1. Primary Criterion ............................................................................................................... 78
    13.7.1.1. Primary Analysis ............................................................................................................ 78
    13.7.1.2. Supportive Analysis ....................................................................................................... 78
  13.7.2. Secondary Criteria ............................................................................................................. 79
    13.7.2.1. Numbers of Atrial Fibrillation Episodes ........................................................................ 79
    13.7.2.2. Duration of Atrial Fibrillation Episodes ......................................................................... 79
    13.7.2.3. Time to first AF recurrence less than 10 minutes or symptomatic .................................. 79
    13.7.2.4. Clinical parameters evaluation ....................................................................................... 79
    13.7.2.5. Biomarker analysis: red blood cell concentrations of DHA ........................................... 80
13.8. SAFETY ANALYSIS .......................................................................................................... 80
  13.8.1. Adverse Events .................................................................................................................. 80
  13.8.2. Clinical Laboratory Evaluation ......................................................................................... 82
  13.8.3. Global Physical Examination ............................................................................................ 83
  13.8.4. Vital Signs, Physical Findings and Other Observations Related to Safety ....................... 83
    13.8.4.1. Vital Sign Measurements Over Time ............................................................................. 83
    13.8.4.2. Body weight ................................................................................................................... 83
    13.8.4.3. Individual Patient Changes ............................................................................................. 84
    13.8.5. ECG ................................................................................................................................... 84
    13.8.6. Coagulation parameters ..................................................................................................... 84
13.9. CONCOMITANT TREATMENTS ..................................................................................... 84
13.10. COMPLIANCE .................................................................................................................... 85
13.11. INTERIM ANALYSIS AND DATA MONITORING ........................................................ 85

14. GENERAL ETHICAL CONSIDERATIONS .................................................................... 85
  14.1. ETHICAL CONDITIONS .................................................................................................. 85
  14.2. ETHICS COMMITTEE AND LEGAL REQUIREMENTS ............................................... 85
14.3. PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM...........86
14.4. PERSONAL DATA PROTECTION .................................................................87
14.5. INSURANCE POLICY ..................................................................................87
15. ADMINISTRATIVE PROCEDURES .................................................................87
15.1. PROTOCOL AMENDMENT .........................................................................87
15.2. SOURCE DOCUMENTS, INVESTIGATOR'S FILE STORAGE ................................88
15.3. END OF THE STUDY ....................................................................................88
15.3.1. Definition of the End of Study .................................................................88
15.3.2. Early Study Termination ..........................................................................89
15.3.2.1. Early Study Termination Decided by the Sponsor .................................89
15.3.2.2. Early Study Termination Decided by the Competent Authorities ..........89
15.4. AUDIT ..........................................................................................................89
15.5. INSPECTION ...............................................................................................90
15.6. CONFIDENTIALITY .....................................................................................90
15.7. CLINICAL STUDY REPORT .......................................................................90
15.8. STUDY RESULTS COMMUNICATION ......................................................90
15.9. STUDY RESULTS PUBLICATION ..............................................................90
16. REFERENCES .................................................................................................92
17. APPENDICES .................................................................................................95
17.1. DECLARATION OF HELSINKI .................................................................96
17.2. SAE REPORT FORM ..................................................................................100
17.3. PREDEFINED LIMITS OF LABORATORY AND VITAL SIGN POTENTIALLY CLINICALLY SIGNIFICANT CHANGES AND VALUES...........103
**SYNOPSIS**

<table>
<thead>
<tr>
<th>Name of Sponsor:</th>
<th>Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Finished Product:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Name of Active Substance:</td>
<td>F373280 (Panthenyl-Ester of DHA)</td>
</tr>
<tr>
<td><strong>Title of the Study:</strong></td>
<td>Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.</td>
</tr>
<tr>
<td><strong>Abbreviated Title:</strong></td>
<td>Not applicable</td>
</tr>
<tr>
<td>Study Coordinating Investigator:</td>
<td>Pr Savina NODARI</td>
</tr>
<tr>
<td><strong>Study Centres:</strong></td>
<td>International, multicentric</td>
</tr>
<tr>
<td>Publication / Rationale:</td>
<td>F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation (AF) patients with chronic heart failure. The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of Atrial Fibrillation (AF) induced by burst pacing.[1] Moreover, the effectiveness of PUFA (Poly Unsaturated Fatty Acid) has been proven in the following conditions: - prevention of Atrial Fibrillation recurrence in patients with persistent Atrial Fibrillation, in co-administration with amiodarone (add on therapy) [2] - Improvement of ventricular functional parameters, morbidity and mortality and duration of hospitalisation in patients with heart failure [3, 4, 5] Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent atrial fibrillation and chronic heart failure. This phase IIa study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after electrical cardioversion (ECV) in patients with persistent atrial fibrillation and chronic heart failure.</td>
</tr>
<tr>
<td>Planned Study Period:</td>
<td>January 2013 – April 2014</td>
</tr>
<tr>
<td><strong>Clinical Phase:</strong></td>
<td>Ila</td>
</tr>
<tr>
<td><strong>Objectives:</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Primary:</strong></td>
<td></td>
</tr>
</tbody>
</table>
- Efficacy of F373280 on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure |
| **Secondary:** |  
- Efficacy of F373280 on the efficiency of direct electrical cardioversion  
- Effect of F373280 on echocardiographic parameters  
- Safety and tolerability of F373280 |
| **Methodology:** |  
- International, multicentre, randomised, double-blind, placebo-controlled  
- Selection period  
- Start of treatment 4 weeks before ECV  
  - Condition to ECV:  
    - INR 2-3 (anti-vitamin K should be given at least 3 weeks before ECV)  
    - No spontaneous cardioversion before ECV  
- Follow-up 20 weeks after visit 3 (ECV visit)  
  - Condition: successful ECV or spontaneous CV  
- Cardiac monitoring:  
  - 7-days continuous ECG ambulatory recording (Holter ECG) between visit 3 (ECV visit) and visit 4 (week 5) in patients with sinus rhythm  
  - TTEM: daily transmission from week 6 to week 8; then every two days from week 9 to week 24, and in case of AF symptoms  
- Treatment duration: 24 weeks |
| Study Schedule |  
- 9 visits will be scheduled:  
  - V1/W-4 to W-1: selection visit (7 to 28 days before the inclusion visit)  
  - V2/D1: Inclusion visit (start of treatment)  
  - V3/W4 (D28 -2/+7 days): cardioversion visit (Outpatient or hospitalization according to final version 366/1185
clinical practice of the centre) (installation of the Holter device)
- V4/ W5 (D35± 2 days): follow-up visit (removing of the Holter device and installation of the TTEM)
- V5/ W8 (D56± 7 days): follow-up visit
- V6/ W12 (D84 ± 7 days): follow-up visit
- V7/ W16 (D112 ± 7 days): follow-up visit
- V8/ W20 (D140 ± 7 days): follow-up visit
- V9/ W24 (D168 ± 7 days): final study visit

<table>
<thead>
<tr>
<th>Number of Patients:</th>
<th>76 x 2 patients</th>
</tr>
</thead>
</table>

**Diagnosis and Criteria for Inclusion:**

**Inclusion Criteria:**

*Demographic Characteristics and Other Baseline Characteristics:*

1. Men or women aged more than 18 years (inclusive),
2. Patients with persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted.
3. History of first documented persistent AF less than 1 year
4. History of ischemic or non ischemic heart failure
5. NYHA class I or II chronic heart failure at selection and at inclusion
6. Reduced left ventricular ejection fraction between 30% and 45% inclusive (using the two-dimensional echocardiography biplane Simpson’s rule) at selection and at inclusion
7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or beta blockers
8. Left atrial area ≤ 40 cm² at selection and at inclusion
9. Patients treated or having to be treated by anti-vitamin K
10. For female patient of child-bearing potential:
    - **in all the countries except Italy:**
      - use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator, for at least 2 months before the selection in the study, and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment
      - documented as surgically sterilized
    - **in Italy only:**
      - absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
      - use of double barrier contraception method (use of effective medical contraception method) from at least 2 months before the start of the study to the entire duration of the study and for a month after the end of the study or
      - documented as surgically sterilized
11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion
12. For male with a child-bearing potential partner (in Italy only):
    - Absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
    - use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to a month after the end of the study.

**Ethical/legal considerations:**

13. Having signed his/her written informed consent,
14. Affiliated to a social security system, or is beneficiary (if applicable in the national regulation)

**Non-Inclusion Criteria:**

*Criteria related to pathologies:*

1. History of first documented episode of persistent AF more than 1 year
2. More than two successful cardioversions (electrical or pharmacological) in the last 6 months
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV)
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be checked in case of treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic coronary artery assessed by coronaryography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
7. Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration rate < 30 mL/min) at selection
8. Bradycardia (HR ≤ 50 bpm)
9. Hyperkalemia or hypokalemia (K>5.5 mEq/L or K < 3.5 mEq/L) at selection
10. Cardiac surgery within 3 months before selection or planned during the study duration

Criteria related to treatments:
11. Previously ineffective pharmacological or electrical cardioversion
12. Concomitant treatment with any anti-arrhythmic drug (within 7 days prior to selection), except stable dose of digoxin, betablockers, calcium-blockers
13. Previous treatment with oral amiodarone within 12 months prior to inclusion
14. Previous treatment with intravenous amiodarone within 6 months prior to inclusion
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT implantation within the last 6 months
16. Treatment with any Polyunsaturated Fatty Acid (PUFA) within the last 3 months
17. Dietary supplement with ω3 or ω6 according to investigator’s judgement
18. Having undergone any form of ablation therapy for AF
19. Patient treated with other anticoagulant treatment than antivitamin K: thrombin inhibitor such as Dabigatran or treated with antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel

Other criteria:
20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection
22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to participate himself/herself to its constraints
23. Patient family member or work associate (secretary, nurse, technician,..) of the Investigator
24. Patient having forfeited his / her freedom by administrative or legal award or being under guardianship
25. Breastfeeding female patient

Exclusion criteria before V3:
Patients not stabilized for INR (i.e. values not between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO – TE (trans-esophageal echocardiograph) performed in the same day (before ECV)
ECV will be performed in patients without dyskalemia
If necessary for obtaining stabilized INR between 2 and 3, the ECV (and following visits) could be postponed by 7 days.

Test Product:
F373280
Soft Capsules

Dose:
Arm with 1g of F373280

Mode of Administration:
Oral, one capsule each evening with dinner.

Duration of Treatment:
24 weeks of treatment exposure with F373280 (25 weeks if ECV postponed by 1 week)

Reference Therapy
Placebo soft capsules
Placebo will be administered in the same conditions as the tested product.
Mode of Administration: Oral, one capsule each evening with dinner

Evaluation Criteria:

<table>
<thead>
<tr>
<th>Efficacy evaluation variables:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary evaluation variable:</td>
</tr>
<tr>
<td>- Time to first Atrial Fibrillation recurrence defined by the first episode of Atrial Fibrillation lasting for at least 10 minutes (Follow up of 20 weeks after visit 3 (ECV visit)) Handling of AF recurrences: 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) between visit 3 (ECV visit) and visit 4 (week 5). Then, the follow up will be documented using the TTEM: daily transmission from week 6 to week 8. Then, every two days from week 9 to week 24. For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF will be assessed after visit 3 (week 5). Moreover, during this TTEM period, if patient experiences any AF symptoms, it should be recorded and documented using the TTEM. All ECG traces will be evaluated by a Central Reading Laboratory.</td>
</tr>
<tr>
<td>Secondary evaluation variables:</td>
</tr>
<tr>
<td>During the 7-day continuous ECG monitoring,</td>
</tr>
<tr>
<td>- Numbers of AF episodes</td>
</tr>
<tr>
<td>- Duration of AF episodes</td>
</tr>
<tr>
<td>Clinical parameters:</td>
</tr>
<tr>
<td>During the whole study:</td>
</tr>
<tr>
<td>- Number of recurrence of symptomatic AF episodes</td>
</tr>
<tr>
<td>- EHRA score</td>
</tr>
<tr>
<td>- Hospitalization for cardiovascular events</td>
</tr>
<tr>
<td>- Hospitalization for thromboembolic stroke</td>
</tr>
<tr>
<td>- All cause of hospitalization</td>
</tr>
<tr>
<td>Cardioversion:</td>
</tr>
<tr>
<td>- Assessment of spontaneous cardioversion</td>
</tr>
<tr>
<td>- Assessment of successful cardioversion</td>
</tr>
<tr>
<td>- Number of patients needing an other cardioversion after the initial ECV</td>
</tr>
<tr>
<td>Other:</td>
</tr>
<tr>
<td>- Evolution of echocardiographic parameters (from V4 to V6 and V9) (Left atrial diameter (mm), Left atrial area (cm²), Left atrial volume (mL), Left atrial volume/BSA (mL/m²), Left ventricular ejection fraction (%), Left ventricular volume (mL), Left ventricular volume/BSA (mL/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL) Left ventricular end systolic diameter (mm), Left ventricular end systolic volume (mL))</td>
</tr>
<tr>
<td>- Evolution of omega 3 index and intra erythrocyte DHA (For this assessment samples will be centralized).</td>
</tr>
</tbody>
</table>

Safety criteria: |
- Adverse events (observed and / or spontaneously reported) |
- Vital signs (Blood pressure (supine and standing), heart rate) |
- Physical examination (body weight), |
- Standard 12-lead ECG: heart rate (bpm), PR (ms), QRS (ms), QT (ms), repolarisation patterns (ECG not centralized). |
- Haematology: haematocrit, haemoglobin, RBC, WBC, differential count, platelets |
- Biochemistry: sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatin phosphokinase (CPK) fibrinogen (local laboratory) |
- Coagulation parameters: Activated partial thromboplastin time (aPTT), thrombin clotting time (TCT), INR (local laboratory), Prothrombine Time (PT) |

Statistical Methods: |
- Sample Size: Assuming an AF recurrence rate under placebo of 85%, a power of 80%, an alpha risk of 5% and a rate of not assessable patients of 15%, 76 randomised patients per group will be necessary, using a log-rank test of survival curves, a difference between groups of 20%. |
<table>
<thead>
<tr>
<th><strong>Primary Efficacy Analysis</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>The primary analysis, performed on the Full Analysis Set (FAS; all randomised patients with at least one dose of treatment and with a successful cardioversion observed at visit 3), will be a survival analysis using the Kaplan Meier method and Cox regression model.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Secondary Analyses</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>All secondary efficacy criteria will be described and compared using appropriate tests on the FAS.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Safety Analyses</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Descriptive statistics will be performed on the Safety Set (all randomised patients with at least one dose of treatment)</td>
</tr>
</tbody>
</table>
STUDY FLOW-CHART
<table>
<thead>
<tr>
<th>Weeks</th>
<th>V1</th>
<th>V2</th>
<th>V3</th>
<th>V4</th>
<th>V5</th>
<th>V6</th>
<th>V7</th>
<th>V8</th>
<th>V9</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Outpatient or Hospitalization (1)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td><strong>Informed consent</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Demographic characteristics</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Medico-surgical history</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Concomitant disease</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Concomitant treatment</strong></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Habits</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Global physical examination (body weight)</strong></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Echocardiography</strong></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td><strong>Eligibility criteria check</strong></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Blood pressure, heart rate</strong></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>12-Lead ECG Recording</strong></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>INR</strong></td>
<td>(2)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>aPTT, TCT</strong></td>
<td></td>
<td>(5)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Biochemistry</strong></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hematology</strong></td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Urinary pregnancy test</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Red Blood Cell concentrations of DHA</strong></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td><strong>Treatment allocation</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IVRS</strong></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ECV (3)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>X</td>
</tr>
<tr>
<td><strong>Drug administration</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adverse events recording</strong></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Holter ECG</strong></td>
<td></td>
<td>(4)</td>
<td>(4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TTEM (5)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(6)</td>
</tr>
</tbody>
</table>

---

1. Outpatient or hospitalization according to clinical practice of the centre (less or more than 24 hours).
2. In case of AVK introduction: INR 2 to 3 times a week, then weekly until the ECV, then every 4 weeks after ECV.
3. In patients with AF.
4. 24-hour Holter ECG.
5. 7-day Holter ECG.
6. TTEM everyday from week 6 to week 8. Then every 2 days from week 9 to week 24. In case of AF symptoms. In case of AF recurrence for at least 10 minutes and the patient does not stop the study treatment than TTEM everyday 4 weeks.

---

Final version
LIST OF ABBREVIATIONS

aPTT: Activated partial thromboplastin time
AE: Adverse event
AERP: Atrial effective refractory period
AF: Atrial fibrillation
ALA: Alpha-linoleic acid
ALT: Alanine aminotransferase
AST: Aspartate aminotransferase
AUC: Area under the plasma concentration versus time curve
AUC_{inf}: Total area under the curve extrapolated to infinity
AVK: Anti vitamin K
βHCG: beta human chorionic gonadotrophin
BLQ: Below the limit of quantification
BMI: Body mass index
BP: Blood pressure
BSA: Body Surface Area
CEP: Protocol evaluation committee
CHF: Congestive heart failure
CHMP: Committee for medicinal products for human use
C_{max}: Maximum concentration
C_{min}: Minimum concentration
CNALV: Clinically noteworthy abnormal laboratory value
CPK: Creatin phosphokinase
CPP: Comité de protection des personnes
CRA: Clinical research associate
CRT: Cardiac resynchronization therapy
CSC: “Clinically Significant Change”, i.e., Predefined potentially clinically significant change leading to a potentially clinically significant value (vital signs)
CV: Coefficient of variation
DBP: Diastolic blood pressure
DHA: Docosahexaenoic acid
EC: Ethics committee
ECG: Electrocardiogram
ECHO –TE: Trans-esophageal echocardiograph
ECV: Electrical cardioversion
EHRA: European heart rhythm association
EPA: Eicosapentaenoic acid
eCRF: Electronic case report form
FAS: Full analysis set
Fe: Fraction of the administered drug excreted in urine
GCP: Good clinical practice
GFR: Glomerular Filtration Rate
HBs : Hepatitis B antigen
HCV : Hepatitis C virus
HDL : High density lipoprotein
HF : Heart failure
HIV : Human immunodeficiency virus
HR : Heart rate
ICH : International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use
IDMC : Independent data monitoring committee
INR : International normalized ratio
IRPF : Institut de Recherche Pierre Fabre
IVRS : Interactive voice response system
LAA : Left atrial area
LC/MS-MS : Liquid chromatography with tandem mass spectrometry
LDL : Low density lipoprotein
LOQ : Limit of quantification
LVEF : Left ventricular ejection fraction
MedDRA : Medical dictionary for regulatory activities
MR : Mineralocorticoid receptor
MR perfusion : Magnetic Resonance perfusion
MTD : Maximum tolerated dose
N : Number of determinations or replicates
NOAEL : No observed adverse effect level
NYHA : New York heart association
od : Once a day
“Predefined Change”, i.e., Predefined potentially clinically significant change (lab or vital signs)
PCA : PC leading to an out-of-range value (lab values)
PK : Pharmacokinetics
p.o. : Per os
PP : Per protocol data set
RBC : Red blood cells
SAE : Serious adverse event
SBP : Systolic blood pressure
SD : Standard deviation
T1/2 : Terminal half-life
T0 : Time of drug administration
Tmax : Time to reach the maximal concentration
TCT : Thrombin clotting time
TEAEs : Treatment emergent adverse events
TTEM : TransTelephonic ECG monitoring
VTP : Ventricular tachypacing
WBC : White blood cells
WHO-DRUG : World health organization drug reference list
1. INTRODUCTION AND STUDY RATIONALE

1.1. TARGET PATHOLOGY AND THERAPY

Atrial Fibrillation (AF) is a supraventricular arrhythmia characterized by uncoordinated atrial electric activity with consequent deterioration of atrial mechanical function. It is the most common sustained cardiac rhythm disorder, increasing in prevalence with age. Haemodynamic impairment and thromboembolic events related to AF result in significant morbidity and mortality [7].

In 2009, Decision Resources estimated that there were 7.8 million diagnosed prevalent cases of atrial fibrillation (AF) in US, Europe and Japan. This age-related pathology should increase to 9.4 million cases in 2019.

Except for the conventional class I and class III anti-arrhythmic agents, the PUFAs (Polyunsaturated Fatty Acids) constitute one emerging antiarrhythmic therapy. These compounds potently address the AF substrate by directly targeting both the electrical and the structural remodelling of the deficient atria. The n-3 PUFAs, essential for human, are ALA, EPA and DHA. First, PUFAs specifically modulate ionic channels by fastening their inactivating mode which renders these compounds selective for pathological situations (such as AF) without any major effect in normal conditions. PUFAs are “open K_{v1.5} channel blockers” leading to a lengthening of atrial action potential duration and are “persistent Na_{v1.5} channel blockers” leading to hyperpolarization of diastolic resting potential. Second, PUFAs influence structural remodelling through their anti-inflammatory effects as they directly compete with arachidonic acid in the production of inflammatory eicosanoids. In summary, PUFAs share unique, well-tolerated antiarrhythmic potential by interacting with the electrical and structural remodelling during sustained AF. In animal studies, it was recently demonstrated that DHA is particularly effective in pathologic conditions such as ischemia and/or atrial fibrillation.

The potential anti-arrhythmic effects of a PUFA was previously developed in atrial fibrillation: nicotinyl ester of DHA (pro-drug based on DHA delivery) were assessed in a two-week
ventricular tachypaced canine model. Dogs were subjected to 4 weeks of medication prior to undergoing an electrophysiology study, and received either placebo or nicotinyl ester of DHA. Dogs were tachypaced at 240 beats per min for the final two weeks of the treatment plan. The results showed that the tested PUFA reduced the duration of atrial fibrillation (AF) induced by burst pacing, and the incidence of sustained AF, compared to dogs treated with the placebo [1].

In clinical practice, Nodari and coll assessed n-3 Polyunsaturated Fatty Acids in the prevention of atrial fibrillation recurrences after electrical cardioversion. All included patients were treated with amiodarone and a renin-angiotensin-aldosterone system inhibitor. The 199 patients were assigned either to placebo or n-3 PUFAs 2 g/d and then underwent direct electrical cardioversion (ECV) 4 weeks later. The primary end point was the maintenance of sinus rhythm at 1 year after cardioversion. At the 1-year follow up, the maintenance of sinus rhythm was significantly higher in the n-3 PUFAs treated patients compared with the placebo group (hazard ratio, 0.62 [95% confidence interval, 0.52 to 0.72] and 0.36 [95% confidence interval, 0.26 to 0.46], respectively; p = 0.0001). The study concludes that in patients with persistent atrial fibrillation on amiodarone and a renin-angiotensin-aldosterone system inhibitor, the addition of n-3 PUFAs 2 g/d improves the probability of the maintenance of sinus rhythm after direct current cardioversion [2].

Previously, during the World Congress of Cardiology in 2006, an abstract reported the effectiveness of PUFA on top of traditional treatment (amiodarone, beta blockers, renin-angiotensin-aldosterone system inhibitor) in the prevention of AF relapses in patients having undergone ECV. In the PUFA group, AF relapses were significantly lower than placebo group at one month (3.3% vs 10%; p=0.043), at 3 months (10% vs 25%; p=0.004) and at 6 months (13.3% vs 40%; p<0.0001) [19].

In contrast, in the general AF population (paroxystic atrial fibrillation and persistent atrial fibrillation), PUFAs failed to prove their efficacy [7] because of the absence of cardiac remodelling or because of a short pre-treatment duration before ECV (1 week) [8]. The effect of PUFAs were only observed in patients with persistent AF on add on therapy and after a sufficient pre-treatment before ECV. Persistent AF is commonly associated to heart failure. Previous studies performed in heart failure population demonstrated the benefit of PUFAs on the improvement of functional ventricular parameters and morbi-mortality, and on the reduction of hospitalisation [3, 4, 5].
Nodari and coll [3] performed a trial in patients with a chronic heart failure (NYHA I to III and LVEF< 45%). After a treatment of 133 patients with PUFAs (n=67) or placebo (n=66) at a dosage of 5 g/day for 1 month, then 2 g/day for 11 months, the n-3 PUFAs group and the placebo group differed significantly (p <0.001) in regard to:

- LVEF (increased by 10.4% and decreased by 5.0%, respectively)
- peak VO₂ (increased by 6.2% and decreased by 4.5%, respectively)
- exercise duration (increased by 7.5% and decreased by 4.8%, respectively)
- mean New York Heart Association functional class (decreased from 1.88 +/- 0.33 to 1.61 +/- 0.49 and increased from 1.83 +/- 0.38 to 2.14 +/- 0.65, respectively).

The hospitalization rates for HF were 6% in the n-3 PUFAs and 30% in the placebo group (p <0.0002).

Moertl and coll [4] performed a dose-ranging study in patients with a more severe chronic heart failure (NYHA III and IV and LVEF < 35%). It was a double-blind, randomised, controlled pilot trial in 43 patients treated with PUFAs or placebo for 3 months (1 g/d n3-PUFA (n = 14), 4 g/d n3-PUFA (n = 13), or placebo (n = 16)). After treatment, left ventricular ejection fraction increased in a dose-dependent manner (P = 0.01 for linear trend) in the 4 g/d (baseline vs 3 months [mean ± SD]: 24% ± 7% vs 29% ± 8%, p = 0.005) and 1 g/d treatment groups (24% ± 8% vs 27% ± 8%, P = 0.02).

No changes in any investigated parameters were noted with placebo.

Taking into account these studies performed with PUFAs, it seems that the best target for DHA is persistent AF in patients with heart failure. The aim of this proof of concept study is to assess in stand alone therapy (without association of other anti-arrhythmic treatments), the effect of F373280 in patients with persistent atrial fibrillation and heart failure in the maintenance of sinus rhythm after electrical cardioversion.

1.2. INFORMATION ON THE TEST PRODUCT

F373280 or panthenyl ester of DHA (docosahexaenoic acid) is the mono-ester of panthotenic alcohol and DHA, selected to be developed for the management of atrial fibrillation.

F373280 is a prodrug of DHA.
A brief summary of F373280 known characteristics is presented in this section. For further details, please refer to the F373280 Investigator’s Brochure. [1]

1.2.1. Chemical and pharmaceutical characteristics

1.2.1.1. Nomenclature and structure

Chemical name (IUPAC):

(4Z,7Z,10Z,13Z,16Z,19Z)-3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido) propyl docosa-4,7,10,13,16,19-hexaenoate

Structural formula:

![Structural formula of F373280](image)

Laboratory code: F373280

Molecular formula: C_{31}H_{49}NO_{5}

Molecular mass: 515.7

1.2.1.2. Physical and chemical general properties

Appearance: Clear oily viscous liquid

Solubilities:

- Water: Practically insoluble
- Alcohol: Very soluble
- Trimethylpentane: Slightly soluble
1.2.2. Non-clinical Data

Non-clinical data are exhaustively detailed in the Investigator’s brochure [1]. A brief summary is provided below.

1.2.2.1. Pharmacological profile

F373280 (mono-ester of panthotenic alcohol and DHA) is a novel pro-drug of DHA which exerts antiarrhythmic properties by interacting with the electrical and structural remodelling of the atria.

Experimental investigations were conducted in HEK293 cell line transfected with human Kv1.5 channel using the whole cell patch clamp technique to evaluate whether F373280 could block the sustained component of I_{Kv1.5}. F373280 concentration-dependently reduced Kv1.5 channel activity with an IC_{50} value of 13.7 µM.

The effects of F373280 on atrial effective refractory period (AERP) were investigated in anesthetized pig using a conventional pacing protocol through epicardial electrodes placed on the left atrium. F373280 administered as a bolus and an infusion (10 mg/kg) significantly increased AERP (23.8 ± 2.2 ms versus -7.3 ± 11.5 ms in the presence of vehicle, P<0.05). In addition, F373280 was devoid of significant effect on the hemodynamic and the ECG intervals.

Proof of the pharmacological concept was performed with a different DHA derivative named: Nicotinyl ester of DHA (pro-drug based on DHA delivery). Ventricular tachypacing (VTP)-induced congestive heart failure (CHF) provides a clinically-relevant animal model of AF associated with structural remodelling, as is often seen clinically. It has been shown that sustained oral PUFA administration suppresses CHF-induced AF-promotion and fibrosis in the VTP canine model. Nicotinyl ester of DHA was tested in this model, at 1g/day and 5g/day, during 4 weeks, to prevent CHF-related atrial structural remodelling and AF promotion in dogs. Nicotinyl ester of DHA dose dependently reduced heart failure-induced increases in atrial fibrillation duration (989 ± 111 sec, n=5 in the presence of placebo versus 637 ± 196 sec, n=5 in the presence of 1g/kg/d Nicotinyl ester of DHA and 79 ± 51 sec, n=5, in the presence of 5g/kg/d Nicotinyl ester of DHA. The protective effect of Nicotinyl ester of DHA was associated with a marked increase of plasma level of DHA and important incorporation of DHA in the left atrial tissue. Because F373280
similarly to Nicotinyl ester of DHA increases plasma level of DHA, it could be estimated that the compound may exert a similar protective effect [1].

1.2.2.2. Safety pharmacology

A battery of safety pharmacology studies was performed to evaluate the effects of F373280 on the central nervous, cardiovascular and respiratory systems. Data of these studies are exhaustively detailed in the Investigator’s brochure [1]. No particular alerts were evidenced with F373280.

1.2.2.3. Toxicology profile

Concerning the toxicological data, 4-week and 26-week repeat-dose studies in rat and dog were performed. Compared to the high administered doses of F373280 (500 to 2000 gm/kg/day), low circulating concentrations of F373280 were measured.

During these toxicity studies, no toxicity was observed in rat after 4 and 26 weeks of dosing and in dog after 4 weeks of dosing. A NOAEL of 2000 mg/kg/day was established in these repeat toxicity studies.

During the 26-week toxicity study in dogs, the NOAEL was set at 1000 mg/kg/day based on changes observed on red blood cell parameters.

Based on toxicological profiles, F373280 is considered to support the proposed clinical trial.

1.2.2.4. Pharmacokinetic data

According to animal studies described in the Investigator’s brochure [1], the non-clinical pharmacokinetic profile of F373280 is not associated with particular alerts concerning the proposed clinical phase IIa study.

1.2.3. Clinical data

Part A: single dose
6 consecutive single ascending doses were tested (0.5g, 1g, 2g, 4g, 8g and 16g) on 6 independent cohorts of 8 subjects (6 verum + 2 placebo). 49 subjects were treated and 48 completed the study.

No Serious Adverse Events occurred in the course of the study.

Regarding the reported Treatment Emergent Adverse Events (TEAEs) that were judged by the Investigator as having a causal relationship with the study drug administration in the absence of an alternative explanation, 4 were observed in the placebo group (palpitation, dizziness in standing position, 2 symptomatic orthostatic hypotensions without loss of consciousness) and 4 in the group of F373280 at the dosage of 16g (meteorism, liquid stool, symptomatic orthostatic hypotension and dizziness in standing position). None of these adverse events were reported in the groups of F373280 at the dosages of 0.5g, 1g, 2g, 4g and 8g.

After a single administration of the different tested doses no difference between the tested product and placebo has been reported, regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters (related to coagulation: platelets and fibrinogen) and coagulation parameters (bleeding time, prothrombin time/INR, activated partial thromboplastin time, thrombin clotting time). Variations of these parameters were within the physiological ranges.

After single oral administration of F373280 from 0.5g to 16 g in 36 young male healthy subjects (6 per dose level), the following was observed:

- **F373280**: Whatever the tested dose there is no circulating F373280 in plasma: only few, sparse and non consecutive samples with quantifiable level of F373280 close to LOQ were observed. This confirm that F373280 is a prodrug.

- **Panthenol**: Cmax and AUC increased with the administered dose between 0.5 and 16g. Panthenol concentrations were rapidly cleared from plasma with a mean terminal half-life around 2 hours.

- **DHA**: after 0.5 and 1g, low increased in DHA plasma concentrations compared to the baseline levels led to a high inter-individual variability of the corresponding PK parameters. Plasma exposure in DHA increased with the administered dose between 2 and 16g with no departure from proportionality (baseline corrected parameters).
**Part B: Multiple dose**

Three consecutive repeated ascending doses (1, 2 and 4g) were tested on 3 independent cohorts of 12 subjects (9 verum + 3 placebo, double blind). 36 subjects completed the study. Each treatment was administered over a period of 28 days. Pharmacokinetic parameters were assessed over a period of 14 days.

Among the TEAE judged by the investigator as suspected to F373280 5/9 TEAE were classified according the SOC in vascular system disorder with orthostatic hypotension (2 in the 1 g group, 1 in the 2 g group and 2 in the 4 g group) and 4/9 were classified in nervous system disorder with 3 dizziness (2 in the 2 g group and 1 in the 4 g group) and 1 migraine (in the 1 g group). These TEAE have already been reported with Poly Unsaturated Fatty Acids and are commonly observed in phase I studies.

After a repeated administration of the different tested doses, no difference between the tested products and placebo was reported regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters. The assessment of coagulation parameters and platelet function after administration of repeated dose of F373280 did not report any bleeding issue. The reported changes in coagulation parameters and platelet function were within physiological ranges.

After a 14-day repeated oral administration of F373280 from 1 g to 4 g, the following was observed:

- **Panthenol**: Cmax and AUC increased with the administered dose between 1 and 4 g. No accumulation of panthenol in plasma was observed.

- **DHA**: Plasma exposure increased with dose. A 2-fold accumulation in total plasma exposure of DHA was observed after 14 days of administration, whatever the administered dose.
1.3. STUDY RATIONALE

F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation (AF) patients with chronic heart failure.

The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of atrial fibrillation (AF) induced by burst pacing [1].

Moreover, the effectiveness of PUFA has been proven in the following conditions:

- Prevention of atrial fibrillation recurrence in patients with persistent atrial fibrillation in co-administration with amiodarone (add on therapy) [2],

- Improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]

Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent atrial fibrillation and chronic heart failure.

This phase IIa study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure.

1.4. OVERALL RISK AND BENEFIT ASSESSMENT

F373280 is a new pro-drug of DHA.

DHA is a well-known long chain PUFAs with a long-term clinical experience in cardiovascular diseases. DHA is contained in several medicinal products such as Omacor®, (1g of Omacor contains about 320 mg of DHA acid) marketed by Laboratoires Pierre Fabre for hypertriglyceridermia and as an adjuvant treatment for secondary prevention after myocardial infarction. According to the summary product characteristics of Omacor®, [9];
- The frequencies of adverse reactions are ranked according to the following: common (>1/100, < 1/10); uncommon (>1/1000 < 1/100); rare (>1/10000, < 1/1000); very rare (< 1/10000), not known (cannot be estimated from the available data).

- The reported adverse events are:

- Infection and infestations
  - Uncommon: gastroenteritis
- Immune system disorders:
  - Uncommon: hypersensitivity
- Metabolism and nutrition disorders:
  - Rare: hyperglycaemia
- Nervous system disorders:
  - Uncommon: dizziness, dysgeusia
  - Rare: headache
- Vascular disorders:
  - Very rare: hypotension
- Respiratory thoracic and mediastinal disorders:
  - Very rare: nasal dryness
- Gastrointestinal disorders:
  - Common: dyspepsia, nausea
  - Uncommon: abdominal pain, gastrointestinal disorders, gastritis, abdominal pain upper
  - Rare: gastrointestinal pain
  - Very rare: lower gastrointestinal haemorrhage
- Hepatobiliary disorders:
  - Rare: hepatic disorders
- Skin and subcutaneous tissue disorders:
  - Rare: acne, rash pruritic
  - Very rare: urticaria
- General disorders and administration site conditions:
  - Rare: malaise sensation
• Investigations:
  Very rare: white blood count increased, blood lactate dehydrogenase increased

Moderate elevation of transaminases has been reported in patients with hypertriglyceridaemia.

Panthenol is a well-known substance with a long-term experience in medical, nutraceutical and cosmetic uses. According to the summary product characteristics of a product such as Bépanthene® (tablet indicated in alopecia) which contains panthenol (100 mg), adverse event observed are rare cases of urticaria and erythema [10]. Panthenol is metabolised in panthotenic acid, i.e. B5 vitamin.

Concerning toxicological studies performed results can support the administration of F373280 in the proposed clinical phase II study without particular alert [1].

Any safety warning was reported during a phase I study performed with F373280 administered to 84 healthy volunteers in single dose in a range between 500 mg and 16 g or in repeated dose during 28 days in a range between 1g and 4g. Adverse events reported and related to study treatment were minor to moderate. The adverse events were palpitations, orthostatic hypotension, dizziness, meteorism and liquid stool. Most were reported in both groups (placebo and F373280) without a dose relationship. The assessment of coagulation parameters and platelet function after administration of repeated dose of F373280 did not report any bleeding concern: the reported changes in coagulation parameters and platelet function were within physiological ranges.

Moreover, DHA has been associated with anticoagulant products in Atrial Fibrillation studies [2, 8]. The range of PUFAs doses tested was between 2g to 3g (640 mg to 960 mg of DHA) and the range of study durations between 6 to 12 months. This association did not report a significant side effect of bleeding.

DHA has already been used in heart failure patients in several studies without safety concern [3, 4, 5]. The range of PUFAs doses tested was between 1g to 5g (1g of the tested PUFAs contains about 320 mg of DHA acid) and the range of study durations was between 3 months to 3.9 years.
Thus, inclusion of patients with no specific antiarrhythmic treatment is acceptable. They will receive an anticoagulant treatment to prevent the thrombo-embolic complications of AF (particularly stroke) and the adequate treatments to control the heart rate and heart failure.

In conclusion, the overall available data allow in safe conditions the treatment of patients with persistent AF and chronic heart failure with F373280 in safe conditions.

2. STUDY OBJECTIVES

2.1. PRIMARY OBJECTIVE

The primary objective of the study is to assess the efficacy of F373280 on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure.

2.2. SECONDARY OBJECTIVES

The secondary objectives of the study are to assess:

- the efficacy of F373280 on the efficiency of direct electrical cardioversion
- the effect of F373280 on echocardiographic parameters
- the safety and tolerability of F373280

3. ETHICAL CONSIDERATIONS RELATING TO THE STUDY

The trial is conducted according to Good Clinical Practices (CPMP/ICH/135/95), the National regulations and the Declaration of Helsinki and its subsequent amendments (see Appendix 17.1). This protocol and the informed consent form will be submitted for approval to independent local or national Institutional Review Boards/Ethics Committees before the study set up, according to national regulation.

All the protocol amendments or critical events liable to increase the risks incurred by the patients or to compromise the validity of the study or patients' rights will be submitted to the coordinator and to the Ethics Committees.
After being informed orally and in writing of all potential risks and constraints of the trial, as well as their freedom to withdraw their participation at any time, patients will then sign a consent.

A time of reflection will be given to the patients, before giving a written consent and starting the study procedures.

The use of a placebo is in accordance with EMA Addendum to the guideline on antiarrhythmics on atrial fibrillation and atrial flutter (EMA/CHMP/EWP/213056/2010) [21] and is acceptable because the included patients will remain under the standard treatment of atrial fibrillation and chronic heart failure. Except antiarrythmics, they will receive anticoagulant (AVK), rate control treatment, chronic heart failure treatment. During the study, in case of AF recurrence that would require a cardioversion or an introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms, patients will be withdrawn and the tested product stopped. These patients will be considered as treatment failure.

In this study, patients will be carefully screened, particularly for their cardiac condition, with ECG, 24-hour holter monitor and echocardiographic data, and their biologic and coagulation condition.

The study will be addressed only to patients requiring an ECV due to their persistent AF, in the following conditions:

- ECV in patients not presenting a contra-indication,
- Anticoagulation with anti-vitamin K for at least 3 weeks before ECV,
- ECV in patients with stabilized INR (i.e. values between 2 and 3) on at least 3 consecutive weekly tests performed. Patients not stabilized for INR (i.e. values not between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed in the same day (before ECV)
Patients who do not revert to sinus rhythm or present an early relapse within the observation period after ECV will be withdrawn and the tested product stopped.

During the whole study, patients will remain under medical control: visits in cardiology units will be scheduled at least every month. This follow up will include clinical signs, ECG, biological and coagulation parameters. Moreover, patient’s cardiac rhythm will be monitored between visits using daily, then every 2 days Trans Telephonic ECG Monitoring (TTEM) reviewed by a Central Reading Laboratory.

Patients may withdraw from the study at any time without having to give a reason and can expect to receive regular conventional therapy.

4. STUDY DESIGN

4.1. OVERALL DESCRIPTION

This phase IIa trial will be conducted as an international, multicentric, 24 weeks, double-blind, placebo-controlled, randomised, parallel group design, trial in 152 patients suffering from persistent atrial fibrillation and chronic heart failure.

After a 1 to 4-week of run-in period without treatment, patients will be randomised into one of the following treatment groups: F373280 1g or placebo for 24 weeks.

Nine visits are planned for the study:

- Visit 1 (V1): W-4 to W-1: Selection visit (7 to 28 days before the Inclusion Visit)
- Visit 2 (V2): D1: Inclusion visit (start of treatment)
- Visit 3 (V3): W4 (D28 -2/+7D): cardioversion visit (outpatient or hospitalization according to clinical practice of the centre) (installation of the Holter ECG device)
- Visit 4 (V4): W5 (D35 ± 2D): follow-up visit (removing of Holter ECG device and installation of the TTEM)
- Visit 5 (V5): W8 (D56 ± 7D): follow-up visit
- Visit 6 (V6): W12 (D84 ± 7D): follow-up visit
- Visit 7 (V7): W16 (D112 ± 7D): follow-up visit
- Visit 8 (V8): W20 (D140 ± 7D): follow-up visit
4.2. DISCUSSION OF THE STUDY DESIGN

4.2.1. Choice of the Study Population

The target indication of F373280 will be the maintenance of sinus rhythm after cardioversion of patients with persistent atrial fibrillation and chronic heart failure. In the present proof of concept study, the evaluation will focus on patients within this indication. This target population is justified by:

- The proved efficacy of PUFAs in patients with persistent atrial fibrillation with or without heart failure in co-administration with amiodarone (add on therapy) [2]
- The proved efficacy of PUFAs on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]

The study aim is to investigate the product effect in patients with:

- early persistent atrial fibrillation history (less than one year) with a duration of a the current episode between 7 days to 6 months
- a moderately abnormal moderately systolic heart failure (Left Ventricular Ejection Fraction (LVEF) between 30 to 45% as defined in the report from the American Society of Echocardiography’s Guideline). According to a sub-group analysis performed in patients with persistent atrial fibrillation associated to heart failure (Nodari S. personnal data), PUFAs would be effective to prevent recurrence of AF after cardioversion in patients with moderately abnormal LVEF.

- A Left Atrial Area (LAA) not severely abnormal (less than 40 cm² as defined in the report from the American Society of Echocardiography’s Guideline). According to a sub-group analysis performed in patients with persistent atrial fibrillation associated to heart failure (Nodari S. personnal data), PUFAs would not be effective to prevent recurrence of AF after cardioversion of patients with severely abnormal LAA.

For the successful rate of electrical cardioversion, patients should have a stable medical treatment of heart failure and should not have myocardial infarction or unstable angina or
unstable ischemic coronaryopathy (assessed by coronaryography or cardiac stress test or effort test within 6 months before selection).

4.2.2. Choice of the Study Design

As the target indication would be the prevention of AF recurrence after ECV, the study design meets the requirements of EMA guideline on anti-arrhythmics on atrial fibrillation (EMA/CHMP/EWP/213056/2010) [21].

As F373280 aims to be developed as a safe treatment for the prevention of AF recurrence, it will not be tested as an add-on therapy during the study. To avoid any interaction with the tested product, anti-arhythmics class I and III will be forbidden during the study.

The study design is defined in order to avoid methodological bias. A double blind study is appropriate to assess the efficacy and safety of the use of F373280 to prevent recurrence of AF episodes. Moreover, this study design is similar to the design of almost all trials that have assessed intervention for rhythm control [2, 8, 11, 12].

According to the target indication, only patients with persistent atrial fibrillation and requiring an electrical cardioversion will be included in order to assess the time to first documented recurrence of atrial fibrillation since cardioversion.

To confirm the persistent nature of atrial fibrillation, a 24-hour holter monitoring will be performed during the selection visit.

Eligible participants will enter a selection phase in which anticoagulant treatment (anti-vitamin K) will be adjusted to achieve an International Normalized Ratio (INR) of 2.0 to 3.0 before electrical cardioversion. According to guidelines for the management of atrial fibrillation [6], anti-vitamin K should be given at least 3 weeks before cardioversion because of risk of thrombo-embolism due to post-cardioversion.

Experimental data suggest that the maximal incorporation, of n-3 PUFAs in the myocardial cell membrane takes up to 28 days to occur [22]. In addition, as shown in Nodary study [2], the duration of pre-treatment with PUFA before cardioversion appears to be a contributing factor in
success. Therefore, before starting follow up for the assessment of AF recurrence, treatment with F373280 should be started 28 days before ECV.

Detection of atrial fibrillation recurrence will be performed using systematic (scheduled) ECG recording, thus allowing detection of asymptomatic (about 50% of episodes) as well as symptomatic AF episodes. According to previous studies, most of atrial fibrillation recurrence occurred during the first days after cardioversion [11, 15]. So that, the heart rhythm will be closely monitored during the first week after successful cardioversion using an ambulatory continuous 7-day holter ECG recording in order to increase sensibility to detect asymptomatic AF episodes. Thereafter, to improve patient compliance, this follow up will be continued using a more easy to carry and easy to use device, a TTEM.

Finally, during the study, patients will be scheduled for a clinical visit every month (with an additional visit 7 days after visit 3 (ECV visit)) in order to ensure a close medical monitoring and to assess efficacy and safety parameters.

4.2.3. Choice of the Dose

According to a previous study in patients with atrial fibrillation [2], the tested PUFA product (Omacor®) at the dose of 2 g (i.e. 640 mg of DHA acid) was effective in the prevention of atrial fibrillation after cardioversion. Moreover, PUFAs at dosage of 1g and 2g were also effective on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5].

From the F373280 phase I study, after a 14-day repeated administration of F373280 (1g/day), observed plasma concentrations of DHA measured before treatment (Cmin) were similar to that of an effective dose of Omacor® at 2 g/day (60 to 95mg/mL and 60 to 90mg/mL, respectively) (phase I study of F373280 and Salm and coll study) [16]. With regard to the rhythm of administration, mean peak/trough fluctuation (baseline corrected) was around 0.3. This value supports a once-daily administration allowing a 24-hour plasma exposure in DHA. Therefore, a dose of 1 g daily of F373280 is considered to be appropriate to be tested in this POC study.
4.2.4. Choice of the Sample Size

See chapter 13.

5. STUDY POPULATION

Each patient fulfilling all the inclusion criteria and none of the non inclusion criteria will be eligible.

5.1. INCLUSION CRITERIA

Demographic Characteristics and Other Baseline Characteristics:

1. Men or women aged more than 18 years (inclusive),
2. Patient with persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted.
3. History of first documented persistent AF less than 1 year
4. History of ischemic or non ischemic heart failure
5. NYHA class I or II chronic heart failure at selection and at inclusion
6. Reduced left ventricular ejection fraction between 30% and 45% inclusive (using the two-dimensional echocardiography biplane Simpson’s rule) at selection and at inclusion
7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers
8. Left atrial area ≤ 40 cm² at selection and at inclusion
9. Patient treated or having to be treated by anti-vitamin K
10. For female patient of child-bearing potential:
    - in all the countries except Italy:
      - use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator, for at least 2 months before the selection in the study and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment or
      - documented as surgically sterilized
    
    - in Italy only:
      - absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
      - use of double barrier contraception method (use of effective medical contraception method) from at least 2 months before the start of the study to the entire duration of the study and for a month after the end of the study or
      - documented as surgically sterilized

11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion
12. For male with a child-bearing potential partner (in Italy only):
absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or

Ethical/legal considerations:
13. Having signed his/her written informed consent,
14. Affiliated to a social security system, or is a beneficiary (if applicable in the national regulation),

5.2. NON INCLUSION CRITERIA

Criteria related to pathologies:
1. History of first documented episode of persistent AF more than 1 year,
2. More than two successful cardioversions (electrical or pharmacological) in the last 6 months,
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV),
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be check in case of treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic coronaryopathy assessed by coronarography or cardiac stress test (Echo stress, exercice stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
7. Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration rate < 30 mL/min) at selection
8. Bradycardia (HR ≤ 50 bpm)
9. Hyperkalemia or hypokalemia (K > 5.5 mEq/L or K < 3.5 mEq/L) at selection
10. Cardiac surgery within 3 months before selection or planned during the study duration

Criteria related to treatments:
11. Previously ineffective pharmacological or electrical cardioversion
12. Concomitant treatment with any anti-arrhythmic drug (within 7 days prior to selection), except stable dose of digoxin, beta-blockers, calcium-blockers.
13. Previous treatment with oral amiodarone within 12 months prior to inclusion
14. Previous treatment with intravenous amiodarone within 6 months prior to inclusion
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT implantation within the last 6 months
16. Treatment with any Polyunsaturated Fatted Acid within the last 3 months
   Dietary supplement with ω3 or ω6 according to investigator’s judgment
18. Having undergone any form of ablation therapy for AF
19. Patient treated with other anticoagulant treatment than antivitamin K: thrombin inhibitor such as Dabigatran or treated with antiagregant P2Y12 inhibitors such as Clopidogrel or Prasugrel

Others criteria:
20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion,
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection,
22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself/herself to its constraints,
23. Patient family member or work associate (secretary, nurse, technician…) of the Investigator,
24. Patient having forfeited his/her freedom by administrative or legal award or being under guardianship,

5.3. NUMBER OF PATIENTS

76 x 2 patients (taking into account 15% of non evaluable patients).

5.4. RECRUITMENT MODALITIES

Patients will be recruited within the medical consultation of each centre involved in the study. If necessary and when authorized by local and national regulation, some specific supports or tools will be used to improve the recruitment (announcement, mailing to general practitioners, leaflet, website including ClinicalTrials.gov, CRO,…).

Before implementation, the documents will be submitted to and approved by the Ethics Committee.

5.5. PATIENTS IDENTIFICATION

The patient's code will contain 7 digits: the 2 first digits corresponding to the country number, the following 2 digits corresponding to the centre number and the last 3 digits corresponding to the patient's chronological order once having signed the written informed consent.

5.6. WITHDRAWAL CRITERIA

The reasons for a patient's premature withdrawal from the study may be the following:

- The patient's decision. A patient who wishes to withdraw from the study for any reason may do so at any time but must inform the investigator. In all cases, the Investigator should attempt to contact the patient as soon as possible for a final assessment in order to:
  - have the patient's decision written on the consent form
− obtain the reason(s) for withdrawal and report it/them in the case report form
− evaluate the patient's clinical condition
− if necessary, take appropriate therapeutic measures: management of an adverse effect or concomitant disease, prescription of another treatment.

• The Investigator's decision in the patient's interest. Particularly, if a serious adverse event occurs and is considered by the Investigator liable to threaten the health of the patient. The monitor will be informed by phone or fax and a letter or report explaining the withdrawal will be forwarded to the monitor as soon as possible.

• An erroneous inclusion according to the study protocol. Any inclusion not respecting inclusion / non inclusion criteria will immediately be withdrawn and an appropriate treatment will be instored by the investigator under his/her responsibility. Erroneous inclusions will not be paid to the investigator.

• Patients who could not be treated with anti-vitamin K for at least 3 weeks before ECV,

• Patients who will not stabilize INR between 2 and 3 on at least 3 consecutive weekly tests

• Patients with only 2 consecutives INR tests between 2 and 3 in the last 3 week for whom a trans-oesophageal echocardiography can not be performed before ECV or for whom a trans-oesophageal echocardiography shows a thrombus in the atria.

• Patients who will not revert to sinus rhythm or with early relapse within the observation period after ECV (i.e. unsuccessful ECV) will be considered to have finished follow-up.

• An occurrence of AF recurrence that would require, at the investigator’s judgement, a cardioversion or an introduction of an anti-arrhythmic because of intolerable and uncomfortable clinical symptoms.

5.7. REPLACEMENT OF PATIENTS

Withdrawn patients will not be replaced.
5.8. POST-STUDY EXCLUSION PERIOD

Patients will not be allowed to participate to another clinical trial during 3 months following the study termination.

5.9. STUDY CARD AND LETTER FOR GENERAL PRACTITIONER(S)

The patient will receive from the Investigating Centre at Visit 1 - Selection Visit,

- a personal card to be kept all along the study duration and providing the following information: patient's name, sponsor's name, study code, EUDRACT number, start date and expected end date of the study, complete address of the Investigating Centre with the name and phone number of the Investigator and a sponsor 24H/24 phone contact number in case of emergency (French and English languages): 33 (0)5 63 35 25 83. For Italy, this card will be in Italian only, without any English mention.

- in Italy, a letter to be given to his/her general practitioner. This letter intends to inform the general practitioner(s) (and any other doctors who take care of the patient) that the patient participates to the clinical study. It describes the study treatment and includes some information on the forbidden treatment during the study.

6. STUDY TREATMENT

The Clinical Pharmacy Department of the Institut de Recherche Pierre Fabre (IRPF) will supply the investigational centres with the treatment necessary for the conduct of the trial.

6.1. SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT

F373280 and placebo will be prepared in Soft Capsules similar presentation.

- F373280
Formulation of F373280, 1g, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: Panthenyl ester of DHA, gelatine, glycerol, titanium, dioxide, purified water.

- Placebo

Formulation of placebo matching tested product, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: paraffin liquid, fish flavour, gelatine, glycerol, titanium, dioxide, purified water.

Placebo and F373280 capsules will be packaged in opaque blisters.

6.2. PACKAGING AND LABELLING

The treatment units will be packed and labelled by the Clinical Pharmacy Department of the IRPF according to European Directive and local requirements.

6.2.1. Packaging

Each treatment unit will be composed of 3 cases for a 12-week treatment period.

The Investigator will provide the patient with the treatment according to the following schedule:

At Inclusion Visit (V2): a 12-week treatment unit will contain 3 cases, each case containing:
- 10 blister packs of four 1g F373280 soft capsules or placebo soft capsules each.

At Visit 6 (V6): a 12-week treatment unit will contain 3 cases, each case containing:
- 10 blister packs of four 1g F373280 soft capsules or placebo soft capsules each.

6.2.2. Labelling

Investigational Products will be labelled according to the following rules:

Labelling should comply with the local requirements for Investigational Medicinal Products.

On the treatment units and cases, the labels will bear the following indications:

a) name and address of the sponsor
b) protocol number,
c) packaging batch number,
d) the treatment number
e) storage conditions
f) expiry date

g) pharmaceutical dose form

h) route of administration

i) quantity of dosage units

j) direction for use

k) legal statements:
   - “for clinical trial only”, “keep out of the reach and the sight of children”, “please return to your doctor any unused product”, respect the prescribed dose”.

On the treatment unit, another label will be affixed with the mention of the investigator name and patient number (completed by the investigator).

In addition, on each case, will be mentioned the case number and a detachable label will bear the following indications:
   - Protocol number
   - Packaging batch number
   - Expiry date
   - Case number
   - Treatment number

On the blister pack, the label will mention the protocol number, the packaging batch number, the case number and the treatment number.

6.3. DISTRIBUTION TO CENTRE AND STORAGE

The Clinical Pharmacy Department of the IRPF will supply the Investigational Centre with the treatment units along the study according to the need, upon request triggered by the patient’s selection.

As soon as the Pharmacist or the Investigator receives the trial medication, he/she will check the contents and immediately acknowledges the receipt in the IVRS/IWRS. The copy of the acknowledgement will be kept in the Investigator's file. The same procedure will be applied to all further supplies during the course of the trial.

At the time of the delivery to the Centre, the following information will be provided:

- Details of storage conditions that should be respected
• And, upon request and for the 1st delivery only, a letter of release for the Investigational Medicinal Product from the Sponsor's Qualified Person.

The CRA will ensure during the monitoring visits that trial medications have been received in good conditions and the acknowledgment of receipt has been performed adequately.

Treatment units should remain intact until dispensation to the patients. They should be kept at temperature below 30°C in an appropriate lockable room only accessible to the person authorised to dispense them, under the responsibility of the Pharmacist or the Investigator.

In the case of undue delay in study execution, the Pharmacist or the Investigator should ensure that the expiry date has not been exceeded.

6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT

A randomisation list will be established by the Clinical Pharmacy Department of the IRPF. This list will be computer-generated with internal software. The randomisation methodology is validated by the Biometry Department before generation.

Treatments F373280 or placebo will be balanced in a 1:1 ratio.

As the treatment units are prepared for 12-week treatment periods, the Investigator will have to allocate a treatment number at inclusion Visit and another one at Visit 6.

For each patient, the treatment number given at Visit 6 will not be the same that the one given at inclusion visit (V2).

The treatment numbers will be given through the IVRS/IWRS.

Practically, once the patient’s eligibility is confirmed, at selection visit:

• The Investigator:
  – Calls the vocal server
  – Answers the questions relating to the patient
  – In return, the treatment number to be allocated for the first 12-week period to the patient is given by the vocal server.
• The IVRS/IWRS company:
  – Confirms this information by fax/email to the Investigator
  – Fills the “Request for Delivery of Investigational Product” form and sends it by email and/or fax to the Clinical Pharmacy Department of the IRPF.

• The Clinical Pharmacy Department of the IRPF sends the corresponding treatment unit to the Investigator within 5 days from reception of the email request form.

The Investigator will dispense to the patient the case which label indicates the treatment number and the administration period.

At visit 5, the Investigator will contact again the IVRS/IWRS to obtain for visit 6 the treatment number for the last 12-week period of treatment according to the same process as described above.

6.5. DRUG ADMINISTRATION

6.5.1. Duration of Treatment

For a patient completing the study, the theoretical study treatment exposure will be 24 weeks, with F373280 or placebo.

If the ECV is postponed by 1 week to allow INR stabilization, the treatment duration will be 25 weeks.

6.5.2. Dose Schedule

One soft capsule of 1g of F373280 or placebo to be taken each day during 24 weeks.

6.5.3. Route and Conditions of Administration

The soft capsules are to be taken orally. One soft capsule is to be taken each evening with the dinner during 24 weeks.
6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT

The Investigator should maintain accurate written records of drug received, dispensed, returned and any remaining treatment units, on the drug accountability form. These records should be made available for Clinical Research Associate (CRA) monitoring. The packaging of the medication should remain intact until just before the dispensation.

At each visit, the Investigator will record the number of soft capsules returned by each patient using the appropriate page of the e-CRF.

At the end of the study, all used and unused treatments including packaging should be noted, and return is organised by the CRA to the Clinical Pharmacy Department of the IRPF for destruction. A copy of the drug accountability form should be provided by the Investigator to the CRA.

6.7. RECALL OF INVESTIGATIONAL PRODUCTS

In case of recall of investigational products (decided by the Competent Authorities or the Sponsor), the Investigator will immediately be informed by the Sponsor.

The Investigator, in collaboration with the Sponsor representatives (Study Manager, CRA) must urgently:

- Stop the delivery of the concerned investigational products to the patients.
- Inform the concerned patients that they must immediately stop taking these investigational products and bring them back.

The Study Manager/CRA organises the return of the recalled products to the Clinical Pharmacy Department of the IRPF, according to the Sponsor’s procedures.

7. CONCOMITANT TREATMENTS

Any existing concomitant treatment (Selection Visit), any new concomitant treatment or change in the dosage of an existing concomitant treatment during the course of the study must be noted
on e-CRF. All treatments should be evaluated by the investigator at selection and their prolongation during the study or their stop should be considered.

For all concomitant treatments taken during the study, the following information must be noted in the relevant section(s) of the e-CRF:

- The name of the treatment and its form
- The reason for prescription
- The route of administration
- The daily dose
- The duration of treatment.

7.1. **ANTI-VITAMIN K TREATMENT**

Anti-vitamin K should be given for at least 3 weeks before ECV and continued for the whole study duration. The anti-vitamin K used will be left to the decision of the each investigator according to his/her local practice.

7.2. **PROHIBITED TREATMENTS**

- Class I and class III antiarrhythmic treatments:
  - Class I
    - Class IA: Disopyramide, Procainamide, Quinidine
    - Class IB: Lidocaine, Mexiletine
    - Class IC: Flecaïnide, Propafenone
  - Class III: Dofetilide, Ibutilide, Sotalol, Amiodarone, Dronedaron.
- Any Polyunsaturated Fatty Acid (PUFA)
- Any anticoagulant treatment other than antivitamin K: thrombin inhibitor such as Dabigatran or antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel
- Dietary supplement with Omega 3 or Omega 6

Prohibited treatments at selection must not be prescribed for the duration of the study except in case of occurrence of an adverse event or AF episode that requires a corrective treatment in the interest of the patient’s health.
7.3. **AUTHORISED TREATMENTS**

Other treatments will be authorised during the study duration.

However, if medication other than study drugs is administered at any time from the start of the study, details must be recorded in the case report form. During the study, patients must be asked whether they have been on a course of prescribed drug treatment or have taken any OTC or herbal drugs since the visit.

8. **EVALUATION CRITERIA**

8.1. **PRIMARY EFFICACY CRITERION:**

8.1.1. **Time to the first Atrial Fibrillation Recurrence**

8.1.1.1. **Definition**

Time to first Atrial Fibrillation recurrence is defined by the first episode of Atrial Fibrillation (symptomatic or not) lasting for at least 10 minutes.

8.1.1.2. **Schedule**

The heart rhythm follow up will be performed from the end of electrical cardioversion visit (visit 3) to the final study visit (visit 9).

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF will be assessed after visit 3 (week 5).

8.1.1.3. **Evaluation Methods**

- 7-day holter monitor:

The heart rhythm monitoring will be carried out from visit 3 to visit 4 using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) fixed after ECV visit.

Following holter monitoring the heart rhythm will be documented using Trans Telephonic ECG Monitoring (TTEM)
• Trans Telephonic ECG Monitoring (TTEM):

Thus, the follow up will be documented using the TTEM: daily transmission from visit 4 (week 6) to visit 5 (week 8). Then, every two days from visit 5 (week 8) to visit 9 (week 24 – End of study).

Moreover, during this TTEM period, if patient experiences AF symptoms, it should be documented using the TTEM.

In case of AF recurrence, and provided that the patient does not required a cardioversion or an introduction of an anti-arrhythmic at the investigator’s judgement, he/she could be maintained in the study with the treatment, in order to assess a spontaneous cardioversion. For that purpose the patient will continue to transmit a TTEM once a week.

The TTEM will be centralized by the Central Reading Laboratory. The patient will be requested to contact the Central Reading Laboratory for transmission of each stored TTEM. The TTEM will be validated by a trained technician, then analysed by a cardiologist. The cardiologist interpretation will be faxed to the site. The investigator will be asked to review and sign this document.

The TTEM process will be fully described in a separate document.

8.1.2. Secondary Efficacy Criteria

8.1.2.1. Numbers of Atrial Fibrillation episodes in the first week following visit 3 (ECV visit)

8.1.2.1.1. Definition

Number of Atrial Fibrillation episodes will consist in the assessment of episodes of AF with duration at least 10 minutes (N_{Sup10}) and of less than 10 minutes (N_{Inf10}), respectively.

8.1.2.1.2. Schedule

The heart rhythm follow up will be performed from the end of successful electrical cardioversion visit (visit 3) to the study visit 4.
8.1.2.1.3. **Evaluation Methods**
- 7-day holter monitor:

The heart rhythm monitoring will start using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) after ECV visit from visit 3 to visit 4.

8.1.2.2. **Duration of Atrial Fibrillation episodes in the first week following visit 3 (ECV visit)**

8.1.2.2.1. **Definition**
Duration of AF episodes will consist in the sum of duration of each AF episodes.

8.1.2.2.2. **Schedule**
The heart rhythm follow up will be performed from the end of successful electrical cardioversion visit (visit 3) to the follow up study visit (visit 4).

8.1.2.2.3. **Evaluation Methods**
Duration of AF episodes will be assessed using the 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording.

8.1.2.3. **Clinical parameters evaluation**

8.1.2.3.1. **EHRA score assessment**

8.1.2.3.1.1. **Definition:**
AF related symptoms will be evaluated by the EHRA (European Heart Rhythm Association) score [20]. The following items “during presumed arrhythmia episodes” are checked to determine the score: palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety.

Classification of AF-related symptoms (EHRA score) are as follows:

- **EHRA I** - ‘No symptoms’
- **EHRA II** - ‘Mild symptoms’; normal daily activity not affected
• EHRA III - ‘Severe symptoms’; normal daily activity affected
• EHRA IV - ‘Disabling symptoms’; normal daily activity discontinued

This classification relates exclusively to the patient-reported symptoms.

In addition to this score, the frequency will be classified in three groups, namely occasionally (less than once per month); intermediate (1/month to almost daily); and frequent at least daily.

8.1.2.3.1.2. Schedule

This evaluation will be performed in case of symptoms evocative of arrhythmia.

8.1.2.3.1.3. Evaluation Methods

This evaluation will be collected by Central Reading Laboratory during all the study period.

8.1.2.3.2. Number of recurrence of symptomatic AF

It consists of number of AF recurrence associated with a symptom (Palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety) and confirmed by an ECG in atrial fibrillation.

8.1.2.3.3. Number and duration of hospitalization

• Number and duration of hospitalization for cardiovascular events
  – Hospitalization for AF treatment
  – Hospitalization for worsening of heart failure
  – Hospitalization for myocardial infarction
  – All cause of hospitalization

• Number and duration of hospitalization for thromboembolic stroke

8.1.2.4. Cardioversion assessment

• Assessment of spontaneous cardioversion before visit 3

• Assessment of successful cardioversion at visit 3 (i.e. return to sinus rhythm)

• Shock distribution (1, 2 or 3 shocks)
8.1.2.5. **Evolution of echocardiographic parameters**

8.1.2.5.1. **Definition**

The following echocardiographic parameters will be assessed: Left atrial diameter (mm), Left atrial area (cm²), Left atrial volume (mL), Left atrial volume/BSA (mL/m²), Left ventricular ejection fraction (%), Left ventricular volume (mL), Left ventricular volume/BSA (mL/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL), Left ventricular end systolic diameter (mm) and Left ventricular end systolic volume (mL).

8.1.2.5.2. **Schedule**

The measurements will be performed at visit 1 and visit 2 to check the eligibility of the patient.

The measurements performed at visit 4, visit 6 and visit 9 are done to follow the echocardiographic evolution of the patients in sinus rhythm.

8.1.2.5.3. **Evaluation method**

The echography evaluations will be carried out according to the recommendations for chamber quantification drawn up by the American Society of Echocardiography and the European Association of Echocardiography [23]. So, for volume measurements, the recommended method is to use the biplane method of discs (modified Simpson’s rule) from 2-D measurement.

8.2. **BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA**

8.2.1. **Definition**

Because of the limited accessibility of human tissues for biopsy, red blood cell DHA contents is a marker for tissue DHA concentration [13], [14].
8.2.2. Blood samples

8.2.2.1. Collection schedule

Blood samples will be collected for determination of red blood cells (RBC) concentrations of DHA.

Blood samples will be performed as follows:

- Visit 2 before treatment, visit 3, visit 6 and visit 9.

Actual sampling times will be individually reported in the electronic Case Report Forms (e-CRFs).

8.2.2.2. Technical handling

Two blood samples (4ml) will be collected in tubes containing EDTA. They will be gently shaken, stored at +4°C (no freezing will be allowed) and sent to Analytical Centre in refrigerated conditions (between +2°C and +8°C). Analysis will be performed within 2 weeks following reception at the Analytical centre.

8.2.3. DHA concentration measurement

Analytical determination of RBC concentrations of DHA will be carried out by the Analytical Centre.

Lipids will be extracted from red blood cells samples with a mixture of hexane/isopropanol, after acidification [17]. Total lipid extracts will be saponified and methylated. The fatty acid methyl esters (FAME) will be extracted and analyzed by Gas Chromatography.

Identification of FAME will be based on retention times obtained for FAME prepared from fatty acid standards. The area under peaks will be determined using ChemStation Software (Agilent) and results will be expressed as % of total fatty acids. DHA concentration will be calculated using the internal standard and expressed as µg/g for red blood cells samples. Thus, omega-3 index will be assessed. The omega-3 index represents the content of EPA plus DHA in red blood cells.
(expressed as a percent of total fatty acids). It is a biomarker considered as a new marker of risk for death from coronary disease [18].

Results of this analytical determination will be kept confidential by the dosing centre until the end of the study, and will be provided only at the end of the study (after database lock), in a separate file.

8.3. SAFETY ASSESSMENT

8.3.1. Adverse Events

At selection, any concomitant disease will be reported on the e-CRF. At each further visit, the occurrence of adverse events (AEs) since the last visit will be based on the patient's spontaneous reporting, the investigator's non-leading questioning and his/her clinical evaluation. All AEs will be reported on the e-CRF (see section 10).

8.3.2. Laboratory Investigations

8.3.2.1. Schedule

Laboratory investigations will be performed at visit 1 (before treatment) and visit 9 (end of treatment) or End of Treatment visit.

At visit 3 and 6, only a standard haematologic dosage will be performed.

Furthermore the kaliemia will be checked before electrical cardioversion at visit 3.

The volume of blood samples complete haematology, biochemistry should not exceed 30 mL.

8.3.2.2. Technical Procedures and Parameters

The following tests will be performed:

Haematology: Hematocrit, haemoglobin, Red blood cells (RBC) count, white blood cells (WBC) count, WBC differential counts (% and absolute), reticulocytes, platelets.
Chemistry: sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatine phosphokinase (CPK), fibrinogen.

Blood samples will be taken in the morning, in fasting conditions.

The estimation of GFR at selection relies on the measurement of serum creatinine and the Cockcroft-Gault formula

Cockcroft-Gault formula
- with serum creatinine expressed as mg/L:
  in men: 
  \[ \text{GFR (mL/min)} = \left(\frac{140 - \text{age}}{7.2} \times \frac{\text{weight}}{\text{serum creatinine in mg/L}}\right) \]
  in women: 
  \[ \text{GFR (mL/min)} = \left(\frac{140 - \text{age}}{7.2} \times \frac{\text{weight}}{\text{serum creatinine in mg/L}}\right) \times 0.85 \]
- with serum creatinine expressed as \( \mu \text{mol/l} \):
  \[ \text{GFR (mL/min)} = \left(\frac{140 - \text{age}}{\text{serum creatinine in } \mu \text{mol/l}}\right) \times k, \text{where } k = 1.23 \text{ for men, 1.04 for women.} \]

(weight in kg, age in years)

Additional tests may be done at the Investigator’s discretion, in the patients’ interest. In case of any abnormal or clinically significant results, the Investigator will order laboratory control tests.

8.3.3. Global Physical Examination

A global physical examination including the measurement of body weight will be carried out on each body system at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.

The physical examination will be globally evaluated as “normal/abnormal”. Further target inspection will be undertaken for any abnormal finding.

8.3.4. Vital Signs

Vital signs will consist in blood pressure and heart rate at rest.
8.3.4.1.  **Schedule**

Vital signs will be measured at each visit.

8.3.4.2.  **Technical Procedure and Parameters**

Systolic (SBP) and diastolic (DBP), expressed in mmHg, will be measured after at least 5 minutes in supine position and after 2 minutes in standing position.

The heart rate (HR), expressed in beats per minute (bpm), will be measured by auscultation, after at least 5 minutes in supine position and after 2 minutes in standing position by counting the beats for at least 30 seconds.

Bodyweight will be measured in patient in underwear and with the same balance at each visit.

8.3.5.  **Electrocardiogram (ECG)**

8.3.5.1.  **Schedule**

An electrocardiogram will be recorded at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9 using an usual standardised 12-lead cardiograph.

8.3.5.2.  **Technical Procedure and Parameters**

- Electrocardiogram (ECG):

  The global interpretation from manual reading (normality, clinical relevance) and heart rate (bpm), PR (ms), QRS (ms), QT (ms), repolarisation patterns will be reported in the e-CRF. Each print-out will include the patient’s code, date, time, technician's initials and investigator's signature.

  In case of thermic paper ECG print out, a photocopy will be made by the centre to ensure safe filing.

- 24 hour-Holter - ECG

  An ambulatory continuous 24-hour ECG (5-leads/2 or 3 channels) will be recorded at selection visit using a holter ECG, in order to confirm persistent atrial fibrillation.
8.3.6. Coagulation parameters

The assessment of coagulation will be evaluated by the following parameters:

- Prothrombin Time/INR (PT/INR)
- Activated Partial Thromboplastin Time (aPTT)
- Thrombin Clotting Time (TCT)

During the pre-cardioversion period, if the anticoagulation by AVK should be initiated, then the INR monitoring will be as follow:

- INR 2-3 times a week for the first week of treatment
- INR weekly up to ECV,
- INR every 4 weeks after ECV

For patients already treated with AVK, INR monitoring will be as follow:

- INR weekly up to ECV,
- INR every 4 weeks after ECV

aPTT and TCT will be performed at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.

Anti-coagulation by anti-vitamin K should be given at least 3 weeks before ECV and continued for the whole study duration.

The quantity of blood samples collected at each time for coagulation parameters will be 2 mL.

8.3.7. Concomitant Treatments

Concomitant treatments will be evaluated at each study visit.

Requirements relating to patient's concomitant treatments started before screening visit and continued throughout the trial, or started during the trial can be found in section 7.

8.4. COMPLIANCE

The patient will be reminded at each visit to bring back any remaining soft capsules, blister, case (used or unused) at the following visit.

At each visit, the Investigator will record the number of supplied and remaining Soft Capsules in the e-CRF.
9. STUDY PROCEDURES

Visit 1 - Selection Visit (Week -4 to Week -1)

The patient considered eligible for selection by the Investigator will be informed of the characteristics and the consequences of the trial both verbally and by reviewing the patient's information sheet and consent form (see section 14.3). If he/she accepts to participate in the study, he/she will sign the informed consent and will keep a copy.

The patient will be assessed for the following:

- Demographic characteristics (gender, age, height, body surface area)
- Personal and medico-surgical history
- Habits (Tobacco, alcohol consumption, dietary habits including fish consumption…)
- Cardiovascular diseases, mainly detailed history of Heart Failure and Atrial Fibrillation characteristics
- Echocardiography using a two-dimensional echocardiography.
- 12-lead ECG
- Concomitant diseases, adverse signs or symptoms (able to be used for treatment emergent AE determination)
- Concomitant treatments (authorised, disallowed)
- Global physical examination/bodyweight
- Vital signs
- Biology: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Biology assessment of renal function: creatinine or estimated glomerular filtration rate

If the results of the above assessments are compatible with the selection criteria
• A 24-hour continuous ECG ambulatory recording (Holter ECG) device will be installed on the patient to monitor the patient heart rhythm. The patient will be requested to bring back the device after the termination of 24 hours recording. The recording will be transmitted from the Investigational site to the Central Reading Laboratory (CRL). The CRL will send his/her assessment regarding the confirmation of persistent atrial fibrillation within 2 working days to the Investigator.

• The patient will enter the selection period in which anticoagulant (anti-vitamin K) will be adjusted to achieve an International Normalized Ratio (INR) of 2 to 3 before electrical cardioversion.

At the end of the visit, the Investigator will contact the IVRS/IWRS system to confirm the patient selection and order the treatment delivery and organise the appointment for the next visit.

The patient will receive from the investigational centre the study card to be kept for the duration of the study.

Visit 2 - Inclusion Visit (Day 1)

If the patient's behaviour during the selection period and/or the result of complementary examinations particularly the confirmation of the presence of persistent atrial fibrillation by the CRL during this period, the INR and laboratory tests, are compatible with the inclusion criteria, the patient will be assessed for the following:

• Adverse events

• Concomitant treatments (authorised, disallowed)

• Laboratory examination: red blood cell concentrations of DHA and coagulation parameters Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)

• Global Physical examination/bodyweight

• Vital signs

• Echocardiography using a two-dimensional echocardiography.
• 12-lead ECG
• Urine pregnancy test for women of child bearing potential.

If the results of the above assessments are compatible with the inclusion criteria, the patient will be included and allocated a treatment number using the IVRS/IWRS system.

Between this Inclusion visit and the next visit (V3), the INR will be closely monitored (refer to paragraph 8.3.6), in order to ensure that the INR is stable, between 2 to 3 before electrical cardioversion.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week period.

Visit 3 (Week 4: D28 -2/+7 days) cardioversion

Patient will be assessed for the following criteria:

• Adverse events
• Concomitant treatments (authorised, disallowed)
• Laboratory examination: Haematology, Red Blood Cell concentrations of DHA, Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
• Global Physical examination /bodyweight
• Vital signs
• 12-lead ECG
• Electrocardioversion (ECV): ECV has to be scheduled 4 weeks after randomization and after target international normalized ratio levels will be stabilized (between 2 and 3) on at least 3 consecutive weekly tests in patients with AF. Patients not stabilized for INR (i.e. values not between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed in the same day (before ECV). ECV will be performed in the morning, with the patient in the fasting state and without dyskalemia. Anesthesia will be
induced and patients will be cardioverted with administration of a synchronized, biphasic current. The initial shock will be set at 100 J if the body weight is less than 70 kg and at 150 J for higher body weights. Successful cardioversion will be defined as recovery of sinus rhythm lasting at least 1 minute after the shock. If unsuccessful, a second 200-J shock, and eventually a third 200-J shock, will be administered. Failure of ECV is defined as the persistence of AF after the third attempt at cardioversion. After the procedure, patients will be monitored on telemetry for at least 6 hours before discharge. Patients who will not revert to sinus rhythm or with early relapse within the observation period after ECV will be withdrawn from the study and will be considered to have finished their follow-up.

At the end of the visit, a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) will be installed on the patient in order to monitor the patient heart rhythm after ECV.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week period.

Visit 4 (Week 5: D35 ± 2 days)

After removal of the continuous ECG ambulatory device, the patient will be assessed for the following criteria:

- Assessment of Adverse Events
- Concomitant treatments (authorised, disallowed)
- Vitals Signs
- Echocardiography using a two-dimensional echocardiography

At the end of the visit, the patient will be given the TTEM device (Trans Telephonic ECG Monitoring) for cardiac monitoring. The patient will be clearly instructed on the frequency and modalities of transmission. The patient will be requested to performed daily transmission from week 6 to week 8, then every 2 days from week 9 to week 24. Moreover, in case of AF symptoms additional transmission may be performed.
Visit 5 (Week 8: D56 ± 7 days) – Visit 6 (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days) - Visit 8 (Week 20: D140 ± 7 days)

Patient will be assessed for the following criteria:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT). However, in case of discontinuation of anticoagulation after ECV, the monitoring of INR, aPTT and TCT should be stopped.
- Global Physical examination/bodyweight
- Vital signs
- 12-lead ECG
- The cardiac monitoring will be continued using a TTEM device (Trans Telephonic ECG Monitoring). The device will be given to the patient who will be requested to performed daily transmission from week 6 to week 8, then every 2 days from week 9 to week 24. Moreover, in case of AF symptoms additional transmission may be performed.

The Investigator will collect all the cases, blisters and any unused soft capsules and count the unused capsules for each 4-week treatment period.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week treatment period.

In addition:

- at visit 5, the investigator will contact the IVRS/IWRS to obtain another treatment unit to be dispensed at visit 6 for the last 12-week period.

- at visit 6, an echocardiography will be performed, an haematology examination will be done and the red blood cell concentration of DHA will be measured.
End-of-Study Visit - Visit 9 (Week 24: D168 ± 7 days)

Patient will be assessed for the following:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Global Physical examination/bodyweight
- Vital signs
- 12-lead ECG
- Laboratory examination: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT). Red blood cell concentration of DHA.
- Urine pregnancy test for women of childbearing potential
- Echocardiography using a two-dimensional echocardiography

The Investigator will collect all the cases, blisters and any unused soft capsules and count the unused soft capsules.

10. ADVERSE EVENTS: DEFINITION AND REPORTING

10.1. ADVERSE EVENTS

10.1.1. Definition of Adverse Events

An adverse event is any adverse change from the patient's baseline condition, i.e. any subjective signs and symptoms or change in a concomitant disease present at the Selection Visit considered or not related to the treatment.

This includes intercurrent signs, symptoms, illnesses and significant deviations from baseline for vital signs and laboratory values, which may occur during the course of the clinical study.

All laboratory tests for which abnormal results are collected after study treatment initiation should be repeated until the values return to normal or to a stable status. Abnormal results are defined as
those falling out of the laboratory normal ranges and that are clinically significant. The frequency of such checks should be defined by the Investigator according to the degree of abnormality.

In all cases, the aetiology should, as much as possible, be identified and Pierre Fabre Médicament notified.

10.1.2. Grading of Adverse Events

Adverse or intercurrent events are graded as follows:

- Mild: awareness of signs or symptoms, but easily tolerated
- Moderate: uncomfortable enough to cause interference with usual activity
- Severe: incapacity with inability to work or do usual activity.

10.1.3. Reporting of Adverse Events

The records of adverse events in the electronic Case Report Form (e-CRF) describe the nature (diagnosis, signs and symptoms), severity, onset date, stop date, outcome and actions taken, and relationship to study treatment (in the Investigator's opinion). It must be specified whether the event is serious or not.

10.2. SERIOUS ADVERSE EVENTS (SAE)

10.2.1. Definition

A serious adverse event (SAE) includes, but is not necessarily restricted to any event which:

- Results in death (whatever may be the cause)
- Is life-threatening
- Results in persistent or significant disability/incapacity
- Requires the patient's hospitalisation or prolongation of current hospitalisation *
- Is a congenital anomaly or birth defect.
Other events such as cancer, and any additional adverse experience or abnormal laboratory values occurring during the study period, defined by the protocol as serious or which the Investigator considers significant enough, or that suggest a significant hazard, contra-indications, side effect or precaution, must be handled as serious adverse events.

Any overdosage meeting a seriousness criteria should be reported as a SAE (see section 10.3).

Any pregnancy occurring during/after exposure to the study drug(s) should be reported on the SAE notification form (see section 10.4).

* any hospitalisation, or prolongation of hospitalisation due to the circumstances listed below:
  - planned (as per protocol) medical/surgical procedure,
  - preparation for routine health assessment/procedure (e.g. routine colonoscopy),
  - planned medical/surgical admission (planned prior to entry into study trial, appropriate documentation required),
  - administrative or social reasons (e.g. lack of housing, economic inadequacy, care-giver respite, family circumstances)

will not be reported as a SAE.

10.2.2. Reporting of SAE

All serious adverse events, according to the above-mentioned definitions and regardless of treatment or relationship to study drug, must be recorded by the Investigator as soon as he/she is informed of the event.

The Investigator must notify the Sponsor of this event by sending, within 24 hours, the "Notification of serious adverse event" form ("first notification") (see appendix 17.2) with all the available information about the event, to the Sponsor's representative:

Gaëlle ALCARAZ
INSTITUT DE RECHERCHE PIERRE FABRE,
Centre de R&D Pierre Fabre – BP 13562
3 Avenue Hubert Curien
31035 TOULOUSE Cedex 1
Phone: +33 5 35 50 62 16
Fax: + 33 5 34 50 65 92
Email: gaelle.alcaraz@pierre-fabre.com
In case of non-inclusion the reporting period ends when the non-inclusion is documented.

10.2.3. Follow-up of SAE

The Investigator must draw-up a specific clinical report and use the "Notification of serious adverse event" form ("follow-up") (see appendix 17.2) and collect the results of the carried out examinations and the reports of hospitalisation.

The serious adverse events must be followed up until resolution or stabilisation.

10.2.4. SAE Occurring After the Study

Any SAE occurring during 30 days following the end of the study for the patient should be notified to the Sponsor.

Must also be notified to the Sponsor any event occurring at any time after the end of the study for the patient which may be related to the study treatment in the Investigator's opinion.

10.3. REPORTING OF OVERDOSAGE TO THE SPONSOR

For the purpose of this trial an overdosage will be defined as any dose exceeding the planned prescribed dose of the study drug or the administration of any dose of an associated product that is considered both excessive and medically important.

In the absence of seriousness criteria, the overdosage, and associated adverse event if any, are reported only on the Adverse Event page of the CRF. If the definition of seriousness criteria is met, the SAE notification form must be also transmitted to the sponsor.

10.4. REPORTING OF PREGNANCY TO THE SPONSOR

Pregnancies discovered in the period in between the informed consent form signed but before any study drug exposure are not to be reported to the sponsor unless associated to a seriousness criteria (e.g. serious adverse event study-protocol related procedure). If pregnancy is confirmed, the women must not be administered the study drug and be withdrawn immediately from the study.
If pregnancy is suspected while the patient is receiving study treatment, the study drug(s) should be discontinued immediately until the result of the pregnancy testing is known. If pregnancy is confirmed, then the study treatment is permanently discontinued in an appropriate manner and the patient is discontinued from the study.

The investigators must report to the sponsor any pregnancy which occurs during or after the patient has been exposed to the study drug and until 30 days after the last study drug administration. The investigator must immediately notify the sponsor using the SAE notification form and also report the pregnancy on the AE page of the e-CRF.

Women who become pregnant after exposure to the study drug must be followed by the investigator until the completion/termination of the pregnancy. If the pregnancy goes to term, the outcome will have to be reported to the sponsor (baby's healthy status).

10.5. SPONSOR'S RESPONSIBILITIES FOR SAFETY REPORTING PURPOSES

Sponsor will submit expedited and periodic reports to both Competent Authorities and Ethics Committees per corporate standard operating procedures as regards to the EU directive 2001/20/EC taking into account local specific requirements.

11. DATA COLLECTION AND STUDY MONITORING

11.1. DATA COLLECTION

11.1.1. Case Report Form

An electronic Case Report Forms (e-CRF) will be used to record all patient data required by the protocol except the central ECG (Holter ECG, TTEM) and DHA data which will be transferred from vendors to the subcontractor as electronic data files and which will be loaded into the study database.

The e-CRF should be fully validated, compliant with ICH-GCP requirements and European regulations and include a traceability system for data corrections and deletions (audit trail).
Prior to the start of the study, the Investigator will complete a "Delegation of significant study-related duties" form. The signature and initials of all personal in charge of e-CRF completion should be recorded on this form. Each person involved in e-CRF completion, review, correction and / or validation will be trained and will have an individual login and access code to the e-CRF.

Training sessions will be held by the subcontractor for all participants who will use this tool. An e-CRF user manual will be available for investigators and CRAs.

All the information included into the e-CRF will be recorded from source documents onto the e-CRF by an authorised person.

The Investigator is responsible for the management and accuracy of the information on the e-CRF. At each monitoring visit, the e-CRF(s) should be at the CRA's disposition for review and validation.

At the end of the study, a CD-ROM containing the pdf version of all e-CRF (including audit-trail) will be sent by the subcontractor to the Sponsor and to the investigational sites for archiving. The subcontractor must store all study data for at least 15 years after the end of the study and ensure their legibility and accessibility during all the storage period.

11.1.2. Source Documents

A source document is an original record or certified copy of an original record of clinical findings, observations or any other medical or paramedical activities performed during the clinical trial, necessary for the transcription and the verification of the collected data.

Source documents along with all other trial-related documents (copies of all "informed consent" forms, e-CRFs CD-ROM, drug inventories and any correspondence related to the study) must be kept in the investigator's file throughout the study, and then, must be stored in the study centre's archives for a period of at least 15 years or as per local legal requirements, whatever is the longest.

For further details see section 15.2.
11.2. STUDY MONITORING

11.2.1. Monitoring visits

On-site visits will be carried out by a representative of the Sponsor's staff (Study Manager or CRA) prior to study initiation and at regular intervals (every 4 to 6 weeks) throughout the study. Additional visits and communication by telephone, fax or meeting may be performed if necessary. Any site visit performed by the Sponsor's representatives will be recorded in the Investigator's study file.

11.2.1.1. Site Preselection Visit

Before selecting a centre for the study, a visit will be carried out by the CRA and/or the Study Manager to ensure that the Investigator has the necessary capacities (availability, patient's recruitment, environment), technical means and staff to carry out the study.

11.2.1.2. Initiation Visit

Before the start of the study at all investigation sites, an initiation visit will be carried out by the CRA to check at the latest that:

- The Investigator:
  - has received the technical protocol, administrative and financial agreement signed by all parties
  - has received the written statement of the Ethics Committee approval and the list of its members and their functions
- The original dated and signed curriculum vitae of the investigator(s) has been collected
- Laboratory normal ranges have been collected
- All study materials are available on the study site
- All participants agree with the monitoring procedures and know the study procedures
- All participants are aware of a possible audit or inspection
The CRA has also to provide training on the study protocol requirements and study specific procedures.

11.2.1.3. **Follow-up Visits**

Throughout the study, regular follow-up visits will be carried out by the CRA to check compliance with GCP, patient’s informed consents, strict application of the protocol, conformity of the data entered on the e-CRF with the source documents and ensure its correct completion, adverse events reporting, proper retention, storage and management of the study medication, as well as the source and other trial-related documents.

11.2.1.4. **Closing Visit**

At the end of the study, a final visit will be carried out by the CRA to:

- Verify that the e-CRFs CD-ROM with pdf files are correctly stored
- Control the accountability of intact and used treatment units and return them to the Clinical Pharmacy Department of the IRPF for destruction
- Obtain the last data clarifications and/or solutions if any
- Collect the patient's consent forms in sealed envelopes (except in case of specific country requirements),
- Make an on-site review of all study documentation and complete it if necessary
- And finally, remind the Investigator of his regulatory obligations, study document archiving process and duration.

11.2.2. **Direct Access to Source Documents**

In accordance to the requirements of the GCP, all Sponsor representatives (Study Manager, CRA and Auditors) have to be given a direct access to all source and study data to perform quality monitoring/audit, thus ensuring accuracy and completeness of data).

Investigators are reminded that all Sponsor representatives keep professional confidentiality with regards to the patient data.
11.3. INDEPENDENT DATA MONITORING COMMITTEE

An Independent Data Monitoring Committee (IDMC) will be established to assess at intervals the progress of the clinical trial, the compliance with the inclusion criteria, the quality of follow up, the quality of measures of primary end point, the safety data and to recommend to the Sponsor whether to continue, modify, or to stop the study.

The IDMC operating procedures will be described in an independent document.

12. DATA MANAGEMENT

All clinical data related to the study will be collected and saved in a computerised database by the Data Management Department of the subcontractor and under the supervision of the Data Manager of Pierre Fabre Biometry (PFB) according to the following procedures.

12.1. DATA ENTRY

All required data will be collected by the Investigator or authorised designee (duly identified into the delegation task list) on a e-CRF.

The e-CRF used for this study will be developed and maintained by the Data Management Department of the subcontractor and approved by the Sponsor.

Electronic data (Holter ECG, TTEM and DHA) will be transferred by the 3rd party vendor according to the specifications given by the Data Manager of the subcontractor. These data will be captured and handled in accordance with the European GCP ICH E6 guideline.

12.2. DATA CLEANING

The subcontractor will define in the Data Validation Plan for reviewing and querying data, descriptions of both manual and electronic edit checks. Upon Sponsor approval, the subcontractor will program the checks.
The subcontractor will review the data over the course of the study, working with the Sponsor to identify data inconsistencies. The Investigator will be asked to resolve queries by making changes directly into the e-CRF.

12.3. DATA CODING

Adverse events, concomitant diseases, medical/surgical histories will be coded by the subcontractor using the MedDRA dictionary (latest version in use).

Concomitant medication will be coded by the subcontractor using the WHO-DRUG dictionary (latest version in use).

The Sponsor Clinical Development Physician will validate coding.

12.4. DATA STORAGE

The computer data files, as well as their modifications, will be archived by the subcontractor and kept available upon request of the Sponsor.

12.5. DATABASE LOCK

The validated database will be locked by the subcontractor upon request of the Data Manager of PFB following the completion of all steps required, i.e.: data entry and check of all data, resolution of all queries, validation of the coding, Clinical and Products Safety databases reconciliation and validation committee.

Then, the subcontractor will transfer the locked database in SAS format to the Data Manager of PFB who assume storage on the PFB secured server.

13. STATISTICAL ANALYSIS

After the database lock and the randomisation code release, the statistical analysis will be performed by Pierre Fabre Biométrie (PFB) or under the supervision of the statistician of PFB using SAS® software, according to the Statistical Analysis Plan (SAP) approved by the Validation Committee.
13.1. GENERAL CONSIDERATIONS

The main objective of the study is to assess the efficacy of F373280 versus placebo on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure.

Only the primary analysis of the primary efficacy criterion, on which is based the sample size justification, may lead to a causal interpretation. All other statistical results are to be regarded within a descriptive perspective.

The statistical significance level of the various two sided tests of all analyses will be 5 %.

13.2. SAMPLE SIZE

Assuming an AF recurrence rate of 85% under placebo and 65% under active group, i.e. a clinically relevant difference $\Delta$ of 20%, a sample size of 64 evaluable patients per group is required, using a log-rang test of survival curves with a 80 % power and a 5 % two-sided significance level.

According to the previous assumptions and assuming a rate of not assessable patients of 15%, a minimum of 76 patients will have to be randomised per group.

13.3. PROTOCOL DEVIATIONS

Prior to the database lock and the randomisation code release, the Validation Committee members will review the protocol deviations and will classify them as either minor or major. A protocol deviation will be considered major when it is likely to bias significantly the treatment effect estimate based on the primary efficacy criterion.

Patients with major deviation(s) will be excluded from the Per Protocol data set (see section 13.4).

A listing of all protocol deviations will be provided for all randomised patients, including the type (major/minor) of protocol deviations according to the decisions made by the members of the Validation Committee.
The number and percentage of patients with major protocol deviations will be tabulated by treatment group and type of major protocol deviations on the Full Analysis Set defined in section 13.4.

13.4. DATA SETS ANALYSED
The following 2 data sets will be analysed (as defined by the Validation Committee):

- The Safety Set composed of all randomised patients having received at least one dose of the study treatment. This data set will be used to perform analyses of Safety.
- The Full Analysis Set (FAS) composed of all randomised patients having received at least one dose of the study treatment and with a successful cardioversion observed at visit 3. This data set will be used to perform analyses of Efficacy.
- The Per Protocol Set (PP) which is the subset of the Full Analysis Set composed of all patients with a primary efficacy criteria available and without any major protocol deviation or other source of bias for primary criteria analyses.

13.5. HANDLING OF DROPOUTS AND MISSING DATA

13.5.1. Dropouts
The number of patients who withdraw from the study after their randomisation will be provided by treatment group for all treated patients (Safety Set). All withdrawn patients will be further described regarding their time to dropout and reasons for withdrawal.

13.5.2. Repositioning of Visits
No repositioning of visits will be done.

13.5.3. Missing Data
Missing values will not be substituted by estimated values, but considered as missing in statistical analysis.
13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS

Before the first trial drug intake, patient’s background, medical and surgical history, demographic data and disease characteristics will be described by treatment group on the Safety Set.

- **Quantitative parameters** will be described by treatment group and overall using the following: number of patients, number of missing data, mean, standard deviation, minimum, median and maximum values.

- **Qualitative parameters** will be described by treatment group and overall using frequencies.

Concomitant diseases, as well as medical and surgical histories will be tabulated descriptively by treatment group and overall using the MedDRA codes of System Organ Classes and preferred terms.

If more than 10% of patients are excluded from the FAS and PP set, the description of patients by treatment group at selection and inclusion will be repeated on the FAS and PP set for all parameters.

No statistical test of comparability of treatment groups at baseline will be performed.

13.7. EFFICACY ANALYSIS

13.7.1. Primary Criterion

13.7.1.1. Primary Analysis

The primary criteria, time to first recurrence, will be analysed using the Kaplan Meier method and compared with the Log rank test. Hazard ratios and 95% confidence intervals will be estimated with the Cox regression model.

The primary analysis will be performed on the FAS.

13.7.1.2. Supportive Analysis

The primary analysis will be repeated on the PP set.
13.7.2. Secondary Criteria

All secondary analyses will be performed on the FAS. If more than 10% of patients are excluded from the PP set, the secondary analyses will be repeated on the PP set.

13.7.2.1. Numbers of Atrial Fibrillation Episodes

Both the numbers of AF episodes (symptomatic or not) lasting for at least 10 minutes and with duration less than 10 minutes ($N_{\text{Sup10}}$ and $N_{\text{Inf10}}$) will be described by treatment group and compared by the chi-square test (or CMH test adjusted for centre) or Fisher’s exact Test.

13.7.2.2. Duration of Atrial Fibrillation Episodes

The duration of all AF Episodes will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centres effects) or Wilcoxon test.

13.7.2.3. Time to first AF recurrence less than 10 minutes or symptomatic

The time to the first AF recurrence less than 10 minutes and the time to the first symptomatic AF recurrence will be analysed as the primary analysis.

13.7.2.4. Clinical parameters evaluation

The EHRA score will be described by treatment group and analysed using a chi-squared test (or CMH test adjusted for centre) or Fisher’s exact Test.

The frequency of presumed arrhythmia will be described by treatment group.

The number of recurrence of symptomatic AF, of hospitalizations (for cardiovascular events, for thromboembolic stroke and for all causes), of spontaneous cardioversion, of successful cardioversion (including number of shocks distribution) and the number of patients needing cardioversion after initial ECV will be described by treatment group and compared using a chi-square test or a Fisher Test (if the numbers are relevant).
The duration of hospitalizations for cardiovascular events, for thromboembolic stroke and for any cause will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centre effects) or Wilcoxon test.

The echocardiographic parameters values will be described at each time (V1, V2, V4, V6 and V9) and changes described from V4 to V9 and from V2 to V9.

13.7.2.5. Biomarker analysis: red blood cell concentrations of DHA

Values and changes from baseline for red blood cell concentration of DHA will be performed by treatment group and assessment time.

13.8. SAFETY ANALYSIS

The Safety Set will be used to perform all analyses of the safety criteria.

13.8.1. Adverse Events

Any adverse event having been reported during the study for a given patients will be classified by preferred term and corresponding system organ class using the MedDRA terminology.

Adverse events will be classified as:

- Treatment emergent adverse events, *i.e.*, any adverse event which occurs or worsens on study treatment during the randomised period.
- Or non treatment emergent adverse events, *i.e.*, any adverse event which occurs during the run-in period (before V2) or is reported as concomitant disease with the same intensity.

For each study period, any patient with at least one reported adverse event will be classified as a patient:

- With at least one adverse event
- With at least one treatment emergent adverse event
- With one TEAE
- With two TEAE
• With at least three TEAE
• With at least one related TEAE
• With an adverse event leading to the study treatment discontinuation (definitive or temporary)
• With an adverse event leading to withdrawal
• With at least one serious adverse event.

• Numbers and percentages of patients with at least one reported treatment-emergent adverse event will be tabulated by treatment group:
  • By system organ class
  • By system organ class and preferred term
  • By system organ class and preferred term, taking into consideration its most severe intensity
  • And by system organ class and preferred term, taking into consideration the most severe relationship to the study treatment.

Recurring adverse events (i.e., adverse events classified with the same preferred term) for a given patient will only be counted once and only their most severe intensity or most severe relationship to the study treatment will be tabulated.

"The number and percentage of patients with at least one most common (reported in 1% patients in any group) drug-related TEAE ("not excluded or unassessable") will be tabulated by Preferred Term and Treatment group in decreasing order for the treatment group (for all patients)."

The number and percentage of patients with at least one reported most common treatment-emergent adverse event will also be plotted by treatment group. This graphical representation will highlight the frequencies of the most severe intensities reported by system organ class and preferred term.

Serious adverse events will also be described on an individual basis: treatment group, patient's code, sex and age, Investigator's reported term, preferred term, time of onset according to the time
of the first study treatment administration, duration, action taken regarding the study treatment administration, use of a corrective treatment, outcome and relationship to the study treatment in the Investigator’s opinion.

13.8.2. Clinical Laboratory Evaluation

For each laboratory parameter, data will be tabulated by treatment group and assessment time. The absolute changes post-trial drug administration - baseline (the baseline value being the value measured on the last blood sample collected before the first trial drug administration) will be calculated and tabulated by parameter, treatment group and post-trial drug administration assessment time. Results of retests performed post-trial drug administration will not be analysed and tabulated. They will only be displayed in individual data listings.

For all biochemistry parameters, scatter plots highlighting individual results will display the baseline and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 24 value in the ordinate.

For all haematology parameters, scatter plots highlighting individual results will display the baseline and week 4, week 12 and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 4, week 12 and week 24 value in the ordinate.

Each treatment group will be identified differently. The first bisecting line (45° line), the lines of lower and upper normal range, the lines of PSC range and CNALV range added on the plots (see Appendix 17.3).

For all blood laboratory parameters, shift tables will be provided to depict the numbers of patients with post-trial drug administration variations at each assessment time as compared to the baseline values (measured on the last blood sample collected before the first trial drug administration) by treatment group. A 3-point scale (low, normal, high) will be used as defined by the normal ranges in use in the laboratory in charge of the assays.
Clinically noteworthy abnormal laboratory values (CNALV) (see in Appendix 17.3) will be identified and described on an individual basis. If relevant, five separate individual data listings by treatment group will be provided:

- CNALV for haemoglobin (including corresponding individual results of erythrocytes and haematocrit)
- CNALV for neutrophils or leucocytes (including corresponding individual results of basophils, eosinophils, lymphocytes and monocytes)
- CNALV for platelets (including corresponding individual results of erythrocytes and leucocytes)
- CNALV for liver function parameters (including corresponding individual results of gamma-GT)
- CNALV for serum creatinine

13.8.3. **Global Physical Examination**

Recorded data of the global physical examination performed will not be tabulated as any abnormal findings post-randomisation should be reported as AEs (if clinically significant).

Physical examination assessments will be provided in the listings of individual data.

13.8.4. **Vital Signs, Physical Findings and Other Observations Related to Safety**

13.8.4.1. **Vital Sign Measurements Over Time**

For each parameter (systolic blood pressure, diastolic blood pressure and heart rate in supine and standing positions), descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.

13.8.4.2. **Body weight**

Descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.
13.8.4.3. Individual Patient Changes

The number and percentage of patient with at least one Predefined Potentially Clinically Significant Change (PSC) and with at least one PSC Leading to Clinically Significant Value (PSCV) will be tabulated by treatment group (see Table 1 in Appendix 17.3).

According to the pharmacological drug profile mentioned previously in this Protocol, the changes from baseline to the maximum and/or minimum post-baseline value could be categorized and tabulated by treatment group with frequencies and decreasing cumulative percentages.

If there is a signal of a drug effect toward one direction rather than the other, additionally shift tables of variations from baseline to the maximum or minimum post-baseline value could be also provided (see Table 2 to 4 in Appendix 17.3).

An individual data listing of patients with symptomatic or asymptomatic orthostatic hypotension will be provided by treatment group (see Table 5 in Appendix 17.3).

13.8.5. ECG

Frequencies on the clinical interpretation (normal, abnormal CS or NCS) will be presented by treatment group and assessment time. Individual tabulated data for ECG abnormalities will be also displayed.

13.8.6. Coagulation parameters

Scatter plots highlighting individual results for coagulation parameters (prothrombin time/INR, activated partial thromboplastin time and thrombin clotting time) before and after study treatment administration will be produced.

13.9. CONCOMITANT TREATMENTS

Concomitant treatments will be tabulated by treatment group within a descriptive perspective. They will be classified by therapeutic area according to the WHO-DRUG dictionary using the "anatomical therapeutic chemical" (ATC) classification on the safety set.
13.10. COMPLIANCE

The percentage of compliance will be described by treatment group using the quantity

\[
\text{Compliance(%) = } \frac{\text{Estimated actual consumption}}{\text{Theoretical consumption}} \times 100
\]

with: Estimated actual consumption = number of tablets provided at the start of study (Visit 2) – number of tablets returned at the end of study (Visit 9)

Theoretical consumption = number of days of treatment intake planned between the start and the end of study (168 days ± 7 days).

13.11. INTERIM ANALYSIS AND DATA MONITORING

No interim analysis is planned.

14. GENERAL ETHICAL CONSIDERATIONS

14.1. ETHICAL CONDITIONS

This study is performed in accordance with the principles stated in the Declaration of Helsinki (1964) and subsequent amendments and in accordance with the Good Clinical Practice Guideline (CPMP/ICH/135/95).

14.2. ETHICS COMMITTEE AND LEGAL REQUIREMENTS

All the documents required by National Regulations and any other informative documents that may be requested are submitted for review to an Ethics Committee whose procedures and operations meet the GCP and National Legal Requirements.

Depending on National Regulations, the application is submitted to the Ethics Committee by the Sponsor (or representative) or by the Investigator.
A copy of the formal written approval from the Ethics Committee is provided to the Sponsor (directly by the Ethics Committee or via the Investigator) with a list of names and qualifications of its members.

The request for authorisation by the Competent Authority or its notification if required (depending on National Regulations) is carried out by the Sponsor.

The screening of patients does not start before the approval of the Ethics Committee has been obtained and the study authorised by the Competent Authority or notified to the Competent Authority (depending on National Regulations).

14.3. PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM

An information must be given to the patients before their decision to participate or abstain from participation.

This information is based on the elements set out in the Declaration of Helsinki and the ICH GCP Guidelines. It must also describe the measures taken to safeguard patient’s privacy and protection of personal data, according to European Directive 95/46 EC or other local regulation.

Restraints and risks must be explained, as well as the right to discontinue participation in the study at any stage, without affecting their further relationship with the Investigator and/or their future care.

The written information and consent form must be submitted to the patient with an oral explanation. It must be agreed and signed by the patient before any study-related procedure starts.

This information and consent procedure is under the Investigator’s responsibility.

The information and consent document are made in triplicate: the original copy is kept by the Investigator, one copy is given to the patient and the last copy is kept by the Clinical Quality Assurance Unit of the Sponsor in a sealed envelope at the end of study (except in case of specific country requirement).
Specific areas of the Sponsor’s copy are not triplicated to avoid the reading of the patient’s surname (except the first 3 letters), first name, address and signature.

If any information becomes available during the trial that may be relevant to the patient’s willingness to keep on participating in the trial, an updated written informed consent must be submitted to the patient to confirm agreement to continue participating.

14.4. PERSONAL DATA PROTECTION

All information from this study (excluding data from the informed consent) is entered into a computer under the Sponsor’s responsibility in accordance with the French law, "Loi Informatique et Libertés" (January 6, 1978, and subsequent amendments) and with the European Directive 95/46/CE.

14.5. INSURANCE POLICY

In accordance with the provisions of the law and the GCP, the Sponsor Pierre Fabre Médicament, has an insurance policy intended to guarantee against possible damage resulting from the research.

The studies and/or experiments performed on behalf of the Sponsor Pierre Fabre Médicament, are specifically and expressly guaranteed.

It is advisable to underline that non compliance with the Research Legal Conditions is a cause for guarantee exclusion.

15. ADMINISTRATIVE PROCEDURES

15.1. PROTOCOL AMENDMENT

Neither the Investigator nor the Sponsor may alter the protocol without the authorisation of the other party.

All changes to the protocol are subject to an amendment which must be dated and signed by both parties and must appear as an amendment to the protocol.
Substantial amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities

Urgent amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities, but could be implemented immediately under specific conditions defined with the Sponsor.

15.2. SOURCE DOCUMENTS, INVESTIGATOR'S FILE STORAGE

The Investigator:

- Keeps all trial-related documents in appropriate file folders. Records of patient, original informed consent forms, source documents, a CD Rom containing a pdf copy of e-CRF, drug inventory, Ethics Committees and Sponsor correspondence pertaining to the study must be kept on file.
- Retains all documents relating to the screening (consent and investigation results) of all patients included in the trial or not
- Retains a list of the patient’s names, addresses (and/or number of medical file), code numbers to allow checking of data reported on e-CRFs with those from source documents
- Authorises direct access to source documents for monitoring, audits and inspections
- The trial-related documents must be retained as strictly confidential at the Investigator’s site for at least 15 years or according to local requirements, whatever is the longest after the completion or discontinuation of the trial (European Directive 2003/63/EC).

15.3. END OF THE STUDY

15.3.1. Definition of the End of Study

The end of study is the last visit of the last patient undergoing the trial.

Any change to this definition during the study, for whatever reason, must be notified as a substantial amendment.
15.3.2. Early Study Termination

15.3.2.1. Early Study Termination Decided by the Sponsor

The Sponsor may discontinue the study at any time for any of the following reasons:

- Lack of recruitment
- Deviations from good clinical practice and/or regulations
- Poor product safety
- New information that could jeopardise the patient’s safety
- Stopping of the development …

15.3.2.2. Early Study Termination Decided by the Competent Authorities

The Competent Authorities may suspend or prohibit a study if it considers that the conditions of authorisation are not being met or has doubt about the safety or scientific validity of the study.

15.4. AUDIT

The Sponsor is responsible for making sure that both his representatives (Study Manager, CRA, ...) and the Investigator fulfil the requirements as specified by the GCP Guideline.

An audit can be organised internally at Pierre Fabre Médicament and at the investigational site where the e-CRFs are matched against source documents.

All study documentation must be directly accessible to auditors.

The practical conditions for the audit are discussed between the Investigator and the Clinical Quality Assurance Department.

Oral information about the audit results are given to the Investigator.
15.5. **INSPECTION**

The Health Authorities may inspect any investigation site or the Sponsor in the course of the study or after its completion, to verify the conduct of the study and quality of the data. The Investigator must provide to the inspectors direct access to study documents.

15.6. **CONFIDENTIALITY**

The present materials (protocol and related documentation, e-CRF, Investigator's Brochure) contain confidential information.

Except if agreed to in writing with the Study Manager, the investigators must hold such information confidential, and must not disclose it to others (except where required by Applicable Law).

15.7. **CLINICAL STUDY REPORT**

Data analysis, and clinical study report writing are under the Sponsor’s responsibility.

Upon completion of the data analysis, a final report, including a review of the objectives and methods, a presentation and discussion of the results are drawn up according to ICH Guidelines (Structure and Content of Clinical Study Reports, ICH-E3, CPMP/ICH/137/95).

The report is a clinical and statistical integrated report. It must be signed by the Sponsor's representative(s) and the Coordinating Investigator.

15.8. **STUDY RESULTS COMMUNICATION**

Upon completion of the study, the global results of the Research are communicated to the investigator. According to the Local Regulation, the patient can ask the Investigator for the results.

15.9. **STUDY RESULTS PUBLICATION**

The information and data collected during the conduct of this clinical study are considered confidential and are used by the Sponsor in connection with the development of the study drug. This information may be disclosed if deemed necessary by the Sponsor.
To allow use of the information derived from this clinical study and to insure compliance with Current Regulations, the Investigator must provide the Sponsor with complete test results and all data collected during the study.

Only the Sponsor may make study information available to physicians and to Regulatory Agencies, except as required by Current Regulations.

All the results of this study including data, reports, discoveries and inventions resulting from the study, are the property of the Sponsor.

In the event the Sponsor chooses to publish study data, the manuscript must be provided to the author(s) at least 30 days prior to the expected date of submission to the intended publisher.

The investigator(s) can reserve the right to publish or present study data; if so, the manuscript or abstract must be provided to the Sponsor for review at least 30 days prior to the expected date of submission to the intended publisher or of planned presentation.

In addition, if necessary, (the) investigator(s) shall withhold publication for an additional 60 days, to allow the filing of a patent application, or to allow the Sponsor to take any measures he deems appropriate to establish and preserve his proprietary rights.

It is agreed that publication of study results by each site shall be made only as part of a publication of the study results obtained by all sites performing the protocol, once the study is completed and finalised.

The authors list is agreed by all investigators prior to publication. The names of the authors are provided according to their participation in the design of the protocol as well as their recruitment of eligible and analysable patients.
16. REFERENCES


  n-3 Polyunsaturated Fatty Acids in the prevention of atrial Fibrillation Recurrences after
electrical cardioversion. A prospective, Randomised study
  Circulation, 2011; 124:1100-1106

  Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional
capacity in patients with dilated cardiomyopathy
  J. Am. Coll. Cardiol. 2011;57;870-879

  BERGER R.
  Dose-dependant effects of omega-3-polyunsaturated fatty acids on systolic left ventricular
  function, endothelial function, and markers of inflammation in chronic heart failure of non
  ischemic origin: A double-blind, placebo-controlled, 3-arm study
  American Heart Journal 2011; 161:915.e1-915.e9 - volume 161, number 5

[5] GISSI-HF INVESTIGATORS
  Effects of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GSSI-
  HF Trial): a randomised, double-blind, placebo-controlled trial
  The lancet on line - August 2008

  VAN GELDER I.C., AL-ATTAR N., HINDRICKS G., PRENDERGAST B.,
  HEIDBUCHEL H., ALFIERI O., ANGELINI A., ATAR D., COLONNA P., DE
  CATERINA R., DE SUTTER J., GOETTE A., GORENEK B., HELDAL M.,
  HOHLOSER S.H., KOLH P., LE HEUZEY J.Y., PONIKOWSKI P., RUTTEN F.H.
  Guidelines for the management of atrial fibrillation: the Task Force for the Management of
  Atrial Fibrillation of the European Society of Cardiology (ESC).
  European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery,

[7] KOWEY PR, REIFFEL JA, ELLENBOGEN KA, NACCARELLI GV, PRATT CM.
  Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent
  symptomatic atrial fibrillation: a randomised controlled trial.
BIANCONI L., CALO L., MENNUNI M., SANTINI L., MOROSETTI P., AZZOLINI P., BARBATO G., BISCIONE F., ROMANO P., SANTINI M.
N-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomised, double-blind, multicentre study
*Europace* (2011) 13, 174-181

OMACOR® SUMMARY PRODUCT CHARACTERISTICS (SPC) dated 17/02/2012

BEPANTHENE® SUMMARY PRODUCT CHARACTERISTICS (SPC)

TOUBOUL P, BRUGADA J, CAPUCCI A, CRIJNS HJ, EDVARDSSON N, HOHNLOSER SH.
Dronedarone for prevention of atrial fibrillation: a dose-ranging study.

LE HEUZÉY JY AND ALL.
A Short-Term, Randomised, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study.
*J Cardiovasc Electrophysiol.*

Effects of fish-oil supplementation on myocardial fatty acids in humans.

ARTERBURN M.L. & OKEN H.
Distribution, interconversion and dose response of n-3 fatty acids in humans.
*Am J Clin Nutr* (2006); 83 : 1469-1473S.

TIELEMAN RG, VAN GELDER IC, CRIJNS HJ, DE KAM PJ, VAN DEN BERG MP, HAAKSMA J, VAN DER WOUDE HJ, AND ALLESSIE MA.
Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodelling of the atria?
*J. Am. Coll. Cardiol.* 1998;31;167-173

SALM P, TAYLOR PJ, KOSTNER K
Simultaneous quantification of total eicosapentaenoic acid, docosahexaenoic acid and arachidonic acid in plasma by high-performance liquid chromatography-tandem mass spectrometry.
The consumption of food products from linseed-fed animals maintains erythrocyte omega-3 fatty acids in obese human

[18] HARRIS WS, VON SCHACKY C.
The Omega-3 Index: a new risk factor for death from coronary heart disease?

Effects of Polyunsaturated Fatty Acids n-3 (PUFA n-3) in the prophylaxis of atrial fibrillation relapses after external electric cardioversion
World Congress of Cardiology 2006, 2-6 September, Barcelona – Spain

Outcome parameters from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association.
Europace 2007, 9, 1006-1023

[21] EUROPEAN MEDICINES AGENCY
Addendum to the guideline on antiarrhythmics on atrial fibrillation and atrial flutter.
EMA/CHMA/EWP/213056/2010

Dietary fish oil dose- and time-response effects on cardiac phospholipid fatty acid composition.
Lipids. 2004;39:955–961

[23] ROBERTO M. LANG, MICHELLE BIERIG, RICHARD B. DEVEREUX, FRANK A. FLACHSKAMPF*, ELYSE FOSTER, PATRICIA A. PELLIKKA, MICHAEL H. PICARD, MARY J. ROMAN, JAMES SEWARD, JACK SHANEWISE, SCOTT SOLOMON, KIRK T. SPENCER, MARTIN ST. JOHN SUTTON, WILLIAM STEWART.
Recommendations for chamber quantification
17. APPENDICES
17.1. DECLARATION OF HELSINKI

WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI
ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING
HUMAN SUBJECTS

Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the: 29th WMA
General Assembly, Tokyo, Japan, October 1975 35th WMA General Assembly, Venice, Italy, October 1983 41st
WMA General Assembly, Hong Kong, September 1989 48th WMA General Assembly, Somerset West, Republic of
South Africa, October 1996 52nd WMA General Assembly, Edinburgh, Scotland, October 2000 53th WMA General
Assembly, Washington 2002 (Note of Clarification on paragraph 29 added) 55th WMA General Assembly, Tokyo
2004 (Note of Clarification on Paragraph 30 added) 59th WMA General Assembly, Seoul, October 2008

A. INTRODUCTION

1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of
ethical principles for medical research involving human subjects, including research on identifiable
human material and data. The Declaration is intended to be read as a whole and each of its constituent
paragraphs should not be applied without consideration of all other relevant paragraphs.

2. Although the Declaration is addressed primarily to physicians, the WMA encourages other participants
in medical research involving human subjects to adopt these principles.

3. It is the duty of the physician to promote and safeguard the health of patients, including those who are
involved in medical research. The physician's knowledge and conscience are dedicated to the fulfilment
of this duty.

4. The Declaration of Geneva of the WMA binds the physician with the words, “The health of my patient
will be my first consideration,” and the International Code of Medical Ethics declares that, “A physician
shall act in the patient's best interest when providing medical care.”

5. Medical progress is based on research that ultimately must include studies involving human subjects.
Populations that are underrepresented in medical research should be provided appropriate access to
participation in research.

6. In medical research involving human subjects, the well-being of the individual research subject must
take precedence over all other interests.

7. The primary purpose of medical research involving human subjects is to understand the causes,
development and effects of diseases and improve preventive, diagnostic and therapeutic interventions
(methods, procedures and treatments). Even the best current interventions must be evaluated continually
through research for their safety, effectiveness, efficiency, accessibility and quality.

8. In medical practice and in medical research, most interventions involve risks and burdens.

9. Medical research is subject to ethical standards that promote respect for all human subjects and protect
their health and rights. Some research populations are particularly vulnerable and need special
protection. These include those who cannot give or refuse consent for themselves and those who may be
vulnerable to coercion or undue influence.

10. Physicians should consider the ethical, legal and regulatory norms and standards for research involving
human subjects in their own countries as well as applicable international norms and standards. No
national or international ethical, legal or regulatory requirement should reduce or eliminate any of the
protections for research subjects set forth in this Declaration.
B. PRINCIPLES FOR ALL MEDICAL RESEARCH

11. It is the duty of physicians who participate in medical research to protect the life, health, dignity, integrity, right to self-determination, privacy, and confidentiality of personal information of research subjects.

12. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and adequate laboratory and, as appropriate, animal experimentation. The welfare of animals used for research must be respected.

13. Appropriate caution must be exercised in the conduct of medical research that may harm the environment.

14. The design and performance of each research study involving human subjects must be clearly described in a research protocol. The protocol should contain a statement of the ethical considerations involved and should indicate how the principles in this Declaration have been addressed. The protocol should include information regarding funding, sponsors, institutional affiliations, other potential conflicts of interest, incentives for subjects and provisions for treating and/or compensating subjects who are harmed as a consequence of participation in the research study. The protocol should describe arrangements for post-study access by study subjects to interventions identified as beneficial in the study or access to other appropriate care or benefits.

15. The research protocol must be submitted for consideration, comment, guidance and approval to a research ethics committee before the study begins. This committee must be independent of the researcher, the sponsor and any other undue influence. It must take into consideration the laws and regulations of the country or countries in which the research is to be performed as well as applicable international norms and standards but these must not be allowed to reduce or eliminate any of the protections for research subjects set forth in this Declaration. The committee must have the right to monitor ongoing studies. The researcher must provide monitoring information to the committee, especially information about any serious adverse events. No change to the protocol may be made without consideration and approval by the committee.

16. Medical research involving human subjects must be conducted only by individuals with the appropriate scientific training and qualifications. Research on patients or healthy volunteers requires the supervision of a competent and appropriately qualified physician or other health care professional. The responsibility for the protection of research subjects must always rest with the physician or other health care professional and never the research subjects, even though they have given consent.

17. Medical research involving a disadvantaged or vulnerable population or community is only justified if the research is responsive to the health needs and priorities of this population or community and if there is a reasonable likelihood that this population or community stands to benefit from the results of the research.

18. Every medical research study involving human subjects must be preceded by careful assessment of predictable risks and burdens to the individuals and communities involved in the research in comparison with foreseeable benefits to them and to other individuals or communities affected by the condition under investigation.

19. Every clinical trial must be registered in a publicly accessible database before recruitment of the first subject.
20. Physicians may not participate in a research study involving human subjects unless they are confident that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians must immediately stop a study when the risks are found to outweigh the potential benefits or when there is conclusive proof of positive and beneficial results.

21. Medical research involving human subjects may only be conducted if the importance of the objective outweighs the inherent risks and burdens to the research subjects.

22. Participation by competent individuals as subjects in medical research must be voluntary. Although it may be appropriate to consult family members or community leaders, no competent individual may be enrolled in a research study unless he or she freely agrees.

23. Every precaution must be taken to protect the privacy of research subjects and the confidentiality of their personal information and to minimize the impact of the study on their physical, mental and social integrity.

24. In medical research involving competent human subjects, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail, and any other relevant aspects of the study. The potential subject must be informed of the right to refuse to participate in the study or to withdraw consent to participate at any time without reprisal. Special attention should be given to the specific information needs of individual potential subjects as well as to the methods used to deliver the information. After ensuring that the potential subject has understood the information, the physician or another appropriately qualified individual must then seek the potential subject’s freely-given informed consent, preferably in writing. If the consent cannot be expressed in writing, the non-written consent must be formally documented and witnessed.

25. For medical research using identifiable human material or data, physicians must normally seek consent for the collection, analysis, storage and/or reuse. There may be situations where consent would be impossible or impractical to obtain for such research or would pose a threat to the validity of the research. In such situations the research may be done only after consideration and approval of a research ethics committee.

26. When seeking informed consent for participation in a research study the physician should be particularly cautious if the potential subject is in a dependent relationship with the physician or may consent under duress. In such situations the informed consent should be sought by an appropriately qualified individual who is completely independent of this relationship.

27. For a potential research subject who is incompetent, the physician must seek informed consent from the legally authorized representative. These individuals must not be included in a research study that has no likelihood of benefit for them unless it is intended to promote the health of the population represented by the potential subject, the research cannot instead be performed with competent persons, and the research entails only minimal risk and minimal burden.

28. When a potential research subject who is deemed incompetent is able to give assent to decisions about participation in research, the physician must seek that assent in addition to the consent of the legally authorized representative. The potential subject’s dissent should be respected.
29. Research involving subjects who are physically or mentally incapable of giving consent, for example, unconscious patients, may be done only if the physical or mental condition that prevents giving informed consent is a necessary characteristic of the research population. In such circumstances the physician should seek informed consent from the legally authorized representative. If no such representative is available and if the research cannot be delayed, the study may proceed without informed consent provided that the specific reasons for involving subjects with a condition that renders them unable to give informed consent have been stated in the research protocol and the study has been approved by a research ethics committee. Consent to remain in the research should be obtained as soon as possible from the subject or a legally authorized representative.

30. Authors, editors and publishers all have ethical obligations with regard to the publication of the results of research. Authors have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports. They should adhere to accepted guidelines for ethical reporting. Negative and inconclusive as well as positive results should be published or otherwise made publicly available. Sources of funding, institutional affiliations and conflicts of interest should be declared in the publication. Reports of research not in accordance with the principles of this Declaration should not be accepted for publication.

C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH MEDICAL CARE

31. The physician may combine medical research with medical care only to the extent that the research is justified by its potential preventive, diagnostic or therapeutic value and if the physician has good reason to believe that participation in the research study will not adversely affect the health of the patients who serve as research subjects.

32. The benefits, risks, burdens and effectiveness of a new intervention must be tested against those of the best current proven intervention, except in the following circumstances:

- The use of placebo, or no treatment, is acceptable in studies where no current proven intervention exists; or
- Where for compelling and scientifically sound methodological reasons the use of placebo is necessary to determine the efficacy or safety of an intervention and the patients who receive placebo or no treatment will not be subject to any risk of serious or irreversible harm. Extreme care must be taken to avoid abuse of this option.

33. At the conclusion of the study, patients entered into the study are entitled to be informed about the outcome of the study and to share any benefits that result from it, for example, access to interventions identified as beneficial in the study or to other appropriate care or benefits.

34. The physician must fully inform the patient which aspects of the care are related to the research. The refusal of a patient to participate in a study or the patient’s decision to withdraw from the study must never interfere with the patient-physician relationship.

35. In the treatment of a patient, where proven interventions do not exist or have been ineffective, the physician, after seeking expert advice, with informed consent from the patient or a legally authorized representative, may use an unproven intervention if in the physician's judgement it offers hope of saving life, re-establishing health or alleviating suffering. Where possible, this intervention should be made the object of research, designed to evaluate its safety and efficacy. In all cases, new information should be recorded and, where appropriate, made publicly available.
17.2. SAE REPORT FORM
**NOTIFICATION OF SERIOUS ADVERSE EVENT (SAE) OR PREGNANCY**
TO PIERRE FABRE PRODUCT SAFETY DEPARTMENT

**TO BE TRANSMITTED TO THE MONITOR BY FAX WITHIN 24H :** G. ALCARAZ ............... Fax n° +33 5 34 50 65 92

Transmission date  ______  ______  ______  ______  ______ (ddmmyyyy)  Country:  _______________

SAE N°  ______  FIRST NOTIFICATION □  FOLLOW-UP □

**SUBJECT CHARACTERISTICS**

<table>
<thead>
<tr>
<th>Surname</th>
<th>First name</th>
<th>Birth date</th>
<th>Gender 1=M, 2=F</th>
<th>Height</th>
<th>cm</th>
<th>Weight</th>
<th>kg</th>
</tr>
</thead>
</table>

**DESCRIPTION OF THE EVENT**

The serious adverse event resulted in:
- ☐ Death (whatever may be the cause)
- ☐ Hospitalisation (*) or extension thereof
- ☐ Life threatening
- ☐ Invalidity or disability
- ☐ Congenital abnormality or abnormal pregnancy outcome
- ☐ Cancer
- ☐ Other (any other serious clinical or laboratory event according to the investigator or the protocol, overdosage meeting seriousness criteria, suicide attempts)
- ☐ Other fact to be notified:
  - ☐ Pregnancy exposure

Nature of the event (if clinical nature, indicate the diagnosis or the major symptom):
...........................................................................................................................................................................................................
...........................................................................................................................................................................................................
...........................................................................................................................................................................................................

AE onset date  ______  ______  ______  ______  ______ (ddmmyyyy)

Seriousness onset date  ______  ______  ______  ______  ______  ______  ______ (ddmmyyyy)

Summary description (if clinical cause, significant history, progression of event, available laboratory results, etc...):

(*) Except hospitalisations with durations and goals planned in the protocol

**THE SAE IN RELATION TO THE TRIAL**

<table>
<thead>
<tr>
<th>Treatment number</th>
</tr>
</thead>
<tbody>
<tr>
<td>____________</td>
</tr>
</tbody>
</table>

- ☐ Time of occurrence of SAE
  - ☐ During the selection or run-in period
  - ☐ During the administration phase of the study treatment
  - ☐ After the administration phase of the study treatment

- ☐ Date of first study treatment administration  ______  ______  ______  ______  ______ (ddmmyyyy)
- ☐ Date of last study treatment administration before the occurrence of SAE  ______  ______  ______  ______  ______ (ddmmyyyy)

- ☐ Was the blind broken?  ☐ Yes  ☐ No  ☐ Not applicable
  - If yes, or if this is an open study, drug(s) administered:
  - Conditions of administration (cycles(s), daily dose(s), route(s) of administration, etc...):
CONCOMITANT MEDICATION SINCE TRIAL INITIATION and UP UNTIL THE OCCURRENCE OF THE SAE
(EXCEPT THE TREATMENTS GIVEN FOR THE SAE)

<table>
<thead>
<tr>
<th>INN or trade name</th>
<th>Daily dose</th>
<th>Start date (ddmmyy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (ddmmyy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><strong>/</strong>/____</td>
<td>❑</td>
<td><strong>/</strong>/____</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>/</strong>/____</td>
<td>❑</td>
<td><strong>/</strong>/____</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>/</strong>/____</td>
<td>❑</td>
<td><strong>/</strong>/____</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>/</strong>/____</td>
<td>❑</td>
<td><strong>/</strong>/____</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MEASURES TAKEN FOLLOWING THE SAE

• Study treatment
  ❑ No change
  ❑ Dosage modification, specify :…………………………………… Modification Date : __/__/____
  ❑ Temporarily discontinued Readministration date : __/__/____
  ❑ Withdrawn End date : __/__/____
  ❑ Not applicable

• The event led to :
  ❑ Prescription of corrective or symptomatic treatments (specify names and dosages) :
  ❑ Discontinuation of concomitant treatments (specify names) :
  ❑ Others, specify :

OUTCOME

❑ Not recovered/Not resolved ❑ Recovering/Resolving ❑ Recovered/Resolved
❑ Recovered/Resolved with sequelae ❑ Fatal ❑ Unknown

In case of death, has an autopsy been conducted ? ❑ Yes ❑ No

INVESTIGATOR CAUSALITY ASSESSMENT (investigator’s assessment to be done as soon as possible)

❑ Not Suspected ❑ Suspected ❑ Insufficient data

comments : .............................................................................................................................................................
## 17.3. PREDEFINED LIMITS OF LABORATORY AND VITAL SIGN POTENTIALLY CLINICALLY SIGNIFICANT CHANGES AND VALUES

List of Predefined Potentially Clinically Significant Change For Laboratory Values

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>UNIT</th>
<th>PSC</th>
<th>Decrease</th>
<th>Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MUSCLE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatine Phosphokinase</td>
<td>U / l</td>
<td></td>
<td>-</td>
<td>236</td>
</tr>
<tr>
<td><strong>KIDNEY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine</td>
<td>µmol/l</td>
<td></td>
<td>-</td>
<td>35</td>
</tr>
<tr>
<td>Urea</td>
<td>mmol/l</td>
<td></td>
<td>-</td>
<td>3.2</td>
</tr>
<tr>
<td>Uric acid</td>
<td>µmol/l</td>
<td></td>
<td>-</td>
<td>119</td>
</tr>
<tr>
<td>Phosphate</td>
<td>mmol/l</td>
<td></td>
<td>0.39</td>
<td>0.39</td>
</tr>
<tr>
<td>Calcium</td>
<td>mmol/l</td>
<td></td>
<td>0.30</td>
<td>0.30</td>
</tr>
<tr>
<td><strong>ELECTROLYTES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium</td>
<td>mmol/l</td>
<td></td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Potassium</td>
<td>mmol/l</td>
<td></td>
<td>1.1</td>
<td>1.1</td>
</tr>
<tr>
<td>Chloride</td>
<td>mmol/l</td>
<td></td>
<td>8</td>
<td>7</td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>mmol/l</td>
<td></td>
<td>7</td>
<td>8</td>
</tr>
<tr>
<td><strong>METABOLISM/ NUTRITIONAL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose (random)</td>
<td>mmol/l</td>
<td></td>
<td>3</td>
<td>3.7</td>
</tr>
<tr>
<td>Albumin</td>
<td>g/l</td>
<td></td>
<td>6</td>
<td>6</td>
</tr>
<tr>
<td>Protein</td>
<td>g/l</td>
<td></td>
<td>11</td>
<td>10</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>mmol/l</td>
<td></td>
<td>-</td>
<td>1.97</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>mmol/l</td>
<td></td>
<td>0.91</td>
<td>0.85</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>mmol/l</td>
<td></td>
<td>2.17</td>
<td>2.04</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>mmol/l</td>
<td></td>
<td>-</td>
<td>2.91</td>
</tr>
<tr>
<td><strong>ERYTHROCYTES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythrocyte count</td>
<td>T/l</td>
<td></td>
<td>0.7</td>
<td>0.7</td>
</tr>
<tr>
<td>Haemoglobin</td>
<td>g/l</td>
<td></td>
<td>20</td>
<td>-</td>
</tr>
<tr>
<td>Haematocrit</td>
<td>l</td>
<td></td>
<td>0.06</td>
<td>0.06</td>
</tr>
<tr>
<td>MCV</td>
<td>fl</td>
<td></td>
<td>7</td>
<td>7</td>
</tr>
<tr>
<td>MCH (Fe)</td>
<td>fmol</td>
<td></td>
<td>0.19</td>
<td>0.19</td>
</tr>
<tr>
<td>MCHC (Fe)</td>
<td>mmol/l</td>
<td></td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td><strong>LEUKOCYTES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukocyte count</td>
<td>G/l</td>
<td></td>
<td>4.2</td>
<td>3.8</td>
</tr>
<tr>
<td><strong>DIFFERENTIAL COUNT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophils</td>
<td>G/l</td>
<td></td>
<td>3.47</td>
<td>3.19</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>G/l</td>
<td></td>
<td>1.76</td>
<td>1.63</td>
</tr>
<tr>
<td>Monocytes</td>
<td>G/l</td>
<td></td>
<td>-</td>
<td>0.49</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>G/l</td>
<td></td>
<td>-</td>
<td>0.41</td>
</tr>
<tr>
<td>Basophils</td>
<td>G/l</td>
<td></td>
<td>-</td>
<td>0.14</td>
</tr>
<tr>
<td><strong>URINE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specific gravity</td>
<td>-</td>
<td></td>
<td>0.017</td>
<td>0.015</td>
</tr>
<tr>
<td>pH</td>
<td>-</td>
<td></td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td><strong>LIVER</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>µmol/l</td>
<td></td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td>ASAT (SGOT)</td>
<td>U/l</td>
<td></td>
<td>-</td>
<td>N x (23/36)</td>
</tr>
<tr>
<td>ALAT (SGPT)</td>
<td>U/l</td>
<td></td>
<td>-</td>
<td>N x (28/45)</td>
</tr>
<tr>
<td>Gamma GT</td>
<td>U/l</td>
<td></td>
<td>-</td>
<td>N x (25/38)</td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>U/l</td>
<td></td>
<td>-</td>
<td>N x (30/95)</td>
</tr>
</tbody>
</table>

N = upper limit of normal range

### Definition of Clinically Noteworthy Abnormal Laboratory Values (CNALV)

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>CNALV</th>
</tr>
</thead>
</table>
| **HAEMOGLOBIN**        | • Decrease of at least 2 g/dl and value < 10 g/dl whatever the baseline value  
                        | • If missing baseline : value < 10 g/dl                               |
| **NEUTROPHILS**        | • < 1 500/mm³ whatever the baseline value                             |
| **WBC**                | • < 3 000/mm³ whatever the baseline value                             |
| (if missing value for neutrophils) |                                                                  |
| **PLATELETS**          | • < 100 000/mm³ whatever the baseline value                           |
| **SERUM CREATININE**   | • Increase of at least 30 % as compared to baseline value and value > 150 µmol/l whatever the baseline value  
                        | • If missing baseline : value > 150 µmol/l                             |
| **LIVER FUNCTION TESTS** |                                                      |
| **ALAT**               | • If normal baseline :  
                        | • ALAT > 2 N  
                        | • If abnormal baseline :  
                        | → if baseline value ≤ 2.5 N :  
                        | • increase of at least 100 % as compared to baseline value  
                        | → if baseline value > 2.5 N :  
                        | • value > 5 N  
                        | and/or **ASAT**  
                        | • If normal baseline :  
                        | • ASAT > 2 N  
                        | • If abnormal baseline :  
                        | → if baseline value ≤ 2.5 N :  
                        | • increase of at least 100 % as compared to baseline value  
                        | → if baseline value > 2.5 N :  
                        | • value > 5 N  
                        | and/or **Alkaline phosphatase (AP)**  
                        | • If normal baseline :  
                        | • AP > 1.25 N  
                        | • If abnormal baseline :  
                        | • AP > 2 N  
                        | and/or **Total bilirubin (TB)**  
                        | • If normal baseline :  
                        | • TB > 1.5 N  
                        | • If abnormal baseline :  
                        | • TB > 2 N                             |

N=upper limit of normal range


Cardiovascular Safety

Table 1: Predefined Limits for Potentially Clinically Significant Changes (PSC) and PSC Leading to Clinically Significant Values (PSCV)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>PSC</th>
<th>PSCV</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP</td>
<td>Increase ≥ 20 mmHg</td>
<td>SBP ≥ 160 mmHg and increase ≥ 20 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 20 mmHg</td>
<td>SBP ≤ 90 mmHg and decrease ≥ 20 mmHg</td>
</tr>
<tr>
<td></td>
<td>Increase ≥ 10 mmHg</td>
<td>DBP ≥ 100 mmHg and increase ≥ 10 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 mmHg</td>
<td>DBP ≤ 50 mmHg and decrease ≥ 10 mmHg</td>
</tr>
<tr>
<td>HR</td>
<td>Increase ≥ 10 bpm</td>
<td>HR ≥ 110 bpm and increase ≥ 10 bpm</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 bpm</td>
<td>HR ≤ 50 bpm and decrease ≥ 10 bpm</td>
</tr>
</tbody>
</table>

Table 2: Predefined Classes for changes from Baseline to the Maximum (and/or Minimum) Post-baseline Value

<table>
<thead>
<tr>
<th>Classes of Change from Baseline to the Maximum Post-baseline Value</th>
<th>Classes of Change from Baseline to the Minimum Post-baseline Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>All</td>
<td>All</td>
</tr>
<tr>
<td>≥ 0</td>
<td>≥ 0</td>
</tr>
<tr>
<td>&gt; 0</td>
<td>&gt; 0</td>
</tr>
<tr>
<td>≥ 10</td>
<td>≥ 5</td>
</tr>
<tr>
<td>≥ 20</td>
<td>≥ 10</td>
</tr>
<tr>
<td>≥ 30</td>
<td>≥ 15</td>
</tr>
<tr>
<td>≥ 40</td>
<td>≥ 20</td>
</tr>
<tr>
<td>≥ 25</td>
<td>≥ 15</td>
</tr>
<tr>
<td>≥ 30</td>
<td>≥ 15</td>
</tr>
</tbody>
</table>

Table 3: Classes for Vital Signs Maximum or Minimum Values

<table>
<thead>
<tr>
<th>Classes for the Maximum Post-baseline Value for each parameter</th>
<th>Classes for the Minimum Post-baseline Value for each parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>&lt; 120</td>
<td>&lt; 80</td>
</tr>
<tr>
<td>[120;140]</td>
<td>[80;90]</td>
</tr>
<tr>
<td>[140;160]</td>
<td>[90;100]</td>
</tr>
<tr>
<td>≥ 160</td>
<td>≥ 100</td>
</tr>
</tbody>
</table>

Table 4: Classes for Maximum or Minimum of BP in its entirety

<table>
<thead>
<tr>
<th>Classification of Maximum Values for Blood Pressure (mmHg)</th>
<th>Classification of Minimum Values Blood Pressure (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP &lt; 140 and DBP &lt; 90</td>
<td>SBP &gt; 90 and DBP &gt; 50</td>
</tr>
<tr>
<td>SBP [140;160] and DBP &lt; 100 or DBP [90;100] and SBP &lt; 160</td>
<td>SBP ≤ 90 or DBP ≤ 50</td>
</tr>
<tr>
<td>SBP ≥ 160 or DBP ≥ 100</td>
<td></td>
</tr>
</tbody>
</table>

Table 5: Definition of orthostatic hypotension

<table>
<thead>
<tr>
<th>Orthostatic Hypotension *</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP Decrease ≥ 20 mmHg or DBP Decrease ≥ 10 mmHg between supine and standing positions</td>
</tr>
</tbody>
</table>

16.1.1.5. Protocol amendment n° PA03
General and substantial dated on 23 October 2013 linked to Protocol and appendices
(version 5: 23 October 2013)
Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Pierre Fabre Study Code: F373280 CA 2 01
EudraCT Number or equivalent: 2012-003487-48
Gaëlle ALCARAZ
INSTITUT DE RECHERCHE PIERRE FABRE - Centre de R&D Pierre Fabre - BP 13562
3 avenue Hubert Curien
31035 TOULOUSE Cedex 1

Sponsor’s Representative:
Pr Savina NODARI
Department of Clinical and Surgical Specialities, Radiological Science and Public Health
Section of Cardiovascular Diseases

Study Coordinating Investigator:
University Medical School and Spedali Civili Hospital of Brescia
c/o Spedali Civili di Brescia
Piazzale Spedali Civili, 1
25123 - BRESCIA, ITALY

Date of amendment PA03: 23 October 2013
APPROVAL FORM

STUDY: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Clinical Study Protocol Amendment n° PA03 Version 1
(General – Substantial)
Dated: 23/10/2013

Sponsor's representative(s)

- Medical Director
  Date: 29/10/2013 Signature: 
  Dr Richard ROCHE

- Clinical Study Manager:
  Date: 29/10/2013 Signature: 
  Gaëlle ALCARAZ

Study Coordinating Investigator:

Pr Savina NODARI 20 Oct 2013
COUNTRY COORDINATING INVESTIGATOR SIGNATURE FORM

STUDY: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Clinical Study Protocol Amendment n° PA03 Version 1
(General – Substantial)
Dated: 23/10/2013

Country Coordinating Investigator: SAVINIA NONNIN
Date: 13/01/2014
Signature: [Signature Image]
INVESTIGATOR SIGNATURE FORM

STUDY: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Clinical Study Protocol Amendment n° PA03 Version 1
(General – Substantial)
Dated: 23/10/2013

By my signature below, I, Dr __________________________, hereby confirm that I have read, taken note of (and will apply) the modifications brought by the protocol amendment n° PA03 and I will conduct the trial according to these new modalities.

Date: __________________________ Signature: __________________________
<table>
<thead>
<tr>
<th>N°</th>
<th>TYPE</th>
<th>APPLICATION AREA</th>
<th>DATE</th>
<th>MODIFICATIONS</th>
</tr>
</thead>
</table>
| NA   | NA           | General          | NA         | Following French CA request (ANSM) and leading to protocol version 2:  
- Add of a non inclusion criteria: "Breast-feeding female patient"  
- Add of haematology examination at visit 3 and 6                                                                                                                   |
| PA01 | Substantial  | Local (Italy)    | 01.03.2013 | Corresponding to Protocol Version 3:  
- Integration of the modification included in the protocol version 2  
- Harmonisation of the protocol and the Informed Consent Form:  
  * adjustment of the selection criteria n°10 related to the contraception method  
  * addition of a letter that is given by the patient to his/her general practitioner (GP)  
  * precision that the sponsor can not collect a copy of the Informed Consent Form  
  * precision that the patient card is in Italian language only (without any English mention)                                                                 |
| PA02 | Non Substantial | General         | 28.03.2013 | Corresponding to Protocol Version 4:  
- change of Sponsor’s Representative (Clinical Study Manager),  
- modification of the technical handling of the blood samples for determination of red blood cells concentration of DHA: the centrifugation is no more needed,  
- precision on the function and address of the International Study Coordinator Pr Nodari,  
- add of address and contacts details of two CRO newly involved in the study: Theradis (in charge of transportation of blood samples to the Analytical centre and material supply) and “Clinact” (in charge of refund of patients expenses linked to the study),  
- adjustment of the wording, in agreement with the commitment to the French Ethics Committee. In the paragraphe 8.3.2.1, the wording “hematology examination” is replaced by “standard hematologic dosage”,  
- precision of the full title in the study synopsis (in agreement with the commitment to the Spanish Ethics Committee),  
- correction of a mistake in section 8.1.1.3 (related to TTEM transmission) and sections 3, 9 and study synopsis (related to the definition of INR not stabilized).  
- addition of the changes included in the local Italian substantial protocol amendment (i.e: contraception method, letter to General Practionner, patient card in Italian and no collection of the consent form by the sponsor in Italy).  

Final version

464/1185
1. AMENDMENT RATIONALE

This amendment relates to an adjustment of some criteria in order to improve the feasibility of the study and to minor changes as typographical errors or style. Finally a change affects the recipient of the SAEs reports.

The clinical study protocol is updated with the following changes:
- Due to a recruitment rate significantly lower than expected the planned end of study is postponed to January 2015.
- The authorized history of the first documented persistent atrial fibrillation passes from less than 1 year to less than 3 years. This modification will expand our target population without changing the characteristics of the selected patients by enabling the management of patients who experienced a longer period without relapse.
- At selection a hyperkalemia or a hypokalemia will be better defined by the standards of the local laboratories.
- Regarding previous treatments by amiodarone the non inclusion criteria of the protocol are adapted as follow:
  - Previous treatment with oral amiodarone within 4 months prior to inclusion
  - Intake of oral amiodarone for more than 1 month within 4 to 12 months before inclusion
  - Previous treatment with intravenous amiodarone within 4 weeks prior to inclusion

Despite the long half life of amiodarone, these time limits relating to its non-use before inclusion allow to ensure the absence of amiodarone at sufficient levels to interfere with the assessment of the product.
- For male with a child-bearing potential partner (in Italy only):
  Taking into account the duration of spermatogenesis the absolute abstention from sexual intercourse or the use of double barrier contraception method are extended to 3 months after the end of the study.
- Ranolazine is an antiangina treatment with antiarrhythmic properties. This treatment is added to the prohibited treatments in order to exclude a potential association between the study product and a treatment having an antiarrhythmic effect.
- Updated Serious Adverse Events (SAEs) form. Main change is the SAE sending: SAEs have to be reported to the Corporate Vigilance Department, and not anymore to the clinical study manager. Also SAEs can be sent by e-mail and by fax.
- Addition of Alpha Bioresearch as CRO involved for Feasibility, Monitoring and Regulatory issues in Spain.
- Some minor typographic errors are corrected in the protocol.
2. **CHANGES DESCRIPTION**

<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sponsor's Representative:</strong></td>
<td><strong>Sponsor's Representative:</strong></td>
</tr>
<tr>
<td>Gaëlle ALCARAZ</td>
<td>Gaëlle ALCARAZ</td>
</tr>
<tr>
<td>INSTITUT DE RECHERCHE PIERRE FABRE - Centre de R&amp;D Pierre Fabre - BP 13562</td>
<td>INSTITUT DE RECHERCHE PIERRE FABRE - Centre de R&amp;D Pierre Fabre - BP 13562</td>
</tr>
<tr>
<td>3 avenue Hubert Curien</td>
<td>3 avenue Hubert Curien</td>
</tr>
<tr>
<td>31035 TOULOUSE Cédex 1</td>
<td>31035 TOULOUSE Cédex 1</td>
</tr>
<tr>
<td>Phone: +33 5 34 50 62 16</td>
<td>Phone: +33 5 34 50 62 16</td>
</tr>
<tr>
<td>Fax: +33 5 34 50 65 92</td>
<td>Fax: +33 5 34 50 69 69</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:gaelle.alcaraz@pierre-fabre.com">gaelle.alcaraz@pierre-fabre.com</a></td>
<td>E-mail: <a href="mailto:gaelle.alcaraz@pierre-fabre.com">gaelle.alcaraz@pierre-fabre.com</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>Medical Director:</strong></th>
<th><strong>Medical Director:</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard ROCHE, MD</td>
<td>Richard ROCHE, MD</td>
</tr>
<tr>
<td>Institut de Recherche Pierre Fabre</td>
<td>Institut de Recherche Pierre Fabre</td>
</tr>
<tr>
<td>Centre de R&amp;D Pierre Fabre</td>
<td>Centre de R&amp;D Pierre Fabre</td>
</tr>
<tr>
<td>BP 13 562</td>
<td>BP 13 562</td>
</tr>
<tr>
<td>3, Avenue Hubert Curien</td>
<td>3, Avenue Hubert Curien</td>
</tr>
<tr>
<td>31035 TOULOUSE Cedex 1</td>
<td>31035 TOULOUSE Cedex 1</td>
</tr>
<tr>
<td>Phone: +33 5 34 50 61 94</td>
<td>Phone: +33 5 34 50 61 94</td>
</tr>
<tr>
<td>Fax: +33 5 34 50 69 69</td>
<td>Fax: +33 5 34 50 69 69</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:richard.roche@pierre-fabre.com">richard.roche@pierre-fabre.com</a></td>
<td>E-mail: <a href="mailto:richard.roche@pierre-fabre.com">richard.roche@pierre-fabre.com</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>CONTRACT RESEARCH ORGANISATIONS</strong></th>
<th><strong>CONTRACT RESEARCH ORGANISATIONS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>For Feasibility, Monitoring and Regulatory issues:</strong></td>
<td><strong>For Feasibility, Monitoring and Regulatory issues:</strong></td>
</tr>
<tr>
<td>Pharmaceutical Service Network (PSN)</td>
<td>Pharmaceutical Service Network (PSN)</td>
</tr>
<tr>
<td>Rufino Gonzalez</td>
<td>Rufino Gonzalez</td>
</tr>
<tr>
<td>28 037 Madrid - SPAIN</td>
<td>28 037 Madrid - SPAIN</td>
</tr>
<tr>
<td>Phone: +34 91 375 6930 - Fax: +34 91 375 6931</td>
<td>Phone: +34 91 375 6930 - Fax: +34 91 375 6931</td>
</tr>
<tr>
<td>E-mail: <a href="http://www.psnorglobal.org">www.psnorglobal.org</a></td>
<td>E-mail: <a href="http://www.psnorglobal.org">www.psnorglobal.org</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><strong>SYNOPSIS</strong></th>
<th><strong>SYNOPSIS</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Planned Study Period:</strong></td>
<td><strong>Planned Study Period:</strong></td>
</tr>
<tr>
<td><strong>Diagnosis and Criteria for Inclusion:</strong></td>
<td><strong>Diagnosis and Criteria for Inclusion:</strong></td>
</tr>
<tr>
<td>Inclusion Criteria:</td>
<td>Inclusion Criteria:</td>
</tr>
<tr>
<td>2. Patients with persistent AF between 7 days and 6 months duration for whom electrical cardioversion is</td>
<td>2. Patients with current episode of persistent AF between 7 days and 6 months duration for whom electrical</td>
</tr>
</tbody>
</table>
warranted.

3. History of first documented persistent AF less than 1 year.

12. For male with a child-bearing potential partner (In Italy only):
   - absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
   - use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to a month after the end of the study

Non-Inclusion Criteria:
Criteria related to pathologies:
1. History of first documented episode of persistent AF more than 1 year

[...]
9. Hyperkalemia or hypokalemia (K>5.5 mEq/L or K < 3.5 mEq/L) at selection

Criteria related to treatments:
[...]
12. Concomitant treatment with any anti-arrhythmic drug (within 7 days prior to selection), except stable dose of digoxin, betablockers, calcium-blockers
13. Previous treatment with oral amiodarone within 12 months prior to inclusion
14. Previous treatment with intravenous amiodarone within 6 months prior to inclusion

Evaluation Criteria:
Efficacy evaluation variables:
Other:
• Evolution of echocardiographic parameters (from V4 to V6 and V9) (Left atrial diameter (mm), Left atrial area (cm²), Left atrial volume (mL), Left atrial volume/BSA (mL/m²), Left ventricular ejection fraction (%), Left ventricular volume (mL), Left ventricular volume/BSA (mL/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL) Left ventricular end systolic diameter (mm), Left ventricular end systolic volume (mL))

Safety criteria:
- Haematology: haematocrit, haemoglobin, RBC, WBC, differential count, platelets

STUDY FLOW-CHART
Please see flow-chart of previous version in appendix 1.
1. INTRODUCTION AND STUDY RATIONALE

1.2. Information on the test product

1.2.3. Clinical data

Part A: Single dose

Regarding the reported Treatment Emergent Adverse Events (TEAEs) that were judged by the Investigator as having a causal relationship with the study drug administration in the absence of an alternative explanation, 4 were observed in the placebo group (palpitation, dizziness in standing position, 2 symptomatic orthostatic hypotensions without loss of consciousness) and 4 in the group of F373280 at the dosage of 16g (meteorism, liquid stool, symptomatic orthostatic hypotension and dizziness in standing position).

3. ETHICAL CONSIDERATIONS RELATING TO THE STUDY

During the study, in case of AF recurrence that would require cardioversion or the introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms, patients will be withdrawn and the tested product stopped. These patients will be considered as treatment failure.

4. STUDY DESIGN

4.1. Overall description

- Visit 4 (V4): W5 (D35 ± 2D): follow-up visit (removing of Holter ECG device and installation of the TTEM)

4.2. Discussion of the study design

4.2.1. Choice of the study population

The study aim is to investigate the product effect in patients with:

Persistent AF history (less than one year) with a duration of the current episode from 7 days to 6 months

 [...] For the successful rate of electrical cardioversion, patients should have a stable medical treatment of heart failure and should not have myocardial infarction or unstable angina or unstable ischemic coronary artery (assessed by coronary angiography or cardiac stress test or effort test within 6 months before selection).

5. STUDY POPULATION

5.1. Inclusion criteria

Final version 468/1185
### Demographic Characteristics and Other Baseline Characteristics:

1. [...] 
2. Patient with persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted 
3. History of first documented persistent AF less than 1 year 

 [...]

12. For male with a child-bearing potential partner (in Italy only): 
- absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or 
- use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to a month after the end of the study 

### 5.2. Non Inclusion criteria

**Criteria related to pathologies:**

1. History of first documented episode of persistent AF more than 3 years, 
[...] 
9. Hyperkalemia or hypokalemia (K > 5.5 mEq/L or K < 3.5 mEq/L) at selection 

**Criteria related to treatments:**

12. Concomitant treatment with any anti-arrhythmic drug (within 7 days prior to selection), except stable dose of digoxin, betablockers, calcium-blockers 
13. Previous treatment with oral amiodarone within 12 months prior to inclusion 
14. Previous treatment with intravenous amiodarone within 6 months prior to inclusion 

### 5.6. Withdrawal criteria

- Patients who will not revert to sinus rhythm or with early relapse within the observation period after ECV (i.e. unsuccessful ECV) will be considered to have finished follow-up. 
- An occurrence of AF recurrence that would require, at the investigator’s judgement, a cardioversion or an introduction of an anti-arrhythmic because of intolerable and uncomfortable clinical symptoms.

### Demographic Characteristics and Other Baseline Characteristics:

1. [...] 
2. Patient with current episode of persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted 
3. History of first documented persistent AF less than 3 years 

 [...]

12. For male with a child-bearing potential partner (in Italy only): 
- absolute abstention from sexual intercourse during the whole duration of the study and for 3 months after the end of the study or 
- use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to 3 months after the end of the study 

### 5.2. Non Inclusion criteria

**Criteria related to pathologies:**

1. History of first documented episode of persistent AF more than 3 years, 
[...] 
9. Hyperkalemia or hypokalemia (according to the standards of local laboratories) at selection 

**Criteria related to treatments:**

12. Concomitant treatment with ranolazine or any anti-arrhythmic drug (within 7 days prior to selection), except stable dose of digoxin, betablockers, calcium-blockers 
13. Oral amiodarone:
   13a Previous treatment with oral amiodarone within 4 months prior to inclusion 
   13b Intake of oral amiodarone for more than 1 month within 4 to 12 months before inclusion 
14. Previous treatment with intravenous amiodarone within 4 weeks prior to inclusion 

### 5.6. Withdrawal criteria

- Patients who will not revert to sinus rhythm (i.e. unsuccessful ECV) or with early relapse within the observation period after ECV will be considered to have finished follow-up. 
- Occurrence of AF recurrence that would require, at the investigator’s judgement, a cardioversion or an introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms for instance.
6. STUDY TREATMENT
6.3. Distribution to centre and storage
As soon as the Pharmacist or the Investigator receives the trial medication, he/she will check the contents and immediately acknowledges the receipt in the IVRS/IWRS. The copy of the acknowledgement will be kept in the Investigator’s file.

6.4. Allocation of treatments and dispensation to patient
Practically, once the patient’s eligibility is confirmed, at selection visit:
   • The Investigator:
     − Calls the vocal server
     − Answers the questions relating to the patient
     − In return, the treatment number to be allocated for the first 12-week period to the patient is given by the vocal server.

   […]
At visit 5, the Investigator will contact again the IVRS/IWRS to obtain for visit 6 the treatment number for the last 12-week period of treatment according to the same process as described above.

7. CONCOMITANT TREATMENTS
7.2. Prohibited treatments
   [...]  

8. EVALUATION CRITERIA
8.1.2.5. Evolution of echocardiographic parameters
8.1.2.5.1. Definition
The following echocardiographic parameters will be assessed:
Left atrial diameter (mm), Left atrial area (cm²), Left atrial volume (mL), Left atrial volume/BSA (mL/m²), Left ventricular ejection fraction (%), Left ventricular volume (mL), Left ventricular volume/BSA (mL/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL), Left ventricular end systolic diameter (mm) and Left ventricular end systolic volume (mL).

9. STUDY PROCEDURES
Visit 1 - Selection Visit (Week -4 to Week -1)
   • The patient will enter the selection period in which anticoagulant (anti-vitamin K) will be adjusted to achieve an
International Normalized Ratio (INR) of 2 to 3 before electrical cardioversion.

Visit 4 (Week 5: D35 ± 2 days)

Visit 5 (Week 8: D56 ± 7 days) – Visit 6 (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days) - Visit 8 (Week 20: D140 ± 7 days)

In addition:
- at visit 5, the investigator will contact the IVRS/IWRS to obtain another treatment unit to be dispensed at visit 6 for the last 12-week period.
- at visit 6, an echocardiography will be performed, an haematology examination will be done and the red blood cell concentration of DHA will be measured.

10.2.2. Reporting of SAE

All serious adverse events, according to the above-mentioned definitions and regardless of treatment or relationship to study drug, must be reported by the Investigator as soon as he/she is informed of the event.

The Investigator must notify the Sponsor of this event by sending, within 24 hours, the "Notification of serious adverse event" form ("first notification") with all the available information about the event, to the Sponsor's representative:

Gaëlle ALCARAZ
INSTITUT DE RECHERCHE PIERRE FABRE,
Centre de R&D Pierre Fabre – BP 13562
3 Avenue Hubert Curien
31035 TOULOUSE Cedex 1
Phone: +33 5 35 50 62 16
Fax: + 33 5 34 50 65 92
Email: gaelle.alcaraz@pierre-fabre.com

In case of non-inclusion the reporting period ends when the non-inclusion is documented.

13. STATISTICAL ANALYSIS

13.4. Data sets analysed

The following 2 data sets will be analysed (as defined by the Validation Committee): […]

- The Per Protocol Set (PP) which is the subset of the Full Analysis Set composed of all patients with a primary efficacy
criteria available and without any major protocol deviation or other source of bias for primary criteria analyses.

criteria available and without any major protocol deviation or other source of bias for primary criteria analyses. This data set will be used to perform the supportive analysis of the primary efficacy criterion.

16. REFERENCES


16. REFERENCES

[1] F373280 INVESTIGATOR'S BROCHURE, version October 2013
APPENDIX 1

STUDY FLOW-CHART FROM PROTOCOL VERSION 4
<table>
<thead>
<tr>
<th>Weeks</th>
<th>V1</th>
<th>V2</th>
<th>V3</th>
<th>V4</th>
<th>V5</th>
<th>V6</th>
<th>V7</th>
<th>V8</th>
<th>V9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outpatient or Hospitalization (1)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographic characteristics</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medico-surgical history</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant disease</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Concomitant treatment</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Habil</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global physical examination (body weight)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Echocardiography</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Eligibility criteria check</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Blood pressure, heart rate</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>12-Lead ECG Recording</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>INR (2)</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>aPTT, TCT</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
</tr>
<tr>
<td>Biochemistry</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematology</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary pregnancy test</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Red Blood Cell concentrations of DHA</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment allocation</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IVRS (3)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug administration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events recording</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Holter ECG (4)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TTEM (5)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(1) Outpatient or hospitalization according to clinical practice of the centre (less or more than 24 hours)
(2) In case of AVK introduction: INR 2 to 3 times a week, then weekly until the ECV, then every 4 weeks after ECV.
(3) 7-day Holter ECG
(4) 24-hour Holter ECG
(5) 7-day Holter ECG
(6) TTEM everyday from week 6 to week 8. Then every 2 days from week 9 to week 24. In case of AF symptoms. In case of AF recurrence for at least 10 minutes and the patient does not stop the study treatment then TTEM every 4 weeks.
APPENDIX 2

STUDY FLOW-CHART FROM PROTOCOL VERSION 5 (modified version)
<table>
<thead>
<tr>
<th>Weeks</th>
<th>V1</th>
<th>V2</th>
<th>V3</th>
<th>V4</th>
<th>V5</th>
<th>V6</th>
<th>V7</th>
<th>V8</th>
<th>V9</th>
</tr>
</thead>
<tbody>
<tr>
<td>D1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W4 (28 -2D+/+7 D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W5 (35 -2D+/+7 D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W8 (56+/7D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W12 (84+/7D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W16 (112+/7D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W20 (140+/7D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W24 (168+/7D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Outpatient or Hospitalization (1) | X |
| Informed consent | X |
| Demographic characteristics | X |
| Medico-surgical history | X |
| Concomitant disease | X |
| Concomitant treatment | X | X | X | X | X | X | X | X | X |
| Habits | X |
| Global physical examination (body weight) | X | X | X | X | X | X | X | X | X |
| Echocardiography | X | X | X |
| Eligibility criteria check | X | X |
| Blood pressure, heart rate | X | X | X | X | X | X | X | X | X |
| INR | X | X | X | X | X | X | X | X | X |
| aPTT, TCT | X | X | X | X | X | X | X | X | X |
| Blood pressure, heart rate | X | X | X | X | X | X | X | X | X |
| 12-Lead ECG Recording | X | X | X | X | X | X | X | X | X |
| Biochemistry | X |
| Hematology | X | X | X |
| Urinary pregnancy test | X |
| Red Blood Cell concentrations of DHA | X | X | X |
| Treatment allocation | X |
| IVRS/IWRS | X | X | X |
| ECV (3) | X |

| Drug administration | X |
| Adverse events recording | X | X | X | X | X | X | X | X | X |
| Holter ECG | X | X | X | X | X | X | X | X | X |
| TTEGM (6) | X | X | X |

(1) Outpatient or hospitalization according to clinical practice of the centre (less or more than 24 hours)
(2) In case of AVK introduction: INR 2 to 3 times a week, then weekly untill the ECV, then every 4 weeks after ECV.
(3) In patients with AF
(4) 24-hour Holter ECG
(5) 7-day Holter ECG
(6) TTEGM: everyday from week 6 to week 8; then every 2 days from week 9 to week 24; at any time in case of AF symptoms.

In case of AF recurrence for at least 10 minutes and if the patient does not stop the study treatment then TTEGM once a week.
CLINICAL STUDY PROTOCOL

Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

F373280 / Soft Capsules / 1g

Pierre Fabre Study Code:  F 373280 CA 2 01
EudraCT Number:  2012 – 003487 - 48

Sponsor's Representative:  Gaëlle ALCARAZ
INSTITUT DE RECHERCHE PIERRE FABRE - Centre de R&D Pierre Fabre - BP 13562
3 avenue Hubert Curien
31035 TOULOUSE Cédex 1, FRANCE
Phone: +33 5 34 50 62 16
Fax:+33 5 34 50 69 69
E-mail:gaelle.alcaraz@pierre-fabre.com

Study Coordinating Investigator  Pr Savina NODARI
Associate Professor of Cardiology
Department of Clinical and Surgical Specialities,
Radiological Science and Public Health
Section of Cardiovascular Diseases
University Medical School and Spedali Civili Hospital of Brescia
c/o Spedali Civili di Brescia
Piazzale Spedali Civili, 1
25123 - BRESCIA, ITALY
Phone: +39 030 3996 587 – +39 030 393849
Fax: +39 030 3700 359
E-mail: savinanodari@gmail.com; nodari@med.unibs.it

Version 5 –23OCT2013

The information contained in this document is confidential and is the property of the Sponsor, Pierre Fabre Medicament. This information is given for the needs of the study and must not be disclosed without prior written consent of the Sponsor Pierre Fabre Medicament. Persons to whom this information is given for the needs of the study must be informed that it is confidential and must not be disclosed.
SPONSOR PERSONNEL

PIERRE FABRE MEDICAMENT
represented by
Institut de Recherche Pierre Fabre

Clinical Study Manager (Monitor)
Gaëlle ALCARAZ
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1, FRANCE

Medical Director
Richard ROCHE, MD
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1, FRANCE
CONTRACT RESEARCH ORGANISATIONS

For Feasibility, Monitoring and Regulatory issues:
Pharmaceutical Service Network (PSN)
Rufino Gonzalez
28 037 Madrid - SPAIN
Phone: +34 91 375 6930 - Fax: +34 91 375 6931
E-mail: www.psnglobal.org

For Feasibility, Monitoring and Regulatory issues (in Spain):
Alpha Bioresearch
Paseo de la Castellana, 163 - 2º Izquierda
28 046 Madrid - SPAIN
Phone: +34 91 745 2520 - Fax: +34 91 745 0653
E-mail: teresa.bricio@alphabioresearch.com

For Centralised Randomisation and Electronic Case Report Form
S-Clinica
6, Chaussée de Boondael
B-1050 Brussels - BELGIUM
Phone: +32 2 645 0567 - Fax: +32 2 645 0569
E-mail: irena.seredina@s-clinica.com

For Centralised Reading of Holder ECG and TTEM and equipment supply:
Biomedical System
1945 Chaussée de Wavre
B-1160 Brussels - BELGIUM
Phone: +32 2 661 20 70 - Fax: +32 2 661 20 71
E-mail: sjacobs@biomedsys.com

For intra erythrocyte DHA dosage:
Agrocampus Ouest
Laboratoire de Biochimie
65 rue de Saint Brieuc – CS 84215
35042 RENNES Cedex - FRANCE
Phone: +33 2 23 48 55 49 - Fax: +33 2 23 48 55 50
E-mail: daniel.catheline@agrocampus-ouest.fr

For transportation of blood sample to the Analytical centre (Agrocampus) and material supply:
Theradis Pharma
41, chemin des Presses
06800 CAGNES-SUR-MER – FRANCE
Phone: +33 (0)4 97 02 07 07 - Fax: +33 (0)4 97 10 08 78
E-mail: chantal.raffy@theradis.pharma.com
For refund of patients expenses linked to the study (in France):
CLINACT
6-10 rue TROYON
92310 SEVRES – FRANCE
Phone: +33 1 46 90 27 27 - Fax: +33 1 46 23 01 56
Email: sebastien.beaumont@clinact.com
Protocol F 373280 CA 2 01
APPROVAL FORM
Protocol Version 5 – 23 OCT 2013

Sponsor's Representative:
Medical Director:
Richard ROCHE, MD

Date: 29/10/2013 Signature:

Study Coordinating Investigator:
Savina NODARI, MD

Date: 30/10/2013 Signature:

F373280 Clinical Study Protocol – Version 5– 23OCT2013
Country Coordinating Investigator:

<table>
<thead>
<tr>
<th>&quot;Name&quot;</th>
<th>Date:</th>
<th>Signature:</th>
</tr>
</thead>
</table>

Country: ………………………
By my signature below, I, Dr / Pr "

, hereby confirm that I agree:

- to conduct the trial described in the protocol F 373280 CA 2 01, dated 23 October 2013 in compliance with GCP, with applicable regulatory requirements and with the protocol agreed upon by the Sponsor Pierre Fabre Médicament and given approval / favourable* opinion by the Ethics Committee;
- to document the delegation of significant study-related tasks and to notify the Sponsor of changes in site personnel involved in the study;
- to comply with the procedure for data recording and reporting;
- to allow monitoring, auditing and inspection;
- to retain the trial-related essential documents until the Sponsor informs that these documents are no longer needed.

Furthermore, I hereby confirm that I will have and will use the available adequate resources, personnel and facilities for conduct this trial.

I have been informed that certain regulatory authorities require the Sponsor Pierre Fabre Médicament to obtain and supply details about the investigator’s ownership interest in the Sponsor or the study drug, and more generally about his/her financial relationships with the Sponsor. The Sponsor will use and disclose the information solely for the purpose of complying with regulatory requirements.

Hence I agree:

- to supply the Sponsor with any information regarding ownership interest and financial relationships with the Sponsor (including those of my spouse and dependent children);
- to promptly update this information if any relevant changes occur during the course of the study and for 1 year following completion of the study;
- that the Sponsor may disclose this information about such ownership interests and financial relationships to regulatory authorities.

* To be adapted

Date: 
Signature:
# TABLE OF CONTENTS OF CLINICAL STUDY PROTOCOL

1. **INTRODUCTION AND STUDY RATIONALE** ......................................................... 22
   1.1. TARGET PATHOLOGY AND THERAPY .......................................................... 22
   1.2. INFORMATION ON THE TEST PRODUCT ..................................................... 24
      1.2.1. Chemical and pharmaceutical characteristics ........................................ 25
         1.2.1.1. Nomenclature and structure ............................................................... 25
         1.2.1.2. Physical and chemical general properties ......................................... 25
      1.2.2. Non-clinical Data ....................................................................................... 26
         1.2.2.1. Pharmacological profile ....................................................................... 26
         1.2.2.2. Safety pharmacology ........................................................................... 27
         1.2.2.3. Toxicology profile ................................................................................ 27
         1.2.2.4. Pharmacokinetic data .......................................................................... 27
      1.2.3. Clinical data ............................................................................................... 27
   1.3. STUDY RATIONALE ......................................................................................... 30
   1.4. OVERALL RISK AND BENEFIT ASSESSMENT .............................................. 30

2. **STUDY OBJECTIVES** ....................................................................................... 33
   2.1. PRIMARY OBJECTIVE ..................................................................................... 33
   2.2. SECONDARY OBJECTIVES .............................................................................. 33

3. **ETHICAL CONSIDERATIONS RELATING TO THE STUDY** ............................. 33

4. **STUDY DESIGN** ............................................................................................. 35
   4.1. OVERALL DESCRIPTION ................................................................................ 35
   4.2. DISCUSSION OF THE STUDY DESIGN ......................................................... 35
      4.2.1. Choice of the Study Population ................................................................. 35
      4.2.2. Choice of the Study Design ....................................................................... 36
      4.2.3. Choice of the Dose .................................................................................... 38
      4.2.4. Choice of the Sample Size ....................................................................... 38

5. **STUDY POPULATION** ..................................................................................... 38
   5.1. INCLUSION CRITERIA ....................................................................................... 38
   5.2. NON INCLUSION CRITERIA ........................................................................... 39
   5.3. NUMBER OF PATIENTS ................................................................................... 40
   5.4. RECRUITMENT MODALITIES ....................................................................... 41
   5.5. PATIENT IDENTIFICATION .......................................................................... 41
   5.6. WITHDRAWAL CRITERIA .............................................................................. 41
   5.7. REPLACEMENT OF PATIENTS ..................................................................... 42
   5.8. POST-STUDY EXCLUSION PERIOD ............................................................... 42
   5.9. STUDY CARD AND LETTER FOR GENERAL PRACTITIONER(S) .................. 42
6. STUDY TREATMENT

6.1. SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT

6.2. PACKAGING AND LABELLING

6.2.1. Packaging

6.2.2. Labelling

6.3. DISTRIBUTION TO CENTRE AND STORAGE

6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT

6.5. DRUG ADMINISTRATION

6.5.1. Duration of Treatment

6.5.2. Dose Schedule

6.5.3. Route and Conditions of Administration

6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT

6.7. RECALL OF INVESTIGATIONAL PRODUCTS

7. CONCOMITANT TREATMENTS

7.1. ANTI-VITAMIN K TREATMENT

7.2. PROHIBITED TREATMENTS

7.3. AUTHORISED TREATMENTS

8. EVALUATION CRITERIA

8.1. PRIMARY EFFICACY CRITERION

8.1.1. Time to the first Atrial Fibrillation Recurrence

8.1.1.1. Definition

8.1.1.2. Schedule

8.1.1.3. Evaluation Methods

8.1.2. Secondary Efficacy Criteria

8.1.2.1. Numbers of AF episodes in the first week following visit 3 (ECV visit)

8.1.2.2. Duration of AF episodes in the first week following visit 3 (ECV visit)

8.1.2.3. Clinical parameters evaluation

8.1.2.4. Cardioversion assessment

8.1.2.5. Evolution of echocardiographic parameters

8.2. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA

8.2.1. Definition

8.2.2. Blood samples

8.2.2.1. Collection schedule

8.2.2.2. Technical handling

8.2.3. DHA concentration measurement

8.3. SAFETY ASSESSMENT

8.3.1. Adverse Events

8.3.2. Laboratory Investigations
8.3.2.1 Schedule ......................................................................................................................... 56
8.3.2.2 Technical Procedures and Parameters ................................................................................. 56
8.3.3 Global Physical Examination .................................................................................................. 57
8.3.4 Vital Signs .............................................................................................................................. 57
8.3.4.1 Schedule .............................................................................................................................. 57
8.3.4.2 Technical Procedure and Parameters ..................................................................................... 57
8.3.5 Electrocardiogram (ECG) ........................................................................................................ 58
8.3.5.1 Schedule .............................................................................................................................. 58
8.3.5.2 Technical Procedure and Parameters ..................................................................................... 58
8.3.6 Coagulation parameters .......................................................................................................... 58
8.3.7 Concomitant Treatments ......................................................................................................... 59
8.4 COMPLIANCE .............................................................................................................................. 59

9. STUDY PROCEDURES ................................................................................................................. 59

10. ADVERSE EVENTS: DEFINITION AND REPORTING ............................................................. 65
10.1 ADVERSE EVENTS ..................................................................................................................... 65
10.1.1 Definition of Adverse Events .................................................................................................. 65
10.1.2 Grading of Adverse Events ..................................................................................................... 66
10.1.3 Reporting of Adverse Events .................................................................................................. 66
10.2 SERIOUS ADVERSE EVENTS (SAE) ...................................................................................... 66
10.2.1 Definition ............................................................................................................................... 66
10.2.2 Reporting of SAE .................................................................................................................... 67
10.2.3 Follow-up of SAE ................................................................................................................... 67
10.2.4 SAE Occurring After the Study ............................................................................................ 68
10.3 REPORTING OF OVERDOSAGE TO THE SPONSOR .............................................................. 68
10.4 REPORTING OF PREGNANCY TO THE SPONSOR ............................................................... 68
10.5 SPONSOR'S RESPONSIBILITIES FOR SAFETY REPORTING PURPOSES ............................... 69

11. DATA COLLECTION AND STUDY MONITORING .................................................................. 69
11.1 DATA COLLECTION .................................................................................................................. 69
11.1.1 Case Report Form ................................................................................................................... 69
11.1.2 Source Documents .................................................................................................................. 70
11.2 STUDY MONITORING .............................................................................................................. 70
11.2.1 Monitoring visits ...................................................................................................................... 70
11.2.1.1 Site Preselection Visit ......................................................................................................... 71
11.2.1.2 Initiation Visit ........................................................................................................................ 71
11.2.1.3 Follow-up Visits .................................................................................................................... 71
11.2.1.4 Closing Visit .......................................................................................................................... 72
11.2.2 Direct Access to Source Documents ....................................................................................... 72
11.3 INDEPENDENT DATA MONITORING COMMITTEE ............................................................ 72

12. DATA MANAGEMENT .................................................................................................................. 73
12.1 DATA ENTRY .............................................................................................................................. 73
12.2 DATA CLEANING ....................................................................................................................... 73
12.3. DATA CODING .................................................................................................................. 73
12.4. DATA STORAGE ............................................................................................................... 74
12.5. DATABASE LOCK ............................................................................................................. 74

13. STATISTICAL ANALYSIS ......................................................................................................... 74
13.1. GENERAL CONSIDERATIONS ........................................................................................ 74
13.2. SAMPLE SIZE ..................................................................................................................... 75
13.3. PROTOCOL DEVIATIONS ................................................................................................ 75
13.4. DATA SETS ANALYSED .................................................................................................. 75
13.5. HANDLING OF DROPOUTS AND MISSING DATA ..................................................... 76
13.5.1. Dropouts ............................................................................................................................ 76
13.5.2. Repositioning of Visits ...................................................................................................... 76
13.5.3. Missing Data ...................................................................................................................... 76
13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS ............................... 76
13.7. EFFICACY ANALYSIS ...................................................................................................... 77
13.7.1. Primary Criterion ............................................................................................................... 77
13.7.1.1. Primary Analysis ............................................................................................................ 77
13.7.1.2. Supportive Analysis ....................................................................................................... 77
13.7.2. Secondary Criteria ............................................................................................................. 77
13.7.2.1. Numbers of Atrial Fibrillation Episodes ........................................................................ 77
13.7.2.2. Duration of Atrial Fibrillation Episodes ......................................................................... 78
13.7.2.3. Time to first AF recurrence less than 10 minutes or symptomatic .................................. 78
13.7.2.4. Clinical parameters evaluation ....................................................................................... 78
13.7.2.5. Biomarker analysis: red blood cell concentrations of DHA ........................................... 78
13.8. SAFETY ANALYSIS .......................................................................................................... 79
13.8.1. Adverse Events .................................................................................................................. 79
13.8.2. Clinical Laboratory Evaluation ......................................................................................... 80
13.8.3. Global Physical Examination ............................................................................................ 82
13.8.4. Vital Signs, Physical Findings and Other Observations Related to Safety ....................... 82
13.8.4.1. Vital Sign Measurements Over Time ............................................................................. 82
13.8.4.2. Body weight ................................................................................................................... 82
13.8.4.3. Individual Patient Changes ............................................................................................. 82
13.8.5. ECG ................................................................................................................................... 83
13.8.6. Coagulation parameters ..................................................................................................... 83
13.9. CONCOMITANT TREATMENTS ..................................................................................... 83
13.10. COMPLIANCE .................................................................................................................... 83
13.11. INTERIM ANALYSIS AND DATA MONITORING ........................................................ 84

14. GENERAL ETHICAL CONSIDERATIONS ........................................................................ 84
14.1. ETHICAL CONDITIONS ................................................................................................... 84
14.2. ETHICS COMMITTEE AND LEGAL REQUIREMENTS ................................................... 84
14.3. PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM............. 85
14.4. PERSONAL DATA PROTECTION ..................................................................................... 85
SYNOPSIS

<table>
<thead>
<tr>
<th>Name of Sponsor:</th>
<th>Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Finished Product:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Name of Active Substance:</td>
<td>F373280 (Panthenyl-Ester of DHA)</td>
</tr>
<tr>
<td>Title of the Study:</td>
<td>Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.</td>
</tr>
<tr>
<td>Abbreviated Title:</td>
<td>International, multicentric, randomised, double-blind, placebo controlled study</td>
</tr>
<tr>
<td>Study Coordinating Investigator:</td>
<td>Pr Savina NODARI</td>
</tr>
<tr>
<td>Study Centres:</td>
<td>International, multicentric</td>
</tr>
</tbody>
</table>
| Publication / Rationale: | F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation (AF) patients with chronic heart failure. The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of AF induced by burst pacing.[1] Moreover, the effectiveness of PolyUnsaturated Fatty Acid (PUFA) has been proven in the following conditions:  
- prevention of AF recurrence in patients with persistent AF, in co-administration with amiodarone (add on therapy) [2]  
- Improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]  
Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent atrial fibrillation and chronic heart failure. This phase IIa study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after electrical cardioversion (ECV) in patients with persistent atrial fibrillation and chronic heart failure. |
| Planned Study Period: | January 2013 – January 2015 |
| Clinical Phase: | Ila |
| Objectives: | Primary:  
- Efficacy of F373280 on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure |
| | Secondary:  
- Efficacy of F373280 on the efficiency of direct electrical cardioversion  
- Effect of F373280 on echocardiographic parameters  
- Safety and tolerability of F373280 |
| Methodology: | - International, multicentre, randomised, double-blind, placebo-controlled  
- Selection period  
- Start of treatment 4 weeks before ECV  
  - Condition to ECV:  
    - INR 2-3 anti-vitamin K should be given at least 3 weeks before ECV)  
    - No spontaneous cardioversion before ECV  
- Follow-up 20 weeks after visit 3 (ECV visit)  
  - Condition: successful ECV or spontaneous CV  
- Cardiac monitoring:  
  - 7-days continuous ECG ambulatory recording (Holter ECG) between visit 3 (ECV visit) and visit 4 (week 5) in patients with sinusal rhythm  
  - TTEM: daily transmission from week 6 to week 8; then every two days from week 9 to week 24, and in case of AF symptoms  
- Treatment duration: 24 weeks |
| Study Schedule: | 9 visits will be scheduled:  
- V1/ W-4 to W-1: selection visit (7 to 28 days before the inclusion visit)  
- V2/ D1: Inclusion visit (start of treatment)  
- V3/ W4 (D28 -2+/7 days): cardioversion visit (outpatient or hospitalization according to
clinical practice of the centre) (installation of the Holter device)
- V4/ W5 (D35± 2 days): follow-up visit (removing of the Holter device and installation of the TTEM)
- V5/ W8 (D56± 7 days): follow-up visit
- V6/ W12 (D84 ± 7 days): follow-up visit
- V7/ W16 (D112 ± 7 days): follow-up visit
- V8/ W20 (D140 ± 7 days): follow-up visit
- V9/ W24 (D168 ± 7 days): final study visit

<table>
<thead>
<tr>
<th>Number of Patients:</th>
<th>76 x 2 patients</th>
</tr>
</thead>
</table>

### Diagnosis and Criteria for Inclusion:

**Inclusion Criteria:**

**Demographic Characteristics and Other Baseline Characteristics:**

1. Men or women aged more than 18 years (inclusive)
2. Patients with current episode of persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted
3. History of first documented persistent AF less than 3 years.
4. History of ischemic or non ischemic heart failure
5. NYHA class I or II chronic heart failure at selection and at inclusion
6. Reduced left ventricular ejection fraction between 30% and 45% inclusive (using the two-dimensional echocardiography biplane Simpson’s rule) at selection and at inclusion
7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers
8. Left atrial area ≤ 40 cm² at selection and at inclusion
9. Patients treated or having to be treated by anti-vitamin K
10. For female patient of child-bearing potential:
    - **in all the countries except Italy:**
      - use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator, for at least 2 months before the selection in the study, and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment
      - documented as surgically sterilized
    - **in Italy only:**
      - absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
      - use of double barrier contraception method (use of effective medical contraception method) from at least 2 months before the start of the study to the entire duration of the study and for a month after the end of the study or
      - documented as surgically sterilized
11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion
12. For male with a child-bearing potential partner (in Italy only):
    - Absolute abstention from sexual intercourse during the whole duration of the study and for 3 months after the end of the study or
    - use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to 3 months after the end of the study.

### Ethical /legal considerations:

13. Having signed his/her written informed consent,
14. Affiliated to a social security system, or is beneficiary (if applicable in the national regulation)

**Non-Inclusion Criteria:**

**Criteria related to pathologies:**

1. History of first documented episode of persistent AF more than 3 years
2. More than two successful cardioversions (electrical or pharmacological) in the last 6
<table>
<thead>
<tr>
<th>Exclusion criteria before V3:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients not stabilized for INR (i.e. values not between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed in the same day (before ECV) ECV will be performed in patients without dyskalemia If necessary for obtaining stabilized INR between 2 and 3, the ECV (and following visits) could be postponed by 7 days.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Test Product:</th>
</tr>
</thead>
<tbody>
<tr>
<td>F373280 Soft Capsules</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dose:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arm with 1g of F373280</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Mode of Administration:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral, one capsule each evening with dinner.</td>
</tr>
</tbody>
</table>
### Duration of Treatment:
24 weeks of treatment exposure with F373280 (25 weeks if ECV postponed by 1 week)

### Reference Therapy
Placebo soft capsules
Placebo will be administered in the same conditions as the tested product.

### Mode of Administration:
Oral, one capsule each evening with dinner

### Evaluation Criteria:

#### Efficacy evaluation variables:

**Primary evaluation variable:**
- Time to first Atrial Fibrillation recurrence defined by the first episode of AF lasting for at least 10 minutes (Follow up of 20 weeks after visit 3 (ECV visit)).

Handling of AF recurrences: 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) between visit 3 (ECV visit) and visit 4 (week 5). Then, the follow up will be documented using the TTEM: daily transmission from week 6 to week 8. Then, every two days from week 9 to week 24.

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF will be assessed after visit 3 (week 5).

Moreover, during this TTEM period, if patient experiences any AF symptoms, it should be recorded and documented using the TTEM.

All ECG traces will be evaluated by a Central Reading Laboratory.

**Secondary evaluation variables:**
During the 7-day continuous ECG monitoring,
- Numbers of AF episodes
- Duration of AF episodes

**Clinical parameters:**
During the whole study:
- Number of recurrence of symptomatic AF episodes
- EHRA score
- Hospitalization for cardiovascular events
- Hospitalization for thromboembolic stroke
- All causes of hospitalization

**Cardioversion:**
- Assessment of spontaneous cardioversion
- Assessment of successful cardioversion
- Number of patients needing another cardioversion after the initial ECV

**Other:**
- Evolution of echocardiographic parameters (from V4 to V6 and V9) (Left atrial diameter (mm), Left atrial area (cm²), Left atrial volume (mL), Left atrial volume/BSA (mL/m²), Left ventricular ejection fraction (%), Left ventricular end diastolic volume/BSA (mL/m²), Left ventricular end systolic volume/BSA(mL/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL) Left ventricular end systolic diameter (mm), Left ventricular end systolic volume (mL))
- Evolution of omega 3 index and intra erythrocyte DHA (*For this assessment samples will be centralized*).

**Safety criteria:**
- Adverse events (observed and / or spontaneously reported)
- Vital signs (Blood pressure (supine and standing), heart rate
- Physical examination (body weight)
- Standard 12-lead ECG: heart rate (bpm), PR (ms), QRS (ms), QT (ms), repolarisation patterns (ECG not centralized)
- Haematology: haematocrit, haemoglobin, red blood cell (RBC) count, white blood cell (WBC) count, WBC differential count, reticulocytes, platelets
- Biochemistry: sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatin phosphokinase (CPK) fibrinogen *(local laboratory)*
Coagulation parameters: Activated partial thromboplastin time (aPTT), thrombin clotting time (TCT), INR (local laboratory), Prothrombine Time (PT)

<table>
<thead>
<tr>
<th>Statistical Methods:</th>
<th>Sample Size:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assuming an AF recurrence rate under placebo of 85%, a power of 80%, an alpha risk of 5% and a rate of not assessable patients of 15%, 76 randomised patients per group will be necessary, using a log-rank test of survival curves, a difference between groups of 20%.</td>
</tr>
</tbody>
</table>

Primary Efficacy Analysis
The primary analysis, performed on the Full Analysis Set (FAS: all randomised patients with at least one dose of treatment and with a successful cardioversion observed at visit 3), will be a survival analysis using the Kaplan Meier method and Cox regression model.

Secondary Analyses
All secondary efficacy criteria will be described and compared using appropriate tests on the FAS.

Safety Analyses
Descriptive statistics will be performed on the Safety Set (all randomised patients with at least one dose of treatment).
### STUDY FLOW-CHART

<table>
<thead>
<tr>
<th>V1</th>
<th>V2</th>
<th>V3</th>
<th>V4</th>
<th>V5</th>
<th>V6</th>
<th>V7</th>
<th>V8</th>
<th>V9</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Weeks</strong></td>
<td>W-4 to W-1</td>
<td>D1</td>
<td>W4 (28-2D/+7 D)</td>
<td>W5 (35-2D/+7 D)</td>
<td>W8 (56+/-7D)</td>
<td>W12 (84+/-7D)</td>
<td>W16 (112+/-7D)</td>
<td>W20 (140+/-7D)</td>
</tr>
<tr>
<td><strong>Outpatient or Hospitalization (1)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Informed consent</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Demographic characteristics</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Medico-surgical history</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Concomitant disease</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Concomitant treatment</strong></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Habits</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Global physical examination (body weight)</strong></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Echocardiography</strong></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Eligibility criteria check</strong></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Blood pressure, heart rate</strong></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>12-Lead ECG Recording</strong></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>INR</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>aPTT, TCT</strong></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Biochemistry</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hematology</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Urinary pregnancy test</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Red Blood Cell concentrations of DHA</strong></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Treatment allocation</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IVRS/IWRS</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ECV (3)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Drug administration</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adverse events recording</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Holter ECG</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>TTEM (6)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

---

1. **Outpatient or hospitalization according to clinical practice of the centre (less or more than 24 hours)**
2. **INR** (in case of AVK introduction: INR 2 to 3 times a week, then weekly until the ECV, then every 4 weeks after ECV)
3. **INR** (in patients with AF)
4. **TTEM**: everyday from week 6 to week 8, then every 2 days from week 9 to week 24; at any time in case of AF symptoms.
5. **TTEM**: at any time in case of AF recurrence for at least 10 minutes and if the patient does not stop the study treatment, then TTEM once a week.
### LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>aPTT</td>
<td>Activated partial thromboplastin time</td>
</tr>
<tr>
<td>AE</td>
<td>Adverse event</td>
</tr>
<tr>
<td>AF</td>
<td>Atrial fibrillation</td>
</tr>
<tr>
<td>ALA</td>
<td>Alpha-linoleic acid</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine aminotransferase</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate aminotransferase</td>
</tr>
<tr>
<td>AUC</td>
<td>Area under the plasma concentration versus time curve</td>
</tr>
<tr>
<td>AUC_{inf}</td>
<td>Total area under the curve extrapolated to infinity</td>
</tr>
<tr>
<td>AVK</td>
<td>Anti-vitamin K</td>
</tr>
<tr>
<td>βHCG</td>
<td>beta human chorionic gonadotrophin</td>
</tr>
<tr>
<td>BLQ</td>
<td>Below the limit of quantification</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>BP</td>
<td>Blood pressure</td>
</tr>
<tr>
<td>BSA</td>
<td>Body Surface Area</td>
</tr>
<tr>
<td>CEP</td>
<td>Protocol evaluation committee</td>
</tr>
<tr>
<td>CHMP</td>
<td>Committee for medicinal products for human use</td>
</tr>
<tr>
<td>C_{max}</td>
<td>Maximum concentration</td>
</tr>
<tr>
<td>C_{min}</td>
<td>Minimum concentration</td>
</tr>
<tr>
<td>CNALV</td>
<td>Clinically noteworthy abnormal laboratory value</td>
</tr>
<tr>
<td>CPK</td>
<td>Creatin phosphokinase</td>
</tr>
<tr>
<td>CPP</td>
<td>Comité de protection des personnes</td>
</tr>
<tr>
<td>CRA</td>
<td>Clinical research associate</td>
</tr>
<tr>
<td>CRT</td>
<td>Cardiac resynchronization therapy</td>
</tr>
<tr>
<td>CSC</td>
<td>&quot;Clinically Significant Change&quot;, i.e., Predefined potentially clinically significant change leading to a potentially clinically significant value (vital signs)</td>
</tr>
<tr>
<td>CV</td>
<td>Coefficient of variation</td>
</tr>
<tr>
<td>DBP</td>
<td>Diastolic blood pressure</td>
</tr>
<tr>
<td>DHA</td>
<td>Docosahexaenoic acid</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics committee</td>
</tr>
<tr>
<td>ECG</td>
<td>Electrocardiogram</td>
</tr>
<tr>
<td>ECHO –TE</td>
<td>Trans-esophageal echocardiograph</td>
</tr>
<tr>
<td>ECV</td>
<td>Electrical cardioversion</td>
</tr>
<tr>
<td>EHRA</td>
<td>European heart rhythm association</td>
</tr>
<tr>
<td>EPA</td>
<td>Eicosapentaenoic acid</td>
</tr>
<tr>
<td>e-CRF</td>
<td>Electronic case report form</td>
</tr>
<tr>
<td>FAS</td>
<td>Full analysis set</td>
</tr>
<tr>
<td>Fe</td>
<td>Fraction of the administered drug excreted in urine</td>
</tr>
<tr>
<td>GCP</td>
<td>Good clinical practice</td>
</tr>
<tr>
<td>GFR</td>
<td>Glomerular Filtration Rate</td>
</tr>
<tr>
<td>HBs</td>
<td>Hepatitis B antigen</td>
</tr>
<tr>
<td>HCV</td>
<td>Hepatitis C virus</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Description</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------</td>
</tr>
<tr>
<td>HDL</td>
<td>High density lipoprotein</td>
</tr>
<tr>
<td>HF</td>
<td>Heart failure</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>HR</td>
<td>Heart rate</td>
</tr>
<tr>
<td>ICH</td>
<td>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use</td>
</tr>
<tr>
<td>IDMC</td>
<td>Independent data monitoring committee</td>
</tr>
<tr>
<td>INR</td>
<td>International normalized ratio</td>
</tr>
<tr>
<td>IRPF</td>
<td>Institut de Recherche Pierre Fabre</td>
</tr>
<tr>
<td>IVRS</td>
<td>Interactive voice response system</td>
</tr>
<tr>
<td>LAA</td>
<td>Left atrial area</td>
</tr>
<tr>
<td>LC/MS-MS</td>
<td>Liquid chromatography with tandem mass spectrometry</td>
</tr>
<tr>
<td>LDL</td>
<td>Low density lipoprotein</td>
</tr>
<tr>
<td>LOQ</td>
<td>Limit of quantification</td>
</tr>
<tr>
<td>LVEF</td>
<td>Left ventricular ejection fraction</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical dictionary for regulatory activities</td>
</tr>
<tr>
<td>MR</td>
<td>Mineralocorticoid receptor</td>
</tr>
<tr>
<td>MR perfusion</td>
<td>Magnetic Resonance perfusion</td>
</tr>
<tr>
<td>MTD</td>
<td>Maximum tolerated dose</td>
</tr>
<tr>
<td>N</td>
<td>Number of determinations or replicates</td>
</tr>
<tr>
<td>NOAEL</td>
<td>No observed adverse effect level</td>
</tr>
<tr>
<td>NYHA</td>
<td>New York heart association</td>
</tr>
<tr>
<td>od</td>
<td>Once a day</td>
</tr>
<tr>
<td>PC</td>
<td>“Predefined Change”, i.e., Predefined potentially clinically significant change (lab or vital signs)</td>
</tr>
<tr>
<td>PCA</td>
<td>PC leading to an out-of-range value (lab values)</td>
</tr>
<tr>
<td>PFB</td>
<td>Pierre Fabre Biométrie</td>
</tr>
<tr>
<td>PSC</td>
<td>Potentially Clinically Significant Change</td>
</tr>
<tr>
<td>PSCV</td>
<td>Potentially Clinically Significant Value</td>
</tr>
<tr>
<td>PUFA</td>
<td>PolyUnsaturated fatty acid</td>
</tr>
<tr>
<td>p.o.</td>
<td>Per os</td>
</tr>
<tr>
<td>PP</td>
<td>Per protocol data set</td>
</tr>
<tr>
<td>RBC</td>
<td>Red blood cells</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious adverse event</td>
</tr>
<tr>
<td>SBP</td>
<td>Systolic blood pressure</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>T1/2</td>
<td>Terminal half-life</td>
</tr>
<tr>
<td>T0</td>
<td>Time of drug administration</td>
</tr>
<tr>
<td>T_max</td>
<td>Time to reach the maximal concentration</td>
</tr>
<tr>
<td>TCT</td>
<td>Thrombin clotting time</td>
</tr>
<tr>
<td>TEAEs</td>
<td>Treatment emergent adverse events</td>
</tr>
<tr>
<td>TTTEM</td>
<td>TransTelephonic ECG monitoring</td>
</tr>
<tr>
<td>WBC</td>
<td>White blood cells</td>
</tr>
<tr>
<td>WHO-DRUG</td>
<td>World health organization drug reference list</td>
</tr>
</tbody>
</table>
1. INTRODUCTION AND STUDY RATIONALE

1.1. TARGET PATHOLOGY AND THERAPY

Atrial Fibrillation (AF) is a supraventricular arrhythmia characterized by uncoordinated atrial electric activity with consequent deterioration of atrial mechanical function. It is the most common sustained cardiac rhythm disorder, increasing in prevalence with age. Haemodynamic impairment and thromboembolic events related to AF result in significant morbidity and mortality [7].

In 2009, Decision Resources estimated that there were 7.8 million diagnosed prevalent cases of AF in US, Europe and Japan. This age-related pathology should increase to 9.4 million cases in 2019.

Except for the conventional class I and class III anti-arrhythmic agents, the Polyunsaturated Fatty Acids (PUFAs) constitute one emerging antiarrhythmic therapy. These compounds potently address the AF substrate by directly targeting both the electrical and the structural remodelling of the deficient atria. The n-3 PUFAs, essential for human, are alpha-linoleic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). First, PUFAs specifically modulate ionic channels by fastening their inactivating mode which renders these compounds selective for pathological situations (such as AF) without any major effect in normal conditions. PUFAs are “open Kv1.5 channel blockers” leading to a lengthening of atrial action potential duration and are “persistent Na\textsuperscript{+}v1.5 channel blockers” leading to hyperpolarization of diastolic resting potential. Second, PUFAs influence structural remodelling through their anti-inflammatory effects as they directly compete with arachidonic acid in the production of inflammatory eicosanoids. In summary, PUFAs share unique, well-tolerated antiarrhythmic potential by interacting with the electrical and structural remodelling during sustained AF. In animal studies, it was recently demonstrated that DHA is particularly effective in pathologic conditions such as ischemia and/or AF.
The potential anti-arrhythmic effects of a PUFA were previously developed in AF: nicotinyl ester of DHA (pro-drug based on DHA delivery) was assessed in a two-week ventricular tachypaced canine model. Dogs were subjected to 4 weeks of medication prior to undergoing an electrophysiology study, and received either placebo or nicotinyl ester of DHA. Dogs were tachypaced at 240 beats per min for the final two weeks of the treatment plan. The results showed that the tested PUFA reduced the duration of AF induced by burst pacing, and the incidence of sustained AF, compared to dogs treated with the placebo [1].

In clinical practice, Nodari and coll [2] assessed n-3 PUFAs in the prevention of AF recurrences after electrical cardioversion (ECV). All included patients were treated with amiodarone and a renin-angiotensin-aldosterone system inhibitor. The 199 patients were assigned either to placebo or n-3 PUFAs 2 g/d and then underwent direct ECV 4 weeks later. The primary end point was the maintenance of sinus rhythm at 1 year after cardioversion. At the 1-year follow up, the maintenance of sinus rhythm was significantly higher in the n-3 PUFAs treated patients compared with the placebo group (hazard ratio, 0.62 [95% confidence interval, 0.52 to 0.72] and 0.36 [95% confidence interval, 0.26 to 0.46], respectively; p = 0.0001). The study concludes that in patients with persistent AF on amiodarone and a renin-angiotensin-aldosterone system inhibitor, the addition of n-3 PUFAs 2 g/d improves the probability of the maintenance of sinus rhythm after direct current cardioversion. Previously, during the World Congress of Cardiology in 2006, an abstract reported the effectiveness of PUFAs on top of traditional treatment (amiodarone, beta blockers, renin-angiotensin-aldosterone system inhibitor) in the prevention of AF relapses in patients having undergone ECV. In the PUFA group, AF relapses were significantly lower than in the placebo group at 1 month (3.3% vs 10%; p = 0.043), at 3 months (10% vs 25%; p = 0.004) and at 6 months (13.3% vs 40%; p < 0.0001) [19].

In contrast, in the general AF population (paroxystic atrial fibrillation and persistent atrial fibrillation), PUFAs failed to prove their efficacy [7] because of the absence of cardiac remodelling or because of a short pre-treatment duration before ECV (1 week) [8]. The effects of PUFAs were only observed in patients with persistent AF on add on therapy and after a sufficient pre-treatment before ECV. Persistent AF is commonly associated to heart failure. Previous studies performed in heart failure population demonstrated the benefit of PUFAs on the improvement of
functional ventricular parameters and morbi-mortality, and on the reduction of hospitalisation [3, 4, 5].

Nodari and coll [3] performed a trial in patients with chronic heart failure (NYHA I to III and LVEF< 45%). After a treatment of 133 patients with PUFAs (n=67) or placebo (n=66) at a dosage of 5 g/day for 1 month, then 2 g/day for 11 months, the n-3 PUFAs group and the placebo group differed significantly (p <0.001) in regard to:

- LVEF (increased by 10.4% and decreased by 5.0%, respectively)
- peak VO₂ (increased by 6.2% and decreased by 4.5%, respectively)
- exercise duration (increased by 7.5% and decreased by 4.8%, respectively)
- mean New York Heart Association functional class (decreased from 1.88 +/- 0.33 to 1.61 +/- 0.49 and increased from 1.83 +/- 0.38 to 2.14 +/- 0.65, respectively).

The hospitalization rates for patients with HF were 6% in the n-3 PUFAs and 30% in the placebo group (p <0.0002).

Moertl and coll [4] performed a dose-ranging study in patients with a more severe chronic heart failure (NYHA III and IV and LVEF < 35%). It was a double-blind, randomised, controlled pilot trial in 43 patients treated with PUFAs or placebo for 3 months (1 g/d n3-PUFA (n = 14), 4 g/d n3-PUFA (n = 13), or placebo (n = 16)). After treatment, left ventricular ejection fraction increased in a dose-dependent manner (p = 0.01 for linear trend) in the 4 g/d (baseline vs 3 months [mean ± SD]: 24% ± 7% vs 29% ± 8%, p = 0.005) and 1 g/d treatment groups (24% ± 8% vs 27% ± 8%, p = 0.02).

No changes in any investigated parameters were noted with placebo.

Taking into account these studies performed with PUFAs, it seems that the best target for DHA is persistent AF in patients with heart failure. The aim of this proof of concept study is to assess in stand alone therapy (without association of other anti-arrhythmic treatments), the effect of F373280 in patients with persistent AF and heart failure in the maintenance of sinus rhythm after ECV.

### 1.2. INFORMATION ON THE TEST PRODUCT

F373280 or panthenyl ester of DHA is the mono-ester of panthotenic alcohol and DHA, selected to be developed for the management of AF.

F373280 is a prodrug of DHA.
A brief summary of F373280 known characteristics is presented in this section. For further details, please refer to the F373280 *Investigator’s Brochure*. [1]

1.2.1. **Chemical and pharmaceutical characteristics**

1.2.1.1. **Nomenclature and structure**

Chemical name (IUPAC):

\[(4Z,7Z,10Z,13Z,16Z,19Z)-3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido) \text{ propyl docosa-4,7,10,13,16,19-hexaenoate}\]

Structural formula:

![Structural formula of F373280](image)

Laboratory code: F373280

Molecular formula: C\(_{31}\)H\(_{49}\)NO\(_5\)

Molecular mass: 515.7

**1.2.1.2. Physical and chemical general properties**

**Appearance**: Clear oily viscous liquid

**Solubilities**:

- Water: Practically insoluble
- Alcohol: Very soluble
- Trimethylpentane: Slightly soluble
1.2.2. Non-clinical Data

Non-clinical data are exhaustively detailed in the Investigator’s brochure [1]. A brief summary is provided below.

1.2.2.1. Pharmacological profile

F373280 (mono-ester of panthotenic alcohol and DHA) is a novel pro-drug of DHA which exerts antiarrhythmic properties by interacting with the electrical and structural remodelling of the atria.

Experimental investigations were conducted in HEK293 cell line transfected with human Kv1.5 channel using the whole cell patch clamp technique to evaluate whether F373280 could block the sustained component of IKv1.5. F373280 concentration-dependently reduced Kv1.5 channel activity with an IC$_{50}$ value of 13.7 µM.

The effects of F373280 on atrial effective refractory period were investigated in anesthetized pig using a conventional pacing protocol through epicardial electrodes placed on the left atrium. F373280 administered as a bolus and an infusion (10 mg/kg) significantly increased atrial effective refractory period (23.8 ± 2.2 ms versus -7.3 ± 11.5 ms in the presence of vehicle, p < 0.05). In addition, F373280 was devoid of significant effect on the hemodynamic and the electrocardiogram (ECG) intervals.

Proof of the pharmacological concept was performed with a different DHA derivative named: Nicotinyl ester of DHA (pro-drug based on DHA delivery). Ventricular tachypacing-induced congestive heart failure provides a clinically-relevant animal model of AF associated with structural remodelling, as is often seen clinically. It has been shown that sustained oral PUFA administration suppresses congestive heart failure-induced AF-promotion and fibrosis in the ventricular tachypacing canine model. Nicotinyl ester of DHA was tested in this model, at 1 g/day and 5 g/day, during 4 weeks, to prevent congestive heart failure-related atrial structural remodelling and AF promotion in dogs. Nicotinyl ester of DHA dose dependently reduced heart failure-induced increases in AF duration (989 ± 111 sec, n=5 in the presence of placebo versus 637 ± 196 sec, n=5 in the presence of 1 g/kg/d Nicotinyl ester of DHA and 79 ± 51 sec, n=5, in the presence of 5 g/kg/d Nicotinyl ester of DHA). The protective effect of Nicotinyl ester of DHA was associated with a marked increase of plasma level of DHA and important incorporation of
DHA in the left atrial tissue. Because F373280 similarly to Nicotinyl ester of DHA increases plasma level of DHA, it could be estimated that the compound may exert a similar protective effect [1].

1.2.2.2. Safety pharmacology

A battery of safety pharmacology studies was performed to evaluate the effects of F373280 on the central nervous, cardiovascular and respiratory systems. Data of these studies are exhaustively detailed in the Investigator’s brochure [1]. No particular alerts were evidenced with F373280.

1.2.2.3. Toxicology profile

Concerning the toxicological data, 4-week and 26-week repeat-dose studies in rat and dog were performed. Compared to the high administered doses of F373280 (500 to 2000 mg/kg/day), low circulating concentrations of F373280 were measured.

During these toxicity studies, no toxicity was observed in rat after 4 and 26 weeks of dosing and in dog after 4 weeks of dosing. A NOAEL of 2000 mg/kg/day was established in these repeat toxicity studies.

During the 26-week toxicity study in dogs, the NOAEL was set at 1000 mg/kg/day based on changes observed on red blood cell parameters.

Based on toxicological profiles, F373280 is considered to support the proposed clinical trial.

1.2.2.4. Pharmacokinetic data

According to animal studies described in the Investigator’s brochure [1], the non-clinical pharmacokinetic profile of F373280 is not associated with particular alerts concerning the proposed clinical phase IIa study.

1.2.3. Clinical data

Part A: single dose
Six consecutive single ascending doses were tested (0.5 g, 1 g, 2 g, 4 g, 8 g and 16 g) on 6 independent cohorts of 8 subjects (6 verum + 2 placebo). 49 subjects were treated and 48 completed the study.

No Serious Adverse Events (SAE) occurred in the course of the study.

Regarding the reported Treatment Emergent Adverse Events (TEAEs) that were judged by the Investigator as having a causal relationship with the study drug administration in the absence of an alternative explanation, 3 TEAEs were observed in the placebo group (palpitation, dizziness in standing position, symptomatic orthostatic hypotension without loss of consciousness) and 4 in the group of F373280 at the dosage of 16 g (meteorism, liquid stool, symptomatic orthostatic hypotension and dizziness in standing position). None of these adverse events (AE) were reported in the groups of F373280 at the dosages of 0.5 g, 1 g, 2 g, 4 g and 8 g.

After a single administration of the different tested doses no difference between the tested product and placebo has been reported, regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters (related to coagulation: platelets and fibrinogen) and coagulation parameters (bleeding time, prothrombin time/INR, activated partial thromboplastin time, thrombin clotting time). Variations of these parameters were within the physiological ranges.

After single oral administration of F373280 from 0.5 g to 16 g in 36 young healthy male subjects (6 per dose level), the following was observed:

- **F373280**: Whatever the tested dose there is no circulating F373280 in plasma: only few, sparse and non consecutive samples with quantifiable level of F373280 close to LOQ were observed. This confirms that F373280 is a prodrug.

- **Panthenol**: Cmax and AUC increased with the administered dose between 0.5 and 16 g. Panthenol concentrations were rapidly cleared from plasma with a mean terminal half-life around 2 hours.

- **DHA**: after 0.5 and 1 g, low increased in DHA plasma concentrations compared to the baseline levels led to a high inter-individual variability of the corresponding Pharmacokinetics parameters. Plasma exposure in DHA increased with the administered dose between 2 and 16 g with no departure from proportionality (baseline corrected parameters).
**Part B: Multiple doses**

Three consecutive repeated ascending doses (1, 2 and 4 g) were tested on 3 independent cohorts of 12 subjects (9 verum + 3 placebo, double blind). 36 subjects completed the study. Each treatment was administered over a period of 28 days. Pharmacokinetic parameters were assessed over a period of 14 days.

Among the TEAE judged by the investigator as suspected to F373280, 5/9 TEAEs were classified according the System Organ Class in vascular system disorder with orthostatic hypotension (2 in the 1 g group, 1 in the 2 g group and 2 in the 4 g group) and 4/9 were classified in nervous system disorder with 3 dizziness (2 in the 2 g group and 1 in the 4 g group) and 1 migraine (in the 1 g group). These TEAEs have already been reported with PUFAs and are commonly observed in phase I studies.

After a repeated administration of the different tested doses, no difference between the tested products and placebo was reported regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters. The assessment of coagulation parameters and platelet function after administration of repeated dose of F373280 did not report any bleeding issue. The reported changes in coagulation parameters and platelet function were within physiological ranges.

After a 14-day repeated oral administration of F373280 from 1 g to 4 g, the following was observed:

- **Panthenol**: Cmax and AUC increased with the administered dose between 1 and 4 g. No accumulation of panthenol in plasma was observed.

- **DHA**: Plasma exposure increased with dose. A 2-fold accumulation in total plasma exposure of DHA was observed after 14 days of administration, whatever the administered dose.
1.3. STUDY RATIONALE

F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after ECV in persistent AF patients with chronic heart failure.

The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of AF induced by burst pacing [1].

Moreover, the effectiveness of PUFAs has been proven in the following conditions:

- Prevention of AF recurrence in patients with persistent AF in co-administration with amiodarone (add on therapy) [2],
- Improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5].

Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent AF and chronic heart failure.

This phase IIa study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after ECV in patients with persistent AF and chronic heart failure.

1.4. OVERALL RISK AND BENEFIT ASSESSMENT

F373280 is a new pro-drug of DHA.

DHA is a well-known long chain PUFAs with a long-term clinical experience in cardiovascular diseases. DHA is contained in several medicinal products such as Omacor®, (1 g of Omacor contains about 320 mg of DHA acid) marketed by Laboratoires Pierre Fabre for hypertriglyceridemia and as an adjuvant treatment for secondary prevention after myocardial infarction. According to the summary product characteristics of Omacor® [9]:

- The frequencies of adverse reactions are ranked according to the following: common (>1/100, <1/10); uncommon (>1/1000, <1/100); rare (>1/10000, <1/1000); very rare (<1/10000), not known (cannot be estimated from the available data).
The reported adverse events are:

- Infection and infestations:
  Uncommon: gastroenteritis

- Immune system disorders:
  Uncommon: hypersensitivity

- Metabolism and nutrition disorders:
  Rare: hyperglycaemia

- Nervous system disorders:
  Uncommon: dizziness, dysgeusia
  Rare: headache

- Vascular disorders:
  Very rare: hypotension

- Respiratory thoracic and mediastinal disorders:
  Very rare: nasal dryness

- Gastrointestinal disorders:
  Common: dyspepsia, nausea
  Uncommon: abdominal pain, gastrointestinal disorders, gastritis, abdominal pain upper
  Rare: gastrointestinal pain
  Very rare: lower gastrointestinal haemorrhage

- Hepatobiliary disorders:
  Rare: hepatic disorders

- Skin and subcutaneous tissue disorders:
  Rare: acne, rash pruritic
  Very rare: urticaria

- General disorders and administration site conditions:
  Rare: malaise sensation

- Investigations:
  Very rare: white blood count increased, blood lactate dehydrogenase increased

Moderate elevation of transaminases has been reported in patients with hypertriglyceridaemia.
Panthenol is a well-known substance with a long-term experience in medical, nutraceutic and cosmetic uses. According to the summary product characteristics of a product such as Bépanthene® (tablet indicated in alopecia) which contains panthenol (100 mg), adverse event observed are rare cases of urticaria and erythema [10]. Panthenol is metabolised in panthotenic acid, i.e. B5 vitamin.

Concerning toxicological studies performed results can support the administration of F373280 in the proposed clinical phase II study without particular alert [1].

Any safety warning was reported during a phase I study performed with F373280 administered to 84 healthy volunteers in single dose in a range between 500 mg and 16 g or in repeated dose during 28 days in a range between 1 g and 4 g. Adverse events reported and related to study treatment were minor to moderate. The adverse events were palpitations, orthostatic hypotension, dizziness, meteorism and liquid stool. Most were reported in both groups (placebo and F373280) without a dose relationship. The assessment of coagulation parameters and platelet function after administration of repeated dose of F373280 did not report any bleeding concern: the reported changes in coagulation parameters and platelet function were within physiological ranges.

Moreover, DHA has been associated with anticoagulant products in AF studies [2, 8]. The range of PUFAs doses tested was between 2 g to 3 g (640 mg to 960 mg of DHA) and the range of study durations between 6 to 12 months. This association did not report a significant side effect of bleeding.

DHA has already been used in HF patients in several studies without safety concern [3, 4, 5]. The range of PUFAs doses tested was between 1 g to 5 g (1 g of the tested PUFAs contains about 320 mg of DHA acid) and the range of study durations was between 3 months to 3.9 years.

Thus, inclusion of patients with no specific antiarrhythmic treatment is acceptable. They will receive an anticoagulant treatment to prevent the thrombo-embolic complications of AF (particularly stroke) and the adequate treatments to control the heart rate and heart failure.

In conclusion, the overall available data allow in safe conditions the treatment of patients with persistent AF and chronic heart failure with F373280 in safe conditions.
2. STUDY OBJECTIVES

2.1. PRIMARY OBJECTIVE

The primary objective of the study is to assess the efficacy of F373280 on the maintenance of sinus rhythm after direct ECV in patients with persistent AF and chronic heart failure.

2.2. SECONDARY OBJECTIVES

The secondary objectives of the study are to assess:

- the efficacy of F373280 on the efficiency of direct ECV
- the effect of F373280 on echocardiographic parameters
- the safety and tolerability of F373280

3. ETHICAL CONSIDERATIONS RELATING TO THE STUDY

The trial is conducted according to Good Clinical Practices (CPMP/ICH/135/95), the National regulations and the Declaration of Helsinki and its subsequent amendments (see Appendix 17.1). This protocol and the informed consent form will be submitted for approval to independent local or national Institutional Review Boards/Ethics Committees before the study set up, according to national regulation.

All the protocol amendments or critical events liable to increase the risks incurred by the patients or to compromise the validity of the study or patients' rights will be submitted to the coordinator and to the Ethics Committees.

After being informed orally and in writing of all potential risks and constraints of the trial, as well as their freedom to withdraw their participation at any time, patients will then sign a consent form. A time of reflection will be given to the patients, before giving a written consent and starting the study procedures.

The use of a placebo is in accordance with EMA Addendum to the guideline on antiarrhythmics on AF and atrial flutter (EMA/CHMP/EWP/213056/2010) [21] and is acceptable because the...
included patients will remain under the standard treatment of AF and chronic heart failure. Except anti-arrhythmics, they will receive anticoagulant (anti-vitamin K), rate control treatment, chronic heart failure treatment. During the study, in case of AF recurrence that would require cardioversion or the introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms for instance, patients will be withdrawn and the tested product stopped. These patients will be considered as treatment failure.

In this study, patients will be carefully screened, particularly for their cardiac condition, with ECG, 24-hour holter monitor and echocardiographic data, and their biologic and coagulation condition.

The study will be addressed only to patients requiring an ECV due to their persistent AF, in the following conditions:

- ECV in patients not presenting a contra-indication
- Anticoagulation with anti-vitamin K (AVK) for at least 3 weeks before ECV
- ECV in patients with stabilized INR (i.e. values between 2 and 3; sp to ) on at least 3 consecutive weekly tests performed. Patients not stabilized for INR (i.e. values not between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed in the same day (before ECV). Patients who do not revert to sinus rhythm or present an early relapse within the observation period after ECV will be withdrawn and the tested product stopped.

During the whole study, patients will remain under medical control: visits in cardiology units will be scheduled at least every month. This follow up will include clinical signs, ECG, biological and coagulation parameters. Moreover, patient’s cardiac rhythm will be monitored between visits using daily, then every 2 days Trans Telephonic ECG Monitoring (TTEM) reviewed by a Central Reading Laboratory.
Patients may withdraw from the study at any time without having to give a reason and can expect to receive regular conventional therapy.

4. STUDY DESIGN

4.1. OVERALL DESCRIPTION

This phase IIa trial will be conducted as an international, multicentric, 24 weeks, double-blind, placebo-controlled, randomised, parallel group design, trial in 152 patients suffering from persistent AF and chronic heart failure.

After a 1 to 4-week of run-in period without treatment, patients will be randomised into one of the following treatment groups: F373280 1 g or placebo for 24 weeks.

Nine visits are planned for the study:

- Visit 1 (V1): W-4 to W-1: Selection visit (7 to 28 days before the Inclusion Visit)
- Visit 2 (V2): D1: Inclusion visit (start of treatment)
- Visit 3 (V3): W4 (D28 -2/+7D): cardioversion visit (outpatient or hospitalization according to clinical practice of the centre) (installation of the Holter ECG device)
- Visit 4 (V4): W5 (D35 -2/+7D): follow-up visit (removing of Holter ECG device and installation of the TTEM)
- Visit 5 (V5): W8 (D56 ± 7D): follow-up visit
- Visit 6 (V6): W12 (D84 ± 7D): follow-up visit
- Visit 7 (V7): W16 (D112 ± 7D): follow-up visit
- Visit 8 (V8): W20 (D140 ± 7D): follow-up visit
- Visit 9 (V9): W24 (D168 ± 7D): final study visit

4.2. DISCUSSION OF THE STUDY DESIGN

4.2.1. Choice of the Study Population

The target indication of F373280 will be the maintenance of sinus rhythm after cardioversion of patients with persistent AF and chronic heart failure. In the present proof of concept study, the evaluation will focus on patients within this indication. This target population is justified by:
– The proved efficacy of PUFAs in patients with persistent AF with or without heart failure in co-administration with amiodarone (add on therapy) [2]
– The proved efficacy of PUFAs on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]

The study aim is to investigate the product effect in patients with:
– Persistent AF history (less than three years) with a duration of the current episode from 7 days to 6 months.
– a moderately abnormal systolic heart failure (Left Ventricular Ejection Fraction (LVEF) between 30 to 45% as defined in the report from the American Society of Echocardiography’s Guideline). According to a sub-group analysis performed in patients with persistent AF associated to heart failure (Nodari S. personal data), PUFAs would be effective to prevent recurrence of AF after cardioversion in patients with moderately abnormal LVEF.
– a Left Atrial Area (LAA) not severely abnormal (less than 40 cm$^2$ as defined in the report from the American Society of Echocardiography’s Guideline). According to a sub-group analysis performed in patients with persistent AF associated to heart failure (Nodari S. personal data), PUFAs would not be effective to prevent recurrence of AF after cardioversion of patients with severely abnormal LAA.

For the successful rate of ECV, patients should have a stable medical treatment of heart failure and should not have any myocardial infarction or unstable angina or unstable ischemic coronaropathy assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection.

4.2.2. Choice of the Study Design

As the target indication would be the prevention of AF recurrence after ECV, the study design meets the requirements of EMA guideline on antiarrhythmics in AF (EMA/CHMP/EWP/213056/2010) [21].
As F373280 aims to be a safe treatment for the prevention of AF recurrence, it will not be tested as an add-on therapy during the study. To avoid any interaction with the tested product, antiarrhythmic class I and III will be forbidden during the study.

The study design is defined in order to avoid methodological bias. A double blind study is appropriate to assess the efficacy and safety of the use of F373280 to prevent recurrence of AF episodes. Moreover, this study design is similar to the design of almost all trials that have assessed intervention for rhythm control [2, 8, 11, 12].

According to the target indication, only patients with persistent AF and requiring an ECV will be included in order to assess the time to first documented recurrence of AF since cardioversion.

To confirm the persistent nature of AF, a 24-hour holter monitoring will be performed during the selection visit.

Eligible participants will enter a selection phase in which anticoagulant treatment (AVK) will be adjusted to achieve an International Normalized Ratio (INR) of 2.0 to 3.0 before ECV. According to guidelines for the management of AF [6], AVK should be given at least 3 weeks before cardioversion because of risk of thrombo-embolism due to post-cardioversion.

Experimental data suggest that the maximal incorporation of n-3 PUFAs in the myocardial cell membrane takes up to 28 days to occur [22]. In addition, as shown in Nodari’s study [2], the duration of pre-treatment with PUFAs before cardioversion appears to be a contributing factor in success. Therefore, before starting follow up for the assessment of AF recurrence, treatment with F373280 should be started 28 days before ECV.

Detection of AF recurrence will be performed using systematic (scheduled) ECG recording, thus allowing detection of asymptomatic (about 50% of episodes) as well as symptomatic AF episodes. According to previous studies, most of AF recurrences occurred during the first days after cardioversion [11, 15]. So that, the heart rhythm will be closely monitored during the first week after successful cardioversion using an ambulatory continuous 7-day holter ECG recording in order to increase sensibility to detect asymptomatic AF episodes. Thereafter, to improve patient compliance, this follow up will be continued using an easier device to carry and to use, i.e. a TTEM.
Finally, during the study, patients will be scheduled for a clinical visit every month (with an additional visit 7 days after visit 3 (ECV visit)) in order to ensure a close medical monitoring and to assess efficacy and safety parameters.

4.2.3. Choice of the Dose

According to a previous study in patients with AF [2], the tested PUFA product (Omacor®) at the dose of 2 g (i.e. 640 mg of DHA acid) was effective in the prevention of AF after cardioversion. Moreover, PUFAs at dosage of 1 g and 2 g were also effective on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5].

From the F373280 phase I study, after a 14-day repeated administration of F373280 (1 g/day), observed plasma concentrations of DHA measured before treatment (Cmin) were similar to that of an effective dose of Omacor® at 2 g/day (60 to 95 mg/mL and 60 to 90 mg/mL, respectively) (phase I study of F373280 and [16]). With regard to the rhythm of administration, mean peak/trough fluctuation (baseline corrected) was around 0.3. This value supports an once-daily administration allowing a 24-hour plasma exposure in DHA. Therefore, a 1 g daily dose of F373280 is considered to be appropriate for this proof of concept study.

4.2.4. Choice of the Sample Size

See chapter 13.

5. STUDY POPULATION

Each patient fulfilling all the inclusion criteria and none of the non inclusion criteria will be eligible.

5.1. INCLUSION CRITERIA

Demographic Characteristics and Other Baseline Characteristics:

1. Men or women aged more than 18 years (inclusive)
2. Patient with current episode of persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted
3. History of first documented persistent AF less than 3 years
4. History of ischemic or non ischemic heart failure
5. NYHA class I or II chronic heart failure at selection and at inclusion
6. Reduced left ventricular ejection fraction between 30% and 45% inclusive (using the two-dimensional echocardiography biplane Simpson’s rule) at selection and at inclusion
7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers
8. Left atrial area ≤ 40 cm² at selection and at inclusion
9. Patient treated or having to be treated by anti-vitamin K
10. For female patient of child-bearing potential:

   - **in all the countries except Italy:**
     - use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator for at least 2 months before the selection in the study and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment or
     - documented as surgically sterilized

   - **in Italy only:**
     - absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
     - use of double barrier contraception method (use of effective medical contraception method) from at least 2 months before the start of the study to the entire duration of the study and for a month after the end of the study or
     - documented as surgically sterilized

11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion
12. For male with a child-bearing potential partner (in Italy only):

   - absolute abstention from sexual intercourse during the whole duration of the study and for 3 months after the end of the study or
   - use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to 3 months after the end of the study.

**Ethical/legal considerations:**
13. Having signed his/her written informed consent,
14. Affiliated to a social security system, or is a beneficiary (if applicable in the national regulation)

### 5.2. NON INCLUSION CRITERIA

**Criteria related to pathologies:**
1. History of first documented episode of persistent AF more than 3 years,
2. More than two successful cardioversions (electrical or pharmacological) in the last 6 months,
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV),
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be checked in case of treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic coronaryopathy assessed by coronaryography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
7. Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration rate < 30 mL/min) at selection
8. Bradycardia (HR ≤ 50 bpm)
9. Hyperkalemia or hypokalemia (according to the standards of local laboratories) at selection
10. Cardiac surgery within 3 months before selection or planned during the study duration

Criteria related to treatments:
11. Previously ineffective pharmacological or electrical cardioversion
12. Concomitant treatment with ranolazine or any anti-arrhythmic drug (within 7 days prior to selection), except stable dose of digoxin, beta-blockers, calcium-blockers.
13. Oral amiodarone:
   13a   Previous treatment with oral amiodarone within 4 months prior to inclusion
   13b   Intake of oral amiodarone for more than 1 month within 4 to 12 months before inclusion
14. Previous treatment with intravenous amiodarone within 4 weeks prior to inclusion
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT implantation within the last 6 months
16. Treatment with any Polyunsaturated Fatted Acid within the last 3 months
   Dietary supplement with ω3 or ω6 according to investigator’s judgment
18. Having undergone any form of ablation therapy for AF
19. Patient treated with other anticoagulant treatment than antivitamin K: thrombin inhibitor such as Dabigatran or treated with antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel

Others criteria:
20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion,
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection,
22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself/herself to its constraints,
23. Patient family member or work associate (secretary, nurse, technician…) of the Investigator,
24. Patient having forfeited his/her freedom by administrative or legal award or being under guardianship,

5.3. NUMBER OF PATIENTS

76 x 2 patients (taking into account 15 % of non evaluable patients).
5.4. RECRUITMENT MODALITIES

Patients will be recruited within the medical consultation of each centre involved in the study. If necessary and when authorized by local and national regulation, some specific supports or tools will be used to improve the recruitment (announcement, mailing to general practitioners, leaflet, website including ClinicalTrials.gov, CRO…).

Before implementation, the documents will be submitted to and approved by the Ethics Committee.

5.5. PATIENT IDENTIFICATION

Patient's code will contain 7 digits: the 2 first digits corresponding to the country number, the following 2 digits corresponding to the centre number and the last 3 digits corresponding to the patient's chronological order once having signed the written informed consent.

5.6. WITHDRAWAL CRITERIA

Reasons for a patient's premature withdrawal from the study may be the following:

- Patient's decision. A patient who wishes to withdraw from the study for any reason may do so at any time but must inform the investigator. In all cases, the Investigator should attempt to contact the patient as soon as possible for a final assessment in order to:
  - have the patient's decision written on the consent form
  - obtain the reason(s) for withdrawal and report it/them in the case report form
  - evaluate the patient's clinical condition
  - if necessary, take appropriate therapeutic measures: management of an adverse effect or concomitant disease, prescription of another treatment.

- Investigator's decision in the patient's interest, particularly if a serious adverse event occurs and is considered by the Investigator liable to threaten the health of the patient. The monitor will be informed by phone or fax and a letter or report explaining the withdrawal will be forwarded to the monitor as soon as possible.
• Erroneous inclusion according to the study protocol. Any inclusion not respecting inclusion/non-inclusion criteria will immediately be withdrawn and an appropriate treatment will be given by the investigator under his/her responsibility. Erroneous inclusions will not be paid to the investigator.

• Patients who could not be treated with AVK for at least 3 weeks before ECV.

• Patients who will not have a stabilized INR between 2 and 3 on at least 3 consecutive weekly tests.

• Patients with only 2 consecutive INR tests between 2 and 3 in the last 3 weeks for whom a trans-oesophageal echocardiography can not be performed before ECV or for whom a trans-oesophageal echocardiography shows a thrombus in the atria.

• Patients who will not revert to sinus rhythm (i.e. unsuccessful ECV) or with early relapse within the observation period after ECV will be considered to have finished follow-up.

• Occurrence of AF recurrence that would require, at the investigator’s judgement, a cardioversion or an introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms for instance.

5.7. REPLACEMENT OF PATIENTS
Withdrawn patients will not be replaced.

5.8. POST-STUDY EXCLUSION PERIOD
Patients will not be allowed to participate to another clinical trial during 3 months following the study termination.

5.9. STUDY CARD AND LETTER FOR GENERAL PRACTITIONER(S)
The patient will receive from the Investigating Centre at Visit 1 - Selection Visit:

- a personal card to be kept all along the study duration and providing the following information: patient's name, sponsor's name, study code, EUDRACT number, start date and expected end date of the study, complete address of the Investigating Centre with the name and phone number of the
Investigator and a sponsor 24H/24 phone contact number in case of emergency (French and English languages): 33 (0)5 63 35 25 83. For Italy, this card will be in Italian only, without any English mention.

- in Italy, a letter to be given to his/her general practitioner. This letter intends to inform the general practitioner(s) (and any other doctors who take care of the patient) that the patient participates to the clinical study. It describes the study treatment and includes some information on the forbidden treatment during the study.

6. STUDY TREATMENT

The Clinical Pharmacy Department of the Institut de Recherche Pierre Fabre (IRPF) will supply the investigational centres with the treatment necessary for the conduct of the trial.

6.1. SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT

F373280 and placebo will be prepared in Soft Capsules similar presentation.

- F373280

Formulation of F373280, 1 g, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: Panthenyl ester of DHA, gelatine, glycerol, titanium, dioxide, purified water.

- Placebo

Formulation of placebo matching tested product, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: paraffin liquid, fish flavour, gelatine, glycerol, titanium, dioxide, purified water.

Placebo and F373280 capsules will be packaged in opaque blisters.

6.2. PACKAGING AND LABELLING

The treatment units will be packed and labelled by the Clinical Pharmacy Department of the IRPF according to European Directive and local requirements.
6.2.1. Packaging

Each treatment unit will be composed of 3 cases for a 12-week treatment period.

The Investigator will provide the patient with the treatment according to the following schedule:

At Inclusion Visit (V2): a 12-week treatment unit will contain 3 cases, each case containing:
   - 10 blister packs of four 1 g F373280 soft capsules or placebo soft capsules each.

At Visit 6 (V6): a 12-week treatment unit will contain 3 cases, each case containing:
   - 10 blister packs of four 1 g F373280 soft capsules or placebo soft capsules each.

6.2.2. Labelling

Investigational Products will be labelled according to the following rules:

Labelling should comply with the local requirements for Investigational Medicinal Products.

On the treatment units and cases, the labels will bear the following indications:
   a) name and address of the sponsor
   b) protocol number
   c) packaging batch number
   d) treatment number
   e) storage conditions
   f) expiry date
   g) pharmaceutical dose form
   h) route of administration
   i) quantity of dosage units
   j) direction for use
   k) legal statements:
      - “for clinical trial only”, “keep out of the reach and the sight of children”, “please return to your doctor any unused product”, respect the prescribed dose”

On the treatment unit, another label will be affixed with the mention of the Investigator’s name and patient’s code (completed by the Investigator).

In addition, on each case will be mentioned the case number, and a detachable label will bear the following indications:
   - Protocol number
   - Packaging batch number
   - Expiry date
On the blister pack, the label will mention the protocol number, the packaging batch number, the case number and the treatment number.

6.3. DISTRIBUTION TO CENTRE AND STORAGE

The Clinical Pharmacy Department of the IRPF will supply the Investigational Centre with the treatment units along the study according to the need, upon request triggered by the patient’s selection.

As soon as the Pharmacist or the Investigator receives the trial medication, he/she will check the contents and immediately acknowledges the receipt in the IVRS/IWRS. The copy of the acknowledgement will be kept in the Investigator’s or the Pharmacist’s file. The same procedure will be applied to all further supplies during the course of the trial.

At the time of the delivery to the Centre, the following information will be provided:

- Details of storage conditions that should be respected
- And, upon request and for the 1st delivery only, a letter of release for the Investigational Medicinal Product from the Sponsor’s Qualified Person

The CRA will ensure during the monitoring visits that trial medications have been received in good conditions and the acknowledgment of receipt has been performed adequately.

Treatment units should remain intact until dispensation to the patients. They should be kept at temperature below 30°C in an appropriate lockable room only accessible to the person authorised to dispense them, under the responsibility of the Pharmacist or the Investigator.

In the case of undue delay in study execution, the Pharmacist or the Investigator should ensure that the expiry date has not been exceeded.
6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT

A randomisation list will be established by the Clinical Pharmacy Department of the IRPF. This list will be computer-generated with internal software. The randomisation methodology is validated by the Biometry Department before generation.

Treatments F373280 or placebo will be balanced in a 1:1 ratio.

As the treatment units are prepared for 12-week treatment periods, the Investigator will have to allocate a treatment number at inclusion visit (V2) and another one at visit 6.

For each patient, the treatment number given at visit 6 will not be the same that the one given at inclusion visit (V2).

The treatment numbers will be given through the IVRS/IWRS.

Practically, once patient’s eligibility is confirmed at selection visit (V1):

- The Investigator:
  - Contacts the IVRS/IWRS
  - Answers the questions relating to the patient
  - In return, the treatment number to be allocated for the first 12-week period to the patient is given by the IVRS/IWRS.

- The IVRS/IWRS company:
  - Confirms this information by fax/email to the Investigator
  - Fills the “Request for Delivery of Investigational Product” form and sends it by email and/or fax to the Clinical Pharmacy Department of the IRPF.

- The Clinical Pharmacy Department of the IRPF sends the corresponding treatment unit to the Investigator within 5 days from reception of the email request form.

The Investigator will dispense to the patient the case which label indicates the treatment number and the administration period.

At visit 6, the Investigator will contact again the IVRS/IWRS to obtain the treatment number for the last 12-week period of treatment according to the same process as described above.
6.5. DRUG ADMINISTRATION

6.5.1. Duration of Treatment

For a patient completing the study, the theoretical study treatment exposure to F373280 or placebo will be 24 weeks.

If the ECV is postponed by 1 week to allow INR stabilization, the treatment duration will be 25 weeks.

6.5.2. Dose Schedule

One soft capsule of 1g of F373280 or placebo to be taken each day during 24 weeks.

6.5.3. Route and Conditions of Administration

The soft capsules are to be taken orally. One soft capsule is to be taken each evening with the dinner during 24 weeks.

6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT

The Investigator should maintain accurate written records of drug received, dispensed, returned and any remaining treatment units, on the drug accountability form. These records should be made available for Clinical Research Associate (CRA) monitoring. The packaging of the medication should remain intact until just before the dispensation.

At each visit, the Investigator will record the number of soft capsules returned by each patient using the appropriate page of the e-CRF.

At the end of the study, all used and unused treatments including packaging should be noted, and return is organised by the CRA to the Clinical Pharmacy Department of the IRPF for destruction. A copy of the drug accountability form should be provided by the Investigator to the CRA.
6.7. **RECALL OF INVESTIGATIONAL PRODUCTS**

In case of recall of investigational products (decided by the Competent Authorities or the Sponsor), the Investigator will immediately be informed by the Sponsor.

The Investigator in collaboration with the Sponsor’s representatives (Study Manager, CRA) must urgently:

- Stop the delivery of the concerned investigational products to the patients.
- Inform the concerned patients that they must immediately stop taking these investigational products and bring them back.

The Study Manager/CRA organises the return of the recalled products to the Clinical Pharmacy Department of the IRPF according to the Sponsor’s procedures.

7. **CONCOMITANT TREATMENTS**

Any existing concomitant treatment (at selection visit), any new concomitant treatment or change in the dosage of an existing concomitant treatment during the course of the study must be noted on the electronic Case Report Forms (e-CRF). All treatments should be evaluated by the Investigator at patient’s selection, and treatment prolongation or stop during the study should be considered.

For all concomitant treatments taken during the study, the following information must be noted in the relevant section(s) of the e-CRF:

- The name of the treatment and its form
- The reason for prescription
- The route of administration
- The daily dose
- The duration of treatment.
7.1. **ANTI-VITAMIN K TREATMENT**

AVK should be given for at least 3 weeks before ECV and continued for the whole study duration. The AVK used will be left to the decision of each Investigator according to his/her local practice.

7.2. **PROHIBITED TREATMENTS**

- Class I and class III antiarrhythmic treatments:
  - Class I
    - Class IA: Disopyramide, Procainamide, Quinidine
    - Class IB: Lidocaine, Mexiletine
    - Class IC: Flecaïnide, Propafenone
  - Class III: Dofetilide, Ibutilide, Sotalol, Amiodarone, Dronedarone.

- Ranolazine
- Any PUFA
- Any anticoagulant treatment other than AVK: thrombin inhibitor such as Dabigatran or antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel
- Dietary supplement with Omega 3 or Omega 6

Prohibited treatments at selection must not be prescribed for the duration of the study except in case of occurrence of an adverse event or AF episode that requires a corrective treatment in the interest of the patient’s health.

7.3. **AUTHORISED TREATMENTS**

Other treatments will be authorised during the study duration.

However, if medication other than study drugs is administered at any time from the start of the study, details must be recorded in the e-CRF. During the study, patients must be asked whether they have been on a course of prescribed drug treatment or have taken any OTC or herbal drugs since the visit.
8. EVALUATION CRITERIA

8.1. PRIMARY EFFICACY CRITERION

8.1.1. Time to the first Atrial Fibrillation Recurrence

8.1.1.1. Definition
Time to first AF recurrence is defined by the first episode of AF (symptomatic or not) lasting for at least 10 minutes.

8.1.1.2. Schedule
The heart rhythm follow up will be performed from the end of ECV visit (visit 3) to the final study visit (visit 9).

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF will be assessed after visit 3 (week 5).

8.1.1.3. Evaluation Methods
- 7-day holter monitor:

The heart rhythm monitoring will be carried out from visit 3 to visit 4 using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) fixed after ECV visit.

Following holter monitoring, the heart rhythm will be documented using Trans Telephonic ECG Monitoring (TTEM).

- Trans Telephonic ECG Monitoring:

The ECG follow up will be documented using the TTEM: daily transmission from visit 4 (week 5) to visit 5 (week 8). Then every two days from visit 5 (week 8) to visit 9 (week 24 – End of study).

Moreover, if patient experiences AF symptoms during this TTEM period, it should be documented using the TTEM.
In case of AF recurrence and provided that the patient does not required a cardioversion or an introduction of an anti-arrhythmic at Investigator’s judgement, the patient could be maintained in the study with the treatment in order to assess a spontaneous cardioversion. For that purpose the patient will continue to transmit a TTEM once a week.

The TTEM will be centralized by the Central Reading Laboratory. The patient will be requested to contact the Central Reading Laboratory for transmission of each stored TTEM. The TTEM will be validated by a trained technician, then analysed by a cardiologist. The cardiologist interpretation will be faxed to the site. The investigator will be asked to review and sign this document.

The TTEM process will be fully described in a separate document.

8.1.2. Secondary Efficacy Criteria

8.1.2.1. Numbers of AF episodes in the first week following visit 3 (ECV visit)

8.1.2.1.1. Definition

Number of AF episodes will consist in the assessment of AF episodes with duration at least 10 minutes ($N_{\text{Sup10}}$) and of less than 10 minutes ($N_{\text{Inf10}}$), respectively.

8.1.2.1.2. Schedule

The heart rhythm follow up will be performed from the end of successful ECV visit (visit 3) to the study visit 4.

8.1.2.1.3. Evaluation Methods

- 7-day holter monitor:

The heart rhythm monitoring will start using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) after ECV visit from visit 3 to visit 4.
8.1.2.2. **Duration of AF episodes in the first week following visit 3 (ECV visit)**

8.1.2.2.1. **Definition**
Duration of AF episodes will consist in the sum of duration of each AF episode.

8.1.2.2.2. **Schedule**
The heart rhythm follow up will be performed from the end of successful ECV visit (visit 3) to the follow up study visit (visit 4).

8.1.2.2.3. **Evaluation Methods**
Duration of AF episodes will be assessed using the 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording.

8.1.2.3. **Clinical parameters evaluation**

8.1.2.3.1. **EHRA score assessment**

8.1.2.3.1.1. **Definition**
AF related symptoms will be evaluated by the EHRA (European Heart Rhythm Association) score [20]. The following items “during presumed arrhythmia episodes” are checked to determine the score: palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety.

Classification of AF-related symptoms (EHRA score) are as follows:

- EHRA I - ‘No symptoms’
- EHRA II - ‘Mild symptoms’; normal daily activity not affected
- EHRA III - ‘Severe symptoms’; normal daily activity affected
- EHRA IV - ‘Disabling symptoms’; normal daily activity discontinued

This classification relates exclusively to the patient-reported symptoms.

In addition to this score, the frequency will be classified in three groups, namely occasionally (less than once per month), intermediate (1/month to almost daily) and frequent at least daily.
8.1.2.3.1.2. **Schedule**

EHRA evaluation will be performed in case of evocative symptoms of arrhythmia.

8.1.2.3.1.3. **Evaluation Methods**

EHRA evaluation will be collected by Central Reading Laboratory during all the study period.

8.1.2.3.2. **Number of recurrence of symptomatic AF**

It consists of the number of AF recurrences associated with a symptom (palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety) and confirmed by an ECG.

8.1.2.3.3. **Number and duration of hospitalizations**

- Number and duration of hospitalizations for cardiovascular events
  - Hospitalization for AF treatment
  - Hospitalization for worsening of heart failure
  - Hospitalization for myocardial infarction
  - All cause of hospitalization
- Number and duration of hospitalizations for thromboembolic stroke

8.1.2.4. **Cardioversion assessment**

- Assessment of spontaneous cardioversion before visit 3
- Assessment of successful cardioversion at visit 3 (i.e. return to sinus rhythm)
- Shock distribution (1, 2 or 3 shocks)
- Number of patients needing another cardioversion after initial ECV

8.1.2.5. **Evolution of echocardiographic parameters**

8.1.2.5.1. **Definition**

The following echocardiographic parameters will be assessed: Left atrial diameter (mm), LAA (cm²), Left atrial volume (mL), Left atrial volume/BSA (mL/m²), LVEF (%), Left ventricular end diastolic volume/BSA (mL/m²), Left ventricular end systolic volume/BSA (mL/m²), Left
ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL), Left ventricular end systolic diameter (mm) and Left ventricular end systolic volume (mL).

8.1.2.5.2. Schedule

Measurements will be performed at visit 1 and visit 2 to check the eligibility of the patient. Measurements performed at visit 4, visit 6 and visit 9 are done to follow the echocardiographic evolution of the patients in sinus rhythm.

8.1.2.5.3. Evaluation method

The echography evaluations will be carried out according to the recommendations for chamber quantification drawn up by the American Society of Echocardiography and the European Association of Echocardiography [23]. So, the recommended method for volume measurements is to use the biplane method of discs (modified Simpson’s rule) from 2-D measurement.

8.2. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA

8.2.1. Definition

Because of the limited human tissue accessibility for biopsy, red blood cell DHA contents is a marker of tissue DHA concentration [13], [14].

8.2.2. Blood samples

8.2.2.1. Collection schedule

Blood samples will be collected to determine the red blood cells (RBC) concentrations of DHA. Blood samples will be performed at visit 2 before treatment, visit 3, visit 6 and visit 9. Actual sampling times will be individually reported in the e-CRFs.
8.2.2.2. **Technical handling**

Two blood samples (4 ml) will be collected in EDTA tubes. They will be gently shaken, stored at +4°C (no freezing will be allowed) and sent to Analytical Centre in refrigerated conditions (between +2°C and +8°C). Analysis will be performed within 2 weeks following reception at the Analytical Centre.

8.2.3. **DHA concentration measurement**

Analytical determination of RBC concentrations of DHA will be carried out by the Analytical Centre.

Lipids will be extracted from red blood cells samples with a mixture of hexane/isopropanol after acidification [17]. Total lipid extracts will be saponified and methylated. The fatty acid methyl esters (FAME) will be extracted and analyzed by Gas Chromatography.

Identification of FAME will be based on retention times obtained for FAME prepared from fatty acid standards. The area under peaks will be determined using ChemStation Software (Agilent) and results will be expressed as % of total fatty acids. DHA concentration will be calculated using the internal standard and expressed as µg/g for red blood cells samples. Thus, omega-3 index will be assessed. The omega-3 index represents the content of EPA plus DHA in red blood cells (expressed as a percent of total fatty acids). It is a biomarker considered as a new marker of risk for death from coronary disease [18].

Results of this analytical determination will be kept confidential by the dosing centre until the end of the study, and will be provided only at the end of the study (after database lock) in a separate file.

8.3. **SAFETY ASSESSMENT**

8.3.1. **Adverse Events**

At selection, any concomitant disease will be reported on the e-CRF. At each further visit, the occurrence of AEs since the last visit will be based on the patient's spontaneous reporting, the
Investigator's non-leading questioning and his/her clinical evaluation. All AEs will be reported on the e-CRF (see section 10).

8.3.2. Laboratory Investigations

8.3.2.1. Schedule

Laboratory investigations will be performed at visit 1 (before treatment) and visit 9 (end of treatment) or End of Treatment visit.

At visit 3 and 6, only a standard haematologic dosage will be performed.

Furthermore the kaliemia will be checked before electrical cardioversion at visit 3.

The total volume of blood samples taken for haematology and biochemistry analysis should not exceed 30 mL.

8.3.2.2. Technical Procedures and Parameters

The following tests will be performed:

**Haematology:** hematocrit, haemoglobin, RBC count, white blood cells (WBC) count, WBC differential counts (% and absolute), reticulocytes, platelets.

**Chemistry:** sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatine phosphokinase (CPK), fibrinogen.

Blood samples will be taken in the morning in fasting conditions.

The estimation of GFR at selection relies on the measurement of serum creatinine and the Cockcroft- Gault formula:

Cockcroft-Gault formula

- with serum creatinine expressed as mg/L:

  in men:
  
  \[
  \text{GFR (mL/min)} = \frac{[(140-\text{age})] \times \text{weight}}{7.2 \times \text{serum creatinine in mg/L}}
  \]

  in women:
GFR (mL/min) = [(140-age) x weight / 7.2 x serum creatinine in mg/L] x 0.85

- with serum creatinine expressed as μmol/l:
GFR (mL/min) = [(140-age) x weight / serum creatinine in μmol/l] x k, where k = 1.23 for men, 1.04 for women.

(weight in kg, age in years)

Additional tests may be done at the Investigator’s discretion, in the patient’s interest. In case of any abnormal or clinically significant results, the Investigator will order laboratory control tests.

8.3.3. Global Physical Examination

A global physical examination including the measurement of body weight will be carried out on each body system at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.

The physical examination will be globally evaluated as “normal/abnormal”. Further target inspection will be undertaken for any abnormal finding.

8.3.4. Vital Signs

Vital signs will consist in blood pressure and heart rate at rest.

8.3.4.1. Schedule

Vital signs will be measured at each visit.

8.3.4.2. Technical Procedure and Parameters

Systolic blood pressure (SBP) and diastolic blood pressure (DBP), expressed in mmHg, will be measured after at least 5 minutes in supine position and after 2 minutes in standing position.

The heart rate (HR), expressed in beats per minute (bpm), will be measured by auscultation by counting the beats for at least 30 seconds, after at least 5 minutes in supine position and after 2 minutes in standing position.

Bodyweight will be measured with patient in underwear and with the same balance at each visit.
8.3.5. Electrocardiogram (ECG)

8.3.5.1. Schedule

An ECG will be recorded at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9 using an usual standardised 12-lead cardiograph.

8.3.5.2. Technical Procedure and Parameters

- Electrocardiogram:

The global interpretation from manual reading (normality, clinical relevance) and HR (bpm), PR (ms), QRS (ms), QT (ms), repolarisation patterns will be reported in the e-CRF. Each print-out will include the patient's code, date, time, technician's initials and investigator's signature.

In case of thermic paper ECG print out, a photocopy will be made by the centre to ensure safe filing.

- 24 hour-Holter - ECG

An ambulatory continuous 24-hour ECG (5-leads/2 or 3 channels) will be recorded at selection visit using a holter ECG, in order to confirm persistent AF.

8.3.6. Coagulation parameters

Coagulation assessment will be evaluated by the following parameters:

- Prothrombin Time/INR (PT/INR)
- Activated Partial Thromboplastin Time (aPTT)
- Thrombin Clotting Time (TCT)

During the pre-cardioversion period, if the anticoagulation by AVK should be initiated, then the INR monitoring will be as follow:

- INR 2-3 times a week for the first week of treatment
- INR weekly up to ECV
- INR every 4 weeks after ECV

For patients already treated with AVK, INR monitoring will be as follow:

- INR weekly up to ECV
- INR every 4 weeks after ECV
aPTT and TCT will be performed at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.

Anti-coagulation by AVK should be given at least 3 weeks before ECV and continued for the whole study duration.
The quantity of blood samples collected at each time for coagulation parameters will be 2 mL.

8.3.7. Concomitant Treatments

Concomitant treatments will be evaluated at each study visit.

Requirements relating to patient's concomitant treatments started before screening visit and continued throughout the trial, or started during the trial, can be found in section 7.

8.4. COMPLIANCE

The patient will be reminded at each visit to bring back at the following visit any used or unused remaining soft capsule, blister and case.

At each visit, the Investigator will record the number of supplied and remaining soft capsules in the e-CRF.

9. STUDY PROCEDURES

Visit 1 - Selection Visit (Week -4 to Week -1)

The patient considered eligible for selection by the Investigator will be informed of the characteristics and the consequences of the trial both verbally and by reviewing the patient's information sheet and consent form (see section 14.3). If the patient accepts to participate in the study, he/she will sign the informed consent form and will keep a copy.

The patient will be assessed for the following:

- Demographic characteristics (gender, age, height, body surface area)
- Personal and medico-surgical history
• Habits (Tobacco, alcohol consumption, dietary habits including fish consumption…)
• Cardiovascular diseases, mainly detailed history of Heart Failure and AF characteristics
• Echocardiography using a two-dimensional echocardiography
• 12-lead ECG
• Concomitant diseases, adverse signs or symptoms (able to be used for treatment emergent AE determination)
• Concomitant treatments (authorised, disallowed)
• Global physical examination/bodyweight
• Vital signs
• Biology: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
• Biology assessment of renal function: creatinine or estimated glomerular filtration rate

If the results of the above assessments are compatible with the selection criteria
• A 24-hour continuous ECG ambulatory recording (Holter ECG) device will be installed on the patient to monitor the patient heart rhythm. The patient will be requested to bring back the device after the termination of 24 hours recording. The recording will be transmitted from the Investigational site to the Central Reading Laboratory. The Central Reading Laboratory will send his/her assessment regarding the confirmation of persistent AF within 2 working days to the Investigator.
• The patient will enter the selection period in which anticoagulant (AVK) will be adjusted to achieve an International Normalized Ratio (INR) of 2 to 3 before ECV.

At the end of the visit, the Investigator will contact the IVRS/IWRS to confirm the patient selection (which will automatically order the treatment delivery) and organise the appointment for the next visit.
The patient will receive from the investigational centre the study card to be kept for the duration of the study.

**Visit 2 - Inclusion Visit (Day 1)**

If the patient's behaviour during the selection period and/or the result of complementary examinations particularly the confirmation of the presence of persistent AF by the Central Reading Laboratory during this period, the INR and laboratory tests, are compatible with the inclusion criteria, the patient will be assessed for the following:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: red blood cell concentrations of DHA and coagulation parameters Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Global Physical examination/bodyweight
- Vital signs
- Echocardiography using a two-dimensional echocardiography
- 12-lead ECG
- Urine pregnancy test for women of child bearing potential

If the results of the above assessments are compatible with the inclusion criteria, the patient will be included and allocated a treatment number using the IVRS/IWRS.

Between this Inclusion visit and the next visit (V3), the INR will be closely monitored (refer to paragraph 8.3.6) in order to ensure that the INR is stable (between 2 to 3 before electrical cardioversion).

At the end of the visit, the Investigator will organise the appointment for the next visit and will give the treatment for the next 4-week period.

**Visit 3 (Week 4: D28 -2/+7 days) cardioversion**
Patient will be assessed for the following criteria:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: Haematology, RBC concentrations of DHA, Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Global Physical examination /bodyweight
- Vital signs
- 12-lead ECG
- Electrocardioversion (ECV): ECV has to be scheduled 4 weeks after randomization and after target international normalized ratio levels will be stabilized (between 2 and 3) on at least 3 consecutive weekly tests in patients with AF. Patients not stabilized for INR (i.e. values not between 2 and 3) on at least 3 consecutive weekly tests before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE performed in the same day (and before ECV). ECV will be performed in the morning, with the patient in the fasting state and without dyskalemia. Anesthesia will be induced and patients will be cardioverted with administration of a synchronized, biphasic current. The initial shock will be set at 100 J if the body weight is less than 70 kg and at 150 J for higher body weights. Successful cardioversion will be defined as recovery of sinus rhythm lasting at least 1 minute after the shock. If unsuccessful, a second 200-J shock, and eventually a third 200-J shock, will be administered. Failure of ECV is defined as the persistence of AF after the third attempt at cardioversion. After the procedure, patients will be monitored on telemetry for at least 6 hours before discharge. Patients who will not revert to sinus rhythm or with early relapse within the observation period after ECV will be withdrawn from the study and will be considered to have finished their follow-up.
At the end of the visit, a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) will be installed on the patient in order to monitor the patient heart rhythm after ECV.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week period.

**Visit 4 (Week 5: D35 -2/+7 days)**

After removal of the continuous ECG ambulatory device, the patient will be assessed for the following criteria:

- Assessment of AE
- Concomitant treatments (authorised, disallowed)
- Body weight (body weight measured at V3 to be used)
- Vitals Signs
- Echocardiography using a two-dimensional echocardiography

At the end of the visit, the patient will be given the TTEM device for cardiac monitoring. The patient will be clearly instructed on the frequency and modalities of transmission. The patient will be requested to performed daily transmission from week 6 to week 8, then every 2 days from week 9 to week 24. Moreover, in case of AF symptoms, additional transmissions may be performed.

**Visit 5 (Week 8: D56 ± 7 days) – Visit 6 (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days) - Visit 8 (Week 20: D140 ± 7 days)**

Patient will be assessed for the following criteria:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT). However, in case of
discontinuation of anticoagulation after ECV, the monitoring of INR, aPTT and TCT should be stopped.

- Global Physical examination/bodyweight
- Vital signs
- 12-lead ECG

- The cardiac monitoring will be continued using a TTEM device. The device will be given to the patient who will be requested to perform daily transmission from week 6 to week 8, then every 2 days from week 9 to week 24. Moreover, in case of AF symptoms, additional transmissions may be performed.

The Investigator will collect all unused cases, blisters and soft capsules, and will count the unused capsules for each 4-week treatment period.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week treatment period.

In addition:

- at visit 6:
  
  - the investigator will contact the IVRS/IWRS to obtain the treatment unit number to be dispensed at visit 6 for the last 12-week period.
  
  - an echocardiography will be performed, an haematology examination will be done and the RBC concentration of DHA will be measured.

**End-of-Study Visit - Visit 9 (Week 24: D168 ± 7 days)**

Patient will be assessed for the following:

- Adverse events
- Concomitant treatments (authorised, disallowed)
• Global Physical examination/bodyweight
• Vital signs
• 12-lead ECG
• Laboratory examination: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT), Red blood cell concentration of DHA.
• Urine pregnancy test for women of childbearing potential
• Echocardiography using a two-dimensional echocardiography

The Investigator will collect all unused cases, blisters and soft capsules, and will count the unused soft capsules.

10. ADVERSE EVENTS: DEFINITION AND REPORTING

10.1. ADVERSE EVENTS

10.1.1. Definition of Adverse Events

An AE is any adverse change from the patient's baseline condition, *i.e.* any subjective signs and symptoms or change in a concomitant disease present at the Selection Visit considered or not related to the treatment.

AE includes intercurrent signs, symptoms, illnesses and significant deviations from baseline for vital signs and laboratory values which may occur during the course of the clinical study.

All laboratory tests for which abnormal results are collected after study treatment initiation should be repeated until the values return to normal or to a stable status. Abnormal results are defined as those falling out of the laboratory normal ranges and that are clinically significant. The frequency of such checks should be defined by the Investigator according to the degree of abnormality.

In all cases, the aetiology should, as much as possible, be identified and *Pierre Fabre Médicament* notified.
10.1.2. Grading of Adverse Events

Adverse or intercurrent events are graded as follows:

- Mild: awareness of signs or symptoms, but easily tolerated
- Moderate: uncomfortable enough to cause interference with usual activity
- Severe: incapacity with inability to work or do usual activity

10.1.3. Reporting of Adverse Events

The records of AE in the e-CRF describe the nature (diagnosis, signs and symptoms), severity, onset date, stop date, outcome and actions taken, and relationship to study treatment (in the Investigator's opinion). It must be specified whether the event is serious or not.

10.2. SERIOUS ADVERSE EVENTS (SAE)

10.2.1. Definition

A SAE includes, but is not necessarily restricted to, any event which:

- Results in death (whatever may be the cause)
- Is life-threatening
- Results in persistent or significant disability/incapacity
- Requires the patient's hospitalisation or prolongation of current hospitalisation *
- Is a congenital anomaly or birth defect

Other events such as cancer and any additional adverse experience or abnormal laboratory values occurring during the study period, defined by the protocol as serious or which the Investigator considers significant enough or that suggest a significant hazard, contra-indications, side effect or precaution, must be handled as serious adverse events.

Any overdosage meeting a seriousness criteria should be reported as a SAE (see section 10.3).

Any pregnancy occurring during/after exposure to the study drug(s) should be reported on the SAE notification form (see section 10.4).
any hospitalisation, or prolongation of hospitalisation due to the circumstances listed below:

- planned (as per protocol) medical/surgical procedure
- preparation for routine health assessment/procedure (e.g. routine colonoscopy)
- planned medical/surgical admission (planned prior to entry into study trial, appropriate documentation required)
- administrative or social reasons (e.g. lack of housing, economic inadequacy, care-giver respite, family circumstances)

will not be reported as a SAE.

10.2.2. Reporting of SAE

All Serious Adverse Events, according to the above-mentioned definitions and regardless of treatment or relationship to study drug, and occurring once the informed consent form has been signed, must be reported by the Investigator as soon as he/she is informed of the event.

The Investigator must notify the Sponsor of this event by sending, within 24 hours, the "Notification of serious adverse event" form ("first notification") with all the available information about the event (see appendix 17.2), to the Sponsor's Corporate Vigilances e-mail dedicated box:

HQ.pharmacovigilance@pierre-fabre.com

In case it is not possible to send the report by e-mail it can be sent by FAX at the following number:

+ 33 1 49 10 80 90

In case of non-inclusion, the reporting period ends when the non-inclusion is documented.

10.2.3. Follow-up of SAE

The Investigator must draw-up a specific clinical report and use the "Notification of serious adverse event" form ("follow-up") (see appendix 17.2) and collect the results of the carried out examinations and the reports of hospitalisation.

The serious adverse events must be followed up until resolution or stabilisation.
10.2.4. SAE Occurring After the Study

Any SAE occurring during 30 days following the end of the study for the patient should be notified to the Sponsor.

Must also be notified to the Sponsor any event occurring at any time after the end of the study for the patient which may be related to the study treatment in the Investigator's opinion.

10.3. REPORTING OF OVERDOSAGE TO THE SPONSOR

For the purpose of this trial, an overdosage will be defined as any dose exceeding the planned prescribed dose of the study drug or the administration of any dose of an associated product that is considered both excessive and medically important.

In the absence of seriousness criteria, the overdosage and associated adverse event if any, are reported only on the Adverse Event page of the e-CRF. If the definition of seriousness criteria is met, the SAE notification form must also be transmitted to the Sponsor.

10.4. REPORTING OF PREGNANCY TO THE SPONSOR

Pregnancies discovered in the period in between the informed consent form signed but before any study drug exposure are not to be reported to the Sponsor unless associated to a seriousness criteria (e.g. serious adverse event study-protocol related procedure). If pregnancy is confirmed, the women must not be administered the study drug and must be withdrawn immediately from the study.

If pregnancy is suspected while the patient is receiving study treatment, the study drug should be discontinued immediately until the result of the pregnancy testing is known. If pregnancy is confirmed, then the study treatment is permanently discontinued in an appropriate manner and the patient is withdrawn from the study.

The Investigator must report to the Sponsor any pregnancy which occurs during or after the patient has been exposed to the study drug and until 30 days after the last study drug administration. The Investigator must immediately notify the Sponsor using the SAE notification form and also report the pregnancy on the AE page of the e-CRF.
Women who become pregnant after exposure to the study drug must be followed by the Investigator until the completion/termination of the pregnancy. If the pregnancy goes to term, the outcome will have to be reported to the Sponsor (baby's healthy status).

10.5. SPONSOR'S RESPONSIBILITIES FOR SAFETY REPORTING PURPOSES

Sponsor will submit expedited and periodic reports to both Competent Authorities and Ethics Committees per corporate standard operating procedures as regards to the EU directive 2001/20/EC taking into account local specific requirements.

11. DATA COLLECTION AND STUDY MONITORING

11.1. DATA COLLECTION

11.1.1. Case Report Form

An e-CRF will be used to record all patient data required by the protocol except the central ECG (Holter ECG, TTEM) and DHA data which will be transferred from vendors to the subcontractor as electronic data files that will be loaded into the study database.

The e-CRF should be fully validated, compliant with ICH-GCP requirements and European regulations and should include a traceability system for data corrections and deletions (audit trail).

Prior to the start of the study, the Investigator will complete a "Delegation of significant study-related duties" form. The signature and initials of all personal in charge of e-CRF completion should be recorded on this form. Each person involved in e-CRF completion, review, correction and / or validation will be trained and will have an individual login and access code to the e-CRF.

Training sessions will be held by the subcontractor for all participants using this tool. An e-CRF user manual will be available for investigators and CRAs.

All the information included into the e-CRF will be recorded from source documents onto the e-CRF by an authorised person.
The Investigator is responsible for the management and accuracy of the information on the e-CRF. At each monitoring visit, the e-CRF(s) should be at the CRA's disposition for review and validation.

At the end of the study, a CD-ROM containing the pdf version of all e-CRFs (including audit-trail) will be sent by the subcontractor to the Sponsor and to the investigational sites for archiving. The subcontractor must store all study data for at least 15 years after the end of the study and ensure their legibility and accessibility during all the storage period.

11.1.2. Source Documents

A source document is an original record or certified copy of an original record of clinical findings, observations or any other medical or paramedical activities performed during the clinical trial, necessary for the transcription and the verification of the collected data.

Source documents along with all other trial-related documents (copies of all "informed consent" forms, e-CRFs CD-ROM, drug inventories and any correspondence related to the study) must be kept in the investigator's file throughout the study, and then, must be stored in the study centre's archives for a period of at least 15 years or as per local legal requirements, whatever is the longest.

For further details see section 15.2.

11.2. STUDY MONITORING

11.2.1. Monitoring visits

On-site visits will be carried out by a representative of the Sponsor's staff (Study Manager or CRA) prior to study initiation and at regular intervals (every 4 to 6 weeks) throughout the study. Additional visits and communication by telephone fax or meeting may be performed if necessary. Any site visit performed by the Sponsor's representatives will be recorded in the Investigator's study file.
11.2.1.1. **Site Preselection Visit**

Before selecting a centre for the study, a visit will be carried out by the CRA and/or the Study Manager to ensure that the Investigator has the necessary capacities (availability, patient's recruitment, environment), technical means and staff to carry out the study.

11.2.1.2. **Initiation Visit**

Before the start of the study at all investigational sites, an initiation visit will be carried out by the CRA to check at the latest that:

- The Investigator:
  - has received the technical protocol, administrative and financial agreement signed by all parties
  - has received the written statement of the Ethics Committee approval and the list of its members and their functions
- The original dated and signed *curriculum vitae* of the investigator(s) has been collected
- Laboratory normal ranges have been collected
- All study materials are available on the study site
- All participants agree with the monitoring procedures and know the study procedures
- All participants are aware of a possible audit or inspection

The CRA has also to provide training on the study protocol requirements and study specific procedures.

11.2.1.3. **Follow-up Visits**

Throughout the study, regular follow-up visits will be carried out by the CRA to check compliance with GCP, patient’s informed consents, strict application of the protocol, conformity of the data entered on the e-CRF with the source documents and ensure its correct completion, adverse events reporting, proper retention, storage and management of the study medication, as well as the source and other trial-related documents.
11.2.1.4. **Closing Visit**

At the end of the study, a final visit will be carried out by the CRA to:

- Verify that the e-CRFs CD-ROM with pdf files are correctly stored
- Control the accountability of intact and used treatment units and return them to the Clinical Pharmacy Department of the IRPF for destruction
- Obtain the last data clarifications and/or solutions if any
- Collect the patient's consent forms in sealed envelopes (except in case of specific country requirements),
- Make an on-site review of all study documentation and complete it if necessary
- And finally, remind the Investigator of his regulatory obligations, study document archiving process and duration.

11.2.2. **Direct Access to Source Documents**

In accordance to the requirements of the GCP, all Sponsor representatives (Study Manager, CRA and Auditors) have to be given a direct access to all source and study data to perform quality monitoring/audit, thus ensuring accuracy and completeness of data).

Investigators are reminded that all Sponsor representatives keep professional confidentiality with regards to the patient data.

11.3. **INDEPENDENT DATA MONITORING COMMITTEE**

An Independent Data Monitoring Committee (IDMC) will be established to assess at intervals the progress of the clinical trial, the compliance with the inclusion criteria, the quality of follow up, the quality of primary end point measures, the safety data. The IDMC will thereafter recommend to the Sponsor whether to continue, modify, or stop the study.

The IDMC operating procedures will be described in an independent document.
12. DATA MANAGEMENT

All clinical data related to the study will be collected and saved in a computerised database by the Data Management Department of the subcontractor and under the supervision of the Data Manager of Pierre Fabre Biometry (PFB) according to the following procedures.

12.1. DATA ENTRY

All required data will be collected by the Investigator or authorised designee (duly identified into the delegation task list) on the e-CRFs.

The e-CRFs used for this study will be developed and maintained by the Data Management Department of the subcontractor and approved by the Sponsor.

Electronic data (Holter ECG, TTEM and DHA) will be transferred by the 3rd party vendor according to the specifications given by the Data Manager of the subcontractor. These data will be captured and handled in accordance with the European GCP ICH E6 guideline.

12.2. DATA CLEANING

The subcontractor will define in the Data Validation Plan for reviewing and querying data, descriptions of both manual and electronic edit checks. Upon Sponsor approval, the subcontractor will program the checks.

The subcontractor will review the data over the course of the study, working with the Sponsor to identify data inconsistencies. The Investigator will be asked to resolve queries by making changes directly into the e-CRF.

12.3. DATA CODING

Adverse events, concomitant diseases, medical/surgical histories will be coded by the subcontractor using the MedDRA dictionary (latest version in use).

Concomitant medication will be coded by the subcontractor using the WHO-DRUG dictionary (latest version in use).
The Sponsor Clinical Development Physician will validate the coding.

12.4. DATA STORAGE
Computer data files as well as their modifications will be archived by the subcontractor and kept available upon request of the Sponsor.

12.5. DATABASE LOCK
The validated database will be locked by the subcontractor upon request of the Data Manager of PFB following the completion of all steps required, i.e. data entry and check of all data, resolution of all queries, validation of the coding, Clinical and Products Safety databases reconciliation and validation committee.

Then, the subcontractor will transfer the locked database in SAS format to the Data Manager of PFB who assume storage on the PFB secured server.

13. STATISTICAL ANALYSIS
After the database lock and the randomisation code release, the statistical analysis will be performed by PFB or under the supervision of the statistician of PFB using SAS® software, according to the Statistical Analysis Plan approved by the Validation Committee.

13.1. GENERAL CONSIDERATIONS
The main objective of the study is to assess the efficacy of F373280 versus placebo on the maintenance of sinus rhythm after direct ECV in patients with persistent AF and chronic heart failure.

Only the primary analysis of the primary efficacy criterion, on which is based the sample size justification, may lead to a causal interpretation. All other statistical results are to be regarded within a descriptive perspective.

The statistical significance level of the various two sided tests of all analyses will be 5 %.
13.2. **SAMPLE SIZE**

Assuming an AF recurrence rate of 85% under placebo and 65% under active group, i.e. a clinically relevant difference $\Delta$ of 20%, a sample size of 64 assessable patients per group is required, using a log-rank test of survival curves with a 80 % power and a 5 % two-sided significance level.

According to the previous assumptions and assuming a rate of not assessable patients of 15%, a minimum of 76 patients will have to be randomised per group.

13.3. **PROTOCOL DEVIATIONS**

Prior to the database lock and the randomisation code release, the Validation Committee members will review the protocol deviations and will classify them as either minor or major. A protocol deviation will be considered major when it is likely to bias significantly the treatment effect estimate based on the primary efficacy criterion.

Patients with major deviation(s) will be excluded from the Per Protocol data set (see section 13.4).

A listing of all protocol deviations will be provided for all randomised patients, including the type (major/minor) of protocol deviations according to the decisions made by the members of the Validation Committee.

The number and percentage of patients with major protocol deviations will be tabulated by treatment group and type of major protocol deviations on the Full Analysis Set defined in section 13.4.

13.4. **DATA SETS ANALYSED**

The following 3 data sets will be analysed (as defined by the Validation Committee):

- The Safety Set composed of all randomised patients having received at least one dose of the study treatment. This data set will be used to perform analyses of Safety.
• The Full Analysis Set (FAS) composed of all randomised patients having received at least one dose of the study treatment and with a successful cardioversion observed at visit 3. This data set will be used to perform analyses of Efficacy.

• The Per Protocol Set (PP) which is the subset of the Full Analysis Set composed of all patients with a primary efficacy criteria available and without any major protocol deviation or other source of bias for primary criteria analyses. This data set will be used to perform the supportive analysis of the primary efficacy criterion.

13.5. HANDLING OF DROPOUTS AND MISSING DATA

13.5.1. Dropouts

The number of patients who withdraw from the study after their randomisation will be provided by treatment group for all treated patients (Safety Set). All withdrawn patients will be further described regarding their time to dropout and reasons for withdrawal.

13.5.2. Repositioning of Visits

No repositioning of visits will be done.

13.5.3. Missing Data

Missing values will not be substituted by estimated values, but considered as missing in statistical analysis.

13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS

Before the first trial drug intake, patient’s background, medical and surgical history, demographic data and disease characteristics will be described by treatment group on the Safety Set.

- **Quantitative parameters** will be described by treatment group and overall using the following: number of patients, number of missing data, mean, standard deviation, minimum, median and maximum values.

- **Qualitative parameters** will be described by treatment group and overall using frequencies.
Concomitant diseases, as well as medical and surgical histories will be tabulated descriptively by treatment group and overall using the MedDRA codes of System Organ Classes and preferred terms.

If more than 10% of patients are excluded from the FAS and PP set, the description of patients by treatment group at selection and inclusion will be repeated on the FAS and PP set for all parameters.

No statistical test of comparability of treatment groups at baseline will be performed.

13.7. EFFICACY ANALYSIS

13.7.1. Primary Criterion

13.7.1.1. Primary Analysis

The primary criteria, time to first recurrence, will be analysed using the Kaplan Meier method and compared with the Log rank test. Hazard ratios and 95% confidence intervals will be estimated with the Cox regression model.

The primary analysis will be performed on the FAS.

13.7.1.2. Supportive Analysis

The primary analysis will be repeated on the PP set.

13.7.2. Secondary Criteria

All secondary analyses will be performed on the FAS. If more than 10% of patients are excluded from the PP set, the secondary analyses will be repeated on the PP set.

13.7.2.1. Numbers of Atrial Fibrillation Episodes

Both the numbers of AF episodes (symptomatic or not) lasting for at least 10 minutes and with duration less than 10 minutes ($N_{\text{sup10}}$ and $N_{\text{inft0}}$) will be described by treatment group and compared by the chi-square test (or CMH test adjusted for centre) or Fisher's exact Test.
13.7.2.2. Duration of Atrial Fibrillation Episodes

The duration of all AF Episodes will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centres effects) or Wilcoxon test.

13.7.2.3. Time to first AF recurrence less than 10 minutes or symptomatic

The time to the first AF recurrence less than 10 minutes and the time to the first symptomatic AF recurrence will be analysed as the primary analysis.

13.7.2.4. Clinical parameters evaluation

The EHRA score will be described by treatment group and analysed using a chi-squared test (or CMH test adjusted for centre) or Fisher’s exact Test.

The frequency of presumed arrhythmia will be described by treatment group.

The number of recurrence of symptomatic AF, of hospitalizations (for cardiovascular events, for thromboembolic stroke and for all causes), of spontaneous cardioversion, of successful cardioversion (including number of shocks distribution) and the number of patients needing cardioversion after initial ECV will be described by treatment group and compared using a chi-square test or a Fisher Test (if the numbers are relevant).

The duration of hospitalizations for cardiovascular events, for thromboembolic stroke and for any cause will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centre effects) or Wilcoxon test.

The echocardiographic parameters values will be described at each time (V1, V2, V4, V6 and V9) and changes described from V4 to V9 and from V2 to V9.

13.7.2.5. Biomarker analysis: red blood cell concentrations of DHA

Values and changes from baseline for red blood cell concentration of DHA will be performed by treatment group and assessment time.
13.8. SAFETY ANALYSIS

The Safety Set will be used to perform all analyses of the safety criteria.

13.8.1. Adverse Events

Any adverse event having been reported during the study for a given patient will be classified by preferred term and corresponding system organ class using the MedDRA terminology.

Adverse events will be classified as:

- Treatment emergent adverse events, *i.e.*, any adverse event which occurs or worsens on study treatment during the randomised period.
- Or non treatment emergent adverse events, *i.e.*, any adverse event which occurs during the run-in period (before V2) or is reported as concomitant disease with the same intensity.

For each study period, any patient with at least one reported adverse event will be classified as a patient:

- With at least one adverse event
- With at least one treatment emergent adverse event
- With one TEAE
- With two TEAEs
- With at least three TEAEs
- With at least one related TEAE
- With an adverse event leading to the study treatment discontinuation (definitive or temporary)
- With an adverse event leading to withdrawal
- With at least one serious adverse event.

Numbers and percentages of patient with at least one reported treatment emergent adverse event will be tabulated by treatment group:
• By system organ class
• By system organ class and preferred term
• By system organ class and preferred term, taking into consideration its most severe intensity
• And by system organ class and preferred term, taking into consideration the most severe relationship to the study treatment.

Recurring adverse events (i.e., adverse events classified with the same preferred term) for a given patient will only be counted once and only their most severe intensity or most severe relationship to the study treatment will be tabulated.

The number and percentage of patient with at least one most common (reported in 1% patients in any group) drug related TEAE ("not excluded or unassessable") will be tabulated by Preferred Term and Treatment group in decreasing order for the treatment group (for all patients).

The number and percentage of patients with at least one reported most common treatment emergent adverse event will also be plotted by treatment group. This graphical representation will highlight the frequencies of the most severe intensities reported by system organ class and preferred term.

SAE will also be described on an individual basis: treatment group, patient's code, sex and age, Investigator's reported term, preferred term, time of onset according to the time of the first study treatment administration, duration, action taken regarding the study treatment administration, use of a corrective treatment, outcome and relationship to the study treatment in the Investigator’s opinion.

13.8.2. Clinical Laboratory Evaluation

For each laboratory parameter, data will be tabulated by treatment group and assessment time.

The absolute changes post-trial drug administration - baseline (the baseline value being the value measured on the last blood sample collected before the first trial drug administration) will be calculated and tabulated by parameter, treatment group and post-trial drug administration
assessment time. Results of retests performed post-trial drug administration will not be analysed and tabulated. They will only be displayed in individual data listings.

For all biochemistry parameters, scatter plots highlighting individual results will display the baseline and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 24 value in the ordinate.

For all haematology parameters, scatter plots highlighting individual results will display the baseline and week 4, week 12 and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 4, week 12 and week 24 value in the ordinate.

Each treatment group will be differently identified. The first bisecting line (45° line), the lines of lower and upper normal range, the lines of Potentially Clinically Significant Change (PSC) range and Clinically noteworthy abnormal laboratory value (CNALV) range added on the plots (see Appendix 17.3).

For all blood laboratory parameters, shift tables will be provided to depict the numbers of patients with post-trial drug administration variations at each assessment time as compared to the baseline values (measured on the last blood sample collected before the first trial drug administration) by treatment group. A 3-point scale (low, normal, high) will be used as defined by the normal ranges in use in the laboratory in charge of the assays.

CNALV (see in Appendix 17.3) will be identified and described on an individual basis. If relevant, five separate individual data listings by treatment group will be provided:

- CNALV for haemoglobin (including corresponding individual results of erythrocytes and haematocrit)
- CNALV for neutrophils or leucocytes (including corresponding individual results of basophils, eosinophils, lymphocytes and monocytes)
- CNALV for platelets (including corresponding individual results of erythrocytes and leucocytes)
• CNALV for liver function parameters (including corresponding individual results of gamma-GT)
• CNALV for serum creatinine

13.8.3. Global Physical Examination

Recorded data of the global physical examination performed will not be tabulated as any abnormal findings post-randomisation should be reported as AEs (if clinically significant).

Physical examination assessments will be provided in the listings of individual data.

13.8.4. Vital Signs, Physical Findings and Other Observations Related to Safety

13.8.4.1. Vital Sign Measurements Over Time

For each parameter (systolic blood pressure, diastolic blood pressure and HR in supine and standing positions), descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.

13.8.4.2. Body weight

Descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.

13.8.4.3. Individual Patient Changes

The number and percentage of patient with at least one Predefined Potentially Clinically Significant Change (PSC) and with at least one PSC Leading to Clinically Significant Value (PSCV) will be tabulated by treatment group (see Table 1 in Appendix 17.3).

According to the pharmacological drug profile mentioned previously in this Protocol, the changes from baseline to the maximum and/or minimum post-baseline value could be categorized and tabulated by treatment group with frequencies and decreasing cumulative percentages.
If there is a signal of a drug effect toward one direction rather than the other, additionally shift tables of variations from baseline to the maximum or minimum post-baseline value could be also provided (see Table 2 to 4 in Appendix 17.3).

An individual data listing of patients with symptomatic or asymptomatic orthostatic hypotension will be provided by treatment group (see Table 5 in Appendix 17.3).

13.8.5. ECG

Frequencies on the clinical interpretation (normal, abnormal CS or NCS) will be presented by treatment group and assessment time. Individual tabulated data for ECG abnormalities will be also displayed.

13.8.6. Coagulation parameters

Scatter plots highlighting individual results for coagulation parameters (prothrombin time/INR, activated partial thromboplastin time and thrombin clotting time) before and after study treatment administration will be produced.

13.9. CONCOMITANT TREATMENTS

Concomitant treatments will be tabulated by treatment group within a descriptive perspective. They will be classified by therapeutic area according to the WHO-DRUG dictionary using the "anatomical therapeutic chemical" classification on the safety set.

13.10. COMPLIANCE

The percentage of compliance will be described by treatment group using the quantity

\[ \text{Compliance(\%)} = \frac{\text{Estimated actual consumption}}{\text{Theoretical consumption}} \times 100 \]

with: Estimated actual consumption = number of tablets provided at the start of study (Visit 2) minus number of tablets returned at the end of study (Visit 9)
Theoretical consumption = number of days of treatment intake planned between the start and the end of study (168 days ± 7 days)

13.11. INTERIM ANALYSIS AND DATA MONITORING

No interim analysis is planned.

14. GENERAL ETHICAL CONSIDERATIONS

14.1. ETHICAL CONDITIONS

This study is performed in accordance with the principles stated in the Declaration of Helsinki (1964) and subsequent amendments and in accordance with the Good Clinical Practice Guideline (CPMP/ICH/135/95).

14.2. ETHICS COMMITTEE AND LEGAL REQUIREMENTS

All the documents required by National Regulations and any other informative documents that may be requested are submitted for review to an Ethics Committee whose procedures and operations meet the GCP and National Legal Requirements.

Depending on National Regulations, the application is submitted to the Ethics Committee by the Sponsor (or representative) or by the Investigator.

A copy of the formal written approval from the Ethics Committee is provided to the Sponsor (directly by the Ethics Committee or via the Investigator) with a list of names and qualifications of its members.

The request for authorisation by the Competent Authority or its notification if required (depending on National Regulations) is carried out by the Sponsor.

The screening of patients does not start before the approval of the Ethics Committee has been obtained and the study authorised by the Competent Authority or notified to the Competent Authority (depending on National Regulations).
14.3. PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM

An information must be given to the patients before their decision to participate or abstain from participation.

This information is based on the elements set out in the Declaration of Helsinki and the ICH GCP Guidelines. It must also describe the measures taken to safeguard patient’s privacy and protection of personal data, according to European Directive 95/46 EC or other local regulation.

Restraints and risks must be explained, as well as the right to discontinue participation in the study at any stage, without affecting their further relationship with the Investigator and/or their future care.

The written information and consent form must be submitted to the patient with an oral explanation. It must be agreed and signed by the patient before any study-related procedure starts.

This information and consent procedure is under the Investigator’s responsibility.

The information and consent document are made in triplicate: the original copy is kept by the Investigator, one copy is given to the patient and the last copy is kept by the Clinical Quality Assurance Unit of the Sponsor in a sealed envelope at the end of study (except in case of specific country requirement).

Specific areas of the Sponsor’s copy are not triplicated to avoid the reading of the patient’s surname (except the first 3 letters), first name, address and signature.

If any information becomes available during the trial that may be relevant to the patient’s willingness to keep on participating in the trial, an updated written informed consent must be submitted to the patient to confirm agreement to continue participating.

14.4. PERSONAL DATA PROTECTION

All information from this study (excluding data from the informed consent) is entered into a computer under the Sponsor’s responsibility in accordance with the French law, "Loi
Informatique et Libertés” (January 6, 1978, and subsequent amendments) and with the European Directive 95/46/CE.

14.5. INSURANCE POLICY

In accordance with the provisions of the law and the GCP, the Sponsor Pierre Fabre Médicament, has an insurance policy intended to guarantee against possible damage resulting from the research.

The studies and/or experiments performed on behalf of the Sponsor Pierre Fabre Médicament are specifically and expressly guaranteed.

It is advisable to underline that non compliance with the Research Legal Conditions is a cause for guarantee exclusion.

15. ADMINISTRATIVE PROCEDURES

15.1. PROTOCOL AMENDMENT

Neither the Investigator nor the Sponsor may alter the protocol without the authorisation of the other party.

All changes to the protocol are subject to an amendment which must be dated and signed by both parties and must appear as an amendment to the protocol.

Substantial amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities

Urgent amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities, but could be implemented immediately under specific conditions defined with the Sponsor.

15.2. SOURCE DOCUMENTS, INVESTIGATOR'S FILE STORAGE

The Investigator:
• Keeps all trial-related documents in appropriate file folders. Records of patient, original informed consent forms, source documents, a CD Rom containing a pdf copy of e-CRF, drug inventory, Ethics Committees and Sponsor correspondence pertaining to the study must be kept on file.

• Retains all documents relating to the screening (consent and investigation results) of all patients included in the trial or not.

• Retains a list of the patient’s names, addresses (and/or number of medical file), code numbers to allow checking of data reported on e-CRFs with those from source documents.

• Authorises direct access to source documents for monitoring, audits and inspections.

• The trial-related documents must be retained as strictly confidential at the Investigator’s site for at least 15 years or according to local requirements, whatever is the longest after the completion or discontinuation of the trial (European Directive 2003/63/EC).

15.3. END OF THE STUDY

15.3.1. Definition of the End of Study

The end of study is the last visit of the last patient undergoing the trial.

Any change to this definition during the study, for whatever reason, must be notified as a substantial amendment.

15.3.2. Early Study Termination

15.3.2.1. Early Study Termination Decided by the Sponsor

The Sponsor may discontinue the study at any time for any of the following reasons:

• Lack of recruitment

• Deviations from good clinical practice and/or regulations

• Poor product safety

• New information that could jeopardise the patient’s safety
• Stopping of the development …

15.3.2.2. Early Study Termination Decided by the Competent Authorities

The Competent Authorities may suspend or prohibit a study if they consider that either the conditions of authorisation are not being met or has doubt about the safety or scientific validity of the study.

15.4. AUDIT

The Sponsor is responsible for making sure that both its representatives (Study Manager, CRA...) and the Investigator fulfil the requirements as specified by the GCP Guideline.

An audit can be organised internally at Pierre Fabre Médicament and at the investigational site where the e-CRFs are matched against source documents.

All study documentation must be directly accessible to auditors.

The practical conditions for the audit are discussed between the Investigator and the Clinical Quality Assurance Department.

Oral information about the audit results are given to the Investigator.

15.5. INSPECTION

The Health Authorities may inspect any investigation site or the Sponsor in the course of the study or after its completion, to verify the conduct of the study and quality of the data. The Investigator must provide to the inspectors direct access to study documents.

15.6. CONFIDENTIALITY

The present materials (protocol and related documentation, e-CRF, Investigator's Brochure) contain confidential information.

Except if agreed in writing with the Study Manager, the Investigators must hold such information confidential, and must not disclose it to others (except where required by Applicable Law).
15.7. **CLINICAL STUDY REPORT**

Data analysis and clinical study report writing are under the Sponsor’s responsibility. Upon data analysis completion, a final report including a review of the objectives and methods, a presentation and a discussion of the results is drawn up according to ICH Guidelines (Structure and Content of Clinical Study Reports, ICH-E3, CPMP/ICH/137/95).

The report is a clinical and statistical integrated report. It must be signed by the Sponsor's representative(s) and the Coordinating Investigator.

15.8. **STUDY RESULTS COMMUNICATION**

Upon completion of the study, the global results of the Research are communicated to the Investigator. According to the Local Regulation, the patient can ask the Investigator for the results.

15.9. **STUDY RESULTS PUBLICATION**

The information and data collected during the conduct of this clinical study are considered confidential and are used by the Sponsor in connection with the development of the study drug. This information may be disclosed if deemed necessary by the Sponsor.

To allow the use of the information derived from this clinical study and to insure compliance with Current Regulations, the Investigator must provide the Sponsor with complete test results and all data collected during the study.

Only the Sponsor may make study information available to physicians and to Regulatory Agencies, except as required by Current Regulations.

All the results of this study including data, reports, discoveries and inventions resulting from the study, are the property of the Sponsor.

In the event the Sponsor chooses to publish study data, the manuscript must be provided to the author(s) at least 30 days prior to the expected date of submission to the intended publisher.

The Investigator(s) can reserve the right to publish or present study data; if so, the manuscript or abstract must be provided to the Sponsor for review at least 30 days prior to the expected date of submission to the intended publisher or of planned presentation.
In addition, if necessary, (the) Investigator(s) shall withhold publication for an additional 60 days, to allow the filing of a patent application, or to allow the Sponsor to take any measures he deems appropriate to establish and preserve his proprietary rights.

It is agreed that publication of study results by each site shall be made only as part of a publication of the study results obtained by all sites performing the protocol, once the study is completed and finalised.

The authors list is agreed by all Investigators prior to publication. The names of the authors are provided according to their participation in the design of the protocol as well as their recruitment of eligible and analysable patients.
16. REFERENCES

[1] F373280 INVESTIGATOR'S BROCHURE, version October 2013

 n-3 Polyunsaturated Fatty Acids in the prevention of atrial Fibrillation Recurrences after electrical cardioversion. A prospective, Randomised study  
 Circulation, 2011; 124:1100-1106

 Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy  
 J. Am. Coll. Cardiol. 2011;57;870-879

 Dose-dependant effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of non ischemic origin: A double-blind, placebo-controlled, 3-arm study  
 American Heart Journal 2011; 161:915.e1-915.e9 - volume 161, number 5

[5] GISSI-HF INVESTIGATORS  
 Effects of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GSSI-HF Trial): a randomised, double-blind, placebo-controlled trial  
 The lancet on line - August 2008

 Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).  
 European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery,  

[7] KOWEY PR, REIFFEL JA, ELLENBOGEN KA, NACCARELLI GV, PRATT CM.  
 Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomised controlled trial.  

[9] OMACOR® SUMMARY PRODUCT CARACTERISTICS (SPC) dated 17/02/2012

[10] BEPANTHENE® SUMMARY PRODUCT CARACTERISTICS (SPC)


The consumption of food products from linseed-fed animals maintains erythrocyte omega-3 fatty acids in obese human

[18] HARRIS WS, VON SCHACKY C.
The Omega-3 Index: a new risk factor for death from coronary heart disease?

Effects of Polyunsaturated Fatty Acids n-3 (PUFA n-3) in the prophylaxis of atrial fibrillation relapses after external electric cardioversion
*World Congress of Cardiology 2006, 2-6 September, Barcelona – Spain*

Outcome parameters from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association.
*Europace* 2007, 9, 1006-1023

[21] EUROPEAN MEDICINES AGENCY
Addendum to the guideline on antiarrhythmics on atrial fibrillation and atrial flutter.
*EMA/CHMA/EWP/213056/2010*

Dietary fish oil dose- and time-response effects on cardiac phospholipid fatty acid composition.
*Lipids.* 2004;39:955–961

[23] ROBERTO M. LANG, MICHELLE BIERIG, RICHARD B. DEVEREUX, FRANK A. FLACHSKAMPF*, ELYSE FOSTER, PATRICIA A. PELLIKKA, MICHAEL H. PICARD, MARY J. ROMAN, JAMES SEWARD, JACK SHANEWISE, SCOTT SOLOMON, KIRK T. SPENCER, MARTIN ST. JOHN SUTTON, WILLIAM STEWART.
Recommendations for chamber quantification
17. APPENDICES
17.1. DECLARATION OF HELSINKI

WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI
ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING HUMAN SUBJECTS


A. INTRODUCTION

1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of ethical principles for medical research involving human subjects, including research on identifiable human material and data. The Declaration is intended to be read as a whole and each of its constituent paragraphs should not be applied without consideration of all other relevant paragraphs.

2. Although the Declaration is addressed primarily to physicians, the WMA encourages other participants in medical research involving human subjects to adopt these principles.

3. It is the duty of the physician to promote and safeguard the health of patients, including those who are involved in medical research. The physician's knowledge and conscience are dedicated to the fulfilment of this duty.

4. The Declaration of Geneva of the WMA binds the physician with the words, “The health of my patient will be my first consideration,” and the International Code of Medical Ethics declares that, “A physician shall act in the patient's best interest when providing medical care.”

5. Medical progress is based on research that ultimately must include studies involving human subjects. Populations that are underrepresented in medical research should be provided appropriate access to participation in research.

6. In medical research involving human subjects, the well-being of the individual research subject must take precedence over all other interests.

7. The primary purpose of medical research involving human subjects is to understand the causes, development and effects of diseases and improve preventive, diagnostic and therapeutic interventions (methods, procedures and treatments). Even the best current interventions must be evaluated continually through research for their safety, effectiveness, efficiency, accessibility and quality.

8. In medical practice and in medical research, most interventions involve risks and burdens.

9. Medical research is subject to ethical standards that promote respect for all human subjects and protect their health and rights. Some research populations are particularly vulnerable and need special protection. These include those who cannot give or refuse consent for themselves and those who may be vulnerable to coercion or undue influence.

10. Physicians should consider the ethical, legal and regulatory norms and standards for research involving human subjects in their own countries as well as applicable international norms and standards. No national or international ethical, legal or regulatory requirement should reduce or eliminate any of the protections for research subjects set forth in this Declaration.
B. PRINCIPLES FOR ALL MEDICAL RESEARCH

11. It is the duty of physicians who participate in medical research to protect the life, health, dignity, integrity, right to self-determination, privacy, and confidentiality of personal information of research subjects.

12. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and adequate laboratory and, as appropriate, animal experimentation. The welfare of animals used for research must be respected.

13. Appropriate caution must be exercised in the conduct of medical research that may harm the environment.

14. The design and performance of each research study involving human subjects must be clearly described in a research protocol. The protocol should contain a statement of the ethical considerations involved and should indicate how the principles in this Declaration have been addressed. The protocol should include information regarding funding, sponsors, institutional affiliations, other potential conflicts of interest, incentives for subjects and provisions for treating and/or compensating subjects who are harmed as a consequence of participation in the research study. The protocol should describe arrangements for post-study access by study subjects to interventions identified as beneficial in the study or access to other appropriate care or benefits.

15. The research protocol must be submitted for consideration, comment, guidance and approval to a research ethics committee before the study begins. This committee must be independent of the researcher, the sponsor and any other undue influence. It must take into consideration the laws and regulations of the country or countries in which the research is to be performed as well as applicable international norms and standards but these must not be allowed to reduce or eliminate any of the protections for research subjects set forth in this Declaration. The committee must have the right to monitor ongoing studies. The researcher must provide monitoring information to the committee, especially information about any serious adverse events. No change to the protocol may be made without consideration and approval by the committee.

16. Medical research involving human subjects must be conducted only by individuals with the appropriate scientific training and qualifications. Research on patients or healthy volunteers requires the supervision of a competent and appropriately qualified physician or other health care professional. The responsibility for the protection of research subjects must always rest with the physician or other health care professional and never the research subjects, even though they have given consent.

17. Medical research involving a disadvantaged or vulnerable population or community is only justified if the research is responsive to the health needs and priorities of this population or community and if there is a reasonable likelihood that this population or community stands to benefit from the results of the research.

18. Every medical research study involving human subjects must be preceded by careful assessment of predictable risks and burdens to the individuals and communities involved in the research in comparison with foreseeable benefits to them and to other individuals or communities affected by the condition under investigation.

19. Every clinical trial must be registered in a publicly accessible database before recruitment of the first subject.
20. Physicians may not participate in a research study involving human subjects unless they are confident that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians must immediately stop a study when the risks are found to outweigh the potential benefits or when there is conclusive proof of positive and beneficial results.

21. Medical research involving human subjects may only be conducted if the importance of the objective outweighs the inherent risks and burdens to the research subjects.

22. Participation by competent individuals as subjects in medical research must be voluntary. Although it may be appropriate to consult family members or community leaders, no competent individual may be enrolled in a research study unless he or she freely agrees.

23. Every precaution must be taken to protect the privacy of research subjects and the confidentiality of their personal information and to minimize the impact of the study on their physical, mental and social integrity.

24. In medical research involving competent human subjects, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail, and any other relevant aspects of the study. The potential subject must be informed of the right to refuse to participate in the study or to withdraw consent to participate at any time without reprisal. Special attention should be given to the specific information needs of individual potential subjects as well as to the methods used to deliver the information. After ensuring that the potential subject has understood the information, the physician or another appropriately qualified individual must then seek the potential subject’s freely-given informed consent, preferably in writing. If the consent cannot be expressed in writing, the non-written consent must be formally documented and witnessed.

25. For medical research using identifiable human material or data, physicians must normally seek consent for the collection, analysis, storage and/or reuse. There may be situations where consent would be impossible or impractical to obtain for such research or would pose a threat to the validity of the research. In such situations the research may be done only after consideration and approval of a research ethics committee.

26. When seeking informed consent for participation in a research study the physician should be particularly cautious if the potential subject is in a dependent relationship with the physician or may consent under duress. In such situations the informed consent should be sought by an appropriately qualified individual who is completely independent of this relationship.

27. For a potential research subject who is incompetent, the physician must seek informed consent from the legally authorized representative. These individuals must not be included in a research study that has no likelihood of benefit for them unless it is intended to promote the health of the population represented by the potential subject, the research cannot instead be performed with competent persons, and the research entails only minimal risk and minimal burden.

28. When a potential research subject who is deemed incompetent is able to give assent to decisions about participation in research, the physician must seek that assent in addition to the consent of the legally authorized representative. The potential subject’s dissent should be respected.
29. Research involving subjects who are physically or mentally incapable of giving consent, for example, unconscious patients, may be done only if the physical or mental condition that prevents giving informed consent is a necessary characteristic of the research population. In such circumstances the physician should seek informed consent from the legally authorized representative. If no such representative is available and if the research cannot be delayed, the study may proceed without informed consent provided that the specific reasons for involving subjects with a condition that renders them unable to give informed consent have been stated in the research protocol and the study has been approved by a research ethics committee. Consent to remain in the research should be obtained as soon as possible from the subject or a legally authorized representative.

30. Authors, editors and publishers all have ethical obligations with regard to the publication of the results of research. Authors have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports. They should adhere to accepted guidelines for ethical reporting. Negative and inconclusive as well as positive results should be published or otherwise made publicly available. Sources of funding, institutional affiliations and conflicts of interest should be declared in the publication. Reports of research not in accordance with the principles of this Declaration should not be accepted for publication.

C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH MEDICAL CARE

31. The physician may combine medical research with medical care only to the extent that the research is justified by its potential preventive, diagnostic or therapeutic value and if the physician has good reason to believe that participation in the research study will not adversely affect the health of the patients who serve as research subjects.

32. The benefits, risks, burdens and effectiveness of a new intervention must be tested against those of the best current proven intervention, except in the following circumstances:
   - The use of placebo, or no treatment, is acceptable in studies where no current proven intervention exists; or
   - Where for compelling and scientifically sound methodological reasons the use of placebo is necessary to determine the efficacy or safety of an intervention and the patients who receive placebo or no treatment will not be subject to any risk of serious or irreversible harm. Extreme care must be taken to avoid abuse of this option.

33. At the conclusion of the study, patients entered into the study are entitled to be informed about the outcome of the study and to share any benefits that result from it, for example, access to interventions identified as beneficial in the study or to other appropriate care or benefits.

34. The physician must fully inform the patient which aspects of the care are related to the research. The refusal of a patient to participate in a study or the patient’s decision to withdraw from the study must never interfere with the patient-physician relationship.

35. In the treatment of a patient, where proven interventions do not exist or have been ineffective, the physician, after seeking expert advice, with informed consent from the patient or a legally authorized representative, may use an unproven intervention if in the physician's judgement it offers hope of saving life, re-establishing health or alleviating suffering. Where possible, this intervention should be made the object of research, designed to evaluate its safety and efficacy. In all cases, new information should be recorded and, where appropriate, made publicly available.
17.2. SAE REPORT FORM
NOTIFICATION OF SERIOUS ADVERSE EVENT (SAE) OR PREGNANCY TO PIERRE FABRE CORPORATE VIGILANCES DIVISION

TO BE TRANSMITTED TO THE CORPORATE VIGILANCES DIVISION BY E-MAIL WITHIN 24H TO HQ.pharmacovigilance@pierre-fabre.com OR BY FAX WITHIN 24H – Fax N°: 33 (0) 1.49.10.80.90

Transmission date [ ] [ ] [ ] [ ] [ ] (ddmmyyyy) Country: ........................................

SAE N° [ ] [ ] FIRST NOTIFICATION ☐ FOLLOW-UP ☐ N°

SUBJECT CHARACTERISTICS

Gender 1=M, 2=F Height [ ] [ ] cm Weight [ ] [ ] [ ] kg Birth date [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ]

DESCRIPTION OF THE EVENT

The serious adverse event resulted in:
☐ Death (whatever may be the cause)
☐ Hospitalisation (*) or extension thereof
☐ Life threatening
☐ Invalidity or disability
☐ Congenital abnormality or abnormal pregnancy outcome
☐ Cancer
☐ Other (any other serious clinical or laboratory event according to the investigator or the protocol, overdosage meeting seriousness criteria, suicide attempts)

Other fact to be notified:
☐ Pregnancy exposure

Nature of the event (if clinical nature, indicate the diagnosis or the major symptom):
...........................................................................................................................................................................................................
...........................................................................................................................................................................................................
...........................................................................................................................................................................................................

AE onset date [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)

Seriousness onset date [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)

Summary description (if clinical cause, significant history, progression of event, available laboratory results, etc...):
...........................................................................................................................................................................................................
...........................................................................................................................................................................................................
...........................................................................................................................................................................................................

(*) Except hospitalisations with durations and goals planned in the protocol

THE SAE IN RELATION TO THE TRIAL

TREATMENT NUMBER [ ] [ ] [ ] [ ] [ ] [ ] [ ]

• Time of occurrence of SAE

☐ During the selection or run-in period
☐ During the administration phase of the study treatment
☐ After the administration phase of the study treatment

• Date of first study treatment administration [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)

• Date of last study treatment administration before the occurrence of SAE [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)

• Was the blind broken? ☐ Yes ☐ No ☐ Not applicable
If yes, or if this is an open study, drug(s) administered:

Conditions of administration (cycles(s), daily dose(s), route(s) of administration, etc...):
### CONCOMITANT MEDICATION SINCE TRIAL INITIATION and UP UNTIL THE OCCURRENCE OF THE SAE

*(EXCEPT THE TREATMENTS GIVEN FOR THE SAE)*

<table>
<thead>
<tr>
<th>Trade name (or INN)</th>
<th>Daily dose</th>
<th>Start date (dd/mm/yy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (dd/mm/yy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>_/<strong>/</strong></td>
<td>[ ]</td>
<td>_/<strong>/</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>_/<strong>/</strong></td>
<td>[ ]</td>
<td>_/<strong>/</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>_/<strong>/</strong></td>
<td>[ ]</td>
<td>_/<strong>/</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>_/<strong>/</strong></td>
<td>[ ]</td>
<td>_/<strong>/</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### MEASURES TAKEN FOLLOWING THE SAE

- **Study treatment**
  - [ ] No change
  - [ ] Dosage modification, specify: ………………………………………. Modification Date: _/__/__
  - [ ] Temporarily discontinued Readministration date: _/__/__
  - [ ] Withdrawn End date: _/__/__
  - [ ] Not applicable
**The event led to:**

- Prescription of corrective or symptomatic treatments:

<table>
<thead>
<tr>
<th>Trade name (or INN)</th>
<th>Daily dose</th>
<th>Start date (dd/mm/yyyy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (dd/mm/yyyy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Discontinuation of concomitant treatments:

<table>
<thead>
<tr>
<th>Trade name (or INN)</th>
<th>Daily dose</th>
<th>Start date (dd/mm/yyyy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (dd/mm/yyyy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Others, specify:

**OUTCOME**

- Not recovered/Not resolved
- Recovering/Resolving
- Recovered/Resolved
- Recovered/Resolved with sequelae
- Fatal
- Unknown

In case of death, has an autopsy been conducted?  Yes  No

**INVESTIGATOR CAUSALITY ASSESSMENT** (investigator’s assessment to be done as soon as possible)

| Study drug: | Related to study protocol:
|--------------|---------------------------|
| Not Suspected | Suspected
| Not Suspected | Suspected

Comments: .............................................................................................................................................................

Enclose in the notification the results of carried out examinations, reports of hospitalisation, etc...
## 17.3. PREDEFINED LIMITS OF LABORATORY AND VITAL SIGN 
POTENTIALLY CLINICALLY SIGNIFICANT CHANGES AND VALUES

List of Predefined Potentially Clinically Significant Change For Laboratory Values

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>UNIT</th>
<th>PSC</th>
<th>Decrease</th>
<th>Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>MUSCLE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatine Phosphokinase</td>
<td>U / l</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KIDNEY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine</td>
<td>µmol/l</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urea</td>
<td>mmol/l</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Uric acid</td>
<td>µmol/l</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phosphate</td>
<td>mmol/l</td>
<td>0.39</td>
<td>0.39</td>
<td></td>
</tr>
<tr>
<td>Calcium</td>
<td>mmol/l</td>
<td>0.30</td>
<td>0.30</td>
<td></td>
</tr>
<tr>
<td>ELECTROLYTES</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium</td>
<td>mmol/l</td>
<td>8</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>Potassium</td>
<td>mmol/l</td>
<td>1.1</td>
<td></td>
<td>1.1</td>
</tr>
<tr>
<td>Chloride</td>
<td>mmol/l</td>
<td>8</td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>mmol/l</td>
<td>7</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>METABOLISM/</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NUTRITIONAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose (random)</td>
<td>mmol/l</td>
<td>3</td>
<td></td>
<td>3.7</td>
</tr>
<tr>
<td>Albumin</td>
<td>g/l</td>
<td>6</td>
<td></td>
<td>6</td>
</tr>
<tr>
<td>Protein</td>
<td>g/l</td>
<td>11</td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>mmol/l</td>
<td></td>
<td></td>
<td>1.97</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>mmol/l</td>
<td>0.91</td>
<td></td>
<td>0.85</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>mmol/l</td>
<td>2.17</td>
<td></td>
<td>2.04</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>mmol/l</td>
<td></td>
<td></td>
<td>2.91</td>
</tr>
<tr>
<td>ERYTHROCYTES</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythrocyte count</td>
<td>T/l</td>
<td>0.7</td>
<td></td>
<td>0.7</td>
</tr>
<tr>
<td>Haemoglobin</td>
<td>g/l</td>
<td>20</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Haematocrit</td>
<td>l</td>
<td>0.06</td>
<td></td>
<td>0.06</td>
</tr>
<tr>
<td>MCV</td>
<td>fl</td>
<td>7</td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>MCH (Fe)</td>
<td>fmol</td>
<td>0.19</td>
<td></td>
<td>0.19</td>
</tr>
<tr>
<td>MCHC (Fe)</td>
<td>mmol/l</td>
<td>2</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>LEUKOCYTES</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukocyte count</td>
<td>G/l</td>
<td>4.2</td>
<td></td>
<td>3.8</td>
</tr>
<tr>
<td>DIFFERENTIAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>COUNT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophils</td>
<td>G/l</td>
<td>3.47</td>
<td></td>
<td>3.19</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>G/l</td>
<td>1.76</td>
<td></td>
<td>1.63</td>
</tr>
<tr>
<td>Monocytes</td>
<td>G/l</td>
<td></td>
<td></td>
<td>0.49</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>G/l</td>
<td></td>
<td></td>
<td>0.41</td>
</tr>
<tr>
<td>Basophils</td>
<td>G/l</td>
<td></td>
<td></td>
<td>0.14</td>
</tr>
<tr>
<td>URINE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specific gravity</td>
<td></td>
<td>-</td>
<td>0.017</td>
<td>0.015</td>
</tr>
<tr>
<td>pH</td>
<td></td>
<td>-</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>LIVER</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>µmol/l</td>
<td></td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>ASAT (SGOT)</td>
<td>U/l</td>
<td></td>
<td></td>
<td>N x (23/36)</td>
</tr>
<tr>
<td>ALAT (SGPT)</td>
<td>U/l</td>
<td></td>
<td></td>
<td>N x (28/45)</td>
</tr>
<tr>
<td>Gamma GT</td>
<td>U/l</td>
<td></td>
<td></td>
<td>N x (25/38)</td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>U/l</td>
<td></td>
<td></td>
<td>N x (30/95)</td>
</tr>
</tbody>
</table>

N = upper limit of normal range

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>CNALV</th>
</tr>
</thead>
</table>
| HAEMOGLOBIN    | • Decrease of at least 2g/dl and value < 10 g/dl whatever the baseline value  
• If missing baseline : value <10g/dl |
| NEUTROPHILS   | • < 1 500/mm³ whatever the baseline value                                                                                          |
| WBC (if missing value for neutrophils) | • < 3 000/mm³ whatever the baseline value                                                                                         |
| PLATELETS     | • < 100 000/mm³ whatever the baseline value                                                                                       |
| SERUM CREATININE | • Increase of at least 30 % as compared to baseline value and value > 150 µmol/l whatever the baseline value                        
• If missing baseline : value > 150 µmol/l |
| LIVER FUNCTION TESTS |                                                                                                                                   |
| ALAT           | • If normal baseline :  
  • ALAT > 2 N  
• If abnormal baseline :  
  → if baseline value ≤ 2.5 N :  
  • increase of at least 100 % as compared to baseline value  
  → if baseline value > 2.5 N :  
  • value > 5 N |
| ASAT           | • If normal baseline :  
  • ASAT > 2 N  
• If abnormal baseline :  
  → if baseline value ≤ 2.5 N :  
  • increase of at least 100 % as compared to baseline value  
  → if baseline value > 2.5 N :  
  • value > 5 N |
| Alkaline phosphatase (AP) | • If normal baseline :  
  • AP > 1.25 N  
• If abnormal baseline :  
  • AP > 2 N |
| Total bilirubin (TB) | • If normal baseline :  
  • TB > 1.5 N  
• If abnormal baseline :  
  • TB > 2 N |

N=upper limit of normal range

Cardiovascular Safety

Table 1: Predefined Limits for Potentially Clinically Significant Changes (PSC) and PSC Leading to Clinically Significant Values (PSCV)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>PSC</th>
<th>PSCV</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP</td>
<td>Increase ≥ 20 mmHg</td>
<td>SBP ≥ 160 mmHg and increase ≥ 20 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 20 mmHg</td>
<td>SBP ≤ 90 mmHg and decrease ≥ 20 mmHg</td>
</tr>
<tr>
<td>DBP</td>
<td>Increase ≥ 10 mmHg</td>
<td>DBP ≥ 100 mmHg and increase ≥ 10 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 mmHg</td>
<td>DBP ≤ 50 mmHg and decrease ≥ 10 mmHg</td>
</tr>
<tr>
<td>HR</td>
<td>Increase ≥ 10 bpm</td>
<td>HR ≥ 110 bpm and increase ≥ 10 bpm</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 bpm</td>
<td>HR ≤ 50 bpm and decrease ≥ 10 bpm</td>
</tr>
</tbody>
</table>

Table 2: Predefined Classes for changes from Baseline to the Maximum (and/or Minimum) Post-baseline Value

<table>
<thead>
<tr>
<th>Classes of Change from Baseline to the Maximum Post-baseline Value</th>
<th>Classes of Change from Baseline to the Minimum Post-baseline Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>-----------</td>
<td>----------</td>
</tr>
<tr>
<td>All</td>
<td>All</td>
</tr>
<tr>
<td>≥ 0</td>
<td>&gt; 0</td>
</tr>
<tr>
<td>&gt; 0</td>
<td>&gt; 0</td>
</tr>
<tr>
<td>≥ 10</td>
<td>≥ 5</td>
</tr>
<tr>
<td>≥ 20</td>
<td>≥ 10</td>
</tr>
<tr>
<td>≥ 30</td>
<td>≥ 15</td>
</tr>
<tr>
<td>≥ 40</td>
<td>≥ 20</td>
</tr>
<tr>
<td></td>
<td>≥ 25</td>
</tr>
<tr>
<td></td>
<td>≥ 30</td>
</tr>
</tbody>
</table>

Table 3: Classes for Vital Signs Maximum or Minimum Values

<table>
<thead>
<tr>
<th>Classes for the Maximum Post-baseline Value for each parameter</th>
<th>Classes for the Minimum Post-baseline Value for each parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>&lt; 120</td>
<td>[80;90]</td>
</tr>
<tr>
<td>[120;140]</td>
<td>[90;100]</td>
</tr>
<tr>
<td>≥ 160</td>
<td>≥ 100</td>
</tr>
</tbody>
</table>

Table 4: Classes for Maximum or Minimum of BP in its entirety

<table>
<thead>
<tr>
<th>Classification of Maximum Values for Blood Pressure (mmHg)</th>
<th>Classification of Minimum Values Blood Pressure (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP &lt; 140 and DBP &lt; 90</td>
<td>SBP &gt; 90 and DBP &gt; 50</td>
</tr>
<tr>
<td>SBP [140;160] and DBP &lt; 100</td>
<td>SBP ≤ 90 or DBP ≤ 50</td>
</tr>
<tr>
<td>or DBP [90;100] and SBP &lt; 160</td>
<td></td>
</tr>
<tr>
<td>SBP ≥ 160 or DBP ≥ 100</td>
<td></td>
</tr>
</tbody>
</table>

Table 5: Definition of orthostatic hypotension

<table>
<thead>
<tr>
<th>Orthostatic Hypotension *</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP Decrease ≥ 20 mmHg or DBP Decrease ≥ 10 mmHg between supine and standing positions</td>
</tr>
</tbody>
</table>

16.1.1.6. Protocol and appendices
(version 06: 02 December 2013)
CLINICAL STUDY PROTOCOL

Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

F373280 / Soft Capsules / 1g

Pierre Fabre Study Code: F 373280 CA 2 01
EudraCT Number: 2012 – 003487 - 48

Sponsor's Representative:
Gaëlle ALCARAZ
INSTITUT DE RECHERCHE PIERRE FABRE - Centre de R&D Pierre Fabre - BP 13562
3 avenue Hubert Curien
31035 TOULOUSE Cèdex 1, FRANCE
Phone: +33 5 34 50 62 16
Fax:+33 5 34 50 69 69
E-mail:gaelle.alcaraz@pierre-fabre.com

Study Coordinating Investigator
Pr Savina NODARI
Associate Professor of Cardiology
Department of Clinical and Surgical Specialities, Radiological Science and Public Health
Section of Cardiovascular Diseases
University Medical School and Spedali Civili Hospital of Brescia
c/o Spedali Civili di Brescia
Piazzale Spedali Civili, 1
25123 - BRESCIA, ITALY
Phone: +39 030 3996 587 – +39 030 393849
Fax: +39 030 3700 359
E-mail: savinanodari@gmail.com; nodari@med.unibs.it

Version 6 –02DEC2013

The information contained in this document is confidential and is the property of the Sponsor, Pierre Fabre Medicament. This information is given for the needs of the study and must not be disclosed without prior written consent of the Sponsor Pierre Fabre Medicament. Persons to whom this information is given for the needs of the study must be informed that it is confidential and must not be disclosed.
SPONSOR PERSONNEL

PIERRE FABRE MEDICAMENT
represented by
Institut de Recherche Pierre Fabre

**Clinical Study Manager (Monitor)**

Gaëlle ALCARAZ
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1, FRANCE

Phone: +33 5 34 50 62 16
Fax: +33 5 34 50 69 69
E-mail: gaelle.alcaraz@pierre-fabre.com

**Medical Director**

Richard ROCHE, MD
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1, FRANCE

Phone: +33 5 34 50 61 94
Fax: +33 5 34 50 69 69
E-mail: richard.roche@pierre-fabre.com
CONTRACT RESEARCH ORGANISATIONS

For Feasibility, Monitoring and Regulatory issues:
Pharmaceutical Service Network (PSN)
Rufino Gonzalez
28 037 Madrid - SPAIN
Phone: +34 91 375 6930 - Fax: +34 91 375 6931
E-mail: www.psnglobal.org

For Feasibility, Monitoring and Regulatory issues (in Spain):
Alpha Bioresearch
Paseo de la Castellana, 163 - 2º Izquierda
28 046 Madrid - SPAIN
Phone: +34 91 745 2520 - Fax: +34 91 745 0653
E-mail: teresa.bricio@alphabioresearch.com

For Centralised Randomisation and Electronic Case Report Form
S-Clinica
6, Chaussée de Boondael
B-1050 Brussels - BELGIUM
Phone: +32 2 645 0567 - Fax: +32 2 645 0569
E-mail: irena.seredina@s-clinica.com

For Centralised Reading of Holder ECG and TTEM and equipment supply:
Biomedical System
1945 Chaussée de Wavre
B-1160 Brussels - BELGIUM
Phone: +32 2 661 20 70 - Fax: +32 2 661 20 71
E-mail: sjacobs@biomedsys.com

For intra erythrocyte DHA dosage:
Agrocampus Ouest
Laboratoire de Biochimie
65 rue de Saint Brieuc – CS 84215
35042 RENNES Cedex - FRANCE
Phone: +33 2 23 48 55 49 - Fax: +33 2 23 48 55 50
E-mail: daniel.catheline@agrocampus-ouest.fr

For transportation of blood sample to the Analytical centre (Agrocampus) and material supply:
Theradis Pharma
41, chemin des Presses
06800 CAGNES-SUR-MER – FRANCE
Phone: +33 (0)4 97 02 07 07 - Fax: +33 (0)4 97 10 08 78
E-mail: chantal.raffy@theradis.pharma.com
For refund of patients expenses linked to the study (in France):
CLINACT
6-10 rue TROYON
92310 SEVRES – FRANCE
Phone: +33 1 46 90 27 27 - Fax: +33 1 46 23 01 56
Email: sebastien.beaumont@clinact.com
Protocol F 373280 CA 2 01

APPROVAL FORM

Protocol Version 6 – 02 DEC 2013

Sponsor's Representative:
Medical Director:
Richard ROCHE, MD

Date: 02/12/2013 Signature: 

Study Coordinating Investigator:
Savina NODARI, MD

Date: 
Signature: 02/12/2013 

F373280 Clinical Study Protocol – Version 6– 02DEC2013
6/105
Country: ……………………

Country Coordinating Investigator:

<table>
<thead>
<tr>
<th>&quot;Name&quot;</th>
<th>Date:</th>
<th>Signature:</th>
</tr>
</thead>
</table>


By my signature below, I, Dr / Pr " ______________ ", hereby confirm that I agree:

- to conduct the trial described in the protocol F 373280 CA 2 01, dated 02 December 2013 in compliance with GCP, with applicable regulatory requirements and with the protocol agreed upon by the Sponsor Pierre Fabre Médicament and given approval / favourable* opinion by the Ethics Committee;
- to document the delegation of significant study-related tasks and to notify the Sponsor of changes in site personnel involved in the study;
- to comply with the procedure for data recording and reporting;
- to allow monitoring, auditing and inspection;
- to retain the trial-related essential documents until the Sponsor informs that these documents are no longer needed.

Furthermore, I hereby confirm that I will have and will use the available adequate resources, personnel and facilities for conduct this trial.

I have been informed that certain regulatory authorities require the Sponsor Pierre Fabre Médicament to obtain and supply details about the investigator’s ownership interest in the Sponsor or the study drug, and more generally about his/her financial relationships with the Sponsor. The Sponsor will use and disclose the information solely for the purpose of complying with regulatory requirements.

Hence I agree:

- to supply the Sponsor with any information regarding ownership interest and financial relationships with the Sponsor (including those of my spouse and dependent children);
- to promptly update this information if any relevant changes occur during the course of the study and for 1 year following completion of the study;
- that the Sponsor may disclose this information about such ownership interests and financial relationships to regulatory authorities.

* To be adapted

Date: ___________________________ Signature: ___________________________
# TABLE OF CONTENTS OF CLINICAL STUDY PROTOCOL

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. INTRODUCTION AND STUDY RATIONALE</td>
<td>22</td>
</tr>
<tr>
<td>1.1. TARGET PATHOLOGY AND THERAPY</td>
<td>22</td>
</tr>
<tr>
<td>1.2. INFORMATION ON THE TEST PRODUCT</td>
<td>24</td>
</tr>
<tr>
<td>1.2.1. Chemical and pharmaceutical characteristics</td>
<td>25</td>
</tr>
<tr>
<td>1.2.1.1. Nomenclature and structure</td>
<td>25</td>
</tr>
<tr>
<td>1.2.1.2. Physical and chemical general properties</td>
<td>25</td>
</tr>
<tr>
<td>1.2.2. Non-clinical Data</td>
<td>26</td>
</tr>
<tr>
<td>1.2.2.1. Pharmacological profile</td>
<td>26</td>
</tr>
<tr>
<td>1.2.2.2. Safety pharmacology</td>
<td>27</td>
</tr>
<tr>
<td>1.2.2.3. Toxicology profile</td>
<td>27</td>
</tr>
<tr>
<td>1.2.2.4. Pharmacokinetic data</td>
<td>27</td>
</tr>
<tr>
<td>1.2.3. Clinical data</td>
<td>27</td>
</tr>
<tr>
<td>1.3. STUDY RATIONALE</td>
<td>30</td>
</tr>
<tr>
<td>1.4. OVERALL RISK AND BENEFIT ASSESSMENT</td>
<td>30</td>
</tr>
<tr>
<td>2. STUDY OBJECTIVES</td>
<td>33</td>
</tr>
<tr>
<td>2.1. PRIMARY OBJECTIVE</td>
<td>33</td>
</tr>
<tr>
<td>2.2. SECONDARY OBJECTIVES</td>
<td>33</td>
</tr>
<tr>
<td>3. ETHICAL CONSIDERATIONS RELATING TO THE STUDY</td>
<td>33</td>
</tr>
<tr>
<td>4. STUDY DESIGN</td>
<td>35</td>
</tr>
<tr>
<td>4.1. OVERALL DESCRIPTION</td>
<td>35</td>
</tr>
<tr>
<td>4.2. DISCUSSION OF THE STUDY DESIGN</td>
<td>35</td>
</tr>
<tr>
<td>4.2.1. Choice of the Study Population</td>
<td>35</td>
</tr>
<tr>
<td>4.2.2. Choice of the Study Design</td>
<td>36</td>
</tr>
<tr>
<td>4.2.3. Choice of the Dose</td>
<td>38</td>
</tr>
<tr>
<td>4.2.4. Choice of the Sample Size</td>
<td>38</td>
</tr>
<tr>
<td>5. STUDY POPULATION</td>
<td>38</td>
</tr>
<tr>
<td>5.1. INCLUSION CRITERIA</td>
<td>38</td>
</tr>
<tr>
<td>5.2. NON INCLUSION CRITERIA</td>
<td>39</td>
</tr>
<tr>
<td>5.3. NUMBER OF PATIENTS</td>
<td>40</td>
</tr>
<tr>
<td>5.4. RECRUITMENT MODALITIES</td>
<td>41</td>
</tr>
<tr>
<td>5.5. PATIENT IDENTIFICATION</td>
<td>41</td>
</tr>
<tr>
<td>5.6. WITHDRAWAL CRITERIA</td>
<td>41</td>
</tr>
<tr>
<td>5.7. REPLACEMENT OF PATIENTS</td>
<td>42</td>
</tr>
<tr>
<td>5.8. POST-STUDY EXCLUSION PERIOD</td>
<td>42</td>
</tr>
<tr>
<td>5.9. STUDY CARD AND LETTER FOR GENERAL PRACTITIONER(S)</td>
<td>42</td>
</tr>
</tbody>
</table>
## 6. STUDY TREATMENT

### 6.1. SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT

### 6.2. PACKAGING AND LABELLING

#### 6.2.1. Packaging

#### 6.2.2. Labelling

### 6.3. DISTRIBUTION TO CENTRE AND STORAGE

### 6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT

### 6.5. DRUG ADMINISTRATION

#### 6.5.1. Duration of Treatment

#### 6.5.2. Dose Schedule

#### 6.5.3. Route and Conditions of Administration

### 6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT

### 6.7. RECALL OF INVESTIGATIONAL PRODUCTS

## 7. CONCOMITANT TREATMENTS

### 7.1. ANTI-VITAMIN K TREATMENT

### 7.2. PROHIBITED TREATMENTS

### 7.3. AUTHORISED TREATMENTS

## 8. EVALUATION CRITERIA

### 8.1. PRIMARY EFFICACY CRITERION

#### 8.1.1. Time to the first Atrial Fibrillation Recurrence

#### 8.1.1.1. Definition

#### 8.1.1.2. Schedule

#### 8.1.1.3. Evaluation Methods

#### 8.1.2. Secondary Efficacy Criteria

#### 8.1.2.1. Numbers of AF episodes in the first week following visit 3 (ECV visit)

#### 8.1.2.2. Duration of AF episodes in the first week following visit 3 (ECV visit)

#### 8.1.2.3. Clinical parameters evaluation

#### 8.1.2.4. Cardioversion assessment

#### 8.1.2.5. Evolution of echocardiographic parameters

### 8.2. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA

#### 8.2.1. Definition

#### 8.2.2. Blood samples

#### 8.2.2.1. Collection schedule

#### 8.2.2.2. Technical handling

#### 8.2.3. DHA concentration measurement

### 8.3. SAFETY ASSESSMENT

#### 8.3.1. Adverse Events

#### 8.3.2. Laboratory Investigations
8.3.2.1. Schedule ......................................................................................................................... 56
8.3.2.2. Technical Procedures and Parameters ............................................................................ 56
8.3.3. Global Physical Examination ............................................................................................ 57
8.3.4. Vital Signs .......................................................................................................................... 57
8.3.4.1. Schedule ......................................................................................................................... 57
8.3.4.2. Technical Procedure and Parameters .............................................................................. 57
8.3.5. Electrocardiogram (ECG) .................................................................................................. 58
8.3.5.1. Schedule ......................................................................................................................... 58
8.3.5.2. Technical Procedure and Parameters .............................................................................. 58
8.3.6. Coagulation parameters ..................................................................................................... 58
8.3.7. Concomitant Treatments ................................................................................................... 59
8.4. COMPLIANCE .................................................................................................................... 59

9. STUDY PROCEDURES ........................................................................................................ 59

10. ADVERSE EVENTS: DEFINITION AND REPORTING .................................................. 65
10.1. ADVERSE EVENTS ............................................................................................................ 65
10.1.1. Definition of Adverse Events .......................................................................................... 65
10.1.2. Grading of Adverse Events ............................................................................................ 66
10.1.3. Reporting of Adverse Events ......................................................................................... 66
10.2. SERIOUS ADVERSE EVENTS (SAE) ............................................................................. 66
10.2.1. Definition ....................................................................................................................... 66
10.2.2. Reporting of SAE ......................................................................................................... 67
10.2.3. Follow-up of SAE ....................................................................................................... 67
10.2.4. SAE Occurring After the Study .................................................................................... 68
10.3. REPORTING OF OVERDOSAGE TO THE SPONSOR ................................................... 68
10.4. REPORTING OF PREGNANCY TO THE SPONSOR ..................................................... 68
10.5. SPONSOR'S RESPONSIBILITIES FOR SAFETY REPORTING PURPOSES .................. 69

11. DATA COLLECTION AND STUDY MONITORING .................................................................. 69
11.1. DATA COLLECTION ......................................................................................................... 69
11.1.1. Case Report Form ........................................................................................................... 69
11.1.2. Source Documents ......................................................................................................... 70
11.2. STUDY MONITORING ..................................................................................................... 70
11.2.1. Monitoring visits ......................................................................................................... 70
11.2.1.1. Site Preselection Visit .............................................................................................. 71
11.2.1.2. Initiation Visit ......................................................................................................... 71
11.2.1.3. Follow-up Visits .................................................................................................... 71
11.2.1.4. Closing Visit .......................................................................................................... 72
11.2.2. Direct Access to Source Documents ............................................................................. 72
11.3. INDEPENDENT DATA MONITORING COMMITTEE .................................................... 72

12. DATA MANAGEMENT ....................................................................................................... 73
12.1. DATA ENTRY ................................................................................................................... 73
12.2. DATA CLEANING ........................................................................................................... 73
12.3. DATA CODING .................................................................................................................. 73
12.4. DATA STORAGE ............................................................................................................... 74
12.5. DATABASE LOCK ............................................................................................................. 74
13. STATISTICAL ANALYSIS .................................................................................................... 74
   13.1. GENERAL CONSIDERATIONS ......................................................................................... 74
   13.2. SAMPLE SIZE ..................................................................................................................... 75
   13.3. PROTOCOL DEVIATIONS ............................................................................................... 75
   13.4. DATA SETS ANALYSED ................................................................................................. 75
   13.5. HANDLING OF DROPOUTS AND MISSING DATA ..................................................... 76
     13.5.1. Dropouts ............................................................................................................................ 76
     13.5.2. Repositioning of Visits ...................................................................................................... 76
     13.5.3. Missing Data ...................................................................................................................... 76
   13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS ............................... 76
   13.7. EFFICACY ANALYSIS ...................................................................................................... 77
     13.7.1. Primary Criterion ............................................................................................................. 77
     13.7.1.1. Primary Analysis ............................................................................................................ 77
     13.7.1.2. Supportive Analysis .................................................................................................... 77
     13.7.2. Secondary Criteria ............................................................................................................. 77
       13.7.2.1. Numbers of Atrial Fibrillation Episodes ................................................................. 77
       13.7.2.2. Duration of Atrial Fibrillation Episodes ............................................................... 78
       13.7.2.3. Time to first AF recurrence less than 10 minutes or symptomatic .................... 78
       13.7.2.4. Clinical parameters evaluation ................................................................................. 78
       13.7.2.5. Biomarker analysis: red blood cell concentrations of DHA .............................. 78
   13.8. SAFETY ANALYSIS .......................................................................................................... 79
     13.8.1. Adverse Events .................................................................................................................. 79
     13.8.2. Clinical Laboratory Evaluation ..................................................................................... 80
     13.8.3. Global Physical Examination ....................................................................................... 82
     13.8.4. Vital Signs, Physical Findings and Other Observations Related to Safety ............... 82
       13.8.4.1. Vital Sign Measurements Over Time ........................................................................ 82
       13.8.4.2. Body weight ................................................................................................................ 82
       13.8.4.3. Individual Patient Changes ....................................................................................... 82
       13.8.5. ECG ................................................................................................................................. 83
       13.8.6. Coagulation parameters ................................................................................................. 83
     13.9. CONCOMITANT TREATMENTS ..................................................................................... 83
     13.10. COMPLIANCE .................................................................................................................. 83
     13.11. INTERIM ANALYSIS AND DATA MONITORING ......................................................... 84
14. GENERAL ETHICAL CONSIDERATIONS ........................................................................... 84
   14.1. ETHICAL CONDITIONS .................................................................................................... 84
   14.2. ETHICS COMMITTEE AND LEGAL REQUIREMENTS .................................................... 84
   14.3. PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM .................... 85
   14.4. PERSONAL DATA PROTECTION ................................................................................... 85
14.5. INSURANCE POLICY .................................................................................................................86

15. ADMINISTRATIVE PROCEDURES .................................................................................................86

15.1. PROTOCOL AMENDMENT ........................................................................................................86

15.2. SOURCE DOCUMENTS, INVESTIGATOR’S FILE STORAGE .................................................86

15.3. END OF THE STUDY ..................................................................................................................87

15.3.1. Definition of the End of Study .............................................................................................87

15.3.2. Early Study Termination .......................................................................................................87

15.3.2.1. Early Study Termination Decided by the Sponsor ..........................................................87

15.3.2.2. Early Study Termination Decided by the Competent Authorities ....................................88

15.4. AUDIT .......................................................................................................................................88

15.5. INSPECTION ...............................................................................................................................88

15.6. CONFIDENTIALITY ...................................................................................................................88

15.7. CLINICAL STUDY REPORT .....................................................................................................89

15.8. STUDY RESULTS COMMUNICATION .....................................................................................89

15.9. STUDY RESULTS PUBLICATION ............................................................................................89

16. REFERENCES ..................................................................................................................................91

17. APPENDICES ..................................................................................................................................94

17.1. DECLARATION OF HELSINKI ...............................................................................................95

17.2. SAE REPORT FORM ...............................................................................................................99

17.3. PREDEFINED LIMITS OF LABORATORY AND VITAL SIGN POTENTIALLY CLINICALLY SIGNIFICANT CHANGES AND VALUES .........................................................103
**SYNOPSIS**

<table>
<thead>
<tr>
<th>Name of Sponsor:</th>
<th>Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Finished Product:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Name of Active Substance:</td>
<td>F373280 (Panthenyl-Ester of DHA)</td>
</tr>
<tr>
<td>Title of the Study:</td>
<td>Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.</td>
</tr>
<tr>
<td>Abbreviated Title:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Study Coordinating Investigator:</td>
<td>Pr Savina NODARI</td>
</tr>
<tr>
<td>Study Centres:</td>
<td>International, multicentric</td>
</tr>
</tbody>
</table>
| Publication / Rationale: | F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation (AF) patients with chronic heart failure. The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of AF induced by burst pacing.[1] Moreover, the effectiveness of PolyUnsaturated Fatty Acid (PUFA) has been proven in the following conditions:  
  – prevention of AF recurrence in patients with persistent AF, in co-administration with amiodarone (add on therapy) [2]  
  – Improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]  
Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent atrial fibrillation and chronic heart failure. This phase IIa study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after electrical cardioversion (ECV) in patients with persistent atrial fibrillation and chronic heart failure. |
| Planned Study Period: | January 2013 – January 2015 |
| Objectives: | **Primary:**  
  - Efficacy of F373280 on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure  
**Secondary:**  
  - Efficacy of F373280 on the efficiency of direct electrical cardioversion  
  - Effect of F373280 on echocardiographic parameters  
  - Safety and tolerability of F373280 |
| Methodology: | - International, multicentre, randomised, double-blind, placebo-controlled  
  - Selection period  
  - Start of treatment 4 weeks before ECV  
    - Condition to ECV:  
      - INR 2-3 anti-vitamin K should be given at least 3 weeks before ECV)  
      - No spontaneous cardioversion before ECV  
  - Follow-up 20 weeks after visit 3 (ECV visit)  
    - Condition: successful ECV or spontaneous CV  
  - Cardiac monitoring:  
    - 7-days continuous ECG ambulatory recording (Holter ECG) between visit 3 (ECV visit) and visit 4 (week 5) in patients with sinusal rhythm  
    - TTEM: daily transmission from week 6 to week 8; then every two days from week 9 to week 24, and in case of AF symptoms  
  - Treatment duration: 24 weeks |
| Study Schedule: | 9 visits will be scheduled:  
  - V1/W-4 to W-1: selection visit (7 to 28 days before the inclusion visit)  
  - V2/D1: Inclusion visit (start of treatment)  
  - V3/W4 (D28 -2/7 days): cardioversion visit (outpatient or hospitalization according to
clinical practice of the centre) (installation of the Holter device)
- V4/ W5 (D35 ± 7 days): follow-up visit (removing of the Holter device and installation of the TTEM)
- V5/ W8 (D56 ± 7 days): follow-up visit
- V6/ W12 (D84 ± 7 days): follow-up visit
- V7/ W16 (D112 ± 7 days): follow-up visit
- V8/ W20 (D140 ± 7 days): follow-up visit
- V9/ W24 (D168 ± 7 days): final study visit

<table>
<thead>
<tr>
<th>Number of Patients:</th>
<th>76 x 2 patients</th>
</tr>
</thead>
</table>

**Diagnosis and Criteria for Inclusion:**

**Inclusion Criteria:**

**Demographic Characteristics and Other Baseline Characteristics:**

1. Men or women aged more than 18 years (inclusive)
2. Patients with current episode of persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted
3. History of first documented persistent AF less than 3 years.
4. History of ischemic or non ischemic heart failure
5. NYHA class I or II chronic heart failure at selection and at inclusion
6. Reduced left ventricular ejection fraction between 30% and 45% inclusive (using the two-dimensional echocardiography biplane Simpson’s rule) at selection and at inclusion
7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers
8. Left atrial area ≤ 40 cm² at selection and at inclusion
9. Patients treated or having to be treated by anti-vitamin K
10. For female patient of child-bearing potential:
    - **in all the countries except Italy:**
      - use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator, for at least 2 months before the selection in the study, and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment
      - documented as surgically sterilized
    - **in Italy only:**
      - absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
      - use of double barrier contraception method (use of effective medical contraception method) from at least 2 months before the start of the study to the entire duration of the study and for a month after the end of the study or
      - documented as surgically sterilized
11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion
12. For male with a child-bearing potential partner *(in Italy only)*:
    - Absolute abstention from sexual intercourse during the whole duration of the study and for 3 months after the end of the study or
    - use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to 3 months after the end of the study.

**Ethical/legal considerations:**

13. Having signed his/her written informed consent,
14. Affiliated to a social security system, or is beneficiary (if applicable in the national regulation)

**Non-Inclusion Criteria:**

**Criteria related to pathologies:**

1. History of first documented episode of persistent AF more than 3 years
2. More than two successful cardioversions (electrical or pharmacological) in the last 6
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV)
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be checked in case of treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic coronaryopathy assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
7. Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration rate < 30 mL/min) at selection
8. Bradycardia (HR ≤ 50 bpm)
9. Hyperkalemia or hypokalemia (according to the standards of local laboratories) at selection
10. Cardiac surgery within 3 months before selection or planned during the study duration

**Criteria related to treatments:**
11. Previously ineffective pharmacological or electrical cardioversion
12. Concomitant treatment with ranolazine or any antiarrhythmic drug (within 7 days prior to selection), except stable dose of digoxin, betablockers, calcium-blockers
13. Oral amiodarone:
   13a Previous treatment with oral amiodarone within 4 months prior to inclusion
   13b Intake of oral amiodarone for more than 1 month within 4 to 12 months before inclusion
14. Previous treatment with intravenous amiodarone within 4 weeks prior to inclusion
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT implantation within the last 6 months
16. Treatment with any Polyunsaturated Fatty Acid (PUFA) within the last 3 months
17. Dietary supplement with ω 3 or ω 6 according to investigator’s judgement
18. Having undergone any form of ablation therapy for AF
19. Patient treated with other anticoagulant treatment than antivitamin K: thrombin inhibitor such as Dabigatran or treated with antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel

**Other criteria:**
20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection
22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself/herself to its constraints
23. Patient family member or work associate (secretary, nurse, technician,..) of the Investigator
24. Patient having forfeited his / her freedom by administrative or legal award or being under guardianship
25. Breastfeeding female patient

**Exclusion criteria before V3:**
Patients not stabilized for INR (i.e. values not between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed in the same day (before ECV)
ECV will be performed in patients without dyskalemia
If necessary for obtaining stabilized INR between 2 and 3, the ECV (and following visits) could be postponed by 7 days.

**Test Product:**
F373280
Soft Capsules

**Dose:**
Arm with 1g of F373280

**Mode of Administration:**
Oral, one capsule each evening with dinner.
**Duration of Treatment:** 24 weeks of treatment exposure with F373280 (25 weeks if ECV postponed by 1 week)

**Reference Therapy**
Placebo soft capsules
Placebo will be administered in the same conditions as the tested product.

**Mode of Administration:** Oral, one capsule each evening with dinner

**Evaluation Criteria:**

**Efficacy evaluation variables:**

**Primary evaluation variable:**
- Time to first Atrial Fibrillation recurrence defined by the first episode of AF lasting for at least 10 minutes (Follow up of 20 weeks after visit 3 (ECV visit)).

Handling of AF recurrences: 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) between visit 3 (ECV visit) and visit 4 (week 5). Then, the follow up will be documented using the TTEM: daily transmission from week 6 to week 8. Then, every two days from week 9 to week 24.

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF will be assessed after visit 3 (week 5).

Moreover, during this TTEM period, if patient experiences any AF symptoms, it should be recorded and documented using the TTEM.

All ECG traces will be evaluated by a Central Reading Laboratory.

**Secondary evaluation variables:**
During the 7-day continuous ECG monitoring,
- Numbers of AF episodes
- Duration of AF episodes

**Clinical parameters:**
During the whole study:
- Number of recurrence of symptomatic AF episodes
- EHRA score
- Hospitalization for cardiovascular events
- Hospitalization for thromboembolic stroke
- All causes of hospitalization

**Cardioversion:**
- Assessment of spontaneous cardioversion
- Assessment of successful cardioversion
- Number of patients needing an other cardioversion after the initial ECV

**Other:**
- Evolution of echocardiographic parameters (from V4 to V6 and V9) (Left atrial diameter (mm), Left atrial area (cm²), Left atrial volume (mL), Left atrial volume/BSA (mL/m²), Left ventricular ejection fraction (%), Left ventricular end diastolic volume/BSA (mL/m²), Left ventricular end systolic volume/BSA(mL/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL) Left ventricular end systolic diameter (mm), Left ventricular end systolic volume (mL))
- Evolution of omega 3 index and intra erythrocyte DHA (For this assessment samples will be centralized).

**Safety criteria:**
- **Adverse events** (observed and / or spontaneously reported)
- **Vital signs** (Blood pressure (supine and standing), heart rate
- **Physical examination** (body weight)
- **Standard 12-lead ECG:** heart rate (bpm), PR (ms), QRS (ms), QT (ms), repolarisation patterns (ECG not centralized)
- **Haematology:** haematocrit, haemoglobin, red blood cell (RBC) count, white blood cell (WBC) count, WBC differential count, reticulocytes, platelets
- **Biochemistry:** sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatin phosphokinase (CPK) fibrinogen (local laboratory)
- **Coagulation parameters:** Activated partial thromboplastin time (aPTT), thrombin clotting time (TCT), INR *(local laboratory)*, Prothrombine Time *(PT)*

| Statistical Methods: | Sample Size:  
Assuming an AF recurrence rate under placebo of 85%, a power of 80%, an alpha risk of 5% and a rate of not assessable patients of 15%, 76 randomised patients per group will be necessary, using a log-rank test of survival curves, a difference between groups of 20%.  
**Primary Efficacy Analysis**  
The primary analysis, performed on the Full Analysis Set (FAS: all randomised patients with at least one dose of treatment and with a successful cardioversion observed at visit 3), will be a survival analysis using the Kaplan Meier method and Cox regression model.  
**Secondary Analyses**  
All secondary efficacy criteria will be described and compared using appropriate tests on the FAS.  
**Safety Analyses**  
Descriptive statistics will be performed on the Safety Set (all randomised patients with at least one dose of treatment). |
### STUDY FLOW-CHART

<table>
<thead>
<tr>
<th>Weeks</th>
<th>V1</th>
<th>V2</th>
<th>V3</th>
<th>V4</th>
<th>V5</th>
<th>V6</th>
<th>V7</th>
<th>V8</th>
<th>V9</th>
</tr>
</thead>
<tbody>
<tr>
<td>Outpatient or Hospitalization (1)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Informed consent</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Demographic characteristics</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medico-surgical history</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant disease</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Concomitant treatment</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Habits</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Global physical examination (body weight)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Echocardiography</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Eligibility criteria check</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood pressure, heart rate</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>12-Lead ECG Recording</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>INR</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(2)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>aPTT, TCT</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Biochemistry</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hematology</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Urinary pregnancy test</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Red Blood Cell concentrations of DHA</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment allocation</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IVRS/IWRS</td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ECV (3)</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Drug administration</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adverse events recording</td>
<td></td>
<td>(4)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td>Holter ECG</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>TTEM (6)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Outpatient or hospitalization according to clinical practice of the centre (less or more than 24 hours)
2. In case of AVK introduction: INR 2 to 3 times a week, then weekly until the ECV, then every 4 weeks after ECV
3. In patients with AF
4. 24-hour Holter ECG
5. In case of AF recurrence for at least 10 minutes and if the patient does not stop the study treatment, then TTEM once a week

---

Final version 601/1185
LIST OF ABBREVIATIONS

aPTT : Activated partial thromboplastin time
AE : Adverse event
AF : Atrial fibrillation
ALA : Alpha-linoleic acid
ALT : Alanine aminotransferase
AST : Aspartate aminotransferase
AUC : Area under the plasma concentration versus time curve
AUC_{inf} : Total area under the curve extrapolated to infinity
AVK : Anti-vitamin K
βHCG : beta human chorionic gonadotrophin
BLQ : Below the limit of quantification
BMI : Body mass index
BP : Blood pressure
BSA : Body Surface Area
CEP : Protocol evaluation committee
CHMP : Committee for medicinal products for human use
C_{max} : Maximum concentration
C_{min} : Minimum concentration
CNALV : Clinically noteworthy abnormal laboratory value
CPK : Creatin phosphokinase
CPP : Comité de protection des personnes
CRA : Clinical research associate
CRT : Cardiac resynchronization therapy
CSC : “Clinically Significant Change”, i.e., Predefined potentially clinically significant change leading to a potentially clinically significant value (vital signs)
CV : Coefficient of variation
DBP : Diastolic blood pressure
DHA : Docosahexaenoic acid
EC : Ethics committee
ECG : Electrocardiogram
ECHO –TE : Trans-esophageal echocardiograph
ECV : Electrical cardioversion
EHRA : European heart rhythm association
EPA : Eicosapentaenoic acid
e-CRF : Electronic case report form
FAS : Full analysis set
Fe : Fraction of the administered drug excreted in urine
GCP : Good clinical practice
GFR : Glomerular Filtration Rate
HBs : Hepatitis B antigen
HCV : Hepatitis C virus
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>HDL</td>
<td>High density lipoprotein</td>
</tr>
<tr>
<td>HF</td>
<td>Heart failure</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>HR</td>
<td>Heart rate</td>
</tr>
<tr>
<td>ICH</td>
<td>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use</td>
</tr>
<tr>
<td>IDMC</td>
<td>Independent data monitoring committee</td>
</tr>
<tr>
<td>INR</td>
<td>International normalized ratio</td>
</tr>
<tr>
<td>IRPF</td>
<td>Institut de Recherche Pierre Fabre</td>
</tr>
<tr>
<td>IVRS</td>
<td>Interactive voice response system</td>
</tr>
<tr>
<td>LAA</td>
<td>Left atrial area</td>
</tr>
<tr>
<td>LC/MS-MS</td>
<td>Liquid chromatography with tandem mass spectrometry</td>
</tr>
<tr>
<td>LDL</td>
<td>Low density lipoprotein</td>
</tr>
<tr>
<td>LOQ</td>
<td>Limit of quantification</td>
</tr>
<tr>
<td>LVEF</td>
<td>Left ventricular ejection fraction</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical dictionary for regulatory activities</td>
</tr>
<tr>
<td>MR</td>
<td>Mineralocorticoid receptor</td>
</tr>
<tr>
<td>MR perfusion</td>
<td>Magnetic Resonance perfusion</td>
</tr>
<tr>
<td>MTD</td>
<td>Maximum tolerated dose</td>
</tr>
<tr>
<td>N</td>
<td>Number of determinations or replicates</td>
</tr>
<tr>
<td>NOAEL</td>
<td>No observed adverse effect level</td>
</tr>
<tr>
<td>NYHA</td>
<td>New York heart association</td>
</tr>
<tr>
<td>od</td>
<td>Once a day</td>
</tr>
<tr>
<td>PC</td>
<td>“Predefined Change”, i.e., Predefined potentially clinically significant change (lab or vital signs)</td>
</tr>
<tr>
<td>PCA</td>
<td>PC leading to an out-of-range value (lab values)</td>
</tr>
<tr>
<td>PFB</td>
<td><em>Pierre Fabre Biométrie</em></td>
</tr>
<tr>
<td>PSC</td>
<td>Potentially Clinically Significant Change</td>
</tr>
<tr>
<td>PSCV</td>
<td>Potentially Clinically Significant Value</td>
</tr>
<tr>
<td>PUFA</td>
<td>PolyUnsaturated fatty acid</td>
</tr>
<tr>
<td>p.o.</td>
<td>Per os</td>
</tr>
<tr>
<td>PP</td>
<td>Per protocol data set</td>
</tr>
<tr>
<td>RBC</td>
<td>Red blood cells</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious adverse event</td>
</tr>
<tr>
<td>SBP</td>
<td>Systolic blood pressure</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>T1/2</td>
<td>Terminal half-life</td>
</tr>
<tr>
<td>T0</td>
<td>Time of drug administration</td>
</tr>
<tr>
<td>T_max</td>
<td>Time to reach the maximal concentration</td>
</tr>
<tr>
<td>TCT</td>
<td>Thrombin clotting time</td>
</tr>
<tr>
<td>TEAEs</td>
<td>Treatment emergent adverse events</td>
</tr>
<tr>
<td>TTEM</td>
<td>TransTelephonic ECG monitoring</td>
</tr>
<tr>
<td>WBC</td>
<td>White blood cells</td>
</tr>
<tr>
<td>WHO-DRUG</td>
<td>World health organization drug reference list</td>
</tr>
</tbody>
</table>
1. INTRODUCTION AND STUDY RATIONALE

1.1. TARGET PATHOLOGY AND THERAPY

Atrial Fibrillation (AF) is a supraventricular arrhythmia characterized by uncoordinated atrial electric activity with consequent deterioration of atrial mechanical function. It is the most common sustained cardiac rhythm disorder, increasing in prevalence with age. Haemodynamic impairment and thromboembolic events related to AF result in significant morbidity and mortality [7].

In 2009, Decision Resources estimated that there were 7.8 million diagnosed prevalent cases of AF in US, Europe and Japan. This age-related pathology should increase to 9.4 million cases in 2019.

Except for the conventional class I and class III anti-arrhythmic agents, the Polyunsaturated Fatty Acids (PUFAs) constitute one emerging antiarrhythmic therapy. These compounds potently address the AF substrate by directly targeting both the electrical and the structural remodelling of the deficient atria. The n-3 PUFAs, essential for human, are alpha-linoleic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). First, PUFAs specifically modulate ionic channels by fastening their inactivating mode which renders these compounds selective for pathological situations (such as AF) without any major effect in normal conditions. PUFAs are “open $K_{v1.5}$ channel blockers” leading to a lengthening of atrial action potential duration and are “persistent $Na_{v1.5}$ channel blockers” leading to hyperpolarization of diastolic resting potential. Second, PUFAs influence structural remodelling through their anti-inflammatory effects as they directly compete with arachidonic acid in the production of inflammatory eicosanoids. In summary, PUFAs share unique, well-tolerated antiarrhythmic potential by interacting with the electrical and structural remodelling during sustained AF. In animal studies, it was recently demonstrated that DHA is particularly effective in pathologic conditions such as ischemia and/or AF.
The potential anti-arrhythmic effects of a PUFA were previously developed in AF: nicotinyl ester of DHA (pro-drug based on DHA delivery) was assessed in a two-week ventricular tachypaced canine model. Dogs were subjected to 4 weeks of medication prior to undergoing an electrophysiology study, and received either placebo or nicotinyl ester of DHA. Dogs were tachypaced at 240 beats per min for the final two weeks of the treatment plan. The results showed that the tested PUFA reduced the duration of AF induced by burst pacing, and the incidence of sustained AF, compared to dogs treated with the placebo [1].

In clinical practice, Nodari and coll [2] assessed n-3 PUFAs in the prevention of AF recurrences after electrical cardioversion (ECV). All included patients were treated with amiodarone and a renin-angiotensin-aldosterone system inhibitor. The 199 patients were assigned either to placebo or n-3 PUFAs 2 g/d and then underwent direct ECV 4 weeks later. The primary end point was the maintenance of sinus rhythm at 1 year after cardioversion. At the 1-year follow up, the maintenance of sinus rhythm was significantly higher in the n-3 PUFAs treated patients compared with the placebo group (hazard ratio, 0.62 [95% confidence interval, 0.52 to 0.72] and 0.36 [95% confidence interval, 0.26 to 0.46], respectively; \( p = 0.0001 \)). The study concludes that in patients with persistent AF on amiodarone and a renin-angiotensin-aldosterone system inhibitor, the addition of n-3 PUFAs 2 g/d improves the probability of the maintenance of sinus rhythm after direct current cardioversion. Previously, during the World Congress of Cardiology in 2006, an abstract reported the effectiveness of PUFAs on top of traditional treatment (amiodarone, beta blockers, renin-angiotensin-aldosterone system inhibitor) in the prevention of AF relapses in patients having undergone ECV. In the PUFA group, AF relapses were significantly lower than in the placebo group at 1 month (3.3% vs 10%; \( p = 0.043 \)), at 3 months (10% vs 25%; \( p = 0.004 \)) and at 6 months (13.3% vs 40%; \( p < 0.0001 \)) [19].

In contrast, in the general AF population (paroxystic atrial fibrillation and persistent atrial fibrillation), PUFAs failed to prove their efficacy [7] because of the absence of cardiac remodelling or because of a short pre-treatment duration before ECV (1 week) [8]. The effects of PUFAs were only observed in patients with persistent AF on add on therapy and after a sufficient pre-treatment before ECV. Persistent AF is commonly associated to heart failure. Previous studies performed in heart failure population demonstrated the benefit of PUFAs on the improvement of
functional ventricular parameters and morbi-mortality, and on the reduction of hospitalisation [3, 4, 5].

Nodari and coll [3] performed a trial in patients with chronic heart failure (NYHA I to III and LVEF< 45%). After a treatment of 133 patients with PUFAs (n=67) or placebo (n=66) at a dosage of 5 g/day for 1 month, then 2 g/day for 11 months, the n-3 PUFAs group and the placebo group differed significantly (p <0.001) in regard to:

- LVEF (increased by 10.4% and decreased by 5.0%, respectively)
- peak VO2 (increased by 6.2% and decreased by 4.5%, respectively)
- exercise duration (increased by 7.5% and decreased by 4.8%, respectively)
- mean New York Heart Association functional class (decreased from 1.88 +/- 0.33 to 1.61 +/- 0.49 and increased from 1.83 +/- 0.38 to 2.14 +/- 0.65, respectively).

The hospitalization rates for patients with HF were 6% in the n-3 PUFAs and 30% in the placebo group (p <0.0002).

Moertl and coll [4] performed a dose-ranging study in patients with a more severe chronic heart failure (NYHA III and IV and LVEF < 35%). It was a double-blind, randomised, controlled pilot trial in 43 patients treated with PUFAs or placebo for 3 months (1 g/d n3-PUFA (n = 14), 4 g/d n3-PUFA (n = 13), or placebo (n = 16)). After treatment, left ventricular ejection fraction increased in a dose-dependent manner (p = 0.01 for linear trend) in the 4 g/d (baseline vs 3 months [mean ± SD]: 24% ± 7% vs 29% ± 8%, p = 0.005) and 1 g/d treatment groups (24% ± 8% vs 27% ± 8%, p = 0.02).

No changes in any investigated parameters were noted with placebo.

Taking into account these studies performed with PUFAs, it seems that the best target for DHA is persistent AF in patients with heart failure. The aim of this proof of concept study is to assess in stand alone therapy (without association of other anti-arrhythmic treatments), the effect of F373280 in patients with persistent AF and heart failure in the maintenance of sinus rhythm after ECV.

1.2. INFORMATION ON THE TEST PRODUCT

F373280 or panthenyl ester of DHA is the mono-ester of panthotenic alcohol and DHA, selected to be developed for the management of AF.

F373280 is a prodrug of DHA.
A brief summary of F373280 known characteristics is presented in this section. For further details, please refer to the F373280 Investigator’s Brochure. [1]

1.2.1. Chemical and pharmaceutical characteristics

1.2.1.1. Nomenclature and structure

Chemical name (IUPAC):

(4Z,7Z,10Z,13Z,16Z,19Z)-3-((R)-2,4-dihydroxy-3,3-diméthylbutanamido) propyl docos-4,7,10,13,16,19-hexaenoate

Structural formula:

![Structural formula]

Laboratory code: F373280

Molecular formula: C_{31}H_{49}NO_{5}

Molecular mass: 515.7

1.2.1.2. Physical and chemical general properties

Appearance: Clear oily viscous liquid

Solubilities:

- Water: Practically insoluble
- Alcohol: Very soluble
- Trimethylpentane: Slightly soluble
1.2.2. **Non-clinical Data**

Non-clinical data are exhaustively detailed in the Investigator’s brochure [1]. A brief summary is provided below.

1.2.2.1. **Pharmacological profile**

F373280 (mono-ester of panthotenic alcohol and DHA) is a novel pro-drug of DHA which exerts antiarrhythmic properties by interacting with the electrical and structural remodelling of the atria.

Experimental investigations were conducted in HEK293 cell line transfected with human Kv1.5 channel using the whole cell patch clamp technique to evaluate whether F373280 could block the sustained component of $I_{Kv1.5}$. F373280 concentration-dependently reduced Kv1.5 channel activity with an IC$_{50}$ value of 13.7 µM.

The effects of F373280 on atrial effective refractory period were investigated in anesthetized pig using a conventional pacing protocol through epicardial electrodes placed on the left atrium. F373280 administered as a bolus and an infusion (10 mg/kg) significantly increased atrial effective refractory period (23.8 ± 2.2 ms versus -7.3 ± 11.5 ms in the presence of vehicle, p < 0.05). In addition, F373280 was devoid of significant effect on the hemodynamic and the electrocardiogram (ECG) intervals.

Proof of the pharmacological concept was performed with a different DHA derivative named: Nicotinyl ester of DHA (pro-drug based on DHA delivery). Ventricular tachypacing-induced congestive heart failure provides a clinically-relevant animal model of AF associated with structural remodelling, as is often seen clinically. It has been shown that sustained oral PUFA administration suppresses congestive heart failure-induced AF-promotion and fibrosis in the ventricular tachypacing canine model. Nicotinyl ester of DHA was tested in this model, at 1 g/day and 5 g/day, during 4 weeks, to prevent congestive heart failure-related atrial structural remodelling and AF promotion in dogs. Nicotinyl ester of DHA dose dependently reduced heart failure-induced increases in AF duration (989 ± 111 sec, n=5 in the presence of placebo versus 637 ± 196 sec, n=5 in the presence of 1 g/kg/d Nicotinyl ester of DHA and 79 ± 51 sec, n=5, in the presence of 5 g/kg/d Nicotinyl ester of DHA). The protective effect of Nicotinyl ester of DHA was associated with a marked increase of plasma level of DHA and important incorporation of
DHA in the left atrial tissue. Because F373280 similarly to Nicotinyl ester of DHA increases plasma level of DHA, it could be estimated that the compound may exert a similar protective effect [1].

1.2.2.2. **Safety pharmacology**

A battery of safety pharmacology studies was performed to evaluate the effects of F373280 on the central nervous, cardiovascular and respiratory systems. Data of these studies are exhaustively detailed in the Investigator’s brochure [1].

No particular alerts were evidenced with F373280.

1.2.2.3. **Toxicology profile**

Concerning the toxicological data, 4-week and 26-week repeat-dose studies in rat and dog were performed. Compared to the high administered doses of F373280 (500 to 2000 mg/kg/day), low circulating concentrations of F373280 were measured.

During these toxicity studies, no toxicity was observed in rat after 4 and 26 weeks of dosing and in dog after 4 weeks of dosing. A NOAEL of 2000 mg/kg/day was established in these repeat toxicity studies.

During the 26-week toxicity study in dogs, the NOAEL was set at 1000 mg/kg/day based on changes observed on red blood cell parameters.

Based on toxicological profiles, F373280 is considered to support the proposed clinical trial.

1.2.2.4. **Pharmacokinetic data**

According to animal studies described in the Investigator’s brochure [1], the non-clinical pharmacokinetic profile of F373280 is not associated with particular alerts concerning the proposed clinical phase IIa study.

1.2.3. **Clinical data**

*Part A: single dose*
Six consecutive single ascending doses were tested (0.5 g, 1 g, 2 g, 4 g, 8 g and 16 g) on 6 independent cohorts of 8 subjects (6 verum + 2 placebo). 49 subjects were treated and 48 completed the study.

No Serious Adverse Events (SAE) occurred in the course of the study.

Regarding the reported Treatment Emergent Adverse Events (TEAEs) that were judged by the Investigator as having a causal relationship with the study drug administration in the absence of an alternative explanation, 3 TEAEs were observed in the placebo group (palpitation, dizziness in standing position, symptomatic orthostatic hypotension without loss of consciousness) and 4 in the group of F373280 at the dosage of 16 g (meteorism, liquid stool, symptomatic orthostatic hypotension and dizziness in standing position). None of these adverse events (AE) were reported in the groups of F373280 at the dosages of 0.5 g, 1 g, 2 g, 4 g and 8 g.

After a single administration of the different tested doses no difference between the tested product and placebo has been reported, regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters (related to coagulation: platelets and fibrinogen) and coagulation parameters (bleeding time, prothrombin time/INR, activated partial thromboplastin time, thrombin clotting time). Variations of these parameters were within the physiological ranges.

After single oral administration of F373280 from 0.5 g to 16 g in 36 young healthy male subjects (6 per dose level), the following was observed:

- **F373280**: Whatever the tested dose there is no circulating F373280 in plasma: only few, sparse and non consecutive samples with quantifiable level of F373280 close to LOQ were observed. This confirms that F373280 is a prodrug.

- **Panthenol**: Cmax and AUC increased with the administered dose between 0.5 and 16 g. Panthenol concentrations were rapidly cleared from plasma with a mean terminal half-life around 2 hours.

- **DHA**: after 0.5 and 1 g, low increased in DHA plasma concentrations compared to the baseline levels led to a high inter-individual variability of the corresponding Pharmacokinetics parameters. Plasma exposure in DHA increased with the administered dose between 2 and 16 g with no departure from proportionality (baseline corrected parameters).
**Part B: Multiple doses**

Three consecutive repeated ascending doses (1, 2 and 4 g) were tested on 3 independent cohorts of 12 subjects (9 verum + 3 placebo, double blind). 36 subjects completed the study. Each treatment was administered over a period of 28 days. Pharmacokinetic parameters were assessed over a period of 14 days.

Among the TEAE judged by the investigator as suspected to F373280, 5/9 TEAEs were classified according the System Organ Class in vascular system disorder with orthostatic hypotension (2 in the 1 g group, 1 in the 2 g group and 2 in the 4 g group) and 4/9 were classified in nervous system disorder with 3 dizziness (2 in the 2 g group and 1 in the 4 g group) and 1 migraine (in the 1 g group). These TEAEs have already been reported with PUFAs and are commonly observed in phase I studies.

After a repeated administration of the different tested doses, no difference between the tested products and placebo was reported regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters. The assessment of coagulation parameters and platelet function after administration of repeated dose of F373280 did not report any bleeding issue. The reported changes in coagulation parameters and platelet function were within physiological ranges.

After a 14-day repeated oral administration of F373280 from 1 g to 4 g, the following was observed:

- **Panthenol**: Cmax and AUC increased with the administered dose between 1 and 4 g. No accumulation of panthenol in plasma was observed.

- **DHA**: Plasma exposure increased with dose. A 2-fold accumulation in total plasma exposure of DHA was observed after 14 days of administration, whatever the administered dose.
1.3. STUDY RATIONALE

F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after ECV in persistent AF patients with chronic heart failure.

The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of AF induced by burst pacing [1].

Moreover, the effectiveness of PUFAs has been proven in the following conditions:

- Prevention of AF recurrence in patients with persistent AF in co-administration with amiodarone (add on therapy) [2],
- Improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5].

Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent AF and chronic heart failure.

This phase IIa study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after ECV in patients with persistent AF and chronic heart failure.

1.4. OVERALL RISK AND BENEFIT ASSESSMENT

F373280 is a new pro-drug of DHA.

DHA is a well-known long chain PUFAs with a long-term clinical experience in cardiovascular diseases. DHA is contained in several medicinal products such as Omacor®, (1 g of Omacor contains about 320 mg of DHA acid) marketed by Laboratoires Pierre Fabre for hypertriglyceridemia and as an adjuvant treatment for secondary prevention after myocardial infarction. According to the summary product characteristics of Omacor® [9]:

- The frequencies of adverse reactions are ranked according to the following: common (>1/100, <1/10); uncommon (>1/1000, <1/100); rare (>1/10000, <1/1000); very rare (<1/10000), not known (cannot be estimated from the available data).
- The reported adverse events are:

- Infection and infestations:
  Uncommon: gastroenteritis

- Immune system disorders:
  Uncommon: hypersensitivity

- Metabolism and nutrition disorders:
  Rare: hyperglycaemia

- Nervous system disorders:
  Uncommon: dizziness, dysgeusia
  Rare: headache

- Vascular disorders:
  Very rare: hypotension

- Respiratory thoracic and mediastinal disorders:
  Very rare: nasal dryness

- Gastrointestinal disorders:
  Common: dyspepsia, nausea
  Uncommon: abdominal pain, gastrointestinal disorders, gastritis, abdominal pain upper
  Rare: gastrointestinal pain
  Very rare: lower gastrointestinal haemorrhage

- Hepatobiliary disorders:
  Rare: hepatic disorders

- Skin and subcutaneous tissue disorders:
  Rare: acne, rash pruritic
  Very rare: urticaria

- General disorders and administration site conditions:
  Rare: malaise sensation

- Investigations:
  Very rare: white blood count increased, blood lactate dehydrogenase increased

Moderate elevation of transaminases has been reported in patients with hypertriglyceridaemia.
Panthenol is a well-known substance with a long-term experience in medical, nutraceutic and cosmetic uses. According to the summary product characteristics of a product such as Bépanthene® (tablet indicated in alopecia) which contains panthenol (100 mg), adverse event observed are rare cases of urticaria and erythema [10]. Panthenol is metabolised in panthotenic acid, i.e. B5 vitamin.

Concerning toxicological studies performed results can support the administration of F373280 in the proposed clinical phase II study without particular alert [1].

Any safety warning was reported during a phase I study performed with F373280 administered to 84 healthy volunteers in single dose in a range between 500 mg and 16 g or in repeated dose during 28 days in a range between 1 g and 4 g. Adverse events reported and related to study treatment were minor to moderate. The adverse events were palpitations, orthostatic hypotension, dizziness, meteorism and liquid stool. Most were reported in both groups (placebo and F373280) without a dose relationship. The assessment of coagulation parameters and platelet function after administration of repeated dose of F373280 did not report any bleeding concern: the reported changes in coagulation parameters and platelet function were within physiological ranges.

Moreover, DHA has been associated with anticoagulant products in AF studies [2, 8]. The range of PUFAs doses tested was between 2 g to 3 g (640 mg to 960 mg of DHA) and the range of study durations between 6 to 12 months. This association did not report a significant side effect of bleeding.

DHA has already been used in HF patients in several studies without safety concern [3, 4, 5]. The range of PUFAs doses tested was between 1 g to 5 g (1 g of the tested PUFAs contains about 320 mg of DHA acid) and the range of study durations was between 3 months to 3.9 years.

Thus, inclusion of patients with no specific antiarrhythmic treatment is acceptable. They will receive an anticoagulant treatment to prevent the thrombo-embolic complications of AF (particularly stroke) and the adequate treatments to control the heart rate and heart failure.

In conclusion, the overall available data allow in safe conditions the treatment of patients with persistent AF and chronic heart failure with F373280 in safe conditions.
2. STUDY OBJECTIVES

2.1. PRIMARY OBJECTIVE

The primary objective of the study is to assess the efficacy of F373280 on the maintenance of sinus rhythm after direct ECV in patients with persistent AF and chronic heart failure.

2.2. SECONDARY OBJECTIVES

The secondary objectives of the study are to assess:

- the efficacy of F373280 on the efficiency of direct ECV
- the effect of F373280 on echocardiographic parameters
- the safety and tolerability of F373280

3. ETHICAL CONSIDERATIONS RELATING TO THE STUDY

The trial is conducted according to Good Clinical Practices (CPMP/ICH/135/95), the National regulations and the Declaration of Helsinki and its subsequent amendments (see Appendix 17.1). This protocol and the informed consent form will be submitted for approval to independent local or national Institutional Review Boards/Ethics Committees before the study set up, according to national regulation.

All the protocol amendments or critical events liable to increase the risks incurred by the patients or to compromise the validity of the study or patients' rights will be submitted to the coordinator and to the Ethics Committees.

After being informed orally and in writing of all potential risks and constraints of the trial, as well as their freedom to withdraw their participation at any time, patients will then sign a consent form.

A time of reflection will be given to the patients, before giving a written consent and starting the study procedures.

The use of a placebo is in accordance with EMA Addendum to the guideline on antiarrhythmics on AF and atrial flutter (EMA/CHMP/EWP/213056/2010) [21] and is acceptable because the
included patients will remain under the standard treatment of AF and chronic heart failure. Except antiarrythmics, they will receive anticoagulant (anti-vitamin K), rate control treatment, chronic heart failure treatment. During the study, in case of AF recurrence that would require cardioversion or the introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms for instance, patients will be withdrawn and the tested product stopped. These patients will be considered as treatment failure.

In this study, patients will be carefully screened, particularly for their cardiac condition, with ECG, 24-hour holter monitor and echocardiographic data, and their biologic and coagulation condition.

The study will be addressed only to patients requiring an ECV due to their persistent AF, in the following conditions:

- ECV in patients not presenting a contra-indication

- Anticoagulation with anti-vitamin K (AVK) for at least 3 weeks before ECV

- ECV in patients with stabilized INR (i.e. values between 2 and 3;sp to ) on at least 3 consecutive weekly tests performed. Patients not stabilized for INR (i.e. values not between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed in the same day (before ECV). Patients who do not revert to sinus rhythm or present an early relapse within the observation period after ECV will be withdrawn and the tested product stopped.

During the whole study, patients will remain under medical control: visits in cardiology units will be scheduled at least every month. This follow up will include clinical signs, ECG, biological and coagulation parameters. Moreover, patient’s cardiac rhythm will be monitored between visits using daily, then every 2 days Trans Telephonic ECG Monitoring (TTEM) reviewed by a Central Reading Laboratory.
Patients may withdraw from the study at any time without having to give a reason and can expect to receive regular conventional therapy.

4. STUDY DESIGN

4.1. OVERALL DESCRIPTION

This phase IIa trial will be conducted as an international, multicentric, 24 weeks, double-blind, placebo-controlled, randomised, parallel group design, trial in 152 patients suffering from persistent AF and chronic heart failure.

After a 1 to 4-week of run-in period without treatment, patients will be randomised into one of the following treatment groups: F373280 1 g or placebo for 24 weeks.

Nine visits are planned for the study:

- Visit 1 (V1): W-4 to W-1: Selection visit (7 to 28 days before the Inclusion Visit)
- Visit 2 (V2): D1: Inclusion visit (start of treatment)
- Visit 3 (V3): W4 (D28 -2/+7D): cardioversion visit (outpatient or hospitalization according to clinical practice of the centre) (installation of the Holter ECG device)
- Visit 4 (V4): W5 (D35 -2/+7D): follow-up visit (removing of Holter ECG device and installation of the TTEM)
- Visit 5 (V5): W8 (D56 ± 7D): follow-up visit
- Visit 6 (V6): W12 (D84 ± 7D): follow-up visit
- Visit 7 (V7): W16 (D112 ± 7D): follow-up visit
- Visit 8 (V8): W20 (D140 ± 7D): follow-up visit
- Visit 9 (V9): W24 (D168 ± 7D): final study visit

4.2. DISCUSSION OF THE STUDY DESIGN

4.2.1. Choice of the Study Population

The target indication of F373280 will be the maintenance of sinus rhythm after cardioversion of patients with persistent AF and chronic heart failure. In the present proof of concept study, the evaluation will focus on patients within this indication. This target population is justified by:
− The proved efficacy of PUFAs in patients with persistent AF with or without heart failure in co-administration with amiodarone (add on therapy) [2]
− The proved efficacy of PUFAs on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]

The study aim is to investigate the product effect in patients with:
− Persistent AF history (less than three years) with a duration of the current episode from 7 days to 6 months.
− a moderately abnormal systolic heart failure (Left Ventricular Ejection Fraction (LVEF) between 30 to 45% as defined in the report from the American Society of Echocardiography’s Guideline). According to a sub-group analysis performed in patients with persistent AF associated to heart failure (Nodari S. personal data), PUFAs would be effective to prevent recurrence of AF after cardioversion in patients with moderately abnormal LVEF.

− a Left Atrial Area (LAA) not severely abnormal (less than 40 cm$^2$ as defined in the report from the American Society of Echocardiography’s Guideline). According to a sub-group analysis performed in patients with persistent AF associated to heart failure (Nodari S. personal data), PUFAs would not be effective to prevent recurrence of AF after cardioversion of patients with severely abnormal LAA.

For the successful rate of ECV, patients should have a stable medical treatment of heart failure and should not have any myocardial infarction or unstable angina or unstable ischemic coronaryopathy assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection.

4.2.2. Choice of the Study Design

As the target indication would be the prevention of AF recurrence after ECV, the study design meets the requirements of EMA guideline on antiarrhythmics in AF (EMA/CHMP/EWP/213056/2010) [21].
As F373280 aims to be a safe treatment for the prevention of AF recurrence, it will not be tested as an add-on therapy during the study. To avoid any interaction with the tested product, antiarrhythmic class I and III will be forbidden during the study.

The study design is defined in order to avoid methodological bias. A double blind study is appropriate to assess the efficacy and safety of the use of F373280 to prevent recurrence of AF episodes. Moreover, this study design is similar to the design of almost all trials that have assessed intervention for rhythm control [2, 8, 11, 12].

According to the target indication, only patients with persistent AF and requiring an ECV will be included in order to assess the time to first documented recurrence of AF since cardioversion.

To confirm the persistent nature of AF, a 24-hour holter monitoring will be performed during the selection visit.

Eligible participants will enter a selection phase in which anticoagulant treatment (AVK) will be adjusted to achieve an International Normalized Ratio (INR) of 2.0 to 3.0 before ECV. According to guidelines for the management of AF [6], AVK should be given at least 3 weeks before cardioversion because of risk of thrombo-embolism due to post-cardioversion.

Experimental data suggest that the maximal incorporation of n-3 PUFAs in the myocardial cell membrane takes up to 28 days to occur [22]. In addition, as shown in Nodari’s study [2], the duration of pre-treatment with PUFAs before cardioversion appears to be a contributing factor in success. Therefore, before starting follow up for the assessment of AF recurrence, treatment with F373280 should be started 28 days before ECV.

Detection of AF recurrence will be performed using systematic (scheduled) ECG recording, thus allowing detection of asymptomatic (about 50% of episodes) as well as symptomatic AF episodes. According to previous studies, most of AF recurrences occurred during the first days after cardioversion [11, 15]. So that, the heart rhythm will be closely monitored during the first week after successful cardioversion using an ambulatory continuous 7-day holter ECG recording in order to increase sensibility to detect asymptomatic AF episodes. Thereafter, to improve patient compliance, this follow up will be continued using an easier device to carry and to use, i.e. a TTEM.
Finally, during the study, patients will be scheduled for a clinical visit every month (with an additional visit 7 days after visit 3 (ECV visit)) in order to ensure a close medical monitoring and to assess efficacy and safety parameters.

4.2.3. Choice of the Dose

According to a previous study in patients with AF [2], the tested PUFA product (Omacor®) at the dose of 2 g (i.e. 640 mg of DHA acid) was effective in the prevention of AF after cardioversion. Moreover, PUFAs at dosage of 1 g and 2 g were also effective on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5].

From the F373280 phase I study, after a 14-day repeated administration of F373280 (1 g/day), observed plasma concentrations of DHA measured before treatment (Cmin) were similar to that of an effective dose of Omacor® at 2 g/day (60 to 95 mg/mL and 60 to 90 mg/mL, respectively) (phase I study of F373280 and [16]). With regard to the rhythm of administration, mean peak/trough fluctuation (baseline corrected) was around 0.3. This value supports an once-daily administration allowing a 24-hour plasma exposure in DHA. Therefore, a 1 g daily dose of F373280 is considered to be appropriate for this proof of concept study.

4.2.4. Choice of the Sample Size

See chapter 13.

5. STUDY POPULATION

Each patient fulfilling all the inclusion criteria and none of the non inclusion criteria will be eligible.

5.1. INCLUSION CRITERIA

Demographic Characteristics and Other Baseline Characteristics:

1. Men or women aged more than 18 years (inclusive)
2. Patient with current episode of persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted
3. History of first documented persistent AF less than 3 years
4. History of ischemic or non ischemic heart failure
5. NYHA class I or II chronic heart failure at selection and at inclusion
6. Reduced left ventricular ejection fraction between 30% and 45% inclusive (using the two-dimensional echocardiography biplane Simpson’s rule) at selection and at inclusion
7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers
8. Left atrial area \( \leq 40 \text{ cm}^2 \) at selection and at inclusion
9. Patient treated or having to be treated by anti-vitamin K
10. For female patient of child-bearing potential:
   - **in all the countries except Italy:**
     - use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator for at least 2 months before the selection in the study and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment or
     - documented as surgically sterilized
   - **in Italy only:**
     - absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
     - use of double barrier contraception method (use of effective medical contraception method) from at least 2 months before the start of the study to the entire duration of the study and for a month after the end of the study or
     - documented as surgically sterilized
11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion
12. For male with a child-bearing potential partner (in Italy only):
   - absolute abstention from sexual intercourse during the whole duration of the study and for 3 months after the end of the study or
   - use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to 3 months after the end of the study.

**Ethical/legal considerations:**
13. Having signed his/her written informed consent,
14. Affiliated to a social security system, or is a beneficiary (if applicable in the national regulation)

**5.2. NON INCLUSION CRITERIA**

**Criteria related to pathologies:**
1. History of first documented episode of persistent AF more than 3 years,
2. More than two successful cardioversions (electrical or pharmacological) in the last 6 months,
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV),
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be checked in case of treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic coronaropathy assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
7. Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration rate < 30 mL/min) at selection
8. Bradycardia (HR ≤ 50 bpm)
9. Hyperkalemia or hypokalemia (according to the standards of local laboratories) at selection
10. Cardiac surgery within 3 months before selection or planned during the study duration

Criteria related to treatments:
11. Previously ineffective pharmacological or electrical cardioversion
12. Concomitant treatment with ranolazine or any anti-arrhythmic drug (within 7 days prior to selection), except stable dose of digoxin, beta-blockers, calcium-blockers.
13. Oral amiodarone:
   13a Previous treatment with oral amiodarone within 4 months prior to inclusion
   13b Intake of oral amiodarone for more than 1 month within 4 to 12 months before inclusion
14. Previous treatment with intravenous amiodarone within 4 weeks prior to inclusion
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT implantation within the last 6 months
16. Treatment with any Polyunsaturated Fatted Acid within the last 3 months
   Dietary supplement with ω3 or ω6 according to investigator’s judgment
18. Having undergone any form of ablation therapy for AF
19. Patient treated with other anticoagulant treatment than antivitamin K: thrombin inhibitor such as Dabigatran or treated with antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel

Others criteria:
20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion,
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection,
22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself / herself to its constraints,
23. Patient family member or work associate (secretary, nurse, technician…) of the Investigator,
24. Patient having forfeited his / her freedom by administrative or legal award or being under guardianship,

5.3. NUMBER OF PATIENTS
76 x 2 patients (taking into account 15 % of non evaluable patients).
5.4. RECRUITMENT MODALITIES

Patients will be recruited within the medical consultation of each centre involved in the study. If necessary and when authorized by local and national regulation, some specific supports or tools will be used to improve the recruitment (announcement, mailing to general practitioners, leaflet, website including ClinicalTrials.gov, CRO…).

Before implementation, the documents will be submitted to and approved by the Ethics Committee.

5.5. PATIENT IDENTIFICATION

Patient's code will contain 7 digits: the 2 first digits corresponding to the country number, the following 2 digits corresponding to the centre number and the last 3 digits corresponding to the patient's chronological order once having signed the written informed consent.

5.6. WITHDRAWAL CRITERIA

Reasons for a patient's premature withdrawal from the study may be the following:

- Patient's decision. A patient who wishes to withdraw from the study for any reason may do so at any time but must inform the investigator. In all cases, the Investigator should attempt to contact the patient as soon as possible for a final assessment in order to:
  - have the patient's decision written on the consent form
  - obtain the reason(s) for withdrawal and report it/them in the case report form
  - evaluate the patient's clinical condition
  - if necessary, take appropriate therapeutic measures: management of an adverse effect or concomitant disease, prescription of another treatment.

- Investigator's decision in the patient's interest, particularly if a serious adverse event occurs and is considered by the Investigator liable to threaten the health of the patient. The monitor will be informed by phone or fax and a letter or report explaining the withdrawal will be forwarded to the monitor as soon as possible.
• Erroneous inclusion according to the study protocol. Any inclusion not respecting inclusion/non inclusion criteria will immediately be withdrawn and an appropriate treatment will be given by the investigator under his/her responsibility. Erroneous inclusions will not be paid to the investigator.

• Patients who could not be treated with AVK for at least 3 weeks before ECV.

• Patients who will not have a stabilized INR between 2 and 3 on at least 3 consecutive weekly tests.

• Patients with only 2 consecutives INR tests between 2 and 3 in the last 3 weeks for whom a trans-oesophageal echocardiography can not be performed before ECV or for whom a trans-oesophageal echocardiography shows a thrombus in the atria.

• Patients who will not revert to sinus rhythm (i.e. unsuccessful ECV) or with early relapse within the observation period after ECV will be considered to have finished follow-up.

• Occurrence of AF recurrence that would require, at the investigator’s judgement, a cardioversion or an introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms for instance.

5.7. REPLACEMENT OF PATIENTS
Withdrawn patients will not be replaced.

5.8. POST-STUDY EXCLUSION PERIOD
Patients will not be allowed to participate to another clinical trial during 3 months following the study termination.

5.9. STUDY CARD AND LETTER FOR GENERAL PRACTITIONER(S)
The patient will receive from the Investigating Centre at Visit 1 - Selection Visit:

- a personal card to be kept all along the study duration and providing the following information: patient's name, sponsor's name, study code, EUDRACT number, start date and expected end date of the study, complete address of the Investigating Centre with the name and phone number of the
Investigator and a sponsor 24H/24 phone contact number in case of emergency (French and English languages): 33 (0)5 63 35 25 83. For Italy, this card will be in Italian only, without any English mention.

- in Italy, a letter to be given to his/her general practitioner. This letter intends to inform the general practitioner(s) (and any other doctors who take care of the patient) that the patient participates to the clinical study. It describes the study treatment and includes some information on the forbidden treatment during the study.

6. **STUDY TREATMENT**

The Clinical Pharmacy Department of the *Institut de Recherche Pierre Fabre (IRPF)* will supply the investigational centres with the treatment necessary for the conduct of the trial.

6.1. **SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT**

F373280 and placebo will be prepared in Soft Capsules similar presentation.

- **F373280**

  Formulation of F373280, 1 g, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: Panthenyl ester of DHA, gelatine, glycerol, titanium, dioxide, purified water.

- **Placebo**

  Formulation of placebo matching tested product, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: paraffin liquid, fish flavour, gelatine, glycerol, titanium, dioxide, purified water.

Placebo and F373280 capsules will be packaged in opaque blisters.

6.2. **PACKAGING AND LABELLING**

The treatment units will be packed and labelled by the Clinical Pharmacy Department of the *IRPF* according to European Directive and local requirements.
6.2.1. Packaging

Each treatment unit will be composed of 3 cases for a 12-week treatment period.

The Investigator will provide the patient with the treatment according to the following schedule:

At Inclusion Visit (V2): a 12-week treatment unit will contain 3 cases, each case containing:
   - 10 blister packs of four 1 g F373280 soft capsules or placebo soft capsules each.

At Visit 6 (V6): a 12-week treatment unit will contain 3 cases, each case containing:
   - 10 blister packs of four 1 g F373280 soft capsules or placebo soft capsules each.

6.2.2. Labelling

Investigational Products will be labelled according to the following rules:

Labelling should comply with the local requirements for Investigational Medicinal Products.

On the treatment units and cases, the labels will bear the following indications:
   a) name and address of the sponsor
   b) protocol number
   c) packaging batch number
   d) treatment number
   e) storage conditions
   f) expiry date
   g) pharmaceutical dose form
   h) route of administration
   i) quantity of dosage units
   j) direction for use
   k) legal statements:
       - “for clinical trial only”, “keep out of the reach and the sight of children”, “please return to
         your doctor any unused product”, respect the prescribed dose”

On the treatment unit, another label will be affixed with the mention of the Investigator’s name
and patient’s code (completed by the Investigator).

In addition, on each case will be mentioned the case number, and a detachable label will bear the
following indications:
   - Protocol number
   - Packaging batch number
   - Expiry date
On the blister pack, the label will mention the protocol number, the packaging batch number, the case number and the treatment number.

6.3. DISTRIBUTION TO CENTRE AND STORAGE

The Clinical Pharmacy Department of the IRPF will supply the Investigational Centre with the treatment units along the study according to the need, upon request triggered by the patient’s selection.

As soon as the Pharmacist or the Investigator receives the trial medication, he/she will check the contents and immediately acknowledges the receipt in the IVRS/IWRS. The copy of the acknowledgement will be kept in the Investigator’s or the Pharmacist’s file. The same procedure will be applied to all further supplies during the course of the trial.

At the time of the delivery to the Centre, the following information will be provided:

- Details of storage conditions that should be respected
- And, upon request and for the 1st delivery only, a letter of release for the Investigational Medicinal Product from the Sponsor's Qualified Person

The CRA will ensure during the monitoring visits that trial medications have been received in good conditions and the acknowledgment of receipt has been performed adequately.

Treatment units should remain intact until dispensation to the patients. They should be kept at temperature below 30°C in an appropriate lockable room only accessible to the person authorised to dispense them, under the responsibility of the Pharmacist or the Investigator.

In the case of undue delay in study execution, the Pharmacist or the Investigator should ensure that the expiry date has not been exceeded.
6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT

A randomisation list will be established by the Clinical Pharmacy Department of the IRPF. This list will be computer-generated with internal software. The randomisation methodology is validated by the Biometry Department before generation.

Treatments F373280 or placebo will be balanced in a 1:1 ratio.

As the treatment units are prepared for 12-week treatment periods, the Investigator will have to allocate a treatment number at inclusion visit (V2) and another one at visit 6.

For each patient, the treatment number given at visit 6 will not be the same that the one given at inclusion visit (V2).

The treatment numbers will be given through the IVRS/IWRS.

Practically, once patient’s eligibility is confirmed at selection visit (V1):

- The Investigator:
  - Contacts the IVRS/IWRS
  - Answers the questions relating to the patient
  - In return, the treatment number to be allocated for the first 12-week period to the patient is given by the IVRS/IWRS.

- The IVRS/IWRS company:
  - Confirms this information by fax/email to the Investigator
  - Fills the “Request for Delivery of Investigational Product” form and sends it by email and/or fax to the Clinical Pharmacy Department of the IRPF.

- The Clinical Pharmacy Department of the IRPF sends the corresponding treatment unit to the Investigator within 5 days from reception of the email request form.

The Investigator will dispense to the patient the case which label indicates the treatment number and the administration period.

At visit 6, the Investigator will contact again the IVRS/IWRS to obtain the treatment number for the last 12-week period of treatment according to the same process as described above.
6.5. DRUG ADMINISTRATION

6.5.1. Duration of Treatment

For a patient completing the study, the theoretical study treatment exposure to F373280 or placebo will be 24 weeks.

If the ECV is postponed by 1 week to allow INR stabilization, the treatment duration will be 25 weeks.

6.5.2. Dose Schedule

One soft capsule of 1g of F373280 or placebo to be taken each day during 24 weeks.

6.5.3. Route and Conditions of Administration

The soft capsules are to be taken orally. One soft capsule is to be taken each evening with the dinner during 24 weeks.

6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT

The Investigator should maintain accurate written records of drug received, dispensed, returned and any remaining treatment units, on the drug accountability form. These records should be made available for Clinical Research Associate (CRA) monitoring. The packaging of the medication should remain intact until just before the dispensation.

At each visit, the Investigator will record the number of soft capsules returned by each patient using the appropriate page of the e-CRF.

At the end of the study, all used and unused treatments including packaging should be noted, and return is organised by the CRA to the Clinical Pharmacy Department of the IRPF for destruction. A copy of the drug accountability form should be provided by the Investigator to the CRA.
6.7. RECALL OF INVESTIGATIONAL PRODUCTS

In case of recall of investigational products (decided by the Competent Authorities or the Sponsor), the Investigator will immediately be informed by the Sponsor.

The Investigator in collaboration with the Sponsor’s representatives (Study Manager, CRA) must urgently:

- Stop the delivery of the concerned investigational products to the patients.
- Inform the concerned patients that they must immediately stop taking these investigational products and bring them back.

The Study Manager/CRA organises the return of the recalled products to the Clinical Pharmacy Department of the IRPF according to the Sponsor’s procedures.

7. CONCOMITANT TREATMENTS

Any existing concomitant treatment (at selection visit), any new concomitant treatment or change in the dosage of an existing concomitant treatment during the course of the study must be noted on the electronic Case Report Forms (e-CRF). All treatments should be evaluated by the Investigator at patient’s selection, and treatment prolongation or stop during the study should be considered.

For all concomitant treatments taken during the study, the following information must be noted in the relevant section(s) of the e-CRF:

- The name of the treatment and its form
- The reason for prescription
- The route of administration
- The daily dose
- The duration of treatment.
7.1. **ANTI-VITAMIN K TREATMENT**

AVK should be given for at least 3 weeks before ECV and continued for the whole study duration. The AVK used will be left to the decision of the each Investigator according to his/her local practice.

7.2. **PROHIBITED TREATMENTS**

- Class I and class III antiarrhythmic treatments:
  - Class I
    - Class IA: Disopyramide, Procainamide, Quinidine
    - Class IB: Lidocaine, Mexiletine
    - Class IC: Flecainide, Propafenone
  
  - Class III: Dofetilide, Ibutilide, Sotalol, Amiodarone, Dronedarone.

- Ranolazine
- Any PUFA
- Any anticoagulant treatment other than AVK: thrombin inhibitor such as Dabigatran or antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel
- Dietary supplement with Omega 3 or Omega 6

Prohibited treatments at selection must not be prescribed for the duration of the study except in case of occurrence of an adverse event or AF episode that requires a corrective treatment in the interest of the patient’s health.

7.3. **AUTHORISED TREATMENTS**

Other treatments will be authorised during the study duration.

However, if medication other than study drugs is administered at any time from the start of the study, details must be recorded in the e-CRF. During the study, patients must be asked whether they have been on a course of prescribed drug treatment or have taken any OTC or herbal drugs since the visit.
8. EVALUATION CRITERIA

8.1. PRIMARY EFFICACY CRITERION

8.1.1. Time to the first Atrial Fibrillation Recurrence

8.1.1.1. Definition
Time to first AF recurrence is defined by the first episode of AF (symptomatic or not) lasting for at least 10 minutes.

8.1.1.2. Schedule
The heart rhythm follow up will be performed from the end of ECV visit (visit 3) to the final study visit (visit 9).

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF will be assessed after visit 3 (week 5).

8.1.1.3. Evaluation Methods

- 7-day holter monitor:

The heart rhythm monitoring will be carried out from visit 3 to visit 4 using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) fixed after ECV visit.

Following holter monitoring, the heart rhythm will be documented using Trans Telephonic ECG Monitoring (TTEM).

- Trans Telephonic ECG Monitoring:

The ECG follow up will be documented using the TTEM: daily transmission from visit 4 (week 5) to visit 5 (week 8). Then every two days from visit 5 (week 8) to visit 9 (week 24 – End of study).

Moreover, if patient experiences AF symptoms during this TTEM period, it should be documented using the TTEM.
In case of AF recurrence and provided that the patient does not required a cardioversion or an introduction of an anti-arrhythmic at Investigator’s judgement, the patient could be maintained in the study with the treatment in order to assess a spontaneous cardioversion. For that purpose the patient will continue to transmit a TTEM once a week.

The TTEM will be centralized by the Central Reading Laboratory. The patient will be requested to contact the Central Reading Laboratory for transmission of each stored TTEM. The TTEM will be validated by a trained technician, then analysed by a cardiologist. The cardiologist interpretation will be faxed to the site. The investigator will be asked to review and sign this document.

The TTEM process will be fully described in a separate document.

8.1.2. Secondary Efficacy Criteria

8.1.2.1. Numbers of AF episodes in the first week following visit 3 (ECV visit)

8.1.2.1.1. Definition

Number of AF episodes will consist in the assessment of AF episodes with duration at least 10 minutes (N_{Sup10}) and of less than 10 minutes (N_{Inf10}), respectively.

8.1.2.1.2. Schedule

The heart rhythm follow up will be performed from the end of successful ECV visit (visit 3) to the study visit 4.

8.1.2.1.3. Evaluation Methods

- 7-day holter monitor:

The heart rhythm monitoring will start using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) after ECV visit from visit 3 to visit 4.
8.1.2.2. **Duration of AF episodes in the first week following visit 3 (ECV visit)**

8.1.2.2.1. **Definition**

Duration of AF episodes will consist in the sum of duration of each AF episode.

8.1.2.2.2. **Schedule**

The heart rhythm follow up will be performed from the end of successful ECV visit (visit 3) to the follow up study visit (visit 4).

8.1.2.2.3. **Evaluation Methods**

Duration of AF episodes will be assessed using the 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording.

8.1.2.3. **Clinical parameters evaluation**

8.1.2.3.1. **EHRA score assessment**

8.1.2.3.1.1. **Definition**

AF related symptoms will be evaluated by the EHRA (European Heart Rhythm Association) score [20]. The following items “during presumed arrhythmia episodes” are checked to determine the score: palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety.

Classification of AF-related symptoms (EHRA score) are as follows:

- EHRA I - ‘No symptoms’
- EHRA II - ‘Mild symptoms’; normal daily activity not affected
- EHRA III - ‘Severe symptoms’; normal daily activity affected
- EHRA IV - ‘Disabling symptoms’; normal daily activity discontinued

This classification relates exclusively to the patient-reported symptoms.

In addition to this score, the frequency will be classified in three groups, namely occasionally (less than once per month), intermediate (1/month to almost daily) and frequent at least daily.
8.1.2.3.1.2. Schedule

EHRA evaluation will be performed in case of evocative symptoms of arrhythmia.

8.1.2.3.1.3. Evaluation Methods

EHRA evaluation will be collected by Central Reading Laboratory during all the study period.

8.1.2.3.2. Number of recurrence of symptomatic AF

It consists of the number of AF recurrences associated with a symptom (palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety) and confirmed by an ECG.

8.1.2.3.3. Number and duration of hospitalizations

- Number and duration of hospitalizations for cardiovascular events
  - Hospitalization for AF treatment
  - Hospitalization for worsening of heart failure
  - Hospitalization for myocardial infarction
  - All cause of hospitalization
- Number and duration of hospitalizations for thromboembolic stroke

8.1.2.4. Cardioversion assessment

- Assessment of spontaneous cardioversion before visit 3
- Assessment of successful cardioversion at visit 3 (i.e. return to sinus rhythm)
- Shock distribution (1, 2 or 3 shocks)
  - Number of patients needing another cardioversion after initial ECV

8.1.2.5. Evolution of echocardiographic parameters

8.1.2.5.1. Definition

The following echocardiographic parameters will be assessed: Left atrial diameter (mm), LAA (cm²), Left atrial volume (mL), Left atrial volume/BSA (mL/m²), LVEF (%), Left ventricular end diastolic volume/BSA (mL/m²), Left ventricular end systolic volume/BSA (mL/m²), Left
ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL), Left ventricular end systolic diameter (mm) and Left ventricular end systolic volume (mL).

8.1.2.5.2. Schedule
Measurements will be performed at visit 1 and visit 2 to check the eligibility of the patient. Measurements performed at visit 4, visit 6 and visit 9 are done to follow the echocardiographic evolution of the patients in sinus rhythm.

8.1.2.5.3. Evaluation method
The echography evaluations will be carried out according to the recommendations for chamber quantification drawn up by the American Society of Echocardiography and the European Association of Echocardiography [23]. So, the recommended method for volume measurements is to use the biplane method of discs (modified Simpson’s rule) from 2-D measurement.

8.2. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA

8.2.1. Definition
Because of the limited human tissue accessibility for biopsy, red blood cell DHA contents is a marker of tissue DHA concentration [13], [14].

8.2.2. Blood samples

8.2.2.1. Collection schedule
Blood samples will be collected to determine the red blood cells (RBC) concentrations of DHA. Blood samples will be performed at visit 2 before treatment, visit 3, visit 6 and visit 9. Actual sampling times will be individually reported in the e-CRFs.
8.2.2.2. **Technical handling**

Two blood samples (4 ml) will be collected in EDTA tubes. They will be gently shaken, stored at +4°C (no freezing will be allowed) and sent to Analytical Centre in refrigerated conditions (between +2°C and +8°C). Analysis will be performed within 2 weeks following reception at the Analytical Centre.

8.2.3. **DHA concentration measurement**

Analytical determination of RBC concentrations of DHA will be carried out by the Analytical Centre.

Lipids will be extracted from red blood cells samples with a mixture of hexane/isopropanol after acidification [17]. Total lipid extracts will be saponified and methylated. The fatty acid methyl esters (FAME) will be extracted and analyzed by Gas Chromatography.

Identification of FAME will be based on retention times obtained for FAME prepared from fatty acid standards. The area under peaks will be determined using ChemStation Software (Agilent) and results will be expressed as % of total fatty acids. DHA concentration will be calculated using the internal standard and expressed as µg/g for red blood cells samples. Thus, omega-3 index will be assessed. The omega-3 index represents the content of EPA plus DHA in red blood cells (expressed as a percent of total fatty acids). It is a biomarker considered as a new marker of risk for death from coronary disease [18].

Results of this analytical determination will be kept confidential by the dosing centre until the end of the study, and will be provided only at the end of the study (after database lock) in a separate file.

8.3. **SAFETY ASSESSMENT**

8.3.1. **Adverse Events**

At selection, any concomitant disease will be reported on the e-CRF. At each further visit, the occurrence of AEs since the last visit will be based on the patient's spontaneous reporting, the
Investigator's non-leading questioning and his/her clinical evaluation. All AEs will be reported on the e-CRF (see section 10).

8.3.2. Laboratory Investigations

8.3.2.1. Schedule

Laboratory investigations will be performed at visit 1 (before treatment) and visit 9 (end of treatment) or End of Treatment visit.

At visit 3 and 6, only a standard haematologic dosage will be performed.

Furthermore, the kaliemia will be checked before electrical cardioversion at visit 3.

The total volume of blood samples taken for haematology and biochemistry analysis should not exceed 30 mL.

8.3.2.2. Technical Procedures and Parameters

The following tests will be performed:

**Haematology:** hematocrit, haemoglobin, RBC count, white blood cells (WBC) count, WBC differential counts (% and absolute), reticulocytes, platelets.

**Chemistry:** sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatine phosphokinase (CPK), fibrinogen.

Blood samples will be taken in the morning in fasting conditions.

The estimation of GFR at selection relies on the measurement of serum creatinine and the Cockcroft- Gault formula:

**Cockcroft-Gault formula**

- with serum creatinine expressed as mg/L:

  in men: GFR (mL/min) = [(140-age)] x weight / 7.2 x serum creatinine in mg/L

  in women:
GFR (mL/min) = [(140-age)] x weight / 7.2 x serum creatinine in mg/L] x 0.85

- with serum creatinine expressed as μmol/l:
GFR (mL/min) = [(140-age) x weight / serum creatinine in μmol/l] x k, where k = 1.23 for men, 1.04 for women.

(weight in kg, age in years)

Additional tests may be done at the Investigator’s discretion, in the patient’s interest. In case of any abnormal or clinically significant results, the Investigator will order laboratory control tests.

8.3.3. Global Physical Examination

A global physical examination including the measurement of body weight will be carried out on each body system at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.

The physical examination will be globally evaluated as “normal/abnormal”. Further target inspection will be undertaken for any abnormal finding.

8.3.4. Vital Signs

Vital signs will consist in blood pressure and heart rate at rest.

8.3.4.1. Schedule

Vital signs will be measured at each visit.

8.3.4.2. Technical Procedure and Parameters

Systolic blood pressure (SBP) and diastolic blood pressure (DBP), expressed in mmHg, will be measured after at least 5 minutes in supine position and after 2 minutes in standing position.

The heart rate (HR), expressed in beats per minute (bpm), will be measured by auscultation by counting the beats for at least 30 seconds, after at least 5 minutes in supine position and after 2 minutes in standing position.

Bodyweight will be measured with patient in underwear and with the same balance at each visit.
8.3.5. Electrocardiogram (ECG)

8.3.5.1. Schedule

An ECG will be recorded at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9 using an usual standardised 12-lead cardiograph.

8.3.5.2. Technical Procedure and Parameters

- Electrocardiogram:

The global interpretation from manual reading (normality, clinical relevance) and HR (bpm), PR (ms), QRS (ms), QT (ms), repolarisation patterns will be reported in the e-CRF. Each print-out will include the patient’s code, date, time, technician's initials and investigator's signature.

In case of thermic paper ECG print out, a photocopy will be made by the centre to ensure safe filing.

- 24 hour-Holter - ECG

An ambulatory continuous 24-hour ECG (5-leads/2 or 3 channels) will be recorded at selection visit using a holter ECG, in order to confirm persistent AF.

8.3.6. Coagulation parameters

Coagulation assessment will be evaluated by the following parameters:

- Prothrombin Time/INR (PT/INR)
- Activated Partial Thromboplastin Time (aPTT)
- Thrombin Clotting Time (TCT)

During the pre-cardioversion period, if the anticoagulation by AVK should be initiated, then the INR monitoring will be as follow:

- INR 2-3 times a week for the first week of treatment
- INR weekly up to ECV
- INR every 4 weeks after ECV

For patients already treated with AVK, INR monitoring will be as follow:

- INR weekly up to ECV
- INR every 4 weeks after ECV
aPTT and TCT will be performed at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.

Anti-coagulation by AVK should be given at least 3 weeks before ECV and continued for the whole study duration.
The quantity of blood samples collected at each time for coagulation parameters will be 2 mL.

8.3.7. Concomitant Treatments
Concomitant treatments will be evaluated at each study visit.
Requirements relating to patient's concomitant treatments started before screening visit and continued throughout the trial, or started during the trial, can be found in section 7.

8.4. COMPLIANCE
The patient will be reminded at each visit to bring back at the following visit any used or unused remaining soft capsule, blister and case.
At each visit, the Investigator will record the number of supplied and remaining soft capsules in the e-CRF.

9. STUDY PROCEDURES
Visit 1 - Selection Visit (Week -4 to Week -1)
The patient considered eligible for selection by the Investigator will be informed of the characteristics and the consequences of the trial both verbally and by reviewing the patient's information sheet and consent form (see section 14.3). If the patient accepts to participate in the study, he/she will sign the informed consent form and will keep a copy.
The patient will be assessed for the following:
- Demographic characteristics (gender, age, height, body surface area)
- Personal and medico-surgical history
- Habits (Tobacco, alcohol consumption, dietary habits including fish consumption…)
- Cardiovascular diseases, mainly detailed history of Heart Failure and AF characteristics
- Echocardiography using a two-dimensional echocardiography
- 12-lead ECG
- Concomitant diseases, adverse signs or symptoms (able to be used for treatment emergent AE determination)
- Concomitant treatments (authorised, disallowed)
- Global physical examination/bodyweight
- Vital signs
- Biology: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Biology assessment of renal function: creatinine or estimated glomerular filtration rate

If the results of the above assessments are compatible with the selection criteria

- A 24-hour continuous ECG ambulatory recording (Holter ECG) device will be installed on the patient to monitor the patient heart rhythm. The patient will be requested to bring back the device after the termination of 24 hours recording. The recording will be transmitted from the Investigational site to the Central Reading Laboratory. The Central Reading Laboratory will send his/her assessment regarding the confirmation of persistent AF within 2 working days to the Investigator.

- The patient will enter the selection period in which anticoagulant (AVK) will be adjusted to achieve an International Normalized Ratio (INR) of 2 to 3 before ECV.

At the end of the visit, the Investigator will contact the IVRS/IWRS to confirm the patient selection (which will automatically order the treatment delivery) and organise the appointment for the next visit.
The patient will receive from the investigational centre the study card to be kept for the duration of the study.

**Visit 2 - Inclusion Visit (Day 1)**

If the patient's behaviour during the selection period and/or the result of complementary examinations particularly the confirmation of the presence of persistent AF by the Central Reading Laboratory during this period, the INR and laboratory tests, are compatible with the inclusion criteria, the patient will be assessed for the following:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: red blood cell concentrations of DHA and coagulation parameters Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Global Physical examination/bodyweight
- Vital signs
- Echocardiography using a two-dimensional echocardiography
- 12-lead ECG
- Urine pregnancy test for women of child bearing potential

If the results of the above assessments are compatible with the inclusion criteria, the patient will be included and allocated a treatment number using the IVRS/IWRS.

Between this Inclusion visit and the next visit (V3), the INR will be closely monitored (refer to paragraph 8.3.6) in order to ensure that the INR is stable (between 2 to 3 before electrical cardioversion).

At the end of the visit, the Investigator will organise the appointment for the next visit and will give the treatment for the next 4-week period.

**Visit 3 (Week 4: D28 -2/+7 days) cardioversion**
Patient will be assessed for the following criteria:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: Haematology, RBC concentrations of DHA, Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Global Physical examination /bodyweight
- Vital signs
- 12-lead ECG

Electrocardioversion (ECV): ECV has to be scheduled 4 weeks after randomization and after target international normalized ratio levels will be stabilized (between 2 and 3) on at least 3 consecutive weekly tests in patients with AF. Patients not stabilized for INR (i.e. values not between 2 and 3) on at least 3 consecutive weekly tests before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE performed in the same day (and before ECV). ECV will be performed in the morning, with the patient in the fasting state and without dyskalemia. Anesthesia will be induced and patients will be cardioverted with administration of a synchronized, biphasic current. The initial shock will be set at 100 J if the body weight is less than 70 kg and at 150 J for higher body weights. Successful cardioversion will be defined as recovery of sinus rhythm lasting at least 1 minute after the shock. If unsuccessful, a second 200-J shock, and eventually a third 200-J shock, will be administered. Failure of ECV is defined as the persistence of AF after the third attempt at cardioversion. After the procedure, patients will be monitored on telemetry for at least 6 hours before discharge. Patients who will not revert to sinus rhythm or with early relapse within the observation period after ECV will be withdrawn from the study and will be considered to have finished their follow-up.
At the end of the visit, a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) will be installed on the patient in order to monitor the patient heart rhythm after ECV.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week period.

Visit 4 (Week 5: D35 -2/+7 days)

After removal of the continuous ECG ambulatory device, the patient will be assessed for the following criteria:

- Assessment of AE
- Concomitant treatments (authorised, disallowed)
- Body weight (body weight measured at V3 to be used)
- Vitals Signs
- Echocardiography using a two-dimensional echocardiography

At the end of the visit, the patient will be given the TTEM device for cardiac monitoring. The patient will be clearly instructed on the frequency and modalities of transmission. The patient will be requested to performed daily transmission from week 6 to week 8, then every 2 days from week 9 to week 24. Moreover, in case of AF symptoms, additional transmissions may be performed.

Visit 5 (Week 8: D56 ± 7 days) – Visit 6 (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days) - Visit 8 (Week 20: D140 ± 7 days)

Patient will be assessed for the following criteria:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT). However, in case of
discontinuation of anticoagulation after ECV, the monitoring of INR, aPTT and TCT should be stopped.

- Global Physical examination/bodyweight
- Vital signs
- 12-lead ECG
- The cardiac monitoring will be continued using a TTEM device. The device will be given to the patient who will be requested to perform daily transmission from week 6 to week 8, then every 2 days from week 9 to week 24. Moreover, in case of AF symptoms, additional transmissions may be performed.

The Investigator will collect all unused cases, blisters and soft capsules, and will count the unused capsules for each 4-week treatment period.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week treatment period.

In addition:

- at visit 6:
  - the investigator will contact the IVRS/IWRS to obtain the treatment unit number to be dispensed at visit 6 for the last 12-week period.
  - an echocardiography will be performed, an haematology examination will be done and the RBC concentration of DHA will be measured.

**End-of-Study Visit - Visit 9 (Week 24: D168 ± 7 days)**

Patient will be assessed for the following:

- Adverse events
- Concomitant treatments (authorised, disallowed)
• Global Physical examination/bodyweight
• Vital signs
• 12-lead ECG
• Laboratory examination: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT), Red blood cell concentration of DHA.
• Urine pregnancy test for women of childbearing potential
• Echocardiography using a two-dimensional echocardiography

The Investigator will collect all unused cases, blisters and soft capsules, and will count the unused soft capsules.

10. ADVERSE EVENTS: DEFINITION AND REPORTING

10.1. ADVERSE EVENTS

10.1.1. Definition of Adverse Events

An AE is any adverse change from the patient's baseline condition, i.e. any subjective signs and symptoms or change in a concomitant disease present at the Selection Visit considered or not related to the treatment.

AE includes intercurrent signs, symptoms, illnesses and significant deviations from baseline for vital signs and laboratory values which may occur during the course of the clinical study.

All laboratory tests for which abnormal results are collected after study treatment initiation should be repeated until the values return to normal or to a stable status. Abnormal results are defined as those falling out of the laboratory normal ranges and that are clinically significant. The frequency of such checks should be defined by the Investigator according to the degree of abnormality.

In all cases, the aetiology should, as much as possible, be identified and Pierre Fabre Médicament notified.
10.1.2. Grading of Adverse Events

Adverse or intercurrent events are graded as follows:

- Mild: awareness of signs or symptoms, but easily tolerated
- Moderate: uncomfortable enough to cause interference with usual activity
- Severe: incapacity with inability to work or do usual activity

10.1.3. Reporting of Adverse Events

The records of AE in the e-CRF describe the nature (diagnosis, signs and symptoms), severity, onset date, stop date, outcome and actions taken, and relationship to study treatment (in the Investigator's opinion). It must be specified whether the event is serious or not.

10.2. SERIOUS ADVERSE EVENTS (SAE)

10.2.1. Definition

A SAE includes, but is not necessarily restricted to, any event which:

- Results in death (whatever may be the cause)
- Is life-threatening
- Results in persistent or significant disability/incapacity
- Requires the patient's hospitalisation or prolongation of current hospitalisation *
- Is a congenital anomaly or birth defect

Other events such as cancer and any additional adverse experience or abnormal laboratory values occurring during the study period, defined by the protocol as serious or which the Investigator considers significant enough or that suggest a significant hazard, contra-indications, side effect or precaution, must be handled as serious adverse events.

Any overdosage meeting a seriousness criteria should be reported as a SAE (see section 10.3).

Any pregnancy occurring during/after exposure to the study drug(s) should be reported on the SAE notification form (see section 10.4).
* any hospitalisation, or prolongation of hospitalisation due to the circumstances listed below:

- planned (as per protocol) medical/surgical procedure
- preparation for routine health assessment/procedure (e.g. routine colonoscopy)
- planned medical/surgical admission (planned prior to entry into study trial, appropriate documentation required)
- administrative or social reasons (e.g. lack of housing, economic inadequacy, care-giver respite, family circumstances)

will not be reported as a SAE.

10.2.2. Reporting of SAE

All Serious Adverse Events, according to the above-mentioned definitions and regardless of treatment or relationship to study drug, and occurring once the informed consent form has been signed, must be reported by the Investigator as soon as he/she is informed of the event.

The Investigator must notify the Sponsor of this event by sending, within 24 hours, the "Notification of serious adverse event" form ("first notification") with all the available information about the event (see appendix 17.2), to the Sponsor's Corporate Vigilances e-mail dedicated box:

HQ.pharmacovigilance@pierre-fabre.com

In case it is not possible to send the report by e-mail it can be sent by FAX at the following number:

+ 33 1 49 10 80 90

In case of non-inclusion, the reporting period ends when the non-inclusion is documented.

10.2.3. Follow-up of SAE

The Investigator must draw-up a specific clinical report and use the "Notification of serious adverse event" form ("follow-up") (see appendix 17.2) and collect the results of the carried out examinations and the reports of hospitalisation.

The serious adverse events must be followed up until resolution or stabilisation.
10.2.4. SAE Occurring After the Study

Any SAE occurring during 30 days following the end of the study for the patient should be notified to the Sponsor.

Must also be notified to the Sponsor any event occurring at any time after the end of the study for the patient which may be related to the study treatment in the Investigator's opinion.

10.3. REPORTING OF OVERDOSAGE TO THE SPONSOR

For the purpose of this trial, an overdosage will be defined as any dose exceeding the planned prescribed dose of the study drug or the administration of any dose of an associated product that is considered both excessive and medically important.

In the absence of seriousness criteria, the overdosage and associated adverse event if any, are reported only on the Adverse Event page of the e-CRF. If the definition of seriousness criteria is met, the SAE notification form must also be transmitted to the Sponsor.

10.4. REPORTING OF PREGNANCY TO THE SPONSOR

Pregnancies discovered in the period in between the informed consent form signed but before any study drug exposure are not to be reported to the Sponsor unless associated to a seriousness criteria (e.g. serious adverse event study-protocol related procedure). If pregnancy is confirmed, the women must not be administered the study drug and must be withdrawn immediately from the study.

If pregnancy is suspected while the patient is receiving study treatment, the study drug should be discontinued immediately until the result of the pregnancy testing is known. If pregnancy is confirmed, then the study treatment is permanently discontinued in an appropriate manner and the patient is withdrawn from the study.

The Investigator must report to the Sponsor any pregnancy which occurs during or after the patient has been exposed to the study drug and until 30 days after the last study drug administration. The Investigator must immediately notify the Sponsor using the SAE notification form and also report the pregnancy on the AE page of the e-CRF.
Women who become pregnant after exposure to the study drug must be followed by the Investigator until the completion/termination of the pregnancy. If the pregnancy goes to term, the outcome will have to be reported to the Sponsor (baby's healthy status).

10.5. SPONSOR'S RESPONSIBILITIES FOR SAFETY REPORTING PURPOSES

Sponsor will submit expedited and periodic reports to both Competent Authorities and Ethics Committees per corporate standard operating procedures as regards to the EU directive 2001/20/EC taking into account local specific requirements.

11. DATA COLLECTION AND STUDY MONITORING

11.1. DATA COLLECTION

11.1.1. Case Report Form

An e-CRF will be used to record all patient data required by the protocol except the central ECG (Holter ECG, TTEM) and DHA data which will be transferred from vendors to the subcontractor as electronic data files that will be loaded into the study database.

The e-CRF should be fully validated, compliant with ICH-GCP requirements and European regulations and should include a traceability system for data corrections and deletions (audit trail).

Prior to the start of the study, the Investigator will complete a "Delegation of significant study-related duties" form. The signature and initials of all personal in charge of e-CRF completion should be recorded on this form. Each person involved in e-CRF completion, review, correction and / or validation will be trained and will have an individual login and access code to the e-CRF.

Training sessions will be held by the subcontractor for all participants using this tool. An e-CRF user manual will be available for investigators and CRAs.

All the information included into the e-CRF will be recorded from source documents onto the e-CRF by an authorised person.
The Investigator is responsible for the management and accuracy of the information on the e-CRF. At each monitoring visit, the e-CRF(s) should be at the CRA's disposition for review and validation.

At the end of the study, a CD-ROM containing the pdf version of all e-CRFs (including audit-trail) will be sent by the subcontractor to the Sponsor and to the investigational sites for archiving. The subcontractor must store all study data for at least 15 years after the end of the study and ensure their legibility and accessibility during all the storage period.

11.1.2. Source Documents

A source document is an original record or certified copy of an original record of clinical findings, observations or any other medical or paramedical activities performed during the clinical trial, necessary for the transcription and the verification of the collected data.

Source documents along with all other trial-related documents (copies of all "informed consent" forms, e-CRFs CD-ROM, drug inventories and any correspondence related to the study) must be kept in the investigator's file throughout the study, and then, must be stored in the study centre's archives for a period of at least 15 years or as per local legal requirements, whatever is the longest.

For further details see section 15.2.

11.2. STUDY MONITORING

11.2.1. Monitoring visits

On-site visits will be carried out by a representative of the Sponsor's staff (Study Manager or CRA) prior to study initiation and at regular intervals (every 4 to 6 weeks) throughout the study. Additional visits and communication by telephone fax or meeting may be performed if necessary. Any site visit performed by the Sponsor's representatives will be recorded in the Investigator's study file.
11.2.1.1. **Site Preselection Visit**

Before selecting a centre for the study, a visit will be carried out by the CRA and/or the Study Manager to ensure that the Investigator has the necessary capacities (availability, patient's recruitment, environment), technical means and staff to carry out the study.

11.2.1.2. **Initiation Visit**

Before the start of the study at all investigational sites, an initiation visit will be carried out by the CRA to check at the latest that:

- The Investigator:
  - has received the technical protocol, administrative and financial agreement signed by all parties
  - has received the written statement of the Ethics Committee approval and the list of its members and their functions
- The original dated and signed *curriculum vitae* of the investigator(s) has been collected
- Laboratory normal ranges have been collected
- All study materials are available on the study site
- All participants agree with the monitoring procedures and know the study procedures
- All participants are aware of a possible audit or inspection

The CRA has also to provide training on the study protocol requirements and study specific procedures.

11.2.1.3. **Follow-up Visits**

Throughout the study, regular follow-up visits will be carried out by the CRA to check compliance with GCP, patient’s informed consents, strict application of the protocol, conformity of the data entered on the e-CRF with the source documents and ensure its correct completion, adverse events reporting, proper retention, storage and management of the study medication, as well as the source and other trial-related documents.
11.2.1.4. **Closing Visit**

At the end of the study, a final visit will be carried out by the CRA to:

- Verify that the e-CRFs CD-ROM with pdf files are correctly stored
- Control the accountability of intact and used treatment units and return them to the Clinical Pharmacy Department of the IRPF for destruction
- Obtain the last data clarifications and/or solutions if any
- Collect the patient's consent forms in sealed envelopes (except in case of specific country requirements),
- Make an on-site review of all study documentation and complete it if necessary
- And finally, remind the Investigator of his regulatory obligations, study document archiving process and duration.

11.2.2. **Direct Access to Source Documents**

In accordance to the requirements of the GCP, all Sponsor representatives (Study Manager, CRA and Auditors) have to be given a direct access to all source and study data to perform quality monitoring/audit, thus ensuring accuracy and completeness of data).

Investigators are reminded that all Sponsor representatives keep professional confidentiality with regards to the patient data.

11.3. **INDEPENDENT DATA MONITORING COMMITTEE**

An Independent Data Monitoring Committee (IDMC) will be established to assess at intervals the progress of the clinical trial, the compliance with the inclusion criteria, the quality of follow up, the quality of primary end point measures, the safety data. The IDMC will thereafter recommend to the Sponsor whether to continue, modify, or stop the study.

The IDMC operating procedures will be described in an independent document.
12. DATA MANAGEMENT

All clinical data related to the study will be collected and saved in a computerised database by the Data Management Department of the subcontractor and under the supervision of the Data Manager of Pierre Fabre Biometry (PFB) according to the following procedures.

12.1. DATA ENTRY

All required data will be collected by the Investigator or authorised designee (duly identified into the delegation task list) on the e-CRFs.

The e-CRFs used for this study will be developed and maintained by the Data Management Department of the subcontractor and approved by the Sponsor.

Electronic data (Holter ECG, TTEM and DHA) will be transferred by the 3rd party vendor according to the specifications given by the Data Manager of the subcontractor. These data will be captured and handled in accordance with the European GCP ICH E6 guideline.

12.2. DATA CLEANING

The subcontractor will define in the Data Validation Plan for reviewing and querying data, descriptions of both manual and electronic edit checks. Upon Sponsor approval, the subcontractor will program the checks.

The subcontractor will review the data over the course of the study, working with the Sponsor to identify data inconsistencies. The Investigator will be asked to resolve queries by making changes directly into the e-CRF.

12.3. DATA CODING

Adverse events, concomitant diseases, medical/surgical histories will be coded by the subcontractor using the MedDRA dictionary (latest version in use).

Concomitant medication will be coded by the subcontractor using the WHO-DRUG dictionary (latest version in use).
The Sponsor Clinical Development Physician will validate the coding.

12.4. DATA STORAGE
Computer data files as well as their modifications will be archived by the subcontractor and kept available upon request of the Sponsor.

12.5. DATABASE LOCK
The validated database will be locked by the subcontractor upon request of the Data Manager of PFB following the completion of all steps required, i.e. data entry and check of all data, resolution of all queries, validation of the coding, Clinical and Products Safety databases reconciliation and validation committee.

Then, the subcontractor will transfer the locked database in SAS format to the Data Manager of PFB who assume storage on the PFB secured server.

13. STATISTICAL ANALYSIS
After the database lock and the randomisation code release, the statistical analysis will be performed by PFB or under the supervision of the statistician of PFB using SAS® software, according to the Statistical Analysis Plan approved by the Validation Committee.

13.1. GENERAL CONSIDERATIONS
The main objective of the study is to assess the efficacy of F373280 versus placebo on the maintenance of sinus rhythm after direct ECV in patients with persistent AF and chronic heart failure.

Only the primary analysis of the primary efficacy criterion, on which is based the sample size justification, may lead to a causal interpretation. All other statistical results are to be regarded within a descriptive perspective.

The statistical significance level of the various two sided tests of all analyses will be 5 %.
13.2. SAMPLE SIZE

Assuming an AF recurrence rate of 85% under placebo and 65% under active group, i.e. a clinically relevant difference $\Delta$ of 20%, a sample size of 64 assessable patients per group is required, using a log-rank test of survival curves with a 80% power and a 5% two-sided significance level.

According to the previous assumptions and assuming a rate of not assessable patients of 15%, a minimum of 76 patients will have to be randomised per group.

13.3. PROTOCOL DEVIATIONS

Prior to the database lock and the randomisation code release, the Validation Committee members will review the protocol deviations and will classify them as either minor or major. A protocol deviation will be considered major when it is likely to bias significantly the treatment effect estimate based on the primary efficacy criterion.

Patients with major deviation(s) will be excluded from the Per Protocol data set (see section 13.4).

A listing of all protocol deviations will be provided for all randomised patients, including the type (major/minor) of protocol deviations according to the decisions made by the members of the Validation Committee.

The number and percentage of patients with major protocol deviations will be tabulated by treatment group and type of major protocol deviations on the Full Analysis Set defined in section 13.4.

13.4. DATA SETS ANALYSED

The following 3 data sets will be analysed (as defined by the Validation Committee):

- The Safety Set composed of all randomised patients having received at least one dose of the study treatment. This data set will be used to perform analyses of Safety.
• The Full Analysis Set (FAS) composed of all randomised patients having received at least one dose of the study treatment and with a successful cardioversion observed at visit 3. This data set will be used to perform analyses of Efficacy.

• The Per Protocol Set (PP) which is the subset of the Full Analysis Set composed of all patients with a primary efficacy criteria available and without any major protocol deviation or other source of bias for primary criteria analyses. This data set will be used to perform the supportive analysis of the primary efficacy criterion.

13.5. HANDLING OF DROPOUTS AND MISSING DATA

13.5.1. Dropouts
The number of patients who withdraw from the study after their randomisation will be provided by treatment group for all treated patients (Safety Set). All withdrawn patients will be further described regarding their time to dropout and reasons for withdrawal.

13.5.2. Repositioning of Visits
No repositioning of visits will be done.

13.5.3. Missing Data
Missing values will not be substituted by estimated values, but considered as missing in statistical analysis.

13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS
Before the first trial drug intake, patient’s background, medical and surgical history, demographic data and disease characteristics will be described by treatment group on the Safety Set.

- Quantitative parameters will be described by treatment group and overall using the following: number of patients, number of missing data, mean, standard deviation, minimum, median and maximum values.

- Qualitative parameters will be described by treatment group and overall using frequencies.
Concomitant diseases, as well as medical and surgical histories will be tabulated descriptively by treatment group and overall using the MedDRA codes of System Organ Classes and preferred terms.

If more than 10% of patients are excluded from the FAS and PP set, the description of patients by treatment group at selection and inclusion will be repeated on the FAS and PP set for all parameters.

No statistical test of comparability of treatment groups at baseline will be performed.

13.7. EFFICACY ANALYSIS

13.7.1. Primary Criterion

13.7.1.1. Primary Analysis

The primary criteria, time to first recurrence, will be analysed using the Kaplan Meier method and compared with the Log rank test. Hazard ratios and 95% confidence intervals will be estimated with the Cox regression model.

The primary analysis will be performed on the FAS.

13.7.1.2. Supportive Analysis

The primary analysis will be repeated on the PP set.

13.7.2. Secondary Criteria

All secondary analyses will be performed on the FAS. If more than 10% of patients are excluded from the PP set, the secondary analyses will be repeated on the PP set.

13.7.2.1. Numbers of Atrial Fibrillation Episodes

Both the numbers of AF episodes (symptomatic or not) lasting for at least 10 minutes and with duration less than 10 minutes (N_{Sup10} and N_{Inf10}) will be described by treatment group and compared by the chi-square test (or CMH test adjusted for centre) or Fisher’s exact Test.
13.7.2.2. **Duration of Atrial Fibrillation Episodes**

The duration of all AF Episodes will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centres effects) or Wilcoxon test.

13.7.2.3. **Time to first AF recurrence less than 10 minutes or symptomatic**

The time to the first AF recurrence less than 10 minutes and the time to the first symptomatic AF recurrence will be analysed as the primary analysis.

13.7.2.4. **Clinical parameters evaluation**

The EHRA score will be described by treatment group and analysed using a chi-squared test (or CMH test adjusted for centre) or Fisher’s exact Test.

The frequency of presumed arrhythmia will be described by treatment group.

The number of recurrence of symptomatic AF, of hospitalizations (for cardiovascular events, for thromboembolic stroke and for all causes), of spontaneous cardioversion, of successful cardioversion (including number of shocks distribution) and the number of patients needing cardioversion after initial ECV will be described by treatment group and compared using a chi-square test or a Fisher Test (if the numbers are relevant).

The duration of hospitalizations for cardiovascular events, for thromboembolic stroke and for any cause will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centre effects) or Wilcoxon test.

The echocardiographic parameters values will be described at each time (V1, V2, V4, V6 and V9) and changes described from V4 to V9 and from V2 to V9.

13.7.2.5. **Biomarker analysis: red blood cell concentrations of DHA**

Values and changes from baseline for red blood cell concentration of DHA will be performed by treatment group and assessment time.
13.8. SAFETY ANALYSIS

The Safety Set will be used to perform all analyses of the safety criteria.

13.8.1. Adverse Events

Any adverse event having been reported during the study for a given patient will be classified by preferred term and corresponding system organ class using the MedDRA terminology.

Adverse events will be classified as:

- Treatment emergent adverse events, *i.e.*, any adverse event which occurs or worsens on study treatment during the randomised period.

- Or non treatment emergent adverse events, *i.e.*, any adverse event which occurs during the run-in period (before V2) or is reported as concomitant disease with the same intensity.

For each study period, any patient with at least one reported adverse event will be classified as a patient:

- With at least one adverse event
- With at least one treatment emergent adverse event
- With one TEAE
- With two TEAEs
- With at least three TEAEs
- With at least one related TEAE
- With an adverse event leading to the study treatment discontinuation (definitive or temporary)
- With an adverse event leading to withdrawal
- With at least one serious adverse event.

Numbers and percentages of patient with at least one reported treatment emergent adverse event will be tabulated by treatment group:
• By system organ class
• By system organ class and preferred term
• By system organ class and preferred term, taking into consideration its most severe intensity
• And by system organ class and preferred term, taking into consideration the most severe relationship to the study treatment.

Recurring adverse events (i.e., adverse events classified with the same preferred term) for a given patient will only be counted once and only their most severe intensity or most severe relationship to the study treatment will be tabulated.

The number and percentage of patient with at least one most common (reported in 1% patients in any group) drug related TEAE ("not excluded or unassessable") will be tabulated by Preferred Term and Treatment group in decreasing order for the treatment group (for all patients).

The number and percentage of patients with at least one reported most common treatment emergent adverse event will also be plotted by treatment group. This graphical representation will highlight the frequencies of the most severe intensities reported by system organ class and preferred term.

SAE will also be described on an individual basis: treatment group, patient's code, sex and age, Investigator's reported term, preferred term, time of onset according to the time of the first study treatment administration, duration, action taken regarding the study treatment administration, use of a corrective treatment, outcome and relationship to the study treatment in the Investigator’s opinion.

13.8.2. Clinical Laboratory Evaluation

For each laboratory parameter, data will be tabulated by treatment group and assessment time.

The absolute changes post-trial drug administration - baseline (the baseline value being the value measured on the last blood sample collected before the first trial drug administration) will be calculated and tabulated by parameter, treatment group and post-trial drug administration
assessment time. Results of retests performed post-trial drug administration will not be analysed and tabulated. They will only be displayed in individual data listings.

For all biochemistry parameters, scatter plots highlighting individual results will display the baseline and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 24 value in the ordinate.

For all haematology parameters, scatter plots highlighting individual results will display the baseline and week 4, week 12 and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 4, week 12 and week 24 value in the ordinate.

Each treatment group will be differently identified. The first bisecting line (45° line), the lines of lower and upper normal range, the lines of Potentially Clinically Significant Change (PSC) range and Clinically noteworthy abnormal laboratory value (CNALV) range added on the plots (see Appendix 17.3).

For all blood laboratory parameters, shift tables will be provided to depict the numbers of patients with post-trial drug administration variations at each assessment time as compared to the baseline values (measured on the last blood sample collected before the first trial drug administration) by treatment group. A 3-point scale (low, normal, high) will be used as defined by the normal ranges in use in the laboratory in charge of the assays.

CNALV (see in Appendix 17.3) will be identified and described on an individual basis. If relevant, five separate individual data listings by treatment group will be provided:

- CNALV for haemoglobin (including corresponding individual results of erythrocytes and haematocrit)
- CNALV for neutrophils or leucocytes (including corresponding individual results of basophils, eosinophils, lymphocytes and monocytes)
- CNALV for platelets (including corresponding individual results of erythrocytes and leucocytes)
- CNALV for liver function parameters (including corresponding individual results of gamma-GT)
- CNALV for serum creatinine

13.8.3. Global Physical Examination

Recorded data of the global physical examination performed will not be tabulated as any abnormal findings post-randomisation should be reported as AEs (if clinically significant).

Physical examination assessments will be provided in the listings of individual data.

13.8.4. Vital Signs, Physical Findings and Other Observations Related to Safety

13.8.4.1. Vital Sign Measurements Over Time

For each parameter (systolic blood pressure, diastolic blood pressure and HR in supine and standing positions), descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.

13.8.4.2. Body weight

Descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.

13.8.4.3. Individual Patient Changes

The number and percentage of patient with at least one Predefined Potentially Clinically Significant Change (PSC) and with at least one PSC Leading to Clinically Significant Value (PSCV) will be tabulated by treatment group (see Table 1 in Appendix 17.3).

According to the pharmacological drug profile mentioned previously in this Protocol, the changes from baseline to the maximum and/or minimum post-baseline value could be categorized and tabulated by treatment group with frequencies and decreasing cumulative percentages.
If there is a signal of a drug effect toward one direction rather than the other, additionally shift tables of variations from baseline to the maximum or minimum post-baseline value could be also provided (see Table 2 to 4 in Appendix 17.3).

An individual data listing of patients with symptomatic or asymptomatic orthostatic hypotension will be provided by treatment group (see Table 5 in Appendix 17.3).

**13.8.5. ECG**

Frequencies on the clinical interpretation (normal, abnormal CS or NCS) will be presented by treatment group and assessment time. Individual tabulated data for ECG abnormalities will be also displayed.

**13.8.6. Coagulation parameters**

Scatter plots highlighting individual results for coagulation parameters (prothrombin time/INR, activated partial thromboplastin time and thrombin clotting time) before and after study treatment administration will be produced.

**13.9. CONCOMITANT TREATMENTS**

Concomitant treatments will be tabulated by treatment group within a descriptive perspective. They will be classified by therapeutic area according to the WHO-DRUG dictionary using the "anatomical therapeutic chemical" classification on the safety set.

**13.10. COMPLIANCE**

The percentage of compliance will be described by treatment group using the quantity

\[
Compliance(\%) = \frac{\text{Estimated actual consumption}}{\text{Theoretical consumption}} \times 100
\]

with: Estimated actual consumption = number of tablets provided at the start of study (Visit 2) minus number of tablets returned at the end of study (Visit 9)
Theoretical consumption = number of days of treatment intake planned between the start and the end of study (168 days ± 7 days)

13.11. INTERIM ANALYSIS AND DATA MONITORING

No interim analysis is planned.

14. GENERAL ETHICAL CONSIDERATIONS

14.1. ETHICAL CONDITIONS

This study is performed in accordance with the principles stated in the Declaration of Helsinki (1964) and subsequent amendments and in accordance with the Good Clinical Practice Guideline (CPMP/ICH/135/95).

14.2. ETHICS COMMITTEE AND LEGAL REQUIREMENTS

All the documents required by National Regulations and any other informative documents that may be requested are submitted for review to an Ethics Committee whose procedures and operations meet the GCP and National Legal Requirements.

Depending on National Regulations, the application is submitted to the Ethics Committee by the Sponsor (or representative) or by the Investigator.

A copy of the formal written approval from the Ethics Committee is provided to the Sponsor (directly by the Ethics Committee or via the Investigator) with a list of names and qualifications of its members.

The request for authorisation by the Competent Authority or its notification if required (depending on National Regulations) is carried out by the Sponsor.

The screening of patients does not start before the approval of the Ethics Committee has been obtained and the study authorised by the Competent Authority or notified to the Competent Authority (depending on National Regulations).
14.3. PATIENT’S INFORMATION LEAFLET AND INFORMED CONSENT FORM

An information must be given to the patients before their decision to participate or abstain from participation.

This information is based on the elements set out in the Declaration of Helsinki and the ICH GCP Guidelines. It must also describe the measures taken to safeguard patient’s privacy and protection of personal data, according to European Directive 95/46 EC or other local regulation.

Restraints and risks must be explained, as well as the right to discontinue participation in the study at any stage, without affecting their further relationship with the Investigator and/or their future care.

The written information and consent form must be submitted to the patient with an oral explanation. It must be agreed and signed by the patient before any study-related procedure starts.

This information and consent procedure is under the Investigator’s responsibility.

The information and consent document are made in triplicate: the original copy is kept by the Investigator, one copy is given to the patient and the last copy is kept by the Clinical Quality Assurance Unit of the Sponsor in a sealed envelope at the end of study (except in case of specific country requirement).

Specific areas of the Sponsor’s copy are not triplicated to avoid the reading of the patient’s surname (except the first 3 letters), first name, address and signature.

If any information becomes available during the trial that may be relevant to the patient’s willingness to keep on participating in the trial, an updated written informed consent must be submitted to the patient to confirm agreement to continue participating.

14.4. PERSONAL DATA PROTECTION

All information from this study (excluding data from the informed consent) is entered into a computer under the Sponsor’s responsibility in accordance with the French law, "Loi
Informatique et Libertés” (January 6, 1978, and subsequent amendments) and with the European Directive 95/46/CE.

14.5. INSURANCE POLICY

In accordance with the provisions of the law and the GCP, the Sponsor Pierre Fabre Médicament, has an insurance policy intended to guarantee against possible damage resulting from the research.

The studies and/or experiments performed on behalf of the Sponsor Pierre Fabre Médicament are specifically and expressly guaranteed.

It is advisable to underline that non compliance with the Research Legal Conditions is a cause for guarantee exclusion.

15. ADMINISTRATIVE PROCEDURES

15.1. PROTOCOL AMENDMENT

Neither the Investigator nor the Sponsor may alter the protocol without the authorisation of the other party.

All changes to the protocol are subject to an amendment which must be dated and signed by both parties and must appear as an amendment to the protocol.

Substantial amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities

Urgent amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities, but could be implemented immediately under specific conditions defined with the Sponsor.

15.2. SOURCE DOCUMENTS, INVESTIGATOR'S FILE STORAGE

The Investigator:
• Keeps all trial-related documents in appropriate file folders. Records of patient, original informed consent forms, source documents, a CD Rom containing a pdf copy of e-CRF, drug inventory, Ethics Committees and Sponsor correspondence pertaining to the study must be kept on file.

• Retains all documents relating to the screening (consent and investigation results) of all patients included in the trial or not.

• Retains a list of the patient’s names, addresses (and/or number of medical file), code numbers to allow checking of data reported on e-CRFs with those from source documents.

• Authorises direct access to source documents for monitoring, audits and inspections.

• The trial-related documents must be retained as strictly confidential at the Investigator’s site for at least 15 years or according to local requirements, whatever is the longest after the completion or discontinuation of the trial (European Directive 2003/63/EC).

15.3. END OF THE STUDY

15.3.1. Definition of the End of Study

The end of study is the last visit of the last patient undergoing the trial.

Any change to this definition during the study, for whatever reason, must be notified as a substantial amendment.

15.3.2. Early Study Termination

15.3.2.1. Early Study Termination Decided by the Sponsor

The Sponsor may discontinue the study at any time for any of the following reasons:

• Lack of recruitment

• Deviations from good clinical practice and/or regulations

• Poor product safety

• New information that could jeopardise the patient’s safety
• Stopping of the development …

15.3.2.2. Early Study Termination Decided by the Competent Authorities

The Competent Authorities may suspend or prohibit a study if they consider that either the conditions of authorisation are not being met or has doubt about the safety or scientific validity of the study.

15.4. AUDIT

The Sponsor is responsible for making sure that both its representatives (Study Manager, CRA...) and the Investigator fulfil the requirements as specified by the GCP Guideline.

An audit can be organised internally at Pierre Fabre Médicament and at the investigational site where the e-CRFs are matched against source documents.

All study documentation must be directly accessible to auditors.

The practical conditions for the audit are discussed between the Investigator and the Clinical Quality Assurance Department.

Oral information about the audit results are given to the Investigator.

15.5. INSPECTION

The Health Authorities may inspect any investigation site or the Sponsor in the course of the study or after its completion, to verify the conduct of the study and quality of the data. The Investigator must provide to the inspectors direct access to study documents.

15.6. CONFIDENTIALITY

The present materials (protocol and related documentation, e-CRF, Investigator's Brochure) contain confidential information.

Except if agreed in writing with the Study Manager, the Investigators must hold such information confidential, and must not disclose it to others (except where required by Applicable Law).
15.7. CLINICAL STUDY REPORT

Data analysis and clinical study report writing are under the Sponsor’s responsibility.

Upon data analysis completion, a final report including a review of the objectives and methods, a presentation and a discussion of the results is drawn up according to ICH Guidelines (Structure and Content of Clinical Study Reports, ICH-E3, CPMP/ICH/137/95).

The report is a clinical and statistical integrated report. It must be signed by the Sponsor's representative(s) and the Coordinating Investigator.

15.8. STUDY RESULTS COMMUNICATION

Upon completion of the study, the global results of the Research are communicated to the Investigator. According to the Local Regulation, the patient can ask the Investigator for the results.

15.9. STUDY RESULTS PUBLICATION

The information and data collected during the conduct of this clinical study are considered confidential and are used by the Sponsor in connection with the development of the study drug. This information may be disclosed if deemed necessary by the Sponsor.

To allow the use of the information derived from this clinical study and to insure compliance with Current Regulations, the Investigator must provide the Sponsor with complete test results and all data collected during the study.

Only the Sponsor may make study information available to physicians and to Regulatory Agencies, except as required by Current Regulations.

All the results of this study including data, reports, discoveries and inventions resulting from the study, are the property of the Sponsor.

In the event the Sponsor chooses to publish study data, the manuscript must be provided to the author(s) at least 30 days prior to the expected date of submission to the intended publisher.

The Investigator(s) can reserve the right to publish or present study data; if so, the manuscript or abstract must be provided to the Sponsor for review at least 30 days prior to the expected date of submission to the intended publisher or of planned presentation.
In addition, if necessary, (the) Investigator(s) shall withhold publication for an additional 60 days, to allow the filing of a patent application, or to allow the Sponsor to take any measures he deems appropriate to establish and preserve his proprietary rights.

It is agreed that publication of study results by each site shall be made only as part of a publication of the study results obtained by all sites performing the protocol, once the study is completed and finalised.

The authors list is agreed by all Investigators prior to publication. The names of the authors are provided according to their participation in the design of the protocol as well as their recruitment of eligible and analysable patients.
16. REFERENCES

[1] F373280 INVESTIGATOR'S BROCHURE, version October 2013

   n-3 Polyunsaturated Fatty Acids in the prevention of atrial Fibrillation Recurrences after electrical cardioversion. A prospective, Randomised study
   Circulation, 2011; 124:1100-1106

   Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy
   J. Am. Coll. Cardiol. 2011;57;870-879

   Dose-dependant effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of non ischemic origin: A double-blind, placebo-controlled, 3-arm study
   American Heart Journal 2011; 161:915.e1-915.e9 - volume 161, number 5

[5] GISSI-HF INVESTIGATORS
   Effects of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GSSI-HF Trial): a randomised, double-blind, placebo-controlled trial
   The lancet on line - August 2008

   HEIDBUCHEL H., ALFIERI O., ANGELINI A., ATAR D., COLOMONA P., DE CATERINA R., DE SUTTER J., GOETTE A., GORENEK B., HELDAL M.,
   HOHLOSER S.H., KOLH P., LE HEUZEY J.Y., PONIKOWSKI P., RUTTEN F.H.
   Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
   European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Eur Heart J. 2010 Oct;31(19):2369-429

[7] KOWEY PR, REIFFEL JA, ELLENBOGEN KA, NACCARELLI GV, PRATT CM.
   Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomised controlled trial.
[8] BIANCONI L., CALO L., MENNUNI M., SANTINI L., MOROSETTI P.,
AZZOLINI P., BARBATO G., BISCIONE F., ROMANO P., SANTINI M.
N-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical
cardioreversion of chronic persistent atrial fibrillation: a randomised, double-blind,
multicentre study
Europace (2011) 13, 174-181

[9] OMACOR® SUMMARY PRODUCT CHARACTERISTICS (SPC) dated 17/02/2012

[10] BEPANTHENE® SUMMARY PRODUCT CHARACTERISTICS (SPC)

HOHNLOSER SH.
Dronedarone for prevention of atrial fibrillation: a dose-ranging study.

[12] LE HEUZEY JY AND ALL.
A Short-Term, Randomised, Double-Blind, Parallel-Group Study to Evaluate the Efficacy
and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial
Fibrillation: The DIONYSOS Study.
J Cardiovasc Electrophysiol.

STUKLIS R., YOUNG D.G., ROBERTS-THOMSON K. & CLELAND G.L.M.L. &
OKEN H.
Effects of fish-oil supplementation on myocardial fatty acids in humans.
Am J Clin Nutr (2007); 85 : 1225.

Distribution, interconversion and dose response of n-3 fatty acids in humans.
Am J Clin Nutr (2006);83 : 1469-1473S.

[15] TIELEMAN RG, VAN GELDER IC, CRIJNS HJ, DE KAM PJ, VAN DEN BERG
MP, HAAKSMA J, VAN DER WOUDE HJ, AND ALLESSIE MA.
Early recurrences of atrial fibrillation after electrical cardioversion: a result of
fibrillation-induced electrical remodelling of the atria?
J. Am. Coll. Cardiol. 1998;31;167-173

[16] SALM P, TAYLOR PJ, KOSTNER K
Simultaneous quantification of total eicosapentaenoic acid, docosahexaenoic acid and
arachidonic acid in plasma by high-performance liquid chromatography-tandem mass
spectrometry.
The consumption of food products from linseed-fed animals maintains erythrocyte omega-3 fatty acids in obese human

[18] HARRIS WS, VON SCHACKY C.
The Omega-3 Index: a new risk factor for death from coronary heart disease?

Effects of Polynsaturated Fatty Acids n-3 (PUFA n-3) in the prophylaxis of atrial fibrillation relapses after external electric cardioversion
World Congress of Cardiology 2006, 2-6 September, Barcelona – Spain

Outcome parameters from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association.
Europace 2007, 9, 1006-1023

[21] EUROPEAN MEDICINES AGENCY
Addendum to the guideline on antiarrhythmics on atrial fibrillation and atrial flutter.
EMA/CHMA/EWP/213056/2010

Dietary fish oil dose- and time-response effects on cardiac phospholipid fatty acid composition.
Lipids. 2004;39:955–961

[23] ROBERTO M. LANG, MICHELLE BIERIG, RICHARD B. DEVEREUX, FRANK A. FLACHSKAMPF*, ELYSE FOSTER, PATRICIA A. PELLIKKA, MICHAEL H. PICARD, MARY J. ROMAN, JAMES SEWARD, JACK SHANEWISE, SCOTT SOLOMON, KIRK T. SPENCER, MARTIN ST. JOHN SUTTON, WILLIAM STEWART.
Recommendations for chamber quantification
17. APPENDICES
17.1. DECLARATION OF HELSINKI

WORLD MEDICAL ASSOCIATION
DECLARATION OF HELSINKI
ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING
HUMAN SUBJECTS

Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the: 29th WMA
General Assembly, Tokyo, Japan, October 1975 35th WMA General Assembly, Venice, Italy, October 1983 41st
WMA General Assembly, Hong Kong, September 1989 48th WMA General Assembly, Somerset West, Republic of
South Africa, October 1996 52nd WMA General Assembly, Edinburgh, Scotland, October 2000 53rd WMA General
Assembly, Washington 2002 (Note of Clarification on paragraph 29 added) 55th WMA General Assembly, Tokyo
2004 (Note of Clarification on Paragraph 30 added) 59th WMA General Assembly, Seoul, October 2008

A. INTRODUCTION

1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of
ethical principles for medical research involving human subjects, including research on identifiable
human material and data. The Declaration is intended to be read as a whole and each of its constituent
paragraphs should not be applied without consideration of all other relevant paragraphs.

2. Although the Declaration is addressed primarily to physicians, the WMA encourages other participants
in medical research involving human subjects to adopt these principles.

3. It is the duty of the physician to promote and safeguard the health of patients, including those who are
involved in medical research. The physician's knowledge and conscience are dedicated to the fulfilment
of this duty.

4. The Declaration of Geneva of the WMA binds the physician with the words, “The health of my patient
will be my first consideration,” and the International Code of Medical Ethics declares that, “A physician
shall act in the patient's best interest when providing medical care.”

5. Medical progress is based on research that ultimately must include studies involving human subjects.
Populations that are underrepresented in medical research should be provided appropriate access to
participation in research.

6. In medical research involving human subjects, the well-being of the individual research subject must
take precedence over all other interests.

7. The primary purpose of medical research involving human subjects is to understand the causes,
development and effects of diseases and improve preventive, diagnostic and therapeutic interventions
(methods, procedures and treatments). Even the best current interventions must be evaluated continually
through research for their safety, effectiveness, efficiency, accessibility and quality.

8. In medical practice and in medical research, most interventions involve risks and burdens.

9. Medical research is subject to ethical standards that promote respect for all human subjects and protect
their health and rights. Some research populations are particularly vulnerable and need special
protection. These include those who cannot give or refuse consent for themselves and those who may be
vulnerable to coercion or undue influence.

10. Physicians should consider the ethical, legal and regulatory norms and standards for research involving
human subjects in their own countries as well as applicable international norms and standards. No
national or international ethical, legal or regulatory requirement should reduce or eliminate any of the
protections for research subjects set forth in this Declaration.
B. PRINCIPLES FOR ALL MEDICAL RESEARCH

11. It is the duty of physicians who participate in medical research to protect the life, health, dignity, integrity, right to self-determination, privacy, and confidentiality of personal information of research subjects.

12. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and adequate laboratory and, as appropriate, animal experimentation. The welfare of animals used for research must be respected.

13. Appropriate caution must be exercised in the conduct of medical research that may harm the environment.

14. The design and performance of each research study involving human subjects must be clearly described in a research protocol. The protocol should contain a statement of the ethical considerations involved and should indicate how the principles in this Declaration have been addressed. The protocol should include information regarding funding, sponsors, institutional affiliations, other potential conflicts of interest, incentives for subjects and provisions for treating and/or compensating subjects who are harmed as a consequence of participation in the research study. The protocol should describe arrangements for post-study access by study subjects to interventions identified as beneficial in the study or access to other appropriate care or benefits.

15. The research protocol must be submitted for consideration, comment, guidance and approval to a research ethics committee before the study begins. This committee must be independent of the researcher, the sponsor and any other undue influence. It must take into consideration the laws and regulations of the country or countries in which the research is to be performed as well as applicable international norms and standards but these must not be allowed to reduce or eliminate any of the protections for research subjects set forth in this Declaration. The committee must have the right to monitor ongoing studies. The researcher must provide monitoring information to the committee, especially information about any serious adverse events. No change to the protocol may be made without consideration and approval by the committee.

16. Medical research involving human subjects must be conducted only by individuals with the appropriate scientific training and qualifications. Research on patients or healthy volunteers requires the supervision of a competent and appropriately qualified physician or other health care professional. The responsibility for the protection of research subjects must always rest with the physician or other health care professional and never the research subjects, even though they have given consent.

17. Medical research involving a disadvantaged or vulnerable population or community is only justified if the research is responsive to the health needs and priorities of this population or community and if there is a reasonable likelihood that this population or community stands to benefit from the results of the research.

18. Every medical research study involving human subjects must be preceded by careful assessment of predictable risks and burdens to the individuals and communities involved in the research in comparison with foreseeable benefits to them and to other individuals or communities affected by the condition under investigation.

19. Every clinical trial must be registered in a publicly accessible database before recruitment of the first subject.
20. Physicians may not participate in a research study involving human subjects unless they are confident that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians must immediately stop a study when the risks are found to outweigh the potential benefits or when there is conclusive proof of positive and beneficial results.

21. Medical research involving human subjects may only be conducted if the importance of the objective outweighs the inherent risks and burdens to the research subjects.

22. Participation by competent individuals as subjects in medical research must be voluntary. Although it may be appropriate to consult family members or community leaders, no competent individual may be enrolled in a research study unless he or she freely agrees.

23. Every precaution must be taken to protect the privacy of research subjects and the confidentiality of their personal information and to minimize the impact of the study on their physical, mental and social integrity.

24. In medical research involving competent human subjects, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail, and any other relevant aspects of the study. The potential subject must be informed of the right to refuse to participate in the study or to withdraw consent to participate at any time without reprisal. Special attention should be given to the specific information needs of individual potential subjects as well as to the methods used to deliver the information. After ensuring that the potential subject has understood the information, the physician or another appropriately qualified individual must then seek the potential subject’s freely-given informed consent, preferably in writing. If the consent cannot be expressed in writing, the non-written consent must be formally documented and witnessed.

25. For medical research using identifiable human material or data, physicians must normally seek consent for the collection, analysis, storage and/or reuse. There may be situations where consent would be impossible or impractical to obtain for such research or would pose a threat to the validity of the research. In such situations the research may be done only after consideration and approval of a research ethics committee.

26. When seeking informed consent for participation in a research study the physician should be particularly cautious if the potential subject is in a dependent relationship with the physician or may consent under duress. In such situations the informed consent should be sought by an appropriately qualified individual who is completely independent of this relationship.

27. For a potential research subject who is incompetent, the physician must seek informed consent from the legally authorized representative. These individuals must not be included in a research study that has no likelihood of benefit for them unless it is intended to promote the health of the population represented by the potential subject, the research cannot instead be performed with competent persons, and the research entails only minimal risk and minimal burden.

28. When a potential research subject who is deemed incompetent is able to give assent to decisions about participation in research, the physician must seek that assent in addition to the consent of the legally authorized representative. The potential subject’s dissent should be respected.
29. Research involving subjects who are physically or mentally incapable of giving consent, for example, unconscious patients, may be done only if the physical or mental condition that prevents giving informed consent is a necessary characteristic of the research population. In such circumstances the physician should seek informed consent from the legally authorized representative. If no such representative is available and if the research cannot be delayed, the study may proceed without informed consent provided that the specific reasons for involving subjects with a condition that renders them unable to give informed consent have been stated in the research protocol and the study has been approved by a research ethics committee. Consent to remain in the research should be obtained as soon as possible from the subject or a legally authorized representative.

30. Authors, editors and publishers all have ethical obligations with regard to the publication of the results of research. Authors have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports. They should adhere to accepted guidelines for ethical reporting. Negative and inconclusive as well as positive results should be published or otherwise made publicly available. Sources of funding, institutional affiliations and conflicts of interest should be declared in the publication. Reports of research not in accordance with the principles of this Declaration should not be accepted for publication.

C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH MEDICAL CARE

31. The physician may combine medical research with medical care only to the extent that the research is justified by its potential preventive, diagnostic or therapeutic value and if the physician has good reason to believe that participation in the research study will not adversely affect the health of the patients who serve as research subjects.

32. The benefits, risks, burdens and effectiveness of a new intervention must be tested against those of the best current proven intervention, except in the following circumstances:
   • The use of placebo, or no treatment, is acceptable in studies where no current proven intervention exists; or
   • Where for compelling and scientifically sound methodological reasons the use of placebo is necessary to determine the efficacy or safety of an intervention and the patients who receive placebo or no treatment will not be subject to any risk of serious or irreversible harm. Extreme care must be taken to avoid abuse of this option.

33. At the conclusion of the study, patients entered into the study are entitled to be informed about the outcome of the study and to share any benefits that result from it, for example, access to interventions identified as beneficial in the study or to other appropriate care or benefits.

34. The physician must fully inform the patient which aspects of the care are related to the research. The refusal of a patient to participate in a study or the patient’s decision to withdraw from the study must never interfere with the patient-physician relationship.

35. In the treatment of a patient, where proven interventions do not exist or have been ineffective, the physician, after seeking expert advice, with informed consent from the patient or a legally authorized representative, may use an unproven intervention if in the physician's judgement it offers hope of saving life, re-establishing health or alleviating suffering. Where possible, this intervention should be made the object of research, designed to evaluate its safety and efficacy. In all cases, new information should be recorded and, where appropriate, made publicly available.
17.2. SAE REPORT FORM
NOTIFICATION OF SERIOUS ADVERSE EVENT (SAE) OR PREGNANCY
TO PIERRRE FABRE CORPORATE VIGILANCES DIVISION

TO BE TRANSMITTED TO THE CORPORATE VIGILANCES DIVISION BY E-MAIL WITHIN 24H TO
HQ.pharmacovigilance@pierre-fabre.com OR BY FAX WITHIN 24H – Fax N°: 33 (0) 1.49.10.80.90

Transmission date ___________________________ (ddmmyyyy) Country : ..................................................

SAE N° ___________________________ FIRST NOTIFICATION ☐ FOLLOW-UP ☐ N°

SUBJECT CHARACTERISTICS

Gender □ 1=M, 2=F Height ______ ______ ______ cm Weight ______ ______ ______ kg

DESCRIPTION OF THE EVENT

The serious adverse event resulted in :
❑ Death (whatever may be the cause)
❑ Hospitalisation (*) or extension thereof
❑ Life threatening
❑ Invalidity or disability
❑ Congenital abnormality or abnormal pregnancy outcome
❑ Cancer
❑ Other (any other serious clinical or laboratory event according to the investigator or the protocol, overdosage meeting seriousness criteria, suicide attempts)

Other fact to be notified :
❑ Pregnancy exposure

Nature of the event (if clinical nature, indicate the diagnosis or the major symptom) :
...........................................................................................................................................................................................................
...........................................................................................................................................................................................................
...........................................................................................................................................................................................................

AE onset date ___________________________ (ddmmyyyy)
Seriousness onset date ___________________________ (ddmmyyyy)
Summary description (if clinical cause, significant history, progression of event, available laboratory results, etc...):
...........................................................................................................................................................................................................

(*) Except hospitalisations with durations and goals planned in the protocol

THE SAE IN RELATION TO THE TRIAL

TREATMENT NUMBER ___________________________

• Time of occurrence of SAE
  ❑ During the selection or run-in period
  ❑ During the administration phase of the study treatment
  ❑ After the administration phase of the study treatment

• Date of first study treatment administration ___________________________ (ddmmyyyy)
• Date of last study treatment administration ___________________________ (ddmmyyyy)
before the occurrence of SAE

• Was the blind broken ?  ❑ Yes  ❑ No  ❑ Not applicable
  If yes, or if this is an open study, drug(s) administered :

  Conditions of administration (cycles(s), daily dose(s), route(s) of administration, etc...) :
Transmission date   [ ] [ ] [ ] [ ] [ ] [ ] (dd/mm/yyyy)  Country : ............................................

SAE N°   [ ] [ ]  FIRST NOTIFICATION  ☐  FOLLOW-UP  ☐ N°

> CONCOMITANT MEDICATION SINCE TRIAL INITIATION and UP UNTIL THE OCCURRENCE OF THE SAE
(Except the treatments given for the SAE)

<table>
<thead>
<tr>
<th>Trade name (or INN)</th>
<th>Daily dose</th>
<th>Start date (dd/mm/yy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (dd/mm/yy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><em><strong>/</strong></em></td>
<td>☐</td>
<td><em><strong>/</strong></em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em><strong>/</strong></em></td>
<td>☐</td>
<td><em><strong>/</strong></em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em><strong>/</strong></em></td>
<td>☐</td>
<td><em><strong>/</strong></em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em><strong>/</strong></em></td>
<td>☐</td>
<td><em><strong>/</strong></em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

> MEASURES TAKEN FOLLOWING THE SAE

- **Study treatment**
  - ☐ No change
  - ☐ Dosage modification, specify : ......................................................  Modification Date : ___/___/___
  - ☐ Temporarily discontinued  Readministration date : ___/___/___
  - ☐ Withdrawn  End date : ___/___/___
  - ☐ Not applicable

Final version 683/1185
The event led to:

- Prescription of corrective or symptomatic treatments:

<table>
<thead>
<tr>
<th>Trade name (or INN)</th>
<th>Daily dose</th>
<th>Start date (dd/mm/yy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (dd/mm/yy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em><strong>/</strong></em></td>
<td></td>
<td></td>
<td><em><strong>/</strong></em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em><strong>/</strong></em></td>
<td></td>
<td></td>
<td><em><strong>/</strong></em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em><strong>/</strong></em></td>
<td></td>
<td></td>
<td><em><strong>/</strong></em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Discontinuation of concomitant treatments:

<table>
<thead>
<tr>
<th>Trade name (or INN)</th>
<th>Daily dose</th>
<th>Start date (dd/mm/yy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (dd/mm/yy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em><strong>/</strong></em></td>
<td></td>
<td></td>
<td><em><strong>/</strong></em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em><strong>/</strong></em></td>
<td></td>
<td></td>
<td><em><strong>/</strong></em></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td><em><strong>/</strong></em></td>
<td></td>
<td></td>
<td><em><strong>/</strong></em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Others, specify:

OUTCOME

- Not recovered/Not resolved
- Recovering/Resolving
- Recovered/Resolved
- Recovered/Resolved with sequelae
- Fatal
- Unknown

In case of death, has an autopsy been conducted? Yes No

INVESTIGATOR CAUSALITY ASSESSMENT (investigator’s assessment to be done as soon as possible)

Study drug: Related to study protocol:

- Not Suspected
- Suspected

Comments: ..............................................................................................................................................................

Enclose in the notification the results of carried out examinations, reports of hospitalisation, etc...
### 17.3. PREDEFINED LIMITS OF LABORATORY AND VITAL SIGN POTENTIALLY CLINICALLY SIGNIFICANT CHANGES AND VALUES

List of Predefined Potentially Clinically Significant Change For Laboratory Values

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>UNIT</th>
<th>Decrease</th>
<th>PSC</th>
<th>Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MUSCLE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatine Phosphokinase</td>
<td>U / l</td>
<td>-</td>
<td>-</td>
<td>236</td>
</tr>
<tr>
<td><strong>KIDNEY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine</td>
<td>µmol/l</td>
<td>-</td>
<td>-</td>
<td>35</td>
</tr>
<tr>
<td>Urea</td>
<td>mmol/l</td>
<td>-</td>
<td>-</td>
<td>3.2</td>
</tr>
<tr>
<td>Uric acid</td>
<td>µmol/l</td>
<td>-</td>
<td>-</td>
<td>119</td>
</tr>
<tr>
<td>Phosphate</td>
<td>mmol/l</td>
<td>0.39</td>
<td>0.39</td>
<td></td>
</tr>
<tr>
<td>Calcium</td>
<td>mmol/l</td>
<td>0.30</td>
<td>0.30</td>
<td></td>
</tr>
<tr>
<td><strong>ELECTROLYTES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium</td>
<td>mmol/l</td>
<td>8</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Potassium</td>
<td>mmol/l</td>
<td>1.1</td>
<td>1.1</td>
<td></td>
</tr>
<tr>
<td>Chloride</td>
<td>mmol/l</td>
<td>8</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>mmol/l</td>
<td>7</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td><strong>METABOLISM/ NUTRITIONAL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose (random)</td>
<td>mmol/l</td>
<td>3</td>
<td>3.7</td>
<td></td>
</tr>
<tr>
<td>Albumin</td>
<td>g/l</td>
<td>6</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Protein</td>
<td>g/l</td>
<td>11</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Cholesterol</td>
<td>mmol/l</td>
<td>-</td>
<td>1.97</td>
<td></td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>mmol/l</td>
<td>0.91</td>
<td>0.85</td>
<td></td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>mmol/l</td>
<td>2.17</td>
<td>2.04</td>
<td></td>
</tr>
<tr>
<td>Triglycerides</td>
<td>mmol/l</td>
<td>-</td>
<td>2.91</td>
<td></td>
</tr>
<tr>
<td><strong>ERYTHROCYTES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythrocyte count</td>
<td>T/l</td>
<td>0.7</td>
<td>0.7</td>
<td></td>
</tr>
<tr>
<td>Haemoglobin</td>
<td>g/l</td>
<td>20</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Haematocrit</td>
<td>l</td>
<td>0.06</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>MCV</td>
<td>fl</td>
<td>7</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>MCH (Fe)</td>
<td>fmol</td>
<td>0.19</td>
<td>0.19</td>
<td></td>
</tr>
<tr>
<td>MCHC (Fe)</td>
<td>mmol/l</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>LEUKOCYTES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukocyte count</td>
<td>G/l</td>
<td>4.2</td>
<td>3.8</td>
<td></td>
</tr>
<tr>
<td><strong>DIFFERENTIAL COUNT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophils</td>
<td>G/l</td>
<td>3.47</td>
<td>3.19</td>
<td></td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>G/l</td>
<td>1.76</td>
<td>1.63</td>
<td></td>
</tr>
<tr>
<td>Monocytes</td>
<td>G/l</td>
<td>-</td>
<td>0.49</td>
<td></td>
</tr>
<tr>
<td>Eosinophils</td>
<td>G/l</td>
<td>-</td>
<td>0.41</td>
<td></td>
</tr>
<tr>
<td>Basophils</td>
<td>G/l</td>
<td>-</td>
<td>0.14</td>
<td></td>
</tr>
<tr>
<td><strong>URINE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specific gravity</td>
<td>-</td>
<td>0.017</td>
<td>0.015</td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>-</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>LIVER</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>µmol/l</td>
<td>-</td>
<td>-</td>
<td>10</td>
</tr>
<tr>
<td>ASAT (SGOT)</td>
<td>U/l</td>
<td>-</td>
<td>N x (23/36)</td>
<td></td>
</tr>
<tr>
<td>ALAT (SGPT)</td>
<td>U/l</td>
<td>-</td>
<td>N x (28/45)</td>
<td></td>
</tr>
<tr>
<td>Gamma GT</td>
<td>U/l</td>
<td>-</td>
<td>N x (25/38)</td>
<td></td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>U/l</td>
<td>-</td>
<td>N x (30/95)</td>
<td></td>
</tr>
</tbody>
</table>

N = upper limit of normal range

**Definition of Clinically Noteworthy Abnormal Laboratory Values (CNALV)**

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>CNALV</th>
</tr>
</thead>
</table>
| **HAEMOGLOBIN**          | • Decrease of at least 2 g/dl and value < 10 g/dl whatever the baseline value  
                          | • If missing baseline: value <10g/dl                                                                                                                                                                    |
| **NEUTROPHILS**          | • < 1 500/mm³ whatever the baseline value                                                                                                                                                              |
| **WBC** (if missing value for neutrophils) | • < 3 000/mm³ whatever the baseline value                                                                                                                                                             |
| **PLATELETS**            | • < 100 000/mm³ whatever the baseline value                                                                                                                                                             |
| **SERUM CREATININE**     | • Increase of at least 30 % as compared to baseline value and value > 150 µmol/l whatever the baseline value  
                          | • If missing baseline: value > 150 µmol/l                                                                                                                                                              |
| **LIVER FUNCTION TESTS** |                                                                                                                                                                                                     |
| **ALAT**                 | • If normal baseline:  
                          | • ALAT > 2 N  
                          | • If abnormal baseline:  
                          | → if baseline value ≤ 2.5 N:  
                          | • increase of at least 100 % as compared to baseline value  
                          | → if baseline value > 2.5 N:  
                          | • value > 5 N  
                          | and/or **ASAT**  
                          | • If normal baseline:  
                          | • ASAT > 2 N  
                          | • If abnormal baseline:  
                          | → if baseline value ≤ 2.5 N:  
                          | • increase of at least 100 % as compared to baseline value  
                          | → if baseline value > 2.5 N:  
                          | • value > 5 N  
                          | and/or **Alkaline phosphatase (AP)**  
                          | • If normal baseline:  
                          | • AP > 1.25 N  
                          | • If abnormal baseline:  
                          | • AP > 2 N  
                          | and/or **Total bilirubin (TB)**  
                          | • If normal baseline:  
                          | • TB > 1.5 N  
                          | • If abnormal baseline:  
                          | • TB > 2 N  

N=upper limit of normal range

Cardiovascular Safety

Table 1: Predefined Limits for Potentially Clinically Significant Changes (PSC) and PSC Leading to Clinically Significant Values (PSCV)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>PSC</th>
<th>PSCV</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP</td>
<td>Increase ≥ 20 mmHg</td>
<td>SBP ≥ 160 mmHg and increase ≥ 20 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 20 mmHg</td>
<td>SBP ≤ 90 mmHg and decrease ≥ 20 mmHg</td>
</tr>
<tr>
<td>DBP</td>
<td>Increase ≥ 10 mmHg</td>
<td>DBP ≥ 100 mmHg and increase ≥ 10 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 mmHg</td>
<td>DBP ≤ 50 mmHg and decrease ≥ 10 mmHg</td>
</tr>
<tr>
<td>HR</td>
<td>Increase ≥ 10 bpm</td>
<td>HR ≥ 110 bpm and increase ≥ 10 bpm</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 bpm</td>
<td>HR ≤ 50 bpm and decrease ≥ 10 bpm</td>
</tr>
</tbody>
</table>

Table 2: Predefined Classes for changes from Baseline to the Maximum (and/or Minimum) Post-baseline Value

<table>
<thead>
<tr>
<th>Classes of Change from Baseline to the Maximum Post-baseline Value</th>
<th>Classes of Change from Baseline to the Minimum Post-baseline Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>SBP mmHg</td>
</tr>
<tr>
<td>DBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>HR bpm</td>
<td>HR bpm</td>
</tr>
<tr>
<td>All</td>
<td>All</td>
</tr>
<tr>
<td>≥ 0</td>
<td>≥ 0</td>
</tr>
<tr>
<td>&gt; 0</td>
<td>&gt; 0</td>
</tr>
<tr>
<td>≥ 10</td>
<td>≥ 5</td>
</tr>
<tr>
<td>≥ 20</td>
<td>≥ 10</td>
</tr>
<tr>
<td>≥ 30</td>
<td>≥ 15</td>
</tr>
<tr>
<td>≥ 40</td>
<td>≥ 20</td>
</tr>
<tr>
<td></td>
<td>≤ -40</td>
</tr>
<tr>
<td></td>
<td>≤ -20</td>
</tr>
<tr>
<td></td>
<td>≤ -30</td>
</tr>
</tbody>
</table>

Table 3: Classes for Vital Signs Maximum or Minimum Values

<table>
<thead>
<tr>
<th>Classes for the Maximum Post-baseline Value for each parameter</th>
<th>Classes for the Minimum Post-baseline Value for each parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>SBP mmHg</td>
</tr>
<tr>
<td>DBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>HR bpm</td>
<td>HR bpm</td>
</tr>
<tr>
<td>&lt; 120</td>
<td>≤ 50</td>
</tr>
<tr>
<td>[120;140]</td>
<td>[50;75]</td>
</tr>
<tr>
<td>[140;160]</td>
<td>[75;100]</td>
</tr>
<tr>
<td>≥ 160</td>
<td>≥ 100</td>
</tr>
<tr>
<td></td>
<td>≥ 100</td>
</tr>
<tr>
<td></td>
<td>≥ 100</td>
</tr>
<tr>
<td></td>
<td>≥ 100</td>
</tr>
<tr>
<td></td>
<td>≥ 100</td>
</tr>
<tr>
<td></td>
<td>≥ 100</td>
</tr>
</tbody>
</table>

Table 4: Classes for Maximum or Minimum of BP in its entirety

<table>
<thead>
<tr>
<th>Classification of Maximum Values for Blood Pressure (mmHg)</th>
<th>Classification of Minimum Values Blood Pressure (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP &lt; 140 and DBP &lt; 90</td>
<td>SBP &gt; 90 and DBP &gt; 50</td>
</tr>
<tr>
<td>[140;160] and DBP &lt; 100</td>
<td>SBP ≤ 90 or DBP ≤ 50</td>
</tr>
<tr>
<td>or DBP [90;100] and SBP &lt; 160</td>
<td></td>
</tr>
<tr>
<td>SBP ≥ 160 or DBP ≥ 100</td>
<td></td>
</tr>
</tbody>
</table>

Table 5: Definition of orthostatic hypotension

<table>
<thead>
<tr>
<th>Orthostatic Hypotension *</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP Decrease ≥ 20 mmHg or DBP Decrease ≥ 10 mmHg between supine and standing positions</td>
</tr>
</tbody>
</table>

16.1.1.7. Protocol amendment n° PA04
General and non-substantial dated on 03 June 2014 linked to Protocol and appendices
(version 7: 03 June 2014)
Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Pierre Fabre Study Code: F373280 CA 2 01

EudraCT Number or equivalent: 2012-003487-48

Gaëlle ALCARAZ
INSTITUT DE RECHERCHE PIERRE FABRE
Centre de R&D Pierre Fabre - BP 13562
3 avenue Hubert Curien
31055 TOULOUSE Cedex 1

Pr Savina NODARI
Department of Clinical and Surgical Specialities, Radiological Science and Public Health
Section of Cardiovascular Diseases
University Medical School and Spedali Civili Hospital of Brescia
c/o Spedali Civili di Brescia
Piazzale Spedali Civili, 1
25123 - BRESCIA, ITALY

Study Coordinating Investigator:

Date of amendment PA04: 03 Jun 2014
APPROVAL FORM

STUDY: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Clinical Study Protocol Amendment n° PA04 Version 1
(General – Non Substantial)
Dated: 03JUN2014

Sponsor's representative(s)

· Medical Director
  Date: 06/06/2014
  Signature: Dr Richard ROCHE

· Clinical Study Manager:
  Date: 06/06/2014
  Signature: Gaëlle ALCARAZ

Study Coordinating Investigator:
  Date: 
  Signature: Pr Savina NODARI
APPROVAL FORM

STUDY: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Clinical Study Protocol Amendment n° PA04 Version 1
(General – Non Substantial)
Dated: 03JUN2014

Sponsor’s representative(s)

- Medical Director
  Date: 
  Signature:
  
  Dr Richard ROCHE

- Clinical Study Manager
  Date: 
  Signature:
  Gaëlle ALCARAZ

Study Coordinating Investigator:

  Pr Savina NODARI
  11/06/2014

Clinical study protocol amendment n° PA04 Version 1
(General – Non Substantial)
Date: 03JUN2014
Page 3 on 12
COUNTRY COORDINATING INVESTIGATOR SIGNATURE FORM

STUDY: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Clinical Study Protocol Amendment n° PA04 Version 1
(General – Non Substantial)
Dated: 03JUN2014

Country Coordinating Investigator: Date: Signature:
INVESTIGATOR SIGNATURE FORM

STUDY: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Clinical Study Protocol Amendment n° PA04 Version 1
(General – Non Substantial)
Dated: 03JUN2014

By my signature below, I, Dr __________________________, hereby confirm that I have read, taken note of (and will apply) the modifications brought by the protocol amendment n° PA04 and I will conduct the trial according to these new modalities.

Date: __________________________                Signature: __________________________
<table>
<thead>
<tr>
<th>Nº</th>
<th>TYPE</th>
<th>APPLICATION AREA</th>
<th>DATE</th>
<th>MODIFICATIONS</th>
</tr>
</thead>
</table>
| NA  | NA            | General          | NA         | Following French CA request (ANSM) and leading to protocol version 2:  
- Add of a non inclusion criteria: "Breast-feeding female patient"  
- Add of haematology examination at visit 3 and 6                                                                                                                                         |
| PA01| Substantial   | Local (Italy)    | 01MAR2013  | Corresponding to Protocol Version 3:  
- Integration of the modification included in the protocol version 2  
- Harmonisation of the protocol and the Informed Consent Form:  
  * adjustment of the selection criteria n°10 related to the contraception method  
  * addition of a letter that is given by the patient to his/her general practitioner (GP)  
  * precision that the sponsor can not collect a copy of the Informed Consent Form  
  * precision that the patient card is in Italian language only (without any English mention)                                                                                               |
| PA02| Non Substantial | General         | 28MAR2013  | Corresponding to Protocol Version 4:  
- change of Sponsor’s Representative (Clinical Study Manager),  
- modification of the technical handling of the blood samples for determination of red blood cells concentration of DHA: the centrifugation is no more needed,  
- precision on the function and address of the International Study Coordinator Pr Nodari,  
- add of address and contacts details of two CRO newly involved in the study: Theradis (in charge of transportation of blood samples to the Analytical centre and material supply) and “Clinact” (in charge of refund of patients expenses linked to the study),  
- adjustment of the wording, in agreement with the commitment to the French Ethics Committee. In the paragraphe 8.3.2.1, the wording “hematology examination” is replaced by "standard hematologic dosage",  
- precision of the full title in the study synopsis (in agreement with the commitment to the Spanish Ethics Committee),  
- correction of a mistake in section 8.1.1.3 (related to TTEM transmission) and sections 3, 9 and study synopsis (related to the definition of INR not stabilized),  
- addition of the changes included in the local italian substantial protocol amendment (i.e: contraception method, letter to General Practitioner, patient card in Italian and no collection of the consent form by the sponsor in Italy). |
1. AMENDMENT RATIONALE

The purpose of this non-substantial amendment is to clarify or specify some points of the protocol. Theses changes do not affect the balance of the risk and benefits in the study nor change the specific aims or design of the study.
## 2. CHANGES DESCRIPTION

<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SYNOPSIS</strong></td>
<td><strong>SYNOPSIS</strong></td>
</tr>
<tr>
<td><strong>Study Schedule:</strong></td>
<td><strong>Study Schedule:</strong></td>
</tr>
<tr>
<td>- V2/ D1: Inclusion visit (start of treatment)</td>
<td>- V2/ D1: Inclusion visit (start of <strong>study</strong> treatment)</td>
</tr>
<tr>
<td><strong>Evaluation Criteria:</strong></td>
<td><strong>Evaluation Criteria:</strong></td>
</tr>
<tr>
<td>Efficacy evaluation variables:</td>
<td>Efficacy evaluation variables:</td>
</tr>
<tr>
<td>- Assessment of spontaneous cardioversion</td>
<td>- Assessment of spontaneous cardioversion</td>
</tr>
<tr>
<td>- Assessment of successful cardioversion</td>
<td>- Assessment of successful cardioversion</td>
</tr>
<tr>
<td>- Number of patients needing an other cardioversion after the initial ECV</td>
<td>- <strong>Shocks distribution (1, 2 or 3 shocks)</strong></td>
</tr>
<tr>
<td>- Number of patients needing an other cardioversion after the initial ECV</td>
<td>- Number of patients needing an other cardioversion after the initial ECV</td>
</tr>
<tr>
<td><strong>Other:</strong></td>
<td><strong>Other:</strong></td>
</tr>
<tr>
<td>- Evolution of echocardiographic parameters (from V4 to V6 and V9)</td>
<td>- Evolution of echocardiographic parameters (at V4, V6 and V9)</td>
</tr>
<tr>
<td>(Left atrial diameter (mm), Left atrial area (cm²), Left atrial volume (mL), Left ventricular ejection fraction (%), Left ventricular end diastolic volume/BSA (mL/m²), Left ventricular end systolic volume/BSA(mL/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL))</td>
<td>(Left atrial diameter (mm), Left atrial area (cm²), Left atrial volume (mL), Left ventricular ejection fraction (%), Left ventricular end diastolic volume/BSA (mL/m²), Left ventricular end systolic volume/BSA(mL/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL), Left ventricular end systolic diameter (mm), Left ventricular end systolic volume (mL))</td>
</tr>
<tr>
<td>- Physical examination (body weight)</td>
<td>- Physical examination (body weight, <strong>body surface area</strong>)</td>
</tr>
<tr>
<td>- Standard 12-lead ECG: heart rate (bpm), PR (ms), QRS (ms), QT (ms), repolarisation patterns (ECG not centralized)</td>
<td>- Standard 12-lead ECG: heart rate (bpm), PR (ms), QRS (ms), QT (ms), QTcB (ms), QTcF (ms), repolarisation patterns (ECG not centralized)</td>
</tr>
<tr>
<td><strong>Safety criteria:</strong></td>
<td><strong>Safety criteria:</strong></td>
</tr>
<tr>
<td>- Adverse events (observed and / or spontaneously reported)</td>
<td>- Adverse events (observed and / or spontaneously reported)</td>
</tr>
<tr>
<td>- Vital signs (Blood pressure (supine and standing), heart rate)</td>
<td>- Vital signs (Blood pressure (supine and standing), heart rate)</td>
</tr>
<tr>
<td>- Physical examination (body weight)</td>
<td>- Physical examination (body weight, <strong>body surface area</strong>)</td>
</tr>
<tr>
<td>- Standard 12-lead ECG: heart rate (bpm), PR (ms), QRS (ms), QT (ms), QTcB (ms), QTcF (ms), repolarisation patterns (ECG not centralized)</td>
<td></td>
</tr>
</tbody>
</table>

**Concomitant treatments**

**Compliance**
4. STUDY DESIGN
4.1 OVERALL DESCRIPTION

[...] After a 1 to 4-week of run-in period without treatment, patients will be randomised into one of the following treatment groups: F373280 1 g or placebo for 24 weeks.

Nine visits are planned for the study:
- Visit 1 (V1): W-4 to W-1: Selection visit (7 to 28 days before the Inclusion Visit)
- Visit 2 (V2): D1: Inclusion visit (start of treatment)

8. EVALUATION CRITERIA
8.1 PRIMARY EFFICACY CRITERION

8.1.1.3 Evaluation Methods

[...] Trans Telephonic ECG Monitoring:

The ECG follow up will be documented using the TTEM: daily transmission from visit 4 (week 5) to visit 5 (week 8). Then every two days from visit 5 (week 8) to visit 9 (week 24 – End of study).

[...] The cardiologist interpretation will be faxed to the site.

8.1.2.4 Cardioversion assessment

[...] Shock distribution (1, 2 or 3 shocks)
8.2. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA

8.2.2 Blood samples

8.2.2.2. Technical handling

Two blood samples (4 ml) will be collected in EDTA tubes. They will be gently shaken, stored at +4°C (no freezing will be allowed) and sent to Analytical Centre in refrigerated conditions (between +2°C and +8°C). Analysis will be performed within 2 weeks following reception at the Analytical Centre.

8.3. SAFETY ASSESSMENT

8.3.3 Global physical examination

A global physical examination including the measurement of body weight will be carried out on each body system at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.

The physical examination will be globally evaluated as “normal/abnormal”. Further target inspection will be undertaken for any abnormal finding.

8.3.5. Electrocardiogram (ECG)

8.3.5.1. Schedule

An ECG will be recorded at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9 using an usual standardised 12-lead cardiograph.

8.3.5.2. Technical Procedure and Parameters

- Electrocardiogram:

The global interpretation from manual reading (normality, clinical relevance) and HR (bpm), PR (ms), QRS (ms), QT (ms), repolarisation patterns will be reported in the e-CRF.
### 8.3.7. Concomitant Treatments

### 8.4. COMPLIANCE

The patient will be reminded at each visit to bring back at the following visit any used or unused remaining soft capsule, blister and case.

At each visit, the Investigator will record the number of supplied and remaining soft capsules in the e-CRF.

### 9. STUDY PROCEDURES

#### Visit 4 (Week 5: D35 -2/+7 days)

[...]

The patient will be requested to perform daily transmission from week 6 to week 8, then every 2 days from week 9 to week 24.

#### Visit 5 (Week 8: D56 ± 7 days) – Visit 6 (Week 12: D84 ± 7 days) – Visit 7 (Week 16: D112 ± 7 days) – Visit 8 (Week 20: D140 ± 7 days)

[...]

The cardiac monitoring will be continued using a TTEM device. The device will be given to the patient who will be requested to perform daily transmission from week 6 to week 8, then every 2 days from week 9 to week 24.

#### Visit 5 (Week 8: D56 ± 7 days) – Visit 6 (Week 12: D84 ± 7 days) – Visit 7 (Week 16: D112 ± 7 days) – Visit 8 (Week 20: D140 ± 7 days)

[...]

The cardiac monitoring will be continued using a TTEM device. The device will be given to the patient who will be requested to perform daily transmission from the day after visit 4 (week 6) to visit 5 (week 8), then every two days from the day after visit 5 (week 9) to visit 9 (week 24 – End of study).
<table>
<thead>
<tr>
<th>13. STATISTICAL ANALYSIS</th>
<th>13. STATISTICAL ANALYSIS</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.11. INTERIM ANALYSIS AND DATA MONITORING</td>
<td>13.11. INTERIM ANALYSIS AND DATA MONITORING</td>
</tr>
<tr>
<td>No interim analysis is planned.</td>
<td>No analyses of efficacy data are planned for IDMC that ensures that the overall probability of type I error is controlled. No Type I error and sample size adjustments are necessary. Any recommendations of the IDMC to alter study conduct will be based on safety, so IDMC monitoring of the study will not affect the statistical operating characteristics of the final analysis. The IDMC will review, three times during the study period (after the first 30 subjects will have been randomized, when the first 80 subjects will have terminated their study participation and when 130 subjects will have terminated their study participation), safety data results across treatment groups and judges whether the overall safety and feasibility (not futility) of the trial remain acceptable.</td>
</tr>
</tbody>
</table>
CLINICAL STUDY PROTOCOL

Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

F373280 / Soft Capsules / 1g

Pierre Fabre Study Code: F 373280 CA 2 01
EudraCT Number: 2012 – 003487 - 48

Sponsor's Representative: Gaëlle ALCARAZ
INSTITUT DE RECHERCHE PIERRE FABRE - Centre de R&D Pierre Fabre - BP 13562
3 avenue Hubert Curien
31035 TOULOUSE Cèdex 1, FRANCE
Phone: +33 5 34 50 62 16
Fax:+33 5 34 50 69 69
E-mail:gaelle.alcaraz@pierre-fabre.com

Study Coordinating Investigator: Pr Savina NODARI
Associate Professor of Cardiology
Department of Clinical and Surgical Specialities, Radiological Science and Public Health
Section of Cardiovascular Diseases
University Medical School and Spedali Civili Hospital of Brescia
c/o Spedali Civili di Brescia
Piazzale Spedali Civili, 1
25123 - BRESCIA, ITALY
Phone: +39 030 3996 587 – +39 030 393849
Fax: +39 030 3700 359
E-mail: savinanodari@gmail.com; nodari@med.unibs.it

Version 7 – 03JUN2014

The information contained in this document is confidential and is the property of the Sponsor, Pierre Fabre Medicament. This information is given for the needs of the study and must not be disclosed without prior written consent of the Sponsor Pierre Fabre Medicament. Persons to whom this information is given for the needs of the study must be informed that it is confidential and must not be disclosed.
**SPONSOR PERSONNEL**

**PIERRE FABRE MEDICAMENT**  
represented by  
Institut de Recherche Pierre Fabre

**Clinical Study Manager (Monitor)**

**Gaëlle ALCARAZ**  
Institut de Recherche Pierre Fabre  
Centre de R&D Pierre Fabre  
BP 13 562  
3, Avenue Hubert Curien  
31035 TOULOUSE Cedex 1, FRANCE

Phone: +33 5 34 50 62 16  
Fax: + 33 5 34 50 69 69  
E-mail: gaelle.alcaraz@pierre-fabre.com

**Medical Director**

**Richard ROCHE, MD**  
Institut de Recherche Pierre Fabre  
Centre de R&D Pierre Fabre  
BP 13 562  
3, Avenue Hubert Curien  
31035 TOULOUSE Cedex 1, FRANCE

Phone: +33 5 34 50 61 94  
Fax: +33 5 34 50 69 69  
E-mail: richard.roche@pierre-fabre.com
CONTRACT RESEARCH ORGANISATIONS

For Feasibility, Monitoring and Regulatory issues:
Pharmaceutical Service Network (PSN)
Rufino Gonzalez
28 037 Madrid - SPAIN
Phone: +34 91 375 6930 - Fax: +34 91 375 6931
E-mail: www.psnglobal.org

For Feasibility, Monitoring and Regulatory issues (in Spain):
Alpha Bioresearch
Paseo de la Castellana, 163 - 2º Izquierda
28 046 Madrid - SPAIN
Phone: +34 91 745 2520 - Fax: +34 91 745 0653
E-mail: teresa.bricio@alphabioresearch.com

For Centralised Randomisation and Electronic Case Report Form
S-Clinica
6, Chaussée de Boondael
B-1050 Brussels - BELGIUM
Phone: +32 2 645 0567 - Fax: +32 2 645 0569
E-mail: irena.seredina@s-clinica.com

For Centralised Reading of Holder ECG and TTEM and equipment supply:
Biomedical System
1945 Chaussée de Wavre
B-1160 Brussels - BELGIUM
Phone: +32 2 661 20 70 - Fax: +32 2 661 20 71
E-mail: sjacobs@biomedsys.com

For intra erythrocyte DHA dosage:
Agrocampus Ouest
Laboratoire de Biochimie
65 rue de Saint Brieuc – CS 84215
35042 RENNES Cedex - FRANCE
Phone: +33 2 23 48 55 49 - Fax: +33 2 23 48 55 50
E-mail: daniel.catheline@agrocampus-ouest.fr

For transportation of blood sample to the Analytical centre (Agrocampus) and material supply:
Theradis Pharma
41, chemin des Presses
06800 CAGNES-SUR-MER – FRANCE
Phone: +33 (0)4 97 02 07 07 - Fax: +33 (0)4 97 10 08 78
E-mail: chantal.raffy@theradis.pharma.com
For refund of patients expenses linked to the study (in France):
CLINACT
6-10 rue TROYON
92310 SEVRES – FRANCE
Phone: +33 1 46 90 27 27 - Fax: +33 1 46 23 01 56
Email: sebastien.beaumont@clinact.com
Protocol F 373280 CA 2 01

APPROVAL FORM
Protocol Version 7 – 03 JUN2014

Sponsor’s Representative:  

Medical Director:  
Richard ROCHE, MD  

Date: 06/06/14  Signature:

Study Coordinating Investigator:  
Savina NODARI, MD  

Date:  
Signature:
Protocol F 373280 CA 2 01

APPROVAL FORM
Protocol Version 7 – 03 JUN2014

Sponsor’s Representative:

Medical Director:
Richard ROCHE, MD

Date: 
Signature:

Study Coordinating Investigator:
Savina NODARI, MD

Date: 
Signature: 

11/06/2014

F373280 Clinical Study Protocol – Version 7 – 03 JUN2014
Country: ……………………

Country Coordinating Investigator:

<table>
<thead>
<tr>
<th>&quot;Name&quot;</th>
<th>Date:</th>
<th>Signature:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
By my signature below, I, Dr / Pr "            ", hereby confirm that I agree:

- to conduct the trial described in the protocol F 373280 CA 2 01, dated 03 June 2014 in compliance with GCP, with applicable regulatory requirements and with the protocol agreed upon by the Sponsor Pierre Fabre Médicament and given approval / favourable* opinion by the Ethics Committee;
- to document the delegation of significant study-related tasks and to notify the Sponsor of changes in site personnel involved in the study;
- to comply with the procedure for data recording and reporting;
- to allow monitoring, auditing and inspection;
- to retain the trial-related essential documents until the Sponsor informs that these documents are no longer needed.

Furthermore, I hereby confirm that I will have and will use the available adequate resources, personnel and facilities for conduct this trial.

I have been informed that certain regulatory authorities require the Sponsor Pierre Fabre Médicament to obtain and supply details about the investigator’s ownership interest in the Sponsor or the study drug, and more generally about his/her financial relationships with the Sponsor. The Sponsor will use and disclose the information solely for the purpose of complying with regulatory requirements.

Hence I agree:

- to supply the Sponsor with any information regarding ownership interest and financial relationships with the Sponsor (including those of my spouse and dependent children);
- to promptly update this information if any relevant changes occur during the course of the study and for 1 year following completion of the study;
- that the Sponsor may disclose this information about such ownership interests and financial relationships to regulatory authorities.

* To be adapted

Date:                     Signature:
## TABLE OF CONTENTS OF CLINICAL STUDY PROTOCOL

1. **INTRODUCTION AND STUDY RATIONALE** ................................................................ 22
   1.1. TARGET PATHOLOGY AND THERAPY ................................................................. 22
   1.2. INFORMATION ON THE TEST PRODUCT .............................................................. 24
   1.2.1. Chemical and pharmaceutical characteristics .................................................. 25
   1.2.1.1. Nomenclature and structure ........................................................................... 25
   1.2.1.2. Physical and chemical general properties ....................................................... 25
   1.2.2. Non-clinical Data .............................................................................................. 26
   1.2.2.1. Pharmacological profile .................................................................................. 26
   1.2.2.2. Safety pharmacology ..................................................................................... 27
   1.2.2.3. Toxicology profile ......................................................................................... 27
   1.2.2.4. Pharmacokinetic data ..................................................................................... 27
   1.2.3. Clinical data ..................................................................................................... 27
   1.3. STUDY RATIONALE ............................................................................................. 30
   1.4. OVERALL RISK AND BENEFIT ASSESSMENT ................................................... 30

2. **STUDY OBJECTIVES** ............................................................................................... 33
   2.1. PRIMARY OBJECTIVE .......................................................................................... 33
   2.2. SECONDARY OBJECTIVES .................................................................................. 33

3. **ETHICAL CONSIDERATIONS RELATING TO THE STUDY** ............................... 33

4. **STUDY DESIGN** ...................................................................................................... 35
   4.1. OVERALL DESCRIPTION ...................................................................................... 35
   4.2. DISCUSSION OF THE STUDY DESIGN ................................................................. 35
   4.2.1. Choice of the Study Population ........................................................................ 35
   4.2.2. Choice of the Study Design ............................................................................. 36
   4.2.3. Choice of the Dose ......................................................................................... 38
   4.2.4. Choice of the Sample Size ............................................................................. 38

5. **STUDY POPULATION** ........................................................................................... 38
   5.1. INCLUSION CRITERIA .......................................................................................... 38
   5.2. NON INCLUSION CRITERIA ................................................................................. 39
   5.3. NUMBER OF PATIENTS ....................................................................................... 40
   5.4. RECRUITMENT MODALITIES ............................................................................. 41
   5.5. PATIENT IDENTIFICATION ............................................................................... 41
   5.6. WITHDRAWAL CRITERIA ................................................................................... 41
   5.7. REPLACEMENT OF PATIENTS .......................................................................... 42
   5.8. POST-STUDY EXCLUSION PERIOD .................................................................... 42
   5.9. STUDY CARD AND LETTER FOR GENERAL PRACTITIONER(S) ..................... 42
6. STUDY TREATMENT ......................................................................................................... 43
6.1. SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT .................................................................................................................. 43
6.2. PACKAGING AND LABELLING ..................................................................................... 43
6.2.1. Packaging .................................................................................................................. 44
6.2.2. Labelling .................................................................................................................... 44
6.3. DISTRIBUTION TO CENTRE AND STORAGE ............................................................. 45
6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT ................... 46
6.5. DRUG ADMINISTRATION ........................................................................................... 47
6.5.1. Duration of Treatment ............................................................................................... 47
6.5.2. Dose Schedule ........................................................................................................... 47
6.5.3. Route and Conditions of Administration ................................................................. 47
6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT ...................................................................................... 47
6.7. RECALL OF INVESTIGATIONAL PRODUCTS ............................................................. 48
7. CONCOMITANT TREATMENTS ..................................................................................... 48
7.1. ANTI-VITAMIN K TREATMENT ..................................................................................... 49
7.2. PROHIBITED TREATMENTS ........................................................................................ 49
7.3. AUTHORISED TREATMENTS ....................................................................................... 49
8. EVALUATION CRITERIA ................................................................................................. 50
8.1. PRIMARY EFFICACY CRITERION ................................................................................. 50
8.1.1. Time to the first Atrial Fibrillation Recurrence ................................................................. 50
8.1.1.1. Definition ................................................................................................................ 50
8.1.1.2. Schedule ..................................................................................................................... 50
8.1.1.3. Evaluation Methods ..................................................................................................... 50
8.1.2. Secondary Efficacy Criteria .......................................................................................... 51
8.1.2.1. Numbers of AF episodes in the first week following visit 3 (ECV visit) ...................... 51
8.1.2.2. Duration of AF episodes in the first week following visit 3 (ECV visit) ...................... 52
8.1.2.3. Clinical parameters evaluation .................................................................................... 52
8.1.2.4. Cardioversion assessment ......................................................................................... 53
8.1.2.5. Evolution of echocardiographic parameters ................................................................ 53
8.2. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA ......................................................................................................................... 54
8.2.1. Definition ................................................................................................................... 54
8.2.2. Blood samples ............................................................................................................ 54
8.2.2.1. Collection schedule ..................................................................................................... 54
8.2.2.2. Technical handling ..................................................................................................... 55
8.2.3. DHA concentration measurement ................................................................................. 55
8.3. SAFETY ASSESSMENT ................................................................................................. 55
8.3.1. Adverse Events ............................................................................................................ 55
8.3.2. Laboratory Investigations ........................................................................................... 56
12.3. DATA CODING .................................................................................................................. 74
12.4. DATA STORAGE ............................................................................................................... 74
12.5. DATABASE LOCK ............................................................................................................. 74

13. STATISTICAL ANALYSIS ................................................................................................. 74

13.1. GENERAL CONSIDERATIONS ......................................................................................... 75
13.2. SAMPLE SIZE ..................................................................................................................... 75
13.3. PROTOCOL DEVIATIONS ................................................................................................ 75
13.4. DATA SETS ANALYSED .................................................................................................. 76
13.5. HANDLING OF DROPOUTS AND MISSING DATA ..................................................... 76
13.5.1. Dropouts ............................................................................................................................ 76
13.5.2. Repositioning of Visits ...................................................................................................... 76
13.5.3. Missing Data ...................................................................................................................... 76
13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS ..................................... 77

13.7. EFFICACY ANALYSIS ...................................................................................................... 77

13.7.1. Primary Criterion ............................................................................................................... 77
13.7.1.1. Primary Analysis ............................................................................................................ 77
13.7.1.2. Supportive Analysis ....................................................................................................... 77
13.7.2. Secondary Criteria ............................................................................................................. 78
13.7.2.1. Numbers of Atrial Fibrillation Episodes ........................................................................ 78
13.7.2.2. Duration of Atrial Fibrillation Episodes ........................................................................ 78
13.7.2.3. Time to first AF recurrence less than 10 minutes or symptomatic .................................. 78
13.7.2.4. Clinical parameters evaluation ....................................................................................... 78
13.7.2.5. Biomarker analysis: red blood cell concentrations of DHA ........................................... 79

13.8. SAFETY ANALYSIS .......................................................................................................... 79

13.8.1. Adverse Events .................................................................................................................. 79
13.8.2. Clinical Laboratory Evaluation ......................................................................................... 81
13.8.3. Global Physical Examination ............................................................................................ 82
13.8.4. Vital Signs, Physical Findings and Other Observations Related to Safety ....................... 82
13.8.4.1. Vital Sign Measurements Over Time ............................................................................. 82
13.8.4.2. Body weight ................................................................................................................... 82
13.8.4.3. Individual Patient Changes ............................................................................................. 83
13.8.5. ECG ................................................................................................................................... 83
13.8.6. Coagulation parameters ..................................................................................................... 83

13.9. CONCOMITANT TREATMENTS ....................................................................................... 83
13.10. COMPLIANCE ................................................................................................................. 84

13.11. INTERIM ANALYSIS AND DATA MONITORING ........................................................ 84

14. GENERAL ETHICAL CONSIDERATIONS ........................................................................ 84

14.1. ETHICAL CONDITIONS ................................................................................................... 84
14.2. ETHICS COMMITTEE AND LEGAL REQUIREMENTS ................................................... 85
14.3. PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM .................. 85
14.4. PERSONAL DATA PROTECTION ....................................................................................... 86
**SYNOPSIS**

<table>
<thead>
<tr>
<th>Name of Sponsor:</th>
<th>Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Finished Product:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Name of Active Substance:</td>
<td>F373280 (Panthenyl-Ester of DHA)</td>
</tr>
<tr>
<td>Title of the Study:</td>
<td>Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure. <em>International, multicentric, randomised, double-blind, placebo controlled study</em></td>
</tr>
<tr>
<td>Abbreviated Title:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Study Coordinating Investigator:</td>
<td>Pr Savina NODARI</td>
</tr>
<tr>
<td>Study Centres:</td>
<td>International, multicentric</td>
</tr>
<tr>
<td>Publication / Rationale:</td>
<td>F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation (AF) patients with chronic heart failure. The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of AF induced by burst pacing [1]. Moreover, the effectiveness of PolyUnsaturated Fatty Acid (PUFA) has been proven in the following conditions: prevention of AF recurrence in patients with persistent AF, in co-administration with amiodarone (add on therapy) [2]; improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]. Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent atrial fibrillation and chronic heart failure. This phase IIa study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after electrical cardioversion (ECV) in patients with persistent atrial fibrillation and chronic heart failure.</td>
</tr>
<tr>
<td>Planned Study Period:</td>
<td>January 2013 – January 2015</td>
</tr>
<tr>
<td>Clinical Phase:</td>
<td>IIa</td>
</tr>
<tr>
<td>Objectives:</td>
<td><strong>Primary:</strong></td>
</tr>
<tr>
<td></td>
<td>- Efficacy of F373280 on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure</td>
</tr>
<tr>
<td></td>
<td><strong>Secondary:</strong></td>
</tr>
<tr>
<td></td>
<td>- Efficacy of F373280 on the efficiency of direct electrical cardioversion</td>
</tr>
<tr>
<td></td>
<td>- Effect of F373280 on echocardiographic parameters</td>
</tr>
<tr>
<td></td>
<td>- Safety and tolerability of F373280</td>
</tr>
<tr>
<td>Methodology:</td>
<td>- International, multicentre, randomised, double-blind, placebo-controlled</td>
</tr>
<tr>
<td></td>
<td>- Selection period</td>
</tr>
<tr>
<td></td>
<td>- Start of treatment 4 weeks before ECV</td>
</tr>
<tr>
<td></td>
<td>- Condition to ECV:</td>
</tr>
<tr>
<td></td>
<td>- INR 2-3 anti-vitamin K should be given at least 3 weeks before ECV)</td>
</tr>
<tr>
<td></td>
<td>- No spontaneous cardioversion before ECV</td>
</tr>
<tr>
<td></td>
<td>- Follow-up 20 weeks after visit 3 (ECV visit)</td>
</tr>
<tr>
<td></td>
<td>- Condition: successful ECV or spontaneous CV</td>
</tr>
<tr>
<td></td>
<td>- Cardiac monitoring:</td>
</tr>
<tr>
<td></td>
<td>- 7-days continuous ECG ambulatory recording (Holter ECG) between visit 3 (ECV visit) and visit 4 (week 5) in patients with sinusal rhythm</td>
</tr>
<tr>
<td></td>
<td>- TTEM: daily transmission from week 6 to week 8; then every two days from week 9 to week 24, and in case of AF symptoms</td>
</tr>
<tr>
<td></td>
<td>- Treatment duration: 24 weeks</td>
</tr>
<tr>
<td>Study Schedule:</td>
<td>9 visits will be scheduled:</td>
</tr>
<tr>
<td></td>
<td>- V1/W-4 to W-1: selection visit (7 to 28 days before the inclusion visit)</td>
</tr>
<tr>
<td></td>
<td>- V2/D1: Inclusion visit (start of study treatment)</td>
</tr>
<tr>
<td></td>
<td>- V3/ W4 (D28 -2/+7 days): cardioversion visit (outpatient or hospitalization according to...</td>
</tr>
</tbody>
</table>
clinical practice of the centre) (installation of the Holter device)
- V4/ W5 (D35 -2/+7 days): follow-up visit (removing of the Holter device and installation of the TTEM)
- V5/ W8 (D56± 7 days): follow-up visit
- V6/ W12 (D84 ± 7 days): follow-up visit
- V7/ W16 (D112 ± 7 days): follow-up visit
- V8/ W20 (D140 ± 7 days): follow-up visit
- V9/ W24 (D168 ± 7 days): final study visit

<table>
<thead>
<tr>
<th>Number of Patients:</th>
<th>76 x 2 patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnosis and Criteria for Inclusion:</td>
<td><strong>Inclusion Criteria:</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Demographic Characteristics and Other Baseline Characteristics:</strong></td>
</tr>
<tr>
<td></td>
<td>1. Men or women aged more than 18 years (inclusive)</td>
</tr>
<tr>
<td></td>
<td>2. Patients with current episode of persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted</td>
</tr>
<tr>
<td></td>
<td>3. History of first documented persistent AF less than 3 years.</td>
</tr>
<tr>
<td></td>
<td>4. History of ischemic or non ischemic heart failure</td>
</tr>
<tr>
<td></td>
<td>5. NYHA class I or II chronic heart failure at selection and at inclusion</td>
</tr>
<tr>
<td></td>
<td>6. Reduced left ventricular ejection fraction between 30% and 45% inclusive (using the two-dimensional echocardiography biplane Simpson’s rule) at selection and at inclusion</td>
</tr>
<tr>
<td></td>
<td>7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers</td>
</tr>
<tr>
<td></td>
<td>8. Left atrial area ≤ 40 cm² at selection and at inclusion</td>
</tr>
<tr>
<td></td>
<td>9. Patients treated or having to be treated by anti-vitamin K</td>
</tr>
<tr>
<td></td>
<td>10. For female patient of child-bearing potential: in all the countries except Italy:</td>
</tr>
<tr>
<td></td>
<td>- use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator, for at least 2 months before the selection in the study, and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment</td>
</tr>
<tr>
<td></td>
<td>- documented as surgically sterilized</td>
</tr>
<tr>
<td></td>
<td>in Italy only:</td>
</tr>
<tr>
<td></td>
<td>- absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or</td>
</tr>
<tr>
<td></td>
<td>- use of double barrier contraception method (use of effective medical contraception method) from at least 2 months before the start of the study to the entire duration of the study and for a month after the end of the study or</td>
</tr>
<tr>
<td></td>
<td>- documented as surgically sterilized</td>
</tr>
<tr>
<td></td>
<td>11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion</td>
</tr>
<tr>
<td></td>
<td>12. For male with a child-bearing potential partner (In Italy only):</td>
</tr>
<tr>
<td></td>
<td>- Absolute abstention from sexual intercourse during the whole duration of the study and for 3 months after the end of the study or</td>
</tr>
<tr>
<td></td>
<td>- use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to 3 months after the end of the study.</td>
</tr>
<tr>
<td><strong>Ethical/legal considerations:</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>13. Having signed his/her written informed consent,</td>
</tr>
<tr>
<td></td>
<td>14. Affiliated to a social security system, or is beneficiary (if applicable in the national regulation)</td>
</tr>
<tr>
<td><strong>Non-Inclusion Criteria:</strong></td>
<td><strong>Criteria related to pathologies:</strong></td>
</tr>
<tr>
<td></td>
<td>1. History of first documented episode of persistent AF more than 3 years</td>
</tr>
</tbody>
</table>
| | 2. More than two successful cardioversions (electrical or pharmacological) in the last 6
1. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV)
2. NYHA class III or IV heart failure at selection or at inclusion
3. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be checked in case of treatment for thyroid disease
4. Myocardial infarction or unstable angina or presence of unstable ischemic coronaropathy assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
5. Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration rate < 30 mL/min) at selection
6. Bradycardia (HR ≤ 50 bpm)
7. Hyperkalemia or hypokalemia (according to the standards of local laboratories) at selection
8. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be checked in case of treatment for thyroid disease
9. Myocardial infarction or unstable angina or presence of unstable ischemic coronaropathy assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
10. Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration rate < 30 mL/min) at selection
11. Previous ineffective pharmacological or electrical cardioversion
12. Concomitant treatment with ranolazine or any antiarrhythmic drug (within 7 days prior to selection), except stable dose of digoxin, betablockers, calcium-blockers
13. Oral amiodarone:
   13a Previous treatment with oral amiodarone within 4 months prior to inclusion
   13b Intake of oral amiodarone for more than 1 month within 4 to 12 months before inclusion
14. Previous treatment with intravenous amiodarone within 4 weeks prior to inclusion
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT implantation within the last 6 months
16. Treatment with any Polyunsaturated Fatty Acid (PUFA) within the last 3 months
17. Dietary supplement with ω-3 or ω-6 according to investigator’s judgement
18. Having undergone any form of ablation therapy for AF
19. Patient treated with other anticoagulant treatment than antivitamin K: thrombin inhibitor such as Dabigatran or treated with antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel

Other criteria:
20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection
22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself/herself to its constraints
23. Patient family member or work associate (secretary, nurse, technician,..) of the Investigator
24. Patient having forfeited his / her freedom by administrative or legal award or being under guardianship
25. Breastfeeding female patient

Exclusion criteria before V3:
Patients not stabilized for INR (i.e. values are not between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed in the same day (before ECV). ECV will be performed in patients without dyskalemia.
If necessary for obtaining stabilized INR between 2 and 3, the ECV (and following visits) could be postponed by 7 days.

Test Product: F373280
Dose: Soft Capsules
Mode of Administration: Arm with 1g of F373280
Oral, one capsule each evening with dinner.
**Duration of Treatment:**
24 weeks of treatment exposure with F373280 (25 weeks if ECV postponed by 1 week)

**Reference Therapy**
Placebo soft capsules
Placebo will be administered in the same conditions as the tested product.

**Mode of Administration:**
Oral, one capsule each evening with dinner

**Evaluation Criteria:**

**Efficacy evaluation variables:**

**Primary evaluation variable:**
- Time to first Atrial Fibrillation recurrence defined by the first episode of AF lasting for at least 10 minutes (Follow up of 20 weeks after visit 3 (ECV visit)).
Handling of AF recurrences: 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) between visit 3 (ECV visit) and visit 4 (week 5). Then, the follow up will be documented using the TTEM: daily transmission from week 6 to week 8. Then, every two days from week 9 to week 24.
For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF will be assessed after visit 3 (week 5).
Moreover, during this TTEM period, if patient experiences any AF symptoms, it should be recorded and documented using the TTEM.
All ECG traces will be evaluated by a Central Reading Laboratory.

**Secondary evaluation variables:**
During the 7-day continuous ECG monitoring,
- Numbers of AF episodes
- Duration of AF episodes

**Clinical parameters:**
During the whole study:
- Number of recurrence of symptomatic AF episodes
- EHRA score
- Hospitalization for cardiovascular events
- Hospitalization for thromboembolic stroke
- All causes of hospitalization

**Cardioversion:**
- Assessment of spontaneous cardioversion
- Assessment of successful cardioversion
- Shocks distribution (1, 2 or 3 shocks)
- Number of patients needing an other cardioversion after the initial ECV

**Other:**
- Evolution of echocardiographic parameters (at V4, V6 and V9) (Left atrial diameter (mm), Left atrial area (cm²), Left atrial volume (mL), Left atrial volume/BSA (mL/m²), Left ventricular ejection fraction (%), Left ventricular end diastolic volume/BSA (mL/m²), Left ventricular end systolic volume/BSA(mL/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL) Left ventricular end systolic diameter (mm), Left ventricular end systolic volume (mL))
- Evolution of omega 3 index and intra erythrocyte DHA (*For this assessment samples will be centralized*).

**Safety criteria:**
- **Adverse events** (observed and / or spontaneously reported)
- **Vital signs** (Blood pressure (supine and standing), heart rate)
- **Physical examination** (body weight, body surface area)
- **Standard 12-lead ECG**: heart rate (bpm), PR (ms), QRS (ms), QT (ms), QTcB. (ms), QTcF. (ms), repolarisation patterns (ECG not centralized)
- **Haematology**: haematocrit, haemoglobin, red blood cell (RBC) count, white blood cell (WBC) count, WBC differential count, reticulocytes, platelets
- **Biochemistry**: sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol
(HDL, LDL), triglycerides, creatin phosphokinase (CPK) fibrinogen (*local laboratory*)

- **Coagulation parameters**: Activated partial thromboplastin time (aPTT), thrombin clotting time (TCT), INR (*local laboratory*), Prothrombine Time (*PT*)

Concomitant treatments

Compliance

<table>
<thead>
<tr>
<th>Statistical Methods:</th>
<th>Sample Size:</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Assuming an AF recurrence rate under placebo of 85%, a power of 80%, an alpha risk of 5% and a rate of not assessable patients of 15%, 76 randomised patients per group will be necessary, using a log-rank test of survival curves, a difference between groups of 20%.</td>
</tr>
</tbody>
</table>

**Primary Efficacy Analysis**
The primary analysis, performed on the Full Analysis Set (FAS: all randomised patients with at least one dose of treatment and with a successful cardioversion observed at visit 3), will be a survival analysis using the Kaplan Meier method and Cox regression model.

**Secondary Analyses**
All secondary efficacy criteria will be described and compared using appropriate tests on the FAS.

**Safety Analyses**
Descriptive statistics will be performed on the Safety Set (all randomised patients with at least one dose of treatment).
## STUDY FLOW-CHART

### F373280 CA 201

<table>
<thead>
<tr>
<th>Weeks</th>
<th>V1</th>
<th>V2</th>
<th>V3</th>
<th>V4</th>
<th>V5</th>
<th>V6</th>
<th>V7</th>
<th>V8</th>
<th>V9</th>
</tr>
</thead>
<tbody>
<tr>
<td>W-4 to W-1</td>
<td>D1</td>
<td>W4</td>
<td>W5</td>
<td>W8</td>
<td>W12</td>
<td>W16</td>
<td>W20</td>
<td>W24</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(28-2D/+7D)</td>
<td>(35-2D/+7D)</td>
<td>(56+/7D)</td>
<td>(84+/7D)</td>
<td>(112+/7D)</td>
<td>(140+/7D)</td>
<td>(168+/7D)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

| Outpatient or Hospitalization (1) | X |
| Informed consent                 | X |
| Demographic characteristics      | X |
| Medico-surgical history          | X |
| Concomitant disease              | X |
| Concomitant treatment            | X | X | X | X | X | X | X | X | X |
| Habits                           | X |
| Global physical examination (body weight) | X | X | X | X | X | X | X | X | X |
| Echocardiography                 | X | X | X | X | X | X | X | X | X |
| Eligibility criteria check       | X | X |
| Blood pressure, heart rate       | X | X | X | X | X | X | X | X | X |
| 12-Lead ECG Recording            | X | X | X | X | X | X | X | X | X |
| INR                               | X | X | X | X | X | X | X | X | X |
| aPTT, TCT                         | X | X | X | X | X | X | X | X | X |
| Biochemistry                      | X |
| Hematology                        | X | X | X | X | X | X | X | X | X |
| Urinary pregnancy test           | X | X | X | X | X | X | X | X | X |
| Red Blood Cell concentrations of DHA | X | X | X | X | X | X | X | X | X |
| Treatment allocation             | X |
| IVRS/IWRS                         | X | X | X | X | X | X | X | X | X |
| ECV (3)                           | X | X | X | X | X | X | X | X | X |
| Drug administration              | X |
| Adverse events recording         | X | X | X | X | X | X | X | X | X |
| Holter ECG (4)                   | X | X | X | X | X | X | X | X | X |
| TTEM (5)                          | X |

(1) Outpatient or hospitalization according to clinical practice of the centre (less or more than 24 hours)
(2) INR monitoring: INR 2 to 3 times a week, then weekly until the ECV, then every 4 weeks after ECV
(3) In patients with AF
(4) 24-hour Holter ECG
(5) 7-day Holter ECG
(6) TTEM: everyday from week 6 to week 8; then every 2 days from week 9 to week 24; at any time in case of AF symptoms.

In case of AF recurrence for at least 10 minutes and if the patient does not stop the study treatment, then TTEM once a week.
LIST OF ABBREVIATIONS

aPTT : Activated partial thromboplastin time
AE : Adverse event
AF : Atrial fibrillation
ALА : Alpha-linoleic acid
ALT : Alanine aminotransferase
AST : Aspartate aminotransferase
AUC : Area under the plasma concentration versus time curve
AUCinf : Total area under the curve extrapolated to infinity
AVK : Anti-vitamin K
βHCG : beta human chorionic gonadotrophin
BLQ : Below the limit of quantification
BMI : Body mass index
BP : Blood pressure
BSA : Body Surface Area
CEP : Protocol evaluation committee
CHMP : Committee for medicinal products for human use
Cmax : Maximum concentration
Cmin : Minimum concentration
CNALV : Clinically noteworthy abnormal laboratory value
CPK : Creatin phosphokinase
CPP : Comité de protection des personnes
CRA : Clinical research associate
CRT : Cardiac resynchronization therapy
CSC : “Clinically Significant Change”, i.e., Predefined potentially clinically significant change leading to a potentially clinically significant value (vital signs)
CV : Coefficient of variation
DBP : Diastolic blood pressure
DHA : Docosahexaenoic acid
EC : Ethics committee
ECG : Electrocardiogram
ECHO –TE : Trans-esophageal echocardiograph
ECV : Electrical cardioversion
EHRA : European heart rhythm association
EPA : Eicosapentaenoic acid
e-CRF : Electronic case report form
FAS : Full analysis set
Fe : Fraction of the administered drug excreted in urine
GCP : Good clinical practice
GFR : Glomerular Filtration Rate
HBs : Hepatitis B antigen
HCV : Hepatitis C virus
HDL : High density lipoprotein
HF  : Heart failure
HIV : Human immunodeficiency virus
HR  : Heart rate
ICH : International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use
IDMC: Independent data monitoring committee
INR : International normalized ratio
IRPF: Institut de Recherche Pierre Fabre
IVRS: Interactive voice response system
LAA : Left atrial area
LC/MS-MS: Liquid chromatography with tandem mass spectrometry
LDL : Low density lipoprotein
LOQ : Limit of quantification
LVEF : Left ventricular ejection fraction
MedDRA: Medical dictionary for regulatory activities
MR  : Mineralocorticoid receptor
MR perfusion: Magnetic Resonance perfusion
MTD : Maximum tolerated dose
N   : Number of determinations or replicates
NOAEL: No observed adverse effect level
NYHA: New York heart association
od  : Once a day
PC  : “Predefined Change”, i.e., Predefined potentially clinically significant change (lab or vital signs)
PCA : PC leading to an out-of-range value (lab values)
PFB : Pierre Fabre Biométrie
PSC : Potentially Clinically Significant Change
PSCV: Potentially Clinically Significant Value
PUFA: PolyUnsaturated fatty acid
p.o. : Per os
PP  : Per protocol data set
QTcB: QT interval using Bazett’s correction formula
QTcF: QT interval using Fridericia’s correction formula
RBC : Red blood cells
SAE : Serious adverse event
SBP : Systolic blood pressure
SD  : Standard deviation
T1/2 : Terminal half-life
T0  : Time of drug administration
Tmax: Time to reach the maximal concentration
TCT : Thrombin clotting time
TEAEs: Treatment emergent adverse events
TTEM : TransTelephonic ECG monitoring
WBC : White blood cells
WHO-DRUG: World health organization drug reference list
1. INTRODUCTION AND STUDY RATIONALE

1.1. TARGET PATHOLOGY AND THERAPY

Atrial Fibrillation (AF) is a supraventricular arrhythmia characterized by uncoordinated atrial electric activity with consequent deterioration of atrial mechanical function. It is the most common sustained cardiac rhythm disorder, increasing in prevalence with age. Haemodynamic impairment and thromboembolic events related to AF result in significant morbidity and mortality [7].

In 2009, Decision Resources estimated that there were 7.8 million diagnosed prevalent cases of AF in US, Europe and Japan. This age-related pathology should increase to 9.4 million cases in 2019.

Except for the conventional class I and class III anti-arrhythmic agents, the Polyunsaturated Fatty Acids (PUFAs) constitute one emerging antiarrhythmic therapy. These compounds potently address the AF substrate by directly targeting both the electrical and the structural remodelling of the deficient atria. The n-3 PUFAs, essential for human, are alpha-linoleic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). First, PUFAs specifically modulate ionic channels by fastening their inactivating mode which renders these compounds selective for pathological situations (such as AF) without any major effect in normal conditions. PUFAs are “open Kv1.5 channel blockers” leading to a lengthening of atrial action potential duration and are “persistent Na\\textsubscript{v1.5} channel blockers” leading to hyperpolarization of diastolic resting potential. Second, PUFAs influence structural remodelling through their anti-inflammatory effects as they directly compete with arachidonic acid in the production of inflammatory eicosanoids. In summary, PUFAs share unique, well-tolerated antiarrhythmic potential by interacting with the electrical and structural remodelling during sustained AF. In animal studies, it was recently demonstrated that DHA is particularly effective in pathologic conditions such as ischemia and/or AF.
The potential anti-arrhythmic effects of a PUFA were previously developed in AF: nicotinyl ester of DHA (pro-drug based on DHA delivery) was assessed in a two-week ventricular tachypaced canine model. Dogs were subjected to 4 weeks of medication prior to undergoing an electrophysiology study, and received either placebo or nicotinyl ester of DHA. Dogs were tachypaced at 240 beats per min for the final two weeks of the treatment plan. The results showed that the tested PUFA reduced the duration of AF induced by burst pacing, and the incidence of sustained AF, compared to dogs treated with the placebo [1].

In clinical practice, Nodari and coll [2] assessed n-3 PUFAs in the prevention of AF recurrences after electrical cardioversion (ECV). All included patients were treated with amiodarone and a renin-angiotensin-aldosterone system inhibitor. The 199 patients were assigned either to placebo or n-3 PUFAs 2 g/d and then underwent direct ECV 4 weeks later. The primary end point was the maintenance of sinus rhythm at 1 year after cardioversion. At the 1-year follow up, the maintenance of sinus rhythm was significantly higher in the n-3 PUFAs treated patients compared with the placebo group (hazard ratio, 0.62 [95% confidence interval, 0.52 to 0.72] and 0.36 [95% confidence interval, 0.26 to 0.46], respectively; p = 0.0001). The study concludes that in patients with persistent AF on amiodarone and a renin-angiotensin-aldosterone system inhibitor, the addition of n-3 PUFAs 2 g/d improves the probability of the maintenance of sinus rhythm after direct current cardioversion. Previously, during the World Congress of Cardiology in 2006, an abstract reported the effectiveness of PUFAs on top of traditional treatment (amiodarone, beta blockers, renin-angiotensin-aldosterone system inhibitor) in the prevention of AF relapses in patients having undergone ECV. In the PUFA group, AF relapses were significantly lower than in the placebo group at 1 month (3.3% vs 10%; p = 0.043), at 3 months (10% vs 25%; p = 0.004) and at 6 months (13.3% vs 40%; p < 0.0001) [19].

In contrast, in the general AF population (paroxystic atrial fibrillation and persistent atrial fibrillation), PUFAs failed to prove their efficacy [7] because of the absence of cardiac remodelling or because of a short pre-treatment duration before ECV (1 week) [8]. The effects of PUFAs were only observed in patients with persistent AF on add on therapy and after a sufficient pre-treatment before ECV. Persistent AF is commonly associated to heart failure. Previous studies performed in heart failure population demonstrated the benefit of PUFAs on the improvement of
Functional ventricular parameters and morbidity-mortality, and on the reduction of hospitalisation [3, 4, 5].

Nodari and coll [3] performed a trial in patients with chronic heart failure (NYHA I to III and LVEF< 45%). After a treatment of 133 patients with PUFAs (n=67) or placebo (n=66) at a dosage of 5 g/day for 1 month, then 2 g/day for 11 months, the n-3 PUFAs group and the placebo group differed significantly (p <0.001) in regard to:
- LVEF (increased by 10.4% and decreased by 5.0%, respectively)
- peak VO2 (increased by 6.2% and decreased by 4.5%, respectively)
- exercise duration (increased by 7.5% and decreased by 4.8%, respectively)
- mean New York Heart Association functional class (decreased from 1.88 +/- 0.33 to 1.61 +/- 0.49 and increased from 1.83 +/- 0.38 to 2.14 +/- 0.65, respectively).

The hospitalization rates for patients with HF were 6% in the n-3 PUFAs and 30% in the placebo group (p <0.0002).

Moertl and coll [4] performed a dose-ranging study in patients with a more severe chronic heart failure (NYHA III and IV and LVEF < 35%). It was a double-blind, randomised, controlled pilot trial in 43 patients treated with PUFAs or placebo for 3 months (1 g/d n3-PUFA (n = 14), 4 g/d n3-PUFA (n = 13), or placebo (n = 16)). After treatment, left ventricular ejection fraction increased in a dose-dependent manner (p = 0.01 for linear trend) in the 4 g/d (baseline vs 3 months [mean ± SD]: 24% ± 7% vs 29% ± 8%, p = 0.005) and 1 g/d treatment groups (24% ± 8% vs 27% ± 8%, p = 0.02).

No changes in any investigated parameters were noted with placebo.

Taking into account these studies performed with PUFAs, it seems that the best target for DHA is persistent AF in patients with heart failure. The aim of this proof of concept study is to assess in stand alone therapy (without association of other anti-arrhythmic treatments), the effect of F373280 in patients with persistent AF and heart failure in the maintenance of sinus rhythm after ECV.

1.2. INFORMATION ON THE TEST PRODUCT

F373280 or panthenyl ester of DHA is the mono-ester of panthotenic alcohol and DHA, selected to be developed for the management of AF.

F373280 is a prodrug of DHA.
A brief summary of F373280 known characteristics is presented in this section. For further details, please refer to the F373280 Investigator’s Brochure. [1]

1.2.1. Chemical and pharmaceutical characteristics

1.2.1.1. Nomenclature and structure

Chemical name (IUPAC):

\[(4Z,7Z,10Z,13Z,16Z,19Z)-3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido) \text{ propyl } \text{docosa-4,7,10,13,16,19-hexaenoate}\]

Structural formula:

![Structural formula of F373280]

Laboratory code: F373280

Molecular formula: \( \text{C}_{31}\text{H}_{49}\text{NO}_{5} \)

Molecular mass: 515.7

1.2.1.2. Physical and chemical general properties

Appearance: Clear oily viscous liquid

Solubilities:

- Water: Practically insoluble
- Alcohol: Very soluble
- Trimethylpentane: Slightly soluble
1.2.2. Non-clinical Data

Non-clinical data are exhaustively detailed in the Investigator’s brochure [1]. A brief summary is provided below.

1.2.2.1. Pharmacological profile

F373280 (mono-ester of panthotenic alcohol and DHA) is a novel pro-drug of DHA which exerts antiarrhythmic properties by interacting with the electrical and structural remodelling of the atria.

Experimental investigations were conducted in HEK293 cell line transfected with human Kv1.5 channel using the whole cell patch clamp technique to evaluate whether F373280 could block the sustained component of $I_{\text{Kv}1.5}$. F373280 concentration-dependently reduced Kv1.5 channel activity with an IC$_{50}$ value of 13.7 µM.

The effects of F373280 on atrial effective refractory period were investigated in anesthetized pig using a conventional pacing protocol through epicardial electrodes placed on the left atrium. F373280 administered as a bolus and an infusion (10 mg/kg) significantly increased atrial effective refractory period (23.8 ± 2.2 ms versus -7.3 ± 11.5 ms in the presence of vehicle, p < 0.05). In addition, F373280 was devoid of significant effect on the hemodynamic and the electrocardiogram (ECG) intervals.

Proof of the pharmacological concept was performed with a different DHA derivative named: Nicotinyl ester of DHA (pro-drug based on DHA delivery). Ventricular tachypacing-induced congestive heart failure provides a clinically-relevant animal model of AF associated with structural remodelling, as is often seen clinically. It has been shown that sustained oral PUFA administration suppresses congestive heart failure-induced AF-promotion and fibrosis in the ventricular tachypacing canine model. Nicotinyl ester of DHA was tested in this model, at 1 g/day and 5 g/day, during 4 weeks, to prevent congestive heart failure-related atrial structural remodelling and AF promotion in dogs. Nicotinyl ester of DHA dose dependently reduced heart failure-induced increases in AF duration (989 ± 111 sec, n=5 in the presence of placebo versus 637 ± 196 sec, n=5 in the presence of 1 g/kg/d Nicotinyl ester of DHA and 79 ± 51 sec, n=5, in the presence of 5 g/kg/d Nicotinyl ester of DHA). The protective effect of Nicotinyl ester of DHA was associated with a marked increase of plasma level of DHA and important incorporation of
DHA in the left atrial tissue. Because F373280 similarly to Nicotinyl ester of DHA increases plasma level of DHA, it could be estimated that the compound may exert a similar protective effect [1].

1.2.2.2. **Safety pharmacology**

A battery of safety pharmacology studies was performed to evaluate the effects of F373280 on the central nervous, cardiovascular and respiratory systems. Data of these studies are exhaustively detailed in the Investigator’s brochure [1]. No particular alerts were evidenced with F373280.

1.2.2.3. **Toxicology profile**

Concerning the toxicological data, 4-week and 26-week repeat-dose studies in rat and dog were performed. Compared to the high administered doses of F373280 (500 to 2000 mg/kg/day), low circulating concentrations of F373280 were measured.

During these toxicity studies, no toxicity was observed in rat after 4 and 26 weeks of dosing and in dog after 4 weeks of dosing. A NOAEL of 2000 mg/kg/day was established in these repeat toxicity studies.

During the 26-week toxicity study in dogs, the NOAEL was set at 1000 mg/kg/day based on changes observed on red blood cell parameters.

Based on toxicological profiles, F373280 is considered to support the proposed clinical trial.

1.2.2.4. **Pharmacokinetic data**

According to animal studies described in the Investigator’s brochure [1], the non-clinical pharmacokinetic profile of F373280 is not associated with particular alerts concerning the proposed clinical phase IIa study.

1.2.3. **Clinical data**

*Part A: single dose*
Six consecutive single ascending doses were tested (0.5 g, 1 g, 2 g, 4 g, 8 g and 16 g) on 6 independent cohorts of 8 subjects (6 verum + 2 placebo). 49 subjects were treated and 48 completed the study.

No Serious Adverse Events (SAE) occurred in the course of the study.

Regarding the reported Treatment Emergent Adverse Events (TEAEs) that were judged by the Investigator as having a causal relationship with the study drug administration in the absence of an alternative explanation, 3 TEAEs were observed in the placebo group (palpitation, dizziness in standing position, symptomatic orthostatic hypotension without loss of consciousness) and 4 in the group of F373280 at the dosage of 16 g (meteorism, liquid stool, symptomatic orthostatic hypotension and dizziness in standing position). None of these adverse events (AE) were reported in the groups of F373280 at the dosages of 0.5 g, 1 g, 2 g, 4 g and 8 g.

After a single administration of the different tested doses no difference between the tested product and placebo has been reported, regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters (related to coagulation: platelets and fibrinogen) and coagulation parameters (bleeding time, prothrombin time/INR, activated partial thromboplastin time, thrombin clotting time). Variations of these parameters were within the physiological ranges.

After single oral administration of F373280 from 0.5 g to 16 g in 36 young healthy male subjects (6 per dose level), the following was observed:

- **F373280**: Whatever the tested dose there is no circulating F373280 in plasma: only few, sparse and non consecutive samples with quantifiable level of F373280 close to LOQ were observed. This confirms that F373280 is a prodrug.

- **Panthenol**: Cmax and AUC increased with the administered dose between 0.5 and 16 g. Panthenol concentrations were rapidly cleared from plasma with a mean terminal half-life around 2 hours.

- **DHA**: after 0.5 and 1 g, low increased in DHA plasma concentrations compared to the baseline levels led to a high inter-individual variability of the corresponding Pharmacokinetics parameters. Plasma exposure in DHA increased with the administered dose between 2 and 16 g with no departure from proportionality (baseline corrected parameters).
**Part B: Multiple doses**

Three consecutive repeated ascending doses (1, 2 and 4 g) were tested on 3 independent cohorts of 12 subjects (9 verum + 3 placebo, double blind). 36 subjects completed the study. Each treatment was administered over a period of 28 days. Pharmacokinetic parameters were assessed over a period of 14 days.

Among the TEAE judged by the investigator as suspected to F373280, 5/9 TEAEs were classified according the System Organ Class in vascular system disorder with orthostatic hypotension (2 in the 1 g group, 1 in the 2 g group and 2 in the 4 g group) and 4/9 were classified in nervous system disorder with 3 dizziness (2 in the 2 g group and 1 in the 4 g group) and 1 migraine (in the 1 g group). These TEAEs have already been reported with PUFAs and are commonly observed in phase I studies.

After a repeated administration of the different tested doses, no difference between the tested products and placebo was reported regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters. The assessment of coagulation parameters and platelet function after administration of repeated dose of F373280 did not report any bleeding issue. The reported changes in coagulation parameters and platelet function were within physiological ranges.

After a 14-day repeated oral administration of F373280 from 1 g to 4 g, the following was observed:

- **Panthenol**: Cmax and AUC increased with the administered dose between 1 and 4 g. No accumulation of panthenol in plasma was observed.

- **DHA**: Plasma exposure increased with dose. A 2-fold accumulation in total plasma exposure of DHA was observed after 14 days of administration, whatever the administered dose.
1.3. STUDY RATIONALE

F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after ECV in persistent AF patients with chronic heart failure.

The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of AF induced by burst pacing [1].

Moreover, the effectiveness of PUFAs has been proven in the following conditions:

- Prevention of AF recurrence in patients with persistent AF in co-administration with amiodarone (add on therapy) [2],

- Improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5].

Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent AF and chronic heart failure.

This phase IIa study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after ECV in patients with persistent AF and chronic heart failure.

1.4. OVERALL RISK AND BENEFIT ASSESSMENT

F373280 is a new pro-drug of DHA.

DHA is a well-known long chain PUFAs with a long-term clinical experience in cardiovascular diseases. DHA is contained in several medicinal products such as Omacor®, (1 g of Omacor contains about 320 mg of DHA acid) marketed by Laboratoires Pierre Fabre for hypertriglyceridemia and as an adjuvant treatment for secondary prevention after myocardial infarction. According to the summary product characteristics of Omacor® [9]:

- The frequencies of adverse reactions are ranked according to the following: common (>1/100, <1/10); uncommon (>1/1000, <1/100); rare (>1/10000, <1/1000); very rare (<1/10000), not known (cannot be estimated from the available data).
- The reported adverse events are:

  - Infection and infestations:
    Uncommon: gastroenteritis

  - Immune system disorders:
    Uncommon: hypersensitivity

  - Metabolism and nutrition disorders:
    Rare: hyperglycaemia

  - Nervous system disorders:
    Uncommon: dizziness, dysgeusia
    Rare: headache

  - Vascular disorders:
    Very rare: hypotension

  - Respiratory thoracic and mediastinal disorders:
    Very rare: nasal dryness

  - Gastrointestinal disorders:
    Common: dyspepsia, nausea
    Uncommon: abdominal pain, gastrointestinal disorders, gastritis, abdominal pain upper
    Rare: gastrointestinal pain
    Very rare: lower gastrointestinal haemorrhage

  - Hepatobiliary disorders:
    Rare: hepatic disorders

  - Skin and subcutaneous tissue disorders:
    Rare: acne, rash pruritic
    Very rare: urticaria

  - General disorders and administration site conditions:
    Rare: malaise sensation

  - Investigations:
    Very rare: white blood count increased, blood lactate dehydrogenase increased

Moderate elevation of transaminases has been reported in patients with hypertriglyceridaemia.
Panthenol is a well-known substance with a long-term experience in medical, nutraceutic and cosmetic uses. According to the summary product characteristics of a product such as Bépanthene® (tablet indicated in alopecia) which contains panthenol (100 mg), adverse event observed are rare cases of urticaria and erythema [10]. Panthenol is metabolised in panthotenic acid, i.e. B5 vitamin.

Concerning toxicological studies performed results can support the administration of F373280 in the proposed clinical phase II study without particular alert [1].

Any safety warning was reported during a phase I study performed with F373280 administered to 84 healthy volunteers in single dose in a range between 500 mg and 16 g or in repeated dose during 28 days in a range between 1 g and 4 g. Adverse events reported and related to study treatment were minor to moderate. The adverse events were palpitations, orthostatic hypotension, dizziness, meteorism and liquid stool. Most were reported in both groups (placebo and F373280) without a dose relationship. The assessment of coagulation parameters and platelet function after administration of repeated dose of F373280 did not report any bleeding concern: the reported changes in coagulation parameters and platelet function were within physiological ranges.

Moreover, DHA has been associated with anticoagulant products in AF studies [2, 8]. The range of PUFAs doses tested was between 2 g to 3 g (640 mg to 960 mg of DHA) and the range of study durations between 6 to 12 months. This association did not report a significant side effect of bleeding.

DHA has already been used in HF patients in several studies without safety concern [3, 4, 5]. The range of PUFAs doses tested was between 1 g to 5 g (1 g of the tested PUFAs contains about 320 mg of DHA acid) and the range of study durations was between 3 months to 3.9 years.

Thus, inclusion of patients with no specific antiarrhythmic treatment is acceptable. They will receive an anticoagulant treatment to prevent the thrombo-embolic complications of AF (particularly stroke) and the adequate treatments to control the heart rate and heart failure.

In conclusion, the overall available data allow in safe conditions the treatment of patients with persistent AF and chronic heart failure with F373280 in safe conditions.
2. STUDY OBJECTIVES

2.1. PRIMARY OBJECTIVE

The primary objective of the study is to assess the efficacy of F373280 on the maintenance of sinus rhythm after direct ECV in patients with persistent AF and chronic heart failure.

2.2. SECONDARY OBJECTIVES

The secondary objectives of the study are to assess:

- the efficacy of F373280 on the efficiency of direct ECV
- the effect of F373280 on echocardiographic parameters
- the safety and tolerability of F373280

3. ETHICAL CONSIDERATIONS RELATING TO THE STUDY

The trial is conducted according to Good Clinical Practices (CPMP/ICH/135/95), the National regulations and the Declaration of Helsinki and its subsequent amendments (see Appendix 17.1). This protocol and the informed consent form will be submitted for approval to independent local or national Institutional Review Boards/Ethics Committees before the study set up, according to national regulation.

All the protocol amendments or critical events liable to increase the risks incurred by the patients or to compromise the validity of the study or patients' rights will be submitted to the coordinator and to the Ethics Committees.

After being informed orally and in writing of all potential risks and constraints of the trial, as well as their freedom to withdraw their participation at any time, patients will then sign a consent form.

A time of reflection will be given to the patients, before giving a written consent and starting the study procedures.

The use of a placebo is in accordance with EMA Addendum to the guideline on antiarrhythmics on AF and atrial flutter (EMA/CHMP/EWP/213056/2010) [21] and is acceptable because the
included patients will remain under the standard treatment of AF and chronic heart failure. Except antiarrythmics, they will receive anticoagulant (anti-vitamin K), rate control treatment, chronic heart failure treatment. During the study, in case of AF recurrence that would require cardioversion or the introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms for instance, patients will be withdrawn and the tested product stopped. These patients will be considered as treatment failure.

In this study, patients will be carefully screened, particularly for their cardiac condition, with ECG, 24-hour holter monitor and echocardiographic data, and their biologic and coagulation condition.

The study will be addressed only to patients requiring an ECV due to their persistent AF, in the following conditions:

- ECV in patients not presenting a contra-indication
- Anticoagulation with anti-vitamin K (AVK) for at least 3 weeks before ECV
- ECV in patients with stabilized INR (i.e. values between 2 and 3;sp to ) on at least 3 consecutive weekly tests performed. Patients not stabilized for INR (i.e. values not between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed in the same day (before ECV). Patients who do not revert to sinus rhythm or present an early relapse within the observation period after ECV will be withdrawn and the tested product stopped.

During the whole study, patients will remain under medical control: visits in cardiology units will be scheduled at least every month. This follow up will include clinical signs, ECG, biological and coagulation parameters. Moreover, patient’s cardiac rhythm will be monitored between visits using daily, then every 2 days Trans Telephonic ECG Monitoring (TTEM) reviewed by a Central Reading Laboratory.
Patients may withdraw from the study at any time without having to give a reason and can expect to receive regular conventional therapy.

4. STUDY DESIGN

4.1. OVERALL DESCRIPTION

This phase IIa trial will be conducted as an international, multicentric, 24 weeks, double-blind, placebo-controlled, randomised, parallel group design, trial in 152 patients suffering from persistent AF and chronic heart failure.

After a 1 to 4-week of run-in period without study treatment, patients will be randomised into one of the following treatment groups: F373280 1 g or placebo for 24 weeks.

Nine visits are planned for the study:

- Visit 1 (V1): W-4 to W-1: Selection visit (7 to 28 days before the Inclusion Visit)
- Visit 2 (V2): D1: Inclusion visit (start of study treatment)
- Visit 3 (V3): W4 (D28 -2/+7D): cardioversion visit (outpatient or hospitalization according to clinical practice of the centre) (installation of the Holter ECG device)
- Visit 4 (V4): W5 (D35 -2/+7D): follow-up visit (removing of Holter ECG device and installation of the TTEM)
- Visit 5 (V5): W8 (D56 ± 7D): follow-up visit
- Visit 6 (V6): W12 (D84 ± 7D): follow-up visit
- Visit 7 (V7): W16 (D112 ± 7D): follow-up visit
- Visit 8 (V8): W20 (D140 ± 7D): follow-up visit
- Visit 9 (V9): W24 (D168 ± 7D): final study visit

4.2. DISCUSSION OF THE STUDY DESIGN

4.2.1. Choice of the Study Population

The target indication of F373280 will be the maintenance of sinus rhythm after cardioversion of patients with persistent AF and chronic heart failure. In the present proof of concept study, the evaluation will focus on patients within this indication. This target population is justified by:
The proved efficacy of PUFAs in patients with persistent AF with or without heart failure in co-administration with amiodarone (add on therapy) [2]

The proved efficacy of PUFAs on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]

The study aim is to investigate the product effect in patients with:

- Persistent AF history (less than three years) with a duration of the current episode from 7 days to 6 months.
- a moderately abnormal systolic heart failure (Left Ventricular Ejection Fraction (LVEF) between 30 to 45% as defined in the report from the American Society of Echocardiography’s Guideline). According to a sub-group analysis performed in patients with persistent AF associated to heart failure (Nodari S. personal data), PUFAs would be effective to prevent recurrence of AF after cardioversion in patients with moderately abnormal LVEF.
- a Left Atrial Area (LAA) not severely abnormal (less than 40 cm² as defined in the report from the American Society of Echocardiography’s Guideline). According to a sub-group analysis performed in patients with persistent AF associated to heart failure (Nodari S. personal data), PUFAs would not be effective to prevent recurrence of AF after cardioversion of patients with severely abnormal LAA.

For the successful rate of ECV, patients should have a stable medical treatment of heart failure and should not have any myocardial infarction or unstable angina or unstable ischemic coronaryopathy assessed by coronaryography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection.

4.2.2. Choice of the Study Design

As the target indication would be the prevention of AF recurrence after ECV, the study design meets the requirements of EMA guideline on antiarrhythmics in AF (EMA/CHMP/EWP/213056/2010) [21].
As F373280 aims to be a safe treatment for the prevention of AF recurrence, it will not be tested as an add-on therapy during the study. To avoid any interaction with the tested product, antiarrhythmic class I and III will be forbidden during the study.

The study design is defined in order to avoid methodological bias. A double blind study is appropriate to assess the efficacy and safety of the use of F373280 to prevent recurrence of AF episodes. Moreover, this study design is similar to the design of almost all trials that have assessed intervention for rhythm control [2, 8, 11, 12].

According to the target indication, only patients with persistent AF and requiring an ECV will be included in order to assess the time to first documented recurrence of AF since cardioversion.

To confirm the persistent nature of AF, a 24-hour holter monitoring will be performed during the selection visit.

Eligible participants will enter a selection phase in which anticoagulant treatment (AVK) will be adjusted to achieve an International Normalized Ratio (INR) of 2.0 to 3.0 before ECV. According to guidelines for the management of AF [6], AVK should be given at least 3 weeks before cardioversion because of risk of thrombo-embolism due to post-cardioversion.

Experimental data suggest that the maximal incorporation of n-3 PUFAs in the myocardial cell membrane takes up to 28 days to occur [22]. In addition, as shown in Nodari’s study [2], the duration of pre-treatment with PUFAs before cardioversion appears to be a contributing factor in success. Therefore, before starting follow up for the assessment of AF recurrence, treatment with F373280 should be started 28 days before ECV.

Detection of AF recurrence will be performed using systematic (scheduled) ECG recording, thus allowing detection of asymptomatic (about 50% of episodes) as well as symptomatic AF episodes. According to previous studies, most of AF recurrences occurred during the first days after cardioversion [11, 15]. So that, the heart rhythm will be closely monitored during the first week after successful cardioversion using an ambulatory continuous 7-day holter ECG recording in order to increase sensibility to detect asymptomatic AF episodes. Thereafter, to improve patient compliance, this follow up will be continued using an easier device to carry and to use, i.e. a TTEM.
Finally, during the study, patients will be scheduled for a clinical visit every month (with an additional visit 7 days after visit 3 (ECV visit)) in order to ensure a close medical monitoring and to assess efficacy and safety parameters.

4.2.3. Choice of the Dose

According to a previous study in patients with AF [2], the tested PUFA product (Omacor®) at the dose of 2 g (i.e. 640 mg of DHA acid) was effective in the prevention of AF after cardioversion. Moreover, PUFAs at dosage of 1 g and 2 g were also effective on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5].

From the F373280 phase I study, after a 14-day repeated administration of F373280 (1 g/day), observed plasma concentrations of DHA measured before treatment (Cmin) were similar to that of an effective dose of Omacor® at 2 g/day (60 to 95 mg/mL and 60 to 90 mg/mL, respectively) (phase I study of F373280 and [16]). With regard to the rhythm of administration, mean peak/trough fluctuation (baseline corrected) was around 0.3. This value supports an once-daily administration allowing a 24-hour plasma exposure in DHA. Therefore, a 1 g daily dose of F373280 is considered to be appropriate for this proof of concept study.

4.2.4. Choice of the Sample Size

See chapter 13.

5. STUDY POPULATION

Each patient fulfilling all the inclusion criteria and none of the non inclusion criteria will be eligible.

5.1. INCLUSION CRITERIA

Demographic Characteristics and Other Baseline Characteristics:

1. Men or women aged more than 18 years (inclusive)
2. Patient with current episode of persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted
3. History of first documented persistent AF less than 3 years
4. History of ischemic or non ischemic heart failure
5. NYHA class I or II chronic heart failure at selection and at inclusion
6. Reduced left ventricular ejection fraction between 30% and 45% inclusive (using the two-dimensional echocardiography biplane Simpson’s rule) at selection and at inclusion
7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers
8. Left atrial area ≤ 40 cm² at selection and at inclusion
9. Patient treated or having to be treated by anti-vitamin K
10. For female patient of child-bearing potential:
   - in all the countries except Italy:
     - use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator for at least 2 months before the selection in the study and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment or
     - documented as surgically sterilized
   - in Italy only:
     - absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
     - use of double barrier contraception method (use of effective medical contraception method) from at least 2 months before the start of the study to the entire duration of the study and for a month after the end of the study or
     - documented as surgically sterilized
11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion
12. For male with a child-bearing potential partner (in Italy only):
   - absolute abstention from sexual intercourse during the whole duration of the study and for 3 months after the end of the study or
   - use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to 3 months after the end of the study.

Ethical/legal considerations:
13. Having signed his/her written informed consent,
14. Affiliated to a social security system, or is a beneficiary (if applicable in the national regulation)

5.2. NON INCLUSION CRITERIA

Criteria related to pathologies:
1. History of first documented episode of persistent AF more than 3 years,
2. More than two successful cardioversions (electrical or pharmacological) in the last 6 months,
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV),
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be checked in case of
treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic coronaropathy
assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or
MR perfusion evaluation methods) within 6 months before selection
7. Severe chronic kidney disease (creatinine $\geq 25$ mg/L or estimated glomerular filtration rate $<
30$ mL/min) at selection
8. Bradycardia (HR $\leq 50$ bpm)
9. Hyperkalemia or hypokalemia (according to the standards of local laboratories) at selection
10. Cardiac surgery within 3 months before selection or planned during the study duration

Criteria related to treatments:
11. Previously ineffective pharmacological or electrical cardioversion
12. Concomitant treatment with ranolazine or any anti-arrhythmic drug (within 7 days prior to
selection), except stable dose of digoxin, beta-blockers, calcium-blockers.
13. Oral amiodarone:
   13a Previous treatment with oral amiodarone within 4 months prior to inclusion
   13b Intake of oral amiodarone for more than 1 month within 4 to 12 months before inclusion
14. Previous treatment with intravenous amiodarone within 4 weeks prior to inclusion
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT
implantation within the last 6 months
16. Treatment with any Polyunsaturated Fatted Acid within the last 3 months
   Dietary supplement with $\omega3$ or $\omega6$ according to investigator’s judgment
18. Having undergone any form of ablation therapy for AF
19. Patient treated with other anticoagulant treatment than antivitamin K: thrombin inhibitor such
as Dabigatran or treated with antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel

Others criteria:
20. Patient liable not to comply with protocol instructions and/or with treatment, in the
investigator’s opinion,
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at
the time of selection,
22. Patient linguistically or mentally unable to understand the nature, objectives and possible
consequences of the trial, or refusing to patient himself / herself to its constraints,
23. Patient family member or work associate (secretary, nurse, technician…) of the Investigator,
24. Patient having forfeited his / her freedom by administrative or legal award or being under
guardianship,

5.3. NUMBER OF PATIENTS

76 x 2 patients (taking into account 15 % of non evaluable patients).
5.4. RECRUITMENT MODALITIES

Patients will be recruited within the medical consultation of each centre involved in the study. If necessary and when authorized by local and national regulation, some specific supports or tools will be used to improve the recruitment (announcement, mailing to general practitioners, leaflet, website including ClinicalTrials.gov, CRO…).

Before implementation, the documents will be submitted to and approved by the Ethics Committee.

5.5. PATIENT IDENTIFICATION

Patient's code will contain 7 digits: the 2 first digits corresponding to the country number, the following 2 digits corresponding to the centre number and the last 3 digits corresponding to the patient's chronological order once having signed the written informed consent.

5.6. WITHDRAWAL CRITERIA

Reasons for a patient's premature withdrawal from the study may be the following:

- Patient's decision. A patient who wishes to withdraw from the study for any reason may do so at any time but must inform the investigator. In all cases, the Investigator should attempt to contact the patient as soon as possible for a final assessment in order to:
  - have the patient's decision written on the consent form
  - obtain the reason(s) for withdrawal and report it/them in the case report form
  - evaluate the patient's clinical condition
  - if necessary, take appropriate therapeutic measures: management of an adverse effect or concomitant disease, prescription of another treatment.

- Investigator's decision in the patient's interest, particularly if a serious adverse event occurs and is considered by the Investigator liable to threaten the health of the patient. The monitor will be informed by phone or fax and a letter or report explaining the withdrawal will be forwarded to the monitor as soon as possible.
• Erroneous inclusion according to the study protocol. Any inclusion not respecting inclusion/non inclusion criteria will immediately be withdrawn and an appropriate treatment will be given by the investigator under his/her responsibility. Erroneous inclusions will not be paid to the investigator.

• Patients who could not be treated with AVK for at least 3 weeks before ECV.

• Patients who will not have a stabilized INR between 2 and 3 on at least 3 consecutive weekly tests.

• Patients with only 2 consecutives INR tests between 2 and 3 in the last 3 weeks for whom a trans-oesphagoal echocardiography can not be performed before ECV or for whom a trans-oesphagoal echocardiography shows a thrombus in the atria.

• Patients who will not revert to sinus rhythm (i.e. unsuccessful ECV) or with early relapse within the observation period after ECV will be considered to have finished follow-up.

• Occurrence of AF recurrence that would require, at the investigator’s judgement, a cardioversion or an introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms for instance.

5.7. REPLACEMENT OF PATIENTS
Withdrawn patients will not be replaced.

5.8. POST-STUDY EXCLUSION PERIOD
Patients will not be allowed to participate to another clinical trial during 3 months following the study termination.

5.9. STUDY CARD AND LETTER FOR GENERAL PRACTITIONER(S)
The patient will receive from the Investigating Centre at Visit 1 - Selection Visit:

- a personal card to be kept all along the study duration and providing the following information: patient's name, sponsor's name, study code, EUDRACT number, start date and expected end date of the study, complete address of the Investigating Centre with the name and phone number of the
Investigator and a sponsor 24H/24 phone contact number in case of emergency (French and English languages): 33 (0)5 63 35 25 83. For Italy, this card will be in Italian only, without any English mention.

- in Italy, a letter to be given to his/her general practitioner. This letter intends to inform the general practitioner(s) (and any other doctors who take care of the patient) that the patient participates to the clinical study. It describes the study treatment and includes some information on the forbidden treatment during the study.

6. STUDY TREATMENT

The Clinical Pharmacy Department of the Institut de Recherche Pierre Fabre (IRPF) will supply the investigational centres with the treatment necessary for the conduct of the trial.

6.1. SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT

F373280 and placebo will be prepared in Soft Capsules similar presentation.

- F373280

Formulation of F373280, 1 g, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: Panthenyl ester of DHA, gelatine, glycerol, titanium, dioxide, purified water.

- Placebo

Formulation of placebo matching tested product, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: paraffin liquid, fish flavour, gelatine, glycerol, titanium, dioxide, purified water.

Placebo and F373280 capsules will be packaged in opaque blisters.

6.2. PACKAGING AND LABELLING

The treatment units will be packed and labelled by the Clinical Pharmacy Department of the IRPF according to European Directive and local requirements.
6.2.1. Packaging

Each treatment unit will be composed of 3 cases for a 12-week treatment period.

The Investigator will provide the patient with the treatment according to the following schedule:

At Inclusion Visit (V2): a 12-week treatment unit will contain 3 cases, each case containing:
   – 10 blister packs of four 1 g F373280 soft capsules or placebo soft capsules each.

At Visit 6 (V6): a 12-week treatment unit will contain 3 cases, each case containing:
   – 10 blister packs of four 1 g F373280 soft capsules or placebo soft capsules each.

6.2.2. Labelling

Investigational Products will be labelled according to the following rules:

Labelling should comply with the local requirements for Investigational Medicinal Products.

On the treatment units and cases, the labels will bear the following indications:
   a) name and address of the sponsor
   b) protocol number
   c) packaging batch number
   d) treatment number
   e) storage conditions
   f) expiry date
   g) pharmaceutical dose form
   h) route of administration
   i) quantity of dosage units
   j) direction for use
   k) legal statements:
      - “for clinical trial only”, “keep out of the reach and the sight of children”, “please return to
        your doctor any unused product”, respect the prescribed dose”

On the treatment unit, another label will be affixed with the mention of the Investigator’s name
and patient’s code (completed by the Investigator).

In addition, on each case will be mentioned the case number, and a detachable label will bear the
following indications:
   – Protocol number
   – Packaging batch number
   – Expiry date
– Case number
– Treatment number

On the blister pack, the label will mention the protocol number, the packaging batch number, the case number and the treatment number.

### 6.3. DISTRIBUTION TO CENTRE AND STORAGE

The Clinical Pharmacy Department of the IRPF will supply the Investigational Centre with the treatment units along the study according to the need, upon request triggered by the patient’s selection.

As soon as the Pharmacist or the Investigator receives the trial medication, he/she will check the contents and immediately acknowledges the receipt in the IVRS/IWRS. The copy of the acknowledgement will be kept in the Investigator’s or the Pharmacist’s file. The same procedure will be applied to all further supplies during the course of the trial.

At the time of the delivery to the Centre, the following information will be provided:

- Details of storage conditions that should be respected
- And, upon request and for the 1st delivery only, a letter of release for the Investigational Medicinal Product from the Sponsor's Qualified Person

The CRA will ensure during the monitoring visits that trial medications have been received in good conditions and the acknowledgment of receipt has been performed adequately.

Treatment units should remain intact until dispensation to the patients. They should be kept at temperature below 30°C in an appropriate lockable room only accessible to the person authorised to dispense them, under the responsibility of the Pharmacist or the Investigator.

In the case of undue delay in study execution, the Pharmacist or the Investigator should ensure that the expiry date has not been exceeded.
6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT

A randomisation list will be established by the Clinical Pharmacy Department of the IRPF. This list will be computer-generated with internal software. The randomisation methodology is validated by the Biometry Department before generation.

Treatments F373280 or placebo will be balanced in a 1:1 ratio.

As the treatment units are prepared for 12-week treatment periods, the Investigator will have to allocate a treatment number at inclusion visit (V2) and another one at visit 6.

For each patient, the treatment number given at visit 6 will not be the same that the one given at inclusion visit (V2).

The treatment numbers will be given through the IVRS/IWRS.

Practically, once patient’s eligibility is confirmed at selection visit (V1):

- The Investigator:
  - Contacts the IVRS/IWRS
  - Answers the questions relating to the patient
  - In return, the treatment number to be allocated for the first 12-week period to the patient is given by the IVRS/IWRS.

- The IVRS/IWRS company:
  - Confirms this information by fax/email to the Investigator
  - Fills the “Request for Delivery of Investigational Product” form and sends it by email and/or fax to the Clinical Pharmacy Department of the IRPF.

- The Clinical Pharmacy Department of the IRPF sends the corresponding treatment unit to the Investigator within 5 days from reception of the email request form.

The Investigator will dispense to the patient the case which label indicates the treatment number and the administration period.

At visit 6, the Investigator will contact again the IVRS/IWRS to obtain the treatment number for the last 12-week period of treatment according to the same process as described above.
6.5. **DRUG ADMINISTRATION**

6.5.1. **Duration of Treatment**

For a patient completing the study, the theoretical study treatment exposure to F373280 or placebo will be 24 weeks.

If the ECV is postponed by 1 week to allow INR stabilization, the treatment duration will be 25 weeks.

6.5.2. **Dose Schedule**

One soft capsule of 1g of F373280 or placebo to be taken each day during 24 weeks.

6.5.3. **Route and Conditions of Administration**

The soft capsules are to be taken orally. One soft capsule is to be taken each evening with the dinner during 24 weeks.

6.6. **ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT**

The Investigator should maintain accurate written records of drug received, dispensed, returned and any remaining treatment units, on the drug accountability form. These records should be made available for Clinical Research Associate (CRA) monitoring. The packaging of the medication should remain intact until just before the dispensation.

At each visit, the Investigator will record the number of soft capsules returned by each patient using the appropriate page of the e-CRF.

At the end of the study, all used and unused treatments including packaging should be noted, and return is organised by the CRA to the Clinical Pharmacy Department of the IRPF for destruction. A copy of the drug accountability form should be provided by the Investigator to the CRA.
6.7. RECALL OF INVESTIGATIONAL PRODUCTS

In case of recall of investigational products (decided by the Competent Authorities or the Sponsor), the Investigator will immediately be informed by the Sponsor.

The Investigator in collaboration with the Sponsor’s representatives (Study Manager, CRA) must urgently:

- Stop the delivery of the concerned investigational products to the patients.
- Inform the concerned patients that they must immediately stop taking these investigational products and bring them back.

The Study Manager/CRA organises the return of the recalled products to the Clinical Pharmacy Department of the IRPF according to the Sponsor’s procedures.

7. CONCOMITANT TREATMENTS

Any existing concomitant treatment (at selection visit), any new concomitant treatment or change in the dosage of an existing concomitant treatment during the course of the study must be noted on the electronic Case Report Forms (e-CRF). All treatments should be evaluated by the Investigator at patient’s selection, and treatment prolongation or stop during the study should be considered.

For all concomitant treatments taken during the study, the following information must be noted in the relevant section(s) of the e-CRF:

- The name of the treatment and its form
- The reason for prescription
- The route of administration
- The daily dose
- The duration of treatment.
7.1. **ANTI-VITAMIN K TREATMENT**

AVK should be given for at least 3 weeks before ECV and continued for the whole study duration. The AVK used will be left to the decision of the each Investigator according to his/her local practice.

7.2. **PROHIBITED TREATMENTS**

- Class I and class III antiarrhythmic treatments:
  - Class I: Disopyramide, Procainamide, Quinidine
  - Class IB: Lidocaine, Mexiletine
  - Class IC: Flecainide, Propafenone

- Class III: Dofetilide, Ibutilide, Sotalol, Amiodarone, Dronedarone.

- Ranolazine
- Any PUFA
- Any anticoagulant treatment other than AVK: thrombin inhibitor such as Dabigatran or antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel
- Dietary supplement with Omega 3 or Omega 6

Prohibited treatments at selection must not be prescribed for the duration of the study except in case of occurrence of an adverse event or AF episode that requires a corrective treatment in the interest of the patient’s health.

7.3. **AUTHORISED TREATMENTS**

Other treatments will be authorised during the study duration.

However, if medication other than study drugs is administered at any time from the start of the study, details must be recorded in the e-CRF. During the study, patients must be asked whether they have been on a course of prescribed drug treatment or have taken any OTC or herbal drugs since the visit.
8. EVALUATION CRITERIA

8.1. PRIMARY EFFICACY CRITERION

8.1.1. Time to the first Atrial Fibrillation Recurrence

8.1.1.1. Definition
Time to first AF recurrence is defined by the first episode of AF (symptomatic or not) lasting for at least 10 minutes.

8.1.1.2. Schedule
The heart rhythm follow up will be performed from the end of ECV visit (visit 3) to the final study visit (visit 9).

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF will be assessed after visit 3 (week 5).

8.1.1.3. Evaluation Methods

- 7-day holter monitor:

The heart rhythm monitoring will be carried out from visit 3 to visit 4 using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) fixed after ECV visit.

Following holter monitoring, the heart rhythm will be documented using Trans Telephonic ECG Monitoring (TTEM).

- Trans Telephonic ECG Monitoring:

The ECG follow up will be documented using the TTEM: daily transmission from the day after visit 4 (week 6) to visit 5 (week 8). Then every two days from the day after visit 5 (week 9) to visit 9 (week 24 – End of study).

Moreover, if patient experiences AF symptoms during this TTEM period, it should be documented using the TTEM.
In case of AF recurrence and provided that the patient does not required a cardioversion or an introduction of an anti-arrhythmic at Investigator’s judgement, the patient could be maintained in the study with the treatment in order to assess a spontaneous cardioversion. For that purpose the patient will continue to transmit a TTEM once a week.

The TTEM will be centralized by the Central Reading Laboratory. The patient will be requested to contact the Central Reading Laboratory for transmission of each stored TTEM. The TTEM will be validated by a trained technician, then analysed by a cardiologist. The cardiologist interpretation will be emailed to the site (or per fax on request of the site). The investigator will be asked to review and sign this document.

The TTEM process will be fully described in a separate document.

8.1.2. Secondary Efficacy Criteria

8.1.2.1. Numbers of AF episodes in the first week following visit 3 (ECV visit)

8.1.2.1.1. Definition

Number of AF episodes will consist in the assessment of AF episodes with duration at least 10 minutes (N_{Sup10}) and of less than 10 minutes (N_{Inf10}), respectively.

8.1.2.1.2. Schedule

The heart rhythm follow up will be performed from the end of successful ECV visit (visit 3) to the study visit 4.

8.1.2.1.3. Evaluation Methods

- 7-day holter monitor:

The heart rhythm monitoring will start using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) after ECV visit from visit 3 to visit 4.
8.1.2.2. **Duration of AF episodes in the first week following visit 3 (ECV visit)**

8.1.2.2.1. **Definition**

Duration of AF episodes will consist in the sum of duration of each AF episode.

8.1.2.2.2. **Schedule**

The heart rhythm follow up will be performed from the end of successful ECV visit (visit 3) to the follow up study visit (visit 4).

8.1.2.2.3. **Evaluation Methods**

Duration of AF episodes will be assessed using the 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording.

8.1.2.3. **Clinical parameters evaluation**

8.1.2.3.1. **EHRA score assessment**

8.1.2.3.1.1. **Definition**

AF related symptoms will be evaluated by the EHRA (European Heart Rhythm Association) score [20]. The following items “during presumed arrhythmia episodes” are checked to determine the score: palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety.

Classification of AF-related symptoms (EHRA score) are as follows:

- EHRA I - ‘No symptoms’
- EHRA II - ‘Mild symptoms’; normal daily activity not affected
- EHRA III - ‘Severe symptoms’; normal daily activity affected
- EHRA IV - ‘Disabling symptoms’; normal daily activity discontinued

This classification relates exclusively to the patient-reported symptoms.

In addition to this score, the frequency will be classified in three groups, namely occasionally (less than once per month), intermediate (1/month to almost daily) and frequent at least daily.
8.1.2.3.1.2. Schedule
EHRA evaluation will be performed in case of evocative symptoms of arrhythmia.

8.1.2.3.1.3. Evaluation Methods
EHRA evaluation will be collected by Central Reading Laboratory during all the study period.

8.1.2.3.2. *Number of recurrence of symptomatic AF*
It consists of the number of AF recurrences associated with a symptom (palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety) and confirmed by an ECG.

8.1.2.3.3. *Number and duration of hospitalizations*
- Number and duration of hospitalizations for cardiovascular events
  - Hospitalization for AF treatment
  - Hospitalization for worsening of heart failure
  - Hospitalization for myocardial infarction
  - All cause of hospitalization
- Number and duration of hospitalizations for thromboembolic stroke

8.1.2.4. *Cardioversion assessment*
- Assessment of spontaneous cardioversion before visit 3
- Assessment of successful cardioversion at visit 3 (i.e. return to sinus rhythm)
- Shocks distribution (1, 2 or 3 shocks)
- Number of patients needing another cardioversion after initial ECV

8.1.2.5. *Evolution of echocardiographic parameters*

8.1.2.5.1. *Definition*
The following echocardiographic parameters will be assessed: Left atrial diameter (mm), LAA (cm²), Left atrial volume (mL), Left atrial volume/BSA (mL/m²), LVEF (%), Left ventricular end diastolic volume/BSA (mL/m²), Left ventricular end systolic volume/BSA (mL/m²), Left
ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (mL), Left ventricular end systolic diameter (mm) and Left ventricular end systolic volume (mL).

8.1.2.5.2. **Schedule**

Measurements will be performed at visit 1 and visit 2 to check the eligibility of the patient.

Measurements performed at visit 4, visit 6 and visit 9 are done to follow the echocardiographic evolution of the patients in sinus rhythm.

8.1.2.5.3. **Evaluation method**

The echography evaluations will be carried out according to the recommendations for chamber quantification drawn up by the American Society of Echocardiography and the European Association of Echocardiography [23]. So, the recommended method for volume measurements is to use the biplane method of discs (modified Simpson’s rule) from 2-D measurement.

8.2. **BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA**

8.2.1. **Definition**

Because of the limited human tissue accessibility for biopsy, red blood cell DHA contents is a marker of tissue DHA concentration [13], [14].

8.2.2. **Blood samples**

8.2.2.1. **Collection schedule**

Blood samples will be collected to determine the red blood cells (RBC) concentrations of DHA.

Blood samples will be performed at visit 2 before treatment, visit 3, visit 6 and visit 9.

Actual sampling times will be individually reported in the e-CRFs.
8.2.2.2. **Technical handling**

Two blood samples (4 ml) will be collected in EDTA tubes. They will be gently shaken, stored between +2°C/+8°C in a fridge (no freezing will be allowed) and sent to Analytical Centre in refrigerated conditions (between +2°C and +8°C). Analysis will be performed within 2 weeks following reception at the Analytical Centre.

8.2.3. **DHA concentration measurement**

Analytical determination of RBC concentrations of DHA will be carried out by the Analytical Centre.

Lipids will be extracted from red blood cells samples with a mixture of hexane/isopropanol after acidification [17]. Total lipid extracts will be saponified and methylated. The fatty acid methyl esters (FAME) will be extracted and analyzed by Gas Chromatography.

Identification of FAME will be based on retention times obtained for FAME prepared from fatty acid standards. The area under peaks will be determined using ChemStation Software (Agilent) and results will be expressed as % of total fatty acids. DHA concentration will be calculated using the internal standard and expressed as µg/g for red blood cells samples. Thus, omega-3 index will be assessed. The omega-3 index represents the content of EPA plus DHA in red blood cells (expressed as a percent of total fatty acids). It is a biomarker considered as a new marker of risk for death from coronary disease [18].

Results of this analytical determination will be kept confidential by the dosing centre until the end of the study, and will be provided only at the end of the study (after database lock) in a separate file.

8.3. **SAFETY ASSESSMENT**

8.3.1. **Adverse Events**

At selection, any concomitant disease will be reported on the e-CRF. At each further visit, the occurrence of AEs since the last visit will be based on the patient's spontaneous reporting, the
8.3.2. Laboratory Investigations

8.3.2.1. Schedule

Laboratory investigations will be performed at visit 1 (before treatment) and visit 9 (end of treatment) or End of Treatment visit.

At visit 3 and 6, only a standard haematologic dosage will be performed.

Furthermore the kaliemia will be checked before electrical cardioversion at visit 3.

The total volume of blood samples taken for haematology and biochemistry analysis should not exceed 30 mL.

8.3.2.2. Technical Procedures and Parameters

The following tests will be performed:

**Haematology:** hematocrit, haemoglobin, RBC count, white blood cells (WBC) count, WBC differential counts (% and absolute), reticulocytes, platelets.

**Chemistry:** sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatine phosphokinase (CPK), fibrinogen.

Blood samples will be taken in the morning in fasting conditions.

The estimation of GFR at selection relies on the measurement of serum creatinine and the Cockcroft-Gault formula:

Cockcroft-Gault formula

- with serum creatinine expressed as mg/L:

  in men:
  
  $\text{GFR (mL/min)} = \left(\frac{(140-\text{age}) \times \text{weight}}{7.2 \times \text{serum creatinine in mg/L}}\right)$

  in women:
GFR (mL/min) = \[(140 - \text{age}) \times \text{weight} / (7.2 \times \text{serum creatinine in mg/L})\] \times 0.85

- with serum creatinine expressed as μmol/l:
GFR (mL/min) = \[(140 - \text{age}) \times \text{weight} / \text{serum creatinine in μmol/l}\] \times k, where k = 1.23 for men, 1.04 for women.

(weight in kg, age in years)

Additional tests may be done at the Investigator’s discretion, in the patient’s interest. In case of any abnormal or clinically significant results, the Investigator will order laboratory control tests.

8.3.3. Global Physical Examination

A global physical examination including the measurement of body weight will be carried out on each body system at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.

The Body surface area (BSA) will be calculated at the same visits using Mostellers’ formula:
BSA = \([\text{Weight} \times \text{Height}/3600]^{1/2}\)

(Weight in kg, height in cm)

The physical examination will be globally evaluated as “normal/abnormal”. Further target inspection will be undertaken for any abnormal finding.

8.3.4. Vital Signs

Vital signs will consist in blood pressure and heart rate at rest.

8.3.4.1. Schedule

Vital signs will be measured at each visit.

8.3.4.2. Technical Procedure and Parameters

Systolic blood pressure (SBP) and diastolic blood pressure (DBP), expressed in mmHg, will be measured after at least 5 minutes in supine position and after 2 minutes in standing position.
The heart rate (HR), expressed in beats per minute (bpm), will be measured by auscultation by counting the beats for at least 30 seconds, after at least 5 minutes in supine position and after 2 minutes in standing position.

Bodyweight will be measured with patient in underwear and with the same balance at each visit.

8.3.5. **Electrocardiogram (ECG)**

8.3.5.1. **Schedule**

An ECG will be recorded after at least 10 minutes of rest at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9 using an usual standardised 12-lead cardiograph.

8.3.5.2. **Technical Procedure and Parameters**

- Electrocardiogram:

The global interpretation from manual reading (normality, clinical relevance) and HR (bpm), PR (ms), QRS (ms), QT (ms), QTcB (ms), QTcF (ms), repolarisation patterns will be reported in the e-CRF. Each print-out will include the patient's code, date, time, technician's initials and investigator's signature.

In case of thermic paper ECG print out, a photocopy will be made by the centre to ensure safe filing.

- 24 hour-Holter - ECG

An ambulatory continuous 24-hour ECG (5-leads/2 or 3 channels) will be recorded at selection visit using a holter ECG, in order to confirm persistent AF.

8.3.6. **Coagulation parameters**

Coagulation assessment will be evaluated by the following parameters:

- Prothrombin Time/INR (PT/INR)
- Activated Partial Thromboplastin Time (aPTT)
- Thrombin Clotting Time (TCT)
During the pre-cardioversion period, if the anticoagulation by AVK should be initiated, then the INR monitoring will be as follow:

- INR 2-3 times a week for the first week of treatment
- INR weekly up to ECV
- INR every 4 weeks after ECV

For patients already treated with AVK, INR monitoring will be as follow:

- INR weekly up to ECV
- INR every 4 weeks after ECV

aPTT and TCT will be performed at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.

Anti-coagulation by AVK should be given at least 3 weeks before ECV and continued for the whole study duration.

The quantity of blood samples collected at each time for coagulation parameters will be 2 mL.

### 8.4. CONCOMITANT TREATMENTS

Concomitant treatments will be evaluated at each study visit.

Requirements relating to patient's concomitant treatments started before screening visit and continued throughout the trial, or started during the trial, can be found in section 7.

### 8.5. COMPLIANCE

The patient will be reminded at each visit to bring back at the following visit any used or unused remaining soft capsule, blister and case.

At each visit (except at visit 4), the Investigator will record the number of supplied and remaining soft capsules in the e-CRF.

### 9. STUDY PROCEDURES

Visit 1 - Selection Visit (Week -4 to Week -1)
The patient considered eligible for selection by the Investigator will be informed of the characteristics and the consequences of the trial both verbally and by reviewing the patient's information sheet and consent form (see section 14.3). If the patient accepts to participate in the study, he/she will sign the informed consent form and will keep a copy.

The patient will be assessed for the following:

- Demographic characteristics (gender, age, height, body surface area)
- Personal and medico-surgical history
- Habits (Tobacco, alcohol consumption, dietary habits including fish consumption…)
- Cardiovascular diseases, mainly detailed history of Heart Failure and AF characteristics
- Echocardiography using a two-dimensional echocardiography
- 12-lead ECG
- Concomitant diseases, adverse signs or symptoms (able to be used for treatment emergent AE determination)
- Concomitant treatments (authorised, disallowed)
- Global physical examination/bodyweight
- Vital signs
- Biology: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Biology assessment of renal function: creatinine or estimated glomerular filtration rate

If the results of the above assessments are compatible with the selection criteria

- A 24-hour continuous ECG ambulatory recording (Holter ECG) device will be installed on the patient to monitor the patient heart rhythm. The patient will be requested to bring back the device after the termination of 24 hours recording. The recording will be transmitted from the Investigational site to the Central Reading Laboratory. The Central
Reading Laboratory will send his/her assessment regarding the confirmation of persistent AF within 2 working days to the Investigator.

- The patient will enter the selection period in which anticoagulant (AVK) will be adjusted to achieve an International Normalized Ratio (INR) of 2 to 3 before ECV.

At the end of the visit, the Investigator will contact the IVRS/IWRS to confirm the patient selection (which will automatically order the treatment delivery) and organise the appointment for the next visit.

The patient will receive from the investigational centre the study card to be kept for the duration of the study.

**Visit 2 - Inclusion Visit (Day 1)**

If the patient's behaviour during the selection period and/or the result of complementary examinations particularly the confirmation of the presence of persistent AF by the Central Reading Laboratory during this period, the INR and laboratory tests, are compatible with the inclusion criteria, the patient will be assessed for the following:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: red blood cell concentrations of DHA and coagulation parameters Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Global Physical examination/bodyweight
- Vital signs
- Echocardiography using a two-dimensional echocardiography
- 12-lead ECG
- Urine pregnancy test for women of child bearing potential
If the results of the above assessments are compatible with the inclusion criteria, the patient will be included and allocated a treatment number using the IVRS/IWRS.

Between this Inclusion visit and the next visit (V3), the INR will be closely monitored (refer to paragraph 8.3.6) in order to ensure that the INR is stable (between 2 to 3 before electrical cardioversion).

At the end of the visit, the Investigator will organise the appointment for the next visit and will give the treatment for the next 4-week period.

**Visit 3 (Week 4: D28 -2/+7 days) cardioversion**

Patient will be assessed for the following criteria:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: Haematology, RBC concentrations of DHA, Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Global Physical examination /bodyweight
- Vital signs
- 12-lead ECG

- Electrocardioversion (ECV): ECV has to be scheduled 4 weeks after randomization and after target international normalized ratio levels will be stabilized (between 2 and 3) on at least 3 consecutive weekly tests in patients with AF. Patients not stabilized for INR (i.e. values not between 2 and 3) on at least 3 consecutive weekly tests before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE performed in the same day (and before ECV). ECV will be performed in the morning, with the patient in the fasting state and without dyskalemia. Anesthesia will be induced and patients will be cardioverted with administration of a synchronized, biphasic current. The initial shock will be set at 100 J if the body weight is less than 70 kg and at 150 J for higher body weights. Successful cardioversion will be defined as recovery of
sinus rhythm lasting at least 1 minute after the shock. If unsuccessful, a second 200-J shock, and eventually a third 200-J shock, will be administered. Failure of ECV is defined as the persistence of AF after the third attempt at cardioversion. After the procedure, patients will be monitored on telemetry for at least 6 hours before discharge. Patients who will not revert to sinus rhythm or with early relapse within the observation period after ECV will be withdrawn from the study and will be considered to have finished their follow-up.

At the end of the visit, a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) will be installed on the patient in order to monitor the patient heart rhythm after ECV.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week period.

Visit 4 (Week 5: D35 -2/+7 days)

After removal of the continuous ECG ambulatory device, the patient will be assessed for the following criteria:

- Assessment of AE
- Concomitant treatments (authorised, disallowed)
- Body weight (body weight measured at V3 to be used)
- Vitals Signs
- Echocardiography using a two-dimensional echocardiography

At the end of the visit, the patient will be given the TTEM device for cardiac monitoring. The patient will be clearly instructed on the frequency and modalities of transmission. The patient will be requested to perform daily transmission from the day after visit 4 (week 6) to visit 5 (week 8), then every two days from the day after visit 5 (week 9) to visit 9 (week 24 – End of study). Moreover, in case of AF symptoms, additional transmissions may be performed.
Visit 5 (Week 8: D56 ± 7 days) – Visit 6 (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days) - Visit 8 (Week 20: D140 ± 7 days)

Patient will be assessed for the following criteria:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT). However, in case of discontinuation of anticoagulation after ECV, the monitoring of INR, aPTT and TCT should be stopped.
- Global Physical examination/bodyweight
- Vital signs
- 12-lead ECG
- The cardiac monitoring will be continued using a TTEM device. The device will be given to the patient who will be requested to perform daily transmission from the day after visit 4 (week 6) to visit 5 (week 8), then every two days from the day after visit 5 (week 9) to visit 9 (week 24 – End of study). Moreover, in case of AF symptoms, additional transmissions may be performed.

The Investigator will collect all unused cases, blisters and soft capsules, and will count the unused capsules for each 4-week treatment period.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week treatment period.

In addition:

- at visit 6:
  - the investigator will contact the IVRS/IWRS to obtain the treatment unit number to be dispensed at visit 6 for the last 12-week period.
End-of-Study Visit - Visit 9 (Week 24: D168 ± 7 days)

Patient will be assessed for the following:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Global Physical examination/bodyweight
- Vital signs
- 12-lead ECG
- Laboratory examination: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT), Red blood cell concentration of DHA.
- Urine pregnancy test for women of childbearing potential
- Echocardiography using a two-dimensional echocardiography

The Investigator will collect all unused cases, blisters and soft capsules, and will count the unused soft capsules.

10. ADVERSE EVENTS: DEFINITION AND REPORTING

10.1. ADVERSE EVENTS

10.1.1. Definition of Adverse Events

An AE is any adverse change from the patient's baseline condition, *i.e.* any subjective signs and symptoms or change in a concomitant disease present at the Selection Visit considered or not related to the treatment.
AE includes intercurrent signs, symptoms, illnesses and significant deviations from baseline for vital signs and laboratory values which may occur during the course of the clinical study.

All laboratory tests for which abnormal results are collected after study treatment initiation should be repeated until the values return to normal or to a stable status. Abnormal results are defined as those falling out of the laboratory normal ranges and that are clinically significant. The frequency of such checks should be defined by the Investigator according to the degree of abnormality.

In all cases, the aetiology should, as much as possible, be identified and Pierre Fabre Médicament notified.

10.1.2. Grading of Adverse Events

Adverse or intercurrent events are graded as follows:

- Mild: awareness of signs or symptoms, but easily tolerated
- Moderate: uncomfortable enough to cause interference with usual activity
- Severe: incapacity with inability to work or do usual activity

10.1.3. Reporting of Adverse Events

The records of AE in the e-CRF describe the nature (diagnosis, signs and symptoms), severity, onset date, stop date, outcome and actions taken, and relationship to study treatment (in the Investigator's opinion). It must be specified whether the event is serious or not.

10.2. SERIOUS ADVERSE EVENTS (SAE)

10.2.1. Definition

A SAE includes, but is not necessarily restricted to, any event which:

- Results in death (whatever may be the cause)
- Is life-threatening
- Results in persistent or significant disability/incapacity
- Requires the patient's hospitalisation or prolongation of current hospitalisation *
• Is a congenital anomaly or birth defect

Other events such as cancer and any additional adverse experience or abnormal laboratory values occurring during the study period, defined by the protocol as serious or which the Investigator considers significant enough or that suggest a significant hazard, contra-indications, side effect or precaution, must be handled as serious adverse events.

Any overdosage meeting a seriousness criteria should be reported as a SAE (see section 10.3).

Any pregnancy occurring during/after exposure to the study drug(s) should be reported on the SAE notification form (see section 10.4).

* any hospitalisation, or prolongation of hospitalisation due to the circumstances listed below:
  - planned (as per protocol) medical/surgical procedure
  - preparation for routine health assessment/procedure (e.g. routine colonoscopy)
  - planned medical/surgical admission (planned prior to entry into study trial, appropriate documentation required)
  - administrative or social reasons (e.g. lack of housing, economic inadequacy, care-giver respite, family circumstances)

will not be reported as a SAE.

**10.2.2. Reporting of SAE**

All Serious Adverse Events, according to the above-mentioned definitions and regardless of treatment or relationship to study drug, and occurring once the informed consent form has been signed, must be reported by the Investigator as soon as he/she is informed of the event.

The Investigator must notify the Sponsor of this event by sending, within 24 hours, the "Notification of serious adverse event" form ("first notification") with all the available information about the event (see appendix 17.2), to the Sponsor's Corporate Vigilances e-mail dedicated box:

HQ.pharmacovigilance@pierre-fabre.com

In case it is not possible to send the report by e-mail it can be sent by FAX at the following number:

+ 33 1 49 10 80 90
In case of non-inclusion, the reporting period ends when the non-inclusion is documented.

10.2.3. Follow-up of SAE

The Investigator must draw-up a specific clinical report and use the "Notification of serious adverse event" form ("follow-up") (see appendix 17.2) and collect the results of the carried out examinations and the reports of hospitalisation.

The serious adverse events must be followed up until resolution or stabilisation.

10.2.4. SAE Occurring After the Study

Any SAE occurring during 30 days following the end of the study for the patient should be notified to the Sponsor.

Must also be notified to the Sponsor any event occurring at any time after the end of the study for the patient which may be related to the study treatment in the Investigator's opinion.

10.3. REPORTING OF OVERDOSAGE TO THE SPONSOR

For the purpose of this trial, an overdosage will be defined as any dose exceeding the planned prescribed dose of the study drug or the administration of any dose of an associated product that is considered both excessive and medically important.

In the absence of seriousness criteria, the overdosage and associated adverse event if any, are reported only on the Adverse Event page of the e-CRF. If the definition of seriousness criteria is met, the SAE notification form must also be transmitted to the Sponsor.

10.4. REPORTING OF PREGNANCY TO THE SPONSOR

Pregnancies discovered in the period in between the informed consent form signed but before any study drug exposure are not to be reported to the Sponsor unless associated to a seriousness criteria (e.g. serious adverse event study-protocol related procedure). If pregnancy is confirmed, the women must not be administered the study drug and must be withdrawn immediately from the study.
If pregnancy is suspected while the patient is receiving study treatment, the study drug should be discontinued immediately until the result of the pregnancy testing is known. If pregnancy is confirmed, then the study treatment is permanently discontinued in an appropriate manner and the patient is withdrawn from the study.

The Investigator must report to the Sponsor any pregnancy which occurs during or after the patient has been exposed to the study drug and until 30 days after the last study drug administration. The Investigator must immediately notify the Sponsor using the SAE notification form and also report the pregnancy on the AE page of the e-CRF.

Women who become pregnant after exposure to the study drug must be followed by the Investigator until the completion/termination of the pregnancy. If the pregnancy goes to term, the outcome will have to be reported to the Sponsor (baby's healthy status).

10.5. SPONSOR’S RESPONSIBILITIES FOR SAFETY REPORTING PURPOSES

Sponsor will submit expedited and periodic reports to both Competent Authorities and Ethics Committees per corporate standard operating procedures as regards to the EU directive 2001/20/EC taking into account local specific requirements.

11. DATA COLLECTION AND STUDY MONITORING

11.1. DATA COLLECTION

11.1.1. Case Report Form

An e-CRF will be used to record all patient data required by the protocol except the central ECG (Holter ECG, TTEM) and DHA data which will be transferred from vendors to the subcontractor as electronic data files that will be loaded into the study database.

The e-CRF should be fully validated, compliant with ICH-GCP requirements and European regulations and should include a traceability system for data corrections and deletions (audit trail).
Prior to the start of the study, the Investigator will complete a "Delegation of significant study-related duties" form. The signature and initials of all personal in charge of e-CRF completion should be recorded on this form. Each person involved in e-CRF completion, review, correction and / or validation will be trained and will have an individual login and access code to the e-CRF.

Training sessions will be held by the subcontractor for all participants using this tool. An e-CRF user manual will be available for investigators and CRAs.

All the information included into the e-CRF will be recorded from source documents onto the e-CRF by an authorised person.

The Investigator is responsible for the management and accuracy of the information on the e-CRF. At each monitoring visit, the e-CRF(s) should be at the CRA's disposition for review and validation.

At the end of the study, a CD-ROM containing the pdf version of all e-CRFs (including audit-trail) will be sent by the subcontractor to the Sponsor and to the investigational sites for archiving. The subcontractor must store all study data for at least 15 years after the end of the study and ensure their legibility and accessibility during all the storage period.

11.1.2. Source Documents

A source document is an original record or certified copy of an original record of clinical findings, observations or any other medical or paramedical activities performed during the clinical trial, necessary for the transcription and the verification of the collected data.

Source documents along with all other trial-related documents (copies of all "informed consent" forms, e-CRFs CD-ROM, drug inventories and any correspondence related to the study) must be kept in the investigator's file throughout the study, and then, must be stored in the study centre's archives for a period of at least 15 years or as per local legal requirements, whatever is the longest.

For further details see section 15.2.
11.2. STUDY MONITORING

11.2.1. Monitoring visits

On-site visits will be carried out by a representative of the Sponsor's staff (Study Manager or CRA) prior to study initiation and at regular intervals (every 4 to 6 weeks) throughout the study. Additional visits and communication by telephone, fax, or meeting may be performed if necessary. Any site visit performed by the Sponsor's representatives will be recorded in the Investigator's study file.

11.2.1.1. Site Preselection Visit

Before selecting a centre for the study, a visit will be carried out by the CRA and/or the Study Manager to ensure that the Investigator has the necessary capacities (availability, patient's recruitment, environment), technical means and staff to carry out the study.

11.2.1.2. Initiation Visit

Before the start of the study at all investigational sites, an initiation visit will be carried out by the CRA to check at the latest that:

- The Investigator:
  - has received the technical protocol, administrative and financial agreement signed by all parties
  - has received the written statement of the Ethics Committee approval and the list of its members and their functions

- The original dated and signed curriculum vitae of the investigator(s) has been collected

- Laboratory normal ranges have been collected

- All study materials are available on the study site

- All participants agree with the monitoring procedures and know the study procedures

- All participants are aware of a possible audit or inspection
The CRA has also to provide training on the study protocol requirements and study specific procedures.

11.2.1.3. **Follow-up Visits**

Throughout the study, regular follow-up visits will be carried out by the CRA to check compliance with GCP, patient’s informed consents, strict application of the protocol, conformity of the data entered on the e-CRF with the source documents and ensure its correct completion, adverse events reporting, proper retention, storage and management of the study medication, as well as the source and other trial-related documents.

11.2.1.4. **Closing Visit**

At the end of the study, a final visit will be carried out by the CRA to:

- Verify that the e-CRFs CD-ROM with pdf files are correctly stored
- Control the accountability of intact and used treatment units and return them to the Clinical Pharmacy Department of the IRPF for destruction
- Obtain the last data clarifications and/or solutions if any
- Collect the patient's consent forms in sealed envelopes (except in case of specific country requirements),
- Make an on-site review of all study documentation and complete it if necessary
- And finally, remind the Investigator of his regulatory obligations, study document archiving process and duration.

11.2.2. **Direct Access to Source Documents**

In accordance to the requirements of the GCP, all Sponsor representatives (Study Manager, CRA and Auditors) have to be given a direct access to all source and study data to perform quality monitoring/audit, thus ensuring accuracy and completeness of data).

Investigators are reminded that all Sponsor representatives keep professional confidentiality with regards to the patient data.
11.3. INDEPENDENT DATA MONITORING COMMITTEE

An Independent Data Monitoring Committee (IDMC) will be established to assess at intervals the progress of the clinical trial, the compliance with the inclusion criteria, the quality of follow up, the quality of primary end point measures, the safety data. The IDMC will thereafter recommend to the Sponsor whether to continue, modify, or stop the study.

The IDMC operating procedures will be described in an independent document.

12. DATA MANAGEMENT

All clinical data related to the study will be collected and saved in a computerised database by the Data Management Department of the subcontractor and under the supervision of the Data Manager of Pierre Fabre Biometry (PFB) according to the following procedures.

12.1. DATA ENTRY

All required data will be collected by the Investigator or authorised designee (duly identified into the delegation task list) on the e-CRFs.

The e-CRFs used for this study will be developed and maintained by the Data Management Department of the subcontractor and approved by the Sponsor.

Electronic data (Holter ECG, TTEM and DHA) will be transferred by the 3rd party vendor according to the specifications given by the Data Manager of the subcontractor. These data will be captured and handled in accordance with the European GCP ICH E6 guideline.

12.2. DATA CLEANING

The subcontractor will define in the Data Validation Plan for reviewing and querying data, descriptions of both manual and electronic edit checks. Upon Sponsor approval, the subcontractor will program the checks.
The subcontractor will review the data over the course of the study, working with the Sponsor to identify data inconsistencies. The Investigator will be asked to resolve queries by making changes directly into the e-CRF.

12.3. DATA CODING

Adverse events, concomitant diseases, medical/surgical histories will be coded by the subcontractor using the MedDRA dictionary (latest version in use).

Concomitant medication will be coded by the subcontractor using the WHO-DRUG dictionary (latest version in use).

The Sponsor Clinical Development Physician will validate the coding.

12.4. DATA STORAGE

Computer data files as well as their modifications will be archived by the subcontractor and kept available upon request of the Sponsor.

12.5. DATABASE LOCK

The validated database will be locked by the subcontractor upon request of the Data Manager of PFB following the completion of all steps required, i.e. data entry and check of all data, resolution of all queries, validation of the coding, Clinical and Products Safety databases reconciliation and validation committee.

Then, the subcontractor will transfer the locked database in SAS format to the Data Manager of PFB who assume storage on the PFB secured server.

13. STATISTICAL ANALYSIS

After the database lock and the randomisation code release, the statistical analysis will be performed by PFB or under the supervision of the statistician of PFB using SAS® software, according to the Statistical Analysis Plan approved by the Validation Committee.
13.1. GENERAL CONSIDERATIONS

The main objective of the study is to assess the efficacy of F373280 versus placebo on the maintenance of sinus rhythm after direct ECV in patients with persistent AF and chronic heart failure.

Only the primary analysis of the primary efficacy criterion, on which is based the sample size justification, may lead to a causal interpretation. All other statistical results are to be regarded within a descriptive perspective.

The statistical significance level of the various two sided tests of all analyses will be 5 %.

13.2. SAMPLE SIZE

Assuming an AF recurrence rate of 85% under placebo and 65% under active group, i.e. a clinically relevant difference $\Delta$ of 20%, a sample size of 64 assessable patients per group is required, using a log-rank test of survival curves with a 80 % power and a 5 % two-sided significance level.

According to the previous assumptions and assuming a rate of not assessable patients of 15%, a minimum of 76 patients will have to be randomised per group.

13.3. PROTOCOL DEVIATIONS

Prior to the database lock and the randomisation code release, the Validation Committee members will review the protocol deviations and will classify them as either minor or major. A protocol deviation will be considered major when it is likely to bias significantly the treatment effect estimate based on the primary efficacy criterion.

Patients with major deviation(s) will be excluded from the Per Protocol data set (see section 13.4).

A listing of all protocol deviations will be provided for all randomised patients, including the type (major/minor) of protocol deviations according to the decisions made by the members of the Validation Committee.
The number and percentage of patients with major protocol deviations will be tabulated by treatment group and type of major protocol deviations on the Full Analysis Set defined in section 13.4.

13.4. DATA SETS ANALYSED
The following 3 data sets will be analysed (as defined by the Validation Committee):

- The Safety Set composed of all randomised patients having received at least one dose of the study treatment. This data set will be used to perform analyses of Safety.

- The Full Analysis Set (FAS) composed of all randomised patients having received at least one dose of the study treatment and with a successful cardioversion observed at visit 3. This data set will be used to perform analyses of Efficacy.

- The Per Protocol Set (PP) which is the subset of the Full Analysis Set composed of all patients with a primary efficacy criteria available and without any major protocol deviation or other source of bias for primary criteria analyses. This data set will be used to perform the supportive analysis of the primary efficacy criterion.

13.5. HANDLING OF DROPOUTS AND MISSING DATA

13.5.1. Dropouts
The number of patients who withdraw from the study after their randomisation will be provided by treatment group for all treated patients (Safety Set). All withdrawn patients will be further described regarding their time to dropout and reasons for withdrawal.

13.5.2. Repositioning of Visits
No repositioning of visits will be done.

13.5.3. Missing Data
Missing values will not be substituted by estimated values, but considered as missing in statistical analysis.
13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS

Before the first trial drug intake, patient’s background, medical and surgical history, demographic data and disease characteristics will be described by treatment group on the Safety Set.

- **Quantitative parameters** will be described by treatment group and overall using the following: number of patients, number of missing data, mean, standard deviation, minimum, median and maximum values.

- **Qualitative parameters** will be described by treatment group and overall using frequencies.

Concomitant diseases, as well as medical and surgical histories will be tabulated descriptively by treatment group and overall using the MedDRA codes of System Organ Classes and preferred terms.

If more than 10% of patients are excluded from the FAS and PP set, the description of patients by treatment group at selection and inclusion will be repeated on the FAS and PP set for all parameters.

No statistical test of comparability of treatment groups at baseline will be performed.

13.7. EFFICACY ANALYSIS

13.7.1. Primary Criterion

13.7.1.1. Primary Analysis

The primary criteria, time to first recurrence, will be analysed using the Kaplan Meier method and compared with the Log rank test. Hazard ratios and 95% confidence intervals will be estimated with the Cox regression model.

The primary analysis will be performed on the FAS.

13.7.1.2. Supportive Analysis

The primary analysis will be repeated on the PP set.
13.7.2. Secondary Criteria

All secondary analyses will be performed on the FAS. If more than 10% of patients are excluded from the PP set, the secondary analyses will be repeated on the PP set.

13.7.2.1. Numbers of Atrial Fibrillation Episodes

Both the numbers of AF episodes (symptomatic or not) lasting for at least 10 minutes and with duration less than 10 minutes (\(N_{\text{Sup10}}\) and \(N_{\text{Inf10}}\)) will be described by treatment group and compared by the chi-square test (or CMH test adjusted for centre) or Fisher’s exact Test.

13.7.2.2. Duration of Atrial Fibrillation Episodes

The duration of all AF Episodes will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centres effects) or Wilcoxon test.

13.7.2.3. Time to first AF recurrence less than 10 minutes or symptomatic

The time to the first AF recurrence less than 10 minutes and the time to the first symptomatic AF recurrence will be analysed as the primary analysis.

13.7.2.4. Clinical parameters evaluation

The EHRA score will be described by treatment group and analysed using a chi-squared test (or CMH test adjusted for centre) or Fisher’s exact Test.

The frequency of presumed arrhythmia will be described by treatment group.

The number of recurrence of symptomatic AF, of hospitalizations (for cardiovascular events, for thromboembolic stroke and for all causes), of spontaneous cardioversion, of successful cardioversion (including number of shocks distribution) and the number of patients needing cardioversion after initial ECV will be described by treatment group and compared using a chi-square test or a Fisher Test (if the numbers are relevant).
The duration of hospitalizations for cardiovascular events, for thromboembolic stroke and for any cause will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centre effects) or Wilcoxon test.

The echocardiographic parameters values will be described at each time (V1, V2, V4, V6 and V9) and changes described from V4 to V9 and from V2 to V9.

13.7.2.5. Biomarker analysis: red blood cell concentrations of DHA

Values and changes from baseline for red blood cell concentration of DHA will be performed by treatment group and assessment time.

13.8. SAFETY ANALYSIS

The Safety Set will be used to perform all analyses of the safety criteria.

13.8.1. Adverse Events

Any adverse event having been reported during the study for a given patient will be classified by preferred term and corresponding system organ class using the MedDRA terminology.

Adverse events will be classified as:

- Treatment emergent adverse events, i.e., any adverse event which occurs or worsens on study treatment during the randomised period.
- Or non treatment emergent adverse events, i.e., any adverse event which occurs during the run-in period (before V2) or is reported as concomitant disease with the same intensity.

For each study period, any patient with at least one reported adverse event will be classified as a patient:

- With at least one adverse event
- With at least one treatment emergent adverse event
- With one TEAE
- With two TEAEs
• With at least three TEAEs
• With at least one related TEAE
• With an adverse event leading to the study treatment discontinuation (definitive or temporary)
• With an adverse event leading to withdrawal
• With at least one serious adverse event.

Numbers and percentages of patient with at least one reported treatment emergent adverse event will be tabulated by treatment group:
• By system organ class
• By system organ class and preferred term
• By system organ class and preferred term, taking into consideration its most severe intensity
• And by system organ class and preferred term, taking into consideration the most severe relationship to the study treatment.

Recurring adverse events (i.e., adverse events classified with the same preferred term) for a given patient will only be counted once and only their most severe intensity or most severe relationship to the study treatment will be tabulated.

The number and percentage of patient with at least one most common (reported in 1% patients in any group) drug related TEAE ("not excluded or unassessable") will be tabulated by Preferred Term and Treatment group in decreasing order for the treatment group (for all patients).

The number and percentage of patients with at least one reported most common treatment emergent adverse event will also be plotted by treatment group. This graphical representation will highlight the frequencies of the most severe intensities reported by system organ class and preferred term.

SAE will also be described on an individual basis: treatment group, patient's code, sex and age, Investigator's reported term, preferred term, time of onset according to the time of the first study
treatment administration, duration, action taken regarding the study treatment administration, use of a corrective treatment, outcome and relationship to the study treatment in the Investigator’s opinion.

13.8.2. Clinical Laboratory Evaluation

For each laboratory parameter, data will be tabulated by treatment group and assessment time.

The absolute changes post-trial drug administration - baseline (the baseline value being the value measured on the last blood sample collected before the first trial drug administration) will be calculated and tabulated by parameter, treatment group and post-trial drug administration assessment time. Results of retests performed post-trial drug administration will not be analysed and tabulated. They will only be displayed in individual data listings.

For all biochemistry parameters, scatter plots highlighting individual results will display the baseline and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 24 value in the ordinate.

For all haematology parameters, scatter plots highlighting individual results will display the baseline and week 4, week 12 and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 4, week 12 and week 24 value in the ordinate.

Each treatment group will be differently identified. The first bisecting line (45° line), the lines of lower and upper normal range, the lines of Potentially Clinically Significant Change (PSC) range and Clinically noteworthy abnormal laboratory value (CNALV) range added on the plots (see Appendix 17.3).

For all blood laboratory parameters, shift tables will be provided to depict the numbers of patients with post-trial drug administration variations at each assessment time as compared to the baseline values (measured on the last blood sample collected before the first trial drug administration) by treatment group. A 3-point scale (low, normal, high) will be used as defined by the normal ranges in use in the laboratory in charge of the assays.
CNALV (see in Appendix 17.3) will be identified and described on an individual basis. If relevant, five separate individual data listings by treatment group will be provided:

- CNALV for haemoglobin (including corresponding individual results of erythrocytes and haematocrit)
- CNALV for neutrophils or leucocytes (including corresponding individual results of basophils, eosinophils, lymphocytes and monocytes)
- CNALV for platelets (including corresponding individual results of erythrocytes and leucocytes)
- CNALV for liver function parameters (including corresponding individual results of gamma-GT)
- CNALV for serum creatinine

13.8.3. **Global Physical Examination**

Recorded data of the global physical examination performed will not be tabulated as any abnormal findings post-randomisation should be reported as AEs (if clinically significant).

Physical examination assessments will be provided in the listings of individual data.

13.8.4. **Vital Signs, Physical Findings and Other Observations Related to Safety**

13.8.4.1. **Vital Sign Measurements Over Time**

For each parameter (systolic blood pressure, diastolic blood pressure and HR in supine and standing positions), descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.

13.8.4.2. **Body weight**

Descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.
13.8.4.3. **Individual Patient Changes**

The number and percentage of patients with at least one Predefined Potentially Clinically Significant Change (PSC) and with at least one PSC Leading to Clinically Significant Value (PSCV) will be tabulated by treatment group (see Table 1 in Appendix 17.3).

According to the pharmacological drug profile mentioned previously in this Protocol, the changes from baseline to the maximum and/or minimum post-baseline value could be categorized and tabulated by treatment group with frequencies and decreasing cumulative percentages.

If there is a signal of a drug effect toward one direction rather than the other, additionally shift tables of variations from baseline to the maximum or minimum post-baseline value could be also provided (see Table 2 to 4 in Appendix 17.3).

An individual data listing of patients with symptomatic or asymptomatic orthostatic hypotension will be provided by treatment group (see Table 5 in Appendix 17.3).

13.8.5. **ECG**

Frequencies on the clinical interpretation (normal, abnormal CS or NCS) will be presented by treatment group and assessment time. Individual tabulated data for ECG abnormalities will be also displayed.

13.8.6. **Coagulation parameters**

Scatter plots highlighting individual results for coagulation parameters (prothrombin time/INR, activated partial thromboplastin time and thrombin clotting time) before and after study treatment administration will be produced.

13.9. **CONCOMITANT TREATMENTS**

Concomitant treatments will be tabulated by treatment group within a descriptive perspective. They will be classified by therapeutic area according to the WHO-DRUG dictionary using the "anatomical therapeutic chemical" classification on the safety set.
13.10. COMPLIANCE

The percentage of compliance will be described by treatment group using the quantity

\[
\text{Compliance}(\%) = \frac{\text{Estimated actual consumption}}{\text{Theoretical consumption}} \times 100
\]

with: Estimated actual consumption = number of tablets provided at the start of study (Visit 2) minus number of tablets returned at the end of study (Visit 9)

Theoretical consumption = number of days of treatment intake planned between the start and the end of study (168 days ± 7 days)

13.11. INTERIM ANALYSIS AND DATA MONITORING

No analyses of efficacy data are planned for IDMC that ensures that the overall probability of type I error is controlled. No Type I error and sample size adjustments are necessary. Any recommendations of the IDMC to alter study conduct will be based on safety, so IDMC monitoring of the study will not affect the statistical operating characteristics of the final analysis. The IDMC will review, three times during the study period (after the first 30 subjects will have been randomized, when the first 80 subjects will have terminated their study participation and when 130 subjects will have terminated their study participation), safety data results across treatment groups and judges whether the overall safety and feasibility (not futility) of the trial remain acceptable.

14. GENERAL ETHICAL CONSIDERATIONS

14.1. ETHICAL CONDITIONS

This study is performed in accordance with the principles stated in the Declaration of Helsinki (1964) and subsequent amendments and in accordance with the Good Clinical Practice Guideline (CPMP/ICH/135/95).
14.2. ETHICS COMMITTEE AND LEGAL REQUIREMENTS

All the documents required by National Regulations and any other informative documents that may be requested are submitted for review to an Ethics Committee whose procedures and operations meet the GCP and National Legal Requirements.

Depending on National Regulations, the application is submitted to the Ethics Committee by the Sponsor (or representative) or by the Investigator.

A copy of the formal written approval from the Ethics Committee is provided to the Sponsor (directly by the Ethics Committee or via the Investigator) with a list of names and qualifications of its members.

The request for authorisation by the Competent Authority or its notification if required (depending on National Regulations) is carried out by the Sponsor.

The screening of patients does not start before the approval of the Ethics Committee has been obtained and the study authorised by the Competent Authority or notified to the Competent Authority (depending on National Regulations).

14.3. PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM

An information must be given to the patients before their decision to participate or abstain from participation.

This information is based on the elements set out in the Declaration of Helsinki and the ICH GCP Guidelines. It must also describe the measures taken to safeguard patient’s privacy and protection of personal data, according to European Directive 95/46 EC or other local regulation.

Restraints and risks must be explained, as well as the right to discontinue participation in the study at any stage, without affecting their further relationship with the Investigator and/or their future care.

The written information and consent form must be submitted to the patient with an oral explanation. It must be agreed and signed by the patient before any study-related procedure starts.
This information and consent procedure is under the Investigator’s responsibility.

The information and consent document are made in triplicate: the original copy is kept by the Investigator, one copy is given to the patient and the last copy is kept by the Clinical Quality Assurance Unit of the Sponsor in a sealed envelope at the end of study (except in case of specific country requirement).

Specific areas of the Sponsor’s copy are not triplicated to avoid the reading of the patient’s surname (except the first 3 letters), first name, address and signature.

If any information becomes available during the trial that may be relevant to the patient’s willingness to keep on participating in the trial, an updated written informed consent must be submitted to the patient to confirm agreement to continue participating.

14.4. PERSONAL DATA PROTECTION

All information from this study (excluding data from the informed consent) is entered into a computer under the Sponsor’s responsibility in accordance with the French law, "Loi Informatique et Libertés" (January 6, 1978, and subsequent amendments) and with the European Directive 95/46/CE.

14.5. INSURANCE POLICY

In accordance with the provisions of the law and the GCP, the Sponsor Pierre Fabre Médicament, has an insurance policy intended to guarantee against possible damage resulting from the research.

The studies and/or experiments performed on behalf of the Sponsor Pierre Fabre Médicament are specifically and expressly guaranteed.

It is advisable to underline that non compliance with the Research Legal Conditions is a cause for guarantee exclusion.
15. ADMINISTRATIVE PROCEDURES

15.1. PROTOCOL AMENDMENT

Neither the Investigator nor the Sponsor may alter the protocol without the authorisation of the other party.

All changes to the protocol are subject to an amendment which must be dated and signed by both parties and must appear as an amendment to the protocol.

Substantial amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities

Urgent amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities, but could be implemented immediately under specific conditions defined with the Sponsor.

15.2. SOURCE DOCUMENTS, INVESTIGATOR'S FILE STORAGE

The Investigator:

- Keeps all trial-related documents in appropriate file folders. Records of patient, original informed consent forms, source documents, a CD Rom containing a pdf copy of e-CRF, drug inventory, Ethics Committees and Sponsor correspondence pertaining to the study must be kept on file.

- Retains all documents relating to the screening (consent and investigation results) of all patients included in the trial or not.

- Retains a list of the patient’s names, addresses (and/or number of medical file), code numbers to allow checking of data reported on e-CRFs with those from source documents.

- Authorises direct access to source documents for monitoring, audits and inspections.

- The trial-related documents must be retained as strictly confidential at the Investigator’s site for at least 15 years or according to local requirements, whatever is the longest after the completion or discontinuation of the trial (European Directive 2003/63/EC).
15.3. END OF THE STUDY

15.3.1. Definition of the End of Study

The end of study is the last visit of the last patient undergoing the trial. Any change to this definition during the study, for whatever reason, must be notified as a substantial amendment.

15.3.2. Early Study Termination

15.3.2.1. Early Study Termination Decided by the Sponsor

The Sponsor may discontinue the study at any time for any of the following reasons:

- Lack of recruitment
- Deviations from good clinical practice and/or regulations
- Poor product safety
- New information that could jeopardise the patient’s safety
- Stopping of the development …

15.3.2.2. Early Study Termination Decided by the Competent Authorities

The Competent Authorities may suspend or prohibit a study if they consider that either the conditions of authorisation are not being met or has doubt about the safety or scientific validity of the study.

15.4. AUDIT

The Sponsor is responsible for making sure that both its representatives (Study Manager, CRA...) and the Investigator fulfil the requirements as specified by the GCP Guideline.

An audit can be organised internally at Pierre Fabre Médicament and at the investigational site where the e-CRFs are matched against source documents.

All study documentation must be directly accessible to auditors.
The practical conditions for the audit are discussed between the Investigator and the Clinical Quality Assurance Department.

Oral information about the audit results are given to the Investigator.

15.5. **INSPECTION**

The Health Authorities may inspect any investigation site or the Sponsor in the course of the study or after its completion, to verify the conduct of the study and quality of the data. The Investigator must provide to the inspectors direct access to study documents.

15.6. **CONFIDENTIALITY**

The present materials (protocol and related documentation, e-CRF, Investigator's Brochure) contain confidential information.

Except if agreed in writing with the Study Manager, the Investigators must hold such information confidential, and must not disclose it to others (except where required by Applicable Law).

15.7. **CLINICAL STUDY REPORT**

Data analysis and clinical study report writing are under the Sponsor’s responsibility.

Upon data analysis completion, a final report including a review of the objectives and methods, a presentation and a discussion of the results is drawn up according to ICH Guidelines (Structure and Content of Clinical Study Reports, ICH-E3, CPMP/ICH/137/95).

The report is a clinical and statistical integrated report. It must be signed by the Sponsor's representative(s) and the Coordinating Investigator.

15.8. **STUDY RESULTS COMMUNICATION**

Upon completion of the study, the global results of the Research are communicated to the Investigator. According to the Local Regulation, the patient can ask the Investigator for the results.
15.9. **STUDY RESULTS PUBLICATION**

The information and data collected during the conduct of this clinical study are considered confidential and are used by the Sponsor in connection with the development of the study drug. This information may be disclosed if deemed necessary by the Sponsor.

To allow the use of the information derived from this clinical study and to insure compliance with Current Regulations, the Investigator must provide the Sponsor with complete test results and all data collected during the study.

Only the Sponsor may make study information available to physicians and to Regulatory Agencies, except as required by Current Regulations.

All the results of this study including data, reports, discoveries and inventions resulting from the study, are the property of the Sponsor.

In the event the Sponsor chooses to publish study data, the manuscript must be provided to the author(s) at least 30 days prior to the expected date of submission to the intended publisher.

The Investigator(s) can reserve the right to publish or present study data; if so, the manuscript or abstract must be provided to the Sponsor for review at least 30 days prior to the expected date of submission to the intended publisher or of planned presentation.

In addition, if necessary, (the) Investigator(s) shall withhold publication for an additional 60 days, to allow the filing of a patent application, or to allow the Sponsor to take any measures he deems appropriate to establish and preserve his proprietary rights.

It is agreed that publication of study results by each site shall be made only as part of a publication of the study results obtained by all sites performing the protocol, once the study is completed and finalised.

The authors list is agreed by all Investigators prior to publication. The names of the authors are provided according to their participation in the design of the protocol as well as their recruitment of eligible and analysable patients.
16. REFERENCES

[1] F373280 INVESTIGATOR'S BROCHURE, version October 2013

Effects of n-3 polyunsaturated fatty acids in the prevention of atrial fibrillation recurrences after electrical cardioversion. A prospective, randomised study
Circulation, 2011; 124:1100-1106

Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy
J. Am. Coll. Cardiol. 2011; 57; 870-879

Dose-dependant effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of non ischemic origin: A double-blind, placebo-controlled, 3-arm study
American Heart Journal 2011; 161:915.e1-915.e9 - volume 161, number 5

[5] GISSI-HF INVESTIGATORS
Effects of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GSSI-HF Trial): a randomised, double-blind, placebo-controlled trial
The lancet on line - August 2008

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Eur Heart J. 2010 Oct;31(19):2369-429

[7] KOWEY PR, REIFFEL JA, ELLENBOGEN KA, NACCARELLI GV, PRATT CM.
Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomised controlled trial.
N-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomised, double-blind, multicentre study
*Europace (2011) 13, 174-181*

[9] **OMACOR®** SUMMARY PRODUCT CARACTERISTICS (SPC) dated 17/02/2012

[10] **BEPANTHENE®** SUMMARY PRODUCT CARACTERISTICS (SPC)

Dronedarone for prevention of atrial fibrillation: a dose-ranging study.
*Eur Heart J 2003;24(16):1481-7.*

[12] LE HEUZEY JY AND ALL.
A Short-Term, Randomised, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study.
*J Cardiovasc Electrophysiol.*

Effects of fish-oil supplementation on myocardial fatty acids in humans.
*Am J Clin Nutr (2007); 85 : 1225.*

Distribution, interconversion and dose response of n-3 fatty acids in humans.
*Am J Clin Nutr (2006);83 : 1469-1473S.*

Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodelling of the atria?
*J. Am. Coll. Cardiol. 1998;31;167-173*

[16] SALM P, TAYLOR PJ, KOSTNER K
Simultaneous quantification of total eicosapentaenoic acid, docosahexaenoic acid and arachidonic acid in plasma by high-performance liquid chromatography-tandem mass spectrometry.
The consumption of food products from linseed-fed animals maintains erythrocyte omega-3 fatty acids in obese human 

[18] HARRIS WS, VON SCHACKY C.
The Omega-3 Index: a new risk factor for death from coronary heart disease? 

Effects of Polynsaturated Fatty Acids n-3 (PUFA n-3) in the prophylaxis of atrial fibrillation relapses after external electric cardioversion
*World Congress of Cardiology 2006, 2-6 September, Barcelona – Spain*

Outcome parameters from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. 
*Europace 2007, 9, 1006-1023*

[21] EUROPEAN MEDICINES AGENCY
Addendum to the guideline on antiarrhythmics on atrial fibrillation and atrial flutter. 
*EMA/CHMA/EWP/213056/2010*

Dietary fish oil dose- and time-response effects on cardiac phospholipid fatty acid composition. 

[23] ROBERTO M. LANG, MICHELLE BIERIG, RICHARD B. DEVEREUX, FRANK A. FLACHSKAMPF*, ELYSE FOSTER, PATRICIA A. PELLIKKA, MICHAEL H. PICARD, MARY J. ROMAN, JAMES SEWARD, JACK SHANEWISE, SCOTT SOLOMON, KIRK T. SPENCER, MARTIN ST. JOHN SUTTON, WILLIAM STEWART.
Recommendations for chamber quantification 
17. APPENDICES
17.1. DECLARATION OF HELSINKI

WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI
ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING
HUMAN SUBJECTS

Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the: 29th WMA
General Assembly, Tokyo, Japan, October 1975 35th WMA General Assembly, Venice, Italy, October 1983 41st
WMA General Assembly, Hong Kong, September 1989 48th WMA General Assembly, Somerset West, Republic of
South Africa, October 1996 52nd WMA General Assembly, Edinburgh, Scotland, October 2000 53th WMA General
Assembly, Washington 2002 (Note of Clarification on paragraph 29 added) 55th WMA General Assembly, Tokyo
2004 (Note of Clarification on Paragraph 30 added) 59th WMA General Assembly, Seoul, October 2008

A. INTRODUCTION

1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of
ethical principles for medical research involving human subjects, including research on identifiable
human material and data. The Declaration is intended to be read as a whole and each of its constituent
paragraphs should not be applied without consideration of all other relevant paragraphs.

2. Although the Declaration is addressed primarily to physicians, the WMA encourages other participants
in medical research involving human subjects to adopt these principles.

3. It is the duty of the physician to promote and safeguard the health of patients, including those who are
involved in medical research. The physician's knowledge and conscience are dedicated to the fulfilment
of this duty.

4. The Declaration of Geneva of the WMA binds the physician with the words, “The health of my patient
will be my first consideration,” and the International Code of Medical Ethics declares that, “A physician
shall act in the patient's best interest when providing medical care.”

5. Medical progress is based on research that ultimately must include studies involving human subjects.
Populations that are underrepresented in medical research should be provided appropriate access to
participation in research.

6. In medical research involving human subjects, the well-being of the individual research subject must
take precedence over all other interests.

7. The primary purpose of medical research involving human subjects is to understand the causes,
development and effects of diseases and improve preventive, diagnostic and therapeutic interventions
(methods, procedures and treatments). Even the best current interventions must be evaluated continually
through research for their safety, effectiveness, efficiency, accessibility and quality.

8. In medical practice and in medical research, most interventions involve risks and burdens.

9. Medical research is subject to ethical standards that promote respect for all human subjects and protect
their health and rights. Some research populations are particularly vulnerable and need special
protection. These include those who cannot give or refuse consent for themselves and those who may be
vulnerable to coercion or undue influence.

10. Physicians should consider the ethical, legal and regulatory norms and standards for research involving
human subjects in their own countries as well as applicable international norms and standards. No
national or international ethical, legal or regulatory requirement should reduce or eliminate any of the
protections for research subjects set forth in this Declaration.
B. PRINCIPLES FOR ALL MEDICAL RESEARCH

11. It is the duty of physicians who participate in medical research to protect the life, health, dignity, integrity, right to self-determination, privacy, and confidentiality of personal information of research subjects.

12. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and adequate laboratory and, as appropriate, animal experimentation. The welfare of animals used for research must be respected.

13. Appropriate caution must be exercised in the conduct of medical research that may harm the environment.

14. The design and performance of each research study involving human subjects must be clearly described in a research protocol. The protocol should contain a statement of the ethical considerations involved and should indicate how the principles in this Declaration have been addressed. The protocol should include information regarding funding, sponsors, institutional affiliations, other potential conflicts of interest, incentives for subjects and provisions for treating and/or compensating subjects who are harmed as a consequence of participation in the research study. The protocol should describe arrangements for post-study access by study subjects to interventions identified as beneficial in the study or access to other appropriate care or benefits.

15. The research protocol must be submitted for consideration, comment, guidance and approval to a research ethics committee before the study begins. This committee must be independent of the researcher, the sponsor and any other undue influence. It must take into consideration the laws and regulations of the country or countries in which the research is to be performed as well as applicable international norms and standards but these must not be allowed to reduce or eliminate any of the protections for research subjects set forth in this Declaration. The committee must have the right to monitor ongoing studies. The researcher must provide monitoring information to the committee, especially information about any serious adverse events. No change to the protocol may be made without consideration and approval by the committee.

16. Medical research involving human subjects must be conducted only by individuals with the appropriate scientific training and qualifications. Research on patients or healthy volunteers requires the supervision of a competent and appropriately qualified physician or other health care professional. The responsibility for the protection of research subjects must always rest with the physician or other health care professional and never the research subjects, even though they have given consent.

17. Medical research involving a disadvantaged or vulnerable population or community is only justified if the research is responsive to the health needs and priorities of this population or community and if there is a reasonable likelihood that this population or community stands to benefit from the results of the research.

18. Every medical research study involving human subjects must be preceded by careful assessment of predictable risks and burdens to the individuals and communities involved in the research in comparison with foreseeable benefits to them and to other individuals or communities affected by the condition under investigation.

19. Every clinical trial must be registered in a publicly accessible database before recruitment of the first subject.
20. Physicians may not participate in a research study involving human subjects unless they are confident that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians must immediately stop a study when the risks are found to outweigh the potential benefits or when there is conclusive proof of positive and beneficial results.

21. Medical research involving human subjects may only be conducted if the importance of the objective outweighs the inherent risks and burdens to the research subjects.

22. Participation by competent individuals as subjects in medical research must be voluntary. Although it may be appropriate to consult family members or community leaders, no competent individual may be enrolled in a research study unless he or she freely agrees.

23. Every precaution must be taken to protect the privacy of research subjects and the confidentiality of their personal information and to minimize the impact of the study on their physical, mental and social integrity.

24. In medical research involving competent human subjects, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail, and any other relevant aspects of the study. The potential subject must be informed of the right to refuse to participate in the study or to withdraw consent to participate at any time without reprisal. Special attention should be given to the specific information needs of individual potential subjects as well as to the methods used to deliver the information. After ensuring that the potential subject has understood the information, the physician or another appropriately qualified individual must then seek the potential subject’s freely-given informed consent, preferably in writing. If the consent cannot be expressed in writing, the non-written consent must be formally documented and witnessed.

25. For medical research using identifiable human material or data, physicians must normally seek consent for the collection, analysis, storage and/or reuse. There may be situations where consent would be impossible or impractical to obtain for such research or would pose a threat to the validity of the research. In such situations the research may be done only after consideration and approval of a research ethics committee.

26. When seeking informed consent for participation in a research study the physician should be particularly cautious if the potential subject is in a dependent relationship with the physician or may consent under duress. In such situations the informed consent should be sought by an appropriately qualified individual who is completely independent of this relationship.

27. For a potential research subject who is incompetent, the physician must seek informed consent from the legally authorized representative. These individuals must not be included in a research study that has no likelihood of benefit for them unless it is intended to promote the health of the population represented by the potential subject, the research cannot instead be performed with competent persons, and the research entails only minimal risk and minimal burden.

28. When a potential research subject who is deemed incompetent is able to give assent to decisions about participation in research, the physician must seek that assent in addition to the consent of the legally authorized representative. The potential subject’s dissent should be respected.
29. Research involving subjects who are physically or mentally incapable of giving consent, for example, unconscious patients, may be done only if the physical or mental condition that prevents giving informed consent is a necessary characteristic of the research population. In such circumstances the physician should seek informed consent from the legally authorized representative. If no such representative is available and if the research cannot be delayed, the study may proceed without informed consent provided that the specific reasons for involving subjects with a condition that renders them unable to give informed consent have been stated in the research protocol and the study has been approved by a research ethics committee. Consent to remain in the research should be obtained as soon as possible from the subject or a legally authorized representative.

30. Authors, editors and publishers all have ethical obligations with regard to the publication of the results of research. Authors have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports. They should adhere to accepted guidelines for ethical reporting. Negative and inconclusive as well as positive results should be published or otherwise made publicly available. Sources of funding, institutional affiliations and conflicts of interest should be declared in the publication. Reports of research not in accordance with the principles of this Declaration should not be accepted for publication.

C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH MEDICAL CARE

31. The physician may combine medical research with medical care only to the extent that the research is justified by its potential preventive, diagnostic or therapeutic value and if the physician has good reason to believe that participation in the research study will not adversely affect the health of the patients who serve as research subjects.

32. The benefits, risks, burdens and effectiveness of a new intervention must be tested against those of the best current proven intervention, except in the following circumstances:
   • The use of placebo, or no treatment, is acceptable in studies where no current proven intervention exists; or
   • Where for compelling and scientifically sound methodological reasons the use of placebo is necessary to determine the efficacy or safety of an intervention and the patients who receive placebo or no treatment will not be subject to any risk of serious or irreversible harm. Extreme care must be taken to avoid abuse of this option.

33. At the conclusion of the study, patients entered into the study are entitled to be informed about the outcome of the study and to share any benefits that result from it, for example, access to interventions identified as beneficial in the study or to other appropriate care or benefits.

34. The physician must fully inform the patient which aspects of the care are related to the research. The refusal of a patient to participate in a study or the patient’s decision to withdraw from the study must never interfere with the patient-physician relationship.

35. In the treatment of a patient, where proven interventions do not exist or have been ineffective, the physician, after seeking expert advice, with informed consent from the patient or a legally authorized representative, may use an unproven intervention if in the physician's judgement it offers hope of saving life, re-establishing health or alleviating suffering. Where possible, this intervention should be made the object of research, designed to evaluate its safety and efficacy. In all cases, new information should be recorded and, where appropriate, made publicly available.
17.2. SAE REPORT FORM
NOTIFICATION OF SERIOUS ADVERSE EVENT (SAE) OR PREGNANCY TO PIERRE FABRE CORPORATE VIGILANCES DIVISION

TO BE TRANSMITTED TO THE CORPORATE VIGILANCES DIVISION BY E-MAIL WITHIN 24H TO HQ.pharmacovigilance@pierre-fabre.com OR BY FAX WITHIN 24H – Fax N°: 33 (0) 1.49.10.80.90

Transmission date [ ] [ ] [ ] [ ] [ ] [ ] [ ] (ddmmyyyy) Country : ........................................

SAE N° [ ] [ ] FIRST NOTIFICATION [ ] FOLLOW-UP [ ] N°

SUBJECT CHARACTERISTICS

Gender [ ] M, [ ] F Height [ ] [ ] cm Weight [ ] [ ] [ ] [ ] [ ] kg

DESCRIPTION OF THE EVENT

The serious adverse event resulted in :

- Death (whatever may be the cause)
- Hospitalisation (*) or extension thereof
- Life threatening
- Invalidity or disability
- Congenital abnormality or abnormal pregnancy outcome
- Cancer
- Other (any other serious clinical or laboratory event according to the investigator or the protocol, overdosage meeting seriousness criteria, suicide attempts)
- Other fact to be notified :

Pregnancy exposure

Nature of the event (if clinical nature, indicate the diagnosis or the major symptom) :

...........................................................................................................................................................................................................
...........................................................................................................................................................................................................
...........................................................................................................................................................................................................

AE onset date [ ] [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)

Seriousness onset date [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)

Summary description (if clinical cause, significant history, progression of event, available laboratory results, etc...) :

(*) Except hospitalisations with durations and goals planned in the protocol

THE SAE IN RELATION TO THE TRIAL

TREATMENT NUMBER [ ] [ ] [ ] [ ] [ ] [ ]

- Time of occurrence of SAE
  - During the selection or run-in period
  - During the administration phase of the study treatment
  - After the administration phase of the study treatment

- Date of first study treatment administration [ ] [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)

- Date of last study treatment administration before the occurrence of SAE [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)

- Was the blind broken ? [ ] Yes [ ] No [ ] Not applicable

If yes, or if this is an open study, drug(s) administered :

Conditions of administration (cycles(s), daily dose(s), route(s) of administration, etc..) :
CONCOMITANT MEDICATION SINCE TRIAL INITIATION and up UNTIL THE OCCURRENCE OF THE SAE (EXCEPT THE TREATMENTS GIVEN FOR THE SAE)

<table>
<thead>
<tr>
<th>Trade name (or INN)</th>
<th>Daily dose</th>
<th>Start date (dd/mm/yy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (dd/mm/yy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><em>/</em>/____</td>
<td></td>
<td><em>/</em>/____</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>/__/</em>___</td>
<td></td>
<td><em>/__/</em>___</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>/__/</em>___</td>
<td></td>
<td><em>/__/</em>___</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MEASURES TAKEN FOLLOWING THE SAE

- **Study treatment**
  - [ ] No change
  - [ ] Dosage modification, specify :……………………………..…. Modification Date : _/_/____
  - [ ] Temporarily discontinued Readministration date : _/_/____
  - [ ] Withdrawn End date : _/_/____
  - [ ] Not applicable

- **The event led to**:
  - [ ] Prescription of corrective or symptomatic treatments:
    | Trade name (or INN) | Daily dose | Start date (dd/mm/yy) | Ongoing at occurrence of the event | Stop date (dd/mm/yy) | Route of admin. | Indication |
    |---------------------|------------|-----------------------|-----------------------------------|---------------------|-----------------|------------|
    |                     |            | _/_/____               |                                   | _/_/____            |                 |            |
    |                     |            | _/__/____              |                                   | _/__/____           |                 |            |
    |                     |            | _/__/____              |                                   | _/__/____           |                 |            |

- [ ] Discontinuation of concomitant treatments:
<table>
<thead>
<tr>
<th>Trade name (or INN)</th>
<th>Daily dose</th>
<th>Start date (dd/mm/yy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (dd/mm/yy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><em>/</em>/____</td>
<td></td>
<td><em>/</em>/____</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>/__/</em>___</td>
<td></td>
<td><em>/__/</em>___</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>/__/</em>___</td>
<td></td>
<td><em>/__/</em>___</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- [ ] Others, specify :

OUTCOME

- [ ] Not recovered/Not resolved
- [ ] Recovering/Resolving
- [ ] Recovered/Resolved
- [ ] Recovered/Resolved with sequelae
- [ ] Fatal
- [ ] Unknown

In case of death, has an autopsy been conducted ?  [ ] Yes  [ ] No

INVESTIGATOR CAUSALITY ASSESSMENT (investigator’s assessment to be done as soon as possible)

<table>
<thead>
<tr>
<th>Study drug:</th>
<th>Related to study protocol:</th>
</tr>
</thead>
<tbody>
<tr>
<td>[ ] Not Suspected</td>
<td>[ ] Suspected</td>
</tr>
</tbody>
</table>

Comments: .............................................................................................................................................................

Enclose in the notification the results of carried out examinations, reports of hospitalisation, etc...
### 17.3. PREDEFINED LIMITS OF LABORATORY AND VITAL SIGN POTENTIALLY CLINICALLY SIGNIFICANT CHANGES AND VALUES

List of Predefined Potentially Clinically Significant Change For Laboratory Values

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>UNIT</th>
<th>PSC</th>
<th>Decrease</th>
<th>Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MUSCLE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine Phosphokinase</td>
<td>U / l</td>
<td>-</td>
<td>236</td>
<td></td>
</tr>
<tr>
<td><strong>KIDNEY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine</td>
<td>µmol/l</td>
<td>-</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>Urea</td>
<td>mmol/l</td>
<td>-</td>
<td>3.2</td>
<td></td>
</tr>
<tr>
<td>Uric acid</td>
<td>µmol/l</td>
<td>-</td>
<td>119</td>
<td></td>
</tr>
<tr>
<td>Phosphate</td>
<td>mmol/l</td>
<td>0.39</td>
<td>0.39</td>
<td></td>
</tr>
<tr>
<td>Calcium</td>
<td>mmol/l</td>
<td>0.30</td>
<td>0.30</td>
<td></td>
</tr>
<tr>
<td><strong>ELECTROLYTES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium</td>
<td>mmol/l</td>
<td>8</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Potassium</td>
<td>mmol/l</td>
<td>1.1</td>
<td>1.1</td>
<td></td>
</tr>
<tr>
<td>Chloride</td>
<td>mmol/l</td>
<td>8</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>mmol/l</td>
<td>7</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td><strong>METABOLISM/ NUTRITIONAL</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose (random)</td>
<td>mmol/l</td>
<td>3</td>
<td>3.7</td>
<td></td>
</tr>
<tr>
<td>Albumin</td>
<td>g/l</td>
<td>6</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Protein</td>
<td>g/l</td>
<td>11</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Cholesterol</td>
<td>mmol/l</td>
<td>-</td>
<td>1.97</td>
<td></td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>mmol/l</td>
<td>0.91</td>
<td>0.85</td>
<td></td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>mmol/l</td>
<td>2.17</td>
<td>2.04</td>
<td></td>
</tr>
<tr>
<td>Triglycerides</td>
<td>mmol/l</td>
<td>-</td>
<td>2.91</td>
<td></td>
</tr>
<tr>
<td><strong>ERYTHROCYTES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythrocyte count</td>
<td>T/l</td>
<td>0.7</td>
<td>0.7</td>
<td></td>
</tr>
<tr>
<td>Haemoglobin</td>
<td>g/l</td>
<td>20</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Haematocrit</td>
<td>1</td>
<td>0.06</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>MCV</td>
<td>fl</td>
<td>7</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>MCH (Fe)</td>
<td>fmol</td>
<td>0.19</td>
<td>0.19</td>
<td></td>
</tr>
<tr>
<td>MCHC (Fe)</td>
<td>mmol/l</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>LEUKOCYTES</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukocyte count</td>
<td>G/l</td>
<td>4.2</td>
<td>3.8</td>
<td></td>
</tr>
<tr>
<td><strong>DIFFERENTIAL COUNT</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophils</td>
<td>G/l</td>
<td>3.47</td>
<td>3.19</td>
<td></td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>G/l</td>
<td>1.76</td>
<td>1.63</td>
<td></td>
</tr>
<tr>
<td>Monocytes</td>
<td>G/l</td>
<td>-</td>
<td>0.49</td>
<td></td>
</tr>
<tr>
<td>Eosinophils</td>
<td>G/l</td>
<td>-</td>
<td>0.41</td>
<td></td>
</tr>
<tr>
<td>Basophils</td>
<td>G/l</td>
<td>-</td>
<td>0.14</td>
<td></td>
</tr>
<tr>
<td><strong>URINE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specific gravity</td>
<td>-</td>
<td>0.017</td>
<td>0.015</td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td>-</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>LIVER</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>µmol/l</td>
<td>-</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>ASAT (SGOT)</td>
<td>U/l</td>
<td>-</td>
<td>N x (23/36)</td>
<td></td>
</tr>
<tr>
<td>ALAT (SGPT)</td>
<td>U/l</td>
<td>-</td>
<td>N x (28/45)</td>
<td></td>
</tr>
<tr>
<td>Gamma GT</td>
<td>U/l</td>
<td>-</td>
<td>N x (25/38)</td>
<td></td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>U/l</td>
<td>--</td>
<td>N x (30/95)</td>
<td></td>
</tr>
</tbody>
</table>

N = upper limit of normal range

# Definition of Clinically Noteworthy Abnormal Laboratory Values (CNALV)

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>CNALV</th>
</tr>
</thead>
</table>
| **HAEMOGLOBIN**           | • Decrease of at least 2g/dl and value < 10 g/dl whatever the baseline value  
                           |   • If missing baseline : value <10g/dl                                |
| **NEUTROPHILS**          | • < 1 500/mm³ whatever the baseline value                               |
| (if missing value for neutrophils) |                                                                       |
| **WBC**                  | • < 3 000/mm³ whatever the baseline value                               |
| **PLATELETS**            | • < 100 000/mm³ whatever the baseline value                             |
| **SERUM CREATININE**     | • Increase of at least 30 % as compared to baseline value and value > 150 µmol/l whatever the baseline value  
                           |   • If missing baseline : value > 150 µmol/l                           |
| **LIVER FUNCTION TESTS** |                                                                       |
| **ALAT**                 | • If normal baseline :                                               
                           |   • ALAT > 2 N                                                        |
|                           | • If abnormal baseline :                                             
                           |   → if baseline value ≤ 2.5 N :                                      
                           |     • increase of at least 100 % as compared to baseline value       
                           |     → if baseline value > 2.5 N :                                    
                           |     • value > 5 N                                                    |
| and/or **ASAT**          | • If normal baseline :                                               
                           |   • ASAT > 2 N                                                        |
|                           | • If abnormal baseline :                                             
                           |   → if baseline value ≤ 2.5 N :                                      
                           |     • increase of at least 100 % as compared to baseline value       
                           |     → if baseline value > 2.5 N :                                    
                           |     • value > 5 N                                                    |
| and/or **Alkaline phosphatase (AP)** |                                 |
|                           | • If normal baseline :                                               
                           |   • AP > 1.25 N                                                       |
|                           | • If abnormal baseline :                                             
                           |   • AP > 2 N                                                          |
| and/or **Total bilirubin (TB)** |                                                                     |
|                           | • If normal baseline :                                               
                           |   • TB > 1.5 N                                                        |
|                           | • If abnormal baseline :                                             
                           |   • TB > 2 N                                                          |

N=upper limit of normal range


Cardiovascular Safety

Table 1: Predefined Limits for Potentially Clinically Significant Changes (PSC) and PSC Leading to Clinically Significant Values (PSCV)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>PSC</th>
<th>PSCV</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP</td>
<td>Increase ≥ 20 mmHg</td>
<td>SBP ≥ 160 mmHg and increase ≥ 20 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 20 mmHg</td>
<td>SBP ≤ 90 mmHg and decrease ≥ 20 mmHg</td>
</tr>
<tr>
<td>DBP</td>
<td>Increase ≥ 10 mmHg</td>
<td>DBP ≥ 100 mmHg and increase ≥ 10 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 mmHg</td>
<td>DBP ≤ 50 mmHg and decrease ≥ 10 mmHg</td>
</tr>
<tr>
<td>HR</td>
<td>Increase ≥ 10 bpm</td>
<td>HR ≥ 110 bpm and increase ≥ 10 bpm</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 bpm</td>
<td>HR ≤ 50 bpm and decrease ≥ 10 bpm</td>
</tr>
</tbody>
</table>

Table 2: Predefined Classes for changes from Baseline to the Maximum (and/ or Minimum) Post-baseline Value

<table>
<thead>
<tr>
<th>Classes of Change from Baseline to the Maximum Post-baseline Value</th>
<th>Classes of Change from Baseline to the Minimum Post-baseline Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>All</td>
<td>All</td>
</tr>
<tr>
<td>≥ 0</td>
<td>≥ 0</td>
</tr>
<tr>
<td>&gt; 0</td>
<td>&gt; 0</td>
</tr>
<tr>
<td>≥ 10</td>
<td>≥ 10</td>
</tr>
<tr>
<td>≥ 20</td>
<td>≥ 20</td>
</tr>
<tr>
<td>≥ 30</td>
<td>≥ 30</td>
</tr>
<tr>
<td>≥ 40</td>
<td>≥ 40</td>
</tr>
<tr>
<td></td>
<td>≥ 25</td>
</tr>
<tr>
<td></td>
<td>≥ 30</td>
</tr>
</tbody>
</table>

Table 3: Classes for Vital Signs Maximum or Minimum Values

<table>
<thead>
<tr>
<th>Classes for the Maximum Post-baseline Value for each parameter</th>
<th>Classes for the Minimum Post-baseline Value for each parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>&lt; 120</td>
<td>&lt; 80</td>
</tr>
<tr>
<td>[120;140]</td>
<td>[80;90]</td>
</tr>
<tr>
<td>[140;160]</td>
<td>[90;100]</td>
</tr>
<tr>
<td>≥ 160</td>
<td>≥ 100</td>
</tr>
</tbody>
</table>

Table 4: Classes for Maximum or Minimum of BP in its entirety

<table>
<thead>
<tr>
<th>Classification of Maximum Values for Blood Pressure (mmHg)</th>
<th>Classification of Minimum Values Blood Pressure (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP &lt; 140 and DBP &lt; 90</td>
<td>SBP &gt; 90 and DBP &gt; 50</td>
</tr>
<tr>
<td>SBP [140;160] and DBP &lt; 100 or DBP [90;100] and SBP &lt; 160</td>
<td>SBP ≤ 90 or DBP ≤ 50</td>
</tr>
<tr>
<td>SBP ≥ 160 or DBP ≥ 100</td>
<td></td>
</tr>
</tbody>
</table>

Table 5: Definition of orthostatic hypotension

<table>
<thead>
<tr>
<th>Orthostatic Hypotension *</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP Decrease ≥ 20 mmHg or DBP Decrease ≥ 10 mmHg between supine and standing positions</td>
</tr>
</tbody>
</table>

16.1.1.8. Protocol amendment n° PA05 - General and substantial dated on 22 October 2014 linked to Protocol and appendices (version 8: 22 October 2014)
CLINICAL STUDY PROTOCOL AMENDMENT n° PA05
(General – Substantial)
Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study
APPROVAL FORM

STUDY: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo-controlled study

Clinical Study Protocol Amendment n° PA05
(General – Substantial)
Dated: 22OCT2014

Sponsor's representative(s)

* Medical Director
Dr Richard ROCHE
Date: 07/11/2014
Signature: [Signature]

* Clinical Study Manager:
Gaëlle ALCARAZ
Date: 07/10/2014
Signature: [Signature]

Study Coordinating Investigator:
Pr Savina NODARI
Date: 07/10/2014
Signature: [Signature]
COUNTRY COORDINATING INVESTIGATOR SIGNATURE FORM

STUDY: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Clinical Study Protocol Amendment n° PA05
(General – Substantial)
Dated: 22OCT2014

Country Coordinating Investigator: Date: Signature:
INVESTIGATOR SIGNATURE FORM

STUDY: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Clinical Study Protocol Amendment n° PA05
(General – Substantial)
Dated: 22OCT2014

By my signature below, I, Dr ______________________, hereby confirm that I have read, taken note of (and will apply) the modifications brought by the protocol amendment n° PA05 and I will conduct the trial according to these new modalities.

Date: ______________________ Signature: ______________________
# HISTORY OF AMENDMENTS

<table>
<thead>
<tr>
<th>Nº</th>
<th>TYPE</th>
<th>APPLICATION AREA</th>
<th>DATE</th>
<th>MODIFICATIONS</th>
</tr>
</thead>
</table>
| NA  | NA    | General          | NA         | Corresponding to Protocol Version 2: Following French CA request (ANSM) and leading to protocol version 2:  
- Add of a non inclusion criteria: “Breast-feeding female patient”  
- Add of haematology examination at visit 3 and 6 |
| PA01| Substantial | Local (Italy)  | 01MAR2013  | Corresponding to Protocol Version 3:  
- Integration of the modification included in the protocol version 2  
- Harmonisation of the protocol and the Informed Consent Form:  
  - adjustment of the selection criteria n°10 related to the contraception method  
  - addition of a letter that is given by the patient to his/her general practitioner (GP)  
  - precision that the sponsor can not collect a copy of the Informed Consent Form  
  - precision that the patient card is in Italian language only (without any English mention) |
| PA02| Non Substantial | General         | 28MAR2013  | Corresponding to Protocol Version 4:  
- change of Sponsor’s Representative (Clinical Study Manager),  
- modification of the technical handling of the blood samples for determination of red blood cells concentration of DHA: the centrifugation is no more needed,  
- precision on the function and address of the International Study Coordinator Pr Nodari,  
- add of address and contacts details of two CRO newly involved in the study: Theradis (in charge of transportation of blood samples to the Analytical centre and material supply) and “Clinact” (in charge of refund of patients expenses linked to the study),  
- adjustment of the wording, in agreement with the commitment to the French Ethics Committee. In the paragraphe 8.3.2.1, the wording “hematology examination” is replaced by “standard hematologic dosage”,  
- precision of the full title in the study synopsis (in agreement with the commitment to the Spanish Ethics Committee),  
- correction of a mistake in section 8.1.1.3 (related to TTEM transmission) and sections 3, 9 and study synopsis (related to the definition of INR not stabilized).  
- addition of the changes included in the local italian substantial protocol amendment (i.e. contraception method, letter to General Practitioner, patient card|
<table>
<thead>
<tr>
<th>Nº</th>
<th>TYPE</th>
<th>APPLICATION AREA</th>
<th>DATE</th>
<th>MODIFICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td><strong>Corresponding to Protocol Version 5:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Fax modification of the sponsor’s representatives</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Planned end of study postponed to January 2015.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- The authorized history of the first documented persistent atrial fibrillation is less than 3 years.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- At selection a hyperkalemia or a hypokalemia is better defined by the standards of the local laboratories.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Regarding previous treatments by amiodarone the non inclusion criteria of the protocol are adapted as follow:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Previous treatment with oral amiodarone within 4 months prior to inclusion</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Intake of oral amiodarone for more than 1 month within 4 to 12 months before inclusion</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Previous treatment with intravenous amiodarone within 4 weeks prior to inclusion.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- For male with a child-bearing potential partner (in Italy only): taking into account the duration of spermatogenesis the absolute abstention from sexual intercourse or the use of double barrier contraception method are extended to 3 months after the end of the study.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Ranolazine is an antiarrhythmic treatment added to the prohibited treatments.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Update of Serious Adverse Events (SAEs) form: Main change is the SAE sending: SAEs have to be reported to the Corporate Vigilance Department, and not anymore to the clinical study manager. Also SAEs can be sent by e-mail and by fax.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Addition of Alpha Bioresearch as CRO involved for Feasibility, Monitoring and Regulatory issues in Spain.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Correction of some minor typographic errors</td>
</tr>
<tr>
<td>PA03</td>
<td>Substantial</td>
<td>General</td>
<td>23OCT2013</td>
<td></td>
</tr>
<tr>
<td>PA04</td>
<td>Non Substantial</td>
<td>General</td>
<td>03JUN2014</td>
<td><strong>Corresponding to protocol V7:</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Precision on the temperature storage of DHA samples</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Precision on the BSA formula</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Addition of QTcB and QTcF</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Precision on TTEM recording timelines</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Clarification of the section Interim analysis and data monitoring (13.11)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Clarifications and specifications on some minor points</td>
</tr>
</tbody>
</table>

*in Italian and no collection of the consent form by the sponsor in Italy*.
1. AMENDMENT RATIONALE

The purpose of this amendment is mainly to clarify some points of the protocol regarding the management of vitamin K antagonist (VKA) treatment and to decrease constraints of the study for patients. This amendment relates also to a precision regarding the primary efficacy criterion, to an adjustment of some selection criteria in order to improve the feasibility of the study and relates to minor changes as typographical errors or style.

The clinical study protocol is updated with the following changes:

- Due to a recruitment rate lower than expected the planned end of study is postponed to April 2016.
- In order to have a better harmonization between the centres in the management of treatment with VKA some clarifications are incorporated in Chapter 8.4.6 Coagulation parameters.
- Atrial fibrillation and Atrial flutter are not the same rhythm disorder, but they are very similar and both are the expression of abnormal electrical impulses starting in the atria. So regarding the definition of the primary criterion, the atrial flutter emergence should be considered as having the same meaning as a recurrence in persistent AF. This primary criterion will be more precisely defined by the time to the first Atrial Fibrillation recurrence or Atrial Flutter emergence.
- To reduce constraints of patients follow-up, the number of scheduled visits passes from 9 to 7 and the TTEM will be weekly transmitted from week 6 to the end of the study instead of to be transmitted daily from week 6 to week 8 and then every two days from week 9 to week 24. These changes do not affect the overall risk of the study. The frequency of visits remains what is usually done in daily practice. A weekly TTEM has no impact on patient safety because on one hand patients are treated with an anticoagulant throughout the study and on the other hand a TTEM can be performed at any time in case of AF or atrial flutter symptoms.
- Patients must have a previous history of a first documented persistent Atrial Fibrillation without limitation in time instead of no longer than 3 years. This modification will expand the target population without changing the characteristics of the selected patients by enabling the management of patients who could experience a long period without AF relapse nor atrial flutter emergence.
- Patients must have a systolic heart failure defined by a reduced ventricular ejection fraction and or defined also through other echocardiographic parameters mentioned in the ESC guidelines for the diagnosis and treatment of acute and chronic heart failure (2012).
- Regarding previous prohibited treatments by amiodarone or droderanone, the non inclusion criteria of the protocol are adapted as follow:
  - Concomitant treatment with oral amiodarone or dronedarone from selection
  - Concomitant treatment with intravenous amiodarone from selection
Despite the long half life of amiodarone, these time limits relating to its non-use before inclusion should not interfere in a major way with the assessment of the product 6 months after inclusion.
### 2. CHANGES DESCRIPTION

<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>CLINICAL RESEARCH ORGANISATIONS</strong></td>
<td><strong>CLINICAL RESEARCH ORGANISATIONS</strong></td>
</tr>
<tr>
<td>For Feasibility, Monitoring and Regulatory issues: Pharmaceutical Service Network (PSN) Rufino Gonzalez 28 037 Madrid - SPAIN Phone: +34 91 375 6930 - Fax: +34 91 375 6931 E-mail: <a href="http://www.psn.global.org">www.psn.global.org</a></td>
<td>For Feasibility, Monitoring and Regulatory issues (in Hungary, Czech Republic and Italy): Pharmaceutical Service Network (PSN) Rufino Gonzalez 28 037 Madrid - SPAIN Phone: +34 91 375 6930 - Fax: +34 91 375 6931 E-mail: <a href="mailto:rzurita@psnglobal.org">rzurita@psnglobal.org</a></td>
</tr>
<tr>
<td>For refund of patients expenses linked to the study (in France): CLINACT 6-10 rue TROYON 92310 SEVRES – FRANCE Phone: +33 1 46 90 27 27 - Fax: +33 1 46 23 01 56 Email: <a href="mailto:sebastien.beaumont@clinact.com">sebastien.beaumont@clinact.com</a></td>
<td>For refund of patients expenses linked to the study (in France): CLINACT 6-10 rue TROYON 92310 SEVRES – FRANCE Phone: +33 1 46 90 27 27 - Fax: +33 1 46 23 01 56 Email: <a href="mailto:sebastien.beaumont@clinact.com">sebastien.beaumont@clinact.com</a></td>
</tr>
</tbody>
</table>

### SYNOPSIS

**Planned Study Period:** January 2013 – January 2015

**Methodology:**
- Start of treatment 4 weeks before ECV
  - Condition to ECV:
    - INR 2-3 (anti-vitamin K should be given at least 3 weeks before ECV)
    - No spontaneous cardioversion before ECV
  - Cardiac monitoring:
    - TTEM: daily transmission from week 6 to week 8; then every two days from week 9 to week 24, and in case of AF symptoms.

**Study Schedule:**
9 visits will be scheduled:
- V1/ W-4 to W-1: selection visit (7 to 28 days before the inclusion visit)
- V2/ D1: Inclusion visit (start of study treatment)
- V3/ W4 (D28 -2/+7 days): cardioversion visit (outpatient or hospitalization according to clinical

**SYNOPSIS**

**Planned Study Period:** January 2013 – April 2016

**Methodology:**
- Start of treatment 4 weeks before ECV
  - Condition to ECV:
    - Ideally INR 2-3 (vitamin K antagonist should be given at least 3 weeks before ECV)
    - No spontaneous cardioversion before ECV
  - Cardiac monitoring:
    - TTEM: one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24) and at any time in case of AF or atrial flutter symptoms.

**Study Schedule:**
7 visits will be scheduled:
- V1/ W-4 to W-1: selection visit (7 to 28 days before the inclusion visit)
- V2/ D1: Inclusion visit (start of study treatment)
- V3/ W4 (D28 -2/+7 days): cardioversion visit (outpatient or hospitalization according to clinical practice of the...
Diagnosis and Criteria for Inclusion:

Inclusion Criteria:

3. History of first documented persistent AF less than 3 years.
4. History of ischemic or non ischemic heart failure

6. Reduced left ventricular ejection fraction between 30% and 45% inclusive (using the two-dimensional echocardiography biplane Simpson’s rule) at selection and at inclusion
### Non-Inclusion Criteria:

**Criteria related to pathologies:**

1. History of first documented episode of persistent AF more than 3 years

2. Concomitant treatment with ranolazine or any antiarrhythmic drug (within 7 days prior to selection), except stable dose of digoxin, betablockers, calcium-blockers

3. Oral amiodarone:
   - 13a Previous treatment with oral amiodarone within 4 months prior to inclusion
   - 13b Intake of oral amiodarone for more than 1 month within 4 to 12 months before inclusion

4. Previous treatment with intravenous amiodarone within 4 weeks prior to inclusion

5. Concomitant treatment with oral amiodarone or dronedarone from selection

6. Previous treatment with intravenous amiodarone from selection

7. Patient treated with other anticoagulant treatment than antivitamin K: thrombin inhibitor such as Dabigatran or treated with antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel

### Exclusion criteria before V3:

Patients not stabilized for INR (i.e. values not between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO–TE (trans-esophageal echocardiograph) performed in the same day (before ECV) ECV will be performed in patients without dyskalemia
<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>If necessary for obtaining stabilized INR between 2 and 3, the ECV (and following visits) could be</td>
<td>same day (before ECV) and the patient can continue the study.</td>
</tr>
<tr>
<td>postponed by 7 days.</td>
<td>If necessary, for meeting these INR conditions, the ECV (and following visits) could be postponed by</td>
</tr>
<tr>
<td>[…]</td>
<td>7 days.</td>
</tr>
<tr>
<td>Evaluation Criteria:</td>
<td>Evaluation Criteria:</td>
</tr>
<tr>
<td>Efficacy evaluation variables:</td>
<td>Efficacy evaluation variables:</td>
</tr>
<tr>
<td>Primary evaluation variable:</td>
<td>Primary evaluation variable:</td>
</tr>
<tr>
<td>- Time to first Atrial Fibrillation recurrence defined by the first episode of AF lasting for at</td>
<td>- Time to first Atrial Fibrillation recurrence or atrial flutter emergence defined by the time to</td>
</tr>
<tr>
<td>least 10 minutes (Follow up of 20 weeks after visit 3 – ECV visit). Handling of AF recurrences:</td>
<td>first episode of AF or atrial flutter lasting for at least 10 minutes (Follow up of 20 weeks after</td>
</tr>
<tr>
<td>7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) between visit 3</td>
<td>visit 3 – ECV visit). Handling of AF recurrences or atrial flutter emergences: 7-day continuous ECG</td>
</tr>
<tr>
<td>(ECV visit) and visit 4 (week 5). Then, the follow up will be documented using the TTEM: daily</td>
<td>(5-leads/2 or 3 channels) ambulatory recording (holter ECG) between visit 3 (ECV visit) and visit 4</td>
</tr>
<tr>
<td>transmission from week 6 to week 8. Then, every two days from week 9 to week 24. For randomised</td>
<td>(week 5). Then, the follow up will be documented using the TTEM: one transmission per week from the</td>
</tr>
<tr>
<td>patients with spontaneous cardioversion before ECV, the recurrence of AF will be assessed after</td>
<td>day of visit 4 (end of week 5) to visit 9 (week 24).</td>
</tr>
<tr>
<td>visit 3 (week 5).</td>
<td>For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF or the</td>
</tr>
<tr>
<td>Moreover, during this TTEM period, if patient experiences any AF symptoms, it should be recorded</td>
<td>emergence of atrial flutter will be assessed after visit 3 (from week 5).</td>
</tr>
<tr>
<td>and documented using the TTEM.</td>
<td>Moreover, during this TTEM period, if patient experiences any AF or atrial flutter symptoms, it</td>
</tr>
<tr>
<td>All ECG traces will be evaluated by a Central Reading Laboratory.</td>
<td>should be recorded and documented using the TTEM.</td>
</tr>
<tr>
<td>[…]</td>
<td>All ECG (Holter and TTEM) will be evaluated by a Central Reading Laboratory.</td>
</tr>
<tr>
<td>Statistical Methods:</td>
<td>Statistical Methods:</td>
</tr>
<tr>
<td>Sample Size:</td>
<td>Sample Size:</td>
</tr>
<tr>
<td>Assuming an AF recurrence rate under placebo of 85%, a power of 80%, an alpha risk of 5% and a</td>
<td>Assuming an AF recurrence or atrial flutter emergence rate under placebo of 85%, a power of 80%,</td>
</tr>
<tr>
<td>rate of not assessable patients of 15%, 76 randomised patients per week.</td>
<td>an alpha risk of 5% and a rate of not assessable patients of 15%, 76</td>
</tr>
</tbody>
</table>
group will be necessary, using a log-rank test of survival curves, a difference between groups of 20%.

randomised patients per group will be necessary, using a log-rank test of survival curves, a difference between groups of 20%.

STUDY FLOW CHART
Please see flow-chart of previous version in appendix 1

STUDY FLOW CHART
Please see flow-chart of modified version in appendix 2

3. ETHICAL CONSIDERATIONS RELATING TO THE STUDY

[...]
During the study, in case of AF recurrence that would require cardioversion or the introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms for instance, patients will be withdrawn and the tested product stopped.

[...]
- ECV in patients with stabilized INR (i.e. values between 2 and 3; sp to) on at least 3 consecutive weekly tests performed. Patients not stabilized for INR (i.e. values not between 2 and 3) on at least 3 consecutive weekly tests performed before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE (trans-esophageal echocardiograph) performed in the same day (before ECV). Patients who do not revert to sinus rhythm or present an early relapse within the observation period after ECV will be withdrawn and the tested product stopped.

During the whole study, patients will remain under medical control: visits in cardiology units will be scheduled at least every month. This follow up will include clinical signs, ECG, biological and coagulation parameters. Moreover, patient’s cardiac rhythm will be monitored between visits using daily, then every 2 days Trans Telephonic ECG Monitoring (TTEM) reviewed by a Central Reading Laboratory.

[...]
4. STUDY DESIGN
4.1 OVERALL DESCRIPTION

[...]

Nine visits are planned for the study:

- Visit 1 (V1): W-4 to W-1: Selection visit (7 to 28 days before the Inclusion Visit)
- Visit 2 (V2): D1: Inclusion visit (start of study treatment)
- Visit 3 (V3): W4 (D28 -2/+7D): cardioversion visit (outpatient or hospitalization according to clinical practice of the centre) (installation of the Holter ECG device)
- Visit 4 (V4): W5 (D35 -2/+7D): follow-up visit (removing of Holter ECG device and installation of the TTEM)
- Visit 5 (V5): W8 (D56 ± 7D): follow-up visit
- Visit 6 (V6): W12 (D84 ± 7D): follow-up visit
- Visit 7 (V7): W16 (D112 ± 7D) : follow-up visit
- Visit 8 (V8): W20 (D140 ± 7D): follow-up visit
- Visit 9 (V9): W24 (D168 ± 7D): final study visit

4.2. DISCUSSION OF THE STUDY DESIGN
4.2.1. Choice of the Study Population

[...]

The study aim is to investigate the product effect in patients with:

- Persistent AF history (less than three years) with a duration of the current episode from 7 days to 6 months.
- A moderately abnormal systolic heart failure (Left Ventricular Ejection Fraction (LVEF) between 30 to 45% as defined in the report from the American Society of Echocardiography’s Guideline).
- a Left Atrial Area (LAA) not severely abnormal (less than 40 cm$^2$ as defined in the report from the American Society of Echocardiography’s Guideline).

4.2.2. Choice of the Study Design

According to the target indication, only patients with persistent AF and requiring an ECV will be included in order to assess the time to first documented recurrence of AF since cardioversion. To confirm the persistent nature of AF, a 24-hour holter monitoring will be performed during the selection visit. Eligible participants will enter a selection phase in which anticoagulant treatment (AVK) will be adjusted to achieve an International Normalized Ratio (INR) of 2.0 to 3.0 before ECV. According to guidelines for the management of AF [6], AVK should be given at least 3 weeks before cardioversion because of risk of thrombo-embolism due to post-cardioversion.

Finally, during the study, patients will be scheduled for a clinical visit every month (with an additional visit 7 days after visit 3 (ECV visit)) in order to ensure a close medical monitoring and to assess efficacy and safety parameters.
### 5. STUDY POPULATION

#### 5.1 INCLUSION CRITERIA

**Demographic Characteristics and Other Baseline Characteristics:**

[...]

3. History of first documented persistent AF less than 3 years

4. History of ischemic or non ischemic heart failure

[...]

6. Reduced left ventricular ejection fraction between 30% and 45% inclusive (using the two-dimensional echocardiography biplane Simpson’s rule) at selection and at inclusion

[...]

### MODIFIED VERSION

#### 5. STUDY POPULATION

#### 5.1 INCLUSION CRITERIA

**Demographic Characteristics and Other Baseline Characteristics:**

[...]

3. **Previous** history of first documented episode of persistent AF

4. **Previous** history of ischemic or non ischemic heart failure

[...]

6. Left ventricular systolic dysfunction defined at selection and at inclusion by a reduced left ventricular ejection fraction (LVEF) \(\geq 30\%\) and \(\leq 45\%\) or for patients with a LVEF > 45%:

- an increased left ventricular end-diastolic size (diameter \(\geq 60\) mm and/or \(> 32\) mm/m\(^2\) and/or volume \(> 97\) ml/m\(^2\))
- and/or an increased left ventricular end-systolic size (diameter \(> 45\) mm and/or \(> 25\) mm/m\(^2\) and/or volume \(> 43\) ml/m\(^2\))
- and/or a reduced left ventricular outflow tract velocity time integral < 15 cm

[...]
<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>5.2 NON INCLUSION CRITERIA</strong></td>
<td><strong>5.2 NON INCLUSION CRITERIA</strong></td>
</tr>
<tr>
<td><em>Criteria related to pathologies:</em></td>
<td><em>Criteria related to pathologies:</em></td>
</tr>
<tr>
<td>1. History of first documented episode of persistent AF more than 3 years,</td>
<td>1. No previous history of first documented episode of persistent Atrial Fibrillation</td>
</tr>
<tr>
<td>[...]</td>
<td>[...]</td>
</tr>
<tr>
<td><em>Criteria related to treatments:</em></td>
<td><em>Criteria related to treatments:</em></td>
</tr>
<tr>
<td>[...]</td>
<td>[...]</td>
</tr>
<tr>
<td>12. Concomitant treatment with ranolazine or any antiarrhythmic drug (within 7 days prior to selection), except stable dose of digoxin, betablockers, calcium-blockers</td>
<td>12. Concomitant treatment with ranolazine or any antiarrhythmic drug (within 7 days prior to selection), except amiodarone, dronedarone and stable dose of digoxin, betablockers, calcium-blockers</td>
</tr>
<tr>
<td>13. Oral amiodarone:</td>
<td>13. Concomitant treatment with oral amiodarone or dronedarone from selection</td>
</tr>
<tr>
<td>13a Previous treatment with oral amiodarone within 4 months prior to inclusion</td>
<td>14. Concomitant treatment with intravenous amiodarone from selection</td>
</tr>
<tr>
<td>13b Intake of oral amiodarone for more than 1 month within 4 to 12 months before inclusion</td>
<td>[...]</td>
</tr>
<tr>
<td>14. Previous treatment with intravenous amiodarone within 4 weeks prior to inclusion</td>
<td>19. Patient treated with oral anticoagulant treatment other than vitamin K antagonist: new oral anticoagulants (dabigatran, rivaroxaban, apixaban), or treated with irreversible antiplatelet agents P2Y12 inhibitors such as ticlopidine, clopidogrel or prasugrel</td>
</tr>
<tr>
<td>[...]</td>
<td>[...]</td>
</tr>
<tr>
<td>19. Patient treated with other anticoagulant treatment than antivitamin K: thrombin inhibitor such as Dabigatran or treated with antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel</td>
<td></td>
</tr>
</tbody>
</table>
## PREVIOUS VERSION

under his/her responsibility. Erroneous inclusions will not be paid to the investigator.

- Patients who could not be treated with AVK for at least 3 weeks before ECV.
- Patients who will not have a stabilized INR between 2 and 3 on at least 3 consecutive weekly tests.
- Patients with only 2 consecutives INR tests between 2 and 3 in the last 3 weeks for whom a trans-oesophageal echocardiography can not be performed before ECV or for whom a trans-oesophageal echocardiography shows a thrombus in the atria.
- Patients who will not revert to sinus rhythm (i.e. unsuccessful ECV) or with early relapse within the observation period after ECV will be considered to have finished follow-up.
- Occurrence of AF recurrence that would require, at the investigator’s judgement, a cardioversion or an introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms for instance.

[...]

## MODIFIED VERSION

- Patients who could not be treated with VKA for at least 3 weeks before ECV or who will experience a VKA intolerance during the study.
- Patients without dyskalemia who will not have INR values ≥ 2 on the 3 last tests performed before ECV should not have an ECV and will be excluded from the study. However, if only 2 INR values are ≥ 2 among those 3 last tests, an ECV can be performed if the presence of atrial thrombosis can be excluded with an ECHO–TE (transesophageal echocardiography) performed on the same day (before ECV) and the patient can continue the study.
- Patients who will not revert to sinus rhythm (i.e. unsuccessful ECV) or with early AF relapse or early atrial flutter emergence within the observation period after ECV will be considered to have finished follow-up.
- Occurrence of AF recurrence or atrial flutter emergence that would require, at the investigator’s judgement, a cardioversion or an introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms for instance.

[...]

## 6. STUDY TREATMENT

### 6.2. PACKAGING AND LABELLING

#### 6.2.1. Packaging

[...]

The Investigator will provide the patient with the treatment according to the following schedule:

At Inclusion Visit (V2): a 12-week treatment unit will contain 3 cases, each case containing:
- 10 blister packs of four 1 g F373280 soft capsules or placebo soft capsules each.

At Visit 6 (V6): a 12-week treatment unit will contain 3 cases, each case containing:

### 6.2. PACKAGING AND LABELLING

#### 6.2.1. Packaging

[...]

Two 12-week treatment units will contain 3 cases, each case of 4-week treatment containing: 10 blister packs of four 1 g F373280 soft capsules or 1 g placebo soft capsules each.

[...]

Final version 826/1185
- 10 blister packs of four 1 g F373280 soft capsules or placebo soft capsules each.

[...]

**6.4 ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT**

[...]

Practically, once patient’s eligibility is confirmed at selection visit (V1):

- The Investigator:
  - Contacts the IVRS/IWRS
  - Answers the questions relating to the patient
  - In return, the treatment number to be allocated for the first 12-week period to the patient is given by the IVRS/IWRS.

[...]

The Investigator will dispense to the patient the case which label indicates the treatment number and the administration period.

At visit 6, the Investigator will contact again the IVRS/IWRS to obtain the treatment number for the last 12-week period of treatment according to the same process as described above.

**7. CONCOMITANT TREATMENTS**

**7.1. ANTI-VITAMIN K TREATMENT**

AVK should be given for at least 3 weeks before ECV and continued for the whole study duration. The AVK used will be left to the decision of the each Investigator according to his/her local practice.

---

**MODIFIED VERSION**

**6.4 ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT**

[...]

At selection visit (V1), practically, once patient’s eligibility is confirmed:

- The Investigator:
  - Contacts the IVRS/IWRS
  - Answers the questions related to the patient

[...]

At inclusion visit (V2), the treatment number to be allocated for the first 12-week period to the patient is given by the IVRS/IWRS.

At visit 6, the Investigator will contact again the IVRS/IWRS to obtain the treatment number for the last 12-week period of treatment according to the same process as described above.

**7. CONCOMITANT TREATMENTS**

**7.1. VITAMIN K ANTAGONIST TREATMENT**

VKA should be given for at least 3 weeks before ECV and continued for the whole study duration. However, VKA should be stopped in case of occurrence of VKA intolerance during the study and the patient should be withdrawn from the study. The VKA used will be left to the decision of each Investigator according to his/her local practice.
### 7.2. PROHIBITED TREATMENTS

Any anticoagulant treatment other than AVK: thrombin inhibitor such as Dabigatran or antiaggregant P2Y12 inhibitors such as Clopidogrel or Prasugrel

### 8. EVALUATION CRITERIA

#### 8.1 PRIMARY EFFICACY CRITERIA

**8.1.1. Time to the first Atrial Fibrillation Recurrence**

**8.1.1.1. Definition**

Time to first AF recurrence is defined by the first episode of AF (symptomatic or not) lasting for at least 10 minutes.

**8.1.1.2. Schedule**

The heart rhythm follow up will be performed from the end of ECV visit (visit 3) to the final study visit (visit 9).

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF will be assessed after visit 3 (week 5).

**8.1.1.3. Evaluation Methods**

- Trans Telephonic ECG Monitoring:
  The ECG follow up will be documented using the TTEM: daily transmission from the day after visit 4 (week 6) to visit 5 (week 8). Then every two days from the day after visit 5 (week 9) to visit 9 (week 24 – End of study).

Moreover, if patient experiences AF symptoms during this TTEM period, it should be documented using the TTEM.

In case of AF recurrence and provided that the patient does not require a cardioversion or an introduction of an anti-

---

**MODIFIED VERSION**

Any oral anticoagulant treatment other than VKA: new oral anticoagulants (dabigatran, rivaroxaban, apixaban), or irreversible antiplatelet agents P2Y12 inhibitors such as ticlopidine, clopidogrel or prasugrel

### 8. EVALUATION CRITERIA

#### 8.1 PRIMARY EFFICACY CRITERIA

**8.1.1. Time to the first Atrial Fibrillation Recurrence**

**or Atrial Flutter Emergence**

**8.1.1.1. Definition**

Time to first AF recurrence or atrial flutter emergence is defined by the time to first episode of AF or atrial flutter (symptomatic or not) lasting for at least 10 minutes.

**8.1.1.2. Schedule**

The heart rhythm follow up will be performed from the end of ECV visit (visit 3) to the final study visit (visit 9).

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF or the emergence of atrial flutter will be assessed after visit 3 (from week 5).

**8.1.1.3. Evaluation Methods**

- Trans Telephonic ECG Monitoring:
  The ECG follow up will be documented using the TTEM: one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24, end of study). The patient will be requested to contact the Central Reading Laboratory for transmission of each stored TTEM.

Moreover, if patient experiences AF or atrial flutter symptoms during this TTEM period, it should be documented using the TTEM.
<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>arrhythmic at Investigator’s judgement, the patient could be maintained in the study with the treatment in order to assess a spontaneous cardioversion. For that purpose the patient will continue to transmit a TTEM once a week. The TTEM will be centralized by the Central Reading Laboratory. The patient will be requested to contact the Central Reading Laboratory for transmission of each stored TTEM. The TTEM will be validated by a trained technician, then analysed by a cardiologist. The cardiologist interpretation will be emailed to the site (or per fax on request of the site). The investigator will be asked to review and sign this document. The TTEM process will be fully described in a separate document.</td>
<td>In case of AF recurrence or atrial flutter emergence and provided that the patient does not require a cardioversion or an introduction of an anti-arrhythmic at Investigator’s judgement, the patient could be maintained in the study with the treatment in order to assess a spontaneous cardioversion. For that purpose the patient will continue to transmit a TTEM once a week. <strong>Process of centralisation of ECG (Holter and TTEM)</strong> ECG (Holter and TTEM) will be centralized by the Central Reading Laboratory. The ECG will be validated by a trained technician, then analysed by a cardiologist. The cardiologist interpretation will be emailed to the site (or per fax on request of the site). The investigator will be asked to review and sign these documents. The Holter and TTEM process will be fully described in separate documents.</td>
</tr>
<tr>
<td>PREVIOUS VERSION</td>
<td>MODIFIED VERSION</td>
</tr>
<tr>
<td>------------------</td>
<td>------------------</td>
</tr>
</tbody>
</table>
| **8.1.2 Secondary Efficacy Criteria**  
8.1.2.3. Clinical parameters evaluation  
8.1.2.3.1. EHRA score assessment  
8.1.2.3.1.3. Evaluation Methods  
EHRA evaluation will be collected by Central Reading Laboratory during all the study period. | **8. 2 SECONDARY EFFICACY CRITERIA**  
8.2.3. Clinical parameters evaluation  
8.2.3.1. EHRA score assessment  
8.2.3.1.3. Evaluation Methods  
EHRA evaluation will be collected by Central Reading Laboratory during **TTEM** period. |
| **8.1.2.3.2. Number of recurrence of symptomatic AF**  
It consists of the number of AF recurrences associated with a symptom (palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety) and confirmed by an ECG. | **8.2.3.2. **Time to first AF recurrence less than 10 minutes  
Time to first AF recurrence less than 10 minutes will be assessed during **TTEM** period. |
| **8.2. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA**  
8.2.2 Blood samples  
8.2.2.2. Technical handling  
Two blood samples (4 ml) will be collected in EDTA tubes. They will be gently shaken, stored between +2°C/+8°C in a fridge (**no freezing will be allowed**) and sent to Analytical Centre in refrigerated conditions (between +2°C and +8°C).  
[…] | **8.3. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA**  
8.3.2 Blood samples  
8.3.2.2. Technical handling  
Two blood samples (**2 x 4 ml**) will be collected in EDTA tubes. They will be **homogenized slowly by inverting the tube without shaking**, stored between +2°C/+8°C in a fridge (**no freezing will be allowed**) and sent to Analytical Centre in refrigerated conditions (between +2°C and +8°C).  
[…] |
8.3 SAFETY ASSESSMENT
8.3.2 Laboratory Investigations
8.3.2.2 Technical Procedures and Parameters

Haematology: hematocrit, haemoglobin, RBC count, white blood cells (WBC) count, WBC differential counts (% and absolute), reticulocytes, platelets.

Chemistry: […]

Additional tests may be done at the Investigator’s discretion, in the patient’s interest. In case of any abnormal or clinically significant results, the Investigator will order laboratory control tests.

8.3.3. Global Physical Examination
A global physical examination including the measurement of body weight will be carried out on each body system at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.
[…]

8.3.5. Electrocardiogram (ECG)
8.3.5.1. Schedule
An ECG will be recorded after at least 10 minutes of rest at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9 using an usual standardised 12-lead cardiograph.
[…]

8.3.6 Coagulation parameters
[…]
During the pre-cardioversion period, if the anticoagulation by AVK should be initiated, then the INR monitoring will be as follow:
- INR 2-3 times a week for the first week of treatment

8.4 SAFETY ASSESSMENT
8.4.2 Laboratory Investigations
8.4.2.2 Technical Procedures and Parameters

Haematology: hematocrit, haemoglobin, RBC count, white blood cells (WBC) count, WBC differential counts (% and/or absolute), reticulocytes, platelets.

Biochemistry: […]

Additional tests may be done at the Investigator’s discretion, in the patient’s interest. In case of any abnormal and/or clinically significant results, the Investigator should order laboratory control tests.

8.4.3. Global Physical Examination
A global physical examination including the measurement of body weight will be carried out on each body system at visit 1, visit 2, visit 3, visit 4, visit 5, visit 6, visit 7, visit 8 and visit 9.
[…].

8.4.5. Electrocardiogram (ECG)
8.4.5.1. Schedule
An ECG will be recorded after at least 10 minutes of rest at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9 using an usual standardised 12-lead cardiograph.
[…]

8.4.6 Coagulation parameters
[…]
The recommendations for the controls of INR are the following [25, 26]:

1) During the pre-cardioversion period, if the anticoagulation by VKA has to be initiated, the treatment must be initiated at least 3 weeks prior to
PREVIOUS VERSION

- INR weekly up to ECV
- INR every 4 weeks after ECV

For patients already treated with AVK, INR monitoring will be as follow:
- INR weekly up to ECV
- INR every 4 weeks after ECV

aPTT and TCT will be performed at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.

Anti-coagulation by AVK should be given at least 3 weeks before ECV and continued for the whole study duration.

The quantity of blood samples collected at each time for coagulation parameters will be 2 mL.

Additional tests may be done at the Investigator’s discretion, in the patient’s interest. In case of any abnormal or clinically significant results, the Investigator will order laboratory control tests.

[...]

FINAL VERSION

cardioversion then the INR will be monitored as follow:
- The adjustment of the dosage of VKA should be performed stepwise by controlling INR 2 to 3 times a week until stabilization within the target range (2 - 3) on 2 successive tests.
- When the INR is within the target range (2 - 3) on 2 successive tests, the dose of VKA should be maintained. Then the controls of INR will be progressively spaced within a few weeks.
- When INR is stabilized, at least one test should be performed each week.
- In all cases, an INR control must be performed within 24 h before ECV.

2) During the pre-cardioversion period, if the anticoagulation by VKA was already initiated, the INR will be monitored as follow:
- One INR per week up to ECV
- An INR control must be performed within 24 h before ECV

3) After cardioversion: one INR each month

4) Throughout the duration of the study if INR > 3 the advocated actions are:
- No transeosophageal echocardiography before cardioversion
- For asymptomatic patients:
  - 3 < INR < 4: no omission of VKA (dose adjustment if required), no vitamin K
  - 4 ≤ INR < 6: omit one dose of VKA, no vitamin K
  - 6 ≤ INR < 10: interrupt VKA, vitamin K 2 mg orally
  - INR ≥ 10: interrupt VKA, vitamin K 5 mg orally

For INR ≥ 6, an adverse event has to be reported (asymptomatic overdose).

Anti-coagulation by VKA should be given at least 3 weeks before ECV and continued for the whole study duration.
aPTT and TCT will be performed at visit 1, visit 2, visit 3, visit 5, visit 6, visit 7, visit 8 and visit 9.
The quantity of blood samples collected at each time for coagulation parameters will be 2 ml.

Additional tests may be done at the Investigator’s discretion, in the patient’s interest. In case of any abnormal and/or clinically significant results, the Investigator should order laboratory control tests.

8.4 CONCOMITANT TREATMENTS
Concomitant treatments will be evaluated at each study visit.
Requirements relating to patient's concomitant treatments started before screening visit and continued throughout the trial, or started during the trial, can be found in section 7.

8.5 CONCOMITANT TREATMENTS
Concomitant treatments will be evaluated at each study visit.
Requirements related to patient's concomitant treatments started before selection visit and continued throughout the trial, or started during the trial, can be found in section 7.

9. STUDY PROCEDURES
Visit 1 - Selection Visit (Week - 4 to Week -1):

• The patient will enter the selection period in which anticoagulant (AVK) will be adjusted to achieve an International Normalized Ratio (INR) of 2 to 3 before ECV.

The patient will receive from the investigational centre the study card to be kept for the duration of the study.

Visit 2 - Inclusion Visit (Day 1)
If the patient's behaviour during the selection period and/or the result of complementary examinations, particularly the confirmation of the presence of persistent AF by the
During this period, the INR and laboratory tests, are compatible with the inclusion criteria, the patient will be assessed for the following:

[...]

If the results of the above assessments are compatible with the inclusion criteria, the patient will be included and allocated a treatment number using the IVRS/IWRS.

Between this Inclusion visit and the next visit (V3), the INR will be closely monitored (refer to paragraph 8.3.6) in order to ensure that the INR is stable (between 2 to 3 before electrical cardioversion).

[...]

At the end of the visit, the Investigator will organise the appointment for the next visit and will give the treatment for the next 4-week period.

Vist 3 (Week 4: D28 -2/+7 days) cardioversion

[...]

Electrocardioversion (ECV): ECV has to be scheduled 4 weeks after randomization and after target International Normalized Ratio levels will be stabilized (between 2 and 3) on at least 3 consecutive weekly tests in patients with AF. Patients not stabilized for INR (i.e. values not between 2 and 3) on at least 3 consecutive weekly tests before ECV will be excluded from the study, unless the presence of atrial thrombosis may be excluded with ECHO –TE performed in the same day (and before ECV). ECV will be performed in the morning, with the patient in the fasting state and without dyskalemia.

[...]

Patients who will not revert to sinus rhythm or with early relapse within the observation period after ECV will be withdrawn from the study and will be considered to have finished their follow-up.

[...]

Vist 3 (Week 4: D28 -2/+7 days) cardioversion

Electrocardioversion (ECV): ECV has to be performed 4 weeks after randomization in patients with AF. ECV will be performed in the morning, with the patient in the fasting state and without dyskalemia. An INR value control must be performed within 24h before ECV. INR values ≥ 2 on the 3 last tests performed before ECV are required. However, if only 2 INR values are ≥ 2 among those 3 last tests, an ECV can be performed if the presence of atrial thrombosis can be excluded with an ECHO–TE (transesophageal echocardiography) performed on the same day (before ECV) and the patient can continue the study.

[...]

Patients who will not revert to sinus rhythm or with early AF relapse or early atrial flutter emergence within the observation period after ECV will be withdrawn from the study and will be considered to have finished their follow-up.
At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week period.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 8-week period (two cases of treatment).

Visit 4 (Week 5: D35 -2/+7 days)

The patient will be requested to perform daily transmission from the day after visit 4 (week 6) to visit 5 (week 8), then every two days from the day after visit 5 (week 9) to visit 9 (week 24 – End of study). Moreover, in case of AF symptoms, additional transmissions may be performed.

Visit 4 (Week 5: D35 -2/+7 days)

The patient will be requested to perform one transmission per week from this visit (initial call to perform with the patient) to the visit 9 (week 24 – end of study). Moreover, in case of AF or atrial flutter symptoms, additional transmissions may be performed.

Visit 5 (Week 8: D56 ± 7 days) – Visit 6 (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days) - Visit 8 (Week 20: D140 ± 7 days)

- Laboratory examination: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT). However, in case of discontinuation of anticoagulation after ECV, the monitoring of INR, aPTT and TCT should be stopped.

Visit 5 (Week 8: D56 ± 7 days) – Visit 6 (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days) - Visit 8 (Week 20: D140 ± 7 days):

- Laboratory examination: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT). However, in case of discontinuation of anticoagulation after ECV due to occurrence of VKA intolerance, the monitoring of INR, aPTT and TCT should be stopped.

- The cardiac monitoring will be continued using a TTEM device. The device will be given to the patient who will be requested to perform daily transmission from the day after visit 4 (week 6) to visit 5 (week 8), then every two days from the day after visit 5 (week 9) to visit 9 (week 24 – End of study). Moreover, in case of AF or atrial flutter symptoms, additional transmissions may be performed.

- The cardiac monitoring will be continued using the TTEM device through one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24, end of study). Moreover, in case of AF or atrial flutter symptoms, additional transmissions may be performed.

Visit 5 (Week 8: D56 ± 7 days) – Visit 6 (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days) - Visit 8 (Week 20: D140 ± 7 days):
9) to visit 9 (week 24 – End of study). Moreover, in case of AF symptoms, additional transmissions may be performed.

[...]

The Investigator will collect all unused cases, blisters and soft capsules, and will count the unused capsules for each 4-week treatment period.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 4-week treatment period.

In addition,:
- at visit 6:
  • the investigator will contact the IVRS/IWRS to obtain the treatment unit number to be dispensed at visit 6 for the last 12-week period.
  • an echocardiography will be performed, an haematology examination will be done and the RBC concentration of DHA will be measured.

[...]

End-of-Study Visit - Visit 9 (Week 24: D168 ± 7 days):
[...]

The Investigator will collect all unused cases, blisters and soft capsules, and will count the unused soft capsules

[...]
### 13. STATISTICAL ANALYSIS

#### 13.2. SAMPLE SIZE

Assuming an AF recurrence or *atrial flutter emergence* rate of 85% under placebo and 65% under active group, i.e. a clinically relevant difference \( \Delta \) of 20%, a sample size of 64 assessable patients per group is required, using a log-rank test of survival curves with a 80% power and a 5% two-sided significance level.

### 13.7. EFFICACY ANALYSIS

#### 13.7.1. Primary Criterion

**13.7.1.1. Primary Analysis**

The primary criteria, time to first recurrence, will be analysed using the Kaplan Meier method and compared with the Log rank test. Hazard ratios and 95% confidence intervals will be estimated with the Cox regression model. […]

#### 13.7.2. Secondary Criteria

**13.7.2.1. Numbers of Atrial Fibrillation Episodes**

 […]

**13.7.2.2. Duration of Atrial Fibrillation Episodes**

 […]

### 16. REFERENCES

3 added references:

<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
</table>
| TRINDADE, ADRIAAN A. VOORS, FAIEZ ZANNAD, ANDREAS ZEIHER  | ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012  
*European Heart Journal* (2012) 33, 1787–1847                                                                                      |
| [25]. AGENCE NATIONALE DE SECURITE DU MEDICAMENT ET DES PRODUITS DE SANTE (ANSM).                | Bon usage des médicaments antivitamine K (AVK)  
*Actualisation – Juillet 2012*                                                                                                                       |
| [26]. GILLES PERNOD, ANNE GODIER, CLAIRE GOZALO, BENJAMIN TREMEY, PIERRE SIE                          | French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding)  
*Thrombosis Research* 126 (2010) e167–e174                                                                                      |
ANNEXE 1
STUDY FLOW-CHART FROM PROTOCOL VERSION 7
### Table of Activities

<table>
<thead>
<tr>
<th>Weeks</th>
<th>V1</th>
<th>V2</th>
<th>V3</th>
<th>V4</th>
<th>V5</th>
<th>V6</th>
<th>V7</th>
<th>V8</th>
<th>V9</th>
</tr>
</thead>
<tbody>
<tr>
<td>W-4 to W-1</td>
<td>D1</td>
<td>W4</td>
<td>W5</td>
<td>W8</td>
<td>W12</td>
<td>W16</td>
<td>W20</td>
<td>W24</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(28 -2D/+7 D)</td>
<td>(35 -2D/+7 D)</td>
<td>(56+/-7D)</td>
<td>(84+/-7D)</td>
<td>(112+/-7D)</td>
<td>(140+/-7D)</td>
<td>(168+/-7D)</td>
<td></td>
</tr>
</tbody>
</table>

**Outpatient or Hospitalization (1)**

**Informed consent**

**Demographic characteristics**

**Medico-surgical history**

**Concomitant disease**

**Concomitant treatment**

**Habits**

**Global physical examination (body weight)**

**Echocardiography**

**Eligibility criteria check**

**Blood pressure, heart rate**

**12-Lead ECG Recording**

**INR**

**aPTT, TCT**

**Biochemistry**

**Hematology**

**Urinary pregnancy test**

**Red Blood Cell concentrations of DHA**

**Treatment allocation**

**IVRS/IWRS**

**ECV (3)**

**Drug administration**

**Adverse events recording**

**Holter ECG**

**TTEM (6)**

1. Outpatient or hospitalization according to clinical practice of the centre (less or more than 24 hours)
2. INR: 2 to 3 times a week, then weekly until ECV, then every 4 weeks after ECV
3. In patients with AF
4. 24-hour Holter ECG
5. 7-day Holter ECG
6. TTEM: everyday from week 6 to week 8, then every 2 days from week 9 to week 24; at any time in case of AF symptoms.

In case of AF recurrence for at least 10 minutes and if the patient does not stop the study treatment, then TTEM once a week.
ANNEXE 2
STUDY FLOW-CHART FROM PROTOCOL VERSION 8
<table>
<thead>
<tr>
<th>Weeks</th>
<th>V1</th>
<th>V2</th>
<th>V3</th>
<th>V4</th>
<th>V6</th>
<th>V7</th>
<th>V9</th>
</tr>
</thead>
<tbody>
<tr>
<td>W-4 to W-1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D1 (28-2D+7 D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W4 (35-2D+7 D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W5 (84+/-7D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W12 (112+/-7D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W16 (168+/-7D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **Outpatient or Hospitalization (1)**
  - W-4 to W-1:
    - **X**
  - W1:
    - **X**

- **Informed consent**
  - **X**

- **Demographic characteristics**
  - **X**

- **Medico-surgical history**
  - **X**

- **Concomitant disease**
  - **X**

- **Concomitant treatment**
  - **X**
  - **X**
  - **X**
  - **X**
  - **X**
  - **X**

- **Habits**
  - **X**

- **Global physical examination (body weight)**
  - **X**
  - **X**
  - **X**
  - **X**
  - **X**
  - **X**

- **Echocardiography**
  - **X**
  - **X**
  - **X**
  - **X**
  - **X**

- **Eligibility criteria check**
  - **X**
  - **X**

- **Blood pressure, heart rate**
  - **X**
  - **X**
  - **X**
  - **X**
  - **X**
  - **X**
  - **X**

- **12-Lead ECG Recording**
  - **X**
  - **X**
  - **X**
  - **X**
  - **X**
  - **X**
  - **X**

- **INR**
  - (2)

- **aPTT, TCT**
  - **X**
  - **X**
  - **X**
  - **X**
  - **X**
  - **X**
  - **X**

- **Biochemistry**
  - **X**
  - **X**
  - **X**
  - **X**

- **Haematology**
  - **X**
  - **X**
  - **X**
  - **X**
  - **X**

- **Urinary pregnancy test**
  - **X**

- **Red Blood Cell concentrations of DHA**
  - **X**
  - **X**
  - **X**
  - **X**

- **Treatment number allocation**
  - **X**

- **IVRS/IWRS**
  - **X**

- **ECV (3)**
  - **X**

- **Drug administration**
  - **X**

- **Adverse events recording**
  - **X**
  - **X**
  - **X**
  - **X**

- **Holter ECG**
  - (4)

- **TTEM (6)**
  - (5)

---

1. Outpatient or hospitalization according to clinical practice of the centre (less or more than 24 hours)
2. In case of VKA introduction: INR 2 to 3 times a week until stabilization, then weekly until the ECV, then every 4 weeks after ECV
3. In patients with AF
4. 24-hour Holter ECG
5. 7-day Holter ECG
6. TTEM: one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24) and at any time in case of AF or atrial flutter symptoms.

TTEM once a week even in case of AF recurrence or atrial flutter emergence for at least 10 minutes.
F 373280 CA 2 01
CLINICAL STUDY PROTOCOL

Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

F373280 / Soft Capsules / 1g

Pierre Fabre Study Code: F 373280 CA 2 01
EudraCT Number: 2012 – 003487 - 48

Sponsor's Representative:
Gaëlle ALCARAZ
INSTITUT DE RECHERCHE PIERRE FABRE - Centre de R&D Pierre Fabre - BP 13562
3 avenue Hubert Curien
31035 TOULOUSE Cédex 1, FRANCE
Phone: +33 5 34 50 62 16
Fax: +33 5 34 50 69 69
E-mail: gaelle.alcaraz@pierre-fabre.com

Study Coordinating Investigator
Pr Savina NODARI
Associate Professor of Cardiology
Department of Clinical and Surgical Specialities, Radiological Science and Public Health
Section of Cardiovascular Diseases
University Medical School and Spedali Civili Hospital of Brescia
c/o Spedali Civili di Brescia
Piazzale Spedali Civili, 1
25123 - BRESCIA, ITALY
Phone: +39 030 3996 587 – +39 030 393849
Fax: +39 030 3700 359
E-mail: savinanodari@gmail.com; nodari@med.unibs.it

Version 8 – 22OCT2014

The information contained in this document is confidential and is the property of the Sponsor, Pierre Fabre Medicament. This information is given for the needs of the study and must not be disclosed without prior written consent of the Sponsor Pierre Fabre Medicament. Persons to whom this information is given for the needs of the study must be informed that it is confidential and must not be disclosed.
SPONSOR PERSONNEL

PIERRE FABRE MEDICAMENT
represented by
Institut de Recherche Pierre Fabre

Clinical Study Manager (Monitor)
Gaëlle ALCARAZ
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1, FRANCE
Phone: +33 5 34 50 62 16
Fax: +33 5 34 50 69 69
E-mail: gaelle.alcaraz@pierre-fabre.com

Medical Director
Richard ROCHE, MD
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1, FRANCE
Phone: +33 5 34 50 61 94
Fax: +33 5 34 50 69 69
E-mail: richard.roche@pierre-fabre.com
CONTRACT RESEARCH ORGANISATIONS

For Feasibility, Monitoring and Regulatory issues (in Hungary, Czech Republic and Italy):
Pharmaceutical Service Network (PSN)
Rufino Gonzalez
28 037 Madrid - SPAIN
Phone: +34 91 375 6930 - Fax: +34 91 375 6931
E-mail: rzurita@psnglobal.org

For Feasibility, Monitoring and Regulatory issues (in Spain):
Alpha Bioresearch
Paseo de la Castellana, 163 - 2º Izquierda
28 046 Madrid - SPAIN
Phone: +34 91 745 2520 - Fax: +34 91 745 0653
E-mail: teresa.bricio@alphabioresearch.com

For Centralised Randomisation and Electronic Case Report Form
S-Clinica
6, Chaussée de Boondael
B-1050 Brussels - BELGIUM
Phone: +32 2 645 0567 - Fax: +32 2 645 0569
E-mail: irena.seredina@s-clinica.com

For Centralised Reading of Holder ECG and TTEM and equipment supply:
Biomedical System
1945 Chaussée de Wavre
B-1160 Brussels - BELGIUM
Phone: +32 2 661 20 70 - Fax: +32 2 661 20 71
E-mail: sjacobs@biomedsys.com

For intra erythrocyte DHA dosage:
Agrocampus Ouest
Laboratoire de Biochimie
65 rue de Saint Brieuc – CS 84215
35042 RENNES Cedex - FRANCE
Phone: +33 2 23 48 55 49 - Fax: +33 2 23 48 55 50
E-mail: daniel.catheline@agrocampus-ouest.fr

For transportation of blood sample to the Analytical centre (Agrocampus) and material supply:
Theradis Pharma
41, chemin des Presses
06800 CAGNES-SUR-MER – FRANCE
Phone: +33 (0)4 97 02 07 07 - Fax: +33 (0)4 97 10 08 78
E-mail: chantal.raffy@theradis.pharma.com
Protocol F 373280 CA 2 01

APPROVAL FORM
Protocol Version 8 – 22OCT2014

Sponsor’s Representative:

Medical Director:
Richard ROCHE, MD

Date: 28/1/2014
Signature:

Study Coordinating Investigator:

Savina NODARI, MD

Date: 22 October 2014
Signature: [Signature]
Country Coordinating Investigator:

<table>
<thead>
<tr>
<th>&quot;Name&quot;</th>
<th>Date:</th>
<th>Signature:</th>
</tr>
</thead>
</table>


By my signature below, I, Dr / Pr "                                          ", hereby confirm that I agree:

- to conduct the trial described in the protocol F 373280 CA 2 01, dated 22OCT2014 in compliance with GCP, with applicable regulatory requirements and with the protocol agreed upon by the Sponsor Pierre Fabre Médicament and given approval / favourable* opinion by the Ethics Committee;
- to document the delegation of significant study-related tasks and to notify the Sponsor of changes in site personnel involved in the study;
- to comply with the procedure for data recording and reporting;
- to allow monitoring, auditing and inspection;
- to retain the trial-related essential documents until the Sponsor informs that these documents are no longer needed.

Furthermore, I hereby confirm that I will have and will use the available adequate resources, personnel and facilities for conduct this trial.

I have been informed that certain regulatory authorities require the Sponsor Pierre Fabre Médicament to obtain and supply details about the investigator’s ownership interest in the Sponsor or the study drug, and more generally about his/her financial relationships with the Sponsor. The Sponsor will use and disclose the information solely for the purpose of complying with regulatory requirements.

Hence I agree:

- to supply the Sponsor with any information regarding ownership interest and financial relationships with the Sponsor (including those of my spouse and dependent children);
- to promptly update this information if any relevant changes occur during the course of the study and for 1 year following completion of the study;
- that the Sponsor may disclose this information about such ownership interests and financial relationships to regulatory authorities.

* To be adapted

Date: Signature:
# TABLE OF CONTENTS OF CLINICAL STUDY PROTOCOL

1. **INTRODUCTION AND STUDY RATIONALE** ................................................................. 22  
   1.1. TARGET PATHOLOGY AND THERAPY .................................................................. 22  
   1.2. INFORMATION ON THE TEST PRODUCT ............................................................. 24  
   1.2.1. Chemical and pharmaceutical characteristics .................................................. 25  
   1.2.1.1. Nomenclature and structure ...................................................................... 25  
   1.2.1.2. Physical and chemical general properties .................................................. 25  
   1.2.2. Non-clinical Data ............................................................................................. 25  
   1.2.2.1. Pharmacological profile .............................................................................. 26  
   1.2.2.2. Safety pharmacology .................................................................................... 27  
   1.2.2.3. Toxicology profile ....................................................................................... 27  
   1.2.2.4. Pharmacokinetic data .................................................................................. 27  
   1.2.3. Clinical data .................................................................................................... 27  
   1.3. STUDY RATIONALE ............................................................................................. 29  
   1.4. OVERALL RISK AND BENEFIT ASSESSMENT ..................................................... 30  

2. **STUDY OBJECTIVES** ............................................................................................... 32  
   2.1. PRIMARY OBJECTIVE ......................................................................................... 32  
   2.2. SECONDARY OBJECTIVES .................................................................................. 32  

3. **ETHICAL CONSIDERATIONS RELATING TO THE STUDY** .................................... 33  

4. **STUDY DESIGN** ...................................................................................................... 34  
   4.1. OVERALL DESCRIPTION ..................................................................................... 34  
   4.2. DISCUSSION OF THE STUDY DESIGN ............................................................... 35  
   4.2.1. Choice of the Study Population ........................................................................ 35  
   4.2.2. Choice of the Study Design ............................................................................. 36  
   4.2.3. Choice of the Dose .......................................................................................... 37  
   4.2.4. Choice of the Sample Size ............................................................................. 38  

5. **STUDY POPULATION** ............................................................................................ 38  
   5.1. INCLUSION CRITERIA ......................................................................................... 38  
   5.2. NON INCLUSION CRITERIA ............................................................................... 40  
   5.3. NUMBER OF PATIENTS ...................................................................................... 41  
   5.4. RECRUITMENT MODALITIES ............................................................................. 41  
   5.5. PATIENT IDENTIFICATION ............................................................................... 42  
   5.6. WITHDRAWAL CRITERIA .................................................................................... 42  
   5.7. REPLACEMENT OF PATIENTS .......................................................................... 43  
   5.8. POST-STUDY EXCLUSION PERIOD ................................................................. 43  
   5.9. STUDY CARD AND LETTER FOR GENERAL PRACTITIONER(S) ...................... 43  

6. **STUDY TREATMENT** ............................................................................................. 44
6.1. SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT ................................................................. 44
6.2. PACKAGING AND LABELLING ............................................................................................................................................. 44
6.2.1. Packaging .............................................................................................................................................................. 44
6.2.2. Labelling .............................................................................................................................................................. 44
6.3. DISTRIBUTION TO CENTRE AND STORAGE .............................................................................................................. 45
6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT ......................................................................................... 46
6.5. DRUG ADMINISTRATION ................................................................................................................................................ 47
6.5.1. Duration of Treatment ............................................................................................................................................... 47
6.5.2. Dose Schedule ........................................................................................................................................................ 47
6.5.3. Route and Conditions of Administration ................................................................................................................ 47
6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT .............................................................. 48
6.7. RECALL OF INVESTIGATIONAL PRODUCTS ............................................................................................................. 48
7. CONCOMITANT TREATMENTS ............................................................................................................................................... 48
7.1. VITAMIN K ANTAGONIST TREATMENT .......................................................................................................................... 49
7.2. PROHIBITED TREATMENTS .......................................................................................................................................... 49
7.3. AUTHORISED TREATMENTS ......................................................................................................................................... 50
8. EVALUATION CRITERIA ........................................................................................................................................................ 50
8.1. PRIMARY EFFICACY CRITERION .................................................................................................................................... 50
8.1.1. Time to the first Atrial Fibrillation Recurrence or Atrial Flutter Emergence .......................................................... 50
8.1.1.1. Definition ........................................................................................................................................................... 50
8.1.1.2. Schedule ........................................................................................................................................................... 50
8.1.1.3. Evaluation Methods ........................................................................................................................................... 50
8.2. SECONDARY EFFICACY CRITERA .................................................................................................................................. 51
8.2.1. Numbers of AF episodes in the first week following visit 3 (ECV visit) ........................................................................ 51
8.2.1.1. Definition ........................................................................................................................................................... 51
8.2.1.2. Schedule ........................................................................................................................................................... 52
8.2.1.3. Evaluation Methods ........................................................................................................................................... 52
8.2.2. Duration of AF episodes in the first week following visit 3 (ECV visit) ........................................................................ 52
8.2.2.1. Definition ........................................................................................................................................................... 52
8.2.2.2. Schedule ........................................................................................................................................................... 52
8.2.2.3. Evaluation Methods ........................................................................................................................................... 52
8.2.3. Clinical parameters evaluation ...................................................................................................................................... 52
8.2.3.1. EHRA score assessment ........................................................................................................................................ 52
8.2.3.2. Time to first AF recurrence less than 10 minutes ............................................................................................... 53
8.2.3.3. Recurrence of symptomatic AF ......................................................................................................................... 53
8.2.3.4. Number and duration of hospitalizations ........................................................................................................... 53
8.2.4. Cardioversion assessment ............................................................................................................................................ 54
8.2.5. Evolution of echocardiographic parameters ............................................................................................................ 54
8.2.5.1. Definition.............................................................................................................................................................. 54
8.2.5.2. Schedule ......................................................................................................................... 54
8.2.5.3. Evaluation method.............................................................................................................. 54
8.3. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA ..................................................................................................................................... 55
8.3.1. Definition ........................................................................................................................... 55
8.3.2. Blood samples ................................................................................................................... 55
8.3.2.1. Collection schedule ........................................................................................................ 55
8.3.2.2. Technical handling ......................................................................................................... 55
8.3.3. DHA concentration measurement ..................................................................................... 55
8.4. SAFETY ASSESSMENT .................................................................................................... 56
8.4.1. Adverse Events .................................................................................................................. 56
8.4.2. Laboratory Investigations .................................................................................................. 56
8.4.2.1. Schedule ......................................................................................................................... 56
8.4.2.2. Technical Procedures and Parameters ............................................................................ 56
8.4.3. Global Physical Examination ............................................................................................ 57
8.4.4. Vital Signs ......................................................................................................................... 58
8.4.4.1. Schedule ......................................................................................................................... 58
8.4.4.2. Technical Procedure and Parameters .............................................................................. 58
8.4.5. Electrocardiogram (ECG) .................................................................................................. 58
8.4.5.1. Schedule ......................................................................................................................... 58
8.4.5.2. Technical Procedure and Parameters .............................................................................. 58
8.4.6. Coagulation parameters ..................................................................................................... 59
8.5. CONCOMITANT TREATMENTS ..................................................................................... 60
8.6. COMPLIANCE .................................................................................................................... 60
9. STUDY PROCEDURES ....................................................................................................... 60
10. ADVERSE EVENTS: DEFINITION AND REPORTING ............................................... 66
10.1. ADVERSE EVENTS ......................................................................................................... 66
10.1.1. Definition of Adverse Events ............................................................................................ 66
10.1.2. Grading of Adverse Events ............................................................................................. 67
10.1.3. Reporting of Adverse Events ......................................................................................... 67
10.2. SERIOUS ADVERSE EVENTS (SAE) .............................................................................. 67
10.2.1. Definition ........................................................................................................................ 67
10.2.2. Reporting of SAE .............................................................................................................. 68
10.2.3. Follow-up of SAE ............................................................................................................. 68
10.2.4. SAE Occurring After the Study ......................................................................................... 69
10.3. REPORTING OF OVERDOSAGE TO THE SPONSOR ................................................... 69
10.4. REPORTING OF PREGNANCY TO THE SPONSOR ...................................................... 69
10.5. SPONSOR’S RESPONSIBILITIES FOR SAFETY REPORTING PURPOSES ............... 70
11. DATA COLLECTION AND STUDY MONITORING ..................................................... 70
11.1. DATA COLLECTION ......................................................................................................... 70
11.1.1. Case Report Form ............................................................................................................ 70
11.2. STUDY MONITORING ...................................................................................................... 71
11.2.1. Monitoring visits ........................................................................................................... 71
11.2.1.1. Site Preselection Visit ................................................................................................. 72
11.2.1.2. Initiation Visit ................................................................................................................ 72
11.2.1.3. Follow-up Visits ............................................................................................................. 72
11.2.1.4. Closing Visit .................................................................................................................. 73
11.2.2. Direct Access to Source Documents ............................................................................... 73
11.3. INDEPENDENT DATA MONITORING COMMITTEE ................................................... 73

12. DATA MANAGEMENT ...................................................................................................... 74
12.1. DATA ENTRY ..................................................................................................................... 74
12.2. DATA CLEANING ............................................................................................................. 74
12.3. DATA CODING .................................................................................................................. 74
12.4. DATA STORAGE ............................................................................................................... 75
12.5. DATABASE LOCK ............................................................................................................. 75

13. STATISTICAL ANALYSIS ................................................................................................. 75
13.1. GENERAL CONSIDERATIONS ......................................................................................... 75
13.2. SAMPLE SIZE .................................................................................................................... 75
13.3. PROTOCOL DEVIATIONS ............................................................................................... 76
13.4. DATA SETS ANALYSED .................................................................................................. 76
13.5. HANDLING OF DROPOUTS AND MISSING DATA ...................................................... 77
13.5.1. Dropouts ........................................................................................................................ 77
13.5.2. Repositioning of Visits .................................................................................................... 77
13.5.3. Missing Data .................................................................................................................... 77
13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS ............................... 77
13.7. EFFICACY ANALYSIS .................................................................................................... 78
13.7.1. Primary Criterion ............................................................................................................. 78
13.7.1.1. Primary Analysis .......................................................................................................... 78
13.7.1.2. Supportive Analysis .................................................................................................... 78
13.7.2. Secondary Criteria ........................................................................................................... 78
13.7.2.1. Numbers of Atrial Fibrillation Episodes in the first week following V3 .................... 78
13.7.2.2. Duration of Atrial Fibrillation Episodes in the first week following V3 .................... 78
13.7.2.3. Time to first AF recurrence less than 10 minutes or symptomatic ................................ 79
13.7.2.4. Clinical parameters evaluation .................................................................................... 79
13.7.2.5. Biomarker analysis: red blood cell concentrations of DHA ...................................... 79
13.8. SAFETY ANALYSIS ....................................................................................................... 79
13.8.1. Adverse Events .............................................................................................................. 79
13.8.2. Clinical Laboratory Evaluation ....................................................................................... 81
13.8.3. Global Physical Examination ....................................................................................... 82
13.8.4. Vital Signs, Physical Findings and Other Observations Related to Safety .................. 83
13.8.4.1. Vital Sign Measurements Over Time ................................................................. 83
13.8.4.2. Body weight .................................................................................................. 83
13.8.4.3. Individual Patient Changes ......................................................................... 83
13.8.5. ECG ..................................................................................................................... 83
13.8.6. Coagulation parameters .................................................................................. 84
13.9. CONCOMITANT TREATMENTS ........................................................................... 84
13.10. COMPLIANCE ...................................................................................................... 84
13.11. INTERIM ANALYSIS AND DATA MONITORING ............................................... 84

14. GENERAL ETHICAL CONSIDERATIONS ................................................................. 85
14.1. ETHICAL CONDITIONS ....................................................................................... 85
14.2. ETHICS COMMITTEE AND LEGAL REQUIREMENTS ......................................... 85
14.3. PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM .... 86
14.4. PERSONAL DATA PROTECTION ......................................................................... 86
14.5. INSURANCE POLICY ............................................................................................ 87

15. ADMINISTRATIVE PROCEDURES ........................................................................ 87
15.1. PROTOCOL AMENDMENT ................................................................................... 87
15.2. SOURCE DOCUMENTS, INVESTIGATOR'S FILE STORAGE ............................... 87
15.3. END OF THE STUDY ............................................................................................. 88
15.3.1. Definition of the End of Study .............................................................................. 88
15.3.2. Early Study Termination .................................................................................. 88
15.3.2.1. Early Study Termination Decided by the Sponsor ......................................... 88
15.3.2.2. Early Study Termination Decided by the Competent Authorities .............. 88
15.4. AUDIT .................................................................................................................... 89
15.5. INSPECTION ......................................................................................................... 89
15.6. CONFIDENTIALITY ............................................................................................... 89
15.7. CLINICAL STUDY REPORT ............................................................................... 89
15.8. STUDY RESULTS COMMUNICATION ................................................................... 90
15.9. STUDY RESULTS PUBLICATION ....................................................................... 90

16. REFERENCES .......................................................................................................... 92

17. APPENDICES ........................................................................................................... 96
17.1. DECLARATION OF HELSINKI ............................................................................ 97
17.2. SAE REPORT FORM ........................................................................................ Blogs
17.3. PREDEFINED LIMITS OF LABORATORY AND VITAL SIGN POTENTIALLY
     CLINICALLY SIGNIFICANT CHANGES AND VALUES ............................................. 104
**SYNOPSIS**

<table>
<thead>
<tr>
<th>Name of Sponsor:</th>
<th>Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Finished Product:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Name of Active Substance:</td>
<td>F373280 (Panthenyl-Ester of DHA)</td>
</tr>
<tr>
<td>Title of the Study:</td>
<td>Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure. <em>International, multicentric, randomised, double-blind, placebo controlled study</em></td>
</tr>
<tr>
<td>Abbreviated Title:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Study Coordinating Investigator:</td>
<td>Pr Savina NODARI</td>
</tr>
<tr>
<td>Study Centres:</td>
<td>International, multicentric</td>
</tr>
</tbody>
</table>
| Publication / Rationale: | F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation (AF) patients with chronic heart failure. The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of AF induced by burst pacing [1]. Moreover, the effectiveness of PolyUnsaturated Fatty Acid (PUFA) has been proven in the following conditions:
- prevention of AF recurrence in patients with persistent AF, in co-administration with amiodarone (add on therapy) [2]
- Improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]
Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent atrial fibrillation and chronic heart failure. This phase Ila study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after electrical cardioversion (ECV) in patients with persistent atrial fibrillation and chronic heart failure. |
| Planned Study Period: | January 2013 – April 2016 |
| Clinical Phase: | Ila |

| Objectives: | **Primary:**
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>- Efficacy of F373280 on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure</td>
</tr>
</tbody>
</table>
|             | **Secondary:**
|             | - Efficacy of F373280 on the efficiency of direct electrical cardioversion
|             | - Effect of F373280 on echocardiographic parameters
|             | - Safety and tolerability of F373280 |

| Methodology: | - International, multicentre, randomised, double-blind, placebo-controlled
|             | - Selection period
|             | - Start of treatment 4 weeks before ECV
|             |     - Condition to ECV:
|             |         - Ideally INR 2-3 (vitamin K antagonist should be given at least 3 weeks before ECV)
|             |         - No spontaneous cardioversion before ECV
|             | - Follow-up 20 weeks after visit 3 (ECV visit)
|             |     - Condition: successful ECV or spontaneous CV
|             | - Cardiac monitoring: |
**Study Schedule:**

- 7 days continuous ECG ambulatory recording (Holter ECG) between visit 3 (ECV visit) and visit 4 (week 5) in patients with sinus rhythm
- TTEM: one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24) and at any time in case of AF or atrial flutter symptoms.

- Treatment duration: 24 weeks

**Number of Patients:** 76 x 2 patients

**Diagnosis and Criteria for Inclusion:**

**Inclusion Criteria:**

- **Demographic Characteristics and Other Baseline Characteristics:**
  - Men or women aged more than 18 years (inclusive)
  - Patients with current episode of persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted
  - Previous history of first documented episode of persistent AF.
  - Previous history of ischemic or non ischemic heart failure
  - NYHA class I or II chronic heart failure at selection and at inclusion
  - Left ventricular systolic dysfunction defined at selection and at inclusion by a reduced left ventricular ejection fraction (LVEF) ≥ 30% and ≤ 45% or for patients with a LVEF > 45%:
    - an increased left ventricular end-diastolic size (diameter ≥ 60 mm and/or > 32 mm/m² and/or volume > 97 ml/m²)
    - and/or an increased left ventricular end-systolic size (diameter > 45 mm and/or > 25 mm/m² and/or volume > 43 ml/m²)
    - and/or a reduced left ventricular outflow tract velocity time integral < 15 cm
  - On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers
  - Left atrial area ≤ 40 cm² at selection and at inclusion
  - Patients treated or having to be treated by vitamin K antagonist
  - For female patient of child-bearing potential:
    - In all the countries except Italy:
      - Use of an effective method of contraception (hormonal contraception or intrauterine device) assessed by the investigator, for at least 2 months before the selection in the study, and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment
      - Documented as surgically sterilized
    - In Italy only:
      - Absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
      - Use of double barrier contraception method (use of effective medical contraception)
method) from at least 2 months before the start of the study to the entire duration of
the study and for a month after the end of the study or
- Documented as surgically sterilized

11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion
12. For male with a child-bearing potential partner (In Italy only):
   - Absolute abstention from sexual intercourse during the whole duration of the study
   and for 3 months after the end of the study or
   - Use of double barrier contraception method (use of condom for male and effective
   contraception method for the partner) from the entire duration of the study to 3
   months after the end of the study.

Ethical/legal considerations:
13. Having signed his/her written informed consent,
14. Affiliated to a social security system, or is beneficiary (if applicable in the national
regulation)

Non-Inclusion Criteria:
Criteria related to pathologies:
1. No previous history of first documented episode of persistent AF
2. More than two successful cardioversions (electrical or pharmacological) in the last 6
   months
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to
   IV)
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be checked in case of
   treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic
   coronary artery assessed by coronaryography or cardiac stress test (Echo stress, exercise
   stress test, nuclear or MR perfusion evaluation methods) within 6 months before
   selection
7. Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration
   rate < 30 ml/min) at selection
8. Bradycardia (HR ≤ 50 bpm)
9. Hyperkalemia or hypokalemia (according to the standards of local laboratories) at
   selection
10. Cardiac surgery within 3 months before selection or planned during the study duration

Criteria related to treatments:
11. Previously ineffective pharmacological or electrical cardioversion
12. Concomitant treatment with ranolazine or any antiarrhythmic drug (within 7 days prior
    to selection), except amiodarone, dronedarone and stable dose of digoxin, betablockers,
    calcium-blockers
13. Concomitant treatment with oral amiodarone or dronedarone from selection
14. Concomitant treatment with intravenous amiodarone from selection
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT
    implantation within the last 6 months
16. Treatment with any Polynsaturated Fatty Acid (PUFA) within the last 3 months
17. Dietary supplement with ω 3 or ω 6 according to investigator’s judgement
18. Having undergone any form of ablation therapy for AF
19. Patient treated with oral anticoagulant treatment other than vitamin K antagonist: new
    oral anticoagulants (dabigatran, rivaroxaban, apixaban), or treated with irreversible
**antiplatelet agents P2Y12 inhibitors such as ticlopidine, clopidogrel or prasugrel**

**Other criteria:**
- Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion
- Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection
- Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself/herself to its constraints
- Patient family member or work associate (secretary, nurse, technician,..) of the Investigator
- Patient having forfeited his / her freedom by administrative or legal award or being under guardianship
- Breastfeeding female patient

**Exclusion criteria before V3:**
Patients without dyskalemia who will not have INR values ≥ 2 on the 3 last tests performed before ECV should not have an ECV and will be excluded from the study.
However, if only 2 INR values are ≥ 2 among those 3 last tests, an ECV can be performed if the presence of atrial thrombosis can be excluded with an ECHO–TE (transesophageal echocardiography) performed on the same day (before ECV) and the patient can continue the study.

If necessary, for meeting these INR conditions, the ECV (and following visits) could be postponed by 7 days.

<table>
<thead>
<tr>
<th><strong>Test Product:</strong></th>
<th>F373280 Soft Capsules</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Dose:</strong></td>
<td>Arm with 1g of F373280</td>
</tr>
<tr>
<td><strong>Mode of Administration:</strong></td>
<td>Oral, one capsule each evening with dinner.</td>
</tr>
<tr>
<td><strong>Duration of Treatment:</strong></td>
<td>24 weeks of treatment exposure with F373280 (25 weeks if ECV postponed by 1 week)</td>
</tr>
<tr>
<td><strong>Reference Therapy:</strong></td>
<td>Placebo soft capsules</td>
</tr>
<tr>
<td><strong>Mode of Administration:</strong></td>
<td>Oral, one capsule each evening with dinner</td>
</tr>
</tbody>
</table>

**Evaluation Criteria:**

**Efficacy evaluation variables:**

**Primary evaluation variable:**
- Time to first Atrial Fibrillation recurrence or atrial flutter emergence defined by the time to first episode of AF or atrial flutter lasting for at least 10 minutes (Follow up of 20 weeks after visit 3 – ECV visit).

Handling of AF recurrences or atrial flutter emergences: 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) between visit 3 (ECV visit) and visit 4 (week 5). Then, the follow up will be documented using the TTEM: one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24).

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF or the emergence of atrial flutter will be assessed after visit 3 (from week 5).
Moreover, during this TTEM period, if patient experiences any AF or atrial flutter symptoms, it should be recorded and documented using the TTEM.
All ECG (Holter and TTEM) will be evaluated by a Central Reading Laboratory.

**Secondary evaluation variables:**
During the 7-day continuous ECG monitoring,
- Numbers of AF episodes
- Duration of AF episodes

**Clinical parameters:**
During the whole study:
- Number of recurrence of symptomatic AF episodes
- EHRA score
- Hospitalization for cardiovascular events
- Hospitalization for thromboembolic stroke
- All causes of hospitalization

**Cardioversion:**
- Assessment of spontaneous cardioversion
- Assessment of successful cardioversion
- Shocks distribution (1, 2 or 3 shocks)
- Number of patients needing an other cardioversion after the initial ECV

**Other:**
- Evolution of echocardiographic parameters (at V4, V6 and V9) (Left atrial diameter (mm), Left atrial area (cm²), Left atrial volume (ml), Left atrial volume/BSA (ml/m²), Left ventricular ejection fraction (%), Left ventricular end diastolic volume/BSA (ml/m³), Left ventricular end systolic volume/BSA(ml/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (ml) Left ventricular end systolic diameter (mm), Left ventricular end systolic volume (ml))
- Evolution of omega 3 index and intra erythrocyte DHA (*For this assessment samples will be centralized.*)

**Safety criteria:**
- Adverse events (observed and / or spontaneously reported)
- Vital signs (Blood pressure (supine and standing), heart rate)
- Physical examination (body weight, body surface area)
- Standard 12-lead ECG: heart rate (bpm), PR (ms), QRS (ms), QT (ms), QTcB (ms), QTcF (ms), repolarisation patterns (ECG not centralized)
- Haematology: haematocrit, haemoglobin, red blood cell (RBC) count, white blood cell (WBC) count, WBC differential count, reticulocytes, platelets
- Biochemistry: sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatin phosphokinase (CPK) fibrinogen (*local laboratory*)
- Coagulation parameters: Activated partial thromboplastin time (aPTT), thrombin clotting time (TCT), INR (*local laboratory*), Prothrombine Time (*PT*).

**Concomitant treatments**

**Compliance**

**Statistical Methods:**

**Sample Size:**
Assuming an AF recurrence or atrial flutter emergence rate under placebo of 85%, a power of 80%, an alpha risk of 5% and a rate of not assessable patients of 15%, 76 randomised patients per group will be necessary, using a log-rank test of survival curves, a difference between groups of 20%.

**Primary Efficacy Analysis**
The primary analysis, performed on the Full Analysis Set (FAS: all randomised patients with at least one dose of treatment and with a successful cardioversion observed at visit 3), will be a survival analysis using the Kaplan Meier method and Cox regression model.

**Secondary Analyses**

All secondary efficacy criteria will be described and compared using appropriate tests on the FAS.

**Safety Analyses**

Descriptive statistics will be performed on the Safety Set (all randomised patients with at least one dose of treatment).
### STUDY FLOW-CHART

#### F373280 CA 201

<table>
<thead>
<tr>
<th>Weeks</th>
<th>V1</th>
<th>V2</th>
<th>V3</th>
<th>V4</th>
<th>V6</th>
<th>V7</th>
<th>V9</th>
</tr>
</thead>
<tbody>
<tr>
<td>W-4 to W-1</td>
<td></td>
<td>D1</td>
<td>W4 (28-2D/+/7 D)</td>
<td>W5 (35-2D/+/7 D)</td>
<td>W12 (84+/-7D)</td>
<td>W16 (112+/-7D)</td>
<td>W24 (168+/-7D)</td>
</tr>
</tbody>
</table>

**Outpatient or Hospitalization (1)**

- Informed consent
- Demographic characteristics
- Medico-surgical history
- Concomitant disease
- Concomitant treatment
- Habits
- Global physical examination (body weight)
- Echocardiography
- Eligibility criteria check
- Blood pressure, heart rate
- 12-Lead ECG Recording
- INR
- aPTT, TCT
- Biochemistry
- Haematology
- Urinary pregnancy test
- Red Blood Cell concentrations of DHA
- Treatment number allocation
- IVRS/IWRS
- ECV (3)

**Drug administration**

**Adverse events recording**

- Holter ECG
- TTEM (6)

- Outpatient or hospitalization according to clinical practice of the centre (less or more than 24 hours)
- In case of VKA introduction: INR 2 to 3 times a week until stabilization, then weekly until the ECV, then every 4 weeks after ECV
- In patients with AF
- 24-hour Holter ECG
- 7-day Holter ECG
- TTEM: one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24) and at any time in case of AF or atrial flutter symptoms. TTEM once a week even in case of AF recurrence or atrial flutter emergence for at least 10 minutes.
### LIST OF ABBREVIATIONS

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>aPTT</td>
<td>Activated partial thromboplastin time</td>
</tr>
<tr>
<td>AE</td>
<td>Adverse event</td>
</tr>
<tr>
<td>AF</td>
<td>Atrial fibrillation</td>
</tr>
<tr>
<td>ALA</td>
<td>Alpha-linoleic acid</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine aminotransferase</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate aminotransferase</td>
</tr>
<tr>
<td>AUC</td>
<td>Area under the plasma concentration versus time curve</td>
</tr>
<tr>
<td>AUC_{inf}</td>
<td>Total area under the curve extrapolated to infinity</td>
</tr>
<tr>
<td>βHCG</td>
<td>Beta human chorionic gonadotrophin</td>
</tr>
<tr>
<td>BLQ</td>
<td>Below the limit of quantification</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>BP</td>
<td>Blood pressure</td>
</tr>
<tr>
<td>BSA</td>
<td>Body Surface Area</td>
</tr>
<tr>
<td>CEP</td>
<td>Protocol evaluation committee</td>
</tr>
<tr>
<td>CHMP</td>
<td>Committee for medicinal products for human use</td>
</tr>
<tr>
<td>C_{max}</td>
<td>Maximum concentration</td>
</tr>
<tr>
<td>C_{min}</td>
<td>Minimum concentration</td>
</tr>
<tr>
<td>CNALV</td>
<td>Clinically noteworthy abnormal laboratory value</td>
</tr>
<tr>
<td>CPK</td>
<td>Creatin phosphokinese</td>
</tr>
<tr>
<td>CPP</td>
<td>Comité de protection des personnes</td>
</tr>
<tr>
<td>CRA</td>
<td>Clinical research associate</td>
</tr>
<tr>
<td>CRT</td>
<td>Cardiac resynchronization therapy</td>
</tr>
<tr>
<td>CSC</td>
<td>“Clinically Significant Change”, i.e., Predefined potentially clinically significant change leading to a potentially clinically significant value (vital signs)</td>
</tr>
<tr>
<td>CV</td>
<td>Coefficient of variation</td>
</tr>
<tr>
<td>DBP</td>
<td>Diastolic blood pressure</td>
</tr>
<tr>
<td>DHA</td>
<td>Docosahexaenoic acid</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics committee</td>
</tr>
<tr>
<td>ECG</td>
<td>Electrocardiogram</td>
</tr>
<tr>
<td>ECHO–TE</td>
<td>Transesophageal echocardiograph</td>
</tr>
<tr>
<td>ECV</td>
<td>Electrical cardioversion</td>
</tr>
<tr>
<td>EHRA</td>
<td>European heart rhythm association</td>
</tr>
<tr>
<td>EPA</td>
<td>Eicosapentaenoic acid</td>
</tr>
<tr>
<td>e-CRF</td>
<td>Electronic case report form</td>
</tr>
<tr>
<td>FAS</td>
<td>Full analysis set</td>
</tr>
<tr>
<td>Fe</td>
<td>Fraction of the administered drug excreted in urine</td>
</tr>
<tr>
<td>GCP</td>
<td>Good clinical practice</td>
</tr>
<tr>
<td>GFR</td>
<td>Glomerular Filtration Rate</td>
</tr>
<tr>
<td>HBs</td>
<td>Hepatitis B antigen</td>
</tr>
<tr>
<td>HCV</td>
<td>Hepatitis C virus</td>
</tr>
<tr>
<td>HDL</td>
<td>High density lipoprotein</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>--------------</td>
<td>------------</td>
</tr>
<tr>
<td>HF</td>
<td>Heart failure</td>
</tr>
<tr>
<td>HIV</td>
<td>Human immunodeficiency virus</td>
</tr>
<tr>
<td>HR</td>
<td>Heart rate</td>
</tr>
<tr>
<td>ICH</td>
<td>International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use</td>
</tr>
<tr>
<td>IDMC</td>
<td>Independent data monitoring committee</td>
</tr>
<tr>
<td>INR</td>
<td>International normalized ratio</td>
</tr>
<tr>
<td>IRPF</td>
<td>Institut de Recherche Pierre Fabre</td>
</tr>
<tr>
<td>IVRS</td>
<td>Interactive voice response system</td>
</tr>
<tr>
<td>LAA</td>
<td>Left atrial area</td>
</tr>
<tr>
<td>LC/MS-MS</td>
<td>Liquid chromatography with tandem mass spectrometry</td>
</tr>
<tr>
<td>LDL</td>
<td>Low density lipoprotein</td>
</tr>
<tr>
<td>LOQ</td>
<td>Limit of quantification</td>
</tr>
<tr>
<td>LVEF</td>
<td>Left ventricular ejection fraction</td>
</tr>
<tr>
<td>MedDRA</td>
<td>Medical dictionary for regulatory activities</td>
</tr>
<tr>
<td>MR</td>
<td>Mineralocorticoid receptor</td>
</tr>
<tr>
<td>MR perfusion</td>
<td>Magnetic Resonance perfusion</td>
</tr>
<tr>
<td>MTD</td>
<td>Maximum tolerated dose</td>
</tr>
<tr>
<td>N</td>
<td>Number of determinations or replicates</td>
</tr>
<tr>
<td>NOAEL</td>
<td>No observed adverse effect level</td>
</tr>
<tr>
<td>NYHA</td>
<td>New York heart association</td>
</tr>
<tr>
<td>od</td>
<td>Once a day</td>
</tr>
<tr>
<td>PC</td>
<td>“Predefined Change”, i.e., Predefined potentially clinically significant change (lab or vital signs)</td>
</tr>
<tr>
<td>PCA</td>
<td>PC leading to an out-of-range value (lab values)</td>
</tr>
<tr>
<td>PFB</td>
<td><em>Pierre Fabre Biométrie</em></td>
</tr>
<tr>
<td>PSC</td>
<td>Potentially Clinically Significant Change</td>
</tr>
<tr>
<td>PSCV</td>
<td>Potentially Clinically Significant Value</td>
</tr>
<tr>
<td>PUFA</td>
<td>PolyUnsaturated fatty acid</td>
</tr>
<tr>
<td>p.o.</td>
<td>Per os</td>
</tr>
<tr>
<td>PP</td>
<td>Per protocol data set</td>
</tr>
<tr>
<td>QTcB</td>
<td>QT interval using Bazett’s correction formula</td>
</tr>
<tr>
<td>QTcF</td>
<td>QT interval using Fridericia’s correction formula</td>
</tr>
<tr>
<td>RBC</td>
<td>Red blood cells</td>
</tr>
<tr>
<td>SAE</td>
<td>Serious adverse event</td>
</tr>
<tr>
<td>SBP</td>
<td>Systolic blood pressure</td>
</tr>
<tr>
<td>SD</td>
<td>Standard deviation</td>
</tr>
<tr>
<td>T1/2</td>
<td>Terminal half-life</td>
</tr>
<tr>
<td>T0</td>
<td>Time of drug administration</td>
</tr>
<tr>
<td>Tmax</td>
<td>Time to reach the maximal concentration</td>
</tr>
<tr>
<td>TCT</td>
<td>Thrombin clotting time</td>
</tr>
<tr>
<td>TEAEs</td>
<td>Treatment emergent adverse events</td>
</tr>
<tr>
<td>TTEM</td>
<td>TransTelephonic ECG monitoring</td>
</tr>
<tr>
<td>VKA</td>
<td>Vitamin K Antagonist</td>
</tr>
<tr>
<td>WBC</td>
<td>White blood cells</td>
</tr>
<tr>
<td>WHO-DRUG</td>
<td>World health organization drug reference list</td>
</tr>
</tbody>
</table>
1. INTRODUCTION AND STUDY RATIONALE

1.1. TARGET PATHOLOGY AND THERAPY

Atrial Fibrillation (AF) is a supraventricular arrhythmia characterized by uncoordinated atrial electric activity with consequent deterioration of atrial mechanical function. It is the most common sustained cardiac rhythm disorder, increasing in prevalence with age. Haemodynamic impairment and thromboembolic events related to AF result in significant morbidity and mortality [7].

In 2009, Decision Resources estimated that there were 7.8 million diagnosed prevalent cases of AF in US, Europe and Japan. This age-related pathology should increase to 9.4 million cases in 2019.

Except for the conventional class I and class III anti-arrhythmic agents, the Polyunsaturated Fatty Acids (PUFAs) constitute one emerging antiarrhythmic therapy. These compounds potently address the AF substrate by directly targeting both the electrical and the structural remodelling of the deficient atria. The n-3 PUFAs, essential for human, are alpha-linoleic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). First, PUFAs specifically modulate ionic channels by fastening their inactivating mode which renders these compounds selective for pathological situations (such as AF) without any major effect in normal conditions. PUFAs are “open K_v1.5 channel blockers” leading to a lengthening of atrial action potential duration and are “persistent Na_v1.5 channel blockers” leading to hyperpolarization of diastolic resting potential. Second, PUFAs influence structural remodelling through their anti-inflammatory effects as they directly compete with arachidonic acid in the production of inflammatory eicosanoids. In summary, PUFAs share unique, well-tolerated antiarrhythmic potential by interacting with the electrical and structural remodelling during sustained AF. In animal studies, it was recently demonstrated that DHA is particularly effective in pathologic conditions such as ischemia and/or AF.

The potential anti-arrhythmic effects of a PUFA were previously developed in AF: nicotinyl ester of DHA (pro-drug based on DHA delivery) was assessed in a two-week ventricular tachypaced
canine model. Dogs were subjected to 4 weeks of medication prior to undergoing an electrophysiology study, and received either placebo or nicotinyl ester of DHA. Dogs were tachypaced at 240 beats per min for the final two weeks of the treatment plan. The results showed that the tested PUFA reduced the duration of AF induced by burst pacing, and the incidence of sustained AF, compared to dogs treated with the placebo [1].

In clinical practice, Nodari and coll [2] assessed n-3 PUFAs in the prevention of AF recurrences after electrical cardioversion (ECV). All included patients were treated with amiodarone and a renin-angiotensin-aldosterone system inhibitor. The 199 patients were assigned either to placebo or n-3 PUFAs 2 g/d and then underwent direct ECV 4 weeks later. The primary end point was the maintenance of sinus rhythm at 1 year after cardioversion. At the 1-year follow up, the maintenance of sinus rhythm was significantly higher in the n-3 PUFAs treated patients compared with the placebo group (hazard ratio, 0.62 [95% confidence interval, 0.52 to 0.72] and 0.36 [95% confidence interval, 0.26 to 0.46], respectively; p = 0.0001). The study concludes that in patients with persistent AF on amiodarone and a renin-angiotensin-aldosterone system inhibitor, the addition of n-3 PUFAs 2 g/d improves the probability of the maintenance of sinus rhythm after direct current cardioversion. Previously, during the World Congress of Cardiology in 2006, an abstract reported the effectiveness of PUFAs on top of traditional treatment (amiodarone, beta blockers, renin-angiotensin-aldosterone system inhibitor) in the prevention of AF relapses in patients having undergone ECV. In the PUFA group, AF relapses were significantly lower than in the placebo group at 1 month (3.3% vs 10%; p = 0.043), at 3 months (10% vs 25%; p = 0.004) and at 6 months (13.3% vs 40%; p < 0.0001) [19].

In contrast, in the general AF population (paroxystic atrial fibrillation and persistent atrial fibrillation), PUFAs failed to prove their efficacy [7] because of the absence of cardiac remodelling or because of a short pre-treatment duration before ECV (1 week) [8]. The effects of PUFAs were only observed in patients with persistent AF on add on therapy and after a sufficient pre-treatment before ECV. Persistent AF is commonly associated to heart failure. Previous studies performed in heart failure population demonstrated the benefit of PUFAs on the improvement of functional ventricular parameters and morbi-mortality, and on the reduction of hospitalisation [3, 4, 5].

Nodari and coll [3] performed a trial in patients with chronic heart failure (NYHA I to III and LVEF< 45%). After a treatment of 133 patients with PUFAs (n=67) or placebo (n=66) at a dosage
of 5 g/day for 1 month, then 2 g/day for 11 months, the n-3 PUFAs group and the placebo group differed significantly (p <0.001) in regard to:

- LVEF (increased by 10.4% and decreased by 5.0%, respectively)
- peak VO₂ (increased by 6.2% and decreased by 4.5%, respectively)
- exercise duration (increased by 7.5% and decreased by 4.8%, respectively)
- mean New York Heart Association functional class (decreased from 1.88 +/- 0.33 to 1.61 +/- 0.49 and increased from 1.83 +/- 0.38 to 2.14 +/- 0.65, respectively).

The hospitalization rates for patients with HF were 6% in the n-3 PUFAs and 30% in the placebo group (p <0.0002).

Moertl and coll [4] performed a dose-ranging study in patients with a more severe chronic heart failure (NYHA III and IV and LVEF < 35%). It was a double-blind, randomised, controlled pilot trial in 43 patients treated with PUFAs or placebo for 3 months (1 g/d n3-PUFA (n = 14), 4 g/d n3-PUFA (n = 13), or placebo (n = 16)). After treatment, left ventricular ejection fraction increased in a dose-dependent manner (p = 0.01 for linear trend) in the 4 g/d (baseline vs 3 months [mean ± SD]: 24% ± 7% vs 29% ± 8%, p = 0.005) and 1 g/d treatment groups (24% ± 8% vs 27% ± 8%, p = 0.02).

No changes in any investigated parameters were noted with placebo.

Taking into account these studies performed with PUFAs, it seems that the best target for DHA is persistent AF in patients with heart failure. The aim of this proof of concept study is to assess in stand alone therapy (without association of other anti-arrhythmic treatments), the effect of F373280 in patients with persistent AF and heart failure in the maintenance of sinus rhythm after ECV.

1.2. INFORMATION ON THE TEST PRODUCT

F373280 or panthenyl ester of DHA is the mono-ester of panthotenic alcohol and DHA, selected to be developed for the management of AF.

F373280 is a prodrug of DHA.

A brief summary of F373280 known characteristics is presented in this section. For further details, please refer to the F373280 Investigator’s Brochure. [1]
1.2.1. Chemical and pharmaceutical characteristics

1.2.1.1. Nomenclature and structure

Chemical name (IUPAC):

\[(4Z,7Z,10Z,13Z,16Z,19Z)-3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido)\text{ propyl docosa-}4,7,10,13,16,19\text{-hexaenoate}\]

Structural formula:

![Structural formula]

Laboratory code: F373280

Molecular formula: \(C_{31}H_{49}NO_5\)

Molecular mass: 515.7

1.2.1.2. Physical and chemical general properties

**Appearance:** Clear oily viscous liquid

**Solubilities:**

- Water: Practically insoluble
- Alcohol: Very soluble
- Trimethylpentane: Slightly soluble

1.2.2. Non-clinical Data

Non-clinical data are exhaustively detailed in the Investigator’s brochure [1]. A brief summary is provided below.
1.2.2.1. Pharmacological profile

F373280 (mono-ester of panthotenic alcohol and DHA) is a novel pro-drug of DHA which exerts antiarrhythmic properties by interacting with the electrical and structural remodelling of the atria.

Experimental investigations were conducted in HEK293 cell line transfected with human Kv1.5 channel using the whole cell patch clamp technique to evaluate whether F373280 could block the sustained component of I\textsubscript{Kv1.5}. F373280 concentration-dependently reduced Kv1.5 channel activity with an IC\textsubscript{50} value of 13.7 µM.

The effects of F373280 on atrial effective refractory period were investigated in anesthetized pig using a conventional pacing protocol through epicardial electrodes placed on the left atrium. F373280 administered as a bolus and an infusion (10 mg/kg) significantly increased atrial effective refractory period (23.8 ± 2.2 ms versus -7.3 ± 11.5 ms in the presence of vehicle, p < 0.05). In addition, F373280 was devoid of significant effect on the hemodynamic and the electrocardiogram (ECG) intervals.

Proof of the pharmacological concept was performed with a different DHA derivative named: Nicotinyl ester of DHA (pro-drug based on DHA delivery). Ventricular tachypacing-induced congestive heart failure provides a clinically-relevant animal model of AF associated with structural remodelling, as is often seen clinically. It has been shown that sustained oral PUFA administration suppresses congestive heart failure-induced AF-promotion and fibrosis in the ventricular tachypacing canine model. Nicotinyl ester of DHA was tested in this model, at 1 g/day and 5 g/day, during 4 weeks, to prevent congestive heart failure-related atrial structural remodelling and AF promotion in dogs. Nicotinyl ester of DHA dose dependently reduced heart failure-induced increases in AF duration (989 ± 111 sec, n=5 in the presence of placebo versus 637 ± 196 sec, n=5 in the presence of 1 g/kg/d Nicotinyl ester of DHA and 79 ± 51 sec, n=5, in the presence of 5 g/kg/d Nicotinyl ester of DHA). The protective effect of Nicotinyl ester of DHA was associated with a marked increase of plasma level of DHA and important incorporation of DHA in the left atrial tissue. Because F373280 similarly to Nicotinyl ester of DHA increases plasma level of DHA, it could be estimated that the compound may exert a similar protective effect [1].
1.2.2.2.  Safety pharmacology
A battery of safety pharmacology studies was performed to evaluate the effects of F373280 on the central nervous, cardiovascular and respiratory systems. Data of these studies are exhaustively detailed in the Investigator’s brochure [1].
No particular alerts were evidenced with F373280.

1.2.2.3.  Toxicology profile
Concerning the toxicological data, 4-week and 26-week repeat-dose studies in rat and dog were performed. Compared to the high administered doses of F373280 (500 to 2000 mg/kg/day), low circulating concentrations of F373280 were measured.
During these toxicity studies, no toxicity was observed in rat after 4 and 26 weeks of dosing and in dog after 4 weeks of dosing. A NOAEL of 2000 mg/kg/day was established in these repeat toxicity studies.
During the 26-week toxicity study in dogs, the NOAEL was set at 1000 mg/kg/day based on changes observed on red blood cell parameters.
Based on toxicological profiles, F373280 is considered to support the proposed clinical trial.

1.2.2.4.  Pharmacokinetic data
According to animal studies described in the Investigator’s brochure [1], the non-clinical pharmacokinetic profile of F373280 is not associated with particular alerts concerning the proposed clinical phase IIa study.

1.2.3.  Clinical data
Part A: Single dose
Six consecutive single ascending doses were tested (0.5 g, 1 g, 2 g, 4 g, 8 g and 16 g) on 6 independent cohorts of 8 subjects (6 verum + 2 placebo). 49 subjects were treated and 48 completed the study.
No Serious Adverse Events (SAE) occurred in the course of the study.
Regarding the reported Treatment Emergent Adverse Events (TEAEs) that were judged by the Investigator as having a causal relationship with the study drug administration in the absence of
an alternative explanation, 3 TEAEs were observed in the placebo group (palpitation, dizziness in standing position, symptomatic orthostatic hypotension without loss of consciousness) and 4 in the group of F373280 at the dosage of 16 g (meteorism, liquid stool, symptomatic orthostatic hypotension and dizziness in standing position). None of these adverse events (AE) were reported in the groups of F373280 at the dosages of 0.5 g, 1 g, 2 g, 4 g and 8 g.

After a single administration of the different tested doses no difference between the tested product and placebo has been reported, regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters (related to coagulation: platelets and fibrinogen) and coagulation parameters (bleeding time, prothrombin time/INR, activated partial thromboplastin time, thrombin clotting time). Variations of these parameters were within the physiological ranges.

After single oral administration of F373280 from 0.5 g to 16 g in 36 young healthy male subjects (6 per dose level), the following was observed:

- **F373280**: Whatever the tested dose there is no circulating F373280 in plasma: only few, sparse and non consecutive samples with quantifiable level of F373280 close to LOQ were observed. This confirms that F373280 is a prodrug.
- **Panthenol**: Cmax and AUC increased with the administered dose between 0.5 and 16 g. Panthenol concentrations were rapidly cleared from plasma with a mean terminal half-life around 2 hours.
- **DHA**: after 0.5 and 1 g, low increased in DHA plasma concentrations compared to the baseline levels led to a high inter-individual variability of the corresponding Pharmacokinetics parameters. Plasma exposure in DHA increased with the administered dose between 2 and 16 g with no departure from proportionality (baseline corrected parameters).

**Part B: Multiple doses**

Three consecutive repeated ascending doses (1, 2 and 4 g) were tested on 3 independent cohorts of 12 subjects (9 verum + 3 placebo, double blind). 36 subjects completed the study. Each treatment was administered over a period of 28 days. Pharmacokinetic parameters were assessed over a period of 14 days.
Among the TEAE judged by the investigator as suspected to F373280, 5/9 TEAEs were classified according the System Organ Class in vascular system disorder with orthostatic hypotension (2 in the 1 g group, 1 in the 2 g group and 2 in the 4 g group) and 4/9 were classified in nervous system disorder with 3 dizziness (2 in the 2 g group and 1 in the 4 g group) and 1 migraine (in the 1 g group). These TEAEs have already been reported with PUFAs and are commonly observed in phase I studies.

After a repeated administration of the different tested doses, no difference between the tested products and placebo was reported regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters. The assessment of coagulation parameters and platelet function after administration of repeated dose of F373280 did not report any bleeding issue. The reported changes in coagulation parameters and platelet function were within physiological ranges.

After a 14-day repeated oral administration of F373280 from 1 g to 4 g, the following was observed:

✔ **Panthenol**: Cmax and AUC increased with the administered dose between 1 and 4 g. No accumulation of panthenol in plasma was observed.

✔ **DHA**: Plasma exposure increased with dose. A 2-fold accumulation in total plasma exposure of DHA was observed after 14 days of administration, whatever the administered dose.

1.3. **STUDY RATIONALE**

F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after ECV in persistent AF patients with chronic heart failure.

The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of AF induced by burst pacing [1].

Moreover, the effectiveness of PUFAs has been proven in the following conditions:

- Prevention of AF recurrence in patients with persistent AF in co-administration with amiodarone (add on therapy) [2],
- Improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5].
Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent AF and chronic heart failure.

This phase IIa study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after ECV in patients with persistent AF and chronic heart failure.

1.4. OVERALL RISK AND BENEFIT ASSESSMENT

F373280 is a new pro-drug of DHA.

DHA is a well-known long chain PUFAs with a long-term clinical experience in cardiovascular diseases. DHA is contained in several medicinal products such as Omacor®, (1 g of Omacor contains about 320 mg of DHA acid) marketed by Laboratoires Pierre Fabre for hypertriglyceridemia and as an adjuvant treatment for secondary prevention after myocardial infarction. According to the summary product characteristics of Omacor® [9]:

- The frequencies of adverse reactions are ranked according to the following: common (>1/100, <1/10); uncommon (>1/1000, <1/100); rare (>1/10000, <1/1000); very rare (<1/10000), not known (cannot be estimated from the available data).

- The reported adverse events are:

  - Infection and infestations:
      Uncommon: gastroenteritis
  - Immune system disorders:
      Uncommon: hypersensitivity
  - Metabolism and nutrition disorders:
      Rare: hyperglycaemia
  - Nervous system disorders:
      Uncommon: dizziness, dysgeusia
      Rare: headache
  - Vascular disorders:
      Very rare: hypotension
  - Respiratory thoracic and mediastinal disorders:
Very rare: nasal dryness

- Gastrointestinal disorders:
  - Common: dyspepsia, nausea
  - Uncommon: abdominal pain, gastrointestinal disorders, gastritis, abdominal pain upper
  - Rare: gastrointestinal pain
  - Very rare: lower gastrointestinal haemorrhage

- Hepatobiliary disorders:
  - Rare: hepatic disorders

- Skin and subcutaneous tissue disorders:
  - Rare: acne, rash pruritic
  - Very rare: urticaria

- General disorders and administration site conditions:
  - Rare: malaise sensation

- Investigations:
  - Very rare: white blood count increased, blood lactate dehydrogenase increased

Moderate elevation of transaminases has been reported in patients with hypertriglyceridaemia.

Panthenol is a well-known substance with a long-term experience in medical, nutraceutic and cosmetic uses. According to the summary product characteristics of a product such as Bépanthene® (tablet indicated in alopecia) which contains panthenol (100 mg), adverse event observed are rare cases of urticaria and erythema [10]. Panthenol is metabolised in panthotenic acid, i.e. B5 vitamin.

Concerning toxicological studies performed results can support the administration of F373280 in the proposed clinical phase II study without particular alert [1].

Any safety warning was reported during a phase I study performed with F373280 administered to 84 healthy volunteers in single dose in a range between 500 mg and 16 g or in repeated dose during 28 days in a range between 1 g and 4 g. Adverse events reported and related to study treatment were minor to moderate. The adverse events were palpitations, orthostatic hypotension, dizziness, meteorism and liquid stool. Most were reported in both groups (placebo and F373280) without a dose relationship. The assessment of coagulation parameters and platelet function after
administration of repeated dose of F373280 did not report any bleeding concern: the reported changes in coagulation parameters and platelet function were within physiological ranges. Moreover, DHA has been associated with anticoagulant products in AF studies [2, 8]. The range of PUFAs doses tested was between 2 g to 3 g (640 mg to 960 mg of DHA) and the range of study durations between 6 to 12 months. This association did not report a significant side effect of bleeding.

DHA has already been used in HF patients in several studies without safety concern [3, 4, 5]. The range of PUFAs doses tested was between 1 g to 5 g (1 g of the tested PUFAs contains about 320 mg of DHA acid) and the range of study durations was between 3 months to 3.9 years. Thus, inclusion of patients with no specific antiarrhythmic treatment is acceptable. They will receive an anticoagulant treatment to prevent the thrombo-embolic complications of AF (particularly stroke) and the adequate treatments to control the heart rate and heart failure.

In conclusion, the overall available data allow in safe conditions the treatment of patients with persistent AF and chronic heart failure with F373280 in safe conditions.

2. STUDY OBJECTIVES

2.1. PRIMARY OBJECTIVE
The primary objective of the study is to assess the efficacy of F373280 on the maintenance of sinus rhythm after direct ECV in patients with persistent AF and chronic heart failure.

2.2. SECONDARY OBJECTIVES
The secondary objectives of the study are to assess:

- the efficacy of F373280 on the efficiency of direct ECV
- the effect of F373280 on echocardiographic parameters
- the safety and tolerability of F373280
3. ETHICAL CONSIDERATIONS RELATING TO THE STUDY

The trial is conducted according to Good Clinical Practices (CPMP/ICH/135/95), the National regulations and the Declaration of Helsinki and its subsequent amendments (see Appendix 17.1). This protocol and the informed consent form will be submitted for approval to independent local or national Institutional Review Boards/Ethics Committees before the study set up, according to national regulation.

All the protocol amendments or critical events liable to increase the risks incurred by the patients or to compromise the validity of the study or patients' rights will be submitted to the coordinator and to the Ethics Committees.

After being informed orally and in writing of all potential risks and constraints of the trial, as well as their freedom to withdraw their participation at any time, patients will then sign a consent form. A time of reflection will be given to the patients, before giving a written consent and starting the study procedures.

The use of a placebo is in accordance with EMA Addendum to the guideline on antiarrhythmics on AF and atrial flutter (EMA/CHMP/EWP/213056/2010) [21] and is acceptable because the included patients will remain under the standard treatment of AF and chronic heart failure. Except antiarrhythmics, they will receive anticoagulant (vitamin K antagonist, VKA), rate control treatment, chronic heart failure treatment. During the study, in case of AF recurrence or atrial flutter emergence that would require cardioversion or the introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms for instance, patients will be withdrawn and the tested product stopped. These patients will be considered as treatment failure.

In this study, patients will be carefully screened, particularly for their cardiac condition, with ECG, 24-hour holter monitor and echocardiographic data, and their biologic and coagulation condition.

The study will be addressed only to patients requiring an ECV due to their persistent AF, in the following conditions:

- ECV in patients not presenting a contra-indication
- Anticoagulation with vitamin K antagonist (VKA) for at least 3 weeks before ECV
- ECV will be performed in patients with AF and without dyskalemia. An INR value control must be performed within 24h before ECV. INR values ≥ 2 on the 3 last
tests performed before ECV are required. However, if only 2 INR values are \( \geq 2 \) among those 3 last tests, an ECV can be performed if the presence of atrial thrombosis can be excluded with an ECHO–TE (transesophageal echocardiography) performed on the same day (before ECV) and the patient can continue the study. Patients who do not revert to sinus rhythm or present an early AF relapse or an early atrial flutter emergence within the observation period after ECV will be withdrawn and the tested product stopped.

During the whole study, patients will remain under medical control: visits in cardiology units will be performed throughout the study period. This follow up will include clinical signs, ECG, biological and coagulation parameters. Moreover, patient’s cardiac rhythm will be monitored once a week between visits using Trans Telephonic ECG Monitoring (TTEM) reviewed by a Central Reading Laboratory.

Patients may withdraw from the study at any time without having to give a reason and can expect to receive regular conventional therapy.

4. STUDY DESIGN

4.1. OVERALL DESCRIPTION

This phase IIa trial will be conducted as an international, multicentric, 24 weeks, double-blind, placebo-controlled, randomised, parallel group design, trial in 152 patients suffering from persistent AF and chronic heart failure.

After a 1 to 4-week of run-in period without study treatment, patients will be randomised into one of the following treatment groups: F373280 1g or placebo for 24 weeks.

Seven visits are planned for the study:

- Visit 1 (V1): W-4 to W-1: Selection visit (7 to 28 days before the Inclusion Visit)
- Visit 2 (V2): D1: Inclusion visit (start of study treatment)
- Visit 3 (V3): W4 (D28-2/+7D): cardioversion visit (outpatient or hospitalization according to clinical practice of the centre) (installation of the Holter ECG device)
- Visit 4 (V4): W5 (D35 -2/+7D): follow-up visit (removing of Holter ECG device and installation of the TTEM)
- Visit 6* (V6): W12 (D84 ± 7D): follow-up visit
  *see amendment PA05 dated 22OCT2014
- Visit 7 (V7): W16 (D112 ± 7D): follow-up visit
- Visit 9* (V9): W24 (D168 ± 7D): final study visit
  *see amendment PA05 dated 22OCT2014

4.2. DISCUSSION OF THE STUDY DESIGN

4.2.1. Choice of the Study Population

The target indication of F373280 will be the maintenance of sinus rhythm after cardioversion of patients with persistent AF and chronic heart failure. In the present proof of concept study, the evaluation will focus on patients within this indication. This target population is justified by:

- The proved efficacy of PUFAs in patients with persistent AF with or without heart failure in co-administration with amiodarone (add on therapy) [2]
- The proved efficacy of PUFAs on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]

The study aim is to investigate the product effect in patients with:

- Previous history of persistent AF with duration of the current episode from 7 days to 6 months.
- A systolic heart failure defined by a reduced left ventricular ejection fraction (≥ 30% and ≤ 45%) or for patients with a LVEF > 45%:
  - an increased left ventricular end-diastolic size (diameter ≥ 60 mm and/or > 32 mm/m² and/or volume > 97 ml/m²),
  - and/or an increased left ventricular end-systolic size (diameter > 45 mm and/or > 25 mm/m² and/or volume > 43 ml/m²),
  - and/or a reduced left ventricular outflow tract velocity time integral < 15 cm [23, 24].
According to a sub-group analysis performed in patients with persistent AF associated to heart failure (Nodari S. personal data), PUFAs would be effective to prevent recurrence of AF after cardioversion in patients with moderately abnormal LVEF.

- A Left Atrial Area (LAA) not severely abnormal (no greater than 40 cm² as defined in the report from the American Society of Echocardiography’s Guideline) [23]. According to a sub-group analysis performed in patients with persistent AF associated to heart failure (Nodari S. personal data), PUFAs would not be effective to prevent recurrence of AF after cardioversion of patients with severely abnormal LAA.

For the successful rate of ECV, patients should have a stable medical treatment of heart failure and should not have any myocardial infarction or unstable angina or unstable ischemic coronaropathy assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection.

4.2.2. Choice of the Study Design

As the target indication would be the prevention of AF recurrence after ECV, the study design meets the requirements of EMA guideline on antiarrhythmics in AF (EMA/CHMP/EWP/213056/2010) [21].

As F373280 aims to be a safe treatment for the prevention of AF recurrence, it will not be tested as an add-on therapy during the study. To avoid any interaction with the tested product, antiarrhythmics class I and III will be forbidden during the study.

The study design is defined in order to avoid methodological bias. A double blind study is appropriate to assess the efficacy and safety of the use of F373280 to prevent recurrence of AF episodes. Moreover, this study design is similar to the design of almost all trials that have assessed intervention for rhythm control [2, 8, 11, 12].

According to the target indication, only patients with persistent AF and requiring an ECV will be included in order to assess the time to first documented recurrence of AF (or emergence of atrial flutter) since cardioversion.

To confirm the persistent nature of AF, a 24-hour holter monitoring will be performed during the selection visit.
Eligible participants will enter a selection phase in which anticoagulant treatment (VKA) will be adjusted to achieve ideally an International Normalized Ratio (INR) of 2 to 3 before ECV. According to guidelines for the management of AF [6], VKA should be given at least 3 weeks before cardioversion because of risk of thrombo-embolism due to post-cardioversion.

Experimental data suggest that the maximal incorporation of n-3 PUFAs in the myocardial cell membrane takes up to 28 days to occur [22]. In addition, as shown in Nodari’s study [2], the duration of pre-treatment with PUFAs before cardioversion appears to be a contributing factor in success. Therefore, before starting follow up for the assessment of AF recurrence, treatment with F373280 should be started 28 days before ECV.

Detection of AF recurrence will be performed using systematic (scheduled) ECG recording, thus allowing detection of asymptomatic (about 50% of episodes) as well as symptomatic AF episodes. According to previous studies, most of AF recurrences occurred during the first days after cardioversion [11, 15]. So that, the heart rhythm will be closely monitored during the first week after successful cardioversion using an ambulatory continuous 7-day holter ECG recording in order to increase sensibility to detect asymptomatic AF episodes. Thereafter, to improve patient compliance, this follow up will be continued using an easier device to carry and to use, i.e. a TTEM.

Finally, during the study, patients will be scheduled for a clinical visit every 4 weeks or 8 weeks (with an additional visit 7 days after visit 3 (ECV visit)) in order to ensure a close medical monitoring and to assess efficacy and safety parameters.

4.2.3. Choice of the Dose

According to a previous study in patients with AF [2], the tested PUFA product (Omacor®) at the dose of 2 g (i.e. 640 mg of DHA acid) was effective in the prevention of AF after cardioversion. Moreover, PUFAs at dosage of 1 g and 2 g were also effective on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5].

From the F373280 phase I study, after a 14-day repeated administration of F373280 (1 g/day), observed plasma concentrations of DHA measured before treatment (Cmin) were similar to that of an effective dose of Omacor® at 2 g/day (60 to 95 mg/ml and 60 to 90 mg/ml, respectively) (phase I study of F373280 and [16]). With regard to the rhythm of administration, mean peak/trough
fluctuation (baseline corrected) was around 0.3. This value supports a once-daily administration allowing a 24-hour plasma exposure in DHA. Therefore, a 1 g daily dose of F373280 is considered to be appropriate for this proof of concept study.

4.2.4. Choice of the Sample Size

See chapter 13.

5. STUDY POPULATION

Each patient fulfilling all the inclusion criteria and none of the non inclusion criteria will be eligible.

5.1. INCLUSION CRITERIA

Demographic Characteristics and Other Baseline Characteristics:

1. Men or women aged more than 18 years (inclusive)
2. Patient with current episode of persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted
3. Previous history of first documented episode of persistent AF
4. Previous history of ischemic or non ischemic heart failure
5. NYHA class I or II chronic heart failure at selection and at inclusion
6. Left ventricular systolic dysfunction defined at selection and at inclusion by a reduced left ventricular ejection fraction (LVEF) ≥ 30% and ≤ 45% or for patients with a LVEF > 45%:
   • an increased left ventricular end-diastolic size
     (diameter ≥ 60 mm and/or > 32 mm/m² and/or volume > 97 ml/m²)
   • and/or an increased left ventricular end-systolic size
     (diameter > 45 mm and/or > 25 mm/m² and/or volume > 43 ml/m²)
   • and/or a reduced left ventricular outflow tract velocity time integral < 15 cm
7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers
8. Left atrial area ≤ 40 cm² at selection and at inclusion

9. Patient treated or having to be treated by vitamin K antagonist

10. For female patient of child-bearing potential:

   - **In all the countries except Italy:**
     - Use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator for at least 2 months before the selection in the study and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment or
     - Documented as surgically sterilized

   - **In Italy only:**
     - Absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
     - Use of double barrier contraception method (use of effective medical contraception method) from at least 2 months before the start of the study to the entire duration of the study and for a month after the end of the study or
     - Documented as surgically sterilized

11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion

12. For male with a child-bearing potential partner (**In Italy only**):

   - Absolute abstention from sexual intercourse during the whole duration of the study and for 3 months after the end of the study or
   - Use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to 3 months after the end of the study.

**Ethical/legal considerations:**

13. Having signed his/her written informed consent,
14. Affiliated to a social security system, or is a beneficiary (if applicable in the national regulation)

5.2. **NON INCLUSION CRITERIA**

*Criteria related to pathologies:*

1. No previous history of first documented episode of persistent Atrial Fibrillation
2. More than two successful cardioversions (electrical or pharmacological) in the last 6 months,
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV),
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be checked in case of treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic coronaropathy assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
7. Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration rate < 30 ml/min) at selection
8. Bradycardia (HR ≤ 50 bpm)
9. Hyperkalemia or hypokalemia (according to the standards of local laboratories) at selection
10. Cardiac surgery within 3 months before selection or planned during the study duration

*Criteria related to treatments:*

11. Previously ineffective pharmacological or electrical cardioversion
12. Concomitant treatment with ranolazine or any anti-arrhythmic drug (within 7 days prior to selection), except amiodarone, dronedarone and stable dose of digoxin, beta-blockers, calcium-blockers.
13. Concomitant treatment with oral amiodarone or dronedarone from selection
14. Concomitant treatment with intravenous amiodarone from selection
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT implantation within the last 6 months
16. Treatment with any Polyunsaturated Fatty Acid within the last 3 months
17. Dietary supplement with ω3 or ω6 according to investigator’s judgment
18. Having undergone any form of ablation therapy for AF
19. Patient treated with oral anticoagulant treatment other than vitamin K antagonist: new oral anticoagulants (dabigatran, rivaroxaban, apixaban), or treated with irreversible antiplatelet agents P2Y12 inhibitors such as ticlopidine, clopidogrel or prasugrel

*Others criteria:*

20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion,
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection,
22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself / herself to its constraints,
23. Patient family member or work associate (secretary, nurse, technician…) of the Investigator,
24. Patient having forfeited his / her freedom by administrative or legal award or being under guardianship,

5.3. **NUMBER OF PATIENTS**

76 x 2 patients (taking into account 15 % of non evaluable patients).

5.4. **RECRUITMENT MODALITIES**

Patients will be recruited within the medical consultation of each centre involved in the study. If necessary and when authorized by local and national regulation, some specific supports or tools will be used to improve the recruitment (announcement, mailing to general practitioners, leaflet, website including ClinicalTrials.gov, CRO…).

Before implementation, the documents will be submitted to and approved by the Ethics Committee.
5.5. **PATIENT IDENTIFICATION**

Patient's code will contain 7 digits: the 2 first digits corresponding to the country number, the following 2 digits corresponding to the centre number and the last 3 digits corresponding to the patient's chronological order once having signed the written informed consent.

5.6. **WITHDRAWAL CRITERIA**

Reasons for a patient's premature withdrawal from the study may be the following:

- Patient's decision. A patient who wishes to withdraw from the study for any reason may do so at any time but must inform the investigator. In all cases, the Investigator should attempt to contact the patient as soon as possible for a final assessment in order to:
  - have the patient's decision written on the consent form
  - obtain the reason(s) for withdrawal and report it/them in the case report form
  - evaluate the patient's clinical condition
  - if necessary, take appropriate therapeutic measures: management of an adverse effect or concomitant disease, prescription of another treatment.

- Investigator's decision in the patient's interest, particularly if a serious adverse event occurs and is considered by the Investigator liable to threaten the health of the patient. The monitor will be informed by phone or fax and a letter or report explaining the withdrawal will be forwarded to the monitor as soon as possible.

- Erroneous inclusion according to the study protocol. The decision to maintain or not the patient in the study will be taken jointly by the investigator and the sponsor. Erroneous inclusions will not be paid to the investigator.

- Patients who could not be treated with VKA for at least 3 weeks before ECV or who will experience a VKA intolerance during the study.

- Patients without dyskalemia who will not have INR values \( \geq 2 \) on the 3 last tests performed before ECV should not have an ECV and will be excluded from the study. However, if only 2 INR values are \( \geq 2 \) among those 3 last tests, an ECV can be performed if the presence of atrial thrombosis can be excluded with an ECHO–TE (transesophageal...
echocardiography) performed on the same day (before ECV) and the patient can continue the study.

- Patients who will not revert to sinus rhythm (i.e. unsuccessful ECV) or with early AF relapse or early atrial flutter emergence within the observation period after ECV will be considered to have finished follow-up.

- Occurrence of AF recurrence or atrial flutter emergence that would require, at the investigator’s judgement, a cardioversion or an introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms for instance.

5.7. REPLACEMENT OF PATIENTS

Withdrawn patients will not be replaced.

5.8. POST-STUDY EXCLUSION PERIOD

Patients will not be allowed to participate in another clinical trial during 3 months following the study termination.

5.9. STUDY CARD AND LETTER FOR GENERAL PRACTITIONER(S)

The patient will receive from the Investigating Centre at Visit 1 - Selection Visit:
- a personal card to be kept all along the study duration and providing the following information: patient's name, sponsor's name, study code, EUDRACT number, start date and expected end date of the study, complete address of the Investigating Centre with the name and phone number of the Investigator and a sponsor 24H/24 phone contact number in case of emergency (French and English languages): 33 (0)5 63 35 25 83. For Italy, this card will be in Italian only, without any English mention.
- in Italy, a letter to be given to his/her general practitioner. This letter intends to inform the general practitioner(s) (and any other doctors who take care of the patient) that the patient participates to the clinical study. It describes the study treatment and includes some information on the forbidden treatment during the study.
6. STUDY TREATMENT
The Clinical Pharmacy Department of the Institut de Recherche Pierre Fabre (IRPF) will supply the investigational centres with the treatment necessary for the conduct of the trial.

6.1. SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT
F373280 and placebo will be prepared in Soft Capsules similar presentation.

- **F373280**
  Formulation of F373280, 1 g, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: Panthenyl ester of DHA, gelatine, glycerol, titanium, dioxide, purified water.

- **Placebo**
  Formulation of placebo matching tested product, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: paraffin liquid, fish flavour, gelatine, glycerol, titanium, dioxide, purified water.

Placebo and F373280 capsules will be packaged in opaque blisters.

6.2. PACKAGING AND LABELLING
The treatment units will be packed and labelled by the Clinical Pharmacy Department of the IRPF according to European Directive and local requirements.

6.2.1. Packaging
Each treatment unit will be composed of 3 cases for a 12-week treatment period.
Two 12-week treatment units will contain 3 cases, each case of 4-week treatment containing:
10 blister packs of four 1 g F373280 soft capsules or 1 g placebo soft capsules each.

6.2.2. Labelling
Investigational Products will be labelled according to the following rules:
Labelling should comply with the local requirements for Investigational Medicinal Products.
On the treatment units and cases, the labels will bear the following indications:

a) name and address of the sponsor
b) protocol number
c) packaging batch number
d) treatment number
e) storage conditions
f) expiry date
g) pharmaceutical dose form
h) route of administration
i) quantity of dosage units
j) direction for use
k) legal statements:
   - “for clinical trial only”, “keep out of the reach and the sight of children”, “please return to your doctor any unused product”, respect the prescribed dose”

On the treatment unit, another label will be affixed with the mention of the Investigator’s name and patient’s code (completed by the Investigator).

In addition, on each case will be mentioned the case number and a detachable label will bear the following indications:

- Protocol number
- Packaging batch number
- Expiry date
- Case number
- Treatment number

On the blister pack, the label will mention the protocol number, the packaging batch number, the case number and the treatment number.

6.3. DISTRIBUTION TO CENTRE AND STORAGE

The Clinical Pharmacy Department of the IRPF will supply the Investigational Centre with the treatment units along the study according to the need, upon request triggered by the patient’s selection.
As soon as the Pharmacist or the Investigator receives the trial medication, he/she will check the contents and immediately acknowledges the receipt in the IVRS/IWRS. The copy of the acknowledgement will be kept in the Investigator’s or the Pharmacist’s file. The same procedure will be applied to all further supplies during the course of the trial.

At the time of the delivery to the Centre, the following information will be provided:

- Details of storage conditions that should be respected
- And, upon request and for the 1st delivery only, a letter of release for the Investigational Medicinal Product from the Sponsor's Qualified Person

The CRA will ensure during the monitoring visits that trial medications have been received in good conditions and the acknowledgment of receipt has been performed adequately.

Treatment units should remain intact until dispensation to the patients. They should be kept at temperature below 30°C in an appropriate lockable room only accessible to the person authorised to dispense them, under the responsibility of the Pharmacist or the Investigator.

In the case of undue delay in study execution, the Pharmacist or the Investigator should ensure that the expiry date has not been exceeded.

### 6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT

A randomisation list will be established by the Clinical Pharmacy Department of the IRPF. This list will be computer-generated with internal software. The randomisation methodology is validated by the Biometry Department before generation.

Treatments F373280 or placebo will be balanced in a 1:1 ratio.

As the treatment units are prepared for 12-week treatment periods, the Investigator will have to allocate a treatment number at inclusion visit (V2) and another one at visit 6.

For each patient, the treatment number given at visit 6 will not be the same that the one given at inclusion visit (V2).

The treatment numbers will be given through the IVRS/IWRS.

At selection visit (V1), practically, once patient’s eligibility is confirmed:

- The Investigator:
  - Contacts the IVRS/IWRS
– Answers the questions related to the patient
• The IVRS/IWRS company:
– Confirms this information by fax/email to the Investigator
– Fills the “Request for Delivery of Investigational Product” form and sends it by email and/or fax to the Clinical Pharmacy Department of the IRPF.
• The Clinical Pharmacy Department of the IRPF sends the corresponding treatment unit to the Investigator within 5 days from reception of the email request form.

At inclusion visit (V2), the treatment number to be allocated for the first 12-week period to the patient is given by the IVRS/IWRS.
At visit 6, the Investigator will contact again the IVRS/IWRS to obtain the treatment number for the last 12-week period of treatment.
The Investigator will dispense to the patient the 4-week treatment cases (one or two according to the visit) which label indicates the treatment number and the administration period.

6.5. DRUG ADMINISTRATION

6.5.1. Duration of Treatment
For a patient completing the study, the theoretical study treatment exposure to F373280 or placebo will be 24 weeks.
If the ECV is postponed by 1 week to allow INR stabilization, the treatment duration will be 25 weeks.

6.5.2. Dose Schedule
One soft capsule of 1g of F373280 or placebo to be taken each day during 24 weeks.

6.5.3. Route and Conditions of Administration
The soft capsules are to be taken orally. One soft capsule is to be taken each evening with the dinner during 24 weeks.
6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT

The Investigator should maintain accurate written records of drug received, dispensed, returned and any remaining treatment units, on the drug accountability form. These records should be made available for Clinical Research Associate (CRA) monitoring. The packaging of the medication should remain intact until just before the dispensation.

At each visit, the Investigator will record the number of soft capsules returned by each patient using the appropriate page of the e-CRF.

At the end of the study, all used and unused treatments including packaging should be noted, and return is organised by the CRA to the Clinical Pharmacy Department of the IRPF for destruction. A copy of the drug accountability form should be provided by the Investigator to the CRA.

6.7. RECALL OF INVESTIGATIONAL PRODUCTS

In case of recall of investigational products (decided by the Competent Authorities or the Sponsor), the Investigator will immediately be informed by the Sponsor.

The Investigator in collaboration with the Sponsor’s representatives (Study Manager, CRA) must urgently:

- Stop the delivery of the concerned investigational products to the patients.
- Inform the concerned patients that they must immediately stop taking these investigational products and bring them back.

The Study Manager/CRA organises the return of the recalled products to the Clinical Pharmacy Department of the IRPF according to the Sponsor’s procedures.

7. CONCOMITANT TREATMENTS

Any existing concomitant treatment (at selection visit), any new concomitant treatment or change in the dosage of an existing concomitant treatment during the course of the study must be noted on the electronic Case Report Forms (e-CRF). All treatments should be evaluated by the Investigator at patient’s selection, and treatment prolongation or stop during the study should be considered.
For all concomitant treatments taken during the study, the following information must be noted in the relevant section(s) of the e-CRF:

- The name of the treatment and its form
- The reason for prescription
- The route of administration
- The daily dose
- The duration of treatment.

7.1. VITAMIN K ANTAGONIST TREATMENT

VKA should be given for at least 3 weeks before ECV and continued for the whole study duration. However, VKA should be stopped in case of occurrence of VKA intolerance during the study and the patient should be withdrawn from the study. The VKA used will be left to the decision of each Investigator according to his/her local practice.

7.2. PROHIBITED TREATMENTS

- Class I and class III antiarrhythmic treatments:
  - Class I:
    - Class IA: Disopyramide, Procainamide, Quinidine
    - Class IB: Lidocaine, Mexiletine
    - Class IC: Flecainide, Propafenone
  - Class III: Dofetilide, Ibutilide, Sotalol, Amiodarone, Dronedarone.
- Ranolazine
- Any PUFA
- Any oral anticoagulant treatment other than VKA: new oral anticoagulants (dabigatran, rivaroxaban, apixaban), or irreversible antiplatelet agents P2Y12 inhibitors such as ticlopidine, clopidogrel or prasugrel
- Dietary supplement with Omega 3 or Omega 6
Prohibited treatments at selection must not be prescribed for the duration of the study except in case of occurrence of an adverse event or AF episode that requires a corrective treatment in the interest of the patient’s health.

7.3. AUTHORISED TREATMENTS
Other treatments will be authorised during the study duration.

However, if medication other than study drugs is administered at any time from the start of the study, details must be recorded in the e-CRF. During the study, patients must be asked whether they have been on a course of prescribed drug treatment or have taken any OTC or herbal drugs since the visit.

8. EVALUATION CRITERIA

8.1. PRIMARY EFFICACY CRITERION

8.1.1. Time to the first Atrial Fibrillation Recurrence or Atrial Flutter Emergence

8.1.1.1. Definition
Time to first AF recurrence or atrial flutter emergence is defined by the time to first episode of AF or atrial flutter (symptomatic or not) lasting for at least 10 minutes.

8.1.1.2. Schedule
The heart rhythm follow up will be performed from the end of ECV visit (visit 3) to the final study visit (visit 9).

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF or the emergence of atrial flutter will be assessed after visit 3 (from week 5).

8.1.1.3. Evaluation Methods

- 7-day holter monitor:
The heart rhythm monitoring will be carried out from visit 3 to visit 4 using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) fixed after ECV visit. Following holter monitoring, the heart rhythm will be documented using Trans Telephonic ECG Monitoring (TTEM).

- Trans Telephonic ECG Monitoring:
  The ECG follow up will be documented using the TTEM: one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24, end of study). The patient will be requested to contact the Central Reading Laboratory for transmission of each stored TTEM. Moreover, if patient experiences AF or atrial flutter symptoms during this TTEM period, it should be documented using the TTEM. In case of AF recurrence or atrial flutter emergence and provided that the patient does not require a cardioversion or an introduction of an anti-arrhythmic at Investigator’s judgement, the patient could be maintained in the study with the treatment in order to assess a spontaneous cardioversion. For that purpose the patient will continue to transmit a TTEM once a week.

- Process of centralisation of ECG (Holter and TTEM)
  ECG (Holter and TTEM) will be centralized by the Central Reading Laboratory. The ECG will be validated by a trained technician, then analysed by a cardiologist. The cardiologist interpretation will be emailed to the site (or per fax on request of the site). The investigator will be asked to review and sign these documents. The Holter and TTEM process will be fully described in separate documents.

8.2. SECONDARY EFFICACY CRITERIA

8.2.1. Numbers of AF episodes in the first week following visit 3 (ECV visit)

8.2.1.1. Definition
  Number of AF episodes will consist in the assessment of AF episodes with duration at least 10 minutes ($N_{\text{Sup10}}$) and of less than 10 minutes ($N_{\text{Inf10}}$), respectively.
8.2.1.2. **Schedule**
The heart rhythm follow up will be performed from the end of successful ECV visit (visit 3) to the study visit 4.

8.2.1.3. **Evaluation Methods**
- 7-day holter monitor:
The heart rhythm monitoring will start using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) after ECV visit from visit 3 to visit 4.

8.2.2. **Duration of AF episodes in the first week following visit 3 (ECV visit)**

8.2.2.1. **Definition**
Duration of AF episodes will consist in the sum of duration of each AF episode.

8.2.2.2. **Schedule**
The heart rhythm follow up will be performed from the end of successful ECV visit (visit 3) to the follow up study visit (visit 4).

8.2.2.3. **Evaluation Methods**
Duration of AF episodes will be assessed using the 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording.

8.2.3. **Clinical parameters evaluation**

8.2.3.1. **EHRA score assessment**

8.2.3.1.1. **Definition**
AF related symptoms will be evaluated by the EHRA (European Heart Rhythm Association) score [20]. The following items “during presumed arrhythmia episodes" are checked to determine the score: palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety.

Classification of AF-related symptoms (EHRA score) are as follows:
• EHRA I - ‘No symptoms’
• EHRA II - ‘Mild symptoms’; normal daily activity not affected
• EHRA III - ‘Severe symptoms’; normal daily activity affected
• EHRA IV - ‘Disabling symptoms’; normal daily activity discontinued

This classification relates exclusively to the patient-reported symptoms.

In addition to this score, the frequency will be classified in three groups, namely occasionally (less than once per month), intermediate (1/month to almost daily) and frequent at least daily.

8.2.3.1.2. **Schedule**

EHRA evaluation will be performed in case of evocative symptoms of arrhythmia.

8.2.3.1.3. **Evaluation Methods**

EHRA evaluation will be collected by Central Reading Laboratory during TTEM period.

8.2.3.2. **Time to first AF recurrence less than 10 minutes**

Time to first AF recurrence less than 10 minutes will be assessed during TTEM period.

8.2.3.3. **Recurrence of symptomatic AF**

Recurrence of symptomatic AF will be assessed during TTEM period.

The number of recurrences of symptomatic AF consists of the number of AF recurrences associated with a symptom (palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety) and confirmed by an ECG.

The time to first symptomatic AF recurrence is defined by the time to first episode of symptomatic AF.

8.2.3.4. **Number and duration of hospitalizations**

• Number and duration of hospitalizations for cardiovascular events
  – Hospitalization for AF treatment
– Hospitalization for worsening of heart failure
– Hospitalization for myocardial infarction
– All cause of hospitalization

• Number and duration of hospitalizations for thromboembolic stroke

8.2.4. Cardioversion assessment

• Assessment of spontaneous cardioversion before visit 3
• Assessment of successful cardioversion at visit 3 (i.e. return to sinus rhythm)
• Shocks distribution (1, 2 or 3 shocks)
• Number of patients needing another cardioversion after initial ECV

8.2.5. Evolution of echocardiographic parameters

8.2.5.1. Definition
The following echocardiographic parameters will be assessed: Left atrial diameter (mm), LAA (cm²), Left atrial volume (ml), Left atrial volume/BSA (ml/m²), LVEF (%), Left ventricular end diastolic volume/BSA (ml/m²), Left ventricular end systolic volume/BSA (ml/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (ml), Left ventricular end systolic diameter (mm) and Left ventricular end systolic volume (ml).

8.2.5.2. Schedule
Measurements will be performed at visit 1 and visit 2 to check the eligibility of the patient.
Measurements performed at visit 4, visit 6 and visit 9 are done to follow the echocardiographic evolution of the patients in sinus rhythm.

8.2.5.3. Evaluation method
The echography evaluations will be carried out according to the recommendations for chamber quantification drawn up by the American Society of Echocardiography and the European
Association of Echocardiography [23]. So, the recommended method for volume measurements is to use the biplane method of discs (modified Simpson’s rule) from 2-D measurement.

8.3. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA

8.3.1. Definition

Because of the limited human tissue accessibility for biopsy, red blood cell DHA contents is a marker of tissue DHA concentration [13], [14].

8.3.2. Blood samples

8.3.2.1. Collection schedule

Blood samples will be collected to determine the red blood cells (RBC) concentrations of DHA. Blood samples will be performed at visit 2 before treatment, visit 3, visit 6 and visit 9. Actual sampling times will be individually reported in the e-CRFs.

8.3.2.2. Technical handling

Two blood samples (2 x 4 ml) will be collected in EDTA tubes. They will be homogenized slowly by inverting the tube without shaking, stored between +2°C/+8°C in a fridge (no freezing will be allowed) and sent to Analytical Centre in refrigerated conditions (between +2°C and +8°C). Analysis will be performed within 2 weeks following reception at the Analytical Centre.

8.3.3. DHA concentration measurement

Analytical determination of RBC concentrations of DHA will be carried out by the Analytical Centre.

Lipids will be extracted from red blood cells samples with a mixture of hexane/isopropanol after acidification [17]. Total lipid extracts will be saponified and methylated. The fatty acid methyl esters (FAME) will be extracted and analyzed by Gas Chromatography.

Identification of FAME will be based on retention times obtained for FAME prepared from fatty acid standards. The area under peaks will be determined using ChemStation Software (Agilent)
and results will be expressed as % of total fatty acids. DHA concentration will be calculated using the internal standard and expressed as µg/g for red blood cells samples. Thus, omega-3 index will be assessed. The omega-3 index represents the content of EPA plus DHA in red blood cells (expressed as a percent of total fatty acids). It is a biomarker considered as a new marker of risk for death from coronary disease [18].

Results of this analytical determination will be kept confidential by the dosing centre until the end of the study, and will be provided only at the end of the study (after database lock) in a separate file.

8.4. SAFETY ASSESSMENT

8.4.1. Adverse Events
At selection, any concomitant disease will be reported on the e-CRF. At each further visit, the occurrence of AEs since the last visit will be based on the patient's spontaneous reporting, the Investigator's non-leading questioning and his/her clinical evaluation. All AEs will be reported on the e-CRF (see section 10).

8.4.2. Laboratory Investigations

8.4.2.1. Schedule
Laboratory investigations will be performed at visit 1 (before treatment) and visit 9 (end of treatment) or End of Treatment visit.
At visit 3 and 6, only a standard haematologic dosage will be performed.
Furthermore the kalemia will be checked before electrical cardioversion at visit 3.
The total volume of blood samples taken for haematology and biochemistry analysis should not exceed 30 ml.

8.4.2.2. Technical Procedures and Parameters
The following tests will be performed:
**Haematology:** haematocrit, haemoglobin, RBC count, white blood cells (WBC) count, WBC differential counts (% and/or absolute), reticulocytes, platelets.

**Biochemistry:** sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatine phosphokinase (CPK), fibrinogen.

Blood samples will be taken in the morning in fasting conditions.

The estimation of GFR at selection relies on the measurement of serum creatinine and the Cockcroft-Gault formula:

**Cockcroft-Gault formula**

- with serum creatinine expressed as mg/L:

  in men:

  \[ \text{GFR (ml/min)} = \frac{[(140 - \text{age}) \times \text{weight}}{(7.2 \times \text{serum creatinine in mg/L})] } \]

  in women:

  \[ \text{GFR (ml/min)} = \frac{[(140 - \text{age}) \times \text{weight}}{(7.2 \times \text{serum creatinine in mg/L})] \times 0.85 } \]

- with serum creatinine expressed as µmol/l:

  \[ \text{GFR (ml/min)} = \frac{[(140 - \text{age}) \times \text{weight}}{\text{serum creatinine in µmol/l}] \times k, \text{where } k = 1.23 \text{ for men, 1.04 for women.} \]

(weight in kg, age in years)

Additional tests may be done at the Investigator’s discretion, in the patient’s interest. In case of any abnormal and/or clinically significant results, the Investigator should order laboratory control tests.

**8.4.3. Global Physical Examination**

A global physical examination including the measurement of body weight will be carried out on each body system at visit 1, visit 2, visit 3, visit 6, visit 7, and visit 9.
The Body surface area (BSA) will be calculated at the same visits using Mostellers’ formula:

\[
BSA = \left[\frac{(\text{Weight} \times \text{Height})}{3600}\right]^{1/2}
\]

(Weight in kg, height in cm)

The physical examination will be globally evaluated as “normal/abnormal”. Further target inspection will be undertaken for any abnormal finding.

8.4.4. Vital Signs

Vital signs will consist in blood pressure and heart rate at rest.

8.4.4.1. Schedule

Vital signs will be measured at each visit.

8.4.4.2. Technical Procedure and Parameters

Systolic blood pressure (SBP) and diastolic blood pressure (DBP), expressed in mmHg, will be measured after at least 5 minutes in supine position and after 2 minutes in standing position.

The heart rate (HR), expressed in beats per minute (bpm), will be measured by auscultation by counting the beats for at least 30 seconds, after at least 5 minutes in supine position and after 2 minutes in standing position.

Bodyweight will be measured with patient in underwear and with the same balance at each visit.

8.4.5. Electrocardiogram (ECG)

8.4.5.1. Schedule

An ECG will be recorded after at least 10 minutes of rest at visit 1, visit 2, visit 3, visit 6, visit 7, and visit 9 using a usual standardised 12-lead cardiograph.

8.4.5.2. Technical Procedure and Parameters

- Electrocardiogram:

The global interpretation from manual reading (normality, clinical relevance) and HR (bpm), PR (ms), QRS (ms), QT (ms), QTcB (ms), QTcF (ms), repolarisation patterns will be reported in the
e-CRF. Each print-out will include the patient’s code, date, time, technician's initials and investigator's signature.

In case of thermic paper ECG print out, a photocopy will be made by the centre to ensure safe filing.

- 24 hour-Holter - ECG

An ambulatory continuous 24-hour ECG (5-leads/2 or 3 channels) will be recorded at selection visit using a holter ECG, in order to confirm persistent AF.

### 8.4.6. Coagulation parameters

Coagulation assessment will be evaluated by the following parameters:

- Prothrombin Time/INR (PT/INR)
- Activated Partial Thromboplastin Time (aPTT)
- Thrombin Clotting Time (TCT)

The recommendations for the controls of INR are the following [25, 26]:

1) During the pre-cardioversion period, if the anticoagulation by VKA has to be initiated, the treatment must be initiated at least 3 weeks prior to cardioversion then the INR will be monitored as follow:

   - The adjustment of the dosage of VKA should be performed stepwise by controlling INR 2 to 3 times a week until stabilization within the target range (2 - 3) on 2 successive tests.
   - When the INR is within the target range (2 - 3) on 2 successive tests, the dose of VKA should be maintained. Then the controls of INR will be progressively spaced within a few weeks.
   - When INR is stabilized, at least one test should be performed each week.
   - In all cases, an INR control must be performed within 24 h before ECV.

2) During the pre-cardioversion period, if the anticoagulation by VKA was already initiated, the INR will be monitored as follow:

   - One INR per week up to ECV
   - An INR control must be performed within 24 h before ECV

3) After cardioversion : one INR every 4 weeks

4) Throughout the duration of the study if INR > 3 the advocated actions are:
- No transesophageal echocardiography before cardioversion

- For asymptomatic patients:
  - $3 < \text{INR} < 4$: no omission of VKA (dose adjustment if required), no vitamin K
  - $4 \leq \text{INR} < 6$: omit one dose of VKA, no vitamin K
  - $6 \leq \text{INR} < 10$: interrupt VKA, vitamin K 2 mg orally
  - $\text{INR} \geq 10$: interrupt VKA, vitamin K 5 mg orally

  For $\text{INR} \geq 6$, an adverse event has to be reported (asymptomatic overdose).

Anti-coagulation by VKA should be given at least 3 weeks before ECV and continued for the whole study duration.

aPTT and TCT will be performed at visit 1, visit 2, visit 3, visit 6, visit 7, and visit 9.

The quantity of blood samples collected at each time for coagulation parameters will be 2 ml.

Additional tests may be done at the Investigator’s discretion, in the patient’s interest. In case of any abnormal and/or clinically significant results, the Investigator should order laboratory control tests.

### 8.5. CONCOMITANT TREATMENTS

Concomitant treatments will be evaluated at each study visit.

Requirements related to patient’s concomitant treatments started before selection visit and continued throughout the trial, or started during the trial, can be found in section 7.

### 8.6. COMPLIANCE

The patient will be reminded at each visit to bring back at the following visit any used or unused remaining soft capsule, blister and case.

At each visit (except at visit 4), the Investigator will record the number of supplied and remaining soft capsules in the e-CRF.

### 9. STUDY PROCEDURES

Visit 1 - Selection Visit (Week - 4 to Week -1):
The patient considered eligible for selection by the Investigator will be informed of the characteristics and the consequences of the trial both verbally and by reviewing the patient's information sheet and consent form (see section 14.3). If the patient accepts to participate in the study, he/she will sign the informed consent form and will keep a copy.

The patient will be assessed for the following:

- Demographic characteristics (gender, age, height, body surface area)
- Personal and medico-surgical history
- Habits (Tobacco, alcohol consumption, dietary habits including fish consumption…)
- Cardiovascular diseases, mainly detailed history of Heart Failure and AF characteristics
- Echocardiography using a two-dimensional echocardiography
- 12-lead ECG
- Concomitant diseases, adverse signs or symptoms (able to be used for treatment emergent AE determination)
- Concomitant treatments (authorised, disallowed)
- Global physical examination/bodyweight
- Vital signs
- Biology: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Biology assessment of renal function: creatinine or estimated glomerular filtration rate

If the results of the above assessments are compatible with the selection criteria:

- A 24-hour continuous ECG ambulatory recording (Holter ECG) device will be installed on the patient to monitor the patient heart rhythm. The patient will be requested to bring back the device after the termination of 24 hours recording. The recording will be transmitted from the Investigational site to the Central Reading Laboratory. The Central Reading Laboratory will send his/her assessment regarding the confirmation of persistent AF within 2 working days to the Investigator.
• The patient will enter the selection and pre-cardioversion periods in which anticoagulant (VKA) will be adjusted to achieve ideally an International Normalized Ratio (INR) in the range of 2 to 3 before ECV.

At the end of the visit, the Investigator will contact the IVRS/IWRS to confirm the patient selection (which will automatically order the treatment delivery) and organise the appointment for the next visit.

The patient will receive from the investigational centre the participant card to be kept for all the duration of the study.

Visit 2 - Inclusion Visit (Day 1):

If the patient's behaviour during the selection period and/or the result of complementary examinations, particularly the confirmation of the presence of persistent AF by the Central Reading Laboratory during this period and the laboratory tests, are compatible with the inclusion criteria, the patient will be assessed for the following:

• Adverse events
• Concomitant treatments (authorised, disallowed)
• Laboratory examination: red blood cell concentrations of DHA and coagulation parameters Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
• Global Physical examination/bodyweight
• Vital signs
• Echocardiography using a two-dimensional echocardiography
• 12-lead ECG
• Urine pregnancy test for women of child bearing potential

If the results of the above assessments are compatible with the inclusion criteria, the patient will be included and the investigator will contact the IVRS/IWRS to obtain the treatment unit number to be dispensed at visit 2 for the first 12-week period.

Between this Inclusion visit and the next visit (V3), the INR will be closely monitored (refer to paragraph 8.4.6) in order to fulfil the ECV conditions (refer to paragraph 3).
At the end of the visit, the Investigator will organise the appointment for the next visit and will give the treatment for the next 4-week period (one case of treatment).

**Visit 3 (Week 4: D28 -2/+7 days) cardioversion:**

Patient will be assessed for the following criteria:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: Haematology, RBC concentrations of DHA, Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Global Physical examination /bodyweight
- Vital signs
- 12-lead ECG
- Electrocardioversion (ECV): ECV has to be performed 4 weeks after randomization in patients with AF. ECV will be performed in the morning, with the patient in the fasting state and without dyskalemia. An INR value control must be performed within 24h before ECV. INR values ≥ 2 on the 3 last tests performed before ECV are required. However, if only 2 INR values are ≥ 2 among those 3 last tests, an ECV can be performed if the presence of atrial thrombosis can be excluded with an ECHO–TE (transesophageal echocardiography) performed on the same day (before ECV) and the patient can continue the study. Anesthesia will be induced and patients will be cardioverted with administration of a synchronized, biphasic current. The initial shock will be set at 100 J if the body weight is less than 70 kg and at 150 J for higher body weights. Successful cardioversion will be defined as recovery of sinus rhythm lasting at least 1 minute after the shock. If unsuccessful, a second 200-J shock, and eventually a third 200-J shock, will be administered. Failure of ECV is defined as the persistence of AF after the third attempt at cardioversion. After the procedure, patients will be monitored on telemetry for at least 6 hours before discharge.
Patients who will not revert to sinus rhythm or with early AF relapse or early atrial flutter emergence within the observation period after ECV will be withdrawn from the study and will be considered to have finished their follow-up.

At the end of the visit, a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) will be installed on the patient in order to monitor the patient heart rhythm after ECV.

The Investigator will collect all unused cases, blisters and soft capsules, and will count the unused capsules for each 4-week treatment period.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 8-week period (two cases of treatment).

**Visit 4 (Week 5: D35 -2/+7 days):**

After removal of the continuous ECG ambulatory device, the patient will be assessed for the following criteria:

- Assessment of AE
- Concomitant treatments (authorised, disallowed)
- Bodyweight (bodyweight measured at V3 to be used)
- Vitals Signs
- Echocardiography using a two-dimensional echocardiography

At the end of the visit, the patient will be given the TTEM device for cardiac monitoring. The patient will be clearly instructed on the frequency and modalities of transmission. The patient will be requested to perform one transmission per week from this visit (initial call to perform with the patient) to the visit 9 (week 24 – end of study). Moreover, in case of AF or atrial flutter symptoms, additional transmissions may be performed.

**Visit 6* (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days):**

*see amendment PA05 dated 22OCT2014

Patient will be assessed for the following criteria:

- Adverse events
Concomitant treatments (authorised, disallowed)

Laboratory examination: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT). However, in case of discontinuation of anticoagulation after ECV due to occurrence of VKA intolerance, the monitoring of INR, aPTT and TCT should be stopped.

Global Physical examination/bodyweight

Vital signs

12-lead ECG

The cardiac monitoring will be continued using the TTEM device through one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24, end of study). Moreover, in case of AF or atrial flutter symptoms, additional transmissions may be performed.

The Investigator will collect all unused cases, blisters and soft capsules, and will count the unused capsules for each 4-week treatment period.

In addition, at visit 6:

- the investigator will contact the IVRS/IWRS to obtain the treatment unit number to be dispensed at visit 6 for the last 12-week period.
- an echocardiography will be performed, an haematology examination will be done and the RBC concentration of DHA will be measured.

At the end of each visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next treatment period: one case at visit 6 and two cases at visit 7.

Visit 9* - End-of-Study Visit (Week 24: D168 ± 7 days):

*see amendment PA05 dated 22OCT2014

Patient will be assessed for the following:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Global Physical examination/bodyweight
- Vital signs
- 12-lead ECG
- Laboratory examination: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT), Red blood cell concentration of DHA.
- Urine pregnancy test for women of childbearing potential
- Echocardiography using a two-dimensional echocardiography

The Investigator will collect all unused cases, blisters and soft capsules, and will count the unused soft capsules.

The total volume of blood collected should be about 90 ml for the study duration (30 ml for the total volume of haematology and biochemistry, 2 ml for each blood samples for coagulations parameters and 4 ml for each blood samples of DHA).

10. ADVERSE EVENTS: DEFINITION AND REPORTING

10.1. ADVERSE EVENTS

10.1.1. Definition of Adverse Events

An AE is any adverse change from the patient's baseline condition, i.e. any subjective signs and symptoms or change in a concomitant disease present at the Selection Visit considered or not related to the treatment.

AE includes intercurrent signs, symptoms, illnesses and significant deviations from baseline for vital signs and laboratory values which may occur during the course of the clinical study.

All laboratory tests for which abnormal results are collected after study treatment initiation should be repeated until the values return to normal or to a stable status. Abnormal results are defined as those falling out of the laboratory normal ranges and that are clinically significant. The frequency of such checks should be defined by the Investigator according to the degree of abnormality.
In all cases, the aetiology should, as much as possible, be identified and Pierre Fabre Médicament notified.

10.1.2. Grading of Adverse Events
Adverse or intercurrent events are graded as follows:

- Mild: awareness of signs or symptoms, but easily tolerated
- Moderate: uncomfortable enough to cause interference with usual activity
- Severe: incapacity with inability to work or do usual activity

10.1.3. Reporting of Adverse Events
The records of AE in the e-CRF describe the nature (diagnosis, signs and symptoms), severity, onset date, stop date, outcome and actions taken, and relationship to study treatment (in the Investigator's opinion). It must be specified whether the event is serious or not.

10.2. SERIOUS ADVERSE EVENTS (SAE)

10.2.1. Definition
A SAE includes, but is not necessarily restricted to, any event which:

- Results in death (whatever may be the cause)
- Is life-threatening
- Results in persistent or significant disability/incapacity
- Requires the patient's hospitalisation or prolongation of current hospitalisation *
- Is a congenital anomaly or birth defect

Other events such as cancer and any additional adverse experience or abnormal laboratory values occurring during the study period, defined by the protocol as serious or which the Investigator considers significant enough or that suggest a significant hazard, contra-indications, side effect or precaution, must be handled as serious adverse events.

Any overdosage meeting a seriousness criteria should be reported as a SAE (see section 10.3).
Any pregnancy occurring during/after exposure to the study drug(s) should be reported on the SAE notification form (see section 10.4).

* any hospitalisation, or prolongation of hospitalisation due to the circumstances listed below:
  
  – planned (as per protocol) medical/surgical procedure
  – preparation for routine health assessment/procedure (e.g. routine colonoscopy)
  – planned medical/surgical admission (planned prior to entry into study trial, appropriate documentation required)
  – administrative or social reasons (e.g. lack of housing, economic inadequacy, care-giver respite, family circumstances)

will not be reported as a SAE.

10.2.2. Reporting of SAE

All Serious Adverse Events, according to the above-mentioned definitions and regardless of treatment or relationship to study drug, and occurring once the informed consent form has been signed, must be reported by the Investigator as soon as he/she is informed of the event.

The Investigator must notify the Sponsor of this event by sending, within 24 hours, the "Notification of serious adverse event" form ("first notification") with all the available information about the event (see appendix 17.2), to the Sponsor's Corporate Vigilances e-mail dedicated box:

HQ.pharmacovigilance@pierre-fabre.com

In case it is not possible to send the report by e-mail it can be sent by FAX at the following number:

+ 33 1 49 10 80 90

In case of non-inclusion, the reporting period ends when the non-inclusion is documented.

10.2.3. Follow-up of SAE

The Investigator must draw-up a specific clinical report and use the "Notification of serious adverse event" form ("follow-up") (see appendix 17.2) and collect the results of the carried out examinations and the reports of hospitalisation.
The serious adverse events must be followed up until resolution or stabilisation.

10.2.4. SAE Occurring After the Study

Any SAE occurring during 30 days following the end of the study for the patient should be notified to the Sponsor.

Must also be notified to the Sponsor any event occurring at any time after the end of the study for the patient which may be related to the study treatment in the Investigator's opinion.

10.3. REPORTING OF OVERDOSAGE TO THE SPONSOR

For the purpose of this trial, an overdosage will be defined as any dose exceeding the planned prescribed dose of the study drug or the administration of any dose of an associated product that is considered both excessive and medically important.

In the absence of seriousness criteria, the overdosage and associated adverse event if any, are reported only on the Adverse Event page of the e-CRF. If the definition of seriousness criteria is met, the SAE notification form must also be transmitted to the Sponsor.

10.4. REPORTING OF PREGNANCY TO THE SPONSOR

Pregnancies discovered in the period in between the informed consent form signed but before any study drug exposure are not to be reported to the Sponsor unless associated to a seriousness criteria (e.g. serious adverse event study-protocol related procedure). If pregnancy is confirmed, the women must not be administered the study drug and must be withdrawn immediately from the study.

If pregnancy is suspected while the patient is receiving study treatment, the study drug should be discontinued immediately until the result of the pregnancy testing is known. If pregnancy is confirmed, then the study treatment is permanently discontinued in an appropriate manner and the patient is withdrawn from the study.

The Investigator must report to the Sponsor any pregnancy which occurs during or after the patient has been exposed to the study drug and until 30 days after the last study drug administration. The Investigator must immediately notify the Sponsor using the SAE notification form and also report the pregnancy on the AE page of the e-CRF.
Women who become pregnant after exposure to the study drug must be followed by the Investigator until the completion/termination of the pregnancy. If the pregnancy goes to term, the outcome will have to be reported to the Sponsor (baby's healthy status).

10.5. SPONSOR'S RESPONSIBILITIES FOR SAFETY REPORTING PURPOSES

Sponsor will submit expedited and periodic reports to both Competent Authorities and Ethics Committees per corporate standard operating procedures as regards to the EU directive 2001/20/EC taking into account local specific requirements.

11. DATA COLLECTION AND STUDY MONITORING

11.1. DATA COLLECTION

11.1.1. Case Report Form

An e-CRF will be used to record all patient data required by the protocol except the central ECG (Holter ECG, TTEM) and DHA data which will be transferred from vendors to the subcontractor as electronic data files that will be loaded into the study database.

The e-CRF should be fully validated, compliant with ICH-GCP requirements and European regulations and should include a traceability system for data corrections and deletions (audit trail).

Prior to the start of the study, the Investigator will complete a "Delegation of significant study-related duties" form. The signature and initials of all personal in charge of e-CRF completion should be recorded on this form. Each person involved in e-CRF completion, review, correction and / or validation will be trained and will have an individual login and access code to the e-CRF. Training sessions will be held by the subcontractor for all participants using this tool. An e-CRF user manual will be available for investigators and CRAs.

All the information included into the e-CRF will be recorded from source documents onto the e-CRF by an authorised person.
The Investigator is responsible for the management and accuracy of the information on the e-CRF. At each monitoring visit, the e-CRF(s) should be at the CRA's disposition for review and validation.

At the end of the study, a CD-ROM containing the pdf version of all e-CRFs (including audit-trail) will be sent by the subcontractor to the Sponsor and to the investigational sites for archiving. The subcontractor must store all study data for at least 15 years after the end of the study and ensure their legibility and accessibility during all the storage period.

11.1.2. Source Documents

A source document is an original record or certified copy of an original record of clinical findings, observations or any other medical or paramedical activities performed during the clinical trial, necessary for the transcription and the verification of the collected data.

Source documents along with all other trial-related documents (copies of all "informed consent" forms, e-CRFs CD-ROM, drug inventories and any correspondence related to the study) must be kept in the investigator's file throughout the study, and then, must be stored in the study centre's archives for a period of at least 15 years or as per local legal requirements, whatever is the longest.

For further details see section 15.2.

11.2. STUDY MONITORING

11.2.1. Monitoring visits

On-site visits will be carried out by a representative of the Sponsor's staff (Study Manager or CRA) prior to study initiation and at regular intervals (every 4 to 6 weeks) throughout the study. Additional visits and communication by telephone fax or meeting may be performed if necessary. Any site visit performed by the Sponsor's representatives will be recorded in the Investigator's study file.
11.2.1.1. **Site Preselection Visit**

Before selecting a centre for the study, a visit will be carried out by the CRA and/or the Study Manager to ensure that the Investigator has the necessary capacities (availability, patient's recruitment, environment), technical means and staff to carry out the study.

11.2.1.2. **Initiation Visit**

Before the start of the study at all investigational sites, an initiation visit will be carried out by the CRA to check at the latest that:

- The Investigator:
  - has received the technical protocol, administrative and financial agreement signed by all parties
  - has received the written statement of the Ethics Committee approval and the list of its members and their functions
- The original dated and signed *curriculum vitae* of the investigator(s) has been collected
- Laboratory normal ranges have been collected
- All study materials are available on the study site
- All participants agree with the monitoring procedures and know the study procedures
- All participants are aware of a possible audit or inspection

The CRA has also to provide training on the study protocol requirements and study specific procedures.

11.2.1.3. **Follow-up Visits**

Throughout the study, regular follow-up visits will be carried out by the CRA to check compliance with GCP, patient's informed consents, strict application of the protocol, conformity of the data entered on the e-CRF with the source documents and ensure its correct completion, adverse events reporting, proper retention, storage and management of the study medication, as well as the source and other trial-related documents.
11.2.1.4. **Closing Visit**
At the end of the study, a final visit will be carried out by the CRA to:

- Verify that the e-CRFs CD-ROM with pdf files are correctly stored
- Control the accountability of intact and used treatment units and return them to the Clinical Pharmacy Department of the IRPF for destruction
- Obtain the last data clarifications and/or solutions if any
- Collect the patient's consent forms in sealed envelopes (except in case of specific country requirements),
- Make an on-site review of all study documentation and complete it if necessary
- And finally, remind the Investigator of his regulatory obligations, study document archiving process and duration.

11.2.2. **Direct Access to Source Documents**
In accordance to the requirements of the GCP, all Sponsor representatives (Study Manager, CRA and Auditors) have to be given a direct access to all source and study data to perform quality monitoring/audit, thus ensuring accuracy and completeness of data).

Investigators are reminded that all Sponsor representatives keep professional confidentiality with regards to the patient data.

11.3. **INDEPENDENT DATA MONITORING COMMITTEE**
An Independent Data Monitoring Committee (IDMC) will be established to assess at intervals the progress of the clinical trial, the compliance with the inclusion criteria, the quality of follow up, the quality of primary end point measures, the safety data. The IDMC will thereafter recommend to the Sponsor whether to continue, modify, or stop the study.

The IDMC operating procedures will be described in an independent document.
12. DATA MANAGEMENT

All clinical data related to the study will be collected and saved in a computerised database by the Data Management Department of the subcontractor and under the supervision of the Data Manager of Pierre Fabre Biometry (PFB) according to the following procedures.

12.1. DATA ENTRY

All required data will be collected by the Investigator or authorised designee (duly identified into the delegation task list) on the e-CRFs.

The e-CRFs used for this study will be developed and maintained by the Data Management Department of the subcontractor and approved by the Sponsor.

Electronic data (Holter ECG, TTEM and DHA) will be transferred by the 3rd party vendor according to the specifications given by the Data Manager of the subcontractor. These data will be captured and handled in accordance with the European GCP ICH E6 guideline.

12.2. DATA CLEANING

The subcontractor will define in the Data Validation Plan for reviewing and querying data, descriptions of both manual and electronic edit checks. Upon Sponsor approval, the subcontractor will program the checks.

The subcontractor will review the data over the course of the study, working with the Sponsor to identify data inconsistencies. The Investigator will be asked to resolve queries by making changes directly into the e-CRF.

12.3. DATA CODING

Adverse events, concomitant diseases, medical/surgical histories will be coded by the subcontractor using the MedDRA dictionary (latest version in use).

Concomitant medication will be coded by the subcontractor using the WHO-DRUG dictionary (latest version in use).

The Sponsor Clinical Development Physician will validate the coding.
12.4. DATA STORAGE
Computer data files as well as their modifications will be archived by the subcontractor and kept available upon request of the Sponsor.

12.5. DATABASE LOCK
The validated database will be locked by the subcontractor upon request of the Data Manager of PFB following the completion of all steps required, i.e. data entry and check of all data, resolution of all queries, validation of the coding, Clinical and Products Safety databases reconciliation and validation committee.

Then, the subcontractor will transfer the locked database in SAS format to the Data Manager of PFB who assume storage on the PFB secured server.

13. STATISTICAL ANALYSIS
After the database lock and the randomisation code release, the statistical analysis will be performed by PFB or under the supervision of the statistician of PFB using SAS® software, according to the Statistical Analysis Plan approved by the Validation Committee.

13.1. GENERAL CONSIDERATIONS
The main objective of the study is to assess the efficacy of F373280 versus placebo on the maintenance of sinus rhythm after direct ECV in patients with persistent AF and chronic heart failure.

Only the primary analysis of the primary efficacy criterion, on which is based the sample size justification, may lead to a causal interpretation. All other statistical results are to be regarded within a descriptive perspective.

The statistical significance level of the various two sided tests of all analyses will be 5%.

13.2. SAMPLE SIZE
Assuming an AF recurrence or atrial flutter emergence rate of 85% under placebo and 65% under active group, i.e. a clinically relevant difference $\Delta$ of 20%, a sample size of 64 assessable patients
per group is required, using a log-rank test of survival curves with a 80 % power and a 5 % two-sided significance level.

According to the previous assumptions and assuming a rate of not assessable patients of 15%, a minimum of 76 patients will have to be randomised per group.

13.3. PROTOCOL DEVIATIONS

Prior to the database lock and the randomisation code release, the Validation Committee members will review the protocol deviations and will classify them as either minor or major. A protocol deviation will be considered major when it is likely to bias significantly the treatment effect estimate based on the primary efficacy criterion.

Patients with major deviation(s) will be excluded from the Per Protocol data set (see section 13.4). A listing of all protocol deviations will be provided for all randomised patients, including the type (major/minor) of protocol deviations according to the decisions made by the members of the Validation Committee.

The number and percentage of patients with major protocol deviations will be tabulated by treatment group and type of major protocol deviations on the Full Analysis Set defined in section 13.4.

13.4. DATA SETS ANALYSED

The following 3 data sets will be analysed (as defined by the Validation Committee):

- The Safety Set composed of all randomised patients having received at least one dose of the study treatment. This data set will be used to perform analyses of Safety.

- The Full Analysis Set (FAS) composed of all randomised patients having received at least one dose of the study treatment and with a successful cardioversion observed at visit 3. This data set will be used to perform analyses of Efficacy.

- The Per Protocol Set (PP) which is the subset of the Full Analysis Set composed of all patients with a primary efficacy criteria available and without any major protocol
deviation or other source of bias for primary criteria analyses. This data set will be used to
perform the supportive analysis of the primary efficacy criterion.

13.5. HANDLING OF DROPOUTS AND MISSING DATA

13.5.1. Dropouts
The number of patients who withdraw from the study after their randomisation will be provided
by treatment group for all treated patients (Safety Set). All withdrawn patients will be further
described regarding their time to dropout and reasons for withdrawal.

13.5.2. Repositioning of Visits
No repositioning of visits will be done.

13.5.3. Missing Data
Missing values will not be substituted by estimated values, but considered as missing in statistical
analysis.

13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS
Before the first trial drug intake, patient’s background, medical and surgical history, demographic
data and disease characteristics will be described by treatment group on the Safety Set.

- **Quantitative parameters** will be described by treatment group and overall using the
  following: number of patients, number of missing data, mean, standard deviation,
  minimum, median and maximum values.

- **Qualitative parameters** will be described by treatment group and overall using
  frequencies.

Concomitant diseases, as well as medical and surgical histories will be tabulated descriptively by
 treatment group and overall using the MedDRA codes of System Organ Classes and preferred
terms.
If more than 10% of patients are excluded from the FAS and PP set, the description of patients by treatment group at selection and inclusion will be repeated on the FAS and PP set for all parameters. No statistical test of comparability of treatment groups at baseline will be performed.

13.7. EFFICACY ANALYSIS

13.7.1. Primary Criterion

13.7.1.1. Primary Analysis
The primary criteria, time to first recurrence of AF or atrial flutter emergence, will be analysed using the Kaplan Meier method and compared with the Log rank test. Hazard ratios and 95% confidence intervals will be estimated with the Cox regression model.

The primary analysis will be performed on the FAS.

13.7.1.2. Supportive Analysis
The primary analysis will be repeated on the PP set.

13.7.2. Secondary Criteria
All secondary analyses will be performed on the FAS. If more than 10% of patients are excluded from the PP set, the secondary analyses will be repeated on the PP set.

13.7.2.1. Numbers of Atrial Fibrillation Episodes in the first week following V3
Both the numbers of AF episodes (symptomatic or not) lasting for at least 10 minutes and with duration less than 10 minutes ($N_{\text{Sup10}}$ and $N_{\text{Inf10}}$) will be described by treatment group and compared by the chi-square test (or CMH test adjusted for centre) or Fisher’s exact Test.

13.7.2.2. Duration of Atrial Fibrillation Episodes in the first week following V3
The duration of all AF Episodes will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centres effects) or Wilcoxon test.
13.7.2.3. **Time to first AF recurrence less than 10 minutes or symptomatic**
The time to the first AF recurrence less than 10 minutes and the time to the first symptomatic AF recurrence will be analysed as the primary analysis.

13.7.2.4. **Clinical parameters evaluation**
The EHRA score will be described by treatment group and analysed using a chi-squared test (or CMH test adjusted for centre) or Fisher’s exact Test.

The frequency of presumed arrhythmia will be described by treatment group.

The number of recurrence of symptomatic AF, of hospitalizations (for cardiovascular events, for thromboembolic stroke and for all causes), of spontaneous cardioversion, of successful cardioversion (including number of shocks distribution) and the number of patients needing cardioversion after initial ECV will be described by treatment group and compared using a chi-square test or a Fisher Test (if the numbers are relevant).

The duration of hospitalizations for cardiovascular events, for thromboembolic stroke and for any cause will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centre effects) or Wilcoxon test.

The echocardiographic parameters values will be described at each time (V1, V2, V4, V6 and V9) and changes described from V4 to V9 and from V2 to V9.

13.7.2.5. **Biomarker analysis: red blood cell concentrations of DHA**
Values and changes from baseline for red blood cell concentration of DHA will be performed by treatment group and assessment time.

13.8. **SAFETY ANALYSIS**
The Safety Set will be used to perform all analyses of the safety criteria.

13.8.1. **Adverse Events**
Any adverse event having been reported during the study for a given patient will be classified by preferred term and corresponding system organ class using the MedDRA terminology.

Adverse events will be classified as:
• Treatment emergent adverse events, *i.e.*, any adverse event which occurs or worsens on study treatment during the randomised period.

• Or non treatment emergent adverse events, *i.e.*, any adverse event which occurs during the run-in period (before V2) or is reported as concomitant disease with the same intensity.

For each study period, any patient with at least one reported adverse event will be classified as a patient:

• With at least one adverse event

• With at least one treatment emergent adverse event

• With one TEAE

• With two TEAEs

• With at least three TEAEs

• With at least one related TEAE

• With an adverse event leading to the study treatment discontinuation (definitive or temporary)

• With an adverse event leading to withdrawal

• With at least one serious adverse event.

Numbers and percentages of patient with at least one reported treatment emergent adverse event will be tabulated by treatment group:

• By system organ class

• By system organ class and preferred term

• By system organ class and preferred term, taking into consideration its most severe intensity

• And by system organ class and preferred term, taking into consideration the most severe relationship to the study treatment.
Recurring adverse events (i.e., adverse events classified with the same preferred term) for a given patient will only be counted once and only their most severe intensity or most severe relationship to the study treatment will be tabulated.

The number and percentage of patients with at least one most common (reported in 1% patients in any group) drug related TEAE ("not excluded or unassessable") will be tabulated by Preferred Term and Treatment group in decreasing order for the treatment group (for all patients).

The number and percentage of patients with at least one reported most common treatment emergent adverse event will also be plotted by treatment group. This graphical representation will highlight the frequencies of the most severe intensities reported by system organ class and preferred term.

SAE will also be described on an individual basis: treatment group, patient's code, sex and age, Investigator's reported term, preferred term, time of onset according to the time of the first study treatment administration, duration, action taken regarding the study treatment administration, use of a corrective treatment, outcome and relationship to the study treatment in the Investigator’s opinion.

13.8.2. Clinical Laboratory Evaluation

For each laboratory parameter, data will be tabulated by treatment group and assessment time.

The absolute changes post-trial drug administration - baseline (the baseline value being the value measured on the last blood sample collected before the first trial drug administration) will be calculated and tabulated by parameter, treatment group and post-trial drug administration assessment time. Results of retests performed post-trial drug administration will not be analysed and tabulated. They will only be displayed in individual data listings.

For all biochemistry parameters, scatter plots highlighting individual results will display the baseline and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 24 value in the ordinate.

For all haematology parameters, scatter plots highlighting individual results will display the baseline and week 4, week 12 and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 4, week 12 and week 24 value in the ordinate.
Each treatment group will be differently identified. The first bisecting line (45° line), the lines of lower and upper normal range, the lines of Potentially Clinically Significant Change (PSC) range and Clinically noteworthy abnormal laboratory value (CNALV) range added on the plots (see Appendix 17.3).

For all blood laboratory parameters, shift tables will be provided to depict the numbers of patients with post-trial drug administration variations at each assessment time as compared to the baseline values (measured on the last blood sample collected before the first trial drug administration) by treatment group. A 3-point scale (low, normal, high) will be used as defined by the normal ranges in use in the laboratory in charge of the assays.

CNALV (see in Appendix 17.3) will be identified and described on an individual basis. If relevant, five separate individual data listings by treatment group will be provided:

- CNALV for haemoglobin (including corresponding individual results of erythrocytes and haematocrit)
- CNALV for neutrophils or leucocytes (including corresponding individual results of basophils, eosinophils, lymphocytes and monocytes)
- CNALV for platelets (including corresponding individual results of erythrocytes and leucocytes)
- CNALV for liver function parameters (including corresponding individual results of gamma-GT)
- CNALV for serum creatinine

13.8.3. Global Physical Examination

Recorded data of the global physical examination performed will not be tabulated as any abnormal findings post-randomisation should be reported as AEs (if clinically significant).

Physical examination assessments will be provided in the listings of individual data.
13.8.4. Vital Signs, Physical Findings and Other Observations Related to Safety

13.8.4.1. Vital Sign Measurements Over Time
For each parameter (systolic blood pressure, diastolic blood pressure and HR in supine and standing positions), descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.

13.8.4.2. Body weight
Descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.

13.8.4.3. Individual Patient Changes
The number and percentage of patient with at least one Predefined Potentially Clinically Significant Change (PSC) and with at least one PSC Leading to Clinically Significant Value (PSCV) will be tabulated by treatment group (see Table 1 in Appendix 17.3).

According to the pharmacological drug profile mentioned previously in this Protocol, the changes from baseline to the maximum and/or minimum post-baseline value could be categorized and tabulated by treatment group with frequencies and decreasing cumulative percentages.

If there is a signal of a drug effect toward one direction rather than the other, additionally shift tables of variations from baseline to the maximum or minimum post-baseline value could be also provided (see Table 2 to 4 in Appendix 17.3).

An individual data listing of patients with symptomatic or asymptomatic orthostatic hypotension will be provided by treatment group (see Table 5 in Appendix 17.3).

13.8.5. ECG
Frequencies on the clinical interpretation (normal, abnormal CS or NCS) will be presented by treatment group and assessment time. Individual tabulated data for ECG abnormalities will be also displayed.
13.8.6. Coagulation parameters
Scatter plots highlighting individual results for coagulation parameters (prothrombin time/INR, activated partial thromboplastin time and thrombin clotting time) before and after study treatment administration will be produced.

13.9. CONCOMITANT TREATMENTS
Concomitant treatments will be tabulated by treatment group within a descriptive perspective. They will be classified by therapeutic area according to the WHO-DRUG dictionary using the "anatomical therapeutic chemical" classification on the safety set.

13.10. COMPLIANCE
The percentage of compliance will be described by treatment group using the quantity

\[
Compliance(\%) = \frac{\text{Estimated actual consumption}}{\text{Theoretical consumption}} \times 100
\]

with: Estimated actual consumption = number of tablets provided at the start of study (Visit 2) minus number of tablets returned at the end of study (Visit 9)

Theoretical consumption = number of days of treatment intake planned between the start and the end of study (168 days ± 7 days)

13.11. INTERIM ANALYSIS AND DATA MONITORING
No analyses of efficacy data are planned for IDMC that ensures that the overall probability of type I error is controlled. No Type I error and sample size adjustments are necessary. Any recommendations of the IDMC to alter study conduct will be based on safety, so IDMC monitoring of the study will not affect the statistical operating characteristics of the final analysis.
The IDMC will review, three times during the study period (after the first 30 subjects will have been randomized, when the first 80 subjects will have terminated their study participation and when 130 subjects will have terminated their study participation), safety data results across treatment groups and judges whether the overall safety and feasibility (not futility) of the trial remain acceptable.

14. GENERAL ETHICAL CONSIDERATIONS

14.1. ETHICAL CONDITIONS

This study is performed in accordance with the principles stated in the Declaration of Helsinki (1964) and subsequent amendments and in accordance with the Good Clinical Practice Guideline (CPMP/ICH/135/95).

14.2. ETHICS COMMITTEE AND LEGAL REQUIREMENTS

All the documents required by National Regulations and any other informative documents that may be requested are submitted for review to an Ethics Committee whose procedures and operations meet the GCP and National Legal Requirements.

Depending on National Regulations, the application is submitted to the Ethics Committee by the Sponsor (or representative) or by the Investigator.

A copy of the formal written approval from the Ethics Committee is provided to the Sponsor (directly by the Ethics Committee or via the Investigator) with a list of names and qualifications of its members.

The request for authorisation by the Competent Authority or its notification if required (depending on National Regulations) is carried out by the Sponsor.

The screening of patients does not start before the approval of the Ethics Committee has been obtained and the study authorised by the Competent Authority or notified to the Competent Authority (depending on National Regulations).
14.3. PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM

An information must be given to the patients before their decision to participate or abstain from participation.

This information is based on the elements set out in the Declaration of Helsinki and the ICH GCP Guidelines. It must also describe the measures taken to safeguard patient’s privacy and protection of personal data, according to European Directive 95/46 EC or other local regulation.

Restraints and risks must be explained, as well as the right to discontinue participation in the study at any stage, without affecting their further relationship with the Investigator and/or their future care.

The written information and consent form must be submitted to the patient with an oral explanation. It must be agreed and signed by the patient before any study-related procedure starts.

This information and consent procedure is under the Investigator’s responsibility.

The information and consent document are made in triplicate: the original copy is kept by the Investigator, one copy is given to the patient and the last copy is kept by the Clinical Quality Assurance Unit of the Sponsor in a sealed envelope at the end of study (except in case of specific country requirement).

Specific areas of the Sponsor’s copy are not triplicated to avoid the reading of the patient’s surname (except the first 3 letters), first name, address and signature.

If any information becomes available during the trial that may be relevant to the patient’s willingness to keep on participating in the trial, an updated written informed consent must be submitted to the patient to confirm agreement to continue participating.

14.4. PERSONAL DATA PROTECTION

All information from this study (excluding data from the informed consent) is entered into a computer under the Sponsor’s responsibility in accordance with the French law, "Loi Informatique et Libertés" (January 6, 1978, and subsequent amendments) and with the European Directive 95/46/CE.
14.5. INSURANCE POLICY

In accordance with the provisions of the law and the GCP, the Sponsor Pierre Fabre Médicament, has an insurance policy intended to guarantee against possible damage resulting from the research. The studies and/or experiments performed on behalf of the Sponsor Pierre Fabre Médicament are specifically and expressly guaranteed.

It is advisable to underline that non compliance with the Research Legal Conditions is a cause for guarantee exclusion.

15. ADMINISTRATIVE PROCEDURES

15.1. PROTOCOL AMENDMENT

Neither the Investigator nor the Sponsor may alter the protocol without the authorisation of the other party.

All changes to the protocol are subject to an amendment which must be dated and signed by both parties and must appear as an amendment to the protocol.

Substantial amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities.

Urgent amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities, but could be implemented immediately under specific conditions defined with the Sponsor.

15.2. SOURCE DOCUMENTS, INVESTIGATOR'S FILE STORAGE

The Investigator:

- Keeps all trial-related documents in appropriate file folders. Records of patient, original informed consent forms, source documents, a CD Rom containing a pdf copy of e-CRF, drug inventory, Ethics Committees and Sponsor correspondence pertaining to the study must be kept on file.

- Retains all documents relating to the screening (consent and investigation results) of all patients included in the trial or not.
● Retains a list of the patient’s names, addresses (and/or number of medical file), code numbers to allow checking of data reported on e-CRFs with those from source documents.

● Authorises direct access to source documents for monitoring, audits and inspections.

● The trial-related documents must be retained as strictly confidential at the Investigator’s site for at least 15 years or according to local requirements, whatever is the longest after the completion or discontinuation of the trial (European Directive 2003/63/EC).

15.3. END OF THE STUDY

15.3.1. Definition of the End of Study
The end of study is the last visit of the last patient undergoing the trial.

Any change to this definition during the study, for whatever reason, must be notified as a substantial amendment.

15.3.2. Early Study Termination

15.3.2.1. Early Study Termination Decided by the Sponsor
The Sponsor may discontinue the study at any time for any of the following reasons:

● Lack of recruitment

● Deviations from good clinical practice and/or regulations

● Poor product safety

● New information that could jeopardise the patient’s safety

● Stopping of the development …

15.3.2.2. Early Study Termination Decided by the Competent Authorities
The Competent Authorities may suspend or prohibit a study if they consider that either the conditions of authorisation are not being met or has doubt about the safety or scientific validity of the study.
15.4. AUDIT

The Sponsor is responsible for making sure that both its representatives (Study Manager, CRA...) and the Investigator fulfil the requirements as specified by the GCP Guideline.

An audit can be organised internally at Pierre Fabre Médicament and at the investigational site where the e-CRFs are matched against source documents.

All study documentation must be directly accessible to auditors.

The practical conditions for the audit are discussed between the Investigator and the Clinical Quality Assurance Department.

Oral information about the audit results are given to the Investigator.

15.5. INSPECTION

The Health Authorities may inspect any investigation site or the Sponsor in the course of the study or after its completion, to verify the conduct of the study and quality of the data. The Investigator must provide to the inspectors direct access to study documents.

15.6. CONFIDENTIALITY

The present materials (protocol and related documentation, e-CRF, Investigator's Brochure) contain confidential information.

Except if agreed in writing with the Study Manager, the Investigators must hold such information confidential, and must not disclose it to others (except where required by Applicable Law).

15.7. CLINICAL STUDY REPORT

Data analysis and clinical study report writing are under the Sponsor’s responsibility.

Upon data analysis completion, a final report including a review of the objectives and methods, a presentation and a discussion of the results is drawn up according to ICH Guidelines (Structure and Content of Clinical Study Reports, ICH-E3, CPMP/ICH/137/95).

The report is a clinical and statistical integrated report. It must be signed by the Sponsor's representative(s) and the Coordinating Investigator.
15.8. STUDY RESULTS COMMUNICATION

Upon completion of the study, the global results of the Research are communicated to the Investigator. According to the Local Regulation, the patient can ask the Investigator for the results.

15.9. STUDY RESULTS PUBLICATION

The information and data collected during the conduct of this clinical study are considered confidential and are used by the Sponsor in connection with the development of the study drug. This information may be disclosed if deemed necessary by the Sponsor.

To allow the use of the information derived from this clinical study and to insure compliance with Current Regulations, the Investigator must provide the Sponsor with complete test results and all data collected during the study.

Only the Sponsor may make study information available to physicians and to Regulatory Agencies, except as required by Current Regulations.

All the results of this study including data, reports, discoveries and inventions resulting from the study, are the property of the Sponsor.

In the event the Sponsor chooses to publish study data, the manuscript must be provided to the author(s) at least 30 days prior to the expected date of submission to the intended publisher.

The Investigator(s) can reserve the right to publish or present study data; if so, the manuscript or abstract must be provided to the Sponsor for review at least 30 days prior to the expected date of submission to the intended publisher or of planned presentation.

In addition, if necessary, (the) Investigator(s) shall withhold publication for an additional 60 days, to allow the filing of a patent application, or to allow the Sponsor to take any measures he deems appropriate to establish and preserve his proprietary rights.

It is agreed that publication of study results by each site shall be made only as part of a publication of the study results obtained by all sites performing the protocol, once the study is completed and finalised.
The authors list is agreed by all Investigators prior to publication. The names of the authors are provided according to their participation in the design of the protocol as well as their recruitment of eligible and analysable patients.
16. REFERENCES

[1]. F373280 INVESTIGATOR'S BROCHURE, version October 2013

   n-3 Polyunsaturated Fatty Acids in the prevention of atrial Fibrillation Recurrences after electrical cardioversion. A prospective, Randomised study
   Circulation, 2011; 124:1100-1106

   Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy
   J. Am. Coll. Cardiol. 2011;57;870-879

[4]. MOERTL D., HAMMER A., STEINER S., HUTULEAC R., VONBANK K., BERGER R.
   Dose-dependant effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of non ischemic origin: A double-blind, placebo-controlled, 3-arm study
   American Heart Journal 2011; 161:915.e1-915.e9 - volume 161, number 5

[5]. GISSI-HF INVESTIGATORS
   Effects of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GSSI-HF Trial): a randomised, double-blind, placebo-controlled trial
   The lancet on line - August 2008

   Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
   European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Eur Heart J. 2010 Oct;31(19):2369-429

[7]. KOWEY PR, REIFFEL JA, ELLENBOGEN KA, NACCARELLI GV, PRATT CM.
   Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomised controlled trial.
Europace (2011) 13, 174-181

[9]. OMACOR® SUMMARY PRODUCT CHARACTERISTICS (SPC) dated 17/02/2012

[10]. BEPANTHENE® SUMMARY PRODUCT CHARACTERISTICS (SPC)


[12]. LE HEUZÉY JY AND ALL. A Short-Term, Randomised, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study. 
J Cardiovasc Electrophysiol.

Am J Clin Nutr (2007); 85: 1225.

Am J Clin Nutr (2006); 83: 1469-1473S.

[15]. TIELEMAN RG, VAN GELDER IC, CRIJNS HJ, DE KAM PJ, VAN DEN BERG MP, HAAKSMA J, VAN DER WOUDE HJ, AND ALLESSIE MA. Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodelling of the atria? 
J. Am. Coll. Cardiol. 1998;31;167-173


[17]. LEGRAND P., SCHMITT B., MOUROT J., CATHELLE D., CHESNEAU G., MIREAUX M., KERHOAS N., WEILL P.
The consumption of food products from linseed-fed animals maintains erythrocyte omega-3 fatty acids in obese human.

[18]. HARRIS WS, VON SCHACKY C.
The Omega-3 Index: a new risk factor for death from coronary heart disease?

[19]. ABSTRACT: P5161.
NODARI S, MANERBA A., MADURERI A., BERLINGHIERI N., PULCINI E.,
FRATTINI S., METRA M, DEI CAS L.
Effects of Polyunsaturated Fatty Acids n-3 (PUFA n-3) in the prophylaxis of atrial fibrillation relapses after external electric cardioversion
World Congress of Cardiology 2006, 2-6 September, Barcelona – Spain

[20]. KIRCHHOF P., AURICCHIO A., BAX J., CRIJNS H., CAMM J., DIENER HC.,
GOETTE A., HINDRICKS G., HOHNLOSER S., KAPPENBERGER L., KUCK
KH., LIP HYG., OLSSON B., MEINERTZ T., PRIORI S., RAVENS U.,
STEINBECK G., SVERHAGE E., TIJSSSEN J., VINCENT A., BREITHARDT G.
Outcome parameters from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association.
Europace 2007, 9, 1006-1023

[21]. EUROPEAN MEDICINES AGENCY
Addendum to the guideline on antiarrhythmics on atrial fibrillation and atrial flutter.
EMA/CHMA/EWP/213056/2010

[22]. OWEN AJ, PETER-PRZYBOROWSKA BA, HOY AJ, MCLENNAN PL.
Dietary fish oil dose- and time-response effects on cardiac phospholipid fatty acid composition.
Lipids. 2004;39:955–961

[23]. ROBERTO M. LANG, MICHELLE BIERIG, RICHARD B. DEVEREUX, FRANK
A. FLACHSKAMPF*, ELYSE FOSTER, PATRICIA A. PELLIKKA, MICHAEL H.
PICARD, MARY J. ROMAN, JAMES SEWARD, JACK SHANEWISE, SCOTT
SOLOMON, KIRK T. SPENCER, MARTIN ST. JOHN SUTTON, WILLIAM
STEWART.
Recommendations for chamber quantification

[24]. JOHN J.V. McMURRAY, STAMATIS ADAMOPOULOS, STEFAN D. ANKER,
ANGELO AURICCHIO, MICHAEL BÖHM, KENNETH DICKSTEIN,
VOLKMAR FALK, GERASIMOS FILIPPATOS, CÀNDIDA FONSECA, MIGUEL
ANGEL GOMEZ-SANCHEZ, TINY JAARSMA, LARS KØBER, GREGORY Y.H.
LIP, ALDO PIETRO MAGGIONI, ALEXANDER PARKHOMENKO, BURKERT
M. PIESKE, BOGDAN A. POPEȘCU, PER K. RØNNEVIK, FRANS H. RUTTEN, JUERG SCHWITTER, PETAR SEFEROVIĆ, JANINA STEPINSKA, PEDRO T. TRINDADE, ADRIAAN A. VOORS, FAIEZ ZANNAD, ANDREAS ZEIHER
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
European Heart Journal (2012) 33, 1787–1847

[25]. AGENCE NATIONALE DE SECURITE DU MEDICAMENT ET DES PRODUITS DE SANTE (ANSM).
Bon usage des médicaments antivitamine K (AVK)
Actualisation – Juillet 2012

[26]. GILLES PERNOD, ANNE GODIER, CLAIRE GOZALO, BENJAMIN TREMEY, PIERRE SIE
French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding)
Thrombosis Research 126 (2010) e167–e174
17. APPENDICES
17.1. DECLARATION OF HELSINKI

WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI
ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING
HUMAN SUBJECTS

Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the: 29th WMA
General Assembly, Tokyo, Japan, October 1975 35th WMA General Assembly, Venice, Italy, October 1983 41st
WMA General Assembly, Hong Kong, September 1989 48th WMA General Assembly, Somerset West, Republic of
South Africa, October 1996 52nd WMA General Assembly, Edinburgh, Scotland, October 2000 53th WMA General
Assembly, Washington 2002 (Note of Clarification on paragraph 29 added) 55th WMA General Assembly, Tokyo
2004 (Note of Clarification on Paragraph 30 added) 59th WMA General Assembly, Seoul, October 2008

A. INTRODUCTION

1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of
ethical principles for medical research involving human subjects, including research on identifiable
human material and data. The Declaration is intended to be read as a whole and each of its constituent
paragraphs should not be applied without consideration of all other relevant paragraphs.

2. Although the Declaration is addressed primarily to physicians, the WMA encourages other participants
in medical research involving human subjects to adopt these principles.

3. It is the duty of the physician to promote and safeguard the health of patients, including those who are
involved in medical research. The physician's knowledge and conscience are dedicated to the fulfilment
of this duty.

4. The Declaration of Geneva of the WMA binds the physician with the words, “The health of my patient
will be my first consideration,” and the International Code of Medical Ethics declares that, “A physician
shall act in the patient's best interest when providing medical care.”

5. Medical progress is based on research that ultimately must include studies involving human subjects.
Populations that are underrepresented in medical research should be provided appropriate access to
participation in research.

6. In medical research involving human subjects, the well-being of the individual research subject must
take precedence over all other interests.

7. The primary purpose of medical research involving human subjects is to understand the causes,
development and effects of diseases and improve preventive, diagnostic and therapeutic interventions
(methods, procedures and treatments). Even the best current interventions must be evaluated continually
through research for their safety, effectiveness, efficiency, accessibility and quality.

8. In medical practice and in medical research, most interventions involve risks and burdens.

9. Medical research is subject to ethical standards that promote respect for all human subjects and protect
their health and rights. Some research populations are particularly vulnerable and need special
protection. These include those who cannot give or refuse consent for themselves and those who may be
vulnerable to coercion or undue influence.

10. Physicians should consider the ethical, legal and regulatory norms and standards for research involving
human subjects in their own countries as well as applicable international norms and standards. No
national or international ethical, legal or regulatory requirement should reduce or eliminate any of the
protections for research subjects set forth in this Declaration.

B. PRINCIPLES FOR ALL MEDICAL RESEARCH

11. It is the duty of physicians who participate in medical research to protect the life, health, dignity,
integrity, right to self-determination, privacy, and confidentiality of personal information of research subjects.

12. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and adequate laboratory and, as appropriate, animal experimentation. The welfare of animals used for research must be respected.

13. Appropriate caution must be exercised in the conduct of medical research that may harm the environment.

14. The design and performance of each research study involving human subjects must be clearly described in a research protocol. The protocol should contain a statement of the ethical considerations involved and should indicate how the principles in this Declaration have been addressed. The protocol should include information regarding funding, sponsors, institutional affiliations, other potential conflicts of interest, incentives for subjects and provisions for treating and/or compensating subjects who are harmed as a consequence of participation in the research study. The protocol should describe arrangements for post-study access by study subjects to interventions identified as beneficial in the study or access to other appropriate care or benefits.

15. The research protocol must be submitted for consideration, comment, guidance and approval to a research ethics committee before the study begins. This committee must be independent of the researcher, the sponsor and any other undue influence. It must take into consideration the laws and regulations of the country or countries in which the research is to be performed as well as applicable international norms and standards but these must not be allowed to reduce or eliminate any of the protections for research subjects set forth in this Declaration. The committee must have the right to monitor ongoing studies. The researcher must provide monitoring information to the committee, especially information about any serious adverse events. No change to the protocol may be made without consideration and approval by the committee.

16. Medical research involving human subjects must be conducted only by individuals with the appropriate scientific training and qualifications. Research on patients or healthy volunteers requires the supervision of a competent and appropriately qualified physician or other health care professional. The responsibility for the protection of research subjects must always rest with the physician or other health care professional and never the research subjects, even though they have given consent.

17. Medical research involving a disadvantaged or vulnerable population or community is only justified if the research is responsive to the health needs and priorities of this population or community and if there is a reasonable likelihood that this population or community stands to benefit from the results of the research.

18. Every medical research study involving human subjects must be preceded by careful assessment of predictable risks and burdens to the individuals and communities involved in the research in comparison with foreseeable benefits to them and to other individuals or communities affected by the condition under investigation.

19. Every clinical trial must be registered in a publicly accessible database before recruitment of the first subject.

20. Physicians may not participate in a research study involving human subjects unless they are confident that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians must immediately stop a study when the risks are found to outweigh the potential benefits or when there is conclusive proof of positive and beneficial results.

21. Medical research involving human subjects may only be conducted if the importance of the objective outweighs the inherent risks and burdens to the research subjects.

22. Participation by competent individuals as subjects in medical research must be voluntary. Although it may be appropriate to consult family members or community leaders, no competent individual may be
enrolled in a research study unless he or she freely agrees.

23. Every precaution must be taken to protect the privacy of research subjects and the confidentiality of their personal information and to minimize the impact of the study on their physical, mental and social integrity.

24. In medical research involving competent human subjects, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail, and any other relevant aspects of the study. The potential subject must be informed of the right to refuse to participate in the study or to withdraw consent to participate at any time without reprisal. Special attention should be given to the specific information needs of individual potential subjects as well as to the methods used to deliver the information. After ensuring that the potential subject has understood the information, the physician or another appropriately qualified individual must then seek the potential subject’s freely-given informed consent, preferably in writing. If the consent cannot be expressed in writing, the non-written consent must be formally documented and witnessed.

25. For medical research using identifiable human material or data, physicians must normally seek consent for the collection, analysis, storage and/or reuse. There may be situations where consent would be impossible or impractical to obtain for such research or would pose a threat to the validity of the research. In such situations the research may be done only after consideration and approval of a research ethics committee.

26. When seeking informed consent for participation in a research study the physician should be particularly cautious if the potential subject is in a dependent relationship with the physician or may consent under duress. In such situations the informed consent should be sought by an appropriately qualified individual who is completely independent of this relationship.

27. For a potential research subject who is incompetent, the physician must seek informed consent from the legally authorized representative. These individuals must not be included in a research study that has no likelihood of benefit for them unless it is intended to promote the health of the population represented by the potential subject, the research cannot instead be performed with competent persons, and the research entails only minimal risk and minimal burden.

28. When a potential research subject who is deemed incompetent is able to give assent to decisions about participation in research, the physician must seek that assent in addition to the consent of the legally authorized representative. The potential subject’s dissent should be respected.

29. Research involving subjects who are physically or mentally incapable of giving consent, for example, unconscious patients, may be done only if the physical or mental condition that prevents giving informed consent is a necessary characteristic of the research population. In such circumstances the physician should seek informed consent from the legally authorized representative. If no such representative is available and if the research cannot be delayed, the study may proceed without informed consent provided that the specific reasons for involving subjects with a condition that renders them unable to give informed consent have been stated in the research protocol and the study has been approved by a research ethics committee. Consent to remain in the research should be obtained as soon as possible from the subject or a legally authorized representative.

30. Authors, editors and publishers all have ethical obligations with regard to the publication of the results of research. Authors have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports. They should adhere to accepted guidelines for ethical reporting. Negative and inconclusive as well as positive results should be published or otherwise made publicly available. Sources of funding, institutional affiliations and conflicts of interest should be declared in the publication. Reports of research not in accordance with the principles of this Declaration should not be accepted for publication.
C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH MEDICAL CARE

31. The physician may combine medical research with medical care only to the extent that the research is justified by its potential preventive, diagnostic or therapeutic value and if the physician has good reason to believe that participation in the research study will not adversely affect the health of the patients who serve as research subjects.

32. The benefits, risks, burdens and effectiveness of a new intervention must be tested against those of the best current proven intervention, except in the following circumstances:

• The use of placebo, or no treatment, is acceptable in studies where no current proven intervention exists; or
• Where for compelling and scientifically sound methodological reasons the use of placebo is necessary to determine the efficacy or safety of an intervention and the patients who receive placebo or no treatment will not be subject to any risk of serious or irreversible harm. Extreme care must be taken to avoid abuse of this option.

33. At the conclusion of the study, patients entered into the study are entitled to be informed about the outcome of the study and to share any benefits that result from it, for example, access to interventions identified as beneficial in the study or to other appropriate care or benefits.

34. The physician must fully inform the patient which aspects of the care are related to the research. The refusal of a patient to participate in a study or the patient’s decision to withdraw from the study must never interfere with the patient-physician relationship.

35. In the treatment of a patient, where proven interventions do not exist or have been ineffective, the physician, after seeking expert advice, with informed consent from the patient or a legally authorized representative, may use an unproven intervention if in the physician's judgement it offers hope of saving life, re-establishing health or alleviating suffering. Where possible, this intervention should be made the object of research, designed to evaluate its safety and efficacy. In all cases, new information should be recorded and, where appropriate, made publicly available.
17.2. SAE REPORT FORM
NOTIFICATION OF SERIOUS ADVERSE EVENT (SAE) OR PREGNANCY TO PIERRE FABRE CORPORATE VIGILANCES DIVISION

TO BE TRANSMITTED TO THE CORPORATE VIGILANCES DIVISION BY E-MAIL WITHIN 24H TO HQ.pharmacovigilance@pierre-fabre.com OR BY FAX WITHIN 24H – Fax N°: 33 (0) 1.49.10.80.90

Transmission date [ ] [ ] [ ] [ ] [ ] [ ] (ddmmyyyy) Country : ........................................

SAE N° [ ] [ ] FIRST NOTIFICATION ☐ FOLLOW-UP ☐ N°

SUBJECT CHARACTERISTICS

Gender [ ] 1=M, [ ] 2=F Height [ ] [ ] [ ] cm Weight [ ] [ ] [ ] [ ] [ ] kg

DESCRIPTION OF THE EVENT

The serious adverse event resulted in :
☐ Death (whatever may be the cause)
☐ Hospitalisation (*) or extension thereof
☐ Life threatening
☐ Invalidity or disability

Congenital abnormality or abnormal pregnancy outcome
☐ Cancer
☐ Other (any other serious clinical or laboratory event according to the investigator or the protocol, overdose meeting seriousness criteria, suicide attempts)

Other fact to be notified :
☐ Pregnancy exposure

Nature of the event (if clinical nature, indicate the diagnosis or the major symptom):

...........................................................................................................................................................................................................
...........................................................................................................................................................................................................
...........................................................................................................................................................................................................

AE onset date [ ] [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)

Seriousness onset date [ ] [ ] [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)

Summary description (if clinical cause, significant history, progression of event, available laboratory results, etc...):

...........................................................................................................................................................................................................
...........................................................................................................................................................................................................
...........................................................................................................................................................................................................

(*) Except hospitalisations with durations and goals planned in the protocol

THE SAE IN RELATION TO THE TRIAL

TREATMENT NUMBER [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ]

• Time of occurrence of SAE
  ☐ During the selection or run-in period
  ☐ During the administration phase of the study treatment
  ☐ After the administration phase of the study treatment

• Date of first study treatment administration [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)

• Date of last study treatment administration before the occurrence of SAE [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)

• Was the blind broken ? ☐ Yes ☐ No ☐ Not applicable
  If yes, or if this is an open study, drug(s) administered:

  Conditions of administration (cycles(s), daily dose(s), route(s) of administration, etc...):

...........................................................................................................................................................................................................
...........................................................................................................................................................................................................
...........................................................................................................................................................................................................

Final version 945/1185
SAE N° __________ FIRST NOTIFICATION ☑ FOLLOW-UP ☐ Nº

CONCOMITANT MEDICATION SINCE TRIAL INITIATION and up until the occurrence of the SAE (EXCEPT THE TREATMENTS GIVEN FOR THE SAE)

<table>
<thead>
<tr>
<th>Trade name (or INN)</th>
<th>Daily dose</th>
<th>Start date (dd/mm/yy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (dd/mm/yy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

MEASURES TAKEN FOLLOWING THE SAE

• Study treatment
  - No change
  - Dosage modification, specify: ......................................................... Modification Date: ___/__/___
  - Temporarily discontinued Readministration date: ___/__/___
  - Withdrawn End date: ___/__/___
  - Not applicable

• The event led to:
  - Prescription of corrective or symptomatic treatments:

<table>
<thead>
<tr>
<th>Trade name (or INN)</th>
<th>Daily dose</th>
<th>Start date (dd/mm/yy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (dd/mm/yy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Discontinuation of concomitant treatments:

<table>
<thead>
<tr>
<th>Trade name (or INN)</th>
<th>Daily dose</th>
<th>Start date (dd/mm/yy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (dd/mm/yy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Others, specify:

OUTCOME

- Not recovered/Not resolved
- Recovering/Resolving
- Recovered/Resolved
- Fatal
- Unknown

In case of death, has an autopsy been conducted? ☐ Yes ☐ No

INVESTIGATOR CAUSALITY ASSESSMENT (investigator’s assessment to be done as soon as possible)

Study drug: Related to study protocol:
- Not Suspected
- Suspected
- Not Suspected
- Suspected

Comments: .............................................................................................................................................................

Enclose in the notification the results of carried out examinations, reports of hospitalisation, etc...
### 17.3. PREDEFINED LIMITS OF LABORATORY AND VITAL SIGN POTENTIALLY CLINICALLY SIGNIFICANT CHANGES AND VALUES

List of Predefined Potentially Clinically Significant Change For Laboratory Values

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>UNIT</th>
<th>Decrease</th>
<th>PSC</th>
<th>Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>MUSCLE</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatine Phosphokinase</td>
<td>U / l</td>
<td>-</td>
<td>236</td>
<td></td>
</tr>
<tr>
<td><strong>KIDNEY</strong></td>
<td>µmol/l</td>
<td>-</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>Creatinine</td>
<td>µmol/l</td>
<td>-</td>
<td>3.2</td>
<td></td>
</tr>
<tr>
<td>Urea</td>
<td>mmol/l</td>
<td>-</td>
<td>119</td>
<td></td>
</tr>
<tr>
<td>Uric acid</td>
<td>µmol/l</td>
<td>0.39</td>
<td>0.39</td>
<td></td>
</tr>
<tr>
<td>Phosphate</td>
<td>mmol/l</td>
<td>0.30</td>
<td>0.30</td>
<td></td>
</tr>
<tr>
<td>Calcium</td>
<td>mmol/l</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ELECTROLYTES</strong></td>
<td>µmol/l</td>
<td></td>
<td></td>
<td>35</td>
</tr>
<tr>
<td>Sodium</td>
<td>mmol/l</td>
<td>8</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Potassium</td>
<td>mmol/l</td>
<td>1.1</td>
<td>1.1</td>
<td></td>
</tr>
<tr>
<td>Chloride</td>
<td>mmol/l</td>
<td>8</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>mmol/l</td>
<td>8</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td><strong>METABOLISM/NUTRITIONAL</strong></td>
<td>µmol/l</td>
<td></td>
<td></td>
<td>0.39</td>
</tr>
<tr>
<td>Glucose (random)</td>
<td>mmol/l</td>
<td>3</td>
<td>3.7</td>
<td></td>
</tr>
<tr>
<td>Albumin</td>
<td>g/l</td>
<td>6</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Protein</td>
<td>g/l</td>
<td>11</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Cholesterol</td>
<td>mmol/l</td>
<td>-</td>
<td>1.97</td>
<td></td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>mmol/l</td>
<td>0.91</td>
<td>0.85</td>
<td></td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>mmol/l</td>
<td>2.17</td>
<td>2.04</td>
<td></td>
</tr>
<tr>
<td>Triglycerides</td>
<td>mmol/l</td>
<td>-</td>
<td>2.91</td>
<td></td>
</tr>
<tr>
<td><strong>ERYTHROCYTES</strong></td>
<td>T/l</td>
<td>0.7</td>
<td>0.7</td>
<td></td>
</tr>
<tr>
<td>Erythrocyte count</td>
<td>g/l</td>
<td>20</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Haemoglobin</td>
<td>l</td>
<td>0.06</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>Haematocrit</td>
<td>fl</td>
<td>7</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>MCV</td>
<td>fmol</td>
<td>0.19</td>
<td>0.19</td>
<td></td>
</tr>
<tr>
<td>MCH (Fe)</td>
<td>mmol/l</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>LEUKOCYTES</strong></td>
<td>G/l</td>
<td>4.2</td>
<td>3.8</td>
<td></td>
</tr>
<tr>
<td>Leukocyte count</td>
<td>G/l</td>
<td>3.47</td>
<td>3.19</td>
<td></td>
</tr>
<tr>
<td>Neutrophils</td>
<td>G/l</td>
<td>1.76</td>
<td>1.63</td>
<td></td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>G/l</td>
<td>-</td>
<td>0.49</td>
<td></td>
</tr>
<tr>
<td>Monocytes</td>
<td>G/l</td>
<td>-</td>
<td>0.41</td>
<td></td>
</tr>
<tr>
<td>Basophils</td>
<td>G/l</td>
<td>-</td>
<td>0.14</td>
<td></td>
</tr>
<tr>
<td><strong>URINE</strong></td>
<td>µmol/l</td>
<td>-</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Specific gravity</td>
<td></td>
<td>0.017</td>
<td>0.015</td>
<td></td>
</tr>
<tr>
<td>pH</td>
<td></td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>LIVER</strong></td>
<td>µmol/l</td>
<td>-</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>U/l</td>
<td>-</td>
<td>N x (23/36)</td>
<td></td>
</tr>
<tr>
<td>ASAT (SGOT)</td>
<td>U/l</td>
<td>-</td>
<td>N x (28/45)</td>
<td></td>
</tr>
<tr>
<td>ALAT (SGPT)</td>
<td>U/l</td>
<td>-</td>
<td>N x (25/38)</td>
<td></td>
</tr>
<tr>
<td>Gamma GT</td>
<td>U/l</td>
<td>-</td>
<td>N x (30/95)</td>
<td></td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>U/l</td>
<td>-</td>
<td>N x (30/95)</td>
<td></td>
</tr>
</tbody>
</table>

N = upper limit of normal range

### Definition of Clinically Noteworthy Abnormal Laboratory Values (CNALV)

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>CNALV</th>
</tr>
</thead>
</table>
| **HAEMOGLOBIN**  | • Decrease of at least 2 g/dl and value < 10 g/dl whatever the baseline value  
• If missing baseline: value < 10 g/dl                                                                                                                               |
| **NEUTROPHILS**  | • < 1500/mm³ whatever the baseline value                                                                                                                                                             |
| **WBC** (if missing value for neutrophils) | • < 3000/mm³ whatever the baseline value                                                                                                                                         |
| **PLATELETS**    | • < 100 000/mm³ whatever the baseline value                                                                                                                                                        |
| **SERUM CREATININE** | • Increase of at least 30% as compared to baseline value and value > 150 µmol/l whatever the baseline value  
• If missing baseline: value > 150 µmol/l                                                                                                               |
| **LIVER FUNCTION TESTS** |                                                                                                                                                                                                    |
| **ALAT**         | • If normal baseline:  
• ALAT > 2 N  
• If abnormal baseline:  
→ if baseline value ≤ 2.5 N:  
• increase of at least 100% as compared to baseline value  
→ if baseline value > 2.5 N:  
• value > 5 N  
and/or **ASAT** | • If normal baseline:  
• ASAT > 2 N  
• If abnormal baseline:  
→ if baseline value ≤ 2.5 N:  
• increase of at least 100% as compared to baseline value  
→ if baseline value > 2.5 N:  
• value > 5 N  
and/or **Alkaline phosphatase (AP)** | • If normal baseline:  
• AP > 1.25 N  
• If abnormal baseline:  
• AP > 2 N  
and/or **Total bilirubin (TB)** | • If normal baseline:  
• TB > 1.5 N  
• If abnormal baseline:  
• TB > 2 N  

N=upper limit of normal range

Cardiovascular Safety

Table 1: Predefined Limits for Potentially Clinically Significant Changes (PSC) and PSC Leading to Clinically Significant Values (PSCV)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>PSC</th>
<th>PSCV</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP</td>
<td>Increase ≥ 20 mmHg</td>
<td>SBP ≥ 160 mmHg and increase ≥ 20 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 20 mmHg</td>
<td>SBP ≤ 90 mmHg and decrease ≥ 20 mmHg</td>
</tr>
<tr>
<td>DBP</td>
<td>Increase ≥ 10 mmHg</td>
<td>DBP ≥ 100 mmHg and increase ≥ 10 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 mmHg</td>
<td>DBP ≤ 50 mmHg and decrease ≥ 10 mmHg</td>
</tr>
<tr>
<td>HR</td>
<td>Increase ≥ 10 bpm</td>
<td>HR ≥ 110 bpm and increase ≥ 10 bpm</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 bpm</td>
<td>HR ≤ 50 bpm and decrease ≥ 10 bpm</td>
</tr>
</tbody>
</table>

Table 2: Predefined Classes for changes from Baseline to the Maximum (and/ or Minimum) Post-baseline Value

<table>
<thead>
<tr>
<th>Classes of Change from Baseline to the Maximum Post-baseline Value</th>
<th>Classes of Change from Baseline to the Minimum Post-baseline Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP  mmHg</td>
<td>DBP  mmHg</td>
</tr>
<tr>
<td>All</td>
<td>All</td>
</tr>
<tr>
<td>≥ 0</td>
<td>&gt; 0</td>
</tr>
<tr>
<td>&gt; 10</td>
<td>≥ 15</td>
</tr>
<tr>
<td>≥ 20</td>
<td>≥ 20</td>
</tr>
<tr>
<td>≥ 30</td>
<td>≥ 20</td>
</tr>
<tr>
<td>≥ 40</td>
<td>≥ 20</td>
</tr>
</tbody>
</table>

Table 3: Classes for Vital Signs Maximum or Minimum Values

<table>
<thead>
<tr>
<th>Classes for the Maximum Post-baseline Value for each parameter</th>
<th>Classes for the Minimum Post-baseline Value for each parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>&lt; 120</td>
<td>&lt; 80</td>
</tr>
<tr>
<td>[120;140]</td>
<td>[80;90)</td>
</tr>
<tr>
<td>[140;160]</td>
<td>[90;100]</td>
</tr>
<tr>
<td>≥ 160</td>
<td>≥ 100</td>
</tr>
</tbody>
</table>

Table 4: Classes for Maximum or Minimum of BP in its entirety

<table>
<thead>
<tr>
<th>Classification of Maximum Values for Blood Pressure (mmHg)</th>
<th>Classification of Minimum Values Blood Pressure (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP &lt; 140 and DBP &lt; 90</td>
<td>SBP &gt; 90 and DBP &gt; 50</td>
</tr>
<tr>
<td>SBP [140;160] and DBP &lt; 100 or DBP [90;100] and SBP &lt; 160</td>
<td>SBP ≤ 90 or DBP ≤ 50</td>
</tr>
<tr>
<td>SBP ≥ 160 or DBP ≥ 100</td>
<td></td>
</tr>
</tbody>
</table>

Table 5: Definition of orthostatic hypotension

<table>
<thead>
<tr>
<th>Orthostatic Hypotension *</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP Decrease ≥ 20 mmHg or DBP Decrease ≥ 10 mmHg between supine and standing positions</td>
</tr>
</tbody>
</table>

16.1.1.9. Protocol amendment n° PA06
General and non-substantial dated on 06 June 2016)
CLINICAL STUDY PROTOCOL AMENDMENT n° PA06

(GENERAL – Non-Substantial)

Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Pierre Fabre Study Code: F373280 CA 2 01
EudraCT Number or equivalent: 2012-003487-48

Karim KEDDAD
INSTITUT DE RECHERCHE PIERRE FABRE
Centre de R&D Pierre Fabre - BP 13562
3 avenue Hubert Curien
31035 TOULOUSE Cedex 1, FRANCE

Pr Savina NODARI
Department of Clinical and Surgical Specialities, Radiological Science and Public Health
Section of Cardiovascular Diseases
University Medical School and Spedali Civili Hospital of Brescia
c/o Spedali Civili di Brescia
Piazzale Spedali Civili, 1
25123 - BRESCHIA, ITALY

Date of amendment PA06: 06JUN2016

The information contained in this document is confidential and is the property of the sponsor Pierre Fabre Médicament. This information is given for the needs of the trial and must not be disclosed without prior written consent of the sponsor Pierre Fabre Médicament. Persons to whom this information is given for the needs of the trial must be informed that it is confidential and must be disclosed.
APPROVAL FORM

STUDY: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Clinical Study Protocol Amendment n° PA06
(GENERAL – Non-Substantial)
Dated: 06JUN2016

Sponsor’s representative(s)

- Head of Medical Unit

Date: 10 JUNE 2016
Signature: Dr Karim KEDDAD

Study Coordinating Investigator:

Date: 20/06/2016
Signature: Pr Savina NODARI
COUNTRY COORDINATING INVESTIGATOR SIGNATURE FORM

STUDY: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Clinical Study Protocol Amendment n° PA06
(GENERAL – Non-Substantial)
Dated: 06JUN2016

Country Coordinating Investigator: [Signature]
Date: 20/06/2016
INVESTIGATOR SIGNATURE FORM

STUDY: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Clinical Study Protocol Amendment n° PA06
(GENERAL – Non-Substantial)
Dated: 06JUN2016

By my signature below, I, Dr __________________________, hereby confirm that I have read, taken note of (and will apply) the modifications brought by the protocol amendment n° PA06 and I will conduct the trial according to these new modalities.

Date: __________________________ Signature: __________________________
## HISTORY OF AMENDMENTS

<table>
<thead>
<tr>
<th>N°</th>
<th>TYPE</th>
<th>APPLICATION AREA</th>
<th>DATE</th>
<th>MODIFICATIONS</th>
</tr>
</thead>
</table>
| NA  | NA      | General          | NA         | Corresponding to Protocol Version 2: Following French CA request (ANSM) and leading to protocol version 2:  
- Add of a non inclusion criteria: “Breast-feeding female patient”  
- Add of haematology examination at visit 3 and 6 |
| PA01| Substantial | Local (Italy)     | 01MAR2013  | Corresponding to Protocol Version 3:  
- Integration of the modification included in the protocol version 2  
- Harmonisation of the protocol and the Informed Consent Form:  
  - adjustment of the selection criteria n°10 related to the contraception method  
  - addition of a letter that is given by the patient to his/her GENERAL practitioner (GP)  
  - precision that the sponsor can not collect a copy of the Informed Consent Form  
  - precision that the patient card is in Italian language only (without any English mention) |
| PA02| Non Substantial | General          | 28MAR2013  | Corresponding to Protocol Version 4:  
- change of Sponsor’s Representative (Clinical Study Manager),  
- modification of the technical handling of the blood samples for determination of red blood cells concentration of DHA: the centrifugation is no more needed,  
- precision on the function and address of the International Study Coordinator Pr Nodari,  
- add of address and contacts details of two CRO newly involved in the study: Theradis (in charge of transportation of blood samples to the Analytical centre and material supply) and “Clinact” (in charge of refund of patients expenses linked to the study),  
- adjustment of the wording, in agreement with the commitment to the French Ethics Committee. In the paragraphe 8.3.2.1, the wording “hematology examination” is replaced by “standard hematologic dosage”,  
- precision of the full title in the study synopsis (in agreement with the commitment to the Spanish Ethics Committee),  
- correction of a mistake in section 8.1.1.3 (related to TTEM transmission) and sections 3, 9 and study synopsis (related to the definition of INR not stabilized).  
- addition of the changes included in the local italian Final version |
<table>
<thead>
<tr>
<th>Nº</th>
<th>TYPE</th>
<th>APPLICATION AREA</th>
<th>DATE</th>
<th>MODIFICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Substantial</td>
<td>General</td>
<td>23OCT2013</td>
<td>Corresponding to Protocol Version 5:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Fax modification of the sponsor’s representatives</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Planned end of study postponed to January 2015.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- The authorized history of the first documented persistent atrial fibrillation is less than 3 years.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- At selection a hyperkalemia or a hypokalemia is better defined by the standards of the local laboratories.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Regarding previous treatments by amiodarone the non inclusion criteria of the protocol are adapted as follow:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Previous treatment with oral amiodarone within 4 months prior to inclusion</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Intake of oral amiodarone for more than 1 month within 4 to 12 months before inclusion</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Previous treatment with intravenous amiodarone within 4 weeks prior to inclusion</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- For male with a child-bearing potential partner (in Italy only): taking into account the duration of spermatogenesis the absolute abstention from sexual intercourse or the use of double barrier contraception method are extended to 3 months after the end of the study.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Ranolazine is an antiarrhythmic treatment added to the prohibited treatments.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Update of Serious Adverse Events (SAEs) form: Main change is the SAE sending: SAEs have to be reported to the Corporate Vigilance Department, and not anymore to the clinical study manager. Also SAEs can be sent by e-mail and by fax.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Addition of Alpha Bioresearch as CRO involved for Feasibility, Monitoring and Regulatory issues in Spain.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Correction of some minor typographic errors</td>
</tr>
</tbody>
</table>

<p>| PA04 | Non Substantial | General | 03JUN2014 | Corresponding to protocol V7:                                                                                                                                                                                     |
|      |                 |         |          | - Precision on the temperature storage of DHA samples                                                                                                                                                |
|      |                 |         |          | - Precision on the BSA formula                                                                                                                                                                             |
|      |                 |         |          | - Addition of QTcB and QTcF                                                                                                                                                                               |
|      |                 |         |          | - Precision on TTEM recording timelines                                                                                                                                                                 |
|      |                 |         |          | - Clarification of the section Interim analysis and data monitoring (13.11)                                                                                                                                 |
|      |                 |         |          | - Clarifications and specifications on some                                                                                                                                                               |</p>
<table>
<thead>
<tr>
<th>N°</th>
<th>TYPE</th>
<th>APPLICATION AREA</th>
<th>DATE</th>
<th>MODIFICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>PA05</td>
<td>Substantial</td>
<td>General</td>
<td>22OCT2014</td>
<td>Corresponding to protocol V8:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Planned end of study postponed to April 2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Clarifications regarding the management of VKA treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Precision regarding the primary efficacy criterion (the time to the first Atrial Fibrillation recurrence or Atrial Flutter emergence)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Deletion of Visit 5 and Visit 8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Previous history of a first documented persistent Atrial Fibrillation without limitation in time instead of no longer than 3 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Patients must have a systolic heart failure defined by a reduced ventricular ejection fraction and or defined also through other echocardiographic parameters mentioned in the ESC guidelines for the diagnosis and treatment of acute and chronic heart failure (2012)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Regarding previous prohibited treatments by amiodarone or dronedarone, the non inclusion criteria of the protocol are adapted as follow:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Concomitant treatment with oral amiodarone or dronedarone from selection</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Concomitant treatment with intravenous amiodarone from selection</td>
</tr>
</tbody>
</table>
1. AMENDMENT RATIONALE

This amendment is written to update the Sponsor Personnel list following changes in the Clinical team and to extend the planned end date of the study:

- The previous Clinical Study Manager left the team: Gaëlle Alcaraz, and one new Clinical Study Manager has joined the team: Marine Fagard
- Dr Richard Roche (Medical Director) is replaced by Dr Karim Keddad (Head of medical Unit)
- Due to a recruitment rate lower than expected the planned end of study is postponed to September 2017.

2. CHANGES DESCRIPTION

<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sponsor Personnel, page 2 &amp; page 3</strong></td>
<td><strong>Clinical Study Manager (Monitor)</strong></td>
</tr>
<tr>
<td><strong>Gaëlle ALCARAZ</strong></td>
<td><strong>Marine FAGARD</strong></td>
</tr>
<tr>
<td>Institut de Recherche Pierre Fabre</td>
<td>Institut de Recherche Pierre Fabre</td>
</tr>
<tr>
<td>Centre de R&amp;D Pierre Fabre</td>
<td>Centre de R&amp;D Pierre Fabre</td>
</tr>
<tr>
<td>BP 13 562</td>
<td>BP 13 562</td>
</tr>
<tr>
<td>3, Avenue Hubert Curien</td>
<td>3, Avenue Hubert Curien</td>
</tr>
<tr>
<td>31035 TOULOUSE Cedex 1, France</td>
<td>31035 TOULOUSE Cedex 1, France</td>
</tr>
<tr>
<td>Phone: +33 5 34 50 62 16</td>
<td>Phone: +33 (0)5 34 50 63 54</td>
</tr>
<tr>
<td>Fax: +33 5 34 50 69 69</td>
<td>Fax: +33 (0)5 34 50 65 92</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:gaelle.alcaraz@pierre-fabre.com">gaelle.alcaraz@pierre-fabre.com</a></td>
<td>E-mail: <a href="mailto:marine.fagard@pierre-fabre.com">marine.fagard@pierre-fabre.com</a></td>
</tr>
<tr>
<td><strong>Sponsor Personnel, page 2, page 3 &amp; page 5</strong></td>
<td><strong>Head of Medical Unit</strong></td>
</tr>
<tr>
<td><strong>Medical Director</strong></td>
<td><strong>Karim KEDDAD, MD, PhD</strong></td>
</tr>
<tr>
<td><strong>Richard ROCHE, MD</strong></td>
<td><strong>Karim KEDDAD, MD, PhD</strong></td>
</tr>
<tr>
<td>Institut de Recherche Pierre Fabre</td>
<td>Institut de Recherche Pierre Fabre</td>
</tr>
<tr>
<td>Centre de R&amp;D Pierre Fabre</td>
<td>Centre de R&amp;D Pierre Fabre</td>
</tr>
<tr>
<td>BP 13 562</td>
<td>BP 13 562</td>
</tr>
<tr>
<td>3, Avenue Hubert Curien</td>
<td>3, Avenue Hubert Curien</td>
</tr>
<tr>
<td>31035 TOULOUSE Cedex 1, France</td>
<td>31035 TOULOUSE Cedex 1, France</td>
</tr>
<tr>
<td>Phone: +33 5 34 50 61 94</td>
<td>Phone: +33 5 34 50 61 69</td>
</tr>
<tr>
<td>Fax: +33 5 34 50 69 69</td>
<td>Fax: +33 (0)5 34 50 65 92</td>
</tr>
<tr>
<td>PREVIOUS VERSION</td>
<td>MODIFIED VERSION</td>
</tr>
<tr>
<td>--------------------------------------------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>E-mail: <a href="mailto:richard.roche@pierre-fabre.com">richard.roche@pierre-fabre.com</a></td>
<td>E-mail: <a href="mailto:karim.keddad@pierre-fabre.com">karim.keddad@pierre-fabre.com</a></td>
</tr>
<tr>
<td>SYNOPSIS, page 13</td>
<td></td>
</tr>
<tr>
<td><strong>Planned Study Period:</strong> January 2013 – April 2016</td>
<td><strong>Planned Study Period:</strong> January 2013 – September 2017</td>
</tr>
</tbody>
</table>
16.1.1.10. Protocol amendment n° PA07
General and substantial dated on 28 September 2016
linked to Protocol and appendices
(version 9: 28 September 2016)
CLINICAL STUDY PROTOCOL AMENDMENT n° PA07
(GENERAL –SUBSTANTIAL)
Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Pierre Fabre Study Code: F373280 CA 2 01
EudraCT Number or equivalent: 2012-003487-48

Karim KEDDAD
INSTITUT DE RECHERCHE PIERRE FABRE
Centre de R&D Pierre Fabre - BP 13562
3 avenue Hubert Curien
31035 TOULOUSE Cedex 1, FRANCE

Pr Savina NODARI
Department of Clinical and Surgical Specialities, Radiological Science and Public Health
Section of Cardiovascular Diseases
University Medical School and Spedali Civili Hospital of Brescia
c/o Spedali Civili di Brescia
Piazzale Spedali Civili, 1
25123 - BRESCIA, ITALY

Date of amendment PA07: 28SEP16

The information contained in this document is confidential and is the property of the sponsor Pierre Fabre Médicament. This information is given for the needs of the trial and must not be disclosed without prior written consent of the sponsor Pierre Fabre Médicament. Persons to whom this information is given for the needs of the trial must be informed that it is confidential and must be disclosed.
APPROVAL FORM

STUDY: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Clinical Study Protocol Amendment n° PA07
(GENERAL – SUBSTANTIAL)
Dated: 28SEP16

Sponsor's representative(s)

• Head of Medical Unit
  Dr Karim KEDDAD  Date:  Signature:
  28/9/2016

Study Coordinating Investigator:
  Pr Savina NODARI  Date:  Signature:
  16/10/2016
COUNTRY COORDINATING INVESTIGATOR SIGNATURE FORM

STUDY: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Clinical Study Protocol Amendment n° PA07

(GENERAL – SUBSTANTIAL)

Dated: 28SEP16

Country Coordinating Investigator: __________________________ Date: __/__/2016 \[Signature\]
INVESTIGATOR SIGNATURE FORM

STUDY: Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

Clinical Study Protocol Amendment n° PA07
(GENERAL –SUBSTANTIAL)
Dated: 28SEP16

By my signature below, I, Dr ___________________________, hereby confirm that I have read, taken note of (and will apply) the modifications brought by the protocol amendment n° PA07 and I will conduct the trial according to these new modalities.

Date: ___________________________ Signature: ___________________________
## HISTORY OF AMENDMENTS

<table>
<thead>
<tr>
<th>No</th>
<th>Type</th>
<th>Application Area</th>
<th>Date</th>
<th>Modifications</th>
</tr>
</thead>
<tbody>
<tr>
<td>NA</td>
<td>NA</td>
<td>General</td>
<td>NA</td>
<td>Corresponding to Protocol Version 2:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Following French CA request (ANSM) and leading to protocol version 2:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Add of a non inclusion criteria: &quot;Breast-feeding female patient&quot;</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Add of haematology examination at visit 3 and 6</td>
</tr>
<tr>
<td>PA01</td>
<td>Substantial</td>
<td>Local (Italy)</td>
<td>01MAR2013</td>
<td>Corresponding to Protocol Version 3:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Integration of the modification included in the protocol version 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Harmonisation of the protocol and the Informed Consent Form:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• adjustment of the selection criteria n°10 related to the contraception method</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• addition of a letter that is given by the patient to his/her GENERAL practitioner (GP)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• precision that the sponsor can not collect a copy of the Informed Consent Form</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• precision that the patient card is in Italian language only (without any English mention)</td>
</tr>
<tr>
<td>PA02</td>
<td>Non Substantial</td>
<td>General</td>
<td>28MAR2013</td>
<td>Corresponding to Protocol Version 4:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- change of Sponsor’s Representative (Clinical Study Manager),</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- modification of the technical handling of the blood samples for determination of red blood cells concentration of DHA: the centrifugation is no more needed,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- precision on the function and address of the International Study Coordinator Pr Nodari,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- add of address and contacts details of two CRO newly involved in the study: Theradis (in charge of transportation of blood samples to the Analytical centre and material supply) and “Clinact” (in charge of refund of patients expenses linked to the study),</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- adjustment of the wording, in agreement with the commitment to the French Ethics Committee. In the paragraphe 8.3.2.1, the wording “hematology examination” is replaced by “standard hematologic dosage”,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- precision of the full title in the study synopsis (in agreement with the commitment to the Spanish Ethics Committee),</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- correction of a mistake in section 8.1.1.3 (related to TTEM transmission) and sections 3, 9 and study synopsis (related to the definition of INR not stabilized),</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- addition of the changes included in the local Italian Final version 967/1185</td>
</tr>
<tr>
<td>Nº</td>
<td>TYPE</td>
<td>APPLICATION AREA</td>
<td>DATE</td>
<td>MODIFICATIONS</td>
</tr>
<tr>
<td>------</td>
<td>------------</td>
<td>------------------</td>
<td>-----------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
| PA03 | Substantial| General          | 23OCT2013 | **Corresponding to Protocol Version 5:**  
- Fax modification of the sponsor’s representatives  
- Planned end of study postponed to January 2015.  
- The authorized history of the first documented persistent atrial fibrillation is less than 3 years.  
- At selection a hyperkalemia or a hypokalemia is better defined by the standards of the local laboratories.  
- Regarding previous treatments by amiodarone the non inclusion criteria of the protocol are adapted as follow:  
  - Previous treatment with oral amiodarone within 4 months prior to inclusion  
  - Intake of oral amiodarone for more than 1 month within 4 to 12 months before inclusion  
  - Previous treatment with intravenous amiodarone within 4 weeks prior to inclusion.  
- For male with a child-bearing potential partner (in Italy only): taking into account the duration of spermatogenesis the absolute abstention from sexual intercourse or the use of double barrier contraception method are extended to 3 months after the end of the study.  
- Ranolazine is an antiarrhythmic treatment added to the prohibited treatments.  
- Update of Serious Adverse Events (SAEs) form: Main change is the SAE sending: SAEs have to be reported to the Corporate Vigilance Department, and not anymore to the clinical study manager. Also SAEs can be sent by e-mail and by fax.  
- Addition of Alpha Bioresearch as CRO involved for Feasibility, Monitoring and Regulatory issues in Spain.  
- Correction of some minor typographic errors |
| PA04 | Non Substantial | General | 03JUN2014 | **Corresponding to protocol V7:**  
- Precision on the temperature storage of DHA samples  
- Precision on the BSA formula  
- Addition of QTcB and QTcF  
- Precision on TTEM recording timelines  
- Clarification of the section Interim analysis and data monitoring (13.11)  
- Clarifications and specifications on some
<table>
<thead>
<tr>
<th>Nº</th>
<th>TYPE</th>
<th>APPLICATION AREA</th>
<th>DATE</th>
<th>MODIFICATIONS</th>
</tr>
</thead>
<tbody>
<tr>
<td>PA05</td>
<td>Substantial</td>
<td>General</td>
<td>22OCT2014</td>
<td>Corresponding to protocol V8:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Planned end of study postponed to April 2016</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Clarifications regarding the management of VKA treatment</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Precision regarding the primary efficacy criterion (the time to the first</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Atrial Fibrillation recurrence or Atrial Flutter emergence)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Deletion of Visit 5 and Visit 8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Previous history of a first documented persistent Atrial Fibrillation</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>without limitation in time instead of no longer than 3 years</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Patients must have a systolic heart failure defined by a reduced</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>ventricular ejection fraction and or defined also through other echocardiographic</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>parameters mentioned in the ESC guidelines for the diagnosis and treatment of</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>acute and chronic heart failure (2012)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Regarding previous prohibited treatments by amiodarone or dronedarone, the</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>non inclusion criteria of the protocol are adapted as follow:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Concomitant treatment with oral amiodarone or dronedarone from selection</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Concomitant treatment with intravenous amiodarone from selection</td>
</tr>
<tr>
<td>PA06</td>
<td>Non substantial</td>
<td>General</td>
<td>06JUN2016</td>
<td>Corresponding to protocol V8</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Change of sponsor Clinical Study Manager and Clinical Development Physician</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>- Planned end of study postponed to September 2017</td>
</tr>
</tbody>
</table>
1. AMENDMENT RATIONALE

The F373280 CA 201 planned initially to recruit 152 patients over 6 months across 50 sites in Europe.

Since May 2013, only 134 patients have been randomised and 1 patient is currently enrolled. Due to very slow recruitment over more than 3 years, and, in the absence of any possibility to plan a reliable date for completion of recruitment, the Sponsor has decided to stop the recruitment of patients as of September 23, 2016. This population of maximum 135 randomised patients will be taken into account for efficacy and safety analyses. Despite the loss of power, statistical analyses planned in the protocol are maintained.

There is no unexpected safety signal on the current population, therefore, enrolled patients may continue receiving treatment and participate in the study, as planned by the protocol.

In this context, the purpose of this amendment is limited to the change of the number of patients, the number of IDMC meetings and the planned study period.

This change does apply to all relevant sections of the protocol. Furthermore, all enrolled patients will be informed of this change of recruited patient number.
## 2. CHANGES DESCRIPTION

<table>
<thead>
<tr>
<th>PREVIOUS VERSION</th>
<th>MODIFIED VERSION</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Synopsis</strong></td>
<td><strong>Synopsis</strong></td>
</tr>
<tr>
<td><strong>Planned Study Period:</strong> January 2013 – September 2017 (according to amendment PA06)</td>
<td><strong>Planned Study Period:</strong> January 2013 – April 2017</td>
</tr>
<tr>
<td><strong>Number of Patients:</strong> 76 x 2 patients</td>
<td><strong>Number of Patients:</strong> maximum 135 patients</td>
</tr>
</tbody>
</table>

### 13.11 INTERIM ANALYSIS AND DATA MONITORING

The IDMC will review, three times during the study period (after the first 30 subjects will have been randomized, when the first 80 subjects will have terminated their study participation and when 130 subjects will have terminated their study participation), safety data results across treatment groups and judges whether the overall safety and feasibility (not futility) of the trial remain acceptable.

### 13.11 INTERIM ANALYSIS AND DATA MONITORING

The IDMC will review, two times during the study period (after the first 30 subjects will have been randomized and when the first 80 subjects will have terminated their study participation), safety data results across treatment groups and judges whether the overall safety and feasibility (not futility) of the trial remain acceptable.
CLINICAL STUDY PROTOCOL

Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

F373280 / Soft Capsules / 1g

Pierre Fabre Study Code: F 373280 CA 2 01
EudraCT Number: 2012 – 003487 - 48

Sponsor's Representative: Marine FAGARD
INSTITUT DE RECHERCHE PIERRE FABRE - Centre de R&D Pierre Fabre - BP 13562
3 avenue Hubert Curien
31035 TOULOUSE Cédex 1, FRANCE
Phone: +33 5 34 50 63 54
Fax:+33 5 34 50 65 92
E-mail:marine.fagard@pierre-fabre.com

Study Coordinating Investigator Pr Savina NODARI
Associate Professor of Cardiology
Department of Clinical and Surgical Specialities, Radiological Science and Public Health
Section of Cardiovascular Diseases
University Medical School and Spedali Civili Hospital of Brescia
c/o Spedali Civili di Brescia
Piazzale Spedali Civili, 1
25123 - BRESCIA, ITALY
Phone: +39 030 3996 587 – +39 030 393849
Fax: +39 030 3700 359
E-mail: savinanodari@gmail.com; nodari@med.unibs.it

Version 9 – 28SEP2016

The information contained in this document is confidential and is the property of the Sponsor, Pierre Fabre Medicament. This information is given for the needs of the study and must not be disclosed without prior written consent of the Sponsor Pierre Fabre Medicament. Persons to whom this information is given for the needs of the study must be informed that it is confidential and must not be disclosed.
SPONSOR PERSONNEL

PIERRE FABRE MEDICAMENT
represented by
Institut de Recherche Pierre Fabre

Clinical Study Manager (Monitor)

Marine FAGARD
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1, FRANCE
Phone: +33 5 34 50 63 54
Fax: +33 5 34 50 65 92
E-mail: marine.fagard@pierre-fabre.com

Head of Medical Unit

Karim KEDDAD, MD, PhD
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1, FRANCE
Phone: +33 5 34 50 61 69
Fax: +33 5 34 50 65 29
E-mail: karim.keddad@pierre-fabre.com
CONTRACT RESEARCH ORGANISATIONS

For Feasibility, Monitoring and Regulatory issues (in Hungary, Czech Republic and Italy):
Pharmaceutical Service Network (PSN)
Rufino Gonzalez
28 037 Madrid - SPAIN
Phone: +34 91 375 6930 - Fax: +34 91 375 6931
E-mail: rzurita@psnglobal.org

For Feasibility, Monitoring and Regulatory issues (in Spain):
Alpha Bioresearch
Paseo de la Castellana, 163 - 2º Izquierda
28 046 Madrid - SPAIN
Phone: +34 91 745 2520 - Fax: +34 91 745 0653
E-mail: teresa.bricio@alphabioresearch.com

For Centralised Randomisation and Electronic Case Report Form
S-Clinica
6, Chaussée de Boondael
B-1050 Brussels - BELGIUM
Phone: +32 2 645 0567 - Fax: +32 2 645 0569
E-mail: irena.seredina@s-clinica.com

For Centralised Reading of Holder ECG and TTEM and equipment supply:
Biomedical System
1945 Chaussée de Wavre
B-1160 Brussels - BELGIUM
Phone: +32 2 661 20 70 - Fax: +32 2 661 20 71
E-mail: sjacobs@biomedsys.com

For intra erythrocyte DHA dosage:
Agrocampus Ouest
Laboratoire de Biochimie
65 rue de Saint Brieuc – CS 84215
35042 RENNES Cedex - FRANCE
Phone: +33 2 23 48 55 49 - Fax: +33 2 23 48 55 50
E-mail: daniel.catheline@agrocampus-ouest.fr

For transportation of blood sample to the Analytical centre (Agrocampus) and material supply:
Theradis Pharma
41, chemin des Presses
06800 CAGNES-SUR-MER – FRANCE
Phone: +33 (0)4 97 02 07 07 - Fax: +33 (0)4 97 10 08 78
E-mail: chantal.raffy@theradis.pharma.com
**Protocol F 373280 CA 2 01**

**APPROVAL FORM**


<table>
<thead>
<tr>
<th>Sponsor's Representative:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Head of Medical Unit:</strong></td>
</tr>
<tr>
<td>Karim KEDDAD, MD, PhD</td>
</tr>
<tr>
<td>Date:</td>
</tr>
<tr>
<td>27/08/2015</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Study Coordinating Investigator:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Savina NODARI, MD</td>
</tr>
<tr>
<td>Date:</td>
</tr>
<tr>
<td>10/10/2016</td>
</tr>
</tbody>
</table>
Country: ITALY

Country Coordinating Investigator: SAVIAR NOGARI

Date: 28SEP2016

Signature: [Signature]

Protocol F 373280 CA 2 01
COUNTRY COORDINATING INVESTIGATOR
SIGNATURE FORM
By my signature below, I, Dr / Pr "                                         
, hereby confirm that I agree:

♦ to conduct the trial described in the protocol F 373280 CA 2 01, dated 28SEP2016 in compliance with GCP, with applicable regulatory requirements and with the protocol agreed upon by the Sponsor Pierre Fabre Médicament and given approval / favourable* opinion by the Ethics Committee;
♦ to document the delegation of significant study-related tasks and to notify the Sponsor of changes in site personnel involved in the study;
♦ to comply with the procedure for data recording and reporting;
♦ to allow monitoring, auditing and inspection;
♦ to retain the trial-related essential documents until the Sponsor informs that these documents are no longer needed.

Furthermore, I hereby confirm that I will have and will use the available adequate resources, personnel and facilities for conduct this trial.

I have been informed that certain regulatory authorities require the Sponsor Pierre Fabre Médicament to obtain and supply details about the investigator’s ownership interest in the Sponsor or the study drug, and more generally about his/her financial relationships with the Sponsor. The Sponsor will use and disclose the information solely for the purpose of complying with regulatory requirements.

Hence I agree:
♦ to supply the Sponsor with any information regarding ownership interest and financial relationships with the Sponsor (including those of my spouse and dependent children);
♦ to promptly update this information if any relevant changes occur during the course of the study and for 1 year following completion of the study;
♦ that the Sponsor may disclose this information about such ownership interests and financial relationships to regulatory authorities.

* To be adapted

Date:                     Signature:  

978/1185
# Table of Contents of Clinical Study Protocol

1. Introduction and Study Rationale
   1.1. Target Pathology and Therapy
   1.2. Information on the Test Product
      1.2.1. Chemical and pharmaceutical characteristics
         1.2.1.1. Nomenclature and structure
         1.2.1.2. Physical and chemical general properties
      1.2.2. Non-clinical Data
         1.2.2.1. Pharmacological profile
         1.2.2.2. Safety pharmacology
         1.2.2.3. Toxicology profile
         1.2.2.4. Pharmacokinetic data
      1.2.3. Clinical data
   1.3. Study Rationale
   1.4. Overall Risk and Benefit Assessment

2. Study Objectives
   2.1. Primary Objective
   2.2. Secondary Objectives

3. Ethical Considerations Relating to the Study

4. Study Design
   4.1. Overall Description
   4.2. Discussion of the Study Design
      4.2.1. Choice of the Study Population
      4.2.2. Choice of the Study Design
      4.2.3. Choice of the Dose
      4.2.4. Choice of the Sample Size

5. Study Population
   5.1. Inclusion Criteria
   5.2. Non Inclusion Criteria
   5.3. Number of Patients
   5.4. Recruitment Modalities
   5.5. Patient Identification
   5.6. Withdrawal Criteria
   5.7. Replacement of Patients
   5.8. Post-Study Exclusion Period
   5.9. Study Card and Letter for General Practitioner(s)

6. Study Treatment
6.1. SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT ........................................................................................................................... 44
6.2. PACKAGING AND LABELLING ................................................................................................................................................................................. 44
6.2.1. Packaging ............................................................................................................................................................................................................ 44
6.2.2. Labelling ............................................................................................................................................................................................................ 44
6.3. DISTRIBUTION TO CENTRE AND STORAGE ........................................................................................................................................ 45
6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT ........................................................................................................... 46
6.5. DRUG ADMINISTRATION .................................................................................................................................................................................... 47
6.5.1. Duration of Treatment ................................................................................................................................................................................ 47
6.5.2. Dose Schedule ................................................................................................................................................................................................... 47
6.5.3. Route and Conditions of Administration ........................................................................................................................................ 47
6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT ........................................................................ 48
6.7. RECALL OF INVESTIGATIONAL PRODUCTS ............................................................................................................................................... 48
7. CONCOMITANT TREATMENTS .................................................................................................................................................................................. 48
7.1. VITAMIN K ANTAGONIST TREATMENT ............................................................................................................................................... 49
7.2. PROHIBITED TREATMENTS ........................................................................................................................................................................... 49
7.3. AUTHORISED TREATMENTS ........................................................................................................................................................................... 50
8. EVALUATION CRITERIA ............................................................................................................................................................................................ 50
8.1. PRIMARY EFFICACY CRITERION ....................................................................................................................................................................... 50
8.1.1. Time to the first Atrial Fibrillation Recurrence or Atrial Flutter Emergence ...................................................................................................................... 50
8.1.1.1. Definition ................................................................................................................................................................................................... 50
8.1.1.2. Schedule ................................................................................................................................................................................................... 50
8.1.1.3. Evaluation Methods .................................................................................................................................................................................. 50
8.1.2. SECONDARY EFFICACY CRITERIA .................................................................................................................................................. 51
8.2.1. Numbers of AF episodes in the first week following visit 3 (ECV visit) ........................................................................................................... 51
8.2.1.1. Definition ................................................................................................................................................................................................... 51
8.2.1.2. Schedule ................................................................................................................................................................................................... 52
8.2.1.3. Evaluation Methods .................................................................................................................................................................................. 52
8.2.2. Duration of AF episodes in the first week following visit 3 (ECV visit) ........................................................................................................... 52
8.2.2.1. Definition ................................................................................................................................................................................................... 52
8.2.2.2. Schedule ................................................................................................................................................................................................... 52
8.2.2.3. Evaluation Methods .................................................................................................................................................................................. 52
8.2.3. Clinical parameters evaluation ...................................................................................................................................................................... 52
8.2.3.1. EHRA score assessment .................................................................................................................................................................................. 52
8.2.3.2. Time to first AF recurrence less than 10 minutes ........................................................................................................................................... 53
8.2.3.3. Recurrence of symptomatic AF ........................................................................................................................................................................ 53
8.2.3.4. Number and duration of hospitalizations ........................................................................................................................................... 53
8.2.4. Cardioversion assessment ........................................................................................................................................................................... 54
8.2.5. Evolution of echocardiographic parameters ........................................................................................................................................ 54
8.2.5.1. Definition ................................................................................................................................................................................................... 54
8.2.5.2. Schedule ......................................................................................................................... 54
8.2.5.3. Evaluation method .......................................................................................................... 54
8.3. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA ..................................................................................................................................... 55
  8.3.1. Definition ........................................................................................................................... 55
  8.3.2. Blood samples ................................................................................................................... 55
  8.3.2.1. Collection schedule ........................................................................................................ 55
  8.3.2.2. Technical handling ......................................................................................................... 55
  8.3.3. DHA concentration measurement ..................................................................................... 55
8.4. SAFETY ASSESSMENT .................................................................................................... 56
  8.4.1. Adverse Events .................................................................................................................. 56
  8.4.2. Laboratory Investigations .................................................................................................. 56
  8.4.2.1. Schedule ......................................................................................................................... 56
  8.4.2.2. Technical Procedures and Parameters ............................................................................ 56
  8.4.3. Global Physical Examination ............................................................................................ 57
  8.4.4. Vital Signs ......................................................................................................................... 58
  8.4.4.1. Schedule ......................................................................................................................... 58
  8.4.4.2. Technical Procedure and Parameters .............................................................................. 58
  8.4.5. Electrocardiogram (ECG) .................................................................................................. 58
  8.4.5.1. Schedule ......................................................................................................................... 58
  8.4.5.2. Technical Procedure and Parameters .............................................................................. 58
  8.4.6. Coagulation parameters ..................................................................................................... 59
8.5. CONCOMITANT TREATMENTS ..................................................................................... 60
8.6. COMPLIANCE .................................................................................................................... 60

9. STUDY PROCEDURES ........................................................................................................ 60

10. ADVERSE EVENTS: DEFINITION AND REPORTING .............................................. 66
  10.1. ADVERSE EVENTS ......................................................................................................... 66
  10.1.1. Definition of Adverse Events ............................................................................................ 66
  10.1.2. Grading of Adverse Events ............................................................................................... 67
  10.1.3. Reporting of Adverse Events ............................................................................................ 67
  10.2. SERIOUS ADVERSE EVENTS (SAE) .............................................................................. 67
  10.2.1. Definition ........................................................................................................................... 67
  10.2.2. Reporting of SAE .............................................................................................................. 68
  10.2.3. Follow-up of SAE ............................................................................................................. 68
  10.2.4. SAE Occurring After the Study ......................................................................................... 69
  10.3. REPORTING OF OVERDOSAGE TO THE SPONSOR ................................................... 69
  10.4. REPORTING OF PREGNANCY TO THE SPONSOR ..................................................... 69
  10.5. SPONSOR’S RESPONSIBILITIES FOR SAFETY REPORTING PURPOSES ............... 70

11. DATA COLLECTION AND STUDY MONITORING .................................................. 70
  11.1. DATA COLLECTION ......................................................................................................... 70
  11.1.1. Case Report Form ............................................................................................................ 70
11.1.2. Source Documents ............................................................................................................. 71
11.2. STUDY MONITORING .......................................................................................................... 71
  11.2.1. Monitoring visits .............................................................................................................. 71
  11.2.1.1. Site Preselection Visit .................................................................................................. 72
  11.2.1.2. Initiation Visit .............................................................................................................. 72
  11.2.1.3. Follow-up Visits ......................................................................................................... 72
  11.2.1.4. Closing Visit ............................................................................................................... 73
  11.2.2. Direct Access to Source Documents .............................................................................. 73
  11.3. INDEPENDENT DATA MONITORING COMMITTEE ...................................................... 73
12. DATA MANAGEMENT ............................................................................................................. 74
  12.1. DATA ENTRY ....................................................................................................................... 74
  12.2. DATA CLEANING ............................................................................................................... 74
  12.3. DATA CODING .................................................................................................................... 74
  12.4. DATA STORAGE .................................................................................................................. 75
  12.5. DATABASE LOCK ............................................................................................................... 75
13. STATISTICAL ANALYSIS ....................................................................................................... 75
  13.1. GENERAL CONSIDERATIONS ........................................................................................... 75
  13.2. SAMPLE SIZE ...................................................................................................................... 75
  13.3. PROTOCOL DEVIATIONS .................................................................................................. 76
  13.4. DATA SETS ANALYSED ..................................................................................................... 76
  13.5. HANDLING OF DROPOUTS AND MISSING DATA .......................................................... 77
  13.5.1. Dropouts ........................................................................................................................ 77
  13.5.2. Repositioning of Visits ................................................................................................... 77
  13.5.3. Missing Data .................................................................................................................. 77
  13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS .................................... 77
  13.7. EFFICACY ANALYSIS ...................................................................................................... 78
  13.7.1. Primary Criterion ............................................................................................................ 78
  13.7.1.1. Primary Analysis ........................................................................................................... 78
  13.7.1.2. Supportive Analysis .................................................................................................... 78
  13.7.2. Secondary Criteria ......................................................................................................... 78
  13.7.2.1. Numbers of Atrial Fibrillation Episodes in the first week following V3 .......... 78
  13.7.2.2. Duration of Atrial Fibrillation Episodes in the first week following V3 .......... 78
  13.7.2.3. Time to first AF recurrence less than 10 minutes or symptomatic ...................... 79
  13.7.2.4. Clinical parameters evaluation ................................................................................. 79
  13.7.2.5. Biomarker analysis: red blood cell concentrations of DHA ................................. 79
  13.8. SAFETY ANALYSIS ......................................................................................................... 79
  13.8.1. Adverse Events .............................................................................................................. 79
  13.8.2. Clinical Laboratory Evaluation ...................................................................................... 81
  13.8.3. Global Physical Examination ......................................................................................... 82
  13.8.4. Vital Signs, Physical Findings and Other Observations Related to Safety .............. 83
13.8.4.1. Vital Sign Measurements Over Time
13.8.4.2. Body weight
13.8.4.3. Individual Patient Changes
13.8.5. ECG
13.8.6. Coagulation parameters
13.9. CONCOMITANT TREATMENTS
13.10. COMPLIANCE
13.11. INTERIM ANALYSIS AND DATA MONITORING

14. GENERAL ETHICAL CONSIDERATIONS
14.1. ETHICAL CONDITIONS
14.2. ETHICS COMMITTEE AND LEGAL REQUIREMENTS
14.3. PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM
14.4. PERSONAL DATA PROTECTION
14.5. INSURANCE POLICY

15. ADMINISTRATIVE PROCEDURES
15.1. PROTOCOL AMENDMENT
15.2. SOURCE DOCUMENTS, INVESTIGATOR'S FILE STORAGE
15.3. END OF THE STUDY
15.3.1. Definition of the End of Study
15.3.2. Early Study Termination
15.3.2.1. Early Study Termination Decided by the Sponsor
15.3.2.2. Early Study Termination Decided by the Competent Authorities
15.4. AUDIT
15.5. INSPECTION
15.6. CONFIDENTIALITY
15.7. CLINICAL STUDY REPORT
15.8. STUDY RESULTS COMMUNICATION
15.9. STUDY RESULTS PUBLICATION

16. REFERENCES

17. APPENDICES
17.1. DECLARATION OF HELSINKI
17.2. SAE REPORT FORM
17.3. PREDEFINED LIMITS OF LABORATORY AND VITAL SIGN POTENTIALLY CLINICALLY SIGNIFICANT CHANGES AND VALUES
# SYNOPSIS

<table>
<thead>
<tr>
<th>Name of Sponsor:</th>
<th>Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Finished Product:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Name of Active Substance:</td>
<td>F373280 (Panthenyl-Ester of DHA)</td>
</tr>
<tr>
<td>Title of the Study:</td>
<td>Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.</td>
</tr>
<tr>
<td>Abbreviated Title:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Study Coordinating Investigator:</td>
<td>Pr Savina NODARI</td>
</tr>
<tr>
<td>Study Centres:</td>
<td>International, multicentric</td>
</tr>
<tr>
<td>Publication / Rationale:</td>
<td>F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation (AF) patients with chronic heart failure. The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of AF induced by burst pacing [1]. Moreover, the effectiveness of PolyUnsaturated Fatty Acid (PUFA) has been proven in the following conditions: prevention of AF recurrence in patients with persistent AF, in co-administration with amiodarone (add on therapy) [2], improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]. Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent atrial fibrillation and chronic heart failure. This phase Ila study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after electrical cardioversion (ECV) in patients with persistent atrial fibrillation and chronic heart failure.</td>
</tr>
<tr>
<td>Planned Study Period:</td>
<td>January 2013 – April 2017</td>
</tr>
<tr>
<td>Clinical Phase:</td>
<td>Ila</td>
</tr>
<tr>
<td>Objectives:</td>
<td>Primary:</td>
</tr>
<tr>
<td></td>
<td>- Efficacy of F373280 on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure</td>
</tr>
<tr>
<td></td>
<td>Secondary:</td>
</tr>
<tr>
<td></td>
<td>- Efficacy of F373280 on the efficiency of direct electrical cardioversion</td>
</tr>
<tr>
<td></td>
<td>- Effect of F373280 on echocardiographic parameters</td>
</tr>
<tr>
<td></td>
<td>- Safety and tolerability of F373280</td>
</tr>
<tr>
<td>Methodology:</td>
<td></td>
</tr>
<tr>
<td></td>
<td>- International, multicentre, randomised, double-blind, placebo-controlled</td>
</tr>
<tr>
<td></td>
<td>- Selection period</td>
</tr>
<tr>
<td></td>
<td>- Start of treatment 4 weeks before ECV</td>
</tr>
<tr>
<td></td>
<td>- Condition to ECV:</td>
</tr>
<tr>
<td></td>
<td>- Ideally INR 2-3 (vitamin K antagonist should be given at least 3 weeks before ECV)</td>
</tr>
<tr>
<td></td>
<td>- No spontaneous cardioversion before ECV</td>
</tr>
<tr>
<td></td>
<td>- Follow-up 20 weeks after visit 3 (ECV visit)</td>
</tr>
<tr>
<td></td>
<td>- Condition: successful ECV or spontaneous CV</td>
</tr>
<tr>
<td></td>
<td>- Cardiac monitoring:</td>
</tr>
</tbody>
</table>
- 7-days continuous ECG ambulatory recording (Holter ECG) between visit 3 (ECV visit) and visit 4 (week 5) in patients with sinus rhythm
- TTEM: one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24) and at any time in case of AF or atrial flutter symptoms.

**Study Schedule:**

<table>
<thead>
<tr>
<th>Visit</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>W-1</td>
<td>Selection visit (7 to 28 days before the inclusion visit)</td>
</tr>
<tr>
<td>W-4</td>
<td>Inclusion visit (start of study treatment)</td>
</tr>
<tr>
<td>W4</td>
<td>Cardioversion visit (outpatient or hospitalization according to clinical practice of the centre) (installation of the Holter device)</td>
</tr>
<tr>
<td>W5</td>
<td>Follow-up visit (removing of the Holter device and installation of the TTEM)</td>
</tr>
<tr>
<td>W12*</td>
<td>Follow-up visit</td>
</tr>
<tr>
<td>W16</td>
<td>Follow-up visit</td>
</tr>
<tr>
<td>W24*</td>
<td>Final study visit</td>
</tr>
</tbody>
</table>

*see amendment PA05 dated 22OCT2014

**Number of Patients:**

Maximum 135 patients

**Diagnosis and Criteria for Inclusion:**

**Inclusion Criteria:**

*Demographic Characteristics and Other Baseline Characteristics:*

1. Men or women aged more than 18 years (inclusive)
2. Patients with current episode of persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted
3. Previous history of first documented episode of persistent AF.
4. Previous history of ischemic or non ischemic heart failure
5. NYHA class I or II chronic heart failure at selection and at inclusion
6. Left ventricular systolic dysfunction defined at selection and at inclusion by a reduced left ventricular ejection fraction (LVEF) ≥ 30% and ≤ 45% or for patients with a LVEF > 45%:
   - an increased left ventricular end-diastolic size (diameter ≥ 60 mm and/or > 32 mm/m² and/or volume > 97 ml/m³)
   - and/or an increased left ventricular end-systolic size (diameter > 45 mm and/or > 25 mm/m² and/or volume > 43 ml/m³)
   - and/or a reduced left ventricular outflow tract velocity time integral < 15 cm
7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers
8. Left atrial area ≤ 40 cm² at selection and at inclusion
9. Patients treated or having to be treated by vitamin K antagonist
10. For female patient of child-bearing potential:

   **In all the countries except Italy:**
   - Use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator, for at least 2 months before the selection in the study, and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment
   - Documented as surgically sterilized

   **In Italy only:**
   - Absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
   - Use of double barrier contraception method (use of effective medical contraception)
method) from at least 2 months before the start of the study to the entire duration of the study and for a month after the end of the study or
- Documented as surgically sterilized

11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion
12. For male with a child-bearing potential partner (In Italy only):
   - Absolute abstention from sexual intercourse during the whole duration of the study and for 3 months after the end of the study or
   - Use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to 3 months after the end of the study.

Ethical / legal considerations:
13. Having signed his/her written informed consent,
14. Affiliated to a social security system, or is beneficiary (if applicable in the national regulation)

Non-Inclusion Criteria:
Criteria related to pathologies:
1. No previous history of first documented episode of persistent AF
2. More than two successful cardioversions (electrical or pharmacological) in the last 6 months
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV)
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be checked in case of treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic coronaropathy assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
7. Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration rate < 30 ml/min) at selection
8. Bradycardia (HR ≤ 50 bpm)
9. Hyperkalemia or hypokalemia (according to the standards of local laboratories) at selection
10. Cardiac surgery within 3 months before selection or planned during the study duration

Criteria related to treatments:
11. Previously ineffective pharmacological or electrical cardioversion
12. Concomitant treatment with ranolazine or any antiarrhythmic drug (within 7 days prior to selection), except amiodarone, dronedarone and stable dose of digoxin, betablockers, calcium-blockers
13. Concomitant treatment with oral amiodarone or dronedarone from selection
14. Concomitant treatment with intravenous amiodarone from selection
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT implantation within the last 6 months
16. Treatment with any Polyunsaturated Fatty Acid (PUFA) within the last 3 months
17. Dietary supplement with ω 3 or ω 6 according to investigator’s judgement
18. Having undergone any form of ablation therapy for AF
19. Patient treated with oral anticoagulant treatment other than vitamin K antagonist: new oral anticoagulants (dabigatran, rivaroxaban, apixaban), or treated with irreversible
antiplatelet agents P2Y12 inhibitors such as ticlopidine, clopidogrel or prasugrel

Other criteria:
20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection
22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself/herself to its constraints
23. Patient family member or work associate (secretary, nurse, technician,..) of the Investigator
24. Patient having forfeited his / her freedom by administrative or legal award or being under guardianship
25. Breastfeeding female patient

Exclusion criteria before V3:
Patients without dyskalemia who will not have INR values ≥ 2 on the 3 last tests performed before ECV should not have an ECV and will be excluded from the study.

However, if only 2 INR values are ≥ 2 among those 3 last tests, an ECV can be performed if the presence of atrial thrombosis can be excluded with an ECHO–TE (transesophageal echocardiography) performed on the same day (before ECV) and the patient can continue the study.

If necessary, for meeting these INR conditions, the ECV (and following visits) could be postponed by 7 days.

Test Product: F373280
Soft Capsules

Dose: Arm with 1g of F373280

Mode of Administration: Oral, one capsule each evening with dinner.

Duration of Treatment: 24 weeks of treatment exposure with F373280 (25 weeks if ECV postponed by 1 week)

Reference Therapy Placebo soft capsules
Placebo will be administered in the same conditions as the tested product.

Mode of Administration: Oral, one capsule each evening with dinner

Evaluation Criteria: Efficacy evaluation variables:

Primary evaluation variable:
- Time to first Atrial Fibrillation recurrence or atrial flutter emergence defined by the time to first episode of AF or atrial flutter lasting for at least 10 minutes (Follow up of 20 weeks after visit 3 – ECV visit).

Handling of AF recurrences or atrial flutter emergences: 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) between visit 3 (ECV visit) and visit 4 (week 5). Then, the follow up will be documented using the TTEM: one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24).

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF or the emergence of atrial flutter will be assessed after visit 3 (from week 5).
Moreover, during this TTEM period, if patient experiences any AF or atrial flutter symptoms, it should be recorded and documented using the TTEM.
All ECG (Holter and TTEM) will be evaluated by a Central Reading Laboratory.

Secondary evaluation variables:
During the 7-day continuous ECG monitoring,
- Numbers of AF episodes
- Duration of AF episodes

**Clinical parameters:**
During the whole study:
- Number of recurrence of symptomatic AF episodes
- EHRA score
- Hospitalization for cardiovascular events
- Hospitalization for thromboembolic stroke
- All causes of hospitalization

**Cardioversion:**
- Assessment of spontaneous cardioversion
- Assessment of successful cardioversion
- Shocks distribution (1, 2 or 3 shocks)
- Number of patients needing another cardioversion after the initial ECV

**Other:**
- Evolution of echocardiographic parameters (at V4, V6 and V9) (Left atrial diameter (mm), Left atrial area (cm²), Left atrial volume (ml), Left atrial volume/BSA (ml/m²), Left ventricular ejection fraction (%), Left ventricular end diastolic volume/BSA (ml/m²), Left ventricular end systolic volume/BSA/ml/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (ml), Left ventricular end systolic diameter (mm), Left ventricular end systolic volume (ml))
- Evolution of omega 3 index and intra erythrocyte DHA (*For this assessment samples will be centralized*).

**Safety criteria:**
- **Adverse events** (observed and/or spontaneously reported)
- **Vital signs** (Blood pressure (supine and standing), heart rate)
- **Physical examination** (body weight, body surface area)
- **Standard 12-lead ECG**: heart rate (bpm), PR (ms), QRS (ms), QT (ms), QTcB (ms), QTcF (ms), repolarisation patterns (ECG not centralized)
- **Haematology**: haematocrit, haemoglobin, red blood cell (RBC) count, white blood cell (WBC) count, WBC differential count, reticulocytes, platelets
- **Biochemistry**: sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatin phosphokinase (CPK) fibrinogen (*local laboratory*)
- **Coagulation parameters**: Activated partial thromboplastin time (aPTT), thrombin clotting time (TCT), INR (*local laboratory*), Prothrombine Time (*PT*).

**Concomitant treatments**

**Compliance**

**Statistical Methods:**

**Sample Size:**
Assuming an AF recurrence or atrial flutter emergence rate under placebo of 85%, a power of 80%, an alpha risk of 5% and a rate of not assessable patients of 15%, 76 randomised patients per group will be necessary, using a log-rank test of survival curves, a difference between groups of 20%.

**Primary Efficacy Analysis**
The primary analysis, performed on the Full Analysis Set (FAS: all randomised patients with at least one dose of treatment and with a successful cardioversion observed at visit 3), will be a survival analysis using the Kaplan Meier method and Cox regression model.

**Secondary Analyses**

All secondary efficacy criteria will be described and compared using appropriate tests on the FAS.

**Safety Analyses**

Descriptive statistics will be performed on the Safety Set (all randomised patients with at least one dose of treatment).
## STUDY FLOW-CHART

**F373280 CA 201**

<table>
<thead>
<tr>
<th>Weeks</th>
<th>V1</th>
<th>V2</th>
<th>V3</th>
<th>V4</th>
<th>V6</th>
<th>V7</th>
<th>V9</th>
</tr>
</thead>
<tbody>
<tr>
<td>W-4 to W-1</td>
<td>D1</td>
<td>W4 (28 -2D/+7 D)</td>
<td>W5 (35 -2D/+7 D)</td>
<td>W12 (84+/-7D)</td>
<td>W16 (112+/-7D)</td>
<td>W24 (168+/-7D)</td>
<td></td>
</tr>
<tr>
<td><strong>Outpatient or Hospitalization (1)</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Informed consent</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Demographic characteristics</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Medico-surgical history</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Concomitant disease</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Concomitant treatment</strong></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Habits</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Global physical examination (body weight)</strong></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Echocardiography</strong></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td>X</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Eligibility criteria check</strong></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Blood pressure, heart rate</strong></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>12-Lead ECG Recording</strong></td>
<td>X</td>
<td></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td></td>
</tr>
<tr>
<td><strong>INR</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(2)</td>
</tr>
<tr>
<td><strong>aPTT, TCT</strong></td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Haematology</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Biochemistry</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Urinary pregnancy test</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Red Blood Cell concentrations of DHA</strong></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Treatment number allocation</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>IVRS/IWRS</strong></td>
<td>X</td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>ECV (3)</strong></td>
<td>X</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Drug administration</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adverse events recording</strong></td>
<td></td>
<td></td>
<td>(4)</td>
<td>X</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>Holter ECG</strong></td>
<td></td>
<td></td>
<td></td>
<td>(5)</td>
<td>X</td>
<td>X</td>
<td>X</td>
</tr>
<tr>
<td><strong>TTEM (6)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. Outpatient or hospitalization according to clinical practice of the centre (less or more than 24 hours)
2. INR 2 to 3 times a week until stabilization, then weekly until the ECV, then every 4 weeks after ECV
3. In patients with AF
4. 24-hour Holter ECG
5. 7-day Holter ECG
6. TTEM: one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24) and at any time in case of AF or atrial flutter symptoms. TTEM once a week even in case of AF recurrence or atrial flutter emergence for at least 10 minutes.

Final version 990/1185
**LIST OF ABBREVIATIONS**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>aPTT</td>
<td>Activated partial thromboplastin time</td>
</tr>
<tr>
<td>AE</td>
<td>Adverse event</td>
</tr>
<tr>
<td>AF</td>
<td>Atrial fibrillation</td>
</tr>
<tr>
<td>ALA</td>
<td>Alpha-linoleic acid</td>
</tr>
<tr>
<td>ALT</td>
<td>Alanine aminotransferase</td>
</tr>
<tr>
<td>AST</td>
<td>Aspartate aminotransferase</td>
</tr>
<tr>
<td>AUC</td>
<td>Area under the plasma concentration versus time curve</td>
</tr>
<tr>
<td>AUC_{inf}</td>
<td>Total area under the curve extrapolated to infinity</td>
</tr>
<tr>
<td>βHCG</td>
<td>beta human chorionic gonadotrophin</td>
</tr>
<tr>
<td>BLQ</td>
<td>Below the limit of quantification</td>
</tr>
<tr>
<td>BMI</td>
<td>Body mass index</td>
</tr>
<tr>
<td>BP</td>
<td>Blood pressure</td>
</tr>
<tr>
<td>BSA</td>
<td>Body Surface Area</td>
</tr>
<tr>
<td>CEP</td>
<td>Protocol evaluation committee</td>
</tr>
<tr>
<td>CHMP</td>
<td>Committee for medicinal products for human use</td>
</tr>
<tr>
<td>C_{max}</td>
<td>Maximum concentration</td>
</tr>
<tr>
<td>C_{min}</td>
<td>Minimum concentration</td>
</tr>
<tr>
<td>CNALV</td>
<td>Clinically noteworthy abnormal laboratory value</td>
</tr>
<tr>
<td>CPK</td>
<td>Creatin phosphokinase</td>
</tr>
<tr>
<td>CPP</td>
<td>Comité de protection des personnes</td>
</tr>
<tr>
<td>CRA</td>
<td>Clinical research associate</td>
</tr>
<tr>
<td>CRT</td>
<td>Cardiac resynchronization therapy</td>
</tr>
<tr>
<td>CSC</td>
<td>“Clinically Significant Change”, i.e., Predefined potentially clinically significant change leading to a potentially clinically significant value (vital signs)</td>
</tr>
<tr>
<td>CV</td>
<td>Coefficient of variation</td>
</tr>
<tr>
<td>DBP</td>
<td>Diastolic blood pressure</td>
</tr>
<tr>
<td>DHA</td>
<td>Docosahexaenoic acid</td>
</tr>
<tr>
<td>EC</td>
<td>Ethics committee</td>
</tr>
<tr>
<td>ECG</td>
<td>Electrocardiogram</td>
</tr>
<tr>
<td>ECHO –TE</td>
<td>Transesophageal echocardiograph</td>
</tr>
<tr>
<td>ECV</td>
<td>Electrical cardioversion</td>
</tr>
<tr>
<td>EHRA</td>
<td>European heart rhythm association</td>
</tr>
<tr>
<td>EPA</td>
<td>Eicosapentaenoic acid</td>
</tr>
<tr>
<td>e-CRF</td>
<td>Electronic case report form</td>
</tr>
<tr>
<td>FAS</td>
<td>Full analysis set</td>
</tr>
<tr>
<td>Fe</td>
<td>Fraction of the administered drug excreted in urine</td>
</tr>
<tr>
<td>GCP</td>
<td>Good clinical practice</td>
</tr>
<tr>
<td>GFR</td>
<td>Glomerular Filtration Rate</td>
</tr>
<tr>
<td>HBs</td>
<td>Hepatitis B antigen</td>
</tr>
<tr>
<td>HCV</td>
<td>Hepatitis C virus</td>
</tr>
<tr>
<td>HDL</td>
<td>High density lipoprotein</td>
</tr>
</tbody>
</table>
HF : Heart failure
HIV : Human immunodeficiency virus
HR : Heart rate
ICH : International conference on harmonisation of technical requirements for
registration of pharmaceuticals for human use
IDMC : Independent data monitoring committee
INR : International normalized ratio
IRPF : Institut de Recherche Pierre Fabre
IVRS : Interactive voice response system
LAA : Left atrial area
LC/MS-MS : Liquid chromatography with tandem mass spectrometry
LDL : Low density lipoprotein
LOQ : Limit of quantification
LVEF : Left ventricular ejection fraction
MedDRA : Medical dictionary for regulatory activities
MR : Mineralocorticoid receptor
MR perfusion : Magnetic Resonance perfusion
MTD : Maximum tolerated dose
N : Number of determinations or replicates
NOAEL : No observed adverse effect level
NYHA : New York heart association
od : Once a day
PC : "Predefined Change", i.e., Predefined potentially clinically significant change (lab
or vital signs)
PCA : PC leading to an out-of-range value (lab values)
PFB : Pierre Fabre Biométrie
PSC : Potentially Clinically Significant Change
PSCV : Potentially Clinically Significant Value
PUFA : PolyUnsaturated fatty acid
p.o. : Per os
PP : Per protocol data set
QTcB : QT interval using Bazett’s correction formula
QTcF : QT interval using Fridericia’s correction formula
RBC : Red blood cells
SAE : Serious adverse event
SBP : Systolic blood pressure
SD : Standard deviation
T1/2 : Terminal half-life
T0 : Time of drug administration
Tmax : Time to reach the maximal concentration
TCT : Thrombin clotting time
TEAEs : Treatment emergent adverse events
TTEM : TransTelephonic ECG monitoring
VKA : Vitamin K Antagonist
WBC : White blood cells
WHO-DRUG : World health organization drug reference list
1. INTRODUCTION AND STUDY RATIONALE

1.1. TARGET PATHOLOGY AND THERAPY

Atrial Fibrillation (AF) is a supraventricular arrhythmia characterized by uncoordinated atrial electric activity with consequent deterioration of atrial mechanical function. It is the most common sustained cardiac rhythm disorder, increasing in prevalence with age. Haemodynamic impairment and thromboembolic events related to AF result in significant morbidity and mortality [7].

In 2009, Decision Resources estimated that there were 7.8 million diagnosed prevalent cases of AF in US, Europe and Japan. This age-related pathology should increase to 9.4 million cases in 2019.

Except for the conventional class I and class III anti-arrhythmic agents, the Polyunsaturated Fatty Acids (PUFAs) constitute one emerging antiarrhythmic therapy. These compounds potently address the AF substrate by directly targeting both the electrical and the structural remodelling of the deficient atria. The n-3 PUFAs, essential for human, are alpha-linoleic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). First, PUFAs specifically modulate ionic channels by fastening their inactivating mode which renders these compounds selective for pathological situations (such as AF) without any major effect in normal conditions. PUFAs are “open Kv1.5 channel blockers” leading to a lengthening of atrial action potential duration and are “persistent Na\textsubscript{v}1.5 channel blockers” leading to hyperpolarization of diastolic resting potential. Second, PUFAs influence structural remodelling through their anti-inflammatory effects as they directly compete with arachidonic acid in the production of inflammatory eicosanoids. In summary, PUFAs share unique, well-tolerated antiarrhythmic potential by interacting with the electrical and structural remodelling during sustained AF. In animal studies, it was recently demonstrated that DHA is particularly effective in pathologic conditions such as ischemia and/or AF.

The potential anti-arrhythmic effects of a PUFA were previously developed in AF: nicotinyl ester of DHA (pro-drug based on DHA delivery) was assessed in a two-week ventricular tachypaced
canine model. Dogs were subjected to 4 weeks of medication prior to undergoing an electrophysiology study, and received either placebo or nicotinyl ester of DHA. Dogs were tachypaced at 240 beats per min for the final two weeks of the treatment plan. The results showed that the tested PUFA reduced the duration of AF induced by burst pacing, and the incidence of sustained AF, compared to dogs treated with the placebo [1].

In clinical practice, Nodari and coll [2] assessed n-3 PUFAs in the prevention of AF recurrences after electrical cardioversion (ECV). All included patients were treated with amiodarone and a renin-angiotensin-aldosterone system inhibitor. The 199 patients were assigned either to placebo or n-3 PUFAs 2 g/d and then underwent direct ECV 4 weeks later. The primary end point was the maintenance of sinus rhythm at 1 year after cardioversion. At the 1-year follow up, the maintenance of sinus rhythm was significantly higher in the n-3 PUFAs treated patients compared with the placebo group (hazard ratio, 0.62 [95% confidence interval, 0.52 to 0.72] and 0.36 [95% confidence interval, 0.26 to 0.46], respectively; p = 0.0001). The study concludes that in patients with persistent AF on amiodarone and a renin-angiotensin-aldosterone system inhibitor, the addition of n-3 PUFAs 2 g/d improves the probability of the maintenance of sinus rhythm after direct current cardioversion. Previously, during the World Congress of Cardiology in 2006, an abstract reported the effectiveness of PUFAs on top of traditional treatment (amiodarone, beta blockers, renin-angiotensin-aldosterone system inhibitor) in the prevention of AF relapses in patients having undergone ECV. In the PUFA group, AF relapses were significantly lower than in the placebo group at 1 month (3.3% vs 10%; p = 0.043), at 3 months (10% vs 25%; p = 0.004) and at 6 months (13.3% vs 40%; p < 0.0001) [19].

In contrast, in the general AF population (paroxystic atrial fibrillation and persistent atrial fibrillation), PUFAs failed to prove their efficacy [7] because of the absence of cardiac remodelling or because of a short pre-treatment duration before ECV (1 week) [8]. The effects of PUFAs were only observed in patients with persistent AF on add on therapy and after a sufficient pre-treatment before ECV. Persistent AF is commonly associated to heart failure. Previous studies performed in heart failure population demonstrated the benefit of PUFAs on the improvement of functional ventricular parameters and morbi-mortality, and on the reduction of hospitalisation [3, 4, 5].

Nodari and coll [3] performed a trial in patients with chronic heart failure (NYHA I to III and LVEF< 45%). After a treatment of 133 patients with PUFAs (n=67) or placebo (n=66) at a dosage
of 5 g/day for 1 month, then 2 g/day for 11 months, the n-3 PUFAs group and the placebo group differed significantly (p <0.001) in regard to:

- LVEF (increased by 10.4% and decreased by 5.0%, respectively)
- peak VO2 (increased by 6.2% and decreased by 4.5%, respectively)
- exercise duration (increased by 7.5% and decreased by 4.8%, respectively)
- mean New York Heart Association functional class (decreased from 1.88 +/- 0.33 to 1.61 +/- 0.49 and increased from 1.83 +/- 0.38 to 2.14 +/- 0.65, respectively).

The hospitalization rates for patients with HF were 6% in the n-3 PUFAs and 30% in the placebo group (p <0.0002).

Moertl and coll [4] performed a dose-ranging study in patients with a more severe chronic heart failure (NYHA III and IV and LVEF < 35%). It was a double-blind, randomised, controlled pilot trial in 43 patients treated with PUFA s or placebo for 3 months (1 g/d n3-PUFA (n = 14), 4 g/d n3-PUFA (n = 13), or placebo (n = 16)). After treatment, left ventricular ejection fraction increased in a dose-dependent manner (p = 0.01 for linear trend) in the 4 g/d (baseline vs 3 months [mean ± SD]: 24% ± 7% vs 29% ± 8%, p = 0.005) and 1 g/d treatment groups (24% ± 8% vs 27% ± 8%, p = 0.02).

No changes in any investigated parameters were noted with placebo.

Taking into account these studies performed with PUFA s, it seems that the best target for DHA is persistent AF in patients with heart failure. The aim of this proof of concept study is to assess in stand alone therapy (without association of other anti-arrhythmic treatments), the effect of F373280 in patients with persistent AF and heart failure in the maintenance of sinus rhythm after ECV.

1.2. INFORMATION ON THE TEST PRODUCT

F373280 or panthenyl ester of DHA is the mono-ester of panthotenic alcohol and DHA, selected to be developed for the management of AF.

F373280 is a prodrug of DHA.

A brief summary of F373280 known characteristics is presented in this section. For further details, please refer to the F373280 Investigator’s Brochure. [1]
1.2.1. Chemical and pharmaceutical characteristics

1.2.1.1. Nomenclature and structure

Chemical name (IUPAC):

(4Z,7Z,10Z,13Z,16Z,19Z)-3-((R)-2,4-dihydroxy-3,3-dimethylbutanamido) propyl docosa-4,7,10,13,16,19-hexaenoate

Structural formula:

![Structural formula diagram]

Laboratory code: F373280

Molecular formula: C₃₁H₄₉NO₅

Molecular mass: 515.7

1.2.1.2. Physical and chemical general properties

Appearance: Clear oily viscous liquid

Solubilities:

- Water: Practically insoluble
- Alcohol: Very soluble
- Trimethylpentane: Slightly soluble

1.2.2. Non-clinical Data

Non-clinical data are exhaustively detailed in the Investigator’s brochure [1]. A brief summary is provided below.
1.2.2.1. Pharmacological profile

F373280 (mono-ester of panthotenic alcohol and DHA) is a novel pro-drug of DHA which exerts antiarrhythmic properties by interacting with the electrical and structural remodelling of the atria. Experimental investigations were conducted in HEK293 cell line transfected with human Kv1.5 channel using the whole cell patch clamp technique to evaluate whether F373280 could block the sustained component of I_{Kv1.5}. F373280 concentration-dependently reduced Kv1.5 channel activity with an IC_{50} value of 13.7 µM.

The effects of F373280 on atrial effective refractory period were investigated in anesthetized pig using a conventional pacing protocol through epicardial electrodes placed on the left atrium. F373280 administered as a bolus and an infusion (10 mg/kg) significantly increased atrial effective refractory period (23.8 ± 2.2 ms versus -7.3 ± 11.5 ms in the presence of vehicle, p < 0.05). In addition, F373280 was devoid of significant effect on the hemodynamic and the electrocardiogram (ECG) intervals.

Proof of the pharmacological concept was performed with a different DHA derivative named: Nicotinyl ester of DHA (pro-drug based on DHA delivery). Ventricular tachypacing-induced congestive heart failure provides a clinically-relevant animal model of AF associated with structural remodelling, as is often seen clinically. It has been shown that sustained oral PUFA administration suppresses congestive heart failure-induced AF-promotion and fibrosis in the ventricular tachypacing canine model. Nicotinyl ester of DHA was tested in this model, at 1 g/day and 5 g/day, during 4 weeks, to prevent congestive heart failure-related atrial structural remodelling and AF promotion in dogs. Nicotinyl ester of DHA dose dependently reduced heart failure-induced increases in AF duration (989 ± 111 sec, n=5 in the presence of placebo versus 637 ± 196 sec, n=5 in the presence of 1 g/kg/d Nicotinyl ester of DHA and 79 ± 51 sec, n=5, in the presence of 5 g/kg/d Nicotinyl ester of DHA). The protective effect of Nicotinyl ester of DHA was associated with a marked increase of plasma level of DHA and important incorporation of DHA in the left atrial tissue. Because F373280 similarly to Nicotinyl ester of DHA increases plasma level of DHA, it could be estimated that the compound may exert a similar protective effect [1].
1.2.2.2. **Safety pharmacology**
A battery of safety pharmacology studies was performed to evaluate the effects of F373280 on the central nervous, cardiovascular and respiratory systems. Data of these studies are exhaustively detailed in the Investigator’s brochure [1].

No particular alerts were evidenced with F373280.

1.2.2.3. **Toxicology profile**
Concerning the toxicological data, 4-week and 26-week repeat-dose studies in rat and dog were performed. Compared to the high administered doses of F373280 (500 to 2000 mg/kg/day), low circulating concentrations of F373280 were measured.

During these toxicity studies, no toxicity was observed in rat after 4 and 26 weeks of dosing and in dog after 4 weeks of dosing. A NOAEL of 2000 mg/kg/day was established in these repeat toxicity studies.

During the 26-week toxicity study in dogs, the NOAEL was set at 1000 mg/kg/day based on changes observed on red blood cell parameters.

Based on toxicological profiles, F373280 is considered to support the proposed clinical trial.

1.2.2.4. **Pharmacokinetic data**
According to animal studies described in the Investigator’s brochure [1], the non-clinical pharmacokinetic profile of F373280 is not associated with particular alerts concerning the proposed clinical phase IIa study.

1.2.3. **Clinical data**

**Part A: Single dose**
Six consecutive single ascending doses were tested (0.5 g, 1 g, 2 g, 4 g, 8 g and 16 g) on 6 independent cohorts of 8 subjects (6 verum + 2 placebo). 49 subjects were treated and 48 completed the study.

No Serious Adverse Events (SAE) occurred in the course of the study.

Regarding the reported Treatment Emergent Adverse Events (TEAEs) that were judged by the Investigator as having a causal relationship with the study drug administration in the absence of
an alternative explanation, 3 TEAEs were observed in the placebo group (palpitation, dizziness in standing position, symptomatic orthostatic hypotension without loss of consciousness) and 4 in the group of F373280 at the dosage of 16 g (meteorism, liquid stool, symptomatic orthostatic hypotension and dizziness in standing position). None of these adverse events (AE) were reported in the groups of F373280 at the dosages of 0.5 g, 1 g, 2 g, 4 g and 8 g.

After a single administration of the different tested doses no difference between the tested product and placebo has been reported, regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters (related to coagulation: platelets and fibrinogen) and coagulation parameters (bleeding time, prothrombin time/INR, activated partial thromboplastin time, thrombin clotting time). Variations of these parameters were within the physiological ranges.

After single oral administration of F373280 from 0.5 g to 16 g in 36 young healthy male subjects (6 per dose level), the following was observed:

- **F373280**: Whatever the tested dose there is no circulating F373280 in plasma: only few, sparse and non consecutive samples with quantifiable level of F373280 close to LOQ were observed. This confirms that F373280 is a prodrug.

- **Panthenol**: Cmax and AUC increased with the administered dose between 0.5 and 16 g. Panthenol concentrations were rapidly cleared from plasma with a mean terminal half-life around 2 hours.

- **DHA**: after 0.5 and 1 g, low increased in DHA plasma concentrations compared to the baseline levels led to a high inter-individual variability of the corresponding Pharmacokinetics parameters. Plasma exposure in DHA increased with the administered dose between 2 and 16 g with no departure from proportionality (baseline corrected parameters).

**Part B: Multiple doses**

Three consecutive repeated ascending doses (1, 2 and 4 g) were tested on 3 independent cohorts of 12 subjects (9 verum + 3 placebo, double blind). 36 subjects completed the study. Each treatment was administered over a period of 28 days. Pharmacokinetic parameters were assessed over a period of 14 days.
Among the TEAE judged by the investigator as suspected to F373280, 5/9 TEAEs were classified according the System Organ Class in vascular system disorder with orthostatic hypotension (2 in the 1 g group, 1 in the 2 g group and 2 in the 4 g group) and 4/9 were classified in nervous system disorder with 3 dizziness (2 in the 2 g group and 1 in the 4 g group) and 1 migraine (in the 1 g group). These TEAEs have already been reported with PUFAs and are commonly observed in phase I studies.

After a repeated administration of the different tested doses, no difference between the tested products and placebo was reported regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters. The assessment of coagulation parameters and platelet function after administration of repeated dose of F373280 did not report any bleeding issue. The reported changes in coagulation parameters and platelet function were within physiological ranges.

After a 14-day repeated oral administration of F373280 from 1 g to 4 g, the following was observed:

- **Panthenol**: Cmax and AUC increased with the administered dose between 1 and 4 g. No accumulation of panthenol in plasma was observed.

- **DHA**: Plasma exposure increased with dose. A 2-fold accumulation in total plasma exposure of DHA was observed after 14 days of administration, whatever the administered dose.

### 1.3. STUDY RATIONALE

F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after ECV in persistent AF patients with chronic heart failure.

The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of AF induced by burst pacing [1].

Moreover, the effectiveness of PUFAs has been proven in the following conditions:

- Prevention of AF recurrence in patients with persistent AF in co-administration with amiodarone (add on therapy) [2],

- Improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5].
Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent AF and chronic heart failure.

This phase IIa study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after ECV in patients with persistent AF and chronic heart failure.

1.4. OVERALL RISK AND BENEFIT ASSESSMENT

F373280 is a new pro-drug of DHA.

DHA is a well-known long chain PUFAs with a long-term clinical experience in cardiovascular diseases. DHA is contained in several medicinal products such as Omacor®, (1 g of Omacor contains about 320 mg of DHA acid) marketed by Laboratoires Pierre Fabre for hypertriglyceridemia and as an adjuvant treatment for secondary prevention after myocardial infarction. According to the summary product characteristics of Omacor® [9]:

- The frequencies of adverse reactions are ranked according to the following: common (>1/100, <1/10); uncommon (>1/1000, <1/100); rare (>1/10000, <1/1000); very rare (<1/10000), not known (cannot be estimated from the available data).

- The reported adverse events are:

  - Infection and infestations:
    Uncommon: gastroenteritis
  - Immune system disorders:
    Uncommon: hypersensitivity
  - Metabolism and nutrition disorders:
    Rare: hyperglycaemia
  - Nervous system disorders:
    Uncommon: dizziness, dysgeusia
    Rare: headache
  - Vascular disorders:
    Very rare: hypotension
  - Respiratory thoracic and mediastinal disorders:
Very rare: nasal dryness

- Gastrointestinal disorders:
  - Common: dyspepsia, nausea
  - Uncommon: abdominal pain, gastrointestinal disorders, gastritis, abdominal pain upper
  - Rare: gastrointestinal pain
  - Very rare: lower gastrointestinal haemorrhage

- Hepatobiliary disorders:
  - Rare: hepatic disorders

- Skin and subcutaneous tissue disorders:
  - Rare: acne, rash pruritic
  - Very rare: urticaria

- General disorders and administration site conditions:
  - Rare: malaise sensation

- Investigations:
  - Very rare: white blood count increased, blood lactate dehydrogenase increased

Moderate elevation of transaminases has been reported in patients with hypertriglyceridaemia.

Panthenol is a well-known substance with a long-term experience in medical, nutraceutic and cosmetic uses. According to the summary product characteristics of a product such as Bépanthene® (tablet indicated in alopecia) which contains panthenol (100 mg), adverse event observed are rare cases of urticaria and erythema [10]. Panthenol is metabolised in panthotenic acid, i.e. B5 vitamin.

Concerning toxicological studies performed results can support the administration of F373280 in the proposed clinical phase II study without particular alert [1].

Any safety warning was reported during a phase I study performed with F373280 administered to 84 healthy volunteers in single dose in a range between 500 mg and 16 g or in repeated dose during 28 days in a range between 1 g and 4 g. Adverse events reported and related to study treatment were minor to moderate. The adverse events were palpitations, orthostatic hypotension, dizziness, meteorism and liquid stool. Most were reported in both groups (placebo and F373280) without a dose relationship. The assessment of coagulation parameters and platelet function after
administration of repeated dose of F373280 did not report any bleeding concern: the reported changes in coagulation parameters and platelet function were within physiological ranges.

Moreover, DHA has been associated with anticoagulant products in AF studies [2, 8]. The range of PUFAs doses tested was between 2 g to 3 g (640 mg to 960 mg of DHA) and the range of study durations between 6 to 12 months. This association did not report a significant side effect of bleeding.

DHA has already been used in HF patients in several studies without safety concern [3, 4, 5]. The range of PUFAs doses tested was between 1 g to 5 g (1 g of the tested PUFAs contains about 320 mg of DHA acid) and the range of study durations was between 3 months to 3.9 years.

Thus, inclusion of patients with no specific antiarrhythmic treatment is acceptable. They will receive an anticoagulant treatment to prevent the thrombo-embolic complications of AF (particularly stroke) and the adequate treatments to control the heart rate and heart failure.

In conclusion, the overall available data allow in safe conditions the treatment of patients with persistent AF and chronic heart failure with F373280 in safe conditions.

2. STUDY OBJECTIVES

2.1. PRIMARY OBJECTIVE

The primary objective of the study is to assess the efficacy of F373280 on the maintenance of sinus rhythm after direct ECV in patients with persistent AF and chronic heart failure.

2.2. SECONDARY OBJECTIVES

The secondary objectives of the study are to assess:

- the efficacy of F373280 on the efficiency of direct ECV
- the effect of F373280 on echocardiographic parameters
- the safety and tolerability of F373280
3. ETHICAL CONSIDERATIONS RELATING TO THE STUDY

The trial is conducted according to Good Clinical Practices (CPMP/ICH/135/95), the National regulations and the Declaration of Helsinki and its subsequent amendments (see Appendix 17.1). This protocol and the informed consent form will be submitted for approval to independent local or national Institutional Review Boards/Ethics Committees before the study set up, according to national regulation.

All the protocol amendments or critical events liable to increase the risks incurred by the patients or to compromise the validity of the study or patients' rights will be submitted to the coordinator and to the Ethics Committees.

After being informed orally and in writing of all potential risks and constraints of the trial, as well as their freedom to withdraw their participation at any time, patients will then sign a consent form. A time of reflection will be given to the patients, before giving a written consent and starting the study procedures.

The use of a placebo is in accordance with EMA Addendum to the guideline on antiarrhythmics on AF and atrial flutter (EMA/CHMP/EWP/213056/2010) [21] and is acceptable because the included patients will remain under the standard treatment of AF and chronic heart failure. Except antiarrhythmics, they will receive anticoagulant (vitamin K antagonist, VKA), rate control treatment, chronic heart failure treatment. During the study, in case of AF recurrence or atrial flutter emergence that would require cardioversion or the introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms for instance, patients will be withdrawn and the tested product stopped. These patients will be considered as treatment failure.

In this study, patients will be carefully screened, particularly for their cardiac condition, with ECG, 24-hour holter monitor and echocardiographic data, and their biologic and coagulation condition.

The study will be addressed only to patients requiring an ECV due to their persistent AF, in the following conditions:

- ECV in patients not presenting a contra-indication
- Anticoagulation with vitamin K antagonist (VKA) for at least 3 weeks before ECV
- ECV will be performed in patients with AF and without dyskalemia. An INR value control must be performed within 24h before ECV. INR values ≥ 2 on the 3 last
tests performed before ECV are required. However, if only 2 INR values are ≥ 2 among those 3 last tests, an ECV can be performed if the presence of atrial thrombosis can be excluded with an ECHO–TE (transesophageal echocardiography) performed on the same day (before ECV) and the patient can continue the study. Patients who do not revert to sinus rhythm or present an early AF relapse or an early atrial flutter emergence within the observation period after ECV will be withdrawn and the tested product stopped.

During the whole study, patients will remain under medical control: visits in cardiology units will be performed throughout the study period. This follow up will include clinical signs, ECG, biological and coagulation parameters. Moreover, patient’s cardiac rhythm will be monitored once a week between visits using Trans Telephonic ECG Monitoring (TTEM) reviewed by a Central Reading Laboratory.

Patients may withdraw from the study at any time without having to give a reason and can expect to receive regular conventional therapy.

4. STUDY DESIGN

4.1. OVERALL DESCRIPTION

This phase IIa trial will be conducted as an international, multicentric, 24 weeks, double-blind, placebo-controlled, randomised, parallel group design, trial in 152 patients suffering from persistent AF and chronic heart failure.

After a 1 to 4-week of run-in period without study treatment, patients will be randomised into one of the following treatment groups: F373280 1g or placebo for 24 weeks.

Seven visits are planned for the study:

- Visit 1 (V1): W-4 to W-1: Selection visit (7 to 28 days before the Inclusion Visit)
- Visit 2 (V2): D1: Inclusion visit (start of study treatment)
- Visit 3 (V3): W4 (D28-2/+7D): cardioversion visit (outpatient or hospitalization according to clinical practice of the centre) (installation of the Holter ECG device)
- Visit 4 (V4): W5 (D35 -2/+7D): follow-up visit (removing of Holter ECG device and installation of the TTEM)
- Visit 6* (V6): W12 (D84 ± 7D): follow-up visit
  *see amendment PA05 dated 22OCT2014
- Visit 7 (V7): W16 (D112 ± 7D): follow-up visit
- Visit 9* (V9): W24 (D168 ± 7D): final study visit
  *see amendment PA05 dated 22OCT2014

4.2. DISCUSSION OF THE STUDY DESIGN

4.2.1. Choice of the Study Population

The target indication of F373280 will be the maintenance of sinus rhythm after cardioversion of patients with persistent AF and chronic heart failure. In the present proof of concept study, the evaluation will focus on patients within this indication. This target population is justified by:

- The proved efficacy of PUFAs in patients with persistent AF with or without heart failure in co-administration with amiodarone (add on therapy) [2]
- The proved efficacy of PUFAs on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]

The study aim is to investigate the product effect in patients with:

- Previous history of persistent AF with duration of the current episode from 7 days to 6 months.
- A systolic heart failure defined by a reduced left ventricular ejection fraction (≥ 30% and ≤ 45%) or for patients with a LVEF > 45%:
  - an increased left ventricular end-diastolic size (diameter ≥ 60 mm and/or > 32 mm/m² and/or volume > 97 ml/m³),
  - and/or an increased left ventricular end-systolic size (diameter > 45 mm and/or > 25 mm/m² and/or volume > 43 ml/m²),
  - and/or a reduced left ventricular outflow tract velocity time integral < 15 cm [23, 24].
According to a sub-group analysis performed in patients with persistent AF associated to heart failure (Nodari S. personal data), PUFAs would be effective to prevent recurrence of AF after cardioversion in patients with moderately abnormal LVEF.

- A Left Atrial Area (LAA) not severely abnormal (no greater than 40 cm² as defined in the report from the American Society of Echocardiography’s Guideline) [23]. According to a sub-group analysis performed in patients with persistent AF associated to heart failure (Nodari S. personal data), PUFAs would not be effective to prevent recurrence of AF after cardioversion of patients with severely abnormal LAA.

For the successful rate of ECV, patients should have a stable medical treatment of heart failure and should not have any myocardial infarction or unstable angina or unstable ischemic coronaropathy assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection.

### 4.2.2. Choice of the Study Design

As the target indication would be the prevention of AF recurrence after ECV, the study design meets the requirements of EMA guideline on antiarrhythmics in AF (EMA/CHMP/EWP/213056/2010) [21].

As F373280 aims to be a safe treatment for the prevention of AF recurrence, it will not be tested as an add-on therapy during the study. To avoid any interaction with the tested product, antiarrhythmics class I and III will be forbidden during the study.

The study design is defined in order to avoid methodological bias. A double blind study is appropriate to assess the efficacy and safety of the use of F373280 to prevent recurrence of AF episodes. Moreover, this study design is similar to the design of almost all trials that have assessed intervention for rhythm control [2, 8, 11, 12].

According to the target indication, only patients with persistent AF and requiring an ECV will be included in order to assess the time to first documented recurrence of AF (or emergence of atrial flutter) since cardioversion.

To confirm the persistent nature of AF, a 24-hour holter monitoring will be performed during the selection visit.
Eligible participants will enter a selection phase in which anticoagulant treatment (VKA) will be adjusted to achieve ideally an International Normalized Ratio (INR) of 2 to 3 before ECV. According to guidelines for the management of AF [6], VKA should be given at least 3 weeks before cardioversion because of risk of thrombo-embolism due to post-cardioversion.

Experimental data suggest that the maximal incorporation of n-3 PUFAs in the myocardial cell membrane takes up to 28 days to occur [22]. In addition, as shown in Nodari’s study [2], the duration of pre-treatment with PUFAs before cardioversion appears to be a contributing factor in success. Therefore, before starting follow up for the assessment of AF recurrence, treatment with F373280 should be started 28 days before ECV.

Detection of AF recurrence will be performed using systematic (scheduled) ECG recording, thus allowing detection of asymptomatic (about 50% of episodes) as well as symptomatic AF episodes. According to previous studies, most of AF recurrences occurred during the first days after cardioversion [11, 15]. So that, the heart rhythm will be closely monitored during the first week after successful cardioversion using an ambulatory continuous 7-day holter ECG recording in order to increase sensibility to detect asymptomatic AF episodes. Thereafter, to improve patient compliance, this follow up will be continued using an easier device to carry and to use, i.e. a TTEM.

Finally, during the study, patients will be scheduled for a clinical visit every 4 weeks or 8 weeks (with an additional visit 7 days after visit 3 (ECV visit)) in order to ensure a close medical monitoring and to assess efficacy and safety parameters.

4.2.3. Choice of the Dose

According to a previous study in patients with AF [2], the tested PUFA product (Omacor®) at the dose of 2 g (i.e. 640 mg of DHA acid) was effective in the prevention of AF after cardioversion. Moreover, PUFAs at dosage of 1 g and 2 g were also effective on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5].

From the F373280 phase I study, after a 14-day repeated administration of F373280 (1 g/day), observed plasma concentrations of DHA measured before treatment (Cmin) were similar to that of an effective dose of Omacor® at 2 g/day (60 to 95 mg/ml and 60 to 90 mg/ml, respectively) (phase I study of F373280 and [16]). With regard to the rhythm of administration, mean peak/trough
fluctuation (baseline corrected) was around 0.3. This value supports a once-daily administration allowing a 24-hour plasma exposure in DHA. Therefore, a 1 g daily dose of F373280 is considered to be appropriate for this proof of concept study.

4.2.4. Choice of the Sample Size

See chapter 13.

5. STUDY POPULATION

Each patient fulfilling all the inclusion criteria and none of the non inclusion criteria will be eligible.

5.1. INCLUSION CRITERIA

Demographic Characteristics and Other Baseline Characteristics:

1. Men or women aged more than 18 years (inclusive)
2. Patient with current episode of persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted
3. Previous history of first documented episode of persistent AF
4. Previous history of ischemic or non ischemic heart failure
5. NYHA class I or II chronic heart failure at selection and at inclusion
6. Left ventricular systolic dysfunction defined at selection and at inclusion by a reduced left ventricular ejection fraction (LVEF) ≥ 30% and ≤ 45% or for patients with a LVEF > 45%:
   - an increased left ventricular end-diastolic size
     (diameter ≥ 60 mm and/or > 32 mm/m² and/or volume > 97 ml/m²)
   - and/or an increased left ventricular end-systolic size
     (diameter > 45 mm and/or > 25 mm/m² and/or volume > 43 ml/m²)
   - and/or a reduced left ventricular outflow tract velocity time integral < 15 cm
7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers
8. Left atrial area ≤ 40 cm² at selection and at inclusion
9. Patient treated or having to be treated by vitamin K antagonist
10. For female patient of child-bearing potential:
   - **In all the countries except Italy:**
     - Use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator for at least 2 months before the selection in the study and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment or
     - Documented as surgically sterilized
   - **In Italy only:**
     - Absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
     - Use of double barrier contraception method (use of effective medical contraception method) from at least 2 months before the start of the study to the entire duration of the study and for a month after the end of the study or
     - Documented as surgically sterilized
11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion
12. For male with a child-bearing potential partner (In Italy only):
   - Absolute abstention from sexual intercourse during the whole duration of the study and for 3 months after the end of the study or
   - Use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to 3 months after the end of the study.

**Ethical/legal considerations:**
13. Having signed his/her written informed consent,
14. Affiliated to a social security system, or is a beneficiary (if applicable in the national regulation)

5.2. NON INCLUSION CRITERIA

Criteria related to pathologies:
1. No previous history of first documented episode of persistent Atrial Fibrillation
2. More than two successful cardioversions (electrical or pharmacological) in the last 6 months,
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV),
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be checked in case of treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic coronaryopathy assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
7. Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration rate < 30 ml/min) at selection
8. Bradycardia (HR ≤ 50 bpm)
9. Hyperkalemia or hypokalemia (according to the standards of local laboratories) at selection
10. Cardiac surgery within 3 months before selection or planned during the study duration

Criteria related to treatments:
11. Previously ineffective pharmacological or electrical cardioversion
12. Concomitant treatment with ranolazine or any anti-arrhythmic drug (within 7 days prior to selection), except amiodarone, dronedarone and stable dose of digoxin, beta-blockers, calcium-blockers.
13. Concomitant treatment with oral amiodarone or dronedarone from selection
14. Concomitant treatment with intravenous amiodarone from selection
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT implantation within the last 6 months
16. Treatment with any Polyunsaturated Fatty Acid within the last 3 months
17. Dietary supplement with ω3 or ω6 according to investigator’s judgment
18. Having undergone any form of ablation therapy for AF
19. Patient treated with oral anticoagulant treatment other than vitamin K antagonist: new oral anticoagulants (dabigatran, rivaroxaban, apixaban), or treated with irreversible antiplatelet agents P2Y12 inhibitors such as ticlopidine, clopidogrel or prasugrel

Others criteria:

20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion,
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection,
22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself / herself to its constraints,
23. Patient family member or work associate (secretary, nurse, technician…) of the Investigator,
24. Patient having forfeited his / her freedom by administrative or legal award or being under guardianship,

5.3. NUMBER OF PATIENTS
76 x 2 patients (taking into account 15 % of non evaluable patients).

5.4. RECRUITMENT MODALITIES
Patients will be recruited within the medical consultation of each centre involved in the study. If necessary and when authorized by local and national regulation, some specific supports or tools will be used to improve the recruitment (announcement, mailing to general practitioners, leaflet, website including ClinicalTrials.gov, CRO…).

Before implementation, the documents will be submitted to and approved by the Ethics Committee.
5.5. PATIENT IDENTIFICATION

Patient's code will contain 7 digits: the 2 first digits corresponding to the country number, the following 2 digits corresponding to the centre number and the last 3 digits corresponding to the patient's chronological order once having signed the written informed consent.

5.6. WITHDRAWAL CRITERIA

Reasons for a patient's premature withdrawal from the study may be the following:

- Patient's decision. A patient who wishes to withdraw from the study for any reason may do so at any time but must inform the investigator. In all cases, the Investigator should attempt to contact the patient as soon as possible for a final assessment in order to:
  - have the patient's decision written on the consent form
  - obtain the reason(s) for withdrawal and report it/them in the case report form
  - evaluate the patient's clinical condition
  - if necessary, take appropriate therapeutic measures: management of an adverse effect or concomitant disease, prescription of another treatment.

- Investigator's decision in the patient's interest, particularly if a serious adverse event occurs and is considered by the Investigator liable to threaten the health of the patient. The monitor will be informed by phone or fax and a letter or report explaining the withdrawal will be forwarded to the monitor as soon as possible.

- Erroneous inclusion according to the study protocol. The decision to maintain or not the patient in the study will be taken jointly by the investigator and the sponsor. Erroneous inclusions will not be paid to the investigator.

- Patients who could not be treated with VKA for at least 3 weeks before ECV or who will experience a VKA intolerance during the study.

- Patients without dyskalemia who will not have INR values \( \geq 2 \) on the 3 last tests performed before ECV should not have an ECV and will be excluded from the study. However, if only 2 INR values are \( \geq 2 \) among those 3 last tests, an ECV can be performed if the presence of atrial thrombosis can be excluded with an ECHO–TE (transesophageal
echocardiography) performed on the same day (before ECV) and the patient can continue the study.

- Patients who will not revert to sinus rhythm (i.e. unsuccessful ECV) or with early AF relapse or early atrial flutter emergence within the observation period after ECV will be considered to have finished follow-up.

- Occurrence of AF recurrence or atrial flutter emergence that would require, at the investigator’s judgement, a cardioversion or an introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms for instance.

5.7. REPLACEMENT OF PATIENTS

Withdrawn patients will not be replaced.

5.8. POST-STUDY EXCLUSION PERIOD

Patients will not be allowed to participate in another clinical trial during 3 months following the study termination.

5.9. STUDY CARD AND LETTER FOR GENERAL PRACTITIONER(S)

The patient will receive from the Investigating Centre at Visit 1 - Selection Visit:

- a personal card to be kept all along the study duration and providing the following information: patient's name, sponsor's name, study code, EUDRACT number, start date and expected end date of the study, complete address of the Investigating Centre with the name and phone number of the Investigator and a sponsor 24H/24 phone contact number in case of emergency (French and English languages): 33 (0)5 63 35 25 83. For Italy, this card will be in Italian only, without any English mention.

- in Italy, a letter to be given to his/her general practitioner. This letter intends to inform the general practitioner(s) (and any other doctors who take care of the patient) that the patient participates to the clinical study. It describes the study treatment and includes some information on the forbidden treatment during the study.
6. **STUDY TREATMENT**

The Clinical Pharmacy Department of the Institut de Recherche Pierre Fabre (IRPF) will supply the investigational centres with the treatment necessary for the conduct of the trial.

6.1. **SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT**

F373280 and placebo will be prepared in Soft Capsules similar presentation.

- **F373280**
  
  Formulation of F373280, 1 g, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: Panthenyl ester of DHA, gelatine, glycerol, titanium, dioxide, purified water.

- **Placebo**
  
  Formulation of placebo matching tested product, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: paraffin liquid, fish flavour, gelatine, glycerol, titanium, dioxide, purified water.

Placebo and F373280 capsules will be packaged in opaque blisters.

6.2. **PACKAGING AND LABELLING**

The treatment units will be packed and labelled by the Clinical Pharmacy Department of the IRPF according to European Directive and local requirements.

6.2.1. **Packaging**

Each treatment unit will be composed of 3 cases for a 12-week treatment period.

Two 12-week treatment units will contain 3 cases, each case of 4-week treatment containing: 10 blister packs of four 1 g F373280 soft capsules or 1 g placebo soft capsules each.

6.2.2. **Labelling**

Investigational Products will be labelled according to the following rules:

Labelling should comply with the local requirements for Investigational Medicinal Products.
On the treatment units and cases, the labels will bear the following indications:

a) name and address of the sponsor  
b) protocol number  
c) packaging batch number  
d) treatment number  
e) storage conditions  
f) expiry date  
g) pharmaceutical dose form  
h) route of administration  
i) quantity of dosage units  
j) direction for use  
k) legal statements:  
   - “for clinical trial only”, “keep out of the reach and the sight of children”, “please return to your doctor any unused product”, respect the prescribed dose”  

On the treatment unit, another label will be affixed with the mention of the Investigator’s name and patient’s code (completed by the Investigator).

In addition, on each case will be mentioned the case number and a detachable label will bear the following indications:

- Protocol number  
- Packaging batch number  
- Expiry date  
- Case number  
- Treatment number

On the blister pack, the label will mention the protocol number, the packaging batch number, the case number and the treatment number.

6.3. DISTRIBUTION TO CENTRE AND STORAGE
The Clinical Pharmacy Department of the IRPF will supply the Investigational Centre with the treatment units along the study according to the need, upon request triggered by the patient’s selection.
As soon as the Pharmacist or the Investigator receives the trial medication, he/she will check the contents and immediately acknowledges the receipt in the IVRS/IWRS. The copy of the acknowledgement will be kept in the Investigator’s or the Pharmacist’s file. The same procedure will be applied to all further supplies during the course of the trial.

At the time of the delivery to the Centre, the following information will be provided:

- Details of storage conditions that should be respected
- And, upon request and for the 1st delivery only, a letter of release for the Investigational Medicinal Product from the Sponsor's Qualified Person

The CRA will ensure during the monitoring visits that trial medications have been received in good conditions and the acknowledgment of receipt has been performed adequately.

Treatment units should remain intact until dispensation to the patients. They should be kept at temperature below 30°C in an appropriate lockable room only accessible to the person authorised to dispense them, under the responsibility of the Pharmacist or the Investigator.

In the case of undue delay in study execution, the Pharmacist or the Investigator should ensure that the expiry date has not been exceeded.

### 6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT

A randomisation list will be established by the Clinical Pharmacy Department of the IRPF. This list will be computer-generated with internal software. The randomisation methodology is validated by the Biometry Department before generation.

Treatments F373280 or placebo will be balanced in a 1:1 ratio.

As the treatment units are prepared for 12-week treatment periods, the Investigator will have to allocate a treatment number at inclusion visit (V2) and another one at visit 6.

For each patient, the treatment number given at visit 6 will not be the same that the one given at inclusion visit (V2).

The treatment numbers will be given through the IVRS/IWRS.

At selection visit (V1), practically, once patient’s eligibility is confirmed:

- The Investigator:
  - Contacts the IVRS/IWRS
– Answers the questions related to the patient

• The IVRS/IWRS company:
  – Confirms this information by fax/email to the Investigator
  – Fills the “Request for Delivery of Investigational Product” form and sends it by email and/or fax to the Clinical Pharmacy Department of the IRPF.

• The Clinical Pharmacy Department of the IRPF sends the corresponding treatment unit to the Investigator within 5 days from reception of the email request form.

At inclusion visit (V2), the treatment number to be allocated for the first 12-week period to the patient is given by the IVRS/IWRS.

At visit 6, the Investigator will contact again the IVRS/IWRS to obtain the treatment number for the last 12-week period of treatment.

The Investigator will dispense to the patient the 4-week treatment cases (one or two according to the visit) which label indicates the treatment number and the administration period.

6.5. DRUG ADMINISTRATION

6.5.1. Duration of Treatment

For a patient completing the study, the theoretical study treatment exposure to F373280 or placebo will be 24 weeks.

If the ECV is postponed by 1 week to allow INR stabilization, the treatment duration will be 25 weeks.

6.5.2. Dose Schedule

One soft capsule of 1g of F373280 or placebo to be taken each day during 24 weeks.

6.5.3. Route and Conditions of Administration

The soft capsules are to be taken orally. One soft capsule is to be taken each evening with the dinner during 24 weeks.
6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT

The Investigator should maintain accurate written records of drug received, dispensed, returned and any remaining treatment units, on the drug accountability form. These records should be made available for Clinical Research Associate (CRA) monitoring. The packaging of the medication should remain intact until just before the dispensation.

At each visit, the Investigator will record the number of soft capsules returned by each patient using the appropriate page of the e-CRF.

At the end of the study, all used and unused treatments including packaging should be noted, and return is organised by the CRA to the Clinical Pharmacy Department of the IRPF for destruction. A copy of the drug accountability form should be provided by the Investigator to the CRA.

6.7. RECALL OF INVESTIGATIONAL PRODUCTS

In case of recall of investigational products (decided by the Competent Authorities or the Sponsor), the Investigator will immediately be informed by the Sponsor.

The Investigator in collaboration with the Sponsor’s representatives (Study Manager, CRA) must urgently:

- Stop the delivery of the concerned investigational products to the patients.
- Inform the concerned patients that they must immediately stop taking these investigational products and bring them back.

The Study Manager/CRA organises the return of the recalled products to the Clinical Pharmacy Department of the IRPF according to the Sponsor’s procedures.

7. CONCOMITANT TREATMENTS

Any existing concomitant treatment (at selection visit), any new concomitant treatment or change in the dosage of an existing concomitant treatment during the course of the study must be noted on the electronic Case Report Forms (e-CRF). All treatments should be evaluated by the Investigator at patient’s selection, and treatment prolongation or stop during the study should be considered.
For all concomitant treatments taken during the study, the following information must be noted in the relevant section(s) of the e-CRF:

- The name of the treatment and its form
- The reason for prescription
- The route of administration
- The daily dose
- The duration of treatment.

7.1. VITAMIN K ANTAGONIST TREATMENT
VKA should be given for at least 3 weeks before ECV and continued for the whole study duration. However, VKA should be stopped in case of occurrence of VKA intolerance during the study and the patient should be withdrawn from the study. The VKA used will be left to the decision of each Investigator according to his/her local practice.

7.2. PROHIBITED TREATMENTS
- Class I and class III antiarrhythmic treatments:
  - Class I:
    - Class IA: Disopyramide, Procainamide, Quinidine
    - Class IB: Lidocaine, Mexiletine
    - Class IC: Flecainide, Propafenone
  - Class III: Dofetilide, Ibutilide, Sotalol, Amiodarone, Dronedarone.
- Ranolazine
- Any PUFA
- Any oral anticoagulant treatment other than VKA: new oral anticoagulants (dabigatran, rivaroxaban, apixaban), or irreversible antiplatelet agents P2Y12 inhibitors such as ticlopidine, clopidogrel or prasugrel
- Dietary supplement with Omega 3 or Omega 6
Prohibited treatments at selection must not be prescribed for the duration of the study except in case of occurrence of an adverse event or AF episode that requires a corrective treatment in the interest of the patient’s health.

7.3. AUTHORISED TREATMENTS
Other treatments will be authorised during the study duration.

However, if medication other than study drugs is administered at any time from the start of the study, details must be recorded in the e-CRF. During the study, patients must be asked whether they have been on a course of prescribed drug treatment or have taken any OTC or herbal drugs since the visit.

8. EVALUATION CRITERIA

8.1. PRIMARY EFFICACY CRITERION

8.1.1. Time to the first Atrial Fibrillation Recurrence or Atrial Flutter Emergence

8.1.1.1. Definition
Time to first AF recurrence or atrial flutter emergence is defined by the time to first episode of AF or atrial flutter (symptomatic or not) lasting for at least 10 minutes.

8.1.1.2. Schedule
The heart rhythm follow up will be performed from the end of ECV visit (visit 3) to the final study visit (visit 9).

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF or the emergence of atrial flutter will be assessed after visit 3 (from week 5).

8.1.1.3. Evaluation Methods

- 7-day holter monitor:
The heart rhythm monitoring will be carried out from visit 3 to visit 4 using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) fixed after ECV visit.

Following holter monitoring, the heart rhythm will be documented using Trans Telephonic ECG Monitoring (TTEM).

- **Trans Telephonic ECG Monitoring:**
  The ECG follow up will be documented using the TTEM: one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24, end of study). The patient will be requested to contact the Central Reading Laboratory for transmission of each stored TTEM.

Moreover, if patient experiences AF or atrial flutter symptoms during this TTEM period, it should be documented using the TTEM.

In case of AF recurrence or atrial flutter emergence and provided that the patient does not require a cardioversion or an introduction of an anti-arrhythmic at Investigator’s judgement, the patient could be maintained in the study with the treatment in order to assess a spontaneous cardioversion. For that purpose the patient will continue to transmit a TTEM once a week.

- **Process of centralisation of ECG (Holter and TTEM)**
  ECG (Holter and TTEM) will be centralized by the Central Reading Laboratory. The ECG will be validated by a trained technician, then analysed by a cardiologist. The cardiologist interpretation will be emailed to the site (or per fax on request of the site). The investigator will be asked to review and sign these documents.

The Holter and TTEM process will be fully described in separate documents.

### 8.2. SECONDARY EFFICACY CRITERIA

#### 8.2.1. Numbers of AF episodes in the first week following visit 3 (ECV visit)

**8.2.1.1. Definition**
Number of AF episodes will consist in the assessment of AF episodes with duration at least 10 minutes ($N_{\text{Sup10}}$) and of less than 10 minutes ($N_{\text{Inf10}}$), respectively.
8.2.1.2. **Schedule**
The heart rhythm follow up will be performed from the end of successful ECV visit (visit 3) to the study visit 4.

8.2.1.3. **Evaluation Methods**
- 7-day holter monitor:
The heart rhythm monitoring will start using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) after ECV visit from visit 3 to visit 4.

8.2.2. **Duration of AF episodes in the first week following visit 3 (ECV visit)**

8.2.2.1. **Definition**
Duration of AF episodes will consist in the sum of duration of each AF episode.

8.2.2.2. **Schedule**
The heart rhythm follow up will be performed from the end of successful ECV visit (visit 3) to the follow up study visit (visit 4).

8.2.2.3. **Evaluation Methods**
Duration of AF episodes will be assessed using the 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording.

8.2.3. **Clinical parameters evaluation**

8.2.3.1. **EHRA score assessment**

8.2.3.1.1. **Definition**
AF related symptoms will be evaluated by the EHRA (European Heart Rhythm Association) score [20]. The following items “during presumed arrhythmia episodes” are checked to determine the score: palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety.

Classification of AF-related symptoms (EHRA score) are as follows:
• EHRA I - ‘No symptoms’
• EHRA II - ‘Mild symptoms’; normal daily activity not affected
• EHRA III - ‘Severe symptoms’; normal daily activity affected
• EHRA IV - ‘Disabling symptoms’; normal daily activity discontinued

This classification relates exclusively to the patient-reported symptoms.

In addition to this score, the frequency will be classified in three groups, namely occasionally (less than once per month), intermediate (1/month to almost daily) and frequent at least daily.

8.2.3.1.2. **Schedule**
EHRA evaluation will be performed in case of evocative symptoms of arrhythmia.

8.2.3.1.3. **Evaluation Methods**
EHRA evaluation will be collected by Central Reading Laboratory during TTEM period.

8.2.3.2. **Time to first AF recurrence less than 10 minutes**
Time to first AF recurrence less than 10 minutes will be assessed during TTEM period.

8.2.3.3. **Recurrence of symptomatic AF**
Recurrence of symptomatic AF will be assessed during TTEM period.

The number of recurrences of symptomatic AF consists of the number of AF recurrences associated with a symptom (palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety) and confirmed by an ECG.

The time to first symptomatic AF recurrence is defined by the time to first episode of symptomatic AF.

8.2.3.4. **Number and duration of hospitalizations**

• Number and duration of hospitalizations for cardiovascular events
  – Hospitalization for AF treatment
– Hospitalization for worsening of heart failure
– Hospitalization for myocardial infarction
– All cause of hospitalization

• Number and duration of hospitalizations for thromboembolic stroke

8.2.4. Cardioversion assessment

• Assessment of spontaneous cardioversion before visit 3
• Assessment of successful cardioversion at visit 3 (i.e. return to sinus rhythm)
• Shocks distribution (1, 2 or 3 shocks)
• Number of patients needing another cardioversion after initial ECV

8.2.5. Evolution of echocardiographic parameters

8.2.5.1. Definition
The following echocardiographic parameters will be assessed: Left atrial diameter (mm), LAA (cm²), Left atrial volume (ml), Left atrial volume/BSA (ml/m²), LVEF (%), Left ventricular end diastolic volume/BSA (ml/m²), Left ventricular end systolic volume/BSA (ml/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (ml), Left ventricular end systolic diameter (mm) and Left ventricular end systolic volume (ml).

8.2.5.2. Schedule
Measurements will be performed at visit 1 and visit 2 to check the eligibility of the patient. Measurements performed at visit 4, visit 6 and visit 9 are done to follow the echocardiographic evolution of the patients in sinus rhythm.

8.2.5.3. Evaluation method
The echography evaluations will be carried out according to the recommendations for chamber quantification drawn up by the American Society of Echocardiography and the European
Association of Echocardiography [23]. So, the recommended method for volume measurements is to use the biplane method of discs (modified Simpson’s rule) from 2-D measurement.

8.3. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA

8.3.1. Definition
Because of the limited human tissue accessibility for biopsy, red blood cell DHA contents is a marker of tissue DHA concentration [13], [14].

8.3.2. Blood samples

8.3.2.1. Collection schedule
Blood samples will be collected to determine the red blood cells (RBC) concentrations of DHA. Blood samples will be performed at visit 2 before treatment, visit 3, visit 6 and visit 9. Actual sampling times will be individually reported in the e-CRFs.

8.3.2.2. Technical handling
Two blood samples (2 x 4 ml) will be collected in EDTA tubes. They will be homogenized slowly by inverting the tube without shaking, stored between +2°C/+8°C in a fridge (no freezing will be allowed) and sent to Analytical Centre in refrigerated conditions (between +2°C and +8°C). Analysis will be performed within 2 weeks following reception at the Analytical Centre.

8.3.3. DHA concentration measurement
Analytical determination of RBC concentrations of DHA will be carried out by the Analytical Centre.
Lipids will be extracted from red blood cells samples with a mixture of hexane/isopropanol after acidification [17]. Total lipid extracts will be saponified and methylated. The fatty acid methyl esters (FAME) will be extracted and analyzed by Gas Chromatography.
Identification of FAME will be based on retention times obtained for FAME prepared from fatty acid standards. The area under peaks will be determined using ChemStation Software (Agilent)
and results will be expressed as % of total fatty acids. DHA concentration will be calculated using the internal standard and expressed as µg/g for red blood cells samples. Thus, omega-3 index will be assessed. The omega-3 index represents the content of EPA plus DHA in red blood cells (expressed as a percent of total fatty acids). It is a biomarker considered as a new marker of risk for death from coronary disease [18].

Results of this analytical determination will be kept confidential by the dosing centre until the end of the study, and will be provided only at the end of the study (after database lock) in a separate file.

8.4. SAFETY ASSESSMENT

8.4.1. Adverse Events
At selection, any concomitant disease will be reported on the e-CRF. At each further visit, the occurrence of AEs since the last visit will be based on the patient's spontaneous reporting, the Investigator's non-leading questioning and his/her clinical evaluation. All AEs will be reported on the e-CRF (see section 10).

8.4.2. Laboratory Investigations

8.4.2.1. Schedule
Laboratory investigations will be performed at visit 1 (before treatment) and visit 9 (end of treatment) or End of Treatment visit.
At visit 3 and 6, only a standard haematologic dosage will be performed.
Furthermore the kalemia will be checked before electrical cardioversion at visit 3.
The total volume of blood samples taken for haematology and biochemistry analysis should not exceed 30 ml.

8.4.2.2. Technical Procedures and Parameters
The following tests will be performed:
Haematology: hematocrit, haemoglobin, RBC count, white blood cells (WBC) count, WBC differential counts (% and/or absolute), reticulocytes, platelets.

Biochemistry: sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatine phosphokinase (CPK), fibrinogen.

Blood samples will be taken in the morning in fasting conditions.

The estimation of GFR at selection relies on the measurement of serum creatinine and the Cockcroft-Gault formula:

Cockcroft-Gault formula

- with serum creatinine expressed as mg/L:

  in men:
  GFR (ml/min) = \[\frac{(140-\text{age}) \times \text{weight}}{(7.2 \times \text{serum creatinine in mg/L})}\]

  in women:
  GFR (ml/min) = \[\frac{(140-\text{age}) \times \text{weight}}{(7.2 \times \text{serum creatinine in mg/L}) \times 0.85}\]

- with serum creatinine expressed as μmol/l:
  GFR (ml/min) = \[\frac{(140-\text{age}) \times \text{weight}}{\text{serum creatinine in μmol/l} \times k}\], where k = 1.23 for men, 1.04 for women.

(\text{weight in kg, age in years})

Additional tests may be done at the Investigator’s discretion, in the patient’s interest. In case of any abnormal and/or clinically significant results, the Investigator should order laboratory control tests.

8.4.3. Global Physical Examination

A global physical examination including the measurement of body weight will be carried out on each body system at visit 1, visit 2, visit 3, visit 6, visit 7, and visit 9.
The Body surface area (BSA) will be calculated at the same visits using Mostellers’ formula:

\[ \text{BSA} = \left(\frac{\text{Weight} \times \text{Height}}{3600}\right)^{1/2} \]

(Weight in kg, height in cm)

The physical examination will be globally evaluated as “normal/abnormal”. Further target inspection will be undertaken for any abnormal finding.

8.4.4. Vital Signs

Vital signs will consist in blood pressure and heart rate at rest.

8.4.4.1. Schedule

Vital signs will be measured at each visit.

8.4.4.2. Technical Procedure and Parameters

Systolic blood pressure (SBP) and diastolic blood pressure (DBP), expressed in mmHg, will be measured after at least 5 minutes in supine position and after 2 minutes in standing position.

The heart rate (HR), expressed in beats per minute (bpm), will be measured by auscultation by counting the beats for at least 30 seconds, after at least 5 minutes in supine position and after 2 minutes in standing position.

Bodyweight will be measured with patient in underwear and with the same balance at each visit.

8.4.5. Electrocardiogram (ECG)

8.4.5.1. Schedule

An ECG will be recorded after at least 10 minutes of rest at visit 1, visit 2, visit 3, visit 6, visit 7, and visit 9 using a usual standardised 12-lead cardiograph.

8.4.5.2. Technical Procedure and Parameters

- Electrocardiogram:

  The global interpretation from manual reading (normality, clinical relevance) and HR (bpm), PR (ms), QRS (ms), QT (ms), QTcB (ms), QTcF (ms), repolarisation patterns will be reported in the
e-CRF. Each print-out will include the patient’s code, date, time, technician's initials and investigator's signature.

In case of thermic paper ECG print out, a photocopy will be made by the centre to ensure safe filing.

- 24 hour-Holter - ECG

An ambulatory continuous 24-hour ECG (5-leads/2 or 3 channels) will be recorded at selection visit using a holter ECG, in order to confirm persistent AF.

8.4.6. Coagulation parameters

Coagulation assessment will be evaluated by the following parameters:

- Prothrombin Time/INR (PT/INR)
- Activated Partial Thromboplastin Time (aPTT)
- Thrombin Clotting Time (TCT)

The recommendations for the controls of INR are the following [25, 26]:

1) During the pre-cardioversion period, if the anticoagulation by VKA has to be initiated, the treatment must be initiated at least 3 weeks prior to cardioversion then the INR will be monitored as follow:
   - The adjustment of the dosage of VKA should be performed stepwise by controlling INR 2 to 3 times a week until stabilization within the target range (2 - 3) on 2 successive tests.
   - When the INR is within the target range (2 - 3) on 2 successive tests, the dose of VKA should be maintained. Then the controls of INR will be progressively spaced within a few weeks.
   - When INR is stabilized, at least one test should be performed each week.
   - In all cases, an INR control must be performed within 24 h before ECV.

2) During the pre-cardioversion period, if the anticoagulation by VKA was already initiated, the INR will be monitored as follow:
   - One INR per week up to ECV
   - An INR control must be performed within 24 h before ECV

3) After cardioversion : one INR every 4 weeks

4) Throughout the duration of the study if INR > 3 the advocated actions are:
- No transesophageal echocardiography before cardioversion
- For asymptomatic patients:
  - $3 < \text{INR} < 4$: no omission of VKA (dose adjustment if required), no vitamin K
  - $4 \leq \text{INR} < 6$: omit one dose of VKA, no vitamin K
  - $6 \leq \text{INR} < 10$: interrupt VKA, vitamin K 2 mg orally
  - $\text{INR} \geq 10$: interrupt VKA, vitamin K 5 mg orally

For INR $\geq 6$, an adverse event has to be reported (asymptomatic overdose).

Anti-coagulation by VKA should be given at least 3 weeks before ECV and continued for the whole study duration.

aPTT and TCT will be performed at visit 1, visit 2, visit 3, visit 6, visit 7, and visit 9.

The quantity of blood samples collected at each time for coagulation parameters will be 2 ml. Additional tests may be done at the Investigator’s discretion, in the patient’s interest. In case of any abnormal and/or clinically significant results, the Investigator should order laboratory control tests.

### 8.5. CONCOMITANT TREATMENTS

Concomitant treatments will be evaluated at each study visit.

Requirements related to patient's concomitant treatments started before selection visit and continued throughout the trial, or started during the trial, can be found in section 7.

### 8.6. COMPLIANCE

The patient will be reminded at each visit to bring back at the following visit any used or unused remaining soft capsule, blister and case.

At each visit (except at visit 4), the Investigator will record the number of supplied and remaining soft capsules in the e-CRF.

### 9. STUDY PROCEDURES

Visit 1 - Selection Visit (Week - 4 to Week -1):
The patient considered eligible for selection by the Investigator will be informed of the characteristics and the consequences of the trial both verbally and by reviewing the patient's information sheet and consent form (see section 14.3). If the patient accepts to participate in the study, he/she will sign the informed consent form and will keep a copy.

The patient will be assessed for the following:

- Demographic characteristics (gender, age, height, body surface area)
- Personal and medico-surgical history
- Habits (Tobacco, alcohol consumption, dietary habits including fish consumption…)
- Cardiovascular diseases, mainly detailed history of Heart Failure and AF characteristics
- Echocardiography using a two-dimensional echocardiography
- 12-lead ECG
- Concomitant diseases, adverse signs or symptoms (able to be used for treatment emergent AE determination)
- Concomitant treatments (authorised, disallowed)
- Global physical examination/bodyweight
- Vital signs
- Biology: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Biology assessment of renal function: creatinine or estimated glomerular filtration rate

If the results of the above assessments are compatible with the selection criteria:

- A 24-hour continuous ECG ambulatory recording (Holter ECG) device will be installed on the patient to monitor the patient heart rhythm. The patient will be requested to bring back the device after the termination of 24 hours recording. The recording will be transmitted from the Investigational site to the Central Reading Laboratory. The Central Reading Laboratory will send his/her assessment regarding the confirmation of persistent AF within 2 working days to the Investigator.
The patient will enter the selection and pre-cardioversion periods in which anticoagulant (VKA) will be adjusted to achieve ideally an International Normalized Ratio (INR) in the range of 2 to 3 before ECV.

At the end of the visit, the Investigator will contact the IVRS/IWRS to confirm the patient selection (which will automatically order the treatment delivery) and organise the appointment for the next visit.

The patient will receive from the investigational centre the participant card to be kept for all the duration of the study.

Visit 2 - Inclusion Visit (Day 1):

If the patient's behaviour during the selection period and/or the result of complementary examinations, particularly the confirmation of the presence of persistent AF by the Central Reading Laboratory during this period and the laboratory tests, are compatible with the inclusion criteria, the patient will be assessed for the following:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: red blood cell concentrations of DHA and coagulation parameters Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Global Physical examination/bodyweight
- Vital signs
- Echocardiography using a two-dimensional echocardiography
- 12-lead ECG
- Urine pregnancy test for women of child bearing potential

If the results of the above assessments are compatible with the inclusion criteria, the patient will be included and the investigator will contact the IVRS/IWRS to obtain the treatment unit number to be dispensed at visit 2 for the first 12-week period.

Between this Inclusion visit and the next visit (V3), the INR will be closely monitored (refer to paragraph 8.4.6) in order to fulfil the ECV conditions (refer to paragraph 3).
At the end of the visit, the Investigator will organise the appointment for the next visit and will give the treatment for the next 4-week period (one case of treatment).

**Visit 3 (Week 4: D28 -2/+7 days) cardioversion:**

Patient will be assessed for the following criteria:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: Haematology, RBC concentrations of DHA, Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Global Physical examination /bodyweight
- Vital signs
- 12-lead ECG
- Electrocardioversion (ECV): ECV has to be performed 4 weeks after randomization in patients with AF. ECV will be performed in the morning, with the patient in the fasting state and without dyskalemia. An INR value control must be performed within 24h before ECV. INR values ≥ 2 on the 3 last tests performed before ECV are required. However, if only 2 INR values are ≥ 2 among those 3 last tests, an ECV can be performed if the presence of atrial thrombosis can be excluded with an ECHO–TE (transesophageal echocardiography) performed on the same day (before ECV) and the patient can continue the study. Anesthesia will be induced and patients will be cardioverted with administration of a synchronized, biphasic current. The initial shock will be set at 100 J if the body weight is less than 70 kg and at 150 J for higher body weights. Successful cardioversion will be defined as recovery of sinus rhythm lasting at least 1 minute after the shock. If unsuccessful, a second 200-J shock, and eventually a third 200-J shock, will be administered. Failure of ECV is defined as the persistence of AF after the third attempt at cardioversion. After the procedure, patients will be monitored on telemetry for at least 6 hours before discharge.
Patients who will not revert to sinus rhythm or with early AF relapse or early atrial flutter emergence within the observation period after ECV will be withdrawn from the study and will be considered to have finished their follow-up.

At the end of the visit, a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) will be installed on the patient in order to monitor the patient heart rhythm after ECV.

The Investigator will collect all unused cases, blisters and soft capsules, and will count the unused capsules for each 4-week treatment period.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 8-week period (two cases of treatment).

Visit 4 (Week 5: D35 -2/+7 days):
After removal of the continuous ECG ambulatory device, the patient will be assessed for the following criteria:

- Assessment of AE
- Concomitant treatments (authorised, disallowed)
- Bodyweight (bodyweight measured at V3 to be used)
- Vitals Signs
- Echocardiography using a two-dimensional echocardiography

At the end of the visit, the patient will be given the TTEM device for cardiac monitoring. The patient will be clearly instructed on the frequency and modalities of transmission. The patient will be requested to perform one transmission per week from this visit (initial call to perform with the patient) to the visit 9 (week 24 – end of study). Moreover, in case of AF or atrial flutter symptoms, additional transmissions may be performed.

Visit 6* (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days):
*see amendment PA05 dated 22OCT2014
Patient will be assessed for the following criteria:

- Adverse events
• Concomitant treatments (authorised, disallowed)

• Laboratory examination: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT). However, in case of discontinuation of anticoagulation after ECV due to occurrence of VKA intolerance, the monitoring of INR, aPTT and TCT should be stopped.

• Global Physical examination/bodyweight

• Vital signs

• 12-lead ECG

• The cardiac monitoring will be continued using the TTEM device through one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24, end of study). Moreover, in case of AF or atrial flutter symptoms, additional transmissions may be performed.

The Investigator will collect all unused cases, blisters and soft capsules, and will count the unused capsules for each 4-week treatment period.

In addition, at visit 6:

• the investigator will contact the IVRS/IWRS to obtain the treatment unit number to be dispensed at visit 6 for the last 12-week period.

• an echocardiography will be performed, an haematology examination will be done and the RBC concentration of DHA will be measured.

At the end of each visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next treatment period: one case at visit 6 and two cases at visit 7.

Visit 9* - End-of-Study Visit (Week 24: D168 ± 7 days):

*see amendment PA05 dated 22OCT2014

Patient will be assessed for the following:

• Adverse events

• Concomitant treatments (authorised, disallowed)

• Global Physical examination/bodyweight
• Vital signs
• 12-lead ECG
• Laboratory examination: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT), Red blood cell concentration of DHA.
• Urine pregnancy test for women of childbearing potential
• Echocardiography using a two-dimensional echocardiography

The Investigator will collect all unused cases, blisters and soft capsules, and will count the unused soft capsules.

The total volume of blood collected should be about 90 ml for the study duration (30 ml for the total volume of haematology and biochemistry, 2 ml for each blood samples for coagulations parameters and 4 ml for each blood samples of DHA).

10. ADVERSE EVENTS: DEFINITION AND REPORTING

10.1. ADVERSE EVENTS

10.1.1. Definition of Adverse Events

An AE is any adverse change from the patient's baseline condition, i.e. any subjective signs and symptoms or change in a concomitant disease present at the Selection Visit considered or not related to the treatment.

AE includes intercurrent signs, symptoms, illnesses and significant deviations from baseline for vital signs and laboratory values which may occur during the course of the clinical study.

All laboratory tests for which abnormal results are collected after study treatment initiation should be repeated until the values return to normal or to a stable status. Abnormal results are defined as those falling out of the laboratory normal ranges and that are clinically significant. The frequency of such checks should be defined by the Investigator according to the degree of abnormality.
In all cases, the aetiology should, as much as possible, be identified and Pierre Fabre Médicament notified.

10.1.2. Grading of Adverse Events

Adverse or intercurrent events are graded as follows:

- **Mild**: awareness of signs or symptoms, but easily tolerated
- **Moderate**: uncomfortable enough to cause interference with usual activity
- **Severe**: incapacity with inability to work or do usual activity

10.1.3. Reporting of Adverse Events

The records of AE in the e-CRF describe the nature (diagnosis, signs and symptoms), severity, onset date, stop date, outcome and actions taken, and relationship to study treatment (in the Investigator's opinion). It must be specified whether the event is serious or not.

10.2. SERIOUS ADVERSE EVENTS (SAE)

10.2.1. Definition

A SAE includes, but is not necessarily restricted to, any event which:

- Results in death (whatever may be the cause)
- Is life-threatening
- Results in persistent or significant disability/incapacity
- Requires the patient's hospitalisation or prolongation of current hospitalisation *
- Is a congenital anomaly or birth defect

Other events such as cancer and any additional adverse experience or abnormal laboratory values occurring during the study period, defined by the protocol as serious or which the Investigator considers significant enough or that suggest a significant hazard, contra-indications, side effect or precaution, must be handled as serious adverse events.

Any overdose meeting a seriousness criteria should be reported as a SAE (see section 10.3).
Any pregnancy occurring during/after exposure to the study drug(s) should be reported on the SAE notification form (see section 10.4).

* any hospitalisation, or prolongation of hospitalisation due to the circumstances listed below:
  - planned (as per protocol) medical/surgical procedure
  - preparation for routine health assessment/procedure (e.g. routine colonoscopy)
  - planned medical/surgical admission (planned prior to entry into study trial, appropriate documentation required)
  - administrative or social reasons (e.g. lack of housing, economic inadequacy, care-giver respite, family circumstances)

will not be reported as a SAE.

10.2.2. Reporting of SAE

All Serious Adverse Events, according to the above-mentioned definitions and regardless of treatment or relationship to study drug, and occurring once the informed consent form has been signed, must be reported by the Investigator as soon as he/she is informed of the event.

The Investigator must notify the Sponsor of this event by sending, within 24 hours, the "Notification of serious adverse event" form ("first notification") with all the available information about the event (see appendix 17.2), to the Sponsor's Corporate Vigilances e-mail dedicated box:

HQ.pharmacovigilance@pierre-fabre.com

In case it is not possible to send the report by e-mail it can be sent by FAX at the following number:

+ 33 1 49 10 80 90

In case of non-inclusion, the reporting period ends when the non-inclusion is documented.

10.2.3. Follow-up of SAE

The Investigator must draw-up a specific clinical report and use the "Notification of serious adverse event" form ("follow-up") (see appendix 17.2) and collect the results of the carried out examinations and the reports of hospitalisation.
The serious adverse events must be followed up until resolution or stabilisation.

10.2.4. SAE Occurring After the Study
Any SAE occurring during 30 days following the end of the study for the patient should be notified to the Sponsor.

Must also be notified to the Sponsor any event occurring at any time after the end of the study for the patient which may be related to the study treatment in the Investigator's opinion.

10.3. REPORTING OF OVERDOSAGE TO THE SPONSOR
For the purpose of this trial, an overdosage will be defined as any dose exceeding the planned prescribed dose of the study drug or the administration of any dose of an associated product that is considered both excessive and medically important.

In the absence of seriousness criteria, the overdosage and associated adverse event if any, are reported only on the Adverse Event page of the e-CRF. If the definition of seriousness criteria is met, the SAE notification form must also be transmitted to the Sponsor.

10.4. REPORTING OF PREGNANCY TO THE SPONSOR
Pregnancies discovered in the period in between the informed consent form signed but before any study drug exposure are not to be reported to the Sponsor unless associated to a seriousness criteria (e.g. serious adverse event study-protocol related procedure). If pregnancy is confirmed, the women must not be administered the study drug and must be withdrawn immediately from the study.

If pregnancy is suspected while the patient is receiving study treatment, the study drug should be discontinued immediately until the result of the pregnancy testing is known. If pregnancy is confirmed, then the study treatment is permanently discontinued in an appropriate manner and the patient is withdrawn from the study.

The Investigator must report to the Sponsor any pregnancy which occurs during or after the patient has been exposed to the study drug and until 30 days after the last study drug administration. The Investigator must immediately notify the Sponsor using the SAE notification form and also report the pregnancy on the AE page of the e-CRF.
Women who become pregnant after exposure to the study drug must be followed by the Investigator until the completion/termination of the pregnancy. If the pregnancy goes to term, the outcome will have to be reported to the Sponsor (baby's healthy status).

10.5. SPONSOR'S RESPONSIBILITIES FOR SAFETY REPORTING

PURPOSES
Sponsor will submit expedited and periodic reports to both Competent Authorities and Ethics Committees per corporate standard operating procedures as regards to the EU directive 2001/20/EC taking into account local specific requirements.

11. DATA COLLECTION AND STUDY MONITORING

11.1. DATA COLLECTION

11.1.1. Case Report Form
An e-CRF will be used to record all patient data required by the protocol except the central ECG (Holter ECG, TTEM) and DHA data which will be transferred from vendors to the subcontractor as electronic data files that will be loaded into the study database.

The e-CRF should be fully validated, compliant with ICH-GCP requirements and European regulations and should include a traceability system for data corrections and deletions (audit trail).

Prior to the start of the study, the Investigator will complete a "Delegation of significant study-related duties" form. The signature and initials of all personal in charge of e-CRF completion should be recorded on this form. Each person involved in e-CRF completion, review, correction and/or validation will be trained and will have an individual login and access code to the e-CRF. Training sessions will be held by the subcontractor for all participants using this tool. An e-CRF user manual will be available for investigators and CRAs.

All the information included into the e-CRF will be recorded from source documents onto the e-CRF by an authorised person.
The Investigator is responsible for the management and accuracy of the information on the e-CRF. At each monitoring visit, the e-CRF(s) should be at the CRA's disposition for review and validation.

At the end of the study, a CD-ROM containing the pdf version of all e-CRFs (including audit-trail) will be sent by the subcontractor to the Sponsor and to the investigational sites for archiving. The subcontractor must store all study data for at least 15 years after the end of the study and ensure their legibility and accessibility during all the storage period.

11.1.2. Source Documents
A source document is an original record or certified copy of an original record of clinical findings, observations or any other medical or paramedical activities performed during the clinical trial, necessary for the transcription and the verification of the collected data.

Source documents along with all other trial-related documents (copies of all "informed consent" forms, e-CRFs CD-ROM, drug inventories and any correspondence related to the study) must be kept in the investigator's file throughout the study, and then, must be stored in the study centre's archives for a period of at least 15 years or as per local legal requirements, whatever is the longest.

For further details see section 15.2.

11.2. STUDY MONITORING

11.2.1. Monitoring visits
On-site visits will be carried out by a representative of the Sponsor's staff (Study Manager or CRA) prior to study initiation and at regular intervals (every 4 to 6 weeks) throughout the study. Additional visits and communication by telephone fax or meeting may be performed if necessary. Any site visit performed by the Sponsor's representatives will be recorded in the Investigator's study file.
11.2.1.1. **Site Preselection Visit**

Before selecting a centre for the study, a visit will be carried out by the CRA and/or the Study Manager to ensure that the Investigator has the necessary capacities (availability, patient's recruitment, environment), technical means and staff to carry out the study.

11.2.1.2. **Initiation Visit**

Before the start of the study at all investigational sites, an initiation visit will be carried out by the CRA to check at the latest that:

- The Investigator:
  - has received the technical protocol, administrative and financial agreement signed by all parties
  - has received the written statement of the Ethics Committee approval and the list of its members and their functions
- The original dated and signed *curriculum vitae* of the investigator(s) has been collected
- Laboratory normal ranges have been collected
- All study materials are available on the study site
- All participants agree with the monitoring procedures and know the study procedures
- All participants are aware of a possible audit or inspection

The CRA has also to provide training on the study protocol requirements and study specific procedures.

11.2.1.3. **Follow-up Visits**

Throughout the study, regular follow-up visits will be carried out by the CRA to check compliance with GCP, patient's informed consents, strict application of the protocol, conformity of the data entered on the e-CRF with the source documents and ensure its correct completion, adverse events reporting, proper retention, storage and management of the study medication, as well as the source and other trial-related documents.
11.2.1.4. Closing Visit

At the end of the study, a final visit will be carried out by the CRA to:

- Verify that the e-CRFs CD-ROM with pdf files are correctly stored
- Control the accountability of intact and used treatment units and return them to the Clinical Pharmacy Department of the IRPF for destruction
- Obtain the last data clarifications and/or solutions if any
- Collect the patient's consent forms in sealed envelopes (except in case of specific country requirements),
- Make an on-site review of all study documentation and complete it if necessary
- And finally, remind the Investigator of his regulatory obligations, study document archiving process and duration.

11.2.2. Direct Access to Source Documents

In accordance to the requirements of the GCP, all Sponsor representatives (Study Manager, CRA and Auditors) have to be given a direct access to all source and study data to perform quality monitoring/audit, thus ensuring accuracy and completeness of data).

Investigators are reminded that all Sponsor representatives keep professional confidentiality with regards to the patient data.

11.3. INDEPENDENT DATA MONITORING COMMITTEE

An Independent Data Monitoring Committee (IDMC) will be established to assess at intervals the progress of the clinical trial, the compliance with the inclusion criteria, the quality of follow up, the quality of primary end point measures, the safety data. The IDMC will thereafter recommend to the Sponsor whether to continue, modify, or stop the study.

The IDMC operating procedures will be described in an independent document.
12. DATA MANAGEMENT

All clinical data related to the study will be collected and saved in a computerised database by the Data Management Department of the subcontractor and under the supervision of the Data Manager of Pierre Fabre Biometry (PFB) according to the following procedures.

12.1. DATA ENTRY

All required data will be collected by the Investigator or authorised designee (duly identified into the delegation task list) on the e-CRFs.

The e-CRFs used for this study will be developed and maintained by the Data Management Department of the subcontractor and approved by the Sponsor.

Electronic data (Holter ECG, TTEM and DHA) will be transferred by the 3rd party vendor according to the specifications given by the Data Manager of the subcontractor. These data will be captured and handled in accordance with the European GCP ICH E6 guideline.

12.2. DATA CLEANING

The subcontractor will define in the Data Validation Plan for reviewing and querying data, descriptions of both manual and electronic edit checks. Upon Sponsor approval, the subcontractor will program the checks.

The subcontractor will review the data over the course of the study, working with the Sponsor to identify data inconsistencies. The Investigator will be asked to resolve queries by making changes directly into the e-CRF.

12.3. DATA CODING

Adverse events, concomitant diseases, medical/surgical histories will be coded by the subcontractor using the MedDRA dictionary (latest version in use).

Concomitant medication will be coded by the subcontractor using the WHO-DRUG dictionary (latest version in use).

The Sponsor Clinical Development Physician will validate the coding.
12.4. DATA STORAGE
Computer data files as well as their modifications will be archived by the subcontractor and kept available upon request of the Sponsor.

12.5. DATABASE LOCK
The validated database will be locked by the subcontractor upon request of the Data Manager of PFB following the completion of all steps required, i.e. data entry and check of all data, resolution of all queries, validation of the coding, Clinical and Products Safety databases reconciliation and validation committee.
Then, the subcontractor will transfer the locked database in SAS format to the Data Manager of PFB who assume storage on the PFB secured server.

13. STATISTICAL ANALYSIS
After the database lock and the randomisation code release, the statistical analysis will be performed by PFB or under the supervision of the statistician of PFB using SAS® software, according to the Statistical Analysis Plan approved by the Validation Committee.

13.1. GENERAL CONSIDERATIONS
The main objective of the study is to assess the efficacy of F373280 versus placebo on the maintenance of sinus rhythm after direct ECV in patients with persistent AF and chronic heart failure.
Only the primary analysis of the primary efficacy criterion, on which is based the sample size justification, may lead to a causal interpretation. All other statistical results are to be regarded within a descriptive perspective.
The statistical significance level of the various two sided tests of all analyses will be 5%.

13.2. SAMPLE SIZE
Assuming an AF recurrence or atrial flutter emergence rate of 85% under placebo and 65% under active group, i.e. a clinically relevant difference $\Delta$ of 20%, a sample size of 64 assessable patients
per group is required, using a log-rank test of survival curves with a 80 % power and a 5 % two-sided significance level.

According to the previous assumptions and assuming a rate of not assessable patients of 15%, a minimum of 76 patients will have to be randomised per group.

13.3. PROTOCOL DEVIATIONS

Prior to the database lock and the randomisation code release, the Validation Committee members will review the protocol deviations and will classify them as either minor or major. A protocol deviation will be considered major when it is likely to bias significantly the treatment effect estimate based on the primary efficacy criterion.

Patients with major deviation(s) will be excluded from the Per Protocol data set (see section 13.4).

A listing of all protocol deviations will be provided for all randomised patients, including the type (major/minor) of protocol deviations according to the decisions made by the members of the Validation Committee.

The number and percentage of patients with major protocol deviations will be tabulated by treatment group and type of major protocol deviations on the Full Analysis Set defined in section 13.4.

13.4. DATA SETS ANALYSED

The following 3 data sets will be analysed (as defined by the Validation Committee):

- The Safety Set composed of all randomised patients having received at least one dose of the study treatment. This data set will be used to perform analyses of Safety.

- The Full Analysis Set (FAS) composed of all randomised patients having received at least one dose of the study treatment and with a successful cardioversion observed at visit 3. This data set will be used to perform analyses of Efficacy.

- The Per Protocol Set (PP) which is the subset of the Full Analysis Set composed of all patients with a primary efficacy criteria available and without any major protocol deviation.
deviation or other source of bias for primary criteria analyses. This data set will be used to perform the supportive analysis of the primary efficacy criterion.

13.5. HANDLING OF DROPOUTS AND MISSING DATA

13.5.1. Dropouts
The number of patients who withdraw from the study after their randomisation will be provided by treatment group for all treated patients (Safety Set). All withdrawn patients will be further described regarding their time to dropout and reasons for withdrawal.

13.5.2. Repositioning of Visits
No repositioning of visits will be done.

13.5.3. Missing Data
Missing values will not be substituted by estimated values, but considered as missing in statistical analysis.

13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS
Before the first trial drug intake, patient’s background, medical and surgical history, demographic data and disease characteristics will be described by treatment group on the Safety Set.

- **Quantitative parameters** will be described by treatment group and overall using the following: number of patients, number of missing data, mean, standard deviation, minimum, median and maximum values.

- **Qualitative parameters** will be described by treatment group and overall using frequencies.

Concomitant diseases, as well as medical and surgical histories will be tabulated descriptively by treatment group and overall using the MedDRA codes of System Organ Classes and preferred terms.
If more than 10% of patients are excluded from the FAS and PP set, the description of patients by treatment group at selection and inclusion will be repeated on the FAS and PP set for all parameters.

No statistical test of comparability of treatment groups at baseline will be performed.

13.7. EFFICACY ANALYSIS

13.7.1. Primary Criterion

13.7.1.1. Primary Analysis
The primary criteria, time to first recurrence of AF or atrial flutter emergence, will be analysed using the Kaplan Meier method and compared with the Log rank test. Hazard ratios and 95% confidence intervals will be estimated with the Cox regression model.

The primary analysis will be performed on the FAS.

13.7.1.2. Supportive Analysis
The primary analysis will be repeated on the PP set.

13.7.2. Secondary Criteria
All secondary analyses will be performed on the FAS. If more than 10% of patients are excluded from the PP set, the secondary analyses will be repeated on the PP set.

13.7.2.1. Numbers of Atrial Fibrillation Episodes in the first week following V3
Both the numbers of AF episodes (symptomatic or not) lasting for at least 10 minutes and with duration less than 10 minutes (N_{Sup10} and N_{Inf10}) will be described by treatment group and compared by the chi-square test (or CMH test adjusted for centre) or Fisher’s exact Test.

13.7.2.2. Duration of Atrial Fibrillation Episodes in the first week following V3
The duration of all AF Episodes will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centres effects) or Wilcoxon test.
13.7.2.3. **Time to first AF recurrence less than 10 minutes or symptomatic**

The time to the first AF recurrence less than 10 minutes and the time to the first symptomatic AF recurrence will be analysed as the primary analysis.

13.7.2.4. **Clinical parameters evaluation**

The EHRA score will be described by treatment group and analysed using a chi-squared test (or CMH test adjusted for centre) or Fisher’s exact Test.

The frequency of presumed arrhythmia will be described by treatment group.

The number of recurrence of symptomatic AF, of hospitalizations (for cardiovascular events, for thromboembolic stroke and for all causes), of spontaneous cardioversion, of successful cardioversion (including number of shocks distribution) and the number of patients needing cardioversion after initial ECV will be described by treatment group and compared using a chi-square test or a Fisher Test (if the numbers are relevant).

The duration of hospitalizations for cardiovascular events, for thromboembolic stroke and for any cause will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centre effects) or Wilcoxon test.

The echocardiographic parameters values will be described at each time (V1, V2, V4, V6 and V9) and changes described from V4 to V9 and from V2 to V9.

13.7.2.5. **Biomarker analysis: red blood cell concentrations of DHA**

Values and changes from baseline for red blood cell concentration of DHA will be performed by treatment group and assessment time.

13.8. **SAFETY ANALYSIS**

The Safety Set will be used to perform all analyses of the safety criteria.

13.8.1. **Adverse Events**

Any adverse event having been reported during the study for a given patient will be classified by preferred term and corresponding system organ class using the MedDRA terminology.

Adverse events will be classified as:
• Treatment emergent adverse events, *i.e.*, any adverse event which occurs or worsens on study treatment during the randomised period.

• Or non treatment emergent adverse events, *i.e.*, any adverse event which occurs during the run-in period (before V2) or is reported as concomitant disease with the same intensity.

For each study period, any patient with at least one reported adverse event will be classified as a patient:

• With at least one adverse event
• With at least one treatment emergent adverse event
• With one TEAE
• With two TEAEs
• With at least three TEAEs
• With at least one related TEAE
• With an adverse event leading to the study treatment discontinuation (definitive or temporary)
• With an adverse event leading to withdrawal
• With at least one serious adverse event.

Numbers and percentages of patient with at least one reported treatment emergent adverse event will be tabulated by treatment group:

• By system organ class
• By system organ class and preferred term
• By system organ class and preferred term, taking into consideration its most severe intensity
• And by system organ class and preferred term, taking into consideration the most severe relationship to the study treatment.
Recurring adverse events (i.e., adverse events classified with the same preferred term) for a given patient will only be counted once and only their most severe intensity or most severe relationship to the study treatment will be tabulated.

The number and percentage of patients with at least one most common (reported in 1% patients in any group) drug related TEAE ("not excluded or unassessable") will be tabulated by Preferred Term and Treatment group in decreasing order for the treatment group (for all patients).

The number and percentage of patients with at least one reported most common treatment emergent adverse event will also be plotted by treatment group. This graphical representation will highlight the frequencies of the most severe intensities reported by system organ class and preferred term.

SAE will also be described on an individual basis: treatment group, patient's code, sex and age, Investigator's reported term, preferred term, time of onset according to the time of the first study treatment administration, duration, action taken regarding the study treatment administration, use of a corrective treatment, outcome and relationship to the study treatment in the Investigator’s opinion.

13.8.2. Clinical Laboratory Evaluation

For each laboratory parameter, data will be tabulated by treatment group and assessment time.

The absolute changes post-trial drug administration - baseline (the baseline value being the value measured on the last blood sample collected before the first trial drug administration) will be calculated and tabulated by parameter, treatment group and post-trial drug administration assessment time. Results of retests performed post-trial drug administration will not be analysed and tabulated. They will only be displayed in individual data listings.

For all biochemistry parameters, scatter plots highlighting individual results will display the baseline and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 24 value in the ordinate.

For all haematology parameters, scatter plots highlighting individual results will display the baseline and week 4, week 12 and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 4, week 12 and week 24 value in the ordinate.
Each treatment group will be differently identified. The first bisecting line (45° line), the lines of lower and upper normal range, the lines of Potentially Clinically Significant Change (PSC) range and Clinically noteworthy abnormal laboratory value (CNALV) range added on the plots (see Appendix 17.3).

For all blood laboratory parameters, shift tables will be provided to depict the numbers of patients with post-trial drug administration variations at each assessment time as compared to the baseline values (measured on the last blood sample collected before the first trial drug administration) by treatment group. A 3-point scale (low, normal, high) will be used as defined by the normal ranges in use in the laboratory in charge of the assays.

CNALV (see in Appendix 17.3) will be identified and described on an individual basis. If relevant, five separate individual data listings by treatment group will be provided:

- CNALV for haemoglobin (including corresponding individual results of erythrocytes and haematocrit)
- CNALV for neutrophils or leucocytes (including corresponding individual results of basophils, eosinophils, lymphocytes and monocytes)
- CNALV for platelets (including corresponding individual results of erythrocytes and leucocytes)
- CNALV for liver function parameters (including corresponding individual results of gamma-GT)
- CNALV for serum creatinine

13.8.3. Global Physical Examination

Recorded data of the global physical examination performed will not be tabulated as any abnormal findings post-randomisation should be reported as AEs (if clinically significant).

Physical examination assessments will be provided in the listings of individual data.
13.8.4. Vital Signs, Physical Findings and Other Observations Related to Safety

13.8.4.1. Vital Sign Measurements Over Time
For each parameter (systolic blood pressure, diastolic blood pressure and HR in supine and standing positions), descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.

13.8.4.2. Body weight
Descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.

13.8.4.3. Individual Patient Changes
The number and percentage of patient with at least one Predefined Potentially Clinically Significant Change (PSC) and with at least one PSC Leading to Clinically Significant Value (PSCV) will be tabulated by treatment group (see Table 1 in Appendix 17.3).

According to the pharmacological drug profile mentioned previously in this Protocol, the changes from baseline to the maximum and/or minimum post-baseline value could be categorized and tabulated by treatment group with frequencies and decreasing cumulative percentages.

If there is a signal of a drug effect toward one direction rather than the other, additionally shift tables of variations from baseline to the maximum or minimum post-baseline value could be also provided (see Table 2 to 4 in Appendix 17.3).

An individual data listing of patients with symptomatic or asymptomatic orthostatic hypotension will be provided by treatment group (see Table 5 in Appendix 17.3).

13.8.5. ECG
Frequencies on the clinical interpretation (normal, abnormal CS or NCS) will be presented by treatment group and assessment time. Individual tabulated data for ECG abnormalities will be also displayed.
13.8.6. Coagulation parameters

Scatter plots highlighting individual results for coagulation parameters (prothrombin time/INR, activated partial thromboplastin time and thrombin clotting time) before and after study treatment administration will be produced.

13.9. CONCOMITANT TREATMENTS

Concomitant treatments will be tabulated by treatment group within a descriptive perspective. They will be classified by therapeutic area according to the WHO-DRUG dictionary using the "anatomical therapeutic chemical" classification on the safety set.

13.10. COMPLIANCE

The percentage of compliance will be described by treatment group using the quantity

\[
Compliance(\%) = \frac{\text{Estimated actual consumption}}{\text{Theoretical consumption}} \times 100
\]

with: Estimated actual consumption = number of tablets provided at the start of study (Visit 2) minus number of tablets returned at the end of study (Visit 9)

Theoretical consumption = number of days of treatment intake planned between the start and the end of study (168 days ± 7 days)

13.11. INTERIM ANALYSIS AND DATA MONITORING

No analyses of efficacy data are planned for IDMC that ensures that the overall probability of type I error is controlled. No Type I error and sample size adjustments are necessary. Any recommendations of the IDMC to alter study conduct will be based on safety, so IDMC monitoring of the study will not affect the statistical operating characteristics of the final analysis.
The IDMC will review, two times during the study period (after the first 30 subjects will have been randomized and when the first 80 subjects will have terminated their study participation), safety data results across treatment groups and judges whether the overall safety and feasibility (not futility) of the trial remain acceptable.

14. GENERAL ETHICAL CONSIDERATIONS

14.1. ETHICAL CONDITIONS
This study is performed in accordance with the principles stated in the Declaration of Helsinki (1964) and subsequent amendments and in accordance with the Good Clinical Practice Guideline (CPMP/ICH/135/95).

14.2. ETHICS COMMITTEE AND LEGAL REQUIREMENTS
All the documents required by National Regulations and any other informative documents that may be requested are submitted for review to an Ethics Committee whose procedures and operations meet the GCP and National Legal Requirements.

Depending on National Regulations, the application is submitted to the Ethics Committee by the Sponsor (or representative) or by the Investigator.

A copy of the formal written approval from the Ethics Committee is provided to the Sponsor (directly by the Ethics Committee or via the Investigator) with a list of names and qualifications of its members.

The request for authorisation by the Competent Authority or its notification if required (depending on National Regulations) is carried out by the Sponsor.

The screening of patients does not start before the approval of the Ethics Committee has been obtained and the study authorised by the Competent Authority or notified to the Competent Authority (depending on National Regulations).
14.3. PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM

An information must be given to the patients before their decision to participate or abstain from participation.

This information is based on the elements set out in the Declaration of Helsinki and the ICH GCP Guidelines. It must also describe the measures taken to safeguard patient’s privacy and protection of personal data, according to European Directive 95/46 EC or other local regulation.

Restraints and risks must be explained, as well as the right to discontinue participation in the study at any stage, without affecting their further relationship with the Investigator and/or their future care.

The written information and consent form must be submitted to the patient with an oral explanation. It must be agreed and signed by the patient before any study-related procedure starts.

This information and consent procedure is under the Investigator’s responsibility.

The information and consent document are made in triplicate: the original copy is kept by the Investigator, one copy is given to the patient and the last copy is kept by the Clinical Quality Assurance Unit of the Sponsor in a sealed envelope at the end of study (except in case of specific country requirement).

Specific areas of the Sponsor’s copy are not triplicated to avoid the reading of the patient’s surname (except the first 3 letters), first name, address and signature.

If any information becomes available during the trial that may be relevant to the patient’s willingness to keep on participating in the trial, an updated written informed consent must be submitted to the patient to confirm agreement to continue participating.

14.4. PERSONAL DATA PROTECTION

All information from this study (excluding data from the informed consent) is entered into a computer under the Sponsor’s responsibility in accordance with the French law, "Loi Informatique et Libertés" (January 6, 1978, and subsequent amendments) and with the European Directive 95/46/CE.
14.5. INSURANCE POLICY

In accordance with the provisions of the law and the GCP, the Sponsor Pierre Fabre Médicament, has an insurance policy intended to guarantee against possible damage resulting from the research. The studies and/or experiments performed on behalf of the Sponsor Pierre Fabre Médicament are specifically and expressly guaranteed.

It is advisable to underline that non compliance with the Research Legal Conditions is a cause for guarantee exclusion.

15. ADMINISTRATIVE PROCEDURES

15.1. PROTOCOL AMENDMENT

Neither the Investigator nor the Sponsor may alter the protocol without the authorisation of the other party.

All changes to the protocol are subject to an amendment which must be dated and signed by both parties and must appear as an amendment to the protocol.

Substantial amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities.

Urgent amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities, but could be implemented immediately under specific conditions defined with the Sponsor.

15.2. SOURCE DOCUMENTS, INVESTIGATOR'S FILE STORAGE

The Investigator:

- Keeps all trial-related documents in appropriate file folders. Records of patient, original informed consent forms, source documents, a CD Rom containing a pdf copy of e-CRF, drug inventory, Ethics Committees and Sponsor correspondence pertaining to the study must be kept on file.

- Retains all documents relating to the screening (consent and investigation results) of all patients included in the trial or not.
• Retains a list of the patient’s names, addresses (and/or number of medical file), code numbers to allow checking of data reported on e-CRFs with those from source documents.
• Authorises direct access to source documents for monitoring, audits and inspections.
• The trial-related documents must be retained as strictly confidential at the Investigator’s site for at least 15 years or according to local requirements, whatever is the longest after the completion or discontinuation of the trial (European Directive 2003/63/EC).

15.3. **END OF THE STUDY**

15.3.1. **Definition of the End of Study**
The end of study is the last visit of the last patient undergoing the trial.

Any change to this definition during the study, for whatever reason, must be notified as a substantial amendment.

15.3.2. **Early Study Termination**

15.3.2.1. **Early Study Termination Decided by the Sponsor**
The Sponsor may discontinue the study at any time for any of the following reasons:

- Lack of recruitment
- Deviations from good clinical practice and/or regulations
- Poor product safety
- New information that could jeopardise the patient’s safety
- Stopping of the development …

15.3.2.2. **Early Study Termination Decided by the Competent Authorities**
The Competent Authorities may suspend or prohibit a study if they consider that either the conditions of authorisation are not being met or has doubt about the safety or scientific validity of the study.
15.4. **AUDIT**

The Sponsor is responsible for making sure that both its representatives (Study Manager, CRA...) and the Investigator fulfil the requirements as specified by the GCP Guideline.

An audit can be organised internally at Pierre Fabre Médicament and at the investigational site where the e-CRFs are matched against source documents.

All study documentation must be directly accessible to auditors.

The practical conditions for the audit are discussed between the Investigator and the Clinical Quality Assurance Department.

Oral information about the audit results are given to the Investigator.

15.5. **INSPECTION**

The Health Authorities may inspect any investigation site or the Sponsor in the course of the study or after its completion, to verify the conduct of the study and quality of the data. The Investigator must provide to the inspectors direct access to study documents.

15.6. **CONFIDENTIALITY**

The present materials (protocol and related documentation, e-CRF, Investigator's Brochure) contain confidential information.

Except if agreed in writing with the Study Manager, the Investigators must hold such information confidential, and must not disclose it to others (except where required by Applicable Law).

15.7. **CLINICAL STUDY REPORT**

Data analysis and clinical study report writing are under the Sponsor’s responsibility.

Upon data analysis completion, a final report including a review of the objectives and methods, a presentation and a discussion of the results is drawn up according to ICH Guidelines (Structure and Content of Clinical Study Reports, ICH-E3, CPMP/ICH/137/95).

The report is a clinical and statistical integrated report. It must be signed by the Sponsor's representative(s) and the Coordinating Investigator.
15.8. STUDY RESULTS COMMUNICATION

Upon completion of the study, the global results of the Research are communicated to the Investigator. According to the Local Regulation, the patient can ask the Investigator for the results.

15.9. STUDY RESULTS PUBLICATION

The information and data collected during the conduct of this clinical study are considered confidential and are used by the Sponsor in connection with the development of the study drug. This information may be disclosed if deemed necessary by the Sponsor.

To allow the use of the information derived from this clinical study and to insure compliance with Current Regulations, the Investigator must provide the Sponsor with complete test results and all data collected during the study.

Only the Sponsor may make study information available to physicians and to Regulatory Agencies, except as required by Current Regulations.

All the results of this study including data, reports, discoveries and inventions resulting from the study, are the property of the Sponsor.

In the event the Sponsor chooses to publish study data, the manuscript must be provided to the author(s) at least 30 days prior to the expected date of submission to the intended publisher.

The Investigator(s) can reserve the right to publish or present study data; if so, the manuscript or abstract must be provided to the Sponsor for review at least 30 days prior to the expected date of submission to the intended publisher or of planned presentation.

In addition, if necessary, (the) Investigator(s) shall withhold publication for an additional 60 days, to allow the filing of a patent application, or to allow the Sponsor to take any measures he deems appropriate to establish and preserve his proprietary rights.

It is agreed that publication of study results by each site shall be made only as part of a publication of the study results obtained by all sites performing the protocol, once the study is completed and finalised.
The authors list is agreed by all Investigators prior to publication. The names of the authors are provided according to their participation in the design of the protocol as well as their recruitment of eligible and analysable patients.
16. REFERENCES

[1]. F373280 INVESTIGATOR'S BROCHURE, version October 2013

   n-3 Polyunsaturated Fatty Acids in the prevention of atrial Fibrillation Recurrences after electrical cardioversion. A prospective, Randomised study
   Circulation, 2011; 124:1100-1106

   Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy
   J. Am. Coll. Cardiol. 2011;57;870-879

[4]. MOERTL D., HAMMER A., STEINER S., HUTULEAC R., VONBANK K., BERGER R.
   Dose-dependant effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of non ischemic origin: A double-blind, placebo-controlled, 3-arm study
   American Heart Journal 2011; 161:915.e1-915.e9 - volume 161, number 5

[5]. GISSI-HF INVESTIGATORS
   Effects of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GSSI-HF Trial): a randomised, double-blind, placebo-controlled trial
   The lancet on line - August 2008

   Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
   European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Eur Heart J. 2010 Oct;31(19):2369-429

[7]. KOWEY PR, REIFFEL JA, ELLENBOGEN KA, NACCARELLI GV, PRATT CM.
   Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomised controlled trial.
N-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomised, double-blind, multicentre study
Europace (2011) 13, 174-181

[9]. OMACOR® SUMMARY PRODUCT CARACTERISTICS (SPC) dated 17/02/2012

[10]. BEPANTHENE® SUMMARY PRODUCT CARACTERISTICS (SPC)

Dronedarone for prevention of atrial fibrillation: a dose-ranging study.

[12]. LE HEUZEY JY AND ALL.
A Short-Term, Randomised, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study.
J Cardiovasc Electrophysiol.

Effects of fish-oil supplementation on myocardial fatty acids in humans.
Am J Clin Nutr (2007); 85 : 1225.

[14]. ARTERBURN M.L. & OKEN H.
Distribution, interconversion and dose response of n-3 fatty acids in humans.
Am J Clin Nutr (2006);83 : 1469-1473S.

[15]. TIELEMAN RG, VAN GELDER IC, CRiJNS HJ, DE KAM PJ, VAN DEN BERG MP, HAAKSMA J, VAN DER WOUDe HJ, AND ALLESSIE MA.
Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodelling of the atria?
J. Am. Coll. Cardiol. 1998;31;167-173

[16]. SALm P, TAYLOR PJ, KOSTNER K
Simultaneous quantification of total eicosapentaenoic acid, docosahexaenoic acid and arachidonic acid in plasma by high-performance liquid chromatography-tandem mass spectrometry.

[17]. LEGRAND P., SCHMITT B., MOUROT J., CATHELINE D., CHESNEAU G., MIREAUX M., KERHOAS N., WEILL P.
The consumption of food products from linseed-fed animals maintains erythrocyte omega-3 fatty acids in obese human. 

[18]. HARRIS WS, VON SCHACKY C. 
The Omega-3 Index: a new risk factor for death from coronary heart disease? 

[19]. ABSTRACT: P5161. 
Effects of Polyunsaturated Fatty Acids n-3 (PUFA n-3) in the prophylaxis of atrial fibrillation relapses after external electric cardioversion 
World Congress of Cardiology 2006, 2-6 September, Barcelona – Spain

Outcome parameters from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association. 
Europace 2007, 9, 1006-1023

[21]. EUROPEAN MEDICINES AGENCY 
Addendum to the guideline on antiarrhythmics on atrial fibrillation and atrial flutter. 
EMA/CHMA/EWP/213056/2010

[22]. OWEN AJ, PETER-PRZYBOROWSKA BA, HOY AJ, MCLENNAN PL. 
Dietary fish oil dose- and time-response effects on cardiac phospholipid fatty acid composition. 
Lipids. 2004;39:955–961

[23]. ROBERTO M. LANG, MICHELLE BIERIG, RICHARD B. DEVEREUX, FRANK A. FLACHSKAMPF*, ELYSE FOSTER, PATRICIA A. PELLIKKA, MICHAEL H. PICARD, MARY J. ROMAN, JAMES SEWARD, JACK SHANEWISE, SCOTT SOLOMON, KIRK T. SPENCER, MARTIN ST. JOHN SUTTON, WILLIAM STEWART. 
Recommendations for chamber quantification 

M. PIEKSE, BOGDAN A. POPESECU, PER K. RØNNEVIK, FRANS H. RUTTEN, JUERG SCHWITTER, PETAR SEFEROVIC, JANINA STEPINSKA, PEDRO T. TRINDADE, ADRIAAN A. VOORS, FAIEZ ZANNAD, ANDREAS ZEIHER
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
*European Heart Journal* (2012) 33, 1787–1847

[25]. AGENCE NATIONALE DE SECURITE DU MEDICAMENT ET DES PRODUITS DE SANTE (ANSM).
Bon usage des médicaments antivitamine K (AVK)
*Actualisation – Juillet 2012*

[26]. GILLES PERNOD, ANNE GODIER, CLAIRE GOZALO, BENJAMIN TREMEY, PIERRE SIE
French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding)
*Thrombosis Research 126 (2010) e167–e174*
17. APPENDICES
17.1. DECLARATION OF HELSINKI

WORLD MEDICAL ASSOCIATION DECLARATION OF HELSINKI
ETHICAL PRINCIPLES FOR MEDICAL RESEARCH INVOLVING
HUMAN SUBJECTS

Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the: 29th WMA
General Assembly, Tokyo, Japan, October 1975 35th WMA General Assembly, Venice, Italy, October 1983 41st
WMA General Assembly, Hong Kong, September 1989 48th WMA General Assembly, Somerset West, Republic of
South Africa, October 1996 52nd WMA General Assembly, Edinburgh, Scotland, October 2000 53th WMA General
Assembly, Washington 2002 (Note of Clarification on paragraph 29 added) 55th WMA General Assembly, Tokyo
2004 (Note of Clarification on Paragraph 30 added) 59th WMA General Assembly, Seoul, October 2008

A. INTRODUCTION

1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of
ethical principles for medical research involving human subjects, including research on identifiable
human material and data. The Declaration is intended to be read as a whole and each of its constituent
paragraphs should not be applied without consideration of all other relevant paragraphs.

2. Although the Declaration is addressed primarily to physicians, the WMA encourages other participants
in medical research involving human subjects to adopt these principles.

3. It is the duty of the physician to promote and safeguard the health of patients, including those who are
involved in medical research. The physician's knowledge and conscience are dedicated to the fulfilment
of this duty.

4. The Declaration of Geneva of the WMA binds the physician with the words, “The health of my patient
will be my first consideration,” and the International Code of Medical Ethics declares that, “A physician
shall act in the patient's best interest when providing medical care.”

5. Medical progress is based on research that ultimately must include studies involving human subjects.
Populations that are underrepresented in medical research should be provided appropriate access to
participation in research.

6. In medical research involving human subjects, the well-being of the individual research subject must
take precedence over all other interests.

7. The primary purpose of medical research involving human subjects is to understand the causes,
development and effects of diseases and improve preventive, diagnostic and therapeutic interventions
(methods, procedures and treatments). Even the best current interventions must be evaluated continually
through research for their safety, effectiveness, efficiency, accessibility and quality.

8. In medical practice and in medical research, most interventions involve risks and burdens.

9. Medical research is subject to ethical standards that promote respect for all human subjects and protect
their health and rights. Some research populations are particularly vulnerable and need special
protection. These include those who cannot give or refuse consent for themselves and those who may be
vulnerable to coercion or undue influence.

10. Physicians should consider the ethical, legal and regulatory norms and standards for research involving
human subjects in their own countries as well as applicable international norms and standards. No
national or international ethical, legal or regulatory requirement should reduce or eliminate any of the
protections for research subjects set forth in this Declaration.

B. PRINCIPLES FOR ALL MEDICAL RESEARCH

11. It is the duty of physicians who participate in medical research to protect the life, health, dignity,
integrity, right to self-determination, privacy, and confidentiality of personal information of research subjects.

12. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and adequate laboratory and, as appropriate, animal experimentation. The welfare of animals used for research must be respected.

13. Appropriate caution must be exercised in the conduct of medical research that may harm the environment.

14. The design and performance of each research study involving human subjects must be clearly described in a research protocol. The protocol should contain a statement of the ethical considerations involved and should indicate how the principles in this Declaration have been addressed. The protocol should include information regarding funding, sponsors, institutional affiliations, other potential conflicts of interest, incentives for subjects and provisions for treating and/or compensating subjects who are harmed as a consequence of participation in the research study. The protocol should describe arrangements for post-study access by study subjects to interventions identified as beneficial in the study or access to other appropriate care or benefits.

15. The research protocol must be submitted for consideration, comment, guidance and approval to a research ethics committee before the study begins. This committee must be independent of the researcher, the sponsor and any other undue influence. It must take into consideration the laws and regulations of the country or countries in which the research is to be performed as well as applicable international norms and standards but these must not be allowed to reduce or eliminate any of the protections for research subjects set forth in this Declaration. The committee must have the right to monitor ongoing studies. The researcher must provide monitoring information to the committee, especially information about any serious adverse events. No change to the protocol may be made without consideration and approval by the committee.

16. Medical research involving human subjects must be conducted only by individuals with the appropriate scientific training and qualifications. Research on patients or healthy volunteers requires the supervision of a competent and appropriately qualified physician or other health care professional. The responsibility for the protection of research subjects must always rest with the physician or other health care professional and never the research subjects, even though they have given consent.

17. Medical research involving a disadvantaged or vulnerable population or community is only justified if the research is responsive to the health needs and priorities of this population or community and if there is a reasonable likelihood that this population or community stands to benefit from the results of the research.

18. Every medical research study involving human subjects must be preceded by careful assessment of predictable risks and burdens to the individuals and communities involved in the research in comparison with foreseeable benefits to them and to other individuals or communities affected by the condition under investigation.

19. Every clinical trial must be registered in a publicly accessible database before recruitment of the first subject.

20. Physicians may not participate in a research study involving human subjects unless they are confident that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians must immediately stop a study when the risks are found to outweigh the potential benefits or when there is conclusive proof of positive and beneficial results.

21. Medical research involving human subjects may only be conducted if the importance of the objective outweighs the inherent risks and burdens to the research subjects.

22. Participation by competent individuals as subjects in medical research must be voluntary. Although it may be appropriate to consult family members or community leaders, no competent individual may be
enrolled in a research study unless he or she freely agrees.

23. Every precaution must be taken to protect the privacy of research subjects and the confidentiality of their personal information and to minimize the impact of the study on their physical, mental and social integrity.

24. In medical research involving competent human subjects, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail, and any other relevant aspects of the study. The potential subject must be informed of the right to refuse to participate in the study or to withdraw consent to participate at any time without reprisal. Special attention should be given to the specific information needs of individual potential subjects as well as to the methods used to deliver the information. After ensuring that the potential subject has understood the information, the physician or another appropriately qualified individual must then seek the potential subject’s freely-given informed consent, preferably in writing. If the consent cannot be expressed in writing, the non-written consent must be formally documented and witnessed.

25. For medical research using identifiable human material or data, physicians must normally seek consent for the collection, analysis, storage and/or reuse. There may be situations where consent would be impossible or impractical to obtain for such research or would pose a threat to the validity of the research. In such situations the research may be done only after consideration and approval of a research ethics committee.

26. When seeking informed consent for participation in a research study the physician should be particularly cautious if the potential subject is in a dependent relationship with the physician or may consent under duress. In such situations the informed consent should be sought by an appropriately qualified individual who is completely independent of this relationship.

27. For a potential research subject who is incompetent, the physician must seek informed consent from the legally authorized representative. These individuals must not be included in a research study that has no likelihood of benefit for them unless it is intended to promote the health of the population represented by the potential subject, the research cannot instead be performed with competent persons, and the research entails only minimal risk and minimal burden.

28. When a potential research subject who is deemed incompetent is able to give assent to decisions about participation in research, the physician must seek that assent in addition to the consent of the legally authorized representative. The potential subject’s dissent should be respected.

29. Research involving subjects who are physically or mentally incapable of giving consent, for example, unconscious patients, may be done only if the physical or mental condition that prevents giving informed consent is a necessary characteristic of the research population. In such circumstances the physician should seek informed consent from the legally authorized representative. If no such representative is available and if the research cannot be delayed, the study may proceed without informed consent provided that the specific reasons for involving subjects with a condition that renders them unable to give informed consent have been stated in the research protocol and the study has been approved by a research ethics committee. Consent to remain in the research should be obtained as soon as possible from the subject or a legally authorized representative.

30. Authors, editors and publishers all have ethical obligations with regard to the publication of the results of research. Authors have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports. They should adhere to accepted guidelines for ethical reporting. Negative and inconclusive as well as positive results should be published or otherwise made publicly available. Sources of funding, institutional affiliations and conflicts of interest should be declared in the publication. Reports of research not in accordance with the principles of this Declaration should not be accepted for publication.
C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH
MEDICAL CARE

31. The physician may combine medical research with medical care only to the extent that the research is justified by its potential preventive, diagnostic or therapeutic value and if the physician has good reason to believe that participation in the research study will not adversely affect the health of the patients who serve as research subjects.

32. The benefits, risks, burdens and effectiveness of a new intervention must be tested against those of the best current proven intervention, except in the following circumstances:
   • The use of placebo, or no treatment, is acceptable in studies where no current proven intervention exists; or
   • Where for compelling and scientifically sound methodological reasons the use of placebo is necessary to determine the efficacy or safety of an intervention and the patients who receive placebo or no treatment will not be subject to any risk of serious or irreversible harm. Extreme care must be taken to avoid abuse of this option.

33. At the conclusion of the study, patients entered into the study are entitled to be informed about the outcome of the study and to share any benefits that result from it, for example, access to interventions identified as beneficial in the study or to other appropriate care or benefits.

34. The physician must fully inform the patient which aspects of the care are related to the research. The refusal of a patient to participate in a study or the patient’s decision to withdraw from the study must never interfere with the patient-physician relationship.

35. In the treatment of a patient, where proven interventions do not exist or have been ineffective, the physician, after seeking expert advice, with informed consent from the patient or a legally authorized representative, may use an unproven intervention if in the physician's judgement it offers hope of saving life, re-establishing health or alleviating suffering. Where possible, this intervention should be made the object of research, designed to evaluate its safety and efficacy. In all cases, new information should be recorded and, where appropriate, made publicly available.
17.2. SAE REPORT FORM
NOTIFICATION OF SERIOUS ADVERSE EVENT (SAE) OR PREGNANCY TO PIERRE FABRE CORPORATE VIGILANCES DIVISION

TO BE TRANSMITTED TO THE CORPORATE VIGILANCES DIVISION BY E-MAIL WITHIN 24H TO
HQ.pharmacovigilance@pierre-fabre.com OR BY FAX WITHIN 24H – Fax N°: 33 (0) 1.49.10.80.90

Transmission date  [ ] [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)  Country : ........................................
SAE N°  [ ]  FIRST NOTIFICATION  □  FOLLOW-UP  □  N°

SUBJECT CHARACTERISTICS

Birth date  [ ] [ ] [ ] [ ] [ ]
Gender  [ ] 1=M,  2=F  Height  [ ] [ ] cm  Weight  [ ] [ ] [ ] [ ] [ ] kg

DESCRIPTION OF THE EVENT

The serious adverse event resulted in :
□ Death (whatever may be the cause)
□ Hospitalisation (*) or extension thereof
□ Life threatening
□ Invalidity or disability
□ Congenital abnormality or abnormal pregnancy outcome
□ Cancer
□ Other (any other serious clinical or laboratory event according to the investigator or the protocol, overdose meeting seriousness criteria, suicide attempts)

Other fact to be notified :
□ Pregnancy exposure

Nature of the event (if clinical nature, indicate the diagnosis or the major symptom) :
...........................................................................................................................................................................................................
...........................................................................................................................................................................................................
...........................................................................................................................................................................................................

AE onset date  [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)
Seriousness onset date  [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)
Summary description (if clinical cause, significant history, progression of event, available laboratory results, etc...) :

(*) Except hospitalisations with durations and goals planned in the protocol

THE SAE IN RELATION TO THE TRIAL

TREATMENT NUMBER  [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ] [ ]

• Time of occurrence of SAE
  □ During the selection or run-in period
  □ During the administration phase of the study treatment
  □ After the administration phase of the study treatment

• Date of first study treatment administration  [ ] [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)
• Date of last study treatment administration before the occurrence of SAE  [ ] [ ] [ ] [ ] [ ] [ ] (ddmmyyyy)
• Was the blind broken ?  □ Yes  □ No  □ Not applicable
  If yes, or if this is an open study, drug(s) administered :
............................................................................................................................................................................................

Conditions of administration (cycles(s), daily dose(s), route(s) of administration, etc...) :
............................................................................................................................................................................................
............................................................................................................................................................................................
**CONCOMITANT MEDICATION SINCE TRIAL INITIATION and up until the occurrence of the SAE**

(Except the treatments given for the SAE)

<table>
<thead>
<tr>
<th>Trade name (or INN)</th>
<th>Daily dose</th>
<th>Start date (dd/mm/yy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (dd/mm/yy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><em>/<strong>/</strong></em></td>
<td>[ ]</td>
<td><strong>/</strong>/___</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em><strong>/</strong>/</em>__</td>
<td>[ ]</td>
<td><em><strong>/</strong>/</em>__</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em><strong>/</strong>/</em>__</td>
<td>[ ]</td>
<td><em><strong>/</strong>/</em>__</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em><strong>/</strong>/</em>__</td>
<td>[ ]</td>
<td><em><strong>/</strong>/</em>__</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**MEASURES TAKEN FOLLOWING THE SAE**

- **Study treatment**
  - [ ] No change
  - [ ] Dosage modification, specify: ____________________________ Modification Date: ___/__/___
  - [ ] Temporarily discontinued Readministration date: ___/__/___
  - [ ] Withdrew End date: ___/__/___
  - [ ] Not applicable

- **The event led to**:
  - [ ] Prescription of corrective or symptomatic treatments:

<table>
<thead>
<tr>
<th>Trade name (or INN)</th>
<th>Daily dose</th>
<th>Start date (dd/mm/yy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (dd/mm/yy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><em>/<strong>/</strong></em></td>
<td>[ ]</td>
<td><strong>/</strong>/___</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em><strong>/</strong>/</em>__</td>
<td>[ ]</td>
<td><em><strong>/</strong>/</em>__</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em><strong>/</strong>/</em>__</td>
<td>[ ]</td>
<td><em><strong>/</strong>/</em>__</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[ ] Discontinuation of concomitant treatments:

<table>
<thead>
<tr>
<th>Trade name (or INN)</th>
<th>Daily dose</th>
<th>Start date (dd/mm/yy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (dd/mm/yy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><em>/<strong>/</strong></em></td>
<td>[ ]</td>
<td><strong>/</strong>/___</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em><strong>/</strong>/</em>__</td>
<td>[ ]</td>
<td><em><strong>/</strong>/</em>__</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em><strong>/</strong>/</em>__</td>
<td>[ ]</td>
<td><em><strong>/</strong>/</em>__</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

[ ] Others, specify:

**OUTCOME**

- [ ] Not recovered/Not resolved
- [ ] Recovering/Resolving
- [ ] Recovered/Resolved
- [ ] Fatal
- [ ] Unknown

In case of death, has an autopsy been conducted? [ ] Yes [ ] No

**INVESTIGATOR CAUSALITY ASSESSMENT** (investigator’s assessment to be done as soon as possible)

Study drug: Related to study protocol:

- [ ] Not Suspected
- [ ] Suspected
- [ ] Not Suspected
- [ ] Suspected

Comments: ___________________________________________
17.3. PREDEFINED LIMITS OF LABORATORY AND VITAL SIGN POTENTIALLY CLINICALLY SIGNIFICANT CHANGES AND VALUES

List of Predefined Potentially Clinically Significant Change For Laboratory Values

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>UNIT</th>
<th>Decrease</th>
<th>PSC</th>
<th>Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td>MUSCLE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatine Phosphokinase</td>
<td>U / l</td>
<td>-</td>
<td></td>
<td>236</td>
</tr>
<tr>
<td>KIDNEY</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine</td>
<td>µmol/l</td>
<td>-</td>
<td></td>
<td>35</td>
</tr>
<tr>
<td>Urea</td>
<td>mmol/l</td>
<td>-</td>
<td></td>
<td>3.2</td>
</tr>
<tr>
<td>Uric acid</td>
<td>µmol/l</td>
<td>-</td>
<td></td>
<td>119</td>
</tr>
<tr>
<td>Phosphate</td>
<td>mmol/l</td>
<td>0.39</td>
<td></td>
<td>0.39</td>
</tr>
<tr>
<td>Calcium</td>
<td>mmol/l</td>
<td>0.30</td>
<td></td>
<td>0.30</td>
</tr>
<tr>
<td>ELECTROLYTES</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium</td>
<td>mmol/l</td>
<td>8</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>Potassium</td>
<td>mmol/l</td>
<td>1.1</td>
<td></td>
<td>1.1</td>
</tr>
<tr>
<td>Chloride</td>
<td>mmol/l</td>
<td>8</td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>mmol/l</td>
<td>7</td>
<td></td>
<td>8</td>
</tr>
<tr>
<td>METABOLISM/NUTRITIONAL</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose (random)</td>
<td>mmol/l</td>
<td>3</td>
<td></td>
<td>3.7</td>
</tr>
<tr>
<td>Albumin</td>
<td>g/l</td>
<td>6</td>
<td></td>
<td>6</td>
</tr>
<tr>
<td>Protein</td>
<td>g/l</td>
<td>11</td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>Cholesterol</td>
<td>mmol/l</td>
<td>-</td>
<td></td>
<td>1.97</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>mmol/l</td>
<td>0.91</td>
<td></td>
<td>0.85</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>mmol/l</td>
<td>2.17</td>
<td></td>
<td>2.04</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>mmol/l</td>
<td>-</td>
<td></td>
<td>2.91</td>
</tr>
<tr>
<td>ERYTHROCYTES</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythrocyte count</td>
<td>T/l</td>
<td>0.7</td>
<td></td>
<td>0.7</td>
</tr>
<tr>
<td>Haemoglobin</td>
<td>g/l</td>
<td>20</td>
<td></td>
<td>-</td>
</tr>
<tr>
<td>Haematocrit</td>
<td>l</td>
<td>0.06</td>
<td></td>
<td>0.06</td>
</tr>
<tr>
<td>MCV</td>
<td>fl</td>
<td>7</td>
<td></td>
<td>7</td>
</tr>
<tr>
<td>MCH (Fe)</td>
<td>fmol</td>
<td>0.19</td>
<td></td>
<td>0.19</td>
</tr>
<tr>
<td>MCHC (Fe)</td>
<td>mmol/l</td>
<td>2</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>LEUKOCYTES</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leukocyte count</td>
<td>G/l</td>
<td>4.2</td>
<td></td>
<td>3.8</td>
</tr>
<tr>
<td>DIFFERENTIAL COUNT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophils</td>
<td>G/l</td>
<td>3.47</td>
<td></td>
<td>3.19</td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>G/l</td>
<td>1.76</td>
<td></td>
<td>1.63</td>
</tr>
<tr>
<td>Monocytes</td>
<td>G/l</td>
<td>-</td>
<td></td>
<td>0.49</td>
</tr>
<tr>
<td>Eosinophils</td>
<td>G/l</td>
<td>-</td>
<td></td>
<td>0.41</td>
</tr>
<tr>
<td>Basophils</td>
<td>G/l</td>
<td>-</td>
<td></td>
<td>0.14</td>
</tr>
<tr>
<td>URINE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specific gravity</td>
<td>-</td>
<td>0.017</td>
<td></td>
<td>0.015</td>
</tr>
<tr>
<td>pH</td>
<td>-</td>
<td>2</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td>LIVER</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>µmol/l</td>
<td>-</td>
<td></td>
<td>10</td>
</tr>
<tr>
<td>ASAT (SGOT)</td>
<td>U/l</td>
<td>-</td>
<td></td>
<td>N x (23/36)</td>
</tr>
<tr>
<td>ALAT (SGPT)</td>
<td>U/l</td>
<td>-</td>
<td></td>
<td>N x (28/45)</td>
</tr>
<tr>
<td>Gamma GT</td>
<td>U/l</td>
<td>-</td>
<td></td>
<td>N x (25/38)</td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>U/l</td>
<td>-</td>
<td></td>
<td>N x (30/95)</td>
</tr>
</tbody>
</table>

N = upper limit of normal range

## Definition of Clinically Noteworthy Abnormal Laboratory Values (CNALV)

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>CNALV</th>
</tr>
</thead>
</table>
| HAEMOGLOBIN            | • Decrease of at least 2 g/dl and value < 10 g/dl whatever the baseline value  
                         | • If missing baseline: value < 10 g/dl                                                                                                  |
| NEUTROPHILS           | • < 1 500/mm³ whatever the baseline value                                                                                               |
| WBC                    | (if missing value for neutrophils)  
                         | • < 3 000/mm³ whatever the baseline value                                                                                               |
| PLATELETS              | • < 100 000/mm³ whatever the baseline value                                                                                               |
| SERUM CREATININE       | • Increase of at least 30 % as compared to baseline value and value > 150 µmol/l whatever the baseline value  
                         | • If missing baseline: value > 150 µmol/l                                                                                                 |
| LIVER FUNCTION TESTS   |                                                                                                                                 |
| ALAT                   | • If normal baseline:  
                         | • ALAT > 2 N  
                         | • If abnormal baseline:  
                         | → if baseline value ≤ 2.5 N:  
                         | • increase of at least 100 % as compared to baseline value  
                         | → if baseline value > 2.5 N:  
                         | • value > 5 N  
                         | and/or ASAT            | • If normal baseline:  
                         | • ASAT > 2 N  
                         | • If abnormal baseline:  
                         | → if baseline value ≤ 2.5 N:  
                         | • increase of at least 100 % as compared to baseline value  
                         | → if baseline value > 2.5 N:  
                         | • value > 5 N  
                         | and/or Alkaline phosphatase (AP) | • If normal baseline:  
                         | • AP > 1.25 N  
                         | • If abnormal baseline:  
                         | • AP > 2 N  
                         | and/or Total bilirubin (TB) | • If normal baseline:  
                         | • TB > 1.5 N  
                         | • If abnormal baseline:  
                         | • TB > 2 N  
                         | **N=upper limit of normal range**

Cardiovascular Safety

Table 1: Predefined Limits for Potentially Clinically Significant Changes (PSC) and PSC Leading to Clinically Significant Values (PSCV)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>PSC</th>
<th>PSCV</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP</td>
<td>Increase ≥ 20 mmHg</td>
<td>SBP ≥ 160 mmHg and increase ≥ 20 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 20 mmHg</td>
<td>SBP ≤ 90 mmHg and decrease ≥ 20 mmHg</td>
</tr>
<tr>
<td>DBP</td>
<td>Increase ≥ 10 mmHg</td>
<td>DBP ≥ 100 mmHg and increase ≥ 10 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 mmHg</td>
<td>DBP ≤ 50 mmHg and decrease ≥ 10 mmHg</td>
</tr>
<tr>
<td>HR</td>
<td>Increase ≥ 10 bpm</td>
<td>HR ≥ 110 bpm and increase ≥ 10 bpm</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 bpm</td>
<td>HR ≤ 50 bpm and decrease ≥ 10 bpm</td>
</tr>
</tbody>
</table>

Table 2: Predefined Classes for changes from Baseline to the Maximum (and/or Minimum) Post-baseline Value

<table>
<thead>
<tr>
<th>Classes of Change from Baseline to the Maximum Post-baseline Value</th>
<th>Classes of Change from Baseline to the Minimum Post-baseline Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>-----------</td>
<td>----------</td>
</tr>
<tr>
<td>All</td>
<td>All</td>
</tr>
<tr>
<td>≥ 0</td>
<td>≥ 0</td>
</tr>
<tr>
<td>&gt; 0</td>
<td>&gt; 0</td>
</tr>
<tr>
<td>≥ 10</td>
<td>≥ 5</td>
</tr>
<tr>
<td>≥ 20</td>
<td>≥ 15</td>
</tr>
<tr>
<td>≥ 40</td>
<td>≥ 20</td>
</tr>
<tr>
<td></td>
<td>≥ 25</td>
</tr>
<tr>
<td></td>
<td>≥ 30</td>
</tr>
</tbody>
</table>

Table 3: Classes for Vital Signs Maximum or Minimum Values

<table>
<thead>
<tr>
<th>Classes for the Maximum Post-baseline Value for each parameter</th>
<th>Classes for the Minimum Post-baseline Value for each parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>&lt; 120</td>
<td>&lt; 80</td>
</tr>
<tr>
<td>[120 ;140]</td>
<td>[80 ;90]</td>
</tr>
<tr>
<td>[140 ;160]</td>
<td>[90 ;100]</td>
</tr>
<tr>
<td>≥ 160</td>
<td>≥ 100</td>
</tr>
</tbody>
</table>

Table 4: Classes for Maximum or Minimum of BP in its entirety

<table>
<thead>
<tr>
<th>Classification of Maximum Values for Blood Pressure (mmHg)</th>
<th>Classification of Minimum Values Blood Pressure (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP &lt; 140 and DBP &lt; 90</td>
<td>SBP &gt; 90 and DBP &gt; 50</td>
</tr>
<tr>
<td>SBP [140;160] and DBP &lt; 100 or DBP [90;100] and SBP &lt; 160</td>
<td>SBP ≤ 90 or DBP ≤ 50</td>
</tr>
<tr>
<td>SBP ≥ 160 or DBP ≥ 100</td>
<td></td>
</tr>
</tbody>
</table>

Table 5: Definition of orthostatic hypotension

Orthostatic Hypotension *

SBP Decrease ≥ 20 mmHg or DBP Decrease ≥ 10 mmHg between supine and standing positions

Title of the study:
Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.
An international, multicentric, randomised, double-blind, placebo controlled study.

Dear patient,

You are currently or you have been taking part of the above-named research study evaluating the effect of F373280 on the maintenance of normal cardiac rhythm after direct electrical cardioversion in patients with persistent Atrial Fibrillation and cardiac failure.

The purpose of this letter is to provide you with new information about the study.

In fact, as it was explained to you at the beginning of your participation in the trial, it was planned to involve in the study 152 male or female patients suffering from persistent Atrial Fibrillation, aged more than 18 years, in several countries.

However, since May 2013, only 88% of needed patients have been involved in the study. Therefore, due to very slow recruitment over more than 3 years, the Sponsor, Pierre Fabre Médicament, has decided to stop prematurely the recruitment of patients. There will be a maximum of 135 patients involved in this trial.

This decision is not related to any new safety information linked to the product. Ongoing patients may therefore, continue being involved in the study, receiving treatment; and, analyses of all collected data are maintained.

All the other information that were given to you previously remain unchanged

CONTACT FOR FURTHER INFORMATION
If you feel that you would need more information or should there be anything that is not clear, don't hesitate to ask your investigator (doctor in charge of the study):

Dr. ___________________________ Telephone number: ___________________________

We thank you for your participation in this study.
16.1.1.11. Protocol amendment n° PA07
Local (Italy) and substantial dated on 06 December 2016 linked to Protocol and appendices
(version 9: 06 December 2016)
CLINICAL STUDY PROTOCOL

Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure.

International, multicentric, randomised, double-blind, placebo controlled study

F373280 / Soft Capsules / 1g

Pierre Fabre Study Code: F 373280 CA 2 01
EudraCT Number: 2012 – 003487 - 48

Sponsor's Representative: Marine FAGARD
INSTITUT DE RECHERCHE PIERRE FABRE - Centre de R&D Pierre Fabre - BP 13562
3 avenue Hubert Curien
31035 TOULOUSE Cédex 1, FRANCE
Phone: +33 5 34 50 63 54
Fax:+33 5 34 50 65 92
E-mail:marine.fagard@pierre-fabre.com

Study Coordinating Investigator: Pr Savina NODARI
Associate Professor of Cardiology
Department of Clinical and Surgical Specialities, Radiological Science and Public Health
Section of Cardiovascular Diseases
University Medical School and Spedali Civili Hospital of Brescia
c/o Spedali Civili di Brescia
Piazzale Spedali Civili, 1
25123 - BRESCIA, ITALY
Phone: +39 030 3996 587 – +39 030 393849
Fax: +39 030 3700 359
E-mail: savinanodari@gmail.com; nodari@med.unibs.it

Version 9 – 06DEC2016

The information contained in this document is confidential and is the property of the Sponsor, Pierre Fabre Medicament. This information is given for the needs of the study and must not be disclosed without prior written consent of the Sponsor Pierre Fabre Medicament. Persons to whom this information is given for the needs of the study must be informed that it is confidential and must not be disclosed.
SPONSOR PERSONNEL

PIERRE FABRE MEDICAMENT
represented by
Institut de Recherche Pierre Fabre

Clinical Study Manager (Monitor)
Marine FAGARD
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1, FRANCE
Phone: +33 5 34 50 63 54
Fax: +33 5 34 50 65 92
E-mail: marine.fagard@pierre-fabre.com

Head of Medical Unit
Karim KEDDAD, MD, PhD
Institut de Recherche Pierre Fabre
Centre de R&D Pierre Fabre
BP 13 562
3, Avenue Hubert Curien
31035 TOULOUSE Cedex 1, FRANCE
Phone: +33 5 34 50 61 69
Fax: +33 5 34 50 65 29
E-mail: karim.keddad@pierre-fabre.com
CONTRACT RESEARCH ORGANISATIONS

For Feasibility, Monitoring and Regulatory issues (in Hungary, Czech Republic and Italy):
Pharmaceutical Service Network (PSN)
Rufino Gonzalez
28 037 Madrid - SPAIN
Phone: +34 91 375 6930 - Fax: +34 91 375 6931
E-mail: rzurita@psnglobal.org

For Feasibility, Monitoring and Regulatory issues (in Spain):
Alpha Bioresearch
Paseo de la Castellana, 163 - 2º Izquierda
28 046 Madrid - SPAIN
Phone: +34 91 745 2520 - Fax: +34 91 745 0653
E-mail: teresa.bricio@alphabioresearch.com

For Centralised Randomisation and Electronic Case Report Form
S-Clinica
6, Chaussée de Boondael
B-1050 Brussels - BELGIUM
Phone: +32 2 645 0567 - Fax: +32 2 645 0569
E-mail: irena.seredina@s-clinica.com

For Centralised Reading of Holter ECG and TTEM and equipment supply:
Biomedical System
1945 Chaussée de Wavre
B-1160 Brussels - BELGIUM
Phone: +32 2 661 20 70 - Fax: +32 2 661 20 71
E-mail: sjacobs@biomedsys.com

For intra erythrocyte DHA dosage:
Agrocampus Ouest
Laboratoire de Biochimie
65 rue de Saint Brieuc – CS 84215
35042 RENNES Cedex - FRANCE
Phone: +33 2 23 48 55 49 - Fax: +33 2 23 48 55 50
E-mail: daniel.catheline@agrocampus-ouest.fr

For transportation of blood sample to the Analytical centre (Agrocampus) and material supply:
Theradis Pharma
41, chemin des Presses
06800 CAGNES-SUR-MER – FRANCE
Phone: +33 (0)4 97 02 07 07 - Fax: +33 (0)4 97 10 08 78
E-mail: chantal.raffy@theradis.pharma.com
Protocol F 373280 CA 2 01
APPROVAL FORM

Sponsor's Representative:

Head of Medical Unit:
Karim KEDDAD, MD, PhD

Date: 06/DEC/2016
Signature:

Study Coordinating Investigator:
Savina NODARI, MD

Date: 13/DEC/2016
Signature:
Country: ITALY

Country Coordinating Investigator:

<table>
<thead>
<tr>
<th>&quot;Name&quot;</th>
<th>Date</th>
<th>Signature</th>
</tr>
</thead>
<tbody>
<tr>
<td>SANINA NOVAREI</td>
<td>13/Dec/2016</td>
<td>Signature</td>
</tr>
</tbody>
</table>

13/Dec/2016
Protocol F 373280 CA 2 01

INVESTIGATOR SIGNATURE FORM


By my signature below, I, Dr / Pr "SAVINAS WOYTA", hereby confirm that I agree:

- to conduct the trial described in the protocol F 373280 CA 2 01, dated 06DEC2016 in compliance with GCP, with applicable regulatory requirements and with the protocol agreed upon by the Sponsor Pierre Fabre Médicament and given approval / favourable* opinion by the Ethics Committee;
- to document the delegation of significant study-related tasks and to notify the Sponsor of changes in site personnel involved in the study;
- to comply with the procedure for data recording and reporting;
- to allow monitoring, auditing and inspection;
- to retain the trial-related essential documents until the Sponsor informs that these documents are no longer needed.

Furthermore, I hereby confirm that I will have and will use the available adequate resources, personnel and facilities for conduct this trial.

I have been informed that certain regulatory authorities require the Sponsor Pierre Fabre Médicament to obtain and supply details about the investigator’s ownership interest in the Sponsor or the study drug, and more generally about his/her financial relationships with the Sponsor. The Sponsor will use and disclose the information solely for the purpose of complying with regulatory requirements.

Hence I agree:

- to supply the Sponsor with any information regarding ownership interest and financial relationships with the Sponsor (including those of my spouse and dependent children);
- to promptly update this information if any relevant changes occur during the course of the study and for 1 year following completion of the study;
- that the Sponsor may disclose this information about such ownership interests and financial relationships to regulatory authorities.

* To be adapted

Date: 13 Dec 2016

Signature: [Signature]
# TABLE OF CONTENTS OF CLINICAL STUDY PROTOCOL

1. **INTRODUCTION AND STUDY RATIONALE** .............................................................. 22  
   1.1. TARGET PATHOLOGY AND THERAPY ................................................................. 22  
   1.2. INFORMATION ON THE TEST PRODUCT ............................................................ 24  
   1.2.1. Chemical and pharmaceutical characteristics .................................................. 25  
   1.2.1.1. Nomenclature and structure ......................................................................... 25  
   1.2.1.2. Physical and chemical general properties ...................................................... 25  
   1.2.2. Non-clinical Data .............................................................................................. 25  
   1.2.2.1. Pharmacological profile ............................................................................... 26  
   1.2.2.2. Safety pharmacology ..................................................................................... 27  
   1.2.2.3. Toxicology profile ......................................................................................... 27  
   1.2.2.4. Pharmacokinetic data .................................................................................... 27  
   1.2.3. Clinical data ...................................................................................................... 27  
   1.3. STUDY RATIONALE ............................................................................................ 29  
   1.4. OVERALL RISK AND BENEFIT ASSESSMENT .................................................... 30  

2. **STUDY OBJECTIVES** .............................................................................................. 32  
   2.1. PRIMARY OBJECTIVE ......................................................................................... 32  
   2.2. SECONDARY OBJECTIVES .................................................................................. 32  

3. **ETHICAL CONSIDERATIONS RELATING TO THE STUDY** ................................... 33  

4. **STUDY DESIGN** .................................................................................................... 34  
   4.1. OVERALL DESCRIPTION ...................................................................................... 34  
   4.2. DISCUSSION OF THE STUDY DESIGN ................................................................ 35  
   4.2.1. Choice of the Study Population ........................................................................ 35  
   4.2.2. Choice of the Study Design ............................................................................. 36  
   4.2.3. Choice of the Dose .......................................................................................... 37  
   4.2.4. Choice of the Sample Size ............................................................................ 38  

5. **STUDY POPULATION** ............................................................................................ 38  
   5.1. INCLUSION CRITERIA .......................................................................................... 38  
   5.2. NON INCLUSION CRITERIA ................................................................................ 40  
   5.3. NUMBER OF PATIENTS ....................................................................................... 41  
   5.4. RECRUITMENT MODALITIES .............................................................................. 41  
   5.5. PATIENT IDENTIFICATION ................................................................................ 42  
   5.6. WITHDRAWAL CRITERIA .................................................................................... 42  
   5.7. REPLACEMENT OF PATIENTS .......................................................................... 43  
   5.8. POST-STUDY EXCLUSION PERIOD .................................................................... 43  
   5.9. STUDY CARD AND LETTER FOR GENERAL PRACTITIONER(S) ....................... 43  

6. **STUDY TREATMENT** ............................................................................................. 44
6.1. SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT

6.2. PACKAGING AND LABELLING
6.2.1. Packaging
6.2.2. Labelling

6.3. DISTRIBUTION TO CENTRE AND STORAGE

6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT

6.5. DRUG ADMINISTRATION
6.5.1. Duration of Treatment
6.5.2. Dose Schedule
6.5.3. Route and Conditions of Administration

6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT

6.7. RECALL OF INVESTIGATIONAL PRODUCTS

7. CONCOMITANT TREATMENTS
7.1. VITAMIN K ANTAGONIST TREATMENT
7.2. PROHIBITED TREATMENTS
7.3. AUTHORISED TREATMENTS

8. EVALUATION CRITERIA
8.1. PRIMARY EFFICACY CRITERION
8.1.1. Time to the first Atrial Fibrillation Recurrence or Atrial Flutter Emergence
8.1.1.1. Definition
8.1.1.2. Schedule
8.1.1.3. Evaluation Methods
8.1.2. Duration of AF episodes in the first week following visit 3 (ECV visit)
8.1.2.1. Definition
8.1.2.2. Schedule
8.1.2.3. Evaluation Methods
8.2. SECONDARY EFFICACY CRITERIA
8.2.1. Numbers of AF episodes in the first week following visit 3 (ECV visit)
8.2.1.1. Definition
8.2.1.2. Schedule
8.2.1.3. Evaluation Methods
8.2.2. Duration of AF episodes in the first week following visit 3 (ECV visit)
8.2.2.1. Definition
8.2.2.2. Schedule
8.2.2.3. Evaluation Methods
8.2.3. Clinical parameters evaluation
8.2.3.1. EHRA score assessment
8.2.3.2. Time to first AF recurrence less than 10 minutes
8.2.3.3. Recurrence of symptomatic AF
8.2.3.4. Number and duration of hospitalizations
8.2.4. Cardioversion assessment
8.2.5. Evolution of echocardiographic parameters
8.2.5.1. Definition
8.3. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA ................................................................. 55
  8.3.1. Definition ................................................................................. 55
  8.3.2. Blood samples ........................................................................ 55
  8.3.2.1. Collection schedule ............................................................. 55
  8.3.2.2. Technical handling ............................................................... 55
  8.3.3. DHA concentration measurement .......................................... 55

8.4. SAFETY ASSESSMENT .......................................................... 56
  8.4.1. Adverse Events ....................................................................... 56
  8.4.2. Laboratory Investigations ...................................................... 56
  8.4.2.1. Schedule ........................................................................... 56
  8.4.2.2. Technical Procedures and Parameters ................................. 56
  8.4.3. Global Physical Examination ................................................ 57
  8.4.4. Vital Signs ............................................................................ 58
  8.4.4.1. Schedule ........................................................................... 58
  8.4.4.2. Technical Procedure and Parameters ................................. 58
  8.4.5. Electrocardiogram (ECG) ...................................................... 58
  8.4.5.1. Schedule ........................................................................... 58
  8.4.5.2. Technical Procedure and Parameters ................................. 58
  8.4.6. Coagulation parameters ........................................................ 59

8.5. CONCOMITANT TREATMENTS ............................................. 60
8.6. COMPLIANCE ............................................................................ 60

9. STUDY PROCEDURES .................................................................. 60

10. ADVERSE EVENTS: DEFINITION AND REPORTING .................. 66
  10.1. ADVERSE EVENTS .................................................................... 66
  10.1.1. Definition of Adverse Events ................................................. 66
  10.1.2. Grading of Adverse Events .................................................. 67
  10.1.3. Reporting of Adverse Events ............................................... 67
  10.2. SERIOUS ADVERSE EVENTS (SAE) ..................................... 67
  10.2.1. Definition ............................................................................ 67
  10.2.2. Reporting of SAE ................................................................. 68
  10.2.3. Follow-up of SAE ................................................................. 68
  10.2.4. SAE Occurring After the Study ............................................ 69
  10.3. REPORTING OF OVERDOSAGE TO THE SPONSOR ............... 69
  10.4. REPORTING OF PREGNANCY TO THE SPONSOR .................. 69
  10.5. SPONSOR'S RESPONSIBILITIES FOR SAFETY REPORTING PURPOSES .... 70

11. DATA COLLECTION AND STUDY MONITORING ....................... 70
  11.1. DATA COLLECTION .................................................................. 70
  11.1.1. Case Report Form ................................................................. 70
11.1.2. Source Documents

11.2. STUDY MONITORING
   11.2.1. Monitoring visits
   11.2.1.1. Site Preselection Visit
   11.2.1.2. Initiation Visit
   11.2.1.3. Follow-up Visits
   11.2.1.4. Closing Visit
   11.2.2. Direct Access to Source Documents

11.3. INDEPENDENT DATA MONITORING COMMITTEE

12. DATA MANAGEMENT
   12.1. DATA ENTRY
   12.2. DATA CLEANING
   12.3. DATA CODING
   12.4. DATA STORAGE
   12.5. DATABASE LOCK

13. STATISTICAL ANALYSIS
   13.1. GENERAL CONSIDERATIONS
   13.2. SAMPLE SIZE
   13.3. PROTOCOL DEVIATIONS
   13.4. DATA SETS ANALYSED
   13.5. HANDLING OF DROPOUTS AND MISSING DATA
   13.5.1. Dropouts
   13.5.2. Repositioning of Visits
   13.5.3. Missing Data
   13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS
   13.7. EFFICACY ANALYSIS
   13.7.1. Primary Criterion
   13.7.1.1. Primary Analysis
   13.7.1.2. Supportive Analysis
   13.7.1.3. Additional Analysis
   13.7.2. Secondary Criteria
   13.7.2.1. Numbers of Atrial Fibrillation Episodes in the first week following V3
   13.7.2.2. Duration of Atrial Fibrillation Episodes in the first week following V3
   13.7.2.3. Time to first AF recurrence less than 10 minutes or symptomatic
   13.7.2.4. Clinical parameters evaluation
   13.7.2.5. Biomarker analysis: red blood cell concentrations of DHA
   13.8. SAFETY ANALYSIS
   13.8.1. Adverse Events
   13.8.2. Clinical Laboratory Evaluation
   13.8.3. Global Physical Examination
13.8.4. Vital Signs, Physical Findings and Other Observations Related to Safety ....................... 83
13.8.4.1. Vital Sign Measurements Over Time ............................................................................. 83
13.8.4.2. Body weight ................................................................................................................... 83
13.8.4.3. Individual Patient Changes ............................................................................................. 83
13.8.5. ECG ................................................................................................................................... 83
13.8.6. Coagulation parameters ..................................................................................................... 84
13.9. CONCOMITANT TREATMENTS ..................................................................................... 84
13.10. COMPLIANCE .................................................................................................................... 84
13.11. INTERIM ANALYSIS AND DATA MONITORING ........................................................ 84

14. GENERAL ETHICAL CONSIDERATIONS ........................................................................... 85
14.1. ETHICAL CONDITIONS ................................................................................................... 85
14.2. ETHICS COMMITTEE AND LEGAL REQUIREMENTS ................................................ 85
14.3. PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM ........... 86
14.4. PERSONAL DATA PROTECTION ................................................................................... 86
14.5. INSURANCE POLICY ........................................................................................................ 87

15. ADMINISTRATIVE PROCEDURES ................................................................................ 87
15.1. PROTOCOL AMENDMENT .............................................................................................. 87
15.2. SOURCE DOCUMENTS, INVESTIGATOR'S FILE STORAGE ..................................... 87
15.3. END OF THE STUDY ......................................................................................................... 88
15.3.1. Definition of the End of Study .......................................................................................... 88
15.3.2. Early Study Termination ................................................................................................... 88
15.3.2.1. Early Study Termination Decided by the Sponsor ......................................................... 88
15.3.2.2. Early Study Termination Decided by the Competent Authorities .................................. 88
15.4. AUDIT .................................................................................................................................. 89
15.5. INSPECTION ....................................................................................................................... 89
15.6. CONFIDENTIALITY .......................................................................................................... 89
15.7. CLINICAL STUDY REPORT ............................................................................................. 89
15.8. STUDY RESULTS COMMUNICATION .......................................................................... 90
15.9. STUDY RESULTS PUBLICATION ................................................................................... 90

16. REFERENCES ...................................................................................................................... 92

17. APPENDICES ....................................................................................................................... 96
17.1. DECLARATION OF HELSINKI ........................................................................................ 97
17.2. SAE REPORT FORM ........................................................................................................ 101
17.3. PREDEFINED LIMITS OF LABORATORY AND VITAL SIGN POTENTIALLY CLINICALLY SIGNIFICANT CHANGES AND VALUES... 104
## SYNOPSIS

<table>
<thead>
<tr>
<th>Name of Sponsor:</th>
<th>Pierre Fabre Médicament represented by the Institut de Recherche Pierre Fabre (IRPF)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Name of Finished Product:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Name of Active Substance:</td>
<td>F373280 (Panthenyl-Ester of DHA)</td>
</tr>
<tr>
<td>Title of the Study:</td>
<td>Efficacy and safety study of F373280 for maintenance of sinus rhythm after electrical cardioversion in patients with persistent Atrial Fibrillation and Chronic Heart Failure. International, multicentric, randomised, double-blind, placebo controlled study</td>
</tr>
<tr>
<td>Abbreviated Title:</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Study Coordinating Investigator:</td>
<td>Pr Savina NODARI</td>
</tr>
<tr>
<td>Study Centres:</td>
<td>International, multicentric</td>
</tr>
</tbody>
</table>
| Publication / Rationale: | F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after electrical cardioversion in persistent atrial fibrillation (AF) patients with chronic heart failure. The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of AF induced by burst pacing [1]. Moreover, the effectiveness of PolyUnsaturated Fatty Acid (PUFA) has been proven in the following conditions:  
   - prevention of AF recurrence in patients with persistent AF, in co-administration with amiodarone (add on therapy) [2]  
   - Improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]  
Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent atrial fibrillation and chronic heart failure. This phase IIA study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after electrical cardioversion (ECV) in patients with persistent atrial fibrillation and chronic heart failure. |
| Planned Study Period: | January 2013 – April 2017 |
| Clinical Phase: | IIA |
| Objectives: | **Primary:**  
   - Efficacy of F373280 on the maintenance of sinus rhythm after direct electrical cardioversion in patients with persistent atrial fibrillation and chronic heart failure  
**Secondary:**  
   - Efficacy of F373280 on the efficiency of direct electrical cardioversion  
   - Effect of F373280 on echocardiographic parameters  
   - Safety and tolerability of F373280 |
| Methodology: | - International, multicentre, randomised, double-blind, placebo-controlled  
   - Selection period  
   - Start of treatment 4 weeks before ECV  
     - Condition to ECV:  
       - Ideally INR 2-3 (vitamin K antagonist should be given at least 3 weeks before ECV)  
       - No spontaneous cardioversion before ECV  
   - Follow-up 20 weeks after visit 3 (ECV visit)  
     - Condition: successful ECV or spontaneous CV  
   - Cardiac monitoring: |
7-days continuous ECG ambulatory recording (Holter ECG) between visit 3 (ECV visit) and visit 4 (week 5) in patients with sinus rhythm
- TTEM: one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24) and at any time in case of AF or atrial flutter symptoms.
- Treatment duration: 24 weeks

**Study Schedule:**

7 visits will be scheduled:
- V1/ W-4 to W-1: selection visit (7 to 28 days before the inclusion visit)
- V2/ D1: Inclusion visit (start of study treatment)
- V3/ W4 (D28 -2/+7 days): cardioversion visit (outpatient or hospitalization according to clinical practice of the centre) (installation of the Holter device)
- V4/ W5 (D35 -2/+7 days): follow-up visit (removing of the Holter device and installation of the TTEM)
- V6/ W12* (D84 ± 7 days): follow-up visit
  *see amendment PA05 dated 22OCT2014
- V7/ W16 (D112 ± 7 days): follow-up visit
- V9/ W24* (D168 ± 7 days): final study visit
  *see amendment PA05 dated 22OCT2014

**Number of Patients:**

Maximum 135 patients

**Diagnosis and Criteria for Inclusion:**

**Inclusion Criteria:**

- **Demographic Characteristics and Other Baseline Characteristics:**
  1. Men or women aged more than 18 years (inclusive)
  2. Patients with current episode of persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted
  3. Previous history of first documented episode of persistent AF.
  4. Previous history of ischemic or non ischemic heart failure
  5. NYHA class I or II chronic heart failure at selection and at inclusion
  6. Left ventricular systolic dysfunction defined at selection and at inclusion by a reduced left ventricular ejection fraction (LVEF) ≥ 30% and ≤ 45% or for patients with a LVEF > 45%:
    - an increased left ventricular end-diastolic size
      (diameter ≥ 60 mm and/or > 32 mm/m² and/or volume > 97 ml/m²)
    - and/or an increased left ventricular end-systolic size
      (diameter > 45 mm and/or > 25 mm/m² and/or volume > 43 ml/m²)
    - and/or a reduced left ventricular outflow tract velocity time integral < 15 cm
  7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers
  8. Left atrial area ≤ 40 cm² at selection and at inclusion
  9. Patients treated or having to be treated by vitamin K antagonist
  10. For female patient of child-bearing potential:
    - **In all the countries except Italy:**
      - Use of an effective method of contraception (hormonal contraception or intrauterine device) assessed by the investigator, for at least 2 months before the selection in the study, and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment
      - Documented as surgically sterilized
    - **In Italy only:**
      - Absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
      - Use of double barrier contraception method (use of effective medical contraception
(method) from at least 2 months before the start of the study to the entire duration of
the study and for a month after the end of the study or
- Documented as surgically sterilized

11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion
12. For male with a child-bearing potential partner *(In Italy only)*:
   - Absolute abstention from sexual intercourse during the whole duration of the study
     and for 3 months after the end of the study or
   - Use of double barrier contraception method (use of condom for male and effective
     contraception method for the partner) from the entire duration of the study to 3
     months after the end of the study.

**Ethical/legal considerations:**
13. Having signed his/her written informed consent,
14. Affiliated to a social security system, or is beneficiary (if applicable in the national
    regulation)

**Non-Inclusion Criteria:**

**Criteria related to pathologies:**
1. No previous history of first documented episode of persistent AF
2. More than two successful cardioversions (electrical or pharmacological) in the last 6
   months
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to
   IV)
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be checked in case of
   treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic
coronaryopathy assessed by coronarography or cardiac stress test (Echo stress, exercise
stress test, nuclear or MR perfusion evaluation methods) within 6 months before
   selection
7. Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration
   rate < 30 ml/min) at selection
8. Bradycardia (HR ≤ 50 bpm)
9. Hyperkalemia or hypokalemia (according to the standards of local laboratories) at
   selection
10. Cardiac surgery within 3 months before selection or planned during the study duration

**Criteria related to treatments:**
11. Previously ineffective pharmacological or electrical cardioversion
12. Concomitant treatment with ranolazine or any antiarrhythmic drug (within 7 days prior
to selection), except amiodarone, dronedarone and stable dose of digoxin, beta blockers,
calcium-blockers
13. Concomitant treatment with oral amiodarone or dronedarone from selection
14. Concomitant treatment with intravenous amiodarone from selection
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT
    implantation within the last 6 months
16. Treatment with any Polysaturated Fatty Acid (PUFA) within the last 3 months
17. Dietary supplement with ω 3 or ω 6 according to investigator’s judgement
18. Having undergone any form of ablation therapy for AF
19. Patient treated with oral anticoagulant treatment other than vitamin K antagonist: new
    oral anticoagulants (dabigatran, rivaroxaban, apixaban), or treated with irreversible
antiplatelet agents P2Y12 inhibitors such as ticlopidine, clopidogrel or prasugrel

**Other criteria:**

- 20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion
- 21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection
- 22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself/herself to its constraints
- 23. Patient family member or work associate (secretary, nurse, technician,..) of the Investigator
- 24. Patient having forfeited his / her freedom by administrative or legal award or being under guardianship
- 25. Breastfeeding female patient

### Exclusion criteria before V3:

Patients without dyskalemia who will not have INR values ≥ 2 on the 3 last tests performed before ECV should not have an ECV and will be excluded from the study. However, if only 2 INR values are ≥ 2 among those 3 last tests, an ECV can be performed if the presence of atrial thrombosis can be excluded with an ECHO–TE (transesophageal echocardiography) performed on the same day (before ECV) and the patient can continue the study. If necessary, for meeting these INR conditions, the ECV (and following visits) could be postponed by 7 days.

### Test Product:

<table>
<thead>
<tr>
<th>F373280 Soft Capsules</th>
</tr>
</thead>
</table>

### Dose:

Arm with 1g of F373280

### Mode of Administration:

Oral, one capsule each evening with dinner.

### Duration of Treatment:

24 weeks of treatment exposure with F373280 (25 weeks if ECV postponed by 1 week)

### Reference Therapy

Placebo soft capsules

Placebo will be administered in the same conditions as the tested product.

### Mode of Administration:

Oral, one capsule each evening with dinner

### Evaluation Criteria:

**Efficacy evaluation variables:**

**Primary evaluation variable:**

- Time to first Atrial Fibrillation recurrence or atrial flutter emergence defined by the time to first episode of AF or atrial flutter lasting for at least 10 minutes (Follow up of 20 weeks after visit 3 – ECV visit).

Handling of AF recurrences or atrial flutter emergences: 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) between visit 3 (ECV visit) and visit 4 (week 5). Then, the follow up will be documented using the TTEM: one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24).

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF or the emergence of atrial flutter will be assessed after visit 3 (from week 5). Moreover, during this TTEM period, if patient experiences any AF or atrial flutter symptoms, it should be recorded and documented using the TTEM.

All ECG (Holter and TTEM) will be evaluated by a Central Reading Laboratory.

**Secondary evaluation variables:**

During the 7-day continuous ECG monitoring,
- Numbers of AF episodes
- Duration of AF episodes

**Clinical parameters:**
During the whole study:
- Number of recurrence of symptomatic AF episodes
- EHRA score
- Hospitalization for cardiovascular events
- Hospitalization for thromboembolic stroke
- All causes of hospitalization

**Cardioversion:**
- Assessment of spontaneous cardioversion
- Assessment of successful cardioversion
- Shocks distribution (1, 2 or 3 shocks)
- Number of patients needing an other cardioversion after the initial ECV

**Other:**
- Evolution of echocardiographic parameters (at V4, V6 and V9) (Left atrial diameter (mm), Left atrial area (cm²), Left atrial volume (ml), Left atrial volume/BSA (ml/m²), Left ventricular ejection fraction (%), Left ventricular end diastolic volume/BSA (ml/m²), Left ventricular end systolic volume/BSA(ml/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (ml) Left ventricular end systolic diameter (mm), Left ventricular end systolic volume (ml))
- Evolution of omega 3 index and intra erythrocyte DHA (*For this assessment samples will be centralized.*)

**Safety criteria:**
- **Adverse events** (observed and / or spontaneously reported)
- **Vital signs** (Blood pressure (supine and standing), heart rate)
- **Physical examination** (body weight, body surface area)
- **Standard 12-lead ECG:** heart rate (bpm), PR (ms), QRS (ms), QT (ms), QTcB (ms), QTcF (ms), repolarisation patterns (ECG not centralized)
- **Haematology:** haematocrit, haemoglobin, red blood cell (RBC) count, white blood cell (WBC) count, WBC differential count, reticulocytes, platelets
- **Biochemistry:** sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatin phosphokinase (CPK) fibrinogen (*local laboratory*)
- **Coagulation parameters:** Activated partial thromboplastin time (aPTT), thrombin clotting time (TCT), INR (*local laboratory*), Prothrombine Time (*PT*)

**Concomitant treatments**

**Compliance**

---

**Statistical Methods:**

**Sample Size:**
Assuming an AF recurrence or atrial flutter emergence rate under placebo of 85%, a power of 80%, an alpha risk of 5% and a rate of not assessable patients of 15%, 76 randomised patients per group will be necessary, using a log-rank test of survival curves, a difference between groups of 20%.

**Primary Efficacy Analysis**
The primary analysis, performed on the Full Analysis Set (FAS: all randomised patients with at least one dose of treatment and with a successful cardioversion observed at visit 3), will be a survival analysis using the Kaplan Meier method and Cox regression model.

**Secondary Analyses**
All secondary efficacy criteria will be described and compared using appropriate tests on the FAS.

**Safety Analyses**
Descriptive statistics will be performed on the Safety Set (all randomised patients with at least one dose of treatment).
### STUDY FLOW-CHART

**F373280 CA 201**

<table>
<thead>
<tr>
<th>Weeks</th>
<th>V1</th>
<th>V2</th>
<th>V3</th>
<th>V4</th>
<th>V6</th>
<th>V7</th>
<th>V9</th>
</tr>
</thead>
<tbody>
<tr>
<td>W-4 to W-1</td>
<td>D1</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W4 (28-2D/+7D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W5 (35-2D/+7D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W12 (84+/-7D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W16 (112+/-7D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W24 (168+/-7D)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

1. **Outpatient or Hospitalization (1)**
2. **Informed consent**
3. **Demographic characteristics**
4. **Medico-surgical history**
5. **Concomitant disease**
6. **Concomitant treatment**
7. **Habits**
8. **Global physical examination (body weight)**
9. **Echocardiography**
10. **Eligibility criteria check**
11. **Blood pressure, heart rate**
12. **12-Lead ECG Recording**
13. **INR**
14. **aPTT, TCT**
15. **Biochemistry**
16. **Haematology**
17. **Urinary pregnancy test**
18. **Red Blood Cell concentrations of DHA**
19. **Treatment number allocation**
20. **IVRS/IWRS**
21. **ECV (3)**
22. **Drug administration**
23. **Adverse events recording**
24. **Holter ECG**
25. **TTEM (6)**

1. **Outpatient or hospitalization according to clinical practice of the centre (less or more than 24 hours)**
2. **In case of VKA introduction: INR 2 to 3 times a week until stabilization, then weekly until the ECV, then every 4 weeks after ECV**
3. **In patients with AF**
4. **24-hour Holter ECG**
5. **7-day Holter ECG**
6. **TTEM: one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24) and at any time in case of AF or atrial flutter symptoms. TTEM once a week even in case of AF recurrence or atrial flutter emergence for at least 10 minutes.**

---

Final version

1098/1185
LIST OF ABBREVIATIONS

aPTT : Activated partial thromboplastin time
AE : Adverse event
AF : Atrial fibrillation
ALA : Alpha-linoleic acid
ALT : Alanine aminotransferase
AST : Aspartate aminotransferase
AUC : Area under the plasma concentration versus time curve
AUC_{inf} : Total area under the curve extrapolated to infinity
βHCG : beta human chorionic gonadotrophin
BLQ : Below the limit of quantification
BMI : Body mass index
BP : Blood pressure
BSA : Body Surface Area
CEP : Protocol evaluation committee
CHMP : Committee for medicinal products for human use
C_{max} : Maximum concentration
C_{min} : Minimum concentration
CNALV : Clinically noteworthy abnormal laboratory value
CPK : Creatin phosphokinase
CPP : Comité de protection des personnes
CRA : Clinical research associate
CRT : Cardiac resynchronization therapy
CSC : "Clinically Significant Change", i.e., Predefined potentially clinically significant change leading to a potentially clinically significant value (vital signs)
CV : Coefficient of variation
DBP : Diastolic blood pressure
DHA : Docosahexaenoic acid
EC : Ethics committee
ECG : Electrocardiogram
ECHOCARDIOGRAPHY –TE : Transesophageal echocardiograph
ECV : Electrical cardioversion
EHRA : European heart rhythm association
EPA : Eicosapentaenoic acid
e-CRF : Electronic case report form
FAS : Full analysis set
Fe : Fraction of the administered drug excreted in urine
GCP : Good clinical practice
GFR : Glomerular Filtration Rate
HBs : Hepatitis B antigen
HCV : Hepatitis C virus
HDL : High density lipoprotein
HF : Heart failure
HIV : Human immunodeficiency virus
HR : Heart rate
ICH : International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use
IDMC : Independent data monitoring committee
INR : International normalized ratio
IRPF : Institut de Recherche Pierre Fabre
IVRS : Interactive voice response system
LAA : Left atrial area
LC/MS-MS : Liquid chromatography with tandem mass spectrometry
LDL : Low density lipoprotein
LOQ : Limit of quantification
LVEF : Left ventricular ejection fraction
MedDRA : Medical dictionary for regulatory activities
MR : Mineralocorticoid receptor
MR perfusion : Magnetic Resonance perfusion
MTD : Maximum tolerated dose
N : Number of determinations or replicates
NOAEL : No observed adverse effect level
NYHA : New York heart association
od : Once a day
PC : “Predefined Change”, i.e., Predefined potentially clinically significant change (lab or vital signs)
PCA : PC leading to an out-of-range value (lab values)
PFB : Pierre Fabre Biométrie
PSC : Potentially Clinically Significant Change
PSCV : Potentially Clinically Significant Value
PUFA : PolyUnsaturated fatty acid
p.o. : Per os
PP : Per protocol data set
QTcB : QT interval using Bazett’s correction formula
QTcF : QT interval using Fridericia’s correction formula
RBC : Red blood cells
SAE : Serious adverse event
SBP : Systolic blood pressure
SD : Standard deviation
T1/2 : Terminal half-life
T0 : Time of drug administration
Tmax : Time to reach the maximal concentration
TCT : Thrombin clotting time
TEAEs : Treatment emergent adverse events
TTEM : TransTelephonic ECG monitoring
VKA : Vitamin K Antagonist
WBC : White blood cells
WHO-DRUG : World health organization drug reference list
1. INTRODUCTION AND STUDY RATIONALE

1.1. TARGET PATHOLOGY AND THERAPY

Atrial Fibrillation (AF) is a supraventricular arrhythmia characterized by uncoordinated atrial electric activity with consequent deterioration of atrial mechanical function. It is the most common sustained cardiac rhythm disorder, increasing in prevalence with age. Haemodynamic impairment and thromboembolic events related to AF result in significant morbidity and mortality [7].

In 2009, Decision Resources estimated that there were 7.8 million diagnosed prevalent cases of AF in US, Europe and Japan. This age-related pathology should increase to 9.4 million cases in 2019.

Except for the conventional class I and class III anti-arrhythmic agents, the Polyunsaturated Fatty Acids (PUFAs) constitute one emerging antiarrhythmic therapy. These compounds potently address the AF substrate by directly targeting both the electrical and the structural remodelling of the deficient atria. The n-3 PUFAs, essential for human, are alpha-linoleic acid (ALA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). First, PUFAs specifically modulate ionic channels by fastening their inactivating mode which renders these compounds selective for pathological situations (such as AF) without any major effect in normal conditions. PUFAs are “open Kv1.5 channel blockers” leading to a lengthening of atrial action potential duration and are “persistent Nav1.5 channel blockers” leading to hyperpolarization of diastolic resting potential. Second, PUFAs influence structural remodelling through their anti-inflammatory effects as they directly compete with arachidonic acid in the production of inflammatory eicosanoids. In summary, PUFAs share unique, well-tolerated antiarrhythmic potential by interacting with the electrical and structural remodelling during sustained AF. In animal studies, it was recently demonstrated that DHA is particularly effective in pathologic conditions such as ischemia and/or AF.

The potential anti-arrhythmic effects of a PUFA were previously developed in AF: nicotinyl ester of DHA (pro-drug based on DHA delivery) was assessed in a two-week ventricular tachypaced
canine model. Dogs were subjected to 4 weeks of medication prior to undergoing an electrophysiology study, and received either placebo or nicotinyl ester of DHA. Dogs were tachypaced at 240 beats per min for the final two weeks of the treatment plan. The results showed that the tested PUFA reduced the duration of AF induced by burst pacing, and the incidence of sustained AF, compared to dogs treated with the placebo [1].

In clinical practice, Nodari and coll [2] assessed n-3 PUFAs in the prevention of AF recurrences after electrical cardioversion (ECV). All included patients were treated with amiodarone and a renin-angiotensin-aldosterone system inhibitor. The 199 patients were assigned either to placebo or n-3 PUFAs 2 g/d and then underwent direct ECV 4 weeks later. The primary end point was the maintenance of sinus rhythm at 1 year after cardioversion. At the 1-year follow up, the maintenance of sinus rhythm was significantly higher in the n-3 PUFAs treated patients compared with the placebo group (hazard ratio, 0.62 [95% confidence interval, 0.52 to 0.72] and 0.36 [95% confidence interval, 0.26 to 0.46], respectively; p = 0.0001). The study concludes that in patients with persistent AF on amiodarone and a renin-angiotensin-aldosterone system inhibitor, the addition of n-3 PUFAs 2 g/d improves the probability of the maintenance of sinus rhythm after direct current cardioversion. Previously, during the World Congress of Cardiology in 2006, an abstract reported the effectiveness of PUFAs on top of traditional treatment (amiodarone, beta blockers, renin-angiotensin-aldosterone system inhibitor) in the prevention of AF relapses in patients having undergone ECV. In the PUFA group, AF relapses were significantly lower than in the placebo group at 1 month (3.3% vs 10%; p = 0.043), at 3 months (10% vs 25%; p = 0.004) and at 6 months (13.3% vs 40%; p < 0.0001) [19].

In contrast, in the general AF population (paroxystic atrial fibrillation and persistent atrial fibrillation), PUFAs failed to prove their efficacy [7] because of the absence of cardiac remodelling or because of a short pre-treatment duration before ECV (1 week) [8]. The effects of PUFAs were only observed in patients with persistent AF on add on therapy and after a sufficient pre-treatment before ECV. Persistent AF is commonly associated to heart failure. Previous studies performed in heart failure population demonstrated the benefit of PUFAs on the improvement of functional ventricular parameters and morbi-mortality, and on the reduction of hospitalisation [3, 4, 5].

Nodari and coll [3] performed a trial in patients with chronic heart failure (NYHA I to III and LVEF< 45%). After a treatment of 133 patients with PUFAs (n=67) or placebo (n=66) at a dosage
of 5 g/day for 1 month, then 2 g/day for 11 months, the n-3 PUFAs group and the placebo group differed significantly (p <0.001) in regard to:

- LVEF (increased by 10.4% and decreased by 5.0%, respectively)
- peak VO₂ (increased by 6.2% and decreased by 4.5%, respectively)
- exercise duration (increased by 7.5% and decreased by 4.8%, respectively)
- mean New York Heart Association functional class (decreased from 1.88 +/- 0.33 to 1.61 +/- 0.49 and increased from 1.83 +/- 0.38 to 2.14 +/- 0.65, respectively).

The hospitalization rates for patients with HF were 6% in the n-3 PUFAs and 30% in the placebo group (p <0.0002).

Moertl and coll [4] performed a dose-ranging study in patients with a more severe chronic heart failure (NYHA III and IV and LVEF < 35%). It was a double-blind, randomised, controlled pilot trial in 43 patients treated with PUFAs or placebo for 3 months (1 g/d n3-PUFA (n = 14), 4 g/d n3-PUFA (n = 13), or placebo (n = 16)). After treatment, left ventricular ejection fraction increased in a dose-dependent manner (p = 0.01 for linear trend) in the 4 g/d (baseline vs 3 months [mean ± SD]: 24% ± 7% vs 29% ± 8%, p = 0.005) and 1 g/d treatment groups (24% ± 8% vs 27% ± 8%, p = 0.02).

No changes in any investigated parameters were noted with placebo.

Taking into account these studies performed with PUFAs, it seems that the best target for DHA is persistent AF in patients with heart failure. The aim of this proof of concept study is to assess in stand alone therapy (without association of other anti-arrhythmic treatments), the effect of F373280 in patients with persistent AF and heart failure in the maintenance of sinus rhythm after ECV.

1.2. INFORMATION ON THE TEST PRODUCT

F373280 or panthenyl ester of DHA is the mono-ester of panthotenic alcohol and DHA, selected to be developed for the management of AF.

F373280 is a prodrug of DHA.

A brief summary of F373280 known characteristics is presented in this section. For further details, please refer to the F373280 Investigator’s Brochure. [1]
1.2.1. Chemical and pharmaceutical characteristics

1.2.1.1. Nomenclature and structure
Chemical name (IUPAC):
(4Z,7Z,10Z,13Z,16Z,19Z)-3-((R)-2,4-dihydroxy-3,3-diméthylbutanamido) propyl docosa-4,7,10,13,16,19-hexaenoate

Structural formula:

```
OO
\NNHH
OO
\OOOH
```

Laboratory code: F373280
Molecular formula: C₃₁H₄₉NO₅
Molecular mass: 515.7

1.2.1.2. Physical and chemical general properties

Appearance: Clear oily viscous liquid

Solubilities:
- Water: Practically insoluble
- Alcohol: Very soluble
- Trimethylpentane: Slightly soluble

1.2.2. Non-clinical Data
Non-clinical data are exhaustively detailed in the Investigator’s brochure [1]. A brief summary is provided below.
1.2.2.1. **Pharmacological profile**

F373280 (mono-ester of panthotenic alcohol and DHA) is a novel pro-drug of DHA which exerts antiarrhythmic properties by interacting with the electrical and structural remodelling of the atria.

Experimental investigations were conducted in HEK293 cell line transfected with human Kv1.5 channel using the whole cell patch clamp technique to evaluate whether F373280 could block the sustained component of $I_{Kv1.5}$. F373280 concentration-dependently reduced Kv1.5 channel activity with an $IC_{50}$ value of 13.7 $\mu$M.

The effects of F373280 on atrial effective refractory period were investigated in anesthetized pig using a conventional pacing protocol through epicardial electrodes placed on the left atrium. F373280 administered as a bolus and an infusion (10 mg/kg) significantly increased atrial effective refractory period (23.8 ± 2.2 ms versus -7.3 ± 11.5 ms in the presence of vehicle, $p < 0.05$). In addition, F373280 was devoid of significant effect on the hemodynamic and the electrocardiogram (ECG) intervals.

Proof of the pharmacological concept was performed with a different DHA derivative named: Nicotinyl ester of DHA (pro-drug based on DHA delivery). Ventricular tachypacing-induced congestive heart failure provides a clinically-relevant animal model of AF associated with structural remodelling, as is often seen clinically. It has been shown that sustained oral PUFA administration suppresses congestive heart failure-induced AF-promotion and fibrosis in the ventricular tachypacing canine model. Nicotinyl ester of DHA was tested in this model, at 1 g/day and 5 g/day, during 4 weeks, to prevent congestive heart failure-related atrial structural remodelling and AF promotion in dogs. Nicotinyl ester of DHA dose-dependently reduced heart failure-induced increases in AF duration (989 ± 111 sec, n=5 in the presence of placebo versus 637 ± 196 sec, n=5 in the presence of 1 g/kg/d Nicotinyl ester of DHA and 79 ± 51 sec, n=5, in the presence of 5 g/kg/d Nicotinyl ester of DHA). The protective effect of Nicotinyl ester of DHA was associated with a marked increase of plasma level of DHA and important incorporation of DHA in the left atrial tissue. Because F373280 similarly to Nicotinyl ester of DHA increases plasma level of DHA, it could be estimated that the compound may exert a similar protective effect [1].
1.2.2.2. **Safety pharmacology**

A battery of safety pharmacology studies was performed to evaluate the effects of F373280 on the central nervous, cardiovascular and respiratory systems. Data of these studies are exhaustively detailed in the Investigator’s brochure [1].

No particular alerts were evidenced with F373280.

1.2.2.3. **Toxicology profile**

Concerning the toxicological data, 4-week and 26-week repeat-dose studies in rat and dog were performed. Compared to the high administered doses of F373280 (500 to 2000 mg/kg/day), low circulating concentrations of F373280 were measured.

During these toxicity studies, no toxicity was observed in rat after 4 and 26 weeks of dosing and in dog after 4 weeks of dosing. A NOAEL of 2000 mg/kg/day was established in these repeat toxicity studies.

During the 26-week toxicity study in dogs, the NOAEL was set at 1000 mg/kg/day based on changes observed on red blood cell parameters.

Based on toxicological profiles, F373280 is considered to support the proposed clinical trial.

1.2.2.4. **Pharmacokinetic data**

According to animal studies described in the Investigator’s brochure [1], the non-clinical pharmacokinetic profile of F373280 is not associated with particular alerts concerning the proposed clinical phase IIa study.

1.2.3. **Clinical data**

**Part A: Single dose**

Six consecutive single ascending doses were tested (0.5 g, 1 g, 2 g, 4 g, 8 g and 16 g) on 6 independent cohorts of 8 subjects (6 verum + 2 placebo). 49 subjects were treated and 48 completed the study.

No Serious Adverse Events (SAE) occurred in the course of the study.

Regarding the reported Treatment Emergent Adverse Events (TEAEs) that were judged by the Investigator as having a causal relationship with the study drug administration in the absence of
an alternative explanation, 3 TEAEs were observed in the placebo group (palpitation, dizziness in standing position, symptomatic orthostatic hypotension without loss of consciousness) and 4 in the group of F373280 at the dosage of 16 g (meteorism, liquid stool, symptomatic orthostatic hypotension and dizziness in standing position). None of these adverse events (AE) were reported in the groups of F373280 at the dosages of 0.5 g, 1 g, 2 g, 4 g and 8 g.

After a single administration of the different tested doses no difference between the tested product and placebo has been reported, regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters (related to coagulation: platelets and fibrinogen) and coagulation parameters (bleeding time, prothrombin time/INR, activated partial thromboplastin time, thrombin clotting time). Variations of these parameters were within the physiological ranges.

After single oral administration of F373280 from 0.5 g to 16 g in 36 young healthy male subjects (6 per dose level), the following was observed:

- **F373280**: Whatever the tested dose there is no circulating F373280 in plasma: only few, sparse and non consecutive samples with quantifiable level of F373280 close to LOQ were observed. This confirms that F373280 is a prodrug.

- **Panthenol**: Cmax and AUC increased with the administered dose between 0.5 and 16 g. Panthenol concentrations were rapidly cleared from plasma with a mean terminal half-life around 2 hours.

- **DHA**: after 0.5 and 1 g, low increased in DHA plasma concentrations compared to the baseline levels led to a high inter-individual variability of the corresponding Pharmacokinetics parameters. Plasma exposure in DHA increased with the administered dose between 2 and 16 g with no departure from proportionality (baseline corrected parameters).

**Part B: Multiple doses**

Three consecutive repeated ascending doses (1, 2 and 4 g) were tested on 3 independent cohorts of 12 subjects (9 verum + 3 placebo, double blind). 36 subjects completed the study. Each treatment was administered over a period of 28 days. Pharmacokinetic parameters were assessed over a period of 14 days.
Among the TEAE judged by the investigator as suspected to F373280, 5/9 TEAEs were classified according the System Organ Class in vascular system disorder with orthostatic hypotension (2 in the 1 g group, 1 in the 2 g group and 2 in the 4 g group) and 4/9 were classified in nervous system disorder with 3 dizziness (2 in the 2 g group and 1 in the 4 g group) and 1 migraine (in the 1 g group). These TEAEs have already been reported with PUFAs and are commonly observed in phase I studies.

After a repeated administration of the different tested doses, no difference between the tested products and placebo was reported regarding vital signs (heart rate, systolic blood pressure and diastolic blood pressure), biological parameters. The assessment of coagulation parameters and platelet function after administration of repeated dose of F373280 did not report any bleeding issue. The reported changes in coagulation parameters and platelet function were within physiological ranges.

After a 14-day repeated oral administration of F373280 from 1 g to 4 g, the following was observed:

- **Panthenol**: Cmax and AUC increased with the administered dose between 1 and 4 g. No accumulation of panthenol in plasma was observed.

- **DHA**: Plasma exposure increased with dose. A 2-fold accumulation in total plasma exposure of DHA was observed after 14 days of administration, whatever the administered dose.

### 1.3. STUDY RATIONALE

F373280 is a new therapy based on DHA delivery (pro-drug) developed for the maintenance of sinus rhythm after ECV in persistent AF patients with chronic heart failure.

The results of a pharmacological study performed in animals evidenced that DHA reduces the duration of AF induced by burst pacing [1].

Moreover, the effectiveness of PUFAs has been proven in the following conditions:

- Prevention of AF recurrence in patients with persistent AF in co-administration with amiodarone (add on therapy) [2],

- Improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5].
Taking into account these studies, it seems that DHA might be of therapeutic interest in the treatment of patients with both persistent AF and chronic heart failure.

This phase IIa study is designed to assess the efficacy and the safety of the investigational product (F373280) for maintenance of sinus rhythm after ECV in patients with persistent AF and chronic heart failure.

1.4. OVERALL RISK AND BENEFIT ASSESSMENT

F373280 is a new pro-drug of DHA.

DHA is a well-known long chain PUFAs with a long-term clinical experience in cardiovascular diseases. DHA is contained in several medicinal products such as Omacor®, (1 g of Omacor contains about 320 mg of DHA acid) marketed by Laboratoires Pierre Fabre for hypertriglyceridemia and as an adjuvant treatment for secondary prevention after myocardial infarction. According to the summary product characteristics of Omacor® [9]:

- The frequencies of adverse reactions are ranked according to the following: common (>1/100, <1/10); uncommon (>1/1000, <1/100); rare (>1/10000, <1/1000); very rare (<1/10000), not known (cannot be estimated from the available data).

- The reported adverse events are:

  - Infection and infestations:
    - Uncommon: gastroenteritis
  - Immune system disorders:
    - Uncommon: hypersensitivity
  - Metabolism and nutrition disorders:
    - Rare: hyperglycaemia
  - Nervous system disorders:
    - Uncommon: dizziness, dysgeusia
    - Rare: headache
  - Vascular disorders:
    - Very rare: hypotension
  - Respiratory thoracic and mediastinal disorders:
Very rare: nasal dryness

- Gastrointestinal disorders:
  - Common: dyspepsia, nausea
  - Uncommon: abdominal pain, gastrointestinal disorders, gastritis, abdominal pain upper
  - Rare: gastrointestinal pain
  - Very rare: lower gastrointestinal haemorrhage

- Hepatobiliary disorders:
  - Rare: hepatic disorders

- Skin and subcutaneous tissue disorders:
  - Rare: acne, rash pruritic
  - Very rare: urticaria

- General disorders and administration site conditions:
  - Rare: malaise sensation

- Investigations:
  - Very rare: white blood count increased, blood lactate dehydrogenase increased

Moderate elevation of transaminases has been reported in patients with hypertriglyceridaemia.

Panthenol is a well-known substance with a long-term experience in medical, nutraceutic and cosmetic uses. According to the summary product characteristics of a product such as Bépanthene® (tablet indicated in alopecia) which contains panthenol (100 mg), adverse event observed are rare cases of urticaria and erythema [10]. Panthenol is metabolised in panthotenic acid, i.e. B5 vitamin.

Concerning toxicological studies performed results can support the administration of F373280 in the proposed clinical phase II study without particular alert [1]. Any safety warning was reported during a phase I study performed with F373280 administered to 84 healthy volunteers in single dose in a range between 500 mg and 16 g or in repeated dose during 28 days in a range between 1 g and 4 g. Adverse events reported and related to study treatment were minor to moderate. The adverse events were palpitations, orthostatic hypotension, dizziness, meteorism and liquid stool. Most were reported in both groups (placebo and F373280) without a dose relationship. The assessment of coagulation parameters and platelet function after
administration of repeated dose of F373280 did not report any bleeding concern: the reported changes in coagulation parameters and platelet function were within physiological ranges.

Moreover, DHA has been associated with anticoagulant products in AF studies [2, 8]. The range of PUFAs doses tested was between 2 g to 3 g (640 mg to 960 mg of DHA) and the range of study durations between 6 to 12 months. This association did not report a significant side effect of bleeding.

DHA has already been used in HF patients in several studies without safety concern [3, 4, 5]. The range of PUFAs doses tested was between 1 g to 5 g (1 g of the tested PUFAs contains about 320 mg of DHA acid) and the range of study durations was between 3 months to 3.9 years.

Thus, inclusion of patients with no specific antiarrhythmic treatment is acceptable. They will receive an anticoagulant treatment to prevent the thrombo-embolic complications of AF (particularly stroke) and the adequate treatments to control the heart rate and heart failure.

In conclusion, the overall available data allow in safe conditions the treatment of patients with persistent AF and chronic heart failure with F373280 in safe conditions.

2. STUDY OBJECTIVES

2.1. PRIMARY OBJECTIVE

The primary objective of the study is to assess the efficacy of F373280 on the maintenance of sinus rhythm after direct ECV in patients with persistent AF and chronic heart failure.

2.2. SECONDARY OBJECTIVES

The secondary objectives of the study are to assess:

- the efficacy of F373280 on the efficiency of direct ECV
- the effect of F373280 on echocardiographic parameters
- the safety and tolerability of F373280
3. ETHICAL CONSIDERATIONS RELATING TO THE STUDY

The trial is conducted according to Good Clinical Practices (CPMP/ICH/135/95), the National regulations and the Declaration of Helsinki and its subsequent amendments (see Appendix 17.1). This protocol and the informed consent form will be submitted for approval to independent local or national Institutional Review Boards/Ethics Committees before the study set up, according to national regulation.

All the protocol amendments or critical events liable to increase the risks incurred by the patients or to compromise the validity of the study or patients' rights will be submitted to the coordinator and to the Ethics Committees.

After being informed orally and in writing of all potential risks and constraints of the trial, as well as their freedom to withdraw their participation at any time, patients will then sign a consent form. A time of reflection will be given to the patients, before giving a written consent and starting the study procedures.

The use of a placebo is in accordance with EMA Addendum to the guideline on antiarrhythmics on AF and atrial flutter (EMA/CHMP/EWP/213056/2010) [21] and is acceptable because the included patients will remain under the standard treatment of AF and chronic heart failure. Except antiarrhythmics, they will receive anticoagulant (vitamin K antagonist, VKA), rate control treatment, chronic heart failure treatment. During the study, in case of AF recurrence or atrial flutter emergence that would require cardioversion or the introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms for instance, patients will be withdrawn and the tested product stopped. These patients will be considered as treatment failure.

In this study, patients will be carefully screened, particularly for their cardiac condition, with ECG, 24-hour holter monitor and echocardiographic data, and their biologic and coagulation condition.

The study will be addressed only to patients requiring an ECV due to their persistent AF, in the following conditions:

- ECV in patients not presenting a contra-indication
- Anticoagulation with vitamin K antagonist (VKA) for at least 3 weeks before ECV
- ECV will be performed in patients with AF and without dyskalemia. An INR value control must be performed within 24h before ECV. INR values $\geq 2$ on the 3 last
tests performed before ECV are required. However, if only 2 INR values are ≥ 2 among those 3 last tests, an ECV can be performed if the presence of atrial thrombosis can be excluded with an ECHO–TE (transesophageal echocardiography) performed on the same day (before ECV) and the patient can continue the study. Patients who do not revert to sinus rhythm or present an early AF relapse or an early atrial flutter emergence within the observation period after ECV will be withdrawn and the tested product stopped.

During the whole study, patients will remain under medical control: visits in cardiology units will be performed throughout the study period. This follow up will include clinical signs, ECG, biological and coagulation parameters. Moreover, patient’s cardiac rhythm will be monitored once a week between visits using Trans Telephonic ECG Monitoring (TTEM) reviewed by a Central Reading Laboratory.

Patients may withdraw from the study at any time without having to give a reason and can expect to receive regular conventional therapy.

4. STUDY DESIGN

4.1. OVERALL DESCRIPTION

This phase IIa trial will be conducted as an international, multicentric, 24 weeks, double-blind, placebo-controlled, randomised, parallel group design, trial in 135 patients suffering from persistent AF and chronic heart failure.

After a 1 to 4-week of run-in period without study treatment, patients will be randomised into one of the following treatment groups: F373280 1g or placebo for 24 weeks.

Seven visits are planned for the study:

- Visit 1 (V1): W-4 to W-1: Selection visit (7 to 28 days before the Inclusion Visit)
- Visit 2 (V2): D1: Inclusion visit (start of study treatment)
- Visit 3 (V3): W4 (D28-2/+7D): cardioversion visit (outpatient or hospitalization according to clinical practice of the centre) (installation of the Holter ECG device)
- Visit 4 (V4): W5 (D35 -2/+7D): follow-up visit (removing of Holter ECG device and installation of the TTEM)
- Visit 6* (V6): W12 (D84 ± 7D): follow-up visit
  *see amendment PA05 dated 22OCT2014
- Visit 7 (V7): W16 (D112 ± 7D): follow-up visit
- Visit 9* (V9): W24 (D168 ± 7D): final study visit
  *see amendment PA05 dated 22OCT2014

4.2. DISCUSSION OF THE STUDY DESIGN

4.2.1. Choice of the Study Population
The target indication of F373280 will be the maintenance of sinus rhythm after cardioversion of patients with persistent AF and chronic heart failure. In the present proof of concept study, the evaluation will focus on patients within this indication. This target population is justified by:
- The proved efficacy of PUFAs in patients with persistent AF with or without heart failure in co-administration with amiodarone (add on therapy) [2]
- The proved efficacy of PUFAs on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5]

The study aim is to investigate the product effect in patients with:
- Previous history of persistent AF with duration of the current episode from 7 days to 6 months.
- A systolic heart failure defined by a reduced left ventricular ejection fraction (≥ 30% and ≤ 45%) or for patients with a LVEF > 45%:
  - an increased left ventricular end-diastolic size (diameter ≥ 60 mm and/or > 32 mm/m² and/or volume > 97 ml/m²),
  - and/or an increased left ventricular end-systolic size (diameter > 45 mm and/or > 25 mm/m² and/or volume > 43 ml/m²),
  - and/or a reduced left ventricular outflow tract velocity time integral < 15 cm [23, 24].
According to a sub-group analysis performed in patients with persistent AF associated to heart failure (Nodari S. personal data), PUFAs would be effective to prevent recurrence of AF after cardioversion in patients with moderately abnormal LVEF.

- A Left Atrial Area (LAA) not severely abnormal (no greater than 40 cm² as defined in the report from the American Society of Echocardiography’s Guideline) [23]. According to a sub-group analysis performed in patients with persistent AF associated to heart failure (Nodari S. personal data), PUFAs would not be effective to prevent recurrence of AF after cardioversion of patients with severely abnormal LAA.

For the successful rate of ECV, patients should have a stable medical treatment of heart failure and should not have any myocardial infarction or unstable angina or unstable ischemic coronaropathy assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection.

### 4.2.2. Choice of the Study Design

As the target indication would be the prevention of AF recurrence after ECV, the study design meets the requirements of EMA guideline on antiarrhythmics in AF (EMA/CHMP/EWP/213056/2010) [21].

As F373280 aims to be a safe treatment for the prevention of AF recurrence, it will not be tested as an add-on therapy during the study. To avoid any interaction with the tested product, antiarrhythmics class I and III will be forbidden during the study.

The study design is defined in order to avoid methodological bias. A double blind study is appropriate to assess the efficacy and safety of the use of F373280 to prevent recurrence of AF episodes. Moreover, this study design is similar to the design of almost all trials that have assessed intervention for rhythm control [2, 8, 11, 12].

According to the target indication, only patients with persistent AF and requiring an ECV will be included in order to assess the time to first documented recurrence of AF (or emergence of atrial flutter) since cardioversion.

To confirm the persistent nature of AF, a 24-hour holter monitoring will be performed during the selection visit.
Eligible participants will enter a selection phase in which anticoagulant treatment (VKA) will be adjusted to achieve ideally an International Normalized Ratio (INR) of 2 to 3 before ECV. According to guidelines for the management of AF [6], VKA should be given at least 3 weeks before cardioversion because of risk of thrombo-embolism due to post-cardioversion.

Experimental data suggest that the maximal incorporation of n-3 PUFAs in the myocardial cell membrane takes up to 28 days to occur [22]. In addition, as shown in Nodari’s study [2], the duration of pre-treatment with PUFAs before cardioversion appears to be a contributing factor in success. Therefore, before starting follow up for the assessment of AF recurrence, treatment with F373280 should be started 28 days before ECV.

Detection of AF recurrence will be performed using systematic (scheduled) ECG recording, thus allowing detection of asymptomatic (about 50% of episodes) as well as symptomatic AF episodes. According to previous studies, most of AF recurrences occurred during the first days after cardioversion [11, 15]. So that, the heart rhythm will be closely monitored during the first week after successful cardioversion using an ambulatory continuous 7-day holter ECG recording in order to increase sensibility to detect asymptomatic AF episodes. Thereafter, to improve patient compliance, this follow up will be continued using an easier device to carry and to use, i.e. a TTEM.

Finally, during the study, patients will be scheduled for a clinical visit every 4 weeks or 8 weeks (with an additional visit 7 days after visit 3 (ECV visit)) in order to ensure a close medical monitoring and to assess efficacy and safety parameters.

4.2.3. Choice of the Dose

According to a previous study in patients with AF [2], the tested PUFA product (Omacor®) at the dose of 2 g (i.e. 640 mg of DHA acid) was effective in the prevention of AF after cardioversion. Moreover, PUFAs at dosage of 1 g and 2 g were also effective on the improvement of ventricular functional parameters, morbi-mortality and duration of hospitalisation in patients with heart failure [3, 4, 5].

From the F373280 phase I study, after a 14-day repeated administration of F373280 (1 g/day), observed plasma concentrations of DHA measured before treatment (Cmin) were similar to that of an effective dose of Omacor® at 2 g/day (60 to 95 mg/ml and 60 to 90 mg/ml, respectively) (phase I study of F373280 and [16]). With regard to the rhythm of administration, mean peak/
fluctuation (baseline corrected) was around 0.3. This value supports a once-daily administration allowing a 24-hour plasma exposure in DHA. Therefore, a 1 g daily dose of F373280 is considered to be appropriate for this proof of concept study.

4.2.4. Choice of the Sample Size
See chapter 13.

5. STUDY POPULATION
Each patient fulfilling all the inclusion criteria and none of the non inclusion criteria will be eligible.

5.1. INCLUSION CRITERIA

*Demographic Characteristics and Other Baseline Characteristics:*

1. Men or women aged more than 18 years (inclusive)
2. Patient with current episode of persistent AF between 7 days and 6 months duration for whom electrical cardioversion is warranted
3. Previous history of first documented episode of persistent AF
4. Previous history of ischemic or non ischemic heart failure
5. NYHA class I or II chronic heart failure at selection and at inclusion
6. Left ventricular systolic dysfunction defined at selection and at inclusion by a reduced left ventricular ejection fraction (LVEF) ≥ 30% and ≤ 45% or for patients with a LVEF > 45%:
   - an increased left ventricular end-diastolic size
     (diameter ≥ 60 mm and/or > 32 mm/m² and/or volume > 97 ml/m²)
   - and/or an increased left ventricular end-systolic size
     (diameter > 45 mm and/or > 25 mm/m² and/or volume > 43 ml/m²)
   - and/or a reduced left ventricular outflow tract velocity time integral < 15 cm
7. On appropriate, stable medical treatments for heart failure, including a diuretic and/or angiotensin-converting enzyme, and/or angiotensin-receptor blocker and/or mineralocorticoid receptor (MR) antagonists, and/or betablockers
8. Left atrial area ≤ 40 cm² at selection and at inclusion

9. Patient treated or having to be treated by vitamin K antagonist

10. For female patient of child-bearing potential:

   - **In all the countries except Italy:**
     - Use of an effective method of contraception (hormonal contraception or intra-uterine device) assessed by the investigator for at least 2 months before the selection in the study and agreement to go on using it during the whole duration of the study and up to 1 month after the last dose of the study treatment or
     - Documented as surgically sterilized

   - **In Italy only:**
     - Absolute abstention from sexual intercourse during the whole duration of the study and for a month after the end of the study or
     - Use of double barrier contraception method (use of effective medical contraception method) from at least 2 months before the start of the study to the entire duration of the study and for a month after the end of the study or
     - Documented as surgically sterilized

11. For female patient of child-bearing potential: negative urine pregnancy test at inclusion

12. For male with a child-bearing potential partner (**In Italy only**):

   - Absolute abstention from sexual intercourse during the whole duration of the study and for 3 months after the end of the study or
   - Use of double barrier contraception method (use of condom for male and effective contraception method for the partner) from the entire duration of the study to 3 months after the end of the study.

**Ethical/legal considerations:**

13. Having signed his/her written informed consent,
14. Affiliated to a social security system, or is a beneficiary (if applicable in the national regulation)

5.2. NON INCLUSION CRITERIA

Criteria related to pathologies:
1. No previous history of first documented episode of persistent Atrial Fibrillation
2. More than two successful cardioversions (electrical or pharmacological) in the last 6 months,
3. Secondary Atrial Fibrillation due to alcohol or severe valvular heart disease (grade III to IV),
4. NYHA class III or IV heart failure at selection or at inclusion
5. Thyroid disease uncontrolled by treatment: TSH ± T4L ± T3L to be checked in case of treatment for thyroid disease
6. Myocardial infarction or unstable angina or presence of unstable ischemic coronaropathy assessed by coronarography or cardiac stress test (Echo stress, exercise stress test, nuclear or MR perfusion evaluation methods) within 6 months before selection
7. Severe chronic kidney disease (creatinine ≥ 25 mg/L or estimated glomerular filtration rate < 30 ml/min) at selection
8. Bradycardia (HR ≤ 50 bpm)
9. Hyperkalemia or hypokalemia (according to the standards of local laboratories) at selection
10. Cardiac surgery within 3 months before selection or planned during the study duration

Criteria related to treatments:
11. Previously ineffective pharmacological or electrical cardioversion
12. Concomitant treatment with ranolazine or any anti-arrhythmic drug (within 7 days prior to selection), except amiodarone, dronedarone and stable dose of digoxin, beta-blockers, calcium-blockers.
13. Concomitant treatment with oral amiodarone or dronedarone from selection
14. Concomitant treatment with intravenous amiodarone from selection
15. Patient requiring a cardiac resynchronization therapy (CRT) or having undergone CRT implantation within the last 6 months
16. Treatment with any Polyunsaturated Fatty Acid within the last 3 months
17. Dietary supplement with ω3 or ω6 according to investigator’s judgment
18. Having undergone any form of ablation therapy for AF
19. Patient treated with oral anticoagulant treatment other than vitamin K antagonist: new oral anticoagulants (dabigatran, rivaroxaban, apixaban), or treated with irreversible antiplatelet agents P2Y12 inhibitors such as ticlopidine, clopidogrel or prasugrel

**Others criteria:**

20. Patient liable not to comply with protocol instructions and/or with treatment, in the investigator’s opinion,
21. Patient having taken part in a clinical trial in the preceding 2 months or taking part in a trial at the time of selection,
22. Patient linguistically or mentally unable to understand the nature, objectives and possible consequences of the trial, or refusing to patient himself / herself to its constraints,
23. Patient family member or work associate (secretary, nurse, technician…) of the Investigator,
24. Patient having forfeited his / her freedom by administrative or legal award or being under guardianship,

5.3. **NUMBER OF PATIENTS**

Maximum 135 patients (taking into account 15% of non-evaluable patients).

5.4. **RECRUITMENT MODALITIES**

Patients will be recruited within the medical consultation of each centre involved in the study. If necessary and when authorized by local and national regulation, some specific supports or tools will be used to improve the recruitment (announcement, mailing to general practitioners, leaflet, website including ClinicalTrials.gov, CRO…).

Before implementation, the documents will be submitted to and approved by the Ethics Committee.
5.5. **PATIENT IDENTIFICATION**

Patient's code will contain 7 digits: the 2 first digits corresponding to the country number, the following 2 digits corresponding to the centre number and the last 3 digits corresponding to the patient's chronological order once having signed the written informed consent.

5.6. **WITHDRAWAL CRITERIA**

Reasons for a patient's premature withdrawal from the study may be the following:

- Patient's decision. A patient who wishes to withdraw from the study for any reason may do so at any time but must inform the investigator. In all cases, the Investigator should attempt to contact the patient as soon as possible for a final assessment in order to:
  - have the patient's decision written on the consent form
  - obtain the reason(s) for withdrawal and report it/them in the case report form
  - evaluate the patient's clinical condition
  - if necessary, take appropriate therapeutic measures: management of an adverse effect or concomitant disease, prescription of another treatment.

- Investigator's decision in the patient's interest, particularly if a serious adverse event occurs and is considered by the Investigator liable to threaten the health of the patient. The monitor will be informed by phone or fax and a letter or report explaining the withdrawal will be forwarded to the monitor as soon as possible.

- Erroneous inclusion according to the study protocol. The decision to maintain or not the patient in the study will be taken jointly by the investigator and the sponsor. Erroneous inclusions will not be paid to the investigator.

- Patients who could not be treated with VKA for at least 3 weeks before ECV or who will experience a VKA intolerance during the study.

- Patients without dyskalemia who will not have INR values $\geq 2$ on the 3 last tests performed before ECV should not have an ECV and will be excluded from the study. However, if only 2 INR values are $\geq 2$ among those 3 last tests, an ECV can be performed if the presence of atrial thrombosis can be excluded with an ECHO–TE (transesophageal...
echocardiography) performed on the same day (before ECV) and the patient can continue the study.

- Patients who will not revert to sinus rhythm (i.e. unsuccessful ECV) or with early AF relapse or early atrial flutter emergence within the observation period after ECV will be considered to have finished follow-up.

- Occurrence of AF recurrence or atrial flutter emergence that would require, at the investigator’s judgement, a cardioversion or an introduction of an anti-arrhythmic because of intolerable and/or uncomfortable clinical symptoms for instance.

5.7. REPLACEMENT OF PATIENTS

Withdrawn patients will not be replaced.

5.8. POST-STUDY EXCLUSION PERIOD

Patients will not be allowed to participate in another clinical trial during 3 months following the study termination.

5.9. STUDY CARD AND LETTER FOR GENERAL PRACTITIONER(S)

The patient will receive from the Investigating Centre at Visit 1 - Selection Visit:
- a personal card to be kept all along the study duration and providing the following information: patient's name, sponsor's name, study code, EUDRACT number, start date and expected end date of the study, complete address of the Investigating Centre with the name and phone number of the Investigator and a sponsor 24H/24 phone contact number in case of emergency (French and English languages): 33 (0)5 63 35 25 83. For Italy, this card will be in Italian only, without any English mention.
- in Italy, a letter to be given to his/her general practitioner. This letter intends to inform the general practitioner(s) (and any other doctors who take care of the patient) that the patient participates to the clinical study. It describes the study treatment and includes some information on the forbidden treatment during the study.
6. STUDY TREATMENT
The Clinical Pharmacy Department of the Institut de Recherche Pierre Fabre (IRPF) will supply the investigational centres with the treatment necessary for the conduct of the trial.

6.1. SOURCE, PRESENTATION AND COMPOSITION OF INVESTIGATIONAL PRODUCT
F373280 and placebo will be prepared in Soft Capsules similar presentation.

- **F373280**
  Formulation of F373280, 1 g, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: Panthenyl ester of DHA, gelatine, glycerol, titanium, dioxide, purified water.

- **Placebo**
  Formulation of placebo matching tested product, Soft Capsules: oral administration, oblong size 20, off-white, Soft Capsules containing: paraffin liquid, fish flavour, gelatine, glycerol, titanium, dioxide, purified water.

Placebo and F373280 capsules will be packaged in opaque blisters.

6.2. PACKAGING AND LABELLING
The treatment units will be packed and labelled by the Clinical Pharmacy Department of the IRPF according to European Directive and local requirements.

6.2.1. Packaging
Each treatment unit will be composed of 3 cases for a 12-week treatment period.
Two 12-week treatment units will contain 3 cases, each case of 4-week treatment containing:
10 blister packs of four 1 g F373280 soft capsules or 1 g placebo soft capsules each.

6.2.2. Labelling
Investigational Products will be labelled according to the following rules:
Labelling should comply with the local requirements for Investigational Medicinal Products.
On the treatment units and cases, the labels will bear the following indications:

a) name and address of the sponsor  
b) protocol number  
c) packaging batch number  
d) treatment number  
e) storage conditions  
f) expiry date  
g) pharmaceutical dose form  
h) route of administration  
i) quantity of dosage units  
j) direction for use  
k) legal statements:
   - “for clinical trial only”, “keep out of the reach and the sight of children”, “please return to your doctor any unused product”, respect the prescribed dose”

On the treatment unit, another label will be affixed with the mention of the Investigator’s name and patient’s code (completed by the Investigator).

In addition, on each case will be mentioned the case number and a detachable label will bear the following indications:

- Protocol number  
- Packaging batch number  
- Expiry date  
- Case number  
- Treatment number

On the blister pack, the label will mention the protocol number, the packaging batch number, the case number and the treatment number.

6.3. DISTRIBUTION TO CENTRE AND STORAGE

The Clinical Pharmacy Department of the IRPF will supply the Investigational Centre with the treatment units along the study according to the need, upon request triggered by the patient’s selection.
As soon as the Pharmacist or the Investigator receives the trial medication, he/she will check the contents and immediately acknowledges the receipt in the IVRS/IWRS. The copy of the acknowledgement will be kept in the Investigator’s or the Pharmacist’s file. The same procedure will be applied to all further supplies during the course of the trial.

At the time of the delivery to the Centre, the following information will be provided:

- Details of storage conditions that should be respected
- And, upon request and for the 1st delivery only, a letter of release for the Investigational Medicinal Product from the Sponsor's Qualified Person

The CRA will ensure during the monitoring visits that trial medications have been received in good conditions and the acknowledgment of receipt has been performed adequately.

Treatment units should remain intact until dispensation to the patients. They should be kept at temperature below 30°C in an appropriate lockable room only accessible to the person authorised to dispense them, under the responsibility of the Pharmacist or the Investigator.

In the case of undue delay in study execution, the Pharmacist or the Investigator should ensure that the expiry date has not been exceeded.

### 6.4. ALLOCATION OF TREATMENTS AND DISPENSATION TO PATIENT

A randomisation list will be established by the Clinical Pharmacy Department of the IRPF. This list will be computer-generated with internal software. The randomisation methodology is validated by the Biometry Department before generation.

Treatments F373280 or placebo will be balanced in a 1:1 ratio.

As the treatment units are prepared for 12-week treatment periods, the Investigator will have to allocate a treatment number at inclusion visit (V2) and another one at visit 6.

For each patient, the treatment number given at visit 6 will not be the same that the one given at inclusion visit (V2).

The treatment numbers will be given through the IVRS/IWRS.

At selection visit (V1), practically, once patient’s eligibility is confirmed:

- The Investigator:
  - Contacts the IVRS/IWRS
- Answers the questions related to the patient

- The IVRS/IWRS company:
  - Confirms this information by fax/email to the Investigator
  - Fills the “Request for Delivery of Investigational Product” form and sends it by email and/or fax to the Clinical Pharmacy Department of the IRPF.

- The Clinical Pharmacy Department of the IRPF sends the corresponding treatment unit to the Investigator within 5 days from reception of the email request form.

At inclusion visit (V2), the treatment number to be allocated for the first 12-week period to the patient is given by the IVRS/IWRS.

At visit 6, the Investigator will contact again the IVRS/IWRS to obtain the treatment number for the last 12-week period of treatment.

The Investigator will dispense to the patient the 4-week treatment cases (one or two according to the visit) which label indicates the treatment number and the administration period.

6.5. DRUG ADMINISTRATION

6.5.1. Duration of Treatment

For a patient completing the study, the theoretical study treatment exposure to F373280 or placebo will be 24 weeks.

If the ECV is postponed by 1 week to allow INR stabilization, the treatment duration will be 25 weeks.

6.5.2. Dose Schedule

One soft capsule of 1g of F373280 or placebo to be taken each day during 24 weeks.

6.5.3. Route and Conditions of Administration

The soft capsules are to be taken orally. One soft capsule is to be taken each evening with the dinner during 24 weeks.
6.6. ACCOUNTABILITY ON SITE AND RETURN/DESTRUCTION OF INVESTIGATIONAL PRODUCT

The Investigator should maintain accurate written records of drug received, dispensed, returned and any remaining treatment units, on the drug accountability form. These records should be made available for Clinical Research Associate (CRA) monitoring. The packaging of the medication should remain intact until just before the dispensation.

At each visit, the Investigator will record the number of soft capsules returned by each patient using the appropriate page of the e-CRF.

At the end of the study, all used and unused treatments including packaging should be noted, and return is organised by the CRA to the Clinical Pharmacy Department of the IRPF for destruction. A copy of the drug accountability form should be provided by the Investigator to the CRA.

6.7. RECALL OF INVESTIGATIONAL PRODUCTS

In case of recall of investigational products (decided by the Competent Authorities or the Sponsor), the Investigator will immediately be informed by the Sponsor.

The Investigator in collaboration with the Sponsor’s representatives (Study Manager, CRA) must urgently:

- Stop the delivery of the concerned investigational products to the patients.
- Inform the concerned patients that they must immediately stop taking these investigational products and bring them back.

The Study Manager/CRA organises the return of the recalled products to the Clinical Pharmacy Department of the IRPF according to the Sponsor’s procedures.

7. CONCOMITANT TREATMENTS

Any existing concomitant treatment (at selection visit), any new concomitant treatment or change in the dosage of an existing concomitant treatment during the course of the study must be noted on the electronic Case Report Forms (e-CRF). All treatments should be evaluated by the Investigator at patient’s selection, and treatment prolongation or stop during the study should be considered.
For all concomitant treatments taken during the study, the following information must be noted in the relevant section(s) of the e-CRF:

- The name of the treatment and its form
- The reason for prescription
- The route of administration
- The daily dose
- The duration of treatment.

7.1. VITAMIN K ANTAGONIST TREATMENT

VKA should be given for at least 3 weeks before ECV and continued for the whole study duration. However, VKA should be stopped in case of occurrence of VKA intolerance during the study and the patient should be withdrawn from the study. The VKA used will be left to the decision of each Investigator according to his/her local practice.

7.2. PROHIBITED TREATMENTS

- Class I and class III antiarrhythmic treatments:
  - Class I:
    - Class IA: Disopyramide, Procainamide, Quinidine
    - Class IB: Lidocaine, Mexiletine
    - Class IC: Flecainide, Propafenone
  - Class III: Dofetilide, Ibutilide, Sotalol, Amiodarone, Dronedarone.
- Ranolazine
- Any PUFA
- Any oral anticoagulant treatment other than VKA: new oral anticoagulants (dabigatran, rivaroxaban, apixaban), or irreversible antiplatelet agents P2Y12 inhibitors such as ticlopidine, clopidogrel or prasugrel
- Dietary supplement with Omega 3 or Omega 6
Prohibited treatments at selection must not be prescribed for the duration of the study except in case of occurrence of an adverse event or AF episode that requires a corrective treatment in the interest of the patient’s health.

7.3. AUTHORISED TREATMENTS
Other treatments will be authorised during the study duration.

However, if medication other than study drugs is administered at any time from the start of the study, details must be recorded in the e-CRF. During the study, patients must be asked whether they have been on a course of prescribed drug treatment or have taken any OTC or herbal drugs since the visit.

8. EVALUATION CRITERIA

8.1. PRIMARY EFFICACY CRITERION

8.1.1. Time to the first Atrial Fibrillation Recurrence or Atrial Flutter Emergence

8.1.1.1. Definition
Time to first AF recurrence or atrial flutter emergence is defined by the time to first episode of AF or atrial flutter (symptomatic or not) lasting for at least 10 minutes.

8.1.1.2. Schedule
The heart rhythm follow up will be performed from the end of ECV visit (visit 3) to the final study visit (visit 9).

For randomised patients with spontaneous cardioversion before ECV, the recurrence of AF or the emergence of atrial flutter will be assessed after visit 3 (from week 5).

8.1.1.3. Evaluation Methods

- 7-day holter monitor:
The heart rhythm monitoring will be carried out from visit 3 to visit 4 using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) fixed after ECV visit.

Following holter monitoring, the heart rhythm will be documented using Trans Telephonic ECG Monitoring (TTEM).

- Trans Telephonic ECG Monitoring:
The ECG follow up will be documented using the TTEM: one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24, end of study). The patient will be requested to contact the Central Reading Laboratory for transmission of each stored TTEM.

Moreover, if patient experiences AF or atrial flutter symptoms during this TTEM period, it should be documented using the TTEM.

In case of AF recurrence or atrial flutter emergence and provided that the patient does not require a cardioversion or an introduction of an anti-arrhythmic at Investigator’s judgement, the patient could be maintained in the study with the treatment in order to assess a spontaneous cardioversion. For that purpose the patient will continue to transmit a TTEM once a week.

- Process of centralisation of ECG (Holter and TTEM)
ECG (Holter and TTEM) will be centralized by the Central Reading Laboratory. The ECG will be validated by a trained technician, then analysed by a cardiologist. The cardiologist interpretation will be emailed to the site (or per fax on request of the site). The investigator will be asked to review and sign these documents.

The Holter and TTEM process will be fully described in separate documents.

8.2. SECONDARY EFFICACY CRITERIA

8.2.1. Numbers of AF episodes in the first week following visit 3 (ECV visit)

8.2.1.1. Definition
Number of AF episodes will consist in the assessment of AF episodes with duration at least 10 minutes (N_{Sup10}) and of less than 10 minutes (N_{Inf10}), respectively.
8.2.1.2. **Schedule**

The heart rhythm follow up will be performed from the end of successful ECV visit (visit 3) to the study visit 4.

8.2.1.3. **Evaluation Methods**

- 7-day holter monitor:

The heart rhythm monitoring will start using a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) after ECV visit from visit 3 to visit 4.

8.2.2. **Duration of AF episodes in the first week following visit 3 (ECV visit)**

8.2.2.1. **Definition**

Duration of AF episodes will consist in the sum of duration of each AF episode.

8.2.2.2. **Schedule**

The heart rhythm follow up will be performed from the end of successful ECV visit (visit 3) to the follow up study visit (visit 4).

8.2.2.3. **Evaluation Methods**

Duration of AF episodes will be assessed using the 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording.

8.2.3. **Clinical parameters evaluation**

8.2.3.1. **EHRA score assessment**

8.2.3.1.1. **Definition**

AF related symptoms will be evaluated by the EHRA (European Heart Rhythm Association) score [20]. The following items “during presumed arrhythmia episodes” are checked to determine the score: palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety.

Classification of AF-related symptoms (EHRA score) are as follows:
• EHRA I - ‘No symptoms’
• EHRA II - ‘Mild symptoms’; normal daily activity not affected
• EHRA III - ‘Severe symptoms’; normal daily activity affected
• EHRA IV - ‘Disabling symptoms’; normal daily activity discontinued

This classification relates exclusively to the patient-reported symptoms.

In addition to this score, the frequency will be classified in three groups, namely occasionally (less than once per month), intermediate (1/month to almost daily) and frequent at least daily.

8.2.3.1.2. Schedule
EHRA evaluation will be performed in case of evocative symptoms of arrhythmia.

8.2.3.1.3. Evaluation Methods
EHRA evaluation will be collected by Central Reading Laboratory during TTEM period.

8.2.3.2. Time to first AF recurrence less than 10 minutes
Time to first AF recurrence less than 10 minutes will be assessed during TTEM period.

8.2.3.3. Recurrence of symptomatic AF
Recurrence of symptomatic AF will be assessed during TTEM period.

The number of recurrences of symptomatic AF consists of the number of AF recurrences associated with a symptom (palpitation, fatigue, dizziness, dyspnea, chest pain and anxiety) and confirmed by an ECG.

The time to first symptomatic AF recurrence is defined by the time to first episode of symptomatic AF.

8.2.3.4. Number and duration of hospitalizations

• Number and duration of hospitalizations for cardiovascular events
  – Hospitalization for AF treatment
– Hospitalization for worsening of heart failure
– Hospitalization for myocardial infarction
– All cause of hospitalization

• Number and duration of hospitalizations for thromboembolic stroke

8.2.4. Cardioversion assessment

• Assessment of spontaneous cardioversion before visit 3
• Assessment of successful cardioversion at visit 3 (i.e. return to sinus rhythm)
• Shocks distribution (1, 2 or 3 shocks)
• Number of patients needing another cardioversion after initial ECV

8.2.5. Evolution of echocardiographic parameters

8.2.5.1. Definition
The following echocardiographic parameters will be assessed: Left atrial diameter (mm), LAA (cm²), Left atrial volume (ml), Left atrial volume/BSA (ml/m²), LVEF (%), Left ventricular end diastolic volume/BSA (ml/m²), Left ventricular end systolic volume/BSA (ml/m²), Left ventricular end diastolic diameter (mm), Left ventricular end diastolic volume (ml), Left ventricular end systolic diameter (mm) and Left ventricular end systolic volume (ml).

8.2.5.2. Schedule
Measurements will be performed at visit 1 and visit 2 to check the eligibility of the patient.
Measurements performed at visit 4, visit 6 and visit 9 are done to follow the echocardiographic evolution of the patients in sinus rhythm.

8.2.5.3. Evaluation method
The echography evaluations will be carried out according to the recommendations for chamber quantification drawn up by the American Society of Echocardiography and the European
Association of Echocardiography [23]. So, the recommended method for volume measurements is to use the biplane method of discs (modified Simpson’s rule) from 2-D measurement.

8.3. BIOMARKER ASSESSMENT: RED BLOOD CELL CONCENTRATIONS OF DHA

8.3.1. Definition
Because of the limited human tissue accessibility for biopsy, red blood cell DHA contents is a marker of tissue DHA concentration [13], [14].

8.3.2. Blood samples

8.3.2.1. Collection schedule
Blood samples will be collected to determine the red blood cells (RBC) concentrations of DHA. Blood samples will be performed at visit 2 before treatment, visit 3, visit 6 and visit 9. Actual sampling times will be individually reported in the e-CRFs.

8.3.2.2. Technical handling
Two blood samples (2 x 4 ml) will be collected in EDTA tubes. They will be homogenized slowly by inverting the tube without shaking, stored between +2°C/+8°C in a fridge (no freezing will be allowed) and sent to Analytical Centre in refrigerated conditions (between +2°C and +8°C). Analysis will be performed within 2 weeks following reception at the Analytical Centre.

8.3.3. DHA concentration measurement
Analytical determination of RBC concentrations of DHA will be carried out by the Analytical Centre.
Lipids will be extracted from red blood cells samples with a mixture of hexane/isopropanol after acidification [17]. Total lipid extracts will be saponified and methylated. The fatty acid methyl esters (FAME) will be extracted and analyzed by Gas Chromatography.
Identification of FAME will be based on retention times obtained for FAME prepared from fatty acid standards. The area under peaks will be determined using ChemStation Software (Agilent)
and results will be expressed as % of total fatty acids. DHA concentration will be calculated using the internal standard and expressed as µg/g for red blood cells samples. Thus, omega-3 index will be assessed. The omega-3 index represents the content of EPA plus DHA in red blood cells (expressed as a percent of total fatty acids). It is a biomarker considered as a new marker of risk for death from coronary disease [18].

Results of this analytical determination will be kept confidential by the dosing centre until the end of the study, and will be provided only at the end of the study (after database lock) in a separate file.

8.4. SAFETY ASSESSMENT

8.4.1. Adverse Events
At selection, any concomitant disease will be reported on the e-CRF. At each further visit, the occurrence of AEs since the last visit will be based on the patient's spontaneous reporting, the Investigator's non-leading questioning and his/her clinical evaluation. All AEs will be reported on the e-CRF (see section 10).

8.4.2. Laboratory Investigations

8.4.2.1. Schedule
Laboratory investigations will be performed at visit 1 (before treatment) and visit 9 (end of treatment) or End of Treatment visit.

At visit 3 and 6, only a standard haematologic dosage will be performed.
Furthermore the kalemia will be checked before electrical cardioversion at visit 3.

The total volume of blood samples taken for haematology and biochemistry analysis should not exceed 30 ml.

8.4.2.2. Technical Procedures and Parameters
The following tests will be performed:
**Haematology:** haematocrit, haemoglobin, RBC count, white blood cells (WBC) count, WBC differential counts (% and/or absolute), reticulocytes, platelets.

**Biochemistry:** sodium, potassium, bicarbonate, chloride, alkaline phosphatase, gamma GT, albumin, total bilirubin, conjugated bilirubin, creatinine, aspartate aminotransferase (AST), alanine aminotransferase (ALT), fasting glucose, total cholesterol, cholesterol (HDL, LDL), triglycerides, creatine phosphokinase (CPK), fibrinogen.

Blood samples will be taken in the morning in fasting conditions.

The estimation of GFR at selection relies on the measurement of serum creatinine and the Cockcroft-Gault formula:

Cockcroft-Gault formula
- with serum creatinine expressed as mg/L:

in men:

\[
GFR \text{ (ml/min)} = \left(\frac{140 - \text{age}}{7.2 \times \text{serum creatinine in mg/L}}\right) \times \text{weight}
\]

in women:

\[
GFR \text{ (ml/min)} = \left(\frac{140 - \text{age}}{7.2 \times \text{serum creatinine in mg/L}}\right) \times 0.85 \times \text{weight}
\]

- with serum creatinine expressed as \(\mu\text{mol/l}:

\[
GFR \text{ (ml/min)} = \left(\frac{140 - \text{age}}{\text{serum creatinine in } \mu\text{mol/l}}\right) \times k, \text{where } k = 1.23 \text{ for men, } 1.04 \text{ for women.}
\]

(\text{weight in kg, age in years})

Additional tests may be done at the Investigator’s discretion, in the patient’s interest. In case of any abnormal and/or clinically significant results, the Investigator should order laboratory control tests.

**8.4.3. Global Physical Examination**

A global physical examination including the measurement of body weight will be carried out on each body system at visit 1, visit 2, visit 3, visit 6, visit 7, and visit 9.
The Body surface area (BSA) will be calculated at the same visits using Mostellers’ formula: 

\[ \text{BSA} = \left( \frac{\text{Weight} \times \text{Height}}{3600} \right)^{1/2} \]

(Weight in kg, height in cm)

The physical examination will be globally evaluated as “normal/abnormal”. Further target inspection will be undertaken for any abnormal finding.

8.4.4. Vital Signs

Vital signs will consist in blood pressure and heart rate at rest.

8.4.4.1. Schedule

Vital signs will be measured at each visit.

8.4.4.2. Technical Procedure and Parameters

Systolic blood pressure (SBP) and diastolic blood pressure (DBP), expressed in mmHg, will be measured after at least 5 minutes in supine position and after 2 minutes in standing position.

The heart rate (HR), expressed in beats per minute (bpm), will be measured by auscultation by counting the beats for at least 30 seconds, after at least 5 minutes in supine position and after 2 minutes in standing position.

Bodyweight will be measured with patient in underwear and with the same balance at each visit.

8.4.5. Electrocardiogram (ECG)

8.4.5.1. Schedule

An ECG will be recorded after at least 10 minutes of rest at visit 1, visit 2, visit 3, visit 6, visit 7, and visit 9 using a usual standardised 12-lead cardiograph.

8.4.5.2. Technical Procedure and Parameters

- Electrocardiogram:

The global interpretation from manual reading (normality, clinical relevance) and HR (bpm), PR (ms), QRS (ms), QT (ms), QTcB (ms), QTcF (ms), repolarisation patterns will be reported in the
e-CRF. Each print-out will include the patient’s code, date, time, technician's initials and investigator's signature.

In case of thermic paper ECG print out, a photocopy will be made by the centre to ensure safe filing.

- 24 hour-Holter - ECG

An ambulatory continuous 24-hour ECG (5-leads/2 or 3 channels) will be recorded at selection visit using a holter ECG, in order to confirm persistent AF.

8.4.6. Coagulation parameters

Coagulation assessment will be evaluated by the following parameters:

- Prothrombin Time/INR (PT/INR)
- Activated Partial Thromboplastin Time (aPTT)
- Thrombin Clotting Time (TCT)

The recommendations for the controls of INR are the following [25, 26]:

1) During the pre-cardioversion period, if the anticoagulation by VKA has to be initiated, the treatment must be initiated at least 3 weeks prior to cardioversion then the INR will be monitored as follow:

- The adjustment of the dosage of VKA should be performed stepwise by controlling INR 2 to 3 times a week until stabilization within the target range (2 - 3) on 2 successive tests.
- When the INR is within the target range (2 - 3) on 2 successive tests, the dose of VKA should be maintained. Then the controls of INR will be progressively spaced within a few weeks.
- When INR is stabilized, at least one test should be performed each week.
- In all cases, an INR control must be performed within 24 h before ECV.

2) During the pre-cardioversion period, if the anticoagulation by VKA was already initiated, the INR will be monitored as follow:

- One INR per week up to ECV
- An INR control must be performed within 24 h before ECV

3) After cardioversion : one INR every 4 weeks

4) Throughout the duration of the study if INR > 3 the advocated actions are:
No transesophageal echocardiography before cardioversion

For asymptomatic patients:

- 3 < INR < 4: no omission of VKA (dose adjustment if required), no vitamin K
- 4 ≤ INR < 6: omit one dose of VKA, no vitamin K
- 6 ≤ INR < 10: interrupt VKA, vitamin K 2 mg orally
- INR ≥ 10: interrupt VKA, vitamin K 5 mg orally

For INR ≥ 6, an adverse event has to be reported (asymptomatic overdose).

Anti-coagulation by VKA should be given at least 3 weeks before ECV and continued for the whole study duration.

aPTT and TCT will be performed at visit 1, visit 2, visit 3, visit 6, visit 7, and visit 9.

The quantity of blood samples collected at each time for coagulation parameters will be 2 ml.

Additional tests may be done at the Investigator’s discretion, in the patient’s interest. In case of any abnormal and/or clinically significant results, the Investigator should order laboratory control tests.

8.5. CONCOMITANT TREATMENTS

Concomitant treatments will be evaluated at each study visit.

Requirements related to patient's concomitant treatments started before selection visit and continued throughout the trial, or started during the trial, can be found in section 7.

8.6. COMPLIANCE

The patient will be reminded at each visit to bring back at the following visit any used or unused remaining soft capsule, blister and case.

At each visit (except at visit 4), the Investigator will record the number of supplied and remaining soft capsules in the e-CRF.

9. STUDY PROCEDURES

Visit 1 - Selection Visit (Week - 4 to Week -1):
The patient considered eligible for selection by the Investigator will be informed of the characteristics and the consequences of the trial both verbally and by reviewing the patient's information sheet and consent form (see section 14.3). If the patient accepts to participate in the study, he/she will sign the informed consent form and will keep a copy.

The patient will be assessed for the following:

- Demographic characteristics (gender, age, height, body surface area)
- Personal and medico-surgical history
- Habits (Tobacco, alcohol consumption, dietary habits including fish consumption…)
- Cardiovascular diseases, mainly detailed history of Heart Failure and AF characteristics
- Echocardiography using a two-dimensional echocardiography
- 12-lead ECG
- Concomitant diseases, adverse signs or symptoms (able to be used for treatment emergent AE determination)
- Concomitant treatments (authorised, disallowed)
- Global physical examination/bodyweight
- Vital signs
- Biology: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Biology assessment of renal function: creatinine or estimated glomerular filtration rate

If the results of the above assessments are compatible with the selection criteria:

- A 24-hour continuous ECG ambulatory recording (Holter ECG) device will be installed on the patient to monitor the patient heart rhythm. The patient will be requested to bring back the device after the termination of 24 hours recording. The recording will be transmitted from the Investigational site to the Central Reading Laboratory. The Central Reading Laboratory will send his/her assessment regarding the confirmation of persistent AF within 2 working days to the Investigator.
The patient will enter the selection and pre-cardioversion periods in which anticoagulant (VKA) will be adjusted to achieve ideally an International Normalized Ratio (INR) in the range of 2 to 3 before ECV.

At the end of the visit, the Investigator will contact the IVRS/IWRS to confirm the patient selection (which will automatically order the treatment delivery) and organise the appointment for the next visit.

The patient will receive from the investigational centre the participant card to be kept for all the duration of the study.

**Visit 2 - Inclusion Visit (Day 1):**

If the patient's behaviour during the selection period and/or the result of complementary examinations, particularly the confirmation of the presence of persistent AF by the Central Reading Laboratory during this period and the laboratory tests, are compatible with the inclusion criteria, the patient will be assessed for the following:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: red blood cell concentrations of DHA and coagulation parameters Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Global Physical examination/bodyweight
- Vital signs
- Echocardiography using a two-dimensional echocardiography
- 12-lead ECG
- Urine pregnancy test for women of child bearing potential

If the results of the above assessments are compatible with the inclusion criteria, the patient will be included and the investigator will contact the IVRS/IWRS to obtain the treatment unit number to be dispensed at visit 2 for the first 12-week period.

Between this Inclusion visit and the next visit (V3), the INR will be closely monitored (refer to paragraph 8.4.6) in order to fulfil the ECV conditions (refer to paragraph 3).
At the end of the visit, the Investigator will organise the appointment for the next visit and will give the treatment for the next 4-week period (one case of treatment).

**Visit 3 (Week 4: D28-2/+7 days) cardioversion:**

Patient will be assessed for the following criteria:

- Adverse events
- Concomitant treatments (authorised, disallowed)
- Laboratory examination: Haematology, RBC concentrations of DHA, Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT)
- Global Physical examination /bodyweight
- Vital signs
- 12-lead ECG
- Electrocardioversion (ECV): ECV has to be performed 4 weeks after randomization in patients with AF. ECV will be performed in the morning, with the patient in the fasting state and without dyskalemia. An INR value control must be performed within 24h before ECV. INR values ≥ 2 on the 3 last tests performed before ECV are required. However, if only 2 INR values are ≥ 2 among those 3 last tests, an ECV can be performed if the presence of atrial thrombosis can be excluded with an ECHO–TE (transesophageal echocardiography) performed on the same day (before ECV) and the patient can continue the study. Anesthesia will be induced and patients will be cardioverted with administration of a synchronized, biphasic current. The initial shock will be set at 100 J if the body weight is less than 70 kg and at 150 J for higher body weights. Successful cardioversion will be defined as recovery of sinus rhythm lasting at least 1 minute after the shock. If unsuccessful, a second 200-J shock, and eventually a third 200-J shock, will be administered. Failure of ECV is defined as the persistence of AF after the third attempt at cardioversion. After the procedure, patients will be monitored on telemetry for at least 6 hours before discharge.
Patients who will not revert to sinus rhythm or with early AF relapse or early atrial flutter emergence within the observation period after ECV will be withdrawn from the study and will be considered to have finished their follow-up.

At the end of the visit, a 7-day continuous ECG (5-leads/2 or 3 channels) ambulatory recording (holter ECG) will be installed on the patient in order to monitor the patient heart rhythm after ECV.

The Investigator will collect all unused cases, blisters and soft capsules, and will count the unused capsules for each 4-week treatment period.

At the end of the visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next 8-week period (two cases of treatment).

**Visit 4 (Week 5: D35 -2/+7 days):**

After removal of the continuous ECG ambulatory device, the patient will be assessed for the following criteria:

- Assessment of AE
- Concomitant treatments (authorised, disallowed)
- Bodyweight (bodyweight measured at V3 to be used)
- Vitals Signs
- Echocardiography using a two-dimensional echocardiography

At the end of the visit, the patient will be given the TTEM device for cardiac monitoring. The patient will be clearly instructed on the frequency and modalities of transmission. The patient will be requested to perform one transmission per week from this visit (initial call to perform with the patient) to the visit 9 (week 24 – end of study). Moreover, in case of AF or atrial flutter symptoms, additional transmissions may be performed.

**Visit 6* (Week 12: D84 ± 7 days) - Visit 7 (Week 16: D112 ± 7 days):**

*see amendment PA05 dated 22OCT2014

Patient will be assessed for the following criteria:

- Adverse events
• Concomitant treatments (authorised, disallowed)
• Laboratory examination: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT). However, in case of discontinuation of anticoagulation after ECV due to occurrence of VKA intolerance, the monitoring of INR, aPTT and TCT should be stopped.
• Global Physical examination/bodyweight
• Vital signs
• 12-lead ECG
• The cardiac monitoring will be continued using the TTEM device through one transmission per week from the day of visit 4 (end of week 5) to visit 9 (week 24, end of study). Moreover, in case of AF or atrial flutter symptoms, additional transmissions may be performed.

The Investigator will collect all unused cases, blisters and soft capsules, and will count the unused capsules for each 4-week treatment period.

In addition, at visit 6:

• the investigator will contact the IVRS/IWRS to obtain the treatment unit number to be dispensed at visit 6 for the last 12-week period.
• an echocardiography will be performed, an haematology examination will be done and the RBC concentration of DHA will be measured.

At the end of each visit, the Investigator will organise the appointment for the next visit and give the treatment to be taken during the next treatment period: one case at visit 6 and two cases at visit 7.

Visit 9* - End-of-Study Visit (Week 24: D168 ± 7 days):

*see amendment PA05 dated 22OCT2014

Patient will be assessed for the following:

• Adverse events
• Concomitant treatments (authorised, disallowed)
• Global Physical examination/bodyweight
- Vital signs
- 12-lead ECG
- Laboratory examination: haematology, biochemistry, assessment of coagulation parameters: Prothrombin Time/INR (PT/INR), Activated Partial Thromboplastin Time (aPTT), Thrombin Clotting Time (TCT), Red blood cell concentration of DHA.
- Urine pregnancy test for women of childbearing potential
- Echocardiography using a two-dimensional echocardiography

The Investigator will collect all unused cases, blisters and soft capsules, and will count the unused soft capsules.

The total volume of blood collected should be about 90 ml for the study duration (30 ml for the total volume of haematology and biochemistry, 2 ml for each blood samples for coagulations parameters and 4 ml for each blood samples of DHA).

10. ADVERSE EVENTS: DEFINITION AND REPORTING

10.1. ADVERSE EVENTS

10.1.1. Definition of Adverse Events

An AE is any adverse change from the patient's baseline condition, i.e. any subjective signs and symptoms or change in a concomitant disease present at the Selection Visit considered or not related to the treatment.

AE includes intercurrent signs, symptoms, illnesses and significant deviations from baseline for vital signs and laboratory values which may occur during the course of the clinical study.

All laboratory tests for which abnormal results are collected after study treatment initiation should be repeated until the values return to normal or to a stable status. Abnormal results are defined as those falling out of the laboratory normal ranges and that are clinically significant. The frequency of such checks should be defined by the Investigator according to the degree of abnormality.
In all cases, the aetiology should, as much as possible, be identified and *Pierre Fabre Médicament* notified.

10.1.2. **Grading of Adverse Events**

Adverse or intercurrent events are graded as follows:

- Mild: awareness of signs or symptoms, but easily tolerated
- Moderate: uncomfortable enough to cause interference with usual activity
- Severe: incapacity with inability to work or do usual activity

10.1.3. **Reporting of Adverse Events**

The records of AE in the e-CRF describe the nature (diagnosis, signs and symptoms), severity, onset date, stop date, outcome and actions taken, and relationship to study treatment (in the Investigator's opinion). It must be specified whether the event is serious or not.

10.2. **SERIOUS ADVERSE EVENTS (SAE)**

10.2.1. **Definition**

A SAE includes, but is not necessarily restricted to, any event which:

- Results in death (whatever may be the cause)
- Is life-threatening
- Results in persistent or significant disability/incapacity
- Requires the patient's hospitalisation or prolongation of current hospitalisation *
- Is a congenital anomaly or birth defect

Other events such as cancer and any additional adverse experience or abnormal laboratory values occurring during the study period, defined by the protocol as serious or which the Investigator considers significant enough or that suggest a significant hazard, contra-indications, side effect or precaution, must be handled as serious adverse events.

Any overdosage meeting a seriousness criteria should be reported as a SAE (see section 10.3).
Any pregnancy occurring during/after exposure to the study drug(s) should be reported on the
SAE notification form (see section 10.4).

* any hospitalisation, or prolongation of hospitalisation due to the circumstances listed below:
  – planned (as per protocol) medical/surgical procedure
  – preparation for routine health assessment/procedure (e.g. routine colonoscopy)
  – planned medical/surgical admission (planned prior to entry into study trial, appropriate
documentation required)
  – administrative or social reasons (e.g. lack of housing, economic inadequacy, care-giver
respite, family circumstances)

will not be reported as a SAE.

10.2.2. Reporting of SAE

All Serious Adverse Events, according to the above-mentioned definitions and regardless of
treatment or relationship to study drug, and occurring once the informed consent form has been
signed, must be reported by the Investigator as soon as he/she is informed of the event.

The Investigator must notify the Sponsor of this event by sending, within 24 hours, the
"Notification of serious adverse event" form ("first notification") with all the available
information about the event (see appendix 17.2), to the Sponsor's Corporate Vigilances e-mail
dedicated box:

HQ.pharmacovigilance@pierre-fabre.com

In case it is not possible to send the report by e-mail it can be sent by FAX at the
following number:

+ 33 1 49 10 80 90

In case of non-inclusion, the reporting period ends when the non-inclusion is documented.

10.2.3. Follow-up of SAE

The Investigator must draw-up a specific clinical report and use the "Notification of serious
adverse event" form ("follow-up") (see appendix 17.2) and collect the results of the carried out
examinations and the reports of hospitalisation.
The serious adverse events must be followed up until resolution or stabilisation.

10.2.4. SAE Occurring After the Study
Any SAE occurring during 30 days following the end of the study for the patient should be notified to the Sponsor.

Must also be notified to the Sponsor any event occurring at any time after the end of the study for the patient which may be related to the study treatment in the Investigator's opinion.

10.3. REPORTING OF OVERDOSAGE TO THE SPONSOR
For the purpose of this trial, an overdosage will be defined as any dose exceeding the planned prescribed dose of the study drug or the administration of any dose of an associated product that is considered both excessive and medically important.

In the absence of seriousness criteria, the overdosage and associated adverse event if any, are reported only on the Adverse Event page of the e-CRF. If the definition of seriousness criteria is met, the SAE notification form must also be transmitted to the Sponsor.

10.4. REPORTING OF PREGNANCY TO THE SPONSOR
Pregnancies discovered in the period in between the informed consent form signed but before any study drug exposure are not to be reported to the Sponsor unless associated to a seriousness criteria (e.g. serious adverse event study-protocol related procedure). If pregnancy is confirmed, the women must not be administered the study drug and must be withdrawn immediately from the study.

If pregnancy is suspected while the patient is receiving study treatment, the study drug should be discontinued immediately until the result of the pregnancy testing is known. If pregnancy is confirmed, then the study treatment is permanently discontinued in an appropriate manner and the patient is withdrawn from the study.

The Investigator must report to the Sponsor any pregnancy which occurs during or after the patient has been exposed to the study drug and until 30 days after the last study drug administration. The Investigator must immediately notify the Sponsor using the SAE notification form and also report the pregnancy on the AE page of the e-CRF.
Women who become pregnant after exposure to the study drug must be followed by the Investigator until the completion/termination of the pregnancy. If the pregnancy goes to term, the outcome will have to be reported to the Sponsor (baby's healthy status).

10.5. SPONSOR'S RESPONSIBILITIES FOR SAFETY REPORTING

PURPOSES

Sponsor will submit expedited and periodic reports to both Competent Authorities and Ethics Committees per corporate standard operating procedures as regards to the EU directive 2001/20/EC taking into account local specific requirements.

11. DATA COLLECTION AND STUDY MONITORING

11.1. DATA COLLECTION

11.1.1. Case Report Form

An e-CRF will be used to record all patient data required by the protocol except the central ECG (Holter ECG, TTEM) and DHA data which will be transferred from vendors to the subcontractor as electronic data files that will be loaded into the study database.

The e-CRF should be fully validated, compliant with ICH-GCP requirements and European regulations and should include a traceability system for data corrections and deletions (audit trail).

Prior to the start of the study, the Investigator will complete a "Delegation of significant study-related duties" form. The signature and initials of all personal in charge of e-CRF completion should be recorded on this form. Each person involved in e-CRF completion, review, correction and / or validation will be trained and will have an individual login and access code to the e-CRF. Training sessions will be held by the subcontractor for all participants using this tool. An e-CRF user manual will be available for investigators and CRAs.

All the information included into the e-CRF will be recorded from source documents onto the e-CRF by an authorised person.
The Investigator is responsible for the management and accuracy of the information on the e-CRF. At each monitoring visit, the e-CRF(s) should be at the CRA's disposition for review and validation.

At the end of the study, a CD-ROM containing the pdf version of all e-CRFs (including audit-trail) will be sent by the subcontractor to the Sponsor and to the investigational sites for archiving. The subcontractor must store all study data for at least 15 years after the end of the study and ensure their legibility and accessibility during all the storage period.

11.1.2. Source Documents

A source document is an original record or certified copy of an original record of clinical findings, observations or any other medical or paramedical activities performed during the clinical trial, necessary for the transcription and the verification of the collected data.

Source documents along with all other trial-related documents (copies of all "informed consent" forms, e-CRFs CD-ROM, drug inventories and any correspondence related to the study) must be kept in the investigator's file throughout the study, and then, must be stored in the study centre's archives for a period of at least 15 years or as per local legal requirements, whatever is the longest.

For further details see section 15.2.

11.2. STUDY MONITORING

11.2.1. Monitoring visits

On-site visits will be carried out by a representative of the Sponsor's staff (Study Manager or CRA) prior to study initiation and at regular intervals (every 4 to 6 weeks) throughout the study. Additional visits and communication by telephone fax or meeting may be performed if necessary. Any site visit performed by the Sponsor's representatives will be recorded in the Investigator's study file.
11.2.1.1. Site Preselection Visit
Before selecting a centre for the study, a visit will be carried out by the CRA and/or the Study Manager to ensure that the Investigator has the necessary capacities (availability, patient's recruitment, environment), technical means and staff to carry out the study.

11.2.1.2. Initiation Visit
Before the start of the study at all investigational sites, an initiation visit will be carried out by the CRA to check at the latest that:

- The Investigator:
  - has received the technical protocol, administrative and financial agreement signed by all parties
  - has received the written statement of the Ethics Committee approval and the list of its members and their functions
- The original dated and signed curriculum vitae of the investigator(s) has been collected
- Laboratory normal ranges have been collected
- All study materials are available on the study site
- All participants agree with the monitoring procedures and know the study procedures
- All participants are aware of a possible audit or inspection

The CRA has also to provide training on the study protocol requirements and study specific procedures.

11.2.1.3. Follow-up Visits
Throughout the study, regular follow-up visits will be carried out by the CRA to check compliance with GCP, patient's informed consents, strict application of the protocol, conformity of the data entered on the e-CRF with the source documents and ensure its correct completion, adverse events reporting, proper retention, storage and management of the study medication, as well as the source and other trial-related documents.
11.2.1.4. Closing Visit

At the end of the study, a final visit will be carried out by the CRA to:

- Verify that the e-CRFs CD-ROM with pdf files are correctly stored
- Control the accountability of intact and used treatment units and return them to the Clinical Pharmacy Department of the IRPF for destruction
- Obtain the last data clarifications and/or solutions if any
- Collect the patient's consent forms in sealed envelopes (except in case of specific country requirements),
- Make an on-site review of all study documentation and complete it if necessary
- And finally, remind the Investigator of his regulatory obligations, study document archiving process and duration.

11.2.2. Direct Access to Source Documents

In accordance to the requirements of the GCP, all Sponsor representatives (Study Manager, CRA and Auditors) have to be given a direct access to all source and study data to perform quality monitoring/audit, thus ensuring accuracy and completeness of data).

Investigators are reminded that all Sponsor representatives keep professional confidentiality with regards to the patient data.

11.3. INDEPENDENT DATA MONITORING COMMITTEE

An Independent Data Monitoring Committee (IDMC) will be established to assess at intervals the progress of the clinical trial, the compliance with the inclusion criteria, the quality of follow up, the quality of primary end point measures, the safety data. The IDMC will thereafter recommend to the Sponsor whether to continue, modify, or stop the study.

The IDMC operating procedures will be described in an independent document.
12. **DATA MANAGEMENT**

All clinical data related to the study will be collected and saved in a computerised database by the Data Management Department of the subcontractor and under the supervision of the Data Manager of Pierre Fabre Biometry (PFB) according to the following procedures.

12.1. **DATA ENTRY**

All required data will be collected by the Investigator or authorised designee (duly identified into the delegation task list) on the e-CRFs.

The e-CRFs used for this study will be developed and maintained by the Data Management Department of the subcontractor and approved by the Sponsor.

Electronic data (Holter ECG, TTEM and DHA) will be transferred by the 3rd party vendor according to the specifications given by the Data Manager of the subcontractor. These data will be captured and handled in accordance with the European GCP ICH E6 guideline.

12.2. **DATA CLEANING**

The subcontractor will define in the Data Validation Plan for reviewing and querying data, descriptions of both manual and electronic edit checks. Upon Sponsor approval, the subcontractor will program the checks.

The subcontractor will review the data over the course of the study, working with the Sponsor to identify data inconsistencies. The Investigator will be asked to resolve queries by making changes directly into the e-CRF.

12.3. **DATA CODING**

Adverse events, concomitant diseases, medical/surgical histories will be coded by the subcontractor using the MedDRA dictionary (latest version in use).

Concomitant medication will be coded by the subcontractor using the WHO-DRUG dictionary (latest version in use).

The Sponsor Clinical Development Physician will validate the coding.
12.4. **DATA STORAGE**
Computer data files as well as their modifications will be archived by the subcontractor and kept available upon request of the Sponsor.

12.5. **DATABASE LOCK**
The validated database will be locked by the subcontractor upon request of the Data Manager of PFB following the completion of all steps required, i.e. data entry and check of all data, resolution of all queries, validation of the coding, Clinical and Products Safety databases reconciliation and validation committee.

Then, the subcontractor will transfer the locked database in SAS format to the Data Manager of PFB who assume storage on the PFB secured server.

13. **STATISTICAL ANALYSIS**
After the database lock and the randomisation code release, the statistical analysis will be performed by PFB or under the supervision of the statistician of PFB using SAS® software, according to the Statistical Analysis Plan approved by the Validation Committee.

13.1. **GENERAL CONSIDERATIONS**
The main objective of the study is to assess the efficacy of F373280 versus placebo on the maintenance of sinus rhythm after direct ECV in patients with persistent AF and chronic heart failure.

Only the primary analysis of the primary efficacy criterion, on which is based the sample size justification, may lead to a causal interpretation. All other statistical results are to be regarded within a descriptive perspective.

The statistical significance level of the various two sided tests of all analyses will be 5 %.

13.2. **SAMPLE SIZE**
Assuming an AF recurrence or atrial flutter emergence rate of 85% under placebo and 65% under active group, i.e. a clinically relevant difference $\Delta$ of 20%, a sample size of 64 assessable patients
per group is required, using a log-rank test of survival curves with a 80 % power and a 5 % two-sided significance level.

According to the previous assumptions and assuming a rate of not assessable patients of 15%, a minimum of 76 patients will have to be randomised per group.

Due to the premature stop of the recruitment 135 patients were finally randomised.

13.3. PROTOCOL DEVIATIONS

Prior to the database lock and the randomisation code release, the Validation Committee members will review the protocol deviations and will classify them as either minor or major. A protocol deviation will be considered major when it is likely to bias significantly the treatment effect estimate based on the primary efficacy criterion.

Patients with major deviation(s) will be excluded from the Per Protocol data set (see section 13.4). A listing of all protocol deviations will be provided for all randomised patients, including the type (major/minor) of protocol deviations according to the decisions made by the members of the Validation Committee.

The number and percentage of patients with major protocol deviations will be tabulated by treatment group and type of major protocol deviations on the Full Analysis Set defined in section 13.4.

13.4. DATA SETS ANALYSED

The following 3 data sets will be analysed (as defined by the Validation Committee):

- The Safety Set composed of all randomised patients having received at least one dose of the study treatment. This data set will be used to perform analyses of Safety.
- The Full Analysis Set (FAS) composed of all randomised patients having received at least one dose of the study treatment and with a successful cardioversion observed at visit 3. This data set will be used to perform analyses of Efficacy.
- The Per Protocol Set (PP) which is the subset of the Full Analysis Set composed of all patients with a primary efficacy criteria available and without any major protocol
deviation or other source of bias for primary criteria analyses. This data set will be used to perform the supportive analysis of the primary efficacy criterion.

13.5. HANDLING OF DROPOUTS AND MISSING DATA

13.5.1. Dropouts
The number of patients who withdraw from the study after their randomisation will be provided by treatment group for all treated patients (Safety Set). All withdrawn patients will be further described regarding their time to dropout and reasons for withdrawal.

13.5.2. Repositioning of Visits
No repositioning of visits will be done.

13.5.3. Missing Data
Missing values will not be substituted by estimated values, but considered as missing in statistical analysis.

13.6. DEMOGRAPHIC AND OTHER BASELINE CHARACTERISTICS
Before the first trial drug intake, patient’s background, medical and surgical history, demographic data and disease characteristics will be described by treatment group on the Safety Set.

- **Quantitative parameters** will be described by treatment group and overall using the following: number of patients, number of missing data, mean, standard deviation, minimum, median and maximum values.

- **Qualitative parameters** will be described by treatment group and overall using frequencies.

Concomitant diseases, as well as medical and surgical histories will be tabulated descriptively by treatment group and overall using the MedDRA codes of System Organ Classes and preferred terms.
If more than 10% of patients are excluded from the FAS and PP set, the description of patients by treatment group at selection and inclusion will be repeated on the FAS and PP set for all parameters.

No statistical test of comparability of treatment groups at baseline will be performed.

13.7. **EFFICACY ANALYSIS**

13.7.1. **Primary Criterion**

13.7.1.1. **Primary Analysis**

The primary criteria, time to first recurrence of AF or atrial flutter emergence, will be analysed using the Kaplan Meier method and compared with the Log rank test. Hazard ratios and 95% confidence intervals will be estimated with the Cox regression model.

The primary analysis will be performed on the FAS.

13.7.1.2. **Supportive Analysis**

The primary analysis will be repeated on the PP set.

13.7.1.3. **Additional Analysis**

To take into consideration the sample size reduction, the predictive probability of success with the expected sample size based on observed data, the predictive power and the conditional power will be provided to support the statistical decision.

13.7.2. **Secondary Criteria**

All secondary analyses will be performed on the FAS. If more than 10% of patients are excluded from the PP set, the secondary analyses will be repeated on the PP set.

13.7.2.1. **Numbers of Atrial Fibrillation Episodes in the first week following V3**

Both the numbers of AF episodes (symptomatic or not) lasting for at least 10 minutes and with duration less than 10 minutes (NSup10 and NInf10) will be described by treatment group and compared by the chi-square test (or CMH test adjusted for centre) or Fisher’s exact Test.
13.7.2.2.  **Duration of Atrial Fibrillation Episodes in the first week following V3**

The duration of all AF Episodes will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centres effects) or Wilcoxon test.

13.7.2.3.  **Time to first AF recurrence less than 10 minutes or symptomatic**

The time to the first AF recurrence less than 10 minutes and the time to the first symptomatic AF recurrence will be analysed as the primary analysis.

13.7.2.4.  **Clinical parameters evaluation**

The EHRA score will be described by treatment group and analysed using a chi-squared test (or CMH test adjusted for centre) or Fisher’s exact Test.

The frequency of presumed arrhythmia will be described by treatment group.

The number of recurrence of symptomatic AF, of hospitalizations (for cardiovascular events, for thromboembolic stroke and for all causes), of spontaneous cardioversion, of successful cardioversion (including number of shocks distribution) and the number of patients needing cardioversion after initial ECV will be described by treatment group and compared using a chi-square test or a Fisher Test (if the numbers are relevant).

The duration of hospitalizations for cardiovascular events, for thromboembolic stroke and for any cause will be described by treatment group and compared using the Student t (or using an ANOVA with treatment and centre effects) or Wilcoxon test.

The echocardiographic parameters values will be described at each time (V1, V2, V4, V6 and V9) and changes described from V4 to V9 and from V2 to V9.

13.7.2.5.  **Biomarker analysis: red blood cell concentrations of DHA**

Values and changes from baseline for red blood cell concentration of DHA will be performed by treatment group and assessment time.

13.8.  **SAFETY ANALYSIS**

The Safety Set will be used to perform all analyses of the safety criteria.
13.8.1. Adverse Events

Any adverse event having been reported during the study for a given patient will be classified by preferred term and corresponding system organ class using the MedDRA terminology.

Adverse events will be classified as:

- Treatment emergent adverse events, \textit{i.e.}, any adverse event which occurs or worsens on study treatment during the randomised period.

- Or non treatment emergent adverse events, \textit{i.e.}, any adverse event which occurs during the run-in period (before V2) or is reported as concomitant disease with the same intensity.

For each study period, any patient with at least one reported adverse event will be classified as a patient:

- With at least one adverse event

- With at least one treatment emergent adverse event

- With one TEAE

- With two TEAEs

- With at least three TEAEs

- With at least one related TEAE

- With an adverse event leading to the study treatment discontinuation (definitive or temporary)

- With an adverse event leading to withdrawal

- With at least one serious adverse event.

Numbers and percentages of patient with at least one reported treatment emergent adverse event will be tabulated by treatment group:

- By system organ class

- By system organ class and preferred term

- By system organ class and preferred term, taking into consideration its most severe intensity
• And by system organ class and preferred term, taking into consideration the most severe relationship to the study treatment.

Recurring adverse events (i.e., adverse events classified with the same preferred term) for a given patient will only be counted once and only their most severe intensity or most severe relationship to the study treatment will be tabulated.

The number and percentage of patient with at least one most common (reported in 1% patients in any group) drug related TEAE ("not excluded or unassessable") will be tabulated by Preferred Term and Treatment group in decreasing order for the treatment group (for all patients).

The number and percentage of patients with at least one reported most common treatment emergent adverse event will also be plotted by treatment group. This graphical representation will highlight the frequencies of the most severe intensities reported by system organ class and preferred term.

SAE will also be described on an individual basis: treatment group, patient's code, sex and age, Investigator's reported term, preferred term, time of onset according to the time of the first study treatment administration, duration, action taken regarding the study treatment administration, use of a corrective treatment, outcome and relationship to the study treatment in the Investigator’s opinion.

13.8.2. Clinical Laboratory Evaluation

For each laboratory parameter, data will be tabulated by treatment group and assessment time.

The absolute changes post-trial drug administration - baseline (the baseline value being the value measured on the last blood sample collected before the first trial drug administration) will be calculated and tabulated by parameter, treatment group and post-trial drug administration assessment time. Results of retests performed post-trial drug administration will not be analysed and tabulated. They will only be displayed in individual data listings.

For all biochemistry parameters, scatter plots highlighting individual results will display the baseline and week 24 of the laboratory measurements for each patient by locating the point defined by the baseline value on the abscissa and respectively week 24 value in the ordinate.

For all haematology parameters, scatter plots highlighting individual results will display the baseline and week 4, week 12 and week 24 of the laboratory measurements for each patient by
locating the point defined by the baseline value on the abscissa and respectively week 4, week 12 and week 24 value in the ordinate.

Each treatment group will be differently identified. The first bisecting line (45° line), the lines of lower and upper normal range, the lines of Potentially Clinically Significant Change (PSC) range and Clinically noteworthy abnormal laboratory value (CNALV) range added on the plots (see Appendix 17.3).

For all blood laboratory parameters, shift tables will be provided to depict the numbers of patients with post-trial drug administration variations at each assessment time as compared to the baseline values (measured on the last blood sample collected before the first trial drug administration) by treatment group. A 3-point scale (low, normal, high) will be used as defined by the normal ranges in use in the laboratory in charge of the assays.

CNALV (see in Appendix 17.3) will be identified and described on an individual basis. If relevant, five separate individual data listings by treatment group will be provided:

- CNALV for haemoglobin (including corresponding individual results of erythrocytes and haematocrit)
- CNALV for neutrophils or leucocytes (including corresponding individual results of basophils, eosinophils, lymphocytes and monocytes)
- CNALV for platelets (including corresponding individual results of erythrocytes and leucocytes)
- CNALV for liver function parameters (including corresponding individual results of gamma-GT)
- CNALV for serum creatinine

13.8.3. Global Physical Examination

Recorded data of the global physical examination performed will not be tabulated as any abnormal findings post-randomisation should be reported as AEs (if clinically significant).

Physical examination assessments will be provided in the listings of individual data.
13.8.4. Vital Signs, Physical Findings and Other Observations Related to Safety

13.8.4.1. Vital Sign Measurements Over Time
For each parameter (systolic blood pressure, diastolic blood pressure and HR in supine and standing positions), descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.

13.8.4.2. Body weight
Descriptive statistics over time of values and changes from baseline will be tabulated by treatment group and assessment time.

13.8.4.3. Individual Patient Changes
The number and percentage of patient with at least one Predefined Potentially Clinically Significant Change (PSC) and with at least one PSC Leading to Clinically Significant Value (PSCV) will be tabulated by treatment group (see Table 1 in Appendix 17.3). According to the pharmacological drug profile mentioned previously in this Protocol, the changes from baseline to the maximum and/or minimum post-baseline value could be categorized and tabulated by treatment group with frequencies and decreasing cumulative percentages. If there is a signal of a drug effect toward one direction rather than the other, additionally shift tables of variations from baseline to the maximum or minimum post-baseline value could be also provided (see Table 2 to 4 in Appendix 17.3). An individual data listing of patients with symptomatic or asymptomatic orthostatic hypotension will be provided by treatment group (see Table 5 in Appendix 17.3).

13.8.5. ECG
Frequencies on the clinical interpretation (normal, abnormal CS or NCS) will be presented by treatment group and assessment time. Individual tabulated data for ECG abnormalities will be also displayed.
13.8.6. Coagulation parameters
Scatter plots highlighting individual results for coagulation parameters (prothrombin time/INR, activated partial thromboplastin time and thrombin clotting time) before and after study treatment administration will be produced.

13.9. CONCOMITANT TREATMENTS
Concomitant treatments will be tabulated by treatment group within a descriptive perspective. They will be classified by therapeutic area according to the WHO-DRUG dictionary using the "anatomical therapeutic chemical" classification on the safety set.

13.10. COMPLIANCE
The percentage of compliance will be described by treatment group using the quantity

\[
\text{Compliance}(\%) = \frac{\text{Estimated actual consumption}}{\text{Theoretical consumption}} \times 100
\]

with: Estimated actual consumption = number of tablets provided at the start of study (Visit 2) minus number of tablets returned at the end of study (Visit 9)

Theoretical consumption = number of days of treatment intake planned between the start and the end of study (168 days ± 7 days)

13.11. INTERIM ANALYSIS AND DATA MONITORING
No analyses of efficacy data are planned for IDMC that ensures that the overall probability of type I error is controlled. No Type I error and sample size adjustments are necessary. Any recommendations of the IDMC to alter study conduct will be based on safety, so IDMC monitoring of the study will not affect the statistical operating characteristics of the final analysis.
The IDMC will review, two times during the study period (after the first 30 subjects will have been randomized and when the first 80 subjects will have terminated their study participation), safety data results across treatment groups and judges whether the overall safety and feasibility (not futility) of the trial remain acceptable.

14. GENERAL ETHICAL CONSIDERATIONS

14.1. ETHICAL CONDITIONS
This study is performed in accordance with the principles stated in the Declaration of Helsinki (1964) and subsequent amendments and in accordance with the Good Clinical Practice Guideline (CPMP/ICH/135/95).

14.2. ETHICS COMMITTEE AND LEGAL REQUIREMENTS
All the documents required by National Regulations and any other informative documents that may be requested are submitted for review to an Ethics Committee whose procedures and operations meet the GCP and National Legal Requirements.

Depending on National Regulations, the application is submitted to the Ethics Committee by the Sponsor (or representative) or by the Investigator.

A copy of the formal written approval from the Ethics Committee is provided to the Sponsor (directly by the Ethics Committee or via the Investigator) with a list of names and qualifications of its members.

The request for authorisation by the Competent Authority or its notification if required (depending on National Regulations) is carried out by the Sponsor.

The screening of patients does not start before the approval of the Ethics Committee has been obtained and the study authorised by the Competent Authority or notified to the Competent Authority (depending on National Regulations).
14.3. PATIENT'S INFORMATION LEAFLET AND INFORMED CONSENT FORM

An information must be given to the patients before their decision to participate or abstain from participation.

This information is based on the elements set out in the Declaration of Helsinki and the ICH GCP Guidelines. It must also describe the measures taken to safeguard patient’s privacy and protection of personal data, according to European Directive 95/46 EC or other local regulation.

Restraints and risks must be explained, as well as the right to discontinue participation in the study at any stage, without affecting their further relationship with the Investigator and/or their future care.

The written information and consent form must be submitted to the patient with an oral explanation. It must be agreed and signed by the patient before any study-related procedure starts.

This information and consent procedure is under the Investigator’s responsibility.

The information and consent document are made in triplicate: the original copy is kept by the Investigator, one copy is given to the patient and the last copy is kept by the Clinical Quality Assurance Unit of the Sponsor in a sealed envelope at the end of study (except in case of specific country requirement).

Specific areas of the Sponsor’s copy are not triplicated to avoid the reading of the patient’s surname (except the first 3 letters), first name, address and signature.

If any information becomes available during the trial that may be relevant to the patient’s willingness to keep on participating in the trial, an updated written informed consent must be submitted to the patient to confirm agreement to continue participating.

14.4. PERSONAL DATA PROTECTION

All information from this study (excluding data from the informed consent) is entered into a computer under the Sponsor’s responsibility in accordance with the French law, "Loi Informatique et Libertés" (January 6, 1978, and subsequent amendments) and with the European Directive 95/46/CE.
14.5. INSURANCE POLICY
In accordance with the provisions of the law and the GCP, the Sponsor Pierre Fabre Médicament, has an insurance policy intended to guarantee against possible damage resulting from the research. The studies and/or experiments performed on behalf of the Sponsor Pierre Fabre Médicament are specifically and expressly guaranteed.
It is advisable to underline that non compliance with the Research Legal Conditions is a cause for guarantee exclusion.

15. ADMINISTRATIVE PROCEDURES

15.1. PROTOCOL AMENDMENT
Neither the Investigator nor the Sponsor may alter the protocol without the authorisation of the other party.
All changes to the protocol are subject to an amendment which must be dated and signed by both parties and must appear as an amendment to the protocol.
Substantial amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities.
Urgent amendments are submitted for approval / authorisation to the Ethics Committees and Competent Authorities, but could be implemented immediately under specific conditions defined with the Sponsor.

15.2. SOURCE DOCUMENTS, INVESTIGATOR'S FILE STORAGE
The Investigator:

- Keeps all trial-related documents in appropriate file folders. Records of patient, original informed consent forms, source documents, a CD Rom containing a pdf copy of e-CRF, drug inventory, Ethics Committees and Sponsor correspondence pertaining to the study must be kept on file.
- Retains all documents relating to the screening (consent and investigation results) of all patients included in the trial or not.
• Retains a list of the patient’s names, addresses (and/or number of medical file), code numbers to allow checking of data reported on e-CRFs with those from source documents.
• Authorises direct access to source documents for monitoring, audits and inspections.
• The trial-related documents must be retained as strictly confidential at the Investigator’s site for at least 15 years or according to local requirements, whatever is the longest after the completion or discontinuation of the trial (European Directive 2003/63/EC).

15.3. **END OF THE STUDY**

15.3.1. **Definition of the End of Study**
The end of study is the last visit of the last patient undergoing the trial.

Any change to this definition during the study, for whatever reason, must be notified as a substantial amendment.

15.3.2. **Early Study Termination**

15.3.2.1. **Early Study Termination Decided by the Sponsor**
The Sponsor may discontinue the study at any time for any of the following reasons:

• Lack of recruitment
• Deviations from good clinical practice and/or regulations
• Poor product safety
• New information that could jeopardise the patient’s safety
• Stopping of the development …

15.3.2.2. **Early Study Termination Decided by the Competent Authorities**
The Competent Authorities may suspend or prohibit a study if they consider that either the conditions of authorisation are not being met or has doubt about the safety or scientific validity of the study.
15.4. AUDIT
The Sponsor is responsible for making sure that both its representatives (Study Manager, CRA...) and the Investigator fulfil the requirements as specified by the GCP Guideline.
An audit can be organised internally at Pierre Fabre Médicament and at the investigational site where the e-CRFs are matched against source documents.
All study documentation must be directly accessible to auditors.
The practical conditions for the audit are discussed between the Investigator and the Clinical Quality Assurance Department.
Oral information about the audit results are given to the Investigator.

15.5. INSPECTION
The Health Authorities may inspect any investigation site or the Sponsor in the course of the study or after its completion, to verify the conduct of the study and quality of the data. The Investigator must provide to the inspectors direct access to study documents.

15.6. CONFIDENTIALITY
The present materials (protocol and related documentation, e-CRF, Investigator's Brochure) contain confidential information.
Except if agreed in writing with the Study Manager, the Investigators must hold such information confidential, and must not disclose it to others (except where required by Applicable Law).

15.7. CLINICAL STUDY REPORT
Data analysis and clinical study report writing are under the Sponsor’s responsibility.
Upon data analysis completion, a final report including a review of the objectives and methods, a presentation and a discussion of the results is drawn up according to ICH Guidelines (Structure and Content of Clinical Study Reports, ICH-E3, CPMP/ICH/137/95).
The report is a clinical and statistical integrated report. It must be signed by the Sponsor's representative(s) and the Coordinating Investigator.
15.8. STUDY RESULTS COMMUNICATION
Upon completion of the study, the global results of the Research are communicated to the Investigator. According to the Local Regulation, the patient can ask the Investigator for the results.

15.9. STUDY RESULTS PUBLICATION
The information and data collected during the conduct of this clinical study are considered confidential and are used by the Sponsor in connection with the development of the study drug. This information may be disclosed if deemed necessary by the Sponsor.

To allow the use of the information derived from this clinical study and to insure compliance with Current Regulations, the Investigator must provide the Sponsor with complete test results and all data collected during the study.

Only the Sponsor may make study information available to physicians and to Regulatory Agencies, except as required by Current Regulations.

All the results of this study including data, reports, discoveries and inventions resulting from the study, are the property of the Sponsor.

In the event the Sponsor chooses to publish study data, the manuscript must be provided to the author(s) at least 30 days prior to the expected date of submission to the intended publisher.

The Investigator(s) can reserve the right to publish or present study data; if so, the manuscript or abstract must be provided to the Sponsor for review at least 30 days prior to the expected date of submission to the intended publisher or of planned presentation.

In addition, if necessary, (the) Investigator(s) shall withhold publication for an additional 60 days, to allow the filing of a patent application, or to allow the Sponsor to take any measures he deems appropriate to establish and preserve his proprietary rights.

It is agreed that publication of study results by each site shall be made only as part of a publication of the study results obtained by all sites performing the protocol, once the study is completed and finalised.
The authors list is agreed by all Investigators prior to publication. The names of the authors are provided according to their participation in the design of the protocol as well as their recruitment of eligible and analysable patients.
16. REFERENCES

[1]. F373280 INVESTIGATOR'S BROCHURE, version October 2013

n-3 Polyunsaturated Fatty Acids in the prevention of atrial Fibrillation Recurrences after electrical cardioversion. A prospective, Randomised study
Circulation, 2011; 124:1100-1106

Effects of n-3 polyunsaturated fatty acids on left ventricular function and functional capacity in patients with dilated cardiomyopathy
J. Am. Coll. Cardiol. 2011;57;870-879

[4]. MOERTL D., HAMMER A., STEINER S., HUTULEAC R., VONBANK K., BERGER R.
Dose-dependant effects of omega-3-polyunsaturated fatty acids on systolic left ventricular function, endothelial function, and markers of inflammation in chronic heart failure of non ischemic origin: A double-blind, placebo-controlled, 3-arm study
American Heart Journal 2011; 161:915.e1-915.e9 - volume 161, number 5

[5]. GISSI-HF INVESTIGATORS
Effects of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GSSI-HF Trial): a randomised, double-blind, placebo-controlled trial
The lancet on line - August 2008

Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC).
European Heart Rhythm Association; European Association for Cardio-Thoracic Surgery, Eur Heart J. 2010 Oct;31(19):2369-429

[7]. KOWEY PR, REIFFEL JA, ELENBOGEN KA, NACCARELLI GV, PRATT CM.
Efficacy and safety of prescription omega-3 fatty acids for the prevention of recurrent symptomatic atrial fibrillation: a randomised controlled trial.
N-3 polyunsaturated fatty acids for the prevention of arrhythmia recurrence after electrical cardioversion of chronic persistent atrial fibrillation: a randomised, double-blind, multicentre study
Europace (2011) 13, 174-181

[9]. OMACOR® SUMMARY PRODUCT CHARACTERISTICS (SPC) dated 17/02/2012

[10]. BEPANTHENE® SUMMARY PRODUCT CHARACTERISTICS (SPC)

Dronedarone for prevention of atrial fibrillation: a dose-ranging study.

[12]. LE HEUZEY JY AND ALL.
A Short-Term, Randomised, Double-Blind, Parallel-Group Study to Evaluate the Efficacy and Safety of Dronedarone versus Amiodarone in Patients with Persistent Atrial Fibrillation: The DIONYSOS Study.
J Cardiovasc Electrophysiol.

Effects of fish-oil supplementation on myocardial fatty acids in humans.
Am J Clin Nutr (2007); 85 : 1225.

[14]. ARTERBURN M.L. & OKEN H.
Distribution, interconversion and dose response of n-3 fatty acids in humans.
Am J Clin Nutr (2006);83 : 1469-1473S.

[15]. TIELEMAN RG, VAN GELDER IC, CRJNS HJ, DE KAM PJ, VAN DEN BERG MP, HAAKSM J, VAN DER WOUE HJ, AND ALLESSIE MA.
Early recurrences of atrial fibrillation after electrical cardioversion: a result of fibrillation-induced electrical remodelling of the atria?
J. Am. Coll. Cardiol. 1998;31;167-173

[16]. SALM P, TAYLOR PJ, KOSTNER K
Simultaneous quantification of total eicosapentaenoic acid, docosahexaenoic acid and arachidonic acid in plasma by high-performance liquid chromatography-tandem mass spectrometry.

[17]. LEGRAND P., SCHMITT B., MOUROT J., CATHELNE D., CHESNEAU G., MIREAUX M., KERHOAS N., WEILL P.
The consumption of food products from linseed-fed animals maintains erythrocyte omega-3 fatty acids in obese human.

*Lipids, 2010, 45, 11-19.*

[18]. HARRIS WS, VON SCHACKY C.
The Omega-3 Index: a new risk factor for death from coronary heart disease?

[19]. ABSTRACT: P5161.
Effects of Polyunsaturated Fatty Acids n-3 (PUFA n-3) in the prophylaxis of atrial fibrillation relapses after external electric cardioversion
*World Congress of Cardiology 2006, 2-6 September, Barcelona – Spain*

Outcome parameters from a consensus conference organized by the German Atrial Fibrillation Competence NETwork and the European Heart Rhythm Association.
*Europace 2007, 9, 1006-1023*

[21]. EUROPEAN MEDICINES AGENCY
Addendum to the guideline on antiarrhythmics on atrial fibrillation and atrial flutter.
EMA/CHMA/EWP/213056/2010

[22]. OWEN AJ, PETER-PRZYBOROWSKA BA, HOY AJ, MCLENNAN PL.
Dietary fish oil dose- and time-response effects on cardiac phospholipid fatty acid composition.
*Lipids. 2004;39:955–961*

[23]. ROBERTO M. LANG, MICHELLE BIERIG, RICHARD B. DEVEREUX, FRANK A. FLACHSKAMPF*, ELYSE FOSTER, PATRICIA A. PELLIKKA, MICHAEL H. PICARD, MARY J. ROMAN, JAMES SEWARD, JACK SHANEWISE, SCOTT SOLOMON, KIRK T. SPENCER, MARTIN ST. JOHN SUTTON, WILLIAM STEWART.
Recommendations for chamber quantification

[24]. JOHN J.V. McMURRAY, STAMATIS ADAMOPOULOS, STEFAN D. ANKER, ANGELO AURICCHIO, MICHAEL BÖHM, KENNETH DICKSTEIN, VOLKMAR FALK, GERASIMOSFilippatos, CÂNDIDA FONSECA, MIGUEL ANGEL GOMEZ-SANCHEZ, TINY JAARSMA, LARS KÖBER, GREGORY Y.H. LIP, ALDO PIETRO MAGGIONI, ALEXANDER PARKHOMENKO, BURKERT...
M. PIESKE, BOGDAN A. POPESCU, PER K. RØNNEVIK, FRANS H. RUTTEN, JUERG SCHWITTER, PETAR SEFEROVIC, JANINA STEPINSKA, PEDRO T. TRINDADE, ADRIAAN A. VOORS, FAIEZ ZANNAD, ANDREAS ZEIHER
ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012
European Heart Journal (2012) 33, 1787–1847

[25]. AGENCE NATIONALE DE SECURITE DU MEDICAMENT ET DES PRODUITS DE SANTE (ANSM).
Bon usage des médicaments antivitamine K (AVK)
Actualisation – Juillet 2012

[26]. GILLES PERNOD, ANNE GODIER, CLAIRE GOZALO, BENJAMIN TREMEY, PIERRE SIE
French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding)
Thrombosis Research 126 (2010) e167–e174
17. APPENDICES
A. INTRODUCTION

1. The World Medical Association (WMA) has developed the Declaration of Helsinki as a statement of ethical principles for medical research involving human subjects, including research on identifiable human material and data. The Declaration is intended to be read as a whole and each of its constituent paragraphs should not be applied without consideration of all other relevant paragraphs.

2. Although the Declaration is addressed primarily to physicians, the WMA encourages other participants in medical research involving human subjects to adopt these principles.

3. It is the duty of the physician to promote and safeguard the health of patients, including those who are involved in medical research. The physician's knowledge and conscience are dedicated to the fulfilment of this duty.

4. The Declaration of Geneva of the WMA binds the physician with the words, “The health of my patient will be my first consideration,” and the International Code of Medical Ethics declares that, “A physician shall act in the patient's best interest when providing medical care.”

5. Medical progress is based on research that ultimately must include studies involving human subjects. Populations that are underrepresented in medical research should be provided appropriate access to participation in research.

6. In medical research involving human subjects, the well-being of the individual research subject must take precedence over all other interests.

7. The primary purpose of medical research involving human subjects is to understand the causes, development and effects of diseases and improve preventive, diagnostic and therapeutic interventions (methods, procedures and treatments). Even the best current interventions must be evaluated continually through research for their safety, effectiveness, efficiency, accessibility and quality.

8. In medical practice and in medical research, most interventions involve risks and burdens.

9. Medical research is subject to ethical standards that promote respect for all human subjects and protect their health and rights. Some research populations are particularly vulnerable and need special protection. These include those who cannot give or refuse consent for themselves and those who may be vulnerable to coercion or undue influence.

10. Physicians should consider the ethical, legal and regulatory norms and standards for research involving human subjects in their own countries as well as applicable international norms and standards. No national or international ethical, legal or regulatory requirement should reduce or eliminate any of the protections for research subjects set forth in this Declaration.

B. PRINCIPLES FOR ALL MEDICAL RESEARCH

11. It is the duty of physicians who participate in medical research to protect the life, health, dignity,
integrity, right to self-determination, privacy, and confidentiality of personal information of research subjects.

12. Medical research involving human subjects must conform to generally accepted scientific principles, be based on a thorough knowledge of the scientific literature, other relevant sources of information, and adequate laboratory and, as appropriate, animal experimentation. The welfare of animals used for research must be respected.

13. Appropriate caution must be exercised in the conduct of medical research that may harm the environment.

14. The design and performance of each research study involving human subjects must be clearly described in a research protocol. The protocol should contain a statement of the ethical considerations involved and should indicate how the principles in this Declaration have been addressed. The protocol should include information regarding funding, sponsors, institutional affiliations, other potential conflicts of interest, incentives for subjects and provisions for treating and/or compensating subjects who are harmed as a consequence of participation in the research study. The protocol should describe arrangements for post-study access by study subjects to interventions identified as beneficial in the study or access to other appropriate care or benefits.

15. The research protocol must be submitted for consideration, comment, guidance and approval to a research ethics committee before the study begins. This committee must be independent of the researcher, the sponsor and any other undue influence. It must take into consideration the laws and regulations of the country or countries in which the research is to be performed as well as applicable international norms and standards but these must not be allowed to reduce or eliminate any of the protections for research subjects set forth in this Declaration. The committee must have the right to monitor ongoing studies. The researcher must provide monitoring information to the committee, especially information about any serious adverse events. No change to the protocol may be made without consideration and approval by the committee.

16. Medical research involving human subjects must be conducted only by individuals with the appropriate scientific training and qualifications. Research on patients or healthy volunteers requires the supervision of a competent and appropriately qualified physician or other health care professional. The responsibility for the protection of research subjects must always rest with the physician or other health care professional and never the research subjects, even though they have given consent.

17. Medical research involving a disadvantaged or vulnerable population or community is only justified if the research is responsive to the health needs and priorities of this population or community and if there is a reasonable likelihood that this population or community stands to benefit from the results of the research.

18. Every medical research study involving human subjects must be preceded by careful assessment of predictable risks and burdens to the individuals and communities involved in the research in comparison with foreseeable benefits to them and to other individuals or communities affected by the condition under investigation.

19. Every clinical trial must be registered in a publicly accessible database before recruitment of the first subject.

20. Physicians may not participate in a research study involving human subjects unless they are confident that the risks involved have been adequately assessed and can be satisfactorily managed. Physicians must immediately stop a study when the risks are found to outweigh the potential benefits or when there is conclusive proof of positive and beneficial results.

21. Medical research involving human subjects may only be conducted if the importance of the objective outweighs the inherent risks and burdens to the research subjects.

22. Participation by competent individuals as subjects in medical research must be voluntary. Although it may be appropriate to consult family members or community leaders, no competent individual may be
enrolled in a research study unless he or she freely agrees.

23. Every precaution must be taken to protect the privacy of research subjects and the confidentiality of their personal information and to minimize the impact of the study on their physical, mental and social integrity.

24. In medical research involving competent human subjects, each potential subject must be adequately informed of the aims, methods, sources of funding, any possible conflicts of interest, institutional affiliations of the researcher, the anticipated benefits and potential risks of the study and the discomfort it may entail, and any other relevant aspects of the study. The potential subject must be informed of the right to refuse to participate in the study or to withdraw consent to participate at any time without reprisal. Special attention should be given to the specific information needs of individual potential subjects as well as to the methods used to deliver the information. After ensuring that the potential subject has understood the information, the physician or another appropriately qualified individual must then seek the potential subject’s freely-given informed consent, preferably in writing. If the consent cannot be expressed in writing, the non-written consent must be formally documented and witnessed.

25. For medical research using identifiable human material or data, physicians must normally seek consent for the collection, analysis, storage and/or reuse. There may be situations where consent would be impossible or impractical to obtain for such research or would pose a threat to the validity of the research. In such situations the research may be done only after consideration and approval of a research ethics committee.

26. When seeking informed consent for participation in a research study the physician should be particularly cautious if the potential subject is in a dependent relationship with the physician or may consent under duress. In such situations the informed consent should be sought by an appropriately qualified individual who is completely independent of this relationship.

27. For a potential research subject who is incompetent, the physician must seek informed consent from the legally authorized representative. These individuals must not be included in a research study that has no likelihood of benefit for them unless it is intended to promote the health of the population represented by the potential subject, the research cannot instead be performed with competent persons, and the research entails only minimal risk and minimal burden.

28. When a potential research subject who is deemed incompetent is able to give assent to decisions about participation in research, the physician must seek that assent in addition to the consent of the legally authorized representative. The potential subject’s dissent should be respected.

29. Research involving subjects who are physically or mentally incapable of giving consent, for example, unconscious patients, may be done only if the physical or mental condition that prevents giving informed consent is a necessary characteristic of the research population. In such circumstances the physician should seek informed consent from the legally authorized representative. If no such representative is available and if the research cannot be delayed, the study may proceed without informed consent provided that the specific reasons for involving subjects with a condition that renders them unable to give informed consent have been stated in the research protocol and the study has been approved by a research ethics committee. Consent to remain in the research should be obtained as soon as possible from the subject or a legally authorized representative.

30. Authors, editors and publishers all have ethical obligations with regard to the publication of the results of research. Authors have a duty to make publicly available the results of their research on human subjects and are accountable for the completeness and accuracy of their reports. They should adhere to accepted guidelines for ethical reporting. Negative and inconclusive as well as positive results should be published or otherwise made publicly available. Sources of funding, institutional affiliations and conflicts of interest should be declared in the publication. Reports of research not in accordance with the principles of this Declaration should not be accepted for publication.
C. ADDITIONAL PRINCIPLES FOR MEDICAL RESEARCH COMBINED WITH MEDICAL CARE

31. The physician may combine medical research with medical care only to the extent that the research is justified by its potential preventive, diagnostic or therapeutic value and if the physician has good reason to believe that participation in the research study will not adversely affect the health of the patients who serve as research subjects.

32. The benefits, risks, burdens and effectiveness of a new intervention must be tested against those of the best current proven intervention, except in the following circumstances:
   - The use of placebo, or no treatment, is acceptable in studies where no current proven intervention exists; or
   - Where for compelling and scientifically sound methodological reasons the use of placebo is necessary to determine the efficacy or safety of an intervention and the patients who receive placebo or no treatment will not be subject to any risk of serious or irreversible harm. Extreme care must be taken to avoid abuse of this option.

33. At the conclusion of the study, patients entered into the study are entitled to be informed about the outcome of the study and to share any benefits that result from it, for example, access to interventions identified as beneficial in the study or to other appropriate care or benefits.

34. The physician must fully inform the patient which aspects of the care are related to the research. The refusal of a patient to participate in a study or the patient’s decision to withdraw from the study must never interfere with the patient-physician relationship.

35. In the treatment of a patient, where proven interventions do not exist or have been ineffective, the physician, after seeking expert advice, with informed consent from the patient or a legally authorized representative, may use an unproven intervention if in the physician's judgement it offers hope of saving life, re-establishing health or alleviating suffering. Where possible, this intervention should be made the object of research, designed to evaluate its safety and efficacy. In all cases, new information should be recorded and, where appropriate, made publicly available.
17.2. SAE REPORT FORM
NOTIFICATION OF SERIOUS ADVERSE EVENT (SAE) OR PREGNANCY
TO PIERRE FABRE CORPORATE VIGILANCES DIVISION

TO BE TRANSMITTED TO THE CORPORATE VIGILANCES DIVISION BY E-MAIL WITHIN 24H TO HQ.pharmacovigilance@pierre-fabre.com OR BY FAX WITHIN 24H – Fax N°: 33 (0) 1.49.10.80.90

Transmission date __ __ __ __ __ __ __ __ __ __ (ddmmyyyy) Country : ........................................

SAE N° __ __ __ __ __ __ __ __ __ __ FIRST NOTIFICATION  ❑  FOLLOW-UP  ❑ N°

SUBJECT CHARACTERISTICS

<table>
<thead>
<tr>
<th>Gender</th>
<th>1=M, 2=F</th>
<th>Birth date __ __ __ __ __ __</th>
</tr>
</thead>
<tbody>
<tr>
<td>Height</td>
<td>__ __ __ cm</td>
<td>Weight __ __ __ . ___ kg</td>
</tr>
</tbody>
</table>

DESCRIPTION OF THE EVENT

The serious adverse event resulted in :
❑ Death (whatever may be the cause)
❑ Hospitalisation (*) or extension thereof
❑ Life threatening
❑ Invalidity or disability
❑ Congenital abnormality or abnormal pregnancy outcome
❑ Cancer
❑ Other (any other serious clinical or laboratory event according to the investigator or the protocol, overdosage meeting seriousness criteria, suicide attempts)

Other fact to be notified :
❑ Pregnancy exposure

Nature of the event (if clinical nature, indicate the diagnosis or the major symptom) :
...........................................................................................................................................................................................................................................................................................................
...........................................................................................................................................................................................................................................................................................................

AE onset date __ __ __ __ __ __ __ __ __ __ (ddmmyyyy)

Seriousness onset date __ __ __ __ __ __ __ __ __ __ (ddmmyyyy)

Summary description (if clinical cause, significant history, progression of event, available laboratory results, etc...) :

(*) Except hospitalisations with durations and goals planned in the protocol

THE SAE IN RELATION TO THE TRIAL

TREATMENT NUMBER __________

• Time of occurrence of SAE
  ❑ During the selection or run-in period
  ❑ During the administration phase of the study treatment
  ❑ After the administration phase of the study treatment

• Date of first study treatment administration __ __ __ __ __ __ __ __ __ __ (ddmmyyyy)

• Date of last study treatment administration __ __ __ __ __ __ __ __ __ __ (ddmmyyyy)

• Was the blind broken ? ❑ Yes ❑ No ❑ Not applicable

If yes, or if this is an open study, drug(s) administered :
...........................................................................................................................................................................................................................................................................................................

Conditions of administration (cycles(s), daily dose(s), route(s) of administration, etc...) :
...........................................................................................................................................................................................................................................................................................................
**CONCOMITANT MEDICATION SINCE TRIAL INITIATION and up UNTIL THE OCCURRENCE OF THE SAE (EXCEPT THE TREATMENTS GIVEN FOR THE SAE)**

<table>
<thead>
<tr>
<th>Trade name (or INN)</th>
<th>Daily dose</th>
<th>Start date (dd/mm/yy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (dd/mm/yy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><em>/</em>/_____</td>
<td></td>
<td><em>/</em>/_____</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>/</em>_____</td>
<td></td>
<td><em>/</em>_____</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>/</em>_____</td>
<td></td>
<td><em>/</em>_____</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**MEASURES TAKEN FOLLOWING THE SAE**

- **Study treatment**
  - [ ] No change
  - [ ] Dosage modification, specify: ……………………………………… Modification Date: _/_/_____  
  - [ ] Temporarily discontinued Readministration date: _/_/_____  
  - [ ] Withdrawn End date: _/_/_____  
  - [X] Not applicable

- **The event led to:**
  - [ ] Prescription of corrective or symptomatic treatments:

<table>
<thead>
<tr>
<th>Trade name (or INN)</th>
<th>Daily dose</th>
<th>Start date (dd/mm/yy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (dd/mm/yy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><em>/</em>/_____</td>
<td></td>
<td><em>/</em>/_____</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>/</em>_____</td>
<td></td>
<td><em>/</em>_____</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>/</em>_____</td>
<td></td>
<td><em>/</em>_____</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- [ ] Discontinuation of concomitant treatments:

<table>
<thead>
<tr>
<th>Trade name (or INN)</th>
<th>Daily dose</th>
<th>Start date (dd/mm/yy)</th>
<th>Ongoing at occurrence of the event</th>
<th>Stop date (dd/mm/yy)</th>
<th>Route of admin.</th>
<th>Indication</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td><em>/</em>/_____</td>
<td></td>
<td><em>/</em>/_____</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>/</em>_____</td>
<td></td>
<td><em>/</em>_____</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td><em>/</em>_____</td>
<td></td>
<td><em>/</em>_____</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- [X] Others, specify:

**OUTCOME**

- [ ] Not recovered/Not resolved
- [ ] Recovering/Resolving
- [ ] Recovered/Resolved
- [X] Fatal
- [X] Unknown

In case of death, has an autopsy been conducted? [ ] Yes [ ] No

**INVESTIGATOR CAUSALITY ASSESSMENT** (investigator’s assessment to be done as soon as possible)

<table>
<thead>
<tr>
<th>Study drug:</th>
<th>Related to study protocol:</th>
</tr>
</thead>
<tbody>
<tr>
<td>[ ] Not Suspected</td>
<td>[ ] Suspected</td>
</tr>
<tr>
<td>[ ] Not Suspected</td>
<td>[ ] Suspected</td>
</tr>
</tbody>
</table>

Comments: …………………………………………………………………………………………………………………………………………………………………………

Enclose in the notification the results of carried out examinations, reports of hospitalisation, etc...
# 17.3. Predefined Limits of Laboratory and Vital Sign Potentially Clinically Significant Changes and Values

List of predefined potentially clinically significant change for laboratory values:

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Unit</th>
<th>Decrease</th>
<th>PSC</th>
<th>Increase</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Muscle</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatine Phosphokinase</td>
<td>U/l</td>
<td>-</td>
<td>236</td>
<td></td>
</tr>
<tr>
<td><strong>Kidney</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatinine</td>
<td>µmol/l</td>
<td>-</td>
<td>35</td>
<td></td>
</tr>
<tr>
<td>Urea</td>
<td>mmol/l</td>
<td>-</td>
<td>3.2</td>
<td></td>
</tr>
<tr>
<td>Uric acid</td>
<td>µmol/l</td>
<td>-</td>
<td>119</td>
<td></td>
</tr>
<tr>
<td>Phosphate</td>
<td>mmol/l</td>
<td>0.39</td>
<td></td>
<td>0.39</td>
</tr>
<tr>
<td>Calcium</td>
<td>mmol/l</td>
<td>0.30</td>
<td></td>
<td>0.30</td>
</tr>
<tr>
<td><strong>Electrolytes</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sodium</td>
<td>mmol/l</td>
<td>8</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>Potassium</td>
<td>mmol/l</td>
<td>1.1</td>
<td>1.1</td>
<td></td>
</tr>
<tr>
<td>Chloride</td>
<td>mmol/l</td>
<td>8</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>Bicarbonate</td>
<td>mmol/l</td>
<td>7</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td><strong>Metabolism/Nutritional</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Glucose (random)</td>
<td>mmol/l</td>
<td>3</td>
<td>3.7</td>
<td></td>
</tr>
<tr>
<td>Albumin</td>
<td>g/l</td>
<td>6</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>Protein</td>
<td>g/l</td>
<td>11</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>Cholesterol</td>
<td>mmol/l</td>
<td>-</td>
<td></td>
<td>1.97</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>mmol/l</td>
<td>0.91</td>
<td></td>
<td>0.85</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>mmol/l</td>
<td>2.17</td>
<td></td>
<td>2.04</td>
</tr>
<tr>
<td>Triglycerides</td>
<td>mmol/l</td>
<td>-</td>
<td></td>
<td>2.91</td>
</tr>
<tr>
<td><strong>Erythrocytes</strong></td>
<td></td>
<td>0.7</td>
<td>0.7</td>
<td></td>
</tr>
<tr>
<td>Haemoglobin</td>
<td>g/l</td>
<td>20</td>
<td>-</td>
<td></td>
</tr>
<tr>
<td>Haematocrit</td>
<td>l</td>
<td>0.06</td>
<td>0.06</td>
<td></td>
</tr>
<tr>
<td>MCV</td>
<td>fl</td>
<td>7</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>MCH (Fe)</td>
<td>fmol</td>
<td>0.19</td>
<td>0.19</td>
<td></td>
</tr>
<tr>
<td>MCHC (Fe)</td>
<td>mmol/l</td>
<td>2</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td><strong>Leukocytes</strong></td>
<td></td>
<td>4.2</td>
<td>3.8</td>
<td></td>
</tr>
<tr>
<td>Leukocyte count</td>
<td>G/l</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Differential Count</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Neutrophils</td>
<td>G/l</td>
<td>3.47</td>
<td>3.19</td>
<td></td>
</tr>
<tr>
<td>Lymphocytes</td>
<td>G/l</td>
<td>1.76</td>
<td>1.63</td>
<td></td>
</tr>
<tr>
<td>Monocytes</td>
<td>G/l</td>
<td>-</td>
<td>0.49</td>
<td></td>
</tr>
<tr>
<td>Eosinophils</td>
<td>G/l</td>
<td>-</td>
<td>0.41</td>
<td></td>
</tr>
<tr>
<td>Basophils</td>
<td>G/l</td>
<td>-</td>
<td>0.14</td>
<td></td>
</tr>
<tr>
<td><strong>Urine</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Specific gravity</td>
<td>-</td>
<td>0.017</td>
<td></td>
<td>0.015</td>
</tr>
<tr>
<td>pH</td>
<td>-</td>
<td>2</td>
<td></td>
<td>2</td>
</tr>
<tr>
<td><strong>Liver</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total bilirubin</td>
<td>µmol/l</td>
<td>-</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>ASAT (SGOT)</td>
<td>U/l</td>
<td>-</td>
<td>N x (23/36)</td>
<td></td>
</tr>
<tr>
<td>ALAT (SGPT)</td>
<td>U/l</td>
<td>-</td>
<td>N x (28/45)</td>
<td></td>
</tr>
<tr>
<td>Gamma GT</td>
<td>U/l</td>
<td>-</td>
<td>N x (25/38)</td>
<td></td>
</tr>
<tr>
<td>Alkaline phosphatase</td>
<td>U/l</td>
<td>-</td>
<td>N x (30/95)</td>
<td></td>
</tr>
</tbody>
</table>

N = upper limit of normal range

### Definition of Clinically Noteworthy Abnormal Laboratory Values (CNALV)

<table>
<thead>
<tr>
<th>PARAMETERS</th>
<th>CNALV</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>HAEMOGLOBIN</strong></td>
<td>• Decrease of at least 2g/dl and value &lt; 10 g/dl whatever the baseline value</td>
</tr>
<tr>
<td></td>
<td>• If missing baseline : value &lt; 10g/dl</td>
</tr>
<tr>
<td><strong>NEUTROPHILS</strong></td>
<td>• &lt; 1 500/mm³ whatever the baseline value</td>
</tr>
<tr>
<td><strong>WBC</strong></td>
<td>(if missing value for neutrophils)</td>
</tr>
<tr>
<td></td>
<td>• &lt; 3 000/mm³ whatever the baseline value</td>
</tr>
<tr>
<td><strong>PLATELETS</strong></td>
<td>• &lt; 100 000/mm³ whatever the baseline value</td>
</tr>
<tr>
<td><strong>SERUM CREATININE</strong></td>
<td>• Increase of at least 30 % as compared to baseline value and value &gt; 150 µmol/l whatever the baseline value</td>
</tr>
<tr>
<td></td>
<td>• If missing baseline : value &gt; 150 µmol/l</td>
</tr>
</tbody>
</table>

#### LIVER FUNCTION TESTS

| ALAT                | • If normal baseline :                                                                         |
|                     |   • ALAT > 2 N                                                                                  |
|                     | • If abnormal baseline :                                                                        |
|                     |   → if baseline value ≤ 2.5 N :                                                                 |
|                     |     • increase of at least 100 % as compared to baseline value                                   |
|                     |   → if baseline value > 2.5 N :                                                                 |
|                     |     • value > 5 N                                                                               |

| ASAT                | • If normal baseline :                                                                         |
|                     |   • ASAT > 2 N                                                                                  |
|                     | • If abnormal baseline :                                                                        |
|                     |   → if baseline value ≤ 2.5 N :                                                                 |
|                     |     • increase of at least 100 % as compared to baseline value                                   |
|                     |   → if baseline value > 2.5 N :                                                                 |
|                     |     • value > 5 N                                                                               |

| Alkaline phosphatase (AP) | • If normal baseline :                                                                         |
|                          |   • AP > 1.25 N                                                                                 |
|                          | • If abnormal baseline :                                                                        |
|                          |   • AP > 2 N                                                                                    |

| Total bilirubin (TB)    | • If normal baseline :                                                                         |
|                         |   • TB > 1.5 N                                                                                  |
|                         | • If abnormal baseline :                                                                        |
|                         |   • TB > 2 N                                                                                    |

N=upper limit of normal range


Cardiovascular Safety

Table 1: Predefined Limits for Potentially Clinically Significant Changes (PSC) and PSC Leading to Clinically Significant Values (PSCV)

<table>
<thead>
<tr>
<th>Parameter</th>
<th>PSC</th>
<th>PSCV</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP</td>
<td>Increase ≥ 20 mmHg</td>
<td>SBP ≥ 160 mmHg and increase ≥ 20 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 20 mmHg</td>
<td>SBP ≤ 90 mmHg and decrease ≥ 20 mmHg</td>
</tr>
<tr>
<td>DBP</td>
<td>Increase ≥ 10 mmHg</td>
<td>DBP ≥ 100 mmHg and increase ≥ 10 mmHg</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 mmHg</td>
<td>DBP ≤ 50 mmHg and decrease ≥ 10 mmHg</td>
</tr>
<tr>
<td>HR</td>
<td>Increase ≥ 10 bpm</td>
<td>HR ≥ 110 bpm and increase ≥ 10 bpm</td>
</tr>
<tr>
<td></td>
<td>Decrease ≥ 10 bpm</td>
<td>HR ≤ 50 bpm and decrease ≥ 10 bpm</td>
</tr>
</tbody>
</table>

Table 2: Predefined Classes for changes from Baseline to the Maximum (and/ or Minimum) Post-baseline Value

<table>
<thead>
<tr>
<th>Classes of Change from Baseline to the Maximum Post-baseline Value</th>
<th>Classes of Change from Baseline to the Minimum Post-baseline Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>All</td>
<td>All</td>
</tr>
<tr>
<td>≥ 0</td>
<td>≥ 0</td>
</tr>
<tr>
<td>&gt; 0</td>
<td>&gt; 0</td>
</tr>
<tr>
<td>≥ 10</td>
<td>≥ 5</td>
</tr>
<tr>
<td>≥ 20</td>
<td>≥ 10</td>
</tr>
<tr>
<td>≥ 30</td>
<td>≥ 15</td>
</tr>
<tr>
<td>≥ 40</td>
<td>≥ 20</td>
</tr>
<tr>
<td></td>
<td>≥ 25</td>
</tr>
<tr>
<td></td>
<td>≥ 30</td>
</tr>
</tbody>
</table>

Table 3: Classes for Vital Signs Maximum or Minimum Values

<table>
<thead>
<tr>
<th>Classes for the Maximum Post-baseline Value for each parameter</th>
<th>Classes for the Minimum Post-baseline Value for each parameter</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP mmHg</td>
<td>DBP mmHg</td>
</tr>
<tr>
<td>&lt; 120</td>
<td>&lt; 80</td>
</tr>
<tr>
<td>[120;140[</td>
<td>[80;90[</td>
</tr>
<tr>
<td>[140;160[</td>
<td>[90;100[</td>
</tr>
<tr>
<td>≥ 160</td>
<td>≥ 100</td>
</tr>
</tbody>
</table>

Table 4: Classes for Maximum or Minimum of BP in its entirety

<table>
<thead>
<tr>
<th>Classification of Maximum Values for Blood Pressure (mmHg)</th>
<th>Classification of Minimum Values Blood Pressure (mmHg)</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP &lt; 140 and DBP &lt; 90</td>
<td>SBP &gt; 90 and DBP &gt; 50</td>
</tr>
<tr>
<td>SBP [140;160] and DBP &lt; 100</td>
<td>SBP ≤ 90 or DBP ≤ 50</td>
</tr>
<tr>
<td>or DBP [90;100] and SBP &lt; 160</td>
<td></td>
</tr>
<tr>
<td>SBP ≥ 160 or DBP ≥ 100</td>
<td></td>
</tr>
</tbody>
</table>

Table 5: Definition of orthostatic hypotension

<table>
<thead>
<tr>
<th>Orthostatic Hypotension *</th>
</tr>
</thead>
<tbody>
<tr>
<td>SBP Decrease ≥ 20 mmHg or DBP Decrease ≥ 10 mmHg between supine and standing positions</td>
</tr>
</tbody>
</table>